<datawarrior-fileinfo>
<version="3.1">
<rowcount="1001">
</datawarrior-fileinfo>
<column properties>
<columnName="idcoordinates2D">
<columnProperty="parent	Structure">
<columnProperty="specialType	idcoordinates2D">
<columnName="FragFp">
<columnProperty="parent	Structure">
<columnProperty="specialType	FragFp">
<columnProperty="version	1.2.1">
<columnName="Flexophore">
<columnProperty="parent	Structure">
<columnProperty="specialType	Flexophore">
<columnProperty="version	4.3">
<columnName="Structure">
<columnProperty="specialType	idcode">
<columnName="PathFp">
<columnProperty="parent	Structure">
<columnProperty="specialType	PathFp">
<columnProperty="version	1.0">
<columnName="SkelSpheres">
<columnProperty="parent	Structure">
<columnProperty="specialType	SkelSpheres">
<columnProperty="version	1.1">
</column properties>
idcoordinates2D	FragFp	Flexophore	PathFp	SkelSpheres	Structure	Reference	affinity	company	drug	mode of action	receptor	receptor class	TestData	DatasetName
36)\W(=.6s,Bx=)\,BJ)yki.|G}_}_|G~lixh.~SF*~Sh.v:`*	:UfzvzirS:vyttEjCuUfvhjQzUeoJCzvx@AEGYRDxTh_Tnqmk4u88_4yFXr1@Y1_@oW8J52R0kNX80XVV0F0	0Z80eF03AV1N05g012s0FF1209w012s0L02W0Aw018g0YV2U0DF01Hs0Xk2D09w0t% O0F08K6T52W08RPDSGYW0c41763t0FVDF482I@_Wcg8320XGl9tBF411GcB4LB8M6lNFJP315YO0FV8C2Q@WWH8J210X3088cdgU6VW0k_BT2331a98BBF62c2Vk8JHAO5W1kV	#c4F#e8#8b#@FV!FB#3Va#2$8cF!4_4$FV!Z2F#G_#9NV#1#2@F!11N0	1012//#A//&1/!4)1&7$2//-1/(A/+1)2011$2)1-1+2)1!1/-11/!2/*2/01$4$1-1/(3.2+4!62!1)1!2/02!1%4$2/!1$2/01$1/$2$11!1(4/)1*1*1/(101)2$1+1$2/%1%404$2,1/,1(2/,2&1(g#1#4#1,1//,1#1/03!101$1)1.15//$5(1/01$1///10126)1&2*402+	feoX`@DXtFlpJrJJJIIVIKJIQIDXJW`mzN[UUSUUTuMTp@@	Bioorg. Med. Chem. Lett. (2003) 13: 1429-1432	Ki: 4.1 nM	University Madrid and Barcelona	no	agonist	5-HT1A	5-HT (I Amine)	yes	5-HT1A_All1(50)
xix=S~xixix=S~S~xixixhx=S~xix=xix=xix=xiS(x=x>S(x>xh	zxzKn1zOOnJ3M42DH9VFXN0HVX!h3d28F2V10203WF1!1!A1V!G2d0gG8F2F08$8H0Ve5404040V8F0	0Pg!_!uF03OF1k07g016J0R01v0Eo01Z40Fk1407!Tk3d& m0W0F888@5YWFoH31WFFN@TD0VY408FP2322FoR75VV9cwo234WksRJB4X0N82PK0VksF62679Vls4852WkccJ94WkVB2VG0VYoRV8N4e6DcGNccJey32l18VwN4DE8W0NcJs2J671O86@D6	#VVk-241$2#3B2$F#F58!8Vk$F$Po!105#GVF#5s!24#259V	&1//I)1(1/,1//,2#101+1!2#2//%2/)3#1)1&2//%5,5(102$2/-4)3#7!1/,1)1+209/!22#1/!2//1/)3&1)1(2/%2/&1&1)6!2//01//$3!601!1/&102*1%1.9/+2#2+1//,1%10l202!11.1!1/B/,1(2)2)201/02/%2%1$204(22/!1-1,1#1!1/$1(1//+	fmwab@GLULD`drljkzjrntyjwQpAEUUUP@TP@@	Curr. Med. Chem. (2001) 8 (9): 999-1034	Ki 5-HT1a: 0.221 nM		no		5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
x=xiS(x=x=S(x=xiS~x=xixix=xix=xix=xiS(x=x=|`S(l0|F`*`*	vzUQvAvOURt2QB3MH9FGdNcHm2HXZ2988PTV50X111FY6F1!A0V023Bl6R33BYF0122F!403%5V0VcFV	0RZ!qJ0Tk3x!G_07R0Tk1w!Fh0440FV2d!KW07R0TV1w0CB# !892GF@566YO0FV@NmP50GGFcNNE9YWcJ67254k894iu724W41lNs331k84ZV116_O0FkA48E@WVcl4Q82810YW0RZC3X0sF4516_FF9Bs	#22V!108#V%2#V$582*14$8#9F$@k#45#G%Ks!2$21GV	*2%2,1(D!1////)301031%3/-2/,1!21%1/(2////*4/(2/)2%2#61)2/&103$1!2$110201(1/&10101%1/)2$2,2&1+2+122$2&3///(2$1)3//%1$101.@$4-1*2(101%1)2$9+1/$1/#12/+1,10o01020202/01$1*D+2$1#1&101$2%1,1(2$2.2/(1*13////,1#1!13*2/05$1(	fcpB@KMvBPRYWVUuVUmvcCVkt\x@Jjjj@HjrD@@	DailyDrugNews.com 21. Nov. 2003 / WO 03087086	not given in publication	Merck KGaA	no	not given in publication	5-HT1A / 5-HT1D / 5-HT2A	5-HT (I Amine)	no	5-HT1A_All1(50)
S~xh.hS~S~.hsp\}Bz}^q5}^q5}^q5^}}^}^^}}^^}q5}^}^q5	;vvfzOzNtIQB37H90tcODHX2H2g30@BHUV59X130Ff601!@90204Rl243E4n01122KZ0D0180F04!FX0GV	0aJ0Tk02R03i!K10480LV1Q0@Z01L40Sk1u07k0ok05OF1k07R0U03i# 06F48296ZkkcHB4WVk4gHL372Ycge31W09FVf8231m0X0G0VLC5WVFRF63W0NBsFR64Y1NcJ@41G0864173V88cw4495lsNP4310WNwj82810W1FRD93WksZH610kNB4219Y4k	#20V!3%V2$2#VV#182#2$814$8#9F$2k#45#G0V#Ks!22N!2W0V	/1/$10B!2.1/&1!1/(6$1,1///(101#3/&1%1201//*21-2/,2(21/(2,302&1/&2101,1#301%1/)1(1//,12%1$1/+1%2(2$1*1+1+1%1-103/03%2.4101*1#6/1!1/)2!1.7/////#1)2!10l1$5(2*1$1%6#H01)3!101#1/-1$1/-4!1//14///#1+101-1!12/!12(2-	fewQ@@ANAdTRTraRRbRrbRhpTdyGN@Bfjji`@J@@@	J. Med. Chem. (2004) 47 (19): 4677-4683	IC50: 5-HT1A: 0.8 nM / D2: 5.6 nM		no	agonist	5-HT1A / D2	5-HT (I Amine)	no	5-HT1A_All1(50)
H)~Uw<.>b+.iS(x>.>.>xhS(x>xhS(x>x>S(x>xhS(x>x>S(xh	vzUtvdUSzKxpQRPQ2U0n39em66H1CV08DPR031X91FlX41WX02NW904R8oF3_J02V1231!J01#106V$k	0o80eF2l!GG06J0Q01v!FL06F0SF3C!GX06J0Tk3F$ !6F4F234Z10cJ95WFFF@410YllsgJ854mcgB296ZWGtRLE4Y0NJZNHS8XocNJFA6E11kV	#20V!1$24V#F4#V2#BV@$4F#1V!6ZR%F#2V#F6#11#43s!2V4#W8V	02//!1!8/.1/.103!206$2#11,1+1011)1-102!12)2*1/#4%4!1#1*2///2&1-1!13//,1/(102//.2201&1$2,1&1.1$1!1%201*2,1%1%1*1/#2(1,4/#1//)101.501!2/#1!1/1(1)7+1.102/-1#1!1/,1j%501%4/&4#E//)2/1/-2!1/01!1!101%5/&11//01$1!2(1(401/*501+	fewHB@LFld@PeL|jornrmbbcQSt]LaAEUT@ED@@@	DailyDrugNews.com 9. Oct. 2003 / WO 03074518	IC50 1A: 0.2 nM / 2A: 13 nM	Merck KGaA	no	agonist	5-HT1A / 5-HT2A	5-HT	no	5-HT1A_All1(50)
*Fl0.iS(:0xhx=S~.=.>xiS(x>xix>xix>S~xixhx>S~\)xi~Os6	;rvrttOuBH_V7D2sHxXR6HkVGX93V24JGpW82k1FF14FG01A1X0VJHs0VG8F21#2268k02X9404040VFF0	0Pg!aJ0Tk02_k2Q!C105c0Lk03OF1k07g01JF0R01v09R0uF$ 6F4829121sZHA2118R4320Ylc84JV24X1VwPB21VkV210VYlOyF483Z140Vl8ZH630FNgF641V9l4440VVN4NJc4AVl0Na84Y0V42N@B0VXt8oD23YFFJ42445t0G08oT4M4VG0Fa443Vd8ogcJGa11NVs@tB22G3WSV6B32ckX2Fk4C4m0WkF	#dWk!2N#404!26W$3#2B@!12GV!F3%o*Po$4#GVF!90s!24#258V	-2/$1!3D////101#4$1.1$1///&209!11(1//!1/!1/%21!1(1)1%1/,31&1/*1*41.1084$3/!2%1(2//*1+2+2&1&401/1-1!1//%2///$1!1/01!7$1/04$1+3/&8//$1///+10n%1$1!3*1&1#2#D,3/&2*1)201/4*2-1+2&112/*1$41/01*1)1#1&104+1)2/!	fm``@G@EdbbdTUVrRbRffQJLxhqVsWPUPQU@DMUA@@@	DailyDrugNews.com 3. Juni 2004 / WO 04035561	Ki: D2: 0.63 nM / 5-HT1A: 6.31 nM	Pierre Fabre	no	D2: antagonist / 5-HT1A: agonist	D2 / 5-HT1A	Dopamine / 5-HT	no	5-HT1A_All1(50)
}J=.W(spp3x=J)S(xix=xiS~x=xixix>xix>S~S(xixhx>S~	;vzfzOrxxfQB@z6A8sAOg1rMP0hW0@BPRV39XC08Ib4!X0at1@0FTN7oAbK320129804R09014140V$V	0_!uF02YF3r!C_06k0R!3FV2d0A4011N0JF1Z07c% #1x@V361WXOl68590FH084PDzDX0kkTF4@22J44cJJD@2CW1m0a276YX2FoRD42FNV61A6_gn0sF352Xt0Fk8gTP9VkcJF41_2XV	/,2#4VN#24F#YV!6V8$F#HHo#15#FV#B7s!2F4#9BV	//#1010B/!12/-1+7&4$2#11/)301/1-13)1$3///#2$2/,1,2/+2/*2!3/%1/01//#2-1&1$5&1/)1!1.2$2$13(3$1%1!1!1-1/#1$1%1%4,21$1//%2!101.201!2/)102/2,12(1/,1///,h%201%1/+8*2/*2!2/-1/@!1#1*2$402)502)1///&2,1#2!1/)5+20	fi{Pb@MADT@QdbbVTJTRVTTRVJ^Bt]LtuUUAAE@@@	J. Med. Chem. (2001) 44 (3): 418-428	Ki: 5 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
h.(S~S>.h.h.>.~Sixi.~S~Sh.~Shxh.~S~Si.~Shxh.~S~Sh.	;QvQztUxxYvwuQ3YGPj8gLy63d_Z0Pd8B22F2112FX!53V9FW08H88JJ3e022!21!1B2O0F0A02V$F	0_!uF03AV0k044!qJ0R01v!C20@!eF04NV1_06c0o# $m0X0Ffo@S4A2H0tJBR6wIVFlkRVk4331nmcFR84CA_Xkg458AZ0XP4aG2VVO0wY8261E7nsB8@95	#20V!1$2$208#V6#5d1$ZF#3V!4Vc$k#42o#X4#GV$fs!204!218V	012/$1.D/!1//01+2$61#502///*21(1-11/)101&13%2//%1,5/)41/+3/6//*1/&1%1!2-1,1/$2*1%2$1$1.3/+1//&4/-2%2!1//$105*1/,1$1(3$2#4202//(1%1/.2/k%3(1(1/!F//%2)102&1!1//*103%202(14%2//!2)1%2+1-3/,@(1$	fewq@@GYjCIELeCDeeDeeDdsakIrN]@AUUUU@@THEKP@	J. Med. Chem. (2001) 44 (25): 4431-4442	Ki: 5-HT1A: 0.028 nM / alpha1: 767 nM		no	agonist	5-HT1A / Adrenergic alpha 1	5-HT / Adrenergic (I Amine)	no	5-HT1A_All1(50)
h.(S~S>.h.hxh.>.~S~Sixi.~Shx~Shxh.~S~Si.~Shxh.~S~Sh.	;QvAzOUxxYQBPU3AFPfNgHy62Vhb0@8NBV3N2118FY!320AGW!H@cJJ3eF22!29!8B29!4A42o8#F	0_!uF03OF1k07g!o80c02d!Fk0440G01v!GX06J0PV3F& !7n9JV120Wm0yF4F2UKYWFVg42951310scA720VF41B7aO0FV8kV@D41k82F@86WlcwR931k8k41B9aO0Fs8ZcCBY1VJ6FE8m0WVF	#X0k!1F#2$218#V6#5d1$ZF#3V!4Vc$k#42o#X5#GVF#fs!204!218V	012//$G+1%1///#61#4$1*1//,101/03//1#1#3)2%1/+1,2%1.3!11/+1/4/*1.1#3/)12/1,1//&2$1$102,3,1-1+13%2/!402/*24/.1.105$2/+21*1!1$1!22$6!2//&2&1//1,10m#10301%1#3/&D,2/(2!21/!1%1//&1$302)5/%1/,1/!1-3%1/%9(1$	fmoq@@OEZCIEMDhcBdhdlhdnBUkIYkhBBjjjj@@haH`@	J. Med. Chem. (2001) 44 (25): 4431-4442	Ki: 5-HT1A: 0.48 nM / D2: 117nM / alpha1: 55nM		no	agonist	5-HT1A / D2 / Adrenergic alpha 1	5-HT / Dopamine / Adrenergic (I Amine)	no	5-HT1A_All1(50)
S~.>.hxh.i.>S~x>S~xhxhS(x>x>S(x>zdW(\}p3}J~Sh.h.~Sh.>.	;UvUzvU:nzyzUmv_uvzdLTJbIUrdDhxDXYCX37AOv1mS2VPKl4wm@d4tIsTIHFV6C40@L6rDSCGZ6XR2010	0YV0s!2J03d!C_06k0R!3OF1k07g!o80eF2l!C307!uF05AV0s04F0Tk3V& #2@0o@4VkFsgTmA231EocFVA82410_HtNNC1W098sZj@1WXVrNoi5462O0FVCNR4723B3cgFX517Xt0GF8VXG94W8N4499ZXau448E4m0WVHHNsA12_FF9B22G7m0VVFFosU321082H@9GjFVNNE826184oONB@B0VXWgV8k4	!10VV!3&2!24%2#4cF#25F!G3V!4Vk*Ho!805#GV#86s!244!258V	/(1-1B/!2+1*1/+202!5#1+31/+1#1/.1//#101)2#1$1#1/!2#3(1#5*2!102/!1/!3%1/2//(2/!1,13#1$2(1!1(2%1$1/!2$4&1,1%131)1(2*1(1/!402+1.1!1!11.1(21*22!5*1/%1(2/%8$1202.2&1%1/1(1/2/m+2!1/%101!B02//#2+2&1//*2%1$204(14/1//,2$202!1+2#1/(4$1(	ec`TB@@AO@FLeldTRbaTJVTTVRVUCDbcgaUPtuAQAUUUPATPHATQD@@	DailyDrugNews.com 17.Jan.2002	Ki: 1.3 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
s6}\O(h.zB.hS(\).>.>|F36S(\)\).>36.i.>S~.i.hS~.>.h.i.>	[r<yvzjjUqUzvCzjjzhpoTjxhpAanbs6fncm6Az7rMlgPAB6qnm4B@Go2lF33oI1ml61ZVmVV0F0	0aJ0Q!2OF1k!DA0@40t!4@0110480eF04Ak1307!uF06@01608g0cF2l0DF0 #R4mcNk8294m0W0OVgH4432O0FFBkL9222lBV8J4ij4XG88NJCZ120XM9V46131WZOwR912Y0k88HEZ140fokgBN413XO0G8DF4J2D713lO526A5VXGV	#8VF!14)14G$@#7ZX$qF!FWV!4WF#8F$Po#F4$k$7k!@44#58V	,1$1&1*21B/%1&1//(@$3$1///)2/!2%1.1/-1#1)2)1$2!2)2/#1%1)2%2-4!1,4(2/02//$1%1%1.1#1101-2(1,1$2$3!3#3/#2%2-4/#2$1*1#1///+111(1!1!4)101-2#2-2(1)3/+2#3/#1+201$1/%3!n%5/#1/H+1)1.2/(1&102(1%201/$1!2)5/!22//(2*12+3!1&101.3-	ec`\L@@DJK@LfdfVmV]WyVuHhTl|bZzVvZjj``bj`@hbAH`@	Tocris catalogue 2000		Roche Bioscience	yes	antagonist	Adrenergic alpha 2 / 5-HT1A	Adrenergic / 5-HT (I Amine)	no	5-HT1A_All1(50)
.ixiS~.=S~x=xi.i.ixi.=x=xix=xix=xiS(x=x=|`S(l0|F	;UvUUvMny1ziYDmd4oTU0HVX_@C1s6Bp2V14HV211G0H10533k0ZG290VG880F08!F!F!X16FZ0FFV0F0	0Pg!aJ0R!2OF1k!C807!uF04Ak1307!uF% $VNRD72lFcH51VI1dV88E@YXNJF62VHlOTF483Z120VVFZHA52WFNH93108BwPT112FkoLB62FsR84172nYJJ@65324ldRZG11H1O0VPWBYlGFJ4FBB7560VV@255	$V#3+4W#2D8!24X$k#F18#VF#8$FNZ#84$V$4k#44#58V	/*1(1#C$1//.1,3#4$1#1$1///$1/!2%1/)1.1/!2/!5,1.12/2$1&2&4%1+1/(1-1$4.1!1.1/!1///5&2//)4/.1#1$2$2//!1/#1)1!2!4$11!103/!2*3%1&1&5/)1//)1/01#2$320h!1102#14#4)1/D%1!1(2//&1&1#101/11/(5(12%1+1*4/$1/#12+1)11/02-	figaP@E@yzhtifYuVUmirVbmzN`jBJj@HjB```@	DailyDrugNews.com 4. Juli 2002		Mitsubishi Pharma	no	agonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S(.hx>.>S(xiS(.=x=x>xiS(x>xhx>xhS(x>x=S(x=xiS(x=x>S(	;QvAzOUxxYQBPU2AFPfNgHy62Vhb0@8NBV3NX118FY!320AGW!H@c4J3eJ22!29!8B29!4942o8$	0aJ0Q!2J03d!C_07!Tk03FV2d0A4013!FF1407g% 02P8uC1VWW8qF482764nNwR30VHG9DF4D228YmcoT8443kF8ob826134Y94XA10VG8sa2G91WVkNg@E73m8g8215Yk88kkD85YWckF74WFV44PGC	#V0k#F)21%6#5d%4F#3V!4VV$F$2o$5#GVF#3s!204!218V	//(G+1%1///#8$4$1*1//.1/03//$1#3)2%1/+1,2%1.3!1/,1/4(2/01/#3/*2*1$1///$201!1&3,3%2%1-1+13%2/!402/*22/#1*101,105$2/+21*2!1$1!22$6/+2-2//(1,10n#10301%1#3/&F,2/(2!21/)1//&1$302)5/%1/,1.2/02%1/%9(1$	fmoQ@@OEAdbfbTQaRTRVTRWAJudlutAAUUUU@@TPdP@	Curr. Med. Chem. (2001) 8 (9): 999-1034	IC50: 0.5 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
ix~S>xixix>xix~S>x(S>x(S>x>.(S(S>.(S>.>xh.(S(S~S>x	zrztzdUOzpxlQN@UHQ0GANe0a620CW9@0stX30X50O0Y!V203G142LP8Bk1V412c029#J0101414FX0V8F0	0_!uF03OF1g07#o80eF2l!DF0@40t!3OF1v0Eo% 0BV8R4JJ533FZL185Z3o9gV70Y1WWNc8961WNwH44VI1s44HP8@53NRJ50VHGOBRq2331VVkZLI530sV840VV882VBF0X1dFRG4X0FB420aXINFwP50XWGRV8N4	#11V#8/02#4VP#25F#dV!4,HZ)1V#12k!246#19V	//%109/!1&1//+41#2#12//$1#1!1+1!3.3/)2/)2*1/&1,2///&2/)1$2%3$1/0201.2/%1$2&1.1)1+1%2$2.3$31$1/$1/#3/!5&1%102301//)101.8$2$1/#302(1*4$2#16/,1(1#1/,1/(10i%4/#1/F//%2!2+1/102.2&1/402)602!2///)1#2(1(3/)1!5-	fegpb@IFbJhIAIe]mVUvYVc@q{N@BZjjhHHH@@	Curr. Med. Chem. (2001) 8 (9): 999-1034	Ki 5-HT1a: 1 nM / D2: 5 nM		no		5-HT1A / D2	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
S(.h.=x=.iS(S(S~.=x>.h.i.>.h.>.hS~.ixiS~.=S~.ixi.iS~.>.h	;QvAzOUxxYQBPU2AFPfNgHy62Vhb0@8NBV3NX118FY!320AGW!H@c4o3eJ32!29!8R29014942o8$	0_!uF02J03d!C_06k0R!3OF1k07g!o80eF2l!Fk0440G01v! 02P18922XlRV8F4NDF_l8R2DA715IdsP2690VGk44LGZ140XW8VaI920V4ZX1113XkW8TG521FF8610I1dZ8NL33WVW90PH410kZB21VV9kov8261m0WkF8wuQ8X088VVGZ130XFlRVG62kO1R2228511VgV@4X0cZ851VFGl8s	#V0k#F)21%6#5dF#24F#3V!4VV$F$Ho$5#GVF#3s!204!218V	//%10I+1%2///#6$4#11*1//01,103.6//$1-2%1/+2,2%1.3//3/)1/01/#3.2/%1$2//01/!2$2&2&3$3%1%1-2+13%3/!402+1-22/.101.5$2/)1041-1(22#17//%1#2//(1,10q#10201%1#3/&D,2/(4!21/)1/+1*1$604)502/#1/,1.2/02%1/%9-	ek`TD@@JK@EldTtRbrvRRbbTVaxTLlZFfvhHJJjj`bHbbBH`@	Curr. Med. Chem. (2001) 8 (9): 999-1034	IC50 HT1: 0.8/2: 330/ D: 18//alpha1:7 / 2: 17 nM		no	antagonist	5-HT1A / 5-HT2 / D2 / Adrenergic alpha 1 / 2	5-HT / Dopamine / Adrenergic (I Amine)	no	5-HT1A_All1(50)
x>S(xh.>x>x>xhxhS~x>xhS(x>x>S(S(x>xhx>xhx>S~xhxhS~xh	:UvzvzvzSznOytUGQLIUueHq0XXZVQN89zM1WF0dI0X0FW281F342Es0TL22804d6206410F%8kV0V8FF	0Pg!WR0Tk03Z02U0DF011R0OF1v0Eo01HN0FF1209w0zF06JF1X06J0SV1v0C! $NdC30FNNJB723W98FK6Z4kN88V1175t0GN8kVKDY0Fkw8325ZO0FcDF4D2312kt0TJ12FVR22C80FGdliH4B2m0VkRV8Z78281LD0VkFcFhEWGGkel8I351WkHgNK733lV	#n4V!18B#H8!1%V$1c@!2V3$YF#48$FF#Hk!104#9$19k#JX#A1V	/02+1)9.1!3!2//1)2*1$1%2$2$1/.1$11/-2(2%21$1/&2/!1/02012!1/(1(2/$2%4-1(2/$2)201/#1/&5&1#2+5!1$1+2#101$1&1,104*201/!2%1%2/$1.3!2%2/,12#1/8%1.4%1,4#1%1*A&1#2/%2//$1/(10j%21/!1/B/$1//$1/)2#2*101/%14$121*1/#1//#12(301)1)1%2-	fmwqC@EIkHDPRPCHILso\kvkJ{NN|N\DAMUUU@AD@@@	DailyDrugNews.com 5. M?rz 2003	Ki: 0.85 nM	Pierre Fabre	no	agonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
J)*Fs6J)J)s6.=B,\).iS~.=.i.i.=.iS~5q(S5q)H^}5q?-5q-?^})Z	<vvztztwYzwvDHdFQiNZLyHGfhYVHdPHX5GX0A8FW6F55V@1W20LLt0ZG94b501024ZdD0@e1404440V8FV	0Pg!ms0B011!G_07!Sk1w!KW06F0Sk1w0CB01L40Sk1u07k0ok05OF1r07g0U03x! $BV8F4F85YGFgL43W0V881D7VFGdsRT7A3W8V4220F8863E5bW1ssLC6WkcZ2120YGk44NR11VlOBPJ4W1F842C6at0FVBgm492c50VsFBJL9_kcF@410Xl9NBNBDa1NJ4194Za2XgBRB15290GdGL4@3864OVFL8FT60l8Q_L442	#20V!1%V$56#Ya#1C*F34#VO#1F$@o#45#GV$Gs!@48!2C9V	&1/*1$D!11-1.1&1(1/102$3$12%1&1.11//06#4#11+1+12!4/#1/&1$1&1-1,121/*1%5#1(31%101)1)1#1.20212(1)2#1)1)1(2+2%2.2-102.1!1%2/$11!1/01/!1.1*1.1/!2+1!4$2/)2!3&1+4#1$9//*1/(102%1-2#110p01,3*3$1*B/01#1/$11,101*1/2/(101)1//*21!1/,1#1!43/,7(2$	ekh\HH@A@el`ICHhdieCDeddeEDhjFAIGOImech@JZjjj@bDh`@@	Bioorg. Med. Chem. Lett. (2005) 15: 911-914	Ki: 1.08 nM	Wyeth	no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S~x>.hxh.>S~S~.hS(xh.>.>S(.=.h.>S(.hx>.>S~.h.hS~	;vvfzOzxxWQB@U2A0lYOcV66H0hW0@BNRV31X108GY#20@G1!JP8Lo3a432012A1!J01014140V03010	0aJ0Tk02jV3W!9F0DZ!qJ0Q01k!C20@Z0gF% 06F4F2nAaVksTF4B2FJY19JJD@CAZlkFZ876VFGO04PI7ZGcFB420mlGNdRI221GFk4FB2C5Wkk4320W8FgNL154GNgP@61VN4gP210F8VRz8271	%V*2*2#4cP#24F#WV!4k%FF#Ho!414#GV$7s!204!258V	//%109/!1///#@$2#1%2//#1!1.3!2#102$3///#2//201&1$2//2/%2/)1!1-1//#2/%1$2+2/!101!1(102#2$2.3$1%1%1-1/#1$1+14-1$1//(3101.6$2/)203+2/014//%1/!1//)h%701#11/(4010H*1/*2!2//.1&1/402)502////02/03/#3(5-	fi{p`@JVbCJTwKN~kKZ|TZwQtDEEUSP@D@`E@	J. Med. Chem. (2001) 44 (3): 418-428	Ki: 17.5 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S(.>x=xiS(x>x=S(x=S(xix=xiS~x=xixix>xhx>S~S(xixhx=S~	;UvUztUzxlQByUHQ0IYRcV666FhW9P8NRVYVX129FY08V20@G142F@86x3X43HV0690V0JB1017141V03010	0YV0s!2J03d!C_06k0R!3OF1g07g!o80eF2l# 31weA2XXV8B6668W61FNNBBKCYlNF461ZYV8B8LLtB3Fc4J@@A4YGkoN83WkF8gP214aO0Fk8owX72GFsiF4B2984nkoRBD61YXONV8310c42L@A	%V/8$@#4ck#25F#GV!4V%FF#Qo$5#GV$Ms!204!218V	//%109,1$2///#4$41!11//,1.3.3/)1/)2#101-2,1,2//$1/02%3/!1.301/1/!2/%1$2//01+2#204$4(101#3#21%3%1-1/#1!3.4#1#3$1/(2/%122!4+81#2/)103/$101%15//%1//(11&2*j%201//!F$2/%1)2!2///&1/402&20502/$3//!2(2/03(1/#7-	fmwpPBHVRABfpeGIMrnvlklroAQRM[P@UUUTDDDPeP@	J. Med. Chem. (2001) 44 (3): 418-428	Ki: 10 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S~.ixi.=S~x=.i.ixiS~.=S~x=.i.ixixi.=x>xhx=S~S(xixix>S~	;vzfzOzxxWQB@zHA0lYOc26620hW1@BNTV31X118GY#20@G1!JP86w3a43280298!J01014140V%	0aJ0U!2J03d!@C0ER!qJ0Q01k!C_07g0U!3FV2d0A40 01O8yH7W0FsZT2N5WWVkFgaJ84FVF24@70FGWNNo8H_lFsiF4B2562WOgq60Z326OsR40XWGFFNRB6YWcJD620F9ck42@Dm0WVFFgLK7Xl0JL415XXkFBeP@40VRVPGZ120VlNcXG72VV8811Vk9kstck2510ksZJ@5Xl8NH410FN42VC0VXZF	%V/%2#4cH#24F#WV!4V%F$Ho#54#GV$7s!206!21BV	)2/+109/!1//$1-8$2#11$1//&1.3.3-1//$2/#2-1,2/!1(2/!1&2/%1!1$2%2$1/#6.2-1!1#1$1&1/)1!1(1%2$2(4%3$1%1#103-1-3!201$1,5-1$1//)101.4$2/)102/-14%4/.1/.3/,o%201//!L*3/%1#2!2//.202$1+4#402)503)1#4///!2!1)1#2/,5%1&	fcP`@IYAwHhhddihddlUEDdIWdqsO[PPPTEEAA@P@@	J. Med. Chem. (2001) 44 (3): 418-428	Ki: 250 nM		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
>.i.(S>.>.(S`*F*0:x>xhS~x>xixhx=xix=xiS~xi.iS~|FS~|`.hlv	<vfzOzxx3UB3UHAFOfOgHm2HXh3V@8uTV51X130GY60120@1c24JTt6oIA4Y1F1224gcD01e14044a4V8FV	16J0R01r07k012o0FF120@Z01L40O01r07k0ok05NF1r07c0U03I!K_07R0Tk1w0Eo# #382510VVsR872XlFJJ52W0FB4220F@cdJ4951FkoJ82WGk8422VJ1P1FZQ7408FRDEH6120FF8@84A0WuNN4142X0kcLD6WVcV831W0VB42F5c20lJZ46X0kF441630848HSZ120_22gR12Y2GV	#20V!1%V$56#YX#1B*F14#VO#1F$@o#45#GV$Gs!@48!2C9V	&1/*1$C!11//#102!1$1/102$3$1.1!1//.3#4#11+1+12!4//+1,1-1,121//05#1(3&12$101/03$1)2221101%1//!1/(11$2/$1$1/01021%2%2-1#1//$1(1%1*1(3%1/102+1!4$4+1,2!4&1+4#1$9-1-1,1/%10102/)110p1102*3*2$1!2&B$1%1$1#1!1//1/-2-1)101)4//*211/.1#1!23/$2&5-	ekh\HH@A@el`ICHhdieBhdldeEDhjFAIO@imech@JZjjj@bDh`@@	DailyDrugNews 10. Juli 2002 / WO 0240465	Ki: 47 nM	Wyeth	no		5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
.hS~.>.i.h.=.iS~.=.i.=.iS~.=.i.i.>.i.>S~S(.i.h.=.>S~.i	:UvzfzOzSxYQB@zH30Of8c2b620_V9888R020X501FX#209F1026N8JR3X4328021808409#104V!80F	0co0xk03FV2d0A4!qJ0Tk3x!G_06k0Sk1w!KX06J0Sk1w0C$ #1Z120Vl0gNB7XGVRD4A90FGdV8BG31WswD441VF46RDDeYkW0L84F21312HkZsE41llV44JF8@Z2NgF62VHGk464AA3WmdgN@20FVFcN2145t0Fs8cgP9XVV8BF68	#@0V!1%V%2#V2F!5c2!1V4F#WV!4V8#1F$2k#45#G%Is!246!219V	11&1*1/!9/&1/.1.41#2$2//$1#1-11//,2%1)1$2!2*1(2/+2/*12.1/01$1/!2%2$1%1*206//%1#21&1//%1%2$1(4+3%2%1/,2(1,104&11&230101/&1)1$10101,7$2$1-1$2*1%1#4$2$5///*1/&12,10p1$201/2(1#1#J*1/-201/*1/02/#2#1+5!2%31$1//%1&1#2(1(3/03*5-	fcqB@CQjHD`drnvkJ{Lk]FAcu\}p@SUUU@@@D@@@	DailyDrugNews.com 7. Mai 2002 / WO 0220491		Merck	no	agonist	5-HT1A / D2	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
>x>.ix(S~S>x>xixh.(S~S~Sh.~Six~SixBz~Wsp\}s6|`|`s6	;OvOUtMpxlQBuU3Q0IAscVi66FC_0@8PRV70X1080f610mV3G1!HD84k3W6W2016AV0VJ@10141J0k01!V	0aJ0Sk02J03d!C_06k0R!3FV2d0A4017R0ik2w0CF% $2GRaI22XVsN86683XnNwH33VFF86@B5VVG9iF4F244X2NRZ73Wl882NB1VFVtnVoH33Wt0FkDF4822A_1G04@642VF8266A0W2W8N44VkVF223VkNC0JV12XlFcF@51l8F85C70V84BJ10W1oV	!12$2%88%V!V@#5Vk#H4F#1V!4YB!2n%FZ$Z$V$2k!214#G8V	(1/,10@+1%1#1//.801103#11$1/01/$1,103)2$3///#2//101,2///&2/2(30101*101/#1#1*2/%1$1//01/!2!101.3$1%3%1-1#1.1#1-4-104&1//$103.4$2/)102/#1$1#1401//#31*1//&2%10i!1!401+1*1*F//%2!2///$101.4402$1#602$1*1/(1/%12/05/,6%1&	fewi@@JVbdhDinV]}Uem^JMXmQshHJJjjd@B`@@	J. Med. Chem. (2001) 44 (3): 418-428			no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
:0|F(Sl0S(xiF*x>x=xhxiS~xiS~x>xhxix>xhx>xhS(x>x>S(	:UvzAvUURxeQDAUS9FkdOcHkB2a_098BTiV50V939G30k1V6AJV0Z3416R23BYF0c38kV2402401GF0W%	0aJ0Tk03OF1g07g012o0FF120@Z01180Ik2V0DF01W80Ik1g07g0c03Z# 0O0F89oq62YGsB2FA8L3VVJTD10H1W6F4@3Z130VqkJXF2Y21W1Rg51XG8R6315ZFN8w42CC761kJ494X0N46210FGssyiC24122WVHL21VG0w82C0VXmV	#D0V!14$BW#4$46#78$24#6W8$H#DJ$2s#15#G3F!B3c!@04!211k	//(B-2/-1/01!1#6$5$1(1/!1/-12,1///.1,1/)14///-1*2/)3(2/&2%1.101%1&1/&2/$33#1.30102#1!1%3/#1$1/-1)1//+1$101$1)7$4*1/#2$1!2,2$601,1,1&2#1,2/#1!2/#k01021504!1/(1%F/-101.6)1/!1*2!1*1)1+3/01-2.2/+1(2*2/05$1(	fewQB@BVp@HRf[W]YWVUIRRhiGNfB@jjj`@b@@@	Bioorg. Med. Chem. Lett. (2002) 12: 1149-1152	Ki: 4 nM		no		5-HT1A / H1	5-HT / Histamine (I Amine)	no	5-HT1A_All1(50)
|F\)sp|F|Fspd,x>~W>.(S>.(S55(S5q(S>.>x`*(S(S0:F*>x	zxzrnYzOttJ3M42DH90OXN0mV2F0h3V28HHV50X430F1601V0A1V!JLtFZG94Y!1020ZcL88e14244F0V8FV	0Pg!qJ0R01r!GU07R0jF3I!KW07R0TV1w0CB01LJ0Sk1v07k0zF% 06F4@212Y18cB54WVcNJ510FF84Z@H0WG8VNC71l0VF1B70FFFg628E0W18sFA4Y0VcD320V9sgw4696GFZ8@2VkFB4P@Cm0W0FVO2M52kNZVFF4DeXkVZ62658_IX8FL8G16BJFFZB	#60k!1%V$76#YX#1B2$1#F14#VN#1F$@o#45#GV#8Ss!848!2C9V	&1(1/01!10A!1//&2!1/%102/*1&1//*1#3#11/(12014*1)1/+1&1/+121/-3!4#1(3!1#1/%1%1#1(1021501%1%1!1/(1+1(1//$101)1$1!1%22/#1.1,101#1$1(1%102/03%2/!32)11!4/,102103&1%1$4#1$8/+1.11/%102/*10i101+3*3$1*C+1$1#1//#101/+2/*1$1#2-1/!1)1//1#1!24/!101/%	fewIB@AVJLHICHhdieBdddhhdiQ`iMgt\@EMUUA@pQ@@@	J. Med. Chem. (2004) 47 (15): 3823-3842	Ki: 0.69 nM	Wyeth	no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
xh.hS~x>S~.>.hxhS(xh.hx>x>.>S~.h.hS~.hF|0:(Six0l>x>xhx	<v:v;QzinUXfB:UAIumr@h3kDBISV5Cn_04Gz6H1@_ffk04LTs2ZQU5n1G132G0BJ0AX1L0Z0G0V0FV	0aJ0R!2J03d!C_07R0U!4Ak1307!uF05FF1205c0Lk2d!KW07R0TV1w0CB0 1Z13VWHmFHG532WYnJX683m0W0H@GT6834Y28JZB2XGN4cH113_W1Ggs25WFO0k@2910kVdNJqM1a1GFR@5334O0G08B8E4ZWsBL420V8B410VF@FK8RP82Gkg@585Z3q9cF8@10X1RV8F44962GkcLE0WG8B4P@Cm0WVF	#2VV!3$4V2#43#Xe#2BX#2k#N1$VN#9F$Po#44#GVV!8Ks#6N!2_8V	#1/%1,A!11-1$2.2/-7$201/,1/!2#1/1#3$4%1/02//1!1/)3.1-1$31$2&2402)2#2*2$2#10101/22-31,1*1,21(101$1//01!1&1$301$3+1$101%101+2&1/01.1/01%1,1#4/111+1!5)1///&6//$1$1/(1$1/)o%3(1*1!101*D01.1#1.2$1//*104211.1$204!1%4/+1//+12&1!12#1%1/02-	ec`TL@@MA`NILdTTTTvVaRrbbRuGBadRSPrvuATQEUMHPDTPHD@@	DailyDrugNews 25. Nov. 2002 / WO 0285896	IC50: 57.3 nM	Wyeth	no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
}JO~hxzd.i~W.=.iS~.=.i.i.=.i.=S~.iS(.iS~.=.=S(	vzUvvfzOrSxlQR@U2A0k39cX66H0hV08BPR039X1!Ge010202N18!R8LJ3bJI20121108J01#104V0W0FV	0aJ0U!3OF1g07k!o80eF2l!KG06F0SF2w0C8$ 048oHJAVWW0lkR22Z1FkF11_32gV8V48M64lFNH554YkF8odZj1WX0wV8F4	#a/!2#V2#4V%4F#3V!4cN!2F&V#46#F$82s!204#1cV	/)3-8(1$2(1&1/.3&6$2#1/$1//&3*3/(2/&1(2/1/.2/%2/%1///#401%1,6//%1$2)1/*1%1!1$2-4+1%1%1*1/03(101*104/#1/)1.10101,111!2/+1/.1/-5/*1/(1#1+i(1#1+1%1*D*2#1/)201//,301/04#1$4%5!2%3%2///!2&11(4/03*5-	fa{H@@@PE[IDhmeDeeEDhc`akYJwluUUU@@@L@@@	DailyDrugNews.com 17. Juni 2003/WO 03042208	not given in publication	Merck KGaA	no	5-HT: agonist/Dopamine: antagonist	5-HT1A	5-HT/ Dopamine (I Amine)	no	5-HT1A_All1(50)
.=.iS(.=.=S(.=S(.i.=.=.i.i.=.i.=.iS(.=.=S(.i.=.=.i	;UvUvvSuiHpabDHtVSqU2FXV1@h3W28GGVW4Hk0kGl0H101A3!6F@cFZG!2!4!240F!X140V0J0V8FF	0Pg!qJ0R01v!C_07g0zF04NV1_07g0o!6Ak1104F0R01v0DZ# $2ZoONP12YX1l8NcH6W1VZ84@65O0G8DF48222ZHORL31VkcRgFL13XWNVH@3X1kF@210F854HXZLZVkcTF4D2lOW3FX2RaH440kcFFN	#Y1k!5N%1#J2#V3#3B@$G#J1N!80T$G$Pw$4#GVF!1Cs!24#25AV	//$2!8/#1/02$1/*5#11)1/)1/)2/#21/(2%1//102.1!1$1&1//02$2.4&2//0101*1#10201%1/!1(2(1)1.1,1/!1&2,2/+1+1/&1$3$1)3*1,1!1/1/A!4%1)1*3$12#1/2$A#1+2(1&1(1/%1!1/*320k%51&1*1/K)1//1$1)2$1(1/01/(1(12/3///&1#1(21%1011/02-	fewQB@ENbBPRYWYUuYVuhsQbuGN@B@Bjj`@BHAH@@	DailyDrugNews.com 15. M?rz 2004	not given in publication	Merck	no	agonist 5-HT / antagonist D2	5-HT1A / D2	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
(Sq5>.>x~Sh.(S(Sqq>.>.>x~S(Shx~ShxBz~Wsp*`\}J}J}*`	zxzrnYzOttJ3M42D290OXN02V2F0h3V28HFV50X4!F16$A1#JLsF4G94Y!102!8J08X04040F0V0Fk	0Pg!qJ0Sk1w!G_07!Sk1w!KX06J0Sk1w0C!1L40Sk1u07k0ok% !351VW4L95WVVg4210IlOs8FGAY1cB@5210F4oJQZ120t0FV8B6C4YG0FDA40l0FoT2113088d0242YX0ZPB41VN84217XnmYBe6940WW21O4Q45X479gBH643a3NsB754220	#20V!1%V$42#VX$B2$1#F1$VN#1F$@o#44#GV#8Ss#48!258V	01/!1,1$@!11/+1)1!1/01%8/01(1//(1)1#1/$1(2!2#1&1/,1/1-1.11%101/#3!2*1$1#2(1,1%1,1#@01%1#1$1////#3.101%3/!2/$1-21.1#1$1/0201%1)1$4/!101(11014/)1%1/1.4(1/!1/11//#1-10m401!402,1#2$101(K*11$1#1//01#1/+2/#2%1$1#2/1/1/*1/#1!13/031/(	fewq@@FRZCIEDhdeLcdhhdlHvgEZN]A@PDURD@D@@@	J. Med. Chem. (2004) 47 (15): 3823-3842	Ki: 0.54 nM	Wyeth	no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
xi.ix=S~.=xi.ixi.iS~x=.hS~.=.i.i.=.i.=S~.iJ).i36S~(O	vrUOv9UOUKxWQ8@U2A0G3NcH6620CY080eNV70X9080X6012!FW!1B8Jk1W4W2012A!c401810106X0VVFk	0G8!RZ!o80eF2l!G_06k0Sk1w!KG06J0SV1v0C!1L40O01r07k0ok0 #FRF7_1NNF40_42gV8F4HMC5FVJ6224YkF8oeVJ2415Hu4T355WFG8p8Z472AYnVNH920F84cX20W3YBV8R5D651H8BB63ZZHJlJH94YGWVlNRj3VFFNRREZ130elGVg8E4SY3cNVE8261	!2@H#S0B#k8#22V!k2V!4d9$_F$Z!48N#1%Fo#E1#1AF#Pk!@dZ#1Ok	!1//$8#1*1!1-1(1(1%1+2$2$1%1/$1/1/$2!332!11-101(2!4!2.1!2//(3!2#2#201.1/&1#3/$1/*1$1)1#1(2*1%1*1$22/(2/!3&2/&1!3%2(1/1$1)1/!401&1&1/$1/%102.5$2/+1/.9-1//#4!11+102+1-10k21,3$1$1&1(A1(1/+2!2/1*1#1/01/$1+502(2/.31*3+2/15/,5-	fmohB@LRMDX@cIEDeDhmJeeEDhaJCGlqkhHbKjj@bDb@@	DailyDrugNews.com 13. Feb. 2003 / WO 03002552	Ki < 50 nM	Lundbeck	no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
.iS(.=S~x=.iS(.ixi.=S~.=x=S~S(xixiS~xizBW~ps`*}\}J}J`*	<vfzOrxxQU43U2A8tAO@3mHH2h1V@BHSV5925!Fj6!X0Yd#LTNH4QE1m1G13210BJ09X0J240G0V0Fk	16J0R01r07k01J40FV1P05g0eF05NV1_07B0U03F!KX06J0Sk1w0C!1L40Rk1u07k0ok% !G18GNW8624WYWN8@544_t0FV88495XWFVF831VFB8410FPFWA82715c0X0kqB322lWuOR683DXGFJi@D7WVFNcY82412210gL672kNgF20VV9sVwLLH_kkccJ	#60F!328!4V2#76#WX$C2#2$N1#8VN#1F$@o#45#GXV!8Ks!86N!2_8V	0211/+2&8/(2.1/&1%7$1/1#1)1/!2*2)1#3/#1/02/+1/)1-1&1&11%10202&24+2*1#2$2(1-2021$1-5(1#1#1/1&1/*1.1301&1$2$1!3*1&1%1-1-2/*1*1%1%1!1-4/1#1!1%1!41/1&1(1+1/04(1//$1#1/.1-10p$1202/01$10101%H01(1#1!1!1/,11!1(1/$104201/2%1)4&1(1*1*1&1//01!14#1,3*2-	ec`RH@@IEAi`LdTRbRbtQVrbbRpfagdRSPrvuA@PEEMHP@T@@@	Bioorg. Med. Chem. Lett Article in press BMCL 5503	Ki: 71.6		no	antagonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S~.=.ixi.i.=S~x=S~xixiS(x=x=S(x=xix=\)xi~O:0s6d,d,:0:0:0	<vfzOzxxWUB@UHA0lYOcH66H0hY1@BPTV71X138GY60120@Gl!JTt6o3jJY2012A1Z8L01@14146V0VVFV	0RZ!qJ0Q01k!C20@Z0gF03Fk1k0DZ016J0Sk1v07k01L40Sk1u07k0ok0 06F4822JZ1sR29443k88kZJLAY18V@21ZZ0F826B0VXIMVR4U44X3Z1cN8B12VNNVTq9241C0sBu5233lWdJuF10VVt4D2270kGWLF483Z140t0GFDF4B233WlswR81WFVB2110F88210V_G044Bg@6Y314DBD10VFc2@8A3Zm0ZNB33_089842F10YVcF26@1VX3V	!12XV!308#V2#42#c2#4cF#24F!11V!4VN#1%NZ#45#GV#8Ps!2ZB!258V	/.1&2B!1//&2!1/(2$2#1$1%21$1/%10101!1)1&1!21$1/(1!1!1#1.21$1/&2#2(1#2*2#22/011-2#1//+1,201#201%3/&13#1#102)3)2#1&1!1.2$2&1,1%23$1-1/#1$1,402+1$1)1&2%1/102+2!5$2/+1/.82///$101*1/%1(o1&1%1*1$1*B02)1$1#1.2!2.32,1/2!1(2%1$102)502///*1%2$1&1!14/!1)5-	ekhRD@@AONc`FLdTRbaTJVRTTRVVhXdT\|jzfVhJHJjjdHBxh@@@	DailyDrugNews.com 9. August 2004 / WO 04054972	not given i n publication	Merck	no	agonist	5-HT1A / 5-HT2A	5-HT	no	5-HT1A_All1(50)
S(.>x>S(S(x>S(.=x=xix=S~xixhS~|F|`lv`*}J63`*`*63`*	:UvzfvOzRCmOJAMHOFOWNeHqFHXhY988PqV70V43Nk16FWZ0A1W526Jl6J03BYIc9020Z0L0A8#4Jk0V8FV	0t!d03Z!C_07g0zF04OF1g07R0U!5B0110480Ik2d!KW07R0TV1w0CB% !m0X0RV8F64P41XFwV944Jd@1WkR2DE7m0YFP1F8H496cXNkB50Z2HBV8N78271	#30V!58$VV$2#ZX#583$5$W4$N#1F$2k#45#G$9Ms#4D!211V	//(8!1/01,1//&204$1/+1!1//!3#1%102*1)12/$101///!1.2//!2*1/%1(2/$102*1(1$1)1)2&1$2-2!2$1(1%2!10104/!2%2%2*1/&201/(11&2302&1/1/!2.8%1(12-2*1*4$23#@+1+1//.1#1#1(1(j%2/#201!1*D/11#2/%1,3+102.4/#1/2$2+1///#2%1#1!33/)1!4-	fewqB@IQFHDadTRVTrbRfTLRVhqwhizN@BZ@BfjjB`@@	J. Med. Chem. (2001) 44 (24):4031-4034	Ki 1F: 1.6 nM / 1A: 11.2 nM / 1B: 136 nM / 1D: 138	Lilly	no	agonist	5-HT1A / 5-HT1B / 5-HT1D / 5-HT1F	5-HT (I Amine)	no	5-HT1A_All1(50)
S(.>x>S(S(x>S(.>x>xhx>S~xhxhS~|F|`lv`*~S}J`*55}J	:Uv7ftGdN5F0J27HN0WVO2H20F0d3904HqV58X03Fk160WV0@9VC24Rl2V13RYFc9021Z0L0185!4J!V8FV	0o80Ik2d!DF0@F0t!3OF1v0Eo016J0Q01r07k01_40SF1r07c0U03I# #BV8J6mA28WO0GcCZL4@2m0WVRV8R5eGE1Wkldwm5C2XGF8BPGDX1VJNHF920XOBo751kd8cZ	#30V!58$Vc$2#g2F!48A$5$Y4$N#1%HV!845#G$9Hs#4D!211V	+2/+5101/01//.1&3$11*5.1//%1/(1*2/$1///$1.1%2/+1*1+1/!21-1$202*1//!5&2$2/&1(1%3!101$1.2#102%2/&1$1$2,1,11&2301&1//#2.8%1%1011!2*2*1*4$2$8+1+1//.1(1(1(h%2/#201#1)D.11#1/3/#1!2(102.6!1/1!1#2(1$2+2%1%1//01*1(3/)2!4-	fi{qB@IQZHD`drnvrmmnuFN}EL@Dt@EMUPP@@	J. Med. Chem. (2001) 44 (24):4031-4034	Ki 1F: 8.2 nM / 1A: 262 nM	Lilly	no	agonist	5-HT1A / 5-HT1F	5-HT (I Amine)	no	5-HT1A_All1(50)
`*:0|Fl0(SS(xhF*>.x>x>(Sxh=.(S>x>.(S(S>.(S>.>xh.(S(S>.>x	zrztzdQOUoCkOFAU3O0G3Ne0a4229Y0@0PtX38X!PVf6FVX02G11VJT8BkWVLG3d029V0VJ1101J140V8$	0aJ0Tk02J03d!C_06k0R!3FV2d0A4!t!bk3Z!Gv09!bk3Z! m0V0G8VDXGW0FscRHD9fkcJNJB32X2NseF31084gR11561FVgaMBXFG1022D0VXXdGFB66311VVsZE51W8F8416YIFVNFJ72l0VB61Vk9ckq2N4VW0kaF4B3Z120t0Fc8ZF4DXXcs8FC84VVVoJ@4WWkw84B8VFGtc88362WVkFA1VVNJ@RF1VF8Nl4	#10V#8%H!1&H#4VP#25F!8Yk!4(V!VHZ)1V#12k!226#18V	/#1/0108/!1///#8$3#12#1,1/*1+1!3)4#13/)2+1,2!1/.1,2/)2/,2/(1102.1//#2/%1$1&24/(1/!3$3.3$1%1/01!1/#5%4+4$202%1//#4(20101.6!102/01&102/)2#16,2/(1///,o!1!6//1#F02//0102!2%4)2/4,4&1!1,302)802///)1&2/0302/*4,2	ek`\L@@DOB`AAdfYeW_YWYeRFMKLbecfjA`Rjj``bH@`t`	Bioorg. Med. Chem. Lett. (2004) 14: 5863-5866	Ki: 5-HT1A: 5 nM / 5-HT7: 36 nM	Polish Academy of Sciences, Poland	no	not given in publication	5-HT1A / 5-HT7	5-HT (I Amine)	no	5-HT1A_All1(50)
s6O(}\zB.>i.ix\).h~S~S.>hx.h.>.hS(.>.>S(.>S(.hx>.=.>S(.i	;tzdzOzpxlQRAU3Q0GAse06622hY0@8PxX39X18Pcf6FVX02G11VJy8BoYX612d029V0VJ0101J1B0V8$	0aJ0Tk02J03d!C_06k0R!3FV2d0A4!t!bk3Z!Gv09!bk3Z! !BV8046E44n94L28541GcS8B820G0ZV4B2WltJNA3W0F8kRN25WW1VaB21Vc8gRM2E10kkN4DC93GFZH5210F8210c2Z08ZXG6XG8Z8410VOckpqM5WV8cJM8261m0W0RV8J4DF3Z1cwFG14YHGFR4A3XWFJNA21VOd442ED121coH94WksR4320VF82XCG	#10V#8%H!1&2#4VP#27F#Yk!4Z%F#VHo$4#9V#13k!206#18V	/#1/010B/!1/*1/(8$3#13//1+1.3.3/)2/)2//!1,2/-2/(2/!2!1!102.1/#2.2/%1!101&24/(1/!3$3.3$1%1%2-1/#5%4+4$2(1//#4(20102.6$2/)102.3-16,2/(1//,1,10o!1!601/-1#F//%2!2%4!1%2/4,4&1(1&402)602////02/03,2.6-	ek`\L@@DOB`AAdfYeW_YWYeRFMKLbecfjA`bjj``bH@@@	J. Med. Chem. (2001) 44 (13): 2118-2132	Ki alpha1: 0.8 nM		no	antagonist	5-HT1A / Adrenergic alpha 1	5-HT / Adrenergic (I Amine)	no	5-HT1A_All1(50)
.c(;Iz6p*Shv*S?v?v|S?v*Shvg0|Sg0|Sgvg0|S|Sg0|Sgvg0|S|Sg0	:UvzfzUzS:QTAzEEStftTQMTubhnF9TrxV5OX3O8Ofgo3b6@9V0Z4Rs3437Kn11oAAp0PB03J0F8JZ18V0F0	0aJ0Tk03OF1g07g!sg0d03Z!Jh03!FF1407g01J40FV1P05g0eF06B01g07g0Xk2Z0DF$ #8BPK9Xm8R820_XHwV8F4668amFwL385ZO0FF84B@8ZGFoL520VF4oDQZ130t0Fc84@74ZmG8N6253HgV8F782710VlcoLE7Y10J81B86O0G088@D9_WkVB610Hm1N4B95Y1NgR82WFV82RDD111O8NC4XW8F630aZIF	#c0V!2F#416!13$56#592#2B#8Y$4$8F$2o!805!2G8V!87c!22J!2W0V	//(F///&1*1#8$5$1&1//%1-1!1%2$2*2/&1%1(1%1,2$3*1//%1/,2*2&2/&21/!13%1.1(4!1#1+1&1/,12#101$1/+1%2(2(1-202/$21&2(1$2&2!21/%4101.7/1/#2(2!1.702#1/)1///!1)2!10r$15$1!1*2+6#G01)2!1*1$1/#1//#4!1,1/#4/#1/%1/&2$2,2/#2(6(1$	ekhTH@@DH`LbbTRTRfjRbRrbRHhdltLjZvNZjB`jjjX@BH`XH@@	J. Med. Chem. (2001) 44 (9): 1337-1340	1A Ki: 170 nM 7 Ki: 3.31 nM / D2A Ki: 105 nM		no	antagonist	5-HT7 / 5-HT1A / D2A	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
~Shxh.~S~S>.ixi.h.(S=.>.=.(S(S=.6s>.(S,A)\,d0:0:,d	~:jjx<Czu<JSzvSeptzIRiOzyZTUayf9eSDxybo7rpzB3KA6G8KR29FGk0EVX4X0GV	0Xw0s!3OF1r07k012o0Ak110D!15!Y03a0DV01Ho0CF110480eF05SF1r07c0U03I!Np0480G01p07c0eF% $6F483Z120t0FsA9Z4A2FkkWcI9Z472m0XVRV8k78251OBVVcLF4D3Z120t0GN@664G2m0Z0RV8o782E1m0X0RV8N78231m0ZkF	#Q0V!18$VR!112#c4F!19c$GV#Y%8#9F$Lk!847#G9#9KN!@48!2A0V	1$1/01.C!11!1*2///1104$@$1#1*1$1*1/(1(1,1/$1#1/!11&1//.1/01/+1/$2(1202!2&1#1/%1$2%1!1/(21%1/&11&1)201$3%10201-101%1/&1!1,2&1/(11/201$2&11(22.3*1$1(3&2/-44.1%1/!1,1//+j%3!2/1/8$2.1/%11/%1/$5102/#2!2!3%2!1)4/02#1-1-2#2(1%2/,5-	feoQ`@GQ@cbSK\vnkJzlmV\gIZcfuUUUUST@U@SAEBIDVh@@	Tocris catalogue 2000	2a Ki: 3.5 nM / 2b Ki: 4.6 nM / 2c Ki: 0.6 nM		yes	antagonist	Adrenergic alpha 2 C	Adrenergic (I Amine)	no	5-HT1A_All1(50)
(Od,J)36.>S(.hS(.>.>.h.>.h.>.hF|0:(Six0l>x>xhxix	zxzrnbzStvJSM46Dy9cpXN2vVnF0w3ZVBHIVKAXR3Vm9611V0e10e04JlH4O55n0V1021Z0L!c1F04#W8FV	0Pg!qJ0R01r!BK07R0nF05NF1r07c0U03I!K_07R0Tk1w0Eo# #382410WW9NR74X0sB4310VF42X9G23GkZZ@331842LB1VXY1NgeG1WkcRF220VGcgo6N21Xd88C8710FFgf824180YKdc8JC142D0G@k4D4617LsFJJ41435ImBH8920WWF	#20V!1V#4V$56#f2#8g%1V!F14#VN!314#48Z#55#GV#8Ns#48!2C9V	&1(1/01$9011//&1!1$1/1/,1&1!1/$1/01#9/-1201%1$1$1/#1#1-1(101/012/#2*2022,3*1/!1%1,1041401%1)1/01%1///*102/!1%1//1$1-1#2-1010101024)1%3%2/!1)111!202#1.1(21)1/%5/&1////)20f1&1#202*2$1*6+104!1#1/.2#1%3/%15!2/&1!2%2//01/-202)1#1!141/01+2!1(	figIA@HHLW`@`\adbRRbQRRTTRVVBBddk^tmRuURDAU@@@	DailyDrugNews.com 29. Juli 2004 / WO 04052886	not given in publication	Merck	no	antagonist	5-HT1A	5-HT	no	5-HT1A_All1(50)
spd,x>S~~WxixhS~x>xiS(x>x=S(x=xix=xiS(x=S~x>S(xixiS~	;QvAvOUwtXQB@M39FlVOcHL40VgY08BDRV782118GX601#4W040BVLJ330X2012AF0c!141#2V$k	0aJ0U!3OF1v07k013!FF120@Z01LB0O01t07k0xF06NV1_07N0TF1w0C& 6F483B1460FkHOw492120XXFX59X0VkoV838WmskLE880FsFkd6DD4FkcVJ4H7YGcoL41WF9Nkg8E4XWFoPD1VFFBkP1156Vldoq932FO0VY8241	#20V!10c#V8#V2#VW#188$X#F1#B08#9k$Hk#46!2G1#8KN!8F#210V	01/&1#1)@//,1#1/!107$3///!1*1%1$103#1/#1)4!1!1///!1(1#2%1*2%2/)2/$1(1&2)1!2/6,2///(1$2*403&1$1(4+1,301/*3$1-1%1/01/,1%1$1#2,4$2/+1/.6(1%1/$1)1!4#1+10201#1$2/q#2*1%2/$H*2/&2%2//(1/*4#101)302,12/*1//1&12+1$41)5-	fmQ@@ANAdbbRtLRVRTTRbNJ\EYs^sWPHEUUP@@DP@@@	DailyDrugNews.com 27. M?rz 2001 / EP 1078928	Ki< 30 nM	ADIR	no	agonist partial	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
6s`|)J|`:vF*6sS~x>lv)J)Jxhxi6sx>x>)JxhxiS()Jx>.=x=S(S(x>S(	:UtzdOOxJ5k1JAUIN0lXOe264!1Y98BTzX70X01Qk10FVX02J15X4wcRsYW4W2d!9VV06114!3FJW!V0F	0RZ!aJ0Tk03Z02V0DF016J0Q01v07k01480Ik2d0A401J80G01g07g0c!5NV1_06c0U03F# 0O0G88mFF33WXaOk68552t0FVDF483L320l0NE24@2m0W0FNW0X61FcsRR7W2312A8G062@3m0XFFs99HP6WFcck4287kVY0888F7Z130sVHs84N45jW3kVtODH31WXN84BEW19VFFFoE82C1m0WVF	#Y2V!588!6W#12@#Z2#BVA$_F#WZ!44N#1V#4@V#a4#G$9us!206!21BV	01+2*1-7//2-1/&1$4!121$1//%2+1,2/)2$1!12!1)1+1!1&1//242//.1+1.1(2/*3%1(2/*1&12%1+101!1$1-1%4$101!1!41*1,3//!2!2*1#4/#21$1!2-11(11!1#101,@+1//)2%3#82!1&2&1(1$1(1%2!1!22&1$1)2/r+1/)1$F!1&11,2#2&2$1%1%32!1-1+3-11#1(1&5,2!21///#2.5/,4-	egdZH@@DBjfc`LbbbbbRRvRRbVaRpbagc`QWVqsU@D@@PVUUPD@@@	Bioorg. Med. Chem. Lett. (2005) 15: 4370-4374	Ki: 1A: 1 nM / 1B: 0.5 nM / 1D: 0.8 nM	GlaxoSmithKline	no	antagonist	5-HT1A / 5-HT1B / 5-HT1D	5-HT (I Amine)	no	5-HT1A_All1(50)
S~.ixi.>S~x>S(.i.hxiS~x>xix>xiS(x>x=S(x=S(xi.>x>x=.hxh	;vzfzOzxxYQB@z2A0OfNg07620hY0@8NRV3GX108FY24020@G1!JPc4o3X43281298!R01014140Z02010	0_!uF02R03i!@C0ER!qJ0Q01k!C20@Z0gF04OF1k07g0vV$ #96_2koP810HGl8RJE4XGcoD92VVGWBmRL23WD_FFJ82CBa2cZ8114XXFVcsK630VB4215YmwV8B46685GVsN621F9Nkg@C6Xl8wH631Fc44PGCS43FNFB45631l0D910kFF631VJ224JVC121WBV8N4246YWVkP94W0N8210bYIk8B@93420ZF420kV86318YoF	#c0V#F%4*6#5dH#24F#YV!4V%F$Ho$4#GcF#3s!206!218V	//%10E/!2/(3/*8$2#12,1/!1+1.3.3///#2%1#1%102-3%1$12/#1$102/!1&2/!1%1+2$1&2+5.2/%1$2$1011-2)1/!2$3(1%3$102#1%1-2/#1.1!4-1$1//)101*15!5$2+1,202.1-16//%3//,1,10n%501/*1&F!1//!2!2//.2&1)1%402)502/,2/#1.2/02/,5-	fcoQ`@GYAsjSLlozrnsJrtgL}mAPQUUTDDD@@@	J. Med. Chem. (2003): 46 (4): 646-649	Ki 1A: 5.8 nM / 5-HT7: 5.8 nM	University of Bari (Italy)	no		5-HT1A / 5-HT7	5-HT (I Amine)	no	5-HT1A_All1(50)
h.>.~Sh.(Sh.>.~S>.qqg-(Sy?}Z=x(Six>x>.(S(S>.(S>x>.(S(S>.	:UvzvzxrSxjvRvvEbQPAcwCzE6f_Z09f@gI@n21s28XV42nF0F5Fc2g8UL3X102!21kHJB2O0F0380V$F	0J4!ms0FF1D!C20@!eF03Xk2U0DF01440Xk2U0DF01L!NV1_06c0o! !10FaA9YFcNH315YmlVJoH7W1V8@HE9m0VFRV8V4FF84HNk@685432GogD55VVNFVU82D11_pORFH713X_JdgF7532t0Fk8g4yC9W70sRJ430G0oVaMZ130t0G08gHF4WXFkN597ZXZNp68E3VYGF	#D0F!8$204$8#V6#5W%6F#eV!4Z8#8FF!Z2k#X4#88$9F!@%180	01.1/%K/%2$2-1/+4$5$2)1%2&1,101.1///$2(3#2//%1.2/)1//*1!4+2#2/)1#11$4+2,8*2&2/0101&2/31#3$1$4)2!2)1//!4-18205/,22%1//(122*1!3/.1!1$1#1#412/$2$2!1///!2/n%3.11-1$61//#1,6*1.1*5!1//05/&1//.1-5!2/01&6(1$	ek`ZD@@D@fac`NLbbbTRaRQbfRrbRXDl\jZvNZjZjjjjh@JbCr`@	Bioorg. Med. Chem. Lett. (2004) 14: 1709-1712	IC50: 4 nM	ArQule Inc.	no	not given in publication	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
S~.ixiS~.=S~|Fxi.i|`lvS~S~.=.i.i.>.i.>S~.iS(.hS~.>.=S(	:Uvzv:rS:vyvzEbCuUfvEjEjU_oJCzdh@@bnbN6jacZ6QqJk5m88dDBJYq49e3Z@l40R5290k0W8BVV$	0aJ0U!3OF1g07k!o80eF2l!DA09w0t!3Xk2U0DF012s0FF1209w01Hs0FV2A09w0t& #6F483Z11Vt0FcDF463Z120t0Fk8dqN2VWFkcNgPF2VNkZNPEC@FVcJKFOC1kFcVJNdH1G1k44N2150VG0sFZF73msF2FD1VXHG8BeCGYFN82H99DaldV6@E0VYFF8ZTFG5WWVmtkRD510V82HA93XltRR92WFVF2LC0VXn0FgNTA1ksJ22@553H14X842VcFZR10W2mnIcV683m0W0F	#c0F)44$F$2#5V%4F#cV!4_%F$2k#J5#8%3V!204#18V	/!1,1&A(1-1//!1)106$5#12/#11////*2!1#2.1(101+101/!3+2$1/*101!2///,1%1,6/!1.2!1,201/01.1(4!202(4+1%1/02/03$4!101,4//)2#1)2&301%1%11#201/%2/(1(21-1/-2&2/,1.3o(1/1)1&D*2/,2!1%1!112%11/1&4/#4.26!2%3%2/(2/$1#2&1)4)1&3*4-	ec`RD@@DFIH`CLbbbbRRTjVTTRbK@bf`TWPrvsUUUMUP@@EPPXT@@	DailyDrugNews 10. Sept. 2002 / see ID 2052	Ki: 4.1 nM	University Madrid and Barcelona	no	agonist	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
(S=x>.(Si.(S=x>.>.)T(S>x>.(S(S>.(S>.>xh.(S(S~S>x	;vzfzUrxzjQT@zEERNQug9ME@_hWFD@tcXAHm508@YV403H6G1F0F@8Bo1V4920J@9#R0101414cX0V0F0	0Xo0FF02J03d!C_06k0R!3FV2d0A4!sg0cF3Z# %33dgg90Y1WW98RP5YkV82HA9XbFFNNB25731VoPA31FVBkJNp@Yl88J@AZ130oXFFJ84D4ZmcwDC0ZXXFFVDB1YGNoH730kWcs228D0VVsgN94Wl0kD41VkF42XA0VXJV	#8,4*6#5WF#24F#dV!4V%F$Ho$4$c$3k!204#18V	//%10I/!1///#4$41!12//$1&1.311,3/)1/)2//!1,2/(3)2/#2/)1+1$1/#7.2/%1$1&1.1#1$1/!2$2.3$11$1/$1/#3/!5-1$1+2/,101.2$2/)102/-32/!1)1!1$1/$1//$10h%2/#1/8//%2!2+1#5/-3&1&1(402)602$2///&1#2/03$4/&A-	fi{p`@DJB@jSKJkvnsJruxKQmUUUUTDDT@@@	Curr. Med. Chem. (2001) 8 (9): 999-1034	Ki 5-HT1a: 0.8 nM / D2: 23 nM		no	antagonist	5-HT1A / D2	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
`*:0|Fl0(SS(F*>.(S=.(S>x>.(S(S>.(S>.>xh.(S(S>.>x	;tzdvSMoCwOJAzE90F3Ne8bC23dW0@8PhX38X!@Vf#Y02G5!FD8BoYVJG31029V!J010W4140V%	0_!uF03OF1g07#o80eF2l!DA09w0t!4FF2A09w0t# $BV844F747K848D@0VX210ock2W084VFF22Wm8sqC4VVF4gR11560ksZXMB2FO1042D10XXcP48D4221GW8L84X0VRF110IlOsBB@9YFkcH631FF82RADSZWFc6@55m0WVF	#8,2)2H#4VH#24F!8WV!44%F#VHo$4$V$3k!224#18V	//%10B/!1///#4$3#12#1/.1(1.304&42!13///#2/%1+1,2/)2/,2/)1/01//#2/%1$1&2/)1/!3$3.3$1%1/01!1+1&5/204&2%1//.101.2!102/01&102/)24!12//%1///!2)g%2//$802//0102!2//.4&1!1,302)802///$2#1&2!3$2#7#302/)34-	fi{q`@DZBCa\bbbRJRbRrbbRHspVcZjYjjhHHhA@T@	Bioorg. Med. Chem. Lett. (2004) 14: 5863-5866	Ki: 5-HT1A: 29 nM / 5-HT7: 63 nM	Polish Academy of Sciences, Poland	no	not given in publication	5-HT1A / 5-HT7	5-HT (I Amine)	no	5-HT1A_All1(50)
F**Fl0S(.h:0~S.>.>`*hx.h~Shx>x~Shxix~Six~S=xh.hxix~S>x	;vzv:rx:vyvzEjCuUQzCjEjUhpJEzvheA7mYND_ncZ6YqHl5m8FjBBoYq59a1Z@tk0JS210l4W40VV$	0_!uF03OF1g07#o80eF2l!Fi0440FV2U!HA08s0bk3Z!Ji08g0YV2U0DF0 038201m0W0RV8J4PIFZ18ccD2810WWn28aE4510F8BBDCB42908310VF4gFLEB_l0R@421VGFkcHPA2l0JB430XWWFcTL52kkF2410VFNoP20W2Ys1sB66312lcsL96Xl0F41B60VG9cVJG4YGNgD51VHlV4449C1XGNJN952kkV861VF9so229FR5GkV2@55m0WVF	#c0F#4%4$F$@#5Wk#24F#dV!4_$8F#VHo#F4#8c$3k!204#18V	//#1110G/!1//&2+4$5#13!1/(1/1,103.3///#2//!1,2*2//+3-2*1.101/#41-2!14)1$101$102$201/&1/!4$3.31#1%1%3-1/#3$2,4(1$1//.101!21*2$2#1/$102$4!1%1)1#12/#1-2!1&1#1/(1/$10l%201//!8/%11+102!2#2+2/-4&1/402)702////02,1#4,2#2*8-	fcI`@DX]dBnyEEEDdd\hdlhhdbLdYNY{ZjjZjjhHHjHDH@@	Curr. Med. Chem. (2001) 8 (9): 999-1034	Ki 5-HT1a: 0.15 nM / D2: 5.3 nM		no		5-HT1A / D2	5-HT / Dopamine (I Amine)	no	5-HT1A_All1(50)
>.i.(S>.~S>.i.(Sh.:0:v~S*`*Fh.~Shxh.~S~Sh.~Shxh.~S~Sh.	:UvzfzSrSxjQRAvE7PNAcw9rE2Y_V09@@gI@n21s28XV42YF0F5FV0g8UL3X102!21kHJ801#380V$F	0J4!o80c02d!DA09w0t!4NV1_06V0o!4FF2A09w0t# !FRPE5YW8k@52VY1laF42211YWswVD3XFV8gRL343mW0Z840mG9DF4F248_mdBF51Z22BV8N4223XW8ZH631kcN@62VV@9042DHm0X0F88LE631coB720VGcko	#D0F$V!204$8#V4#1W%X$XV!4Z8#8k#Z2k#X4#88$9F)180	02/1/$L!1/!2$2-1/+3$3$3)1/%1)1,2///$2(3)3///2/)1//*1!402-2)1/#2%402(2(2$8/!2/+2!2,3$2*4)2!2)2/1/04(1$18204/,2//1.102$2#2#3/.1!2$1(41/%2///,1,10l%301-1-1$6//$1#2(4//#104/1&1+6/$101///-5,2&1&6(1$	fch`@DAktXNYEEDheBdbhdlhdfBlxmU{ZjZjjjj`@j@@@	Structures of launched drugs which act vie GPCR		Bristol-Myers Squibb	yes	agonist partial	5-HT1A	5-HT (I Amine)	no	5-HT1A_All1(50)
=x~S(Six>.>x=x(Sh.hx>.>.h.>.(S>.(S:v:0*F*`*`*F:0	;QvQzvMxzYvyuU2f5PUPd4D6b9hpFDttBe30m10D0Y8043V2G508Fe84o3m4120429F!J290l4140VV$	0_!uF03OF1g07#o80eF2l!Fi0440FV2d!Fi0480GV2d& #382317cY8g6533X1kW8aN52W0RVLFD84Xkg8210kk4gNL36Y2NgJ921FV8B2C76t0G08NTG8Y1FN@61_3V88g228B0X1VgTC5XVk8@1B80VGk824@EW3mNNRE8261	%F#4+F$@#5Vk#24F#1V!4W$8F$Fo$4$V$3k!204#18V	//1$10G/!1///#4$5#11//,1,103.3//%1,2-1/#1,2///&2/)1.101*1(1-12401/!1!201,1*5(101/4$5.3$1%1%2*1!1/#1/!4-1%1(1/%2(101(1$43$2/)10201/&1#12*1/*1+102//+10h%201$1/,8//#202!2(1,1//1-20402!1%802////02/04)1/!6-	figI@@JVbTBTwKN~jrj|TZqZ}GPPTUUUUTUPkP@	Curr. Med. Chem. (2001) 8 (9): 999-1034	Ki 5-HT1a: 12.2 nM / alpha1:323 nM		no		5-HT1A / Adrenergic alpha 1	5-HT / Adrenergic (I Amine)	no	5-HT1A_All1(50)
S(.>x>S(.hS(.>x>.>zdW(.hp3}JS~.>.h.h.>.hS~.>xh.h.hS~.>	;vzfzSrxxjQRAzEEPNANw9rE2YhW0A@ugnAmX5s@2YV42YF6G5FVFi8Eq3X512!29VHFR01F14140X%	0J4!_!uF03OF1g07#o80eF2l!DA09w0t!4FF2A09w0t% 0BV844eJE6F88NDB9CcnN8JD@A6ZHGNT3143H0NgcQDWWWk84N214ZE38wBB6653m0wB9420V82N@B12X90TA52FkB4L@AKblsZ2@55m0WVRV8N782814_GGBw8670F8FgV676Y1kZJF612XF44NL131GFoT@5VW0J8310k@0p0	#8,4*6#5WF#24F#fV!4Z%F#VHo$4#8c$3k!204#18V	$1//10J,1$1!2$2-1/+4$3#12//,1.3.3//$1-2//!1,2///&2,1+1&2#1$1/1)4(2/8$1$1&2/)102/3$3(104#3$1!2!1/$1/#5.8206-1-2//101.2$2(3-10102/-52/%2%1(1///,m%2*1$1/#8//$12!2(4//%4&1/402)602/$1,1/-2/03/,6-	fcq`@DFrCg\bbbTRaRTJVTTRSAV\gL}mUMUUUTDDU@@@	Tocris catalogue 2000			yes	agonist 5HT / antagonist AR	Adrenergic alpha 1D / 5-HT1A	Adrenergic / 5-HT (I Amine)	no	5-HT1A_All1(50)
`*:0|Fl0*FS(x>:0S(v:xhx>xhx>xhS(x>x>S(~Shxh.>x~S~S>xh.	:Uvzv;S:vyfzEjCsUvvCbEjUhnJCzfheA7mYNDhmcZ6YLFk5m80hBBoYq59X1Z@tk0J5090l0W80VV0V!	0RZ!qJ0Q01v!C20@Z0gF04AV110480bk04Xk2D09w0t!5AV2A08s0bk3Z$ #1Z1!t0FVDF4826AX2tZH50Z2X1lFZR5WVNscRaG43lsZR20ZY2FkoHA94GsF83@8540sgaH7WVV44JE@1YkkNNA2XGVZB316ZIPO48D4A56m0kB22VkV82NCB42310T821FVB22B6a11FkXF41FVR431VVN8wRT9aW21k8NE8261	#c2k*4$F$2#5V%6F#cV!4_4#8F#V@k#F4#9%3V!204#1Bk	*4+1(1&E/!1//&2+4$5$302/)1#1+1-2)2//&1/!2-11/(3&2///1%1-2#2%1/01/#2(2)11(6(1%22$2/01/*4$2/#11%1%2*1/&3/!4/$2//(101.3$2&1/#2!5$1%202)1!3/%1/-21/02*1,10l%301//!8/&1-2!2#2#1,1/(602-11!1!1+702%1///*2,1#5)1!2#2*602%3$	fch`@DX]eXEYEEEDdjdhdlhhdbLEINY{ZjjZjjhHLjHDH@@	Bioorg. Med. Chem. Lett. 13 (2003): 2837-2842	1A Ki: 4 nM / alpha1 Ki: 4.9 nM		no	antagonist	5-HT1A / Adrenergic alpha 1	5-HT / Adrenergic (I Amine)	no	5-HT1A_All1(50)
zd6sO~x>ix(Sxh>x>xS~x>(Sxixhx>xix>S(xix>S(x>.>S(S(.>S(.=x=	<v;r:UzynUyzBnUSthuXrAh1sUjjRV52YdH58ma@ZXZY7ND6HB8LoHI1_kk932FcG4802022V1X0Y0GV	0PF!Xw0s!3OF1g07#qJ0Sk1w!Fi0440FV2d!JL06Z0Sk1w0Bo$ $1Ns24WO0FVAx@4C21YVsVaE3X0kN610aYnG1ZBI9XVcN4H9922l8ZZB5XG0F82B@635tZB3233F848JFNV1VkkN48827B2cN240VXGtBoHD341t0Fc@lk442m0XFGNg@DAXkFoB40_Y2kNdaQ45VkVFV4257	#3$1$2V$JB#c@#38a$o#FG#2ZP#OlF!48o#m4#1VF!8pk#B4#E8V	!2/,1&A1/0104///04!104$1/+1/*2.1/+1/%1!1)1-1,11#1&1/1#1/!1)1%2#5)4(101)1!302/201)1&1011/%11/$2,2#201(201$4/+3012!2-2$1/0301&1&101#3$101/)1.2!122!4(1!61#4///1%1#4&2*2&2/(2+1!1*2#1#2*n%2%1,1(12101!F01/.1$1//-1!1!1)11+1)3+1%1#3$1//1&2#2*4/22*5(1$	eghRBHDLBOMdbck`@cZ[nRf[Ug_Vue]lJICGOIejXHJJjj`@fbHHb@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>xhxhx>xhS(x>x>S(x>xhS~x>xhx>`*vl~Sv9xhx>S~xhxhx>S~	:UvzvzxzSxUvwlUTz8nENuzs3IAg0EOjuz253Vg1Ga2ZG_VkX88i03Z0TJ@394VW322641J(JV1V0kV	0G8!WR0Tk025k1v!9g0AN!lR0OF1v!DA0@40t!4AV110480eF04OF1g07g0hV045V1Z07J0nF! !O0G090J4S1VV8RND21VX0s641X0dVJ10VYlWts4M614W1kHOcN4F79FNNkOwa23111GS084XFd1J22I911kV8F942lFR6336_kV8431VFFsxFdF251ALc428D4m0XVRV8B4214VGsF254WmGOB615XV8co42AG12kVsFaR6143V8kR4641kcJF531VkBD70b_ksB8c12W4FF88Re254HFsX72VkV4gcL21W0sBD@51l8RB320F88821e4V848TgPN608VcGDKD2V8cw22C6m0VkFcR8631kcR@72X0FJ2221F@OF4228VVFFtR2134Z8s892WFF4keN130kcBD853W0V422VVF44ZK0WFF4FVgLb13FVtdcD490FH0iF462531kNRD52X0kJD51VV84651e50F42112YaRV8F78261m0YFL@NN6A3m0WVFGhHL20F88VXFj18CFGkF4eR95FkF2FI833YWwT213_F89BV	!235V!J84!2k$H4#V9#1Wc!20K#3dR!2BN$GF#2k!1I4#18#11o!2I4#WOV	/#1.1#A&1)1.2#1/$12211%2$2$1&1/#2&1%1+2#1201$102/(41$201!1)1/!1/!3/1!1!1!2!1+101(1/%121!1/!1/22&24&2*3*1*1#101%3&1,1&1#1%3$11$101!1/&4#1!2!2/1/02&4-1/2#1//2#102.601104!101*4//)1@+1-1!1/(1+1/-1r%1#1#4*1!1!101!1#D/-1*2(1&2*1/!4012!1&1/%3/01$1.2)1/-2$4*1#1*114%111$	e`\RHB@IOFgh`H`bHrBJ`aIf]vUumY]eYcbqshZ{zB@jjjZij@HI@@@					antagonist	CCR	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
p91?y[C/[-1?_xm61g1?1g.GSzG.<s._|in>tcS~uCsjOzwCsjsjwCoo	?xzQxzvxxfUhduihyCUAMAggCNvax2Wv0j83ruoJLGFgF4882o28B22168V120J0486A0sFF8#683V	0Xw0s!35V1Z07c!sg0bk3Z!DG0DN0uV03OF1v0Eo01Hs0FF2A09w0t! %53kG4VA6WYG88gNB9Lb0kJNTB10W1FZ@@21FFF873W0VV4210_GeiF442JE14X9R8T916XXYXJN41WGlcuWPB122W0FBFC2210gB@50kVZ4TCEm0WVMOoF212X1IRZ8J4Na120VG4RC4VkNFF62WkVBsPRQM6VlNNNeG6Vl0kwm41WXmF	#@0V#88$4#22$44!19%3$Y#248#BF$Pk$7!2ON#8Cc!206!291V	,1$1.1$F$11+2*3,1/0201)104$2.1+1(1/%2!2&41/-2/.2//2!11$2*1/*2/&4%1$1//*2011/11/3&4&2)1#1/!1#3%1$4(3+2$2$3011!3%1.1&2-102(11$1#301!2)4/)1!2/9/)1$2*1%1#1$22!15/1/)2)1/#1/)n%201!1!2/+8-1-101//#21/#7!1$1/+1+1#1/(2,1!2*2%1(1*1!2-31,	fk`Q@M\Dxh@`|adbbbaJTTTjTrbRqJ^Bo]RsUTuUT@EPbqFZ@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
_xx_<sSzu?js|hugn>u?tczSS~uCgug1sjzSzSyIIyg1oooozSzSIygug1ugSzu?ugugu?	?xzvxzvxzfUpdvihwUUA7AZg9Pv6w2Zn2Y93GmkJrGF8FZ4@Hg28C3@0aFc0H0J0486A2s!81!6030	0aJ0R!2OF1v!8j0D#qJ0R01v!DA09w0t!3ZF3a0Dc01Hs0FF2A09w0t# !2geW1X41BV884wMFWZG0N8R@JD0m1B2@142X0VgP73W0cZ2241n2V8691VWGk424A0VXK28BmK7X104VN2154_MW8288434WNw8111H2O04X61WVcVkoeWDZ11FWmF4724b7sNkE8261Hb2VwFJ8222WFZFB4Wl0R@8C70FFFcwDJ53FVN2L1Wkc4kHN62WGNgXE3VkVN2ND2VY088c228E0VFF8F53WFFFB72X0cJ8521F85NZ40W3k88g228P0XFNZD@B2kVB4810kF90NWZ140W0H@NP79Xl0kcR4132FkNBA3WlFN@510kF84aD10Y50	#80V!4&4!2&4#192$3$Y$4V#8F$2o$5#tc#85s!202!210V	,1$1!1+1$F$1!1$2#2*3,1#3,2(8!104$2#1,1//1+2(1/!1.3/02(2/,2%1%6//%1/&4///)11/112.3&4#1!2)1&1011!1*204%1$5(3/)11)1!3+1&2-102#2)1*2.1/&2%2)C%1,1*2(1$2!1#4%2!18//*201&1&3$3%1&2/0z%3(1+1*2#P-11$1&101/7)1#2/)502%1/01(21///#1!1!2(102.1*1/031,	eb^XJ@@D@KEcklbbbRrRTTrRbrRfblRQCFSPvrNKUUUUA@@ECP@PBAAFe@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
,dpsW~.>>xS(.h.>S~(S`*:vF*x=0:*FxiS(x=S~S(xixhx=S~S(xiS~x=	;vzv;SzxvyQUEzBI@Q@UiAnMCbJAfmlXEDmhOPrRaF_XqXQVvV4zBcVdWMvbd11VXBNK2GF1F!4C0X0GV	0QB!QF!b!vV03CF1104s!lN0O01u!GE08g0bk3Z!GE09!bk3Z!KE05V0Xk2U0DF01LJ0Q01k07g0vV% $7iW20VL88B41CfIVVgFES24WO0F8846PKb1GNdRu237b1cBBL214YXn0FlNJ2421Wl0TH30VVND6A6_d0Gegc483@721c820Vm111dDQ0X1FkcRaIB3G0B8FD10Y2FYoX94XWlJR48B5Z11Vt0Fs8OPk32WWvcFR8PR94FN8BD84Z34GcP4532GgV8J78261PB0WFLF4D2a912pN8ZBed3bV8cNM8241iVXVs8JA8251NbWsNs25252t0FkDF4D2eS110fc8ZD262m0WFF	!2Y_V!L8#B04#@FV!42#4gP#H5F!8tc!6Z9#4$cHk#4a!2GFk!1Hs!@H6#98V	!2//$7-2#1/(1/*2$6$31+1-1/,3041)5$1//03$12+1#1$3/&201/!3,22/*1$1/!1*4+3//!3$1*1$1&6$103/#3#1/#5$4/+1//402!3!6/-1//-1$21(1101!3/.2//05+5!1/4)1/)1,3-20n!1011#1#5*301%1#3!6/)1+2*2!2/&2!1(9231//&5+3///&1+4/02!4/%	eg`RBH@FKGMcDje`@cIEEidihidmMEihYaQYyuMSMUKURDDMUDAE@@					antagonist	CXCR1 / CXCR2	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
d]SgdIB]d]d]dISgdISgB]d]S(BIdIB]S?d]SgBISgdI@XX@d]d]EEEEdIX@d]EESgdIN@B^d]d]`C?RCFPgdI@Z@ZPgCF@Z@ZCF	~:UzEq:vUzjjUhrzSjzjajaurOEyfcmMfrEK9ndfhBTwnIAjjJa79mWQ733kN8KoAnYV8kF	0WR0Tk02Q02q!9J0Eo!qJ0Sk1w!C10480eF03Xk2U0DF012s0FF1209w012s0FF1209w018s0c02Z0DF018w0bk3Z0DV01GR0OF1g07g0hV05NV1g07R0U03F!Kg08s0c02Z0DF% 6F4@2O71FmsNN65W0s4B296a5FNGgB65YlNZN3890F84BPPaU130bk91B2C25c0WNR@980WlgV8478261331FcB1811VN260WVGskxBy261O0FsAtB492EYFX8Re932VFkZY8251IEVVsF8TDBZ2FJ42984WXdBDJ10lcB8JG10Ymm9Fa63410NVFFHCfW0VVF4B65HskJ588VVGt8VyFIWWGVcH0I6X4G68oN362ZWF90Ny2BI7VW0Ptg462285FZP@F5MCVWNLF4@2432lsN@96WWNZ4NJ10FWtkBF911GFNLD320V84220ZHF44PZA7_lcc8130VFg4NAB31XlcmA1YYGkNFJA71FksF9410GdB22G0VYYkNgJ683m0w@3@7_F2W0BB6l95WFVcI8281m0W0Gkc90823m0FT7245V8426FCU0_2GF8X7Z14VjZkFs8BE2_W94224WFlOJ42HBJ2GcwFk91XVmVs82A3VlFFD76XkNR420VVF84cJ0VY_FssJ8@2aG0B213VkVBVV11VFlVR4HXE3VWcFTBP4108B4969Wk8G0D2D0VXoBV8N4iS41VWBNL@14YWVksL97361888e231FF8JT30W2kk8W0kB8X0V8823VkkBkJ6146YGsg@434GsNFJ@@0bVWtw4Pb1523GcB@32X28Z43A80ksJ48AE3X0s8P5510Fgcq2410msF813X4V88t8mC31aWcVB44XZVc88T816_ZVkGsJ611HNNNgC0XFmF44V216at0FN@g4TO7W3208ZF8E42FkdZBF2@WW0NBX51720GWWcZ4J34W8VD@B40XX1WBe462YX08kR2@7EVYsc8g8@E76VV8D4891k84BR34VFlGkcT4Y51VYl0L34WV8gRg119VVGtiF4@2G5XWFJJi41XW8g6BF20VWc44JRD3VkVRP24VGFo69C90kGs84NUZ11VcXVRFC4X1l0skX423lHsZ6852kFkw41260VG9kog921k8FND3_2kV88FNDAY0VcFI1WXG99w4Pb15bkG8N4PD51lFcRFH30Z08BJ245aWW0ZC245X0VN@C3W0VBge20W4VF8x78291m0W0F	#@ak!C4Z!4V8!10mF!Z@F!5hZ!32J#FX4#Z8!1AGF!2@k#45#OR#cMs!8Ka!218V	,1/#2%N%1.4!2.1!1!101/2!4#47!103(2/!10101)1&2$1(22#1!1)2!25%20101011$1/04!1#1/01.1#1!2/(1/1)2)11%2.3)1#101$122(8&101$1!2#21/1054%302/03$1(1!11$4!1040442#3-2#1!4!6/,210402/.2+2+3!2%1(21$24.11!1#101!1/%2$3%2!1*2@(1%1#1!1/01$1%1/01)5*2$z$2&1)1!3&111%D10101*11#21!11)1*201102106/#1)601+1$3%1)6/11&1,1,1$4*1%3$1!7*1!1!2(10A(31#	ely~BB@BDbo`Q[WHlnPHaRPtdCICHhhmEiEXeEMMDdeleEDeEEUidfNEkcgf]QY[WXtxHBjjifjjjjjjXH@@JhHKB@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
3@S.3fs@3@3@sf3fs@3@sf3fSxs@3@Hysfsf3f(Ss@3@3fSx3@3fS.3@s@S.3fS.sfOx1D.[:o@s.S.S@s	=v;x;yvzUzRQUvvUjAzUhYxUvfzeCjIh9KjiaJ7Amr3gzWQzDeont9gZl5AXL$9eWJ!Ne0V4FV	0aJ0U!3AF1104s!o80eF2f!DA0@40t!3Z02W0DF012B0OF1k07g011N0O01u07k012s0FF120@Z0 #5a4GVB@D5h0XW088D62232FkN641GF8@10b3k88kwajG1XkwV8N48D6_1koN5880kGk44NKX0VFkVRZq4A2J3llJ8565YBq04B@6166X9RJ22Vk9Fkc2221VsFF821VVZD71VFV44220F@sw2126BYX40B8A40VF8cDA4XVkV874108F42H80FFFpF6A83GVFH5410cJkT1160VGF44FTGHYnV8JJ@h175nsFgB@963m8wJ520k8422D5bA31wBB6r14AFFkF8884W0scD7210sR6310VN42cD0VFWPk8uEEZkVl4Q8241110soN74XWNBci740VF44BFFm0XVRN48T4110FVRD52WFcJD42WkcF852@5VF4440XZ088hc8d295o0FwF	#f1V!488!804#4%@4!1Ze$1#Fd8!6Zs#9F$Po#B4#ds#19k#42#C9V	!1#1#11%2$2#1(2H/$4#1)1#1%1$11,2!4!10@$2)1$1*11/1)2.2$1//&2$1$1%1&10102/12021(1)1!1!1!3!3*2!1!1%2022012%1%1!41$101&1%1011$1$1(4#11,2/(5&2%2*101&2/204!3#1,1#2201/02%1%1+4$4&1$201(1$101//&2!1,11!6$1+1#11)1/-28*1011//%2/-1)1!20z%3!1,1!3(21%D01/,1%6$12,4!2+1&11#15011+2&1301(18$1#1/,1$1%1$1!1/$1!5)11#11+4&2%	eeWZLD@MCJfebAg`JqDHrJJIKIIQQIIXjZIJJZEIILBIUYEDtbrpPQUUUUTuTuSP@TDDu@@					antagonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
p91?y[C/[-1?_xm61g1?1g.GSzG.<s._|in>tcS~uCsjIyyIooooyIooIy	?wzQxzvxxfUhduihyCUAMAggCNvax2Wv0j83ruoJLGFgF4882o28B2216NV120J0486A0sFF8#603V	0ZF0IV02OF1v!8j0D#lN0O01u!DA09w0t!3ZF3a0Dc01Hs0FF2A09w0t# !NLiEVkNkwQ822176KNc421YYGpewF6A3m0WVN9gB244X88VFc82D93lN8455WVcF4217Y3o2ki6A335Gss8@67aVN4BLHFI141dc8P615XVlNkD731kNF844VkFNBVF0VkWeG04aa4_1FNJPB23Y1VNBA230kF8C0b3IYBg8D48@aVmkBB8624Gc88RH31XG0RD63VkNB6NP11V8N671VX28B24DL45IFORD281GFFNVH22W18g@64WFVJB42XVV94V116d2Wmd48B4m0WVF	#@0V#88$4#22$44!19%3$X#248#BF$Pk$7!2ON#8C8!206!291V	,1$1.1$J$11+2*3,1/0201)104$2.1+1(1/%2!2&41///-2//2!11$7*1/*2/&9%1$1//,11/11/3&5&2)1#1/!1#3%1$4(3/02$3011!3%1.1&2-102(1%1%1!2)4/)1!2/A/)1/&1#1%2!15/1/)2)1/#1-2*q(1!1!2/+8-1-101%4)3/#1/#7!1$1/+1+1#1/(2,1!2*2.1*1!2-31,	eg`XBH@MNAGB`@cIEEEBThhiTieDedQQxDmmTluUMUU@AUBEaFU@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xhS(.hS(x>x>S~.>.>.iS(S~xh.hS~x>S~.>.hxh.h.hw<^}.>.>tn~U.hS(S~	>U:rzxjLQUvzCrYO@UiakHCnxAzLzX1923IQGzimj24YMcigpyhccQ8QFGtW6968mH1WiKKF4HJR#V	0Z80IV02FV1D!9F0DZ!_!uF03OF1k07g!qJ0R01v!DF09w0t!4Nk1Z07V0xF05CF1204F0Tk2d& 0AF8ZJ262QVn94FH8919W0H88TV2232sg8HGZ120lXVFoJ2@328VWt_2434XfGPR43542W0G8LL83W0BZH2135O0Fk8sJfD1GGFiF4J33114Is8wBJR28ZFGto4JF13Xt0Fk8d@B20YFZRHEZ150qVHNc4R4G@15F@8s6C5m0WVGkcPTFXZ1RV8V4LG7YmccD484Z0VHsB2642kkcLB32Vk881E3cAakFF8D35WVkc@Q1Y0V86P8CQ0X_k8R8F53XlNF847ZYVsR4440WVs44@V80XksJ@47@210NL72Vkl0g429F4Ym9Be65VX190423110FwH96XkkNL310ZFuAOR4421W1cNBD36V8o4316X3Kk8dg272221FVP4221N8H81W0OsV426F20WsR87111NR6A3VkcK0L214cn30FJ8	#tWk!48%L!24_$6#24@$G#FY$Vs)VPZ!B05#GV#98s#42!35@V	!1/3#1-1E(1)2+2#2/+6$34$3$1+5/*11/104*5$9/////&301!2!1/$101.1/#2$2/(2,1/01/$1/(6$111#4.502$1*1$21#5&4!1#1/!1,11&1(2!31104/2!101!1/01&1/)3,3!301(11/011(2/(@+3(1$1%1!1$1/%1/.10z%3)1/!2&B!31(1#1/#8$20101)2/&1%3/(406(26,1////(2-3-2-	elVTJ@@D@`EEk`\bbbbRbJvbbbRVbRRQL\JZfN^~ZhJ`bj`hIJjbFCp`@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
Fy{Ssk.i_y.=xi=x*_x=)G)Gsk`-*_S~s;{S.<.hS(S~.>.=xhS(x>S~	=xzSrpxxzRAzEE8o3SudbEH3hW4ADuxX32XdF@YfZG2Y1XOCeVFT8RofWKG3112908FJ012WJ140X$V	0Xw0IV03OF1g07#o80eF2l!DA09w0t!45V1Z07J0nF05FF1208g0bk3Z$ #6F4F3Z110t0Fs8FXK8Yl8ZBFA0VXHR8B8F4B76mco442Z2V88VZHF6XlsNB4510V42PCCDjGFNwBPD94W0NH410kF42PBCY70FNNB293XFsZJ94X0NFB210VH8o22@H2@kNVF72ZFG8o42A@22FccN5530cR@41VVGss42BF3hWl8B163YNFNFR8	#P1#4F8!8%JB#V2#4ZO#24F!1WV!64N$F$Ho#FJ$V#13k!244#E@V	//$110C//*1/1#1%41#6#1101/)1*1$1)1#1!4&21!11/)1*3-2-1/#1,2/%1/,2!2/1(1+1$201$1/(1!1-1%11$4&1,1+1/!3!203&3&2$1!1!1/$1/#3-20104&1%1/)1/$131+1!201!2/)102/*4#2/-1&1-1//03+n%2/(1#2&8%1/)1$3+1%1/%2%104021*1)101!3%708/$1/1/*3%101(4$3#14/04-	ek`RDH@LFEO@f`@cIEEdhdeEheXhdmLJCOHdaejYjjjfhHHjh@@@					antagonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xi.ixix=.=x=.ixiS(x>.=S~.ixh.hS~.=xiS~0lvl`|F|	yLup2K9G0k4k402!N250N2F04FF11@!2FZ18#FV820W!21VC05J1FV!@0FV34225044084120H01Vckk	0PF!RZ!WR0Tk02K03x!Cc0@R0o!4Nk1Z07V0xF065k1X06J0SV1v0C!1aV0PV1q07g0dk3F$ 04GO8744XO0G0@_@K381t0F8@BV5HWWG8iF4H2X150m9Rc4D5m0WVIlFBf0X_1JF9Fg2H3d0WkX_T4A21kW0aF462U84YcNJT@AR_FlNJB485m0XFRV8R5ak0WXVwV8R78291VckX0GkFI2e1GFiF4@2qM11VgV8g78271m0YFIW_R663m0WVF	#M4k!O@w!208!3N8k!c7#5ej!20xV!lAc#7T$8F!4HV#r$Wc#KcN!8F8#tRk	(1/$1%2!3,1(4//2)501,1)2/-103-1!4)25$23(1(2!1!2%3!2-4/,1%2(2#2&5///.1/,3/01)2//1056#1)1)1&1+1+1!40101.22/$3/#4&4/2/!11//!1/%2(1/1/3,1(A!1/-2/#1)1)1/%10f1/#3$1/6&1-1.2$2&1%3$1/01#201%3!1/1&101/01(2+1/-2%4(601/02/&	fmwY@`BB]dm^`bMRAiBtadTTRRrdTjbbUbSNIsM\AAUTAA]M@`@@					not given in publication	A2	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.=.iS(.=.=S(.=.iS~.=.i.=.iS(.=.=S(.=.iO~,B)\6s	:UvzfzSrSxEQRIvRENmA9cds2HYh0@8Duw051V1H1G6V10WV3V8@02J8qJ275X10A30Fc04%2!X0V0FV	0WR0Tk03Xk2Z0DF011R0OF1g07g012o0FF120@Z01Kw0NF1p0Ao0ok% !1CAW20WdNX632l8N42@90VH0B4RNYAWWkVN1763Z2t4eE133kV88NFUD4XVFJDAZ13VWHW4R222G0NB10a50844147cCG0NN96341gV8B782@1	#64F$4(1%Ze#5Vc!204$V%8#8FF#2k#1a#F3$3s!204#14V	//(C/%1*2//(203$1/+1//1!1%3/4&2%2/,1//,2,1(1/*21&3!4*2%1%1+3/2//.1&1,1)2$1.101101/#2&2%3/.2!2$1!3/+301//#11#101.404!4#23///!1!3//+1/*1%21/#e1!402/!12112$1&8*1///(1/#23-1)1+3/2/01!11//$501%4/,5-	fakIB@NFKvPHaIe][VUuehpLV}`@ijjjiXh@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>q5xh.hx>S(xh.>x>x>xhxhx>xhS~x>xhx>xhS(x>x>S(x>xhS(x>x=S(x=xiS(x=x>S(	<vUzvUvynzyuDmtJQyxaqya_d_WtLdAHX5kX82GFs0A5W4A3l07Oi80gF9@Y!801H01BV8@238V51FY0G0	0Pg!aJ0Tk02OF1v!8j0D#b!vV03AV0k044016J0Q01k0Ds010J0IF3Q0EN0 0m0WkFF84874VkoB84WkOcko88@4GssL534Y2LY08D5Z11VYmksJF5Wlm0J4RF242n@FXBA6m0XkG@9@J442O0Gk84D962lcc@33VW0B2RF10VNNg229H20H8oaC5Wm2VB4Z4180FFFk@2@Cm0X0FV4LI7Y0Vw63@@VkFG442C20XnXVoJ655HVsoR4A22GNVN821Vk8230VZ2c424H10VWc44Le41GX1VFaD61Fc84JN0VV8OF4121YJRV904230ZVVoNF3W0k84PP10F8OF22D20Y4Z89g4A222kJRDI8m0X0FN44B7420Ra245XXm1k8RLC1klFeOw44287FX9Ny236Xb90FJ9B2DU0XkZk9Ow2I2	!1!k!3%42#4%D#A9X#1o#F38#VF#8FF#@o!8FC#GV#FCs!254!258V	&2+2,1%C/!3(1/*4.6#1502!2///,1(5%1//)2%1(1$1(1%3&3,1.11(2)2/!2%1/%1-1#1&2&1#22+11+1!12!2#3*1/,2/05(1+202/)2$1)1/#1$1//%1$6(1&31+1!D!4/!3/&2(201!1#@#1#1/0201/1/$1+1/!z%5/#1,1!N01!4,1%2//1/1/1!1(1(101)14.4.4(2%1.4$2%2(2&6,1&9&12$	eb^TJH@LHhDACO@@cIIChhlleLeDeeDeeDdihut]\cbmPPEUUUT@D@AA`yPeNh@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
p91?y[C/[-1?_xm61g1?1g.GSzG.<s._|in>tcS~uCsjyIIyooooIyyIoo]-yI	?wzQxzvxxfExfuihyUUEMQgg4Nvax6Wv0j92ruoJMGFgF4882o28422168V160L1486A0sF082!683V	0aJ0Tk02Ak3V!9J0Eo!lN0O01u!DA09w0t!3ZF3a0Dc01Hs0FF2A09w0t# #@CK80cBNTCZ110Y3eZF22VllcuhT@35Wt0FkB0o71X2G1swJM49Wk8NBT@3130k8Zc422WFkJ@841VcN@631FF842J8VVGs844B10Xa1tVHE3XZkVBH6E3VYFk8cc432W0NN8B2XlFo8210o204B10X2_3wJ8J426YGsg242Xl0FD11VIlWu1NN35WWXG4P350I8J4JA@CdZFNgBRZ283YcFoD2A512WNVB640VkNF610VsS0V110FlV44FcD19d11NN756Y0VcgL623VNZH723IGk84JSZ130at8FR8	#@0V#88$4#22$44!194$3$X#248#BF$Pk$7!2ON#8C8!206!291V	,1$1.1$F$11+2!4&3,1/02015$2!104$2.1+1(1/%2!2&41///&4%2!1/!1)2!1%2*1)1/2/-2$1//,11/11/3&64%2)1#1)1(1#3%1$4!4$3/&3011!3%1.1&2-102(1%1%1!3)4/)1!2/7&1$1+1/3%1#1%2!15/1/)2)1/#1%1/!r+1!4/+8-1-101/2)2/-@021$1/+1+1#1/(2,1!2*2%3(1*1!2$3(31,	e`TXBB@MNAGB`@bzP^dOiCIEEEBThhiTieDeCHQQxDmmTluUMUU@AUTHVDYT@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
_xx_<sSzu?js|iugn>u?tczSS~uCgug1sjzSzSyIIyg1oooozSzSIygug1gug1zSzSg1	?wzQxzvxxfUpdvihwUUA7AZg9Nv4w2Vn2Y93GmkJrGF8F44@2c28C3206Fc020J4486A0s!81!6030	0aJ0Tk02OF1v!9_07g!Xw0s!3Xk2U0DF!t40tV3e!Ji0440Xk2U0DF% $M5INJFV9Z110bIdgBX6513WGmlF24421WsoN6110c4J13118FwNTDAa4kVcFNY231s4Z28541lVg@72Vks887210F868193V888Lc@16md0883Z30V8cZjC23W2YQwBN7Z130dYGFV8@434GkcH70YkVNB11aX3F8VP841l8c842Wl882218XZFlJw33XVNF2515YFk48JP5310F8D550VsJ@43VVs84110VHl4212WYLFFVZG92VV4B6@80VNFo42A0VXIVAc8R_212lBV8V48611kVNF@3Wl8R6320km9022D10Y088dF	#84V*5*4#192$3$Y8#4$8F$2s$5#O8#858!202!210V	,1$1!1+1$E$1(2#2*3&3$1/02(8!104$2/01//)1!2(1//////!101#4//%1/&4//!1/%11/112.3&3&2)1&1011!1*204%1$4(3/)11)1.1&2-102#2/$3/%8/2/F%1,1/#1$2!1#4%2!1@/3/)2)1&3$3%1&2/0z%5(2/&2#P-1-101$1*2)2#2/)502%1/*11/4//%1!2*2.1&4!1/031,	elVXB@@D@KCklbbbRrRTTrRbrRfbeRHXrZFvaQZjjjhH@@hX@HA@`cR`@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
,@_*~X:vhxp3}JF|zdpspsS(xiF|x>x>xix>xiS(x>.>xh.hS~x>.>xhS(.hx>.>S~.h.iS~	=v?yvzjzTmzvvhyjjzhYox:hvEbnhcTzvVd6eyUp1k_chiDrnrLvi0Z6doG6Kp1o329RcY1Y0l0	0U4!aJ0Tk02AV2g!930D#qJ0Q01v!DA09w0t!3Xk2W0DF012c0FF1209w010J0IF3N0EN01Hc0FV1g07g0q! $m0WFRV8J782@1BC30NoB4DP5WFd4KNa8WX0wV8c6TK271O0Fc@xP732Wt0FVAhH472KiFVsFRNZB51Gkeg4Pt15W0WFwJG9XFsV21A65Vkt4H@6WmFVBJH0VZ2ldRcJ5XlWN84HDYVW1F_2NJB44X0F8FRI52lFgB6363V88koRXA4VsB4DC7422t4gC30V994ZJJB@0N8NJCZ120aqlBBH649VIFZw8143mBV8F4FU4X10gF321mWk84NL68ZGNV8C2WV8F25C80FGll8aB53GVZ82954ZGG0eD@32WYV8wTR5ZW1FcZPP5WVVNL31_40F886BC0VWkZFA4ZW08H22VnW9lB646311F@D152X_VwoE46X1nGFV8A34G_VwoE4429ZkFa854M0X6k8N8JCKWZH0oB6C62W3lNX@6520NFRWH4GWlccVM8271	#V0k!F0V#5#1@%@#5gX#1zF!Fd#6Z$8FF#Eo!8VR#S0F!87s#54!218V	(1*3/#C2/01!202/#12(4.B$5$4/$2,1#1)2$2(2-1,1*2(2.1%1/.5)1$1//!2/#1.2#1!1%1/+1/!33!2/#31107!2#2)1021021!1&22*1$6&1/1!1%2/!1#1*804/!1!101/!2/)1!2%31+4!7#1/1-1)2%1*251!3////01.1,z%8/#1!1$1&H,2!1.1$3)5!1/+11&4!1*1+1(134*1$1/(2/#101!101-4/#3(3&1$2	ejQRFH@LHjchDLaio`@cIICMDdhlmeMDeEhlidnIMG@hlRUj``hjfjfjh@Ha@jaX`@					agonist	Ghrelin 1a	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(.>x>x>S(xhx>S(xh.=x=x>xiS(xhx=x>S~x>S(xhzdW(S~x>p3}J.hxhxhx>S~xhS(xhS~x>x=S(	]U:vzxzjryvzAzUzAjzoXqCzhxQ8rL_dLzqVLrAmCL5nZalaiLqm0@Zc6@VHJ891AJ88#e0a0I0	0J4!WR0Tk025k1v!9_07k!lR0OF1v!C_07g0U!3FF1209w!sg0bk3Z!DA0@40t!3Z02W0DF!sk0tV3e# $lt4s8AWF90kWid21WFm2RDU12X0c8NNNKE_G0JNP215Yh_NBB@6a4fVsVVF4D5ZHO4N40VHWc44J11469q0kBF6A8cXVs220Z22BV8J5Z2A5@0VsNJL64210VBE70kGVk828C8_WGVFFP132WW8oX231Gko8AA65VVVJP842ksN@D310Wko22AE711VVRC33lt94b8271FW290k566YC_kFk8uY27FVckJ64131VkH21YFsBD227YkF88JX43daNVcF235WXFRHB31FFF@13bXV88S0BJI0HscVN26621Fl0P93Zkc844B61VGGc8JC41l9BFA11HlsB210X2IwV8F4422W0kwT95WV8J8217Z08J46B0VXZkVNL65WX8Z875Wn21aF4H270Y4882e143X2dSg246X3Xm8J10X190kV2121l8NP@3XFk8D60VFVO8R_Z120VFJ04D32X2kgJ711FF8@10VF8422K5A0ksVX74YFsVT4A95t0G88VRS45lc48FD8F0Z32k8P615elswJTF1630VJ0FB86XVVZN33WVV88RG0VYkF8_7824110kVRFE4XG0FD510VV86XF10YFF8hE82710Y18ZJE6YFkN41B80VGk44J1147ZalkBP64B22ORZ110HGWDF4J3Z12VW0NFH84Xl8RD54WkVF2VEF7clVOB8S2WYlVFBJ822kcgHB4VVGd8840VF8cl8BKA1mc8Na14VG8Vsc217bHsJJDH0XkVNoc	#d5V#84$4*4#1d@!2V3#FfN!4Z$8FF!V2k!144#O0F!958#F2!218V	&11/.L%1+1!2*3//$8!20303!4/$1&1$1///$1&4%4)2/!1101!1!1-2%5#1*3#21)2%1/01%6//01)2#3/$62%1$2$2#22&9*3&4#2(2!2!63#2(4!1%101!5(7/)201/!1!1#3$6.@&101102)1//#22$1!2,2+1%2/2/,8*1)1.1//!1&102/z.1*202%21%J*2$1#3&1/2#6&3#2$1#2.9.2#4/2/2/%2+1/!1-3*1%4*3&2%	ecP|JD@EONiGF`XPHabHrJIJHsJJKQIJHjJIJIqQJHt\UCO_\bjzpADuSUUMUUSP@@APPSD@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
=xxh=x.>S(.i.>.>.hS(.i.=x=S(S~.>.h.i.>.h.>.h.>.hS~.>xh.h.hS(.>.>.>S(	:UvztzOzKxlQRAU3QHGAseF662FhY088@xq79X18@ce601X!FW1!w8RoYY4W2W16AaGV401!F3N2W!80F	0Xc0IV02K03x!C_06k0Tk03FV2d0A4!sg0c03Z!K_06c0RV1q0C!1pg0MV1g07g0Xk2V0DF% 10kZHC6ZlkR41A7VVGdaF44213YH8sVB4WFF8gR11661mkoVE9WFG0cXBT23W1XOsNF41VG0ZY8251411soX5420sR4226YYRV8R4VN@Xl0R6510XW9F48A3XG90L95W0F462E87t0Fk8BHD62lNgH910kFBoV11778Lkc68@412110L831W0F@61VkN90VV24XG0ZL842WFR4110nls44PWZ130VW0gL94Y1NN@51VnH0844C0VXZ0oBV@0XXGFVFL723GcVD7210N8430cYZRV8g4	#L0k!@0V!602!128#Z6F!4V@#@6F!9cV!4ac$FF!42k#m6#d9$fk!@Y4#1BV	+1/+@/!1!B/&1/!@$42!13$2/#1+1//%4-1)2,301/2-1-1,11#2/&101%2//&10201#1/01!1!1%401#2/*2)2%94%1(4,1!1%2%1$3$1!80101,101#1%2/&1!1&3*4#1!4$1/(2(1/%101-15$2$2#1/02(3%2$1$1#6!2!210102//+1/*1,10x#10301/,2$B//#2$2/3301/*2#2+1&1+6//02//$1$3(5#1(2.6#2)	elVZHL@JIMLam`IABPpdLbdLRTVdTjVRRTTTrVDdRrn~aQj`@jjjjji`PB`@@					antagonist	D3 / D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.=x=S(.ixi.=S~x=.i.hxiS~S~x=.hxhxiS~.>x>xhx>xhS(x>x=S(x=	:Uvzv:rSzjvyvzUjRHUvdQzEjj_ZPRefi2E3k_@3AXVF7YqKFWH4AZ8DJ2HCgD0T31oV1421!11NiV0V8F0	0QF!WR0Tk025k1v!DA0@!t!45k1_06k0Tk04AF110480bk04AV110480eF04IV2A09w0t!4OF1g07g0zF% $FL@13WNZ822W0NJ6410JHF824EIm0XVG94B@5ZG0c260W31dVFL9750kN8631VOW862FCm0WFFWR8BBX1N8@5@5523W0F67WVkB4JH0VZ2ps9Ce2D22en8ZJ3660VFFZWV2DD60W8NVeU63l884FG8FG0WNF9FR91kV4RFEZ130hKsFR8PD62WFkD3510F44PGC10__c9Ge2E394lcoLI20FG8g228@1AFWvJ4L7Z11VhpcFZ8JL7WkcJHC1WVF8kaNj1ACFH0FG2S5X1Fkw4225ZAkHAJ4N5Z11VhKsFcA8241m0WVH0FH96XWNtNJ829VkFF2156b69VFF8HF2ZH8JH91Vkc8kNNMC3WsFR277VF8FkZVU@2XN46DB78ZWcVHB6W08821B664XsZV924091422E10YHV	#84%J(3%4@#5Vk!206#c_4!14$8FF#2k$Z#88$3V$J!211V	//(G,1//(2/%601!3/+1*1#2*2!1/*1&204%3*1///+1!11,2/+1&1%21!4//!132%122(201$1,1-1!1%5&2/#5022/$3$205$1+2204!23!2!6+2/%5&4/!1)6//01#32020122-16$4/4(2*1102(1#11#8)11//&1#1#1//$10z#10201-1!1/D$1*1,1$1/%2.2-51302*1(1+6//&2//$1(5$2$1/0@$1!11#	ejQRDL@ALbkmE`H`bHIdLbbbrtTVbRRtRRbjTRVXxRJfNQq``Jfjjjjfj@BJ@@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
77-]]-7777]-3<1cS~2C8i*>S,._.Gu?<3G.ugu?zSgug1zSzSg1zSgug1	?xzQxzvxxfUpdvihwCUA7AZg9Nv4w2Vn2Y83GmkJqGF8F44@2c28C3206Fc020J0486A0s0F81!6830	0aJ0Tk02Ak3V!DA09w0t!3ZF3a0Dc!qJ0Tk3x!Ji0440Xk2U0DF$ 0FB31t84@142m5OS214820kcoD72W10F4540kV4443Volk44L214et0FF90sM0_lGsZ4PBKDckm8VD4D5CjlFNZBnA2410X14N21Vkk4X122IGkJ4NRIFg0lNNsY5361VF8NT352WFRL511ks8wP2158O0Fk@0uM822W114P832GWts63122XV	#80V*4*4#192$3$Y$4$8F$2k$5#O8#85c!202!211V	,1$1!1+1$E$1(2#2*3,1/02+104$2/01//,2(1/-2////#11$4//%1/&8%1///2011/112.3&4&2)1&1011-204%1$4(3+2$2&11)1.1&2-102#2$1)3$2//&2/D%1,1*2(101%1#4$22!18//*2)1&3$3%1&2/0q%201/-2#F-1-101/.2#21/#5(1/*11///&1!2*2%1(1*1/031,	eg`XBH@KIDck`ICHhdleLeEDdThdliPqyELm@AUUUST@DqB@aAa@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
|F`*vl~S.>v:x>.hxh.>x>.hS(xhS~.>x>.h.hxhS(.>x>x=.hS(S~.>	?wzQxzvxxfUpdvihwCUA7AZg9Nv4w2Vn2Y83GmkJqGF8F44@2c28C3206Fc020J0486A0s!81!6030	0aJ0Tk02OF1v!8j0D#sg0bk3Z!DG0DN0uV05AV1108g0bk3Z! !59Vy3482O0FF9gqU38X10FsJx221XFkW4VD22_V8Z4E48WVk488BCE84cNgBBQWWY0wV8N54T@411FVZVC61GNkwm420G1GGBo29aF8ZRLD343W0R6250VVVD11VW888ZD10XJlkFuF7Y18soRr923W0VFcL@42FccD83XV9ko42@E	#80V*4*4#192$3$X$4$8F$2k$5#O8#858!202!210V	//(E!1*2#2/0101/$1)6$4$2/01/,1.201%1/////)1.4-1$101//&4%2/*1)1(1#2&11)12/&2&2!1)1#1011#1)214%1$4#3#3/)1#1/&1%2/1#2///,2/B/#1*1(1$2!1#3%2#6/!2//01&31#3-2/0p%503)1+2!1#21!H$2/!1/&6-2/)5//#11//,2,2*2$1$1#1*1/03-	fk`P@D@mlzSLkjlvkNkqFYZM[UUUUA@@DM@@@					agonist	PGE2 ( EP4 )	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
,e:0q5^}~W5q}^p3hx^}^}zd}J}^x>xhx>xhx>xhS(x>x>S(x>S(xhix~S	=vzv;nzynvInJQzfQVvmjf_0ODcWS!5Gh2GGX0OZDZ92B26LF82B2k02FcR20R#cY2X2%WFF0	0aJ0Tk02a02Q!@C0ER!qJ0R01v!B90Cc0xV04AV110480eF$ #BV8R4@DIYGcZBDA71WldJTC6W0s84LDA34nsoT65YZGkVFPG7XWcZ@41VV9d8r8261324VRPH3W22O04B@63lNwF920VV8oe119bO0G8DF482qM12VgV8R44873GkoF921VVB2PEC11GFkLD5WlFR6310V9tBw893YWccDA3X0F8610b_Ik	#80k$F#4$4%8#2BX#8k$W#4VF#8FF#@o!805#GY$5s!252!258V	)1/!1#3%@101*2-3/(13.6$23#3(1(1(1(101(1//,1!2/#1$2011/(5,1,132&4%1$1$3/%3)12+1+2/*3#12/!21/#1!1&3/&1#3#2$1#601#14//!1-2/#10111/1-2#1(1//-1!8(2/*1)2!1#2&3!4(1(11,2/#2&1//%p%3#1/%3!1%H.1/#1$1//#4*2101/&1!1$143!1-1/,1/(101)2)1/!1-	eghTBH@LCHDDe`@cIIBhhddlTdhdliihxYYtL]\mPTEEU@AMQEAPP@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
2fSy2@xi2f2fS-sARySy2@2@2@ugS-tg2fS-Sy2@U-(f-SSy@2Syf2-Srj4j@2GwxK_wt@2f@2momo<rxK	]x<vzEjU<CzUzUjrJS:xyErvbwDzrjZTvrUr9mxDxyjqfr5jY2_9vp@rw3OGG81R8vaV0FV	0XZ0IV03OF1r07k!sg0cF3Z!GG06J0Q01v!Fi0440FV2U!HE0@40t03c!LA08s0bk2V0DF01_80NF1r07c0U03L!Ri0440Xk2D09w0c03Z& !W8X96YFNF69@5WVG9TF422493lNgR420kcF@2C4aVn9BVF621lNtBZFAYGckRN6N93XNkFDB7m0WFGe48X244HFJ8B98m0WVHXl2245XO0Fs84BC65H8F61110k4440c34BV8N46I8ZFFsFC3ZZ2RV8k5By241AFGOgu473IEVW8HKNH331i5VFN8PNPXW1kVJHCB31HFFB@310Fkg829Bm0W0G8FPL7XZkVNJ4211WVF4HN672HNNTL1WHFt8FcK11GNw66962FNFZgJ67Z0kN8C1VVFF412VZ1e0d6DC22Vcc8DB36Z1ksJ41Y11FocRJ51llJNNB14YZH8oJF20l8c2JC@m0WFGOgDi3VWWkkkg@3C2kVFL31WW0NZVN_16f2FFcBB743H8d0a2D7VY1F8c@289	#e4k!1%ZJ!12H#hi#5dV$7$h8!6_8!19F#V2k#K5#ONV!8Us#JD!21BV	*11.1+B!1#201%101!4$501022(1/(3!81#7$4$1/+101//2011+2/1&2#1)1(1//-1!2-1/%101$1#201+2$4$5%2-11!2#1&111%1)4!1*1)9&4/#1,1$2$4$5!4%12$2%2#2%11//05!1/#4,1#1-1#1!2&2!2&2$2)6#1/$1&501,1#1)48/01/*1)2&10101#1%4,2%z%6/#2!1$4#1!F!101/$1)101$1*4*1!31/@/&2!1)1#1!2)1&1/)201-1%2$1#5/&2#42&1%	eeWZJ@@DLHndPEJmclbbbbbbRbLqLtRTTrbTbRkFebPVPJOLkUTCTQQMUMLETDTP`qPXP@@					antagonist	CCK-A	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xi.iS(x=S~.=x>S(xixi.iS(xhx=S~x=.=x>xiS(xhxiS(S(S~x=x>x>.>S(xhS(xhx=x>xiS(x=x>S(	:UvzvzyzOyzvytiU_BuyemEjAhUZXKKz_Y@8bHZ90qVVJL1mB41nW@WaNBWV0Dg048VJ0B01@J882080Wk0s0	0Pg!Z80IV02OF1w!9_07k!qJ0Tk1w!C_07g0U!3i02t0BB!sg0cF3Z!DA0@40t!3Xk2a0DF0 %sZB2V8cZK8y11WFqes265311WNwJC7WlFR220aXIFFVqDA3GcscRBC971l08D9715FsBJ5930cFB1B610GGfs4La13WBGkFR25630GFF4FD44W0cZZ@820VF@ND10Y3Ik8gFy23WZ2sk8D3WkVFDJ9@EbWGJFF8132VFVBB56YGNgH620VVF4VAF5Z1csB20X0cJD726YIIc8xB2BF0XVlOwF72VG0NF511I1N84HPg8X1sV8374YVkVBD29XGFoD11W0FB41G6VFF8BHc21YlkZ843W0FR29111054R10W2owV8F48942H0wB1410c882D610GGsBNiI22W3Og6Q47Y0VFgN465XlsgP451VV821D6bO0FV8FT631VVNJ732Gc86RE0VYIkVoD410VkRF64XF8RB210F85FP115eVkNFi4741FF8JC20FkNZ627D7XOVNRBH3LWm8cga2960VFcgP481G8VF411kWsc227F73kIg866430Wck@532GFNP@0a3VF426@20X40VZN420W0g@76VVs84TE10YF848J1111p209L6B4akFNVNBJ233kJNR52WkcVZf8251F5HWcFH85731W4P86W088gJLU15GFFsG4B933X0o8FE1W0WVN4JL34YFsFLD2WG0B6NF10F8NkH2@FGVXoN8Zy273m0VkF	#c0V)44$F)1c%2$d#4_$8F$2k#4Z#O$858(218V	02%1$2!1/%E%1,21-2/,104!B$3$4/)1/,4//%1//)2,202/)2/02%1///01(1)1#3/$D3#1&2$3+1+40301!3/#6#1)40101!3#1!3(81/(2,1#1#402#6$7*10302,1!1%4-1*2,1%2,4/!2/-1-44%4$3(1/-1/03+2.1z/01(4(2&R*502%1/01%2//(1!@02/08/31.62/!1#11//#2%7*2%4*4&2201!	ec_^L@@DJCAklRPMClbbTTRTRTrtRbTVbVlTrLrUTvpKOJnkUUTuAPEPCT@p@@@XXTDTQD@@						MC	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.>S(.hS(.>.>x=.ixiS(.>x=x>.iS(x>xhx>xhS~x>xixhx=	?tzwxIxxnUFv0MEOeHs0IAh38PcPUX598V3FWA60_VV29cA4Jq16o@APoGW9226BW640@4J040_JV0F0	0QB!aJ0Tk02J03d!C_07!Tk03Y03a0DZ012s0FF120@Z01pJ0Lk1k07g0Y03a0DZ# $4sN4341VFkaF44369VFVVZ@1233O0FcAO23522GBV8N5Ju2513Xtoi6560VF4BFFzHW30gV8N4eP9Yk84623VXWs44P115aAosg21552Z3WBH610VF842110F4wNT8A51cJJ930k842NE0VYIFFF8D5YGNNF8210V8410cYZRV8J5kg221O0G0DF4D2c1DVlFNKXQ6VV842FB0VWmF	!2W0k!2@%2#44V!28#15e!2@5#8l8!20k#VF%o!40_!21cF!19k!3LF#50V	1/$101*1#A#1%1$201/%101/*601202$1#1/-1/#2(1!1!61#111$1.1)1!1*2&1/-2,3/01#1!1!1/!2%302#1//$21.2/1$1/(1$101/*4&1)1$301%2/%2!2%1#1!2//!2*1&2-1/+1#1$1+6$4/01/%2*1&6%1/!6*1/)1&2/+p%5%1,101%1&F02//#2/!211+1/3!1&1!1)203(14//*1//*201&2.2!4(1!10	ek`TL@@AL`DOLbbRbRRtRRQRRbRhXTLbrvNZdHHjjjX@H`BBj@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
,S77Iy-]-]Iy3<1cS~2C8i*>S,._.Gu?<3G.ugu?zSgug1zSzSg1zSgug1	?xzQxzvxxfUpdvihwUUA7AZgANv4w2Vn2Y93GmkJrGF8F44@2c28C3206Fc220J0486A0s!81!6030	0WR0Tk02OF1v!8j0D#lR0OF1v!DA09w0t!3ZF3a0Dc01Hs0FF2A09w0t# #N5Ic8FV9Z110anX8BX72W3WGkZc9B2kssk@2@80WlNkB311l08D93W3XN882223V88hBV8C_1ccNR5163a8kNBH6394GV822444m8487111WWlFwl35Wc4@8BD6H8kFlVTF4B2ZE5GVVcF214YG8JF@4XkkBB527YIktBV622WWtc841X2XWl4m18VGFN8HB2VXHV8J@331lFJ451XVsZ632cZk888V111FlXlRFCBW284RT416W08Fcf8231F8JFNZB2621VsRN74Y10V4210V884aAI	#84V!104$4*4#1d2!203$X$4$8FF#2k$5#O8#858!2G2!210V	,3$1!1+1$E$1(2#2*3,1/02(2!104$2/01//,2(1/&2%2////#1%4//%1*2$3!1!4/(1//11/112.3&4&2)1&1011!11)204%1$4(3/)11)1.1&2-102#2/$2//01$2/A%1,1/#1(1#4%2!18*1/.2)1&3$3%1&2/1q%1(4/&2#F-1-101/2)1#2(1/503%1/*11//&1.1!2*2.1*1/031,	eg`XBH@KIDck`HcHhdhULeEDdThdliPqyELm@AUUUST@DqB@aAa@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.=x=S(.ixiS~.=x=.h.ixi.>S~x=.hxhxiS~.>x>.hS(xhx>xhS(x>x=S(	:UvzfzUzSzjQTQzUERHvvdQzEeb_ZPB@fi2E3k5@3QXVF3YqSFWH4AZ8DJ2HCeD0T31oV4423!11NiVV$	0WR0Tk025k1v!9_07g!sg0c03Z!FM06J0Q01v!Fh0440FV2U!Fh0440FV2d!GE08s0bk3Z$ %2m0ZHA6YW0F42163YBV8N4FJ3YmsVF6860kGG9NN4IW0YklP8iB6Vk88VJFX1793cFZE82B1373lBH233X1wV8N64X23W1FcV@752WNR@42WkFJ210d4JVCkB680VWW0sJHC731NN@@1Vn2884RP9B31NJP731k9G441270FGOcFTJ@4GNN4197VkGdF8cA3@BH8FwJXJ4YGdF@20ZXmFH08U215Wt0FNBG04920YWFZH96XFNBH510VN50RVK615XA48V87DalcNN110F9Fgd42GW0Y0gV8B64X2511XWBB61XGNFB40VF9l022D0VY4BV8F4	#84k$J(10F#4@#5ck!206#cV4!15$8FF#2k$Z#O8$3c!20J!210V	//(H,1$1//!201-6$@$3//&1#2-1/*1&404%1////&1!21///01&1*2!2/&133#30122*1$1/.1%4&2/#2024/$6$204$1)302!4#1%6//!2#1!4/,3//01#82#101-16$4/4/$104(1#11#7*1+1/*1#2#1.1/$10z01030504-1/#F$1*3,1$1+6&202.2-4.1(1+6&3)2/$2//-5*2/0@$1#1#	efYRDD@ALbmmE`H`bHrJJKKQQZIIKQIJHqEQIL\IESGDtpPESUUUUSUT@AP@@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
?uguzS,S77Iy-]-]Iy3<1cS~2C8i*>S,._.Gu?<3G.ugu?zSgug1zSzSg1zSgug1	?wzQxzvxxfUpfvihwUUE7QZg9Nv4w6Vn2Y93GmkJrGF8F44@2c28C3206Fc060L1486A0s!83!6830	0aJ0Tk02OF1v!8j0D#_F0zF03Xk2U0DF!t40tV3e!Ji0440Xk2U0DF% #BHdo28F4m0VVIdky6G41FWkdBoB71lH8cB4D2VY208B46Y1210g830VVsZB44W09tB2210FN44D@O5_mN4o@I4WVX0J4PFUTX0l8NFiG40FFFFFI80FcN426675mvNBL6LJ9VlNOFax361t0Fk@VkK722W0F88w331kkkD74Y0sB4220Ilk48135@2mcoB46Y3nFB224555IsReI0VGlNsNJ832FFNH141G88220XFeFs229I90Zl0X70YYGwV8N4dF23W0kkZ@A2Xl8VH921Fdko22@E	#80V*4*4#196$3$X$4$8F$2k$5#O8#858!202!210V	,1$1!1+1$E$1(2#2!4&3,1/02!5$2!104$2/01//,2(1///&4)1/!1,1%4/$1/1/&4%2///!11/112.3&64%2)1&1011!1*204%1$4!4$3/)11)1.1&2-102#2/$3//&2/B%11$1%1/#103%1#4%2!18//*2)1&3$3%1%12/0u.2/&2#F-1-101/2)2#2/)802%1/*11///&1!2*2%3(1*1(3(31,	eh\XBL@@cJo`PIABPpdLbdLRTJfRbbRJTRVTDdRJNnj`@jjjij@BXaCPcp`@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
D{)LS(xix>S(xi.=x=x>xixix>xiS~x>xix>xiS(x>x=S(x=xiS(x=x=S(x=S(xix=xi	?vUvyn:uDmtJUyxaqya_d_YtqdAI25k@83GFs0A_W4A3l47Ru80CF9@2Fc801H01@Z8@238VG5FX0G0	0Pg!ZB0IV02OF1v!8j0D#b!vV03AV0k044!t40tV3c!G_07!Tk3i!F404c0IF3q# m0WkFN@N423Xl8cDB4WVN8km81AVF8428G10YV88hF82W6XlsJX@1XFF8cg41710GWcBB95528g860XFN4oPP465lt8J82W2GWCRP4D2m0WkRV8B482Z14GVZV931FkFcm11@10GcB24@E86WVsN553Z0V8sVPAA8mFcoM82A1EVaFVF2M6a1XFsO@VBX21BV8s4421VlkgP@4XkF84717ZV89042D0VFWHNF4qI6ZGVVPBJ20ZVF90232610GGaF4B3Z140W0IksXF5VlsN8FK0VZVV8o41256_GFJ8CAa1lcs4423JVVcVH852VsV@51VV884VN0VF842@E0VYLF848852GVsD84VFV8sm11@VVHN44X2113JtlN885P514VV88F76XH0RDA20FN8sq218VVGs444AH360N84D43GsJFLJAb5VWFFVLN731NBH6964ZYkFsqH31XWJ09H82G2FG0VVG8y4GD5V8NoJnA22W80GoF4L48B162lBo6J5	%V!1&F#6$1D#39X$l#FY8#Vk#8k$2o#V5#KV$Cs!252!259V	&2+2,1%F/!3(1/*4.21#5$3///,1(5%1+2/,2%1%101/$3&3,3/1(2%1/%2%1/%103%2$1#1+1/$11&2&1#2#5&1!1)2#1,24!101+7(3+202/2012!102$1&401/#1$1/03//(402#1(310@$2/1/.2201!1#9#1&2-2/!1/$1+1*2&x/*1,1!D01!4,1/01#2/2!12%11/02!1!1/0122(11/.24.1#1&2(2(1%1/,9(2$	elZXNH@HhDACOO`P@cIIChhlleLeDeeDeeLeMFnckejB@jjjj`@fhbAr`@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~xhxhS~xhS~.hxh.>S~x>S(.hxhS(.>5qqqx>x>|`S(iy`|l0|F<y~Sxh.hh.S~S~>.~Sh..h	=v?yt;TuUv;v:gZxxzvjUAbI_dUzqVp7zyru3rWdh6vMnrO@g2oeVrI4OL9k0208se1W8kF	0U4!XJ0zF03FF1209w!mV0IV2g!DA09s0t!3Xk2U0DF!sg0cF3Z!C_07g0zF04NV1_07N0o!4Xk2T0B!t! !CVG@s4D41B3l0FFF12FFB44C66WGGJHC1WlFJ6210V842VA1VFW2ISN1361YV8G502E0X08NJF1@WllJaD1Z2XBV8V5R2BP0X0F8NCD2F47WcV4@@6OfVNNJE822110XqXs8D6EC160kR8B5WVF884@6a4LP0BR7Z14V_20G52U2723kHkVB4H1cFH0FPD79W50ckBB5Zl0sk22@@m0W0R8B8H4G9cIkW0I8241l0XFF8N8PN6ZG8V88860VFFZcdE0WX0wV8F78261@40AwFL9Z13VVFH2d84C@VXG0lB8H22GF4@3110kNsX2167WX1lR8I20ZGKnN8R5Z130WlF4uY9351_nN8J41Q13scJN@U196k9gBR5161VGF84DEZ140e3s8o854QVX5c8N8gW27lFcoKH2BE70W8OO@U52213FkVI50Gst0R	#e4V!30c#6B!220k!Z@V!1hc$t#Ff#4Z9#AF#FEk#_6#SCF#_s!2JV!23CV	01$101/#1$1#A.1%@!1/-3&6%4$3$3!41(1$1#1#1/+1-1$1/*2$1*1,1/&1-1#2#1/%1)2)1,11.2,1!1#1%12)401&3*10102*1(@41$3$1&3!1102#1-5$1$4/$104122#6!101-201*21!6/$104101+1//#2%1,2!5,2&14*11&5!1%1#1&7-1/301$2!1!1/&1/,z%4%101$12#3!101!1&D!5%2//%4!1%1201/02(7#101$101+11&13)401$1//$1&1!11(511#3061&4)2)201$1%	emWVBJ@C@jgodYOHk`I@bPydAYBVPrJJKKIJIQSSRIVSQKZIIRIcb[Y{yeVB@jjfZjjjYhHJ`h`tH@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
=xxh=x.>S(.i.>.>.hS(.i.=x=S(S~.>.h.i.>.h.>.h.>S~.h.>S~.hS(xh.h.>S~.>S(	:UvztvSzJhwQJAzEOPFYNeNbCHIhY088QhqE@X10@kf!3Y0@OWG!gsRoYYKn31079mO0401#3J2W!80F	0Xc0IV02K03x!C_06k0Tk03FV2d0A4!sg0c03Z!G204s0Kk1Q!K_06c0RV1q0C!1o40G01g07g0Xk2V0DF$ 0564H9NJ42WV9FwdXn2313mtog610llVyF44257ZXcwL@10V9Fsf825114Yl8e90YXlreR8D4TS30l0OS2E9X0FkcQ825110WVwVC6WW8J82B86BLNFVA827123mlVR@31H1W0FL86ZlNgB3210F44RFDm0WVFWkXM32FFN42@7511FwTC6XVcJ84164I2ZV844520kckLC5XGVR6310kFBwXT33WVsgDD7XVkF610VV@0t3826185GcZPB11VVB2LBA11WNcHA7318N441VIWtklLR822W0FRF742G8sF72WkV8410cYoRV8g4	#i0k!80V!612!128#ZLF!4d@#24F!9cV!44c#8FF!42o#m6#l9$js!@Y4!21BV	#1!1/01-@/!1!B&1//!@$4$3$1!1/1/+2/%2#11*1&2,3)2(2/,1,11#2/&101%2/%21.1#1#1*1#101!102&401/#1*202$101%A4%1(41+1!1)3201$3$1!801$2)1%1//)3*4&402%1*1%1!2(1/%101-14$2$2/%2(5+1$1!26&10202/)2/+1/&1(z#103/,102$B01!1-1%1-2/3!1*1.6*1#1#1%1#1$7////#1!1$31&5/,4-	eb^ZHL@JIMLig`IABPpdLbdLRTVdTjVRTVbbbbHdbVWtJNMT@EUUUSUPLPE@DET@					antagonist	D3 / D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>xhxhx>S(xhx=x>xhx>xix=xhS~x>xhS(x>x>S(x>xiot7tx=	?t:xIzwrUHv0MERemuX7@_0AP8ez2_!x2G0X0OWXW10V42MF8DJ2e84Fc@2#10V1222!FXFV0F0	0WR0Tk025k1v!9_07g!t!cF3Z!FM06J0R01v!Fj0440FV2d!F404c0IF3q& 0eF3WGW8L71ZZ2FVVP9631cVD22132s424J0VYIlSZ8J4RZ13FWP94741WVkkRgS53l8N2FD8m0WkHW0D@AYW8sgR8E4XHNsN630F9O42226at0Fk8B8A52X0kH420kk84RN0VYIwV8o7823134o0ZV830m290BPA4Zlss6@9A0FHVB4TL212GscJ94Xl088210V@1K0RTF5l1FaF46213WmNwgA3X0GFwc22T231ksP@42l0422B8VF8Fsz8241	#15k#84$F#4%D#3Ve!20lV!Vd4!4VF$kF#2o$4#1V#15k#52!259V	)2/-A/*1/+4/1#2$4/,1&1#1.1*15/)4(3/#1-1.1&1)1022/02//(1!3/%102%3!122&2202(11%3/,1%5&1(1%1/4$102#101!4)1)2014*21,1,4%2&4*1/#1//$2!411/@$4$1*4/+1!2*9//*12*1.11/(10p/*1/D/-1/&1#1*1102$2)2021#10102+101)4//4%2/&1/%2*1-1!5-	eohTBL@GHaLck`H`bHvBDfYwYWU[e]ZXxl\Ff``JjjjX@JVH@@@					antagonist	CCR3 / H1	CCR (I Peptide) / Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.=x=S(.ixi.=S~x=.i.hxiS~S~x=.hxhxiix>..ix>xhx>xhS(x>x=S(x=S(xi	]S:vzvzUzRIzvdvzEjj_ZQR@fy2E3kC@3QXVOYYqSFWL6AZ8DS2HCiTcT31oV14a30211NiV07030	0WR0Tk025k1v!9_07g!sg0c03Z!DG0DN0uV045k1_06k0Tk04AF110480eF04AF110480qF041F1C0CZ0xV% O0Fk84o93X1kgD30WV886RBD26ksgq721k886L9AFV_0FFmY472b0k4BO11521o9wX@1331V8k9D441ksR6A1WVVR4310FV82ZJ0VZ088tNH7121kc893X0sBD20b_0F48XX2iW0lk44L836_GsZ832110RDNK0VZYQs486@3j1VVcFRsPB2VN8RFE1GW1kVNoJH8YWNc42@@5118N894XkkgB3110V442G90FFFw42@J3X18kX@5X0NR421aZ088ks5S21X088NFFL92l8cL430F9O0j826123mONg35VX20424C@FV_FV8Ze47XcFFFs8x25X338VBCAX0N4ZLIZ11VVWFgF96Wl8N2210FkB440d4F88dD2Y24W0G8VN983FkB2830VV4wTTW1AWVHQo4V6W1140Yo8N86Cc2cBLBE6m0VkFFVgF3Vks8611XVNRBTKEVckWFFFTN3XFNZL910kGW822FCm0W0F	#84k$J#4#1F$4@#5gm!207F!cV4!14$8FF#@k!80p#G8$3s!21L!210V	//(H,1$1/)1(24/$701!5/)2,1#2-1*2.1)4%1//.1/&1!21///01&1!4*2*1+103%122*1$1/!2+1%4#4!2/#2026(2!20403#2$502$13*2!4#1%4//!204$4/,3//01#32#101-1@$4*2$4/$102&31#11#9*1//&1#2#13#53-2.10z0103#2-1.2#D$1*1,1$1/%2#2/)5!1%2$1(1&2#64//%2*2//!4*2/0@$1#1#	ea]\JL@ALbmEmf^PH`bHzBLbbbrtTVbRRtRRdSRbRrcGBQTuvILDATuUUUTmT@DqP@@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S(S~xh.hS~S~.ixi.iS~x>xh.>.i.>S(.i.>S~.iS(.hxh.>.>S~S~S(xh.>S(.h	:UvzvUyzKzxvTtvCrEmt8uUgEeU4oJCjjd6B303OHR2ck7VH148mc2W4BF0V1041V7Wq1H03F4F0VF2X0V8F0	0Xs0IV02OF1v!9_07g!Z80eF02K03x!9J0Eo!sg0cF3Z& 044H7VccL285411Gwy44WkO0cY82A1h2VVsFBPA9Z0k8H610kWVo6224b11FsgI2VlNB42163FF8cqu723W0WcoVI734lk4444710GGNFVD4ZlclBP3280FGkJ44@Am0XFHmKD2442O0FkDF4B22F4n082@443088c_47IVG1sRJ135Yg5kJBN613YFkcN971VN84320F@0w41260FGHN48D42WcgT710kV8410c3oAFc8@4wJ13VWdNXE60VVJ@315YXk	#11V#8$4/0VB$1$Y#4Z$8%2V$4#G$908(218V	.3$1,1$8.3%8/+1(3$@$61#6$1*2!1/$1/!201//.1/%8//*203#2/&2//,4!4!2/&1,4%1-2#4/01%@8%1!1(1!1%1/%2$1!82///.202*1&401/01/5#1//%4*30301/)26!2(1(28//$1//,5/w#105/#1/F/*1/&4$206/-5//#15+1*1///$6(3/*204-	elZ\HF@@bgd`IABPpdCIBrP\dLbdLRTVdURfbbbRRvtDdv^n~j`@jjijhJBJbHLb@@					antagonist	NK1 / NK2 / NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(.>x>x>xhx>S~S(xhx>S~S(xhxhx>.>S~S(xiS(.>S(	:UvzvU:KzxvyvzUzCmLPvUiEAUCnT9jdjeA5nYIUZVck7@21k9n829CBkWo4961e0t6VJ7010K1W01V0V8F0	0WR0Tk025k1v!BM06J0Tk04AV120@g0gF05Gk1E08g0bk3Z!KG06J0Q01v0Eo0 %@VGQ4H473d4VVsKRP452610XGBXN370WkNBF212Zt0G08pkU35WW0FcXG50WFNBJB21VF8FBRPDAkl8Ng8k375GNFBJCZ120W0sGJDL8WZH8882111WFFD47CGfmFNZBP9NWYY08k82@5m0W0RV8R4	#15V#84#4#30F$@#4Vc!205F#_k!4V&F!V2V!114#1$12V!@F4#1CV	!1#1&1/!1$5/!1$2/*1/(4$104//(3//!1$1+4%62/&5*1/(5,1!2%1#1/,1#14$2///-203/!1(2#1*6&1/!2%2*1&3$2!2/0112#1//)31/01)1&1(102/*22%1.2/%2(2#1%1)1+C%1/$1//1//#10j.3*103-B$1/,2/&6/!2$1$2.1/$4/01$1.2*1.1)12&3)21#3,2$1(	fmwqC@INRXDPrHWHYEDeDUECEDhmEcSbZcg@DUSUTDPQDKT@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
_xx_<sSzu?js|iugn>u?tczSS~uCgug1sjzSzSIyyIg1oooozSyIgug1	?wzQxzvxxfUpdvihwCUA7AZg9Nv4w2Vn2Y83GmkJqGF8F44@2c28C3206Fc020J0486A0s!81!6030	0aJ0Tk02OF1v!8j0D#sg0bk3Z!DG0DN0uV05AV1108g0bk3Z! 02gkS2241BV884uUB1ZG0V8R@QWWVl8NBXF8W1Hk8L2724FkB43466aoPRBL68BkklVTF4B2YE4m0VcFBH73kVgNTN1VkFVccgL1Z2kBJDA722WkVD422FFFF710kNR41H794VdcNF62WlctuB4721VWFoH75218RH73aYV88cs	#80V*4*4#192$3$X$4$8F$2k$5#O8#858!202!210V	,1$1!1+1$E$1(2#2*3,1/02(6!104$2/01//,2(1//////!11$4//%1/&4%1///!11/112.3&3&2)1&1011-204%1$4(3/)11)1.1&2-102#2/$2//&2/B%1,1/#1$2!1#4%2!16//*2)1&3$3%1&2)1&p%503/-2#H-1-101/6-2/)5(1/*11///&1!2*2.1*1/031,	fk`P@D@mlzSLkjlvkNkqFYZM[UUUUA@@DM@`aFj@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>S~.>S(xi.ix=.=x>.>S~S(S(zdW(.i.h.>p3}JS~~W	{xzyzQEnCmzhvCiEaN_ooEh_h2eb2b8HzX8m6P0KJ5lBm8BD4nk!XGZ6GJ02101qk2ZV#2010	0aJ0R!2OF1v!8j0D!1Hw0FF120@Z0s!5CF1E08g0bk3Z& $278sT653Xb41JT11321gV884XhHWWVkGR2TB5GW0kgJ9D_1GOF2487U0Xok8Z88A8YG8NLE2VF8B42D4b0FVgPE42WFc8510FF8wLT@19bnVs850Y30k8cV	#11V#8)144$@$Zc$1F!Fd#4VF#@F$@o$4#GZ#91s#4#258V	//(71/02///#B$6#11*2%1(1&1////(2/01//01#1,1/1&3//.4////!13.201$2&1-1&11#1+2#303!3///02/#2$1.1/01-3&2/#2,1!6/.2-4(1(23//-101#4!1/,3,j!1!8)11/01&J!101&2/%4+4$1/.3!2/!2%11)7/02////#2)11!1+1*1$	fegQ`@DF@r^QQQJYQJIJIKIDMRc[ujjhH@hBbBPRai@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>x>.>S(xhS(x>x=S(x=xix=xix=xix=S~xixhx=S~xixhx=S~	;xzdzSUrxhUR@zTAVFfscP7a21hYA@8PiV71X12dkY!1Y0@GW10GBd4w3fCYH0@3940840W@50107WFV0F0	0WR0Tk025k1v!C20@Z0gF03Xk2Z0DF011R0OF1g07g016J0Q01k07g01o40G01g07g0Xk2Z0DF% %m0WFFFBBA83GsgH320F84sa1180FGk44NX45ZHO4N621XHN42137aO0FFDF4D220WkVcNC62l8NB210ImWsB4G9ZH8gB40_3k88ggBCC6GcV621ZXmRV8V4422Xmd0R9410V42PDC0VVscPF5YG0F8210F850c118VFGuF8HH84WcVD21VmmV44ZOZ11VVF8J89631VZF81W0V82VL0V_089822CIm0XkF88HD8YWNgB330VOdBo225ZXkwL720kFBkVOZ11VVFF8JA72lcNF71W0N8wa118cN0VFNA8241	!1c4V!20J!412!16$42#6cH!20LF!cWZ!CVF$FF#2o$5#GV$7s!244!25BV	/#1(1%1#F-3%1+2//$2!242$2!2/,1+11$1/(2*1#1!4/,1!2*1#1.1!1&101!3/1/-1*1!1+1$1/!11%1+3/!1%1(1!1$2&1$2//&2!112/$102#1%1-1$3-3&2*403%1$1$1//1#2#102+1!5$4/)101.2!1+9021&1/$1*1//&1+110p&11!1!1%2#101$1(B/!3&1-2!1#2%101/)1#2/#1#101(1502/1/#2+1.2/031$1-11%5-	egh\DD@FKAdc`H`bHrJJJYPiYIIJIJYJ\BFV]S[WPQAUUUPAELQ@@@					antagonist	D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
ugu?Szug1gugu?Sz1?SzugJ-:r/B,S9~/d:41?S,1g1?Sz1gugSz1?Sz1g1?u?ugSzu?ugugu?	:UvzvzyzS:vytzEzUQzfzCzEEzgYJSttxP@zHbZTzva4aAuSF5kSDtaDJfmHTeeJ@dJGVOF90l0c0cXBV0F0	0Js!Z80IV02OF1v!9_07g!sg0bk3Z!DA0@40t!3Z02W0DF012s0B01109w0 038281T6WkNVB6sCWZGk8wI8251m0YFLeVD653m0XFRV8N642G1ZFWks4N9Z160WFtc8EDWV8NZLHB4YFkoPB12FN444173IVsVaJ56l8scRs2E5fFccFJ@53ZFcgL779VWN8H71Y2kF8ZswH@6G0cVK3322122d0iF6VWm0tsPJA3WGce664@211kkkL633GFg@616ZVF90sgTMWY0mk_2L72ZWRV8F6u724W5W@8Bc483Vlkks@4I5YXVVc86640VksVL9WkkN4JG@	#d0V#8%J#1%B#1d@$1$e#4Z$8F$2k$5#O8#158!202!218V	//!1#1H#4/08&2*1!1.1)B$6$3!4//!1*1/*1/(102%1/2//+2$2//)202///02/)31/0342/%801!1031)1#501011!1/#1$3/$2)61!20102$2%2#101)8$2,10204$2)3//#2/#2!8/$1(1!3+2/!6/.3/$2)101#1/,z%9/!12(1&H,1/.2!6*2,5!2+6&1+2.22(1//)2/+2%301/01(101$1%	efY\L@@D@f`BelbbTRbraRbQfbRbtblRRfg`TRQMKTDPUUTuTuU@@TDRDND^TUT@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
q5}\O(i.zB.>.iS(.>.=S(.=S(.i.=.iS(.=.>S(.>.hS(	:UvzdUUzKzxQPAQUERkffudaBm6CVU86yt273kCPAMeV10X6aJ9@48J8RN0W5sQWA304c4K01F01P80XVW0FV	0Y!IV03OF1g07g!o80bk2V!BM07J0nF04YV2U0@F0t!55F0M06Z0SF3C$ $7XV8N5Z110t0GcDF4D3Z12Vk4VFR9ee29VV88BNAZ13VmI8GB42C3k0Y0F88D7V1C0FH842136Xt0Gc8E04P0VYVmoc8Z21131BV8N4	!1X4V*V#FN#42#BV#3V4F!4cc!40c!204F!42c#X3#GF$2s$R!218V	#2%1!1/)6/%1/,1/(8$1/&1#101/.1(2*1$2/!1//$2//1.2(1/#2*2$2&203/)4////05&1/#2/(2$104/)2/02%1#2(1&1%2602#4,4#1/-3!1$1%1+3!602//*1)6(23//////#c/*101-8!103///,1&2%62%5!1//04*1/*11/(2.1$51&1/#4-	fakiA@DTYiu`QA@cHheCDeeLhdlhRbmYKMMUTt@EU@@@					antagonist	mGluR1 / mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xiS(.iS(.>S~.=.h.i.>.h.>.h.>S(.hF|0:(Six0l>x>xhx	:UtzdzSzKxhQR@zEE8kftcQ7E21hY28DTgXE3X50@PYV03YF6KWFV0gcBo3Y5W@0239o084114101FDW%	0WR0Tk025k1v!C_06k0Tk03FV2d0A4!sg0c03Z!FM06J0Q01v!K204F0Q01v0@$ $2HdJa920kFZ22A7_t0FV8x4L7W0sl042D0VY20u4qI210N42H99m0X0IGl0@450FNFRQ824113HtFP64W22c82338VVGs44PQZ130WHdogE5810GkF4LD6@_H0cH530VGFw22BAm0VkGtRsC41VNFVPGN611VVcZZJ6Y0kBB110VGcwo@J95G0c642Vk9O822EBm0VkG1soC4Wk8JVX117ZrFsFc82A75WsgD32VmXk8420X4IgV8F4	!1c4V$J!41#12$42#4VF!206F!cWZ!5Z$8FF#2k$4#G$83c!204!21BV	/,1*B/$1#1//(2#6#43$2$1/.1&1#4//%1&4/%1)2%1//#101!2#2///%1/$1102.1&1+1//%1$2&1$2!4!101(1!2/03$1*2)102#2!1011/#3-3&2*4-1$1(1/+2#103.5$3%1/$1.1!1*28#1-1(1/%1%1/)1,10m%301!1!1/&1#D!1(1%3/%2&2//!1#3-1$1#101)602//$2*1+1#2/03%1/%5-	fcqA@FVrdDPRHrJJJYPiYIJZJIK\DZsQkwADEUUSTD@T@@@					antagonist	D3 / D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(S(x>x>xhx>S(xhx>S~S(xhx=.=x>S(S(zdW(.>p3}J~W	]UzxvyzUUvCmzxvUiEaN_oyCh_j2fbXb@IzX8m7P0KJ_lB38BD4nkB0XGi6lJV2501Jk2VV5!X0G0	0QF!WR0Tk025k1v!9_07g!Xw0s!45k1_06k0Tk05Ak110480eF3V!Jp04w0Xk2U0DF$ 0OqD6X1FsdK8Q822W1cZPC52GNk8415YFF8gkuX84F8BNFCZ110VVskNC52W8g6320F842VAF8d5kNNB8K1bXlJNFB85_3cV2812FOFgcHC48X0cga1243_J9s42632WW0JXC42WFgF410VF4sNSZ11VVVVgN952l8VD430FGkw4126821kVNM61FNoZR2155@H18k8C47X10gP852l8J410aYYRV8B4685XWFkD860ksF410VJ1m0s6OBXV8B8FF13FWdLF483P511FWtVRI21lFJVJ2144t0Fk8NJN8Xl8JL210F9VZ227CA51FKJ@@5m0X0RV8Z4	#15V#8J(1&@#4Vs!205F!sdZ!5V$8FF#2k$Z#G$93c!@04!218V	//(7/!2//!2/6$6#11*2%1(11%1///,4////-1!1/$1!3//01!2)4//!2/#3*1.1201$4&1-1&11#1*12#303!2/&4#1//$2#2$104,1/01(1$3%22-2$21(1%6/%4/&2(1$1!271//,1%4//3,l!1!5!1%1)1(1&F!101/-4/01#2/*3012/!2%1*8/01/$2//-3!1$11#1/&1$	fcopa@AFskXH`dPdsNzwMrkN{NUGM\DATuTDEEPRKTSH@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
|F|Fvl`*v:~Sl0~Shxh.~S~Si.~Shxh.~S~Sh.	vzUvvfUOrJxlQRAQ2A0k39e0a4H2CV08BQS039X1!Ge#202N9@!RN4F3WJF31121080401#1!V0VVFV	0RZ!aJ0Q!3FV2d0A401L40O01p07c0ok$ 0ANZ8F4IP6VlsB4H8z@Z0kkTF4B2AX_0lcO4gPAX1HF824A7	#33#1%2$F$V3#4V8$BF$V!40B$F$FV.12k!2V4#1@V	&1//6/&1/%1&2/6$2////01!1%23//.3%1!2/%3/)2+1)1031#1/#1%2-4(2/01-1/01-201(1/-21/*2012)1,1%2///(13!4///!1*101,10201!2/#1/#2(11(1-2,201/&1/&11/#Z%3/#1(1%2@//%2///!3-1.1%5////#2(1(4/,4(1$	fbmH@@@XEYIY]YWYVcCVSgijjj`@X@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(xhS(.hx>.>x>.>xhS(xhS(.hx>x=x>.>x>.>S~xhS(xi.h.>	;vzv;SzxvytzUvCmzfvUbAjUgnSUhKj2@jHb9Mrv8FRA69L0Gh@dWNBYuHHX142kJ08I1Y4S8m09FOm0t0	0aJ0Tk02AV2g!9k0Ds!os0cF33!DA09w0t!5AV1404R0Tk2U!KG06J0R01v0Ds# 0HAdklVcJ485R0XlH88D7Z120WW8FHE7YGcZBJA10X2lmRwF43X2n@8P5531V88FU8241JalVNwJ52WXGb08xN2A2420FVR@4XlNFH410IWN44DTKbW1kbmN8D5Z120Z20NNH92kG0RVfE25W12@8BJ4330NR8DGZ120om8FR86VA70VJNH4111X0VFqJ550csw6723ZXp1gg894	#91V#8%F!1,c8$1F#f#4Z$cF$2k!80_#O$95s(218V	//(9$11+1(1/!1/&4$4$2+101$2//)3-3/)22//%1/#14//%2/#1%1!5/)102/(1%211/$3!123/!8&1//$1$301$2/&8$1/-301&401.16*2(4#201)1!1.2)2,4%2$101&2!1/*1!1(F1///&1//&2!o%4/#1/B///*2/-8%1+2/22/01!1/,1#2/)1#4*3#1,1&1%	fkH`@DLmLAraHRDaHSDQDaDQHRDRLEQlc[mjjjj@HHab@Q``a@@					antagonist	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xhS(.hS(S(S~x>}HS~.>x>x>^).hS(S(S(}H55x>^).>x>}HS(.hS(xhqq^)x>S(	]U:vzx;huzfzUjAjUwzxUjpj@@jLbOMrfsLT9mCL9nhed_8BruHTi14@kJ0NQ3nJS8k@9FOa0n0	0aJ0Tk02AV2g!9k0Ds!sg0bk3Z!DA0@40t!3Y03a0Dc014s0Xk2W0DF01Hs0G01707g0bk05JF1_07!Tk3i# $2V2p361F8FVJ432VFcZFA4X0sJ652WF8J42J6e0ksZT94XWVVD43VF9kcs@56WmkVNX1131sZJLL2FdIcVcF228_mFkD82Vk88kDNR4VklsKc20X2Wl5k8@41122NwTA71Vc8gHLiNWFkcPV4Lw13W1B0FF82121W8wP82Y1NN@20bXnkdcHWCXXGIZB@653m0W0K9Vu6E2VFWFc8843G0l8ND64WkkN4430kN48210ZlmkJ@C3B418Z835Y4GN8wR2BAI0VXOo8Q0X3G_08xs2A23MVVsLF4F2122GNNP96XG888320FF54JX253mkVou2A@VXF88RR7124b0VFNI82413MVWNF5yR211GciF48220WG8ZHA52GNF831WFP0d082F8W1cB4B34XkFt0V4KR13WO0G085yT0X4Fc8wJu4WWXVk	#d1V#8$4J!1+1d8$1F!Ff8!4Z$cF$2k!805#O8F!95s(218V	//01%D)1%202!3///4$5$4-11.1/02*1!21)13/)3&101#1/#1/)4//%2/%1#1!5/101%102-3/$4/!4/#1!19&4,102#4/!3!301$6(3&2%8$3/#1/#7#1%10102!6$1(2$4!14#2/01#2#2/&4!1!2,102-1+2!1*2G1(1/2/,1//01(z%4%1*202&11&B!1/.2)2$21%2/-@1!1-2/22*1%1!1//021/(2#4*3#1%1%1&1%	enYRF@@DJBm`CKOLV\bbTTTRbTRNbRrrfTTTWtbzVaiZjjiihjBbBHfH@@@					antagonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.ixiS(x=.>P~w;3pB,sp|`.>(W~Mc{.i.>.iS(.>.>S(	vzUQvQzvURjnvqvQ3l0HM@UFi43A_V08c1C!5HW0F0X0F7@01FZ!288H43m#1421J!B010V0302!V0FF	0PF!Q4!Z40FV02OF1v!Fi0440FV2d!KX06J0P01e0C! $BV8Z4TZBW20BNRCZ14V_tcFV88V35lkB4E85Z110VR872GVZ@31640F8sr8251V0YVdw8L6I5YmlFB22Z42BV8B78251HF0VVGko_30WGFcx@@HX2WBV8Z4	#71k!88V!2$108#VD#5Wc$_V#8c!408#8kF!4Fk#X4#18#19F!8%18V	01//%F!1-101/%4+1)2$702103//1/,1//*2$11!2,1/(1/,2#2$11//,3+2!1/&1%1-107(1)1/%101)1+2,2/21)1.1,2/-1#1//!1$1///1)6/&1+11(2!2$1)4/!41/$1*2#1//)j%503%1*1-10E%2/,1+5!1%1!2/#1#1#2+2!2/206////&1!1*5)12#1,2-	fewh@@@XISvRJJIJFIIIJjIIgOAbd\pJBjjjj@@h`H`@					not given in publication	CXCR4	CXCR	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xhS(.hS(S(S~x>x>S~.>x>x>S(.hS(S(S(x>55x>S(.>x>.>x>S(.hS(xhx>S(	;vzv;S:vytzUzCuzfvUjAjUgrSUjpj@@jHbOMrfcJT9mCL9nh@d_NBYuHTi14@kJ0RI3vJS8m09Ftm0t0	0aJ0Tk02AV2g!9k0Ds!vV0iF33!DA09w0t!3Xk2W0DF!sg0dV3Z!Ji04F0Gk1v09w01K40OF1k07g0vV% K0YbF8k8F75VmkVNX117YXNNBLJ1FboVVcFmE280MF4BL@4k11F_n88653JVXrN8R85X2212I0soP54XbsN8B@611VkVN2@2XlFVJ211Vk8420V_GN44Hg22XGcwPH4YFF8gLL444INou274YVVlBTP@XV90ZVB56Y1d4N61WFc4kJOZ120eYH4BT683Xkn0sT63@3FH8R4TI164eFHX44VQ171eFGvg4L411VkVR461Wl0NB@1WVNN8310V89RP115gO0FsDF4F215_XNVoq2A7W08NRV3224bkFFNI824112G8ZPA5WFsR8121VGscz82A1WbkFNsE82411VItsFP114kl8o4DF415N0FsLF4F211VW8wJ76XG8Z8410k@0W26V0WZFo0@46@3	#d1V#8$4J!10F)1c8$3F#f8!4_$cF$2k!80_#O$95s(218V	02.1.1%B%1!1%201///#4$5$4-11//02*1!21)13/)3&101/#2/-4//%2/*1!5/101%102-3/$2$1,4/(80301!3,1%4/!1!301$4/2%8/)1/#7#1%10103!6$1&32$4!14#2/01#2#2/&4%2,102/*2!1*2G1$1!103-2/,1//*z%4/0202&11&B//!2)2$21%2/-@1!1-2/22#1%1%3!1//02101/%2#7*3#1%1%1&1!1!	efQ^B@@DJKBago`COJ\bbTTTRbTRNbRrrfbbandWRrIKUUUMMEPTPLQD@@@@					antagonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xi.ix>S~.>xixhS~x>xix>.>S~x>S(S(xhxi.>x>S(xh.>S~x>xhxhx>	;UvQztUxxnzwvQ2nIPj8iLy63v_Z0Pd8CM2kX3WHFX0F73V9FY08H8B4J3e46210a1211g2O2F0902V%	0Z40IV02Fk1D!9_06k!mF0AF11!C_07!Tk03FV2d0A40 %Xs482i20VkLF4F3L711kW4w8TC14WnW0sBP636ZZOV45753Zu8FR9yI211FcgJ622XH9wP624YkV8o610WXIHZk86A3m0Y0RV8J4G6A1Zko9oFF3WF8soR	#11V#8)24%6#5d8$5F#3V!4Vk$F$2o$4#GV#1As!244!258V	//(I-1&1//*1$@$4/#2/1//$1#22/%2!1%1*3%1+2/)1,3/2(1*2//!4021$2,1#5///$203!1$4/(2101/!1$204!1&1,1%2%1-1!1//#403///1,1+2105&101//#2(1)4/+2/04/&101!1/%1r%3(1/+H,2/%1042(1)1,1/2/)21(14/#3,1/01.2)1&2/,8(1$	ek`TH@@EB`LdTRVadTRRVrRfRxDBrRJvNhHBjjjjh@BaBQYH@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(S(x>x>xhx>S(xhx>S~S(xhx=.=x>S(S(zdW(.>p3}J~W	{xzyzUUvCmzxvUiEaN_oyEh_j2fb2b@IzX8m7P0KJ_lBn8BD4ns80XGi6GJ02101qk2ZV10F2010	0WR0Tk025k1v!9_07g!Xw0s!45k1_07!Tk05Ak110480eF3V!Jp04w0Xk2U0DF# %1LssTA53XokGVNL4934Z1VcD852l0B430aXk88ZskX9511FJ4FAZ110VG8kL@4XG0V@53VkGko212584KXNBB63B0Z8wiB8632I2Z@50Vm1cJ4JHA5Xo0kJLK0W21n0xa6C0XFW8c4F464kVN@B4WVVBoR30W2k88_382311VksgP93WG8V@81W0Gss22B10XJFkVFIH1Vc8VT616VkG9KB4TG1612X8w644XW8g4230F84wNUZ11VVGNoN641Fkc@231VN4wT10VFlPG0mc20VVl462E2VXmBV8F4	#15k#84$F!144$@$Zc!201k!kd4!4VF#@FF#@o$4#GZ#91s#4#258V	//(7/!2///#6$6#11*2%1(1&1//01/*4/,1/-1!1#1)1!1/12%3//01!1)4//!2/#3*1.1201$4&1-1&11#1+2#303!3/&4/)1.2#2$104,1/01-3&2-2$2,1!6/%4/&2#1#1(27//-101#4//3,l!1!5)11/01&F!101&2/%4/01#1/*3!2/!2%11)7/02/$2/#1/)2!1$11#1+1*1$	fcoQa@CYEkXH`dPdsNzwMrkN{NUGM\DATuTDEEPRKTSH@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
:v(Odz:v:vdz(O:v`|(S0lF|*`J}36*`*`J}36*`	zRul218K8V4F0J2!N0WV82m!F1#20LF05#1Fk841WV028V90JJ0F!90F0V10224$4!2$W4FV	0Ww0Tk02J03d!BU06J0Tk03OF1k07g01740j02x0C8% !BV8R4UK24W72tFXA56XaYI4BL7Z130XH9Vo312FV861A65ckGdx64@34X1OBLD71FFN2LAAm0VkFFBNC550VgJ21Vk846TB0VXJ0	!1a2V(2G2$2#V1%8#H$21#88V!2J%@Z$3#KW%s$4!211k	%1/01#2*5/!1///#41)1/(1/1+1$102(2%1/(2#1/02//%1,5&1(1//%6/(1#1%102////%2/$11)1$1&11*1///01//&1/)1///%603(1//*1*71!1/#3$1$1//1/,1_%1!1$5,1!1%1#F*1/*2)3)2&1+1!1%2)1(1$202!1$1$1/2!1*1$2)1/%101(3/(3,1$	fj}qB@IJtdFIdTRTJbVTRTuFZMGL@EML@QD@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
0lvl`|.=x=F|.iS(xi.=S~x=S~.i.ixiS(xi.=S~S~.=.=	zxUnrXOSdF4R302DDB8WX82uV0F093!4LG05@VB10k1601V0YZV8V4JcF0815V0c11090V41$204G8VVFV	0PJ!RZ!ZF0IV02OF1v!@H0ER!qJ0Q01v!JL0640PF1u0Bo# !1Z14Vt0FkAc4Te16WO0G8ASP4G2m0WVGWcq6@H0X130scA63kNssRJaC6G0caF4B2f17XnGBBL9Z130aFGV8M2340ck26B916H8F@76XWkBcVJ232kVNLE52W0FB210YldyF4@3Z12Vt0GN@D24D266YNNx82B4m0XVF	#22V!80B!22$FgV!V2#582$JV!8X#248!2F1F!58V!4H2#KHF#@s$6!2A8V	//&36!2.1%1.1/%1%6)32/(1!2#1*1,1021(22$5.1)1/.1/%1/#1/%1$2)1+2#3(3)1(1//!1)2*1*1+22010101)1!1#1/%1)1/+201(1/&1///+1/-1+2!8/)1-1/(72)11%1$2/*101+1//f%4(1*101&101#F!1$1/,6)1(31/-4!1%1(3/#1//(2#1!2//!3//)10	fakqB@LDzH@PeLvw\kK[xYxjZtts@@DPW@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xhS(.hS(S(S~x>}HS~.>x>x>^).hS(S(S(55}H55x>.>x>S(.hS(xhx>S(	]U:vzxzUzhuzfvUjAjUgzSUjpj@@jLbOMrvcJT9mCL9nh@d_cBYuHTi14@kJ0RI3nJS8k29NOa0n0	0aJ0Tk02AV2g!9k0Ds!sg0bk3Z!DA0@40t!3Xk2a0DF!sk0tV3e!Ji04F0Gk1v09w01K40OF1k07g0vV% #4sCm6B0VXG08864111948A3XFsR8110VHNc227J122OoFF50Vd8cZD83W1t4NX42XWsRJLL2C9ZNVcFoBMXW10J4@@E5WVlsWe735Y4u8FJ8TX950cF6D67KgG0NJCJ2AS0WkXK888446_HO0B62XHGG8scKAZk8kVO8q51WFwV8F48bAcG1s44L@110VVB476W0VZDA40ks48ZE1VFWV44H113f1W8V296XF8VL3663k8g8NRU1W4kX08O0XYGpF8xo2A21NVVsLF4F225VWFZXF4VkVFHN@1VX3FcceA1aVFw63@3_25kFZyD232O0FV8A44A2216@0L@D5m0W0FFB@@23lFJHF80n1N84HP47_HcF@270lOFRca2@cVWkgV8V484Q8FVd422E6G_5VNcB	#d1V#8$4J!1,c8$3F#f8!4Z$cF$2k!805#O$95s(218V	//01%@)1%202///#4$5$4-11//02%2#1!21)13/)2&101/#2/+304//%2+1-1!5/1(102-3.12/&4/(8#1!4,1%4/!1!301$6(3&2%8//-7#1(1$6$12%32$4!14#2/01#2#2/&4%2,102/*1!1*2G1(1/2/1+1//*y%4(1(201&11&B//!2.2&2/-@1!1-2/21*1%2!1//02101/%2#4*3#1%1%1&1%	ebVRF@@DJKB`COAil\bbTTTRbTRNbRfUfbbndWVpJKUUUMMEPM@DQ@@@@					antagonist	Opioid delta / m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=.iS(.=.>.iS(.=S~.iS(xi.i.=.>S~S(.hxh.>.hS(.>.=S(	zyvv2Y11801F0411F801V82H!F#1203F048!10F84%8!2!F0808#10F20B&F%2010	0aJ0Tk02OF1v!9k0Ds!os0KF1M!C204w0eF04OF1k07g0vV$ #2XI25WBq8FNA8251m0VkH2l@3462Bq8FV@TK24W6L9ZBD7Z13VamnBBL6lOW4FXfRR@46XO0H0A84cS@W4FwV8V4	#80V!2-V!2&2#2F#818/0V$5#G&s#2#210V	&2//1#5-1///#8$3/03/////$2$2//%1.31$2/)2!1(2//.2////.1+5/-1.4!1!3#11%1//*1/*11///)6//0E304/+1-2&42)@)1/////)m%6(4/#4!2#P//%3/#1/-6//#11/42/(2(2/+2$1&6)1/)	fega@@@`rJIJZZJIKZHqITyzHypADaPQT@@@HBP					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
`|6s}\)J`|`|B,3p}\}\(WS~.>p3`|.h.h.>S~.>.hS(.>S~.=S(~SS~(S	mPPH2F918F1k!25GNH1VN0m040F021!2HZ58V038F8610V02FV42141F801DWF01J@X_V48#GAF2181B0k	0Y!IV027k1v!9_07g!_F0zF047k1_07N0Tk05Rk1r0Ag0j03J!OG0780Rk1q07R0o& 6F482oN12FgV8R4nA23W4WuZBHP13X7WlsBJ56Xt0G0DF4H3Z180t0FkAF4Jk141O0FkDF46298Zm10JA142XBV8w782F1m0YVOdR8B46D8FtcJcAZ1AVZu8FZ8	!161k!NBg!3IJ#9_#Z1F!14T#GJk!Xf8!87O!2S9F!9@V!1BG#M8#VVs$5!2O8V	(1/.1/02#4/,1%1*34$7*1-1//-1#201-25!1#2$201#4(1(7#1/.2(1(101///+2$1*111-11,1!1//,@4//1&2!2/402/02#1$2/$2-1!1.1/02//!11)2#1*7$3011/%401(3*16%2!D01$2//.1(1$1/+1n%5)1#1/%F$1%1//-3!1+101!16///01/%1-201/%1&103(5%101-1/#	eghZ@B@BNMCD`LSZPNdKiCHhheDdiidXcEDeHqIiYDeLmAAQHTAPDEQ@@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>~SF*.i.h`*v:*F.>.>|FxhS(x>S~x=xhS(xhx>x>x=x>xhS(x=	<vvU:rzxzHAU:ClnQPz6jkL8mvA_LQXEEHjIQn@ilbX6XRVS@l65F8tCA8nlY4I3BHL0VVF5m0I5F0c0V	0J8!P#WR0Tk02J03d!C305!wF04JF1_07g0zF055k1G06J0R01v!NL0540PF1p07c0nF0 m0WkFF48QW15WWZsF6O81Wlcw0q7122G1lJwP42Yk88oNwi72G0saF4P3Z130X1Wk818ZW0BZXHF97Hkk4BJ0VZGwV8N782410WXORqI2YYGnYBV447VFGNiF4F3Z130t0GVDF4F2RVWkkcTF4Z3Z15VfqcFV8JV84mkckJRC25cJsFVF22H6llFNBBAEYVHcJZ@PK41sVkI8241	#3Zk#84!28F#Gg#Z3#5pd!20G#s38!20@!3JWF!Z8g#m7#GVF!9Cw!26#23OV	&1&1(3&101$7/!22/01/(1&2$2&1/$2#1#1/*2(10104!32/02*2&102/2!1/!1%1(1,2,11//$1/%1$1*2%2&302/$11,2$1#@#1101#2(1(1$1/1$2$1$1+8#1///!2!1#1&2+3*2/+1-1#1!4!1$1,4!1-30102#1$1)G/-1(1%1&2.1%1/%t2.1.1*@!201/%1)6)1)4,102-5!1/$224)1$1/%2*1(2$1,1!1$1#1#2/,3)1!2	e`TTDL@N@eA`H`pHndLbbbTRRbR\TRbRRtkDfafstDDduUUPVEDQADP@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
~Sixh.~S~Sh.~Sl0lv|`|Fx=xhS(xhx=x=xhS(x=x=xhS(x>x=xhx>xhW~zB}\ps	;xzdzSzpxx7JAUUU8G3N@uaEH0h1jA8HzVE8XCHQZf41WX0YOZxXMT9FZv9CkHlA32VcFK11X_K3JM%V	0WR0Tk02J03d!C_06k0R!35k1_07g!o40FV2d!DF0@!t!45V1Z06g0TV06Pk1u09!c0310DF0 #O0FVDF443Z130aHVReN1Y41V9Re9950k4VaF39aWGNT40Z3HBV8o78291m0YkGVkoF3Z0s82HP9m0X0RV8k782613aXdFa664YO0HcDF4L2l18BkGkGVmRA2211tB@N62lcscRmNA712kaF4B3Z18Vt0GVDF4Z258YI0gDG20XIlDF463Z1B0aI1Ns8O4	!1Y_V!D8g!10@!1B3#Z2J!4g4!28CF!FY8!2cT!22FF#uo#Vo#1t#1Uk!4ZM#hNV	//(B/!1/$1)2/)2$1(11$1*31//*4$4%1&1#2%2/1-2(3+1&2/$1$1!1$11101%1.2(2/1*11%103011,1$1/01,1+2&1#2!1$1#1)5%1!1!2!3#132%4#1$1)1*1%3!1/#2(1)101.31*2/01!1$12$1#1%11!8#2,1&1%2/$41011%8,2+1#1,1(4)1!1)1/%u%31#1$1(1/D$1-1&1)2+2&1.1(1$5!3/#1203#11#3//&1&1/01.1#3(14*1&1!1(10	ehZ\LD@KOCgFi`H`PHRYWYUY~UmuYZFEMO@jno`X@JZif@HjjjFH@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x>S~.hxix>S~S(xixhx>.>S~S~S(xhx>S(.hxhS({C55x>x>xhS(S~x>xh	;tUlOpdo5oVFAEIw0WXNPmV40F9Y@24HnV70XcIOk90OlV03FV5XKLh0VVdDlFW@JdXZ0Ld!751FG1G10V0	0WR0Tk02J03d!9F0DZ!_!uF035k1_07g!qJ0R01v!DA0@N0t!32F3N0EN016J0Q01k07g% $38271B4a8VFB8tKW1kec8gT292m0WkFQB4L455VG0iF4H2FSXklFs4D8J5Y1OcBC74YdVHG08820Gd02F99LVZ12R8N714XO0GF8sVH950FFBF98m0WVHdN@44ZFs42435Xk88Rn8261S@VWVHBDYA22l5Hc8VB1W312F8skS2aG18dRi4K2VXccH@D3VXm52s8V54W3GBV8o46P@WWsNNRL163t0Fk@F6B12l0lBV@11XmRV8V4NIF_l2VB84123X5k8dg2825cGWoR@853YJ14V10X0d8RZiL@VFVBB11Z2W1LF4622D2Wsw2A243V8V8L121232c8wg2CF60WFWVgM3@VFFG4J226VW8J288A	#cZk$4!A7#20FV!a2#6c#21JF#W8!60m%F!2NZ!8VB#GY$2s!@14!25BV	(2*2#103,901/3#1%1%1&1#1!103.4$1$3-1%1//#1&1&2!8#1(3$2+1&3$1!201//#3,3)11//+7!1!1%1/01,1%2*1//,5&1#3#3$1/02)3&6&4#1*2#1/$2/#4#1/02!1$2//,1%102+37011///011*A///,101//#u$13+1)1%41%J%2/.6/1!2#101/&3011(1&1#806!1$113&2(1/$1/!1,1,2+12#1)1.	edRTFD@MEhdlik`PHapHrJJIHqQJIJQXqSHsKL\VAGOPDDDEDmPLDU@@@@					antagonist	OX2	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
lvBz~Olv*`lvd,~O:vS~.=~O:0`|.i.id,d,6s}\.=:0`|`|}\	:UvzfOUfFbw3LAjEB8WmOQcaBP59W044MxVC6V50@kC4V2c6nr0OZ6J8FVXG5W0WWGAV8241140F3J01V1#	0aJ0Q!2OF1g!9_07g!qk0bV2V!DA0@!t!4Xk2V0B!t% $BV8878241m0W0RV8R78281m0XkRV8V78271m0W0RV8w78291m0Y0RV8R782E1m0XVF	#F1k(8$18FV!42V!602#64$l$R1#2F#2@V!4FZ#GF#82s!91o!2M8k	01)3#11////-1.F$2$1$2/+3&1&4/$211//$1$2/!1/*1/&1&1///&4(4#1/#1/%1//#1%1/&1-1!2!2$1!1#1$1-4//%1!2+1/#2///!3*1#8#1!101&1/+4(1)5+1.2//.2)1,k!1!@01#1/!2%4#R.3/&2)1*1#1(1,24-2/////!201/#1!4*1/1.	feoI@@DLEHFQQQQQSSIIJKYE`iJCUKQsZif@H@@@J@@@					antagonist	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
Sytf2f~@SyteS-tfs?g8t?asSyt@S-AH2ftftf3QSy2@t@t@S-2ftftf2@t@S-2f2@t@2@Sy2f2@	;vzv;S:vytzUzSuzfzUzQjzinSUzxj@@zIbSM:dFREqCL0Gx@dYcBYuHLe342kJ0SQ1f5S8k8dHtX0l0	0aJ0Tk02AV2g!9k0Ds!mo0AV11!DA09w0t!3YV2W0DF01Hs0G01707g0bk05JF1_07!Tk3i$ %QEeklVNcN2331cke610XlGNtPI9VWFkfZ4Lf13W0RNFF8NOF4VFcNBB36W6k8JDA7XkcRJ410VGcowTLD2WVR@DA7lVX088N8@A8aWkcL124XmRV8F4BmBZl1sVkL12Wl8RNA5XkWVolm2EKVXkVVo8y111VsNF@3W18c8310FH0tA8271m0X0H9VJ76ZFVVVDGZ120Wm8R8B6Z18c81A65t0GN8N4ZrCY0lkaF482Q8A108JH212YO0G094LF@60FFRR3160VGG8NRYF31H8g944@2	#91k#8%F!10F$4#1d8$1F#f#4_$cF$2k!805#O$95s(218V	//(J/!1#1#1$2,1/&4$C$4+101$1///(3/01&22$1/%1/,114+2&2/02-1$1%1!5-2*102#1*46&1&11/$4!103/!6&2)1+1-1&1$3&1.8$1/-501&401!@+16*2(1#201)3/!2)206*4%2$101&2!1/*1!1(F1//!1/#1/+1*2!z%4/#2(1&B&2/1$1/+2/-4%1$1%2,1!22/01!1/)1!1#2/)1#402(3#1)4!105$1%	enSRL@@DLKI`Jf\bbRbTTTRLRtRLRrttTUt|LBBJrzN^qiZjjjjjihhH@bJhA@Pah`@					agonist k / antagonist d, m?	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixiS~x=xi~SF*S~qq`*v:xix=S~|FzBW~xixips}\x=S~dzS(xi	zyvrTbOG8m5k4GACkN0p0N@m0ZF09Y8@4HQX58V03Qk96GW!2OV9VJL1FWc1Lk1d903X4V650@441J640743V	0Ww0Tk03OF1q07g!t40tV3e!FU06J0R01v!GG06F0SF3L!OG06F0SF1s0Bk0x% #JX30lVP84PUH12FwV8Z4F83Y0koD621kF42611V8G8B_Z160bmsFp8@2522YsG4PK26XFN8J878m0WkHmwy683m0WVJF94yZ261t0GNDF462E191lsFwNZ261ksFVRgG267YsFZF	#30k!f$23F#B6V!VW#2V@#k5F!Hdg!@5U!2Z2#FPg!141#5lV#8k#J6#51k	/,2*3/!1#2+1/&3!3&2#21#11%1//1!1/5102&7$131,1)3!1#302*1//3#101)1*1(1$3/)2/1%1!1(1$1)2,2/,1/!16$101/#1.204%1$4&13/101/$1%1/#101)203(2%101$1!1-1/#1+1!502///$1&208!2&11.104%1!1/#301!3*2/!20p,133/&1#E)1//,1!2/#1)9/*1!4//#3+2//101(2/,11,	eghTBH@ILaNck`LSHhdieDhdhmDleBiPqXxtmtM@ATuTDpSDpd@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
S~55x>S~xh.hS~S~.hxh.hxihx}H.>1mY(^}(M9191C{(MY((Y(YmuC{C{~M(Ymu(Ymu91C{~M(Y(YC{(Y54>y,f)K	=vzt:xnzwvU1v3IENeLya3Qhb8NdNxa1901AIVf6F_2V3G_7e7s9Toe2PFKW963L5W0308oI34Hk8080F	0aJ0Tk02K03x!9J0Eo!p40OF1v!C10480eF03Z02U0DF012s0FF120@!1LV0Qk1q07g0o! $6F4F3Z130t0Gk8C11371WbHFBB65CkVFWBI8271S@VWcKw@472BensOBBsK10_scsKc2N91GckFZ@RMVXsVcF8@BXVcoP52VkV8keNR1@XWcG5J625X_kHGZ4Vo171fVNGRRC5Y12FlRiPD22W0NVgD23H0Z6410Y2dWR4eR18W2GgBLAZ15Vh60Fk8olB1ZVwV8R4VLKYVVdRJPa27d1cFZI8261m0WVF	#b0k!V@s!20T!1GB#hE#34i#Vtk!8Y8#6w!28k#4Hk!4m4#5Vk!1_F!942#pXV	/!1*11(H/%8//)1A01!41!34$1.131)1,11/%1*1*1-1%2/08.2/,1#3)1,101//*4$1*2-201#4$4%2&2&1!2.2011$8A%1$1-1&1(802$3$2!821#1&1!104#1!2023%1)1$1+2+1(1//!1/11!1#1,1!5/+1-6+1$1#G2*2,21/01&5,1.221-z02#4/01/!F-1/&1+2$208/+10421&1/1)61*1%1.3/05+1*61&5101%51#2+15-	eg\zDF@OIeoiTa`IABPpdCIBrP\dLbdLRTVdUbbtRbatRbTQVrbPdgPrqrMOHimmT@EUUMAPPDQQUUQAP@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>xhS(x>x>xhS(x>S(xhW~zB5q}\psS(hxx>~S>xS(hxh.hx.=x=B3>xS(S(dGx>yS@u	^x:xizizuhEx7zIrSxxE4VMzlppGVJWgrgoWWlGasXdV0JPIW85Ml0e558b43Z5#F1F432b0IV	0U4!mZ0AF11!C_06k0Tk03Z02Z0DF!t40tV3e!Ci0CF0vV04JF1_07N0Tk06QV1p07c0j03J0Ds0 BV8R78211m0WVGIkw6E30aYHVB@J50_K@JFT9Z12Vg6VFkA8261GVY888cA82B1BI0XFFeo4B2m0WVRV8N60X11XkoP88ZQ1W3l81w@6C350aG8VXD1318V@11Vn1WcVh1361FG8VsDDHWlFJRP515ZO0FsDF4P3Z14VWkeN8H4X1G0oY8281X4lcNgE8251	#a2V!V$22I#G6F!gb8!6dY!21SF!FY$KO!2H0V!N@k!2Z4#9@V!1DV!447#12V	/&1/E/!2011//#1#13%6!107$2.4+1(1/&1&102/#102/)3-1)1+3/#1%101,1/-2&6/#1#1#1(6103#21$2//1/4&2%4%1!1!1#101(204!1%105!21#3(2$2#2/&3&6)303!61//1//%21#2+1!6!1/-5/,108$2%421)2/*1(4!303/!1$1!2#z%3%101$1$101101%1#F&1&1//1%1101/-A$1(1+1(1///-1/(301/%3!11-	ejU\J@@A@h`DMOBlbfbRfttTTvTRbTbJVbxdBbV^AQaqaIZ@HfZfhHbhjjHj@@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
~Uj/gy~U~Ugyq5}Lx>55yg^}F*~SS(.iy?(S^}}^v:`*x>.>.>^}q5S(xhS(.h>x}^}^x>S~x>(Sq5S(xhS(xh}^q5	{x>Ur:vzjzjzjry:r:j_vzvU:jv:jMrjrjUzjbavzUxUpzrxaWqrvGxrEdxvSJ1#	0WR0Tk02J03d!9F0DZ!_!uF03OF1k07g!qJ0R01v!FM06J0Q01v!Fh02w0FV2d!GE08g0bk3Z!GD08k0tV3c!J908g0q03Z0EN01XF0Q01v08g0q03Z$ $38231763dRH@9514VccLG840N8cFJ4H2ZNs2B862X2Noa@51ks4cDJ8Fgkl0V4B9N611FW9xs683dZFVkHpi462m0WFRV8V4qD531VZJD@20FVt9R46@a1GVwF1344FWORBD7Z14VVgFFR8291XGNgTDG8WVNF6@A210W1k883@X1VVa131VGVgB28C734NNLK65Y4@FFk42@3m0WkQ8g8H4S35HtF4BA6@e09oH@B5m0XFRV8Z5D2F0VYbV8kB22BPAkW0N5c2LX1W0FFP45XVkNH3510VV@T8E21VW0HA22G8NH43VYW1lo4T816h0kFc@2850VYpc8o42AM1VW0iF4B2N183ld128@5E8kW284B6T168kGH044640X224s@66VVGN44HF13WadVHBC60_0Z0L@85GVYGV8he2833ZVl4JL66X1NFRY826186XF86@B8WlNNVWgi2710gFFo8483W0VsJ@3WF8J422Vk@8k270WX50NJH754GNR2HI11FkN41660kNFW4aLA1ZkNoDD473k4NG422D3m0WVG1w8e1E7VlsfGV49220m9FR542H21F4LIZ14VVgFFg8cK293G0V@20XFsB4J7BBVZVHR8T61W30dF8HE1168kG8LF463M5W3kF8oE82A10fFX884R6LW2lJNk8R6812Yk8VKgf11Zk890F	#d_k!18Z!674!1@4V!aD4!5ge!2OzF!Jds!6VF#2HF!2Uo!9Wg#GY#A7s!2K4!2KBV	,2$1211+1$9(11(3101.2%1#1$3!1(2!6#29#15////1+6+33#12%2*1&1102!3!1)1,1&6&1$3(2/$2/!2#14!1011/&1+301%1!1/+3+1*181%3(3,3011%22!301!30410109(3/!1!1/02/#6//$1*2/*51$11.7/.1(3,2*A/)11+1!1*3/#1*1*11z$23(2(1$1$41%J#1101/(110236&201)3&1/%7031$1!101)707#1$24/2/$2/$1(3$1)4%1&11/#1&	egT|ID@AIJXdlnc`RQSPH`pHrJIJYRIQQJQIQVIIZIJEZZYtLBZUMS_H|p@UUTBmT@UDDtMUEAaqQUPuP@@					not given in publication	V1A / V1B	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}Jps`*}JF|}J`*55*`lvS~.>:v~S.h.h`|ixi..>.>x>qq=x~NA,(Shxps\)s6>x>xF|}J(Shx>x>xhx	|vy<Uv:vzjUjzjryUzrzyjbnjzUrv9;yQrjr;hEbYvTzyliTxmbHMzUSzEdwv1530W0	0WR0Tk025k1v!8Z0D#_!uF02J03d!BM06J0Tk03OF1k07g!sg0bk3Z!DA0@N0t!32F3N0EN011R0OF1g07g012s0FF1209w01XF0AV1g07g0q03V# !4R4HS13WO0FcBV4R4B12VnJc8@42b50l0TF4F28VW2NFJDAZ12VkG0Rc8B40clVke8642VFkyF4@3Z120t0GF9@Z462NC0VcJsg4923fFWlcN334WVFknk4Nc151O0Fs8Z4ZI4WmFZJF0Z2HHFxV6@90Wl7PZ8B4TOZklFOPR492EGVWNGR8FBX0NBRH3711XRV8Z4PQ4_30NNNC6E130WsZP5BVWFsoR7244_kH9G@4C3Y0WFiF4J2352FsgB673VFR241VYl1tBy4E7_WVNc2276m0WVJsV6B94lWkmSu4E248GVOBP2F60GkNkB298H5kX8ks4D4m0YFF8R8k48X1NoH331VFFB1C57X1FG9JL27VWsFgQ8261AY0kVRH9YZ1wV8V78221Z0XFWV8B7Z130t0G098Pe4ZGFsiF4@2HV4VlNP_q452EZZcsFP8bJ0m8VwFkXJWWFlYBV6@2Z0Vse8k4@JVWkn2B8LQ712140FP134G8gDH69PYGWNFB82C2mkkJP89W2GwV8B4B@7aksd0B64YG1O8JRN6218l4849WYHK@8k643m0X0Ns98u2C2m0VkK3k8L4APXkt8JTAK7W3F_G48Tc16Wom8Fc8i2J@0ZJV8wc2B4H_kXVRk837Xt0G8@84PNJW2Vk	#cZk!G04!A74!18FV!6@#7wY!2OKF!Fdc!6ZF#@HF!XUo!9Fg#OY#87s!@G4!25BV	,2/!1&9#1!4*3!2*2*1#1$3.5$4$4/$101/#1/,2!6+13$41$22!11)1!1/$1,1#102/)1/!1%2*2(2/%2!201*301%2/.4/(6&2#3#3$1*1%25*1$7&4#1*2#1/01!4.1#5#1(3%10201#1&1)1!1(1.22%602,7#2//*1!2011$2$B/1/.1#2)1//#z#103(2!1*1%1!1!J/)3%1$4&20101#1502$11/1%6!1*1)404!1$313/1%1-2//2,3%1!1!3,12.	ei[\NL@KLlQDfndR^PHbHHjbLbbbRdlTRRbRdt\TRRaeVXxtlBJ^~ai`HJ`hIbVhJ`ZJbHphhThfH@@					antagonist	V1A / V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)H>xS(qq.>x>S~x>S(.hxhxhxh.>q5.>S~x>S~x>.hS(.hqqxh.=x=S~.>x>.iS(xiS(x>	;tUlOpdo5oVFAEIw0WXNPmV40F9Y924HnV70XcHOk90OlV03FV5XKLh0cVdDlFW8JdXZ8Jd08351FL1118V0	0Zw0gF02J03d!9F0DZ!qJ0Q01v!C_07!Tk03Xk2a0DF!kZ0q03q!C_07g0zF$ #VX12kYF8wm2CFYkWFZ94472R0ZWV8wo2A30XGBV8R4@u1_G1Fo4FAZ140t0Fs@04I413WJVGO84H4X7YkmOc4V5170kFFcU82@17Ym1oa165WVG8yF4B2p182YcFkF294E6kXsJB4JC0Y0k8cQ82C12_nNkJ9673FGVyF4B2SPW410c8P9Z140t0Gk9tu9351WF8d0j232GXs88VFB_kVJ4B98m0WVIF9JJA41ZFFBPF52XXIF9N4EA3GNcw252WXmF	#VVk!F$@7X$kV!62#48F#1JF#Y8!60F%F!2NZ!809#GY#42s!@14!25CV	01/%201,7/!2#1,1&1#1#13.2$4$3,1&11//&2-7+1301+1!12%3$1/$1/#203/$11//)1/.1.2%2)4/*6/!7&1#3#3$1/02#2$303$5&6#1(204#1#1/1$1-4#1-1!2(2/!1$1/*202+37/!1%1/204&114)C///,101//#x$1)1!1/41%H$12+3/!4$1*1!2/%3&3!1(1%11#604!1%13&2(3//&11,1#2#1#3+1.1#1*	ebV\JL@LDnhDHli`@czPadLddLTTRRbTTrQVbfTT]aPURNJuPA@PtETETP@@@@					antagonist	OX2	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xhxh.=x>S~S~S(S(xh.>x>x=x>xixhx=xiS(x=S(xix=>xhxxiS~x=g-qq}Zy?yg	]syxryviUxTpLQmzjCOzhYTIhInr9jHZ3Orsa14WD3A3zbGz5NZcWINVVU4eF7cXF0255!lR4WNFk	0YJ0IV025k1v!8M07g!dR0ak02903x!DA0@40t!3Z02W0DF011R0OF1k07g01_40O01p07V0n03o!OX06J0SV1v0C!zF$ !1G0Z@47bH0FkQ8291CVaW1F8iJB14GIHW26@3m0WVIF9Jye291fFG@0g463m0Y0Kc99i2E2m0WVGG4uS44X0V8B@D221kVoT452FNF231VF8F2220pFufFaD60lFsc86B5X0VZH931Vkg8R@D10VsgZA7W0kkB21aX3Kc8pi2A2m0XkKc9Oi2H2m0WFMHc88410Vl14L3320kN4ND3Xkk8FHVP_12kVkVRB0WVs8D565Zkko8VQZ120WFdsNJAWGmFuVBJ2bGH0gFZ485VkVcVcTK0_0cwRFH8m0XkFkJXD4C20V4L6634kcg8VOZ120WGGNaJ9VlmFuFJS2_1H0fFaA61WGNckNL16VcZLFH8m0WkRV8N5gi26WO0Gs@Ws482LD0VVFV8A@_X8Z@294Zf70FZA82G1m0ZFF	#v7k!98B#2N!1JE#X3$c8!201k#fB!4ZT!20IF!VHo$M#llk!19s!2S4!2E9V	02$1/%1(35#2#2//)1%1/!51#3(1-1/%2&101!3*3)2+3042$3%13.13-1/!103(1%2)1#1/)2%2/1(1/01.1&3/$2,1#201#9&2/)1!1%2#1)4!1!11!401%2!4#1$1/&2#4!1#5&1*301103//&1+22/01!2011#2!1*1,1%3!3/!B,3/4)1/!1#3/%1)30x%1%13&2#201%1!1#8#1/02.3)202&3&201(5*7(1)1&1/01(2/%2*2/)33&4/01*41#121%	ejQRBJ@@je`RAgdPHaRH\dOICJPrJJIJIJFIEKQZZQFZIYbRIKXyGFBBb`hBjfjfZXJ`Jh@@					antagonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}Kb{.iS(.=x=.=.iS(S(S(.=.=.=S(S(.=0:v:.i`*|`F*.>l0.hA,.=(OS(.i5qS~.=)LZ}.i.i?y-g.=	]S:QiuAUURvyhEdRBaohZx4Dro0EIX9@SoFVfXkaHJ4Ka6K8N8FG5VFVc50oV2Cj8421GkG0VY0GF	0Pg!Xo0FF02D03V!C_06k0Tk03OF1g07g!ss0bV3Z!B90Cg0xV04NV1_07g0o!4YV2T0As0t# 04293Wkcg844WlVZ830VF@G04226eO0Gk8g8RCXkkB81990kGc44JMZ10VVF8VJ33X0cg691XG0Zwa20VFlk44NbZ170t0Fs8V695WmW4H2212mFB44D0VY3gV8R78271IEVWsGR4aFJX0FBJP614Yt0Fs@dRA371t0G88Fc9310csX51VkF8oV216VVGOyF4B2AH4VVNH430FWFscF@62G0gD77W0F8kX2113V88cwLG4ZI088520XWsB4N1156DVscJ9332WV@VTT72XWF886330kcB@53WFNR652VVcJ421WL2V444G0VYamlBP85Z0kFVcF2I448cJJ@1J1lG4Z5143X18VT881lsFB510V9d4o632WVkRB231VcN@630VNJ6310V85VVk1BYklFk378W0FFs_c2@N0Wkb10FA4XYGGNRcK1WXkNVV216Zc1@ZF40WGlVwV4JR13WB6VFJ84112GFJ4@420sV@720kNB6aHI	#20k!14#24V$F#i64!59#277#kW$_O#N0F#Pk!8@C#OM#@As!@1B!218k	01.1/%I*1&1)3+2&1$3!1!32&3$61#3/01//1$2,12/$1.212$1$21///%3&1#1)1#1(1$1+1&601$204011*102!2%1-5$3/!11%1/1!1#1$1(201*8#2/04%31(2!2&4/04/*11%1#2$1$1/!1!2&13/!1#22.C1!1/&1/01211$2#1$7(1#1/&10101*8.1/1&1!10z!1!3*1!2$1#2$1!2!M$2-1+2,1#4/$1!1!1)2!1%1/!11$133*2#1#1+1//231)1#107(3/#41!2)	eeW^BH@L@djnajXDFg`@cIIBhhddmdhdhbddhmEDdehyYyUtsKrJmP@@AURuUUPTE@QPGD@@					Agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
]i;VAcNkSk>_>_SkSkh_>_SkhGS~>G>_h_>_SkhGSk>Gh_h_>_>_hGSk>G>Gh_>_>_>_hG>G	ztur4asK8e0T016Zm8VdVN0mGFN0N0C20HHVK84831k9411V0e8V1XKLGG8B9NHFc110908F5X!J%703V	0_!uF02J03d!9F0DZ!_!uF02YF3r!C_07!Tk03OF1k07g!qJ0Sk1v!BK07R0nF03Y03a0Dc0 !AqcFgA8281m0W0O9g8L44i13FV8gE82@1m0X0LAB8V5Z16ViFGeg4H5Z130hKsFsA82A1KiFW0LF4B2A18eVGuZ4P615X5mV48610lldJe4@9JVZ2F8pF2@3m0WVIk98oL26_FGFX8Z4B@_0kNVJB2GJVYpF8oL2A4@50NBB40YYHON8JHc184VGdNa494m0WVIF98wK26_VGFWkc4BA4WNNVM82A1PfkX0F84cMX1FFVwJES27WO0Fk@8i4HA50WVXh0N361t0FsDF4D2iQ130XlNsQ4@2AVHQN4X42R14mlF8P9Z130t0GV9RD4M92FXNN8A37_VGd1N84MA20XNN@937_VGd2sL4N62WFNsJ2B6	#@VV!288!BV2!2%20V!886!1@$8W%c!314#ZPo#15#GV#80s!@X2!2W0V	)1)2-1$A032&1&5//&1/%12/&102//,8$6/!2*1#12+2/03(2*4)1!5(2/!2/$2+3///0305//%1*5&21//$1+7&43/&7/2#2%1$1//#1/$1//,602!1//!2,2!4&8%1,3%1!202)1/&1-21/z$2!1#2#1*2-B,1!1%1-8)23#4#2/*2!C!1.3$808!4!202/+3(1.1+2/$21(21!2+1*2$	ejQTNH@HDCK@cgohP@cIDddehhhXmEDdehddelBNAAmekjVeiZf`@@Hjjj@BAR@					antagonist	ET	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.>x>S(.iS(x>.>x>.iS(xh.>S~x>S(.ixixh.>.>x>.h.hS(.>S~x>.>.h.hS~	:UvzfzQzSznQTOzIQMvvtjHzLeXZoQ8BEzI7W27dIOX8kYiZOJ10Z7s0DT3H822fq21wG283A401NFXV%	0WR0Tk025k1v!9_07g!aJ0Tk02IV3r!BM06J0Tk03Z02U0DF012c0FF120@Z01Ho0B0110480bk! 02ldH622Xk88ZQ82513c3GZB367VFGcyF4H28A_l0R@64WVWFVdqd26115XFB35810Gk84NDFe11FVGkkK7VVF82HG0VYV88kg2D6Yl8oF93W0lNkj829183IGR8B20H296F4B2d192L8FoBHBD3W8wJ18A0FHN44RJMA6XNVJZ2173K20FR8LK84lsg@28@0FH98RR944kFF861W10FBRBD2N0VsFVJ97YWcVH530VGWJlgi2513HcgL6611cB44A45b710BP7Z11VVWsRR952GFRNJD0VVNNco4N7WZk895RA2730G8Fc92WVcN6420kcJHVBFm0Y0FdgRF21VFND51W311YhH4E2m0VkGO4DA3XksFB350FWcgp092@ikH0N4Z753ks4D410k8RoT3220FVd78241	#94V!184/$1d@!201$Y4#4$8FF#2k$4#O$95c!2F2!210V	$1//!E!1%1$1#102//01#1#2$D$6$2!3///&1&1*1!2-4&101.1.2/(1(202$1%1+1!1!3$2#1/#1/*2,1&2+11!1%2//4&2&1(2!1!141+1%201!203*1)4*4//!23020104$1/&3/!2/!1201011/A&6!2)24/1%4!1$2#1$@+2/%1&1/,1*1,10z%B//4#P$1(1/#1$12/104/+5#1/#1#3&5/#2*1&2//&201#2/&1$7-	eaSTDD@KBdlPH`bHrJJKKQQIKJKQQIIXqQQHl\VNKWGOL|pPEUUTtEAQTC@DP@@@					antagonist	NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
spO~}Jzd.hixd,.>72o2.h`|(S0lxhF|S~x>xhS~x>xh.hxhx>|F|`lv	zxznrXwStc4R302iTB8VXN2uV0F093E24LIV5A2B31q8491V0ecVdVGLWF899OHFVA108!LVX@7JF011PW0FV	0WR0TV02YF3r!BL06F0TV03H01k0DZ!kZ0qk3q!GG06J0R01v!RM0540KF1p07c0n03o# !461WGFD521lcggJMZ13VacFFk@2@1VX10NRPF61FcJB91Xk8BsJSZ120cYtwBR3162DIG4BF6MO6klFTF4B2M186qFFoB6@@VH2RNH23W12@G88B4814M0FkIKJ534Wt0FkDF462162FlF675Y1c8gJ11W1nKQZ8B414XG90D932l8Z4110Yl9vZ4Lf13W0lNsR7B32FGF@659	#XZk!c0N!2J4!2Zbk!V4B#C#2G4#Bf4!20s!2p0F!Fuo!88A!2Go#FFs#KD!2h5V	#1)101/&8/#1,2(3+3*1.3)2/01/,1021)402!2/&101(1/1$2#202/1!102#1$3/041+2$1$1)1#2!1%1*1&1/2/+5/$1,501$1/!1,2!3)1#6/&4//*1/#2.202/#3%1-12/3%2%1!2/!1)2/&8(1#1//*2%2/01(2(j%1$420141*1-4#101#5.102/&3$2/-A!2/&3(203/,4(1#1(4//2//&1#	ek`TFL@JFBIEHem`H`PH\BLbbbfLabbtJbbVRHX\BFfvNfiiYjV`HJjH@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
mu~Mc+C{mu(YC{C{(Ymu(YC{~Mc+C{(SqqC+5qS~S~.>5qqq.hS(.h.>.=x=.hS(.iS(.>S~x>.h.hS~.h,BO~6s)\	=vzt:xnzwvU1v3IENeLya3Qhb8NdNxa1901AIVf6F_2V3G_7e7s9Toe2PFKW963L5W4308oI34Hk8080F	0aJ0Tk02K03x!9J0Eo!p40OF1v!C10480eF03Z02U0DF012s0FF120@!1LJ0PV1j07g0o! $1Z140t0FkDF4R26FEVlkNT4Q331WnQkB8I4lVFVsFA44D2BmkVsFd8g40GHFdF4ZS18BkGkPRL4MAVGNsFZBJBbI8VcF6E7Xl0oP72W0FB2PJC2YkXVcR4FA8FWNlZ4ZO@7FlkWki29Y0VkRZDOQW32V8cB2A6Z20wF62W0N8keNK2152c94mQ1WXWgV8g5Pr2615atRBZ6lOW1kWlh2D5X_lKk8wFf1WX1BV8N78261	#Y0k!W8F!20q!1JB#cE#7Bj#Vxk!8Y8#6w!28k#4Ho!4X4#1Vk!5jo!146#pXV	*1/!11(H/%8//*A$41!34$101,12/(11/%1*1*1-1%1/08.2//03)1,101//*4$2*2-101#3$4%2.1!2.4011$8A%1$1-1&1(A02$3$2!822#1&1!104#1!2053%1.1+2+1(1//!1,1#1&1,1105//*6+1$1#H2*2,2+1-5,1.22.z02#4/&1,G//%1+2$208!1/*421&1/1)61*1%1*1#3/05+1$1$61!1#4101%51#2+15-	eg\rDF@OIoiTa`IABPpdCIBrP\dLbdLRTVdUbbtRbaTrbTQVrbPdgPvqrMOHimmT@EUUMAQ@DQQUUQAP@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
5q)H^}5q5q)H^}5q5q^})H^}5q)J6sF*)J)JF*)J6sF**Fl0S(.i:0~S.>.=.hS(x=S(xi	>OzAqjk_rUzns0pXUAHiZI29Yd@0MzX7BrV3UlG6HWe5IIkC6MLd8VWO4WIt90AVVcJ0We571oMG8683V	0hN0t!3OF1k07g!sk0tV3e!G_07R0Tk1w!K_06k0R01v0Eo01_40O01p07R0U03L!Rj0480Ik1g07!gF3d# $G96Y311X8qF4@2753X8ge850HGt8NPL21lcVT610XltTF4@262WkcosA1W0V8@6C76VVVNTJ9Yl0BDJL@5VXv88Z8467Wm8gDB2WVk84PICU9VVsI_L4A2OgFW0FwNOE0H0kZOX2BOVXFVFFgo@2Z1FI_H6G3m0W0I846q0Z1WsnCX46221v8NoE8261	#20V!188#VN!342#V@F!6oe#2pF!G_F#1N#18$NZ!145#GV#8Ts!846!259V	/#1%1,62$1&24!1//)1%1!2$4#13$101.1)1+12,1)2$3/)2)2%1$102(4/01%3022+1&101#101$2/01-2!1!2/&2,1+21#2*1%1#1(2*1!5&201//#1#323$5(3+1%2*3)2#11!1*301!1!2$1%2.1*2/%1&2!12!1(2!A/%2(2*1*2*B+2+102$2//!10101(1/0z2-3*104$101101!J$1#1*1/#1!1,1!1.1*701/$1!201&1/01$1/(1,1(1#1201%2&2!1/01,1	ebQTJH@IFfKJd\PICHhdidhmeDeeMEEDcBiQqHheeMl}}@DUUP@STC@TqDPBD@@					antagonist	PGD2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
L}(S|`J)x>,Bp3X(zdX(.h>.}Jp3\}S~.>~W.h.>S~S(.h.hxh.>x>S~.h	zxznrWxSts4R3F2DTB8WXN2uVFF093C04HnV5AXB31q9690V0Xc0dV0JtFV91Kl0c9108ZcLV!7F!112W0FV	0lN0O01u!DF0@F0t!32F3Q0EN!os0YF3r!GG06J0Q01v!OG05J0SF1u0Bk0x% %1ld0N364WsF2JA@7Vllk251Y0Nk410aWnRV8R78271K0YLkF8J7D161kG8VD4642eVWdBLM34Xt0FkDF4B3Z13VkHG4BF7Z16VpGsFcA8261m0WVF	#Y5k!B88!65g#67k!Z24!4B2#FK#8iB!30N!2l0F!2uV!808#GJ#G2s#GE!2C4V	0101/*1(4/#1-1/#3/*4)2/01/2-2101&402/02*5/.4#1/!1!103)3/.3$1/02$1/01///$5/$1,@$40201+1$1)102!3)10105!2/#22,1/+1!2/203,2/%1#1)3$102$1*3%2%101*1(1#1/,A!1$1#1//&1!2#302%2*1)4&m%1%201*10101#2&4*5/01/&3$4/-D!2.1&1*3//*1#1#2/#3+3//1*	eg`\JD@LKHhDA@e`@aPHrRPjJJIJZDzJJJIjFVNCGKTttuMPPSEH@@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>xhS(S~x>x>xhxhS(x>xhx>xhx>xhS(x=.>x>xhS(\)S~x>s6~Oxhxh}\x>	?xzxxzUwvzUE8zjtuvzUTGh_6ABQzXEAX5@@qz45InkftWvVMzOUof_KI7W7AAp84J3A81J146V01!V	0WR0Tk02OF1v!9F0DZ!o80eF2l!DF09s0t!55k1_06k0R01v!Op07c0Z02T0B!t!6JF1p07V0TV3B0EF$ 6F48275Y2cwX57@VF8B48F1VVWGcJBQDYFk8@197VkFFkj8261m0VVF8BTPCXFFR8315YHkl8VO@WGWk825344Z32NR8A10FcNNU828113ZOgJ@@110cNNV2332lswJC310FF4310J1c44DX2442kwBB32FF4gP1156O0Fs8FFH9XlNVH6153FF48JNOU3FksTF4H3Z14VWGNZ8C73G0J232W0Wkwv82A13XGtFT84Wks8cLJ34W1NNFA52W8N831b3k88o21258Vl0RLL72FNZ6210V9l422D10XZ18ckJ61FsN22@80FFFon823112lWJaB3WkN88LEA_aFWFLF4J223W0sZPA520cR821VV8F2ZDH	#I6V!9VJ#2N!242V!VAV!BWu!22Kk!dfs!5oC!2V0F!VQZ$Z!2GtV!92s!6N5!278V	01//%A/!12/*2.3&6$3#12$2/+3!1103#1,112)201!3/!2%3#1!1/02.1/201+12+2%1/-2%101)2%1/#11012(1$12101.2/%1$4&1&1!1*1101+1!2!2$3!1)1!1#1,1-1%1,3/!4#1,11/&1-1#101!1+601!2//(2%1#101#17/-1$3!1*1//-30x$1501#202$1*1%4#F*1/*2!2.120103/&108/!2$303)602-1/%1/%1$2/051%2*1)6-	el^ZLH@FGDleeFg`HcHhdihddbdeDhieDdejNCGNikg`TX@bjjjjViA``j@@@					antagonist	Adrenergic alpha 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(.>S(.ix=.=.>.i.iS~.>.i.>.i.>.iS(.>.=S(.=.i.=S(.i.=S~.i.iS~	;UqUSnAF4k3LeDHN0kkS0H440F10d6g7XV51X031FF0X5V424V4Z36!9FWBWF0c40LV245V401FV711e0p0	0Pg!QF!aJ0Tk02CF2g!8s0D#eF0t!2R03i!C_06k0Tk05OF1g07!Tk3i& $1N9FaT61W8csJ224ZO0FN8g4iD7_GsBHBF50VWGCBJ732WVFVZ4I241NNH430Fdkk42@Ed1WVNJE82715cGFVk@10H196F4J22PAVlFN4BE8YG8gB5255FF46312Y3ouVFB4421VcsVE4XG0B61AA0V88625580VcRD951lFVD710kFB41G90VH084R115e0FdsF661Vkw86A8_VFJFFD@5ZWcVB41VFV421184F888Pac69l0VgF22_110sVZ@72VVB6316_k848Z2180F8448@K0VFcRH93XFsVD531FN50g110VmF44V216@VFFZPK5XW8N8530V9l4v82615VaGdkR90XWXFk24@9m0WFGNRJT7X_kFc8cC0W2HF89sH455FsVD72WmXNF6137WFGc44JVAJW51F98TD40G1cv1c452P0Xa08R9D2@TVX0bV8dF272IVYbc8g84V9VoV8BD97HF0VcFGL4J7aG882@D71Z1P8@H21VG90_s2EJ0Y0V	#40V*V!1%42#4V$25F!FW#4Z$8$82V$5!2G$82s!204!218V	+1,1-8/!2//*12&6$4$103(2$11)1/%1/#2$1.11/%2/)1/$2,3.213!1/+1!202%8)401/(1/#2/!32.1&3&1/%1/+3$1!1)14!2#2/$1$1/01&1#1$2*2,1+4&1.22.E#11/3*1+2(2#2$@+1/(1/!1/,1*10t#105/0103*1$N$1+3+1$1,2&11///+1%13/01!1(1//!2!2/4(3-1$2#2)	e`TRL@@DKFi`FMDeYg^uVUu[eQIBjgof``Jjh@Jj@@AAR`X`@					agonist	Adrenergic beta 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x=S~.hxix=S(xix=S~xixhS~x=S~vl0lF|`|	youpL_OG8k4F4F040N0K0N2F!F083#2l218#FV8!W!2109V4J0N#2!V10224!5$2#1V8kk	0qV0dk3F!DF0@40t!3OF1v0Eo016B0O01s0EJ01LJ0P01q0@R0o& !6F4F2QYVVlVOCHH52k8l0Q8261m0Y0JOWH673m0VFRV8Z4TxB1YFwV8V4	!1M0k#@o!22I!18$V1#10@$lF!of8!2Xy)5Hc#62#W$GVk)Q9V	/(1-13///%1,2!4*1//)3/04#1#105$1/)2%2//.2%2#1#2+5$1&1$1+1.5,1!2-2%2,2!1%2/!2/$1$2&1.1$2/201)2/$102//*4!2#4/1$1+1//$1/%3-1.1+102/#8//$1/)1//010b%3*1(1/B/%3+3(3-3/&1#203(1/01#3#11/01/1/$201/01#1#4//+	fnsHb@AFCEVPRFQQQIESQIQFILyxMVpDEL@ESPH@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
\}6szdix)HO~x>.h)H^)>xS~*F*`qq:vH}}HqqS~x>.ixixhS(.>S~x>>xixxi	;nrYxSts4y3F3iUBNdXN2ulFNV93E04HnV5AXB31q96O1Z0ed0dV4JdFV91Kn1cQ108ZcLV287F04112WFFV	0WR0TV02a02Q!@C0ER!lN0O01u!DF0@F0t!32F3Q0EN01540OF1g07g01lR0JF1K07J0TV3B0EF0 !79WX0cTC412GWDF4D3016d0GNFGN4C@X2sNZM8261m0WkO8sP683m0YFRV8N782611VWsNXI0VWNZB9B4aO0Fs84iw35VFVFVL2664_sVNJBH2BY_0W8NcD@62FcFD83WkVV41E47g6VFZ84WC0lFg241WmVtI567342FFkVpqB3X2l88VM8241m0VkFVBXF@WWc8B91_XXnRZ8B44FbFNZ4B99VWlt88gq27224G0JP86X10NcJ32W1Y0kZB92Y1VBB9310V8@T8E	#f5k!gN8!65Z#a7k!Z24!4C2!2G5#BgB!30N!2l0F#uo!808!2Go#G2s!2GD!2C5V	0101/*103%4/#1-1/#3*3.4)2/01/1-21)402/,5/)1$2#1*5&1!103)3#3,4,2$1.10202!1/01///$5)1*1,701!102/#1)102!3%6!10105!2/#21,101/)1!2/203,2/%3#1/12$1*3%2%101*1(1#1/)3!A!1$1#1//&1!2%2%1*1/0p%1%201$1$10101#2&4*5/01/&3$4.3!4*A!2.1&1*3//%1#1#1#401/-3//1*	e`\\JL@JFDbIEHe`H`PH\BLbbbfLabbtJbbbblQCC`PqustuMKMRtDDqUQ@@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(R=x>.(R(R>.(R=x>.(R(R>.(R:0:v*`\)*F3636\)	vrUtvtQtrJCkOFAQH90k38uVa4HH9V@80PO238X42AVe41F202N18!R8JFdWJF3WA21VV0J01!G101V01!V	0WR0Tk02FV2l!FM06J0Q01v!GX06J0Sk3K!KW06g0Sk2w0CJ# #O0FVC04V@5130p1Fc@482VGViF4D2mO12Fe08Zc272c0_2V8w9Fc2@XVHNc4P9Z11Vo2VFg8	#24#304*2#Z2F!4c#3V4F$V!408!2G0F$V!84V*Hk!214#18V	01//01#4///*1(1#1#3////!1)9/!1$2$12!1+1/(1202/-3/2$2101/2%23&2$1!401/1#1-1/&101/)1$1$2/%101/%202$2$1,1%2+1//#2+4/03//1%1%1,10601&1//,1)3)1/+1/!1//)b%2-1(20101(8$4/%1/(1//#2/.1!144.1/$101!1/(2/04/,403+	ffsHB@NFBdDPdrnrnsJ}FZLEIZp@UUSTreP@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
zd6sO~x>hxxhx>xhS(S~x>S(~S(SxhS(x>x>S(xhx>x>xhxhx>x>xh	;vzv;xzxvyvzUzUmzvvUjQvUinSEjrzm9fFAvMpjhF5CubLVzZIj_jDXuANR152VLHF3GZB4Jk0kNNV0FV	0Pg!Xs0IV02J03d!9F0DZ!lN0O01u!C_07!Tk03Xk2U0DF01J80G01707g0bk$ !1Z120t0FVDF4D2W17_Z8FgL284R0Xo88ZL253FVZZ88wL2BA0XGBV8c782A1m0WVJ89O22J5VYmk8RI8291m0Y0RV8N522ML0ZXk8gE8281AIVW0LF4@2L15nVG8IWN4@2AIVWVGN4YD161IXkFVA8251b0Y2k8VA8271b0Ymk8Z@R2FA0YFgV8F4	#AWV!48#80F!3,Z8$1F#Y8!6Zc#cF$Ho!805#GV#99s(298V	#1//!1A1/02!8//)5+2#110411!1/#1*1/!14*5$9%1/!12,14.1/#1$5!203!2/*1.2//!1///!1/01*2,8&1#4.1/(1!103&4)21.3)1/$2!2/#11/01/$2-2%1(1/)1!1(22//06/.1$1/!1//)4m.4*1(1&4,1/(4/#2/!1*3!1/$404(231//)2.1/*2*1#101*2!1$1$	fcoQb@FZTNX@cIEElhhiMJeLddebb\m{SMTuUT@EUQCa@@					antagonist	OX2	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)Z[).hxi.=S~S~x>.h.hxixiS~x>.hxi.=x>.hS(xi.=x>S(.hS(.=S~x>.=.h.hxiS(S(.=S~.=.=.h.h.i>.ix	]S:vivUUvJnzyeuT4buhbtTBErV51mcAGke0vWmV2KW52EL8DxG1E_FWg50HV36gVB31FcqWVY8G0	0Pg!YV0s!2R03i!C_06k0Tk032F3O0EN!qJ0Tk3x!Fh0440FV3O!HD0@40d03Z!F504o0qk3q!K_06k0R01v0Ds0 #1Z13VVFskHC4X0NBJ5410V44VI0VZ4FcRDB420kNB631FFN4120F@OB22BJG4FX8FZD50lGNsFLG53GNN@@97XkGc44L214a3c9JBT642210V4431kVZL310kNF620e5V89GJ282WksFF63X0V88211F88@20V_Xs82139BWW_8BF68570s_447@3YYcF457W1cJHJE@2YlFkJ44X0NJ444aZ0N8kv82D1m0WFGkF8isA0V84JXDNAVFsFJi5A1VFFJX2175VW8sJ531W8N892109lB62280FGcB4L_Z13Vt0GF8w6ZA_lGciF4D3Z11VZu8FR8286WlFVD510k8R454WFF86aIIJ30XVF4ZG0ZkkVoR253WFcND31Wk8J672WkcJ2510VHtR62KNGXFF4453322Vo@7123n0l8i21W0VtZ8691Fc4NX1177O0Fs9SmJ351VG98iK4X0F861164Y3YNT34520FVgP@4WksRP71VVF82VLFD3_0k@@E5G_nNN8313Z1wV8c5g2@M0X0Wlgu5C2XlH9woK4@0kFG4PeE2310FWgX421Wt82JM0VFXW_N8@35WWesG08326XCVGms4L4iQ11FV	#10k#8$4#1NF#Z2#Bg$17F!FY$WF#9FF!VDk!80S#GI#O3s!214!259V	&3/*1$C.1!2!1*2*1)7%2#1)5$6*2$1(20101$3/%1$1$501#2,3(2!2#1)1#2/#1%1%3&2!4)1/01+1$2%1+4%2&2011*1#3#2$1*1!1!401//+5&11$103$2(201%4&2)7$1,12204#2/$1/(1*1$1.101/!2%1(1&22%1(9#12#2%2$7(211#1#202)1#1$C1$101!1/$2011/+1/.20z3)1#2)1301&1%J$1!1/#11/*1201/)102!2/!1021!2101#57/%1%10401/$1&42*2(502#1/1$6#2!2%	ekPzNB@L@hjbXDBaiU]P@bFPydAPcIICEDdelddhlhmEDeDhTdYEKCG@Z\VUj`hHjijj@@``jV`HFb@@					agonist	Adrenergic beta 1 / 2 / 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
72o2xi.ix>.>S~W(zdS(.i.h}Jp3\}.=x=S~~WS(S(x>S(0:v:`*F*	zxzrIZsKdc4R402DPN0_2N2cVFF093C04HGV10280Fo869VV0Y80hX4JNFW913F0V102!VJg!3F!FF2W0FV	0aJ0Tk02OF1v!B90Cg0xV05NF1Y07F0nF3p!OG05J0SF1u0Bk0x& !oZ4J9B0X884JAZ13Vt0Gk@04R_E12kF8JI8271eYkVsJJy492m0Z0RV8R78281	#24k!908!348#B3F!V1#388#FJ#FA8!20N!2G0F!2@Z!@08#1I#F0F!2GC#41V	/.1!1$3/,3*1-3.4*2///+5!1&4/#302(1/!1+2#1/!1!1+3%1#5(21(2/#2!1/(11/#1$1*3-5,3/$4/$11%1*2#21+4/!1-1(1/&2/(101#1#2!2/!1/&4/030A014//*2&2*7(1#1////#1)4&k%3%2%3)1%1%F%1#5//%21/.1%8!1/&1#3%31-2/*1%1)2/(3//+	fcpR@LVgA@a`BLddJbbbRbbNQrbQdv]Uj}kTDpU@PEMBH@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S(S~xi.iS~S~xh.h.hS~x>.>S~.ixhS(x>S~x=S(xi~SF|`|p3vl}\}\p3	:UvzvzvxSznnqvU3v3vrQPLa6GQgn08xQxi75mb1HGnDFz10AI!g4wm@J3b4Y3d56H3C0J090G8042s4V8FV	0aJ0Tk02K03x!9J0Eo!qJ0Sk1w!DF09w0t!4AV1209w0ek05NF1r07c0U03I& $9k8Zg26287oNNFFB132t0FcDF482d812W8JF@8Edl0VgF623Y130FF421X0FN4A5X0G1VFyU@3WGNiF4L2B430kVN2522GsF44B31VFNVsN871WVNB823XWV844336clmw88B4m0XkFkVR451Wk8J6@7W0FFk8231X3wV8g4g8350GNBD@410VtDF4H3Z130YVHONc432WGck423222gV8N78261	#31V!18$V%2#cW$cD$1$d8!4ZB#1F$2k#44#G$9KN$@!218V	,1/*7!11/08/#1!1!1!1+@$4$2$1////!3#1/$1(2$1/#8////)1+1+102/04!2%101#2,2,401#201%1)1/01%68%1/2/$1%1$1!8)1(1$1//)2/!1/*1%1!1&4/201#1*3//*6&101*291*2)2///01/(10q4$3/#2$1!1%1D$1%101!1#1/.10208/-4/-1%3+1/&2-1!2/$26#2!13!2/01&2&2%	e`\\HF@KFcc@IABPpdGICrPBdLbdLRTRfdtlRQbbRpbeSRqswuT@QMUUURD@TPQD@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.=xi.i.i.=.=.iS~.=.i.=.iS(.=.=S(.=.iO~,B)\6s	zxzpMWOK9k4R4K2DTN0VXN2u!F110A04Ln050e02Gk!11V024VC01J8F911CVF4A1!V04404!H0K02V0FV	0WR0Tk025k1v!9_07g011R0OF1g07g018w0d03Z0DV01Kw0NF1p0Ao0ok0 #FD_GGN2BC624WkV6A310cJF@16YnRV8V78291KVXM88R96828fWNFoF494_GsFNk63WkVNJZ120V8VoxFg81XFwV8B4RJ47G8d0L826YX29BBs46WFVWNF561129TF4L3Z11VekHecR4F3m0W0F	!164k$4$2#2FV!Z2F!5VN!20KF!cX4!188%F#2V#1Y#S3$2s#4L!210V	%2//06/%1*2/#2.1+1/#1&1//*3,2!4&4////-1!4$2/101.12(1&1!9&1/$1.2+1%13+1/&2&1,1//$2/&41!1//%2*43+2/01%1/!1*2%1(1!1!@04&2+4.1/*9/(1!3.1//&1.f#2/$120201+D)11//.212,1,13/*1/01&2/&2//$5(3&1/+102$	fi{pa@AUFkPH`dPdsN{ZrnlkNQSt\DAST@ERpP@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
\}6szdix)HO~x>.i)H^)>xS~*F*`qq:vH}}HqqS~x=5qxixiS()H^}x>5qxi	zxznrWSStk4R3F2DTB8WXN2uV0F093E04HnV5AXB31q9690V0Xc0dV0JdFV91Kl0VA120ZcLV!7F!112Y0GV	0WR0TV035V1Z07c!os0jV3W!DF0@F0t!32F3Q0EN01540OF1g07g01lR0JF1K07J0TV3B0EF% #852HFNLK3WFOFgf8271MVYKcR8J68HW3HO8X695m0WVRV8R46E35m0RNT421G8J2B8Bm0X0GwF8N46W2G91k8B548Ykl0TF4P3Z130t0FkBVs4@2m0VkFc8DEC2lk8@635XXoBB8B48A6W1B6B970Wlld0DD3YW8JJ3@50F8FNm62AFVWkV	#Y5k!g88!65a#a7k!Z24!4C@!2G5#BgB!3FN!2l0F#uV!808!2GoV!G2s#GD!2C5V	#1/*1(4/#1*1!1/#3/*3)2-3!1/1-21!2%602/,5/$1#1$2#1/!1!303)3/04/!1%1(10202!1/11///!105/$1,@01!101#2.1)102!3)10105!2/#21,1/+1!2/203,2/%3/$12$1*3%2%101*1$3!2#1/,A!1!101#1//&1!2%2/01/0m#301%401*10101#2&4*5#4,1/&3$4%1/&A!2.1&1*3//%1#1#1#4//4//1*	eohRJL@JFDebIEHk`H`PH\BLbbbfLabbtJbbbbNHX\BFNfiiYjV``fJh@`f`					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=s6.i\)B,.=S~.ixi.iS~.=x=S~.ixixiS~.=S~.i.i.=	yJup249G0k4F402!N05082F!F!1#2F058!2FV860WV#V924J0F#@V0V1F224V44080F2$V0Fk	0PJ016!NV1g0C!16B0O01s0EJ01L!NV1_07N0o!5NV1c07N0Tk3F# 0BV8V78271m0X0RV8Z782G1KVZ788kA8251m0YFRV8g78251	#L0k#2w!2%N@#Z38!10D!10r#sA$2P)4HV!82$V$GVF$1#GNV	11/)1+2)1//%3.1!1!7///$3(1$4!4*5/$1$2*6/,1/%3#11$2#2#2!5/1/#1/1/+1//%1,1/*1,1)1,1.1&1*3-1-1,11!2&4/*1/*1%4/01$1)6/+1/02(1)6&2/&21/(1%1//10c%6-12#1/D/$1/%2#4)1/&1#101%3/#1/$1#21,1///$207!2/02#1/0	fa{y@@FZMXmV`rQQJEQQPiJKKDhkTRm{ThDDD@@D@@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xiS(xh.hS~x=xiS~xhxi*`lvx>S~.>:vxh.i.hS~x>.>xhS~x>	:vz6bOK8o5w0KAhU801VNH!BN193c20IwV78X0HAk9620V02N010FJk0Vc14lGl91eVcVJ#1G1F0106V3V	0RZ!_!uF03OF1g07#qJ0Sk1w!DB0DN0uV04Ik2A0@!t!5NF1r07c0U03L& 0K_oFNNE827112VWW0643H116F482UGYVlGF4D8Q15mFG8GFF_G22V88VJhD2312l0c@97XlVJ81561n1skkQ470FGOJ4FBC1Wq9cJT115Y69VFk8@33XksR852Xksc@PB310W9sFPAA_WHNN4X4420lWDF4B3Z150j50FN8@QLZVccsLVJ261FkGV44J59W1l08FL82H0VkcVD@@40X1k	#2FV!I04!4VF!10X#Z2#58e#A4#NW$1@#1%2w!444#1VV#Hk#24#12V	*2,1.3!1.3/%2/&201!4$3!102$1////231(1/0201$1(1(2%2(2+1)1,3/03//1$22#4/!1/%12%1/1#1/+303&2%1*1/%22303$4&13/103/$2&2%1$2,1&1//*2/!21-7(102/#2/&1)5%2%2//(1(1(1/*n%32(101/4&F$2(2*3*14%1!2,2)1/9/&2202)1/011*1*1,1/-3/02/)	fkpP@DJr@nsyEEEELdmEhdddlYXL\mfuTapRAPTSD@`r@					antagonist	CRTH2	CRTH2 (PGD2-receptor) (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
x>S~xhxiS~xix=S~xixiS~xix>S~xixhx>S~S(xix=x>xiS(|`|Fl0~Sqqg-y?}Z	<v;Ux;wvQAv1rE8eqy6IShZZshPS25BV11@Ve4YpXVYNW8cXR8LFu3JF0l123Y41420VFF306VW10VV	0qJ0Q01v!Fi0440FV2l!Gc0@R0nV3F!G204B0eF3l!GY06F0T03p!Kl07B0j02x0Bs01qJ0P01n07N0dk3D0C& #m0W0RV8g782714dHssB22VV98wZ8@54Y14DDK20FF8FVL931kFJNM81Vc82NM10F8OBz8211m0WFRV8k4BO94WsJ@51ZZHKY8B6C37XJXF8@E59WVm0oA6@YC60FR8sc@2FFcoM8281m0Y0RV9B5NH5Z1FckM82@1__kFNNB	#aVk$k!21J!18@#VfF!7Zi$w#tA8#aN!2FFF!ZPk!1m4#W$Jnk!1KZ#lAV	+1/+B&1!2(1/(1$1(2$2$2#24/$2&101/+11#41210201!@%1&1#1)2/-2/%101/1#2/%1!1&2//%1/$1#3)1*3/!1)2(1$1,1!5!12/#11!21$2$2&1,1%1!2012/%1(24%4///5!2/)11+2!3*1!1!2//$2(133!102$3!1!2(101.2,11/$2-10t$1#1$1$101!1#21%1#8//!1(2%1&6/&1%6/$1$2%1!43*2$1//(4#1/#1071/+7-	ehV^D@@JMLnaie`KdiWYWYV{VWvTbaSPIIki[[xFjjjh@bVijfjIP@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>.>S(.hx=S~.>S(xi.hS(x=.>S~xiS(S(.h.hx=x>.=.>0:F|S(.i0l(Sx>.>	]Uztvy:UvCmzxvM6D6OhruChrjXbbVbAIvY8m7u0LK51g2g_DZmlKWXGi7GJV2611Ro2FZ01ZX0G0	0WR0Tk025k1v!9_07g!Xw0s!3YV2Z0DF011R0OF1g07g011R0OF1g07g01Hw0FF120@Z0s!5CF1E08g0bk3Z# #nRXF32WlFs9FVX28XWsoBP110Fl98B4w2440scH83XFkN4110VH0l6q92412msgTD3W0VF82A55s0GsF4P474eldc4B7610V8sVD6318J8220V9sZz8281m0X0IOsiH450kG0iF4421118088DF32VVZ88410FN210VVF5FLg24ZXFcL93WFNB8NB0VXYFF86A82lccH820V8861F584JmkBB6N1bXWJ2B7622FNNFiC9150cgV620WWc84HPT3W20No@75YVW8sN6@VktVZLH862ndFJLI0W21rdsH6@36YHFFVD210NF820aXYQs9B43281t0FNDF4L2444FkoLA4WFcB621733WFsHB0ZWkk@HB1VXXVs9VFP81_1NsR6F10Y088cZ612FVVFcV54Wl8JF71VkGl84327VFGXTF463U19VkFG0E82A110VZN8696VW8RD53Wl0B421VFF42cDL120FZ216ZX2sRFF21GH8F4T114bs0Hk844I3	#W4V!184!41#12F#4@#4Vc!20CF!Fd#4V$8FF#2k$Z#GF#93c#F4!258V	,1/)19-2#1!11)21//#6!106!112*2%1(1101//01+2/0141$4#2//+2/)1.1//04(3!4&204-1&1$2//%1,1!201$4&2-1&110102+2#303!3*2/3,1/01)2$1/.4/3&2*1!2$22.@//-2(1(2@//-1%4//3,z201!7&121(12033$1&N$1/$101%4-1!1#1#1/%3024#2-31.17#1+21/$2)1//#402&1#1&1.1$	ejQRLD@ACGAmKBPHcFHRYVuYnvyeUY}^aa[xxFEF@BjYjj@H@hJhBP|haH@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
SSRbxiS~x=.ixixix=x=xix=xiS(x=x=S(x=xiS~x=xixix=xiS~x=xi.ixix=x=xiS~x=xix=	;vzfvSUwCyOJAUTOFFXNePL40XhYE@8@jV78X03OFX0F1V0@0WZ0IDd6J3fCXH18Id0V060W@1480MWNV8F0	0qJ0R01v!C204w0ek03Xk2Z0DF01540OF1g07g013!FF120@Z016J0R01v0Eo0 !44WVe257XW0dwT9@1kVFZaIZ140VF8N8633WcoL5310V44VEFZVY3N8cA827110cV88D31W1NgN83X0VB@228Z088tC4d9WW1kXSa@35Wt0FcDF4H24jVFl0OhoE37WVW8w6EB41FNZPH32VWcN8Q7XW886NDB	#10V#8%V)42#5c8$5F#bc!45%F$2o!105!2lV#57s!244!219V	//&1B/)1&2#1)1/%2$301011/#1&1-101/.1-202+1/!1/,1(2,51(1$12//,52%1,1-112/6$1$1#1/&1%7&1/01$2/$1!102/$20@#1%202+2/!14*1&2+1&3//)101*11!9$2#3+5*3(3/%G%2$1+1&2/%1//2*z#2#12.1301)1#H!7-1%11!21/$1%3)2/#2/*1)402,101/$8+2$2#1#1)302%4*1#102&2014$1(	ef^\DJ@L`R]DPHbBHPdFIARPPMf]]e]YWYe}mDdBbzF^~``J`@jjhBBfhH@@@					not given in text	MCH-R1	MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(xh.>S~S~x>.hS(xhxh.>S~x>.h.hxiS~x=xhS(x>x>S(	;vzvtzjwbgYLQQSZOVm9OBiR0_3F87_7Z042WYL3F49kNa6OL!gHB8c!F5Xk0cG40VH4127N8N0V0VV0F0	0Y!IV02OF1k!9_07g!qJ0Q01k!Ri04s0Ik2D09w0d03Z& $2cC10G0kW44XM21l08c8423ml4X6@558a1021572t0G88F6422lGBLG2Xmm9RwZ3321YYuoBP51VFl8qF4B26A5n8ZPBI0VZGk	%k/F#Z2#48%4$W$42*2o$4#lk#82s$4!218V	%2/2/2/%1/)4201!1!3+B!108$1(1/10101/#1-1/%2!2.3/02/$1#2+201*3///!2*4&206/2///02/$2!6&1//&2$2$2/+201/!4021///1$1&1/2/$1.@/.2-4(2(25//,1///%o%8%1,101-R1/#1/*4//(2-1+1/(2!1/$1//+202/04/)	fcoP`@DX@UIfVym[u_eWQsU^vjjB`@BH@@DDHyP@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)ZD+x=S~xi.ixiW~zB.>S~S~}\ps\).iS(xh~O.>S~.=S(.=.iF*0l(Sl00:S~:0B,~W.hd,S~	;vzdzKxxhw3JAEUT8l3NPvZOF3dYC8DHzXA@29GQq@6OWW0YN0xX4oNFZfYQF0W12XX0VMd!3F20FFAW0kV	0ZF0IV02OF1v!C104F0IV03JF1_07g!t!dV3Z!B90Cg0xV04RF1p0Ao0pV06JF1K07J0TV3B0EF0 0F4iA@3FsoTF143XRV8R4aQ213swNNB20WHO0P46X0kg4NCBm0WVFsRs5A4G8FVLFB17EYFFgE8291AIVVsIWN4920VW8gV942WFJD810FGsgxih2312GdFLG7XFd0k22@9GCWVNgB2DR4VsFNFCL712FgV9078271OBF8NwE82811C4NO4J1272VFFgTA1WFkcJ63WVV8wRUZ130YmkZ631ZGcg8JC@IEVVsFL0U36W_JeF@894GbZFOBB	!1L4k!N08!34t#J3k!VBV!1N8#HKV#jc!21T!2K0F!3Bo!@0A#KIV!l0N!2Gh#C1V	//!1$C$2.1&3/%3103#1%1#8$1!10301//&2-1!101101$2%1$12$2202(1/!1$201#3#1)1$1!1!1+3!1!101#1&1#2/(2$142%1%11$11+2$2/!3%1%15,3/$A&1*5011%1*2#3$201$4/&4#1#33//#3/$101(2!2!3.101%1//!701///.A(1#1/1+1//%1&224&z03#3%2$11#2+1%D%1#5/(101/#2/-C011/%1*131.1/)1/*1-5*1#1/01(1	efYZBH@LKIgdXDAHP@cIIBhhhdhhchbThhheLbXeXxut\|mPSATADETsSUBP@@					antagonist	AT1 / ETA	Angiotensin AT / ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xixix>xix>xiS(x>x=S(x=xiS~x=xix=S~S(xixix=S~x>xixhxix=x>xiS~x=xixix>	=v;xzxzyvvUbBmz@PCjAEU_Vwjjjh2D7m_H1qXVFJYm940nVFhB8JnV5emFBIVJVF412a88F!VVV8F0	0aJ0Tk03OF1g07#sg0cF3Z!HD0@40d03Z!G204B0eF3l!G_07!Tk3x$ 043XG8RHA41FFFD420kF84ZHH7HGcNwBBC9ZlsZD32ZY0F48HLFF6kt02BI613olcF52YX1mok4663m0XFFFNLE62FVZH920VV84TCEm0WkK0_L84620VNFXG5WkFZP2A9VGF8BTR64Y0ksRA4WVVB420b2YXG8BT0alVsnB4Ll13W4H0VF8FBVYXV8gB297	#c0k/F#Z@#4gV$4#Fh8!4Z2#8F$@o#V5#ls#87s#44!219V	!1!2/%2$1$E&1-1*2-2/%6$2$2*1#2&1#10101/!2!2(1/!1&2*2#1/02$2/1.201*5+1/)1/&8&2#1/%101/0205/!1/%102&2,101#101/$1104!4#1/2%2%1-4&1011(2*1#1*1#1#2301$202#2)1/!101&1#2!B/02,2*1!2/027/01/*1$11//,10z%703#1+1301%1&P/10101%11(1)6)3/-5/(302)4+1/!2//1+1%20402$1!1%4*4-	efYRBH@GHf`^@jjPIAIe]YWVvYvUWyVa`rr{xff@B`@ijfhHHjj@hDb@@					antagonist	NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xhxh36x=S~S~d,J)zd=.(Si.>.>x~S(Si.(Sh.>.>x>.h.	vzUtvdQUxFbwIL@ESR8WHO8u4CF49X304LP0C@V908086WXV6XR0RX149F0@57W0VY13W0@41$3F41$k	0Os!WR0Tk025k1v!C10480IV035k1_07g016J0Q01r07k01L80OF1r07k0o!65V1G06Z0SF1u0Bo0 $E52kNcs284m0XVRV8F7828175lkO4L9D1YGaQ48T4zHW20Z9BmJ22WlNP48D4UD628VoI82613WmOBLN673FGNvB4Vl171O0FV8NVjA21GViF4N2DA15Wk9GX2G4m0ZkRV8F4yIFWZX890I8271m0WVRV8R78251m0Y0RV8F782B1m0Z0F	#34V!A04!2c#1Gi#Z3#5Wh!20J#838!20@!3GWF!Z0V#q_#58F#Qk!@24#3NV	01,1/10101!6/#2/011/.6$1&1+1!1!102#1+1#1*1-102/01#6!1!2%1$1#1-2!12#1,1%1/&1(1!1#1/%2(1!1/$1//#4/#1/!1#6#1101,1/%1(3-3-2#22$2/,2(1$2/%2$1/+1*2%101!1(142/$2!2%1!1/+17/-1!12#1%1//#1/o.2/!101%I%2#1(1/.1%1)1)1)4!1/2/1$1#3%1(1,2(5//$3/03*3)1#	fcpC@NNFBHUDFBLbbbTRRaLTRbRbKIZLvZ}pPRSUPPD@D@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(xh.=S~S~x>.hxhxh.=S~x>.i.ixiS~x=xhS(x>x>S(	;vzttz_wbgYLAQSZ9V29NBX8051F83_6Z042VYH3F08FNX61L!gFB8N#5Xk08G!VF4102N8F#VV0FF	0aJ0R!3OF1g07!1680OF1v0C!1ms0IV1E08s0bk2Z0DF0 #162@Ja0VsSFV4826b0kBXK5VH1O2GTG381VVFca952lsFL51a4IBV8Z4	#20F!1,F#Z2#482$4$W$4@*2o$4#kk#82s$4#18V	02!12#1/+14/%1/)4!1!1.9!104$1/+101/#1$2/.2!2.301.2/)2+201*5///-4&2-202#1//.2(2+2!4&1$1//&2$21/*2/$4021$11%2//!1$1&1*1$2/$1.8/.2-3%1*25//,1/!1#1/-l%603/0101-O/$1/*8//(201*2,1/+1////0203!2&1%4/)	fmwp`@DXJCJSLmskNk|kXJRsVuUPP@AD@@DBD@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
+D[)=x~S(Shxi.>.=x~S~Shx(Si.~S=x:0:v~Shxhx*`\)*Fh.}\=x36360lW~ps\)36*`\)	;vzftUxw7w1LAzUNFWmO2ubSN_dYC24MnVE4XB3Oo16tWb6AKVpXKTt38dCCYIcx1AY4XKdX675OJrN1W0kV	0_!uF03OF1k07g!qJ0R01v!DF0@N0t!3H01k0DZ016J0Sk1v07k01FZ0Xk3P0DF0xV06JV1W07R0TV1w0CN$ !joVNZE8241C7KN4FJ96E130ZHBs445XNFGsB4L5Z150bYHc68F4m0WVMeF8c317WhFGsx04B3m0WkH0GXF31lWc44LD9A61FZV976YVlcgTc20WO1822D9m0XFLms8H4Ka12kN8ZE8241_5kX8B4T6U9ZJ0VkFu84212GVT7373t0Gc8NL4MEaVsN4A6840m0g8@920G18a611YXlk88u9E3kVJ@421mHOTF4B26C2W90V8443X0	#AVk!188#aF!38XV!cB8!1B2!1FG$_8#1w#10F!FOZ!8BC#GYV!8Fs!21@!2_0V	1#1/,1$6101&2&1)3/)3*3)41#4#11!3/+101/01$2&1.101/01-2!2/.2%3+13.1/&1*1*3!1.2!101*2,103-1/!101#2(3&2-2(1(2#14%2$7!2#1//)3&1+51!1/(1/)1%1)203(101,A%1$2.1,2)1512(2A$1!1!11,1/$1+3*302$1$2#3(z#1&4#4(1*1%J!1011/$1$2#2%1!2(12,1101,7!1/$206!1$103!1,2+4/1/%1-13//+	ejY\NH@LAbXDALe`\P@cIIBhhehmEDdhdidlduMGJmfakh_`UjA`hBX@j@jI`b`dH@@					antagonist	ETA / ETB	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(xh.=S~S~x>.hxhxh.=S~x>.i.ixiS~x=.hxhS(.>x>x>S(	;vzttzhwbgYLAQSZ9VX9NBX8051F93_6Z042VYH3F08FNX69L!gFB888!5Xk08G!VF41X6N8F#VV0F0	0aJ0R!2J03d!C_06k0R!3OF1k07g01ms0IV1E08s0bk2Z0DF# #5k8sM43XMVkFV8TO8VWd4J285ZAk8lF8C4m0WVGl0R92W0cN474W0Ockoyj@WZ0kF4DP52VO4B@30Y29aF4H232XGNoJ330k8J@621FN48ZFH	%k/F#Z2#48%4$W$42*2o$5#lk#82s$4!218V	$12#1/+16/011!1/)4!1!1.6!104$1/+101/#1//$2!2.4/04/)2+301*8///-9&2-202#1//.2/$2!5&1//,2$3/*22/$6021$11//)1$1&1*1$2/$1.B/.2-2%1*26//2+1//*2*p%301#1,101-P/$1/2)6/-2)201/%203/+1////0202!2&1%4/)	fkQ`@DXAejSLmskNkkJ}`iKl{UUA@@DTD@A@a@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xh5qx>.>xh.hS(x>S~.>.>xh.hS(S(x>xhv:`|vl~Sx>S(xhx>S~xhS(xhS~	zxznrYUStlJSI42DTS8WXN2vV3F0C3126LIV5A0B3Fk9a9WVFY_V@VKLdFV853F0c110E4Z4dV824240G8W0FV	0PF!_!uF02ZV3r!CG06J0Tk032F3P0EN01540OF1k07g01GN0NF1d07c0nF! !4862m8wT81WmWV84HL34cmNc866Z2XBV8R7829122WVZHH7WkVB81B90VGs44NR654HW0F52W0NB4NEBm0WVFF82A62WVwJ@50V9cw62@D10_nFFLR410cNVR3112mpfR8@4110GFcBD5Xl8gN2172IgV8N782710VFVZL651VVcPB3VVF90TV211kkkF63W198F3113lWyF4@2F55WcgV@753Z5W0T8940WlRV8s782A110WNcFM80m0V2L7A	#3Vk$R!26$FBk!V@4!1Ba$FV!8Y#30N!2HWF!5NZ!Bm6#GnF!29s!216!2E0k	/#1-1$9!201,201#1!3$1!2/3(1%4*3$1)1+1#1/*201(2$3/)4/.101/#1%1/.1)2)1(1012!1(1*1(1,1!2%3%3$32/!1*1&1#501!1013&22!1/!21/4/$104#1*1)1,1.101#1/$101,1301!1%1)1/!5!8/)1*1!1101/$B(101&1(1///&1#1*p%4!3$2(101)1%D//%2/#1/-4!2%101+202)23)11#1/(12&2&1/*3/%1!1!1-	eoh\BD@L@lhDIN`@aHHrRPjIQIIJjIKSQQKQpjjyyZ`hJJijXB@P@@						NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xix>.>x>S~S(xh|`|Fl0`*}Jps}Jps}J`*psF|}JpspsF|}J}J	>U:KrxQTtQEUBmmhvviEqJBVoEDMx2A715O@yBZY3eLqy1uV8o0w1uxGFEWW4Vn8LK4140F2V@0VX0GV	0Pg!YV0s!2R03i!9k0Ds016J0R01v0Ds01Kw0PF1p0Ao0pV06Ik2D09!bk2V0DF024w0PF1p08s0Z02U0@!t! 0m0V0RV8F78251211kcR951l8Z@210YWOk4@@5YW8g@941kc822E5bVFkNDA8YWFRF710YGGcJJ75Y18c@73X0FF4RB0VFW@04294XWNZH82Wl0F431830848HZ42WGFkJC7XFk844172YgV8B42242GVgH75WkVFB70VJ1X04@76XWNVH9210sF@20c340FFLA4XGVk@A2VVV82T@Em0VkRV8R46@9ZH8g@62VVONcgDH7Z1kc881VFONcgLLA5VkJ831VHVtLF4D3Z140t0G88RuO83FNF4F883Y3sse865W0FFVVeq52W10B4456LVXas8V9P2BH0XXF8VCPH25d0G8PH0452	!1q4k!F4#2@O#TN#XD#10g!13Kk!GW#6WB!2DJF!Z@V#mJ#KG#d0s!41V!298V	$1//!6)1(3/,1,1$2(7#12!1/1$1)4/*2&2)1/$4%2,3$1//!9//#1241/$101#1)1$2#201/#1/%3//+5!2#2,1)1/02!5$5(2(202-2(1/2!201!2*1!11//*2!1,2%2$2,101,1.3/$1)6//+1$1$12/01*1*10i.31%1!1&1(6/)1#101)1.3/-6/(2#1%23&2)2$1/!1%1(1)1/5&1$1.22!2%1!	fcoiP@DXUhHAYgoHhhhibeddeMDeDrVcCVuUMSUUPADqAI@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
tn/jh.D{^}>.F*~S(Sv:`*>.(S.>S~.h.hS~	<v:yzvurzyx2VxZiRj7ZiVpUwckV7IG0W1GF8sGcF3FdWI2J@0VR4k1010PC05%B40VV82c#V0FV	0U4!aJ0Tk04Ak0s0440wF05Mk1W07J0jF3I! OBVVkFVBLB3WFc62964cIeBBL41424LGs68@4V7VkNJE8271	!160k!1+2$VX#1dc#4OF!F2%9*Fk!4V6#M3$FN!24$90V	1//&9/-1//(6$2////,3*1$4//!1,1//(1/%11/&1!1/)1-1/+1/!13*3-1/!1#1!1%1/%2!1#3/1/!1/%2.1(1/(1!1//2,2!404//!1%102%1+2//+2&22!1*1/%1(X#205/#1#1+@,2//!4/+5+1+1-2(3,1(1//01*2/!2/#1(1-	fluP`@NZAKIEEEBdbhdbTUjJZjifh@JDPHPP@					agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
lvAz~N(XlvlvAz:0~N(X(X:0(X:0(X:0Aze,(Xlv(XAz:v*`*F.=.i.i.=	zrUtzdUUzKzxQPAUEUBlQve9aEm6CYL9LuteEjm5NPafaVXX6at9vVBR8Bkd_Mt@WY3f_8FK01F1F140XVV0FV	0WR0Tk03OF1r07k!o80eF2l!FM06J0Q01v!Kf07J0Sk1w0CB01Ns0Z02U0@F0t!7Pk1p08s0Z02U0@F0t& $m0VFRV8F7825144FXNsgG9W1GcssJ3AaHNNRPDF415ksVR85XGFNVRJG912otc8F8H9ZoNcJD@O5WX0wc6753t0FsDF4F3Z14Vt0FV9J@4Q31Vkg8652WN8cVNO5VGG0mA773WllNPC6WGFFZLH97aWsoB@20XGG8gLA521NZF82W0V4oLQZ11VnXkFN8LB4WW8NB921W8F830bYIk	!1n5V!984!4V8!1@L#Z2F!4Z@!305F!1cV!408#1JF!VHZ#JG#1N#1Hk!@0a!2A8V	$1!1#1/*8#1(2/,1/+8$3$2!11(2/+1!1,1&1/!102&2//21/)1/$2!101$1*201/01&1&1(11203&22$1+1&2(1!1011$1/01*1$1&202//&2!3$2(2&1#102#2/-1#1%3,1$6*1!1.1-2$1%1#102#2)15$2/+5/-26/(2#1////%o%5/#21(1%F,1&1.3#2%1//(6/&21)10602/#1(2$101/+2/15%1/%601+	egdZDH@BCOLndb`HaIfV]}VYoUUXdtLjZFfNn``hjjifj`@d@@@						Adrenergic alpha 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
e]SheIe]e]eIe]eIe]S>eIbDS>e]eIeIS>e]gYgM_BM~AIOgDaab?UAIIeDDJeA\?PA]AI	<v=jrjyzQnj_jrznoyonUzxtobMScr_3qTjGsEnUv5QUx@zYRBqc@IsuEFh0T_8XJAEhd@Ik3F7Y4lk	0PF!ZJ0IV027k1v!8j0D#Xw0s!2Fk3V!BU06J0Tk03PV2q0C!1740ik2w0C401Kw0Rk1r0Ao0pV05Ak0s03Z0s03l!Oc06c0Rk1r0AN0o% 0ET_VFVVI8241m0WkFXZk2D0GWVqF4D2nG131s8cE8221JDVFNgE82516e2FcX16736m0cBPS15VWsFRND131_VFJ8FAX288B2@5aX0lFa8FDVYX08c42871VbFVF4781l8gH83W0F8sR31684kH8NVBDX30F8cT2776dIWNFF854XltFBF23F9FccFDJ611Vo4J@633WFsLD410c862C66W1GwsI4321X9o8Ld61214WO86442O0FF@ha6331iIO0BF6aH5kFVcF832B10kV89331ssB1362YVFJ@C4XlVw4@31VWcVo@ELXY0ccJp@2116plcBF6vJW1VVeJoE8XY1Fc42120kNoFE2XFNFL52VJWHFBBA220soTD3XmlV44HOZ120XX94J8F6Z0Wc8V4982VVkOc42N1VWNNPG811G8s42AD41WlZFaS1840GN84HD210Vs82222FFw@F11FsJ620W5GeccD4J34GcO0u2D10Xm08VY8231M0Yqk8k8D2R11VFOR8951kO4V71WmWV44HT220VncB84P41kNcT52W1F8F5B68XJ8kTB21Fd0w@2C9LcHkNgB8i621kVNR22W2mBV8N448EYl0o88890kFJBRL10VF8868430sVF43X0sF610VF842kBN0VbkNRJ@4Y18BL6210FF420cYJWdl@83WlWNlSNM4X2W0F49@30VVVFB832FsR843WkF8820VVHktY8251GXaV44@95m0XFFVGBG9VkFoVP114Zt0Fs@44M31417NsFJ8cK26XIlB4886BXGFcaM0VX19244S315W11OFX862FNJ82263Y0	#E1k!S0Z!6D8#te#VD4!1d1#Lqk!mf8!C3B!2Tck!4mk!4Xj#SJ#cCN!@Dh!21NV	(2$1-2*8!3.3%1,1!11$2%2/010901(1$2/+1!1/101(5201%1/$3%2(1/,1/!2)3(201(1-1$2-12$401)3(11-3&1!1-101*1#2$2-701&1*1-1$1%11!1$4#13(2(2!2#1&1%1,1$1*1$1%12%1)3$102/+1%10511#2%2!601204/1(1.2&1(19%1!1/!101+1*211!1(101/)1t%201#1,1$1*@%1/&1!1#4,21$2/01)101/*13%402)1#1!1.101$201,102#101)1(@*2!1(1/#	ebQUBH@IKGHlbgo`XSNek`LSHhdleDeLeEeCDhlieePpDdUUMlCC@AUT@QUUUTmPMTBTMTCTSD[D@@					agonist	A2A / A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
>.=x36x=d,J)B,l0l0B,B,)Ji.O(63.>S(x=.=xiS(S(x=x>.>xiS(	;UvUtvMyEV_azUHc2o2U9HiZ3@WWc@45D_Y4mk211F0HG@5IGa0ZI@9HVINB0HFB010X8Z01eg7IV70108VF	0qJ0Q01k!Ce0AN0o!4OF1k07R0U!4Ak110480gF04901k0DZ0zF06OF1e07R0U02q0C% 13mkgFe29W0GB8BC@m0Y0L3F8L5Z12VXG1caL5VVG0oY8291m0VVGGBa6L7XkWsVZ4B7m0Y0RV8R5V2HD5kWcTF4@3ABW1VXmoRH462B0HGRs4B3	!12V#104#V2!14X#ZD8!64Y$pF!F1%P#1$JNo#D4$V#8zk#44#58V	-1$1-1#17/%31(41#1/(1&2$2/101//$1!21/02!1/!1%2%1-2(1%1/&3$1/!1%1%1//*11///!4,1+1)1$30401&2/)1%2!3%101!31#2013&1*1%1-2&1$1#101$1/1%5+1/1-11&1103%1$14/+1#1!1%2+1)6,1/%2/3#3/(1!1$1!32!l+2#1/01(G$1$1/(1/#101$2/$3$1/01%3)2)1%11+2/1+1/2(3)11%2!1#1/0	ec`\LD@MBelB@`IABPRZuU^UvYVzabQQsqjX[Zjh@jj`@@`HHGB@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
l0*F:0~S.iS(i.S~.>.>S(xh.hxhS(S(S~x>S~S~.=xhxhxhS~x>xhx>xhS(x>x>S(	=fOSto5w7JAzUR8l2N@uZ4N19Wce4UvX7@XB2Qk96F1V0XxV9VGLONkt9SlIl91AVZcJ90c5K347WFV0FV	0aJ0Tk02J03d!DA09w0t!3Xk2Z0DF01480Fk2l0E401LJ0Q01k07R0U!55V1d07R0U03C!OM05g0M02A09w0t! !V90WVLF4X3Z120Y3e8i2592s0G8F4D55AX0kkTF4D3Z130t0GF8C83HZkFkgQ8221GkFWkLF4a21645OJBBJ6m0XFMN9CH2G2m0X0RV8N684D1Y0rN8pH2A270_b0cc6H4m0XFJW98@49XB1XJ68M413XtkVD13aGqk91R2D2MCVVsGBRY44kclRN	!2I0k!8e#6V6!1HBV!cL#44E#2hF!OWN!24E#G_V!_XZ!8mo#1sk!9vk!DDJ!2Q8V	01/,1(@/!11/02//6#2204!2.2&1#1*11#41+1+6$3/,1)1*1!2+1,1%11+11&11$1.1%2+1$11+1&1$1/1/!3(1%2.1%1$1&2)1101/1#1)2#1403+1%1%1/$2-1$5%1%202%1!11(1&1/01.2$2*12!6/02)2+1$3(2)6!2021//*101/01/,v#1150301.1)1%D/*11&2021(4)3/-7!1)1#1%2032%203+1%101%1&1/#1&1#2$1*401(1#1#1!1$3-	edVRBH@LBAEm@ai`@cIEELheEDmDldcJeDe`pixTMtlCCSAPMQMULu@AE@@@					not given in publication	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~x=.hxhxhS(S~.>S~x>x>xi.h.hxhxhS(.>X~zAx>S~}\3pps	zyQn61OK8F5s0FACCN0WV8Hm!F01#46k050V01Pk04FWV02JV9V4J0F0V04V0d112e4041$2040VV0Fk	0qJ0Q01v!C_07R0U!3YV2Z0DF!os0YF3r!O_06k0SV1r07k0o!6JV1U0640SF2x0CN$ $6F4D237X0sVXL41VWG4cJ22_ntg2DD7j0kNNgE827167b84FJ8kP12kgV8F422L50m1RDK90H1d8Tu482AZ_8o8167Y@VGnc4N5Z130t0Fs8B4Xe5dkVVgJ	#60k!O28!6VO#FH#_3#74@$K#9W8#58#11$2V!841!2KN#CHs!90M!2W8V	)2/,12&1%3/!3//$6$2$201!1/%1/.1101&3#1$1/)201)1/$1.3$4)1#1/%1$3/%1,1$2//&1#4$3)2!1/,13&2,1,1&2!5%2$201%30103-1%1%1*1*201%2/*6//!1#3,2.31/$1//#3%5+1!1(2,1$1&101#103/#11/p#1%1#1%1012202$10101#I/!1)1/!1!1%2/#1)6/#3/+2$11/.1//#502/!1!3*1#1!	ek`ZD@@DLOFc`AlbbRbbbRTRTNbabL|\JbjVNZh@@@B`ej`D@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~x=.ixixiS(S~.>S~x=x>xh.h.ixh|`S(.>l0|F~S	zovp64OK0k48402BR80_0N0m!F0118246mV50V021!601V025V8XG60FV09BW!9120V0490@04F040VV0Fk	0qJ0Sk1w!DD0@F0t!4OF1g07R0TF06JF1o07R0TF3C0EJ01p40OF1g07N0Sk1w0C$ Cc3NwFV8pMW3FgV8J78271CHVWNLF4D3Z12VWGFGJJVCYl1skw4XV5@klVWeJ482	#20V!C08!4V8$HF!Z2#55d$4#FV4#48!11$VXV#4W#1N$Hk!8B4#1@V	02/,1(3-2%3+2//$4!1$101$1$2)1#301//*1#1(1/02#201/!2+1)1+11&2#1///!1*1&4/-1.1!3$1#3!1/,14&1,1#1/2.201%3+2%2%1!1!1*11)2#1#3)1(1$2!1//01)1&301,21(1+1/+1-6.1(1.1,1#1/%21%1)i1/(2202$101%G/+21*1*1%2/#1)4/#3%1/*1///*3)403/!2/%	figH`@DX}tF\bbRbbbRTRTIVMyqXu[uj`@@@JBhA@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
55x>xh.hx>xhS(x>x>S(|`|Fl0x>S(xhx>S~S(xhx>.>x>S(S(qqg-.=y?}Zyg	{xzy:UvCq:vzjjjUhrwUhbjXjbmzAMzX8vMv3UK_phujhDZnm8imGg6GLV27V3yz6ZVS40Y0G0	0aJ0Tk02Ak3V!G_06k0R01v!F504o0qk3q!Jj0440FV2d0D!1IJ0Ik2A09w0t!5Ak1407!Tk3d& !9tJ8@4NC6FV8B81VHG98DJ941WFsgsg4@2E8Hcs4@D523G8gH942WNV4116ZIRV8F4sYH1XFn8wJL3WVNN81@65O0Fs8NTZ8VksJ@10VV9VZkwc7Y11F84FAZ110W1FoH@61W8ZB420FGl822FE3YH8sZ831VN8430aY3HVVHz45X23fwBB6D1@2WVJF@4620sgiB3W1GG4cc863ZsNNPB53XoW4JLL0W21k	#dWk!J8$4#14_$@#2ge#1KF!Nd#4VH#AFF!V@o!8VB#GZF!95s#54!258V	/&1/9&1*1//#4.6$7#13*3%1(1#2//%5///$1//011$1,1$1/01+2$102/01)4+1/1//$1/!2$5&1-1&11#1#2&2010303!5+1.1/$1$1$2(2$1/1/011+3&2,2%31#2!1&6+1/2(1#1!2(1&10601%1!2/0102,1%41/.3,r!1!5!202#2/!1&F$1/-4/!2!1/*3!2!1.2&1)74/1(1$4!1/#1&401/!3)1#1.1&1$	e`\\JH@L@nhDCOO`@cIIChdieeMEMDdhlmHhYYL]\|mP@USUPPTUDVEaDUEq@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
=.x>.hhxS~.>.h.h.>.i.=S(.iS~.hxhS~.>S~xi.h.hxh.>X~zA}\3pps	zqQl61OK0F5s0FACSN0W08Hk!F0108046k050V82QV04NWV02JV9X4J0F0V04VFW912XZ04d$H#VV0Fk	0qJ0Q01v!C_07R0U!3YV2Z0DF!kR0IF3q!O_06k0SV1r07k0o!6JV1U0640SF2x0CN$ 6F4D2ODa0n0FJ83@394VkT8G4eWl0NgE8271m0YVKvJ8L5Z120WVI1sZZ392VH0d2c482A2JtND167Y8kGo44N5Z13Vt0Fs8N4XT8_msVgJ	#D0k!O28!6VO#FH#_3#748$K#9W8#5N#11$2V!841#5QF!CHk!91M#W9V	//(2&1!2!3%21*3/$401,4$2$301!1/%101/,1!11%3#1!201/)201)102/!1/$4)1#1)2+14/*1*201$2-1/,4$3)2!1/!1)12&1,13/0202!1%2$301%30103-2%1%1*1)4201%2/*6//!1/02.41/$3//#3%4//02#1$1)1#1/%11/p#1/01011202$106%I/,1/%1%1/#1)3!1/3)5/02$11/.1//#502/!1-1#1!	eghZLH@EKBikhDC@@cIICLedieEDhemMDIIdTtMm\m@ASP@@QMPB@@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(.ixiS(.=.>x>x=S(.i.i|`S(x>.>.>S~l0|FS(S(.i.h.=.>S~.i.h.>	zyzvyfOIfkhk3LAEGNFlkOAH640X1V9DBKzX1!13IG30kY84HJV4aMu1882N80Fdc20H4201V604N0k&	0aJ0Tk02J03d!9F0DZ!n!FV1D!C_07!Tk03OF1k07g!t!bk3Z!C807!uF$ !6F4J253151V94Z1Eal1VvV4NACW2Fk8RI8241m0WVGN94q2CU0XklGKP6D3XkcNcNkfFWW0omF8N3AW2G2dO26@BVX10NJ622XXVR8HF6XF8NkJ824b2XP4T21YVF4ZFIZ130WVk8HJ5Y1lko4F1X2HkswPD9XW0c8H@931FYFR@83@VVGgs7133Xne0BD62YVNB8LEZ130XkHtJ44HL40NBFPDXDXVm8Fa4363O0G098V4J2XYNNwZ6263YJGwBHL132630G4F5274mcFgO42GA22skFJAZ130Z0FBJD7W1NFZRF1610GGNFsF20VN82D70W9Vok	#1VV#8)20V$48$@$1$W$4V#8$FHZ#85#GV#98s$2!210V	1)1(1-1$A!1.2//.3#6$5$1///&101,1$6+1/*1.1#1,1!2)4$1&2.1(1(2$1/$11)6,2$2(1*1//&1!1(4&1#3-11/01#101$5&4+2-1%1&2$1012*2$1.12/.1&1/#1/@%1$22-1,2#2&12)@+2/(1/$1#101%1/02%10w!3!5$4#401/(L%1/.4%1%1%2/#1)2/(406(22/-4/01/-1%1(3/#1-	ehRXJ@@D@OFcolbbbbRRbTttRRRNaVtBjZFvVnZhJBj@B`@bh``Dh@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xi.ix=.=S~xiS(.i.ix=x=S~.=S(.i.=S~.i.=S(.iS~.=.i.i.=.i	<yzxrEN4sYLtXBk0mkBXL640G!cJh7W241!1Gk!mGV0841512c0N0F012!V50J02442489HV!1X0lF	0Pg!aJ0Tk02OF1v!8s0D#ms0G01D!Ce0@R0o!3Xk2W0DF01a80OF1e07g0dk3F! $52Ym8wP930VFFgT32133RV884@87YGNoH630FV44110Z1X304PKE12Vo9t064525n0FweU262O0Fs8VRGCW1N8FFD0VkFNc2123at0G8AKP233WXW2kJ5933VV8cTHQ23W1FccwQ2X0l0w422555tcFN8mT14GFw2D970VksV@752kVZ6411FsJ44H80FGmOaL4821W18V8751l0F62210kN4310_1uVJFI7YlNNB9970FF8BJN321kswF@3W18RF120VV54PXD573kVs6D25YB0GIF4F41CeF9NJN814YB0GfF4J5Z11Vh60FJ9k2@L0WkVVZHF6YG0oJ2@7VFNFkk	#30V!18)1%e%89#4_F!FY#4V8#8$4Hk#H5#G$9cs!80B!21BV	!1/1-1$8(1)1+202/(2+8!204$1#2.1//#1//-2%1/(3//*5)101+1+11/.1/,1*1/*123$1/04&1.1(1)2.2$201!1(2//!10201)2.1$1.301!2.2-1(2/C)2/01)1&2(1#1$@/(201/&1/,1/!s!1!7(2)1201-N$4#1/!1/!8)20101+11+202//2021/1/.1/1102.4(102)2&2#2#1$	eohRD@@DLmg`NlbbRTTRRTqtVTtRVL|\bNnZj@@@bjj@B@PRHZH@@					agonist	Adrenergic beta 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~S(xhxh.>x>\)xh~Os6h.~S~Shxh.~S~Sh.}Hqq~QH}i.b{wj~S>.S~h.i.}^1m~S>.S~}H+CY~	~:vjxmzvvzUUzrzpxD:UXUhM7UDzehn7hayS59Svz5MwUIOPPGh2lo02K2rLo488eX0783V	0ZB0IV02GF1D!Bh02s0IV03Y03a0Dc!qJ0Tk3x!Fh03!FV2d!Fk0440FV2d!GZ07J0j03J!G_07!Tk3x# !BV8Z5Dx27WO0Fs8RRKEZ0V88FI8W4l0J4@C55mWNFFD865WWG0J61WVcF8220VH0x0HN6Xl8JB441HWcF4LL2C6GksF70VmFtBco47212GO8F94XkVB@420IXN44XT153HFcV22Xl0822C6aWGdRq8710l0cXHQ2317kGtkRR35X11W4XA42GN8240VIHV44Z1187_1tBVG20V8F4JE@45YOcJ413Xk88ZY82712dIsoR@A5m0WFFIGR6C3m0WVN08_8272DZ1k8RF10VV4cJJ54VlVkTE5WF9Fw2110VF42D7G2W1NZPC3WFcJH420nWc44JT86Y0sVLB4W1F4gV3176KWkFR8MG3VG1kVWXT50V8l8N2E7YllBH61VFGONg223Y0kN8A5WkkR461VVFC8c2199WkskH862VVRD31VFV8wi11154FFRPF3XWcN843VV8461FAVFHP8Fcj7Y08l4N	#j0V*m#42k!V@#1cV#6H#FW#1dN!2NFF#6o$E#KV#8Ks#44!259V	&2%101/02$F*1!13!1%1/$1*1+401!F03!1!31,2///$3$1-1&1!2%3/*1*11$3#2#1,2#7+2$2&2/.1)2#2%3,1313!1,4#3$1*12/&A!1#1/#1!2$1%1(401!312%3+102*2#1)1/01&1.3$2/1&1#1%2112-1-2!6$3)1#1*2#11$202)21(9/(1$1/1!3&101/*1*z#301%104$1&1!1*D1)1#1%2!11(202/1!2/#1)5/#1$2101#1!7&1/01!2$10202!1(211%2(1#10301%4/!2!1%4(11#	ecPrLD@CGNgbAYPIAfPRYeU~UUm]YemV[fXD\|Zzn^qy``biijjjjjBBhZbhpfHVhah@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxhx>x>xix=S~xhxhS~x>xix=S(xhx>xhS(x>x>xiS(ot7tx>	>U:pzOzynzTvBrzUAre2YA40vgSjz@53GC1KIq0PWc_16V603c28FHF9!n230L4!c0Z#VFV1W0k0	0WR0Tk025k1v!9_07g!lR0OF1v!DA0@40t!32F3R0EN01Hw0FV130@Z0wF! $4mtVBaD22kF8JPFQJ80ksTF4N25jW2VVNRJB5W0c8874XFs8230cYk848Na78ZHNsB6410GFccTDIYW0F62854O0FsAlF472110kgZB4W0cZ@131F9sow7W26W0FFFP642kV462210kZH320Jm844P115eWm0oZ75WFVVB4A65t0FN886742WsZJ42VkFFD220V85BNazHW2kVVBD96WFVJD44WFVB8220V89FRc32Xl0kZD5WFkF41C56t0FN844w7311d4B83X0NND40VFH0p78241	#15V!484#4+@$Zc!201#FWJ!1ZF#80F#@V!9V4#GAF!90s!2K#218k	)1/-901/(1%2/$4&1&2!202$303,1#1////+4/)1)1#1//$1!4)3/-1.101!11/*1&22&22*1$103)1/)3$142.1$10101%2+103!41!1!1.4$1//(2#2204#1!1/&1//$2#113+1!6#1$2&11!4//$1$9/(201/)201//+m-11)1101&5%D/%1/!2%201&2(1/$2011)1,1!5%44/-1&2)1/(2*3*1#2+13-	eg`\BL@I@kgDmc`H`bHfBLbbbrrbRaRfTRTtcGEc`rtDAUUUM@DKDPFT@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
+D[)=x~S(Si.hx>.=x>.~S~Shx(Si.hx~S=x:0:v>.~Shxhx*`\)*F}\=x36360lW~ps\)36*`\)	=ftUxw7w5LAzUNFWmO2ubSN_dYC24MnVE4XB3Oo96tWb6AKVpXKTt3cdCUnIcx1AY4XKdXD75OJrN1W0kV	0ZB0IV03OF1k07g!t!dV3Z!C807!uF04JF1_07!Tk04OF1r07g0U!52F2A0Cc0t03q!OH0640Sk1u07k0pV0 019CW2FgV8F4uYEW0FcZK6H27Y4NFkI827181HmN2D23YGsto8N4SJaFVVgF5N27VkGcR4L8F@Y1FVJVK513GwV8c4wYDW12084RAZ130_FI8okI2Vm0l8R4uE1_0N98D2E5m0XFLAB8H4CaW2kcJ8F8KE13mlg8N9Z120nGcG4@2E2VYG2OcV5110sJ4311FF4sDRAO7GFVVF4N9X18c43881FcR43556fakFR86D8a0sdF@52WkFcs611WXVF8Vs4C84W8cF214_FVFB21XYYX1gH9121NNVP31WF8VVk	#AZk!188#aF!3BXV!cBB!1B2!1FG$_$1w#30F!FOZ!8BC#GYV!@Fs!25D!2_0V	1#1*1&1)2$7101!1/%3(1/3*3!12$4$4#11/.101!1-1$2&1$1)101,4/!1//!3%3+1/12/%1*1(1$1.2!1/*103-1,3$101#2(6&2/&1(2#14%2$7!2#1//)1&1+51-1$3&1&1/01%12(203(101)2!@%1$2.1&3$2)1312(2E(1!1-1/$1+3*302$1$2#3(z2*4!241&1*1%H!1011/$1/1+13,1101+17!1(1,25(203!1,2+4011/01/02-13//#2&	en]\NH@LMfXDAECdZP@cIIBhhhmDmEDdeDYddduC@akimolXTUjAhJ`Ih@hBhfBJBP`@					antagonist	ETA / ETB	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
7gH2Sv7?0SqdSvuK``u[Fs}SV(`suJ@6pfU0i8rCrCU0S0qBsaW0j9uL	<v;r:jzyzQjjhjUzlxyqrAzSkorbRcrbIy4i3ojmSv_rMp8SeB@qV2IWV8F_0TZ0a4@81d@3k2F6X0Gk	0G8!QF!Xs0FF02Ak3V!8j0D!12w0DF3V0E401GN0NF1Z07J0nF05N01e07B0Sk3F!KU07B0Sk2x0CN# $6F4826C_18NB63VW9Fc228A6ZGO0@831W0F4116XIR0F8B4lKWkl0OgZY9VGG8edRA331cYO4V653XWHXNT9532kF8ZU8221Kbn8NVBVHPVVkJNFB46@YkJDB96m0VVRV8F4GR25WO0G88NPF71VFR@451kV8oZ2187Aa0JBX62Qc0sFJV@6J6lsN@BG6m0WVRV8J4JH830NN885W0V82PCCYbFWcFP4G5X3113BaG2XYGHwo884E5hX0FJJ@39aG9RaBB1VXWwV8N5Tj1Vl0cVpqM34WFFkW_6@BWGFcc4FFBalsN4FI812Y2VX22YYlk	!271F!S04!6u8!1Qg#VD4!5WB!12LV!k@#6KB#@cF!4Vk!6nR#8N#V5J!87Z#W9F	$1+2/%C+1013!2,1!1%1#1-105!2!1$8$2$1$1(102$2/102+4*5$1//21&1//1.42/#1/&2.1#1/+1.1*1)1!2(1$1*2,2/$2-5#3&11!1$301!2/$1&21)1$3$1&22-1/$1%1/*1.522&1%2$1!2/!1&1/!1)3%1/01010102+1&14011*401/%1$4j.1%1#1/3/-1#1,104/!1/!1!2*1(1!1+3+1*1&1)1/*1)1#6*11*1$1-	ekhVLD@BKHlfnaMG@@c@HrQQHjIQYSQIYYQHbaPqKJikXziZjjjA@jjjKC`aR`p`@					partial agonist	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.>xhS(.iS(x>S~S~.>xhxhxi-h.iS(x=S~kv(V,BO~xhS(Ay7sE*)\x>x>(Vkv)J)JS(AyAyE*kvAy	}yvzjjS:vvC<jroxzvxeEbnbRDzrjqTUqUICmxiSyjJnrZfjI_8r58KK3Ull8WBcu_V0kV	0aJ0Q!2AV2g!Bi03!IV03OF1r07k!ss0bk3Z!Fi0440FV2l!G208s0bk3Z!KW07R0TV1w0CB01J80Ik2A09w0t!5AV0r04B0f03l$ #2BJ51WVkO0TD63m0NVNGZ15VXW9RFA6XkVZZFIZ140o2VFR8J991_FcNT95WVFJ22@56hKcFs42B3GemkNkE422312FtBXF42Fk8BJ7@NC0VsIGV472m0VFRF8R425221H94Z@80Fl8sB2B@L640NkE8241L80WG4B4745XHlNL@CB0XlZ1RcN4423lH0eK54Xt0FcDF4B2kP11VdGV8P215Wg6VFN@8V241C_kF88NhEWXWV8VFT99VmcRR8870kGW8VLE13lFgF2752VN8Vg274XVcVNg72XkVZD70VVV421C49WW8kBH7VlNJ480VYFtcF4@5XmNcB66VFlVskTG@4GFoNL614YW1VcH8220VR6341kkN2VCF9a3sOB@H280VGNlZT4J4X2VJH866ZIHcFk42@3bVX2c8N9Ji50G1FVBHI0VXclB@180W8N8DACA5_NcFX216XVWcFH3410VN473VFFR631WkPVlF	#e0k!1%Z#10u#cX#5h%Lk!FdV!6_8#1F$@k!8Z5#O0F!cMs!24B!218V	/)1-D011102&2&1*14,1$1#21$1$@$D01!202/,1$101/*1#1#2(1%2!2#10202-3!22/!1/%2,1021$1/#1%1,2/!206&13!1-1,102#1(1)4#1%2&1$4&2,1&1%1,2!502!4&1#1(1!1!3%1$1/*102$2#1.102*1/1!2#402!1$2&2+4!5$4$1//!2!1$1$3#4/(1!201/%3//(1$z!2!602/01$1*H)2&1#1+2#1,3$2&2&2(2$6*1!2!1$1!2)5/02%1//,2*1!26-1!201(6-	ee_VB@@DLCOKiPG@X\bbbbffRbbabfftRRbVrQMGEfVuwqNOKHkUUUTuUTaAAPEEUAHLDZT@@					agonist	SST2	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}]`|p46r}]}]`|)Ip46r6r)I6r)I6r)I`|F*6r}]6r(R`|E|730l)[)[73	:UvzfUSzKxxQRQzEE8nfOe9iEP3CY28TzxXEfX58@nja02Xkbx9PZ6wsgkf_Kl7W33Ap84411J10140n4V0FV	0WR0Tk03OF1r07k!o80eF2l!FM06J0Q01v!HA09!bk3Z!Kp07R0TV1w0CB01oF0SF1u08g0Z02U0DF# 1Z120t0F8DF4B2F5VX1NXC243H1O08961l8sH310kGckoc6@bXFJNPBK9XZ98JF@483lt4V731HG98gk@L2WFsiF4D3Z140t0FVDF4H2133WsgD431W8N81C7VF884254d22GFLC6W0F8B3A4_VG8weA7X0sV8JA@1WX8kHA51VsJB21VIWN44HT77aXFgF920HGGDF463DA11VVsRLA6218Z@71VkOcs610WXV88S4	!135V!18Z#aN!1F2#V2F!4c@!205k#fV!6ZN!2WVF!VHV!846#G1#9Hs!@06!21@V	$1//!9!11(1///&108$3$2&1$2/.1%1%1&1/,2$1/*2/$1/*301#1.101/)1011#1)1!2&22!101%1$1!2#2(1!101%1$1/&2$1&202//%22!3$3(102)102#2!1/*1*5,1$6*1!1/01+2+1#102.5$2(1/!5(1%1-26/,1////%p%5/!11(11%F/-1%3#2//-271/&1+602/$1&2$10101/)2#1,4!1!101/#701+	egdRDH@BCOEdb`HcHhheEeldhhihXdlqIhYUtLl]]AAQUUSMHPAT@@@					antagonist	Adrenergic alpha 1B /1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hxh.=x=.ixiS(S~.=x=x=.h.iS(.>S~.=.hxi.i.>w<^}.=tn~U.>	:Uvvv;SzxvyvUPzBnyvQvi6rAhYSCiMUV35nhISltZOre4zM8fZ6JdFZYmK3AWC090cJLd3BEO141F0WVFV	0RZ!aJ0Tk03OF1g07g!kZ0qV3q!FL0640TV3C!Ni0480G01g07g0gF0 !BV8Z5@z23W0IVGD@80WlNyF482c165W9oBF8M6XLsVZGXn2513WNZk68VVl0o@5255O0FsAFmI222lBV8c5F1295Vdk88C647FX30T4B4m0WVHcGN3511ksoR	#XIk!4$85V!1N4#V2#5B2#84F!46#60N$FF#Ao!9F4#G3#97s!214!25DV	//&26(203&1)3/)3(5%6$231!2/#101$1-1#1*14)23$1!1/*1-201011%1/&1/%1%4//(1+1)1,1+1,13,121(1/!2%2%201%1#1#1$1(2+1$2%1-1%1*1/#1$22!101011/01+2/!1,1-1.5//!1$4$2)1(62&1//,1//,k$13/*30111$F#2*1/%21/032/1(1#1!2(101$1&201%23/////$4&1101!3/,	fcHa@LFWnB@ACPcIIBhhddmEddhleiuoEkMZuAPTTDDuXCBa@@					not given in publication	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
:vez(O~W(Si.`|p3hx=.F|=.0lzd}Ji.i.sp=.=.|FJ}i.spsp|FJ}qqsp|F	;vzfzUzxyzQTQyUEUfvvJvzOsbgnK7LnmtCUH2v0rhgK@byjeZOaG6Wn8d9OPO0Kc24MFRGX014V0cFgW0FV	0Xo0FF02OF1v!9F0DZ!_!uF03AF1407g!qJ0R01v!DA0@F0t!5O01d07J0j03H! 038251m0X0RV8o5oe251O0Fc@tg4G2m0XkLV95V2D2m0WVK8gL8451X8qF4R2qM14VgV8N44aLYl2kaF4F2SH4XFVZI8271F3m9VL@E5m0W0I9Ze6J30ZW08P6D7CYG18iA6@3KlcFcA8251AGW0O4E8241PV_X8Vg6H46i3sORE8281	#jVV!8&4!11@#V7#5C8#VC#8f8#6s!2F$4Ho$5#Oc#45s!604!2l2V	/(1+201F&1*2202//$1#1%4$2$1//+1-1101(3$@/!11$1,1(1+1(1(1&2$1//)1*1)6/&1!1/01/023)1//0201$1#3/!2(1$11(103&401%202+2!1-1$2-2.2%3$1.3///%1701/(1-1)101)18$1+1(2!1/01#2%2//&s%5%1$1!2#1$1*D//%4+21%1,12(1%4/!1$4241&1)1///#101/%3&1!2.1.4	eol\L@@DAG@EklbbTbbbRRqRTVVfVtlLB\|JzfvZjijjb@@Hja@@@						NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>S(.ixixh.>x>x>O(,dS(xixh)J63.=x>S(S(xi.>x=x>H))^xiS(xi)^x=.>	?x:JUxoYyRxVpaNHmnVN9hAAViMnXK9Vc3lk965pY02CVEX7oGQd81TlFcA126Zc650B4HH4J18W0FV	0TV!WR0Tk03JF1_07g!sg0cF3Z!DA0@F0t!3Z02Z0DF011R0OF1g07g011J0NF1d0Bo01Hs0FF2A0@40t!7KF1P06k0Tk2A0@F0t! !10d7W10ccM82G11VlNsH432WVBT916XYRV8N4kC770cFNLA14YnmcFgA82A11XIcO0e7510cgNFIZ130t0FkDF442@CZIl0JPAZ19Vt0G0DF4P2BB6XFVB6753t0F88B8B330c8L54WVkc@2E4bVHssV@80kW0gL299513FO4VC22VFBB583_X3d0e9833GgV8Z4JI27bWNVBLI1W21pYV8i5Z17Vt0HNDF4H25B142GBF44Xk8sVb829143lcsTB2W1O8k_kg251O0FNDF4@3Z150XI0JHB630V8ZPB15_O0HFDF4@2YE_VcRJ@@gM2VlkTF4F3Z15Vt0G09BmM5XWVkNQ8281m0XkF	#vJV!L8o#4Z!3H8k!qA#Bcm!3@xk!sY8!16x!20BF!6Xk!9W7#QW#96s!56L!3WBV	,1$1)101(@!1,204#1(401!3/%1.1$403/$2,1*1(11311#1#302!1*1%121///01#1%2,1$1,1)1)1/07//02!21!2*1#1%1!1!1.1(2.7$203//%2)104&1.@/1-3*2!6/01+1(1$2/!1+12$1+1$4&1/,1/)K$2#1!5//%1/$1/&10z#101#1-1401)10108!1*1%1$1/$14(8&4%2&1&@!2/&101#2-5&1+1&1&12.2+5(51+1,101-	ejYZBD@AEGBkn@dbPHcHHrJJIQKIJJIIJjIIQQKEbRrKHh{yyFBAbjZVZ``hjdhhEb@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xhx=.>x=S(xh.iS(.>.>S(.>(S@,@z)I)]I)1n18.>.i.h.>S~	;UvUrvUUvmQDwM2QkNtzhHy66kgj2BNOB8nOI118OfF01F0Q310428V6K3H2H20669L0806901080XkB2010	0WR0Tk025k1v!8s0D#lR0OF1v!CG06J0Tk04B0110480eF05AF0s0440G01v& #8ls8H5Z12VbKGV@8A4BD0soFR9Z13VVHVoPJ73FV4ZRHiQ10kZWNqD0XXGRV8N4NS9XHc4HDD0VXm0cFNl7XkVscU8261122ccD79XWN821B4aO0FV8F4aBD3GVsDBB4VXX5mFP447XO0G084XHE41FJ2197Zt0FV90wJ8X0c82FD8m0WkF	$4V$4!1%1%4#3t#203$2%4#8FF!V2k$5#G%58!2$210V	//(C/!1/.1&1+4#17////.4/2!104!1/01-1%1//%2//(1/02-1+3!6(22&4//$4/!5/.2/$1!201/!22208*202&1$1#1-1$2.2/*1/&2#2#12$1)16$2!1,1*1/!1#1&D///,11/.3$o#2*31/*B1//$1,1$4#2!2//*2!1+203//&2(2/#1)1%1/,601+	fcaA@KEAD\bLbbbTTjVRbRbrRcAFmUlupDQUUUUPADBODIH@@					antagonist	ORL1 Opioid	Orphanin , Nociceptin ORL / Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xiv:0:S~x=F*`*xixil055x=~XB,(Sl0l0>x>.B,(S(S=.(S>.>x(Si.(S>.>.>xh.	:Uvzv;S:vyvvEbSuzfz9zUjj_oFRyhh2@rIY82tacoDEqSL5Ig@c8TJYH0D61o@GF07B334k0A8VV$F	0P#Xo0FF02OF1v!C205g0OV03Xk2U0DF012o0B01209w012s0FF120@Z01680OF1e0C% FkGH44F4g6XVm8VN5323088RXi72VG0kVwVF3W18VB23W2lk824A0VWnXHco540GW8qF4832G11kXYJq6732YlcwaG6W21W08B79ZGcoH51VVGVk228C1ZFtBNB4Xk98w62C10VFNZp4D860NVNFCZ13Vt0GN8FL@73lVR4320VsR4R9D63kkRD922W8F4216ZFNB46C0VXJIGNL753Vsso42A8k10W8L0845211VkgN96WlFB4620kOss42AFQVllkFR9Z12Vt0Fc8_aS4230F8Z22769Zo10822YYFF8c2289W8VVNGwDA9VlskoD6254528Za13VGNoZV10W2Hk	#A0V!1$204!108#VD#59W#2a#8W$48#8k#42k#X4#O8#8bs$4!210V	012//$J/01&1*1)1#1%1+@#2@$3#1//!1/1(1$4%1/$1)1*1/&1!1$1!2//+1!1/+102%1#2!@/$2!201#11%1&6/!1%1/)1#11-102*1*3$1$1/#1$2!2//!2$1/$11#2-1#1#1/!2$1/06$2-1/)3(31(3!2/011#3/&1/.2/z%8/(1+H13+203,301!2/%5/-2.1#1$1*8&21$1/%1-101%2)1&1%4$4,1$1#@-	ebQRH@@DHek`DfYeUWgV]}fUTRSQsIhZZGEjjjj``hjjBAJHPDhdh@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hxhx>.>xi.iS(S~x>.>.=.hxhxiS(x>x>S(xix>xix>.hxhxix>\)xi~Os6xhS~x>xhxhx>	<vUzvUSplnTuUGvHnmRXqi4LOh1dLhMTr50V81Ok84fWX02SYC15y0LfP3@W0VWZ2m02ZgVB21HV610Y0GV	0Pg!aJ0Tk02OF1v!8s0D#b!vV03@01104s!kZ0qk3q!KU0640SF2x0CN01LJ0Q01k07g0vV! !8715G0Fi992YksF86A@m0WkF88DA52lNFL42W0sB2328XoLF8pZ2A2l0XFF8R8B7AYXFkN5860VGGDF462871610FB7AYFNt0@2D40Y2s2F8B4m18BVGcLF4D269_Y9FDBB10WlmnZe6@3IjFW0LF4J2EeW2FV84423W0NRHE4VVVZ831VkV9FL20W25gV8R4B55W_0cNFH4ZFcskF2@AQ0XmlV8D6@5aVlcVi96221k88L35W0WBViD3XkNB4477bt0G0884752GFVF421VNB82210N5BT11135GoNV6E30XkVR@410GNV657118K0Z4188VFkFcN7YW0F4JF10Xmk88@51Vl8g@551kkB611WFkCFV10VFlXv84Jm141B6FFc4253352Oo8I13XVF8VY8231O0YaF8g9Dx22W2lsJ43581c8ZJ61451blZ@8F10Y1F	#60k!F$2B8#F2#VC#9cc#3K#F18!4WR!1Q1F!Vek!80C#GYV!s0s!234!218V	//(6*1$102103%3)3$1$1#3.B$331!2/1///$13$1#1%1//02&1+11+2%13/&4&1#1,1-1#5(1&101+201!1.2$3&1,1/#1&6#1!2,2!2!1!101%3$13$1$4#313+12!2*1-1/3&1*1!1!1&1$2)1+2.1&21.901,1%4*101)4%101&118!1!101!1/%1(1+1#1&1/-z%8/#1)104#P$1*1,1/(1!1/&1!1!1!1/(111%33/!1)1$1/,2/#4/(2#2#2!1%	ejQRBH@LBekhDCD`@cIIBhhdhdTYdiDUDlhdmOG@kglRUj@@`BjjjiX@@bBJ`@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.h.>.>S~.h.h.ixi.>.>S~S~.hxh.>S~xhS~x>xhx>S~xhxhS~|F|`lvd,`|~O~Od,	=v;x<vUUzCnzNuUyEbEhrSOjyzVCAeYQQkfik7XX3Kcn@2BdDx3YUppCcIfeZr6618J1lJ5n@V0F0	0aJ0Tk02ZV3r!C_06k0Tk03Xk2Z0DF!rg0ZV3r!GG06J0Q01v!Fi0440FV2d!HE0@!t03c!S906k0Tk2E0@!t03c& #BV845Fw23W@7VFNA8251m0WkMXV8J4244Y9cR60Z4m0koXI9YksFVZF4EBH04JT@46Y20o8962Fk44NHB1Bnt0FP8PBb10oJL@wJ11kX20Z75VWcsoS522512HdoiE1Y41V8NVE@ZH8J4HD9G@msNkB6E8YlcJN650k9Nwj8241m0WVFdJuO6WV8tJR@E7_2NsF40ZZmK3BH6H332Gt0J45XGVF62B@6O0FFDF4N3Z130VkFJTG8YWNZ83A9_VVscLJ5YWVF@2164I0VNgT@YkFt0R212X18kN762FVV@20VV858V_Z120cZNFow2A3m0X0RV8N4	$4V#4%V!32FV!4@F!CWX$SF#Yc!4Z4!30F$2k!115#S9V!43g!246!2WBV	/-11!2$@&2*1-2#12/.4#23$3!1#2$1$3#1#1/*3%1!1*1$212%1*4/&12/)1*1+1(2%1+2/1+2#1$101/$1$101*21#2/%201$1/2&3*4//03!104/&4#2!2122/)2(3+1(1-3101#1%1$1!1/!10102+1!@01!2$11.1%1/,2F&20201%1#13//%1/!2*1$z2$4011!203)110101#1&J*1//.3/-6-102)1#2$3#1///$2$1&1-3/!2)4-	ebY\B@@L@j`DB`TfVUeU}vvUme^c`sqpI[ZyyGEjjJBbjZ@B`P@b@@@					not given in publication	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
h.xi.==x.hS(.>.>.iS(.=S(.iS~.hxhS~.>S~xi.h.hxh.>X~zA}\3pps	zqQl61OK0F5s0FACCN0W08Hm!F01#46k050V80PV04NWV02JV9V4J0F0V04V0W112X404d$2040VV0Fk	0qJ0Q01v!C_07R0U!3YV2Z0DF!kR0IF3q!O_06k0SV1r07k0o!6JV1U0640SF2x0CN$ !1Z13VVlNBNL93VFF6JG1VFFNooF2J@YoW08@D6eWl0NgE82719j1FgFJ8jPW2kgV8F42245G2O8HFBX3X25F8F4M69HcF4BE0VYGp09m6B0VXGBV8R782713VZF@FLM@XXlV	!1D0k!OH8!6VQ#FH#_3#748$K#9W8#5N#11F#2V!841#5QF!CHs!91M#W9V	//(2&1%3%2+3/$401,6$2#1304!1/%1/.1!1&3#1$1/)201)101/!1/$4)1#1)1+14/*1,1$2-1/,4$3)2!1/,12&1,1/!202!1%2$311%30103-1%1%1*1)4201%2-1+6//!1/05.21/01!1//#3%4/(2,1$1&101#1,1(11/p#1*1%1012202$106%I/,1/!1!1%2/#1)3!1/3)5/02$1101/,1/1/!502/!1-1#1!	eghZLH@IKBikhDC@@cIICLeMieEDhemMDHidTtMm\m@DSP@@QMPB@@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xiS(S~x>x=xhS(S(x=.>xiS(.hx=S(xix=S~xihxxi~SS~xix>xiS(x>x=S(x=	;vzvzvzxznvyvUIv5QUvzLi27AhnQDtfze7glbEM1eDFEf03H_4PIy3Bo2vBWHYE2HFZVD098oJ!JWFV8F0	0WR0Tk02J03d!DA09w0t!3OF1v0Eo014s0Xk2Z0DF01GR0OF1g07!Tk05AV110480bk2d# m0YkGc98w65YI8cg4287m0WkRV8c5HC2B7FHkw44G51VW0ZF96WGssca510VFVs4125cO0FcDF4N2B6Y2Vks273YhYcFsT225X1YGBc8FD0YWRV8J782C140H8V4P2Wl19J6A0VW21cP4R36Wt0HFDF462uK12FZ9J8qS1B3kFGFM82E1m0WVF	#GKV!28J$2#2$a2#5WP!2@5F!cd#5aX#8FF#2o$5#9V#13k#2J!21CV	02(1#1/(@#2-2)1/1/-421!2/*1//+4$4/!2%2011&2//.102&2$101&1/#1/02,4//#1121.2(2+2+1&1#5&2!2$1/&2&20322!203/1#202!203/#1/#5$2/$1&103/-1%101#101%1(6/&1&2*1!4,201!@!2//&1)2011%1.2/#u2$202+2$104$2&1B!1/&1(202/#3-101&2$5/%10202$1!13*2/+1/2+1&1(3*1#3+12-	ehR\LD@IHabK@`H`FPrJJIIYIQFZJJJiQIY`RkihY{zBBJeijjj`@b`BCR@					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.>x>.ixi.>S~x>S(.ixiS(.>S~x>x>.i.hS(S~x>S(xh0:v:S~x>`*F*S(xhS~x>xh	?vzUznvyxUnvpv:jLyLrvywvRh:2np3ACUOuOmzOZPLO2whwJDRIncL7tb2K182F3S4FANcYX0201V	0WR0Tk025k1v!9_07g!Z80eF02Ak3V!8j0D#Xw0s!2Fk3V!BL06F0TV035k1_07g01J80Ik2F09w0t& #142AH6kVNRF66@4H8wJ410V84kPN5242FoN6411F82NCB111O4eA52kVF420aZIFVFPA52GNgH720kN4sVREEbGVoJH@13ZX9BTA2VVN4gPL11X0ksZI2XFVR410b2ndsoF6632cHWBg@550WW8wVG72kk841B7a1G1FVC31VNNH2163VF8koNKWWWVmet0653m0W0FFFJF5ZH0gB31VI29V4897YWsZB821VV821E77XMtkBH7Z120cs8FJA8241652tkH7650FG0tFFT@3lGNF41334J2VFV8DA@bmk8@D@7@l1NNNBG82540VFNFo_B308cZM8271DVZW1ZDQ22XWVVZ8@6YG8FD43VkVF4TF0VFWe84474X1FgH941FkJ410c50N48XZ24X10oHB520VF@41740848PV421FccL74XGFZ8710FH150452218g@A62FcB8510F858XZI5Y18oL65WFF8gLLP414WgJHAZ11VVVcVNA8XGF8H811IGlc8674X1VcL74WkcF420VZGu8B8643X0cJ54X0F841E5bVFcBLE52GFVF44W0F4wRT11WG8gHB4X18BF71b4FF8w22BF12W9FiA61VF86L8A45FXNVL871XNFRJH4DW3YNVy6@5m0VkF8J6@6YGFZL420kFV4TD0VY408BB742W8RF83XVVF430VZX2F448321kwP64VVVV220c3408F@@74WcF821W0VR210VZWXF44842lkRL93VVNF8210V@Ft8e8282NF8DB20V8NVcu2K40ZINF8RQ212lgV8F4	#15V!1NB#2$F%8#5de!223V!FY4!6Z9$FF#2k$4#O$CCc!2F2!29@V	$2/%1+A(1)4(1101!1$1/!1$1$6$C$402/%1!1%3*201/21#4)2-4(21-2&2.3(1/#1&101///#1/)42!4)1&2%301/#111&1!2,7&1#1/!101+1%4$5(1+104*1/.4102$304!14%4/03/!1/#201016&1$2!704!2$1*4(2!1$3$2(2&108+2/.202(1/103&2/z%5011/,5#F$12/*12!2!2(2&1-1!5%1$4!1/$1#3&6/01/$2//&1%3/01*6-	ee[\JL@MOE`hZ^YPH`bHqBLbbbrtRTRffbRRvtTTRtlsGGRtvvILDAUUSTEAESUMUDQ@aCuBICM@@					antagonist	NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
gS]d]BIdEESgBIS?B]B]aEBISgIBB]B]EEd]?S]BSgSg(OSgIBFRd]S?B]IdBIBI]dB]S?aaEaBIBIdIB]EaS?S?S??SdIIBS?dIdIIBIB	=U:U:f<TfMyxAhLTq7fjrODxUDQ6wTIbEOn9FUhVN4W0xHgW6T3QNXI2B3OFG0P1vDScN0XXRV0F0	0Pg!Xo0FF02AF11!Be02o0FF03@V0h044!qJ0R01v!C_07!Tk03Y03a0DZ!sk0tV3d!Je02o0FF1407g022c0AF0i0440FV1407g0eF! !81Y0sF@25W1cZ8820k854ZXc2XHFs462VHGtC8Z492jWFW8Fs@9C3kcZZFF8QVYK8F8J6D63FVo4A32FFN62C8VVGtqF483H911FWd8PFCYGWk44LEZ12VXksZB8P4W1tRH111229YR4ZS7VFlc_w@45225FsRT623lk841B76O0FV8c483VlN8PC210N4@4EA0VN8BZZa1C0J8Z48K20l0O422D9jVYFc8c8J@12mk4H93X2Xs84e319W0FG0v827150FFJ822XW8Z644W3Y0o82124ogV8F5V2DFZVWNNk44PBWVFVLA0YZXFF8RMZ140XkNF8214WNo610WGcB4VG10YoG8@V633VGkV4@8E0kl8Bo21WF8BJcX310kNVD73VkVRH840kFB211VVHkw22BM7EFVJD42YXWk88PD9XX8RV2@4_0F8RD44XFs4823Wksg861VolHNWNT2XVFkgN4221ksVD431kNRJ41VkN8421VKWPk4421VkcN6711FsNH931Fk841K@0FN4BV117BhX0wD6132WclJF14320F882211W0oD920VVB82211884210LGv8B221WG0gaD2YFN44510JGe8FH4G28KFB8@@70VFFP4643X1ccD231l8Rkc4114FF826CJ6VYGG_L422Wl_@8e445X0F8HZ221VVVgD43WkF8843VkV86311kXt5Z22d0VV88411WFkJB663kNJ452Vk882iG0VFWc44Jq16VFVBN84118ZP8C@VkHN44X10W3ZF_F8HB131W_FFgBT7WWlGsoD311VkF636_FGcgo9J61X0k8FN821lNFH35YFNF4TE10FWH8FB611kFRD63Y0skB6185F888X_N14Y0FkKFV45220V8F222WWFRD@52WNN41H9VF8G1F	%V*V!25%4#392#2F$Y%k#cF$Ho!805#GVV!85s!24#2_0V	02/2%2-l#1(3(4$3#B42#1&4)6,2$@!102/02!1#1,2*201/05$4+4//#2!2%1%1/$2,2-1/*1$32!2)2(1!12+1+2$2,@(2#11#1,101&1(211-6!B%1/0202207&14!1+1#1$31$202$2)1#102(1$1#1$2$1/,1/.202#1#6*1/%1*5.1#@#3+302$2%12)203/+104/#110z/#11#2103-B/*2)1/$6&2$2#1+4012/&2(241/$1.37.2/&5%2$4$1+1$9-	efwtB@@E`pDLblbbRbRRfRdTRRrQbrRfbTbrRNrTRa`UWRpvpJMJoNmoi][U@aEUSUUPPQUUUUUUEQUDVDATUTXtP\H					kappa: partial agonist/ m?: partial agonist	Opioid kappa/ m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xh.hx>.>xi.hS(x>.>.>S(.>.h.>.h.>.hS~.>.h.>.hS(.>.>S(	>UzrnqSUyX@y1BFLh29VYZ050w681V2022421aF02!412FW4k0880G#F08)X024V1!X0G0	0Pg!aJ0R!2OF1k!8j0D#sg0cF3Z!C305!wF0 %6QL_FVcJJ445YHVoP71VV8422D@VVHN44X217cVFGJuK3XVVFZcH12_GPcB30VVFJgHMD155VG0FFsYEX3VF8kJ262WVcRB54WVkJJ52VVcB410e__GNg454XkV8H@21kN8820VJXHJwDD341VWO86742G0VB@10YGkB24AE131dRq61Vk84cc20VF882BCF6FVXcFH938XbscFJ8x62513Xtoa@232GV	)1+44$@#24X$k#FW8#VF#2%@Z$4$ZF#4k#4$58V	//(D3/02-2+2$1/!8$2$1.301/)101//-12,2/03!1$1/,3,3/3#1!1/%1+108+1/#2/(8/!15/!2#3$101.1//!6//1/6$1,12!1*23$3/0201//(2,4!6$1(1/2-2*4!1#3,1,2!1/01/!1.1,10o!1!3/#2,1!H0101$1(1/,4#1&2/+2/)25(13//01//#2.2&1/!102-	fgPp@DIAPWj}RYUVU}UVue[NO]jj``Jjjh@@`T`@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
~Shxh.>x~S~Sh.h.~S>.~Si.i.~S=.h.i.>.}Jp3W(x>xhS(x>x=S(	;vzvzvzxznvyvUHvKvzvzLy6bfgbQTxxze3pm_3MOv6VbQVQ7Z4EMu3@JAu@M2eb21LZYD09Bo484ooKV0k0	0WR0Tk02OF1v!9g0AN!_!uF03Z02W0DF012s0FF120@Z01Hs0B0110480eF065k1_06k0R01v0AN0 $3_B537WlIsFoA8231m0WkNsRg683GkFVkLF4D22@X2dZX5763Xn2NTA552t0FsDF462fRW4kcto8V5Z150t0G098ec3A2kc488E7m0WkLew8J4Z3ZINRJP51530WV4N8CYWk8220a3VF8k22@DL8kY904c5192O0FN8JyMJX4G4QNL6D3m0XFRV8c78241130d9B76A0k8J82133n0	!1W5k#84$2$4$6#1h@!2V7V#fF!4Z$8FF#2o!104#OV#95s!2F6!2W8V	//(A/!1$1/*1#1%11%6$5$2*1/$1//+3/012)1!1/01//#111*2$1!1/#11/%1/016/$2$102#1#201/)3/(3$10102#1!2!2+1.1!1$2/$104/#2(1/2$1//*2,1-1%2*1#401!1+3#4(1)1#2(2)9-1*1$1!1/1.1/*1#m%5/#1&2101$D102%1/+2/#2-2!2%1$2#1-2$202)2,1#1$1.1/+2/03/$2&2&1%	fcpb@BZCIPHaIf]V_e[]eV\bdmU{``JZjjj`@J@@@					antagonist	D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(S(.>x>.hS(.>.>S(.h.>.hS(.>.>S(.>.hS~.>.hx=.=.>S~S(S(.h.h.>S~S(.=	;vzv;x:vyvzEzTmzuuUzEfjZVHUjjhnEYHZdFHXVk7WuD4dH1Pi0DL3A1ie1qI1qG30F16048FVW0V0F0	0Z80IV025k1v!9_07g!qJ0R01v!DA0@40t!45k1_07!Tk04@V110480eF04AV110480eF0 #5Ch20VcFcH8_18Z818540W8ZPB5Y10ZB420YH9f_L4623MVVcFFPI6YG8ZF620HllTF4H2DK5H0JJX117Y69VFV8x427VVGVN@4H722WAkN8D4422lNoL642Fk8821VVF54PYZ13VW1ORiI5WFO0wV4M@41FkB60VmW9FF8@5XGsoL73VVFB2RFDm0VkG0gHE7YGVZ440VY1dWV4KB1410F8RL95YG8JJ61W0k422G78WJXNZ2572t0Fk8F@74YFcgD@32FcB220c4k8956w62510mdgV842kN8ZaHgNWVlVNF875X190D7220NF620c4o0	#96V!484/8#1cc!203$W$4V#8FF#2o$4#lc#9Cs(210V	02#1/#3,G$1/2+1/-2$D$3$1#1#2!2/-101)2/$1/!2(101&1)1(2/,2&2$2)1//,5121/+1+5&22&2/$2101.1%4&1/2&3%1!1)202!2/&2&4!4-2/#2!2,1,11+1$2(2/01#3&21(9$406/$10101+2/!8//)1,1/)1,1#z%7(1*1(1&P/-11%2)2)101+2.202+1%1$1&117/#3*2&1+1-11/031)1#2+16$1011!10	efU\DH@OJdRN`HcHhhdmLeBhdleMHhddmlpHYYdU|cCcAA@@UUUMTEAEAP@@@					antagonist	CCR8	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(N:vB,(N(NB,:v(S`|F|550l(SS~>x>..hxi(S(S.=S~x>=.|^^*(S^*>.>xi.(S(S>.>.>x(S	]Uzrv:vYbpuzfzLzLjzpwkRzhC@2pMYO6OXNq7CVOJ50CecBqJMH0D@GZ@lJ0382IJk0A@XV0683F	0P#Xo0FF03FF1204s!sk0tV3e!C_07g0zF04AF0k0480eF04AV110480eF04NV1_06V0o! !808d82820dXFZFXC33F84JLH2f2VFVRF6671X8gR830kN84217XYl9woB6WVFsVTLO23W11VZ876Y0so8120VV44VBF4aGsgPJ20m1G5BR332Wa4tFV8B4Y7VVsGXN48233294aB70F98gZ495Y1d4J41W0FBB3D570VVJJ963GVRD74VnGk44LR21VlFRD@4Y18V@2210F42ZDH12GGcNB53VV42LAAL9lNNFF867@IVF42143088cZ82@QdkFNNF223X1NVLA41W8F8417Yk848NYZ12Vt0Fc85Zc423088ZJRK35WNVF420HWGFJPN4XlFgT1970FGV44JMZ120VVVNRH43GNg84A80VGk424AD	#E0k$V!204$8#VD#19V$X#FW$V8#8k#42k#X4#G8#85s(219V	02$2(1/02$L/101%1#107-1*1+7#2A03!1#1///#2(1+1/$1!2%5.1!1&1%11!1///(1/-2-6/$2!231#1,2#3%2(22/(4&1/#6/(301!5(3+1$1#2!4/1(1-2-1%2/#1#1!211/&1/05$3#2$1#1*2*1021(31(5/*5&2+1/!1.2/z%4(5/+D1//!2(1,1-2,103/#1(1$108&1/*101,40111$2(1%101%5&1,1&7)1#	efUZDH@CKMo`Zf`ICHhdhXhleEDeDkDmMDdePphXTLl]cS@AUUUUSUUTDDEQapPHPxP@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.iS(xix=.>S~x>.i.hxiS(S~x>x=S(x=xiS(x=x>S(	vzUvvvzvzSzlQyeQ2Q4lUdfV66q1hVFBgtS231X10R9X4Wa20HN1806s8LJ3mJ02VZ234!401#3!X0V0F0	0aJ0Q!2OF1v!C20@Z0gF05AV110480cF2z! 8OZ@343XO0Fs9dJ@33F84RDDPL410JJR1153EXW8BB6H1YlG0c@2Z3V88kZ	#10V#88#8V#20V#@#6Vi!10MF#VV!4Z%F#40k$Z#OW#13c!205#1NV	//(9////&B$3.1/!1//1(1#102/$1/!3)2///2/)1/#1)1.4(2(1#1#1/#1/101#1!2*2)1/1/(1%2012)1!2$1#1#102+2//!1$1&4/#1/-1)3101%1%106$2//(5(1)3&1/#2//#1/01/i%8!1/1+4#J////$1%1,1/$1.6$1/1/+1/2&1)4/#11&501$21$	figH@@@XTeJYeoV]}eZ\MzJ^cZj``hj`@bHHH@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=S(.i.=.=.iS(.=S(.ix=.=.=.i.=.i@,@z)I)]H)1n18.>.i.h.=	;UvUrvUUvmQixMnQpsxjhHyLakyzdBNSD8mSI31COfNmFR0O210428WLRIH2H2H46SJ0326A0C1NVWkB281F	0Xw0s!2D03V!GG06J0Tk3x!KX06J0SV1v0C!1Xo0D01104F0SV1v!Nj03!FF120@Z0s! #CZ3kl8O8uFCXWGViF4@3Z140a_2048F49YnsN875WX290BkbAWFckZPRL21WO0Fk9O0G7VkkJRTE5EW0VYm8gB12XGHFwsD6VkkBVLGZ13VZ1WBTB@VkG0ZV	#20V!108$8#1$kZ#19c$3#F3$V8#8F$Hk$7#G1#8Cs!@08!299V	01$1(1,1#102!A/!2!1&1//(3$9//01/+1/#1/)2%1(3(5/&22/#1/.102*2-2/,2-3-1!2/!11/!2%5!2)1/01)2*1$3/#2104*1//!3$3.2.1!2//(14!101*601!1&1(2(302%101!11$1%1$A///0401!2%1//$n#103(31!21+2)B//%1!1/1//$101,1-3.1//01/*102#102/,4*1!	fcPb@GCuTD`drm|szrlzmFV\wj}p@UUUUUT@DAADRhCQd`@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>xhx>S(xhx>S~xhS(xhS~S~xhx>xhS(x>x>S(x>	=tU:pzxzTvQUnCHQdvCiAa@5kzUtdd2@a2b@Iaq8F@@4KH1pCmc8BFIk!XI@2F#101XF0Z0GX!8!	0WR0Tk03Xk2U0DF!qJ0Tk3x!FM06J0R01v!Ji0480IV2U0@Z# 0J2EN7GVNgHZH24W108oiO920k8ZXIZ12Vf0GQV4F4qD4VlcNccRDY1GkiF46242WH1Jq@4Z5FF98_N2ER0XkV	#15V#84)44$2$Z8!201V!Fd#4ZF#20F#@Z$4#1Z#10k#4$59V	//(51/#1///%162#1#1&1//,2//%2%4!1/!1)1/#2!1#1,201&1%1&1/(2(2!8/%401/-201/!41/02$6&1//+12$2,2&2$2&1#1)2%1,2#12.3$1)601/1/#1/!2!@&4!1/#2$2$1/2#271/+2$2,1&1)1/!1,k%401//!F,2!1#1////#2/&1011#2$3/02/$1//$1#1#2*1#1*1/	fmwPa@MQxhDPnPRYWUnY]vUzLCD\x@Jfjjj@BHPX`I@@					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=xi.iS~x=.=xhxi.iS~x>.ixhx>xhx>S~.i.=.iS~.iS~.>xh.h.ix>.>	]nqUUyXiySBFLx6QWYZ1h1t68GYX10203GVGV611433k54G298ZG880F08!2!N0VX560ZGF4X0G0	0Pg!Z40IV02OF1k!8j0D#_!uF02J03d!C_07!Tk03Xk2W0DF$ 1PR482E1p0Ngi294m0WVF884A4Y1cZ8611Y2s44e20VVNF4BD0VVFNdN42Q3XH0ZNC43ZkV94860XG1Gc4690X6kFJZ36Vl0gBHG12kFNl0gaIWZFwV8c4r925W2XNF@C9ZG048J@@0WFsZ673W0sc47420V84429Z4k8BR42Xl8gJ24Yk9cs4125bVFFwFC63W08850VkF84VB0W0W@LF4B24195n9w8A0Y2ltVNZ68334ntgB813YF88cVD83Z1skF8310N8kN2156VF84@5120sV@631VNB@50Vkk84110F85gX10W2rF8cPE8418ZF20_Zmk88422WFsJF541ksJ651WF8N41L@VFHN844FO31XFwZI42X2118e@B_FVkZNZP27_I0FkJ295@30WgF4L6XW11FXV8m2E24WWkVcHG5XWNND310FGl8s	#9VV!18%4!141$@#35e$lF!FW$Vk$F$Po$4#1c#1Ck#4$58V	/#1-2$M/!3-2+2$1%1+8!202$1.1/01+1/-8*1#1/&1/01/,4$1%11)1%2&1/%1&4%1+1/#1$1%1!1(@/!101&1$11!2#6$101#2*1//!6&6)1/.3$1,12-33$33/201/)2-2,2!5-1-102/,1#6%1$1-2!1//$1%1(1,10w!1!3$1%1&2/D01//#4%1&1$102/)102-1!2%406(13)1)1,1//#2!2+2/,2+40	ed\TF@@DF`GHbiklbbRRbRRaVRfRRTTRQggtKUTDEEUUUAA@PYT@@					antagonist	Adrenergic alpha / beta 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
O(.>s6.i\)xhB,S~.>S~x>.h.ixhxh.>x>.hxh.>x>.hS(xh.>.>x>S(S(xh	zrzx79OM1o5c42@QU80V29102B0410c24Lc050X029#V0X6HJ!ZFB8!1G4VFFcG0VV2411X01GF10V$	0aJ0R!3OF1g07#qJ0Q01k!C204w0eF03YV2V0DF015k0YV2V0DF$ $382118jmVO4B7AA1ZFwV8R782711nHVNcE8271m0WkIIgT6N3m0YVOWV8T4O_W3kW9VXQ61kNtoSLWAW_FwV8Z4	#F/06F#Z2#448#H4#FW%H%V#2Z#1V#VkV#2k#44#58V	//(41/*2+1&42/$8$5$1+3!101//1/#22/!2.2/03//%301*3&2(1+1#1/2!2&4&2/!2(1/$1/#1/&3&1/04!1-2(5$3&2)2)4/$6//)1)1,1//%2!2(1!@/02,2#2!4%2(2)5,5/.1+1//)s%3/)2*P$6+2023*2$3)4//(2/*2(11/02////#3/04*42,	eod\L@@DLM`DldfYf{U_UYU^hxlB|bVNZj`@@BjBBJP@@@					not given in publication	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xi.ix>.>S~x=.=S~S(S(xixi.i.i.>x>S~xix>xiS(x>x=xiS(x>xiS(S~x>x=xhS(	;vzv;x:vyvzEzTmzPuUzEfjZVFUjzhnEYHZdFHYVk7Wu@4dH1Hi0DL3A1iX1oI1qG30F06048FVW0V0F0	0aJ0R!2OF1v!9F0DZ!qJ0R01v!DA0@40t!4AV110480eF04@V110480ek! $SO_0lFTF4@2uK11VW2ouC10lX0qB4H113178kFw22C0VXl0sRR94X18Z672VVV823F70FGX8NXF5XF8gLA0VkWVVkH94XWccD821FcB230VZ1H6F4H3Z140jHWBBJ7Z13VYWl90850V90sV232310gH832FVB860W0H8s2225dW0VRPA61l8c@430VFBwTTG84n0NaBB64XWO0L66WVcN@1B6aO0G0DF4B210VG8gHA4XGNk8420FH0w62CG	#9VV!48/0@#18c$3$W$4V#8F$Ho$4#lc#9Ss(210V	//(H$1,1!2+1&2/%2#1D$2$1#1/)101)1+2/$4/+101&1)1(2/,3,2)1//,412//)2(2&2!3-1!21/01%2&1/2&3%1,1$3&3/&4!2-3/#2*2$1#23(1&1#1//$1&23(9$406/$10201$4%2/!7//)1,1//3%1010z%7(1!1&2(1&P/-11%2)2)101+2%1(202+1%1!203&115///#1-11$2$3%31)1#1+15&11!10	ejY\L@@DDl`M`\bbTbbbRRRvNTRTvbbRlR|rbJVNQIZjjBjBb`BHHHh@@@					antagonist	CCR8	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
~SS((SS~=.xh.hi.(SS~x>S~>.>x.h(S(S>.>xh.(S>x(WdzJ}363p*`*`W~3636*`J}36*`0:F|0l(S	?xxzxzrl7URzchYRHzHZG2CA937LnV_2csItkda9WX1@KZ5XKTt0c89EYkg91@XZk6d2865GJJ52W0FV	0Xw0FF02J03d!CG06J0Tk03OF1k07g016J0Q01r07k018w0d03Z0DV01FZ0Z03P0DF0xV06JV1W07R0TV1w0CN$ 0lB28WO0GN8k6Z3C3lVVD2234HRV8F5Z2K690FO4I8271m0XFRV8V4PZ2980coBP@e3gklNN_4BIWWHNiF4B22324cWsB232FkVBDK0VVXGdJLM521VsRcEZ16VXVNFmi2@3NgkWNGBoD@X41FB454443XegBNK14XO0Fk@4cKAVWGci464G241lG0L@U22lsRFm3110FWBq0Z231L1VFo8H4@4HFo@150mX9FFH782kk8823WVVN8310VHGN42HI53Xcg@C33_10B66E2VYHk	#Y0k!508#ak#8HV!Z@#493#FK$_4#1t#10F#@o!85S#SYV#Pw!25D!270V	01//1$E011.101$103#2(1+3.4$3$4$1/01#101//!1$11#4&2(5(1/!1/!2&1-5+11$2//,102$1011,41!13+3%1%2#103&1%1$2&3/$4&2#3/&5#21#4%2$6!3/#2#2/-1*2!401.1-4$101#2%1$1$1$2)12$1)9%1)1#2#1101$1/011#2%D(1!1!1(1)1,1#4.1!3(1!101%1$z01#3!2)2$1103%11!1!J//%2%2$4%221+1,1!6!1!1+1$203(103(1&1////#4-1/,	ei[\FH@LM`XDADd\P@cIIBhhhmDUieeEDddbieDcOHlimkonQUjAb@@bjP`bfjhH`@@						LTD4	Leukotriene LT (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xi.iS~x=.=S~xixi.i.ix=S~xix=xiS(x=x=xiS(x=xiS(S~x=x=xiS(	;vzvzxzxxQvwnzBv8mjNuMu03AZ!QhThX530V1FFY0F5VV24c20Hi0DJ2A1ZV10I0L01#604#W0V0F0	0aJ0R!2OF1v!9F0DZ!qJ0R01v!DA0@40t!4AV110480eF$ 0NC0VkFHy490VWVonc8T20W3088RJBJA1108F84VFNVkFN85XGO0@43VVVF832VVH0d3829189n0oB@A1VXGbXV8D4C9aWsN863VV9Fwc2242G0VF@3WW0B8730VH9422BH9YX1ZT@6631WNwL973W8V41A75t0G0DF4B2121FcRLA7X10RD3C@10HF444EF	#1VV!48/0@#10c$1$W$4V#8F$Ho$4#lc#9Os(210V	//(C/!1!3*21//!1B!202$1#1//%1+2/$4/+101/01(2/,3,4)1//,412)1/.2(2&2/01#1!1-1%2&1//,1$3&3(1-2!2-3/#2/1$3(1#3!1#1//$1&2)9$4$1/#201+2,1$7/01//$1//3*v%7(1!1%1101%1&P/-1&2)8)1/$1(202+1&10203&113///0101-11$2$1%21)1#1+14&11$	e`\TL@@DG@FmdfUfUW}e[ye]GKOJnkofjhJBJ@H``b@@@@					antagonist	CCR8	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)I_|6rG*)I)IG*)IB+2oi.(WW~.=5q)S.?.@*T.>S(.h.>S~.h.iS~.>S~S(.h.=xh.hS~	:Uvzv;S:vyvvUrTnUfvUzCfz_VRSjjxMDbngvMfmVkbYiJoEm5DxBiLYm5gydw7WabI_F1FV1GNfXVV8F0	0W80IF02OF1v!9J0Eo!_F0zF03OF1g07g!t!bk3Z!Fc0440FV2U!LA08s0c02W0DF01XV0Xk2D0@!cF3Z# m0V0RV8J78261m0XVRV8g68V221O0FsDF4D2Na130WmSR6F3220FNBN9Z1t8oZN2K32FtoBM3YYH1VNH_2blWFqF4L2221kFcH691FGJPNGBG9kVJB@G60YlVvcH830FcNVTG94WW0FJLAZ15VYmPZ820XV8J4JI@m0XkKQZ8R4@T7VlkP28492m0WVFsO8PB2ZlRV8N78261m0YVRV8s4OA6WZVlu9@C4A2O0Fs844631lcBa310VFkT5E@bYWW4cD2VkcJ6JP10a2kkRsIBXkVtVR	#f0k!1B)10F#ZA#5Vi$7F#cc!45J$F#V2k#F4#9QF!13V!206#19V	.2+2+9/01#9/*1.@*2$3/+2/01/2/02//1&2$8//*2!1013(2-11(3/+402#42!1*22(2#2,4//!1(1%78%3#2+2!1,1#11!112$3!8#1*1(2%2/%2+4+2//#1#1$2(1-11$2)4//*6+1#1$8!1#1#2!2%2-1)2/(1,1!1(2v/*1)1%D$2-1#1,2)2&206)2/1!6!1%2/*4+1/&2/02/%6(3,1(1%3-	eb^\LN@ACLmKJ`@azP~d@YBFPQdLYCIELeeEEKDeeMDeEiEHqpXxedmmP@ULuUS@AUUQP@@@						NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x=xiS(x=x=S(x=xix=S(xiS~x=xixix=xix=xiS(x=x=S(	?xrzx:wzQUY8LEBe9yf7@_ViP8cg2c22l@3ZX0F02W5F1n0mc8DJI2044F@2#1101X02401X%	0aJ0R!25k1v!DA09w0t!45k1_07!Tk04Ak110480bk! %2VGvRkA35XO0FcAB4Ll1412Xm0kA572t0FNAB4Tl15W2v8FZ82697XVgL388Z2pPsBP632YXlcRD1Z520	$4%4)44$@#3ZX!20kV!FW$ZF#2FF#@o$4#8Z$5k#4$58V	02/#1,2#91////%6$2$1.1/////2%2#2/02*1/!2!1#2,2.21&2/(2(2!4/(1+1*2(11/!1/1%1&1/#1/(1$302*2/$2-41/!2/$1.301+2+1+1$2,1!6$2/)2-2/024//!2,1%11/!1/&f%503//!H,2/1#1,4//(201$10102,12)2//&1//-1*1.104$1(	fakab@M\UDDPdrnk\kkJtYxK^p@UMUU@@P@@					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xix=x>xix=xix>.>S~x=S(S(xi.>S~x=xixix>xix>xiS(x>x=xiS(x>xiS(S~x>x=xhS(	;vzv;x:vyvzSzTuzPyUzEfjZVQUjzhnCnFVdGFYVo7Wu@4dH1Hi0DR2A1iV1qQ1qG38F0605NFVW0V0F0	0Xc0FF02OF1k!8M07g!_!uF035k1_07g!qJ0R01v!DA0@40t!4AV110480eF$ %QA0Vk84862k12FF8NByw27VVc4BL113Y7pssF8@4m0X0FNscI@XGNt062D863ltBT41WFVB62B4a0VkkLA4XlNN831VVV84VBFO0Y0@w8H213210VND951ksR683WVkF410d3V88lCqK8111VaF4L2870XNkRD0XXH0F4RKZ11VVFJN8672Wl0RH63WFNBD630kF42cDK25GcZe88VVd8cZLA62lNZH93W0c82PBCm0X0F88B74Xl8ZD831VNNB210ZWeLF4B234X1NJF841kNND311FF821I69hYks48@4m0WVJPgL510WX044LEZ13VVW8VH63XGFgH710k88420d3ogV8g48741H0gD82WksJ6317Z088l0	#9ZV!484$4*D#1dc!201$Y$4V#8FF#Ho$4#lc#9Os!2$210V	//(K$1,1!2+1/-2#16$2$1#1/)1+1+2/$4/!2%20101&1)1(2/,3,2)1//!1#2$4122/+1+2(2&2!6-1!21/01%3&1/4&1/#1$3&3/&4!2-3/#2,1!1$3(1$301#1//1#1!2#23(A$4/)221$4/)9//)1,1//3%1#z%4#2#1!1&1(1&N/-11%2)2)101+2%1(202+1%1!203&513//&1+1-11$2$5%212(1#1+16&11!10	efUTLH@CJmChPHaIe]iewm]YV~YVaapHjkZ{Ff@BjZjjj`BHHHJ@@@					antagonist	CCR8	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(x>.>.>.iS~.>.i.>.ix>.>S~.>S(S(.h.i.>.>S(7^x>.>S~~Sh..h.h.>S~.>	^x:yyQTrPMzCfUya7s_VjwAAxKaWXGWGOaV03VW90YZXXBBaU3H5a206b1F55Z51V03B0pV0VkF0	0RZ!U4!WR0Tk025k1v!9_07g!aJ0Tk02a02Q!DA0@F0t!45k1_06k0Tk0490110480eF0 $1Tp27WO0G8DF4D2iQ120Xcp8G0XZkV94F2E7Ibm0NwR2B4m0X0FhRF6F3m0XVHos8V5Z180Wpmo28K4m0ZFG_V8k5Z140blOW48F4m0W0OdR8H4I5X0ssaB1Z4kVB8TJ18kWNJJX@223Z1JJF7A3WWCJBX7Z120_tcFV84488mcV4DJ31FX98ZGI391XFBRP65A2t0FsDF482rLW2kgV8J5Rb263VGFTF4D3Z17VbXusBP69hW3FaY08c4T1DZkIN52930GHcsWF4LKX0XNVt6JE26lBV8o7826121HF48J13ml9Z4411_30N@0XQ0VVX8B110F9OFlVLDWZVk	$6V$J!801#2$Z@#5hk!20pF!sW8!1%@FF!V@s#V5#K4#87c#4J!218V	//&3@%1.103(2#3)21(2%1$2!101$1+3.1-11/)2/&204%4.2/#1/(5,1/1/!2!1)4$2//1*1/,2.1+4%22%1012!1&2031-1)601!102//!2/(1$1#2!1+1/&1%1!2#3021&2*2#101)10101B!4%2&2%2*11/#2&C2!3+2/%2-1+1/+1#z$12(3)1101-L01,3(2,2/0137$1,4*2-1+1&203(1&4!2*1&2//-3&2/!102-	ejY\DD@ANbUC@HabHrJIJHjYJQQII[IJJIFZc`kihY{zGF@HijjB`bhJBLb@@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
d,}J>.W(vlp3(SzBzB.hxhJ)>.S(vlS~S~(Sh..>x>xh>.>.xh)Jh.^}x>O(635q}^S(^}x>~S=xxhS(h.hxixx>x==xS((Six>x=xhx	;vzv;x:vyvzUzUuzvvUzAjzjoSM:jzAjIbzUzydoUvyUmjrxQj7iLWxOTz1gcom3KlIpIkBk8O@WW0k0	0aJ0Tk02OF1v!C_07!Tk03Xk2W0DF!sg0cF3Z!DA0@N0t!3H01k0DZ012V0AV1Q09s012V0FF120@g018s0bV2U0DF0 %O0G0DF483Z12VfakFg8JRLWZH08wG0l91YVkVgXD1aWssw86254XoW0Bg21XWFW4L2E8544VB6@52m1W04D41XkVJ8B5YG88F1E8VkGc44JYZ13Vt0GVDF4B2E890m8Fe4D3VY1Xmwe9452DVGmc4J4GJeFm0O5Fe35WVWNNF585WVR@JF1VXkF8ZlJt0WWFp3k8B5Z140cNNFs@6W261O0FV88R62YV8oJ281Hm8N44D1VY3cN8t22B2EV_0tFiD47WFG8kND91W1kJB83W1OW0N226b0VIsZ8D60VGBR412F9W842F1VYYkFVc173FWBD22_YkFB8NP11HVFsVB951kcJ4JP0VkNB622WX28J@4D0VFWHt4Vs35XkG8VZR@@2Wks43152mXYJ4@5W1W8kJ245YGIcgH70VWHs84e710kVFJT516WkGPGcZ6L1WGscwRLC0GHd884H77V_1uRDI22YWVNRR810VV48B@A31VGBL2G1VkWk44LVEA_lkJcBC6ACkFZF464Y5WnVBL814X2WFZ68N2WG0BcC11k88cPRA2YlVJJA0XFNN@1273F88gw	#xVk!8R$45!1Nk#cR8!1cX#@IF!8d#4Z_#8F#kPo!8O5#Ock!1Cs!22F!3_8V	//1&K*1*1&1$1/%4&32!B$601!5/&1(1/1$201$1#1!4#1/01//$2#201*1!1)22,5)1$11/%1+1&201!1#4,1-3,1&32#1&2$38.1&1#1!5/2!5#3%1#1!2$1!307/201/-1$203(1!7*224$204//(1/&1&4$A%1#124!1/4&23!4#1,48%1//#1//01,3%10z%@01!4#4#21#3(2&P!1!1-201#12/02B01$101,1!101&1!A0102/%2(15/11+4+2//#301#8#1%1#11&1#3&2$1	ej}~N@@DLBJfhUPCBeo`Y\bbbbTbRfVbfrvfbRbjTTTRQVfRHXd|bZFv^~m}sKZjjijhF`hjfjhF``@IbABXcF`@					agonist	Motilin	Motilin (II)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxhx>x>xix=S~xhxhS~x>xix=S(xhx>xhS(x>x>S(x>	>U:pzSzinUTzBqUUAUe2Y@50vgUjj853l53K3qVH1c_160603B@cFHFCV0I@306V04!V!FVFVVV0F0	0WR0Tk025k1v!8M07g!lR0OF1v!FM06J0Q01v!HD0@40d03Z!Jj0480Fk2d0E4# %PMMZ10sVwVK55ksRRNEZ140WAk8BH623ZHGJH42WkNF4N9B0W0cVPA5X10N852VVF8220dXZkXd2J4520FsRLH73W8BD510YGGc44w412lNVN9410VF@31W0F42ZAIm0VkHJw66B311X0kZB3VW08BLC3VXn08N465310gB910kVN8118YkF846@Jm0VkRV8F4k@93mVV43874O0GNDF4622211FgN821FcZD31VVN8220e3508@84212WFgH73VkVRB31VkN44aD0VX_FFF8453FsFD4410FBF30VoX84411235V	#15k!4B4*F#4@#4Zc!205#FVJ#Z&F#@V!9V_#1NF!12V#J4#18V	)1/-801/#1*2/,1,2$1.1+101//01&1/&6%2#1,1*1//)1!3)1/-1(2(3!5&2/1!1&22&22*1$103)1/)3$101/$1#1/!103!2#1!1.4#2//.204#1!1/$301//$3#111+1!7#1$2&1#4//*9//#1/201//+i%2/!12012,D/%1%1+2(1&1(1/#2201*1,1)4/2-1!1#3//!2*302&11#2+13-	fmwpc@IAryHH`dPnHrJJKKJIJEJYQIYgKNGNB@jjjf`@bHFh@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S:v:0*FS~*`.hxi.=.>x>S~.ixixhS~x>xix>xiS(x>x=S(	:UvzfzUzOzjQDPECCRuuQ99gBXZh_FBTzgc52l188G7VV2VaIM02Z248co2I5W42Z39k02428J!1JVlZV0F0	0aJ0Q!2OF1v!Fh0440FV2d!HD0@!d03Z!Kg08s0c02Z0DF# #38211ReVW044@6cR0k8VNF6523XGBH@4VFNB2P9C1110sgC6WG0F6216XIH14VQA0GW0qF4@3Z130VouVX890VWlFFFN79WW0ZD73W0F84T9E	%k#4)10F#4@#50V#24$W$5$8F#22k$4#ON#83c$4!218V	,1/*A#1//-1(1%2#@$4$1/!4/1,22////01//01/*2%1//)1*1)2*2/02/#1/#31/-1//,202!1.2+2%2-1$2.1#2.1//01#2/$102.6#1//2(2!1.4.1!1)1&1.2//+10i$17!101-1#2+H.1/102%1%6&2//2-1*11#2$401//1!101/!1/102%3)1/!4+10	figq@@DX\CHhhddeEehThdbLU[p^cZjHJJj`@BHBH@@					agonist	Opioid m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(.iv:0:.>S~F*`*.i.il0:0S~~WB,)^l0l055H}B,)^)^H})^>.6s)\d,,B^}:05q^}5q}^^}^}}^	?yzU:vzxvfjxuzfzhUU:ywoB:S@QxM7RDzexr6CayR59xexJMJUIGP@G_@lo02S3MJk08@cX0703V	0Xo0FF02GF1D!9_07g!aJ0Tk03Y03a0Dc012o0B0120@Z013!FF120@Z01L40SF1u0Ak0p! #4oi4724eZ8cB@D56mGkNVB2551ksgZJ5W0882PB0VFW9sFR643HtJD2940FFWHsqP32WZo8VJ54VlG0s42B9@bm8wF70YX1wV8R4N3E8WVcgF296OVY1mB8D6I53XFC8B@66XWVB8E6YVVN4216Y3F89s611XW8RLA5X0kZ6PF10F8Nk22@H10VkR8D53VkFB830FF4410V_1HXlk452BVOFNRBT42121RDG30mWGF84442G0ZJC5W0kR4RA10FW044BX61118kV65XVNF@21W0@0W16F28X0kFoV2A90XGVFVPCAXFkJ4431088sRR49b2VgB320VGFceeC11Wks2F8D48Dblkk@BB6110VFF74YFsRF620kNB41H80F8FlF851Xl8oF84WW8J4210k@8h4	#i0V*p$2F!WB#19V#22#Fb#1d8!2NFF#6k$E#G8V!8Ks$5!218V	-1+1,O,1$1%1.1$1#1%1+B1#B03!1!31///(1(12/+1/(1/&1%2#1#1,3#4-1!102$2/(1(2$106#2/$311!1+1!6/!14&1.3101#1/#1!2#2/201!202%3/)2*1&3*104&1.2$1+2+1#1&2/1.10801!3%1&1/1&24(21(41#1!1#1/%1///$121&z#20@&101#1*1*J1/)1!3$202)6)6/-6.2#2(1&7!2/)2$101.1&2(1#1#1%4*1/0@$1#1#	emPrD@@BLko`DDfyfUU^]YwvYovUTtlBjFVv~aeUZjjjj``hjijj`@hdppHThth@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~S~.h.h.>S(.h.>.h.>.hxh.hS(S~S~.>.>xhS(S~.>.hspS(.h\}Bz.>.>S(.hS(	:UvzvzxzSxjvwPzTjQQfOgUz63W_ZA8f@yI7WX1Y3GaV47WV90_0e3g8aT32CX20@Y1Fp4B1O0F1805V0VcF0	0RZ!Xs0FF025k1v!9_07g!aJ0Tk03Xk2Z0DF012c0FF120@Z01GR0OF1g07g0zF$ !R8q447XO0Fs88z334Wh5VG48283k10VsF6DN3510FcWGFT325FV8RM0427W0FH_w4X415Wt0G0DF462r252cW4HL981X0k946bH2ZVV8cN22S5WkXNLE43_FF88FJ10VFl4qQ812HGDF4D220XnPRcBC67JVWsF4N6qK15kV98B237ZmNoDD3VXXGFVcW@1kslR62B0VXH7PN66I30VaHnsL6J0VkWsqF4P3Z130ZGFBgT136GN48g3170FG1F9Bl426VF9FJ	#c6V$J!805!3%42#5dF!204#c_8!1%8FF#@s$5#G8$7c!20J!211V	//&3I032)1(2*2#3)21$1!2%21#4!202$1/#1&1,111/)2/01&2///-1(4)1/1/%1/%1&2/01&1*2)2(132)1/(25%1%1)61/$2$101101,2&104#1%2+1/%2!1+1/&12$1)1(2*1%1)1#1D!4%21%4#4-1$1/%C2$1/01/+41+1/+2#z$1)2)1121#1)L02,3/%2+401#34*1/!2//!402.24/%1,52/%1(3&2/$2-	efU\HD@ANjU@H`bPrJJKKJYJQQII[IQQIHsL\E]MC_@hdpPEMUPTDUPTDYD@@@					antagonist	MCH1	melanin-concentrating hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxix>x>xi\)55s6~Ox>xix>xix>\)xi~Os6S~xhx>S~xhS(xix>S~x>S(x>	vzUvvfzUzSzxQTOUUSPnuOfviEHZgXABDbUGA629dQl2ZkWVeuJ5Q45R0LDYL922Wb23lG@0F1JV1P0Y!1!k	0G8!WR0Tk025k1v!BM06J0Tk04OF1r07g0U!4JV1l0Ak0pV05@V110480IV2d!OG06J0SV1r07k0o% !423GkkRA4X0NF4NF0VFWdmD249230mt4X@51Fs4cHKZ12VWF8kTB7YG0J84363nBV8R42442W0cF83WkkB831VkP9421279t0G08BFC7Y1FgD72VkF46RAD110sZP@4WkkN6920F8881H7VFGeNF841W1NkF44WFNB45210FB21K7VFGenGV4922X1NFDB72G8F62110Wskw441X0kRFB3W0sR661VFNB420eY_RV8B42531WFZD941FNB@51VFc461J8VVGuiF4L210W1NsRB4WkVNB30VFF94NX21WG0RPC1X0kBF140VF44ZH1VFWuaF463Z120d0QoBP6IBbHFF4373Yt0FcDF4P210_H9JHA21VN86N@B0Y0ksP85ZFcF421VYWGk42C@Ylsk652VmlkF44AC	!2a4V!G0B!2sR!12XV!V3F#d@!20F$14#GB!2OkF!F@k!274#p$cKw#GB!2A1k	//(9.1%4)1.1$1*2$21#3011%1.1%13$1/%1!202(2/!1$4%2%1,1)1*1/)1021#32#11#1/+1/01&1%11(1.1&2+5!1//(7(1)1#1)101/4-3*2204%2#2!11/$1%1)4#1!2-1(1!1%2$1&2$2&2&13,61/$6!11!1$1/(2#@%2/(103.1201%1$102-1-10y/*1$2010101#G(101/-2)101#1*1!1.3!101/+1114&2(11!1(101$12//+205011%1%1#1&2$1!2$	el^Z@L@CLbjg`H`bHbBLbbbrtbVrRTRftTRbqXxLljZn~Aa``JjjjZj@@@bP`DH@@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
*F3pJ)*F\}*FJ)J)h(|`J)*F0lF*S~0:(Sl0*`:036J}*`*`J}	zrUtztUxzKpxvNvUUz9X2sPUiCLNCXC17qn0EAXbHQa8ZFIXFawVvc1KB80dWSkfW95W_cF511!FlFB0VW8F0	0aJ0Q!3Xk2T0DF018s0cF2Z0DF01K40OF1g07g0zF07IV1E05V0Xk2T0@w0t# #PDcl8VkGck231O0G0DF462I4bX9N4BA66cqVNNE82810_FlVw@I51kX0v1c4C2m0WVF	#kZV!F0F$V!2FFk!B2#BV@#f6F!8fk!401%V#@V!11W#YFk#2V!224!3C9V	/1&1.2$1/+2//$7$3!1121/*1/#2)1/)2/%1!2)1///(1$1)1%3/(2-102$304(2/)2)201%13/$1#2#22#62%2/#1/-2/&4#3/(1&3(2///,1$3/2.5/%4/#1122(1!1$18/(1-2$1(1#1//!1!10h%3$1(3#1201-F/,1!1/)1&21/$7///#2201&2///!1(402/!1/%	fegHb@AZCEW`RBSLomls[vkNAbN\AASTmU@@P@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
x=xiS(x=x=S(x=xix=xix=xix=xiw<^}tn~U	zxzpnWzStnF4MJ02HCV0V80VVXF1g0AV2HF010240WF!10W0@!8!J0F81102!3%J%201!V0FV	0U4!WR0Tk035k1_07g01Kw0NF1p0Ao0ok$ #417XnVsH20VW0B41D5b0VFgPM@XFW1F212W0Ncsr8231A9oNNZ8264RVY4NV8H6OEW3pN8oB	#64k#14.VV#1c8!20F+9%F#2k#V6#G3$4s#4#210V	1/+3*B//////$1,2//&3/4&2%2(1////02,1(1/(3021&2!4/(1//5#2)1#12/&1/$1//$101////2%1$3%1$2.301/&1,1/!2!604!1/*2//4/+1%2(1/&1/.X!12022/!1/8/////)1/*1(1,1#102/#1)2/*5(2&1/1/!	fleQB@OITBHRYWUUVVcHi`@jjjVH@@					antagonist	H3 / H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhx=S~S~xi\)xis6~O:0S~d,d,xh.h:0S~x>S~.>xhS(.h.hx>x>.>	:Uvzv;S:vytzUzSuzfzCzUjzirUCzxh@@zHbRUyfdJLUmBo9ns2daERYq2Pa16DdJ0JO3MJO8k8dX8V0F0	0Xo0FF02FV1D!9204s!WR0Tk02OF1v!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA09w0t!3Xk2W0DF013J0Gk1v0@g% !1G9W1VW2oRC7XXkV8ZOPq0WWFk8ZRE5XW0RL42VVOcooBKDZVkgHDB74CocNgB@CC6WkZ4485ZA_0oBF7Z12VbNsFR8iC51lkFH98620FFZckM6a118w4D@H@W2rc8VB236X2GNV124YkFB8N51W2IGssi6C75GVNZQ8241QVFWGkV474G510gJ330VV4cFJ53Y1FZD942FsJD3C7VV8Fkw6@6538FB32X0F4kJN@915VVgPC72FVF2HAA25WcFJ55YZG8N8220kFsZtV63611Vw4J@b17jFGNF84B4ZHNZH2991FFFBP120kl1t4iD383l0oBNA153t0FN98L4O0Xl0oN41110R2LBC13G8cJ56WVkB@320kN82XBG12GdJc47WFkB2LBA53498e5663@r8FF8cSD_W18V4B954lFV@91VkdVw820W11H08884W10ZH53WFsR4410VF9BP115e0VVRR891kVR@210VV82110V@Vc4123f0FVJLA2XlFB87410cF62G6cVkksZF44GFF42A65WH9NuJ3331b@g884FB740VZF4654WO4@A10VWNw632610GGk4H72WFcRJ73X0NV8220kPFs22@I1WG90JF3X0kJ41B8VFGs842122V848DbZ130VFccTCAYFsN82A8_WWnVJ8111lkuGPH36Wn30FR9Ju24W0VVoT684WFFLJF0VXmkVFBD6210oJ421VF84TEE21GVgJ96YkG9F@63WZ088ZoZTD5FFcVJTSCa0ccVJ	#d4V#84#46*B#1dc!201$f#4Z$8FF#2k#15#G8#95c(21BV	//(O//02&1/(2#4!208$3+4.102.1!4/1/1%1$2%22*1#2*1#1,2/*12#1!1/.2)2(2!4/(1-1/0601/3#2/#5$103#111%3%8!1/$3$30202,3(2!11*1202#1%101&406$4,4/03#2,12/!41$4(1&@*11/#2$1/*8/(1%1/#1/+102/z%601!11!1)3(2&F!101!1#1!1$2.5+4&5-4!3+6+101%1.9/(1-1)2//#5*1(1(@&1%	ecPzLH@IKJndSGHPHcHhdleDhiideEeEdhmECDdePpUtMM\BKk@AUSMUUTDECUUUEE@HP@@					not given in publication	MC4	Melanocortin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi/<|ES~x>N(0ma*xhxi,Bq5,B</x>0mS(xh.>x>x>S(xhx>S~xhS(xhS~	:UvzvztzOKntRvEGt1QXs@0g46Ohb98cHxX59V2@Qs92FZl0AG05@4og8ZX3LnGd849ZV04280F01RF18V0F0	0p40OF1v!C_06k0Tk03OF1g07g!nJ0Ik2d!DF0@!t!3Z02Z0DF01IJ0FF1206k0Tk% #3CX4D2m0WFRV8k78241JcmsNoCgi22WO0G8DF4B3Z130t0G8DF4@2Hd14VgV8N78271m0Y0KQR46I3m0WVGCc26G3D@3c8FZ9S3W2kZJ426M3	#W0V#N#41V!12$B2#58@$7$X$4F$F$2o$4#O$13c!206!2W4V	.3#1*2&16.3!1!1/$3/)18$5$2/+1,1/0101/*1/#1/+1/#1/!1.2//01+2/!3!22&2,3+11)3&1$2/!4$102!3(1/)1%4!102/&4#3%1*1!1/#6(2//*1/01(1#2+511C/$1!1(4.1#2%1#B+2%1!2(1/-2)1)1&1!2$v%8)4)101-N,2!1/#1//#2.4/01*1&1/0201,1//,1%3/,2-	e`\\D@@DLb`AlbbbbbRTRVQtQfbbQdS`WbSwsU@DADEULA@PPND@@					antagonist	V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(0:v:`**`|`F*:036J}\}l0*`*`|`>~J}\}3p|`\}\}|`\}3p	:UtztUxzKpxvNvQUz9XXcPCiCLNCVC17ql0EAXbHQq8ZFHXFaw0vc0KB88dWKkvW95W_cF511!FlF80VW0F0	0ZF0IV02OF1g!C_06k0Tk03Xk2T0DF018s0cF2Z0DF01os0Ik1N08g0bV2j0DF0 #J2VFNA8231EY78NNC8AOVW1NaF4D2L17em94BL9Z140f70FoA8261A0_KW08ZE113lIOwi84VWWsqF4P2D93mlg6177Yt0Fk8gJCC4GFc4FJ8	#kZV!F0F$V!2FFV!B2#BV@#f6F!8dk!401%V#@V#1W#nFk#2c!224!3C8V	%2)1/&6$1/1*2/,2&6$3!1121/*101/02)1$1/#2/%1!2////!6$1)2%3/(2-502$304(2//%1/,1)2#52%2/#1/-2/*24/(1&3(2///,1$3/2.8//+102(1!1%4/01/$2-1#1//!1!10i%3$1(3#1201-H/,1!1$4)3/021/$7///#2!1&2///+402/!1/%	fegH`@DDXDGlbbbbTRrTqtRVQNNbwkUSAPLP@U@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xix>S~xixhx>S~xiS~x>xix>S(xi.=x=x>S(S(xix>x>S~S(x=.=S(S(x>.>x>	:UvzfzUzSrhQDPQT7RYmdVQi42V_VQ467o063X011F4VV3V494W0X@B8i8125X20a11046411401N0_0VVVF0	0RZ!WR0Tk02OF1v!9_07g!o80Ik2d!FM06J0Q01v!HD0@40d03Z# !6F4D27BcH8o@B962WGlJXC21k8V42B5a42s9N25430Fkksg2F40Fks4A2545FtOD895VWWJc88a2L0Vlsk4PBD@0kFVRN7@VVH88L4A@A1VXOl24F5VY1RV8V4bG24WO0FN88BB9XmsN641_3l088NN132lHBa310XGk4H4@A11GlFBL6VFG9J42H0VYlN8ZkBH80lOZ836ZZHFVs6@62kFZL520Y2cR@4DD41WcORcX41Zl088VGZ16Vt0Fk846862GkgH85VV9WR22H20YVc8gw	$6k$4!801$F#42#4cF!206F!cW8!15&F#@s$5#OF#87c$J!218V	//&36//02#3*1/$4$5$1+3&1&1-11#1/$201/&2%2#1*11+1//,2///02$3!1*2+1#1//)2/01!1,34%11$1)11$101/10301!1/$1%1%2//%1*1.1(1)1.2*1%1.D!4%3/(301.202#1$A2/&3*1.101+2//u%1(6)1201-N$401&3)2!1(5)1(34/-2//$2/42/$1//$2(402$2/$6-	e`TRHH@FEBoi@HcHhdimLeEDdehcDeMQqeT\}@DSUPPQT@Q`PFT@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.i.iS~.hS(S~.i.>.=.hS~S(.=.i.=6s>.,B)\d,.h.>S~.h.iS~	?x:x:xzQDzPrESuhyaMvhW0tEyxpbe@lkNlfZ1XXW2CAA04RBqrY7IqXZ17AG3Go41012040Y2V0Fk	0aJ0Tk0490110480eF04Yk2Z0DF0u!5NV1_06k0Tk3F!OG07F0SF1s0Bo0xF07901g07g0Yk2Z0DF0u% #1oR4GFZFsNkM825158FXNsDP523GgV844TH52XkcD7864O0FsDF4@2e16BksFVE8281m0WkGH48k31W4mkwJ3464O0G08d44P3VZkNc8VD3WksVgZDL7Wa0NB8cH3WkNR6375a71kG8D2EOVY10	#X4V!O$65$@N#XfF!7Cc#4p#FY%N!28F$Io!93E#UA#8EN!84@#W0V	01(1+1&101%B01(1(201$1$2*1%1#102+8$1!111$2//01/2-1$1&2#101/01%11,101/-2/01201-1#3/+2/!1.1(1-1,101!103/+2%21,220201-2#1$11$3&1/*3/(1.1,201!1!1*1/-2$101!101,106%1%11(101!1/21)2&501/+1,1*1+21/+20p%702/0101)4#E01/%201/*10102&1/#106/(102(13/#2/1%1/)1.4-11,3-	egdRL@@LGOL`DFlbbRdRRRURTRbLRUCAgeceSQusUUAPUTmP@DP@@@					antagonist	CCR2 / CCR4 / CCR9	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J)*Fs6J)J)s6J)h(|`J)*F0lF*S~0:(Sl0*`:0~WB,36J}*`*`J}	:UvztUzrKpxvTvQUzOXHcvCiELSCVD57rl0EAXbHQq8ZFHeHaw1vd0SBR0dlKkfWA5W_cF511!FlFc0VW0FF	0Xo0IV025k1v!DA09s0t!45k1_06k0Tk04N01X06k0o!4YV2W0@F0t!6Ik1N08g0bV2j0DF% !38271m0WkIZV8P4Z3iFlcTF4F290d3cWB8K283O0FF9mF462m0WVGHBo4C2XlKVkoH47XO0GN8c4mPGW0WJJaCZ11VXWWNoT57Xt0Fk@RZe33Wc8VFk88VA1Ym0FZ30XXHBV8V48P4Zl2G04VC21k8VgZ	#qZF!F0J!4$2FFV!g2#4VD!3f6F!8dk!409%k#@c#1_#YFk#Hk!224!3h8V	//(2/101301*2//$3$9!102/+101/02&201$1/.202#2#102///!12.1$1/2/01(2(2!42%304!1*1&1103/$1/,1-6&2//01.2204/)2//3(2#1//3/&1$3)1%2.6//%1&1(1!1%4/01,11%2&2%1//*10h%5+2031!12012,C/,1//$21/#26/,1/%3021&2,1//+20602/!2/%	fmwXb@NJ|D\yNADYEDedieEELeEJeQg`sW@ASTmUT@A@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xhxix>xhS~xh.hx>.>S~S(xh.ixix>S~S~zdW(xhp3}J63S~`*`*S~x>.h63xhxh.>x>.hS(xhx>	:Uvzv;S:vytzUzUuzfzCUEjzgbUSzxhM@jH_sUyfVFLQmBo3lc2daETYq2TX06adJ0Kt3I4O8F89X8V0F0	0Z80IV025k1v!9_07g!mo0FF1D!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA0@40t!4@0110480eF04CF1707g0ek0 04944GNcBC51G042PDCd4VVkGFcUA1WGkchJE83GGN84HBRZ130auZ865353HtgR810X1O5cJ472Sc18NVE8251AXlVNT432X1VR849@26XVsB768WVVFsJ225_4nskX89@0WlHW48Lz141YHGBBPD@YFl8k8B573GkwT530V84oRQC@0kkcNFgGI3kNksN41PAG1VVBIK1X1l188TE3XmNFJ7@70FGOTF48242WFkNHA4XGFV842VV@0s22BGMW0WH8R474F4GsVB560kG8ZZB@5ZmcBB4320N4kJN68W5VksVA620c42HA0VFVtcF885XlNVLA3VVFJ61E77WHd4@62Xk8JB6A6VVk8BHR1D2Y08JeB19VW8G022D21kWOQB@78X32V8cKB2EU0XkXWBN6F721c8L@@8m0VkG8FNC22mVFVaA513k88ZgPA2BW1VkT81WFFZ8JC0VX088Ns883Xksc@83WkFBH420k@8t4KP22W0HckHM3XlFB4JD@4io0NwB5W0WXkkckHL5X1ctF6121FV8NP115b1A8F4154XW0FRD91VVkFH84Wks86210VF42gBL23190H75XX2kB4c310km0B22122k88_4	#d4V#84$2*8#1dc!201$f#4Z$8FF#2k#15#G$95c(21BV	//(K/%1*2/-402#41020B$2+2!2-2#1-4//21#101$2%2/1,1.2/(2!2//&2#1$2!1$2!4/(101$21!3&2-1/30102-2$7&2#11%22!2!3!1!1+1$303!202#1/#2!31!2/-10104$4,5#2)1!3/01/#21#21(1&@+1(1*2$1/*8-1/1.1//&21*z%601!1-2(2&F!101!1#3!1$2.82*2/$1/4!2*1/%A#1.3#1-1)2//#5*101%1(6&1$1	eeWZDH@IKJnjSG@HcHhdleDhiideEeEdiEdmhcPpUtMM]CcS@AUSMUUTDEQUUQQ@@@					not given in publication	MC4	Melanocortin MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhx=S~S~xi\)xis6~O:0S~d,d,.hxh:0.>S~S~x>.h.hxhxhS~x>	:Uvzv;S:vytzUzSuzfzCUUjzibUCzxh2@UH_RUyfWFLUmBo1ls2daERYq2PX066dJ0JO3I4O8F8dX8V0F0	0Xo0FF02AF11!8M07g!aJ0Tk035k1_07g!o80bk2d!DA09w0t!3Xk2W0DF013J0Gk1v0@g% 09lN8B44IYXl0JL414YA6s4B@635_IdJF31Z2m5eZP683m0WFJNZZ9610VFVN21W2HZ9oRD44XVFscsL4A_VX0lNVc6C@alcNZQ8241OVFWH0V474B61FkJ24VVV8cFJ233HWR6631W0F2N@B7YkFOJFK720kF820ZXn1dVN961184@315YF88469DUWkksFN@152aVGwc4L4D6YVm1FPE363FGFyF462M516FW4V64VFN4840_Y3F84DE7XGNRH32W0NB620cXoF8VkJ82ksNBHB925JP482650FG0sWLh1X1k88JJ2132mcwFA2VkF84420o1@0B863XGNJH932Fc8820W0F5BLa1111OJBC3X2HNJ6410F84411VXkuV8FE4YlcgB621FF82RCD0YYGRZ830FG8kZ8TNZ11VVLDN341VkVcJ79Z1VJ621a3FF88JR210WVgF95X18F8820kP0t0834XWFZTC1VVsF820bYFN8_26S0VFFcNJ	#d4V#84$2*B#1dc!201$f#4Z$8FF#2k#15#G$95c(21BV	/!2/$U//02&1/(2#4!209$2/+102.1!4//01%1$2%22*1#2*1/02/(20221//01#2)2(2!4/#1#1//B01*1$3#2/#1%72#11&3%3!1/01!202!20202/%2!11+401#1%101&804$4,4/03/013/!21$1(1&@*11/0102$1/*8/(1%1/#1/-2/z%601!11,3(2&F!101!1#1!1$2.1+2&@/-4+101/%5/(1-1)2//#4*1(1(F1%1%	emPrDH@IKJncG@HaIe]YYnuYv]YymUzFBnaik`VYQUX@JjYjjj``hjjjbbhAB@@					not given in publication	MC4	Melanocortin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xh.hx>.>S~S(xh.hxhx>S~S~zdW(xhp3}J63S~`*`*S~x>.h63xhxh.>x>.hS(}Hqq	:Uvzv;S:vytzUzUuzfzhUEjzgbUCzxhM@jHhsU:VOLQmBo3lc2daETYq2PX06adJ0KlYI4Q8F89X8V0F0	0WR0Tk02OF1v!840EN!mo0FF1D!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA0@40t!4CF1707g0ek051!c04!FF3q$ !V8oFG4YGFZ@820IGs44PRDB5mks6BD6c50VkHCs5361W_FkZH55VkG8mtV532Wpl8FBD646aY98H210HGGAG6C341t0Fc88qF9WW8l8L2E30kWW9FLC3ZkcNJFB1WFW9GceB@22HV8RJeH25jFG0NwZK36YmNkBHBDf11kVcJPBA4WNF840_Ymk9VT_@0V8soSLt2613PsFV8B793FNsZ242HWk84LMZ11VVVFZDG3XW0RD92X0N4wVTD961l8H2783Y9FsBT7L163VGFF8ZCAYFkB423VVkBoRPCfW2VVFB87320ssD@50kVN630VJWeLF482k112ZFw8D8R93WcR881109FVc497Z2sBF5310cBkJN9715VVoZD6WVk8VN2145VFF48C73VsoH5120F84VDF10VNZ473X1VRF830VsB230VK1mV8k8EVFFg2FI2VkFNwB325aW2FgD93YFFNB510FVBwHTj31XVVkc2@5J0YrV8g8eK61Z1sRL6B60XWwV8B4L48XkFgT989X1N4BR114a0WVseD0XkN8Ze2314VF90631WY3lcg8m15YH8Z8611kWFo428C	!2d4V#84$6!10c$D$cc!201#2f#4o$8kF#2k#15#G4#d5c!31#21CV	//(I$2/1*2/$3(402#41020A$4/-2#1)1#4//21#101$2%2/1,1.2/+2//&2#1$2!1$2!4/(101$21/)1%3$3#2#2/#5&2#11%22!2!3!1!1$2%1$20102402#1/#2!31!2$2/%3010104$4,5#2)1!3(3(1/#21$1(1&@+1(1*2$1/*8/-41.1//&21*z%601!1,12(2&F!101!1#3!1$2.62*2*3&201/4!1*1/%5#1/#1-1)2/(1*4*101!2!1(6&1$1	eeWRBD@IKJncGAYPHbdHRYWVV[mV]gVgWyjFBnaikh\ZX@JjYjjj``jJjeJH@@					not given in publication	MC4	Melanocortin MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
9bSq9D9b9b9D9bS(Sq9DmD9D9b9b9D9D9b9D9b9DSq9b9bSq	;UfUrtEAtndwx3Hln@gha0y47tZg9FV84KVk22VIGkFF4GV9034B084080206010Z1011c280F180F!2410	0Ww0Tk02OF1v!9E0@Z!XZ0s!37k1_07g012F0@F110D! $2D2482m0VkRV8g7612310NtkBD7Z150m0GNwP48351FX0JkN722m088FF5WW2Wc8VT264P7kcNw@7262t0GVDF463Z170m3VFg84C29_WOJP27Y2X0	#10V#84#4$4%4#19$F3#22#8%4%2k$5#K$158!208!210V	/,2*B/!1!3/01/(1$6$3//$2/$1#1*1$2/+2$2)3/)1//2*11/#1///2!11/-1)2,4!2/#4(1.5/%1$3$102)1/&3+2%2//0102.3&202/-2/$@+1//0201/6////+4/&j$27//$H/+2/#6&2////#4/#2&2)1$2#2(1/-1$3//%	fi{aB@AAAbYEDeeHhd]LeDeQco]G@AUUUU@@P@@						ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(xh.>x>x>.hxhx>S(xhx=x>xix=xix=S~xix=S(xiS~x=xhxix>	;UyUxnEs0kYMv6Fs0nkRVL640G02dLhKHX11!11F96mk!@4W43Ie1F9N82H0cW40J4X04248BFV040a0IF	0Pg!aJ0Tk02D03V!9F0DZ!ms0G01D!C_07!Tk03ZF3a0Dc01680OF1v0C! %WH8gH613l19Z450W12V8D33881H0oF824VN4470a3kFN86AEm0WVHGVFi22XGIwJ8e4V@fklkN46A5Y18k@33VkFF@10VkF44cAJm0WkRV8N4VWOWZFwV8N4DK2DYVVJFK3Vkk8ZaLN1X18NNI3WVWFsc_740l0kV4NA6128RB96W0F42RDD0VmcgPI6VV8F2AB46O0GsDF4F2UXW1VgV8g4LF8WZ0gBD97JVXbN8R9F2OT0_F_099s2E2m0VkIsZ4UC0WX0mWs452J0XbV8R8	#20k!1/0e4$82#49#FW8#Vc#8%Hw$5#GV#88s!80@!2W8V	0101.1/#6/!3/!1/#2)203$4#21,1//*2/#3//1///%1&1$2+1-1)11/&4)4////012&2/5$401$1//,4&1301(2,2)3,201/)1/*2$2)2-1(2/E!6!2/-1(12&1)A/!1//%1!3$301/(1$q!1!301#1,1/K/,1(2/#1#11#1%1!1)3/(202(11+2#5#1/*1/02!2.2&2301/02#2#1$	eg`TB@@Lm`DFNlbfbbRJbRrTVTtRPbg`QusPPQ@AUUP@@HIDMD@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
*F3pJ)*F\}*FJ)J)h(|`J)*F0lF*S~0:(Sl0*`:0l0B,~W36J}*`*`J}	:UvztU:KpxvTvUUzQXHsvUiELSCXC57rnFEAXbmQq8ZFIePawWvd1SBB2dlSkfW95W_tF5G1!FlFg0VW8F0	0Js!aJ0Q!3Xk2T0DF018s0cF2Z0DF01K40OF1g07g0zF06Ik1N08g0bV2j0DF0 $B0msBP7Z13Vt0G0DF442836ZFkRBA68K0VkLF4D283AlkWBFF2834@VFoA8261m0WVFIVF6E13VkkFJD6b12208NE8281m0YFF	#oZV!F0F!40V!2FFk!B2#BV@#f6F!8fk!401%V#@V!11_#YFk#HV!224!3h9V	/(1.2/%8*2/-5%7$3!102!4/(1/#2)1///1,1/!3//$1$1)1%2.1/$201&304(2/)2)201%13/$1#2#22#@&2/#1/-2+1*4#3//3%202$1//&1.1$3/2.5/#104.4#1122(1!1$181/%11-2$1(1.1/&1!10n%3-3#1201-F/,1/,1&21/$6///#2201&2///!1(402%1+1/%	fkHb@AZCEW`RFQQQKYSJJJYJQQiLxFNspDEMRuUT@A@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
(GG(4r(Gr4(G4r~_G(r4r4G(r4G(~_r4~_G(r4r4G(r4G(~_r4	:UvzdUUzKzhQ@@QUETkYvc96B24CWO86Dck73m529IXV!X66K1048B8Rs1V5cP08194l0401011Q!VVV8FF	0Xc0IV03OF1g07g!o80bk2l!HD09w0d03Z!OX06J0PV1v0C!zF% 1DA130gV8R78251GDkXNF4T20W2lRV8R6s2B210VsRVe4O1VFX8444B6m0YFNdR8Z42131BV8N4	#20V!1$20V$N#a2#4V1$ZF#dZ!488$V#42V#X1#GF$es!204!219V	011*1/02&5.1%9/,1,7$2$2$1/+101-1*1/.2/!101////1!3.2(201/,2$2&2//$2)2//-7&1/#1/!2$2$102801.202#2/(1/2#12$2&4/01+2,2/#1.8&3/)5(101/!26///!1///i%2&2+101-D!1//03.2(1/*2/%1+3041///)2/01!1$4(1/#401+	fegIB@BTMypICHhhdhTlieDeeHsfcEk@PUUM@AUD@@@					antagonist	mGluR1 / mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhx=S~S~xi\)xis6~O:0S~d,d,.hxh:0S~.>x>.h.hxhS(.>S~x>x>	:Uvzv;S:vytzUzSuzfzCUUjzirUCzxh@@zH_RUzvdFLUqRo1ls2daERYq2PX066dJ0JO3IJO8F8dX8V0F0	0Xo0FF02FV1D!8M07g!aJ0Tk035k1_07g!o80bk2d!DA09w0t!3Xk2W0DF013J0Gk1v0@g014s0Xk2U0DF$ #W0NZRE72W8B6610kGso22AF0ZmcoV941V8B4L@Ac50VkF8N_61lsNFF984elO8X@A0VXGauk26533WacFg8633121JoI5VV90gWkX51X0wV8J48A3_G8NL9310lNs2211XYXVZLB80VVkVN8312HXWRNJ44a0FsdZZ4ARVX0mW4a6C8ZkkNZN22U10VNFPE51l0V673VVF442H69t0FVAJ24@FYFVsXBZ@5XF8V6494ZVlcVeM21kNNB30a2Y0kg8g693WcgN6143088Vg6@5418gB@21Fc842D70VFFd0BF5WWcNLDG20kkF652YXI_NJDJ4660GFek4Ts15W62kkBVH42klVJ4JEZ11VXkkGZ6D73FkF@35X2Wc44FQZ12VVkVFHA7XG8JB411Vk8210d2ZV8cPF31X8cDA@60kGGN88G7Wm0cXC94ZWlkRaM83Gkks82661GNZaC4WVOVs2125VVG9sB2422W0gB62W0cZB42VVF42cAJ10Vkc@94ZGcNB220kGss22A10XJJIcF6@322X8VFD1WG0N8626YV88gsP_35VNw41864680kBN7L7120VN8XG9Z1884HF20kWcJ4LN532VkBH94XVc8J3110e0s22@G1W1dBa77Vm2V8241X3Vc8ZpLV81Xl08ZF	#d4V#84$2*B#1dc!201$f#4Z$8FF#2k#15#O$95c(21BV	//(N//02&1/(3#4!208$3+2.102.1!4/(1(1%1$2%22#1%1#2*1/02/*12//&2)2(2!4/(21)3/$601!1,30102/#5&3#11&3#409!1/$3$30202/%2!11+201#1%101&407$51+4/03)3&12/!21$5(1&@*11$1-4$1/*8/(1%1/#1/-2/z%601!11+23(2&F!101!1#1!101!2.3+2&5/(1$703)101/%8/(1-1)2//#5&1!1(1(@&1%	ecPzLH@IKJnlSGIPHaIe]YYnuYv]Yyugfa`khZZxFdV@BjfZjjhHJJjjZJJ@P`@					not given in publication	MC4	Melanocortin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xh>xh..=S(.i.=x=.=.i.iS~.=.i.=.i.=.iS~.=xi.i.ix=.=	;UnUUvQl4l7DeDHO0lmw0m444FC3d6BKHV112811F92eW!25V40G280dG0@!VV40642Fg0a15FZ201Y0l0	0Pg!aJ0R!2D03V!9F0DZ!p40OF1v!B90Ck0xV0 0BV8N4454WkcZHF3VVNF84D71VFFg22910FVmN46D831Fg8FF3VVNVB@9Cm0XkRV8R4@I34kcoH451kGNZg4742lcZF94WFs86310Z1H08@9@ZGcR@B4_32gV8N422H5738sR513XX21o8Rc163kGFWk4K81414XVFpw2A3IjFVcG84NqD12Fk	$VV$8#4$4%2$4%1#F1#1VF%F#NZ$5#GY#80s!25#258k	!1/.5$7/!3//#4%1(4$2$2.1///,4.12//*1$1/$2/-1/-1&41/0102#1,1/(33/01/1&5%5//02/05&3)112!2.31(2//#1$13/!1/2(1-2,1!6#1/01%10201/$1!2%9////*1/%10g%3$1%11%1)5%D$1/(1&2/#101/.1/$20301&24//1//&2+2/!1#1$2#2&30	fe{QR@LN``tZ`BLddlTRvfRRTTRTe]fm@PUUTDDACU@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
3p*F\}J)3p3ph(\}|`J)*F0lF*S~0:(Sl0*`:036J}*`*`J}	zrUtztUxrKpxvNvUEz9X2sPCiCLNCW617qlVEAXbFPa8ZFHXFax0vc0KB8VdWKlfW35W_8F511!FWF81VW0F0	0aJ0Q!25k1v!DA09s0t!45k1_06k0Tk04YV2W0@F0t!7IV1E05V0Xk2T0@w0t% !7PZ8B44JXpNVgFjC231O0FN8cyv331W29G85932WWN8sRZC2k8cVNi27aVWFgV8B4D442IWVR5844O0G0@_q4C252XeZFZ7513lgV8N428120tsq@14YVc8kc	!2kZ#F0J(2FFV!D2#BV@!2f6F!8dk!401%k#@k#1W#XFk#2V!224!3C8V	/1/&2$1/+2//$@$3!1121//.2)1/01&2*2*1!2//&1//1/3%1/03&5!1$2$204(3$1/#2+1011/)1)2#42%202/01/$1(2/&2#3/(1&3(2///,1$3)1!3!2.4//+102(1!1%4//&2-1#1//!1!10f%5$1!1$3$201-H//1+2$1.21/$7///#2!1&2,1//-402/!1/%	fi{Hb@BJ|FS`QFQQQIZEQQSKSILExOQpPPuKUP@D@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhS~x=S~S~xhxixix>x=S~xhxi.hxhx>.>S~x>.h.hS(xhS~x>x>	:Uvzv;S:vytzUzSuzfzCzQjzirUSzxh@@zH_BMzfdFJEmCL1nx@daDRYm2Ti062VJ!O3IJO8F0dm8V0F0	0PZ!Xo0FF02FV1D!9204s!WR0Tk02OF1v!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA0@40t!5AV1404R0Tk2f# #1Z12Vdp1FBJ6lO0FkcOKXH4230V8cKaa5WX0wV8J4yG11Xkco62A9VXGnGFHL44_VFsdcZ4AR0X0msgc6C75WFNZQ8241m0WkJs8tF151XW88VJJ99_kGVNP915W0G91Be4GD2FWkB4NI1534Gt0Ba918VXVBBPI154AkFNg8BA0XWKV8xk2A2C4l8O0R86WY1F8cU82319_FXW8c4G1VYXN8cN@D4XVVkH921W0B610VZ1P0JTB530kcB94VkN4oJPH92VVsD68WXG99oV6@XGsFRBD2331cFB62YW8J4610YlV8449G1W08JDB41G0VJ220Vs885H60FGHN88A610cV6951kcJ420c3VF486@I0VkVNNC6X1NV861VVN90PV23WlWFPA4XFNB42C5aW1d8i66XVsFZJH7AaGd0H4141X0cRFE6XVVZD42VkV822F5c0VFB@34X1NgH3410cJ6310ZlXN887241Fk663W0kN2211ZGk4249IQfFVcF4LL3_kVFR41VV88oPP87@190@7773ZoPc48B10XWIBJ8243X0VVZPC65G8JDJF0VYFV8gk446XlcgD623kNF220bYFF8h08332GscPG1Z_0N8F6F0VYVc8ZsLc23W1Gk447648WsJu423WlkkZLG7Y1NJ@32_YXkVkLHA50cJ6HB955GPVJ60YXGmOF6p2XWWFVFP@9XVVRP41131cJ4LP11110BHC5YVk84850kF94NX4231GBD52W188@2C7X0Gc424@Fm0VkRV8B5V7271VcNJ	#d5V#84#4F*4#1d8!201$f8!4Z$8FF#2k$5#G$95c(218V	//(P/01/01$1/(12!4$8$2+4.1/01(2$1,113/!2%22.1*1#1(2/.12///02$5!2!4/!1$11&1!5*1(6$1,3#2/#5&2/0403/(3!1020202&1&1%2/201*202&404$11+401.3/!2)31&21#3201-@*1!1*1%2(1/%28!1///1#1/)2,3!z01#601#1+23(1&F$1&2!101!2.5+2$105/(1$4/%1%1&@-1/(1)3/%1,502$1!2/0A&21$	em_ZDH@IKDalSG@HaIe]YYnyU]UYyugZFJanik`ZQX@JjYjjjh`hjjjbBPDH|h@@					not given in publication	MC4	Melanocortin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.>S(.>S(s6(MP(>./;x=c+S(x>S(xh.=x=x>S(xix=	;UvUUvUrzGzinUmv4LUzALeXY@C1viOGEc11I12K1n0H08_33k44I@A0VIN#G@20J!F!X560ZGF404!	0PZ!U4!WR0Tk027k1v!9F0DZ!lw0OF1v!FM06J0R01v& !421l9gV84XFNBgP113aO0Fk8BV842W8oRZ7410NVoF3256Vk8FLA7WHFFD53W09ks22B0VXJBV8B4H9411OB@210ks484D710sFd382311Val04JK@0lsV6315Yk88Zr828120VFVLD4Xl0BJ340nX844F11385o9BBJN13X1mmBu7552X2kFpJR2525Hkp88D3VY1G1caM46Yl8FZNRS9bFccg8296m0X0HWJ8Tr2131BV8g4RS299lkFs82A5m0WFF	#1_k!184$F#41$@#2_e!2FlV!m1#8VF#B0F#NZ#V5#5V#1Jk#48!258V	/!1&102*A/!1)1)1//$201////(3&4/!2#104!1!1//$2/2!2)1)1%1)1,1(2(1!4/%1&1%22/!2/&2/#3$1%3,2)1/1$3&4$1,2&1-1/)1,111.4&2/%1!1$1#11,2!81///(11%8+1%2//#1+1%1/(i2$201%2.1+D/%1.2/#11.1-1/&204)3/!11%1(1!102//101(1*1#1$1#2013+10	fegaa@AVBTFINHrJIKIQIQ[JJIHtY[sQp@UUUTDDQDMT@@					not given in publication	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.h.>.>S(.h.h.>S(.h.>.h.>.hxh.hS(S~S~.>.>xhS(S~.>.hspS(.h\}Bz.>.>S(.hS(	?x:x:wyQTrQUjheUya7t_Zjsf@xMaWXGWIGaV07lW90bZeXgBaU325a202b1F55Z5GVF3B0KV0VVF0	0RZ!U4!Xs0FF025k1v!8M07g!aJ0Tk02OF1v!DA0@F0t!45k1_06k0Tk0490110480eF0 0BLNFwA8291m0WkRV8V704281O0GFDF4V25MAkFWJI82G1m0X0K0WX3482O0FVCZL4925oFFNFX843@XlBDBL61WQVO4E82415qFW0FF9R391W0IK0N43A2O0Fs@pi4628cL84Fc9@C13kYd1R9462AFHnR4c4CA31PJ8BK60VYJB8@L5m0W0Luo8L5Z12Vt0FsDF4T2b7AVlcNPw4C25JG8NcCTp2@14WGZBq1DYkFWNR4n2AAV8GBI82C1m0WVF8Bi116FFwqHO0V_HV8@0Nb10G3PN@10X5XF9FBe13lctNSeQ@1ZVk	$6V$J!801#2$Z@#5hk!20pF!sW8!1%@FF!V@s#V5#K4#87c#4J!218V	//&3G03/#103(2#3)21(2%11#2!102$1/+1-11/)2/&204%4.2/#1/(5!4)1/1/!2!1)4$2-2/01&1//2)1/(25%1012!1&2031-1%2$1!102,2/$202/%1$1#2!1+1/&1%1!2#3011&2*2%1)10101B!4%21%4/011/+C2///#41+1/+1#z$1)3)1101-L01,3(2,2+4$137*1/!2-1+1&202(1&4-1&2,5//3&2/!102-	efU\DD@ANjUC@HabHrJIJHjYJQQII[IQQIHsT\E]MC_@hdpAEMUPTDUPTDYD@@@					antagonist	MCH1	melanin-concentrating hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
=xdz(W3pJ}S~.i.iS~.i.=S(.=.iS(.=S~.i.iS~.=.i.i.=*F*`:v	=QvpUux@jo3jTd1scOBLHX13h39@hLaX58X133GG0FSW0@4V0gIiW0B1ABYF08!FV060YDSBF015RV0F0	0qJ0Q01v!C_07!Tk03FV1E0@Z!sg0d03Z!Fi0440G01v!K304F0R01v0DZ01ZF0Q01v08g0d03Z& #282X1FZ@52Wl0R8520kV58PZ143HFwV5320NF21C56t0G0DF44292218c64410sFB321kVB2ZDH33m8oX6311848LC0VXn0GNqE@1kksgTL2D@1FWFRgm45214nNwg933YGk8VB98X1FN@940kcJsPSZ120t0FV84D63YGNNH62WkkBB4E77mkGGF@473m0WFFVRJF41lVcD72131k461357VlGRs@52VW0c2289m0WkGHRXS20GVskBL97Z1kJL440V9Vck	#VVk*V!36W#42#682$R$Y%k#8F$2o!805#GV#87s!244!254V	//(H//*4#1%2(1!1)3$11+1/#1/&101$1*4///,2*2%2&1+12.2/01,101$1%1.2#1//1#11&1)1)1$2(12%1(1$1!1/*2$2#1)1,1%1/(1)2/1#4+2/%1$1#1(3&1+1!3+2&1!1/101%1,20B01#2/*1/*3/#1#1%1%o#12%6#5&101$1*@#1)3#1&1+1#1#1)5/-2/#1%1(21201-1(2//,1*102*1/02#1#1#1	ec`TD@@DK@IdfUUuV[VuUHhDdrJzFVvZh@jjj`@jBJAp`@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.h.>x>.>.hx>^)}^.>.h.>S~.hxh?y55S~)L8t-gxi5qS~(Shx.hxh>x>xS~S~hxxh>xS~>x	:Uvzv;S:vyvUUzUuzvxUyTYzbqOSzjiU7rnYzEOydFEjaUJ_2R@g8iT3mEei0BbOLlGD2A1F1N0bXVVsF0	0RZ!aJ0Tk02K03x!DM09V0ak03FV1E0@Z012s0FF2M09V018s0bk2Z0DF016J0Q01v0Eo$ 02kB23W7YkNu555XikeFB@6462ltNN55X09Fkd2K@_FFBNHB472q18610Z2X3loZD21GWNnh@4331t0FF88BDC3m0oD195Zt0FkC0c4A24YY2Z231W21d0F844X0kZLF4X0N4B2E67ZlGkZE2340c48PF7QW5F888X2340kF2B@@G7F8Ny@@5m0X0Fk8HE210koL41WW0J4T@E5qFVkF46NB2VF8@A2VkOW042D0VkWGsON@3C0FFGR466XFV42DBB29HkOB@Q2WYlgV8s4F23XG8B6422W0F61210VJ82J5eO0Gc8NkA81kFlg41420k82288VFNFd38261	$2k#4)20F#4D#5dZ$4$b#4_V#8F$@k$5#tN$7c!204!219V	//&2C%1%1(4&401/!1&1$2*5$2/+1$2!1%2-1*2#2,25$1+1/#52(11/+1)1/%1/1(101(201&2/*221!1)3#201&22&101-1)56%11/12-21&204!301!4/0122#1%2+1$1//#4$2#1)2!1-2$2/010102(1#@01!4!2,1/#402-13!2921)1!1(1.1)1011+1/-10z(1/0111-D,3+2)102/!33)1(2!1#1!2(1.1)106,20101&1//+2%40201#5&1/$6-	en]ZHB@MGIlV[@I@RPddEICHhhdiMUMEDhdbhhddmdfNBjbfodX\XBBjfjjjhJBbkJKCpbJ`h`@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(0:v:`**`|`F*:036J}\}l0*`*`|`>~J}\}3p|`\}\}|`\}3p	zrztztUxrppxvNvQUz9X2cPCiCLNCVB37ql0EAXbHQa8ZFHXFaw0vcFKB80dWKkvW95W_cF511!FlF80VW0F0	0aJ0Q!2J03d!C_06k0R!3Xk2T0DF018s0cF2Z0DF01os0Ik1N08g0bV2j0DF0 09WV8B5Z11VbH3RBB6d2h0FVgI8271A0YotJX6A468JNFV@F5m0YFG8ocS641X0qF4B3Z140fLsFoA8261A0_KO48ZG18221kK8A43FW1FV	#kZ#F0F(2FFV!g2#BV@#f6F!8dk!403%V#@Z#1W#Xkk#2k!224!3C8V	%2)1/&4$1,1!1*2//$6$3!1121/*101/02)1$1/#2/%2!2-2//%1,4$1/3/(2-502$304(2//%1/,1)2#42%2/#1/-3/*24/$2!1&3(2///,1$3/2.6//+102(1!1%3/01/$2-1#1//!1!10h%3$1(3#1201-H/,1!1$2)2/021/$7/(202/(2!1&2///)20402.2!1/%	fegI`@DDXDGayEEEDhedichdlb\]EoVjfB`X`@j@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxix>x>xiS~x>xix>S(xi.=x=x>S(S(xix>x>S~S(x=.=S(S(x>.>x>	:UvzfzUzSrhQDPUTERYmtVQi42V_VO467q073X031F4VV3V494W0XAB8i812CX20g110Z6411401N0_0VVcF0	0RZ!aJ0Tk02OF1v!C204w0eF04YV2W0@F0t!4OF1g07g0zF$ $3828110XdBTE20VsR410aXnFdd@A7WGW8koa4@80FkwJ2A78aFXV4@85VWWXFcec44XVFkcoa4Q20XGBP@K10ZWN8k_8629W508BTA16Y510GBqY282VGViF4F235WWNc6@230cZ43C@XkGtkFaI0Yn0F4B98ZX0sk4HFXWmNV24F9m0YFRV8N4	$2k(801!20FF!42#48%6$_8#5+@s!105#OF#87c$4!219V	//&36//02#3*1/$3$5$1+3&1&1-11#1/$201//!1*111*101//*2///-1#2!2+1/(2)4(132/01!1,44%11$1)11$101/10301!1/$204#1%2+1/)1*1/(1/)2/01.D!4%3+4+201$2+2#1$C2/&1*1/01+2//v)1$2)1201-L!40401&3)2!1(5/!33/-2//$2.242///*4(402$2/$6-	eh\RHD@AMJ`U@I@bPrJJKKJYJJIIKQFIJYc`ij{zB@ijhHHj@HpHKJ@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.i.>xix>S(x=.=xiS(S(x=.>xix=xix=S~xiS~x=xixix>S~|F|`xh.hlvS~xhx>xh	;UzOzvUv_ljLQEHt2nXO8Lg401CYd@hJya11X139FO6Fn0BAK20ZH2d0cQ0TIFc909LZcLF2aCEG40F5X8l0	0Pg!aJ0R!2Fk3V!8_0Eo!ms0G01D!C_06k0Tk03Z02a0DF01J80G01g07g0gF$ #6F4D3Z120t0Fk84fD351_c0sBJ6KbW1VVV8HC6YWck@420I28444@D0VVkRLK5VkVVH81aZVF446CF1WVWBHH72G88cV2170kGV44FP4C14odk8T515XZLVRJD532YGlgo@4Y1WWGJRH@WkssRR2@D2H0ZH93ZY088cc22Z210cVLB2WWFRJ720V84210dZ50FNo121W0gP2420F8sPR36YGVZR520kFF8440IlWsBNI11Wl8X7970VGOG9TA62lGNiF4J23210VND45Wl8V8221kk8220VKGef44ROBW2VqOBB6BA0VW8f44Jn13WO0FN8Jm4F5E0WcV8F65228wR810kdVk22@CBFWFNZB	#VVV#8$1V!148$@#4BX$5#FY8#VJ#8%Po!405#GV#82s#56!25BV	/#2/#F/!1!4!1/)1/!6$3$1$1)11/1(1/$1+2.1%1/#1.1/(1!2%2%2/2%1&1$11#11*4%2$2%1/#1/05!1015/!3#1/!174#402,1105%1/$1$4$102$1#1/1-2&201)3/$204/!2/(2$1)1+5!2&1#1/!2*4)3+9&1/#2!1/,3!2/+1%w%3$2&1%1&1(B!1,1#2&1-1&1%401/%1$32.2!1%2)3/01/.2*1(2!2!3(3*1&1%2!22&1!40	elZ\BL@OMkjICdPIABPpdLbdJTTRVrTVbRbRbURtlzFv^jjBBJj`@jZj`h@b@@					not given in publication	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=S~S~.=x=.ixiS~.ixi.>x>.i.>.i.>S~.i.hS~	;QvArQUSvYQDOI23MutAhHTLXXZoFDRCBO2oH3W0OX8F3B8841042806L3P02224XGFI08HA4!80XX02010	0aJ0Tk02R03i!Be0440IV04OF1k07g0vV05@V110480IV2d& !5QZ8D5Z11ViKNFR8ek257kG0TF462UN12Xc8VC28264p0FZFR2K46318B666Ye0FFx6@210VcVR82311NVRH5YXWs8B4BB	%V/%4#19+3*8F$2k$4#G$85s!2$210V	/(1.E/!1!6//)12$9$1+1&1///(1/.2&2$1&1/3(1,2&1$2/%102/1/01-1/(1/#4/#3/&3-2)5$1/%1$1.1/!2%1&31#1/#1.1///+1/07&2/&1,12*2&6,201/$1//(1/$m%6(4/+H//%2!1%6)1!1/#1//!1&13/#1/.2/#3#104%103/03(2-	fewa@@@`rJIJFQRIIWIQITXxOhcg@AUUUUP@EBNDBH@@					antagonist	Opioid delta/m?/kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(.h)Hi..>S(S(S(.h.<|Gi.|G.>.>.iS(}_S(xi.h.=.>x=.iS(xiS~x=xixix=	;vzv;SzjvytvDbUuzdxUyMbfZoFUzhgI2r2YW6OqcF7UkRZ92C@c2iL3T06X242GJG180Q4F080XX0X0G0	0aJ0Tk02R03i!C10480eF03Xk2W0DF016J0R01v0Ds01mc0AF0i0440FV1D0@Z0 6F4F33FW1k_uo8445X53FkN@3X0W0kV8L@Z28B@110mWsB44BBF_1ds8@75W8VWFLF4621C@I0VJP@46ZH10P520VGG4@1270FGWggi2351aVHgR64H36VGWSBB6530FVFF42_0VwD93VkVFwLTCN1Z8WFF	%V/%B#19V*Y$4$8F$2k#14#O8#85s!2$214V	//(L#1-1!2*2%1/&2201!8!208#11(101/$101/-1//$2*101%1#1#1$3!1(1,201*2%2+1$2/(1(11%1,1/!2/1104/!232*1*3&1/%1/%204!2/#1-4-1$1&2%2$4&1&1+1$12.2&1*1$101.7&2022!3/1-2!2.6)1/(101*101/#1#2/&z%6(4*11&1&H/%2(2/6)4/-2,1(10301(15/&2%1/$2/*1%3#1.3(501$11$	ebQ\D@@DA@`ClbbRbRTTbRTTrrNfLRRg`URPrurNKUUUUUPUPTP@UA@PP@@					antagonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix>.>S~S(xi.hxhS~x>S~S~xhxixhx>x>S~xhxi.hxhx>,BO~x>6s)\S(xhx>x>	:Uvzv;S:vytzUzSuzfzCzQjzirUSzxh@@zH_BMzfdFJEmCL5nx@daDRYm2Ti062VJ!O3IJO8F0dm8V0F0	0PZ!Xo0FF02FV1D!9204s!WR0Tk02OF1v!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA0@40t!5AV1404R0Tk2f# $m0WFK2Vc6@3OB0FNJBeo91V88NJBpI2Fl0TF4@2X7VkOF2375_FG91ci6@X2Hs8RJoH25i0G0ONNF36XYNkBHCZ120t0Fs@V4Rc0X0lFc4F@945XsBoBC30FFNZZeJ28al0468B@VXWm94V6I30ZF9F66C@VXX68B6K465kGFek4Ts15W6XVNBV@540lVg4JEZ11V_HVGFVI28VFNFse2@710WNRD67XFsZ891W0882XAG1Y1NZN571WsR4216XYGkwL7811NoBH99C3W9JLE1YWWk8JF73WGcRN8410s84TB10kW@888822lcJD53W10F@220oGV44JZ2220sF8A5XGFB8810VH0s6121XZkFN4C63lFZH450VN84TCE221tFT@32kNB42B5a0W9kZ87XFkFZJH4@bWOBL11Z1X0NB6B9Y18Z832WFV86TB10XZ08F4651m0kD45VVVB4410JWXFB6353GcNF4210kB43383V8446@10X50AdH65316Yso8620kV862B6a5JGJF431WlcvK4B0X2l99Z46731XGkZTH511G906126W0GOV4DA43HFJF54WFdW022260FGGsF@D53GNZLFJ20G0J2@D10FW9sO@A52lVkRDD8I5Ik82B762Wl8waF6W0NF8LDA0XlkwiL21VO8kZBFC8l8F6D974bG@sB@650W18NVF41lc8660WYWOk4661Z18gV80W0sZ4RD10Y3k8JH97XW0c@610kGcwH210W1HDF463Z11ViG1RN864	#d5V#84#4F*4#1d8!201$f8!4Z$8FF#2k$5#G$95c(218V	//(N/01/01$1/(12!4$8$2+4.1/01(2$1-14/!2%24.1*1#1(2//2-1//012$5!2!4/!1$11&1!5*1/+3#2/#5&2/0103/(3$20202&1&1%2/!1)1202)4$11+401*3#3/!1)31&21#3101-@*1!1*1%2(1/%28!1-1//018!1/)2,3!z01#601#1+23(1&F$1&2!1$2.5+6$1/*1$4/%1%1&@//&1)3!503/1,502(2/05&21$	eeWZDH@IKDalSG@HcHhdleDhiihddlddhmEdhUPqTMuM\BSS@AUSMUUUDEEUUQAHBD^T@@					not given in publication	MC4	Melanocortin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
*FJ)3p*F*FJ)3ph(|`J)*F0lF*S~0:(Sl0*`:036J}*`*`J}	zrUtztUxrKpxvNvQEz9X2cPUiCLNCV617ql0EAXbFPa8ZFIXFawVvc0KB80dWKkfW35W_8F511!FWFB0VW0F0	0aJ0Q!25k1v!DA09s0t!45k1_06k0Tk04YV2W0@F0t!7IV1E05V0Xk2T0@w0t% $3GV4620fGeV2@A5m0WkRV8B4NZP1WVkGNZW5YWWNkFBOBdFFkoNZy@1XFwV8B44@752t0VDC7m0X0L3F8P4692_cN4B783t0Fk8N88@_HkR442542V	#kZ#F0J(2FFV!B2#BVP!2f6F!cdk!501%k#@V#1W#XFk#2V!22J!3C8V	/1/&2$1/+2//$8$3!1121/*1/#2)1/)2*2%2#1!2////!1$1/3/(202$3!1$2$304(2$1//1/,1)2#42%2/#1/-2/+3/(1&3(2/-1/!1*1$3)1%2.4//!1(102%201!1%4/(3-2$1%101#1//!1!10f%4$1!4$3#1201-H/,1!1.1)2&21/$7///#2!1&2,1//-402/!1/%	fi{Hb@FJ|FS`QBSJwvsMoZtyxOQpADuKUP@D@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xi.i.>x>.hS(xhD{28.>x>x>(Q/jS(xhxh.>x>.iS(.>.>S(.>.hS(	;nnWOStk4w1F2DTNFWXN2uV5F091C24HIV102B2Go969WV0Y1VhXKL90c9CAFFV10234VJc083K84G8kW0FV	0Y!IV02OF1v!9F0DZ!_!uF03OF1k07g!kZ0qk3q!JL06F0PF1p0CB% 0m0WkRV8Z78271J0YmN8p82A20XG708lN2@2m0WVHV8pD2AJVWVwV8R78261LD0WNLF4F2kP13FaV91V2B2@V_X8wc6F240WcV4HDU414XV8se2A@0XGRV8s6DS29W730GNF_1WZ1GVc8sB2XX0J4660XH0B@4BCDVkk8FgD2ZVFRPBD@m0WVF	#2Vk(25#2F4#a14!4V8$F#F18!24N#H1F!5No!9mW#GYF#1s!27B!21FV	/)1(1$6/!2)3(201-3(1+6$2///+2*2$301,1.1,2!2(101%1/#2,3&1-1#101#1%1(1$2%1)311/1(1&1$3,1-3&1,6/2.2&3$1+4,1//0202////*21/$1/%@.1)102,1*12602012!17(1/+1(1101(1//(k/*1)1%D$5//4/#1/%6!1#2!2(1(1!4041)4///,1#11/02/01/)	fcoPQ@LR`aTPA@`cIIBhhhddebidlhXMg]FmPMATU@ATH@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~.=S~x=.ixi.ixi.=x=xix=xiS(x=x=S(x=	;vzfnQzNuXQ69aI9FtsA40pF8XgY96BKF!BH081G16o24096!Z6FV2B940208o80N0VF1X410F0VF8X0G0	0Pg!aJ0Tk02R03i!@C0ER016J0R01v0Ds01Xo0FF1407g0YF3r! $8gPF@2GVZ64@4_O0FN84@F@ZlsF633Vk9VRk6F3428k8A3108BkJOZ11VVFd0XH81k8B281VF9kVv82411X10VeC3XksV83B5VFG9iF4B2140W0VJD6WkVc8320nlV44JVsGXFkcOBe4@T0X0mdBHn42X@FGng4L4IF5HVVZH265	#80V*4#1%8#182*Y*8F$2k#15#G$85s!202!214V	02//%9/!1///#4$2!301/01///*2.1&102,1//1-2,2%2/02!2/*3%4+1/(2/#2/!11/&1$1011(1)1#101%2/2///02!1/#1&1)3.3//#1/%2!@#1/(101//08#2&2%1.201//,1-10d%6/#1$2*F/)1///$2)2//1!12$1*1///#1!21+1/*103-	ffc``@M@kdTTTTVQrTRVYIQleZBbHj@B`a``@					antagonist	Adrenergic alpha 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xi.ixi.>S~S~.iS(xh.>.=S(.=S(.>.hS(.>x=.=S(S(S(.>x>xhx>	zwvp65OK8k4N4K2gRN050N2F#1939!HkV588!FV960WV021V524J0FW01HV0c012!V44#F24F18VVFF	0PF!RZ!aJ0Tk02OF1v!DA0@F0t!4J02G0DN0u!7JF1X06J0PV1g07g0o# 0Wm8sm71W0kwcNKZ130VWFwJ94YGFND7A5_gkVFlP2@3EGVVsGJ5A122W6N9J82ILVZFwV8R4i2JOaVX8TF4F3L5VklFN88521lkR8@50VFJDA0c2kN48F_Z130WGN4c1IWVVoZLHF1C1VHt44e4J0km8s4TEZ12VX2OokI55Xt0FkDF4D3Z17V_LNFgs293	#3FV!58F!604!128#Z2F!40A!12_#FYg#4N$V#62V!4X4#10V!1Xk#46#16V	01//$17*1&11,2)3*12-5!2!1#2///(11+2%1/-201//,1(2,1)1/+2/11$2&2/&4$1%11!1/,10204/!3$102,31!101!1,3$2$103!201!2)2#21(2)3(2,1!2(1+22)1///!1&11!2!D!4.1011.1/*D&1//)21011#3/+101)r%4(1*201-J/01/#2&3/01/(4/!1%12)1&1#1#2///#12.4/$1/$2	eohRL@@Hlfg`DMlbbTtRbrvRTRbRtJdL\|zFZ``@@j@`ik@@@@					antagonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>.>x>xi.iS(x>x>xiS~x>S(xi.=x=x>.iS(xiS(.=.>wFx>x=.iS(S(tnZ)S(.=.>{D{Dx=S(Z)xiS({Dxi}H	=v;x;TfzUzUsvvvzrEyzhqSE;6EbmbQAzyg53fLqR9vCPxRTRfnUmvWCEOqdJ70OLFGnNYVVV8F0	0Xs0IV02AV1D!9304s!_F0zF03OF1g07#sg0bk3Z!DA0@!t!3OF1v0Eo012o0FF120@Z01J40FV1K05R0gk06KF1M08g0c02z0DF% 01Z120Wl2wBP3940l8kwN4GGVVWlBV4A66@Wt84@6632_8wBa418ZlFFoNFSBckNckM8221m0WVIOV8TA@Z0lNcFct33GGkfRRU33WhlkFky2@349He4FB9Z140h_kFZA8271m0Y0JN916740lNccNa121l20g2c8X2mBV8N4y2AQYVW0NFw2@ZVks@FD8CX09c4@K42FXFF2D37521lJNFB11lkyF4B2i0W5124B547Y0kGq44N4A0YVmc44a4GXFkgFBB@e0Z208s@c93WZVktwHH11FFB6C@71VGWNNH25VF8lN42J10F84k84_m1OxFB@361YWtgw54Y3GeW08D47520nV484M20GckFH1X0G8gv8261m0XFFGlqA442CIk8T8@4m0X0Ndw885Z140VG3cm10Y3Fk8cTc@31YFkW0BFD2WVRVRF62WHGFNF79218FwaNN22W1W8BBE86lNNZRHG33m8oLH243m0u0T@D21WFkJDDBa0Vl8@10VVF8DD@C1WVcNL632Gl4P20aYYGGFTC51kV8Ve2190VH04423610F8BFV36ClkcBBB6	!28ZV!L68$7!14GV!Z2#5Xo#@6k!9vc!B_H#@F$2o#V_#SWF!NMs!2C4!25SV	#11!2$13/(H1$1(3$14$1/&1%11$2$2$@$2/01/)2!1&1!1!1(1/05&2011/$210104!1//101*3/2+1/$1*3%11/&2$1/0202,1$52/&B401#2,1)2#2$2%2220410303!4#1!2)2041!3%2-2/0204$1$1)3!2!1*3/5/*1!2(2!7$3$201$2!1#12-402#1$1(281$1$13*1)1*2.1,1%3/z/*201-D01!2&3#1#1&11/*2(1/!208,1(1!23!2#114#1*1+2/$1-1$1%401010205$201(12(10401+	eo\zLB@GBjkd[OcPI@RPddEICHhhdiMUMEDiheDeDhlldmibfNIgcdRQVYXBBjfjijjjTJ`hjhjHOB@@					antagonist	CXCR3	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
0lvl`|.=F|x=:v.>)^S(xi(Sixx==x=xxiS(ixx=x=S(x=xi^}}H}HxiS~x=	>U:n7x7EzfvSTnmd@969RoC0CDBIS4CA6BXOqR4k!DX82h0FCNV0E51FF1t02410FJV20H!t!683V	0aJ0Tk02K03x!BL06F0TV03OF1k07g!mo0FV2d!DB0DN0uV$ #1Z12VVaGgV8A1VXFF8NNCJ51Wkk84aN@_1Xk4250X4FV8wgmp21VN4@2870FGWC84NH14W0FX4XL4Y6k8B224A0FFGB222871Oc488N10_VFB2448VFGtKB4Z@3W3FwV8N4c7970kR6110HXsF24J10YYHHFu41Xa0N826I1VZ2NkoD242YlRV8V78281	#30V#8$21#61$84!40g#V1#4Y8!20R$1$Fg#14#1d#99k!2K4#SJV	//1!2#61.201!4)1*1/!11%6$3$1!4/!1$1//*2#1!3/*1/!1(201#1/%1,2!1%1%101$1/.1#17//1203/$1!2*101!1/&44!2!1//%2%1$3(3.3/(2(1$1/$4$11/1/&1/%1)1!@(1(3$401.23!2/!6%2/!1#102$12.1!1/,2*q1$501/-6#H//01,1/#201-1#7!1$101!1+1)3/,1//!5+3(1*1#1)1/0	eodXLB@AmKg`@`RPddEICIEEDiLiTeEeleEeLJ@ljfemjYjjB@@BjihH@@					agonist	S1P1 (EDG1)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~S(.hxhxh.>.>S~.iS(.h.>*`F|0:(ShxS(0l>x>x.>hxS(.h	~xUzxCzyzPzyzrQibzhjrn2fDPqNQzxbnyWKjU0zXbo_s4tWIHe_b4jV8HK3LlBN2VFF8V0F0	0QB!WR0Tk025k1v!9_07g!lR0OF1v!Fj03J0G01v!GE08g0bk3Z!GD08k0tV3c!SD04w0L02A09w0jk3Z# CXokNgV60WWWgV8B4P6L1YGcV8JC0VFkd2CeA0X1WBV8R54p6WX0wV8V42W45l2Nk4X10_08Vkb8291d1V8gFR8L166qNFVE82A1AYGkNgqM23Xt0FV8FZ4JI9FNNsM82714_X9F6151V8B26B4a60GBk4D4M9fW046BA6m0W0G0w8Z6BX1kwHBA8m0Y0FlgBO4AXk8GBFE284O0GcBsH4J6VZVwV8F4HC2B2MVZBZAZ13Vt0FcAK4C331t0FkDF483Z16Vt0FsBkk4A2m0ZFF	!29bV!LB4!48L!3FYk!V2$iT!2@Kk!Nv8!4VG#2Gk!Z@k!2VZ#GWV!AKs!2DG!21Nk	)1%1#1$102*4+1/!1(101!2+1&3#6$4$2//#2#1(1+2(102+2)4%2&1/+1/,1(1!2,101!402$1#1(1$21&1,2,2.1+2/&11/$1!7$102*101(2/!2302$3%203$2(2-1/%1(2-1/1$1*1/+2$1$2*7-101$2&101!1!1/$2#@%1//2///01&10q1$4$2!2*1(51%D!2//#1%1+1/&1%9/&2!1/+1/$201%5/$30101*3#1&1/.	eod\LD@NAH`nk`HaRHrJJIQIJFKEQQQI[QbPqrhYXzBAbjYj`hHXhPRHJh@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xiS(S(h.>xxh.>.>x>S~xhS(xhS~x>x>S~xhS(xhS(xhx>x>.=x=~S.ixhS(`|(Sx>x>xh0lF|S(x>S~x>xh.h	:Uvzv;S:vyvzUzCvzvvzjAjUjpUSzhzeAbIjTMzyfxyQqUrCrzEtEgwYq2DiYj@oJ0K1fQKz8k8Ou_W0k0	0Xs0IV025k1v!8M07g!WR0Tk035k1_07g!lR0OF1v!Bi04s0f!3Xk2U0DF!sg0bk3Z!DA09w0t!3Xk2W0DF!kZ0qF3q!Fi0440FV2U!Ni03B0FV2A09w0t!7AV0n0480Xk2U0CZ0t& $6F4@2JI4mkVZFe_27@VGVTF4B3Z140dGlNe655Xt0Fk@@44@2m0WFLeBN693m0WkRV884e_27eVGcTF4J2XW12kgV8878251@dKFNcE8281GFVVkLF4B2FQ60kVZFDb72VlRNLCZ120YYtNq210WlFsxuN32WWosoL444GlNsS@7C_WG8dJPK71HVF4F88122FRBH411cVcL41123@cw8D4373GcsVA30G9FgdX424fV8FNFL2K8YkVg64@0VVBcJ61463G90BRQ5W2l0o4678m0W0P9B8J4F4mklNNF46624VWc4C0bWWOLF4D2C61qO4JL@O17mkGVLF4P2141FFF29@ZXcRgN114a10I0NH78Ym0ZRT811FlOPc4P615h0G0SF4JF13W1kI0VeG0XW9N8FE9880X2B4PF1423FHOo4XH213ZV8gKJ2AS0XF_F8gg29H0WVkkZ8742H0ZLA45YXk8N8q44WF8gB662WsB8417344F9K45296k8FoJZ2BZXFW0NNf035XFG8V4633WkFV6FDC0Y1cVZ68Bm0WVFFgR6D2VY0XoZ68735FWo0H4A490Yd8Z8J61110NZ@31VlOkF46VYl1s44k41W0VFV95XlVV63172FV8S38241F1W8OB4K2YkVJNNIZ170aFH3wN4C33VX0ONmH11YnFF8NGZ15VXVkWPP233WY89@L2D2g30WsFJD21108N8IA40s4oP21570VFGg24230FguB0VkkV21D68O0FV84@RBWG8lFV811YmRV8R5J12WYX2F8J@6b13H08cBD2Q850kF27112sZcVLf2W4lOV8TF142YIcGJZ4280JNFkO8627DVGVPc4T49134V8ZF49210VJLH0VW0gR6D7b208Gs842VkNFHB220sgD410o1eFNs4N4bVXcg4VF173O0FN8Jq@225VtJ8Z4@13V88kZB2RD5G8ZFi5A14GqQ48F5Z12V_JcFtJ2A3J2ZFwFF91GW2kaAB885Z14VXYdJF82YkO0ZV@792ksg2F6VV88BP8C53kWsksX342Vp1Fe7432lVV8F29bGWPB4HD@7W4nVl4695@_XdNFV7413GV	#c4k$J#4_$FV!W8#9gV!28%dB!4ZF#8FF!V@k!8O5#O3V!g_w!@1F!2_BV	!1*14$2,1$@.3#3/&11&105&3,D$6$101/*1.1)1-1-3#16%402*1#11.12#1#1+2/2#1/$2!3/#4$1!3!4/(11)3$1!1(1.1%9/(@&4!1!103*1*12+3#16%2)2%4!2/!1-1#11!8$2.1#1%31104,1(1%1(93)1+8/2$2%1!2!1/+292)1%1-2#1.2/&1*101(z%201%2*1!1$11%D-11+1/01#80410101!1!1+1*8101,1)1)332.1(1+3)2!1!1/(5#6#1#111/(51$1	eo\vFB@IGLbd[^AJegePH``HtbCXcHhheHdXXeDdhedhiiXdheh]FE@hlfjY^QXHEbjjjZijXJBhZhh`@@					agonist	MC4	Melanocortine MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J)*Fs6J)J)s6J)h(|`J)*F0lF*S~0:(Sl0*`:036J}*`*`J}	zrUtztUxrKpxvNvQUz9X2cPCiCLNCVB17ql0EAXbHQa8ZFHXFaw0vc0KB80dWKkfW95W_cF511!FlF80VW8F0	0aJ0Q!3Xk2T0DF018s0cF2Z0DF016J0Q01v0Eo01os0Ik1N08g0bV2j0DF% #2P4YVVkGgi231K20FRA823154Y1NBH65Y34INBB7Z140XXG162594VH0mtg4C2m0WVF	#kZ#F0F(2FFV!B2#BV@#f6F!8hk!401%V#@V#1W#XFk#2V!224!3C9V	/1/&2$1/1*2//$6$3!1121/*101/02)1$1/#2/02#1!2////!1$1(2&3/(2-402$304(2//#201/,1)2#42%2/#1/-2/$2%4/!2$1&3(2/*1)3/&1$3/2.6/.2*1102(1!1%4/01/$2-1#1//!1!10f%5$1(3#1201-H/,1!1//021/$7///#2021&2///!1(402/!1/%	fi{Hb@NJ|FS`RBSJzvsMoZtYxOQp@TuKUP@D@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
x>S(x=xhx>S~xhxiS~xix>S~xixhS~xhx>S~xhS~x>xhxhx>xhS~x>xhx>xhS~x>	;rrpSKtm4o_KEeFJ2p2B20V40F1092B0l6014V2Gk!FV01#5XJk4N0V4!Fc84041!4V203!F80a8IF	0YV0IV02OF1v!9J0Eo!qJ0R01v!DF0@40t!3Y03a0Dc01L80OF1q07g0o# 14VYNFHC421kB@231XlleV4Zd9130pt0Z6790WG508ls282M0YoO88L7Z130t0Gk9F5J68W9FVJ@530VNc821132F824EGJ0cMV9J9F2QT0_0gV8V4@E2GW2F4Bw43WVcR@62Z4VFJ2246ce0IQk4V4c1@E0GkLF4B3Z130W20cND73VsRZVHwJ13FbV8WF262m0_FRV8s4	#30V!188!208#6$X9#28i#Z5$W8#4N*HZ#15#IV#18s!8J@#54V	1/,1!1%5.1!1!4/)2)1%501#1#2$2/+2/+1*1//)2.104(2101/2#301(1#1!1+2/&2/%2%2/02%202/&1/(3!1.64%2+1!1-2&1#3&4!6#13$1$2/,2/#2*1/+5/(1/02/I!4#2!1/.3*21)@//3)12/+1/*u(1/01$1*L$2%2//2/)102.501%1%1*1%1301/2///+5#2#2&2101#2)1*21$	eh\TBL@MMheo`PIABPpdLbdLRVTRVTVbRrfRTDd\|zFj`@`@j`@fjXB@J`@					antagonist / inverse agonist	Glucagon	Glucagon (II)	no	gpcr-ligands_DescriptorsNo5Ht
6s)J`|F*6s6sl0*F`|`|:0*`S(6s}\`*:0*F(SF*>.p3}\F*p3p3F*	vyUvulOrdFhs2JAESNNkVNPm0BFM9W988MQX52V13Pk@4lFV0XO0CV1o1Fce1TlGW968kc241!41QF21V140V	0Y!IV02G01D!8U07g!aJ0Tk047k1_07N0Tk05RF1n07R0jF3L!OG07B0SF1r0Ak0p& #O0FVDF4F3Z14Vt0GFDF4H3S3W40gV8R5Tp241O0FN@gDMCX3W4J88H5Z12VbqO8BN7C155kG0Fx2FH22lBV8w5Rq27WImcFN9Ju2AW5OsFZ8VxAWZVk	!1aVk!G@Z!2IG#CaV!V6N!1pP#IKV!a@V!859!2K0F!1BV!1BQ#MAV!V0s$Z!219V	)1/011*6/$1-12//061!18!4/.1/1.1!1!102%101/02&1!2/03%2#1/&1-2)1+1///-1.1(1/!1/#1-9#101-1/,201/1+2#1/!1&2-1/!1,2#2/*1/!1.7(1/%2$1(2!1$6%2!7+1/01/-1-2&2,10n%603#2&1*1*F$1)1/&101%4%1!1!1+1%6&5//!201//)2/.11*402$1!1#11/2)	fcHB@B\LdFIdTTRbRTtRURVbRYKUhiWnBBbYjZj@@h@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xiS(S(h.>xxh.>.>x>S~xhS(xhS~x>x>S~xhS(xhS(xhx>x>.=x=~S.ixhS(`|(Sx>x>xh0lF|S(x>S~x>xh	:Uvzv;S:vyvzUzCvzvvzjAjUjpUSzhzeAbIjTMzyfxyQqUrCrzEtEgwYq2DiYj@oJ0K1fQKz8k8Ou_W0k0	0Xs0IV025k1v!8M07g!WR0Tk02FV2g!BM06J0Tk035k1_07g!sg0bk3Z!DA09w0t!3Xk2U0DF!sg0cF3Z!B90CZ0xV04AV110480bk06AV0n0480Xk2U0DF01ms0Bk1208g0bk3O0DF# #O0Fc8tDLB22G22J8Ri161t0FkDF4F2_85Y0VkI8261@nkWFLF4@3E@W2VgV8R7822189FWus4P7Z150_OsFgA8221m0WFH2KR6@3m0X0Hgw8B5Z130Z5dsF89458WVFHT65YO0FV8kkSCW0F8RJD@X_FkcNd@@20WOZRLDAE3Gtg8B86m0XkRV8g4BU1Y0@sNLCZ13VXOcsBL7Z160t0Gc8VeT@YlGV822344C0GcV4Lc141q0GFk4D481B2nFk8A250W0wZ8s2870Gck4F8B19dkH9464DDVXlJV8i0292P0XmV8Zs2636XkVZ@6A2FVVDLDAT0_Ic9BL2D373GlNT@3121104N98WW8JBD6VFFFoFPsHWkkkN8H86aWcoH41VHlGPNTBB20FkJNH563kkV624XVcZ64D472l8RcE6X0kJ@J7@m0W0FVBLB8a18R8410I1844BP23W6ksZD43VlVkL93VkGcowV2Be0XFX5F8L46190kNFBRU1632GRBFGZ130XFsFuBD24240GpF4N4F17K0GNF8431242@0L9721W1LF482p41kmOJ4VA172VFFGJ412XFl4JM41VFJ4P7EP10VNsNR252X@0FoN2@34VamtJ4422GXV8Z8385D0VGBs2E60X11XR8eG1W43c8kJs827F0GVQF4T76W33V8ZF8C3VW0BDM0VVkZN1D7b26VGVs2K60YWBV8B4@412FNFD21XGVRJ82VVs58RZ8NVksWN8G292kGkyF4R3J813FYtB41J1V8sgU82A1Xa0sNsE82D1e40WsFF@IFZH8ks2211XHRV8F484P712kk4X@4112dNBE4WVdFo41250FFtiF4D281DCHcRBkA18Xip8FVA825189FWms4L6v15eFG8J944A2JikVVLF4H2@DZVNcDI242H22dJ6832bmlwF365Y11FwJ84Vl0c6532YG1d1J4AK0XFm1FgU4820NFoOJFK1XFk	#c4k$J#4_$FV!W8#9gV!28%dB!4ZF#8FF!V@k!8O5#O3V!g_w!@1F!2_BV	!1*14$5,1$B.3/+11&105/$A$6$1!1/)1.1)1-1-3#16%402*3#11.12#1#1+2/2#1/$2!3/#4$1!3!4/(11.1!1(1.1%6/(8&4!1!103*1*121(203#16%2)2%4!2/!1/!11!8$2/#1&1104,1(13$1(43)1+8*1$2$2%1!2!1/+692)1%1-2#1.2/&1*101(z%201%2*1!1$11%D-11+1/01#50410101%1+1*8101,1)1)532.1(1+3)2301!1/(5#6#1#111/1&51$1	egTvFB@IGLbd[^AJegePH``HtbCXcHhheHdXXeDdhedhiiXdheh\phEEduSKrKA@lUUUSUMSAPUCTTP@@					agonist	MC4	Melanocortine MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xix(S~S>.>xhxh.(S(S~S~S>xh.(S~S>.>xlvl0(S(S|F|`>xxhx>S~xhix~S	:UvzQzvUSzlvyuQHnKIPff4i6Yd_oOBd3w26Vm12IdF80ZX4GF55EDw8643m4VHcB01FV04210k110l!VFF0	0aJ0Q!2OF1v!9_07g!dV0ak03FV1E0@Z!t!d03Z!Fi0440FV2l# 04wI1Y0nJc8@41EeFkRD4143222d664420GWNkA4W0NJ82163F88goz522W2e8461133kF8oU826128nkJH8210994Z2A@ZGsRD33VkF82117Z3puo8q11160848e10W42BV8w4@l6WG0Z@20ZaF848eL293lckF71WFFF82CC0V8GRz8281m0WkFa08B5633WFVZFVQC1GkF@DA10XHAFB@10XX1Q088c5114FN8wJ	#10V#8)1%4@#BVX$5F#Wc!4VF#8F$2k$4#1$13V!206#18V	#2-1/$6/$11///6$4$1*13&1&1/01/-1/!11/$1&1$1%11//#21+2!1//-2)2/$2)2//!1+1$4%221$1$2%1/1(1#60301101&1/#4//)2/)1)11!1%1/06)2&2.F!4#3)1/%1$2&21)8#3//!2,2!1.1(2(1(w1$5/#101-P$22)1/!1//!102#4*2*1/)3!2,41(1/)1/)1%3&601)101!1/0	e`R\H@@D@e`LbbTTRRVrTTRRVLVbeaccTwPswsT@@@TEAQUTATGQ@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J)3p*Fs6J)J)s6J)h(|`J)*F0lF*S~0:(Sl0*`:036J}*`*`J}	zrUtztUxrKpxvNvQUz9X2cPCiCLNCVB17ql0EAXjHQa8ZFHXFaw0vc0KB80dWKkvW95W_cF511!FlF80VW0F0	0W80IF02OF1g!C_06k0Tk03Xk2T0DF018s0cF2Z0DF01os0Ik1N08g0bV2j0DF0 $RekVkLF4626KgkkkOZcq0X2lBV8R4V6IaWVcgM8281MCVWcLF4B2J1dYVW8H227Y1Z9sND2Y41dGc8P486_2OVJ4783t0Fs8RD8FZW8o8FK8	#uZ#G0F(2FFV!g2#BV@#f6F!8dk!40G%V#@V#1W#XIk#2V!224!3C9V	%2)1*2+4$1/1*2//$6$3!1121/*301/02)1$1/#2/%1!2*2///&4$1/3/(2-502$304(2!1//!1/,1)2#42%2/#1/-2/*24/(1&3(2///1)201$3/2.6/%2/$102(1!1%3/01/$2-1#1//!1!12h%3$1(3#1201&1%H/,1!1$2)2/021/$7!1///2!1&2///+402/!1/%	fegHb@AZCEW`ABTvnmls[vkNAbN]@ASTmU@@P@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>0:F|xiS(0l(SS~x>.=x=.=xhS(S(.ix=S~.>xi.ixi.i.>.>.i.i55q5.>5qqq	<rjzStu4z7FDDTCPgXNaQ6_FVC3hX4Lnk5AXJ39q9Z21V0e5WdVlTd0c19CYFV9184l8L10c5KR431NV0FV	0_!uF02J03d!9F0DZ!qJ0Q01k!CG06J0Tk03Z02Z0DF!qF0T03p!Fe0440IV1v! 2BT2610X08ZPC2WlcyF4B3Z12VbckFV84GGfW1VVVL4N44WkoT868WFGlDF4N3Z130_0Hdws86X41GkoL6L71WNZB73VH1dTF4N3Z13V_2GBT8@Y3lgV8N4PH31_WcNLA32Fsssf82B1m0WkHdJTD5ZWWsqF4B3Z15VY18Gs894Y2NZRDL20ZmgV98782B1@0alWkq542_GgV8N5Xn24WBq8FZ8	!2UVV#8%2#BGV!a2#4cF!22K#FY#10P)VHo#F3#KV#1Xs!@26!350V	%1,2!1(2&D%1+301B02//&1$1*21/2&1(1#1/$2#11$4$8+4!1!1/01%1#2+8/%1!3,3////*1)2%1(3//!4)1/0C!1#1/411%1/02#105/&4(4%1/-2#2/2*4/#1#B)3)2$1.1.1)1//&D02&201//(1//+20z$1-1%10201+8//#106/#6(2/$4/!1$608&6.1-1$2+1&1/01,1*1//	eb^XJ@@D@JMKBdfVYVYueguijQQrI[YzEjdJbJJ`bBjjdH@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
x=xiS(x=x=S(x=S(xix=x=xix=x>x=xiS(x=x>S(x>xhx>xh^}w<~Utn	;Sv9zOSpx1742QH30G388022!_0d@80R#21210X#2#402F88F4I$F82&WXV#1#Z0F	0Ww0Tk037k1_07g!qJ0R01v!C10480eF05NV1_07N0Tk3F& !_88oD1AWt0Gc8_6e41WGFiF4H2IWW8lk@0E82M1m0YFFKJ9DA118lBV9c78231	!2@0V!10B$8#J2#VH$B8#F0F!H18!8VQ#4G$No$7#5V$9k#48#5cV	/,21)91+201/(1//!21/$101(3/,1//!1*2%1$1)1/12/#1(1#1.21/+1/222*1%201/+4%1/#1012/#1+2&2$1!1!1!5#2+1$13%1//%3!2//2%101.3&2#2,2//1!G!6-1/!1/+@2+1+1%2/#4//02+q%2/03/!L/(2,4+2%3///*1(13/3/!11#2//+2&204/!1-	ek`THH@EAj`LQIe]e]VUuVVacPsHkXz@B@Bx@Jjj@`@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xixhS~x>xixhS(S~x>x>x=xhxiS(x>x=S(xi	yRsK44cG8V4F4124FN01VN2H$13A20FHV1#3Fk1!W!@1052F2W0d!F2Fc@%240@44040406030	0WR0Tk02OF1v!9_07g!t40tV3e!FM06J0R01v# 6c9BXN26WVGNYJ4PGB1VksaF4B2q16fVG8GZTD3@ZVHNg24F2VYWN8VVRL42HkV@DB5VX2BV8B56G2@ZFH9w4N8p17ZFGWNF484Q0Z5k8k8	#V4k!104#F$D%2$c2!2V1V#W%F%F#2o$1#GVF$s#J2!250V	,1/)16%101$2#1//#2.6*1%1/&1//$1(2/!4%2//+1&3(1,3/1//2(1!4/,1(2#1//!5/&2&1/#1!301)204+3(3#1*1/(1/01/&6.1(101/+1/!1!D//-2&3*A///,3$3-2/0k2$5(2/&2#N,2//!4)1#2(1/3.1*1/,1/#1///(1/!1+10	fegAb@ACfBHRYVuUfUW~hqMRm`@jj@@@I`@@@					agonist	EP1 / EP2 / EP3 / EP4	EP (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
Z})L-gxh?yx>.hS(xhS~.>S~x>xi.i.hxhxhx=.=.>x>.hxh.>x>S~.h.ixiS~S~xhS~5qyggyL}?yjw~Q?y	;vzv;x:vyvUUv1nzuvyy2MAga9ThvzX5_HhAIkf6G_uVeNCEfLq1TRAnALJd522L4W62l0k420G_0V0FV	0Z40IV02OF1v!9F0DZ!qJ0R01v!DF09w0t!3Z02Z0DF012s0FF1209w012s0FF120@Z014s0Xk2W0DF01GN0O01d07J0nF$ #FPF22lNkB7210FB2RL0V_3lm8iH3VlXsq02332WYu8FBc6LJbVk4JJA3FW1VgV8N4FJ43H8w840WV842PGCH@1kcFa82l13kgV9B4JSF2l0ZNRBhQW2kgF8885Z16Vt0G0848451GNcF74X0sR620VVHGd88@44WdJgDT20b221GFM4C2GkGdo4L57DW60gV8V468510kVT841kNBB310V@9g212B9X31BLA20W08231VV84wgTcD17FVF@6411Xd4B4RP160FkFVH82Q1_kXcN4a9Z130t0GV84RKB40kR840VHllNKLm123WBV8Z78261m0WVNto8Z541@VmkG02626XVL9oH9132lV88452WFcBB53Wl0B@22WkN8631VF85cmo23W10RDA3W10R@421kNF4ZPH32WNB8621WckJ520kGtRwa6J112FVZ110GGW8oP42X7kFoX69VkN4VgNh990l0NGuD@X3G1NcB617VVtNJE0Vk8d0k	!234k#8#2%FB#VA#1df$K#Fd8!6ZN!1Nl#42w#m7#OcF!15s!622!23NV	-1+2!1!2%M&1!1&2//(1#2%4#24#25,1#2)1#1/$101011$1!102$31/01)1/.101/&1+421/$201(2#1%11-11/0301202&2%1/!5/!2$1$1#22&6#1103&1$1%1!1#1)41!302$402)1/402!2%1&1/#81/1!21,1#1&2&1/%1!1(1&A01//01-1014*@&1#2/01*1(102/!2)2/z/%1#2(4&D/1#1!1*103%1)1!2+102$1!21$9011/201020201%34/&1*1/01&2,1*5)1+1!2304&3%	em_ZBH@LBMd^QGEiP@cIEEdhihhdddjdhmLeeDeeLJ@bdf`XZVZYi`B@HbijjjjihJ`iH@@					antagonist	CCR2B	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}J}J\}J)*Fs6J)J)s6J)h(|`J)*F0lF*S~0:(Sl0*`:0B,~W36J}*`*`J}	:UvztU:KpxvTvQUzQXHcvCiELSCVC57rl4EAXbHQq8ZFHeHaw1zd0SBR0dlKkvW95W_dF511!GlFc0VW8FF	0Xo0IV02K03x!C_06k0Tk03Xk2T0DF016!NV1g0C!18s0cF2Z0DF01Zw0L02A09s0fk3Z# 0BV8R78271CmFWcLF442QZW1VgV8N5P2DQVY0gV8R4P2KKZkXGN64E5414Wcc66537WuFZ8G4m0YFFFgFb50nFtJRFD1enVBNVCZ130t0Fk@Rec33WcNNFkA82817Zn0BP@5W2190FNIB250NsF71VkFskg	#qZk!F0F!40V!2FFV!g2#4VD!1f6F!8dk!409%V#@c#1_#YFk#Hk!226!3h8V	//(2/101305*2/.5$3$9!102/+101/02&201$1//02(102/04)1/%12.1$1)2%2/01/$22$2304!1/!1103/$1/,1-84%2//01$2)22044/(2//3(2#1)2//-102!3/2.8&2/-1#3!1(1!1%4/01,11%2&2%1//*10l%3+2031!1201-C/,1//$21/$6/,1$3/3!1&2///!3%20602/!2/%	eg`VDL@EKDlmccH`IABPpdLbdLRVRfTTTrTTjPdbVQuuT@EMRuUP@D@@@					agonist	hFPRL1	hFPRL1	no	gpcr-ligands_DescriptorsNo5Ht
xh)^S(xhx>xhS(x>x>S(x>xix>S(xix>xiS(x>x=S(xix=x>S~xix=xiS(x=xix=S~	zrzt7OOl9o5kVFAUI82W28XH64!109206m468XV20V84FGX!FY12FR8J01V4V2V8020X0Z0W28FI06!V8FF	0qJ0R01v!C204w0eF03FV1E0A4!sg0d03Z!BZ0DZ0zF04OF1g07R0U!7JF1_06c0Sk1v07k0o# $6F4828P@0nNS0c4M2JE0WFLF4B2IcW4FgV8N782@14HXFP4CFw2813J9ge25410FkkRkL5Zlckg82970Z2ksLN4YcVF@022T965HG0LG1Vm1t1OLY32We7VGJA82G1m0WkRV8g5Fw2CW1mswXE8VlnNB24N9	!120V!70F!2VV$@#Z2V!4V3#@ZF!8WZ!448#1V#42Z#i$1V$uk!224#18V	!11/)21(4(1,4//02/0205$12*3.1//*4)1+1,201.1!1//!11%121!2/#1$4/%2,2#1/)1/!1&1/&2&4!10101!2822$1/*2-2!6!102$1!3/!1%2-21/!2!1(1%3#4/!11/*201&101$22(71+1#1)1-3$2%1)902/(2$201/&2+3*2(1&v/%5#101$1&1G!1)3$1/!4,1%1/)1#201)1+101)21$4(114/&1%101/#1$3#1#4!1/)5-	edRRDL@ONmobG@IABPpdLbdJbRrRfTRTrbJbrdbaUPruU@ALt@@DUUP@DFd@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
81)]f,18I}~S@,S(.ixixh)I.>.=S~x=S~x>.hxixixh55q5x>xix>S~xiS(xhS~x=xiS~x=xix=xi	=v;S:vyvzUxTQqvvCbCEUhYxStnxyEimZVUztaJ6fDUI3pb8hi8ZYnMfi1J9fk1VKG101F1Js1hX0l0	0aJ0Tk02OF1v!930D#qJ0Q01v!Bc04s0f!3Xk2V0DF!sg0cF3Z!DD0@40t!6AV1104F0Q01v08g# 045XFd4VB410FFB1C56t0Fk8FJ823Gcg8A4VkFF42E67t0FN8BaB44mFRB6960FGGFXs4620VXwN8Z8@82XGFcF@3VlF46PG0VYVVB469Gm0W0RV8c782415XVW4BC5YFc48316XYF88f6272m0WkF88v62820VkcFF953G8V8321Fc862H6915INBB6120kc8D842G8J844WFV8D1I7VFGeVB6652lFNL@4W0cN420c340k86431W0NF73WVNFB2110F821L70F84BJm21VFVVD933G0ND44VVF842I60F8F_K1424W82sNqB542lFGkFPD3520w8FV88z11Z0VoR6A6kVXVN8V8LD82lkoR410XWGH04_41814u8FV@432@VkHGk4V83kW40cN9Z42M1VZIV8wH4V11YkkFp8K321N42H99m0X0F	#d1V!FN#454!1@F#Z2#5c8$5F!Ffc!4ZF#cF$2o$5#O0F!17c!204!21BV	/.1(B/!2!4*21!2&201*1*@$2$3!4!2%1///$1)2/$1$201!1(1//.1*1)1%2/+1)4%21%4%1#2,2.1!1$411/1&2!1,6!1#3/#1010101)304#11$4/!2(1!604(1-1*25/$3.102(1%1/#2&1+201E!4/-2/*1#A1/*1013#21+1%1/(1/0z01#701/13(1&N#12)1/,2-21/+6)1)1/3)4%21#1/#2/1/&30502$1!1#1*101&11#2	ea]ZB@@DFFhRPHl^\bbbbbRRTTvVdsTTRQTrPacfUTwpKUTEP@pEQ@PTuTAAaP@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=S~S~.=S(xi.i.i.ix>x=.>xh.ix>.>S~xh\).iS(.hs6~OS~}\.hp3`|.>	;vzQtvUwEVWquzIc1GXQdHiJQ9Wr9@VITV78H033lGD04X4QG_1DMTtL8At8XH8C0384V62Y2o53415N#F	0Zw0eF02J03d!@C0ER!qJ0R01v!GG06J0R01v!Fi0440FV2V!KX06J0PV1v0C!1pc0MF1k07g0YF3d0ER$ $38271m0YkRV8R782B1m0ZkQFc8o5Z120t0GV8Tu4I2m0X0RV8B78271m0YkRV8s78261OgFXFICX4O2j1VZ0LF4B3Z170t0Hc@lg2391_OsFk8KP22W84do68S44jIkORBso@1ZVkOx6O32clF	#Y0k!1$7JV!188V!Vi#4cj!1XhF!8Yc!68s$c#4mo#X7#QVF#fs!@0D!3W8V	%2(3(1-27!2+3!1,2+1/%1(5$201(1/%2/$21%11%101!2/#3+1)1$21,1%1/2$1&3.1+202/(2%1//2)2/1$201(101#1.126$101*3/&1011$1402!3$111.4)2.1$1//(2*2!1&1,1//$B202,11/%1*20211$1!E(111%11,1/0102/1$1/1%y3/01/(H$2/-102/#2.1&1%4/(303(22/22(2-2!1!1#5,1#1-3)1//0	edV\L@@KDk`EGlbbbbbRRvrTTTRRNTSBagc`TqrvsT`D@APTQQUTAPKD@@					antagonist	MCH1 / MCH2	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=.iS~.=.i.i.=.i.h.iS~.>.h.i.>.h.>J}3p(W.>S(.h.>.>.i.>S(.i	:Uvzv;SzbvyuvIbKIAfd4z6fh_oQ8fdw22VH5@31m8043ZGF50D2c8LJ3m08@0T21F!42GFk130WX10VVF	0WR0Tk035k1_07g!sg0dV3Z!Fi0440FV2V!Fh0440FV2d!KX06J0PV1v0C!1L80OF1q07g0o# !BV8o4BkHX138YSP4C2m0_FRV8R782712dmd82@S7VFY0spe94X4H08sKLt22W2XuVq8A4m0XFRV9N4edEWW4FaF4w26IZ28JKB4618GwV8k782P10eot4GB9Z1G0aJ8gT15JXkcHFU8231	!2A4V!10B!20c!1F@#V@#5cd!2FaF!8Wc!4V@#8lk!4Fk#X6#1%fk!204#1cV	%2/&1)@.1/%1/.3$25!1011)1//%2%2&1+1/!21$2%2$1*1,101/-1/#3/,1#2(2#2/&1*3,14/)1011!1/03&1#2&2&4!2#2#2%1$201!133!102/*2/$2,3+2,1*4!1.1/#1*2*F!6&1%1-2&1-11#11!@2///0102/01*2#2+z1$2+11!22/!J$2(1)2*104/!2/2!1#2%3.2)2*4/31/!101,1/01-5$20201/!4%1&	el^ZHH@EDjedXPHaIe]e]VUvUyWZacPsHhZY{z@B@Bx@Jjjjf@j@X`@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
81)]f,18I}~S@,S(.ixixh)I.>.=S~x=S~x>.hxixixh55q5x>xix>S~xiS(xhS~x=xiS~x=xi	:Uvzv;S:vyvzUxTQqvvCbCEUhYSStnxyEimZVUztaJ6fDUI3pb8hi8ZYnMfi1J9fk1VKG101F1Js1hV0k0	0aJ0Tk02OF1v!C_06k0Tk03@01D0@k!sg0c03Z!DA0@40t!4Ik2D0@40t!6AV1104F0Q01v08g0 $10sZ8D8XlVR6220VF4wHUZ130VG8F8F7WVsZH320VcB4VBFm0VkF8wNABWWNcB2@60FGGNE24621VXw88Z8472W1Fo@C3W0cFDPH0VYkcB469Gm0W0RV8c782413YG8R6E6Y0cN2410YWGkB4KW13WO0Fs8B4SW1418NF4BF6MG0GVsTB86XVYVFsT6@42N0W0F9y4380Gd4BLCU0W0l0P0320X3l2_08H51115FF9By2F42N0X0J0223AVFHc44ZU17YFJ0828D4m0X0F	#d1V!FN#454!1@F#Z2#5c8$5F#fc!4ZF#cF$2o$4#O$17c!204!21BV	/.1(@/!1!4*41!2)1*1*8$2$3!4)1///$1)2/*201!1(1//.1*1)1%2/+1)4%21%4%1#2/,1!1$111/1&2!1,6&3/#10101+304!211$3/!2(1!604(1-1+5/$3.101(1%1/#2&1-1E!4/-2&1/!1#A1/*1!3#11+1$21/(1/0z01#701/14(1&N#12)1//+22&3&1+6)1)1/2)4%22/(2/1/&30503(1#1*101&11#2	efYZL@@DFFhRPHl\bbbbbRRTTvVdsTTRQTpacfUTwpKUTEP@pEQ@PTu@PXT@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
.=.iS(.=x>.>.ixh.hS~.=S~z<.>xh.hW~zB.>}\3pps`*\}*F}J}J3p3p`*ps*F\}}J}J3p3pps\}	]vy;jizxgxyvLE7fxUxjp_zHneCEyo9kqpq6alL@90t0apqAgp5KfVZ18XG0BR!V1V0DB01V0kV	0aJ0U!2OF1w!920@k!qJ0Sk1w!C_07g0U!3AV1D0@k!sg0cF3Z!DB0DN0u!5SF1r07c0U03I& #YFX20VJJAZ13VeaVNB@617Z2GFF530kVB2N@BX2XkNJBwZ@X0F8NFCZ140VYcgc8C@XkcNZU829122GO8H@H3Xlsc8@B10XHwV8F4ZT2aFsNHDA7m0XFFd0g651WcF611W0N8sJSZ160WFkZZI51kVRB4162k88ZoJED_XVFNHB876HGBB70VXFt84B86ZGFwJ52WFWVck@743lcgJ72WFc4410VZ12084mA62m0cF5110FJ840VF@0W78271980WFJ25Vm1l6F4R2A831FRH@2VkFJ21C7VkV4BLW@C13VgV8F4453Y18cP92VkFB@31bYkN846AHm0Y0GNJ6U12GkN8E@5591v0BL611WFsgH43WksV652XVN84Z9Hm0W0RV904@22YGNVF85WF8F641VkF98H_6E14VV	#e0V!18#2VB$2#c3F!AC8!10J#FY8#ZA#9F$Pk!8Z4#O8F!8GN#48!218V	&1//D!1$1$1/!41/01,2#@!205$21//0101/$1.1/!1!1!1,1#1/*1$2///1/03/!1-2&1*1/1#2#G1&1)6/(4#1!201*1$12#1#3%101$1%3(@/1(2/&1#16!302,121(2-1#1%2201*1/01+1!4//(1(2(1$35%4!101/%2//!3+1.1z/%1#21&1&P*3)1!2*103+1/01.1#704/08%1)2$2!1&62//$2)1$1*1!5/0201(5%11%	eaSRL@@JELb`DCLbbTRRbbjTRbabRRffRRqSVsupNKMOKUUUMTuP@@@@@D@HXT\D@@					agonist	SST5	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
O~,dvlO~O~,dvlvlS~|F|`lv~Shxh.~S~Shxh.h.~S~S~Spsi.fzf,zB}\}]}Iu8un	;vvfzUzp:QDQEPUBnfQDvg@m6hZS@TqUV57H1AOp@ZG10aYNVEVG61F4fA9NJ1922L40C2V204F0G02180V	0PZ!Q4!Z40FV03OF1k07g!oV0R03d!C_07g0zF05KF1Z07J0n03o# 0O0G094X17VmWcRHD8320cFPBH74FFoFN@155ckGOF4Hf111W1k9By2G83kWdR4LAZ120YmdFi@30VO0cVaK8Yl8NF20VHWtFZHF6YVkRD72VV882R@D0YGl8RA4YFN841B4aO0FcDF4P2kP12VgV8R4VWC4kV8NFBcF2l0R4B869bltF4630H1l0gBN5XlVgLFC2VXmFOco83aGWNJ4HD1lW0kZYBL6710WG0	#YVV!88$F#10e#VE8!51u$C#FA8#Zu!2NF#FFo#84#1sV!59k!2FB#p1V	&2//I////!3!2!2!2//(1(1,101*3/2*2!6*1#1//%21!107$2&1)1$21/1$1+1)1,1-1%101-1!407/!101!3/!2-1*401!1,1102!1201013+3/%4,11//*1//&1/!2/0301#1$201/401&25%2)11#@%1%1$4)11/#1//1%2%10x+41014/*B%3-2-1/%4/*1!211!1!3(11&2&115$1/(4&1/!1/!2%103*1#1*104-	edV\LD@IKNmAk`IAbPrJIJHqKJIJIIJZIIET\ZFMSGW@ppADtuTDEEUUDT@@@					antagonist	Thrombin PAR-1	Thrombin PAR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(U_*D+;w/;{D)Hwk;w/;xh5qH)x>)H)HxhS(H)x>x>S(x>zdW(p3}Jd,~Olvd,	^i:UjePzuOnfMCrCJzhcC6eIGDSE6BmOrRJ449Dv@Dj4FhR3B911HN0C43410FJc2VG02t!a8IV	0aJ0Tk02K03x!BL06F0TV03OF1k07g!sk0tV3e!Jh03J0FF120@g$ #9e1V8VJI8271A5p8g4@A5L6kXNsR4E46YHG4V61WVc82LGAYVY3c8Z8G02BVVVN6733420ckcC7WkV48320VV441F98FFkG48A71YGRV8N4yX41VNF4114Zks88VLB4YWl0F5122IF84k30VFFWB22GES3Gk8H@E20YGgV8V78281	#A0V#8$25#61%4!59B#V3#4Y8!20R$G$Hw#15#Gd#99s!2K4!2SFV	+2/1011&91*1#301!4)2*1/#1%6$3$1!4&1*1$1/,1*102#1///01(201#1$1-30101*1!1%1%101$1//#13/(1&1(2%1(1-1#11/&44!2!1!1/(1)4#3&3(3/.2(2(1$1/$4$11/1/&1/&2&11!@(101%4&1/3!2(1)6/)1#102$1!1*2%1//&s1!205*1(1#1#4!6#H$2////1-1#7!1$101(1%1!1%1/*101//!5+3(1/)1+1$	e`\XLB@AmGo`@`RPddEICIEEDiLiTeEelhediaPEeTtmmSMUPP@@UUSPP@@					agonist	S1P1	S1P	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(.ixi.=.>.iS(.=.>.iS(S(S~.=x=.ixiS(.iS(xiS~S~.>.=.>x>S~x=xh.h.hxhxhx>xh	=v;xztvyvQEvSmzvfKiTbfipwBxzhe7bI7DMUz9kTDZUMW6Sfc3TJIm@HMIZHJo0212IJR8BJkm0201F	0aJ0Tk02OF1v!930D#_!uF02J03d!9F0DZ!ms0FV2d!DA09w0t!4AV1209w0eF04QF1j07g0o% !B6VFg9V2G98FWcTF4@3Z14Vt0FVDF4H3Z130YZFFoa771XGN8RNRM5aW1ss4LA1433cW8BF7Z130ZoFFoR79WXFs8RNgH5_W1t84L71434cVsBF7Z15Vt0FkA04ZHFW3kq09RuL28Wh60Fs9V2@P0X0aV8dV2827VnGRDE3Vm1l2lk472m0W0J@JDL4523lVR6I61lm0RD31VlGGVBiA1_lNl4L33WY0N8Vc6ECVl30ka31Y1HFB4VJo18XocFkE82B1NC0X0LF4H2D9WmNVx42C3VX1XNsLD47cVGcR4HBo1AeFsFwBL_D_W28YGV4F2m0X0L3F8J5Z14VYZFG8o2E9VYFs8cJaX296VGss4P715XhFHtcR739X3XkFpH2AA0XGBV8Z4	#a1k!V2%8#G4V!XB$gV$k#Fd#6Z8#@F$2k#26#GcF!95N!802!21@V	(101(2#4-1D02/4$2/,31!1$2%B$7$101-2&1//%1+16%1/)2//&1$1/%3-1//0101,11%B&1&201(1#2/(1)2.1!3$4&1!2%1)1$1/203$501/&1%4//$2$3!1)2/(2+1/(11,2!8//-4(4(49//!1//1/.z$1@%2%1/%1L,4(11#2)6/#2,2)1!6!22011#2(31&6%1!6)1+2&1/!1,1/%5!4&2#1,201)10	eaSZJ@@DICG`PFKof\bbbRtrTRfTTTRRTTVrSpdacbtIrHIKUUUUUP@@ADAEU@H\DZD@@					antagonist	NK	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xi~SF*S~qq`*v:.ix=S~|FS~.>xixhxh.h.ix=S~.>.>S(xi	yqupT_OG8k5k4GA5FN0G0N@H04F09Y8@0HQX58V03PV96FW!2GV90JL10Wc1Lk1d903X4V640@441J6406B3V	0Ww0Tk03OF1q07g!t40tV3e!C_07g0zF047k1_07!Tk04JF1Z07J0pV0 #m0XFFwkX6B3K0YH2c8H7Z160b3NFp2C2522WVJL292VkF840VFV8wH4138O0Fs9KNY341W5N4BV9B13FcR2543Zt0FkDF4L3Z11VeFHAg4N4A191m0FwLa261l8FVRgA2684NFZF	#30k!Y$23F#E4V!V1#2V@#k5F!2Yc!8_Q#42$Pg!141#5V$8k#46#_1k	&1/$2$1$2/!1#2+1/!2#3*2$1$1%1//1(1*2102&4$231/&4!1%2*1//3%1!3%1*1(1$3/)2%2)1%1+1%1(2#1(2!4/&101/#6$101%1+11.204%1$3&13+2020101/$1%1/#1+104(2%2&1!1-1/#1+1!701&11*2(2*202)1&20D!2(1.1+1/#301!3*2!1/0t3)1#5/&1#J)1//,1!3/#1)6/*1//&3+2//102(1%1$1&1(1-	e`\XLL@IAGo`LSjPndLbbRfTRbRbtRtRaReCEccVtqt@ESUPPAAALH@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.=S~x=S~.ixiS(xixiF|0:S~x>S~(S0lS(.hxhxi:v*Fx>x>S(xhx=.=x>xi	;vzdzSzxxxQRAUUUNGANuvaAH2gYCA@HzXAc05PQZfaGXX0YOWxXMq1T4efAFId120V8k51W04J24FJN#V	0_!uF02J03d!Bh0440IV03JF1_07g!qJ0R01v!DF09w0t!5JF1l07J0jF3L& %cT120bV8pF2@2m0WVOOZ8F48E4lNVgHF1110l0cV64YlkNFFB3W0W8F4DLX@YWG84B90VWlpPFL@43260GkNJ8NX2F848BDA9Xlcw4921VkBgFLP5W3mVky6@5m0WkRV8N42974FcwL65VkNFkHNC43HOFRA0Z227c9BgG26Wt0GVDF4B2A7VVNgN96XV84gT11VkV8JHVL111cW4D2@6VN4NJJjPW2FV	#r0k!F8%G#44V!XB#5J@!12G$YV#58$F#1Ho$J#9VV!W1k$X#E0V	!1!1,21#1-911-11221///04$8!111/-1/.1!1$1$4/$1/*2//%201%11!32,1&4/-207%1%1+21!2/!203&2/&1/(C2010101,1101!1012#1-20201!3/&4*11&2$1&1+2///2/&1)1/7+2/$1/+1!@+2(1(101/&1/+2-y%4/1+1&D!2(3,2+@/#1/-7/(404)3/&4*1%1!2!1//$3*1#1,6-	edR\L@@DKG@ENlbbbbRbTRVTTrRIfbQdRVPLKUATCTUUUPD@`@@						GLP1	Glucagon-like peptide GLP (II)	no	gpcr-ligands_DescriptorsNo5Ht
.i}^^).hS~.>.h.h.>.h.>.hS~.>.h.>S~.h.hS~.>.h.hS(.>.h,BO~6s)\	;xUltK9k5w4J@EUF2F28@P040FWVh@02i440X021V#1V!FZ_0k48F0305VF08510W040VXV1707!V8FF	0_F0zF03OF1k07g!o40FV2l!DA0@F0t!4OF1g07R0U!7JF1_06c0Sk1v07k0o% !O0FV@lk4@2m0WVIJc8D4ARc0lFOtTL381YbGFBa30VVFVsS2u281VGcB4L9Q152FG0FBat726V88614@Z5ckGc612@0VH884TBWS15Vk9462E4hVZ188o8BdMWcF842112_mBV8N4	#30V!50F!2VV!14D#Z2#447$ZF!FW4#4N#3V#42o#a4#1Z#8nk#46#58V	!1/+1(91/$4*2/.5*1$12)5/1.1/!1,1*1$2.1!1+104)1$2/#2&1$2/1&14//#2#1021/%1/*2/#1/%2541$1//,1!102!401!3/!1%2-41)1#1#2!1/01/01/01$2&201)1+1!71%202!1#1)1)1#3+13(9//201,1#4/,1(1&q/)3101$4(G)1!1//$21%10101/)201/%101&302/11/&1%101/#1$3#1#3201%4/1/	eod\DL@GFeeK@IABPpdLbdLRVRTrbRfTQTRDdrJzfn^j`@jZ@@BJj@`@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixix=S~xiS(S~x=xiS(x=x>S(xix=S~S(xixi.ix>.>x=S~S~xhxixh.hx>xhx>	;vzQUvUJzlvTvI1n5Gt9fLi42P5JFPdAt24VW35Hs28Fhc0GHW1S6w44FXs4V0f0L0X4042F0F01F6V02810	0aJ0Tk02R03i!C205g0OV04AV1204s0eF04Ik2F0@!t!4OF1k07g0vV04OF1g07g0zF% $8T70ZHd4LFE1VVF8FHNjPW1VVX8FU9W1WNlNiH43FFkwF6254O0GF8tkK4X3108ZVI93FVB4HI1WFV4FPPUL5VNVsF49HclVJNXBzHW1VWkkB44YFGJD220V9cg21247t0FN@Rk537aVV8BJCZ160X_OZZ357XhFGew4F5Z14VfqcFNA8291Lg0sNsC8UF1XVk	#91V#8,V!43#4V@#2K#8W8!4VJ*2V!104#G$32s!106!219V	1//%24/101(1#11*1*2!2*7#19$301(2//+2.4)1/!104%6%1*53/*2&2//%2!1%1!1)1$2/03+4201/2&2#2)1*6#1#2)2$7!1#1/%2+1!1%4$2&1&2$1%1/$1/#2#12.21#1$2/%11/*1+1!9#1!4!1/#5*1+3)A+3.1//+1/*z%2(@/&1#N03+201#1$2/.4/-2#1/01,15#1$1&1/*1%2/!1$1(3//+	eb^\DH@FDkeO`ICHhdiihXdhXhhhdeeMUQqxDm\\C@DTp@UTEPUEHQaEPTPlP@@					agonist	Opioid delta / m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.iS(~S.h.>S~.h.iS~.>S~S(.=(S.h.>S(.h.>S~.hS(.hxhS~.>.>x>S~.h.hS(S(.>x>	yqPlLlOF8F4k0F040N2G082H040F81#Fl608!1FV960W%1V4F0N0802F0V04225V01#F!201V8kF	0aJ0Tk02OF1v!970@k!_F0zF02K03x!C_07R0U!3Z02W0DF01MN0Sk1v07k0o% $1Z130t0FVDF4J2I7ZH14RBD69c4NNkR2@485WFcJH50m211RX8DWm0ksNiQGWY1s8cF2AAY2FwN514Z2RV8g78261T@0VkLF4J223XGNgJ97XFNJ650b23VFNLB62GNZH421VN4sFSZ140t0FsDF4H27321d0F42WW8F86C4VFFtkJH98XlFBB55VkFN6R8DT@0WVHD24C2GkFW0HhNB381t0FkDF4B2455GFcPA7W2G1@F4TL16ZlFNB876	#I2V!188#VU!1F2#V1F#8D$1k!4YN#2R!21%Hg#4$10V!1NF$2#O2V	#101/+1$4+6)8/#1/%@$@$1$1/)1)1&1//3//1/08//(10201#1(11,11%1/#1-104/(2/104%3/)1#1!1201$178%1.3)1/(11082#3/101%1/$1&2$2!2/01.101!1/01#6/*1%41%1-1/#6!2/!C(2/$1/&1/+1,1!z%5/#1&101$2O/*2*2,1#206-202,4/#3/3+1#31///*6(3/*1/	eb^\HF@ONkh`IABPpdCIBrP\dLbdLRTVdUTtTTTTrRVpdgTwrLNMT@EUTpDPA@@@@@@					agonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~.i.hS~.>S(.=x=.iS(xiS~.=.>x=.iS(.hS(S(xi.=.>.=.>x>x=S(.iS(xi.>.=x>.>xhS~}H.h	^y;xyjr;jrUznhjqckpz_lTmrUodovoGLzApS632Zas2s4G!DiZJ8#481@_8c0VV01a8nF	0aJ0Sk03@F1D0D#t!cF3Z!DA0@N0t!3Y03a0DV!sk0tV3e!C_07g0zF04NV1q07R0o! !1V94LQGYl1FdFT10W1FJL611H1Vo42A0VWnVVoDC940ksw654VkFcZksE8411WV4J@D8@VlNw4HB13XnkG9J4D42423GFT85VHGW8J4U4ZmcFRN42W22FV48H11IW02A2109cZoBF41XVAJV666m0WVGVRyF93lVkk8cC33WdF8410F9VVk8d83Y0cNJ4DHXYNV2D870WVNB6@4Y1O0N6113WV84JT@1AZ1ckwE1Y40F8oV244c0sRT31Vk8BLPBC27Y8oFP89VFl8to3634WVVt0HF73FkwZL314_O0FV8k4e2M9VFVoK622C21sB812VFN4418a3088RxP2AWW1tV4P@G115XP48a9@141gV8c4872CVkNGVJJ62GF4@84ZYYF	#PGV!1%VB!1F2#m68!1C8$HV!FYV#49!21J$@k#V4#O8F!9ps!24#2AAV	&2)2/2$F+1$22!4*2/%1,37$401!4/)1/-4/+1%1*2020106///#3)111!2%2/2+1/!3%1#1/*2!132*1%203/301#1/#801$4,1!5014/01#3&7(7+1&1$2-1)1#2!205$2-1104!1$1%5/2/01!10101$1*4$1/1(2*1$2&1(5%301//,2.2/#1(z%1#11!4*101$22&I*2/!3!1#1)2!2#401#2/)@04!1)2#2#101/*211///#1$1(4$4#11/021$12%	eeSRNH@IDiccGBmbZVPICHhdhUDhhehhheeDibdhiEPqL}cK@AUUMPMPSPTCU@F@aBeDQ@@					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
:0|Fl0(SS(xi=x=.x=(Six(Sxi=.=x=xx=ixxix=S(xi.=x=S~x=.ixixi	;UvUUvUrylziuDXv4LTz3Lia_NCYka9G1c11I01F1102!1I3o04F@B0WG8%41408F40XW60Z#V0F0	0Pg!aJ0R!2OF1w!9F0DZ!_!uF03OF1v07k012F0Ak130E4# %m0WkFWgLB53FkF@30Vn11V4895310ZL941ksB41E60FGH08iB63XN8651VVOVVk886XFkkH65XVV8420bXnwV8g6q9241O0FV88@8411VVJA3WkcF42E70V8Fg229H11kVo692XlFoD71VYWs44N214c1YOwVC2VWlVs8F9641sNP640VF4oPQZ130t0Fk8FF@4YGkVD@20kFB8RDDf3VVcFgRTG22kcJ8FBeA12nk8ZB264H5VWP44H81322nWc8K311lFtN4O0712Fk	$VV!1+6c#2@$4V$t#F1$VF*NZ#Z4#CV#V4k#4$58V	*1/01*B/102//+1&8$2/1#1)1%1)1//06&1&1/*1/*1(1&31/,1$7/(1&2/!101/01!1+1(9/!111&1-2%1!1/)1+1)5&44/+1*12-301%1%1*1/$1#101.1/1!2)2!4//)1#1#1-5!1///02+1%1)2-10t.111(1/J*2/)142,1#1!1//1-14#407)2)3%2/1//&2+2#2%1%4#3%1(1$	eghXJ@@I@LLnidif{YV_}fYWB`qpIIXzjhHB@b`bHh@@@					antagonist	Adrenergic alpha 1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xh.hS(x>S~.>.=xhxhS(h.S~.=}^xh.iS(i.S~.=.>}^.iS(i.^}S~.=}^C+}^5q.i.=.i	=vOOzqCF_FHUmN1lYNAL@V!91deZLvX50X07HkY!WX025V5PMT90VG8BVFs8208Z0J01eG444J!V0F0	0PZ!U4!Xs0IV02AV1D!9304s!aJ0Tk02OF1v!9F0DZ!co0xk03OF1g07#t!d03Z# 01Z130f70G88cNE6G2saF4N3Z130Y428e8S4m0WVRV8k5Ns2618NNG8A82E1m0_FRV8N782Q1m0X0KNJ89DX0FtFRXD9VVdBFA20HY1JkX473VWFktgP22Xm0cB2@E5@l8O0@582jnkRBL67@2lt4Z81Z2k88ZZDXIZ11N8248621W0VFF5YGcN620a_nGkKPH0XY1VF8HD954ktJX64VXGt8R8591Y8wL6155XV8@k8311ksRH941VkZ67110N82aNJ72n0sV53VkN44L9A43pWJ860VH110849@2W0wH52W0cB2RN0V_Ill4aE9XY2088HD79Z3FNB620VWFw222660WkwiC3WkkJ6JM0V_FF9Bk412W18kF72Wl8RD410VV86aPIi20VcIV4ig1@17YNgJL5BXt0FV9Zy295kFlsOk2GL0YkgV8c7823110e0kR894W20cF73W0NFsmT222kt0L34XFsN8410VH1_0e9E12FwNL314YabkgBH11320kcVPK5ZG0R420VIHldc84CXVFWFWJHJE0H0l062C7@_3ccL66AVV8GFV4432FkoH641VcJ@61VVH9_78231m0VkFVVP48Xl0RH5210WdZo	!11ZV!28%3#4V#Z2#442$K#FY8$H#2%Pg#V4#GZ#92s#46!258V	!1%1$6#1/#@1-6!102$2*301/$1(4#27$203(1#101)1/#1/+403/2//!2(2/&2+21(1!2#1&2!2/%1*1)2-27!104$11/!4(1)6#1/#A&2$2+1*1(2%1!10501$3)1$1#1/$1$1(1$2/01!12!1,1&1)1&2/01+4!D!4+101/!1/2*A/%101//.1/01(z%1(3!1&101)1#L#1+101/!2%2,3+102&1&4!1/$224)1+2#4////!102&2,1#1!1-	enYTJ@@DI`GDgb\bbTTRRVfRTRRVfbfbfZTlL|FvZ`@@HjB`hijjh@@@					not given in publication	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xi~SF*S~qq`*v:.hx>S~|FS~.>xhxh.h.hx>S~S~.>S(xh	yqupT_OG8k5k4GA5FN0G0N@H04F09Y@@0HQX58V03PV96FW!2GV90JL10Wc1Lk1dA03X4V640@441J640643V	0WR0Tk027k1v!BM06J0Tk03OF1q07g!t40tV3e!FU06J0R01v!GG06F0SF3L& 38291m0Y0J1V8PU612WBV8R4ikDWX0wV8N4or9WY0m2B8PQA12G0VgD732lFZD74VF884T@10FNNO8VW28ZVk82B2W0G0Rf82A1m0VkGc98LE27XoNFkF6243_m0Fl0S24XC0H9cg4B34bFVVRE8121O2VL4ECVYHk8cF8512Fsc8B40l0V830bYFFF46810WZkG0H6J6_VcF48110kFcH2137O0FN9164ICVZ2k8kF	#34k!Y04!23F#D4V!V1#2V@!2k5F!2Wc!85Q#42F!VPg!141#5V$8k#J6#51k	,2.2*2/!1#2+1/!1#3*4$1$1%1//1*1(2102#1!4$131/2%4!1%2*1/-103%1)1!1&1(1$3/)22$3!1%1%1+101#1(2#1(2/,1*3(5$101/#1$1)204%1$3&13.1101/$1%1/1!1+104(2%1&1!1-1,1%1+1!801///$1&20B!2$1!1.1+1/#301!3*2/$s01#1#1#7/!1#1#L)1!1//!1%1!3/#1)6/*1//&3)102//1*1/,1-	eodXLD@IAKg`LSZHRYVvVUgeunzabqqiXXz@BijhH@BHXP@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.=S~x=.ixixiS(S~x>x=x>xhxiS(xix>x>x=xh	vzMQPIlm9N@FVo16Hk0kVA22V013V010g53204201FG!FJ!96!4&V02!4(2488$1V0k0	0Pg!aJ0Tk02OF1w!920@k!qJ0Tk1w& !D9L41V4B4834O0FV8NaLB20kB851522W0F8VI78GkRJJ11442Y8Fdo283VWW0kN2@7ZlcoH31VY1GaF4D2TY11FgV8g4w2@Y0WkV	#11V#8/&88$1$1#4,2k#44#G$948(218V	%1//06/#2#1//-@01!1,1////#1/$1//,2//!3)1/////)3*1(6/!1*1,1//)1/)4/)3#1.1#1#3/*1//+1//06//-2/!4%4///2-3$1/&e%523#1,1+2#N*301/%102)6//*2/04/3.141-1//+11&2*1/01(1$	ffcP@@@LRfU[eUo^p_IKVjj@@@@@BDB@@						NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~.h.hS~S~xi.i|FS~S~lv.h|`S~.hxhS~x>xhxhx>	:PnTntr0N7o0k9W2N0W08@k0FNJ8V#LG05B2!Pk84llV02N09V4JFF0c1FH0W102f4041!8F$V140k	0d80xk037k1q0C!1680OF1q0C!1L40Rk1u0Ak0nV067k1X06J0SV1v0C!1a80OF1n07N0nV3F$ #m0X0RV8F6PM24WFFGWZJ483VaGFO4E8291m0XkRV884NnHWXkmOKg649X8s8FR8nA27WO0FkDF4B2pMW4FV	#bVF!W0c!21A!206V!ZWV!A8@#FJV!6W#8DR!2NJ#V2V!803#K5$cR!21E!2G9V	02/+1&1$2!2(1%1///5$11#1%1)2/-101%2-601-1)1#3%2&101/&2)1!3.1#2/%1#12$1/-2$1-1/$1//)2+2!11%1$1&1$1/!2+1(2///02&1/%1$11)1!3/.2%1/$401*2&1/&11/015/&1//)1.1*1%d%401%4$1#1%1%5#D/#1!3/$1,1/,1601/01*10101%1&1!2(2//!1%1$11*5&11/%1+	fa{iB@DBT{LPXfQQIKQQIRjZIJcCNmyoX@JZfY`@F@@@						GABA B	GABA (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=S~xiS(.i.iS~x=x>S~.=xixhS(.i.ix=S~x>x=.>S(xi.ixiS(S~S~xh	?yzUyrtyxiYrpvzjr0zFhjqwkFiCl@mo3XNJGkGLyKZO612Zis0v4F!DBVJ8$81@5880VV21X0lF	0Xo0FF02OF1r!9_07g!Xw0s!3Z02W0DF!sg0dV3Z!GX07N0Sk3F# 08C73l1BRA864O0Fk9FVNG0VVkVORHF0l1FVC848Q1kVcYcu@1X112N94DjCWXl12BP44XGWVRJ4344ZV8xD88C0WWGfJ8JN142VFkaF482412HO08A94HGtDF4J2BJcWVVsFV32@1Z@cBR@23WFcwTI8XFN42NABPfkVsFBHOB5GFNRJ2144DGWNH8740XHtRmA2VX1d0R246318kTC60VGVsk	#P1V!1%VB!1F2#k48!198$2V!FYV#48!21J$2k$4#O8F!9pN!2$2A@V	&1/(1&E/!1/#1/1,3@$7$2///(1//!1.102///.11!2/&2(1!1/)1#1!2-2(2#3&2#1(9/201/(201$2//1$1+3(2/$1#1-1)1#2!805$2.1*1)1,3/$10102(2&5$1/1/&202&1(31$3/#1/*2.2/!1)x%503!11,1&21&K*2/%1#1)6!2%5#2&11/501/02//021//4(13)1$1(402(1/07%12%	edZRL@@DJEM`MElbbTTRTRaTRTRVbbZrcaTpspLKTEATD@T@uEPE`PQqPDP@@					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(x>.hS~.>.h.h.>S~.>xh.hS~.h.>S(.h.>S~.hS(.hxhS~.>x>.>S~.h.hS(S(.>.>	yqupLlOF8F4k0F040N2G082H040F81#Fl608!1FV960W%1V4F0N0802F0V04225V05#F!2!X8GF	0aJ0Tk02OF1v!990D#_F0zF02K03x!C_07R0U!3Z02W0DF01MN0Sk1v07k0o% #BV8N78241m0XkHccVH94WWkl4yX364FGFVcgD333NN4FF8D4W1ZFC6736n@8BNC1520GdgPB73Fl14Y82A1m0WVRV8N782@141GkZN93YVcF851aX3FscZ56XkkkB131319aF4F3Z13Vt0G88JB55_1NBB65VFcN4R8D320soR91WFkZB22W3W1qF4N2XW13FZJ88F4dN2Vm0TF4B3Z130VVl4XD5WXFZZFHW17_VGdRJ7221lV	#32V!188#VU!1F2#k1F#8D$1k!JY8#2R!21%Hg#4$10V!1NF$2#O2V	#101/+1$4$1%6%1!8/#1/%@$@$1$1/)1)1//(3//1/08//(10201#1(11,11%1/#1-104/(2/104%3/)1&12011#178%1!2+3)1/(2!82#3/101%1/$1&2$2!2/01.101!1/01#6/*1!2!41%1-1/#6!2/!C(2/$1/&1/+1,1!z%5/#1&101%O//%2,1#206-202,4/#3/1%1$1#3///+6(2/*1+2#	eb^TDF@ONhk`IABPpdCIBrP\dLbdLRTVdUTtTTTTrRVpdgTwrLNMT@EUTpDPA@@@@@@					agonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
=.}Jp3.=vlJ)ze.izAzA,AN~X(vlX(6sF*)\zAzA0:)J)JvlX(F*N~zA0:vlvl.izA	:Uvzv;S:vyvzEjBvzvzCjAzUgbJSzrxeEbmh86zna4LAmEM1m_Dpq84Yr4jj05@XK84S3OJ180B8F5V0kV	0G#aJ0Tk02FV2g!C_07R0U!3Xk2U0DF!sg0cF3Z!KW07R0TV1w0CB% #2gR49K0WkqtoV6B3m0WkRV8F4uT9_W1FXZFD723mk8oJBC@31VNL34VV8B4P9C6Xn0ok@1YXGlWkcJ8VWW8k4F96Y18gH820kNB61E5VFG20gNE2_GNwD498ZeJccBVA16XIlFFZL2732328w@9511d9FJ2285VkkgL62XlcJ6E1W3GcB4LRPD12Kc8RE8251m0WVGPkFD455VFsdtFF1XWGVeZ4Tk5130k	!2e1V!108!4V4#82#cV#1f%4#2d#6gN#9k$Xk#44#tB#8KN#18!219V	1//&H!11)1/+2!1/01!2!B$3$2%1/$1/021%1+1#1&1,1#1010212+1,1$1-1/*2///!2(1#1&202%1/$1*11#611%1!1%13!2-1$10101!2/2!3#2*1(1$2#1/&1%1%1,101+4-2%101/-1)4*2%1101#1!1$7//-2!2)1#25(2%1/!202/+1/1/x4$8)1)2$1!2&H+1$1#1/)7+1(1/!6!1/+1$41&1(1-1///1!14%1-1&4&2%	edZRDH@NID`VL`@cIEDheeEDhdddTmEddiXDetm}CUSUSTDtE@PQPHPDJT@@					agonist	MC1	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
:v|`(SlvS~:0:v*`*F.>.h.iS(.>J}3p(W.>)^)H.hS(.>.>S(.h.>.>.i.h	<vzUyrpzxUwtQEU4qEdeka8qMBWgNDMS03h058Qlv4nGX0Yy18ZXKGJ0eWIFAW120b80J01c4FH!FW10Vk	16V0dk3F0CJ016B0O01s0EJ01L40Rk1w0Ak0p!5RF1n0Ak0jF3K!O204F0Gk1q07g0eF06JF1X06J0SV1v0C!1aV0Rk1w0@R0o03K# 0GCaW8s@2753ZZGBm5552t0FcDF48299_GtNB6143H11gm9BWGWcqF482U65ZNVcG6TD2110aF4D3Z15VYY8VJA92VO1FVFMDZ2F4@DI7m0WkRV8s782116a48ZL7660VGFtVqG2_FckcQ8251m0WVRV8k4	#jWk!G8g!27S#P@#VW#2dB#2p#sA#5WR!2RkF!ZPV!9H7#l1#tNR#OZ!21AV	+1/01%2!7*1!1(1//01#1!201(3&11!1%1/)1!1!11(1!402!1#1@!102/)2%1)1/(1!1$1/!2#1/*1//1!11$1,1)1#322$1/-1/*3/30102#11/$101011#101$1101/&11,1.121%4-101.1.5!1/$1011#1,201)1+1#1(1%1)1)71$11!12%3&1!1(1%2,11#1.1)1#110o2-21#2)2201(4/1/*2%1&2/&1$18(1*1%1%1!43/1&1/01#1#1//9$101!1#1,3!3%1#	eobYH@@FNACK@hbm`LdTRaRRbaRrTRTrRHhDdL\BbFfNnjUiiffjj@Bjh@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xi~SF*S~qq`*v:.ix=S~|FS~.>xixhxh.h.ix=S~.>S(xi.h	yqupT_OG8k5k4GA5FN0G0N@H04F09YA@0HQX58V03PV96FW!2GVC0KL10Wc1Lk1dA03X4V640@441JL406B3V	0WR0Tk027k1v!C_07N0Tk03ZF3a0Dc011w0OF1k07g01540O01p0CN011R0OF1v0Eo# 0RVWklVQB4Pl151O0G88BL631kt0H911kF4440c2Fc8O782B1C6VWe8R4@47ck8O0TE26VGFB8889m0WkHHl@683m0WVLN95D@261t0GNDF462@191XVFwJY262G8FVRZ@268ZkFZI8241G6FcNp42252c594J8942W0cVLA6XVkB@61Vk890H2138VXFZk313l0g440a2341CD6D50Xl0	#34k!Y04!23F#D4V!VW#2Vv!2k5F!2Wc!85Q!242F#Pg!141#5VV#8k!846#M1k	/,2*2/!1#2+1/!2#3*2$1$1%1//1(1*2102&402!231/2!1!4!1%2*1//3%1)1*1(1$3/)2/1%1+11$1(7#1(2!2/)1/#6$101/#1,10224%1$3&13+1020101/$1%1/#1+104(2%2&1!1-11+1%1+1!801/#2!1$2*1+1#1!20D!2(1.1+1/020301!3*2/$t*1#5/&1#J)1+1/01-1!3/#1)6/*1//!1#3)102//101(1/)1!1-	e`\XLL@IAKg`LSjH~dLbbRfTRbRbtRtRatuCEccVtqt@ESUPPAA@tH@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
>xi.xh.>x>S~xhxiS~x>xi~SF*S~qq`*v:xix=S~|FS~x>xixhxhxix=S~x>S(xi	yqupT_OG8k5k4GA5FN0G0N@m04F09Y8@0HQX58V83PV96NW!2GV92JL10Wc1TkGd903X4V6g0@441J640603V	0aJ0Tk03OF1k07g!qJ0SV1v!DG0DN0uV031k1C0EN01540O01p0CN$ BV8o782B160_0tB8VH5Z0lW04FEZ13V_1VFt4X252O0FkDF4F3Z13VbY0FpP2A3b_FW0KZL4B2LVZqs8s8HC22VGBH@110V8kN40W0l0B4BV3NW4FlN8P5312G08RSP2BQVXFV	#@0k!31#22F#DkV!V3#2V@#V5F!4Wc#5Q#42$Pg!14$5YF#8k#56#Z1k	//(2/1010202+1/!5#3*8$1$3%1//1*1(2102#1!4$13/+1%2&1101+1/0103%1)1!1&1(1$34/(2)2%1%1+1%1(1#1(2/#1!103!1/#4$101-1$1!1(2!204%1$5&13.1101/$1%1%4/+3(1.101-1,1%3+1!9//-2(1&209+1.1+1/#3$3*2/$v%5#10101/$501#N)1!2//!4)2/#1&106!1(1-1!5//#3///(1/&1$1-	ehRXJH@CHDMO`P@cIICLeLheDeEhedimAI@hikmgeh@Jfj``@HFD@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
ot7tx>.>xiS~x>.hxhxix>x>S(xix>xix>xiS(x>x=S(x=xiS(x=x>xiS(x=x>xiS(x>xhS~x>S(	[hyiz5MjyUUwpnUHvrg8rhft3BMnVM5yRGln9Vz1W6A5V5a1Dd1dk1Ef20o5064H4_XB6WFarG0Y0G0	0Pg!aJ0Tk02D03V!9k0Ds!qJ0Q01v!DA0@F0t!4J02B0DN0u!41F1C0Cg0xV05OF1g07!Tk3i!Rh04F0Q01v08g0d03Z! $1X0RD8Q24FsFHD33Zk890k223XlNZH74W0VFki210VFJ240VXGeiF4D3I711kN8JBD931WF8JA33Fc8660VF@9C421221FcF6510NB8210kN8B21@ZkF48VjZ110XVkkH16XVs48790IHF44TR11GVl8cB@4WW8ZZm610FN84120HGs864BKCZVWAF6464m0WFIFF8m@115WHF8422Z2F84HK50kW46210VVR2410V89FLcHM80l8B489Z130Z1NBD213720Z8k454FFWB22FCm0VkNX08D4@41VsZK434WVsRL30VVcJge1198XGNZF1111cJ@1AAWl8w28HEE0bGV9cDV5WZkVF8VD4B62G0870Z4XBV8R4BjIX118VJRGCY1Nc210VXmWN4BECa10Z840_4HX0hN@711X0qF4J3Z160_VsG4N6JVl0cgR418ZkVRX56VVVB62D4b0b2RBV3152O0GVDF4F2M3151V4@W5X1Wd1WHL622W6Q48Z4Y15FFG0F8VI8cG048F881fI94F@K10Z1WXNqM48XO0Gs@B4S115W9rcFJA8271	#dGk#N#454!12$62#Bc8#1U#FW8#4$10F!V@o!80C#G2#S7s!254!2WBV	&2#1$3!1)1(A-1#3-4#1/4/2#4$4/12$1//-5%3///%1*1%1%3&2!1)1)1&1/2202/2%2/#101-11)1(1/#1%3/4&2/01011#1%2(12$107$1!2)12!2/)1/#2.1$1&1&1#201-2(1%1&22.E!61/03*1!1*1%1(2D%201!2////01/1010z#1/%201%1&J$1)1*1!1/$12!102-1$1)4!1+1!11%2021$124%1(4,104/.421!2.3!10302!2+1$1#2!2$2	enU\NH@LOChDAK@RZP@cIIChhlmLdhdlhdidhTieMJfmkohUjB@jj@B@HijZ@hCJ@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xix>S~xiS(xhS~.>S~S(.hxhx>.>x>S~S(xhy?,BS~x>[)toH)5qxh|E72|E)Hm0)Hx>to5q	>vSzo5wxGQUES8KXNPRg52FC3idVHlX78@gPQo90H_!AG0_X7FhNVl1PHml@JcX4FJ10V502FGGcW0FF	0ZB0IV025k1v!9_07g!aJ0Tk03901407g!sk0tV3c!FC0@40cV2j!K204w0Z02U0DF01WR0NV1_06c0Tk3F# 382715qFVsFim4D2OVY2lg8F6mO11FVGci6H76FFVFNDQE13VPZ8L81453NoLJ783g60FR62532WVF8eAD1FNB@LF40YI1FZFe4XYFkw8JDB841884B6X0FVgPLiOVkksNB491X0ko874YGN8211c3FF8g228Hm0WFG8sLY42YH0N8JDG8310J4B42k8VgPLkN0kksNB4B21ksg@84XlNB21E70FFFg228Hm0WFRV8c78231m0XVFxo8F4P17a20NBLR14XV_sG067JWXlGlRN@A40FsgRTL722l04DA7@2kFFFO9WkO8ZZTfDYG10VkL531FVZP@61kV8oNPtKW10VFF421218ZN@4XFN48520oWk84Na11FVFNN@511ksRL65WkkB610d3VF846@L10FZ0N@62WG8V@73XksJ4210V@Fo42AK41Wko4E21VW8@316X3F	#b5V!Oc4!42#2NNV!c3#@h9!2Ypk!FXN#B9!2V0F!6uo!1X1#GNF!Wss#oD!2WPV	//(A1%2*2-4//$@$3$302//01/!11(1*502,1!212*1&1//+1,1#2#5*2,2/%16(1/$2-3,1$1,1$1/(4&2/)1+12$2$3$1023-2)1/21!4!1*5/02!5/04#2//1!2*4#4!@*1!1/!6$22,1*C(1!402/%2,101/%2/01!10z%81+1%1(2&J/%1+2/$10101&2,4%6!1/%21)1/01.1$1-1/$1&205/)1#1,	ejQZLD@BJACGMJf`HbpHrJJIIYQSSKQQQSJIQIEcbxE{FDf@`jYjjf@H`b@`@@@					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~.hS(xi.>.=S(.=.i.=S~.hxhS~S~xilv*`:vS~.=`|.i.i.=	]vyzx:iCxyEDzq9zghzhfNk2QlK_tNketldq4XWb4033aBRBF0c03yBZSCA43Wc4#F20V!V8FF	0mF0AF11!DA0@F0t!3ZF3a0DV!qJ0Tk3x!GX06J0Tk3F!GX06V0Tk3F!JZ07g0ZF3a0DV% 6F4Z3Z120bVHgN4Z5I8W6FgV8V4y2SGckY0TF44361@7VHFLF4B361D4GcGZE82B1m0WVIk8yB2B2m0YVNk8sw2B2Y7VVcLF4N2TY11kgV9F78271m0WVF	#E0k!12V!204#I@#Xg#192#4tV!8Y8#F9!20W#4Ho#X5#I8$9s!642!231V	01/%1&1&@/%2/,101)1#206$2$4+1-4/*104///$3/.2$101/(2!1/#1#1#2$2/*4&2//$2)2*2/!1.1&2#2+2!11.5,3&32#1$10102)3$2/!1&1!2*2.12!1!201//)1/#9!2//&102011%3(2A1/!2+11/&1#1%1(1#2/q#205.1!1101-G/(201)1*1%11/!3*104.1*1/*1/(32//01!1$4$2!1/#5-	eolRLH@EMKGoFm`IAIfV]}[e^VUvIMCBjaikghH@@JZjj`P@hPBeT@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~x=xi.iS(xix>.>|F|`.ilvS~.>S~~Sxh.i.hl0lvS~|`|F	vrUtQtOr9J7w02e9EN0WHOAs4BFJ9WB046NVE0202NZN6W1V6mKVOa150FV0G9V!d1AV0X59081F3F20_W0kk	0PF!ZJ0IV02OF1v!Ce0AN0o!4NF1Z0Ak0p!5KF1n07R0jF3L!Oc06c0Rk1r0AN0o& $1Z120t0GNDF4D3Z110t0FcDF4N2@FYZ0cJH@L94mlJJN@@DZmkWF@E28Y2YmNBNL14XO0G0DF4B3Z13Vt0GN@4u94X3W08H6@7m0WFRV8Z782F1m0WkRV8R782A1	#70k!N8Z!32$8e#V4#131#2pV!k88#18!2NVF!ZFV!4Y$12#W2F!8Fa#1cV	//&14//-1/(6!10201(1%2///*6*1&1/!2(101$1,2+102)1+3)1//(1!1)4$4/)1101*1/1+3&22*3!3/$1/-11)13$2*12#2,1/(2/%302/(3-1,1$2!1.4$3-1/)2/!7+1/15.1*1+1&2/$e%5)1#1$1$1(10B//%2)4!2%2!1*1,101!1/.203/01//!1.1/8/,1-	figD@@@XIRR`eRfY]UYU[ugEFrwhpJBjXJBaRH@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>xiS(x>x=S(x=S(xix=xix=xiS(x=x>S(x>xhS(P~w;sp|`~Mc{	:UvztzOzFxnvR9AFG1lV8D4442HZ0A8g4x2#30IF20FV#404e4k48B22!Fd260F!8104F1F0F!V0F0	0PZ!Z40FV02CF1D!8M07g!aJ0Tk02OF1v!BM06J0Tk03Z02W0DF$ $382E1m0WVRV8Z5@EF0W10s4B@k1C6n04Ba8k18d0FsBL9Z19Vt0FNDF4N2k1E9GsGRB4b4_WccsB825YZ40H0BF7XFcdFRNZ2AW20w@62Y3HBV8N5V2Z2Y2Ng8@M60W11JFC@10kV6LB10XY0sw4992c0FBD2210sJ411W0Od58BD22W8k6531VVBB130o1X2k4Js1413WFHNTA2GVVVN422X0k82JM21F8OC5Tp23112OoNF22GlcN4LF2N18F8RF@420c8VaJ5HX0msVD85XFVks42B@m0WkIlJ9813218VD7145XgV8B78231	#14V#84/$1W@!201$W8#4$8FF#2k$5#G$91c$2!210V	)1/-D///*1,12!3$1-1!1//&1//%2!2!2%1%1(2-1//#22+2!2//02(2!42(2-3%2$1/#7/!21/&3&1.1$21.1%1$1/*1&2/$2,2#1!2!1)2.301/1/#1)2+L!8&2(3+2/2#21)B/!4)1&1$1/01*1/(10y%2/#1&1$3!N$22//.4/102.2//#13-204/%1/.2-2&4/01!2-	ehRTHH@OIg@HaIe]e]mVUv[UhXtLZz~A`@`@fj@BjjhB`Fh@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
`*vl~Sv:S~x=*`lvxiS~.>:vS~x=.h.hS~xhxi.>xhx>x>zdW(p3}J	<vjzSUrxt7RDUiA0pYNeV6aH1h348BLRV7VXG08kf610X0XS59V4RsJZAWJl2V13@W0VJ514W03J0101!V	0aJ0Tk03OF1r07k!o40FV2d!KW07R0TV1w0CN01M40S03B0Bo0x& !1Z13Vcm0ZBVK9W3GGuN2i44XO0G8DF482AKe0lVF4495m0XFOVcF646X3mNkL45XlN842A8_ink8F8E0VYGF	!321V!G2#@Wm#c2#V1#288#21#41#4dg!21F$6k!867#KGV#lN!1V5!298V	(1/.A!1!2+1!3//*201!@$2*12#1.3/$1*101(401/+11/(101,21/1%1#1#2)1&1/)1%1/-11//-1(1/+1/!1-5$1*2$1$11#1#1+1/03//1)2(1)1-1*2/!1.701-1/!1(12)1#1#5#2/)1)1+4/!1/*n%9/#10101+H&11!1//1!602)1*1/401/1#2%1%4/!101/#1/01/1&14)4/!2#1#1$	ec`RH@@HBCN`LdRbtRbTRRRrNbVABa`QVSRvuKTpPA@QUUA@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S(S~.hxhS~S~xi.ixi.>S~.ix>~S55c{q5S(S(xiq5+Cx>55x=S~S(xhxi.ixix>x=S~S~xhxhx>x>	:UvzvzTzSzxQT9QEUTGvdvQaEmmgWJC@Ix6Ef05OPwjaFYeJpN1tXDwGT4en3FAW5LXXCk51180F08XG!c0F	0RZ!aJ0Tk02OF1v!9J0Eo!_F0zF03Xk2U0DF!t!bk3Z!Fh0440FV1D!G_07N0Tk3F!SK05V0SV1v09!bk3Z$ #m0W0RV8V782B1m0VVRV8N78271m0WFRV8N78261m0WFGVko6F60YIF8gN296BVZlV94N2DBVY388ZJNBBWYY9Z8L@B19alVkBTB16Y0GFk4FDOBW339Z8H8B6C0m0k4RB162aFHNk4XBBW3Y88kKBB61YWWc8L@B66ZkW0N2@5BVYaF8km2@3m0XkI9_@B452ElVFkm2936EkWGZ4D6OBY0lXJ4J9A146FFkLF4B3Z130t0FsDF4H3Z160t0G0DF4L2B630mdgNB623llXNN6KC30X8d_yB381t0GFDF4B3Z180t0GNDF4J2Q1@Y0HNkN4D60Y1V8cN277BV_GV9Bm2E60Y388cKa2EBVYGV8cN284m0Z0F	!2n3V!3c8!4VQ!10VV!W1$cD#@UF!8uN!4ZS#4JV#Pk#4_#O2F!3ON!@2@!2f8V	#21$11/*25#3(101%8&1/$101*@$601!6$2-102)1!1+1/#1%2/01(1+1/08,1/)1$20101)1#1&111/%1/$5//!1%105/(1/201$18@!1202/0101!1*1!2022!2$2!82.1-1//!4$11/11!2%1//.1!104*9//*6102)1(B#1&2%2/$2,1/&1/$z01#5&1+2+6#K+1-1*2/0237/%1&9)1/*3!1(1$1%1$1%1$1$1/!103%611%41)1#1+12#1)	eeWRDF@OJdYTk`IABPpdCIBrP\dLbdLRTVdUbbtTTTLrfRRvpdgRvsvKMOMT@EUUMSUTp@@EdA@TP@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
5qH))H\}6szdhxO~x>xiS(x>x>S(xix>SutDxhofHq=x}_|G)H|G}_H)5q)H)H5q	<v>vzyzEztrzoU7qywKzjYwahUIzb9mH3vlt7nM_EuUXE4qzpFLsGBmG0h_7qbYjJDc8S3ob40W8FV	0aJ0Tk02J03d!9J0Eo016J0R01q07g01740ik2w0CF01HZ0CF110480ek05@F1305c0Lk3l# $1Z12Vt0Gc8dwG5X41BV8V6PM261O0Fs8gy4EA0YIkN8J@8C1lcVJB50kGFkf8251m0X0RV8V5HV@WG1FaF4R3Z130_OsFo@PM231O0G09oHF3811WsBNCCAW2VWNgk@7WFNsoN1251FNFRh@526_0GP4@465	#jVk!3U4!60F!23YV!X2J!1C@#7M#N34#Z3!2OF$@o#V5!2lXV!91s!27o!2WOV	$3)1.1(@.1!1015/$1/11(6$2#3!14(1//.10101%501!4$1/-1/,1)2*1&2*101+1&1,1!1#3&1%1&4*11.1+11$2+11$1/(440101/!1/1/2/&6#1/01!1+1#1%2&1#1//201#1!3/(10101&1!6&4,3(1+3!2!1!102)6+1#1!1///1*2#1#4#1$s%5-101!1$1*F$1%1!2/%2/1102$2/(4%12#1+203&111-1/+1/&2!1%301%5$1/%11(1$	ehZZDL@JFNAA`j`IABPpdLbdLRabRfTRVfbRaRxDl\JjVv~Ajfj@Bfjjj@AJ@@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
I))Iu8@,S(xif,(S18x=x>63F|`*xi`**`lv}I6363S~.>:v`*`*.h.i63.>	:Uvzvv:RjytqfUEx8tqQQcaCIUhY48wIxeE4mZ8Tpt6Fqf6vI0tZ6xyPZfrMv3d51AW8VK9901N3J0O4V0FV	0qJ0Q01v!C_06k0Tk03OF1r07k!t!c03Z!DF0@40t!5NF1r07c0U03I!Og07g0Z02V0B40t# 0BikWO04H7Z13VeJ8Fcm283m0VVIAg8NF14Wt0G08XN84231BV8F6N2C80Xl08RBW44211VaF4D2vBZ0l0TF4B3Z130X13kFF54Xt0FV9_2O3740GVaF4L3Z130X7W0F8F40YWRV8k4	#Y_V!388!8V#127V!gX#4gD#c5F!2dc!64N!23F$2k#JZ#tWF!OMw!20D!21wV	$1&1%1!1/4!11-1/&1!2/(B$2$2*2#101(1#1/1,1#10102/$1&12&1//01///1//#2*2)2(3#2&3/02!1$21%2)1,1/202$1&1!2!1/1&1$2/(1!3//)5!2///,4/!3+410@//02/.@%2$2!1/1(1///)s4$9/#2$2!202$N01)111!1#1#1*1//!2.7%1%1!1)2%1&1,1/)2/#1/2!14+1(1*1#2%	eobRD@@DICA`LdfVYeUv[Yu_xdt|BJZFVnN^Z`jAhiXB@@```HH@@					antagonist	CCK-A	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
W~0lzd,BW~v:O(0lxh,B,Bx>O(0l,dxhS(,B)J63J}x>x>J).h,dpsS((O36W~~O>x3pdz\}	^jzjyzvjjhjrznwzpfAzSwo_7wcr_3m6jokEqSv5QMpWzYR8LV2IdX0kh9yg0X4A89d@3k2F6X0Gk	0QF!UR!Xs0FF02OF1v!8j0D#Xw0s!2Fk3V!DA0@F0t!4Ak0t0D!wF05P01e07B0Sk3F!KU07B0Sk2x0CN% 01Z120sVFFN9Fd91X0uso8H5Z130XJtBaB55VVG8lKw61Wk8kRNLD7cXN842844Hm0ZB8666W0cgPL31kkBgJ20W1nJ@sc663Ba3GVFF87iW0VXdRHD64V84VH113ZcL0ZH864ID0kNVBeMD5V8FNFCZ110X3104CAWGlVR24993CYFsF89Z120dWFcu7134VF9022D8HXllwFV21710GVkFR76XW0cDA3WFN4oVPb@cVlN8848510VV88422GsFF72W10B8110k85NNg7620FJVD3WkcFJNH10YnFV4L711lcgD54WFcB6418YoHZN8L@14Wt0G8@GX64X4108JR6Cc0XW0d4gN8X0F821@7_14@4e8580FGkkgqLBX0kl4N22R4VFk4Fi8652kZ2610F9FkyiC26WO0GF8ZcLD3G0koQ824120kkgJ323Wl0D5B60VG9cO2I32G0RJFB0VXXFNVkF3Vm8s412_XmlQ48J6G11l08V281I0VsoU8271m0WFOOZ8P4C15pkG8Fgsc3W0kBRPDCMcVkVkFoLKWFVcoJB42AVZXF491340F8oZlB2213A0Fo8	#E1k!S0Z!6@B!1Oc#VD4!5d4!12qV!ke8!41B#@cF!4ms!4XB#ON#V5N!D6Z!218V	$2-1/#G/!3/&1%2(3!1(6!108$3$1#1$2///&2!101/)1%3//)1.4)3*1,1!2#2//(1)1.1)1102+1&1$14/!1#3&201#1%1-5#3&11!1#16#12!1$2$1*1-1/&2*11&221/1-1/!4#4#51(1!2!4!101!2&1$1/&2!2$1)6!1!1301#1-101*11(4!11!1(1&1-12$z%5)2)201-B!1*1.1&2)6042$12/+104/*1&4#3&1#101!1/&1,1+1.6*2+1!1$1*	ejYVF@@DNAKOL`JE`\R\bbTTrRTRbRbRabrRert\rJzNn^~aZfBBbBjBjJjjDhbjcZcxbD`@					not given in publication	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(xh.>x>x>.hS(xi|`.>S~|Fl0.h.h~SS~qqg-.hy?}Z	;xqpSpdo5w7J9AUB8oV8HV08FF80h2BLl23A!FAo843FV0XR08VVp0N8cWGF1W10V_80K1VZ0FH#1Y0lV	0b!vV03PV2b0C#t!cF3Z!G_07!Tk3i!GY06F0T03p!Kl07B0j02x0Bs01q80PV1n07N0dk3D0C$ 38241m0XkRV8R44c290XGc@755YYnFGJ4F94kVcsR8F@Wb0Nw88C0WXWDF4B3Z150t0H89Rca522G88RM8221m0WFRV8k4HA@W1s889@12WOICX4724cFXc8aH5W0VkkWB42B3FlNP2133X11BT6U23V8cX91Y_2gV8B4iJG20kcgH2965XHcOJ8G290G1B@2132mk	#rVk!G2#21G!2Ne#k1#3cB#14V!kdV!84d!2F4V!4Pk!1@5#p$Ocs$5!2AAV	+1/+5/!1&2*1*1*2.1$1*1!1!1//&10404(9/.2,1//.2(1#2*1*102+2,101!1$4%1!1/$1#31!1/1)1)1+1&1!2&1#1#3010201)2&2-103&1//)2(1&2!2#5%1)1%11%1301,5.1(3/$6/.1(1/(41$1/&1#201/$102//#10h%2-1$1#21*8/01(1!1*202%1/+2011%8/$1$1%1011/01,1+102/&1.6(1(11/#1#	fmoY`@DTejpPMFdrrjrvkoJrLFNZsVuSMU@hQMUB@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=S~S~.>x>.hxhS~.ixi.>x>.h.>.h.>S(.h.>.>.i	;QvArQUSvYQDOI23MPt@hHTLXXZoFDN9BO2oH3W0NX8F3B8801#806L3P02224XGFI08HA#80XX02010	0aJ0Tk02R03i!Be0440IV04OF1k07g0vV05@V110480IV2d& $oN11kgV8B5Vo23W6LNFck283m0VkI3B8JO141W22ciD55XVmNkqG3WVc421A65VWOp0D31F90gV29541t0F@2ZZFNB46C0VXIF	%V/%4#19+3*8F$2k$4#G%5s!2$210V	/(1.G/!1!6//)12$9$1+1&1///(1%1/(2&2,1/3/%2&1$2/%102/1//1/(1/#5/#4/&3-2)51!11/%1$1.1/!2%1&3/)1.2/+1/.1/07&2+1*1(1$2!1&2&6,201///-1$1,10o%6(4/+H//%2)6)1!1/#1//!1&23/#1/.2/#3%4%103/04(2-	fmoa@@@`rJIJFQRIIWIJIJcGA}FZx@Jjjjj`@JD\HDP@					antagonist	Opioid delta/m?/kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
o272,fxi.<x>S~.ixiS(xh.>S~S~x>x=.h.hS(S~.>.i.=S(.i.=.=S(.i.i.>.>.h	:UvvfzQrSyIODHT0IJAQf7mP0VV_0F0FdG80FG80F1V09W2Z!V046N8F&X4$8Bc802020V21W0kF	0PF!Xo0FF02OF1w!C_07R0U!3OF1v07k!qc0dk3F!B90Cc0xV06P01e07R0U02b0C% $10W1t0RA4XGN8430VIl9yF44211XWcNTB3WVsNB2172k848FV122GO4L94WFkF@320IlV44JWZ13VVksVJE2WGNZD41WkF84VBFm0W0FNgFC82G8cF51131k44JQZ130Vkl8L76Z0V8622108B2VCF0VF8V@A3X1kVF43WFV4620dXk88_I828110FkBB34Y10cF421ksB410VF@cdM824111VVoL85W0VRD4210Wt02226VFGHGcRSD0lG8ex8D121l2@Va62308sVRwn26Y0sFcFFS77VVk4DA74VHtJZ@4WkG8Zb825133Hl8T950kO8Zb82617XnFZH88VH1c42334_t0G8884k543GVcX44WFNF8NA0VXF88RyiA11WFk	#70F!80V!2Z$H8#V4#15%Zk$8$N#1VF!4Nk!8aJ$3$lk!@14#50V	*1/,B$1/&3/)3&1&@$4$2//,1+1//01/02)101/,1/)11%1/02.4/!1)1$1(101*2&1!1!32!1A//+1(1#101/(2-2!2$2!7,1$1!1!1.1#1$1!3(302*1#1/)1+1$1#12-101*11/$1!3#1//!501%102#2/11/1!1!1/(2)2%z!1#2/!1&10201#N*4*31/(1!2!1!1)1/02$1$1#3%702-23.31///*1(5$1+5*6,2	edVZDH@LFaichD@@cIIBheDhhlmiThdhlehxEddUm\CBmPPE@TUPA@@D@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~x>S(.h.hxhS(S~.>.h.>.h.>.h.>.h.>S~.h.hS~.h,BO~6s)\	<bYyO9e4I5F3iFOk9XOFm1VF0C3920HHV51!3WF861WV0@1VB6KLdGc098HFc902B4820V24J2!4JY0GV	0b!vV02YF3r!Bh0440IV03OF1k07g01740ik2w0C401K40OF1k07g0vV0 0cNa6R2WW988113184cX117b1GsoDF430VBN5A65t0G0CBF9341VXV8H75GVFcZR75VFFB2210IHPF8c241lNgH95VVF843E8bt0Fk90V4X20VYsRR92WFFZ4210F9W50@C6VFsoHD21FVR8PFCd4VVVLF462125kcB4B4409GV4710kVFNX1178WFI9NLB5YF8BF530mld_VN482m0WFF	#e0k!3F%4#42#X1#282$F$W8!80F!2F%2o$5#GVF$s!246!25FV	(1*1*1(A1,2#1/-1.2%2#6$1/01/,3-1(301!1//&1(1/$102-4,1/2*2+1%2#3!2$12#1%1,2%2%2!2.4/!21/&7$101//%1*24/01/#1*3/2%1)2%125+1,1/1/-2!A04!1#1/!1*202%1#2*B//2/&2+2/-q!2#201/%1!4$21B//%6*4/+1&1!3&1*3&2(1*4(2/,1/01/!402//)	eohRB@@Mckg`NGLlbbbTRferRRTRVTRdLFfn^ZB`hjjh@JVB@@@					not given in publication	mGluR2 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(tmt8}IO(}\xhe,zB.>i..hxhx>.hS(xhS(.>.>S(.>.hS(.>.>S(	:Uvvv;S:vyvUUzRmUvvzyErjhYTSDzUXEbmCQQjjZOIfLrp1vZ8g9LoYrMxE1E19bcJMW18EO3Rdl41!k	0WR0Tk03RF2w0CN011R0OF1q07g013!FF120@!1680OF1e0C!10F0Ik3O0EN0 02OFB0XGHVgs4VL171O0G0A04Lo14WB4skBX6kP12VaWc8HL13Wt0GsDF4D3Z140_YFFpc2A3N0_Z988a6kP13FgV8B782B1	!1zDk!184!2Zs!10DF!V2#CWC!20rF!60F#S8!2GkF!4@k!9Xy#11#1Yk!2GZ#E1V	012$20101/*81/01/)4%1!3.411!8!10201//(1&11!11!202(2$12/0201#2%1(3(201&2/)1,2(1/231/$2(1!1)8//3/$4.1!11/31*11&1%1!201%2$1%2$202!1.1%1%2//!103#2$1/(1$1%1%1$1-1%1,104/&1/%10201#1)6!2//)1$1*1!1,6/#r2$3(2-103!1!2#D/.1/&1!1!1/#1%2!1)1-1(4/32*1&102/02,1!1*7%1#1/05#1#1$	ehZ^DD@AIG@lechd`H`pHrJIJYJJJIRFVIGJIJacRqpJY[xF@BjjYVjjh@Bh@@@					antagonist	V1A	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~x>.iS(S~S(55i.xi.ix>S~.>S~.h.iS(.>.=.iS(.=.i.=S(.i.==xhx.iS~.=.iS(.=.>S(	;vzvvzxsiwlqfiUxPGLQHuY99zhYC2c3nrC4Hg1G_s69ZWD332paKz5NZVW2c0VK1X07cVl!7J!kK4WNFF	0dR0ak03Xk2W0DF!t!cF3Z!C_07g0zF04N01X07g0o!4OF1k07g0zF051V0Z0DR0xV3x# 3KT4720W0sgL95XGNBD210kFF41H49320GNiC29XI08BTDaI5kl0TF4H2C8531BBBA61YGO0RB31GNF81B567VHWCP6382O0Fk90ij6X2G0WFcL52l0FVLFN5kFm0Q1c4A26C4VNRE8261541sgL650ksJ8LBA4aWAVFa9Z15VcolcBL7Z12Vh60FF8	#j3k!F@#10F!1FV#V8#4VN$9k#f8!4_8!20FV!V2k$Z#_$11k!61$1QV	&1#2/!3!1#34/!1!4*2$1.30103*5*4,1//*2,1%1)1/%2&1/-4%1%20101,2/(12//+1/$2#103%1!1%4,21+3&1*5&2%1(2/2#11$1%5#1012,1044(1-1,1%14/$1103-1/+1/.9!2#2//!50241/0C02/01$1$1$1$1#2+10703/-4010x%3(1$11#2+4#G/02!41/*1(1$1%402#4*4!1$2)1/01*2$2/!1.201/$253&4!1+11#1/!140	efYRJF@NmlRXDLIo`@abPxdAICRPJdLddJdTlTraRaRTtbLtRSgfUQuqMJuUAD@AESUS@@D@@@					antagonist / inverse agonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(R=x>.(R(R>.(R=x>.(R(R>.(R>.(Ri.>.>.)Ji.O(73	vzUvvvUtrJxlQRAQHA0k39eVa4HHCV@8BQS039X12Ale41F202N9@!RNJFfWJF3WA21Vc0401!G101V01!V	0WR0Tk03FV2d0A4011R0OF1g07g01L80OF1r07g0nV05NF1Z07R0j03D# %O0FV8KFJ730sl42277DboVBFT1142l28sBL114XKGkFV2263m0XFI28D@@0lXV44HDIA_o8WB22A5m0VkRV8k4	#35V!384)F2#Z2#Bc8!205F$V!408!2G0k#FV!84V#1V#1Pk!215#1@V	02$101.1-5*1&3/)2/.3//&1/)11)9/!1$2%2.1)2*1!3203/-3$1*1$1!1/&2301!102$1$1/1+1-1-12!1,2*1$1///$2012)1,1%2//%1/%4-2!3//1%1#101,104$2/#1/)1!1)3///%2//,d%2-1(201!1!1#8$4+2/(4)1/01/03-1/%5//&1/(1102+1$4/,4-	fnkHB@NFcdDPdrnrnlk[QfcIKUl@EUUMMJU@@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
qq}HH}qq^)qq}HH}36H}W()\,Bx>>.xix>S(xix>x>xhS(|`|Fl0~Sl0lv|`|F	<v<x;qtUQz1yUv@mX0IUgnh8yIU@1BF50QWuBnRY4YQ4BgWo3k4eWHF9W520W08F09VoF20FF_W8kV	0PF!qJ0Tk3x!Fi0440FV2d!Gc0@R0nV3F!GY06F0T03p!KK0740j02x0Bs01KJ0P02b0Bs0o# $38241m0XkRV8R78211m0WFRV8k5Hk21XVk8VFLpB1l1cJ4L@QKYW882378YWpWgV2550kG0k4HE65GVVBB0VV9VVkF4912G4B@21F882P@C5VW88g953W04D20VFGswwF513HcwR@0X09Nc428BkVXFF48B7Z12Vt0G8DF4V3Z13VbL9NB@6V171XOVP31Y1lk	#b1k#8#20J$@#V1#1VB$1V!kAV!4V8!2FFF!4Pk!1m4#W$KOV#N4#1AV	01-2.1$109+1//1+2/013///-1!401(9.101,2&2//1(11)2(1!1!1-2/.1101/,222)1#3)2(6&1!1)1/#2#4!1,5#3/)1$1$1)1)1!5+2&101#1.2%14-7!2/1%1%5//,1/&2(2&1!404&101)8#112$4$12*1.2%2!1#2(1/*10o$1.1$2!221*4//+4%2&2$1!1-1%6*1&1#2!1%3!32/1/-1-1,3(8)11#1,1-	e`RQHL@I@dlfnaic`ICbPTdLbbbTRLtVrbRbVrbS@egeSTrswtADUUURuMTtTlFa@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~x=.ixixiS(S~|FS~x=x>3pxilv|`S(dzJ}~S>xlvl0|F|`	>UzrlrxUqvAECBaL9@dgAHKCVo56Mp0CEV58@aRZYHVLYy0uVXKNk0c5Kk5WW10_84J10V0F2!8VW0FV	0aJ0Q!3YV2Z0DF016B0O01s0EJ01M40Rk2w0Ao0nV05P01n07k0nV3F!OH0640Rk1w0Ak0p! #1Z12Vt0G0DF483Z170t0GNDF4D2gR12kgV8R4i29aVWkXs92P2C2DZ60O0B2D4HVYbs8k8T2FL240NgFT2M7VZZc9102D4m0WkF	#aVF#4V!21J!1TP#ZY#6VB#VZ#tf$58!2NFF!ZPV!1m$Vk#FHo!4OZ#1AV	+1*2,1!3+1)3#1#102#1/%1)6$3$1+1.1011-1+1403!1$@1$1/&1$1$1#1#1/.1/101#1&1/%2/#1,2$4*2(1101#3/!1/1/,1&1(3#2.1)1!1&2*1/2//%2&4///5)1/#1.2//-2(11(11$1$1$1+1(2+2&1301/01*1#10i%3-3#1211022*@+21.1-2#401!1/+1%9%1/#1%1/$1/&101+1/010101%802.11#1.11!	ec`QD@@DLFNMODb`AlbbRbbTRTRVRNfQ`SfTRQURvsULEPLiMSTT`@@					antagonist	A1 / A2A / A2B / A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
sp}JO~hxzdS~.>S~.i.h.ixi.>S~S~.ixh.>S~.i.hS~.>.h.i.>	:UvzvzyzS:vy9zEjUtffghrPvbgbJ8jzwI3hH5c@rnZlR_DE411BDwVMLY31@@0K22kI0GFQ4O8!VXBW0F0	0aJ0Tk02OF1v!C10480eF03Xk2X0DF012s0FF1407g018g0cV3!DF$ $LVYFlNTF442LD@G8VcI8251AHVVNNBr922W83VZH422FW0cY82416dHNo8@C4VXkV8ZT@2B4ZVVNRI8281OZWcZH@B5m0XVO88Zq272R0_1k98R4210VcgR	#80V!3*240V$V!18@$2$Y$F1#dF#FAk!855#O4#858!2$250V	*2/,C/%2/.1/B$2$2$2///+1$1$6////#3,3)1//)2-2&6$3*1/&2/1#2!1!1-1/*11#1&1(3%1-11$1$1//!2/(101&2,1&22,2/#2$1//$8#1%1%3/+2!1%1(6///#1//01)3!m#109%1*1&1!1!4#H//$2!1!1/-1-3$1/01$2%12!1///!2#1,1,3*1.103-	fmq@@DDlAIekUgU{VuIQUoQjvZvjjhHHj`@Xb@R@@						ORL1 / Opioid m?	Orphanin , Nociceptin ORL / Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~.i.h.>S~.iS(.>x=.=S(.iS(.=.>.>x>.iS(x=.=xiS(.ix=x>S(	zyUvTntldN4kVJ9D0s0GVOHH040G8W!c0l21!V1Fk820_!@101Z4k4N0V0220V14324041)5V8kF	0aJ0Tk02Q02q!Bp0440IV03OF1r07k!t!cF3Z!C_07g0zF07Q01q07R0Tk1w0AN0o& #m0X0RV8N782C1m0WFPO48N5Z140YMOc48940b2ONa@67YCn9FB8687dnVcJJAZ11Vt0FsDF4@3Z140XZ9kTD542YXQw88A43Wml8FN73Z1o08a82726cVFp4465Y8s8FN86@3bHlg4D97	#Y0V!588!2XA!106#V1F!28@$5F!4YB#4B#1%2s#44#l$1Fs!206!211V	&1%1/#2$5/1//)1+B01!1$1*2/////+2%1(3#101//&1&11$2%1+1$201)1(1.301$4/$2/&20301/1/(4%11&1!2*1/*11%303+4+11+1/%2!2#1)1$1!1$2-1/01/021-71/#11(2*1!2(1)A%2/&1/01$1/%2$1/r%6(4*1#1!131%Q*2/)12*301%1-2!2+2/0103/*1%21///*1(3/%1-11$	egh\HH@AMLd`ICHhdiieELdhchhdmQpYYDT]]@D@PDCEPP@AATP@@					antagonist	NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~x>.hxhxhS~.>x>x>xhS~x>xhx>xhS(x>x=S(x=xix=xix=xix=xiS(x=x>S(	zxzpb_zS9m4U5K2iTOV1X84P1V01_@920Hm049X03Wk9L0WW080V52F490990EmFc8106ZV64V20F!508a0I0	0aJ0Tk03OF1g07g!qJ0R01v!DA0@F0t!3ZF3a0Dc!t40tV3e! $O0Fk8wk4ATVXFwV8k4J9IVFVd86@@VW1d8OV4MD4FXFYN4Li141O0FkDF4B3Z130hVH@BL4B30WH0JGF22VksR6831FNBB211F842ZK0VZk891V@K2L0FkF@72VVsFF620Vc882GBVFHuVsL4U22mNg@421FNRccNIC10NsL6510GFocRA2HVVFZF54XGN8Zq@1160F446JF	#80V*V!14$42#6d2$K$Y#B4F)82o$5#GV$7s!246!2_0V	//(E1/02-2//$6!2&3/0101&1//,1-1!1//01/,2(1,6.11&1/%2(1$9&1//01.7/!47/1%2$803/)1/$1116(6/!1/$2/#2!2/05/01//+1+1!C$20102/+1&2!1.@$3%1+1&2/+6$6//z!2!51/01101#1&10N)1//%6)101&1)2)8/*1(3$1!4#2%1/,1//$1/#1#11/0	elZXF@@C@DIEGNlbfbbTRjfRbRrRRRbRDtjZaQZBAbfh@Jjh@@@@@					agonist	S1P (EDG1)	S1P )Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.h.h.>.h.>S(.h.>>xqq.h(Shx.>>x>xS(.hhx.>S~>x.h.ihx.>S~.h.i.ixi.>	>U:laxYTuiUxTmmxXzaBBp5WzLh7Yr51X83GFNVf7VD75YZ_OjB0dGWEWR0u_WaW2ZpVB21Nkr10Y0G0	0Pg!XF0IV025k1v!8s0D#_!uF02R03i!C_07!Tk03Xk2Z0DF011R0OF1g07g010J0IF3Q0EN01LJ0Q01k07g0vV! 06F4D29315XNZF5@YVVBVPJ752lsgDA1VkV8@1110H0g229G7VZ60Vo3452VF94TE4Z18RBJB10FW9aF4D2F193FHgLD55Y0l0kLA44G0g431VV9kZtTp26WAqcFRA8231DH0VsFZB4OAWVXkVF8720cBRRLE19g0H0Vu4C480_Gc98X2FIYVWccRF4M31kXVoyH2W1Gl8FL942G8FH92WFNF6110V@Fd8JOGa0kd0JSL26WO0Fk8c@4P50VXtRiI11GGtDF4D2LR_FlFNNNEG_l0koNLNVWXFnF8pRQ251t0GF8gRKC5kVksN871XmFdRTG720Nd0c48331ks@634_VF86610VN821@5dt0FNDF4J2Ba30m0NZB4S5ZkYFVH@6XWHFB4VJ@B93kWFF666Z4O8FDF7122llF@@56YHNNeF1XX1O6F4L3Z120t0Fk88FLB@lGciF4N27iW20cls8R4W15FkG0FNsQ28FFkcPy525WO0FcDF4D2W17FkGNKcJ4B2LD0VcJ944E2m0VkF	#15k#84#44!1%42#Bc8!215F!FWV!4V$10F!V@Z!80h#GX#O2s!214!218V	&2//6/!3!3//4)1*2$3/1(101#1)201/&15!1!1/!2%2#1#1,2/11$1%3&3,4/01/02,2$2!2!7/%101////$1&72%1/1(1%2%2(106#21,12!2#2!2$2+3/#2(1%2(2+3/1#2#2*101$22.C/02#3*101&1*1)A%101!1/#2////!x%2(1*2012,L$1*1,1&2)2!1%1%2&1-22!1/$20201$2014.2,104%1)1-42,1#203/,1#2!2%	ebV\FD@NMKiBi`XTPHcxHrJIKISRISIJHqIIPiRTLYM[OP@TuTDE@PTTl@`hQEP@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
s6.>B,xh.i\)x>S~.>63S(xh.h.i/jH)S~x>.>28(Qxhxhx>	zpzpr_OJlk4R5F0@DN0_282c01F080Z04Hl018280FV843VV0X809VZJ0F095GF0V1021!440V0F2!80V0Fk	0t!d03Z!GX06J0Tk3F!GX06J0Tk3F!GY06F0T03p!JL06Z0SF1u0Bo% !O0FsDF4F3Z140t0GVA84am18WO0HVDF4B2m16gVGNI9Z4C2m0WVF	!2I0F!W2V!22#1NB#V38!11A$F#sY#22@!1FW#4HV#m&F!GdF!6X$INV	04*1/*3/!1//,1%6*1/+1#1/&4014*6-1/&2/(1/%1$1101+1/!1011/$1//%2)2!1//+1%4/#1!1$2$1010101/#2+2+1/&3/01#1&6!2#4///6/&1&2-4(2/1/!12(1#103!4/-1//%2!1/(10f%6.1#1+8#D/*1/2/)1302(1%6!1/&1&1/01&1/02//+4!3/&2/	figHb@LDrOW`AFRJJYQJIJZKIJxX{IZ}GSSALD`TAB@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
{cq5S~H)x=S~.=ojq-.ixi.iL}{CC+~Y.>ununn1.i{C.>.i.>S~.i.hS~	~zvjbzyzfvCzwjzrooSzEhULazrwXnadHDgiKLAYRe_DELrH4giIJ3lk3GZHC_FV1GVV%	0Z40IV02OF1g!9_07g!sg0c03Z!GF08k0tV3c!Nc02o0FF1204s0eF0 $lB22W90Fw04@5Z140d60c82542X5sZs22VGlVsV6MBbGGcN4L614Yt0G8AKT462V90VkGOu439YFH0Z44J9C11kq3F8L5Z120VWsFBZDBWFFVoDO254XIFFe2283	#c0V-1%4@#54V$LF!FW$Z$8F$@k$4#G8F!83c!844!218V	//(C/!1!1//%2!2%B$6$2/*1-2/)1///1//01-1(1!2,1//-1+4(2%1*111,2/(3+3*5&21.1/%1!402$3%21203%1)2!4!2/3!2-2$1.1//%3(1+101*1#6//-4(1(43.1+2(1$3///(r%@/(1+L//01&2%6+2/+4/)12)4/#1///02%101%2103/)2+10	eg`TL@@JH`DOLbbTfbbTTQVRNTRQdVSQusUUUPMAQP@PHXTLT@@					agonist	ORL1 / Opioid m? / kappa	Orphanin , Nociceptin ORL / Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}Kb{.iS(.=x>.>.iS(S(S(.>.>.=S(S(.>.=.iS(.i.>.=.h.i.>.=S(.i.i.>.=.h.i.>S~.i.iS~.i	]nqUUaX@yKBlqC6dVVV0_0t6D7k043X82GkFVAVV416F56LJ888F05VFV810JV0Bc0622FVG0VY0G0	0Pg!Z40IV02Ak3V!9k0Ds!qJ0Q01v!C_06k0Tk03OF1k0Ds!kZ0qk3q!HD0@40d03Z# %O0Gk888431VNV8341W8R6720VF8220V_ls44Pk11F1lNgRB63FsB4JK0VVWk84NRb6fklkTF4D251521R8E3VXH0F4P115_t0FsDF4D2112FcJHC5WkVg851VVF94X10W3ZlKc8H421WFNV@52VkcBD83VkkR222VVHlB21280FGn845624XGW8JA5WkWGV41270VGWqF462514GdN@B4XHHNF24D0VY3088D72WksZR64WkcJ@218_0848Xa13XGksJ8410VZ62C8VVFFs22BF392NBD72X0cBcRKO15XVG844D6i6XGcVJ174YVVdFLEB10FF830a3VN8kqm2D50Y088cBFj9Y1884D8720W8wsB510FF840VIX1k4220VVF8B610VcV2541kc44220Vc5Zk410FmV4410X3c0NZLB7YFsVD710kGd842DD20l@NLF20G884LBA10Va8F422VVV4851110J@4110V88210VV8410i508826EW10FFJ@33WkkNH52VkFJD51VVF422N90FH084NoI4XY0V876Z40FB8PJv4WGskJP@ECWmtFFB@6WVXZ88R86X58VNR468643YN4uF6Y3GZJ88@4110FsFH52Xl8R@43W0VB410VVPl1N	%k!1$24V#4F#Z@#79X#1o#FW8#_F#80F#@o!80C#On#87s!254!258V	/01/%K1/02!1%3#2/01!3%22&4$21#3/01)101,201/01$101/#1)2#1!2$1$2!1(1/,3,5/1#1!2*1$1$3-B11$2#1+1*21-3$A/!12/!2#4&1-2/02/0601!13/$4/$4$1,1#11%2!32$2.301%1+1/&22+1!D1(2#1&2(1/01&2!1#8%101#1,2%2211/-1.101#1%10z%2/!1301%11101!N01/1)1/&1/)1$1#2!1&1.1!1$133.1&1)1//212,10402/*2-	ei]RFH@L@jfhDBcoaP@cIIBhhddmddhlddhldeLemGKOF^Uj@@@Jijjjjh@HBAX`@					Agonist	Adrenergic beta 1 / 2 / 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
ShA]e]SheIA]e]e]ShgMSheIe]_dgYe]S>T~eIeIAIOgS>Daab?UAIIeS>A]AIA]	}yzvjjh;nx:jUzxopU7xezbIqRiMojqQvbMrxmxeCDzZHIWcDF_9TZ0q4AC_d@bk2GaX0Gk	0Z80IV02OF1v!8j0D#Xw0s!3Xk2W0DF018s0cF2Z0DF012w0DF3V0E401L!PV1n07R0o!5Mk1n07R0jF3L# !1Z120t0Fs9y@492Z0XIV8RA8271@C2FcFR84k12k_V8s8o25WoXFFJ8BP3CG8d4JZwA1WVm9BuV1XWlRV884aZB3VkcoKsc241GIsFZ8oND5G1FaF442WCc0cFJT@rLW1FgV8F4s2K0XnscJ2670FGNR4FHAE2ZFW042D1VXW88VRPE13mFgP38@VVHN44X22W3Y2XFVE44Y0FscJ665Z1ss891109WJ4310G2208H942m90F720F84oX21W3V88l08752HNsJA20VGOJ220VVFcx18K4a18ckJ2K3VXW8FDD53FWO9y2434WXGFVcB51l0g6JF@IjFVVFdaQ622l0Iou844210N88862l8VJ61VkV843194k895B	#D1k!S44!28B#Ss#VD4!5_Z!12LV!kf#45B#@NF!4ik!BXB#OR#c7N!B6Z!218V	$1*12#1/09.2102-2+1#1)11(9$7$6$1,1//%1,2$1//2%1)1,1#1//2!1&1/,1%1%11,22(1#1*1!11*6(1,1%3/&4&2,102+1,1!1$5$2/$2!1//%12#1%1011%1/04%1/#1.512&1$26$2#2//0302/0251$1/%102#11%1/)1!1/)q2$5(1%1#301-C#2/1,101*60301/*1#1#4/&1!1(13-1%1+1$1#1)1/(2%712$10101&1!1.1#	ehR^J@@DLFEKOG`JicklbbRbRbRRaRTVTvTJtl\|JzFVZhHbFBBbjfhb@@@					agonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xhxiS(x>S~xhx>S(xhx>qqg-y?S~}ZxiS~x>xhxix>	;UvUzvU:3zynEXf5uzxhLsXb3h3mTx5BX1W3106GH0HS1Z96o0CPX80ZHN020F220J0880@6tD0V0J42V10	0RZ!WR0Tk02OF1v!8j0D!11R0OF1k07g012s0FF120@Z0 01kOk84VkVsgRay42FFcFJqt61110ZJ4HN3W1Vk88NL6X1VN@82VV84sL114bYWkNVV410N8ZDHE1@@Hcw@8E1VY1gV8B4qt6111NV44@5_0coF6320V82RD10Y3lGs8V@D408Vg8277m0WVJ@Rq6932Vk8kF9AXW0FF21W09scz8251	$6k!5F4$J#4%@#3dX!22k#k3$VF#8FF#@o$4#GV#85s!24#258V	)1/-@/!1/#1/.8$4/1!1///3%2012!13/02//.1/#1,2/1$3/01-1!1//(3&2)1*2)1/&122)1!2*1-1!21&1$2#1/!3/)1.1)1.1+1-1.2+1$2,1206/.2-2-1#7+1%2&2.1)21,1$1/1!1$j%503%1.1!4(F01-1/$2)601-1.1,1/$1)2!101/$1+1/-2.2)11)1&1#2)	fegPb@NNDXDQdTTRTNTrbbvbRYJNQs``xjjjh@BHZh@@					antagonist	CaSR	Calcium sensing receptor	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~S(xixiS(x=S~xix=S(xix=xi\)s6S~~Oxix>S~S(xixhS~	;UvUzvU:3zynEXf5uzxhLsXb3h3mTx5BX1W3106GH0HS1ZA7o0CPXc0ZHN020F220J0880@6tD0V0J42V10	0RZ!WR0Tk02Ak3V!9k0Ds011R0OF1k07g012s0FF120@Z016J0R01v0Ds% 03Fq48@VWVkFBND531sZD91VV9cg429D716VsF423XlwV8B4Bx65G0kV48C8418oF43WFF4oHP1A0l8ss530l1FNc_72W0FcFJip53W10VNX86XXOZ4F680VVksJ67Xl8ZH310F850LVD1@9mOF62570kGVyF46212Wm8gH96WW8N@10b2nXvJJD45X1FNFH783l8V85410GkcsPU282Y8w48A20WlwV8N4@533G0gDE5WW0B2P9CDAn0NZE8251	#V6k!5F4$J#4%@#3dX!22k#k3$VF#8FF#@o$4#GVF!85s!24#258V	#1$1/%1&@!1.2*2$1!2/02,6#14/1/!1//3%2!2!23/02//&1&1/#3+1/01$3/01-6!1/&1/3&3&2,2)1/#2!132/(1-1!11&1$3/&4+2)2!2)1.1.1/*1.2+1$2,1025/.1/*101#9+1%2&2.1)21,1/.k%3(1/&1#D01-1/$2$3%1,11/,1/$1)2!1/#3&2&1.1-2.2!1%11)1&1-	fmwQb@NND[hHcHhhdh\ieEEmEEfRcfZxHNJjjjB@HQjcq@@					antagonist	CaSR	Calcium sensing receptor	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=xiS(.iS(x=x=.=.=S(xiS(.=.iS(.=.=S(	:UvzfzSzSxzQRAQE7NF38uQL60X_V49@eh060X1G0FXV01X#WV!B8LJ3X5X2103W!F401%4X0V0FF	0sg0d03Z!GG06J0Q01v!Fk0440FV2d!GX06J0SV3F$ 1L711kV8t0M9XF8t422A83CJNF4@A5A@JNNs42@4W8084F@8MaW1VV	#20V!108$8)Z2#5c8$4F#VV!4Z8$F$2k$6#G1$7s!204!218V	01/+1)8,101/02#1//6$3$1/&1#1/+1#2/%1&1#1%4%1(3$1///1#3/)11/+3+1#4/*1//.3/2&1$1/02/$1!301/$1%1%2//!2/-1$3&1//$101,105$2$102//1#2#1)6+1+3/)11//)1$e#20501%4%2!1101%1&F///1)1/-2-1/%3///)2/+3.1,4(1$	fnsq@@DTRCHhdhhddijhdmNlFkVjB`hj@@`@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>xhxix>x>xhxiS(x>x=xhS(xix>x>x=xhxhx>x>xhS(xhx>S~xhxi|FS~lv|`	?tzyxIxwnUFv0rExuLsV3Ah1AugRzX110V3G1A6F_0W31c6ZMm9To@@PJFWA2064W40V@46H4Fk4V0FF	0PF!U4!Xw0IV025k1v!C_07!Tk03Z02W0DF!oV0R03d!Fi0440FV2d!NM0680OF1e07g0o# #VbkVNgBPLI_FVdJKif11XkwV8R5yZ230FFVPKRC10WGscx2a50WHF44R115YsV8FV2263m0W0IJJ8T4160FFsaF462IP41cVoF4G@4210J38@ZO0G888TOA5G0J2FH0VYHFlG475WG0VVLF1121VgDB5WkV86341FX0d0220VVkNB71WkNN@75WkcJ45J90V84BRiJC0l0gT4760WFFVZ2312VcR673WksRD631VFC8V10VVlXcN2MFW1NBJFE0WkWWFRTd51H8F2F8811WVoLE7W0VgB1B560FNN883X0VRJ732FsF2410F@VtFJb2761sFg6823Y0FNFD83XFkZLB31VV8420d3JVswJT53GWks4N1154O0FNDF4B2j@a0c8JF@494lNkTC1Vk9G0f8261BYX1RJ52VH1l6F4H2F6f1FFNB869DWVNRN254	#bZV!184!3$1FgV!cD8!5cd!2VpV#YF#4c!20kF!JHo!1eZ#1c#1js#JD#1MV	//#1#G//#201,1-3)5#11!1&1/.1+211/!101)1!1!2%201#1///%2#1(1)1$1#1/011&1(12#1$1%2/!2$22&2&2!3/!2/01%6$101+1,1/!1$4$1+1,2!2-1,1%2*1)1.1/&11-101013,1!5$41$2/1#1&23/%9!2!1/%1/$1#1/.3!2(w+4!24)2(1&@1$1-42&1&3/#4!101(2.21102)1#2&3(14%1+1*4(1.1/1#1(4*2#1+18&11$	edZRBH@BAEBiLghPHcHhddeEdhddleDXdiePpdU]|CC@ASUUUUU@DTQ@@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
t7to>x>.(Shxh.>x>.5q>.~S(S(Shx>.5q(S=x=.(S(S>.(S>.(S>.>xhx(S>x>xhx(S>x>xxh.>>x	]SxzvzuUSz8mrSezyE7O_WdTjEEXCXV93GFc0f7X03pWJW1iBatH7EWF0c51mV34_VB21GkLW0b0I0	0Pg!Z40IV02OF1g!8s0D#b!vV03Y03a0Dc012s0FF120A4010J0F03N0EN010J0IF3Q0EN01LJ0Q01k07g0vV0 01Z13VXm10aH2WVV4Zg318VFGtN4243Xl0oT93WkcJ2RM0VV8OB22G0VYonOFPV4620GFc4486YHO4LC1_3088cim721YFkNBPC7XVNVL82VFF44TK0VZo08B6543FkVHA320cB6318_k848aafRW1FXXZ86H0aG8NsQ8231PfkVsFRX86YXVJDFP1VFXsB4V116a7H0G4ZS2720GVc8493Z18VH64WkVN42EB0F8GC782716CZFNcCJK4Y0kF8189Z7q1B288444XVR8A62k8F2LK10ZIBV8c4o2@42k4@3881FGO84243Ykt0N@2XkF8oX310Fle6F4D3N611k_t88L3F1211csDM33WV4Va318WFGOHNeC7X0VksN434Yl0gX@5WFN422D@0FGds8674XG0ZH@4WFFJ42EA0kHV422389iJs8487452ptg8@D59_GFwLF30H1108484XkscJA61kk82RM0V_088h0278_2Vk87110N4kZN1AI08VVGP2@QVX0VWBeCK2XlMkJJJ1XZGNH8884c41kVRe610VGG0dP2DQVXkauo8@5216cVGNFcH_A1VkV2FF8	#41k$4#4#1&@#CgX#1KF!FW$W1#90F!V8k!80S#GH#N3s!8G4!218V	&2//G,1$3(1/1)7$1)4$53#5/1/&1-2$1(5%1/&201.1/&1%1%3&2,2/01&1%1!21/02/3+1-1/1!31/01&2*1$6&11%3/01%4)302$8$1014$1#12102#4!2!21$3&1//#1//&4!2%24!1#1&232+107$21)1$3*1(1%2$3)7%101201////#1/!z)1/1/D$5.2(1*22.1*1$1,3!2(1+1#1&4702/(10104/)1$42(2*4/#1(7#2!22#1	eaURAD@LDahXDMCMbZVP@cDHrRPqJIQIGKQIYISQISIRNAM]@hkUPSAEUUUPAEKDPKD@@					Agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>>.x>ix=x(Six>x=xhx>xhx>x~S(Shxp3ix=.=x~Szd}J(Sx>>.xh(Sx>>.xhS(x>x>S(	;vrnvpts4uYJAeT9@sX96WFFNGd092BMl64@2V29kN4GFW0c821ZFkFNB81GHFV810k20V1X28FF#VV8F0	0Z40IV02Kk1Q!9_07g!YB0jk03OF1k07g!sg0cF3Z!BZ0DZ0zF% 0ALkFw22C3m0WkOtB8H213WVFHHk4p372O0GF884MX14W2m0GRZ34XG2FVL54X3FF8cguV560Vd822D692HcsL@E@WVWVvoNK351VG0XcHk371t0FkDF4H3Z120j0H284R615WVVkoXG2X1FVB310YGWcdVR60WFccJHF6Zl8s85252HYPFcC22YWFVVTG9_0kN42@@_C1tgB8A4	!1B4V!I0N!8Ba#89V#FV#N2!1X2#8YB!2J$cJ#c3o#85#OkV!F5s!27N!2W0V	%2/1#102)E/%6//0201)10@$1#12/,1.2#1#1/6/(1/)1!1/03/#1,5//$1#1,1!1104/!1$1#1&101#11)204,102!14!2&401(15&1#1(201+2/%2&1/!1/01#2$1$1(2!1&101221#204-11/#101.2/$@#2//%3!2!2!1#1&5$21%1/!2//%1/+z01#5%2!1$5#102-H!1.1/,601!1&1,1012)8#1&1-11!1$11$4//$1//3!1$3/,1-	eb^\DL@HbnbL`IABPpdLbdJbRrTTTTRVvRRTrTbbUSWRNMU@ASTsLuUP@EDCQ@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>S(.ixixh.>x>x>.iS(S(xixh.>.=.=x>S(S(xiS(.>x>x=H))^S(xiS()^x=	?x:JQxoXyRtVpaN2HmVN9hAAVgMnXK9V03lk960_X02CVEX7JGHd81TlFcA126Zc650B4HH4J18V0FF	0TV!WR0Tk03JF1_07g!sg0d03Z!DF0@F0t!45k1_06k0Tk04AV110480ek05N01X06J0PV3F!SK05c0Q01v08g0d03Z& 1DX4G2D5KcNFL8223G8gJ75ZkVN42C56t0FkDF4N22H4YcR@3753t0GNDF4B2984FGVLC0WmG9DF4B3Z110q1VGB8gYFXF8ckM8281m0YFRV8Z4wu61_kkloFT0VlVR8H79m0YkRV9B78291m0XFGZJa6@357WW0i@E40YGgV8B78251m0XVRV9878251IEVWsGVZd821WBV8V782A1m0X0RV8V782A1	#MJk!T8o!24V!3H8V!qE#4gn!3@xk!sf8!12S!208F!6Xk!1X5#Qd#96s!C6L!3WBV	01*1#12$1#101#1#@!1.4!31(401/)1)3$1$3/2/1!1/011#1$1$12!1*11$121+2*1/-1%2!1&301$1,1)1)1,3#7/,2(1!2*1#1%1!1!1.1(2.7#2202/#3/02&10103$101.@/1-3-4/-1(1/(1$1%12$1+1!2//,11/!L!102#1!1/01%1,1-1%1/1%10z#104#1*1!1402-D!1/01$1/$54#1#8-2&1&7!3/&101&1*2&1+1&1&12//$5,1&1&1-	ejYZLH@AEGNgn@d`HaIfVWUfUWvuYevIKHbnk`_lXHFJhIPh``hjbB`vH@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
q5H)}^q5q5}^q5S(.>x>S(.ixiS~.>S~x>.h.ixiS(.>x>x>.hS(.>S~x>.hS(.hS(xhS~.>x>x>.iS(x==.hxS~.>.>	?Uzx;UAzUUUJvyvCrEerhYQCethqAbubsQufVJ0AIEG1Gd@8gEyYmLQf1L6902Jo13FG01BdV2$	0XZ0IV02CF1D!9204s!WR0Tk02FV2U!BM06J0Tk03OF1g07g!o80bk2l!DA09w0t!3Xk2U0DF014s0Xk2U0DF018w0bk3Z0DV$ $@82Xl8gJB2W1888217ZIwV8c42124lFBVP3XXWs84PLBG9Vm0RF4C531JlFe@6637VFFX826315VtFs60XkG8sZDHL51FcVJy90bYkcVM825122W8Ogk673k8oNc41959FvVBD6HA0Fm9sw4D5m0Y0RV8R4iC6XVksH4212WlF8P411X0N873_4FNgH422XnnGp6@4528kGR44F4H8XVldcu495H2VXWoo4D4m0WFFkcHA5YGFgP220I1taF4@27BhFlNRF4850_l1Rq740X1G0sH8923VcRX417Z33cVV95XVW0gVPF511cZNg932FFB@BEB0XksOgJ72B2FsgBc7190kFBL8C6VXnas916@26WckGw44L4Z192VH1c4NS15290NNBgS186VGkiF462P7X1k8L9322Gd8F6722W8ZH95WFVF6210ZHF44V_Z12VVWcgH66_VsZ82A7VVGWWJwI93GGkdx@E80GG8eBq4@A3kVsV4L450FsoH92VW0R@22VJGX88B64WlcsN93WFN8oX317VFGds4D84270cJ8C2X0NtF42H32k8NsB211XZVNZH48XFk8BH1X0OdB42GDR@FNNFBFF5Z2Fd4NE11YH5ekJ6B3h2VW0LF4B26C0lFWFLD28YWcBBNH13XktNH63410B4NEB33H0gFiA714Wko66A9LD0VcLF4@233W0skD@51ksR641W0P1K382E13bpkOJL528XW1csXI8VksN2JH@11W8FZ95XFscJ310IXdl4TC71G8gH21VXmGTF4J28A0l8wLBQ23Fk84369VVH9c885211NRD@4XFVF8310kF4210f4_Vsk@73YFVFN74VVVB410cZoF	!1d4V#84#54!10J#22#5c8!207F#cV!4V%FF#2k$4#O$17c!246!21BV	(1/1-E#2-1!4$5*101/)2!4$9$41*2.1%1&101//&2*2%2%1)1*1#1/02/&4/%102/#1#21&2!4.2!11#1*301)2/+21!2-1!10C&4(1&1!402/1$5$506(2)1$21!2-4&1.9/!8#6,3,3/(21$31.9-1/124/-473/#1//02//+z%502$2/$101$F01!1*1#34!1%3$3/05//903,1*1)@//$201&102%1*201)26#5*2(1&48-	eoTzJH@CHfeb]@hTSPHcHhdleEEhhehldmDheDh]MHhjFLfae`\X@JijfjjjBHXjjihh`Dh@@					not given in publication	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhS(xhS~x>36S~xiJ)d,S~x>.>xiS(.>)^S(x>x>S(x>xhS(x>S~x>S(xi.iS(x>x>S~xix>	:Uvzv;S:vTOzUzUmuvvUzUergrOCjSjLAiI7tQvjck7EmUp5KCAc_jRYqPP@0o6OH0Hm2IBp1s0vkCV8k0	0Pg!XV0IV02FV2g!Bp0440IV03JF1_07g!sg0bk3Z!C_07g0zF04B0110480bk04AF0k0480eF! #382@1m0X0LAB8L5Z12Vt0FcDF4J3Z190t0G8A44cn181O0Gk85R_824G2et0683D2I2RFX84PdVcVkGTp23W0F8NHI72GcJL6363n0FZ@FAYWFs@2@3_0F8kXA1X1cgL320k84wNT44XI0gBF4XkGFgc@A7anNFNH7211X1ekiE22WWRV8J782D1m0YFRV8c5aQA1_FmXx26L30WVNsc@62Vko81B9a7oVGBVF282G0GH04D4WGZ0mG04T8r6W3Z08kE8281MhFVVHOw4521D18OS22K4	#d1V#8%F*9#18c$3$Y#4Z4#8F$2k#15#O$C5c(29CV	//(F#2!2-4%1+1$1*1+2!109$1+2//1/(1!1/,2.4(5+2/-1%202-2.1-1(1&1/1/1/!403$2,1/&1E!1#1/#1022!1+4$22#102&1$1$62@*242//6//$1-1/%12%101-301/1!8(2%1#202!1!1&1$H/!2//&2//&1z$1(22*102!5)1@/1#2*1!302/#6&102&2+2#2//7/01+1!1(1!1*1!2$1)2(4!2+5,5(1$	ea]RHD@KO@^W@IARPrJJIJKQZ[QRIWJJIJIIGL\FV]CO_PDEUSUUUPDEUUEFEA@eEq@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xh.>h.>x>.(Sh.>x>.>.h.h.>.~Six~Shxh.~S~Si.~Shxh.~S~Sh.~Shx~Sixi.	[UUxrvzyzHvVmrReqz47O_WdThEDX5Va83Gkc0f5X0AKW511i86tH3DYF0c41HV34ZVB21GV7W0b0I0	0Pg!YV0s!2R03i!C_06k0Tk03Y03a0Dc012s0FF120A4010J0IF3Q0EN01LJ0Q01k07g0vV0 #1Z13VYI0W02@32WVFJXC7ZG0kB315XXkFB8981WkF4A10V8FJ30VF89FTc651G8J6641l08@531Ve1J420WZF88xGm2IKVYkWV9Rq873l2F84TK163VFkoNC3WksZ42410Oks2425cO0G0AZ4Lf141O0FNA_L472GVkX9Fa2@231VN8H@3YG8FD915aVF446L0XVF42@F10FWecNBI7VGt0Rc2185FGWDF4D2AL9G0VZFHqHWXFkO0647ZlVJ@920n2N44XP9B1nGJPBD6m0XVJk8dw2821Z40cu80YXGoR4884L1B80cgBE30Wm12B4Q115W9VGns4L4cT11FV	#80k)4V!1&@#CcV#15#FW$V$90F!V@k!80C#G2#N7s#14!218V	&2/.1C,1$3(1/&2!4&2,4$3/1//%22#1(5%1/&201.1/&1%1%3$302,4/01%21)21/02%2/%1-1/1!1/!12%2*1$4&1#21/#1%2)301$6$1014)12102#2!2!2-1//#1!202/04/!2*1#1&22!2)109$2/3*1/$2)8%101!1////#1/!s)1/1/D$3/(1*2/1/1,3!1/$1#1&34/,104/.42/#3*1(1(6#2!22$	eh\\FH@LOJhDAKO`P@cIIChhlmLeDeeDedeEMBjemejB@jjjh@JfH`Lh@@					Agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx=S~xi.iS~x=.=S~xixixhx=xiS~x=zdW(\}p3}J|`3pd,s6\}\}:0~Oh.3p\}	:UvzvzUzSzjvTOzUEUmuvtUUUebgrQCiUiLEiI7tAvbck3jmTp5GCAcWjRYMF@@0q3OF0Hm2IBp1s0dWBV8F0	0XV0IV025k1v!BM06J0Tk03Xk2U0DF!qJ0Tk3x!Fk0440FV2U!Fh03!FV2d!GE08g0cF3Z$ %XsGNBR@_G28lZ4PTL12Fs@B8H496ZWNRNE5WHGtAtB472@948gFJ8P191KtNBP8P_11FgV8J6JP24WE50FVA82H1m0XFHX08cH91FkVsQ82D1_WmFNZE82K1m0Y0Jks8iH1@4WNG4M82G1m0VkHN4B6D5GFF8HI9m0WFPks8P4aU12kZOdB693HXoksFc8_5dWkWRF	#c4V!104.18#1cV!202$Y$4$8FF#2k!815#O$B5c#F#295V	,1*1.B#2!2-4%1#4,1/*408$2+2//1!1/$1!1!2/!2%4.4&17//(101%2.32/-102%101$1/1/1/!4&2//$1@&2/#1022011+4!2022#202&1$3$302$2$242//7/*1)2-1/&21$101-6/!1!2(21$1#202%1&1$B/////$2,1z2,24*201,1B/1.1!3-2&3/-4#2/#1%11#4/01+1(1)1&1!2$1)2(3!2+5#1(4,1	ejQ\DL@KHicL`HbzPIdLbbRfRbbVQTtTRfTRdshX|bFf~q`@jijjZj`hJbJDBbJj@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>^}S(.i.=x=S~.>S(.iS(xi.h.ix>.>.=x>x=.>.>.hS(xi.h.ix=.>xix=xiS(x=x>S(x>W(zd}Jp3	:Uvzv;S:vyvzUzSvzvThzU:jpS5zMpeEEmjNQzShtybLbz8zi6pDvgd_MvzWZ5zo8J4YK5H8nJFO0W0F0	0Xo0Lk02OF1g!9_07g!o80cF2z!DA0@40t!3Xk2Z0DF!kJ0q03q!Fh0440KV1Q!Ni06k0Xk2Z0CV0t& 01VuE83lFsgkk452XbkVkLF442N16bGt0T885a60VsLF4D2Q59lsVJLAM153FFkFo4IM13W64sRBk6210k8JZ417VFGc84LL34XWd8H44WFV44NM1V_FF9B62G10FWm@Za4R131VB24690kNFwcJ2R6bXVV8220X2FB24C10XI2uk8ZL182VGcXZiC3WVV841954VFkRRE73W8R4220VGkss6c81_0FVD84WF8skcH2J6bHsVF366VVFFc428@Af2kNZJ264m0X0RV8F5DTE1XkwV8R78261fYFW8F8kR610NFRi61@WFF4820Y3V88kw8NB3WNN2@10FGNggkS2741sFgT295m0W0RV8c4PADWYm0w8NE14Y3I0o8Q57ZVGckB494WkNJJ95X0cJBRO0V_FF48Z21890VFVJ64X0t0HA20kN8wXTMEYlsVsT2B5	!29Gk#9F!8B5!121k!6D4!4gi#EMF!2dV!448#8FF!6@k!81z#GGV!d3s!@1p!2dRk	&1+10101.D-2/!4*1)3.4!206$4-1!1//$201#2#2310A05!1+13/$1!31/0101.1/2&2%2,1(101/&3%4/102,1#1,53$1/!11/,402&1$101/21!11%3041041/*2$1/&1*15#1%1)1/01!2/&1/51#11#1#@#201/*2/!12)261/!1/1,101//1#1(z%2011/3012$2%1F02(3(6%14//.1$1&6!1#1/+23301.1,2)1&1!11-702,5(2-11%4+	eiWZBH@LOAjVXDDn`@cIICEEEDeDdecDbmeDeeDmOGBhfecd\^QUjfBj`Zaif`@fjbJA``@					not given in publication	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>S(.ixixh.>x>x>S(.iS(xixh.=.>.=x>.iS(S(xi.>x=x>.hS(xiS(xi.>.=x=S(	?x:wQzoXyRvVxjN6LmXO9hAAVhUnXKOV03lkdL0_Y02CVEX7oGFx81TlFcA12LZcD50B4HH4J38V0FF	0TV!WR0Tk03JF1_07g!sg0d03Z!DF0@F0t!45k1_06k0Tk04AV110480ek05N01X06J0PV3F!SK05c0Q01v08g0d03Z& #1LT4G255ZGw6@A511GNkP933l8ND4B5aO0FkDF4N2R644FBBBA6m0XkRV8N44A9319R8E85WVG9DF4B3Z110pWkGB8DQI6FNcoM8281m0YFRV8Z4yr71_kk8Jy9@2FFsFH89m0YkRV9B78291m0XFGo4e6@315lsocK0WH1d6F463Z12Vt0GFDF4Z3Z12Ve7VFw8RJ@@0ccNM8281m0XkRV8V78281m0XkF	#MJk!T8o!24V!3H8V!qE#4hn!3@xk!sf8!12S!28NF!6Xk!1X5#Qd#97s!C6L!3WBV	01*1#1*101#1#D!1.41031*1/)1)3$1$3/2#1*1#1/011#1$1$12!1*11$121+2*1/-1%2!1)1$1,1)1)1#1,7/,2(1!2$1$1#1%1!5101.1(202,7#2202//%2&14103$101.@$2*1-3-4*1/!1(1/(1$1%12$1+1!2//-1!1.L!102&1/01%1,1-1/&1%20z#104#1*1!1402-D!1/01$1/$54(A-2&1&7/(30101&1*2&1+1&1&12-1/%5,11%1&4(2$	en]ZLH@AEGNgn@d`HcHhheDldhhddmeLdhhddVIKHbnk`RVXHFJhIPh``hjjHJCX`@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
xix>S~xixh|FS~lv|`}^^}q5}^}^q5}^w<^}tn~U}H^)qq}H}HqqS(\)xh~O=)s6h.i.>.	vzUvvQvvURzmvyvMHtIOsOjqyLIdhrABtATn7gX3XQtmDFZh0Q15CE7wWLy3I4YHXE2QkpV4@Q0K1@FpV8V0FV	0WR0Tk02OF1v!9_07g!ms0B011!Fe05g0MV1v!FM06J0Sk1v!Gl07R0jF3I!Ne02o0FF1204s0eF$ #8HcZ28I53W88FRFV@WFkWV6@5Xl2O6F4@3Z12VhkINJ@4M4XV8wFVDb6W7l888q19W5VNo8aF8i11kfNZ8R5Q4W4kauo8N41Q2FlcsV634YO0FsDF4N2DI2kmGB2F36YO0FsDF4F26AZ1NJJo8115WF8H348WFGtVFZD71kVls292C0ks8H25@0FVG4z8241KiFWkG4w922VsJL12_3HZW8B44CW18kD35@Zt0G0DF4621K30oFFB4T12FkJD56@_Y@cBBg7Z180WXVkV50VWo0B44110VN820VFOWCB	#D4k!204!6V9#HV#V1#3c@!324$2%8#9FF!FHk$5#G8$KN!201!210V	/01!3/!A012/012/$112#1/1!5!308&1#1#2%5//+1#21!5%1!1)1#2%2/#1+6/,1011/(4/#1,21&11+3//2&1/2101!101#1/#3/2#1!1&2,3%1//011$2+1/+1&1&1.1/!1/0301%2!1%2$E*1%302//122)B/#1/&1(3!101//(z!2!4!1$2*1101,L2#4/#1(1201/#202/+11#1!1/+22&1!2)1/2#3(11/#1#2#103011/)1-	ebU\@H@FIJ`HaIe[We]e^UnyWhxDd\|rJfV^AQq`BF`@jjjjhD@bhpBHrhFh@@						CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xxh.hx>S~S~.>xhS(.h.hS(S~x>x>xhS(xix>.>x>x>S(xhS(S(xhx>x>.>xhS~x>xhxhx>xhS~x>xh	zrzxrdOSvo5w5F@UUR8G2N2PaB2093E202nXE8X43QV840WX02GVpXKL9NW1dEW2c@1eXV8741@5K1FM10V0FF	0WR0Tk025k1v!9_07g!sg0cF3Z!FM06J0Q01v!G_07!Sk1w!GE08g0c03Z!GE09!cF3Z!OG06J0SV1r07k0o# !VkJA10VF4W66420sNP4146V8994ZdB2kccwKRZ8W_kwV8J4464X19BN64WkFBku2316YZJ88V5Z16VZLNoL60VGn0u_q462m0XkGVRRF7W1NR2430n1laF4Z2KL8kkkNgXI3_GNNBFF10YXHFRyEC0WW844BD95XW886BT31X0Oc4B3WW2c44VSZ13Vda0oBV6352lVZZ54XkGGVF2L10Zn18_PN4VFFt8U82A180YuV8o8RFOXkVdo42Q0VaF894WHv251O0GNDF482A77FcweBC1VXk88VVV8Cc1F44DK10Zk88gac2C80XkWusg6Q1WVkON22I7JikVcKFV4@2m0W0IlBuH22X088NNecAVFc4FDF0VY2BV8R4	!1Y4V!38B#V@#62#aX#4Vf!2e5F!8dV!44N#G0F!c2Z#4V#1V#1Pk!266#K8V	#1/-1$6#1#1%1/1//%2!202$3%1(1!1//01#1101)504&1-5%2%1/11+1/&1(6102/011%1/&2&101$2!1&3#1*104*2-4,1*2+101030602$3.1*2*1010202!104(3(2!202!212$1-1/1!7$1.2-1!2011.102.2%103)121B+1#1$2(2#1!2-2)2D02/01/101#2%1!2*1$2103&1#1(2!z(21)1%3&1&1M*1//%2%1(1$2031-6$1,1&2)1(1&22%1$1(2/#1/)4$21*2&1)1&	eiSRBD@B@bnSKNfPHcRHrJJJJIIRyQJIQJEPfIKJYaQkYZ{DfBBhijB@XAJ@BZ@@HMh					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xh.>h.>x>.(Sh.>x>.>.h.h.>.~Shx~Shxh.~S~Sh.~Shxh.~S~Sh.~Sh.hx~S>xhxhx~S>x>xhx	]SxrvzvUIz0nrRuqy47Q_WdTjEzX7VV9IIke0vbX03KW4Y5y8Dxm3DWFtc6WHV34_VB21GVLW0b0I0	0Pg!Z40IV02D03V!9k0Ds!qJ0Q01v!DF09w0t!3Y03a0Dc012s0FF120A4010J0IF3Q0EN01LJ0Q01k07g0vV0 0BV8R4gJ87W1Vk4J@13Yl0wZE5W0V8gJL210FsNRB8XFsR441VYmN424F10Y4V8@B6@3XW0ZF5420cN250VJ2F824DI320XPGX4D4@VbHOo864X_kkJ8VF422WFsH81WkVV821VkV54XYX113FeW08B4J0ZmVoP178VGcFkZ485XGVgF750kVR@20bYIwF8V426270FWSJ4F7Z130t0FNAtB472J0VX9oX4D6VY1F8427321NgP941kF4si510V8W842@I530YtoHC41V8lV8611YXl8o@U1YGktFN125Zt0Fs8l6Z822G2YFq14420Vc4Bu123nVwH41W0NB4NFE0f0cFPH4WH2O1By4@3GVksQ82@111G0gRA4WksF421VVNF42H@90VNNDA32Fk8D63WFNB6710k@WKFuP4_W2N4623X3V88k_LHFWW10VWVO7VlFcesHE7W1FkZN242WlNoH@3WFV461DCVVI844420lHPVBi45XWFkH81Vk842RJ0VZIp08ds2821Ymd90610m113WN4424VaFFB8gIK1kcg2BE9PV_3ss8X217XCFGeo44@3J0YbV8g9Ju22W7kIOoN@2W0FF210_42k	#W1k#8$4V!1&@#Cce#15#FW8#Z$9FF!V@k!80C#O2F!O3s#16!2W8V	&2//G,1#23$2!1/*401,402!5$4,1!1//%2$1(5%1/&203.1/&1%1%3&2,2/01%11&2021/02/,12,1/1!3/!1&2*1$6&2!2/1$1$22$1#302$7$1014&1012102#2!2!3-1/#2.1!201//$2*1#10101!32,109$2$2*3*1.2#22)8!1!101!3///+1&1/!z)1/1(4&D$3!1+2#3#1*2/1/1,5!1/$1#2!1#54/,104/.42/#4/#1(7#2!22$	enYRNH@LOJghDAKKlRP@cIIChhlmLeDeeDeeMDeDUMBjemejB@jjjh@IjijH`Lh@@					Agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
=r-S_wGw=44iw_/_b0Syo:=4tfw__/-SSyt@w_4=G/tftf~`t@Yxq;tfvavaSyq;tfvaSyt@q;tftft@	=v;xzxzyfvUrCkzfvCbAjU_kSEzbh@@bHbPMzmckTfLSq5lgPh4BCYq1@u1g2ko0F15Y6s8k090V0V!	0aJ0Tk02J03d!C_07!Tk03OF1k07g!o40FV2d!HA08s0bk3Z!Ji08g0YV2U0DF# !BV805R4NWXFm21H@442I0G9V4D5B1560FsG0kK31VVkBFA20XHM894TR261iFHFws4B31YH0g254W0cF4410kVW0P315c_J0GJs52WZFFR8LDHI15nko8X8t1B1W1oBX826ZGkWwH91VFFJ6DL0VVs8620VF98lFHQ84GcF@DL1WVWlDF4B3B1@a0HFFi24KB0ZVlkNT@61Vso2510F9d042D20Y3wV8k4PBFVVssNu@1C10HV864G@2328ga2612484B23DVVFGB220WYo0	!2c0k#F*DF#k%c$k1$d#4_F#8F#V2o#F7#OV#c5s#4#258V	-1/!101101G1$2+1(2/-2+6$4$2!1/!1#31//&1//01$1/03#1)1!21)2(2,7*2$1//)1!902$2/$1!1/02/)14+1!101$102$2/+5*1!11301!42/&11(1*3!4)1)2$3,202$2!1-11&11&2$1/!1&1!F)1//1!2)1(8//4/#4+1/%2*z%501#1!1!1#2$1%1%P011)2/(6&20602%2/$2&204!21/#203)5.1////01#3)41%202(4-	ei[\B@@DLC@ACd\bbbbRVRTTRRRNbRRrTRVHXJjzf^AyEZjfjj`zB@`b``J@`XH@@					agonist	SST5	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>xi.ix>.>S~xiS(.i.hx>x=S~xiS(.hs?x=.>qqg-S(x>}^S(.hy?}Z.>.>yg.i	<vUtvUyEk_arUHs2K2TAmeZ3Pd3d@0ILZ_4ms2NV90QWe130Z52MT9HVGN@kGkBJ82W0Jc1eY70VJJ0W8FF	0_F0zF03OF1k07g!kZ0qk3q!G_06k0R01v!GX06J0R03F!Jj0440FV1E0@Z0 $1210kB522m2VkP222FF4RN114c9MsFZ9V@28X48FsFNQCZX0cgM82E1m0WkH0Rc670lVs44@4_O0G8DF4H3Z13VdbkFc9o2KK0Z0gV8N782C1m0YVF	!120k!7$24a#4$V@#2Ba#1o#F1B!20O%F!F8o!8FB#WY$Ck!256#5cV	011-101/!17/%4%3#2-4%3!2+3$31#2!1//(1%1$2,1%1*1501/01+2!1042//!30101(301(3.101%1$1/#301/%1*2.3$1//+74+1(2%2%1#2+301!4!4103/$1/$3-1$4#1/*1$1&1101)1%1&1(11.91&1!1/)2#3!1%2+7(1/&1/#4(1%1/3,t%3/-1%K(1+1+304+4)1//11/%12!1%23/1/)2/&2(3(3)31)1/%	edZ\BB@LCghDOH`@cjPFdIiCIIBhhddmLdeEHheTmhyXD]]}BmP@@DUUUAPPDPID@@					antagonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxh.>x>x>.hS(.=x=xhS~.>.>x>.hS(xhS(x>x=xhS(s?x=qqg-y?}Zyg	<vUtvMyEF_arUHs0K2TAmeV3@d1e@03LV_4ms2FV!QWe131Z52MT9HVGO8VFkDF02Z84c1eY60VJG0W4FF	0Fs!WR0Tk025k1v!8M07g!Ww0Tk035k1_07g!kZ0qk3q!JM06J0Q01k07g01Hw0FF1204w0eF067k1X06J0SV1v0C! $1WlcgRE22lN8F2B465dkFc8r924WO0Fs8wiO8_GGNiF4F3Z150VkF8Bo73XlcZ4521kFFL8172oFdZm26_G8ssRYI281O0FN8F84K2_W0wB@E2WkNRF4646fVGdZs4@3m0XVRV8g4X2@dVX0V844222VVRJ72WG8BJ42cY0FF468J2V_3V98RX27ZVGVd44YI171O0FN96a492MCVWVJG0492m0VkRV8k48PBW_0OZF9473fVH3N4N454XW0WCT328218FkVX2DdVY0V842120VcNL620W8N494VkFNHeBK2Xlc8o2A3ZHF8sVX2JdVZFgV8B782D1m0W0FdF@6MBVkXVcR4G42FWdDF4@2@30lNRT@4XFF8@NB21kW9laL4D2m0YFRV8N78251m0WFRV9078291	!3ApF!fCB!2KD#LF#m@V!2iX!2Oo#mA4!B0s#9VF!FBo!BQC#6rF#Ek#KB!25AV	021/2%1+17-3-3%1&1*301,2$3$2%1%1-1/01)11$11$1%3#2-6!1)1+1#1!1//01)1!101(31!1%1,1!101,3102!101/1!1.3%1%3$1/)1%2%1#7/%1,2#2+201!3#104/6#1.1*3-4&2*1+1/*1-1!3$11.71&1,1+2$2/(C(1/&1/#8/#2+3&1$s.101/!2%F//#4,2(2/-1012/%11!2$123&1&11#1/302,1/-3)31#1$5/%	edZ\LF@JGOcKI`LP`HdBOHcJHNbLbbbRRfdTQttJTrTrS@dQPrwpLDDPKPT@DUUPEAlP@@					antagonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>S(.ixix>.>S~.>x>.h.i.>x>xi.>.>S~x>S~.hS~xh.hxiS(xhx>S~x>S(	=xtzxF7wWLfEUsHWXS@uaB0RdY@04Lzo5BXc3Qk96tWV6AKV5a5Jg8Wd1Un1df59X5eJh183F9JL1cY0G0	0WR0Tk03OF1g07g!qJ0Q01v!BZ04s0s!32F3N0EN011R0OF1g07g01Ns0Z02V0@F0t!6FF1204F0Q01v0CV01qk0Tk2D09!c02Z0DF% #hEa0lcTF4228L@0sVkI8271PYJFNZE8261m0Y0RV8J5Xn25WO0FsDF4F2654Wkc8A6WFtFof8291m0Y0LPNL6E3BVZZ8w8RF512lRV8F4k2G39VcFg@A6LVY60N8H7Z13VWFkRL7@110V81563Fs8cr8251665FsD@F5m0WVRV8k5al281O0Fk8JZ272WsJN@3_3XgV8N5ej26WBq8FJA8231m0XkLAB8L4HCW3luV8N8lOW2VV	!3W6k!FNJ!25Y!1@F#i2#4g2!215F#X#24F!2VFF!e@o!8RR!2GI#Wbs!216!25BV	!3&2%1!2*1&6/!1!41(1+1$1#3.6$2!104/+1//1.2$1$2531#2!1&11*301!1&1/.1)1///)3!2*21$1!11#2(1/(1/.2+6&202%3$1+1$22*1$5!4/#2#3.102!1#1.4#10101+2//%1/1%3*1!38!1,1$12)4%3%111$1!2$2B#1&2)1/+1/01!1/!1&y%3(1*301&1%J)101%1&1/,401/+404!1(2$101)1%13201#1/-101/1%1%1,3%1$1/1-	ebQ\JD@BMLeCHde`HapHrJJIQZJKYRIPqZQQNKLRV^US_PhxpPTLuBpUEPQ@A@@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~|FS~xh.hlv|`S~S~~S.hh.hx>xhx>x~Shxhx~S	zrzxMxOpdo5w4GfUER0Z2NHcaBFF91ZW4HlVE0e0FPZ943FX0Yt0tVVK8FWdWMl2_15cV0FK51V0F3J010W0FV	0aJ0Tk03OF1g07N!t!d03Z!DG0DN0u!4RF2w0Ao0p!7Q01l07N0Z02Z0CF0t% 06F483Z150t0FkDF443Z130t0GNDF4@3Z13Vt0GcDF4D2F8G0m0P664B2FVXNN8R8V2Ie0ZFX09Lc2I2	#LHV!F0V!22N!332#_2#4VC#3UF!lV#14#2K%vV#Xk#1%2V#4Z!191V	//(3/011///#@$1$2%1/*2%1/$2$2!2$1//%1/&1*2*1*1#1%1/01/#1)3/01&2)101//-4/%1%102,1//101031&2.1!2//)3#1(1&1/01%1/.4!102+1!6/1/2%1$2$1!1)41*1*1%1%2/&1!1//!d%7-101!101201*H,201//401-2/&6#1!1/011#1&1+2/,11%1//04*1,1-1#	fa{I`@DTXhG`yEDhhddmhThdf\dhsf}ZfB`aj@BP@@					antagonist	A3	Adenosine (I Nucleotide-like)	no	gpcr-ligands_DescriptorsNo5Ht
1n}]S~.>fzq5un.i.h@z~SS~.=h.hx.ixiS~x=xixix>xix>S(xix>S~S(xixhx=.=S~S(S(.>	?xzUxrtx:GzVnENu0z43@hf9NDmxXKdZcPQVd6JkX03G97X6w8EZX3L_Kd80AZVV410F0F1LFG8a0I0	0G8!aJ0Tk02OF1v!C_06k0Tk03OF1g07g!t!c03Z!DF0@F0t!3Y03a0Dc0 0G4kG91ksR2HF9BBmNNgB284m0Y0G1pF@0WFkskU8261m0WVHQ48LM0VVFFJ@D1CW4VO1BB1XXWt9g8B4R16AnFFRB4D43GNoV42WkFF2PGCm0WkO9g8V59166kGFFoL422lFg84420s8oLP4B2XG8H830mHlDF4B3Z19Vt0GV9g4mBJ4k8W0M8281C_kW344B6E2eIsVJP@6j11VXfBk4442O0Fk8NH@74W8cJ@153XX0l8T32ZlF	#E2V!18%Z!10V#R2#70@#25V#Y8#4J$o$2k#F4#93k!13V#16#W1V	/#1&1%1#1701/1011/$2/)1D$21#3$1/%2///1$1//%11//&3.1*1#2/01/$2%2/!3#2&2$1&1%1/+202/!1$103!3$1!1/(31#301!114(3)4(3!1221#2,1$1*5&22/*1/,6#11&1#2+201F//02+2&21$1#A+2///+3/01!2$z%B/#101%41%X!1)1!1!1,1!1*1(1.2.7!1/%2!1&1*1$201*1!1//*101%21)1/021*10	efUTBH@NNgO@i`@cIEEEDddXhxdleMEDhlmpiIYTu|bSSPUATLp@TpP@@PA@`P@@					antagonist	V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.>x>x>S(.ixixh.>x>x>S(.iS(xixh.=.>.=x>.iS(S(xi.>x=x>H))^xiS(xi)^x=	?x:JQxoXyRtVpaN2HmVN9hAAVgMnXK9V03lk960_X02CVEX7JGHd81TlFcA126Zc650B4HH4J18V0FF	0TV!WR0Tk03JF1_07g!sg0d03Z!DF0@F0t!45k1_06k0Tk04AV110480ek04NV1_06V0o!7KF1P06k0Tk2A0@F0t# #O0H89Bqh422l08ZPC62lFZP42VY1OaF4B3Z160V_Nsw8560VGFqF4L3Z130YXl0@H6XllN84HGZ130t0FFAx@4I2875Nc4@B5m0X0RV8o78291@k1sORBiBCVkOBJ383ZO0GsDF4a3Z14Vt0G8AdJ4@278GG0k@E10YGgV8B78251m0XVRV9878251KDVWsGFVj821WBV8V782A1m0X0RV8V782A1	#MJk!L8o!24V!3H8V!qA#4cn!3@xk!sY8!12S!20cF!6Xk!1X5#QW#96s!56L!3WBV	02*1$2$1#101(@101.4!31(401/)1)3$1$3+1/$1!1/!2#1$1%2!1*11$121&2#2*1&1/%1%2*301$1,1)1)1,3#7/,2(1!2*1#1%1!1!1$2)1(2.7$202/#3/02)103&1.@/1-3-4/-1(1/(1$1%12$1+1!2)2//!11/!L!102#1!1//%1$1.1#1+1%10z#104#1-1402-D!1/01$1/$54#1#8-2&1$107!3/&101&1*2&1+1&1&12/-1%5,1&1&1-	ejYZLH@AEGOGn@d`HaIfVWUfUWvuYevIKHbnk`_lXHFJhIPh``hjbB`vH@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.hx>xh^)S~.h.>S~.hxhS~.>x>.h.hxh.>W~zB.h}\psS~.>dz.h.hS~.>S~	]UzxQiyUUUDnUxdQ6DaJ_XtBDby4bYX5A9@eVX3X66J_0a8B8D4IkEV@Fg79a_2611FV3Gk70VXcG0	0RZ!aJ0Tk02Ak3V!9J0Eo!qJ0Q01v!HD0@!d03Z!G_06k0Tk3x!Jj0440FV2d0D% $23ON@54Xl0FZLH8Db1d0BB76i20VsFRyL531kBRFDhQW3FgV8R4BE7Wl8wLA10VFF2PBCm0WVPG88L4P1@3FchN8E5m0VVFFkZI31GVg861VY1OW0qHBX1GFN4FBE@Z1VkP80Z2H08RDG4XW8gD22Wkc441F684YG8V122G10sW0C2@hkHNTF4T3Z140a0F4L65B2VHmo4aD77Z1FNJ@320NJ4NCB7WXOBD@50kFF8LFA1718FgY6A30g08BZ7Z16VVY8R48S22FYFF2h3A4WVkgFA62l0RB51VVOl0v8261	$2V(80W!20F#4@#4VZ$5F!Fjc!4ZV$F$@s$5#WF$3V!204#19V	//%137%2+1!4.3*101&1*2$4$1/2)11*1!11/)2/025/011&1*401//.1///!1*1&201)1#3/-2*2&1/*56%1%1*1)1$2%2#203302104#1,1020103.1!1$1/#1.4$2#1//#2/22-1B012/!1-1$402)1!1$2B2*1!1(1/+41+1/!3,z.21)101$2(L$2&303/#402/!33/-2(1/)108!1+14///$1%6(4$20201&1*2-	ejQRDB@MGFb[O`I@RPddEICHhhdiMUMEDdehdeEeifNJnmch\XBBjfhHHjhHHpbCX`@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~S~xh.h.hx>D{28S(xh(Q/jx>x>.>xh.iS(.>.>S(	qHuF2G810V1k0F201N01080m04FF#20HF050V!80841VV02FV80F40F0890k0V1J2X!4!20F3F6!180k	1680OF1k0C!1680OF1q0C!1740ik2w0C401LJ0R01q07g0zF$ 6F4F3Z17VgLNFR@8V24180H3J4RE15WVH0O88K36VXFJ64C8	!1Y4#948!6VP#12#X3$V@#14#N34!209!3F%BZ!10V!1lV#F8s#14#9lV	02#101/$101&1.1//401&2%2$8#11(1%2/&1.21$3$1(3*1$1-2%3.1//%4(1#2/*2%1/$4(1/%1+1/02/01/+2,2)1$4/1+1//(1(1/$1/$1(1*1//(1+1!401&1!2)1&2*1!2(1%1!6///(1#1&1/-e%6/)1%4#K!2/01+2&1%4#1$3/-1/011&1/#2#101!1/&1/%11(2(6$1!1$1%1/%	figYB@AJtxIV@dDfUeyeW^uiqwhyzN@Hj`TH@@`@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hS~S~.h.>S~.hxhS~.>S~x>.h.hxhxh.>x>.hxhS~.>W~zB.h.h}\psS~.>S~	:Uvzv;SzjvyvUSjCvEtsUyDbE_oQOjiy252VYQ38Xck7na1Jg2i3g8DJ22CZZ0e31kZI43F0F1GF4XVVcF0	0RZ!Xs0FF025k1v!9_07g!qJ0Q01v!Fi0440FV2d!HD0@!d03Z!JM06J0Q01v0Eo$ 038281G8mkJ8@B5hXFVkG8I936Wt0Fs@gwP341YW0NG059Xt0Gs@g4Zt181O0G0DF4633@Y0l8NciMCX0s8RPDD1WYQ8JR@D1C0X0GRa2KN0ZlFOVXB8XVkZVX117VFGWHNkU2VWGNiF4D24J14Hl8L44632o0GZJ3AVlc84DF973GscaC20Vl9842F0VXmkl083Y0GXkqF4a2f4BFmVTF4P3Z130XkFFBsE4VVv4JgF3F2FnVF4oM5XFmkR24I9	#V6k#44!80W!30F#4@#5Vk!205F!c_8!14$8FF#@s$4#1N$3V$J!219V	+2/!2&3E032//!3*101!1)11#2#24$1/+1-11/$1#2+1$2&2*1//!1/(4)1///-1!1#2//$2)2)33)2/(25%1%1)21#1-102$2$1&1,104#3!2!2+12#1/#1.2/#12.2(2*1%2.B!2&1!1&4+121#21+1(2B2$1/01/+41+1%1(4/z.2*10101+L$2)3,1(2+4%34*1/102//$2.24/%1,5/&3(411!202/$4)1#	ejYRHD@AMNbU@H`bPrJJKKJZJJIIKYJJIIJUccIjkk{DFFB@ijB`hjB`jLH`@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
vl0lF|x=.=`|xi.iS(:vS~x=.=.=(NdzxiS(.i:v:vS~x=.=.=S~dzxixix=xix=	;vznQztkKwnoAfUS9lX9PdV1FGDV9@ZLl25@0i2Ak841sVFYw08cFJ0N8c5GFGW112W!J1Z4FFH!80W0FV	0Xs0IV02OF1v!9F0DZ!qJ0R01v!DA09s0t!3Xk2Z0DF01GN0PF1p07c0nF05Lk2A09s0k03Z$ #1Z14VccFFsA8261m0VVRV8g5Lt2812W1he259XcLcsBN6YVW1kWG4kZ62_GFcNHXEXkNtNRun33W20VXs4C24119sZI4Vm2t6F4B2kP12FgV8V4s_26cVGNQ5BC351_ZFFaJ58XZVVwc461WFZZaI8D11FYZV8L4A4dmWFJRA8D110V8BcI7X1sZHHH90W1NoRA3XG0g@50aZnFHw8TH16Vm0Fc8284VWWk	!230V!G1J!702!2KCV!m3Z!99D#2IV!@Y8!209#k_#ZQo!4m7!2Gmk!89s!624!3jFV	%3/)101$6.3!1!1&4!4!2%1!1!1,1$16!214$2)1/01#1/!1%1$1%6/.1#1/02(1(2,1101!1,51+1(1//01#15/$4/11%2%1/&3/(5#1!2,101-1!2#1+3/1)2/%2*1(4//,1&1.1&1)1#1&@/03&1%1&1#12%1%1#15!2-1+102%2//*1+1#u%5%1&1#1101301#104#H/*1*2(12!3/*2)8!1/#12021/1//)101#1*1+1$4//+	ehRRLH@LBAKMAo`@cIEELheDeLidheEd|lFGDjmkgjZYiiBh@Z@Jh@@@					antagonist	A1/ A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xh.h.hS(x>S~.>.>.>xhS(S(x>x>.>xhxhS(S(S~x>x>x>.>xhS(xhS(x>x=.=xhS(S(S(x>x>.>S(x>S(xix>xiS(x>x>S(	;xzdtSvo5y5J@UUR8G2N@PaB20dYE@8@zXE8X43QV840WX02GVpXKL9Nl3fEW2c@1fXV8741@5K1FMW0V0FF	0WR0Tk025k1v!9_07g!o40FV2l!DA0@40t!3Z02Z0DF011R0OF1g07g016J0R01r07k01680OF1g0C!14w0Xk2V0DF01p40OF1g07N0Sk1w0C$ 02BfXkFJV@31YWFJ617JVkcBB@2WVNB@1ADVFI04433@0FHHs4op90WINiF4@21OBFm0N8F51XlcJH811FFB@610V89Bq21B0V8FxQ82C1PB0VkFBmE62WNJRu42WVNWVj82A10VWNZL213d10NH73WVVB4HO110FO422DJHfX0ONE82610WkcZ856W0cVD22ab10826N1VFXc44Z716e2IccFC3VlmsVH339_2lNZVG12WN8490VIGddKLY331t0Hs84LE5X20gH73VXllNc@V4Y20RFF78m0ZFOtJ8D42NeG0WVF852WGFN4411FFJD4310FF2110_Z884y11C0F84BZ217i5ONFBF7ABW50VcJP42WFF88731FsF@410Fc82eR0V_V8F26FO12GNgV752W8JH20a_IF8RDB40FNFF4610Fc8TL0VFXNB@4F0VXp3YVV6F3m0Y0F8FN921lcVH7@BW0sBBe2114V88w8125d1VWkRA4WFNZB5A75t0FkDF4L211Yks4673WFsRF211FFN4ZP0V_VF8210XZ60V8yu2C1VXVqY08J44651sZ@131VGGoB121V8dNz42251O0FV8cXE8X7G08@31X_lN4F6HB51XsZR566_FsFBHH4SdFmNNVHG6YVk8Re919VlF84556aVVGxs4P415Wh60FJ82H9_kcJ@83VXYF884MBk10WFLF482297GVFL33WmHcN4ZJ2BYn9R831Z1X0KNN6I315HsoN813X20864B@m0WkF	!1Y4V!A8B!4V@!162#aX#5Zf!2e5F!8dV!44P#G0F!c2o#4_#1c#1Qk!@66#K8V	0201)2/!21$C#1#1+13)1//%5!20304103$11(1!1(2#1/#1!21101)502#1!1-5%2%2/11+1/&1(610212.11/-2&101$2$2$3#1*102!1&2-6)1011*2!2(111!1501$3$3)1*201(101!23!204(3$1!2!302!21%3!1$1$1/1!7$1.2/02!1#1*102#1)14%301)111C1*1!11$2(2&2%1!2#2)2F021/1(1)1#2%1!2-1021)2!11!1$1!z%3021/201$1&1R/1$2/$31!42(4%1$122$1)6$1$1&1&2)3/11%1-2/1!1/)6$21/!1!3%1&	ebyvBD@B@bok\sKNcPHcRHrJJJJIIRyQJIQJEQXqQIIXjYQILJM[KWLrbjiypPUEMPPC@IUPTDSP@@P@P[P					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
2;-dW*2;2;W*2;-d2;(b>/h/*S;2;t,`,F/>/h/h/>S|/h/>/hS*	:UtrWzStGKS3J2ETC8lXO2Q03F0h3E0D6pX5@X011o8a01!c4Vd40oc8g1W5Y0V31X!c4!41F!50BV0FV	0WR0Tk035k1_07g!o80Ik2d!DF0@40t!4OF1r07g0U!5O01p07R0U03I$ #6F483Z130t0GF9lo4@70X0r8ws683IAkWks4L687a_FZJT@43cIWg4BH633GmNTC6530FVJBB6Z1FwB330YH9cVRLGZVFl4N64Ba58BNeB76aYkc6@763VVVF@56YGcZJA11VGlBv8231	#I4V!18B#V8!102#V0F#c@!201$W$48#1JF#Ho#45#O$9Ss!@02!2A0V	//(@#1///1)1&2$3$1*13$1.1/*1$1#2$2.1!2%2/)1%1.1$1&1+2/%1/#2%21#2012!4(11-1)1/%2.1!12+2)13!1#1#1*1!1/)3$1/+1%2/&1*2!1&10101$3.311)1-2+12$101,9//202$1(1$1)9+2/%201/+1#1/,l%2#2#1)12/D/01#1.3///013//#12$1+2/$1%20121/#1-3/+14-	fmwqB@ENFXDQdTRVRRTtRRRaReFAbVl@EUMM@EU@@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi,@z@x>S~I)3p])xixh*Fn1*F81S~3p}K?-xhY(q4x>y?S(xhT(xjx>S~x>S(xhxhxhx>.>S~x>S(S(xhS(.>	:UvzfzSzSxzQRAzUUPOfti9r7PYhYC8@Ixn7vV4eQrhaJVYFjO1b26wsDaeYLnQdB8AVnZR03!F1JF18V0F0	0aJ0Tk02OF1v!C105R0Lk03OF1g07g!qJ0Q01v!C204w0eF03Z02V0DF!sg0cF3Z!DF0@F0t!5FF1204F0Q01v$ 0JVYV8VoHu725112Wku420VNB4JG@m0WFRV8k60F@1YVldVRP9VlWkk44A6YlVoD@31V9WR412@72JHR2F52XY1WBmJ40lmF44VGZ12VWIkG82LB3VNccS82EV0YFc@B8B4863IVwF32WFGFsdRq24WO0Fk@CX43910sFwM826133X8gkC31F882LHAGVY6Ns8D7Z12VWIOwRH2Y41gV8N6w624W6W9l88A4m0XFN@B8P43951W0i6783t0Fs8ND94X1cRLC3WVN8ocQ8D140V88B942FcVH751FkJB218_k89C8LG41G8JH42WlkFkNO81670GFFcV96Z18kD130Xm1PGu33@1t0Fk8p2N7W08lc650VG2dLF4a2242H0kJ85210F22CCVFF4BiVZ1BXJcw48F5m0Y0FdoqD9WF8tJU8281	#h0V#O#41b!129#B6#5d@#25#8f8!4ZF$F$2o$4#O8V!13c!226!2WBV	$1-1(1)1C-1#1!3/$201.1&1E$41#401$1#3011+1(2//02$1//1*1//+1+1.2)1/,2%2-1#3#2&3/!2%1/%203.1!2$103!21&1!11/#31%4!10301/4!12#3#221$1/,8!1#12)2/#1.1)6#11%21#2#2&202G//02$1%2&2%1#B$2%2//%1(2(2!11/1102$z%C%12&2#201-X1+1!1!321*1!13,1/01!2.8/0101(1&31.22+1!1-1/+102%4/!1)5-	eg\rL@@DJkaPEclbbbbbRTRVLVRVbffTRTVRtQdS`WbSWVOJmkU@DADESTsAPPDEADD@U@@					antagonist	V1A / V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S=x=.(S(S>.(S>x>.(S(S=.(S5q:v:0*F*`.h.>.>.h.>.h.h	vzUtvdUSzKxxQNAUPE8GYNeQa6H2CYC92eQV78X1I1Fea!20VF9e!B94s1WCWH19330gF60105G101X0VcFV	0RZ!o80eF2l!G_07R0Tk1w!G_06k0Tk3x!KZ07J0Sk1w0CB# %N4IkBFT1142t0FV864D70VFl42267i1kW044@6kP120fs8o82A0VXFmK88L4D9ZmOB667AYt0G09sTe40k8l0N	#I1V!188#V8!302#V2#4V8$5F!F5V!408#1%FV#4$G$1Ps!@04!2A9V	!1/01/!8/$1//(11*102.2//1/01$2!22/#1*2#2*2)2.2/#1#2&4-21%1!1/(1*1/01,1$1/02/,2*1$1&1!1&2%1&1&1*2012)11+3%301/%2$1/(1$4&1)3/.21*102,1071#3/2(2*2*11)8$3///1)1//!j%2%1,1(1&D$4//2/!12#1(1/1,11/%5/!1/$1&1/202(1(41/+4-	fewHB@NF}LD`drnrnljkkQfcQSUl@EUUSPAVP@@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx=xix=S~xiS(.ixix=x>S~S~S(xhx>xhw<^}tn~Ux=xiS~x=S(xi	>U:pzxzstQQUCoj8eCi7qLB4jdXet27E07NIqeZHJ2F_k8i8244BNkV102G3L0W8J02GkFG0FFXW30WV	0WR0Tk02OF1v!920@Z!lR0OF1v!CZ07V0xF06Gk2D09s0dV3W0DF$ #1E@W1VWkNRH6WVcF@42VV9cs22ADJ0ZpcJ8V@1728mO8T7332lecw8F5Z150W20gTC5XFcF4510YGleoaK2WkNkoQ82@1m0XFFNcDC72l8NB2210FVsXRc1AAG8B68F5m0VkRV8o782C1	#O5V!484!2$18GV!V0F#V9!20GF!GV#408%F!VPV!1%G$10c(338V	/1/2%7!1//*1/02$26$51#1!1&2-3-11/02#1103!4/(2%2/)2//!13/1/$3!4/!12(2*30402+1*31/2/%1/(3&1*1*2/!2!2$32+1)21///02$2(4/03#1-1/#1#101&2&@#12$1-1$12)1!2(2%1!6//#1)2$1/-2-20s%7/!1$1#2&H$61/+6.2//%5-1+1)6/01/$1//$1(4/,4-	e`\RLH@ADmofcg`HaIe]fYU_vUvzacqJKHZZ@Bj`hHjZjfHXNJ@@					antagonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(x=S(xix>x=xhx>xhS~xi.ix=S~S~xi.hS~x=xix=S~xixhx=S~S(xi	:UvzAvSURx@QB3UR9FldOcHk02Xh398BTwV50V111G30F1V0A5V0Z24V6w23JY08030N404124#44WZV8F0	0qJ0Q01v!C_06k0Tk03YV2Z0DF!os0YF3r!C_07g0zF04AF110480eF0 #5oD4922W0sgH75XFsVJ10VkFF2X9G10kFR632WW0N651VksN632Vp20B44C1VFWF44Fm774nWR@30Z1m084H@8ZWcVN22Vn1k44JPFAgGNVcF@813G0NB67_0k44P9C10kYkRF911FcJFA11ksR831VJGXTF4B3Z13V_4sZTF54XWn8sTF320N8ZT2160FFtOo4cCJ0X8VwM8271g0YWV8k8	#V4V(41$2F#42#582$4$W$4$8F$2k$5!2GF#83c!206!259V	)2/,1C-2/!21)1/)6$301!2/+1//1.2-1*2#2///03/#3/+3/*4!1!4&2!2!1#1/03(21&2//!1#1%3&2/&2!11)4%1$2/#22$22%3%1/01/.1$1)3/1.3$1$102.B$4/)2*1/2$@+2!2(2+1-1!2$3//%z0102050201!11)320201&1#N/!1&1011/0101&1(2/$5/!21#11*3////,2(302(2,3#5$1%20	elV\DH@KLiahPICHhdleDedeEDehUDeMJFCKJng`X@JjjhHHZ@HX`@@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
P(,@w;/kzf,@(V;/>x(Shx>x63>x)Jhx,d.>.h.>.h.>.hS(.>.>S(	=jzUzyLjUTEyDCsSmO4QaoFWhA0683kX7E2F1cF4qF164h0V80Fac@Z191X2051@J0c!@21480XJ8VFFV	0Z40IV02OF1v!DM09V0ak03Xk2W0DF016J0TF1v07k01LF0T01t07k0xF0 #1Z120W1tgX89XGlFt56F7Z1GFfdJ472m0WVJH50663AYFX0hB6422lXko8cA1962VFwF2C61WG0ZD@6Xksg@410IX8824D0VY4GsNJH6XVkNB615YXlco46AYGkJB3@5_4WWZRB32FO0gY8241H@2sNcB432WkFBB65X18RD52WFF82aG0VF8NlN	!220V$8)V%V#18V$V#FY#448#9J$mk#47#O$V58!@F#2W0V	)1$1,1*E$102/)4//$8!3&1/$1/01/%1(2!1/////)11%21#2///!1+2(1/!101/$2#4#1)1#25/&2!1#1.1/$1$60101!2//&1(11$101)102101$1021101$2$1+2/&1//#7(1//$2&1#1%7+2//&1/01.2*10p%5#2#1&1!1/F/01,1!10101&16!1/3(2!1&3,1,1(21&1(1,1/$1-1%1+1+1&1$2/0	fc``@D@}dTRVbtTRbjRRbRxIp_QWmjjhBHZj@BHPpca@@					agonist	MT1/ MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixiS~|F|`lv`*}J63`*`*63`*?)k/(P@,@,(P	vzUvvfvOzR9mO4AMHOFOdNeHqFHXgY288PUV70V4ANFY6F140A11!6Jl6J234Y313220Z0L0A8#40k0V0FV	0WR0Tk02OF1v!Fk0440FV2d!JM06J0Sk1v07k01L40Sk1u07k0ok% 06F4@3S141kFkJ0RL34WeZGJ28D0VFWFkRqS4XksF@196Z_9s4BF7Z140t0FNB88T35WWJFgV711VkJ630a330	#74V!184#V$F2#VV#1c8!201$2%8#1FF!F2k#44#G$9Ks$8!210V	,1/%2#8!1/.1//#6!203//$1*1/&4#1/(2$12!1/#1///!1)1$3//022&1$31/!1-1&1&1,1-1)1!1%1/+2!201)2(1&2/)1%2//$1//!1/*1+1#101.6$2//(2/!7///&1/#11(1,f#20503%2*1!101*F+1$1#1&1-1!4)1/-2//!203//&1//)1!32*1#1+14$1(	fnkPB@A^ADYEDeLhXdleDeQ`iN}Ul@EMUU@@T@@@					not given in text	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xh.h.hS(x>S~.>.>.>xhS(S(}Hx>.>^)xhS(S(91~Sx>x>.>h.S(xhS(~S.=x=hxh.~S~Si.~Shxh.~Sixi.~S~Si.	zrzxrdOSvo5w5F@UUR8G2N2PaB2093E202nXE8X43QV840WX02GVpXKL9NW1dEW2c@1eXV8741@5K1FM10V0FF	0WR0Tk025k1v!9_07g!Zw0gF03Xk2W0DF!t!d03Z!FM06J0Q01v!G_07!Sk1w!GX06J0Q03F!GE08g0c03Z!SG06J0Q01q07R0U03F& #BecCVFFNRRD834Gk8420Z@08R@771kcu0412DcW_HRH35CXt0Fc890s380kc8BNB34XGd8L95W0F422177kF9o22QFh2VWVH_q46231McwB50YbV89cXo2A310W0NJZ87VFN4S6123W08H70VHI844ZY4CWFmkTF4B2223lNVq812VV8gu2216YHZBB40VWY0ksPC93FcZ411XF9VskRqF1WVwF9R42K26YmscV821VG8w62B@92ItFc264YO0H8DF4B220inNF2210XHG8c@A6XFN4SP22WFkRF51Z908466V0Vaoucw8D5P19XF8FwB4C6Vl8g2Dc0WlNR2740F99s412Cd11VcXG52Vc4D4A@VF8FwoN@53FF8483YXYFRJ23@acMkJBV7W10FlFN8JE5Y2s8DB9BVVVGJgT4TZ0FdF42H6m0WVRV8g4FG20W8g8@510GOsD611aVF9F22HF21@NNo66252eMNFJ8gSI0FF8438CVFHtCR643221BV8F4ifBWaVFF224@YcmlZV2542VVKJ@120Glkt_FP0W1HFF4VB33JklcF8495JikWFF8DSJXkcBS211B4KVVN8884m0W0F99LV22bF89g22O782nk8qA66VVGNs83G50V8BRRDH49Y8V2BL10ZlwV8R4	!1Y4V!A8B!4V@#62#aX#4Zf!2e5F!8dV!44P#G0F!c2Z#4W#1c#1Pk!@66#K8V	0201)2/!21$5#1#1+13)1//%5!205!103$11(1!1&11/(1!21101)502#1!1-5%2%3/11+1/&103%61021/41/!1*2&101$2$2$3#1*102!1&2-2)1011*2!2(101!1701$3$3)1*201(101!25!204(3(2!202!21%1(1$1/1!7$1.2/02!1#1*102#4)12%301)111C2*1!11$2(2&2%1&2)2F021/1/!1#2%1!2-1021)2#1!1$1!z%3021/201$1&1R/1/+1!42(1%1$122$103&6$1$1&1&2)1/13%1-2/1!1/)6$21/!1)1&	ehzvBD@B@boePsKNiPHcRHrJJJJIIRyQJIQJEQXqPiYSJIIaQkYZyggtNBBhijB@XAJj@BZ@@@@HMh					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xh.hxhx>x>xhzdW(S~p3}J~Wh.>.~Slvl0|F|`xhx>x>xi	zpzlrWUStk4S3F2DTS8W2N2v01F0C3724HnV5AXB30a9a1VV0XcVhXGL9FV9dEl0V31X64VL#1J2!5FV0FV	0WR0Tk02J03d!C_07R0U!3Z02Z0DF01GR0JF1_07!Tk055V1Z06Z0SF3C!KZ07J0Sk1w0CB% %O0GV@wqQ391t0G8DF4B3Z130e0mVP8B4m0W0RV905Fi6W_VwV8c4c2JJ0Z3Fo8P9Z140t0Fs9F4Rc166WcFVFc2NCYINoFX@CG8VkWFP2G5m0XkRV8B5F2GM0Ylc8kBPdCWaFk9RP2K5m0XVF	!2I4k!184!2V8!1FD#V3#8WA!20KV!FW8!20s!1G_F!ZHg#q$1VF!1Gk!6H2#AJV	(1&1/&5#2!1*104#1/%2#1%1#1%4!1&1#1/&1#1+1,11%1010402!31/04/#2*1)1.1!1%11,1&2,2.1+1/$4(101$1///&1$1,4#110101#21$1$1#101/(2+1*4#1.2-1*2,1#1#1,101)211/)12$1&1&301!2(1&4/+1$1(B-1.1////$j%3/#21.B!2/$101*2/#2/,15!1/1#202(1/(1.1%201/!2/031/$2#1)1%	fmopa@E^sJHHapPdsKkJ~wJjlyYuVsW@PULuMM@A@@@					agonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh-?x>-gL)55)L.i.>S~.iJ).h36S~(O>.h.~Six~Sixi.~S~Sh.	{jzy:DjgKXQSUiZIAhfFAd3wX7Emo0cIFq05@4xFg@4Fi8@V3t5YX051AJ0c4012W4106J4V0FV	0Z40IV02OF1v!DA0@40t!4OF1g07Z0U!4AV110480gF05O01s07Z0U03p$ $38291m0W0RV8R5ad41YFvVV8@4sL12kW8c8VIG410BJJD61Ym0RD55YFcF@ND0VFWOkZJ4J@0ZXdo8T81W31kVRPD6W18F8930VF86TF0VYJ6uNB14828LO0BH6WSW4108sE824121lNoDA3WkNFD61VV8B210dZ4k	!220V!B&V!1V%@#4cl$4F!FfV!4Z8#94$mk#4b#G8$3c!@04!2W8V	)11#103/%H*1&1-4(11/&1!8!302$1*1%101%1//+2!1/$1,1/%1%11$1/011$1%2///!1/#111//)2#4#1#1#2$34/&3!1#1/+1(1$20101!2/+1/$1$1+104!1)10101!2/011//*1.6/$2*11)102&1*6//)1(113/1-1+10q%51!2#1*1(1&F/01,1!1101(16!1-1/%3,1*101(22&1(1,1//*11*2)1)1.11%	ek`TD@@DA@@lbbRfRtTRbjRRbRDd|bBRvNZjj`Hajh@Hb@``@					agonist	MT1/ MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
->S(.i.>.>.iS(->.>.iS(R(T~->x>.iR(S(xh->D).i*Fl0T~->S(.h:0.i.i.>.>->.h>xhx(S:v:0*F`|*`.h.>.>.h	:Uvzv;S:vyvzUjRvzvvUzE:hbTCzvzeEjn5QExzaJMvLzI1v_DxzDoYrKfEWEAflcoM3AN5O1RWn4V0FV	0Pg!WR0Tk03OF1r07k!qJ0Sk1w!C204w0eF03Z02U0DF!sg0c03Z!FM06J0Q01v!Fh0440FV2U!KW07R0TV1w0CB01Xo0FV1406k0Tk2V!OH06F0SF1r07k0pV$ #242G8wcA3WFk88NEB2319RaA1WFFNcX40W3Y09kw115H8sVU829113XFd2C30k98ZZFJ42YNsF485410NNHD25WN8J62VFGkwv825130kX84q3EX30lN8HF721X9JPE60FF4gHL9D3o08JZB113lsH8884R15H0FsGJoY2Y1G844DC4F11kgV8J44653XW8B92W0WNkg6C5YnFZH62Vk9Nkj82511W0VgLL6VlNND4B6a1Z8t28E320WNk8B432l8kP91Vl88630VZH2Bci332WXm14L327FFNZNH45WGtRRB310dFs22BALh0W0B4@6vGWVl8NF@532WWBD621kcB62E77Vlkkm611G8VH1A90VN4BRR492kcNRG33FlFVf82412Z2lJD611WFBcJJ61@0Wcwe2571XNB4A545WmcVu8@G0WlFVZTP2WG8FH430n1dVJT36VkcZB95ZF9Vk62@Cm0W0FFNND53GcZJ41W32GVFJB9_1NV4FL10Vc44167bO0Gc8F50332G8NRE4W0sN@2C9720OFmE6VWV8ZZIZ150VVVNF752FkcL730VN86VJ10F8O1B8C5_1cJ86310N8kc210V8Vt0241VkVo@793FVR2520VN58T_Z140XFHdJD854FV8eFA912V8FPG8YWcF420aXnRV8B70425110NF8A8XlVo612WFWks22BEM82NNZ6274110FONN4C2G288T620WGNg4HP30VVcV854X1Fo64510FB41I8da5WRF8D4kVXFN8R9J29S0WkbPZ8B4V16G0GFLF4@2vJ0FlFOdP990WGVcCaP3550FsVFiQG31H8do64EX0YFk	#v4V!G84!4WN!122#ge#5ce!207F#WV!6_8#CJF#Ho#4Z#O8#9Ms!2Fi!2EBV	,2/*E!12-1(1(1$1!1-1%1108!10B!102$1%3#1///01#311!1.10121#223/&2+1%1,1#1//!1-1(1!22&1,4(2)1&21-11$1%1&101/%20401$23101+2!2!201.2!7$202%1/!301#2#21%4)1%2$5$5/#2102&1$2/#1412(21$13#2)18$2.1/&12-1#A#1*1*2$1-1/*1/(z602!6(2*201101!1%1L)21101!1#1.3%1,1/011%10107#2#1*101212*5%1*3%1-11&1/$1(301!161#3$2)1&6&11$	e`vvDH@AO@kd^[JPHcHhdidheMhhdUEEDdemmMEDlePqIim]|cCcKj{{@AUTuUUSPUADtu@AT@aIPxP@@					antagonist	SST2	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xi.i^}w<.=~UtnS(.ix>.=qqg-.iS(y?S~}Z.=.=S(.i.=.=.i.iS~.=.i	:UvzfzTzSzxQTOzUUBnuduviAH6B3SCDqU0AE0COQrAZk1Xmio1u6BJWJ8XZAHPdW20zBF701R4FH08081!V	0G8!Z40IV02OF1v!@C0ER01580RF2w0CN01J80G01707g0eF05JV1W06F0SF3L& 021mOFc@4WFN42LDAPfkVkFFLTDXWF48194ZVVsg@@33FkRD91WFF86VCFm0XVFNsH97Y1FV@830Y1GVFFF@3H0g@598VFGtLF48283cXNsB7242mBV8N4425210FD@4210F@12W0F821J5e5qdVBL643XkkRL97XFVB@41VIl9yF482cI_0ksTF4N2PAbGVcJFAZ12VZGdcF73Xl84ZFHQ86mN8HB8652l1cD652W842L8A	!2b0V!G8#2NR!13XV!V3$9@$O#8Y8#GB!3Nk#FTk!D75#p8#f0N#1T!2A5V	)1/,1C/*2$1//01)50110101)11)11!1$1$1#1+1!3011&7$3/1///!1!13//.1!1$2/%1,1(11(1)4$12,4$2/1,1%2%4&1/)1%1$1#205$1$1!2!1!2-2#2/)1$11/01$1/01+1*2$1+1/04/%1#1/$1$1*7*12-1)1&1$3$1/03!4/0110p%1/#1$2#101#6%101/-1-1#2(301/!5!101!1/(1013(1(2,3%1//.5*1#1,3!2$17#	eghZHH@LBFMCM`@cIEDeElhhhdkLdmLqpDdUTMMSUUTuUP@SRp@@@					not given in publication	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
hx>x~S(Shxh.:0:v~S~S*`*F`|i..>.i6s~S.h.>)J`|i..>6s}\.h`|`|.>S~}\.h.iS~.i	>U:pjwQTvUUU8lnSfuiCLLCWdD4EzVE3Y13OmL6mYV6nM0SaMR9ol3pCWFtd7AXZX4CW451IkKVZX0GV	0aJ0Tk02D03V!9F0DZ!qJ0R01v!C_07R0Tk03FV1E0@Z!t!d03Z!Gb07R0jF3L! m0WFJ3RJ345X14Nt85333lgV8F6y524WLG0BBF7Z160t0Fk9JcCH1VNlJQ82F1m0ZVRV8k4iI6cVsFNqCZ1A0t0Fk@N4Fy131EkGHF24734cXtJF313YWom4s683CdZN4FL86GZIG0JV@y169VG0H4qa1X2l094RG50k8tBD46111kV24ACUVYZc8V9Bi6WYkN8oFu92A6nNR48G6m0WVF	#71k!F8N!2e$28#V4#1VA#6lV!FWF!41B#1V#4HZ#b4#GV#dss!402!238V	/1-2$1!9(101&2$1/1/,6!106$1$1,1!2&1/+1+11//301/02!3&2#1/%11+4)1/#11#1#1&1+14&104/$2!101///)1%3&1,1/(1!1015$3!1/2&1,2&2(2*2#11!1)5/1!2//)122.C$401+101$1$1(1!2&21$4#9+2/#2*2*1/1$1!2/0z!1!5/#1/N-1!1+1&2)2)3+102*1#302/%202)6,3#1&1//+2%1(5(301#1)1214#201&	ejYZL@@DNAMlPDjlbbTTRRbrRRTRLrRbrvT\tLrJnAQqZ`XJ`JBjBBbj@JBH`@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
H)q5)HH)H)q5)H(S~S:v:0ixi.*F*`~S~S.>h..hS(.>.>S(	qHuF2G910k1k0F211N01080m04FF#20HF050V!80841VV02FV80F40F0894V0V1J2X!4!20F1F6!180k	1680OF1k0C!1680OF1q0C!1L40SF2v0Ak0p!5OF1k07N0Tk3x! 6F4F3Z17Vt0FsBRu482F0Z3Wc8PC0W2WFkNJZ4@cVHFB@4C7	!1Y$9B8!70P#12#W1#20@!114#B3B!259!3F1F!VCZ!94W#WZV#ck#1K#GWV	02%1/$2)1.1/01-301&2+8$11#1!1%1/&1.21$4-3+1#1-2%3.1/*2*4(1#2/%1#2%1/1#4(1%1.1+1/02$1+1/+2,2)1$4/1+1//%101(1/$1/$1(2///#1+1!401&1!2)1&2)11!2(1)6///(1#1&1/(1$f%6-2/04#K!1/01$1%1&1%4#1$3/#1)1/01(1/#1#101///011(2(5$1.1/%	figiB@AJ\Dk@RBSJr|rkoZtx{t\}G@DUPJD@@P@@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(.hS(x>.>.>x>S(.hzdW(.=p3}JS(.hS~.>.h.h.>.h.>S(.>S(.>S(.h.>.>.h	zxzrbbtS9m4T5F2DTNV_XN2uVVF09Ah20HkV58X03lo963WV0fWVh2oLcFV91KnFc91094cJ0VX1J24JK0W0FV	0aJ0Tk02YF3r!C_07!Tk03Z02Z0DF016J0Q01k07g01740ik2w0C801pJ0Lk1k07g0YF3d0ER% 06F4D3Z120t0G8DF4D3Z140t0FkDF4P3Z15Vt0GVDF4B3Z11Vt0GFDF4B3Z150t0H888LBF31Ng829B0VHc44VL11E2FkcaC8XFNV610a4IFN9x2M3ZFsJNk110Fm9FSDG6ZFVlB82C73VZoWcP91XYFN88JFD7bWNZN31Z6k89V22I@	!2b0k!I8#94$B2V!Z6#68H!12SF!GW#@BF!2F@#BHo#26!2IZ#1Xs!256!25HV	/&3/A1,2%1/+2/02!8(102/01//)41102%5$1///1*2#11#1*1$2,3/1)12/!101$1%2!1-1)1!2/)4/!25.1,102$2/&1(11(11402/)1/$202-2!2!2*1%3/$1!1%504/+1+2!C$2/!1%1*1!2!1#2*9%1#1/$2$1$2/!1(101)1+10z%51&1*102!1&120N/&1/(6&2-102&1&613/1&2(4(11(21/(1/%2/105/#1#21/0	ebQZB@@MKG@h`NDilbbbTRttVRebRrRRTRSGDa`TWPrNKPLECUL@EUP@P`@@@						LT	Leukotriene LT (I)	no	gpcr-ligands_DescriptorsNo5Ht
*Fl0S(.hx>:0.>.>S(xh.hS~x>xi.ixhx=S~S~x>xi.ixhS~S(~S.ixiS~S~xh	:UtzdUSzKpxQRQUEU8I2N@9iEH0Cb49@HxXEAX9NPZ9a02X0YG0v02w88VY1KW6W11AV8JK2101F1J0G$V	0G8!aJ0Tk02OF1w!C_06k0Tk03FV1E0@Z!t!c03Z!FL06F0TV1w# 038261D30Wt0aE35XFG8lKF8BX20V88@BR16H0G0JVs462NbmFNg4294m0W0RV8c4y829YlsNDA56WVGO1k4Y815W1VHGwT@1XlGWR4JDMJ_WV4JJ11430VkgJ9@VVVc8@3VF88wFTl16gkGFFN4g6D21V8L3143HFB8JLF69JFVVI8261G0WsRLG1WVW8Nb8261D0Yt08kA8271	#E1V!588!@0F!108#J@4!60e#25#8V#24N#1V$HV#R4#WvF!12V#16#91V	!1)1/$1#27/$4//01.D!104$1+3.202//!2$2$1(2//#2#2&1/#1)1+1,1/.2$1#2/4(1&1&1(11+1/#3)1,2&1%2/1/02!4#112/#1%1%3//!3,1&2(1$201//,1-19%2!1/01$2+2!1)21#7/)1//,1/+v%@!1-1!1(2%P!1/02-1031(4+1301$1/013!201/01,3*1!1!2//*1/#11!2/+16(1$	e`\THD@ENi@@bHHrQQQISFZIQIKKQPiXLBZYMO_TD`qPTEET@D@@@@					not given in publication	NPY2	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=S(.ix=.=.=.i.iS~.=.i36Bz.hS((O.>x>5qS(S()H^}x>5q5q^}	:UvMvOrdF5w0HeEPN0WmO2uaBFJ90C04Ln0C0X01OoN4WWV6YR0CX5S8F091Ck0cW52X42411#1FG0VW8FV	0aJ0SV02OF1v!DF0@F0t!3OF1v0Eo01LF0PF1p0Ak0p# #6F4P2kP11FgV8R78281m0_0RV8o78271m0YFRV8V782E1	#bVV!88#22L#1@F!V38!4Z2#WC#NY8#7O!2H$4@V#4$98#K0c!446#l3V	&1/%1)1(1)3&1//+B$1!101$2,1/,1)1+3/.1/.1,1/#1#1#1///&3/4(2+2,2)4+101/%1#2#201$1/&1-2!1(1/$104#2//)21/$1/#1*1$1/&101,9/01#4/#2!41%11)9/(1$1/-1%3#1/$1$m%8%11%1$101!1%4#P!4!1!2$1//#1!1!1%11%2.4.1/1)1%2)1+1//)2(3&1/!2/	fcqA@EF]HD`RPRYg^vYyUg]gGAjM^xHBZfhH@@A@@@					not given in publication	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(.hx>.>.>xh.h.h.>.hS(.>.>S(.>B,3p(Wd,.>:0:0.id,.>.i.>	=jvOzwCmO5AUHOFOfNeHqJHXhY9@8PUV70V4AOFf6FW40AO140LLt6p@3TnId12@X4VL4f!41JFo0603V	0Z40IV02J03d!C_07!Tk03OF1r07k!t40tV3e!Fk0440FV2d!KW07R0TV1w0CN# !6F4F2F8XGNJgB20V9Fo228A@7FmoFN9Z120n30FZ84@5YG8wB77W0lO021266WKXwBT20W2GFCw8H413Wt0Fk9K6H12VVN8FC80ZnOoV5690FFFcWmc270kGVTF4D266_XG0H2210OG42126aO0Fk@wgT33WVIeJs50Y31VFBH3421FgL94WkN86TGE3dHNNd82841WGcVqA63FV44LF0VY308V@A731NZL820VGdB229D	#30k!18$cF$2#Wh#18@#21$_8#1B#1F$Xw#44#GVV!AKs!10@!210V	/.1#2#F!1.3//-201!8!204#21$1+1&11.1/+1$3*1&1$1!1/,11/+1,1)1$1//!1)11!1%1(1!1-11/!3(1/+1%4$401&1+2!2+2(2!20302%3&1*1%3-1///%1-2.2*1$101.6$22/.1%1#2.803#1//)1%1$3$3$1/*t#203/!1/0D/$2(1#1!2%1,2!101&1*2$501/!102202)4/!1$1/1/+2-22*1#1)1015-	eodTL@@CN`DFLbfbbRQTRVTTRRVrDTBbjzfvZBBJjjdHHjJ@@@					antagonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
beDehG>Gh_>_hG>GSkS;h_>_>_hGhGSkS;h_jZhGjLa@T~S;@EKj>GhG@aaf;S>_S;h_S;>GEf>G>GhGhGS;>_S;S;>G>_	}yzvjzx;nx:j:xwpU7xez_IyRzrojzQvbMrxrzfCDzZHIdcDF_OTa0q4fChf@zkmF6Y0Gk	0QF!Z80IV02OF1v!9_07g!aJ0Tk02Ak3V!8j0D#sg0cF3Z!Fj03Z0s03l!F504c0qV3q!Ke0780Rk1r0C!1Kw0Rk1r0Ao0pV0 0O0FVAs4RA@WVlFYo4Jb141O0Fs@dNC341aVd8mK56W084BHFaU12kd8ZBB45X4Wd0P72VWNFB4A5_q1VFJ8ghFWWVqk8dL323WXI0Z8A36VW0g44245O0FFAhH482P53VNVC29FWXNcZJe@29W1t8PD56VV8Fc228@m0VVIZV8@5Z120aHNGFR2H2YHFNs@125ZA0H84g1@2WGN84HEZ13VXFF4a96YVc8ZX5110sF4B@E3WG8gF92VkVJH710FVF4XB0VVW2N4D63XkkoH232FN8820W0eF_8L12X0VkD743FV8622VkH8g428H440X0GXL362XX3Je8A40ZGd4k422G88cNJ441l2gk5793Vl0RTO93l11JV4632nP0RDH10Z20NF8296YFJJHI0VZHVG0FF3WkNN893WkF4sR210Vl@@oe4F0Ym04FLBp@XX0VgF232A1G0t8340HF8ZNLIEXkcoX4793VXGV@D52GNJ2JJ@8_lsJVC4VX290wFJ3Y2cNFFJ0VFX9F8292Y0sFH7610N8421VW0GBJbZ14VVM9FN@56XWoGNgA133V88gRJ96Z18RD43XFN4230bXk88W0VeK1XFoZ0884@E9WNgJJ@8LZIkVVF233XG0RD631l8B651VV842210kHsdR2634GtBR91W0F84PJC0YlcgHF4XGN8210a_IRV8R78251TZkWWF4J76E13FVRwP5482B4VwBN6ILZ2NVsFcO5WZkVk8VI16XFGFtc4K@13WHFGGg4D4DKZl8VBBH0VZ1k	!1z1k!S0Z!DBg!1OsV!VD4!5_g!32MV!ofV!41B#@PF!4jk!BXB#OR#cbN!87Z!298V	-1$1&21(109$21&1#2/&1%2$3%1!1$J$9$4!10101012%10203&2(1/-12$1/)2%2/(1%1-1/$2*1///&1$B$1$1(1/11-101$1/*6!4&111*102&1!1$2!1#11!1$6#12%102&1(1/$1/2%1$1#1!22&2)3/1!111&1!1%1051(1$1B!101/1*1+6(5(3@%111101&1(101+1)101,11/*1z2$E!3/2#1$3%V&1&1-1/04!1%210301$1(3)2!2/01$1&4045,2/!1)1,1(1(1!2%7#11/01$1-	e`z~FH@LEMHljmXDIgjUP@cIIBdhhddmEdhcEDhhhlddilSXExeTu]}r[KZmU@@@QUUUU@E@CAPLAGUBuEqGq@@					agonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.h.>.>.hS(.>S(.h.>.>.iS(x>.>S(.=\)(W.>x>B,O(xhx>S(xhx>x>xhx>S(xh	?xzQxzvxxjUxdvihwUzC7QZiANz4y2Vv0Y93Gmm4bGF9J54i2c28C2202Fc262H44@784k0F82086030	0WR0Tk02OF1v!9_07g!YV0s!3Xk2U0DF!t40tV3e!FM0540OF1v!Ji0440Xk2U0DF$ #sNHP7XH8c4HD9XVZWWB8P640YGkR8D20VV8423VYmV8L2380F8FhI82211Wl0sZ873FkN6LDAXVZGV8wa2B3A6aVNZDFR2610kNoXDBY1mFR43370FG9NoJZJX2W8c8kNI241VFNVP@5Wl8R8410kFR61G6VFFFdE8261XVXlV8Za2731YlOFJJ7WH1N44DHM5WaVVJLAZ140VkIVVVH62GHkBL4I21kcNw42C0VXnJN90ZT81Y1BV8N4655_Wk8F76W0kFkLN71C2WW8R@6X0l14b82413210s4841FN8cs330kn0R4g12WVFW442B0VX_0sc6J6Vm8gFHI30FX1Pxe4F20WlNVP951FFFD31Vk8W0X20W3VF8lE82C1	#84V$4$5*4#1d2!203#4Y8#44#8FF#2s$5#O8#81g!2F2!210V	,1$1/$A!1*2#2*3,1/02(2$4$2///.2(1/&2%2,1//01/#1%2///02(1!401&1///1(1!1$111(1$3&6&2)15(1#11)204!1!1$4!1!303#1(14)211)1(1-2-102#1.1/+2*1$2!1,E/01#2$1#1(102)31$2!1F!2/&2)1$2)1$203$3-2$1+z)1$4/%12#L-2//+3#22$1)1(5//$1/4/%102.201/)1#1/(3-	elVXBH@LoAhTPHcHhdimDeCLeEDdUDeeJFCKJngoh@J@BjjjZ@BXH`RH@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xh.hW~zB.>S~}\ps.h.h~OS~.>d,lv.h.h~O~O.>d,lv~O~Olv	zxznrYvKts4B3J2iT98lXN0v01F1g092BLmX522031k1401W0e4V9XKq1PB1C92F0112G4!1V40420180W0F0	0aJ0U!2FF3#9F0DZ!_!uF03OF1k07g!qJ0Tk1w!DA0@40t& 02Ky472Q0Y_k8k88CCelcd8KTN287FGcOoqA225HFFB6G7m0WVLk9GR2H27VYOVcA6AYO0FkDF4F3Z130pFGcw4L5Z140t0GNDF4R2zHW2kgV8F48H5XmG8V489Z11kZZF4WVV886264VF90o8D71X1J8A44a0F9NcFSG3GscsJ	$ZV!2$1$2!V$V!18@#4%l$RW#@F#FPo#5_#OV#85s#1F!2K0V	/-1!1#109/!22,2,1/1%4102&1///*1201%102$6-2/(1//)111!2$1&2&1////011#1,11%1/!7&1+1/&2&1#3/!1!1&1!1+3&44/)2-1-301!2/%2//*2*1/%5/)11/*1$1$6%4/%1)2/#1%1!3(1$1-o%1%1$1%1101!2%1#J!1&302,1*4)1)1/-402/04#4241&1/04-1)1&1+1/&3/*1,1!	ek`\L@@DFE@AmlbbRbbRVTtRRVaVTtl|JzZfZi`hH@@BJd@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.ixiS~.=.i.i.=.iS~.=.i.i.=.i.=.i.=.iS(.=.=S(.i.=.=.i	zrzOv9UOMpxWQ8@UH30F38c066205V8@0c8020X1210X#2!F1!F88JF1V40H08210V0401!1301X0V0FF	0PF!_!uF03OF1g07#qJ0Sk1w!C20@Z0gF05OF1e07R0U03F! 5pdNB8A10VW0qF482C7eHcJ2176VVGN84HHA@c1sNDBG20kWd6F4F2934WX4B52450N88X1165Ykdog931V91J430WZHwV8s4H45YmNw@620k842PK10Zk848VWZ130t0Fc9ggf421lBV8Z4e9FZH8cs42@6A1mGgNB0YZV88wV	#2$1$2V%@#V2#4V1$ZF#1V!40@#1V#40Z#a%V$uk!204#18V	%1-1/!9/!12/.2/!4$2$1///)1!1*1$1/,101(1%2!2/#1-1,6/)1//!13$1/.1$1%1&6+1,12*1#11/)1.1%1#201!1$1014+11$2%1,12&2%2/(501/#1/&1#1*101,1051#2/%1/*1)3%3%2.1/(11-2/*10l/*1&101%K$2$201/(2!2%2!101)1/*1/03#302(16/2///!2/04/02*5-	fmoI@@AVBdBTvnrnjrmjsakU[M]@AUUU@@@D@@@					agonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=S(.ix=.=.=.i.iS~.=.iS~.=.i.i.=.i.=S(.i.=.=S(.i.i.=x=.=.=.i	:UvjvztjOxYdwnjGdFAiOoHO45f_09FV8H01G0V11G!J51V8FV067F8G8!8608#841B08#302!V8FF	0PF!Zw0c!2YF3r!Bh02s0FF03OF1r07k!qJ0Tk3x!Kc06c0Sk1w0C& 07C7oNWJI824122GX5666B3Fo8FZ9gM@VW1NXtg4C21g5cFFT9Z13VVGGx2O59XWfkFRA826170bFOBmK711XkyF4F2X9WK8VkF6N7Ync4RDG7m0WFIV9C2a281t0G8BC24425DZ0NgE82@1	#E0k!80V!2V6#28#V6#592$ZV#Y8$8#1VF!4Hk#a5#G8$ns!@46!211V	&111/$1(A/!3&1//+4$61#1//,1*1102/)1/&2/%201-23/*1*1/2////02$4#1!2)403#2-1/01$14&1+1/)1%3$1$1!3$1%104*1.1-1&2/)2/01$1%1$5-1,1$31/$4/1!2*1!1&8$1/$1%1/#1101/(1/t201/&1&111%F104%22,4/)22!1!2#2/13$102-11#3!1/&202#12/)2/#1+2(4*1!1#1)6(1$	eodRHD@Hlbni@I@bPrJJKKSJIKIQIQJIEccpIhZyzB@fjjh@`h@`PtPT@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>.hx>xhS(x>x>|`S(l0|F~Sx>S(xh.>x>x>.hS(S(xhS(.>.>x>x>x>S(S(x>xhx>xhx>S~xhxhS~	vzUvvvzxzSxzvJvUUzAQAOTzi6HQhWC9fHUa58X3GQFjaFEY0Y1Vgi3BBkZ3YUnG117A2dF4918GG20LF0V8Fk	0PZ!Pg!aJ0Tk02K03x!C_07R0Tk04NV1_07N0o!4RF1r0Ao0ok05CF1104F0SV1v!KX06J0SV1v0C$ $O0FV8BB4BhVXVkN8mLJ24VVFsVFXA8YGkgB499VVFG0gD482GcgN85Wk9Nw42CB4Zl9FH61XVcNcV4175W0gVa8C41VZ9G866B10XWRV8F4H892G8ZH11VXXN8L20W1Gc824@G1WomcJ@H510_ZfJ811XZ1gV8c4414XG8cB@4VVFNki230Vc4210VHGF44FhZ130cbFVBL64IW0lGZs4752hlsNcm254FW70RFL8@W13Y08RBDU6a12G0F4A6Aam0kg@F524m8R4P674kkFgV@f81kVcwk2A6m0WkFWG4A2VGX84i49811VdFZ483_VN9FP330W11aF4D26j11VVps885Z130XHPwT52Y41gV8c5Rq281O0FsAx@4C2	#M0k!188#VP!12$VVF!18j$1#12V$8#1F$Hk#17#G1#1ON!@08!2A0V	121/*2)B.101!14(1$11/)15!106!102&1.1+1/)2$1(1$1/%1%1!2/04&1/1(1!1#1!2#3#1$2/2(1$3(1#2%6%2&1$1#1+1#1%1(311*1!1114/&34+1&101/%101#1(4.3(11/-1)12+11%5)2/01%1/*2.F*103/#2(3!1101#1*B+1/%2/#1//2(10z%501#1!1)21&1&R01/!1/*4(11#14/(1+11(11)32341&1#1/#1//!1%1301%602(1#1#31&1,4	eiWV@L@ICGBhRPIABPpdLbdLRTrVTTRbTRfRIRRbRDTtLZvV^n~yEj`BJjj``B@Jh@A`HOB@@					antagonist	CXCR4 / CCR5	CXCR / CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.>.h.i.>.h.>.h0:S(*`*F:0(S:0:v*`*F.>.h.i.>S~.h.>.hS(	;x3_tKdk5T4J2ETB0_XO2uV0F1d3j04LJV58X011o8631W0fgVdZVJcFc91Kn0V31210cJ50Z1F204FBW0FV	0WR0Tk035k1_07g!o80Ik2d!G_07R0Tk1w!KZ07J0Sk1w0CB01M40S03B0Bo0x% !38271m0XkRV8F4GH27XVGVP9k4@50X0sG0Z683E@Y0FFL8846J8NZ2783X210LN71kG1BV8J8XlFZD22W0FF42D87@lXZ88D44410keF7VX2G0Vi6426Z8oB10X_2F8FPE6YVsF8310kk86418ZJRV8B4	!224V!1BB!2WN#82F!V1F#c@!201#81%8!290F#Lk#67#GG#8Ns!AX4!290V	//(A#1/(1*1/%2%12$3#1*113$1.1/%110111#10104$2.1!2%3-1)11/%1)1!1!1(2%1.1/#21$21#2!2!4)1-1-1/03#1(1#102+1*3/$1/.3$1-1,1#102.1&1*1#1(1&3%1(311,1/&1%1.902/-2021/!1)9!11&2$1+1#2011/.1/,o%21!2#1(101/D(1,1.3///013/-1$21$1+2/$101%121/#1$1(41/*14-	ek`RHH@MC@ek@HcHhdldeDlhddeBeJFKGDlfnh@Jiiih@jh`@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)ZD+S~x>0mvla|.>F|S(*Fl0.hS(:0.>S~.>S(.>.hS(.>x>S(S(x>S(x>.>xhS(S(.h.=.=.>.i	=v;x<vUUzCvUQvzyEYEjrOO;eEbvjQUWvjtbfaIMCMD6wADp3nUprhh3QaZv6a9Fr1WJGn61!V	0qJ0Q01v!DF09w0t!4AV110480bk04AV110480qF04Yk2V0DF0u!41F1C0CZ0xV05JF1_07R0Tk1w!KW06F0Sk1w0CN01oZ0Q01v08w0c03Z0DV# %8JONJ8G4Kf0cVFR9Z120W29FRC6XkNBZe118_GV9VBH51328mXRBL512XO0F89JsQBX4G4Gcy@4720FsgLN7YFcZ61A@5VHdBZF6X0882JI@GikW0N4B6SSXV84JDAZ12VVWOBcG81G042JI@PcWcNNE82C1g30W8FNqJE3GHN84R215YhKsFN8Td95VF42DE77HFWVo4J7Z150t0Fs@B4cf8W4F8F8J@pMW2kYfg8X@113WBV8J7825145lsck830m2084RHH@2XtJ8BE2VYGk8JN9641Nk8520VGdF2128bt0Fk8NR663lskD520F84oZPXPYFl0P8@k36VWNFcJ	#34k!GB8#g#3HH#ZAF!5ge!225F#X8!4_B!31FF#uo!95J#EcV!1Qk!256#WBV	/*2#202%E-1#3(1&1(1#101!501,4!126$4!1)1///1601$3$1$102$11-1!1)2%3%1)101/!1/1/#2(21.1#2&2+3$10112$1$1,2,1-3$1,1$3#4!5&1+1(1!21#1%4$5022/#2#1!21022)1&101,304!1.1$1+1*101!101/#1!12+1!301/012%1$2/#1!1$32B&1#2%1//02/!1)2%1)z%3%2/01102(B$1$1//&1&4#41+1+4101/&1#2$44%2*1*1,1//)411/#1%4-	enSRJH@LEFchDJo`P@cIICMEmEDhlUMDeeEELenIGODlemh\ZVUjjj`RBZjjfB@hh`hH@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xhS(.hx>S~S~.>xhxi|FS~lv|`~SS~x>xiS(xhS~S~x>.hxhxhxhS~S~x>xh	:UvztQUxJbwnLAUUS8WmOuyaCF4CW81Z6zVC2XWHOk06VYX6YMWO_5R9RV35CWkcd1AVZm491441IF60VV0FV	0Xs0IV02OF1v!9_07g!qJ0Q01r!DF0@F0t!4Ok1r0Ao0pV05Ik2D0@!cF3Z& #1pN8J4yI13kgV8J78261m0W0RV8c4aa0_W2FBBA363i0GWwP483BY1GsFL96W1lb08sg2BA0X0l5FF6K3m0Y0RV8N782F162YFO0VC26WlsFZTXI22W7IGNe2562XY18NG6W1m0sx@JD22W18oRC6WWc882210OcsoaH93Wkk@DL7	#70k!R8#2c$2N#Z6#543#6pV!FVB!41B#1V#42V#Y4#GN#dms!B06!238V	/)1*1!5(101/#1)1/,B!106$2$1,101(1&1/#1+11(2!1!2/1)21+2/$1-1+2/-1#11)1,1(12/&2!1//)33/&5&2,1#1#2.1!1013$3!1#1/0102%1(2*1,12(1)111,21//.3.@&1*11*2-4(1$1!27+1&1/1+1/%1/*x%@#1.2(4!4#P$1&11!1/#3)6)1+302(1%5/.1$1!1-1-4)1//*5&3%1*1311-	edZZD@@DLK@h`JlbbbTtRLrRRTVbbRRqcg`UpOtKUPTDMUM@@@A@@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
o3}\F+o3o3~SF+`*u:S(x>.>S(S(.>S(~@xhx>S~xhS(xhS~S~xhS~x>~Sh.	:UvzfvUzRxiQTAzU9FtfOcPrNPbhYA8BUyV78V5A9GY6F1_6A5W067Jt6R23CY30U32FV0L0AB4!4ZkBVFFV	0WR0Tk02a02Q!DA0@F0t!4JF1_06k0Tk04B0110480eF055k1_07R0Tk1w!KW07R0TV1w0CB% $1Z12Vs0G0F4B55EW2VYd8VF7W0Fss22A845mO4P62WH28B24D@P5GskFH86C_l0Z460Wk8484C6aVWGJX@510cF8110VN4wT10W34I@0RD21FFB2H99m0WkFtFgE4VVF8451VF88420cYJFFZJF92VkB650VFN4251cZF88h86OBYm0F6587VV8Fkf82B1m0WFRV8V78231Y3X0NoBo@AYW0R8DK20V84FVL465GVgH620kk8410VF854V11791GFZaA4WkNB4510VGlR610WZkF9422C0VXp0	#@4V!104#VV!102#ZX#5c#204$Y$48#9FF!FHk!844!2G8#8Ms$B!210V	/#2,3%A!1/.1%4!1/%1%203$1*5/1!1//!1#1$2!1*2#2%2/%21/01%1.2)1%1(2//022#3!1!1&1-1-1.1,1-1)1)3&12/!2!2+2%601!10102/$4#1%3//!201/!1&1$101/%1.11#102.6$2/1)4/#1+B+2!1(1)211//&1*3*t#2*21)201!1*B/01#1//#3-4#4*4-3)1+3.1/&1#1!11/+1#1!3302/*5-	eol\HH@FOIm`HaIe[]e]VY_[jNAIGONakgh@bjjj`HJZab@@@					antagonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(.>x>S(|`S(x>l0|FS(~Sx>lvl0S(xh|F|`q5H)}^q5q5}^q5}^	zrzxzxU:k7xUmvEUS8bLO@vg9HJCYi64Ln0CEX0AQaRanlV6Yx0QXqK8k0d5MlJWf12bZV690c9FH!8VW0FV	0WR0Tk02J03d!C_06k0R!3YV2Z0DF016B0O01s0EJ01GR0OF1r07g0U!5RF1n0Ak0jF3D!Oc07B0Sk1w0Bs0o! %O0FVDF4@3Z140t0GNDF4D3Z17Vt0Fs9J4IE13WImcFg8e2EKckWVPJ4Rz1612kH2gJY35X7VHRF4X2171XkHko4ZT513oV8oM827128ZlVFX8@1A3YeFBX@17XVnFdND1351VFV8s63W5WswXI5XZ2RV8o78261m0X0RV8c78231m0Z0RV8w4wI6d12N84X@3C16qss46M5	#aZF!24Z!2WR#TP#ZY#6kB!2VZ#tf$4@!2GFF!ZPZ!1q$Vk#Fmk!4GZ#1AV	%2$11/01(5+1%2!1*2+1!1/*1$1/*11011/*1402011$8(1.2%2#2+1$2(2/!1)1$1!1#4//.102(1!5&2!1/#1#3-1&1-1/+2$101(3#2+1!1#1!1,3/*231/#2#1+2&5/)1%1#1#1%5/&1%2.6///&1)7102(2$1+1%102/0101101/01.10o&1&2$1#1201121*D&1/$1(2$2#201&1/&1%6#1/#204%1//*10101/#2+1%20602*1#2)1#1%1#	eolVLH@AIEKGBhlk`HcHhdieDdeeEDlXdljFEMCKJfmch@JYjjVj@BbT@@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
ot7tx=.=xix=S~xixiS~x=S(xix=xix=xix=xiS(x=x=|`S(l0|F~Od,d,~O~O	<nUUvQl4l7DeDHO0lmw2m444F52d6B7HV51X83GF06f1V!4V02G4801G9BW!dJ260X4ZVa2!V71FY0GV	0Pg!YV0s!2R03i!C_06k0Tk03Sk1w0CB016J0R01r07k010J0IF3Q0EN01LJ0R01r07k0vV0 #20kVJF52WFsF@82WFsF840VK2044PfZ140VVsNL71XG0VD93W0kF6VBFm0W0F8B@741kcR@83XFVR8420oWk44NbZ120VFIsR446XlcwF532kWW8r82710W0cJJQ5Wl8NRLBA0VFk8DE84FsBL926YYRV8B4623WFsR@72WVkRD511ks8610eZ_RV8k782810VVc84D5XX8c656109tFwNC6aX8w@DI7B9IsVFJ82194mdsZ9132lkVcRLC40k42HC9m0WVFVNPCB4H0NVgF91@imNoBX8G56VWNRBA2VVW1184Nx@W2Fl8924B6WY13k8eB2724Va8NkF449Xc8VFJ8	#20k!1%Z$56#W2$g$15#F1$VN#10F!V8Z!84C#GX#8Fs!854!258V	%2$1/&1#7/!2#2/!1!1(4%201%2$201012.1/,1.2(5#3/01)2/%1-101/$3,2/1&2%1#2$1$1%1&1)101)13(1/(3/!1.1(5/!2/$21&11&5$1,22&1/01!2//#1$1.1#2/2/&23+1!9#11/+1/$1)B(1!11#2-4(2//1/%10s.3*2/J/-1#1,1&50301/,20201+2(101%125/.41/$2(4*2)3(1+201$1#2%1!	e`\\JH@LGNhDCHo`@cIIChdhYddeDeLddeHhtMLm\|mP@UUT@QPA@DFe@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xix>S~xixhS~x>xiS(x>xix>S~xix>S(xix=x>S(xi0:v:`*xhF*S~x>	=UUzUmalbUDeXtJpmdXL64NV50H4hMF219a01FkN4VWV424W95BwN01CWJF0VY0264244040F80a!a0IV	0Pg!QF!WR0Tk03AV1204s!n!FV1D!BM06J0Tk03OF1g07g!t40tV3e!KY06F0T01u0EJ% #6F4B3Z140t0G084F552l8JH65WVV8@410JGX8F2822WcZD721ksRoX220FFVk229H22GNNNB63kFRB4B5a0kkkeA@X10B82A6_VVkkRI8VVkNB5163F88Zo279bYcN430VXW1ISP4625CHNs8@B50_ncsN55VH1NB248@ZakW0HZRM@X2W4IRL66311G8VH@4WkVFF43W0F841H6VVGPN4443WkscF@21Vk88611k884cC0VXKFVoN25XlNk226WI1c444@Dm0VkKvJ8H4KBXWtRBBA6m0XkHfg8NJ141t0Fc8RRM46WGcN2A1X22FlZeW6VWVsm2844211H9N@I310FZ83B4a20lRoR433WVG4eK7VkcBD3@5VFG9OBC1322FN48BBs15A0FsLF483Z11VbINFlP2@3J0WrV8J8	$4V!104$4!182$2#5VF!20gF!GYc!4Z@%F#FV$4#G0V!g2g!2F4!2W9V	,2/#11$5!3$1)31/1/$1+4$6$1/+1&1,2)11)4&1%1)21$2%3//+2#1/!1.1$1.1+2(1#101%2(2$1//+1%12.2#2#6&1101/%1+1+3(3)32&1#3/%1*1&1/1/(1+21!1&1$103#1.601//4)5)2)7)101//&1/+1/10o%1(5*2+2#F01/1/1&1#13(2*2+1%6/)11)2/-1(1/%1&2.201/%2#3(1$	fkQb@EN[lxHcHhdhXlhlhdiieMJLsTZx@Jjj`BIjXEGJMD@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
0:v:`*)\F*xi6363x=)\xix=S~xiS(x=S~x=S(xixiS~	vzUvntOSvF4wWFPD@R8GXO2Dg4FF9340V2GX58X01FFB6$W!cV24gVV1W5W!152!841!1F%V0FV	0Pg!YJ0IV02OF1w!C_07R0U!3OF1v07k01LF0SF1r07k0ok$ #1WewBNO1520FciF482JB5Y0VsF27543XdJZ@B310W8V4DGZ120ZY8wL8F5VYWN8k82920Wm508dR286VWVwV8N5H2DDZGcNcGgi23WO0FkDF4D3Z15Vh_kFVA8231	#I0V!18$V@!102#V&8$1+8#1%FV#4$G$1FN(2A0V	//(3#201-4///0@!102//!1,1/&1!52//.11%1//%1#1/(2$1/+1/$4(1//%6/!2/(2/#1+1+1/2$4#1%2&1,1/1$301%1)101/&1/)1/0102,51#2///1*5/!1//2/-2/j%3/#2/L*2/01-1//,1$1&1%4%1)1)3%2/)11#1//$21/4*1(1$	fnkP@@@RrQQQKKZJZIQGEAJSfkZA`bh@@B@ah`@					not given in publication	CaSR	Calcium sensing receptor	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>.>S~xiS(.i.hx>.=x=S~.>S(xi.>S(x=x>x>xiS(x=.=S(S(.>	yJPl619G8F4F0F240N010N2H$11#2kV5#1FV#WV#V104J0FV010V0c#2404%2!10VVFF	0QF!RZ!aJ0Tk03JF1_07g!qJ0Sk1w!DF0@F0t!6PV1g07R0Tk1w0C& 38261m0W0GowD693m0YFRV8R6u7281C0GXZ4H713We0cG4i5274FVF21544WKtBBN4820ksk5H3B11HVFP70VGGdLF4B3L140WVFFE82A19kkWVs4J6LF5V8VZ8291WGwV8J6g2A70XFgV8R6gA1WYkwV8R78261	!132V!O8#2V$2@#Z3#483$_#FV8$R#1V#4PV#a1#18#1uk!BV6#1Kk	#12(1)1.3(1/03//+B)11////%2%13011,2&41$1$1//&103.1#1)1*1&1///+1#2$1*1(3(21)3/&22%1$2$2%1%1,1+1$1!3*2$1(1&1/*2!2%1*2///(1$1.81)1/1-1!2/!C,1-1/)2+1$1&101/r%7(6*201#110101010Q*2&101/3)4!1%2-2$1)3/#3-201/1///01/!41/+1)1#	eghRH@@DNDl`LbbTTRRbfbQVVtRRce`UWQusT@@PP\DP@@@@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.=S(.ix=.=xiS(S(.ix=x=.=.=S(|`.i|Fl0.=`*.i63.=S~`*.i.i|F:0S~S(l0	;tzOzxUpxt3BuUTQ0n3Ncm666Fh38PB6yV7VX1390e611X!J_4VFB9JZ3WDWH09M@VZV6112_1GF50VW0FV	0aJ0R!3OF1g07#o40FV2d!DD0@F0t!4OF1g07R0U!5NF1r07k0j03J$ 06F483BB12VgV8R4@J1c4scVJBQ52lP8NHB6841kBPE7W2Gd99gM2X3lAN8sH2B2m0WkGVNX@8XVsZH30_ZHkGBcL7ZkVtJRa6Kbk8dBJgqB1YVkV8@46X1soD73VVFR2118_4RV8Z4	#@$L,F#Z2#4%24$W#5W@!2GF$2o#64#Vk$3k#14#1NV	%2//0A%2&2&1*2-4/%6!102$1$1!10101$1&3201.2#1,1$1201/02.4/02/021/!201*5/(1//$5&2+11//(1/+1*1&1(1/!51.1$2!2/(4*101#3!4/-1(1+1#1(1//%3.8#1/*2*1!21/07+1!1!1$1/#1&4/+1#1#1(w%3!2*1#3202!2*N/$1&2/!402&1/-2$1/$1)4/!2/%101/)2+120502&4&4*21,	ehZZD@@DLHdi`LdfUfUV}WVUYwQrpJIKY{xEj`@@HfjBBb`b@@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS(S~x>xi.ixhx=.=xi.ix=S~S~.=xiS(xi.ixi.iS~.>S~x>xhxix>	;QvQzvStunnqv6Ft5voQ6LqJ1QiYG2hSIe19F23FG93kM10A7!6Fe50J0V2H!Z47643@0iB8B040JBV0F0	0Pg!aJ0Tk02J03d!CG06J0Tk03OF1k07g01Hs0CF110480ek$ 2giL21lG0cNTH@3GsN@295Zt0G08wkCC40VBRFEZ130t0GkDF4F2A8bHGJJJ41432WVgNE62Gk4ZN21VFl1Vo@R7WkV46B651mbeR885Z13V_Xdos8A4RVXKN8RA8271	#W1k#8%1$4$1$h8$3#438!4V4$F$2w$4#GV#91w!2$218V	/.1(@%101&201///#@$2$1*2.1//1/4/!2/02+2/-1#101////*1*4/+1%3!1(211*1#12*1#1(3/&1%1-7,11$2/4%1!211,1/.1)12$1/#2&1//*A!1//*2!1#111(C+1//*1//%1$r%902&1)2!1,N//%2/#4/*3/+202)2/2/(4/(1/!2+1!1%1%3#1#2$	ek`TH@@IL`LdTtRVRbbbTRJeRxDRZjzvNhBBhJHjH@@aCRap`@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
Q~/jtn^}Bz:0D{<w(W(Wgygy:0<w(WBz(WlvBzBzlv*`:vS~.>`|.i.h6s.>	;UvUzvUUznOgzMmQrvhziHTJaXzb988TUlbdX2YOGY6kQJ88F14Z2BW6q33RYH19HEapXT2A0C19FFW8201V	0ZJ0IV02OF1v!8j0D#qJ0Sk1w!Cr07k0pV04OF1r07g0U!4@V110480eF05@V0j04F0Tk3V$ !O0Fc8twN36Wt0G8@dF94X3l7@8H6A3m0W0G9NmE3YG8t0RNSG611kaF4F3Z120t0FFA_L4529lGVNoBqj7311sVwZEBYFVR8FE8m0WFKQZ8D4BIbFltB4N8VHY0mFZ4R9162W40wZ8K6VZl894H2C7RekVsFwqO@2FVl8NgjCW11saF4F3Z130t0G08RghA11HNcomJ@11HcFD2223XF	#30V!188#V%2#V$198#23$2$18#1F$Hk#45#G$9SN!2$210V	/+1+A)2$1!1!2#2,2$1$2!2*3#@$4#2,2%2/1%1///-2!12/#2#1&2/)4!2$1)1/+2/%11/!1-1!1/#2(21(2/03%3$1,3$2(1/!21#1!3/(2%2/)1////)1/122&10102!@/+1)1/*B)1&2//$1*3/-10v%7$3&1/&L&1/-2)2&302)1/%1!1/.5/2102/%3/$2/$2*1#1+121,	eobTH@@KN`DfZUU_vUmeUHxTlL\JjzFN^jjb`b`@hHHHH``H@@					not given in publication	MCHR2	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J)3p,Bp3W(.i>.~Si.psi.~SzB}\i.xi~SzBW~ixi.ps}\~Shxh.~S~Si.~Shx	>UzrlrxUqvAUCBaL9@dgAHKCVw76Mp0CEVC@AaRZYHVLYy0uVmKNk0c5KkKWd10_c4J10V0FH!8VW0FV	0W80IF02J03d!C_06k0R!3YV2Z0DF016B0O01s0EJ01M40Rk2w0Ao0nV05P01n07k0nV3F!OH07B0SF1w0Ak0p! #O0FcDF4F3Z120t0GkDF4L3Z13V_tcFgA8271BVXON8R8m2E_VYFZW_B6F3M0Yak8k8H2FLZ3kNgFH2L40ZZd0w6D5m0WkJ8Gi6L40_10uRwF42Z1G09NcPE1ZH08wJH2S212VOJVE741216F4P3Z130t0FkDF4F3Z140t0GV8qi4E2C6XNsT@H53Ymcwo@2Y_Wk	!2aVk!14V!6GJ!1TTV!ZY#6XB#VZ#tf#25P!2NFF!ZPZ!1m$VkF!kHo!BOg#3AV	%2$1/+7+1!1!1!1)12+2-101,3$1/+3011$2(1&1#1403011$9%1/+12-1022/+1)1(1#4&1/!1//!5&2-1$1!1#3+1!2/#1/,3&1(3#2.1,202$3*1.22/$2*401!2&4///5%1!1/#11-4+1//*11(21$1$1$1*11(2!1!1,1201/01*1#10p/$31!1201022*8,1.1(2$2#20110102/01&1%@!1/$203%1/$1/&101+1/#11$20802.3/$1120	e`RQLH@LJIEMGOJdbg`@cIEMEBhddlhhecDeeQqhYXxut]]TuTsUTmT@ELh@@@					antagonist	A2A / A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.>x>.ixiS(.>x>x=S(.i|`S(.=.>l0|F.i~S`*.=h.63~S`*)\i.ix6363~S~S)\ix	:UtvdtKSF5w1JAEUN0l2N@u6CF1dW98B6UXC0X82Qk06OWW0XKVSX5R9FZY3CYFW91AXZV4d1061IFJ!W8Fk	0aJ0Tk03OF1r07g!kZ0qV3q!C_07g0zF04NV1_07g0o!4RF1r0Ao0pV0 03g4NW411ktk94H2E20XG88RF@C4_FNNJ28A1FV8D7580VFFoz82@1T0_VFBVC32YWcV8gRH241t0FVAg4VW15X0G8RFZ4C70WkwV8R782917VZ68kN532XWXO0@712IVtB6427WVGOLF4X33FW2VV	#70k!G$4Zs#64V!VZ#1N@#2GV!83Z#1N#18F!1Tk!80P#G7#VNs!@18#71V	01,1#1/#7#11!1(1*3+1,31$1(9!2012#2$11//1/2$1(11/+102!1!1!1#1#1%1/$1-1+3(12-101(1*1-4/&1&1/#3!2/%401/$1,1&11+1!102*11$2!1#1,2%1*1/&1*1-1041#1(13011%1&1#1/&2,20E/#2!1&3$1!101!32+2$A(1/)2%101/$1011!1-1$1%z01#@0301,1+1%U///8)1/-1!2)1.32#2023///-1,1(4*2#11/*	ebQRDD@LKD`XD@@ajPrRPjIIQSIIYIKJJIIKJNAYQI_HpxkTD@PCEUP@@@D@@@					antagonist	LHR	Luteinizing Hormone LHR (I)	no	gpcr-ligands_DescriptorsNo5Ht
6s>.S~,B)\xh.h.iS~S~S~.=xh.h.iS(x>.=S~.>xhS(.ix>.>xhS(S(.i.>S~.i.h.>S~.h	=v;xzvzqfzUvCtUQTMa@QAhktAxQz@3EHj9InuB0jY43PcE@MwP8JAfOFYt52HHB0801XFF!FV0V8FV	0lN0O01u!C_07!Tk03FV1E0@Z!t!bk3Z!DF0@40t!3OF1v0Eo012s0FF1209w# #J_1VlcRJ2T331t0FsD08442G7WNNw6C41XlZ9sm72XWWGW0L420kkcLA30VF4sLR23WlFJD42W088842W0VR641VV85RNi52W1cFH94X0cBD710V88210e2K29BL72XWcgB1@55KkVFk2824252WFH40VVG146841YFV8gkRM90Y8V8585ZO0G08y4G122GBV8Z5D42@X1koH12VVN8ZHLQ6VGOZJL65W08VNb82613W42VP2670F8FgY8281	#11V#N8#2L#J%2#5_@$9#Ff8!6Zy$Fk!HHo$4#9Vk!99k#o2#hAV	$201//D!2.31%2,1/-2$5$2+3!1#1!2#1/$2)1)13//#1-1!1(2,1$1)12#1&1/1%1)1/,1/&2%2#1(201&4041(1(2(102!12(4&2.103,2020102022!4$3/$104(101!1*1/1!41*1(111.1%1)1//&1!601.2#4(1!1&202#1#1)291+1/#1(1/,1/(10z%1(2*1+1#D!4%2*21.3)1&2041)2!2.7!1/&1(33$1%2$2#1/)1011)1,23#1#3#1/#2#7-	ejQ\LL@CNamKC`@aFPIdLdTRbrTTLVbRVrbebRaHhT\JZaqjTHFbjjjjX@bbHOB@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxhx>x>xhS~x>~SF*xh`*v:S~x>S(~SF*.>xh`*v:S(S~x>x>.>xhS(S(x>S~.>S(xhxh.>x>S~	~:Uzh<UzvjUhryxzrz@:nrPr:i6bvrSLhmCAhii5vnEyitDAkRVkS6Qkl2kVB1ga0I0	0U4!UR!WR0Tk025k1v!9_07g!aJ0Tk03Xk2U0DF!t40tV3e!FM06J0Q01v!Fi0440FV2U!HD09w0d03Z!Ji02w0FF1209w$ 06F4@3@14aVFsJco482m0YFRV8V42h61VloNLB2F3FkoD441Fs8gFLH33Gl4L71VVV821C36WVGeKa22221F8RD44Yl8g8820VV8830VV@NSE8251m0WVRV8F5HB97G1NVpN5130d8RDDI2ckkVF930mG98VeH30WcVP8152HXWxD944X1G0FBB310cZF831Vc842G4ct0Fk99o4A20XFNRJVp@2l18VTJE370FNFcJiUCW12888536VVFFcZLSHZFNdF42H0VYlkkZ@@2XG8NB43110J4TE0VF84FJaU@XINNJP4112Wk8Z892WGFVJ@3VksR43F70FGPCZL4D2g30WFG4RI2X0FJ2Q0_2XgV8B42340VVN6763G8FD2110N8420eX5GGsL@3blWVk8D4110VVR430kVcH420VNCBJaCC2n10F17@0FGt6F4V3Z15VW6kVaE572t0FN8VD7930sF83210VB@40VV@F_8HgJ1W1kV4B8520VBB5530NF680W0F5BJa9Cf1k4Ji21@0VHFyF482iI1l8VVG2I7Z1k42D679oFVcFZX73ZkssB411FGVVkB4Q910kVBdC32WfakFR8gC831VNF610V9NkgDC31FNFZI4VVONk6221X3Wd4PG20W8o8615XmwV8F6iC2415LkFoZ1251VFsfCX4F253GcNL93WG8B@426XV88VuJ2@C0X0V8s@D3ZG0JT810V84sHSZ13VXZ@ZV8G4_6VXNHBq891FkkcN	#cJk$4#44#3F#4D#5hm!20zF!se4!7_1#8FF!2@k#V_#SFF#7c!24L!218V	%1!1%1!1+1&C&1$1$1//102-10@$5#34/+1/.1/2*21$14&2!1//#1+2/01102&1/#2)3#1+3!1101$202%1(101!1.2-1$301!1$23$10101(1#3$404/+1/2$601%3-41!1/01%101-2&4&1$1(2.1/%1#1022$1401%1!3!@1/01!4(1!1*2+1$4A-1(31/+2&3$3/!1,z#109/#102-N,2(1#101%2%2$401$202#11/&19*1.1(12&2#1!2-2(22/1(1/!3)1!2*1#1)1!1	em_\FD@AMDeHlmaYPH`bHrJJKKJZJISZIQIPsIJKQZIccpHZZDgeVB@ijjZjjfB@BA`hLCB@jBb@@					antagonist	CCK-A	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
*Er5/[^0wK;8Hv;8;8qh^0^0-0^0^0q>xS;8e3;8S.w[k8^0oqk8w[i6~Ew[|0A3k8D1w[k8S.H0w[W/6=^vk8w[=6a1p=N/	<v[yzUujzy:jUyzr;xU:TzvzIrxj:xmUU:jffxvzxayvQtTEH_XSKQUTMzjSRs_fqRXFGV	0dV0ak02a02Q!8d0D#XZ0s!2R03i!9k0Ds!rJ0TV3I!G_07!Tk3i!G_07!Tk3i!Je03V0R01v0DZ01Hc0D01k07g0uF07@F0e03V0G01p07c0s!7@F0e03V0G01p07c0s!9@F0e02s0FF1204F0Tk2d0D!2HZ0@V0i0440FV1407g0eF3V& 0O0GVDF483Z15Vt0GNDF463Z14Vt0FVDF4J3Z11Vt0G8DF4L3Z120t0G8DF463Z140t0FcDF4H3Z13Vt0GFDF483Z140t0GNDF4@3Z150t0FsDF4D3Z120t0FkDF4F3Z13Vt0FVDF483Z12Vt0FcDF4F3Z13Vt0G0DF4L3Z14Vt0GVDF4@3Z14Vt0FNDF4B3Z150t0GcDF4F3Z160t0G8DF4H3Z12Vt0G0DF463Z14Vt0FkDF463Z16Vt0FNDF4N3Z12Vt0GVDF4F3Z16Vt0G0DF4L3Z17Vt0GcDF463Z160t0FNDF4N3Z12Vt0GVDF4F3Z13Vt0GkDF4L3Z170YING4aCAWG1VmSu4826akXGsTE372Y98wBL6K331OciBC6@WcVJFL8K313lV8pLG252X2VFoJVE1XGK1Vo@46X70HFkwU36270H0cgc36252dBPH533lbmN8J5V14W0FsIgoB1X4W@cg8L4141mWNg88G4DjFkNk82@4bZFXV464G4dYFVNkDFN29W0H8RcLA37VFNFkKsM6W11k_BP4K20Zkucg8F412WinFk68I411XVRcE5YFd98Z	#XVk!IF$F#2EW#vZF!39e#VIk!H3#9Vw#8N$Ho!@07#GWF!8Ks!@48!2C8V	!2.1*2)I2/04!8$2/%2#2.22#6&2)6/+2/%2#2(4.1/0202/&2-2$2%61%2/2*2%204/#2(4+2.2*2//%2/08%44/&2)1%4(B02$602-2%4$2!202(2$202(202#2/.22022%2.2*2%2&22)2$6*2*2!1&2#2$202/!D#604/%2)4&2+42)2/+z)2/12.8/*202&4/!422(2#2$8&2!6#2/$22(44/+2/+204(2(2(5*2!2-2-	eh{|F@@EAfPNLi`URbDaHRDRDcDQHRDIBrDQDaHQDSHRDaLEHHXd\LR|JBbjFVvn^IyiYEeuM}ChJ`fbjjjjjj`jjBjbfbhfDBFJCJFjEbMb@@					antagonist	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.>xh.h.i.>.>S(x=.=S(.iS(.>S~.=.iS~.=.i.i.>.i.>S(.i.=.>S(.i.i.>x>.=.>.i	;vzvztrtxntwnEGt0QDOqHN45Ah10HcPnX510V2F196F_WV2GV04Mo8N489@o0V1F040WB082!3421JV8FF	0PF!Xs0FF02Ik2V!C_07R0U!3Z02W0DF016J0R01v0Eo01L80OF1j07g0o!5P01e07R0U03F$ !3FdBP49X118RRC6XkcR871VFGkwsSL24W4JPwBT1162O0Fk@N4NbA12FwV8F4N1@e384NgB4321NsLC31kNF6310nmGslX_39VFH8aF4B2D0WXFWZqX2A30FFVJ952W8cJ720kc44VHF72WHFk468VFGsyF4F2tKW2FbFK814520WsFaF9Z0cBZLHuJW1V88FCZm26W7HdNs8B4m0WFIV9968E1YW0NkFG64G8N@420Y1WWcyf351t0G8DF4J2tKW10V	!1b0F!d8V!2V$HB#V6#5C8$bV#_8#48!21kF!4Ho!1a4#ccF!9vk!826#13V	01/*1%1#A////&6$5$1//,1*1102/2$1!1!1/#3.1%201.3,1,22)1.1/+2%1/.2$3&2)403&3*2&1)1%4$101+1$2$11/#4$2$1!3+104*1-11-1#2!21/*1!4(1!1#1&2$5,11!2$11$3!51/$4,1!1!2#1)1&@$1/$1%1/#1101%11-101/z201!2/#2&111%L104&2,4/)22!1!2-2&3$1021,12!23!1101/#2#2012/)2(101(101)2(6!1&1!1#1)4&12$	efUVDD@EHaemga@`I@bPrJJKKJIQJUQIYJIJIQHl\N^M]W_DtpPE@PMUUPAAP@PHIKj@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>^}S(.h.>.>S~.iS(.h.h.>.>S~S(.h.>O~,B.h)\6s.>)H.hH)5q.>)H)HS(.h5qS~.>)H.i.h5q.>^}}^^}}^	<mUxnAF4m3Le2FN0lkB6V44FF10d4BMF05GV82Gk04fVV0@B0C26J0F8F10XFVd42JV24g0420FVF!Y0Gk	0Pg!Z40IV02OF1v!9_07g!YV0s!3OF1g07g!kZ0qk3q!FL06F0SF3C!GX06J0Tk3F# !13F8gD33W0WJL4B@W0FG84226c30WcgB20GcFZZ1170FGGTF4T2R19YokVBT816VkG8qF4V3Z13Vt0Fk8Ng620ldVH4154kF944225aXoGJ67434W8886D9RWWFoB70YXGlV9k@A16lcV@51ZZVk48R1166t0G0DF4D3Z14VXlscPR20kNN21A70VGV84JP431VVZ4382FsB8210V8FNZJ0VZV88dI8281m0_FLc9SD82@1WGFJ4@7YkV841111FN21G90VH084LalOW3VVF42210VFJB530VsN@22W0uP4442VFF42210HXk84c116jd10k8K61F90wV4P8Y2N4H720mYGFg896WGsgR34W09Wc212Ab0FF4442WVcNB711kcF4410VcR410VVV9gg11@D9Vkk@F42VN4ZcHZ@6lNJ2B96R0X_V8R9J2L39W0O8@2E5QZFsRR@C5YVXYc8R9Ns22W8VuND8571FGVlJ4u7BW6X0866LB0_0F90V230WkVVD53W0FFD92VkcF840ea089J22HM	#20k!1$24V#F4#e5#888#55#F38!2VR#81F#Pk!8FC#G3#89s!AYB!2WNV	01.1!1.1!I-2#1)3/)3!1!12&8$21#2,1#2$1#11)1*1$2011(112/$1/121#1$4///&5&1#1)11!21$101$1$3&1%@01&401!1(1+2-3#2A/!33)1,3,1&1201.2$2+3%32+2&2/+1/21%1!31$31/1%1+31/%21.M11111//$2!12!2!41(1B(1#1/1%1/&1&1/1*11z!1!3#1.1)1%U/%2///(1)2!2)2$1)11$323*2#1#1011//*21-104(3/0101#2)	ekXrLD@LLnjXDO`@aHHrRPjJIIKYJIIYJIIQFIIKYKQrsriizEdUZ`@@BijjBB`HHj`P`NH@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxix>x>xhxix>x>xix>|`J)s6s6J)zfn2S~zA~Sxh])rqx>|G|GxhrqS~x>	<pyJKv20oW1BaFR0WVs2L640F833042I059481NF8601&2!ZF!520802J@a4V2!80F0F218683F	0G#WR0Tk02OF1v!9_07g!mF0MV1v!DB0DN0uV05OF1q07R0U03F!NM06J0Sk1v07k0zF0 $O0Fc88524320VNN353GFFH50VYm@0R4B22FFcJE4WG8FoT316b4eFGN9kg28W0o286G5Y21_3k8X4ZV130XV906N@3V8VF283Zt0Fc984qMSW60r09KN2I2@0Z0WsZ@11Vs8VDIZ12Vt0G8DF463Z140VF8HB62W22l0FLB21lNRD8B@0VH@184ohHW5kp3k8a4H1D_kIQg4m6H1B_rNGNCkg2915XsFWi263m0W0RV8R7827190amtK@6M4	!3X4V!30B#VN$@V!X%V@!3IGV#Y4$R#1ZF!qFV#B4#GD#8Fs#1F!219V	//(4&1&1!14/)4/(4$1$1$1/%1#1#2//08(2#1*2,1,1.1/!2!3&402301%1!1-1/01&3%1+1+1101%1(1-1!203(1/,2$3&1/2)1$4)3&2!2$6%1&4%1!13-1/#2/&1.421/1/01!12!4+1091/$1*2(1(21+E01#4/-1!1&111$11+13/+z%4(1/!1(M102//&31201*4*2/!3011,2//$2#1/01/(2#1&1(2%1*3*1-	el^XDL@AHTPH`bPZBDfYuUue[YVuWfNEMDlaeg`XH@@f@BjXHHXBHBjHCH					antagonist	LTD4	Leukotriene LT (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.=S(.=.i0:S(*`*F:0(S:0:v*`*F.>.i.hS~.=.hxhS~S~xhS~	;xvhtSSo5w5J@QT80pXNesa4F1dWj80PNV782!9o8631Y0fsWdVVR8Js9WGm2V31A10VJ51V1F303k0W0Fk	0WR0Tk035k1_07g01480Ik2d0A401LF0Rk1p07k0ok05RF1o0Bk0nF3o!OX06J0Q01n07k0o! !m0XkRV8F78271FEkcNRC2S6aW1cYgy@341cmNGRF529_FH8g4PBq16cGcFVC6J29WVsJV8C120WG0ZH45210RN94WFFJ2RF10Y3oOF8o54W5FkVB6G310WWAN4Vi15WBFkGN@928YVkFsB42541W8ND641kVZ634WkVF42G8VFGs44N10W2KRV8B4	!264k!CB4!6Ws#@2F!V3#4c8!205F!89Z!D08!290F#Lk#23#lO#8us!AV4!298V	01.1!1/!@/101/$1/%1%11$3#1*12/-1!1!1&1!101(4/(2%3%1&1)1//01!1!1(6/%101-1#1#121&2!4(11%1&1/*1$2,1#103/01#122/#1!1/#2%13$1$1(1%1,101,1/!1,1$402%1(313!1)1/&1%1,10802/-2101(1.3#8!11,1+1#2!1+2/!1/,o$12#2#1(1011.B(1///02/01*13/-1%4&1$2#1/$101$112/0202%101%6-1-4-	egdVHH@EMOLfcc@HaIe]VWYUV{WhXLlbRjzvN`@jZZZ@bjh``@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
v:`|S(vl~S:v.=x=x>S(S(S(xix>x>S~xiS(xhS~x=xiS~x=xiS(S~x=x>xiS(	=vU:rzxzqvUjzCnUQP_aeI@BnofzQte3EFjNHbvD1iX43Q8A8qy2sFNWIFYt12m48V501VFL040q0V0FV	0aJ0Tk02J03d!C_07!Tk03Z02U0DF!t!cF3Z!JL0540SF1u0Bo01Hs0FV1309w0wF% #3kW2F_lBiA42X0Hc8T992H8J4J7@m0WFRV8N4i_AWVcNN@BXK13GNk8J86815FsNFD9W1Wc8N534_t0Fk9NZF6VHVZ4F9834ltJTF65W0N4BDH64X1NgH961VVB850VF@0S382716YmO4T71WVV4cFKZ130rVNFk6283m0XFFtga48YWWcg4L1144O0G094RK41GHN84X960W04JHL45WlcR4B4WlFV221W0@0d0	#n1k#Nc$o#FB#VD8!1_e$lF!Gf8!64B$1#H@Z#k4#1Vk!1ho!2Z2#A@V	,2/&2!9/!11*2//&@$201032.1#1!3#1*1#1(1%2*2$3/.1/%1!1/,101/*1%11/.2//%2$2/#2)11&1-1#1$3$103,10323,2#101!2!1$4//#30201%101/#4/!1$1$1(1%102&11/-2!1#4!7.101&1$1,12/0261/,1+1,1//*s%8/#1+4#H%1/&1&2%2*202*1!2,108!1/01!203)3+1!2&1+1//&21#1#3#1/(3-	e`\\BH@JKJcBnm`@cIEEEDThcMDdUMEDdQQhydU]}TlDCEUULDDQDGa@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
6s>.S~,B)\d,.hxh.iS~S~S~.=xh.iS(S~.=S~.>S(.h.>S(.h.=.>.i.=.>	:UvzvUzxKzxnqvQUzCnMAP_a@G@CkS9zQt@3EHjHIbuB1iX43P8ED4R@sF9WGFYW92m0805010FF20GX0VcFk	0PF!RZ!t!bk3Z!C_07g0zF04AV1209w0ek055V1G07J0TV3C!KX06J0PV1v0C$ $E3VINsJBC5WVWFV4FHt460kJJDAZ14VWH8sL8I5YG0NwFC25Zt0G8DF4R23A_YFNBB960VVl6F4B3Z12Vt0G0DF4B283X3NsJ@0Z4Fk8wF29@K_FX9w@4C434kd4Fm362kmcJ216X3Vk8kkJKDY0c8BDD41VWODF4@2M17@0GO84HH13XKkFko484H47Flt8q4B595ldsT@55m0Y0F	#I3V!1Fc!20o!1FB#V@#5cd$ZF!9fs!6VB$W#LPV!1m4#10V!1fo!2V4#AQV	,1/&210701*2/0201/(1/02$1+1%1#2#1*1#3+1!2!1%221/-2$11/(3//%2#1.1%11/(1,2/$2.2,3#202(2)11$1+1$32%1,1!21,2%1!2!1$1$101,21,1/!1(2$2/!101$3)3(2)1/&1&2!1&A.1)1$2*101&14!202#281/,1,1%1!101//(10p%2/#2!1&1$D$1/(1&2%2*232#11$1#1+106011/01.5.2///+21#1#6#1/(3-	eodVHD@JKJfagc@@bJPrQQQQEJHqJKHjIKHbcQpjkXziXHFJjj`@nH`|H@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=xi.ix=S(xi.=x=x=xixix=xiS~x=xiS~.hxhS~S~xiS~.hxhS~S~xhS~xi.i.>S~.i.iS~)^S~.hxhS~S~xh	?v;nzyvUntJQzxiqyabf_WtTdAzX5kX8@IFu0Q_Y4AIl47Uy8DwHA@YFd821H01BV@@238VKWFY0G0	0Pg!aJ0Tk02OF1v!8j0D#b!vV03AV0k044!t!bk3Z!Fh0440FV2U!G_06k0R03i!F504o0qk3q! !m0WkFF4222WkkcF82Wl0J822VV882eK0VZk8902126gVF8BF7431FZF630Vc82VL10ZkF48V20W35FF898741m0RH7410c841CA0VF4BZ10VFlV84Jg61FY10ZPH4VksBZi119W0FFBNSH9110V8N89@3H8N6621FF8sNR46a1ssJC212GW8ac7381e7VFs8AU23WO0FN846632G8gF841kc4631860F4210XYVF8hN611Yl0oZ82Vks82PN0V_0V8614594YNgL@42Wm0F4RF37722B4175Yt0GN8ZR642lVo692WVF8oVPR1BVks4gEA34VF90V@bE6l10aF4R2210WccZ84X0cJ45374V88s42A10XJFc9gZC92l8cNc3190VH0N4N4155ZeFFZA8261m0X0Fc9sTG73FFkB20Z_0848X616W08FcwVA221tJgDC10Xm0F@w@42WksN@53W0V845210VF410V_Y084g1114k895g22121NBD64Vks8422VkF8D210k85Ve20W4LgF88F4cS0VlVNNiD5YWsw6FJ810VsR@72Wl0J@2110c82130VF4410VF85ka117iVkkNHA5Xksc6311kF8221d4oWtswJ2XYlG0FeO53FNc@HB9@8FWlRZ5352VG98PO54kd14Vu2JYVZFYgR884KFW4I1R8R8O_W1FYc8uD2A211WNgPD7WVkF461a_3F	!110k!38$42#4%D#A9e#1p#FY8#ZF#8FF#@o!8FC#OV#GCs!256!258V	&2+2,102#K/!3(1/*4.60201802!3,1//.1(5%1/,1+2%1(1$1(1%3&3+23.21&12&202/!2%1*2(1012,3#1&2&1#22+11.12102#3&1!1/1!2&22$1%1$602%1+202*2-2$1)1#2.1$1//%1-1#1!41+1!D$2/3/&2&2201!1#@#1!11!2-201/1(2+1#1!1#1/!z01#504/01,1!N01!4,1*1/06)1/1,2!1201(1(10101&34/.4(2%1.4$2.3*2)11%C$1012$	ekX|FH@LH`XDACOO`@cIIChhlleLeDeeDeeMDedhdeMFnckbZ]SUjB@jjjj`@fjj`@HcAraJ]P@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xix>.>x>S~S(xh.h|`xh|F.>l0x>}^S~x=xixix>xix>xi^}w<~Utnx>xhS(x>x>xhS(S~	;xzhUUzpzxUTQQUUBrQfAvaAm6CVxETLt@A7I5QQbiZWYeLnuVxXqo0s1exGNMWd0XYBFK5WX0F20O0VW0FV	0_!uF03FF1204s!o40FV1D!C_07!Tk03OF1k07g01LZ0RF1p0Ao0ok05YV2F09w0c03Z!Kl07F0n03C0EF01qZ0SF2D09!bk2V0DF% !l0a0F9BA8211l0aFF9FA8241l0ZkF8wA8251m0Y0RF8k4292m0YFRV8R5w_2E0FHcTF4D2nMW7kF9JE42P0VFX0P244H0VFWcWKLY331a_G0V8N0VZlHeh6663Eg2VNRCRq2712Idgu55E2Z5mJB@65B@XkN2BP6FkkVcH9gB34WZ3mZN8F48cnsZB@W0ValVOh4L72XGFlBi6Y7XkVoF@S0VZmLI88L44@_koVgT46XGIl1Zi4U3Z0lF2@O0V_H39RDF62_2048XEZ130Wm8wR923VcFH1AD_VlcwHC3XFsw8216830	!1r4k!F4#618#TT#V3#3VB!10Kk!Gd4!34s!2kFF!o2Z!@mM#5lV!11k!4ZZ!2E6V	/(1.F1,2#1)1)1/&1&6$2$3!1%1&1/.1#102!102(3/#1)21#1/1301//1103#1!1$4&2(1$10101+1)1#142$2%22+1(104/0101$1!1(1&1/%15%12$1&2*1,2!2!2$5.1/!4#1)4/#2!1/01%102&11,1/%2+2&1!B01/01$1/%1$2!1&6#14&1/20204.1/11/$1%11z$1#1$1*1&1#1#F#1/$1+201&1)1(1/$9%1#1,203101$12%12*1$1/%1!21/(3(61%1/3#601+	efUVJ@@DLMKEm`ANcl\bbbbbRrRNbRrRbVTRTsDegeSQurIKUTuUM@ATtpADq@@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.>xh.h.i.>.>.i.>.ixi.>.i.i.>.iS(.>.>.iS(0:E|0l`|(S0lE|	<vzUzSmaOKaXDuOLpqS2mXVFVC0v2BMIK59281GkN4310BYDmBZKR8F0F9NF0V31264!K02020Wk!Y0GV	0Pg!WR0Tk025k1v!BM06J0Tk03OF1k07g!mZ0IV3V!FL06F0TF1w!Kp07Z0U03B0EF$ $1Z11Vbm3JBT6F35lkcJJ773t0G0DF4J3Z150WG8s854XVcB8A20FkB420d2oVFJ6322WNg891WkVF4828YkF8o22AI0eL0cFL8K3VkcRT94VlcRgNL10YGsg647B2l04J9590VVFs4225c0VsJ483XW08J52WVcJ452VJlk44N115@WY1wkD562VFckL821lVZ@85Vk882V@Fm0VkFcwD420lFZ4720W888328YkF48La24VF8BJ94WVVZD210kNB6230_Gk44Ng2JfWNVsFg61VGNBVA1YVNRkROZ11Vt0FV8R4eAE3FW0aBD710a0swF6D30VF@70_Y3BV8J4RN@7G1Nk4HAZ140f70FZA82A1	#Y5V!C8B$2#B3#VA#2Ve!2Vt#F9R!20u!20GF#VZ!104#3VV!95k!1Jh#xNV	//#1#8&2*1103//(1&2/1/%1/01%1%2*4)2-4%11101!1-11&11/)101)1!2)1%1/1/(1!1,1%1/(2!1$6!1&4,1(1#3$3!5%1$1+21!101012*1+3#3/!4/01&1+1!24*4,2///1%2$4,1!602%1,41&1//0@//02///&4&20o,102%3#1+1#D1//(3%2&302#1,1+3!1*1+1(2201,1/&2+1*1*1!1&2/(2.1!	eghTLL@INcOI`H`bHVBDfYwUkvUnvuc`ij[XzzB@jjj@HZf`fCP`@					antagonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.=S(.=.i0:S(*`*F:0(S:0:v*`*F.>.i.h.=S~.hxhS~S~xhS~	<vjtSSw5y5J@UT8FpXNeuq4FWdYj88PJV78X019o8631W0fcWdVVRcLw93Kn2V31A10cJ51V1F@07k8W0FV	0WR0Tk035k1_07g016J0Sk1v07k01I!FF1204w0eF05O01p07R0U03I!Kl07F0n03C0EF$ $BV8R782F1m0XVRV8g78241ZakW0HJ4PZ5YkksWNV4I1Yl18812X219Fo822Y1FVR54XFN8oX117VFFFl0gF2AW1cGBk7281G0FkW@2FMVXls8ZC062A0X08R8333FV4844462Vc8By55WksF485W0cJ820b40F8o2224e0HswBo26Vl0RP27810FF68@Dm0VkF	!224V!1BB!2WN#82F!V1F!1c@!201#81%8!29FF#Lk#67#GG$Ss!9V4!290V	/$1/!B#1/$1-1/%1%12$4#1*11/%1*1!1*111#1#4/(2%3-1)1//01!1!1(6/1$101-1#1$21&2!4(11-1/*1$2,1#102+1)122/#1)2,2&2$1-1%2%1#10203,1&1*3,1&2%1(313,1/&1%1,10902/-2211(1.3#A!11,1+1#2!1+1/!1/,q$121!2#1(101/D(1,1//#2/,13/-1%2/01/$101$112/#2%101%4/,4-	egdRHH@EMOCc@HcHhdldheeDddhXdmPpYYDeTul]@ATttt@UUQA@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~S~.iS~xi.iS~x>.>xhxiS(.ix>.>.i.>O(,d)J63	vzUvnfzKvSJg3R9PUCNkX8FdZ7FWg0A1DHF27220F1k!10W0@!9V0o0HBW502203F0l0FJ$1@F180k0Nk	0WR0Tk02cF33!BM06J0Tk04NV1_07N0o!5Mk1W07J0jF3I& $1NZ8c2BZG8cJ310V9FZkR92@Y30NR35W0G0g229Am0XVJGO81441VFkew4Lp141CFGXw4F4860Vn04VD1YFVVB520F9Vg229Fm0YFRV8B5e2EMVXkV	!164k!30B#4e%k!c$1c8!20F$W$BN#8FF#2k$a#K3$5s(210V	01/(1031)7%1(1*1!4!2#1//4$2#11///(1#121!2#3/4&2%2%1///01,1*2.1#1/%21&2!101&4-1(1/&1#2/!1/#1,1&1.1#1////!1+2#201)301/)302//$1!2/!804*2.2!2,1#20113)5//+11$1//01-g#205/#2(1&F$4//#1//.3//$1//&1/-1$15(5//01$1#	fi{hB@E^CTXHcHhdlhhdeD\eDjL]Ghx@J``Xje`h\h@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(xi.ix=S~.=xixh/jH)S~28Q~(Qxh)^S~55xi.i(Sqq5qS~S~.>5q.iqq.h`|.>F|.>0l.hS(.>.>S(.>.h.>.h.>.h.>.h	=vzx:x:wfvUjdtDtTtrjUAhWCeiYwXEPXj2frwaS6Y0aFJfeJwOFZ375XPVC9AkZVC8d2qG301!V0Fk	0U4!Z40IV03FF1504s!qJ0Q01v!C_07!Tk03Xk2Z0DF!kk0HV3q!Fi0440FV2l!KX06J0PV1v0C!1Kw0NF1p0Ao0pV$ $2WR8u47bkkWNNHI81alG4B950lXODF4D2rLW1Vg0F8i42EFk8WJGJ1296Y0NBNABB12VYgR8J5Z16VXXNZ824XFd0P11a6IBV8V4v727WAZNs@8Q4b5VX0Hk4Ps14WImcG08B_RWYkwV8R78261Rd0c8Fc8pMW1VVNRmPD2lYNk4LHB42FV8FN889osNV@26410XdsqH0YZ1kNVPE8Z28V8HT94@m1gB@A510VFND671l0N87210kN630V_4@VBq6J3G0BRcDJ5XJNoF47CYVFFRHE84GFRH410IJOcNPH9_G8V629C4VYWJeI2W1lVs8BA7ZX0gH520Hnk44qN10VVVJD852W0g@73WkV84Z_H10l8F@95X18RD93W0V910WX19VVH8FXo4P10a0k8wcJ9XW8821@F50HmFyA5BXsVGN84H4154n9ZJ710HIO8886621NgL94WW88p811G76qs8V844	!1U4k!I$6cp!3Lv#qL#59E!1Txk!8W8!41U#8tF!4Pw!2X4#1vF!Vvk#bZ#C5V	#102+1!1)102$Q1%1!1!1&1%1201$101$1*1,62!13!202!22&1$1)1!1/(1011*5#1$1.1+11!1&2!101$1(11)1$20111!1%3!2(1$201$1.2(4021$1$411/,201/01$71/021#202*1#14&1,102/2#21!1!2!104$101+1&2%2301!1#1!2+1#1!3!1*2%1/03(1$1/&3$1(1!3!B!301$201$2!2!1*2/2*A$2(1,1020202(3%102-21#1+1,z!11!2,1$101&1%J&1/!1$11(1&1%12$1$11%1$3$7101$1/02(12#3&11!301,2$101/)1+1%5!1#101/204-	ehvzBH@IGOCkhLiSP@cIIhdeEheleCDeDhdddYdldddaMCGMkg`X\^QV``djjfZ`bHj@BjjabHMjHBh					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xh.h.hS(x>S~.>.>.>S(xhS(x>x>.>xhxhS(S(v:`|x>x>.>vlS(~SS(xhx>S(xhS~x>xhxhx>xhxh	=fzSzlpxURAjUS8lXtPQ7CH1h3A@D7rXCAV5AQu8Z01WFaKVOaKq9FhVAEY8dA1cyVB651D45GND1!V0k	0RZ!WR0Tk025k1v!9_07g!d80xk045k1_06k0Tk04OF1k07R0U!4JV1Z07J0pV04Ik2A0@!t!6JF1_07N0Sk1w0C! #YuwP5133lVkg8493G0ZVe110kkV8276beXtRH253Xt0Fc89oc381X18oB613WFgT3163nBV8o5wa2315FNG0JKHWVFccU82A121kkVDC4VVNg4210k8F620Vp1k844AL44ZGFX1660FGFyF4@2732ksF@531FVZB@10VNK4TX152kmcZZ685lGs484B@3WksV425XFsR8110V8443H9W0kF48DL39WsBaG1YYlucw8F474WkVZ241470VRL73Y10BVaVI1C0FFJPJF1k914b826110YvN8oD2A3U9VVcG0LFE4l8kcPu7251O0FV8FJD@XlkJR32532XF4HCB4VNR@HF0VYHVs8yq2C10XVrmN8J478152cgFL41GWW6844@2m0W0GNk26N52l8JX393Z0V8kgc2T0VkNVH63X3cJcZMZ13VVVsc@22VkFRP31WFN4422VJn04@72X4V891VcQ4WaFe486K10Zlucw8T4161VkF270Vk8444720kFF61e5V899Ja2V0VGFoZT3Y_k89Jb82C1m0WVHN9s@6B6VVdVJ121_2HN@F22W111s8614c1O9Rg	!1P6V!10B#Vu!162k!aX#4cf!2VK#8d$Cs#K4F!cPo#4j#KW$Us!@46!2S0V	)101/%11#6!21#1%2(1&1.2/%2$4!102%1$2!1!1/(3*10102102%2404#1$2#1#1!4%2!2!1/01$1%1,1)1(2/$111!201!2/+101$3!1&3.1,2&3%4(2#1*2/30631$2/01!1/2%4!103(502%2!202!21%1(1$1%2#1$1!3$1%1(2/0201/1#2,2%103)121B+1#1$2$2!2#1/02)2D3/!1/!1*1!3*111-1#1(2!z(2*1*1011(M*1+10201)2*2%13&1(1-6$1,1!1#1/!1$102201)1(2/#1/)4%1*2*1%1!1#	em_RLD@BBneSKDPHcRHrJJJJIIRyQJIQJZIPnZIKIaQkY[xy{dVBBhijB@dBhi`@lA@@@					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xiS(x>S~x>S(jw)^}Hx>~U8tQ~/<S(xhS~-g-gx>S~xh/</<xh}^x>S~S~x>S(xhxhxixhx>S~x>xhx>	zyzvTfOM9kCs0LAjSNHlkOAH6B8b9YA@BMzmC0V03QkA0kWcDHKVKaKTWNVXOElGduI9Xp26GVB459Jm5J#F	0Z80IV025k1v!8M07g!_!uF02J03d!BM06J0Tk03OF1k07g!t!bk3Z!DA0@!t!45k1_06k0Tk04NV1_07g0o!7901D06k0Tk2A0@!t% %FD@1XOBNT@15W0G96F4B2G31Hcc4@443lk8gB28@m0VVFlVBGA10V88HC2W0W9TF4D2uK12k_3k8D4u17eVGNKgH4B2m0XFFsFD@7XkcNB215Zlk94J2DC0VYQk8g@2932rVW044B64E_WcZJZJ173O0FkBZ4RQ1515OsFZA8271m0WkGHs8T2@5FlNeRB4A4AkVsVN474WkV8H91118R841VoGsN4N2159WYF4Bo55VFG8V4BDa13F8VWR2658W0VNPC33H28c4B365t0Fk8co6381Y0488A81VVtAOR4D211188F552lFF222W0VJ420dZFF88R116A0FHOu24E10VWVcKkb36WYnO4254Wlmc4D71X3XwV8N44i3W_08JNH42YX6I88H4eS11Fd894q2B2K0XrF8RA8261m0XkGFdc40VGWGN4FEZ11VVWcBFC0ZksNZJA23FklVlFC4WGH0oH4A7m0XFH89RT2K7_0NB8@E1VYFVZ@6910WYBV8B782A1S0Z5F8g822Gj0YV8F8L8KbW2kW1V8X_A13V88g45243VFHkHFH38VV88BPDe16iVG8FkNM451NkRJDu390l0NV8@5XG0oqFB4VXXFFZPV51WFgBH@9ZakVVF46681lsBLG7Vmm084LNQ15mFG0F44q751m8Z8642VkF86C6VVGOs44E4Wl8g6A220sF411c40F8d4q2EZVXkVFN2I4940VoLJ132kk8Zg	#Y4k!584!532!1H4V!a3#6g@!2FSF#f8#VR!2!F#HZ$Z#GV#9@s#F6!216V	012)101#2!1$1*8/1021041//.3$2#12+2//*12$1103&2!402#2#11%4%201#1.21*2*1-2#2(4/02%101012!2*1#2$3!2!2*11)12$1(1%2!1/+3/(81%2#21-3$1&2#1%2$4&2)1$20101/$1/#4#1//1)12+1.2$21.A/%1#1/0112%1*G#301$2/1!1)2*2!1*1!1%1!1/z%303%2(1$1,O/%2.6&206)4/!1*4-11101$404%2!4&1.1.21//,3*2#2%1/$	eeW\BD@KHlS@`QPHbZHrJJIJSJJZYKQIIJFZIIKGL\VNECHld|pDETpMATU@D@PTPDEA@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.iS(.>.>S(.>.h0:S(*`*F:0(S:0:v*`*F.=.h.i.>S~.hS~.>	;p3_tK9k5R4J3ETN0_XN2uV0F1d3j!HFV58X01Go86I1W0fcVdVVJ8Fc91Mn0W31230cJ50V1F205F8W0FV	0WR0Tk035k1_07g!oR0Ik2d!G_07R0Tk1w!KZ07J0Sk1w0CB01M40S03B0Bo0x% 0m0WkRV8g78241C5VWuVL4B4N@1NNRE42231CFGeBN483F5VXNJF4@23FNN8JFWA15ksN8aM18VVkFoR@713G0VH83XG0Z4210J1k44NXp18AkGNHcP4L1308wD@D40Xm0@8a6P12kXcNH838X08FkcH72XVsRB72WFkBB72VVP9022@Hm0VkF	!234V!1BB!2YN#82F!V1F#c@!201#81%8!290F#Lk#62#GG#1Ns!1V4!290V	//(7#1*3/(1/%2%12$3#1*113/$1-1&1!111#1#4$1/!2%3-1)1//01!1!1(2/%101-1#1$21#1!2!4)1(1$1//2,1#102+1)13/$1/.3$1-1,1#1*1%1&1*1,1&2%1(311,1*1+1%1.902/!1)12!1(1)1)9!11,1+1#2!1/01,1/,k$121!2#1(101)1%D(1/,3///013/-3%1/02/$101$112/*1(4*4#2+1.	fmoIB@EZ|LpHcHhdldheeDddhUJLMZJZm`@jZZZ@Jh`@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.=S(.=.i0:S(*`*F:0(S:0:v*`*F.>.i.h.=S~.hxhS~S~xhS~	;xvhtSSo5w5J@QU80pXNesa4F1dWj80PNV782!9o8631Y0fsWdVVR8Js9WGm2V31A10VJ51V1F303k0W0Fk	0WR0Tk035k1_07g01480Ik2V0@Z01LF0SF1r07k0ok05RF1o0Bk0nF3o!OX06J0PV1r07k0o! $382A1m0W0RV8R5Dx241C_kFs9gi24W9YsGR22IDVZF88sL@2C93FW0PNy4I0WmkNo22A60YlcF8@32VkoD526ZF88ss2hB1aV89JD86WZF88oX@2FEVXkaW88g118Z1VFs22A65XWV84742VVF694VkN82XFGm0VkF	!224V!CBZ!6Wk#8@F!V3#4c9!20_F!81Z!D08!29VF!4Lk!8X3#GO$us!AVZ!298V	01$1,1/!@/.1(1/%1%11$3#1*11//01!1&1!101#1#4/(2%3%1&1)1/$1+1!1!1(6-11%101-1#1#121&2!4(11-1/*1$2,1#102/%122/#1/&2%13$1$1(1%1*10102,1&1*21+1$402%1(313)2!1/&1%1,10802/-2101(1.3#8!11,1+1#2!1+2/!1/,o$12#2#1(101/B(1///02!1/)13/-1$14,2#1/$101$112/#2%101%6)1/!4-	egdVHH@EMOFncc@HcHhdldheeDddhXdmPpYYDeTul]@ATttt@UUQA@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
F|)\psF|F|ps,d>xW~.>.h.>.ixi.h.>.h.>S(.hx>.>.>xh.hx>~Sh.	<vvzvzvo3jLIDmdmvXO0L8XFWx3X2hHHr51X0YVFG60G14@1204LLt2ZG5JY103V21i0q!e1B05!4VFFV	0Pg!aJ0R!25k1v!@N09g!mV0G01D!JM06J0Sk1v07k01L40Sk1u07k0ok! %O0FcB18462EGVW8F42243GsgV820k88oT11WFFBJHZ341kcgN7510FF84110X0o430WX4kG0TA8_lNJVRGZ140t0FN9uB4A21WkkZD74VkFRB61VVVB441Vk85NHg16W0GBiG12FV8gL31461Vkoa359YkNc4@3W1lOW5@4D9akWNXFXU82210FNcD2XF8BH22WVVF4418XJJV8a0272HVY488cy283m0VkHFNZBD2kkskTB2C6ZFW8O44NsCW2Fk	#6ZV!104#V$J3#cX#2g2!20F#F3#8VN#10F!FPo#44#GV#8Fs#48!258V	,1/*9!1/!3$1*3!1!1/(401/$3!1//%1+1#1$2/!2$12/(101//02)2/!22*1/$22#4!1$3/-1)101&1#201%1)1.1(5+1+1(1!1)3!6&2$102$1#1)1/$2-303/(2.1+1&3%1!2(1%1+2!4/1#1)2-1/!7//(102//%2#1!1)p1$3$1!2&4!2!10101(D+1#21#1//#101/4*2/*2!2%1//&2(1$1+3%2&1!12//)40	ek`TDH@ACHj`HcHhdieBiDTeEDemJFAINimch@JZjj``bhb@@@					antagonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
:0(S`*F*0l0:~S(S`*S~0:S(x>F*0:.ixixhS(S~.>S~S~x>x=xh.h.ixhxhxiS(S~.>x>x=x>xh.hxiS(x>S(	=v;x;yvzUzUuzvzUzUjzaqx:fjzAbnbzMzqdoEzyUmErxQjbjTnyCEyGoDlqYRhIxlk5W8xXV2010	0aJ0U!2Ik2l!9F0DZ!b!vV04OF1g07g0U!4@!h0480eF04Xk2D09w0t!4OF1k07g0vV04FV130@Z0wF05@!h03J0FF2U!Jc08g0YV2U0DF# 0O0FV98PJG3WG0cceMA3GNkgOLD@3l1VN2486BFVFVFJ895YGswB620kVN810b33gV8078241E_Yt0FF8r2cFlc881343O0FcDF4622C5Hl883242X1ow8343XO0FcA9Z482m0WkI9BRI50VkBVL214Ze41FF8G4NgkW0LF4L2f642FVs@2B20XV88RRFGKakF82D@71VWFsL@5XkV882213Ws442122ZgV8B4F_6YHFcs@211XV88R_Tf3WXVN8VFFDEaksc41884DF9FT8G0W0FNgSFp28VkVFsF6@53GNkD510kc84310V8821J6@O0Fk@oN4JB2kX848235YWA8Fw642626YX4B32351gV8N4QL0WYFwV8o4DD5Y1kwT40VXWk8210X2I_24Z712_WPcw8P5Z18Vt0Fk8VXRAX1FB4FL89cJ8VFs21VVn0stD4AM0X0qk8dR27214H8FLF320kFBLA0VXI32Jo620V8swRRc25fVG0QN4Pi151O0FV8VJKFWWFN8FG0VYmGm8u65VlXc444G8m0X0F	#dWk#B%Z!18F#V@#5hc$7F!Ff8!4_$8F#VPo#p5#Oc#13s!244!21BV	/#1/#D(1#1$2!1$1#1*1-2+401!@$2*1#202$1!11/!2/!1011%3/*1+2-2(1#111+1!1303)11!2$11%2+302(1-2%102#12,1#11%1!1401111,7&1*1#1$1(11#4&5!1&2-201*1$704015&25,12#1/$1/#2+1%2(5&1&1/$5.101$2%2!63.12&2&1!1/01$1#82$1//%1/&1%1%3$1#1%z/1/1)H//#102(1*4/%4!1#41101.4#503(1701)1!102,2.1,1+1&1#5*1#102*5(1#1	ecTzJ@@DLODhPCLQU\bbbbbbRRarbTRbrTRvRacQC@fcgcRqrKvMLkUUUMPTATAPQATUTDXDDTTBD@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
.hxhF|0:x>(S0lS(xh*F.>zBW~3pJ)S(ps`*}\*F*F.>}J}JJ)3pS(`*`**F*F3p	vzUvvfzUzOzxQTAEUSBluuPvZAm6gYFBDHUXC7m9APk3akYVHeG0QV4olF4Y75f0WW02_Z4L!8102B081W8kk	0G8!Z80f!3OF1r07k!r40j03L!K_07N0Sk1w0C!1L40Sk1u07k0ok05OF1r07g0U03x# %O0FV8885@4FkZ8F9920H0F4R31561Y8VqK590kH0Z4PD62b20VV2763kGF8245@89oVNkH274m0WkFF9sJQ61VVJBA20Fk8kX31771WtgaB435FFN86G9m0W0RV8k4211XGNVH@31VkJB910VF44a8I110NcNC2XGNVF44VFGsZwyS52X0BNHBCD44VNJH@66Y2koT45Z2VF8VZPbDWXm888D@h15CkFsLF4N3Z12Vt0H08W2D6XW8NBF68	!2a0V!I08!2sR#Y2V!e1$Ac!12P#814#GB!3Gk#Fik!675!2p$WFs#3R!2A1V	&1(1/0101!B!1%1$1$1*1)1!1#1-1!106$1!1!1/*2/.201#1#3/%1#1!1201#1//&1$1/01+1%12//!2,3101%2(1+1/!1021@01%1/*1&2//-1%1-3+1%101#2/,2!3.12.2%10201.3$12/!1*101031/$1(201(1%31-6%31/%1#2!1+1!10101*2*1/0u1&2%2%1#2$3010101#I(1021$1#1.1,101#1$1$1/!4011)1!1113/3)1%21-1$1.1/1$1!11!16,1$1)2%1&	ehZV@D@LBFGLm`@bzPrQQIQYJJIQIIKSIIUcbKJjXX{xFfjjiBBB@H`F@@@@					agonist	sst2 / sst5	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
F|lv*`:v~SS~.>`|hxh..i.h~S.=hxh.~S>x~S>.hxl0lv>x|`J)|Fhxs6s6>xJ)hx>x	:Uvzv;S:vyvzEzSvzvuCzQ:irJCzIteEjmaNPrzjoybLEI9n_Dpqj4W_7fjd_8qp8kJ3E11NVBcNhV0kV	0aJ0Tk02FV2g!Bi03!IV03OF1r07k!sg0cF3Z!Gv09!bk3Z!KW07R0TV1w0CB01Ns0Z02U0@40t% %D2C1iZ0NVI82213VZ0Qd06@4IEVW0Kc4J@13WNFNFc8636XHcch4181WmBV8F4D2GA518NZ17YX22oF8N@151hokRBD7Z130qVsBBH63kW10bmN8F422YGswV421VcJ820b2YWO4L74Yl8k@215YXkNJLD7Y18J443VkV84TAE2YndJX63YXGkFVZD3XW0Z@940Y2044PP79XmNoHD11HGN44HKZ13VWkHVCoV372O0FV@Ow4E23V__G08VF1YklNnSB7371VkkcJC4318B2221VFF620d34V	#f0k!G8$V2!18H#cV#1c@$1F#fF!6Z8#dF#V2k#J5#O$9KN$@!218V	//(B!11/-4!22$1-1*@$6$4(1/%1/-2#1#1/2,22/!2/&1///#11/)3!2)101%202(1021(1/$1#7(1)1#1$1,13#2!441,1%1,1(1$401-2*1/(1-106%4#1!21(2-2/#1#4-2#1.7///03+4047$1/,2*2/#1/&1(x!2!71/!3$1!1&F/02#1/1(4/%2#4#2(A//$3,1#3//01/,2!25(1.1&1*	elVZB@@DEDmdPAIHlbbbbTRJttTrfTRRrvHXL\fv^AZhE`bfjfB`bhb@J`@					agonist	SST	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~.hS~/jtn^}.>D{x>.iS(.>.>S(.>.hS(.>S~.h.iS~	vzUvvv:rSzjvyvQShCmUftdyErEhZPRiiR0C2kY@A9XZk4XarJ1PB@48LF2M5gB0f11WV3420FF1IF0VV1!k	0WR0Tk02Ik2V!FM06J0SV1v!Fi0440FV2V!GX06J0PV3F!KG06R0RF2w0CN0 0FVZVINL6D4m0X0J@56683m0X0Gcso840l08293_XHnJc8H4yF1VlcTF4B3Z130_WH0Z8532lgV8k4@A14H10B234YVF8kD924a6aGVBL7Z11VZklJiC3X0O0gV	#b4#124!2VF!10@#V@#5Wd!2VoF!8@$KR!2IVF!48k#X4#8%nk$4#13V	01202/%2)106////&4#25///-1!202!1$2(1.2%201#1///%1//(1/!1!22&2)1!4-1/*2/(103#1)1&402*1%2&1/02#104&2!101(1)12!2102+1/&1//#3/!2$11,102#101,6//-1(2)5!2(1//%1-1/2/j%502201-1!202%2#F$4//*1//(3//$2!1-1*3&202-2/1)2#6)1/!4-	fmoXB@NJt[KPQFQQIYQQSPiYQSITXhtTsW@ATsUUT@AP@@					antagonist	V1A	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=S~.iS(xi.=x>.>S~x>S(.ix>xhxi.>.=S~x>.hS(.i.i.>.=S~S(.i.=.>S~.i	yLuK209G8V5k4021FN010N2F04!1192!FV18V02FV0201#FV12G01FW!B#8020Z044V8411%V0F	0RZ!aJ0Tk02Ik2l!9F0DZ!qJ0Q01v!C_07!Tk05OF1j07N0Tk3F# 0m0X0RV8V78281m0YVRV8N5ej261O0GkACX4B2m0WVGdtFF46XHkGWZ4H5B1@220FwDL2FBVXkVgN8o69W5G0BJ@6J53kWsiF4B3Z16Vt0Gs@xe4H2m0_FRV8k4	#H2k!WF8!@0d!1T2#V38!688#Vp$38!20P$1$Hg#22#1VF!1ek#Z4#5FV	!202/(1)4/!1!2//1(1%6$3/1/#1//%2%1#1/)101.2/,1(103!3!1#402//#2/&3&202/!101)1/(2)23/!2#32/%201#11/$3$201$2*3$1!3$2!1+2//&202/&11/*1)1+1!F!4//*2(4)D/+1#2&1,1//,x#1051//#S$3&2/(4)6)3.1%3(1%101(2$203!1/&32/(2//&1!3!1/)1(1$	ehR\D@@LKC`KdieYf]V~WWudSSsKiZ[Z`b@KB@@@Bj`@@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>x>S(xh.>x>S(x>S(x=S(x>.>xhS(S(x>x>.>xhS(	zxzprWUOtm4GKJ2D0G0G282HVV!502280l201!1F$W!1!20Jm8N!8#c2!6484!2062#1V0kF	0WR0Tk035k1_07g!qc0hV3F!DF0@40t!4OF1k07R0U!6OF1e07R0U02q0C! %m0WFFGVVN6VW0N43@4_1XdoVE532VN8VU8221m0WkHsRVH32kkskD40WX2VF8VN@40s8VX41VFFVRk6C0YHNkR431kV44P@Cm0WkG0siL71VFt4@523VFFdFFHB8YGkNH4154FF48N210Vl1sRJ852lsZ@9210s8oNQZ14VVVVVHE8YWNN4JH0VFFNc4311WZBV8B4	#34V!184#V$42#V8#2Vf!2Vp$WF#4N#10F!42Z!164#1V#1wk#J6#50V	,2%1-1$6/*3$1//%4#1%1%1////!2&1*1!2%4%2/-1/3%1-1.11%1/%102(1(1/!3%2/)7,1$1%1)1$30201$1.1)1(2!1+2$2!3&1/01%1&1/0102*1#1$1/0101/1/01(3(11015/+1&1/,7//*1!1/)1$1#1,2!h%10201#4#1%1&1#1#I*1//!1)101-2.2101/&1)1%1)111/#1/#21/(3/02(1/	fi{pb@IQzJpHcHhdihTdeEDeMJ\rvhx@ajj@@B@@@@					antagonist	MCH1	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hv:0:S~F**``*w(36J}:0~S*`*`ixh.J}=.~S*bh.h.S~.>~S	zyUnLlOpdF5s0JAERN0lVN2V04FG91A08MlX58V!Pk84GkV0XO0CX4oFNcc1LlFd34@c!41!8FIFF10W0FV	0WR0Tk02OF1v!9_07g!t!d03Z!CD08o0xk045k1_07N0Tk06JF1d07J0TV2w0CF# #m0X0RV8s6kB26W7ckFJ@B2CE0XkYuC66H3m0WkMXV8F5Z130X2oNBN7Z160jJsG88x62BWO0Fk9LT4I2m0WkRV8B50N27cGNFkG2m8WXVr08dN272EenNO0B	#bZV!884!22K#3eF!X38!4Z2!2WC#NY8#UO!2J2F!4Tc!241!1S8V!5kc!B07!2l6k	$1#201%2$1.1////&@$1$2+2/(1/$1!1%101)2&1%2#1/$2///#1/)1$3#1/)1(1,1$1%2$1&2-1//)5&202+1!1/1!6+2%1/2#1)1,1/03///*1*3%1%1%1(D&1/)5+2#2!501&19+3%1//$1#4*1+1-s%7-1$11#1%7#P*22!1!1&101)2/+1!302.A///2(1/!1%1//&3!1/%22/	eod\DH@BNKBc`HcHhheEeLhdehcDdhfIECLfmghHJFXJA`HFB@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(.>x>S(.ixi.>x>.ixiS(.>S~x>x>.i.hS(S~.>S~x>)^.>S(5qS~xhxhS(x>x>S(	:UvzvzUzS:QT8nUMTksceQMEepZVO8DEh6DV259GmXVV3W2B41G0880DR3212@0o71m12!1401NFYV0V8F0	0aJ0Tk02OF1v!9J0Eo!_F0zF03Xk2W0DF!qJ0Tk3x!Fk0440FV2d# #24NV620FkcNXHMWlNcZM82811VaWcgLA42kcJD710V9ck2224c4FHlZBF424GFZ8R81543o2FBNF1521V8wL@3XG8R4621FF421192JWs9O02J9WkX8gF4D40XWltx86B8VXWBV8c4HC6XX8ZF24X0WNghy2FHVY0YoN8F5Z130t0FkD8447270KOB8@30F98w22A@635NNBC33YkF8oV233XFsJD71XkVZ671WFP98210WYV848Lg10Vl0cJ421FVR641WkVZ610VFF42kBN2VmVgD52VW8ZH42VFOsw22BF	#90V#8)1&1#18B$3F#W%4#8F$2k$5#G$95c(211V	/#1-1$A/%8//*@$6$5$1//!1+1/02!1//02.4(8//*2%3)1,111(2//04!6/%1#1*104!12/,2&201%78%1.1&3/$1$1!82#101)4,302(1)1*102/$1$1)301/$1-1$1.10@$2/)2*7!2(4#2#2B(2$1$101/#1///$1!z#207/#1/N$4*1/(2#1)206$1/(4/(11*42*1!1///)1!7(4/,6(1$	ea]THN@MGE@IBzP^dOi@FPadDY@hRDQLRDaLQDaHQDQLaDrHRHRAQJFJanif^X@JfjjB`bjjh@BBC``@					not given in publication	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
C,)Sq5E(E||^h//>/hwh/>w>q5|^^|v<}UtmS)|^w>/>q5^|wh|^|^w>^|q5^|whw>whS)w>w>{`S)l1{F	}y>ut:yvvjxVSjzUznOj1rzvyDZWb5yayZvtUqGPB2SNFlVx22ISKSJc6kLk1V80W0FV	0Pg!ZB0IV03B01204s!p40OF1v!C_07!Tk03AV1109w!sg0bk3Z!C807!uF05QV1p07c0j03H& &lNkgH41VFJZT616108FZl8@P1XVF8VF22S0W0sNVB6W0VV863W0850NXBDW0lNqBA6110cVN832FVJL2310VB22H6VFGN44FdZ120ZVHOK2737XVGcR8497m0W0F89g224Xm8gJ62YVtNsB2BC0VVsgN7520sc6A10VFC0N114ct0G08JHDC10k44250VcZ211c2Z5F9Gk2H10YklV9Zk8B0Ic4NZD683YF4815Y2Gcc4LKZ130VmP84E6X0c4ZLH2J13VN8li2@46bk9o4N66392ONP80Y2Gfs86673eYkW0FB445YlcgP73VVFV2RCDm0W0L3F8D411B0k8NsC91W8JB1A60VGGhVN4F21VauVFH8o14g0FsF_X5851GFc42EAVlcoe@950FG1F4FL43mFsFFC30XmMF8dJ2720gFWQ84H6kP110V99RU22XWF	#ack!V&b!21aF!dC8!A1m$s$Y8#7s!2NF#FLw!897#OX#95w#45!2pXV	03/&1)1#I/%6/$1,3(3&107$1//$101/0161$1$1/$1)8&2(1//$2%9,2-11%1$1*1/1#21!1#1#1-11(1,101#2/!5$2)1(@&1104,1&10101(11$1$41011.6%1/01#1/#4#702#1(11%1#1%1/%1//01!301#1$2(1/#23/#21D)1*1-11.4-1/3!10203!110z#4&41024)1$1*B%1+2)1/,7*1(1)6-1+3(22$23,1)4,1.102$31/5-2-1-	ee_RB@@DOHi`KFYRaHRDbDaHPTaDcDaHSDQHQJRDQHqIMECHdmkj^QYVjjjjZZhHHj`BJjB`rH@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
yG<3y_S+j32gj3yG1?7ooougS+X,+Su?S{u?1?G(Gwugugug1gug1?u?S{u?S{u?S+ug1?t=]y1gS+rl{U1?u?S+1gugS+u?u?S+	?yzx<tvExUzPj:yUvjgZFC:xIAjQjxPliZWbbzry5QxBwFu4AMGPjVpX3rS3RI90k0X0V8XV0Fk	0QV!Xc0IV02Ak1D!Bk0480IV03JF1_07g!ms0FF2U!DA09w0t!4B0110480hk04NV1_07g0o!4Yk2z0DF0u!55V1Z07R0TV1w!Kp07R0TV1w0CB$ m0W0Kc8ti2@2LVZ6s8k8Ne@10Nd0R4263YWuoB8G1VYVNc86@8JikWsISP4B210Ymok8N7Z14Vt0FsDF4L3Z13VZ1FNBK6Y10NZRH61YkkJLA31W8BB80b2kF8ZxB9@30FoBDA7OgFWNJG04824YFXtoP4J50ZVNZ8TD1640VIVg837W0kR8452V84D420JGHFFLY39XWFG0P2D32F8NZb8241m0X0RV8k5N127CkGNP8HH@XkVlB62G7QA0X084J6gR14kWooH6H3m0WVFL88D4r15AFG0FtN4F76kWVaF4H2BG3YNkJL@Z185HccBNB152sVFFV8Z@421210c82WWG98Va56X4ZVF6532XmRV8J48_SW_0r@g8R4@22FcsLB5Y0sF4NFB1XFk8HF710cF8330kc84XCGAWW0F8@DEXGNBFFHSB7WcFJJAZ150t0Fk94s4L1WGscFNE4_2F42496VWV4BFN11@2JvBBP9Z120t0G09DX4H20hKkNgBDJ42JFV462ZZ2Kc8_i2720f0WQR4H7Z12VhVeZBN6uK11VYNRaK430ksgR66@6ksRNTA23F8VcdN2BQ0VW8TF482pEZ0l0NKDl32310	#20k!108!6V9#8L#c1F!Edz$4V!VYB!25P#BF#8Hs!8Hb!2tm#8SR!8M8!29FV	06/2/$G/%6&10101*1/2&3!20C$2*101-1!1.3(2061*3,2/08%22/&1$1!11+2$170101/%1$1!1/#1)101&1(4#1#1%1&1$1(1#101$1+1!2$2!21,1D#2!210401&1/(1!1!2$3,1%6$1102+11(1-2!5010712/-101/*2(11$3/2%3*3&2/#1(2&11B%1$1/01#1$1+6%1#1#11-303(2!z1$3201$201#1#2#1!142%C/03%1$1&3!1*1$6%3#1,1$B!111101/11101%3$2,1-2$1%1.2$301,106$1#1#203+1#101&	elyvLH@LOAhTTwF^P@`haHRDSHaDRBaHrDQLaHRDRXQHRDSDrD`dPbc`Sjz[YXxVVMNiZjjXJhJjJfjZjh@IJbBpb@E@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.ixixiS~.>x>.h.ixi.>w<^}.htn~U.>S(g-)L552nL)+D+DL)2nD+/<(U.>.hS(.>.>S(	<vzU:pzxUwvUUU4rEtemaDqKCWCN6vUV7ZX59PVu4WlX0XvWCX5SNJldWSGAW12AYB0J41N1F30LXW18Vk	0o80eF2l!GX06J0SV3F!Gc0@R0nV3F!G_06k0Tk3x!Kl07B0j02x0Bs01L40Rk1w0Ak0p!5NF1Y07F0nF3p!Oc07B0U02b0Bs0o! 0NFX842l8g8535Zk8F4412YJBV8F48A93kFFN931kkF2PDCm0W0FFJN@4WWNJ841W0VJ4120VN5FRdZ13VVGOFeE5VFVJD3A6_t0G08sN788Wc82FC813WVRHG81F8FB416YnRV8442A42FVgL@5WFF82PH3VFFFFNYZ130t0Fc8NTZ3Wl04633WF9Vkn82B110GkFJ424V88820VVV8B4210F82iIMm0YVRV8R4PE2FX0sNR9510FJ810a53gV8k4BSG1GVJFD97FG0WcGBgGJX2G0lcJT2X1c4VNGZ13VVmPkD541Vt0ZV4O4XllB@D0ZZmF	#iVk!G0g!22S#@2#WY#7W8#2wF!t3V!5C8!3RFF!ZDV#H$1$gHo!39Z#1AV	01/)101)7*1#1&1//01&201!41#41&101&1/)1$101(1!502&18!1/1!1-1/012#1/#1/!1#3&5/!1/&1#3&31$1,1)2#11%1)12//$1!1$2,1$103#11/!2010102$1(103)212+1,1)1$12!1/!6!1$1%1/$1/!2014110101*30501!2%12(1#1%2(10131%1*61$11#3!1!3)11(1%2,11!11.1/0z%3&101#2#1%2%4#D/&1/0201%2&1/&1$18/!11#101#301!622!1+1&1-1&1#11,2(1(A&1)1*6)1#	en[]HH@BKOBjackgodW@ICHhheEdehddUDidhelhdfIMKHdnimco`ZVXHJJjZjiejZ`@Ii@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~.i.hxhS~.>x>.h.iS(xh.>x>x>xix>S(xix=x>xiS(|`|Fl0~Sl0lv|`|F	zrzxvxUzrpEwSk9UAS4oAueVa0mLBWa86PO03B048NVe4nFX0YO18VXJ0JFcWHNAW320W!F01V0F2!kW10Vk	0qJ0Sk1w!C20@!eF035k1q0C!16V0dk3D0C!16B0O01s0EJ01KJ0RF2w0Ao0nV05KF1c0@R0nV3F!RM06J0SV1r07g0U03F! $6Xw26F3@g3c4Fa118Xt0FV@94N426WBV8g78271V7kcO4E8211m0WFRV8k78221M_2kZ4@E5H4Hd8@369392cwZ45C10I044eDr46lFW4FfD0WX0wV8V782B1m0ZkRV8Z5HOB2W10aF4@2KNa0cWB22G5DBX8JFg89A82sV@BR61_otNJ20YZWwV8R4grAWY0k	#b5k!184!2V4#F@#V1#1cB!201V!kAV!40N!2G0F!JPV!1q$W$GNJ#N4#1AV	//#20106%2$1*2/$11/(4$3///1,1!401(9$1//1/!2+1*11.1!1%1//%1$1/$1)1#2*1#31&1+3/*1!1%1!1!2/5#3%1/!1$201!102%301(1!201(3.1,202&4#1)4.3%1*5-1(1#1/!2#2%1$1%1#1)1)1$1#1$4#106$4%2)11.2&1%1+1#11/010r$1#1$1$1$1!1210101%A*3*2#2/2%11!2/*1%6*11&3%1%1!521-21/$1/&1/%@*10101,4%1&	ehVYHH@DIHlbnaiek`HaIefuYwvUe}ehxt\BbZzVv~A`BBBbjejZihJT@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~S(.i.hS~S~x>S~.>xixh.ix>S~.>xiS(xh.iS(x>x=.>.=S(xiS(.h.=.iS(.=.>S(	]U:QyyzUUTu:hQzDal_ZQRTEiUjYH1d3OaVZ3WBOLYFZAg8yU3H9X22ab1oG7BM9403QNYX0201F	0WR0Tk025k1v!9_07g!XF0s!35k1_07g!sg0c03Z!KG06J0PV1q0C!1HF0FF120@Z0s!6@V110480Xk2V0DF% $GC7WXVu1F8D41552ccq81Z22BV8844WOYW1FaF4B3Z150ZMFNX8@10WlGC4J6D3m0Y0G3ccD462O0FF8NJK9WWssB294ZbZGBX8B4M_WVNoV2A10XGFvsc311WWkqF4F262VW0ZPX812Gk84JJJMa0m88B4D5FcVXNJ4230GGcs44@9m0WVLQ48L45C7XcRHB@10X1mtgVX47XHYFFoA823195XO4L@C4VXkF8ZRs2180cd8D227W0Gd44LIZ16VbKVZBPF15VVG0iF4Z3Z17Vt0FN@gcA3X3X08k42965DFXcR24H10Z0s8sV2@7m0W0F	#A4V!10B!60B!108#Z@#5dd!20b$W4#48#8kF!42k#X4#O8#8bs!6F4!210V	//(D.1!1!4/)1.13$9$2$1////)2)20201&4%2%4!2$3!1,1$1/.21#3&112/(2/%1$1&1/*1&2(1/,1/05&102+20512!2!2/022$2$1$2&20204*3/!1(1%5&4#1/*1//#12#1/19&4#11(4/&2!1$102%2A021!1)1/3//01/.z%6(4*1$1*M01.1+1*2-202!1!1/&2!2$1.1)104#1%2(2%1+2/.1$1(301/%1#31&1$	ejY\DD@CHdbg`H`bHrJJKKRIISJIQKISVZIIcbpH[YZ{DfB@jjj`ZBbj@@bHAB@@					antagonist	NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>xiS(x>x=S(x=S(xix=xiS(x=S~x>xiS(x=x>S(x>xhW~zB}\ps	:Utz1tGOFCF1J37FN0G0N@2#2W39882zV50V01FV20FVV#4524J0FZ214W0d02!V86#V#J10V8FF	0aJ0Tk03FF120@Z!t!d03Z!C_07g0zF06JF1_06k0Sk1v07k01a80OF1r07g0U03F! 038241m0aVRV9J782@1m0WFRV8w702920Wk_QJ410XXWLeg942117l1nVo11XZ1RV90782B1m0XFRV8N5Lp2BVVFGNF	#30V!98$V$H2#Z2#4BA$5$WN$N#1F$Hk#45#18#1Qk!806#17V	//$2!8/#11//%2/1$1(1/03/,1(1&1!1/)2%1/#1&1$2/(101$211*2!2)1,2)1#2&12$2!2/$2.1&203//+3!1#1$2/%51(1%101101&13&1#2%1%2(1/)2%2/#11(3#1/)1)1$1.F108/$1%2*2*2$2$E///02!4-1#1)1+2#x%2*1(10101!1(N,1(1#1/&2/#112.2//$303%1&5//01/#1$1(3&4041#1)1)1&	ehZ\HH@OFcg@ICHhdlhdlieEDhTleDjFMCJnieo`X@H@IhB@@jj@H@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=.iS~.=.h.i.>.h.i.i.>S~.i.hS~.>.h.iS(.>.h.>.hS(	uTPI2G9G8F40VF34F!108FH$1030V0H$V1$F1$V02#F(2%4%2$VVFF	0QF!Xs0IV025k1v!BM06J0Tk04OF1r07g0U!5NV1_07N0Tk3F!SG06J0PV1r07g0U03F# 0m0ZFRV8F782C14M0YFLF4H3Z1A0t0IkDF4N3Z1C0t0FNDF4F2MaW6FVXlc6A3IEVZFFXk43HWt0FcDF4i3Z14Vt0J0D844Y2m0VkF	!2@4V!10R!2V8#F@#V2#4cA!2FZF#18#4@#1Wk!4FV#a2#1%uk$4#1VV	+1/01)1.1&1///#23-1(1/102/!1.1*103)2%2%2$101/(1/-1#1.2)4/!1#2(20102!1/#1+2,2%1&1*3!1/$701)2&3+1&1/!3#1013/)3/01!2/1(2/(3//04$1!1/!C106/(1#2//D2/////01#2#1&s#102/0101&1(M*1,1,7,1$31$2#1/%102/#1%1/%4/#101//)1#301$5!4*1/$	egh\@H@EFe`HcHhdlhdldhdieDTiPqhYdUuM@A@A\@@DUP@@@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hxh.>S~x>hx5q.hGo.hA6S(xhS~S~`fx>)^jwvSxhQ~/<8tx>S~-g-gxh.hxh/<S~x>S~S~xhxhx>xhS(	^y<yj=rCxzxzyjJK:lzjrzowkzKrZTKzA7@no6pqe6W_4jY6pBYKAIoGN51805cP6a0IV	0aJ0Tk03AF0j044!mV0G01D!C_07R0U!3Xk2W0DF!sg0cF3Z!DB0DN0uV04Yk2W0DF0u!5NF1r07c0U03I# #1_0WOtT48421kc88771lNs4@10VV84XCG130kJVE4XksJ8226YF88gtV2@P0WkY08XN2622aHNVHG5VVO8gZ4C6311kH5212WN4248B23lP8@J21X194R4HS13W1qkse8720WGRV8F4Pq2640GG44F82310k8B75Wl0cD43W0N842I6dgGNkBJR1420WcZLD53kNs440a2k848FRRZ11VgV8J449C10VgJ94XFc8kP115at0FV8Oi87Y0VkZOwa2410mN8a_621lcyF4D22210VBF64Wl0cH720VN8410e3F88g229LA0cVNo8424XVVko@E511NZ@B46331F8kS12ZGs8w4E0WXmOVoH24520WNJBc282l1VD4760VGFN4FN20YlkVyG75YFG91VZP6WkF48494ZXXXB488FVWWIs8a@272120VR45650NBZ220VGsc828F45kWsJq4841G0s444M31X90@G5Xl18og	#f0V!18$Z#10H#eZ$d8$IF#d#6Z9!19F$2k#44#O$9SN#4@!218V	/4/&L!11,21!21#2#14(1!1/(@0120@$4*2.1/,2)1#1,2!1#1(2/3)1/2%1(3(1!1(22!1&2)2!1$1#1%102/$6#1#2%1*42-1%1%2&101(1.3&4)1$1%1/2!4&6!1$3)201%1!2/&10102&2042#@-1%1#1!1#6%1)2&401(1%11#6*8/#1&1/03(3)5////.2/#z4$8/#4$1!21%H&2#101!1#1&2)1/&1/(A/*1$1#2/1*1/#1$1!1,1)10214/)4!105$1%	ekTrF@@L@mc`DOB]S\bbRbdTTTVUTVTVbVTVbQVtlR\rrzfv~qyeZjjjijjZBhHA`bZjAB``Z`@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
*Fl0.iS(}^:0.>S~.>S~x>S(S(.hS(xhxhx>.>.>S~x>xhS(S(.hS(.h.hxhx>.>S~S~x>xhS(x>x>S(	]vMzOijjyOttLST9rOTJyfCABnS0tR2D2OqRJosZLat0jXJSF34d7IHGW_82d80R5h01FV0G!281V	0Xo0IV02OF1v!8j0D#_!uF02YF3r!BL06g0TV03OF1k07g!oR0Ik2d!C_07g0zF07Kk1R06g0TV2C0A40xk0 $4N62BX1l2K88F4NMW4FF4B28VGWG6F4N2cE22N44BC6m0X0RV8F5VK2_kFcRM04231O0G0DF46361W30GF@675_6VVkLF4N3Z12Vt0HF8dVF91FFlBNb84WY0wV8N782D16L0XFJNw4521mFWck2A34XY5GFo8@4m0ZFNls8H56137VFVK8Z4L2J3IswFN214XW4cJHA4WV8RBJE10VWW_0c46213m8Nu42A4bVHVNgCD2DCW3VNc427510_Gso66G55IFgFNFN6Z18V28243Gs8c427@b_FVkF8N449XFRF294ZWq1Na8B1VFW0kxi4IDVZF88wGZl25VFG8Nyc470VWFoPB8m9@0FmciF4824@ZHN8@61XWGFo429A	!2d5k!4NN!4Ir#O2V!42#B1@#HC#NYN!2ZU!1F1F!PLw!80_#Gck!CUs!2s4!197V	&1+1#1.6,103102$1&1,1#3+1&@$A$1$1%1.1*1/$102&1$1*12/11!1&1!5!2$1!1*2#1,11(1!4)1,1!12/%1#51$3)1/.1!201&2&101//#80201031//%1$13$3/$102&1#1!1)2/,1,1#1+21-1)1/2$1*C/!1%1,1!1022&2!2&9/&1&1201$1//(2*1%z$1813)1&1(1&P/$1!1,2!1%6.11#101)1%@!1!2$1#3!1#202&203/01$32/!1$1%2,2%1(2*2#2/(1!	ei[TLD@LDoIg`@cZPrQQQQJIIIIJ[QQQIF[JMHabRrIjyGdVifhIdJ@jhJh`@hBCJ`@					antagonist	RFRP	RFamide related peptide	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xh.hS(x>S~.>.>S(xhxiS(x>S~.>xhS(xh.hx>S~x>S~.>xhS(xixh.h.hS~x>x>x>S~S~.>O~,BS()\6s	:UvzvzyzO:vytjUxRQyfvjjCzUgaSSuYx@9_F_9GpXZ4alXf21zb4xaNBXm1@oc5DVF08438#20k!V0FV	0PZ!YJ0IV02OF1v!9_07k!mo0FV1D!Bh0480IV03OF1v07k!sg0cF3Z!DF0@40t!4NF1l0Ao0ok$ $1k6D212084H@7454sRB7244k88k_Rn1WWFkFFJ95X1FFH94W0VB22F90FH2@JwF3640GFY04Ho13W10FB@841G0cD73W0FR82194V8446DK1Xm14XJ21k8FcFJ2941soV@212G98FD98420ZB610VN84RA0VX3kV8@451VsZH631FkJ8320JXF44Va11Z1l8e8510F8gFL6B2WtNJ80VmG988895ZGVZL63W0N4oP2112YkxND6730VVsBL7520sNH820kNF41H90F8FtF6F8c1kJDDA30XH2tk8Jl141t0FV8F495XWckHA3VV8F6RC0VFWH088142lVkJ83WkNR@3E6bbkGnkF4A0VWGBV8N72325W9WcRJ7441lcs4P6621VVH6610N86R@0VX3k84P6151NZL941FF8sLR1571sJF9781GVFoB2A@12W1FZ@3YVs4ce2114Y5uZN693NC0VVLF4B2444XsV@63XFk822C4aVFlBN962W8RJ21VIGGfWN472F9mNcFP8110l0JHE51lNs@10VkX190aHEWXcNNFBU54YkcJH113Y2W0RVM34kF44JB2VXXwV8F7824120WckXF3VWNg230aXnHNBPBB0mVB6HA9BZl0cq243Xlk	#j1k#8%4!1%V$1c@$3F#c8!448#8F$2k#47#O1#11N!202!218V	//(F%1&2-1%1(1$1,6!2!6$F!102.201-1/%2010401&33///1#1/12//022///!2*4/.2$1!1,3!91&1)32/&A#1102,1%1#1$2&1%1$2!22#4*2-1%1.1%303!4!118.201$1)1/)44,11#2,@//+1$1#2$1#26/!1$4/!2/+1)21,13z#2/#103$1!2!1#L1)26+1,6$1/!2&102+1!5/#4.23)3%2//$1*1,4%5/04&1!2!1#2%	ekPzD@@DCBaYPMLbbTTRTRJRbRfbTRRTVbbfzT\naqUuMZ`hFbjjBhBhBjXhAPHH|H@@					antagonist	CXCR4	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=S~xiS(S(.i.ixiS~x=x>.>.=S~S~xiS(.hxhx=x=xixiS~x=S~x=xixix>	:UvzvzyzOyzvyteE_RuyemCjChzZVJ5zbW@BbFZ80qVVZ6Wm441mW@d6N4VV18g0oOVo06018J!@Fc0Wk0s0	0aJ0Tk02OF1v!9_07g!vV0iF33!DA0@40t!3Xk2W0DF0 $Aq8BB@62532GReB142H0scTM9_FVsZU8281kVYVN8g882L7WkksHC411s422B4aZGl8XB12VcBZJHKKc0l8F4B8111ksRLE43G8J8510V@0h0NQ5Z10RB11Wk9Nwj8281OVYL88g8226YWtsLB14Z2RV8Z4L35YmNRBDG70kVF4@A0VXIF	#c0V*4$FV(1V%H$d#4_$8F$2k$Z#O$818(218V	02.1/1$A%1///*1$H$3$3-1/$1/!201///*1/!1//)2//!2/-1%B01/!1$1/#31#1(1#13/&10301!2.1#1#1/03&2/!2//%2(1!4#1%2#2$1&1)5+2/-2/B/$1/01%6!1$4(46+32/&1$1//-1)z%F/#3(1&T/+1/2!6&6/,1!8//#12/01/%101//*5&1+1(1%11!1!	elZZD@@DGIgo`KLbbTTTTTRRVRvQRbbQbZrzaQZjh@Z@JBjA`@HBB@@					antagonist	NPY	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.=x=.iS(xiS(.=S~.>S~x=x>S(.i.ixiS(.>S~S~.ixh.>S~.i.hS~	=vzt:xnzovU1vWQE9T4yX3Ahf0@t8x2FO0Y8m1eLFi3V1F82BLs@8J22204d022J0V8!2FH#XB$	0aJ0R!2OF1v!9_07g!t!bk3Z!Fi0440FV2U# #1Z12Vt0G8DF4B2NK1FlFJi475m0WkRV8V4qf0Z1VcZJ6I84HVk861ZX2GNJ8cD6ZkNRD97610kFZ227B0X10sTE3W1FR870aXYF	#10V#8%J#4%B#39e$l$Y8!84F#8F$2o$4#9VV!15k#42#50V	//&1A1///)1+F$2$1////01//)2.111//%1,1.21)1%1//#1.2//041/01302&1/!101/01!1#1*3&1$2/!4)1#21-2/#2/$1(1/)2(6$1)2-3!@/.2-4!2-271*2////,1&10r%B//$R,1(1/)4&202*1/!2/(101(11/201*1/01/*5$1#101/01(3-	ek`XD@@D@LlbbbbbTRVbJVVfRT\lRjzvNZhJhJ@``@HB@``@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xhx>S~xhS(xiS~S~xix=S~xiS(.ixix=x>S~S~S(xhx>S(xhS~x>xixh	:UvzvUvUJzlvTtIGn5Gt9fLi42P4oONdAt24V135IN28Fh80GH14U6s4BN2k!Ff0L0X#2F0F10FFV!8!	0Z80IV02FV1D!9_07g!aJ0Tk03Z02U0DF!qJ0Tk3x!Fi0480IV2d# !A0k8H5W1W3VZGV8k1G0FN8JZEZ14Vik@823133WgV8N782918b_VF24673O0GsDF4H29B4FWBJVN1W31lFZJI32k8sHHK10Zl048VNnNW10a88da2722a2VJg@FB0YGWGJc992Z2V88ND24X1FsBG1YG8Bgc618aBLNFF9a2@NVWkX10ZB52Z3N8oQ8261	#11V#8,V)V@$G$W#4V+2V$5#G$10c$2!219V	&1+3-2#27//11/%2-802018$101(241//+1//)1!2*1/$1//(21)1-1!14#3#1)1%3/4!1(4201&1/$2/$5/!2$9&1/#502.1%3$1/$1,1,1/$2#12.21#12/+1/%1!3!2)1!E#1!4!1-1$2*1!2&22)@+2//02/)1/*z%6(4!1/(P$2*1#1/4)1)1/-20301/01%1$107#1$1//*1/02$1(3*1#1/+	eb^\HH@AGOg`ICHhdhUEDlmEEDdemihePqXxMll]@AUUUT@@@SUQAaIQYPDP@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~x>2n{bS(Z}y?Z}x=.=8t{bqq}ZS(S(jwQ~~S.>D{qqg-)Zy?}ZD{nt)Z	[rxrxUyvQECRaLdedaALKhVoM6Ip09E258@aRZYHXLXu1vVkKNq0d5GF1WW!_84J!X0F6888VW0FV	0aJ0R!3AF1104s!sg0d03Z!GY06F0T03p!Kl07B0j02x0Bs01LV0Rk1w0Bs0o!5NF1n07k0j03J& m0W0RV8R78241m0YVRV8g78271_6VW8LF4B2P_11kYF8yJ2B2Sa28NRCq2CJVXkaccJQ46X34ONBA6Y4WZWRcD1VlWklBTM2X0GJDFD8@ckX18BF222lVF9CTB2YW1kZJ4A7110eFcC690WNFs@125_D0GHk4F4463m0VFC4WVVB2NIB	#iVF$V!29J!1DDV!Vf#2oC#XZ#sf#15R!2PkF!Zuo!1u4#cZ#FNo!4SZ#5AV	+2*1)1!1!71/)1%2#1&1-1)6$8$1/!1+1+101+1403!1$@1#21.2&1$2)1&1$1/%1)1(1#1&1(1&1/)1.1#1/!1!1#3/!1/%3/&42%1(3#2)2.1&1!3!1%11//%2/3!2#4/1/01,5)1//1!2/.2-2(12(11$1$1/011&1&11*1301/,1#10s%3-2$11!22*@)1011/(6$2#401!1%2/$1%9/1$1#21!101!1/+2,101!1(1/01%1!17*1%111%105)11!	ehZ^L@@DFNEGHb`JIlbbRbRbbbRRRvtrRLt|BbrzJjNnZijhFTIbfjjbP@@					antagonist	A1/ A2A/ A2B/ A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
:0|Fl0555qS(xi^))^)H^}x=55555q5qxi)^^}x=xix=xiS(x=x=S(	;UvUUvUrylziu@Xn6LyjY4ia_N5Vkq931C41I0VFG!2!1G2M05N8B01G&o1Z10V40XV20k#V0F0	0Pg!aJ0R!2OF1v!9_07g012F0Ak130E4# $O0FsDF4D3Z14VWnX8R830V90gV22P12G8gTG4XkN823113WOs86@7YGcRJ@50VGVw42CCCGFcNJBF9GWY1lcF686DXo8NkRC24X_FGYsX493	%V!1+6cV#@$4V$t#F1$VF*8Z#V4#SV#V4s#4#258V	//(81/01!1,2/(1#2$H$1/$1////,101+2/01//01#1,1/1/1,1)2&1(1/#1/(3/!13/-1/,1.1!1!3//)1&3(4-1+2$1/#21$22/!1,1(6#2!@$108/&2-6!1-15,1$2.1%1*1//+10o%C.1#2/T///4+1//+1*3(12/-1!1/+1/&1/#1(1-	fca`@C@qWIEHihidddmbeDeacdaro]UT@PAAT@DAAA@@					antagonist	Adrenergic alpha 1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
;w|_(UmuT~91;w+b*G-?/j/jR(-?L}4q(Y.>.i.>.iS(.>.>S(.>.iS(.>.>S(.>.h.>.h.>	<v;rx:SwvQUEJqEdeVqBqphVgPDvS01gX0@AVs4YFX0XuG8VkSNLJf3KFOW901Wc0J!m0G301XW10VV	0qJ0Q01k!C305!wF04AF110480gF04P02b0C!pF04Nk1Z07V0xF05NF1n07k0j03J!Kl07B0j02x0CJ01aV0Rk1w0@R0o03K! 38241m0W0RV8R782A1m0WkRV8s78211m0WFRV8N782B17cmcgF96533mtFi857XFGcmJiQ6X2G224PI4X_W89FOJT0XG0ZNJB@5ZlsoJ40VkVB43175IW8oN962kcJ8HT11k8F616AbXHcFNE6XFkV4JM@63GkJH21WkFV440VkNB6119aokNcVH82W8to22Q1VkN8426@70LXJ@5582Z0@VV7134VG48TFE72kX08BL42kXG04u69_3Fl0NXJ41c1WR8u1120FNJiJK79FmcV4ZD313WeW08D45SbFsVZF	#iVF!G0Z!2AK!1D@V!Vf#7lB#@o#sA#51T!2NFF!Zuo!1P4#VV#kIo#UZ#5AV	+1/(2!E1)1&1#1/+2$1)1!2$5(1)1#1/+11(1!412!1#1@!101//)11$1/+1$3#1(1#4/1(11//!211$1!2)1)1#33%1&101!4/!21%2*1$2/30102#1$3/1#1$3&1301)1%2%21,3.12%14)2%1/.5!1,1&101!10121&210401!2%11.1.1)2)21$11#22$2*1(2%2,11#1.1.10z)1%1#2)22*8$2.1/#202%1/*1#1%8/#1#124%10132/1&1/01#1#1//8&1)3*6)1#	ejUQL@@FNACK@hi`@\\dTRaRRbaRrTRVTRVRRHhDdL\BbFf^~jUiiffjjh@Jjjh@@@					antagonist	A2a	Adenosine A (I Nucleotide-Like)	no	gpcr-ligands_DescriptorsNo5Ht
ot7tx=.=xiS(.hx=S~x=.>S(xixh.hS(S~.>.>S(.=S(.i.=.=S(.h.h.>.>.h	zrUtvdUOrKxWQ8@U330l39cm66205V084cN02129!1X0912!FW!4N8JF1Z!2!21!84c1020302X1!VF	0aJ0U!3OF1r07k!qJ0Tk1w!C20@!eF03PV2b0C#kR0F03q!Oc06c0Sk1w0@R0o& !1m50H0VWWkqF442ADc3084BE6m0X0KGZs443XO0G88FTECZGV4410Vk84oNQZ13VWVl8qH60VFBZX317VVGdO8Xa9VWGN42533ZO0FV@JeW3VF8l4Q8261m0Y0FcJXI9Z108210VkGd0o4H82G10H82ZZFk426CBm0X0FFgXC5Y1NZ841W31tVVoK5ZFcN81944t0FV8ka@33VksF41VFGW4k	#D0F!9VV!3V$28#k4$V%ZV$c!48N#1VF!4Fo#a%3F!Fsk!814#19V	(2)1%3-6$1///03&1&@$2$2/01*1,101+1+1/$1/02+101#2)11//$21/(3!1///(1,1*1!4#19/(102%1)1//&22+2$2$2!7+1)1!1/1(103301%3.4///!12)1#1%1%11#2&1+3#1-1)1)401(1#201-101/!1/+31.w!1/.102%N*4*301/2%1!2!1!1)11/1$1$1#2%7#1+51.31////#5$1+5*5-	e`RZDH@MBfnehD@@cIICDhdhmMelhdhldhXyEdUMl}|mA@PEET@P@A@@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=.iS(.=x>S(.iS(.=S~x=.ixixiS~.=S~x>S~x=.iS(xhxi.=x>x>S(.i}H</.=S~U(wjn2.ixiy?y?S~.=wj.i	]Qyzv:ijhgvyvmCjAxUwfoKzrleCbqZ80rlaqL1mEb1n_ipqP4p_4jh058XK84J1@J9@2D8N_q0vV	0aJ0Tk02FV2g!930D#qJ0Sk1w!Ds0AZ0kk03Xk2W0DF!sg0cF3Z!DA0@40t!3Xk2W0DF!sk0tV3e!KW07R0TV1w0CB# 05AYFNc@E21VFcgP215VFFtekc270GGVc4J8143g6F8B@6E9158VVe26533Y0wXB11F8FcLJJL61NVcGy2@HVWkZ2ka5452Bq8FN9Ju2312lVoP14YVksFJ8@1XGVBJ@AWkF8222VW1so22AF3ZlkZeI10VFFcLJkOVFkcPCFG422W0FFH66WFkJ@650Vk863214WV4249J22X9sVH23XGkVgkC8_1N4VHF222VsJN852FcFH510kF94LX333VsoHE2XFkR8NAB10kNFB332W0RD63WkVB2329Yk8826ALm0W0GccHM60kFB883VY1k84N1150FG1tJTCG0FNksB625VFG18RDK5Z1tNRFDBP3HkVc227511WkNT724FNw26B4W0Ftc86422G0NB93W0kF831WkF4420VKlHscZ27ZVsRNF@40VVtF4BA4XGd0@22WFVF42182kF8S4HF5XXVoJDC30XkV8ZZsDS1WFlWKL782XGLdka6530VV8F@71Wl0Z873WFVF8210VXco22250F8FSZ2432lcs859YVlNg426B20ld0N7680W8Z6C432I08RR512XcZ@21VFN4B20VV85FN115@XWG8@J7Vl04210W3GV4249EFC20NZBki1XVVg2DA7m0W0FF86331VkRF@2VW8J@5F@WkFG86127VFGc44Lg42220NLBH32V8oJ@B30XVN8VoPKFcG18W0R4J7XGkoV@C0VXkF8RZw@2YVcckR2@@VX1p08hs2726ZkkoN261G0gcHJJE2Y0VVT26543lkBPB320FNBLC10VFNZs222VkVJcH7YkkB2PD0VY3VNRa222XFcH840I1c84FP88X10gP341HGkV4N6150kG1V8LD20FscH823FsFoV216VVFF_0	#e0V!1%Z4$H#cc#1cV$2#Fd#6_8#9F$6k#4Z#O0F!8KN$8!218V	02*1#4/%I!1101*22,1402%1!101/106!@$403!6*1.1/02)6*1#1/!102(2-2/!3%1)1/(2(1/.2)2%1-201%1/3*1$1#211!2!1)4/(403$5,2!2!9#1/05&7(3+1%1/,201)8*1#4*2+4,1*4/!1+2!7//+202!1-65+3101//!11+1/01/z401!803#1,6$1!5&H+1010111!1.3%2026.1+1+F//$3/02%1(1(1-3/&1!19*1)1&1&5!1!	eoXyN@@BMKJfndVWPDAHga]\bfbRbtRRTTTtRJVbabbRRtqVnIYUmZjfjjfAjBaihJ`XbBLJIJDjOj@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
:0|Fl0555qS(xi^))^)H^}x=55555q5qxi)^^}x=xix=xiS(S~x=x=xiS(	;UvUUvUrylziuDXv6LyzY4ia_NCWkq9I1h51I0VFG102!1I3M05N@B0WG&o1Z10k40XW60o#V0F0	0Pg!aJ0R!2OF1v!9_07g!_!uF049!j04B0wF0 %3lcsFK13GW0oY827111G8sN952FcF8330V890N2158t0Fs88P522kNFNE3XVNF620c34BV8Z4FUJ20sJ2DB7m0WVFFFFD6XksgL@@8VkF82155bVFO0LA94G0N61A7VFGcB4LPRV20kcOsJ4CT0XkmFsw6B@Z0W8ckNe362H0VBFBT16EW0FZB	$VV!1+6cV#@$4V$t#F1$VF*NZ#V4#SV#V4s#4#258V	//(@/!2!1,2/(1#2$F$1/$1///,4.101////1#2/-1/1,1&402&1(1/#1/(3/!1/1&1%1/,1.1!1!4&3)1/&1&3(4/*2$13/!21$22/011,1(6#2!@&8/$102-4!1-16/!2.1%1*1//+10r%C$1%1!1#2/R//%2/%1//+1(205)2/-1!1/+1*2+1/,1+30	eghXB@@C@LJildTbfbfRRRvJTTRVCCbPVVuuUT@PAATDDPDBA@@					antagonist	Adrenergic alpha 1A / 1B / 1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
ftf2@tySft-SftyS@tft-S=4=r/_/G2@2f88l(2f2@.]].@2yS8888f2f2].yS	;vvfzUzxzfQTQUEAUuuQh1yTXYgrFDRzBv7qI3g2Gb8F@i4UM50JHeVL63I12224nGkG082A4V4@JV54F080	0aJ0Tk02OF1v!@U0BB!_!uF039!h044!qJ0R01v!Bh0480bk% $508ls292JE0VNFW24E96WsNgJ2YH6l1N44DAZ130WJ@Fm8D0VXWRV8F5Fw23WO0G0@F4K0141O0G8904eQE2Vm0V4N8153E4s4BB64F2FkVa42VVkFgNLS5bYkVgI8291C0_Hl8o6F30Y0N8cOFOG1WVk8C@M21lFN81@70kGWPBoGA22lBV8Z4	#V0k/0V#4#19%F$Y$4$8F$2o$Z#OV#85s!2$210V	//(B%1+1!22/&1/04$F$5$1.1-1/.2-4/+1//.1*1//,1%1/4,1#1//)1020201-1/*1$101/2$8(2,1$11//%1)1/+1+103#2%1-2%2//+A&B/&1+204,1#27%1-1+1(1-1!101$1/#1)y%C!1/!101+R-1*201&202/(1/$1#2/!4$202)2///,2%2/02/,2-	e`RTH@@EM@LdTtRQfbRRdRbaRRw@cgaUVsuwu@PSUUUP@@@TBCeGa@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xhxh.>x>S~S(.ixiS(xh.>.>x>x>S~x>.hS(.>x>S(.hxh.>S~S~x>S(xixixhx>	:UvzvztURCntwvUGt1IENeHw43Ah_9Nc@zX51VX3Q020F_0V3GV4@7J8Do23B_Fd8H8aZ14208F11FLl108V0	0Q8!Z80IV02FV1D!9_07g!qJ0Q01v!DF09w0t!3Z02a0DF012s0FF120@Z016J0Q01v0Eo% %Ii0cNRE82711aHm8T@A0VXGYwJ8R5V1VFlcOFa5124Vew46C7IjFW0J564827aVVNpBF252t0Fk84qDA2VcZJFB0VXHRN8Z22621_VcoH20VkdV430WIWOkCJ30c20lF22H0VFWt8KLCEWV8ks2297Ac1cJD44WX1W0OFJ0XGVN@FC833VNV62B2VO8cV32W2Y4BB8853158FFsFJNA341koN30VkF4oX116b1HNccC0ZlFBZLH1B1kmGBgG4X3Gkkg234VlORB615Yk90269DWcFVVH44K313W0l8R6E63WcJZe52Wk8W0r8261m0WFNls885Z150t0GVDF4@2mNW3F88JD62FFVY0Z89262B2	#10V#8%k!1&@#50e$5$W$B%F#82k$6#1$13V#4a#l1k	/#3.2#A/!1/*1/(6021241#2+43/,1/%1/&1)1%1///!2/#1)1-1(3#1)1(2/+2,1/22/$1.101%6&2!2/5/05%3$2&1!3)102#2!2!2(1#1/$6/!3//$1#1!1*2!10132.C$2/1*2(1!2%331)@+3/-2+1$3*3!1%2/z%603//!N$201/%1&4)4)101/(1!5+1/1#1207$11*1///*1(4*1#1*114$1(	ejQRDH@BBfeli`ICHhheEhhddeEjeEhhddVI@jdflRXHJ@jBfJfjB`@`@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.=x=.iS(xiS(.=S~.>S~x=x>S(.i.ixiS(.>S~S~S(.ixh.>S~.i.hS~	:UvzvzuzSznvqdU3v5OUAT4a23AgnF8t9x@2BFb8H1uDFi341H!B6s28J2X202d42H!V8010FF#kBV0F0	0aJ0Tk02OF1v!9_07g!t!bk3Z!DF0@40t!4AV110480bk$ #DX1cBB7Z12Ve39BB6231GWnJ8L7C11l1FkVB@XW8N4H99m0WkRV8Z4w744W0ZR314WmRV8N78281BlkNNk22@4m0WVJ1sH6D2YGFNcNHC5ZG1FP687VFFFRcLQ2@VFHGJ8F223GFJ269@	#11V#8%J.1W@$1$f8!4Z%F$2k$4#90V!11%2#18V	//&19////&F$2$2/#1///,2//*1/,1*1/+2///%1.22%3/)31/01!2$101!1-1102.1)1)131%1$2/!4)1#21//!4//&1%1)1(6$1)2-2!B//-4!1-281*2/-1/,1/(20s%E/#1+4#R,1(1//0202+302.4//$2/2,1/0101/(510101#2/)1!3-	eghTD@@DO@FlbbbbbTRVbJVbLrRcebUPqusUAUAPDC@@PDAA@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
ot7tx=.=xi.iS(S~x=.=.>.ixixiS(S(S~S~x=x>.>xhS(xiS(S(x=.=xiS(x=x>S(x>>.x>ix	:Uvzv;SqxvLvPTrEYm9HhiJVO7kO5b7l467XiHGmJdtyX49687Z6RBc0WV5XmVc5K4WH4d65@9F#VW8F0	0aJ0Tk02OF1v!9_07g!_F0zF03OF1g07g!kZ0qV3q!HD0@40d03Z# #wTCY110aF4D2T91W8NN64VmGGDF4P2k1B30NNB8I4VZFNBB3465O0Fk9sNT36XFGG84BAZ13VY2FkT61Y4FN8wZB254WXFkN65BVkNGNB329Y1VFw63256t0FsC8Z4A2WVYJ88g8Zk93l20_84RH15WImcFg9Ju23W7VHQ0e4F3B1ZsZB64YZlrF8lJ262m0X0F	#10k#8$4V!18F#Z2#5B6#85F#d#44F%F#Ak!80K#II#92s!216!278V	!1//$3/%5%3#201/!3)5$H1#23#3*4/101)1%1/1/*1$1)1(1$2$4)1//&1)4$2//-2%2208-1/*3/!1$2/(34%3/%31(2%2*3104/(2%1/!1/010101&2/$4/*2&1+1.F&2//!3!6(2)9(2(1///*1/%z%C)2(1201#3011%a.1!1)1///(6!3!1/*1#3!301//)1/-13(302//)	efY\LB@LGAhDN`@cFPIdJYCIIBhhdhhldimDbmLeeIhDdtl\CBmPT@TA@LD@AU@BEADa@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
ot7t.>x>S(.ixiS(x>.>.>x>x>S(S(S(.iS(.>.>x>S(*`xh0:F|x>S(0l(Sixxh>x>xS~x>hxxixhx>	=vUxxpxxrJvzUz8nYNPca6NOCXhf4UtV71XhHGoe6OkX03s0_XJRgFFtWKlLl96YZVkJd1a211FGY0W0F0	0qJ0Q01v!C_07!Tk03Xk2Z0DF!kZ0q03q!GG06J0Q01v!HA0@80k03Z!G204B0eF3l!Kg07g0Xk2Z0DF$ $74Wm0ZB81Vk8FD620VV441I7dZ@VFR8FI83FcJDB1WVF8kT116aVMs4@24ZllVs4J_@_kV84FI8VVXVoFD81GBkVZJP114Y@LVF68G4@HFsNRE8281m0VVF8cDE51kkF6310FFRD40VVHO46127@Z@VFV82z2910VFi1563VKdwZ2133F88ZRXZ0Y0tRNT20W3088ZZFcMW11NY0P71WI0kVQ42B10XFgV8R4Fd2@WVcc4M133VF8gb82510VVVRR35XG8ZF24VVV4210dZ088tI82910jkFBFVA2YklVsX284W1GcN4LCZ13VVXNGGBT2WZ0V8s42@7	#c0k!10F!@5V!360V!B2V!4B@!39BF!kW8!4FG#V0F#AZ!BVB#Gnk!82s!@54!258V	/1$1(2(A1//2%1#2$1#301(2#4$2$4(102#301$1/02/&1$11$2!1(3+4&2&1!2!1$2/(1!1#1!1)1/1.1$1/&2,2$2)1&1$1(1$4/#1/&2&21&3$2!1!1*2#101$104!6-3,3/$2/#4#5/1.3//(110102%1$303C+2$3(1&1%2*201%1!@#1(1/02*1/#1/#1(1#10z$16$11,1$1!11%N$4&1,1$12/01!1!3/2,5221(1#2&502!1$243)11/!2/*1/*6+21.4(1$	ei[ZFH@LHbk`XD@jcaP@cIICEEDddhlTdmDhhbeEekDoLkgdZ^QUj`B@FBijfBBbhH`HFh					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>S~xhxh.h.hS~.h.>S~S(.h.ixi.>.>S~S~.hxhk;=;S~xhS~x>xhxh\}x>~Wsp	;vzvztztxvvofEGt9tZOEMH1GAhV9AxDzX5O017IG24Fx9FXsZ4yKmI@R2D82Ff8H2I8080c2kBF0FV%	0Z80IV02FV1D!9_07g!aJ0Tk03OF1k07g!t!bk3Z!C807!uF04AV1105R0eF$ 02s8261BLNFw8VA2Zl2kJZA7X3mBV8Z78241KWkXVWH4F4OgFW8G8TI38aFGtV4PAZ130Z4NFwkN262O0GF9Z4aN18_lG4BPAZ180ZYsFxa2C3e40W8GVe4I9WW0cJ@C721VkFF7320scD93W088230dXoquo88425WVkVBA7ZVVBgV5170V8FgtP2@QVWkVGoR6I@1VtNFRDRCW4mNN665XYGkVNB84W0cNF92YFk44110V@NhCPr2210WNkB63Yll043A80V8448AEQVX_c8R84X9WZmN8@J473n30FJ8	#9VV!28#4%2dV#48!11@#2G$W%V#8F#FHo#85#GXV!19s$H!210V	/#3/#F#6/-4/#1*3#6$4$1+41//+1//&2/*2/!1.20202&2!121)1$1(1(3#111/$1/&2#1///2-202&4&2!2/5&1)5%2$3/2/01,11/#21///,1/1!3/E%1$2/!201&33!2&6*@%1$2,1/*2/!1,1#2(z%5$4#4/022!6#N%1-2/4/#1/-601.2%20201%15/-5+2//!1&2%2#1#1)1!2-	ef]TL@@DI`DZ\bbbbRQrbbbRRtVJbRfVaePwTrvtNIMKUAPEHTEEU@DTED@@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(xhS(.hx>.>x>.>xhS(xhS(.hx>x>x>.>x>.>S~xhS(.hx>.>.>S(S(.>	=v=xzyt:vhmzfvUbfjUwnxzhKj2@jHb9rrf8FR929L0GhedW8CnuHHXG42kJ08I5YZS8k09FO20W0	0U4!aJ0Tk02OF1v!8i0@k!b!vV03Xk2U0DF01Hs0G01707g0bk05JF1_07!Tk3i! !2lOB6B61FW0fZ4LDDW1kwV8F78241LbksNwN5252iFGug4L4GdW1kddR8D5Z120ZPNFg8DSD3XFco2291VWlwV8F782813W31kc@G6VYk8B8DFCJclFVZFD2O0WVVVF96WlkgB11VF9s_0wKG2VVcZJB564lsJiD84VFFl84B4S0WkNJ437X1sZF52VnWk4210X2K0sBB56418gLA20kGcRo@GBX0FgTA1VmVtF8P214mkcJC2VF9VVlwBC1WFmVgkLB2WGFFo8g5C20VJT921mGV44HNM1WntcBB70VkVW34m48BVWFwV8R4	#91V#8%F!12%2$B8$OF!Ff#4Z1#cF$@k!8V5#K0F!95s#4#218V	//(@/!1(1/!1/&@$4$1-1///!11)3/)22(1///014,1&1/201/01%1!5$1/#102&1/1#1!1!1/!330103/!6&1/01!1.1&1$3/&81#1/(1$301&401/601!1$3,201)1/!2)2)2!8%2$101&2!1/#2%2+H1///&1//&2!x%9//$L,2//014)2/-2%1+2&1(31+1$1!1//02/)1#2*3#1#1(1&1%	ehRTL@@DF@KKlbbbbbrRTRRbbV\RVTLrFZV~AZjjj`BBH`H@@PpHHH@@					agonist delta  / antagonist m?, kappa	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~x>.h.ixixhx=xix=S~xiS(.hxhx=x>S~S~S(xix>S~S(xhxhx>S~xhxhS~	:UvzfvNxNCuGJ93GO8lV9P1F0F2gV98B@x248#IG24FV!Vs0424FFPR26!Fd0H21+FV1!VF	0Z80IV02FV1D!9_07g!aJ0Tk03Z02U0DF!t!dV3Z!G10480Kk2d!GX06J0SV3F! #BV8Z44n2B3o0GFI82E1MVa22J8c7Z17VXuVJBc6EF0aNW0I8291Y7VWsLF4B2QCW5NW0I8291m0WVOWV8T4qM12FVsFP66Y28o610_ZkVJ8VP7CZkWF847Z3H1t0cF30GXckN4H8MhFVVIJ4Jj13W0IlNBaF2W43848PD93WFkoHG62HHc8873863Xkk2I11mt0oVLC@a10dNLA293hKsFF9T2@PVWkVONi6IAX09JFRE9CW1FV	#I0V!388!408!1!V!V$10@#2G$V%8$F$2k$5#G2V!11N$H!2A0V	01/23)1)A#4*1/,1/)4$2$2+41//02(1/(1.4+1/.1*1&1+1!41/(101#103#1//.2,1///(21%5%22$1-5/09%2#12/2&2)4,1/$52/#2/02//&1013/H,2//1%3C*92!1&2//*1$3*3!1/&z%303/-2010N//%4)4//(9!2-2%1#1&7&2)1/(2$1//$4*1/02$1(	eb^RD@@DIko`ClbbbbRQrbbbRRvRbLRVaePwTrNKUAPEHTEESP@A@@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
HV^}5q}^)H^}^}}^}^xhS(H}x>x=xixhS(S~S~x>.hxh>xxhS~S~~_x>S~xixhxhS~x>S~.hxhxhS~S~x>S~xh_o	?UzxzfzTQzUATyvzhIyDXW_ZQDREiQ7YHWd3Oa0k3VCOJW0ZQc0DT3P9222aY1FG68I9601N8YX!1!	0Xw0IV025k1v!8M07g!aJ0Tk035k1_07g!qJ0R01v!DA09w0t!4@V110480bk04@V110480fV! 03lF4A239H0sBJ65YO0Fc90oF11WN8L5971FGOJNRF351lIsFR8o2ESYkWVP_a833WZ30FkTg24X3lNVBZ78_GVVo4511XHgV8V4PiJ1ZkndVB6L5XmFO8NVF5Z08J624Z_WNJ8a1213nIHO66J370ZLN8x62C3J7IkNZB8F191Fcky28631FNkDU690VFFBPL15WFFtTF462DIXkmmF4c8P19HVGsHWs4A2860Wvk4N6D4XVmc8J4H9aFWsc4LGZ11VW2d9m8L4m0W0FFFDB5YlNo@4@@0FFG0222111P2846FYFFks8525Z248Ftq2B3m0X0FNV8C7Z10F8710FFB@TB0VVW@888@62G9BH120kGWZ42K10FNO0430WY4k8B6A4Xkcg@44WFFBsV5170k884154@0GFGkHA4ZlN82DJ30kF82140VG8d8	$4V!104(24*1d#202$W4#4k#8FF#2o$4#OV#85s!2J#2_0V	/01/#30G/%4/02*1+14!108$4$101%1101/#1,3//&1)4&1!1(1(1%402$1.2&1$1#1!3/#4(1/(1#1$1$1$5/.5+1!4/-1)6!10101/2!201!1/101$2!1&2+4)21-1/#2&41021,1/03/(1&2$4#1+@&6$1(4/#3!2!1+502A*1%1#402(3(1/(1/!3%44#z$15(1,1-N03$1&2/1$3!2#103%1!2!1/*20522)3+1&112+1-1+2)201.2)4&101!1$4#4,1-	ekPtDBDKDldPEfBHhbCXaJS^pIQQYZQIJYSRYIJHiJZKIQC`QrIY{YxGDWVB@jjjfjj``hBB`jBBP`@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
F*p3F**Fl0.hS(:0.>.>`*S(}J63`*`*63`*E-~Sx>.>d-S(S(x>.>x>S(	<vvvtzRxmvRAU3tGtdOe6qJHnhbV8hTSX70279PlY6FRZ0AS11B6ooLoe3FX3G16Ak0cJ0Q4O83J0k0201k	0ZB0s!3OF1v07k!qJ0Tk1w!Fp04F0Tk1w!Fk0440FV2d!KX06J0Rk1w0C!1L40Rk1u07k0pV! $1Z120t0G0BNw492g1kWkJ4N6RI_ks8JR115YMkcFN90z290kFFoFDUJ2kVB4DF0VY2AcR8J5Z120g_VNBT6PDZX0R8BE65nWNNVE8241m0W0IRZ8D46L72kVVFNUFXWkcgJ49D52Nc@414YmFl0mG6XFcF4HH0VFWtN4HECYH8RD11542V	#70k!G@8#VF#22#W_#18@#2GV!F5#81B#9F#42k#44#G2V!dKN$8!218V	0111/+1&A/!1//-2$8!205*12/!1/-1-1!12//01!1)1+2!2///!2!1)11/&1/$1+1//!4%101)102/2$1.1)102!2#2!1,2!20102!1!401%1/2#2///%4)1/1$1&2*1)4%1!2!7%1#1%2/#1%20101!1+7,1/01+2%1/$1)2/s#102//$H*41/.11/*101-2%1*1!102$1&3/401%1+2-1&1(2#1)23#2!1/$7-	egl\H@@LFH`DeYeU{WYeUo`QPpJJkj[Xzzj`Pbjj``@H`HDb@@					not given in text	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>|`S(S(l0|F.>`*}J63`*`*63`*C/~Sx>.>b/S(S(x>.>x>S(	vzUvvvvtzRtmvRAM2tGtdOeLqJHngb28hTSX70V79PlY6FS40A511B6oo6JX34Y31363F48J0Q4N8040l0V0FV	0WR0Tk03OF1v07k!qJ0Tk1w!Fp04F0Tk1w!Fk0440FV2d!JM06J0Sk1v07k01L40Sk1u07k0ok! $1Z120pFG0w4B4sL12V_sc8RU12VlFcC8AB1WN8@295ZmINFN8Vn3Xk84@234XHIGoBH2XZ0c8@112XXVgwD943XO0FV@Fg538VmFND255Z72cVDB40kc84JC10XkF8Zm8P31XFwV8F78241m0WVRV8B5kS7WY0ntFBC4WGc8VRFDE_VkZ4BH30FNNs@2B@88kFgFg25VVsV61143I0	#34V!184#V%2V!cW#1c8!201$1$4B#9FF!F2k#44#G$9Ks$8!21FV	,1/*9!1//-1/$6!204//$1/#1/!1!12/#2$1*1)1!1+2///!2!1)1/(1&1/)1/%1&1#401%1)10201)1#2$1)2+1$2!2#2!1,1!2#2%4(1$24)2#2//1/$4,3/!1&1&2#1%104%101#7%1!11&1/-1!1+9/.11*2//%2/p.1*1$1*H*41/.11/,1-2/01*103$2/2(1+31,1&1/#1!32#2!1/$4-	echT@H@BO@HcHhhdh]DeeEDdeLqIpHyyeUuLmmAAQUUTD@@LA@DP@@					not given in text	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S:v:0*F`|.=*`}H.hxiM(.=\).>x>S~u9+C.i36|Fxixh1mspx>x>+CY~|FJ}1m1mspspY~J}1msp	]xzxzyfzUzTozvQCbEEzhbxhzMhzE7m_uUrxVXLvTUp@nZ2CiQanrMveFw5dZYHpF1Z18QJc9ZV0FF	0U4!U4!ZB0IV02Fk1D!C_06k0Tk03Xk2V0DF!sg0d03Z!GG06J0Q01v!HD0@40d03Z!OG0680OF1e07g0o!6901g07g0Xk2V0DF% 1ZFlT8B4A57FNJBiN4cG84NNBK@DV8VkFk371md0472ZZHRV8V4T_MWWVwV8R4iXB4W0sWVLk382kkFoM82217VZ7Gg8N6L14IVFkGJ4VJSW3Fls8ae272m0WFIFk8X6A_1VVgNc2@ADVVsOF4_F1719FGNxT473m0WkHsGNS44X0VFB@A94kkJ4120VWko2230VNcSB447XHsRF61YHWFV4FL21CW10Fu6221mN445323VNVH69E1WH8oaJ1VVN8F4B46650co884AXn0V4U64Y53tFNF542VFV4462XVFoHH32FVJ210d2ZWNgTM71ksB66@4_1kVV8430HOgF3A80FNFBNR732GH0L811mGNR4HJKE_Fl8gV465A@YVVFL8p39FVVNFu29IcFVkNF4i47X20sP32VFFZ43C4b0VdN8Z2WWFZZFH21B0H08iK593kGsgH4A90VkdV8d1121Fw4FHSIW1o88JBuW255H8FRI8231QXZNNJDF29D0WVVFR8i16YX8gH360FNJgL214b2Gdo4Y10WlFV4FF8210kciD793W0FsF2A@2W1m86H4WH1FR4FI81470FcJVs4@2Z2m8NJE8231m0W0F	!1f0k!GB#61V!1@s#a@#4gW$jF!Ndc!4Z8$k#4Po#Y5#ONF!9js!6J4!21BV	/$1&4#4%B/%5$2$4(1/%2$8!202$302/)101/!2%1&2&1/%4%16#101$1///-3#1*2#1(1.1$1*801$2#2%1/01,10101#1/&1/08&3(2/)1#1$1$5$101/#3//#2$4$1/)2$6!1/!1/&2+4!D#2&2//!103.C1/+1,1&1!2!1(1/!1,z%8/!2302-L/+11!1.1#1#202%1/$26-1*42)101-4/01$113//*502+201!12&6-	ea]ZJ@@DFDjg`O@hblbbbdRRRTTRfVJRbaRRvQGCfTINMKUUEDTpuUP@@APAAaP@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xi18}IS~x=S(.if,xixi.>u8.=@,~Mx>.hr5[)xiS~x>xhxix>xh	zrUtzdQSzJ5wOFAUQS8G2Ne8aCH0CYC90HtXE8X4NQZ94FVX0YG1hX6R8BVWWMl3d109V8F51101F1JF1$V	0aJ0Tk03JF1_07g!qJ0Q01v!DF0@!t!4NF1Z07J0pV! !1Hv23WO0G8AhH462FaFXeZ4V7Z17VeFHfg4V4n413588ZE8261JVY7N8ZA8291	#n0V!18%I!12$Z2#4FD#25F#W8#1N$8$HV#4F#1$12k$a#EZV	/*1,2/!12///!41#2!201012///(1!1&5$1/1!1$4%1////022)1%2%1/+1#2%121!2#2(1#2/+101//.2&1/.1%1%2$1/)101#2//01!3//$5-1/*11!1$1(1I!B+1/12%1)2!2%1#C+2#1+1/+1-1$1&1&2$r%7/,1&N//$1///#3/,1&2%1)4/&1!2/(1/2&4!1#1!1/(	ekhTH@@D@`LbbbbbRTRbqRlRVLR\B|rJjVvZh@`HdJ`@bD@@@					antagonist	V1 / V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
<w(Njw5qS(E|}HX~,B.>*axh0m0mS(.hS~S~x>,B.hH})Hxh.hxhS~S~x>S~.hxhxhx>S~xh	:Uvzv;SrxvyfzEjTlqtvzaUTRhYJCEMxmE7X_kDyOaWIiLMwdnZ0hgTafn5We1pGfgGkK1101F1FB1ZV0FF	0Js!Qw!UR!aJ0Q!2Ik2o!C_06k0Tk03Xk2V0DF01680OF1q0C!18s0cF2Z0DF# #BGYZsVgGR28Q0WVcP48J4W15c4FFNE82@1m0WkFuJiL52XGGVwT@4WVNB8822FGcoo45@ZWNgP8312WWF4444WldBVD4WF9Vkn82715ckXVNFO22WGctsRU3ZWGNcgD530X308FA8m0WVKPw674522FGvc4LW14Wat8FJ@HQ2410Vd0c983FVR6JG10Yk848NPP@akO4JV2213Gpk8Sg252m0WkRV8J7827111n18P@7WFl8k_2CEWm0ccJH2AhVX0WYkDD4610NFZNH2GS4WsNVHHQ23W6kGQcT4830X1GJTB620VB2LG0VVWc44LR56bXt46BG1VkFNkb82414VY7FwZ684	!1X0V!I88!4EP!1@FV!Z2#4V@#8JF#cc!4g8!20J$Hk#F7#SIF#3s!@45!25hV	01&102$1+1)5.1!1!8*2/0121/@$2$3!4/(3$2/%1-1/%1*10102%1/03//%1#4/*12&1/!41,2#1%1#1(1//&1!1/)7$103$1&11/&1%2$3*1/3!6/-2&34(1/)2-31/01!102&3!102%2017,2/#2+1-1#6/(2%3*3(2*1/,1101!z!1!601#101)1401%2!4010N.1,1!13#2#2$2)2!1%1,1%7!1(1/(11/1101!1(1//02/1602/.1)	ejQVL@@DFNLadPODlbbbbbRRTRbLbfZTVVfDt\JN~aqZj`fAibhH@@b`HLB@@					antagonist	CCKB	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>xhS(.h.hx>x=.>S(.h.>S(.h.>x>(S.hS(S(:0:v.>.=x=*`*FS(.>.h.i.>	:UvzvzxzSxzvJvUUz9QAOThi6HQhWC9fHxX58X3FQkjaFiY0Y10hi6RBkZ3YMnGd17A08F4910GF20FF0V0Fk	0PZ!aJ0Sk02OF1v!DF0@F0t!4NV1_06c0o!4RF1r0Ao0ok05CF1104F0SV1v!KX06J0SV1v0C! 0BV8F44FK5Gscc22710W1mN5XG220FsNR8F79n8BNeBA38Y8JD7244X0VgXI62_Hd08RD3@XrcFJV@C3CVVVF514320cZLZ480VGeJ4HCZ130VXldZ8A412bFw8A6431G2VH154YXsFJU82B1m0WVG9S2Q22YF88c42679VJlBD54VX196F48221Ym1JBBM@Z0WO0J4NEX4ok8RJ8299W1k44N_13Y790FN8t8221O0Fk8I04I2m0YFRV8R782@1	#M0k!188!2VP!128#ZX#58f$_#FXV$N#1k#4Hk#X7#G1#1vs!D0D!2A0V	124/*1)@/01!43(1$11/-10@!102$1/-1/(12$1(11#1/(1#1!2/)1/)1!1#1!1!22#1$1/2(3$3(1#2%2)4(2+2)1.211*1!111$21/)1$3&101,1(101#1$1$1%2.21/-1)3)1!1&3/)101%1/*2.E*101/#2+11%3*@!1//(2%12-1$1/01(z%701#1!1)221%1&T01/!1/*4-14%102.3*111(11)31021&1#1///&1)1%6*1#1)1!1,2	ejUVH@@DN@fie`LbbTTRRVvTTRbTRfRJrTlL\FnNA^~qIZ`@@BjjBXJ`@B@`bH@@					antagonist	CXCR4 / CCR5	CXCR / CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xhS(.hS~x>.>.>xh.hxh.hx>x>.>xhq5xh.>S(.hS~x>}^H).>.>1m}^S~}^q5q5.hH)	:UvzvtlzR_mWJAUIsIOXOvH640WdY98cHyr70XXYQkG0FWf0PGY5D5wdDi33RYIc8F9Vn0a018J19JM14V0F0	0aJ0Tk02OF1v!9_07g!t!d03Z!GG06J0Q01v!GD08g0c03Z!RZ02V0FF1D06k0Tk2V# #m0WFRV8N78271DlkWNI1c4B2m0WVN@B8X5H914VgV8k78261m0X0RV8k78281DVY8s8Z8uMMWYVwV9c782Q1m0_0RV8w782813_O0ONB	#d0V#N#43#120V!42#B82$K$W8#4F$F$2o$5!2O$17c!206!214V	1/(4-3%1!1(1017/1*101+2$B$103!2/1$1/,1/(1+1////%4/2%1%2!1//&1)1%2$1)2$2#302(1,1/+1+@&2$2,1)1(13$1!102!2/#2,1)2*2*6/(3//(6/02.F!4#6//!1!4&2*G01)2/$2//!1!1/*z%@3/!101!1*V/01!1$1/,102+102.503!1//(1&4//*1/)241$6&2)1(1(	efUTD@@DD`GlbbTTRTRvRTbbbaRbbRzcegaTuqNMKT@@PEUPT@MP@DD@Q@@					antagonist	FSH	Follicle stimulating hormone FSH (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.h.>x>.>.h>.x=ix.>x=.hS(.>.=S(.=.i.=.i.=S~S(.i.hxh.>.=S~S~.hxh.>S~	;UvUrtUUtmQgwMHOHPgRcHy66kZaAN8@DKbV21W9Fe!1!A03402806U32@2202L9m11269!38F3V02810	0WR0Tk02903V!9J0Eo!lR0OF1v!C_07g0zF03OF1v0Eo01HF0FF120@Z0s# %7W294eE31098cZV57_2NwD30ZXXRV8c6aG24111N4B673WkRB91W3GtcBP141WFwR931Vc82RDDDlkWVF86342VsRH95XG8B4310V@Fs22BI1VkFZBA3318Z@61W0NB410dYJwV8N7822142Wd8TC520G8o62A@52lO0TC5WkW8o62A@m0WkM2k8J5Z160VW0J842XlcsP2211042VFF42FkF8A6Y1c8@430F9t0z8231m0WFRV8c4	$4V!404+V#8#1cZ!20G$1%4#8FF#2k$5#G%5c!2$211V	//(A)1(1!6/-1+1*3////1-4+2!5%2%4&102$3(4///,2%1//(1//02%2/0401//(4!74/$202/2#1%101!1!4.20402*3%1/01!1/$3#1#2!2)6//%11!21,2#E/%1(4*5%1$40205$D02%4//01//(1,10z%4/01/!L$8&3&1/)11&2022/.4/%1)103/#2/!1//$5(1/01*5-	eb^XHF@Hc@H`RPddEIAFPqdLbbbRdudrVRRbbbRRvSG@TUpOtLAAUUUUU@@@ED@@@						D	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
:0|Fl0(SxiF*|`36x=x>)\W(S(xiS(>.>x,Bx>S~x=(S(Sxi.ixi>xS~x>S~x=.hxhxixix>	:Uvzv;S:vyvzEzBvzvzEjAzUgbJSznxeEbmh9LznaJLAmEI1n_Bxq84Yr4jj15@XG8BS3OF180B8F5V0kV	0G#aJ0U!2FV2g!C_07R0U!3OF1v07k!sg0bk3Z!DA0@40t!5NF1r07c0U03I! #40w8Hp13WhY1NBN7Z13V_lOZcC5910F8BNGD17_VGVLF4F3Z120Z41cg8@20WlJkgPC15WWcl4c26W2G82FH1VZ0F8k42@A0VG8kXB41WcJF10VVN50FV435mlVJ624220tVaL9WlW8k4442bGkNB84W0FF81E47W0kZHD6XGFN841WF84wL114c2Y0K6B2350FR8VFv19@FH0HWJH34Wt0FV8wHE5YG8B6E254kF88PN1113kZH96W0k84410YlOtsi49MVWkwV8J78261b0YHk8V8Pc5Y11GR4D@2BbI0RPBB6b0Ymk8g8	!2f1V!188!4V4!182#cV#1f8$5F!2c#6gN#9k$Xk#44#tB#9KN#18!219V	-1/)F!11)1/+2!1/$2!B$3$2%1/$1/11/#1#1&1,1#1010212/.1///+11$1/%1!2,1&202%1/$1*11#B11%1!11$1#2%1&1$10101012/2!3#2)31(101!2(4/!1/,1%3$5-2(1)1/-4*2%1102&1$5/!2/1,2)1#25(2%1/!201/+2/3/z4#13)1)2$1!2&L$1$31$10101//.1/!6!1/4*11#41!1#1&21-1///1!14%2#1#104!1&3&2%	ejYRDH@NIDlVL`@cIEDheeEDhdddXehehmeK@dnmg`TRZjZjZ`f`B@HBJ@P`HTH@@					antagonist	SST5	Somatostatin SST (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>.>x>xiS(.=x=.iS(xiS~.=x=S(.ixiS(x>.>.=x=x>xhS(.h*`xiS(S(x=*F:0S~x=.=x=S(z@,@])I)81n1	]OyztrAiUxRtmQLun8drhYS0wMne5RmZ3Glt6FpW6A7V_a5xhN5dWUvFc51X2ZVDC2BCN20oFBa8IV	0Xo0FF03OF1g07g!qJ0Sk1v!DF0@40t!3Z02W0DF!sg0d03Z!DG0DN0uV03ZF3a0Dc!qJ0Tk3x!GU07R0jF3I$ 04J15110cA46Y12Vkk87XVN82JH@331t42A63kcJcP115_VWcNXG@ZFc42JH@231sw2742mFV2LBAm0XkMXV8T4f15@WkFRCmF25akG8OgV4ARVXFwV8c42IB32Vg690ZXHFF8TE22l0FV550FV8sNR112lkJV532VW0222VIlOtcy482lVkVQ82@12eFuBFFB132aJ1NT3133GWt0wY1VGWcm_k332Wt0FkDF482T7140dca64534n0ks@0WGm8skJBH5lHNN4XCW1W2kgV8N7826129It4L@H56bkX0O455X2WgV8N78261m0WVFNNeB6W1Wt8Z4B2VXXKAV66A3BAnVO0Bym61l1sV48C6YG8RN550k8B82E5bVWFR241WkFFH41W0VFB41VkVF42M5AVkkF84310sF69110VZ4420VV88gAL0XWVZB663H8N4416XYHWdN943X0aW46690F90ZWHh3211VV4H92W0N8@722FVRD71Y0@Fh8	#j3k#88#XF!12$Z6#5d@$5F#fs!44B#1F#BHo!205#O$9Us!206!299V	/2%11)1#3I/!2.1$2*1/!411203$5*1,1!1$1*1&102.2#11!2/!4/+1%2$2!1//01.2/#2-2#5-20102/!4$1%12)208-1#1$5(1)4#12051+1030401.408&201071&6&1#102$2!1-1)101)6$1!102*1#1+2-1*1!2&1%3.31/011,1(302.1!2E+4%6*1,1/6$61/!1+z%3/#401%1!1#H/1/01/&6-4.B(3)2!1-1-1(3/#1)1/#111&1502(101&1!2#5&1%	eo\zNH@IKMkdSGEbZV^PI@hRDaDPhQHRLrDaHQDRDQHSDQHrDFDQDXxzNf~Qqm]`HJif`B@FJJifjj`F`DH@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
8bSr8D8b8b8D8bR~8bnb8DSrnDS48bnbS4Sr8DnDnD8b8bS48D8DnD8b8bnbS48DSrnDnDnb8bS4gk?knDSrDnbn	:Uvzv;S:vyvzUzRmzvvhzEjzhYUSjzhXEjmh8UzfVOJfqUM1n_@hgDwYnLzi066do!KW34A8OJdnBWFF0	0WR0Tk02OF1v!@N09g!lR0OF1v!C_06k0Tk03Xk2U0DF!sg0cF3Z!Fk0440FV2U!F504o0q03q!Ji04F0Gk1v0@g0 0GBFOH1VVt8RPj@ZW1VaF4H3Z12V_HHgP457XhnO8BF6hOW0lFPdo4C2m0WFKfB86533X10V@K5bm216F4D3Z140ZG2BuA572t0Gc@R4X845kVVkX2960X2kwFe7B2W0FJTHBD5XcVkP424Y4mO0s898VWlHWV8Ls141Y1vB@@590kGkF4ND12WX0ZND5129GBB2GAU9VW0GBVc35YWFFVJBA93WVgV43VXWlFZgJAW1FcRNDM7jVl0N48951W8ZRB430WW462ECm0W0GN8gO2VVVo661131tVFeEGX3kk8oa2A6m0WkKc8ta425WW0k8s8LK0ZmF8oNsR28_kGsF4PG152W08cFC4WGc8F820kNJ42G78ZmNGFV2G1a0Wl44JB80ZlNN2I@Z508V86EA9am0cJ353Y0V8cWD84711W44J@h17hkGNFkTj425WF9B62F20XlwV8B44242W0R6A72VsF@517ZFF8x0sR2@0mVG482E8VXWV	#d5k!F84#5F!1&2#5g8!215F#f8!6Z$8FF#@o!80S#O$97s#14!21BV	//(D#2/!1+1$1!1)4+2!8$6$4+3.1/11(2$1-13/!2%22.1*1#1(2#1.101)4//!3-2$5!2!4%1(2!2!101(1-1/+2#2,4%2#4!2/#3!2(2)601$402&101$1012$21%202/#202)604/!1.3/-1&21$11-1C-1*1%24&1/%2A!13/02/,1#1/!1/#3!z01#90101012+3(1&N$1&2!1$2.1/01/$4!2&4!12&2/1&44//%10111$2%105%1%1$1&4*2/05&21$	ekTrBD@IKDhSGNQPH`dHrJIKIQJJZZIIKIIJKQZKRIrabh[jZxGEgTv@BjfZjjjH@HJEjb@dAJOJ@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(x>xhx>S~xi.ix=S~S~xixi.ixiS~x=S~S~xixhS~x=xi.ixiS(S~S~x>.>xh.hS(S(x>.=xhS(x>zdW(p3}J	=v;xzvzyvQUnUQUfzMyDbz_ZzUtfxDBnnYcMhX0FhviKFbKETx@D4nP4VVv621Z15CH9Xk01Nq#8!	0WR09F02OF1v!Bh02s0FF03OF1g07#o40FV2d!DA09w0t!3Z02V0DF!qJ0Tk3x! $6F4D25383NWB82FBVYWVsS6R3XXls8ZN22L0YXcw6K5YYVNR46@A3VH2NZ541m1d0F6962mVZJ52W0F84RFD1VYR88VA232311Jdsk8E1VFWFkguf12kNkZOFu26VVGNPc4Fu131D0Fuk4@4211H0wHA5YG0862C6apl8FBH641B1sRHBJ40ZF88o@2A921kuce643YFN8c2289VckVsF421210VV8753GFg6320k8B2cF0VY_JFk43A_GX0J4RDgR12VYc9VB50bV90JDE0VYHIc4@58Y3ssgU82410Vl8F@843lFc@@2a_0F98220WY4INZP6HHXVWkF4NBg15D0G0IV4LLA120k	!114V!28%2!140F!46#55@!20EF!FW$ZF$F$@o$4#9VF!13k#46#5CV	)1,1+1#I/%4+1$101/%1$8$6$2!4)101*3#3)2+1*1)1.101(2!11!6-1-1!2#1.1,22(1%1//$3/01!1)2,1!1-203101#4!1&1.2(4#1!2#1,1)5)1%301!31%1)1!2%3/03101/0124$2*1#11#1)3%1$201#1/#301#1+101B&3)1!2)2$1$1102&41#21#81*21+101$1/!4/!1/1#2$z%803#401/#1&P//$1&1!502&1/-4/02#1!1101$215$2//03//$10101#3)42#1$1&4,1	ekX|LB@FBaZE`PHaBHpbNYCHiCMEDdhieeihhehidmdmDk@ljkh\Z]SZijjhJBJA`B@bjj`IC``r`@					antagonist	Motolin	Motolin	no	gpcr-ligands_DescriptorsNo5Ht
72o2.ixi.>zBW~S(.ips}\.>.i.>S~S(.i.hx=.=S~S(S(.>S(x=xix=xix=xiS(x=x>S(xiS~xhS~xiS~x=xixix>	zxzprWyStYJSMJ2iTS8WX82vWYF1h3C266l01@2B3Gq8a91W0d4Vd2FJc!18W20V90220V0VV23F#F8W0FV	0G#aJ0Tk02OF1v!BL06F0TV03OF1k07g!qJ0R01v!J908g0qV3Z0EN% !1lFeL9WGWFk8834W0NcLB4XFs88310ZGs44PZBC62ss2BC6m0WVF8cJY7W1FVBHB910VNBF451VkFD73W0VN620VkHcw82AL0VF884221FcJB22WFc8@52WVkJ22N9VV842256VFGQk8663WVkRF@5W1F8oa210kFF6BBI3VZX9JLM464kG8k45T11LVVF8425IW0kNB421FF8@510VFF853W0F82gF0VXrcc8oi824Wt0G08km3A_1s8RcDIJ3W08JR250VNVZZ231VG0B84421kZ4810VF98g3110N4JVi110kFF874XFNR852X0VF2220kF44kDN23FVJTG33m19482275t0Fs845H231FkB@24VVNND72VkcB421Vkel422D0VXqKV8dk28223FFOwD834Fl4F624_I0	!29Vk$8#6F#4*@EH#NKk#f8!2Vw$VF!V@o!84S#l_$Bw#5#2C1V	,5.1%2#G1//2/$3.B*3&103&1)201*1/04*5!102*1/!1*1%4(2%1/%2+15-105.1$2(1&3%2&2///05/!44(11#4/1.201+102!33,6.1!201+2(1%3/2!2!2/06/01.1.1-1)2!G!202!1#4/02#2)2!21$1(B$1!1/&2#1*101(1*101/!201!4z%9#2#1)1/0X#1//+8)101(2+1%3!3(11,2(503.202/&3#3#1//01+2&1%3*1$	egTxJL@LHDAIk`@a`HiBLddJbbVJbbTVVrRRTRTJRTRRfbUWPrNImjuRuTD@@EUP@UT@B@@@@						PGE3	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
55y?(Sg-L):0:v*`*F.=.i.iS(.>.i.>S~.i.h.>S~S(.i.=.>.i.=S(.i.>.=.h.>S(x=xix=	zrzxvxOzSo7w5kAQQN0p28em64FJ9Vg@4PO07BX03AV84YlX0XNl8VkR8JFdWJFHW903YZ0401X0G307VW10VV	0Z80gF03OF1g07#qJ0Q01v!C305!wF04P02b0C!pF04Nk1Z07V0xF05RF1n0Ak0jF3K!S_06V0Rk1q0@R0o03K$ 038241m0XkRV8R78211m0WFRV8k4DKG5WV82DR714XNwTA520G9sZHG92kc44222FkN@217bnkNoTG9YWcN21@C_O0G0DF4N3Z19Vt0GF8CsT11GI0chVV42515FccF21lXclC293F2m0FBo71B3XmVRsN4Y51WAFy844XO0H09hkG36WaoGk8757XeXNGZs43W_1HOKJ@42YGFQW4322Z1RV8V78281	#aVk!10k!21J#B@#VYF!6VD$wF!tAc!46P!2FFF!ZPZ!1H$WV#Jmk!3KZ#pAV	+1/+@1%1!2&11/(1$12&2$2$4$3/&1&1/+1$42210101!@%1&1#1/+1%1/+101!3#1(1#5&4(1$1!21//!2)1/$1#3)1*4/!21/02$2,1!5!12/#11!11$202!3&2,2%3$1.2&1(2%14)2#401/.5/1+12!21&2107,11//(3(151!102$32$2(101.2,11//#10z$1)1$1$1#21%1#F$2/,1(2%1&3/!1#1%6/$1#24%10143*1$1//,1#4.1071/2*4-	ef]^L@@FNACKBe`HR\dTRaRRbJbRffRrbRrRQE@dacfUTrwpMRmMLpAEUP@UUTP@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=.iS(.=.>S(.iS~.=.hxh.iS(S~S~.=.>xiS(S~.>xhS(.hS~x>S~.>xhxh.i.hx>	;vzvQSUoCstOQQSG1ld8eLg42H5Z98ZDt240c21IF20F_V01JV4@6J4BN0V4VFd0M0X!42F0F10FLV2V0F0	0Z80IV02FV1D!9_07g!aJ0Tk02FV2d!C_06k0Tk03Z02U0DF01K!Yk2Z0DF0u% %5FHmZ4c@195kcFsM8281m0YkHccoN92Y1RV8w7829133XlsFR3B12lgV8N78291m0XFFFJBD85XFV241_Z2lloL6MHWV84FZDb9b1VW042D53LFcNVByNE3088NRB52Yksk8324GNF@4C70VGWnSP4422ZXsNi@FA10WVscq925GH1o4PBh15CkFsFZH4@1lNZP220FFR4RFD0VlGRB620VG8L420YWk84NThQW10WGBoA5XZ2s8oNRV41X0d0i2C6QVX_c8R8JB1_GFZL910k88FPGCm0WVF	#91V#8+FV!42#4V@$K$V#44*82V#11!2K$12c$6!218V	/1!3.2#B/!1-4+1/(802!4$2!1&141-1//1!1/#2/$1/$22*1/&1+22$3#1$3(1#1#3#1)1/&1,2,1/2/%1/01%5&2/#502.1#203$3,1-1/#1/$201/401(1/(11/%1013102,E!112$1//!2&22)9+3+202/!2$1!1/1!101#2/z%503%1)2101-P$2/(1&4)502&11/,4/02(201$2091(1///,2*1!4*1#1+14$1(	efYRL@@LCFc`DMlbbVbRabbbRRvRTTtRRTbfSUWRMKU@AUPTDULEAPPPZT@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~.hS~xi.iS~.=xi.i.iS~S~.=S~xh.h.i.ix>.=S~xhS(.ix>x>.>S~xhS(.hS(x>.ixix>x>S~S~S(xh	=v;xzvzyvvUnUQUfzMTDjj_ZtjtfxPBnnYcMdX0FhviJFWKETw@DJnP4VVvJ21oG5BH9XF01NqX!8!	0Js!aJ0Tk03AF0i044!qJ0Q01k!DA09w0t!3Z02V0DF!qJ0Tk3x!G204B0eF3l! %10aFNB8g356Vl4FG1Z3FF8gk2343Z9RN5870FGWDF4D233218NF84WWFN6530k@0w22BG7_1kOF8@54kVco62A9H2IV4o@A52bakN6264Y3kGcZ4MB141mYFFN8c2HHbVWso4L8112m0kJ89W10F61C6aVMscBPH1WFl8lP@484VWVwN48B4xH0kl8NB5432WVNcP@6XG04B10VFF54V1179Vl90@_2WV9182227W1FFkkDJ92GlRNR9143e7VFR982K60HWNH@E60skWFF4B23XW8RF62X0c4261WFkB2cAJCXVXVs24GEWkWkN4N41546WNxD955Xt0FV9J4ZZ17bGkFkF22@lVX0gN8g2292	!110V!28%2!14$46#55@$7F!FW$4F#8F$@o#V4#9V#13k#46#59V	/&1+1#H/%8+1$101/%1$801!6$2!4)103&1&3)2+1*1)101.1(2!11!6-1$2(1&1*1#1,22(1%1/$1//01(1#2,2!101+206101&1&1.2(7#1!2#1,1/#1%305!41%1)1!2%3/!101/0124$2*1#104!1)3%1&1#1/%10101+301B&3)3!2)2*1102&41#21#81*21-1$1//%1/1#2!10z%803%101/01&P//$1&1!5)4/-4/02#1031201$215$2%1/!2/-3-10101#3*2#1$1&7,1	egT|BH@IAkaLgcPICHhdlihhdeELeieLheMHheTmPpDTuMJ[k[@AMPPUEUUSUUAPPEBCeEU@@					antagonist	Motolin	Motolin	no	gpcr-ligands_DescriptorsNo5Ht
ix=x~S(Sl0lv@z@,|`J)|F)]i.)Is6s618I}73O(1nJ).h*`sp.>.>I}I}.hsp	:UvzvU:KbxYyfzEzBlaOIhaBTKCYJ1CMlXE7XZ0DqOaWHe6rz8uZ4xwNVdl7lXVWK@Z0VK1141F3J0OZW0FV	0Qw!aJ0Tk03OF1q07g!qJ0Sk1w!DF0@40t!4RF2v0Ak0p!5NF1r07c0U03I& !12WFWY0wV8N5229WVWkgV8F4V2GOcFWkTF4F33FW40gV8R52WFWXVm11cF48X8J@4BT7Z150cJ@4BH6F1@8ZG0BV9Z150cNNFgA8261FkkVcG04U48130wV8N78261	!1vVV!1C#2eN!1tHk!cVF#8@#5KV#VB#6@!2GF#6PV#oF#K$1Fs#4b!27IV	1/1!1,1$20111,2//01(1)D$2$1$2//+1$1#1010101#5/-2,1//,2///&4+3#11&1&201%2,1)2(21,1//(101,11!1$1)1#1)101*1/2//%1!3/*1,1$1(12&4!1$1#2$2+2!@//02#1&2&1*8$2/&1%1$23/!1/-1101!s%A11#1&1$2$2!1!4010P1-203#1)12///&61#102(2/011(1#1)1/!1/(2-1!17//+	e`Z^H@@DNMKGLb`LbbTTTRTRtRbrarRtf`STUVQVsuwsUMAKAUP@@A@a@QP@@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.hxhxhx>x>xhS(x>x>S(zeW(\}p336}J3p|`d,\}\}~N|`d,~N:0d,d,:0	;vzv;x:vyvzEjUuzvzUzEjzhrLUzxhUAjnbt6znckUQyUr7lhPdg6LYm4D@1qXlJ3Q_II6t8W0cXi$	0aJ0Q!2OF1k!8M07g!lR0OF1v!DA09w0t!4AV1104F0Tk04@0110480eF06@01608g0bk2l0DF0 #6F4@35EW30_fR8D5Z110t0FkCkF4C2J_0X1N4D362jFGWNX483m0W0Mc98y826WbJ0G0@Y262@2VFhF283m0WVKks8Xa1131BV8B6RL25WO0H8@Wi53AWt0GF@0u4R93Vc8FgBM5aVnNgTA125GwV8V78271@8Y9FFH8uK12FXXNRD2XXl08ZNFH75lNsLD@7NbHkO0B	#84k!1B4!14#18F$e#7sV!2F6F#YV!41#18FF!F2o!8N5!2Gk#87s!@N6!358V	1+1*1.E)1+1///D$4$1//(1-1)1&2!2*2&2*3/01/02/1!1,1/*1)1/02!21#202$5(2/!1%1!1)1(1(13#3(2(11&1#1%1$2/$11$3$2!4#1.2#2%2-2$1#1)2/$3/.1!21&101(1!1!1$2!1%8*1%21&2#2-4(1)8-1,2#1////!z%6(1&11/!P/&2-2$1#4*2$11&2-201!1(1#1#1!1)4011*101-1&1/!1+31+13!101$101&1$104(1$	ebY\DH@MHfjc`HcHhheDUhdmEEEBdemDdqqHixDTum\cc@PUUUUSAAD@ATDDa@@					agonist	ORL1 / Opioid m? / kappa / delta	Orphanin , Nociceptin ORL / Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=S~xiS(.iS(.ixiS~x=.>.=.>S~S~xiS(S(xhx=.=xiS(S(x=x>x>.>S(x>	;vzv;OyzvyteUpRuyemCjChzZVS7zbW@BbFZ8GqVVZ6WX541r18d6N4VV18g0oOVo06!cJ!@Fs0Wm0t0	0aJ0Tk02OF1v!9k0Ds!vV0iF33!DA0@40t!3Xk2W0DF016J0R01v0Ds% 0i2@aVX0ZGFR87X1WFmla532WVFVgZA6210J@141FGkcs85@62WV8D9712XGJgH30m196F462M16nFGNH8e6421kVRND122HFoJ82VkVFBNE21VF4FJV233FGBFBH51WFNsX624_gFGfB4L5Z140WGONaM4WFG1042D0VY2VFVLB42_W08F6H5WVWkVT49B9_G0cDAAYZGvs8s@2A2m0X0FV8TA44GkgD42VY1OVG0621lsF8E454HgV8Z4	#d1V#8%4!10FV(1V8$IF#d#4_$8F$2k$Z#O$91s(218V	02.1/1$9%1+1//-1$B$3$3///&2//.2//1/+2,1)1-3)2/*4!1%C01/!1$1*1(31#1(1#11/&20301!2.1#1#1(2(3&3/!2/-2&2(1!4*1#2$1!1#1&305+2/-2/D/.1-4!1$4(48%2$32/$2&1,1//1)y%C/#3(1&R/+1%1)2*6/,1!7/)1*2/01/%101//*5&1/$1%11!1!	elZZL@@DGIo`PKD\bbTTTTTRRVRvQbRTUbZrz^aZjh@Z@JB``X`HBB@@					antagonist	NPY1 / NPFF1 / NPFF2	NPY / NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(x>S(x>.>.hS(.>.>S(.>.hS~.>.h.h.>.h.>.h.>.hS~.>.h.>.hS(.>.>S(.>	}yvQzpBmzje9yfbE_VtTiCh083mW@GkmVH42a5LGM4P88DNI24BR08!JV1401602FVGVVX8G0	0Pg!QF!Xw0s!2R03i!C_06k0Tk03OF1k0Ds!qJ0Tk3x!Fi0440FV2U!HD09w0cF3Z# !382519oFW8F9aj36WVFcVLE4WlVZF41109lZ22M0VZk88t44733GscJA51VdOR42K0VYkF8gs2211lFgHA4Wks84510V882aR0VaV89V212@fgq8FsA82917h48OJB@385H8FZ51VXWsB4P115VFG9cN8@34GFcL73WVF8os11BVFH044NV220l8cZ95318B6NO10FXk44T2158108FBB52WNRD5310WmB410Wbk89o22P0VZpBV8B4@47XINBR@30FGO462EB472VF6631VVN@3B9a14GB244W1NJB2A7_VlW0HC42FcZ6410k88wk11A8LVGNZ4H113WfWVFJC60Wl8xc4R9160FGFQCX492OgFVVF8i@N41H0cJ66B2WFoT69@VF8G822260VGGqF4@251F21GJT38XFW1R42K1VYFF8ckBk0WW2G0F920GGW8ORD2Y1k8RaD2S1kG4RBE62XmdNRF1W0F4ckJDB2HtRDB@6W0XZF8R8RM17mNcNPBXW11FcF8x42B2	#10k!1B%V!1BF#V@#70X$pF!FW8#_F#8%2o$5#Oc#97s#44!259V	//#2#F1#2,2//1*2,421!1.101)1.201(2//2#1)4*101(1(101/*3,5)1$41#1!4/01/!D&2#1/01%3*1%203/!23/102#3&1/#1/(1$402!1.2%2!2!2-4$1/011%1#1$3$1)601+2/-21+110F$2/1(3*1-2021!2@)1/2&411/011*1.10102(10z%401/03*101!N01/1*1#1/01//#21/(11(15/1///#12%1(4*1/06$1!1$	enURBH@AMHeeKofPIAIe]VyWVUuUmYWhX|BZzIi`@jZjj@Bjjh@H``NH@@					agonist	Adrenergic beta 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhS~x=S~S~xhxixix>x=S~xhxixh.hx>S~x>S~.hxhx>S~	:Uvzv;SzxvyvzUzBmzvvCjEjUhYUSjxhXAjm_8UzfVFJAmEM1n_@dgBwYmLUj162dJ!K13498G49m8V0F0	0WR0Tk02OF1v!BM06J0Tk03OF1g07g!oR0Ik2d!C209w0gF03Xk2U0DF!sg0cF3Z!Ji04F0Gk1v0@g# BV8J56ZD1XVpABF6538dncV45653BJkkBF7Z12VVFkkLI3Yl8R@3163kF8oo8H66I0JB21ZYHGeNLQ42Y0F8cNc_670FcRJ4KKY10N@287Z8pdFBT7Z160t0FsD46462G_kVFN40VWl8Z_2O44l18w4D@H7W2sN8VBFJ71YHOgL6960VG0kFC8WWFF492VVGskwg@5WkGFLF874O0FVDF4D2Z1cFd025743W1lRi460WF8@J9@0VWNRN78XksZ2320YWs844AF82HGJH21XF8J@2B6a5mcBZF1Y3FFk8J2144ZmWFBa818VWk448B7VXXMNF8H463kGFe84U215W4X0VBVJ541NVgR2142VskT31XVsJ24120@8o42AH8YWNONJ2J9VZWN90V2D7m0VkHtJ6M4XZFV8w42C6VXVF8VZ	#d5V#84#4F*2#4c8!205F#fc!4Z$8FF#2k$5#G$97c!204!21BV	//(B#2,11/1$1%1/!2!81#7$2+3.1/11(2$1-14/!2%22$1)1*1#1(2//4/+1/$2$7!2!5/!2$1(1-1/+21102-1$3&2/#3/(5$202$3#1!2#11$21/01*202)5/!401.3/-1&21$11.C-1*1%22&1/%2A!1///1#1/,1)3!z01#901#12+3(1&N$1&2!1$2)1$4/01//4/%101#12%6/02/$1)2/02#1,5*6#2,5&21$	eaSZDH@IKDajSG@HcHhdleDhiihddlddhmEdYPqTMuM\CbS@AUSMUUUD@AATPB@aGe@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhS~x=S~S~xhxixix>x=S~xhxixh.hx>S~x>S~.hxhxhx>x>xhS(	:Uvzv;S:vyvzUzCuzvzUzEjUhYUSjxhXAjm_9UzvVFSAmEMWnh@dgBwYmLUj062dJ08K134O8G4EmBV0F0	0WR0Tk02OF1v!9E0@Z!lR0OF1v!C_06k0Tk03FV2U0A4!sg0bk3Z!DA0@40t!4AV1104F0Tk05AV1404R0Tk2f$ &VW8XQ8X0FB2JF@m0WFFOkuK51VNssSHZA1XVu08sc2A2M@lFNJBuaC1W1V84JAF@120b@BF683m0WFFWSDI31kFt0U8241DBlkRFR9Z160t0Fs@FN2431F84E94ZWlVVF95aVVV4JE20YHmtZNO44YkFsdNX4ATVX0mFwa6C94WNNZNeE91VG0TDE40YH0FVJ64WW8gHA12VFB4TD0VXoBV8N4RC7YksNN7110ONk22@BH6H0BFR24X0l8sdgF35_0G8aF4J2420l9BH24VWFN@35b3VF8c428Fm0W0FFVHHC20sF@80VY2044RQZ13VeW1oH60W1l0sRZS@VWNBBFA10XHH94cC5WFVF421VY1dWFo482kckoJ22WX2F8J844XksgHE1WkV8230cYV88d8XL4WZlF948H10W1W04JH73Y1N4XC3Z50kF4@12YYL08HO463kGFeV4Tw15W4mkkBVI42GNVgRaCA1_W04X6H60Z108oY8231210NRV722X2sR@A110842996VVG@GFo56X08ZRT116VGFFc@28A	#d5V#N4#5F*2#4c8!205F#fc!4Z$8FF#2o!805!2G$97c!204!25BV	.3/(G#2*3011-101$1/)2!6$8$2+1.11)1$11(2$2#2)15/!2%22$1)1*1#2(2!1/,4/(1/(2$7!2!4/!1$1(1-1/+31!2%1!2#1$3&2,3%3$1/!5$202)1!1#11$22/01*203)5/!403+1!3/!4*1&22$11.C-1*1%21&1/%2C!2/(2/&1#1.1&2*2#3!z01#601010121*3(1&L$1&2!1$2.1/01/(1&4/!1!1%1&5/02/$1)2/02#1,5*3/06&21$	emPzDH@IKDaaSG@HcHhdleDhiihddlddhmEhbmJFJanik`\RV^X@JjYjjjh`@HJjb@dABOJ@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)LD+8tn2)L)L~UH)8tb+.>w<x>.hS(S(S(xh.>.=x>x>S(xhxh.=x>xhS(x>x>S(xh	<v:v;vzyzMrvczSUQpyyIPxWjcSUScpCkK8yli4nn81nt0j24SLHouMLn5nb6@Y84J09V88GkFW01!k	0WR0Tk025k1v!BM06J0Tk045k1_07N0Tk04JF1_07N0o!5JF1p07c0j03J!Js0480Fk2d0E4% 02kB2317cNFZ412323YFF8Q90VFBZHHDQ_0kJJLAZ140VXsw6274kkJZV110VN4JJRgR13kgV8V4NQ110l8T810VF4kRN_UW2FWm_424XXWRV8R4BA831FFB86WFlNo22A0VWnRV8B6H2ACVX0Znc86H3m0Y0F9FZ31X2NoF30VV9d4r82B1m0VkO88sq2A2	#rbV!38B!22O!11X#iY8#Z9!255F!J38#zS!2J2F#Bc!@Za#K1V!9ks!845#Qck	$1$1/,5#2*2/.101/$6$3/$1/1//%1#1/0104%4%1//*1/#32!1)1+1/01(2$3!3(1,1$2+1&3+102/$1/#6$1#2+1$1$2&21!1%101!1#10101$2%202#1//)11#1%1/(3/$1/02#1112$1$1!@#1011$1#1*1!25.1#4)1@#1&3%1//#1$1*1/*x%5%105$1*1$2$M*2#1%1/2(1%1!1/-603/%101)3/(101#1$102%1(11-1!21)4!101$1#1%1%2-	edVRHD@BNFch`HaZHRYeg[YY]]_eYbQPpkih[xFBBafBhJJh@HbHKJ@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
+D[)=x~S(Shxi.>.=x~S~Shx(Si.~S=x:0:v~Shxhx*`\)*Fi.hx}\=x36360lW~ps\)36X()\,A>.	;vzftUxw7w1LAzUNFWmO2ubSN_dYC24MnVE4XB3Oo96tWb6AKVxXKTtI8dCCYIVx1AY4XKdX675QJrN0W0FV	0Y!IV02OF1v!C_07!Tk03H01k0DZ016J0Sk1v07k01740ik2w0C801FZ0Xk3P0DF0xV06JV1W07R0TV1w0CN$ 2F40NZE82A196mW0F@683O0FV@4kO42WG8fCX4725B_0NkBokAVW1NVk4ku1A1VHW8B4G56DVkNsZ625XZeFFZ9ck24W378GBPH282GFGVoZ493m0W0FmZ6EAXlWNqF4D2I122dZJgC0VV8FJT416__FHHRR540Vkkg829884WkVDN5YYGoNsNb4627WFV669YW90sY82C13X18cH@5110Bci340kmN48237VVGP8ZHH6XlNF8911Xlk444AC44G0FBC43Zkd4J3475_lVJFC74kd0sY8261	#fWk!188#aF!28XV!cC8!1B2!1FG$_$1w!2G0F!FOZ!8BC#GYk!8Fw!21B!2_FV	1#1/,1$5101/%1!3+2,3*3)@1#4#11!3/+101/0104012201#4.1//!2//)2/$5&1/&1*1-1%3!1$2!101%2/0103-1/$1#1(5&1-2/02#111$2$5!2#1//)1&1(2!2#1/(1/)5%1)203(101,C%1$2.1,2)1018(2B#11!1!11,1/$3/&102$1$2#3(z#1$104#4(1%1#1%J!1041/$1%3)1+12,1101$6&5!1)2&1$4!13#103!1%1%1+4/1/!2!1!2*16//+	ea[VJH@LAbZV^XDAMhP@cIIBhhehmEDdheELdTfhehyT\tL|bCBsrmPLE@S@ETATSTDSAHP@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>xiS(.i.hx>.=x=S(xi.iS(S~x>.=.>xiS(x>.>xiS(x>x=S(	yoPlLWOG8F4F0F04FN0G0N2H%2A#n218#GV020W%5X5F0N#8!V30224!1&F!V0FF	0WR0Tk025k1v!8M07g!aJ0Tk035k1_07g!lR0OF1v!DF0@40t!5NV1m07N0Tk3F! $1Z130t0G0CsB4B2m0XFRV8w6eE24188VFo91424112sVR5B3kt0wX@U2@WO0Fs@5Z27X2GBV8F4To258FFsN8F99YHs4X596VVGOLF4N3Z18Vt0FVDF4L24B16Hk9RBF4Zl2FyF4D3Z160t0HN8ye4A2m0VkRV9Z4@9B7G1X44J@uK130V	#M4k!2@Z!24#1FH#V1N#V@!201F#Y8#HP!2F5F!V2V$V#1$1Vk!2%Q0V	/.1!1$2-1+1&12/+1%6*1/%1.101.1(1&2/%6#104%2/,1/,1#1#1)1-1/(4$1!3#1(1,13%2$1%1#1$1/&3(1-3#1!1!1&6#1/$13+1&1*11!2)3/%2,2/$11-411//$3/%E!4/!2&103!1)21%1*F&1/&1//!1//r%7(2*1/Q///4)2/-2&21*1#1)201+1#2!1/!3/!1/$2$3*1//	eod\HL@NGLd`HaRHfbLbbbTRRababVVRfRXdl\jzn^``@bBA`b`@@@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
5q^})H5q5q)H5qS~xi.ix>S~.>S(xi.iS(S~x>.>.=xhxiS(x>x>.=xhxiS(.ix>.>x>.=.hS(xh.=x=S(S(.>x>	:Uvzv;S:vyvzUzCuzvvCjEjUhYUSjxhXAjmb8UzfVFJAmEM1nh@dgBwYmLUj366dJ01K1A4O8G49m9V0k0	0YJ0IV025k1v!9_07g!Xs0f!35k1_07g!qJ0Q01v!C209w0gF03Xk2U0DF!sg0cF3Z!Ji04F0Gk1v0@g01Hs0FF120@Z0f& 0321sVP74XFsR4216YkF8os89BY2VJFE880FGdDF4@22K_3FVw66263951VBJ6eQ10kcO9XL35XVG8W92W410VkcOTd61X0wV8J4hD24W0XHgJ75W0W0wVsv6WYkwV8k78271210ccRE12GkN424VVGsox2L41Gs8NNE14YbmsoZ8970WlGl88M4141YGGNBPECY0l8lJT@524X0oV6D7QAVVFF8H44218sN632FV82210ZGm84DA62WkwN431088oR115b12VVoA62F8882A5_WINwoH20FW0ZVg2CK4HFNZF2221lNZL74210RF710F@8s22AH1VkF8LA4XH8JD2220Gt042D10XZRV8F78271H0YZs8T6@3VX1G0cVO1Zk8Z84@4_2l14aE5@0G8G4L421YHY9J8XM7VFlc4T4@710VN868321FkH95W088410dYk848Ne13VFcgN42YFNRP4C9VFFZ28CG8ZHcOBR2G8VYWs8cOi82ZW1Vs4J@V17l0GNFocC383lFwN8A76_lFONJ2J7VZWV90T2D7m0VkF8B645VW8Z674XVk4D1110PNw42CJB_F9JT@G0VYk88oT2@8@J0VkFRDM82lsZF1980VGlFx6J9XWGsexJ@361qWFFVA82611Vm0oe67VG84D4B6a75tVBD621CYlNR@E7YGmN44X511VFVko636YHsVNgF4VFm8R84BA	#d5V#84#5F$4$2#5c8!207F#fc!4Z$8FF#2k$5#G$97c!204!21BV	//(G#2,11/1$1-1*2!8$9$21/*3%1)11(2$1-13/!2%22$1)1*1#1(2(2/&4/01.1.21#5!2!4.2!2$1$1!1-1#4#1/!61!2-1$4&2,1%3/(3$202)1&11$21%1*1*202&106$1,401.3/!3*1&21$21.C*1!1(101%24&1&1-2A!1/$2/*1#1.1/&3!z01#901#12+4(1&N$1&2!1$2.1/0101/(1$4/%1%1&701.1/!201&102%1#3%20201&2$6*2/07&213#	ekTvDH@IKDaj]SG@HcHhdleDhiihddlddhmEeCLeJFJanik`\RUSX@JjYjjjh`@HJjjHBPDH|h@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxhS~|F|`lv`*~S}J63`*`*63`*C/~Sx>.>b/S(S(x>.=x=S(	vzUvvvvtzRxmvRAMHtGtdOeLqJHnhb@8hTUX78V7APlY6FS40AC19B6op6oX3JY31A63FZ8L0QBR8040k0V0FV	0WR0Tk03OF1v07k!qJ0Tk1w!Fp04F0Tk1w!Fk0440FV2d!JM06J0Sk1v07k01_40SF1r07c0U03I& #m0WFKYV8D4e15iVG8HFu47YlGNe84ZO13FVVoT6253lIsFN8TjAWYkF84612XH3OR8aABVVlk84L211VktCJ8A33Wt0FV9KH838YG0VBNBH811ks89782FkFg82245lWswBH7Z120t0FVDF4H3Z11VeVGcOc4@3CYVFO8F823W1d0B499C20kVFa218Y3FFs42@20Wkk8JcZ74WkW0Na94W3l8R8H2211Y0	#74V!184#V8#F2#VWF!1c8!201$3%B#9FF!FHk#45#G$9Ks$8!210V	)1!11/)9!1///-1!104!204//(3/.1&12/#2%2)1)1.2///!2022%2!1/&21&1!1021!1//%1+4(1)102/2$3/+2!20102!11+1!3#2%4%101)1%2#2/!1$1/!1#2$4,1/!1#1.1%104%1%6%1#1(2/,1!1+901/,1#1//-2!1,r.2*1!1,H*41/.11,1.1-4/01)21&3/2(1$1%21,1&1#1/#2#2!1/$4+10	ekdT@H@A@`HaIe[[[WYeUna`RSpHihY[Xz@BfjjjB@@J@`bH@@					agonist	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xh.h.hS(|FS~.>.>.>lv`*|`S(x>x>.>xhxhS(S(S~x>x>x>.>xhS(xhx>xhS(x>x>S(x>S(xhx>	zrzxrdOSvo5w5F@UPR8G2N2PaBH093E202vXE8X43QV840W20XGVhXKL9NW1dEW2cA1@XV8741@5K1FM10V0Fk	0WR0Tk025k1v!9_07g!sg0cF3Z!FM06J0SV1v!G_07!Sk1w!GW06F0SF3L!GE09!cF3Z!OG06J0SV1r07k0o# 01kVcD71VksV6211l04wm2115VFF4110V8stVi2KMVZkOc8V8ZV160gV8J4474XVNVJ431XYc88210l8N22154V891LDS28WO0Gc994K6YGHkiF4F3Z15VVVVo@E3YFksH1563V88kr82H1HF0VsFNLE5YlkwN20_3HZkwc69CVWl0sRD713W0FVo4210VR2330V8BgR20W2_RV8R59028W0WFBH73W0sg@A1VkFB821d3kF48NcI98VFRaBE6m0XkHs8xT2CDVXkkW8RA70mF4P2@@5790FN@DS251O0FV8kJ_5X2Ik8RJN@72llNNXE173bFGuw4PM151ZXOoDH435WgV8k6PM251O0FV@N4R_164kkFZGB2KCXVXGBB4E5m0WkF	#I4V!38B#XP!17XV!VX$Wf!2e5F!8d$SO#G0k!VTZ#4F#1Z#1Nk#6a#U0V	#1/-11#6#1#1%1/1)1/+2!201!2022$1+1//%101!1&@04&1+105%2$11/011//!1(6102/011#101/%1201$101$1!1&3.104/#1$4,1*2+101030502$2.1*2*1010201!103(3(2!202#12$1-1*1$1!5$1.2-1!2011(1%1/02%103)121B!2.1012,1!21)2012*D02/01/101#2)2*1$2103!1!21#1(2!z(2*1%3&1#1!1M*1#2//03$11(1$2031-5$1,1&2)1(11%11+1(2!1/1/)4$21(102&1/0	eeWRLD@BHjaSAnPHcRHrJJJJIIQGZIQJIPjDqIYSLJV^]G[ODtpPUELtD@pBT@DtP@DAt@					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)\36AzS(.hhx(Nx>.=.==xS(xi.h*`(Shxx>*F:0=xxhS(B,(NhxS~x=(NB,=x~S.hxhS(xiixixS~S~~Sxi	~:EzhvzvvCzAzUhzJSzrxeUjzbRT:iJTQqzUCvxDxyf_YrKzj55AmK8JK7QJtPVD8N6a0IV	0aJ0Tk02OF1v!C_07R0U!3Xk2U0DF!sg0cF3Z!DB0DN0uV04Yk2W0DF0u!5SF1r07c0U03I!Ni03J0G01p07c0bk06AV0p0440Xk2U0DF0 $O0FV8Pw462BmkVNHxT532Wp1NJBH64XWHkVgF4C9bFs4D1@ZX2F8skF40JNscRTM293l2NBR@313WVgH422lc8416723dOZ8B5W1W1Fg88c62729@JVNg@284HclkNRR254m0VVFps8846j11k_f4@6637aHd0FL922FksyF4@26j12VgV8R78241118NJg@D566kXdRw8382j4cFk62833MVWFF4VM840cJVF@882kX0VBJI22lVlF8c9354c4JPD12XGlgP11VFcRH21b2IVcKe6AHVXG1OwLa442FFkcgBDF3lGVJ4JF143VmsGRDY@XW2044NDg1Y3Fo2BA6171loLD680FGct8N30eXN48FF8MVXLc8R8221118BD712FNZ@93WFcF@aB0VXK0kZ8g4I6VmF48A0X3HHWRVP0VlFsgR6Q1WaHtVV6J20ZWk8F2232W0gH52WFcBF6110HNo229J	#v1V!1B$ZR!13H#ccF!1cc$1F#f8!6Z8!1dF$Hk!85M#O9F!9SN!@J@!2ABV	+1/1*C!21-1-2//0110F$5$4/$1*1*1*2*1,1#2#1+1/#1%1$1/*3)1#13$22!1+101-11)1/1#2(1)1$102!2/01#1!1)5301/!101&4,1%1(1,302$6(3$1#1$1101*2/!2%101041%1$1&1+1#11#201/021/02%1$210A/%1/&4/027*1/1/1)2/#2&1.z%C031%2)3(7&R$102011021!1!1/(20@1*1!2#1/#B/&2!1//)2%1*11-1!1!101*4*2(1(1&11#1	emPrF@@DFKO@C@hlR\bbbbbVbRfRrbRRRTTTJRNhxT\rJn^YeEUZjjijZjhJ`@F@@d@pphHHhH@@					antagonist	CCKA	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S~S(xi.>x>S~S(S(.ixix=S~S~x>.>xhxhS(S(*`x>x>*F:0H}S()^55H})^)^H}	:Uvvv;S:vyvQEzTmzffdyCrhhVFNDjSIEYmCcPvXZt2fizJ1QZ8B8LLYI1iD1_W1ZG74l1420@NcV0W0FV	0aJ0Q!2OF1v!9_07g01640RF2x0CN012F0FF120CZ010F0qF3Q0EN$ 38261T0YK08g9sc231@0Gnk4L4cT11kgV8V4BQ3108gcK1ZXmFm886B@bkVNVQ6124110H8Ni3LYVVkcU8271m0XFJlBk6D8VFW8egJA37140FcJ8@21GVcR72YkFR2PA1VXIV	!160k!FV$4m#J0V!V4#1R8#3KF#2V#A8$FF!1Dk!84T#K1F!Z5s#54!230V	//(8/%2/%1$1#3)2$J$23#2!2/$1*1)3,101&13)1$1/!1////&2)102/,1(2,1-102,1)3(102%1/01-1/,1!2&3$102&1#1#123(2,2#2$2//1%2(1/)2*1/$1+1!1+@&602%2/%1%6/!5(1.1//&21//0x#10C03//!T#1&1/%2,8)301/13)1011/!1+2032////#2/4*2#101*2,1	edVRDH@LBBjhD@@cIICDdhleEhideE]DeHXyEulMLCBmUTDE@LEQ@A@`@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
\)36|F\)\)36|F)\W(=.,Bx>)JF*xhF*)Jx>xhx=xhS(S~x>xhxhx>xi	;vnvvOvN4mlR@6HO0OVN2LZ4FFh392cHGX58V41Gk160W!A90C04oo0g01JY0V142240J0c!104FF0X4GV	0Pg!YJ0IV027k1v!9k0Ds!lw0OF1v!C_07R0U!4OF1k07g0vV05SF1r07c0U03I! #8LF9Z18ZRP63W08VVj82412XlNoD56XGG8oJ121WnBV8V44973lVcD@50kFB220bWnwV8k4467Z2cg8514YVkZ8L214aO0FN8B@E70GNVT520Hlk8D210WFu0BDA82WcV673W0NJ21E50FFm6F4L212XFkgFA61VcJ851VVN94FYZ17Vt0FN8ND74XVsVL6310sB4110oGF44FZAA3H98@630XFtDF4D2165GNNNA4Z2kFc8243612OZJA6WkNF6J8@m0XVFsJHA64WFJH520V9cV226DM6GkNZR264m0X0FFwVL82Xlk8ZP26736IckFD23X088NY82A1422FgPH5WVFB4L7Am0VkF	#30V!W8#2W8$6#VWF!@98#F5#238!80@#5F$Hk#65#K$9Ks$8!210V	/,2*7!11-1+2/-1%116$2////(1,1/$14/%1/.3%2//#102/)1%1-20101#2!1/&1*2(1!1%2/(4/(1$1*2#1+1!2,1!2$101/!102(1(1,10101!1/0302$1$1&2$2/!1&1&B02/,1)1&1$1!1$1A/*1///$1*1&q%6#10104*23*1#N$4.1)1/*1+1$1$1%4/&2$1!1#1%1%2/02#1$2//1*3(11/!1(1$	ek`THH@ALc`LSHhdiieDddbeELejNEM@hemh@bZ``jh@H@`JH@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
2fSy2@2f2f2@2f2@2f2@2fSy2@2fS-2f2@S~2@2@tfS-2f2ft@t@2@2@lp:p2@tf2fS-2f2@2@2f2@2fS-2@	;r30sG9V4k402DHNH1XN2k04!91920HFk50282Gk909WV021k52KL9Fc11@kFV8F02G0Jc0@35@4G10W4FF	0Xc0IV02OF1k!8U07g!aJ0Tk02J03d!C104F0IV032F3Q0EN01Lc0Qk1k0780o!57k1X06o0Tk3F& #A0ZG3N8R3412kc8ZND2O8WmGZJ11WX20864CAm0WkGFNB763GkwD9@60FG1QhH462g30WFF4423W10gRVD3XlVsDB9CE0Y8k8Z@BT26W4WNG8eZ22G1cl0F1G25kVkFB491FGlDF4H3Z13VZ4Wgc894J_oNO0E82313Yk8S@G30k98o@2A@3YkVBBR@Y_VNF8a318VVNFok8821kVFP85YmN4kR1146VFNF842YVVg@9@W0Wkk42@1VWo20N86RFVaW8cP449VkH084RJ21@_2t0B642FcBZLKZ140g6VFc8wo27ZVGcTF4B2o18B0GVF8RK34W0JRZH181FGcB4LJ945WsBB67B1G0GJ6A11ZFF8sr82D1m0YFItk8Re161h0sO68J4m0WVGcBe96XbFc9g62O0W0s8P@I10ZFN8stc2LN0Z0V	!16Wk!f2V!658!2W5#n6#8c@#FZ#F94!@0N#F0F!5No!9Hf#lYF!GNs!@5#25XV	/#2/#D)1(1!82$3-2*3(17$8%1#2/010101+1201/02,101#6-101(2%4*23+2/%102#3,2.1,1,2+4%4%101,101/*3$2/1031&1.A#1/02$1&1#2/06!8013301&1/.3%1/11-2053&11$30101/102//!2!B$104,2)2#1/)1!B&11/)2*2+1/,4*z%4%1$11*1$1%L/(1,2-12#2/.221%1!2$1$205!1#3103$2/#1-2/.2+5*1/!1,	emWZFD@BJCHbnEOEkg`LPXHrJIKIIJIQQKJIJIRYVEKJRa`JHzFef@Bj`HJhJ`V`@Jh@@@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S+v?0?S+0gp6/A0?~?0?S{A/Y+S+S+0g0g0?g0zHg0S{0gS+z^S+s:0?0?yb0gS+s:ybY{s:ybybs:	;vzv;SzjvytvEbUuzfxUzUjjZoFUxjgIDrHYW6Omco7zuR4CHC@c2DL3P1DX2oAGoG38FQ4F08FXX0X0G0	0Xc0FF02OF1v!9_07g!b!vV03Xk2W0DF016J0R01v0Ds01mc0AF0i0440FV1D0@Z# 6F4F2zHW1k_f02545XG40FcA8231E9YVJFP9ABW3FW1Bg29Z1VssR_H23W0FGFRI41ll0ZTHHIW3YFFD644Y0WmRBJ10WmFs4VF23X3O444311sF6N8B12ndFa36@X0HNF64F90Vl0wHE42GFJ460VFk50LV6TcFlVNSq78X0FksQ825148HWZ4@13YlqQ48D451Y1cs@E1118F890b2YV	#80V*4*B#19V*Y$4$8F$2k$4#O8#85s!2$210V	$1//!K-11!1!4/0101/$34$D$7#11/1%1%1//111+1/%10201/%1)3!2/%201*2/(2*2,1/%1/*1/#1/!24/&3&1/01!11/%1$2/#1&1!2!1!1*1,1%2$3)8$2+1/%2//!3&A&8021!2$2*1(101!4!1.@)1+3/!1/&1)3*1&2#z%A(4*101%1$20R///604&1#1!1%2(1%25!3/.22//.1#2/*1%2#1.4(1&11$	ea[TD@@DJ`OlbbTbbbRRQdRtTvQTqTRQegaTSUTupKOKUUPUPUPEPTT@EDBAACe@@					antagonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
8b8DSr8b8b8DSr8b5XH6Sr8bnb8DnDS48bnb8DnDR(8bnbS48D8DnDnDS48bS48bS4p\8D8DpJe:8b	?x:x:x:UzcnjsP:37ACjjAj4nXIA6hQGoeXSrHkApcaXKsd9clg@2mlA0V40F2fnaD@02GNNb4I0	0WR0Tk027k1v!9_07g!o40G01v!C_07!Tk03Xk2W0DF!sk0tV3e!B90CZ0xV045k0U06J0Tk! %m0WkH0gHA6XlcJB11_Y088ck898bGNo@212HW1H1a132F8kVNZAYWWVotVw673VWG3NVR460FcoTHA0VX2Wewg46XXWF8VJ44XFcZJ82WFcF62F4VFFm8R8V142kkgN42444XNVB63VGF4R8A6VFGGV8Je@XWVks42B710ksRDA1X0kR8@1W0F8B419XZkF4TF73FVwHA@60FGGTF48255Vk90BC3XVsw43C66VFcVZG30lkJB17a231N@86A9VXG0lcJW446FFkc8432XG8ZHA4XVVJD5E5VFG2044311l8ZD942G0BD920VF5BLbZ120t0GN8wL94ZFNw@80_4FFB26C0VXIeN94D2D50XkmssL30YV8t42D13l1V44FNC@2kkWVB420Vk8454VVlNkw4C31aVG4N52Ylct842F20kWdiF483Z130VVNNa754GsJJ4A5VFG9V4e4B5EVkNVJJ8@YGsBJG1ZXXFkNiC51ksZV2@6_10Ng67242NV676a2k88Zr8271	!284k$4!94Z!240V!1@#8gV!2N$HY#BZk#40F#@o!815#MY#8Vw!@S#25BV	%1/1$2#21$E/101-2*1)3*4#6$2$4.1//)2//3$2%202/1!1/+1&301+13.21(2!1)2/%1$1/1$2(1/#1/!1.1(3&2%103%105-2)3&6(3$1(2.2)1)1)2/!101(1%1!1!21)1$1+1011*1&1!9*14)2/#3!2/!B,1/!11/$1)1)1%1/z#11503!81024)1(61%L01/2/&21#6)2%1%1$1*5!101&11)101$1!223%1(1/%102.2-11+2!1&1/01%511$	ea]TFL@MHiE@do`PLQbHDBLbbRaTabRbrTTRRTTTrJUGAtIOMKL@QKUSUTE@CDE@EAdP@@					antagonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.i.=x=.>.ixi.=x=S~.iS(xixi.=S~x>.>S~x=.i.iS(S(xixiS~.=S~x>xhx>S(xh	]wjqSrfE3AFsrQEmqJHmhY0@8IpX5CH09Dld4GGg4QQk14HyVNZdOFH1W5F0Z08F0321JBJVJB7030	0aJ0Tk02OF1v!C_07!Tk03Xk2T0DF!sk0tV3e!Fh0440G01v!KQ08g0bV3!DF# $KJ4532WWFksXM43ksswF2B0VXV88Rd8XDWXVwV8842M9h0NcN42460W1GRXB6XFV4810aXIHlgkJ451VFViF482Z15F0G0FFTO@5l0kV62510VX8N8d22826X1k8cP70H1F84FH210FVBDB82G0ZD421Ils84N10VFl2RB4PW14W1kHcN89DWHNksBA0VW19TF4H2763WWBNA1VkdFVcD762GNJ8A3WFcJ8210V@8h782A1711kw245YWcN8L@0VX3BV8Z4	#g0k!5G%2!255V!42V!182#2H#@Y#2Zl#2J#FQo#45#OZF#5s!264!2_0V	//(91-2031-2*101(2-D#1501!3#1/,1//$5$3/)1//(2(1*1(1/$1)12/%1#31.B/$1$1/*1!1)1#1/011&2010201//#3&5(3*1(1/#1*1(2$1!2(1!3!1!1*4%201/#1#1,1(1!A)1-1/!104#1#4)9!2!1&1/%2$1/%1&102/%2z$1@%101$1*1*P//*1*106%1/!1%6/!1!1#1(11+2/+1*1/1/2011!1#3$2+2-	ebQTB@@DB@Gd\\bbbRrbbRbbfRRRvercGGaWQtuvwsUKUUP@@@@QSTA@HP@@					agonist	PGI2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xh.hS(S(W~zBS~.>x=x=}\ps\).hS(S(S(hx~S55x>~Six^))^55}H55H})^55	;vzv;SzxvyvzUzCnzvvzbEzUhnSUjrzXEjmbOUzfiFRfHjM9vh@hhNgYvMvi153uo0sM9YJSNnF9FOX0lV	0aJ0Sk02OF1v!8i0@k!b!vV03Xk2U0DF!sg0cF3Z!Ji04F0Gk1v09w01K80RF1r0Ao0pV05JF1_07!Tk3i# 0FFB53YG8gN83WFV86T@EB458NkJ8242YX2Vs1552VHG0BTDDYkkVc4288GFVVsI1c452M0Xqk8R8NXB1GVkNHBgR110Xf0w653m0W0F8FF321l0gP@41FVB630VV@NdBBYC3l1sVJ4@6C2FXNFTD9Xk8kk22@9M0Yqk8g8_H23W2m0kBE62GFJ230a1Y@cw8D4OGW2H9N8B9Z120ZeFFg8B4A6HkgNP410kkt8FcR3110N8831Hl1TF482k15C0FsLF4F2627nckJX817WVG8B4DFJKb10VZF822W10gB532kkJH210kFB41J4eO0FV944ZFK60lkX84Q215W341V68E45FWVk86621VFR864Y0VRD210VVB23K60F8F_R4D3YVksB151VkRkL40W23W9NTA40G8RBHC5VXmV	#z1k!F8$ZN!12$V$1c8$Gk#fc!4_8#dF#12k!80K#G$9Ks$V!2E8V	//#1#9*1&1#1/01$1/%18!106$2$1(11//&2%1(11#3/)22#1//*1+41-3/%2*2(2%1!5/2(302&1$1*1*1#1-3!10301!2#1(7&2,101&1,1&3$3+1*8#21/04$21$201&601/601(1$1!2!22/.2&202,6%2$1)2!1-1+1*2H1///!1#1/$1/02!z%6*1(1/J1%1.2/(2)2/-5%1+2#2+22$1&1#2!1/,1#2,1+1#52)3#1/$1%	efUZL@@DJMCB`KJ\bbTRbTTRRfbRQVRebbjgdRWVqurIKUUTsQUPA@@QD@BFECe@@					antagonist	Opioid delta/m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
h_hGSkh_h_Skh_T~>_h_>GSkhGS;>_h_S;>GSkhGhGS;>_>_jZS;SkSk>GZja@jLBd>_>_kS<MYj>GBdBdYj	:Uvzv;S:vytzUzUuzfzhzU:irUC:hQAjIbsEzjcpLzyzq1n_@hZvTYrIPi2qiwpIJOIUJ98k8du9W0k0	0WR0Tk02OF1v!9_07g!YJ0f!35k1_07g!o40FV2U!DA09w0t!3Xk2W0DF014w0Xk2T0DF01Jw0Xk2T0B!t!6AF0p0440G01v0@k% 12YG8TF50X1l0FNV6YVscDFE8m0VFIBg8@4RHYHNBJL@@A@0ltBF4B559_FcFJ9Z14VccFFc98i8WWFklp6I52Y1RV8J78261M@lNNVCal2212YVND992WlVN@49971G1F@H7Vl88cLJE4WWcZPK410GFkcVQ87G18c4466C30WQs4F6@@aklcwa61221m_084422XHd0PA710V4gNL342m0gT952VN4gPLqM11FXmBg76XXGFVwgR7WVc46H997Ykt4X421kkBcH313_WWNZL42Y0kJDB50YGWc5449VVWkk88h429VVWklsgc9A1Wk82H@9F8FWV54490VWWRN8Z22621VVtNPG2Wm20F4R41XFFVZo445X1cJF532VcV8410k@8_7824110kFwPL430VND110YWWk86845VtFFFI41k848@CCBVXdN8R8iC7XmssNLB33YH1sN530VdFgc@52@_30VV7333FN8c6223_t0Fk84623WkcgL960kcBD420oGV84JZK@0VmNo8G6X3VkJ8JHD5WVl0@D32FVN4NBB72kY0J4gK23l8ZJVA170VGWHgH7DX31F88HBa17WM8FgBiF9WZ1sNP232XXBV8B4@D81FksN41ZYWk8k632460kFZaB62W884JG10YkNF621XXFF8S4J2O@518RJ633YkN8o41250kFFRo	#c4V!304$4!210V!48V!1dc!201$f#4Z1#AFF!FAk#55#OB#8_c!2F#21BV	)1/-C/2$2/!1!1*501!101%@$8$3#1/!1.2%1!1!1/01$2/!2%22.3(101#1/%1/!4//!201+2$3!2014.2(1&1#1%1//3#2/#3#2!3/#221/1$1$3*11-2&101#1%2!2$101)7*1)2.301#3/.21$1,1!D/!1#201%23+2*1%2@-1/+1!302!11//-z%A01#201$23#2$1!1&P//%1#1$6&110201,1#101%7#1&103&1-2/02&1*201$1#2,1031-1#51)1/0301$1%	emPzLH@IKFo`SGG`HcHhdleDhiihdheHYhdemDUjFJeaco`\^YUX@JjYjjjj`Y``@BhHAB@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>.hS~.>.i.h.=.i.=.iS~.=.iS(.=x>S(.iS(.=S~x=.iS(.ixiS(.=.>S~S~.>x>S(xh	:UvzvzyzOyzvyteUpRuyemCjChzZVS5zbW@BbHZ8GqVVZ6WX541r18d6N4VV18w0oOVo06!8J!@Ft0Wk0s0	0aJ0Tk02OF1v!9_07g!vV0iF33!DA0@40t!3Xk2W0DF018s0cF2a0DF% 0B8VIY18ksN8D8ZHFwD310k9Nsheg1WWFk8BD73WlNND44WVVFB210VF421L5A0lW0cFCWGl8sBBH6Zml46F98919kNVCBy2411ptFR3432WVVZL@72G8kB330kWcco451XWsg8621VcZ63D90FF868C10FW@V84p36ekGN_ZL472111NcRK@2VV44LDA0V_mF4mC49320JBR9154Wl8cJG5XVVV@210V842VFFi0YVFN8L6@h11kVc9NJ64YVcwJA2XHWN44HNa2_WccHBG0VYk88oY8291	#d1V#8%4!18FV!V$1V8$IF#d#4_$8F$2k$Z#O$918(218V	02.1/1$A%1///*2$B$3$4///&2/////1//)2)2-3)2/*8!1#30C01/!1$2*2(41#1(1#12/&20301!3#2*1#1#1/06&3/!2//%2(1!4*1#2$2!1#1)9+2/-2-10F//-4!1$4(48+32/%2%1+31//1)z%A/#4(1&R/+1%1)2*6/,1!@/)1*3/02/%101//*7&1!1/01%11!104	enY^L@@DLC@ilRPGBdf]e]VyV^VYUV^QPFeEej`@jZjZj@H@X@HOJ@@					antagonist	NPY1 / NPFF1 / NPFF2	NPY / NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
hx5q}H.>|^hxS(.h}H}Hx>.>.>hxS(.h.hvl`*S~S~v:F*~S.hxh*Fv:`*S~x>S(|Fxhxhx>.>x>S~x>S(S(xh.hS~S(xhx>.>	;vzv;x:vyvzUzUvUv;UjzjpFUzv:EbljzLfzjx:qMnjHxUyAjqeTEwUdpjKq7pge9OmB1ReeF18!	0aJ0Q!2OF1v!9F0DZ!_!uF02K03x!9J0Eo!qJ0R01v!DF09w0t!3Xk2V0DF!kZ0qF3q!Fc02o0FV2U!Fc0440FV3O!Fh08g0c03Z& 38271f3VVNLF4@29hW30gV8J5ub251O0F88ug472m0W0GpN8N5M50kkkOLT452m0W0GdWy693fVlFNRB@iN1YkwV8c5Ns271O0FsAF4Xk17W0W90e556YnsFcRBW43FlJH2860FGG9SJH13GGV4448767GWJg46530V94aC6Ylm0RB4C1VFFNZlB1@WHFo42864O0GN8N@@61FVZL212kV8BRC20FF8FFZI6Z1VW0mD11Y1k91TC230Nsg6288B3m94k16530FGJRC63FFRF1162k8B8FRR45F98X50Z32BV8g42631Gk84670kcJ6840VN46a9Im0XkFcF8a49ZmdgJND@16qVG8Fc4ZfM130wV8R4@429W2VK68DCVY1kNBNN4W114BC@45O0Fk88DA3XkscD750FsBJRB0VXF88S022Q22GFNB532Vkc6921kGsg229GB_Yso@@G0VYkN8kSJk271VGVB4J8CB@lF4JV51W3Gq08lc2@2561tgP768VFGkB4NF44YWkR8K@Z3Vc8cb82610W0kZD64118Z4416ZksF821VFF4VJ10VFkn048441VVNB@3VVVRoa23WkNF420Z2V88WOck25WDoNB4154XWLe44210lkkwsg4822WZW0R65YXkFF8DHaR13FN82695m0WVFWJ26J9VZVNw6I46YFFFZf8261m0WVFF9NHE33G0N896VVkJkHP122FFw@821mHNkN4F13FWc444@0VWZBV8R4R2Cf0Xkeks8J4D18dpkFsE8261fVYkkR8L65M2FmPR4T8S4Xl0RT83VXH884R1145_10oL3A20sFZX2170FGWNF@T3@8kH0B4RM1533WVoBDBY51c9022C1VXmGw0L448VkGk824@7	#9Vk#8F#44!1F$6A4!55i$7F#W8#4J#@FF!VPo!81J#9f#33s!2G6#54V	-1/#1$A/012!9#1*201#1#101013014$2@$6$7$5/,1%1/+2(1!301*3(2(1/208/*2&12+33/#1!1$11!1%1&21$201#11$4!4(2#2*1021%1!104!2/&1/1%88%31&5&23-2$1101!2$7!80101/#2)1!2&2%101*6///$2&2/%1-24&2(2)12#1)6!2(102&@+2)201!2/$1)1$1%1/*z%311&101/01%L!1*1&1.4/0207+1+11#6!1%101+404$1#53#1%1*1(1!2)401$2/$16(3/,2-	ed~|NN@LDchDMHimhP@cVPMdKYAvP}d@yCIICEDeDldhUEMMEiddihdmHiDhyXDtL]]brkFmTEPTUUTsPR@EAUTQP@@@						NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhS~xi.ix=.=S~S(xi.hxhS~x=S~S~xhxixix>x=S~xhxixh.hx>S~x>S~.hxhzBW~ps}\	:Uvzv;SzxvyvzUzBmzvvhjEjUhYUSjzxXAjm_8UzfZFJfmEM1n_@hgRwYmLUj172do!K13498I49m8V0FV	0WR0Tk02OF1v!BM06J0Tk03OF1g07g!o80bk2l!DA09w0t!3Xk2W0DF015w0NF2x0CN01Hs0G01707g0ek% !kkoB95Xl8JH30XF8FwRUZ12VW2VwH85X0sFD40a335u4a6@3CaVVJ4K6VX1O3KJ532WaolVD11Y2WZOc81458VG0fd29341t0Fc8FTo520sB2FE8m0XFJA4Z6E3m0Y0RV8R58F21XF8NNH14YVFNZ8A430ksP710YH0B4P20W2Z2WsLJ44ZVFsd4e4AU0X0ktRe6C7a1FNZNeG72W2G0JC373t0FV84844W1VRDA311N8B6E8VF88BP115dt0FsA04RX22FlFJ4F@A7a2s8NBC40FNNZZaC751c8Na718WkN4BPJFE0XsV6BC80XV88VVLO71ZlN944I274VGFs46821lVR8C5XFs442114Gs8249IO10lJFNI152dkGvo4L4FAXkm0wLB522lm1JP6L5V_1s98J2F60YWwV8B4VU13X044DE80XV88VZ	#j5k!F84#4F#40V!V6#5s8!22KF#fc!4_8#8FF#2k$5#G$d7s!204!21gV	//(B#2,11/1$1/)2!81#5$2/+1/11(2$1)4#14#4-2%22$101&1*1#1(2//4/+1/$22#7!2!504!1,21#1(1-1/+21102-1$1&2,1%3/(3$205$2#1!2#11$21/01*202%2!5/!401.3/-1&21$11.C-1*1%22&1*3*2A!1//(1&1#1/,1)3!z01020901#12+32&1&N1#1&2!1$2.1/01//4/%101!51&6//&1)2/02#1,6*3#1,5&21$	ee_VDH@IKDajQSG@HcHhdleDhiihddlddhmEdXePqTMuM\CbRKK@AUSMUUUD@AATi@R@aGe@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
hx~OJ}dzh.xi.iS~.=.ixiS(S~S~.>x>xh.hS(S(S~.>x=.hS~.>.i.h.=.>.i.h.=	:Un7ntrdN5s0F@E2N0WXN2V0FFJ93604HkV50280Nk96WVV0eO0dV4JNFV91Im0c312W0V412$4#W0Fk	0G8!aJ0Tk02OF1v!C_07R0U!3Z02Z0DF011R0JV1p0CF01a80OF1g07R0U03F!NM0580SF1u0Ak0p% $TK6ZFk4854VkdNVj821112GtRL967W08c@710WktfBXC35Vls4BBCZ130iFGkgP4A4XVVscFLA6WWcg@54VkVF2R@Dm0W0FVZHE4WFscB321kVF6T@EW4H8NZE829111X0wZ75WX1kB840VkFkRv82A11_JVc6@31VW8VZ694XGsgL92VVF88210kH8_5XG61Xmc8ZI82B1NVYYk8ke293m0WVOGc8V4c3aklcs4JB13Xt0Fs99PZ351t0G0DF4B2i49G8VoI8291m0WVF	#joV!K8J!2VK$6k!o3N!5Vn!3Z_#BYB#AR!2O4k#DV#4$WAk!IHk#G7#G1V	%2/&1)3/#2.201//D#13$1#12/%1/+1-1$1/$1!1!1#1+1#1/01#11/*1/)2(1%1#1%20202#1$1,2*12/#2#14$2/$1$22)201!101+1$2$1-1&10101(3+1,1)1.1(2/$1$1(1!102/01$1*11$101)2!81,1/01,2)1(8%3+1)3$101/1%1(201/01(x%8%1&2$101!1010204#T&1!4011)1.1*1!1-1012*1#7011/3/+1$21.1$101//+401,1$1/%	edVRHD@DBFmj`HbPHrJJJEJIIQZKQGQIIIDLNQE]GW@ptuUA@A@q@@@H@@@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(S(.hx>x>.>.>xixhS(.hS(x>x>S~.>xixhS(S(.hS~x>x>x>.>.>xhxiS(S(.h.hx>.>.>.>w<^}.hS(tn~U<wgygy<w	;vzv;x:vzvUUzUvzvvzyDbzhrQQ<7jPjvUvvctbviUJY5iUyjDTYvAqudabOq7UkIdLI5NNnW@$	0aJ0R!25k1v!8M07g!aJ0Tk02J03d!9F0DZ!_!uF02303q!BM06J0Tk03OF1k07g012F0FF120@Z01J80Ik2F09w0t!53!Z04c0Tk3q!NZ04w0Yk2U0DF0uF$ 04VkdDB310W0sVNDEel0cVcZJ@3W0882974Z1F9XH5610GFqF4@2@963NFJ4142X1Vs8RUDYVlFcNN2742FVB410VV8oV2177O0Fs8cN464Xkl88831YVF8kcFjLWX0kk9JRJCYXFcwOP2A@3XVNRF82B@lVc8D@7LVZVW8F680WW8sNRBIYVV8441532gV8B48H95WFk8814YXRV8J4J@11WVNFJ50XXN8B2123YVVcV4EY1F8JHC9221kkZD4521W0F4661WFVB@120FV82E9VVF8BT2159h_kFc882521VcF81210F8410Z1c84LYZ130VY0kR45930VFN8C120WGN8B252VFVF8410F8B810ZH8F4T211350FVRH82WG84HA921WkFF8150kV8410VGt482EFLD0WFF8JF12X0N8D40VVFoRQZ130X2Fs861110NB822YGGcNB651VFVF462VFN821840F88N_Z15VY1kGFVWB1Z1FFkB432WkVR625a0VF46J10YYwV8o48D51akVckD2110tB42EAm0WVKN88i233WFNR2774W1VN4422VkVJB213HkF42224JRV8R78271B0VXlVuD124FV8wU825167kGFZ611X2884RIZ140X118y@21VVF8JJ10Xmkk9RqS721FNNTEZ140W10NR8310ksN2110FFwc214820VVZ8321kNB4AA0VF8BZ217bX10kZJ510VFFJO10XXn08lPU24WW0FV8F431FkN@A75a1l8JF611kss84F821kVNJ95ZZWkkF2233l0NF44520kFRn823160_lVVJ653X0FBHC@13XFkF@J210X8NB421VVkcB27D411GN8@J10VVcN413Y0V8cB423bXYsF4430WmV8N4G220VV4@AD2110sJB341V8cV4313I12xP6A330a0l8BW63VVswWP2DEVY308cB8229369g48C20Xlpc9J8Q27YWFFgM823130_n08cB81WX0NB4C917kkNN@K20WFO4F23111VN4JP8CX0FFJe819X0H8c44D70Y108chP2Q21XF8BB33Ym0k9c8q4130d4Q8241a60VsFFF82410cR450VFFoX415b458ku2552X0I0Vk6231VsRV22130V8cgN636kks4Q87434NNBVS130FVc4288210WF86@1119JJ621ZFV8oo4812W0NR6330lO0J826aW0IFNR@431VcF410VlVooJ440X1g8B84ZmG0kF6R33VX4426@VVVG4829B813cFFXF@0VFF4B9@KW0kOB4D720kck4299	!21_V!584#4F!18s#X6#1c@!203F#fJ!44V!1ckF!kHo!185#OZ#9Cs!3O2!219V	!12//#J/!4!61%2#2!10101%101+112#@$5$302/$102//%2#1$106$102*4%10202/01+21+3&1#601&1!1(2$1/$2/%1)1)1%2,1#1!2!3$1101-101.2%1#7!1#2/3(1%2$21$501!7&4(1%4(403-2*1!11!12&4///!2&1$2!12#1#1!1)@(2#201%4#2#2(2$2!1(1$2F+21,1%3#2)2/&1!1&1)1!10z$1701201/1-R,1-3%2!6!2%5(23!2&5,202!6!1.3!20707%1124,2!1202/!2!2//*3+1/3#2)	ens|NL@IGA`hffQ]PpH`bHmBLbbbrtbbRfbrfTtTRRRVbQRTvbeRXxAiQyIecSk[``JjjZjZ@J@JHjji`@@h`Dh@@					antagonist	NK1 / NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS}.>xh.h.h.hxhx>.>.hS}.>.hS}.>.h.h.>S}.h.hxh.>S}S}.hxhe~00,b_+6r}V.>+`F{1:)Shx1lS)>x>xhx	:UvzvztzSxnvwvUIvIQjtzqy6Mfh_ANtezn7kXfhUOe6NbfVAGhDT7w@Tq33Db6e3XAmSWBeO0k0AFFm1W0kV	0aJ0Sk025k1v!9_07g!mc0AV11!BM06J0Tk03Z02W0DF!kZ0r03q!Fi0340FF2d!KG0740Sk2x0CN# 0O0G08BHG6630ZRwDBAX0lC0BN67cnORFe8xH0V8VsI82A16AHWNFs8YU0kmkTF4B3Z13VX4dwi8F4c50WFHc85NX3WB844643kVkWNG26G391t0GV9RFA10WHNBq4FAVYXB88o22A10XFlSN8V1113GBV8V5BaAWc0rmF46O3m0WVRV8g78231m0YkP908Z3181t0FcAGV4@263VWcF1232O9sZ4n4WaGFc2A32Zm0Xw8424V98VqFp1@X0HOJZ4F45@VXl0JK392eWNF6E33VW1sV	#E4k!J84#gN#20V!WB#9de!2@GV#X#5_R#AFF!1ek$B#O3#Wps!232!210k	/.1!5$J/%2#1+4011+4$1#2$A021061#3$1$11#1//,2!1$1/%242(2%1/(103,101#4$1)1#1.1/01!1.1103*102(2(1!2$1/$3+2$4-1)4%41!2!2%1!5.2$1$121#3+101!1$2#3%1+2%1.2$2.101!2/,1!1/1%2%1(9&6&1#103(2-2&1*9#1/-3/042)1#1!1/1$4#z02#7/#102$215%N12)1/011%4,1%1#2$1#2.4!1*11&201*141)1&2&1(101)2$1!2/*5/,5&11$	egRzLD@IKMbY^AC@H``HrJJIRIjYQIZJIIKSQQUQQQHlJIYKG@hpx|rfvpPKDuUUAAEUUTC@DUBCdr`@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>unS(}IS~u8f,.hxh}]I)~SS~S~n1qqxhS~q5qq}HH}qq^)qq}HH}}H^)	:UvzvU:JbxYufUUjBWatIzaBHJCYT15LnVE7XgIEmOaWHe6Mw0kZ0ChFVdl5We0fGeZZsM1105G1FC1ZV0FF	0Qw!WR0Tk02OF1v!C_06k0U!33F2W0@F011R0OF1g07g01680OF1w0C!14w0Xk2V0DF$ 0s4FA0XlB4F@10X2RV8V4@a11HkcwJ2261GFFRZobG1WkwV8V4f@251FFkNs@FDc1GV84J213Yt0FV8S2F80WGlB44@2VX2BV8R782A19XmNg4766XlNFcL279m0XVNNRa683VWW3ON459XYHk84688m0XkGksg25XkcRVR211kks84@OZ11VVekRBN514X2nl0V2580X08BJ513Zt0GVDF4@22NZkFJR71422BV8R64K6WWFlfF4@9VVFsVU8261m0XVF	#XJV!584!4f$@HV!Z2#4V2!2cJF!4cg!40N!210F#HV#4W#KO$Hs!2J5!25hV	01$1$1#1&1-2*1&1#1#1$2/01/!@$3$2$2//!1#101(2)1#1&2/2%2%1/0201*1!11%1//#11$1%1/01%21#1122)2$1&2+1)2-4,11/,2$101#1(12(101(3!1%2$101%401#1&1#3!2&1,1(222$3//#21,101/#1021%201,7%1&1/2-2/!8!2//3%3,101)1,1,1!y%5%102*2011$2!4010Q*1//.1/%1&5012(1!1#2/(1(11%1(1$1//-5/03(1+1#	edVZHD@AE@nh\`HahHrJIJZIJJIIYFEQQJKT\ZNIUW_@ppACTEPLM@@@DAAiP@@					antagonist	B2	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
72o2xi.iS~.=S~.ixi.i.iS~x=S~S~xi.ixixi.iS~.=x=S~S~.h.iS(xixixh.>S~.=S~xi0lvl`|F|	zJup218G0V4F4F240N0W0N2k!F011820LFV5!82FV909WV021VC2KL1FV012k0V9F22404c0@2424F10WVFk	0JB!aJ0R!2J03d!B90Cg0xV04RF2v0Ak0oV05PV1j07!RV3F!KX06J0SV1v0C!1_40NV1_07N0Tk3F! O0GNDF4J3Z140fkHIJ4L5Z13Vt0GkDF4D3Z160t0Fs@w4ap16W9l3JBX6F1@K0H0G04OJ14W40I@g4ic19Wp20Fo96B28CFGVTF4V3Z140t0HcAKT4@2m0WVH2k8Xb17WZ0GpF4L4F14p0FsFR4ei1920GmR4N8FIf0lkNs44CHVXJFo8B@6HZ58VcF	!3aVk!v2c!65N!317F!l7F!DcP#Fo#NA#20y!3k0F!5To!8Qe#WY#GRk!@54#4kV	01/+1)7/!1+1%3/4)301!5%1#2/010101!101)1(1(2!40102$13$6/1(2#204%1$1#102/*2&3(1+5-102#1/!1%4+1101/#203/#3)1/!12/!4+12#2#4,1!12$11*5$13401(3/-3/3/%1013#1!11$30201,4!1%1/%1&1!9$1/)2.1*1!3!D&11//,2//03*z%41&1!1+11$11#L+1/)6)2#1$3/-1111%1(2$204!13$13)11!32$3#1/1/%4%2+9/-1,	ei[YJH@LFA@`ZV^QXDKLc`@cIIBhhdeEhdmEEdhdiemJmOG@m`Wl^QUj@@HBj@HHHhvh@P@@					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>~SF*.hxh`*v:S~.>S~x>S(.h.hxhS(x>.>x>x>S(.h|`S(x>.>.>l0|FS(S(~Od,.>d,~O	}y:Uzh;vCjfzUhrwjzrxezjnrPr:i66vrzUCugTxyi_nrKvyGCAmKcFK69klHkZ88VV0FV	0U4!aJ0Tk02J03d!C_06k0R!3OF1r07k!sg0bk3Z!HD09w0d03Z!Ji02w0FF1209w01MJ0Sk1u07k0ok06FV1404R0SF1u09w$ %m0W0QV8ZB2231o1sFc2423XD1lc8874PYFVNgq323Xt0FcDF483Y0W1VgV8J78261m0WkRV8F50w2Vl1NZF44EDVFW0aF4J22HVmm042753bGNsX8F0VYVcgH2444skGV44F5Z13V_q1BH8@4E319NFc96WF8VNV2985HssN387Z1mGNa55@W0ss48B9lVZV88kA82C12cq8cFV82B42kZJm32Xl8VZb82612XY@0R30VFFF21B562kFRTM83FF82JD10V8Nc428DDe20wFH8HS40lk8B4@5C4XlRD@C20FWFsg856XmcoF4154088o820WXIW1dLC1XZk894442740mHoZ75BVFc8BaFqGWVlN84133Y3kXNu@560VG842468m0W0RV8Z5cGEWX0mNZTm12YVF8k62@7JikWsHhm4K2m0WkF	#vGk!18$VR!12H#g@F!5gc$zF!Ff#4_A#dF$Po!8ZK#SkF!9Ms#4B!2A8V	%2!1)1/#C!11$1!1$1011$1/$201/20@$4$2&1.1#101/,1%1,1&2,102!2/02//%1*105&1-1$2)1#1&1!1$105&202#2#1)1//!101#101!13/!1#1&201$1+1&1)1%301!401%1.1123%1!1*2!101!1#1%2,101$1.101%1/02#1#102%2311)1!A1/01+102+2-1!27/////%1,z#108/#201%1&P,2&11#101%202#2$6//(7!1#1!1+2203(13/(1%2&11//*204/02%1#4,1	enSRB@@DLKI`CGAdfYYYm^WU[eUutRPHiiY{zDfeejjhF`jJjPj@@H`DBBIJ@@					antagonist	CCK-A	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.=x>*Gi.xh.>x>)^S(*Gx>S~i.i.xhxhS~|F|`lv`*~S~S:0h.hxx>~S~Sxihxq5hxx>xix>S~xixhS~x>S~xhxi	=v;OzvvyvjUtUvyQzrTRQjhbOSxUymCymYfQlj6kb_DPS1OC6wlPw3MUYlXx32np3TJ@BK1NJXV0Y0Gk	0Pg!RF!Xc0IV02HF3V!Bk0480IV03JF1_07g!sg0bk3Z!G_07R0Tk1w!Jh02s0FF1209w01K40OF1q07g0l!5SF1r07c0U03I# 01cFoW40VkFVP1112HXGWe54520VFNB96X0kF6532FcB441VJlPTF482534WORk90VHGk84JKT3120X5F8L420W0kVT63X1VFBA373k848NWZ12Vt0FsDF4F265YINB862WVkB85C56VX0pJQ592t0GVBVs4I2m0WVFHFi69XVNscR8D13n2N8DA76L0W0F84VJNVnFVgLk2960WkVVgRG4aVN8@31Vn1daF4B211G0FNFD43218RH421kVRBVG10F8No62AK0X0d8TC4XGNJ420aYYF8FJ422FscRA3VVN88218YV88l86733GkoH42ZZVkN4212Y08B8H2138VlWceD2W08Z8JA@m0XVFkN4763H8kB51WFWcor8281m0WVRV8F4t82910lBsJ8@410VNJPC5XVVVH93VFGsw22CF94IcwF@H50Z0888LGZ11VVV8FD562VsJ810XVVc44124lmNN@96ZXtB6FH0VYkN8gc420WVkNZ53XFVBH740FX8x4V8B3W2cc4a10XkV44975a8msR8K4VGlVyF4@252VVkkB@7YFVZ@210V@0p1q29JVWkc88gFQ241VkkV6S70m0FH4A55WqcFhB22420GGJw45Ykt0gV8m25fVG8PSu4426B20RB90YXGk8NaYIXY1N08t82A2	#24V!118!2V9$2#s5F!A9@$5#GY8#4D#9FF#Hs!84E#O$8SR!808!290V	)11/02)2G!1+1!103603!1!301%1!1)103(2!2&801!2-2/#2&11&101*21$1/#1)8&2(1+2!1/$2%7(3#2.1201!1&1/!21.1&101/%2,2#102#22!1)2$2/!C&11*22,1*12$110103/2$102!1/2,5(104$12#101&1(1/)2#1,1(1!2(2!34)1(1!1//(1J11//!1#2/.1-1!1$10z.2*2.1F//!1!2-1$@#1(1-305)1+15*113$2/)1-3,102%1!1%101#505$301/!7)2#	eg\rL@DDBciPC[YYM{HhhiEDhUdYeLhhldheUDeDehyiyDdUT|BKJuUUPTASUAAET@EUQA@tP@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xh.hS(S(W~zBS~.>x=x=}\ps\).hS(S(S(hx~Sx>55x>~SixS(xh^))^55}H55H})^55	;vzv;SzxvyvzUzCnzvvzbEzUhnSUjrzXEjmbOUzfiFTfHjM9vh@hhNgYvMvi153vo0sM9YJSNnF9FOX0lV	0aJ0Sk02OF1v!8i0@k!b!vV03Xk2U0DF!sg0cF3Z!DA0@N0t!4RF1r0Ao0pV05AV1404R0Tk2U!KG06J0R01v0Ds0 0IWqVNk429420VsB8691H0NJ221kWscwo@NYl1NV4631Wl8ZFD3Y0s8632VZGF44DZ5C52FJ8D10FWFVf82715XG0NwDk7VG1FuH04521d7cNRB4YGW2NJNDBi15hVFsGXN442Ab2kRT464Y0FlFcE3XWs8ZJ2111moA0Z653m0W0FmVgT47VVGNcF6810G0RDH510NFF7E710FFh4421VVsFB67WlFV44310FF22J5VFFudZ@4I17klg8@C7M0Yqk8g85X23WO0G088HF61WcgV62_2FV8Rg494Xlcg@C3Xkk441D3b34VFZuM232O0FV8A44A232JH0a@D5m0W0FcWN6F63kWcN64@30X20VN4Q32GO4@320FN4sFRZ15F0FsLF4F264eJkFJX217Y94GwBJ6410G0JB@20Wko89C80kFg28@GC0ZYPBP6D4m0W0RV8Z5D2CTVXkWe4e547Xm0FkN842EX0VF611YWkJ@50a4W8R24460VGHN8L3@XGNJ2B4WVlVg829C2bWsRPA1WVO8oB2A@	#z1k!F84#ZO!12$V4#1c8#2Gk#fc!4_N#xF#12k!80M#G$dKs$V!2E8V	//#1#@/!1#1/01#11/%18!105$3$1(11//&2%1(11#3/)22#1#1!3+2/$11+41-21/$2*2(2!1!1!5+1#2(302&1$1*1*1#1-31010301!2#1(7&3,101/$1$302$4+1*8#21/02!1!1$201&901/701(1$1!2#2/.2&202,6%2$1)2!1/*1*2H1///&1/$1/02!z01#602$1!1(1(4&J1%1///!2/-8%1+2#2+23$1+2!1/,1#3(1#1+12!6&2!3#1/$1%	ei[VB@@DJMCB`PKOa\bbTRbTTRRfbRRrrTT|TUT|bRzNn^iyZjjfZJj@J@XBH`@Pph\h@@					antagonist	Opioid delta/m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxiS~x>xi~SF*S~qq`*v:xhx>S~|FS(S~x>xixhx>.>xhxhx>S~S(S(x>S(xi.>	yyurTbOG8k5k4GA5FN0GVN@H04F09Y@@0HQX58V03Pk96FW!2OV90JLG0Wc1Lk1dA03X4V640@441J640603V	0WR0Tk02OF1v!9_07g!qJ0SV1v!DG0DN0uV045k1_07!Tk05JF1Z07J0TV3L& !BV8Z782B1H3kWe8T4@4m0WkHvsT683m0WVP1F8N4x16dkG8FgR230XNV6A2VHlcB4L4112108Nw6l28W20FoDC24X0FsyF4D3Z17VgLNG8@NN27120@RBZ@18@FGkiF4L3Z11VYVHFNR4E@7VWVw4HBM8W33ds8H8x189kGVIlF4G2	#24k!384!22K#T6V!V3F!2V@!2V5k#Yc#7Q#J3F!VPg!1Z$5VV#8k#J6!2J1k	,1/!1&2%1+1$1#1%1)1(1#3*D$1$1%1//+1&101%1!2$131(1$102%2)1*1/-103%1,1/1$3$1/$2!2$1%1%1/!1&13#1//!3/%14$101(1$1$2!101)20601#1$3&14#1*1101/$1//)4(1%1$1!101/+1%1+1!C/03/+4(1&10B022(1&1&101)1/#3$3*1/$z%@#1#3*1+7#X*202$1/,4)2/#1)8/*1//01$1)1//-1/,1-	ebQXLH@IAHTPHaIe[YYVUeyVu{hXl\znvA~q`@jZjB`@@`A`P@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.=x=.iS(xiS~.=.=S~x=.iO(,dxixi.=)Jp363x=S(.iF*F*.=.=p3.i.=	:Uvzv;SyzvqfyUzBtzQHCbAtUgYS1zIleE7mZNGrla4L12A38rZ6Sq@4W_4fY058X58FJ1801804FNZV0FV	0aJ0Tk03JF1_07g!qJ0Sk1w!DA0@40t!3YV2W0DF01L40Sk1u07k0ok0 0LVXldNa674NVXaN8R8dF23WO0FV8RFL831GOc4H813YX59148@4B23kg2866ZVG8tco@8X3HV8gJe2@bVX0V8FFOBYV8t08526YFGOFo4eE3610FX14Z30F8Zcx6241@I8sN7562VVNkN17YVNg64420Wkgs8I6W1Fg8740ktNwF2@B	#f1k!18$V#18H#cV$c8$1F#d#648#1F$2k#45#G$9KN$8!218V	#1(1/$1$8!11/,2(1!1/(@$1$2///&2*1#1/$1(24//,1/,2%2!2-2/)2%1#4%1202(1/02*2#1#101%1)14/&2&2,1012!101/+2/+1/,1*12/$2!1+502+2+4/!1,10E//-2/02A1-1/!21/#1//*w4$A/#4$1!2&P)10101!1#1$1%1,4&1#1&1&1+61/(1(202/(1/%1//01!1402(1)1.1$2	ehRRD@@DLEF`ILbbRbTRfTRRbVbQRqRzJZv^n~ZjihJP``@@H``HH@@					agonist	MC1 / MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
:vez(N:v~X:v:0(Nl0*F*`~X.i.=l0.=.i~Xyg}Hq4q3}G~Xezl0:v~X~Xezl0	;tzdzSzpxxQRAUEE8GAsu9aEH2hY4A@PxXEAX5N@gfa022FXG1t0Fy8BoYY5W2W13fV8oK0101J1R0V$V	0_!uF03OF1g07#qJ0Sk1w!C20@Z0gF03Z02U0DF01LF0SF1r07k0pV07FV1507J0Z02U0CN0t# $1Z120t0FFDF4B25732lNR7142X0cw@G740t0810_XmlGZcK6WVN8VFGZ140t0FVDF4J2571GNoJD42ks4gTL531WW0aE510FBgTL52Wl0ZP862W0RD3C8aWGW8XC82kc421A6_mINFR8@52XFcgD523kNZ@41VZ2H084693lcRD73WFN4420c2o0888D71Vl0@630VNB8210V@NlB496ZGNgN9210F4220bXYs14R54320FFBHB42GFND41Wk8F460Vk@VxI8261	#I1V!G8$VO!102#V2#4VP#2EF#dV!4_8#5J$Ho#44#9V#1Ik!20a#E8V	//!1!10D#1-1///1!8!104#12$1&1!1.1+1.3)2$3/)1!1/%4&1%1/#11+2/%1-1/02/202%2/01/#3.2/%1$1&1/#1!10101,2!4$2!1+3$1%2%2+201/#3/!7-1//.112#2*5$2,1+102.2-15/)11$1$1//,1,10u%501/(1)F//02#2!221201(2&1/(3&11&1$12402$1#802!1//!1&1/!201.41+2.8-	e`RRD@@DFDn`MlbbbbRVRRRLRVTTRS@bf`TSWUwsUSUPPUUPPQA@@@					not given in publication	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
5q^})H5q5q)H5qS~xi.ix>S~.>S(xi.iS(S~x>.>.=xhxiS(x>x>.=xhxiS(.ix>.>x>.=.hS(xh.=.iS(.=.>S(	:Uvzv;S:vyvzUzBuzvvCjEjUhYUSjxheAjn_8UzfVFJAmUM1n_@dgBwYmLUi066dJ01K1A498G49mBV0F0	0Pg!YJ0IV025k1v!9_07g!lR0OF1v!C_06k0Tk03FV2U0A4!sg0bk3Z!DA0@40t!4AV110480ek05AV1404R0Tk2f& $233W1FRL@5XFkZ851bYnwV8J4453Ym0oa740kWNshHd8WXVk8NHCAcWF82HB9MC0FNJBabE20F8NJB462XugB174Yg50gBF7Z12VZpsZJ@10WlstkcV6WWG0dtoB37Wt0GVDF4D2Y80VORJP1@12Gk88652Y1cZL61218Z2218YJIGRBO44ZkFsdNg4AR0X0mVoX6C8610NZNoD62F90FC874O0FV84421X0kZNC4X1FN4110JGsB4P115dt0Fs@c4Rd0XklFF4F@97_3F8TBC50VFNZZT97a1cdF2928XkF8BPJIA14Icc8R1@12WX9BT6I30ZFGJ8R11650GG046321l8ZH73XkFRD7284F888R2169gVFBo8B9VXWKV8xk2A2A60kO0V@6X11NtNZB3A2VHW04Z8183FGkyF462IA1529J8X116_0GFkN6Q822NNH4980FGlFdmW33WXZ1gVA1Y3WZ@906B3X80W0LF4B2423W1ZPA11kNF42C66VVIO0R8331O8Ra120FsVok846Xmd0NgD3VVm8F4235a418gJK3128442A75j50FF8LI7_Gks4386Z@lVl28B4K6FW@04D7Z13VW0NFLJ1_FsRBJF40VFNko6221aWt8FD4XF8J2415YV888LV41W1GJ8632l8cgZ3181VFFkv8231	#d5V#84#5F$4$2#4c8!207F#fc!4Z$8FF#2k$5#G$97c!204!21BV	+2/+I#2,11/1$1/)2!81#7$21/*1#101)11(2$1-13,1$2!3!22$1)1*1#1(2/)2%4(11/&2!1+21#5!2!4#1*2!2$1(1!1*1(3/!51!2&1%1$3&3+21%3/(204!202)1&11$21/01*202)6$1$1&401.3/-1&21$11.C-1*1%24&1&1-2A!1/&2/(2#1#2//!310z01#901#1201)5%101&N$1&2101$2.1/0103/-4/%1%1&7//&1)2#101*2#1,6*2/08&21$	ekTvDH@IKDajUSG@HcHhdleDhiihddlddhmEeChdjFJanik`\R]SX@JjYjjjh`@HJjjHBPDH|h@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
p666wh/hw>S|whwhS|whw>S*whw>h/~j|S>/T|w>S*{^{^/>w>X|w>S*66|X{^85xB^+hwp6h/*SO*|N>w|S|S>/>/hwhwhwh/*S|S|S|Sh/	:Uvzv;S:vyvzEjBvzvuhjAzUgbJS:teEbmhN0rraxLnqEr9n_DpqDJW_5jj1_@Xp8KJYQJA80B8u5W0kV	0aJ0Tk02OF1v!C_07R0U!3FV2d0CZ!sg0cF3Z!DA0@40t!3Xk2W0DF!sg0cF3Z!DA0@40t!4103O0Ck0xV05NF1r07c0U03I# $20V888411GVsJ841FcG0V816cVGcVL6572ncFX899m0YVIVg8HT36FkcdFT623n0sRTDiNWFkcPJ4TT20YNVcJa@8VHOcFDE7NfVcNJE8261HX0WAR4D639YFcB221XVm8gZL6MeVlVJ4J8Bg11VW_V8H4a3aV84JNO112GklJN420WkZk2@@53@NFs@2B36L0W8Fk4IN13WL0Fsk4@4220Vc4D@8YlN46921k@0d38261m0X0HWBBW@XXlHNoRSB2XlFOBa6J21lPJFTDG540cx8BH6m0W0F84432VFNF8961FVg@41XFF86110L1Q04@F4WGcZ@C10FccoF51370HssaL54VWNVB@FK180VRJRA60W0VZ227@3dG1NFJP13XalcJP233Vs8ZL@14VFFlN44221FFZH95W0sRF71W08KBJa594kn0NF6CVVcBRVJ20VlN82K1Xlcsgi60Vk8W8620WYJVkRq4D1WkRVPFu18YlVwBP8ES30lFw4F8u18Y0Gls4N6u63kl8w4B821D30VJcR5W0918613VG1dcJBA3CWGtJ661XG8FZX217aX0HcN24HB22OJ4111m19N4D91W1N88211GFc23EA2lNBBZZ21B0YsoBcJ@VVm0F@4C910ZKVF8Rc2WFlFk884H70Z8kJ8P513Y7lFsBFh12XA0VkBHb13X2l886C4ZVVBZeC5VF88JTR111VFFJ46YkWFgR9161VGFB4FRN414nVsZ412Xk88ZV	#e0k!1%Z%2#cc$cV#8%d#6Z8#9FF#@k!854#O$8KN!218!21BV	,1)1/H!11,21-202%1011(4+4!F$6$7&1!1//02#1$8*1!21/$1!2$2/1!1,2//02&4/.1%22*2$11*1!2(1-1!2$4)1%1!1!1)4&1/1$105+1!12!2+3&3#1$72/#1$11/,202$1#@04!1%2%2)1)1#101/04(1&101.A$2$1//!4)1&87,101(2+1-1!2(15)1%1/z4$C071!2+16$1!6!1#S+1011111!101,1)B/&1#1+B201*102/#6)1%4&1/-202(1-1!19&1!2)1&6&5%	ensyNH@LBIKDbmknXDCHleaP@cIICLedieEEMeDheLhdeDeDdThmdQIOdZ^[T\zvujjjZifjijjZ`dH@@@J`BGBJbIbOb@@					antagonist	NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.i.=S~.i.h55S~(S`*.hF*0:|FS~.>xi.i.hS~.=.>xiS(.hS~x>.=.>xhxi.ix>	yqupT_OG8k5k4GA5FN0G0N@H04F09Y9@0HQX58V03PV96FW!2GV92JL10Wc1Lk1d903X4V64V@441J640603V	0aJ0Tk02OF1v!C_07!Tk03OF1q07g!t40tV3e!GG06F0SF3L! !m0Y0RV8R78261m0X0Lk8tR2A2m0XFNdw8N4B3318NZ678VlF8BP215W0kFV626DNVZJF8oB295VWl3s8m@292m0YVG0N8e29W4Gd08RG164kG11s4V9TW2kwV8V4y2KXVZ0V	#20k!3$22G#D0V!V1#2V@#V5F#Wc#5Q#42#2Pg!1Z2#5V$Bk#46#41k	//(2!1.1#2+102/1#3*D$1$1%1//1*1$1!2102#1!4$13/+1%2*1/-103%1)1!1&1(1$3/)2+1#1%1/!1(1#1(2/)3!1/#3$101.1#1!1+204%1$3&13$1)1101&1,1%1//!3(1.101-106/01+1!D!1//*4(1&20B(1!1.1+1/#3$3*2)1%1#z%@#1#1/&1#X)1!2/&1*4)3/#1)6/*1/*4+3///%101&4/$1-	el^XL@@A@DDlbfbRffbbebRRtTRRVxdl\JZ^aAQZ@HjVBBJ@@@B@@@@					antagonist	EP1	Prostaglandin PGE2 (I Prostanoide)	no	gpcr-ligands_DescriptorsNo5Ht
=xix(S~S:v:0hxh.*F*`>x~S~S.h.>hxh..>.h;v~P>.~S`|)Ipr`*6r{c6r}IM}}I)I`*	]Qyzv:iExgQyQmCjEtUhfJGvIleCjqZ8Nrxa461Xd21vW2xicZWWMvZV5SeV044#1F0H0O8a0IV	0aJ0Tk02OF1v!BZ04F0Tk03OF1r07k!sg0cF3Z!DF0@40t!3Y03a0Dc01LF0SF1r07k0ok0 !94mVZi666108FVY82618cFGoF330X0d2do4A2D_4koFF8ePWFkcTF482H@2m18LBF20VWO6F4J2XW13kXu0ZP47212FSP86330c8cSTo0WXVwV8N46o0XZFd4JRW11ZH0Je422Xm1c9BXD4XGVNDC854_YO0HO552m3VFR8R2G1_HcgJ120WWdDF4@2f414Vs8wFF8WXlVN9BgQ711FcoN321XHI1cFDCXXWQVV8D4g0WVmcRB4G75F8NoY8251m0XVF	#v1V!18$VR!102V!V$1c@$IF#e8!448#WJ#2Ho#45#O0F!1GN!202!2A8V	&1//A#2-104#1)1/1-2!B!102$3/,1/)22)1#2$4,1/)2//(1#3!1/#1+201/+1#6/4(1&1/#1$2$1/02-1)1#1!3!1!2+11/%3&4(3/!1/%2#4011*6,1#2!4/14#2$1/1*201!1&4#2!A$2/+4$2/(2A///$1/%2&1.z%A/#3(2&N///(1,1+5101018///%2/!1)201//!2031/02)101$2%	ebQ\B@@DJC@MFnlbbTTRTRVRRbababTRLbbVUpKrLNKUMTtEAS@AA@AA@PP@@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>.>x>xhS(.hS(S(S~x>x>S~.>x>x>g-qq.hS(S(S(}ZD+y?55x>n2n2.>x>D+S(.hS(xhx>S(	]U:v=hvzvvUjAzUwzxUjrzeEjqbOMrviLT9mEM9nhixp@BrzLzj15@mK8NM3nJS8k69NSa0nV	0aJ0Tk02AV2g!9k0Ds!qJ0Sk1w!DA09w0t!3Xk2W0DF!sk0tV3e!Ji04F0Gk1v09w01L40Sk1u07k0ok05JF1_07!Tk3i! 010kVB@B54WVR864VFOskx88P1Y0F88F@7GZl8NF@20HG98F@61Xlc8P76YG08oJPH15JVFsFZsbAX2W0kgN6E6@WcBFJDRG_1VVV@265OBVVcHWa932Wf0GQV4D45BZmW4D475VVG11y@4426YXtcg26435qdVB@63120kcB953Vsc@22VV@0l382410WmOoR@F50kcVFL314_11l8q8@HVWlFmFgD13VcsVR4975YFR833W09Ncj82410WFN8@84XksZJ@41IX8444D1VY4FuJqN47VVFFcN6630VkRH562kck433VZ1P1RD4I26VtVB2664A0GvV4L4110VNRH33XGNc82420VG4V20W3FF8hF9V23W0FkoLF7YGFZ83A55t0G08Z896X3VBX2351mXH88HNAW1WBV8F4626XHVkJ842VWNk2124aWB0Fg8D6G6n0cs429654kXVwJC73GGc44L11122gV8F4BJBY10N672WFGNRhZ2@O0WkgV8V4FI1VlkFJ82Z0F8220bXIksOJW42ZFF8w4297Cf3kNcB	#f1V!19$ZF!102#cV$c8$1F!Ff8!6Z8#dF$2k!845#G0F!9Ks$8!218V	/#1,1%9!11$1%202!3/#1!1/(8$5$3-11.1/,1!211#1#13.1(22&101///!4//%2/)21!5/3%10202-3/1%1%1)4-1)7&3/2!4/!3$1$5(3&2%8#1//!1%4#1(1$6$1(2(14#2.401#2#2&1%1(7%4.2/*1!1*2J1(1/2/,1*1/.z4$7/0202$1012&J(1!102!1#1+2.2&2/-91!1-2/21*1%1!1//021/(3!14*3#1$11-1%	ei[RJ@@DJJm`CKOA\bbTTTRbTRLtRTVVVftTutbFnfv~QiyZjjiihf`B`@BH``@@@					antagonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S>x>.(S(S>.(S>.e,(O36J):0s6,B0l,B0l,B0l*FS~:v*`	:Uvvv;SzjvydQUjBkyAShaArEgVQCjMJ8A7HdN5FmVOLdLQJ4NV2R0FB1l0@V07!J0FBW34e8H01!W0FV	0WR0Tk035k1_07g010F0qF3P0EN01Kw0NF1p0Ao0ok061!i0480qF3P0EN% %21lSD82Y3VN8gU821144ZFoa@E2VFFNgXRI250kFsN8PD5YWcN4341V84220c3F88h4TQQWXkN8RFUA3WYFN8cF8F6Wlc8N610FVFB210F@8w42CHK0Z6s8s62@3m0VkF	!164k!404#4$N$VV#1hc!280F#2#4V8#8FF#Ak!84L#G3#85s!21#238V	/,3*D/$1)1,1!1%3.1$3$2*1,1/,1/3/4&2%2//$1/,1%131+1(1(1.1021&2!4%1$1+1(1(3#1)5#2)1!31/(1/$1-1#2/02$1/$2//1%201)3%1/$301/&1,1/!1!604-1.21.1#1*4(1//!101/$1#1-3+e#20201#101*1(1%18!1,1/!1/&1/!1)1!1//02//&1)2,1,5$1!4*1&3)1-	fi{Ha@IFjNs`QF`cHhdleDeDTdeDjLt[hx@JjejjebhBH@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x>S~.hxix>xiS(x>x=xixiS(x>S~x=x>xiS(S(x>S~x=S(xixhS~	vzUQvQnvUNeklyt62t0koQX6i41Qg32Fg5121ZH01FGc0FJ!A71052cZ041V22!64#8!2488#F4V0F0	0Pg!Pg!YJ0IV025k1v!9_07g!aJ0U!35k1_07g!qJ0Tk1w! %140VVoRB6Yl0J43C56t0FV884733GswN621VV4230c240F9BoP2aFccoJ2@734kX0cLW71F8kZV2793HVsL22XHWOF8866YWcgB44XFcBoHQZ11VVVFBHE42l8gF81VFNFwH113c0G8weCAWV8J81A3_t0Fk8FRI@_G8N4F@10VVtI5a47220Yc8kO1XX190BNBB3G8VF6152088Nj827134m2FN523X088JWXn241249oBJU14212d0s632110R4259m0VkHF8tLH91XVF8RKgi2312GsVsJ4WFd0ZW82@V0WkYtN8Di12WXYHka880VWWJN8T2252	#15V#84)F+c8!201$1#40F$FF#2k#44#G$958(218V	/+1+6,1/1,2(101.F$3-1)1$1/,1&2*2!1*1&2/&1/01/1.2%2(1/)1/#5!1#1/$101+1&2!1(6/!3/(3///01/05-2//(31#1!1/01+1/.1*1(2,9!1//!1&2/!8+1*1!2/+1/#1%2/y%803/02/V*2*3*2-6/1!1//(4/2)3%2/%1-1/%1$1!201(1%4*3#1#2!10	eodT@H@AC@HcHhhdbhdeEDeMhmDVNBnemkghBBjjB`@@@@@@@					not given in publication	CaSR	Calcium sensing receptor	no	gpcr-ligands_DescriptorsNo5Ht
72o2.hxh46S~x>72<wxhxi+c)Hx>/</fR~.>.h.>S~.iS(.iS~.>.>.i.i.hS(.=.>.>.iS(	:Uvzv;S:vyvUTzSvzfUzyMbfjbSCzpz20UIjGOxrWtxEoC6BYZ6kfPBYkF2cWZ2h40LHfICj9N0V08W8FF	0aJ0Tk03Xk2W0DF!kZ0qV3q!C_07g0zF04AV110480eF04NV1_07g0o!5AV0k0440G01v# 6F4H2k83XN8JJ@10VFFWLT41XGODF4@3T16WVGFH5222210c2F9894I9FD610VF4cNJ12a40kF111kN84NBBm0WkGW4TB4XGNJ821VY1Wa84B212110F8BKR1420vc84854l0XFF8J8idA2k8cg429614X8oPB6VVVB6LEA23GswP823Fk4cX3113FF8Zpck2510kcgRA4XlNRD7264088gr82711bYcFi3671FNFgV	#20k!10F#4*Vg$gV#8%Y#4ZN$FF#Pk!805#O3#8Ss!@18!259V	01$1/$1$1$C!1/)3#3&1!1)4(1%9$53#3&2/!1(1!1&1(2/#21)1-21$101#1$2$2///01)4/11*2/&1*1+1/%1#3!21+1&2&1,1!3!1#3$1&2)1#2#2!1%101$3&1,2&1//(50111/2,121!2.1/1/)8/#21)2#1%1!32+1$9(1#1$2$1&2/#2$101&1/-z2$60401#2*1%3021%M.2/#1$1%4)1/%1&2!1(1#1,1%43101//-1%2/011(4)12/01!1!11%	ejYRLD@LCDhXDH`@cFPrRPjJIIKESJJIQYJKIKQprpZZxEDeZ`hJJZjhH@@`hHJB@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=.i.=.iS~.=.iS(.=x>S(.iS(.=S~x=S(.i.ixixi.>.=S~S~S~x=.hxh	:Uvzv;OyzvyteUpRuyemCjChzZVS5zbW@BbFZ8GqVVZ6WX541r18d6N4VV18g0oOVo06!8J!@Fs0Wk8s0	0aJ0Tk02OF1v!Ds0AZ0kk03Xk2W0DF!sg0cF3Z!C_07g0zF$ #1c4K@141DFls8355XoWFVB@6250lsgP932FcB84172VF48DV53YY98m674YW1WBZO9Vk90VV2C@3GFZNZ16ZVlkB4JKP16XVGNK0c47212l8koH5WFF42LC0VFWGdsL694W8BRX4164M0GkV4L4TY11kVF9NF862FW8L731kN82P8Dm0XFF	#d1V#8%4!10FV(1V8$IF#d#4_$8F$2k$Z#O$91c(219V	02.1/1$9%1///*1$B$32#3///&2//.2//1//)1)1-1)2/*4!1%C01/!1$1*1%2031#1(1#11/&20301!2.1#1#1/03&2/!202//#2(1!4*1#2$1!10101&305+2/-2/D/.2*1!4!1$4#2#48+32/$2&1,1//1)y%C/#3(1&R/+1%1)2*6/,1!7/)1*2/01/%101//01(5&1/$1%11!1!	elZZDH@ACJo`U@`IAIe]VyV^VYUV^a`zEyF@Bijijh@`A`@`th@@					antagonist	NPY	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
|F:0xiS((Sl0x=S~x>=x=.F*xiS(xiS((S(S)Jx>S~x>>.F*6sxhS(.hxhq5xi(Sp3x>x=x>>x}\F*S(p3p3x=F*xi	;vzfzUztzxQTQjUSBnPvAQjUu7hYSEDMx0CEnC@QziZkXdLrz0zaJRNf4fMMsSWh13_cDJ1W01GGNO8V080V	0aJ0Tk02J03d!9F0DZ!qJ0Q01k!BL06g0TV03OF1k07g!oR0Ik2d!C_07g0zF04YV2F0@!t!6Pk1u08s0Z02V0DF0 $38211m0XFFa08H5W1W20a3F8H43S23NFJPAZ160t0GcBN4Z@17Z0VFgI8281m0W0RV8J6B@8110sVE2462m0X0RV8R78261c120NsE22B1VX0gV8w782@1m0YFKnN8N4eJW5H09BBqz3WYkN8kGgi29WC_kFwA8261GFVXFLF4a2iB15kkB8cI1141WCZ46B3m0WVRV8s5522@14ZWVe8L462HuJ227YXWlFgRi470FFwBJD621lNsBHC440s8sakB231@FGuV4P@4W2W31Og6A359XcO4H110l1W04JF1CaGcF431VmH0k@136621HBa7581G04B8A9	!3W6k!JR8#2r!1PF#h3#B1@$5F!JYN!2ZT!3kGF!uLg!8F$1kF!CAk#s4!29jV	01$1/2.8,1!102,1,1/1&8$4$2$1%1.1//!2/(1%1*12/04$1!1/,22(1!7)1,1!111/&1$1!6%12/-1!1!201!2#4/)16/01502$2//01#1022!4$4&1!1)204#2&1!1)4$1021*2!1/1/!21-1/#2&1-1F/!1$111%1$1!204301!1521)C,2)12!1#2/&1!1/$2*1%z%503%1*1(1&V$2/!1,4)8/$101/@!21-1$404!2#203#1!2)1%2,1$1$1&1&1#2%2(3*2#202/%1!	eg\|BL@LGLk@`]P@`zP^dLdTTTRbTRRVTvbbbbVVJbjRqCDcbWWqNHjimSMPSRE@TDQPD@DU@@@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>S(xix>S~x>S(xhxix>x>xhS~x>S(xhxhx>xhS~x>xhS(x>S~x>.>xhS(	=vztzxxnzwtQIvIQjNeoyHIfg_9NdNxM3d05cQFe6G_6VAN32@6k0TT22H66W122L41k2Q8F$V0340F	0RF!ZB0IV027k1v!@y0E8!lw0OF1v!DF09w0t!4AF110480eF05@0110480IV2U!OG0680OF1q07g0l& !jPW2FXvcN7472HGcsBB7Z130t0FcBFJL35WY2ssm42W0k8Zc21142q0sFF4XYkV8oPB2AE0XFXu88iP22FmNF4RB16XmORV579VkkG02225_akXwBP92X0l8luB4624ZFXXBX32X3kkB86A9m0XFFGFX9CVWYNN@32X5VF48VNo915IF984227XZLdsBP6F2ckkZTBM4V_0F88RIZ11Vt0Gc8V667Xl0NL@30k8F420c3FF8W4aC29818R862W1l99s4M614W2Fsw8F4YWmFN64E20FNJ4@9DFG0WVLF482VX140gV8B4p@2610WHBJZ20WlsyF4H2123GdNFC4W0N842174k890w472YHFoN970F844PF10XnV8oDH7WGFFN215aFVB26J0VYnk8Z6@3XGNgB41Wl0F4TG10YV88Z227H	#34V!Y9B#4P!2F8#V8F!18e#F1V!3e#8J8!2CFF!FHo!40C#S@#9ON!20A!252V	-2-4*E/!2!2//.12$6$1&2)1%4/%201%1-1)2/$3//1/$1#1%2#2-2/$11/%2/01&2!13(1)3&2/-2+1&9&1#302)2!2!5,112$2#1302%1-4#11$4/.1!2$1,1/03&21//#1,2!71%1//#3)4&2!B&1#2$1//1/%212&2.z%2%1#101/&A#2(2%1#1!2/0401/&1#22%10203%102/#1&701!2$101/%1$2#11!1/-1#41/$1%61,	eb^RLHDAHageEdPLQzT^rJIKJIQIIERI[JZJJJTL^Q]C@xp@SUUUUUS@QPT@P\P					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
*S>/>wS*/h~j{^/>/>T|w>X|w>S*S*/h{^{^85xB/>w>hwp6h/*SO*S*/h66|X|N|S>/>//>/>hwhwh/*S/h>w|S|S|S/>hwhwh/S*/h|S/>/>/h	=v;x;yvzEjCvzvuCzAzUgbox:xeCbm_N2rraoLlqEb1nhDpqDJnb5jhG_@Xp8KJ3PZO80B8u4V0FV	0aJ0Tk02OF1v!C_07R0U!3Xk2W0DF!sg0cF3Z!DA0@40t!3Xk2W0DF!sg0cF3Z!Fi0440FV2d!G204B0eF3l!KW07R0TV1w0CB% !20VN868650sB6861kN50X117cX08F668Z1G44C1a3Y9lN8D4L0nFl8NJHJ8Z1Nk840VHldO8oI94k8kcN2J0kl1kg4L@544mksDB31XGt94gJ@4V8kcQ8261WVXZ88R8HD6YlsZB820VV4kXN3C6WkRV777Yt0FcDF4H2B0X0m0O@9CX2lknGB446XDKNFR9Vo231C60FNA82B10kkX1J4RA15222WBPA2WVc883164Y0mZT874GX8qF4H3Z13Vt0FsDF4P3Z120WFFBF73X18ZD531kcc41G8cW0sNN45X1coD920IGlc4qIGYkNkZN21H8GFd0T2C1VXlmY4DL450VFsc4J6@XWdBRRA1620GGAJa4H7VZ1F8s62A555VXtZD639W0VG0R2D3VY2FNZJ9730N8D86XF84sgRB2ZWcRB5631OGBeZ2F90Xk_k8p82A90XFoV95R2D90Y0nGJ8aI8140sg8NBZ9AVl8OJ257WWNlNZ331ZVV90821WY3Is9Fc2EL0YFV8V2255531FsB95XFVB650W3Xtkwa95YlkV@29@ZikGuZ4L5Z17VikGHZ4B4v1@_2cG8CH2ASVWkXsV8eI19WktsBR4150FFl0o4eLJ13n08cF	#e0V!1%Z%2#ce#1gV)Fd#6Z8#9F$@k#_4#O$8KN#48!21BV	,1)1/O!11,2.202%1!1/$4!F#27$5&1!1#2&2/$2#1$9)11#1/$1(2/1!1(2#2//)4/.102$2*2%3*1!2(1-1!2.1#301!1!1)5&1/%105+1!12!2+1$1%2$62/#102!11!2!2/%202$1040@$1/&1)1#101)2&4(1&101+2!A$2$2%2/+4)1&87,102/$1-1!2(1*1%3/z4$C071!2)1016$1!6!1#R+1011111!101!2)1)B)3,1#1+B2,102)1)6)101+1//24&1-1!18&1!2)1&9&5%	eiqF@@DJMKJmgoPECO@Q|bbTTRbbTvTrTTRbbRVVtVtRrRtQVz^fvqeiU]Sck{GZjjYijfjBjfBhB@HBbjbBHphHHRHZH@@					antagonist	NK2	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~xh.hS(x>.>|`S(S(l0.>|F.>~SS(S(.hS(hxh.x>.>.>~S~SxhS(S(h.x>.>qqxhS(.i}Hx>x>h.qqS(~Shx	;vzfUUzpzxQTAzUUBlvvfvaAu7CYSETMx@Ejm5PQziZlXeLrz9zaTwNR8fpMsQWd12_cNK1W41FH090VW8FV	0aJ0Tk02pV3Z!9F0DZ!qJ0Q01v!C_07!Tk03Gk1E0@Z!qJ0Tk3x!Gb07J0jF3L!OP05k0Ok2V0CN0t!6J02D0@B0d03Z0E8$ #YI2@1O0H0DF482@IBFNWBI8291m0XFFWdmC47X0gFFVA8261C4M8NsE82R1m0WkRV8k5522710gFFo9Dx241O0GVDF4F3Z16VsVFFVA82I1W8VZ8I1c4C2NC0X8Faa839WVK2Fg8G4m0WVL3F8m46j150gV8878241m0XkFL88B5Z13Vt0GVA1c4C222IFZkF2YZVF84146_Z0@5P3550VG0mwBg0X2VF8VJq48_W2Gk4R2153LWFFN822K40kN4FVhFVVlVB4JH_18AFs4F8A0VXGVV9VB32@cWd4HA0Y3VF8kc22D7VOcNcB285	!3MWk!IO#68r!1HPk!aEV!5XA#6K#NYs!6WS!1HWk!5@Z#bh#Okk!hHs!@1a!2E3V	.1(2&1%19/!2!1&1!2//$@1#401012/+111!1/)1#1#10201/*1021012!1-2$2/01-1%1%5%1011$3#102(2/!1$1$5&2#2/1%1$2!210103#4/!1&8/!5&2,1/(3022014$4/$2040202!1&10101$2$1$1(2(2*2!1.5/1/&1!1-1H)3&1(1.2042%34)1D#1&1/0102%1/1.11&202*1#z1!11503%1)1101%1101#V-2)101*2)6,1%2/#9.1!1$302&203+1!101%2)1$1!101*1+2%2(6*2#2/04%1!	ehvvBD@ICKEj[RbS_PICbPrJJIQVJIJIIJJYIIQ[YJIIZHy`QpKrHzEyGUv@bJfZjX@`B`jB`Xhd@@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
=xxi>x.>S(.h.>.>.hS(.h.>x>S(S~.>.i.h.>.i.>.i.>.i26S(.h.>x>S~.>S(.hS(x=	:UvztzSzKxzQR@zEQPFfNcO7E2GhY088ugqE2X18@kY!3Y0@GWG!gcRo3YKY2!79mG0401F!3J2W!80F	0Xc0IV02K03x!C_06k0Tk03FV2d0A4!sg0c03Z!K_06c0RV1q0C!1o40G01g07g0Xk2V0DF% !446Ym94J431FF82PE0VXYgV8844675mNgD320kV4kT1166VFkwmI@XF844JA@U9VVsFVoRB10k46FA8m0WFF8FLD521kV86510F8sV10W34BV8R4HC@XlsFT420XWV84HL21X18gLE6WFkJ811b4k89422E0VYJRV8N4D9551cZH5210NFka20W3YYIkN2452118RF851lcR873W0V42VH0VYoFFFDC4YWNRD7210V842F80FG@DF4B213YGNcLC4W0VF820VF@0w22BG2FHNkFJ81310kZFC5WkFRF320kF84ZF0VYZwV8g4	#i0k!80V!61#128#Z6F!5c@$4F!1cV!4Zc#8FF!42o#m6#t9$js!@W4!21BV	/)1-F/!1!B,1/,@$4$3$2!1/1+1/.2+1(101&2(1#3)2(2,1.1,11#2/&103%2-1&2/10202#1*1#101!102&401#4/*2)1%94%1(4,1!1)3!1$3$1!801$2)1%1%2//!3*4&402%1*1)2(1/%101%1&14$2$2/%2(3%2$1$1!26&10102////01$1%1%10z#10301/,2$B$1-1/$2/3!1/*2/#1#101)6///#1/!1$3(5(1/#6*1!	eb^ZHL@JIMLig`IABPpdLbdLRTVdTjVRRRbbbbHdbVWtJNMT@EUUUUUPLPE@@@					antagonist	D3 / D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx=xix=xiS(x=x>S(xix=xix=xiS~x=xix=S~xixix=S~S~zdW(.hxhp3}J36x>	:Uvzv;O:QTQAUSNvu@Evu2Hm_09BTjw057m11QkeZGlcV@JVA04R8NRYH5X0f532q40B0A08020_VVW8FV	0qJ0Q01v!C_07g0zF04AF110480eF04Ik2F0@40t!4YV2W0@F0t!5JV1l0Ag0j03J! %YL@JFL9BB130d1c214520FkgP822GsZ814X09ks42BE1X4lJi@A10kFNRV433_WG0B@210VF420VJ1e04B310kNR683WksRF62VVN8431A3V88hR4432WNgF@221NN@217XYk8@J430WFsZF64XG88652VVFB230eYk88_TRL24WO0FsDF4D3Z13VW0WBaB4XlW0wD32650VFB841WWFsL73W0k8wX40WVFVlB	#Y0k!1B$1F$H#ZA#59X#4K#1Y8#44!2NF#8@k#17#KN#17c!306!21OV	01//#11F//02//(30501!2/+1!1/+10101#1031/-2#1////11#3/.1/-401$2#1,1$4!102-4!203/$1/%301$2/$2/2#20102!2/$2!10202$2/1!1$1$1012$1$1#11)1!6%301-11%1/!101.60101$2#1/201(1%1(32$9%1$2%1/11+110201+1#203/$110z010102022*2#1401021*D/,1/,4(2$3*1#5$1/1#1&144*2%2,1//!2&20101!1!802(2,2#4-	ejQQDH@MHbkg`XT\o`ICHhdleDeBdeLhdheMDijFCKImhTX@Jjjjf`BIfjbF@P`@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
7C7cS27CoCS2S27CoCoC7cS2ocSt7C7cS27Cj<S27cs[K3St7Cj<j<s[7c7cK3oCco7C7CtS7c7cco7C4I7cocCo4]@mStStU~ocArBx	]SyzvzQyUzUvvvrUzQdrhrS5:nvEynav1vpiJx_yC6WlbA_hACWWSfueK9mHoFTKPRC8V0hF8a0IV	0Xo0FF02OF1v!Bh04F0Tk03OF1g07g!sg0cF3Z!DA0@40t!3Xk2Z0DF!t40tV3e!DG0DN0uV04OF1r07g0U!5NF1Z07R0U03I# 0m0W0FFsZ74D10kBR95WlmV84Z217aVH90H12WHNJBA164FF8wo6D9WG3VBB564FFZRc31960WlFF8O2XHVOJL71WZHgV8g52l29WVH0R84C53A40N68663O0GNDF4L3G174kGFK44JI13W62tgBVQ17262tgX8572fpkNB@6I17JFGFGB4KG13W22VV@M6X1mV866123XlG8F5C5GXcF630X3XdFcV6B3m0X0GOOB36VVNtB@2G1VYmFOoiK82ZVcB8TEZ130t0FkDF4B2kE_FlNPgRG33lH0F4RCZ140t0FV90FL13WFlBV@2845VGN6N5@0mkG4SHc91Xku9B8@4IcW1Fa099X227WcFVGVTL420VFNT115ZckFGFTF91Fsco22@89_VXVce4G2VYmc8kNJA@1_1G88X717XWcFkWH2ASVWkXdZPL4450Fkch84H5X08BRG6545HNG0PJC1XlJkV8V735FlW824974V_W89FX2HB@0WscVHHBe1Gkc8D83F5VkR@72VVkB@JK30FXF861370F84BJe81X09N4A10kcJ@31Wke1B220WYk848LeZ21VsNR170l1Fodq2F4c0WcODX482H0Vk8663Vl8N273aZ0N8s22BE0cs0NoB@2P620cV648WF98B316Y088cw	#e0V!108#V4!112#a6#5d2$7F#fc!4ZB#9F#BHk!245#O$8Us!@06!218V	//!1#1M02+10202!2/!12(2%1$6%60120A!205*1#4+1.11)2*2#3#14!2!1/-1$3-21//(131$1(2*1&4.3)9*1,1,6!3+1/&1$4/!2&5.11!1.408&20107%106//%1%1!107%1!6$61#2/+2!2*1-2&1%2.4/0111*1-2/06D0101&3&1&2-1$2011(6$64/*1#z01#503#1*20401$11&J/101!1+1!1)6)7,1/B+2/(1/02%1/!1/&1*102!1422(5,2&30101%	ejsrN@@A@h[PDCKGB`\bfbRbVbebRbfbRbVbQRRRdRRQbxdv~^QYEm]CScscKZ@HifjfB`jFbBJjZj`Bj`|h@@					antagonist	CCK2	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>.>x>xhS(.>x>S(*`S(x>*FF|:0x>S(F*(SS(xhh.>.>xx>>.~S(S(Sxhh.>x>.(S(Sh.>x>.>.(Sh.>x>.	=jUUzrzxUUU:URrvvf9ifu7CYSjTrx@EjTKPQziZk2eqqz9vaRwFw8jpINUWd02_8JK4W21mF188V080k	0ZB0IV02pV3Z!Bh04B0IV03OF1k07g!sk0tV3c!C_07g0zF04FV1704w0eF04NV1_07N0o!5PF1p07c0pV3x!OM05k0PF2l0CN0t! m0W0F8oPG241t062@4VVFlNwi4F3YYsFFL21W22BN48D5Z13VnFscB874SVX_88V9gc31X0kFgD420l0oPI20F8FsR1160kG@3V6A521N4RLEZ12VeMNFZ8B311G2PNg137VkGVw848@0qGFNgB6t260VGFK2475m0Y0RV8V4qE31YV8FDB40XX0vd6683Z_FWsN4P7Z18Vr0VFBa7Q11klsNBJI7210sB22VFNB6RCD14ZuN426736qFgB50Y51cdND24B2Ll8FVA8221m0WFGkw6e2ZF8sZ42710WHFCRN653Q10WWJe494m0WVRV8g6s220W2F_ZL492j1VWcFB64P1W0G8q210X28ZB10XlGN8647GG_FlgJ@C5@W0X0Vs4C7VmcNVTVJ221IHsGF94h8108dgKTAJWXFk	!2IWV!M8c!6Bx!3R@k!a@F!6VA#HzV!NYw#jS#HW#4To!9bi#Idk!hLs!2Jo!2z1V	01#2%1$1$1#21!1%@1,21/1/,1(@$@$2//1#1/!1&1%1!20101/#11(1(1%1(1/,2#2#1#202*1011$1#1!1+2&1#52!202&10101&1(1.2$1#2!1-1#4+1*@&2$1&21(1%1$112022014$4(2(110102&1!1#1$1#2$3$1(2(2+2$1+5*1/*2,1#3!A$1%13*1*1%2021&2%1#8+2!3/2102%1(1!1*1&1&101-z$16!1/)101$N*3$2$1.3!1%41+1/*B*2-22#1$3/01$3/1.2,2#302(4&1!1#1*205)1#	egTrBD@AMAj\fnbPI@JPrJJIHqQJJIKJYSJIIXiQIIZL\VN^Q_HrzpDETmUMMATEEAAED`@@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
}Jspd,x>S~~WB,xixhl0l0x>S~B,S(xix>xix>xix>xiS(x>x=S(x=xiS(S~x=x>xiS(	;vzfzOzpxlQR@U2Q0GfseH6620hY0@8PxX79X11NFf60W202G1!JucBo3Y612c0HA@4cJ0101J140W8V0F0	0aJ0Tk02OF1v!9F0DZ!d80xk03OF1g07#o80eF2l!DF0@40t!3Tk2H0ER0 !382814WX94HD61VVF4LDA15nWFJ@20X190FBC32G8RBA31FkF620c4J1d8TH3YVsF8HE9cZkVsLF443Z15VWkkoRB5XlcB860a430NVH83XG0J8A4Vks8640cZoFFFD762l8ZH81WVF8420VF85FRc14XmcwL92Wl844NDBX_188FB9Z130VFVJ8B52FsZF71W0F86210FF9JVfZ120jJsFV82E4XWcwL620VVF62D5b0WNkD95X0cZ641W0FF410d3ZgV8N4674VlFVN@3WVkN6210V858T116VFGPaF483Z130VHNgJJ6210R6JC@140NRJ93XksRD520V9t0z82612WlW0H93XFVF6520FF42XDGm0X0F	#10V#8%J$VV#3#BWP#XMF#Yc!4Z4$F$Ho$4#OVV!33s!306!258V	/.2!2!11C/!1/#2+2/!@$2#13/!3,1+1)2$3.3//1/!2*1/&1,2(3*1$202)1(1&201/1%1#2!1#2$1/#3.2/%1#11$102*2#3)2/!2$3.3$1%1#121-1&2+3*1#1!4-1$1//)101*11!@$2/)102.2(1!101B&2/1,101//*1,10z%6011$201(1/L!1)1/(2!2/.2.4&1(2&403!2%602///01#1*2+2$3,1.5-	el^\L@@@je`OGlbbbbRRftjRRbRrbbRHXdlt\fVAQZ@@BAjjjjBBHH@@@					not given in publication	D2 / D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
qc.>S(.ix=.=.>.i.i.>.iS(.>.=S(.=S(.i.=S~.ixi.iS~.=.i.=S~.i.i.=S~S~.i.ixh.>	;vzv;xzEvynUTjUkzvtUuH7fbFQEjziW5bk_n5PbdFCi4E4V!ID9iT2uCXs0D30JVN403104F0ZXVV4F0	0WR0Tk025k1v!9F0DZ!_!uF02J03d!Bh02s0IV03OF1g07#lR0OF1v!HD0@40d03Z!Jh0440FV1E0@s$ 2do482S8VsNZ2264@XGt0FX28VWcVk@2@9FClcNoE827121H0Z@541GNFB70VFOso82A10FW2HSu482iWkVcFJPICaVNkw4524ZC3GNBL68352dwL2773em@VBH61110cZP92VkcFL52W0F8211e30888HhZ130Z1sRTP@33GWNRaQC2WWsmVXf34WVkFFF871kkF883W0NF62193VN8k229Jm0WVGkg6KD5lWcqF4L2cIYG0W8I82C10W10kJ231WNZB520k9tB2427VkGc84LbZ130_MGJBX7Z13Vt0Fs@cJk35WXl1R827X0k8N310FGkZv82313X1co64510NV431W0cF22H5VFG2NJPCAXG8sBFE20V8NZg413W1kg8440kVNB430kF8421@Y5F884733GNFB910VVN813VV8F42L6A0W0ZN7220NFD43VVNF2410VN9JR116A2@VFsD2B0VXG0O4X36WlXOFF32VlGWTF46244Yl088540Vcc43410P0w82C0VFW@NFTG87l8l822E1W0W988441Xl8Z82120FRD420kF8421f3F88c228N1W0VRJ84VkFB833WkcB821VVF9NPg222lNF4111VNgH240VVB22I90kH0444C10XpwV8F4	!10Zk!104$2$F#a2#5c#204$d4!4Z2#8FF#Ho$5#Gk$3s!2F4!218V	!1)2%2&4&1#D-13!302+2/&201-109$1(2/201/&2/(6.1!4&1!3)1-2/!2+3)1!32$2//1/!1!1&2$5/%22&2/#3*1-2)9&1/%1!1*1%1!1!401$4.4(4//,42/#1%2#4*101%2)2$3%1.3/%4//%1#@/%3/+3#2/%201,2$z$1!1/120101!11&@01(201(2%1(6!21.3/*4!20101-3$606/(1/(202&1//#302&22!23$2/%	ef^\BLDOLiaoh\PJrBHhb@N|g@eEEeeDehmDhiUDeDdmpHyx|CA@UUUUUM@DUTQ@dP@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>xhxix>xhx>~SS(S(x>xix>xiS(x>x=S(xix>xi\)s6~Oxhx>	=v:rUzCvynQyjgmUeshe3rAx0eSjYw81b2dH1@VZF4XFaV8@VVB8T43714c0A!G0J!1#2018VY0GV	0G8!ZF0IV025k1v!930D#lR0OF1v!Bg0480eF045V1d07J0mk04YV2W0@F0t% !1Z13VZ3lFk230WksscTQ4W1sZ@5964VWO4aG62FVJ21163308BF992GVc853VkF842F7VF8Fl@eD0WX0lIss6635AldoFN8AQ61NVZF4@6YlcoR61VkN8kNN23YXGBHC20kNB4NE0VFWWk4454YGVZL72VkNR450c4V8426DIeVYWs8kA82311Xl8wTA7WkkB42B7VFGdhFV4B2m0WVFFRNH911NZD91_ZHk888862W8gD33W0VF420VkF5FXcDFZ38R8BF610kcgH86X0cR@30VkN86310K2N44Xe68_HkwD61VHGF44DJ3341scP@5W0VB4ND10XYOlN885Z13VWn9gV@4VVF4ZHIZ150VkscT@51l0g842Vk9l842EE	!2i4F!144$V#JP#l@$VV!2m2#IX#2BF!2NGF!42o!407#4vF#tF!41$1Ak	11-4#1%1&2#E/!1,25-1#2)14+3$1/+21/,12*2/!11#2%2/!2//%1%2)1)2/-2(2$1302!4&2#4(1!1+4&11$1$1)1#2#12-1!1$4&1/1$1%1,201$2(1/02&1//&1!1/,3!2//#1(1)2!4*1)1#1/,1)31///!3%1%2/&2(1i%201(2(2!102!11%8//01#2//(11(4!2*1/%4/&2.1$1$1.1/!502(1/02-	fcohc@M^KvZ\`bNACPcHhdleEdeDeBhdmQbmCg@AUUUTuMTSAq@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
;q-Jdv5kL(BvzSSz1@e1-\u@1f1f?2zRJyS,uf1@f1fu.^omzSzS@1zSJyJyfuf1fuomzSzSf1fu	:UvzvU:KrxvyfUEjBlqtQzaCHRCYJCEMxXEEX_GDqOaWIeLMwcnZ6xgNVfl5We9WGfg0kK1141F1FB1gV0F0	0Qw!aJ0Tk02YF3r!CG06J0Tk03OF1g07g!sg0c03Z!GG06J0Q01v!HD0@40d03Z! !BV8R51423W3kt8mQ432lZP48LW14WYnsNJ36YGlcBB499m0WkHcheE4820GkRBmAA_0mccL238Zt0GFApD4B2F0YNV8g8V72@6XFZR@56Yt0FcDF4F3Z12VXbH0BJ6O38G9BJT2212k88VY8291m0XVRV90782C1GfXNNJBFJB5INcg2296m0W0RV8N782D1m0XFRV8N4	#V0V#8#4E#1@FV!42#4V2#8JF#fc!4Z#2&HV!8F5#KG#82c!@47!25hV	)101$1!1#1-3/!1-2!1%3&1/!F$2$3$2/%1//2)1(1/%4#101%1///,1/$1%2/%1#41,2#1%1+21+3/*1/,4$203)2!11(1-1%2$3$1$1+4#2//021%3)1/0101$2.1/&2&2+701D//02+2-1#F+1!1!1$3*1%3(2//(1101!z!1!D01#104)1201%2!4010X.1,1!12(2$1)2)1/#7!1(101#2/01&1.21(1//02/1402,1/01)	en]RL@@DFNL`ODlbbbbbRRTRbLTvbRTQrLDt\JNa^QIiZj`fAi`@b@@@J@HLB@@					antagonist	CCK-B	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>x>.hS(S(.>x=.h.>.h`|(S0lF|	zxzpYWxSWm4J5J2D2RV12N0VVVF1d1020HFV11V40VF969VW021080FL8FV812I0V1!40VJ8020424#Y0FV	0qJ0Q01k!KU0640SF2x0CB$ %4L4F9cWcNJ@@2VX20	#60F#1*41#VV#38@!24J$G#80N%F#No$6#GY#FFs#B4#50V	/+43(107/*1/&1/#4*1/(1//-3$1*4/&1/&1/+1/*1!1$1/+1#2%3/!1.3/03#2#2*1!1//*1!1/1*1&13/01)1/$1/201#3$3%1$101#3*101/$1/#1+1!214/,1//02//+1/&1/.T#2021/!1/8#3///$2/.1/*1/,1///)5(3&1!2//	fdyq`BHNbACHRcdfye_VTR`qZBBJiX`@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.=x=.iS(S(xi.=S~.>x>x=S(.ixhS(xi.>.>S~.h.i.h.>S~.hS(.>S~.=S(.h.iS~	:UvzvzszSxnvwtU1n1vjdzLy07AZV0NxBx20l0Y9LGX0FzAV9J92g6s2TJ22064f020L418124N8#V0V0FF	0Pg!aJ0Tk03JF1_07g!qJ0Sk1w!DF09w0t!4AV110480bk06NV1_07R0Tk1w0C$ %AM1330cF685MXm8V851W21G6F4@3Z120XI9gBI5VWl8sZZH93VkVDFC10XXI1NeI49VVVG0231WY2RV8c782711YWVZsH1Vm2F4@3375XW8J62AZ2N8441a2Y2Jc8H8131aHVFg89E0WlFNFH853WkV@E35YFV8ckc2H2X0VCH@B23VW16F4D3Z12Vt0GF99Df341t0Gs9sZ4CL0XW08RF	#30V!18$X%2#VC#19e$1$Y8#4B#9F$2k#44#O8#9GN!202!210V	01/-1&9(2%1//03/!11A$3$1///&11(12/#1#1*8!1!1/&1/&2%7#1(2(1(1%1/+1(1#1+1%2!3)2*1(4,1$2$2*1!1#4&1*1/1%3!1%2$1(3/0101$1$1(1)1#301012$1.1/!1+1!1+1+1#1,51#1!1//$2/!D1&1!2//)1/01)1%1)z%503#102*1&101%R*2/(1+6!1%6/-2/#3#1$1%2.11//02/)1#2#3*1!1!3*3(2$	el^\H@@DDo`LbbbbbRRtRTjRVfbTQTlL|zf^~aQZhJ`hjBB@@@H@PHhlH@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
w>S)whw>/>w>whS)/>w>S),`S)w>,F;1w>S)F,(SS)wh+H>w>/w>H+6p)S)SS)+H>/w>H+)SS)p6+H>/w>/>H+H+)Sh/S)S)+H>//>h/	:UvzfzUzKzxQTQzUUBnvvf9jAu7hYSCTrx@Ejm5PQziZk2fqyz9va8wNwBfpMuUWd12pcJK0101F!88VV8Fk	0Z40IV02OF1v!AL0DF!qJ0Q01v!DA0@40t!3Xk2Z0DF!qJ0Tk3x!G204R0Ik2d!GX06J0SV3F!KZ06Z0SF1u0CN01_R0M01d0A40pV3Z& !38241210X8gJ3A9Vc8RHH432Fo462751FG106u633WgaFFN@8@43W0sZw26721l6OcBE12WlFFJ4140lXksFd3910NFBR215VVG1k6P10W188@FA8m0ZVRV8s4e24XlcNH53XFtNo22@B0g2l0N@B5AaZ0w4268YO0FcDF4H2410F8gH2@Y2GmB2134a0M@cBL63_1FlW84H8pMW5kgV8k7828118kVFq81VWl8cZ9N3VG0sYByC10lGViF4B3Z18Vt0FFDF4822110ltFg7JVGG905me32WnVNFk@D242CKsG4A8261m0XkF8kkT@2lWk44HD786Y8wD2780FGW044420l8FF5220sR8820VFJ4110Kl@s8H934GFoN630ktVsk824YksRNC510VB64D70VGOs48985WVZN71W2nONVPgA2lGF44FB34ZHlBF@545k89BZ425Yn9NV686VFGGB4q83A1lY8JBZ6860VskD@3X0sRF31b43XWoaG60WX0kVeMAZVVBRgEZ12VYbWZ28Q4a60WNGpLP0X5G0FJNI82lNgB210k9dso	!2Q_V!M88!6Bz!1N@k!a@F!4cd#HhV!NYs#bS#PlV!4Pk!8bi#OWk!CMs!2FZ!2z5V	01/1$1$101%1H%1(1$11*2/+1(H!204$3/&1#1(1.1!1&2$13$1*2!1(1(1(1!1//1/01#4$1#1$2#101#1.1&1#51!102$1010101/1.2$1#2023/017#2,1#15&3#11&201#1)1&202201401203/!10102#2!1!1)1)1$1(7!1%11#1$3$1+6/1/$201!1&1&E$1#3012#1(1(1#201023!1#2)1@$2)2,11!1(1(1,1%11$1/#z1#1A/!2201#101&X/01/&1%@1+1%2/#B*2$1/!24+1$1$3*1$1$1)2,2%101%6&1!1#2#1%201#3$1#	ejuvLH@AMFnbVTjkPICHhhdcEDhddeLieDdmddheDeDdTVNKGO@ghSXp|xBBjVjZZBhJJhH@XBHd@@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>S(xi.iS(.hS~.>x=.=S(.iS(S(S~x>.>xhS~x>xhx>xhx>xhS(x>x=S(x=xiS(x=x>xiS(S~	}UzvjzxquAuU:uzxkJA:x8UDyrOurigkUVaeydvcFSRjJjEKuaWW7Gn8FK430FecF6cXV0F0	0_!uF03OF1g07g!qJ0R01v!Fk0440FV2d!HD0@40d03Z!GF08k0tV3c!SF08s0Yk2U0@40t03c!Vp04s0Kk1N08s0bk2W0DF$ BV8F78271AnFWFHGi4D4VY0m2x211XXlL1oa6C0VkWFcB@C8XWVoD71W0F8oX117b0VVwLA9WVkg@21VV9l0sD952GVoH93Vks461D870WWsmH31088ZDH11HWVkZNA6WkkFD310VF8we11VFm@N4493Y1VZ844XFN8431VF@GB420WYpF88D84XFsgF31XFVR610VJXV82137eVVOJVQ5VkVJ63A6VFGOaF4F3Z140_OsFVA8291m0WkFsNPI82l0k241_Y2kFBL24Y294B5@@VFs84157VFGc44JX32WkcRB941VkJD710kF8420e5F848X117fVkNJ@941VkRF511ks8@20VVF42gI0VYpk88B421l0V83421FB621caFN88g2114k848R116B0FVNX@6WWVJB6210842VC0VXoIuZu6A3m0WVF8F2731WFgH91VVsR8310VHO422E0VYKF	#9ak!FD#B$38FV!Ze#58f!12xF!8YN#5V!18F#c2o#lZ!2Gsk!WMs!2LL!31BV	/(1%1(I#1-3-2%1/(2$4$5$5*11&2&1#1/)101!101$1+2!2/!2#1$1&2/.2%1,6$1%2%1!2011/2+301+40301/%101*3(2/!1&2/5&4/%122(11&40201!7(2+2%1%302+1*1&1+1#1!2&1+1$1)1%1*3010410101.601102#2#21/(1)2#3(66%1$1!1!1$202(1%1101#11&11//#10z#2*2(11301-F/3+1(2!2%2)2&1/01#B)1&5%306042$14///#1/02.502/*501+	emWZN@@DLJik`NA@haa\bbbTTVRabVTNfRRbRrbRfXdrZaQyeZjZj`XJIjjjh@bRHJB@@					antagonist	NPY	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.ixixhx=x>xhx>S~xhS(xiS~x=xiS~x=xixix>xiS~x>xiS(x>S~x=xiS(xhS~x=xi	=vzv;nvyvUlvpQzvfLyHYfoyATtdz@GWG1AIOX8Fh6V9H16EMm0TR2P86Jf620J0902u0F6!kVF201F	0WR0Tk025k1v!930D#_!uF035k1_07g!t!bk3Z!Fi0440FV2U!Fh0440FV2d!K_07!Sk1v07k01L80OF1r07k0o% BV8F4qD@XHNVNR2163lXcBB8D4C5mGVF@853MVW8LF4D3Z140t0FkBco4A2m0WFFc8HA@1l0J6710kVB84F7VVGe94i99X6189F4C11G1s44FJiD6Fl8O0cb3840GFV4F@G48G8VJaD1W3F8N8HIZ140t0Fk8CHj3@WVFG8JCT27WO0GV84ZT3EVFkZ28P2YlcOJ22@A2Z19BL@41VkF8LD0VXn2G8X8A0W0RVTGZ130fpNZBJ6UHWWNRFBB6@63soL@952a0k8DJ7XkFB42B8a1F8cFM41FFRZm43W5F89B822111k421359W1dcB37Y6W89RP31W11k44BNjCaFlVN4TMGX4m88gF2968VaZ1BH6L13kWcN4FEZ11VVXOk28W0WFkFFs410VNZNBJ0VWnlcW6D@2WWVk4F813GFwD31VkN82@1c4F8B26CI8YWkZ8260H2kB444WGH084RRBQX38VcFLY29WXsG0X511XGlORB972kNtBP326WFGF84FMZ11VVGVwLD20Gnc4@622kNB8499c1W@NFH22Vl0ZY8241	#34V!18B#X#102#V8#1ce!201$W4#48#9FF#2o#44#Oc#1Os!2F2!210V	01-3)2%2%F1/02.1,1/%201127$1(201/&1%101+1(1,1)2!1!4,1/%1/!1*11!1%1!2/*1$1/)1!2#1/!2+2$1!2%1$3&3$3$1/(4&1*2&31!10101!1,202!502%3-4#1012!3-3/#2$104/)1-1&701)1&2$1,202601(1*4!1#2#1/01)109&1#2!1//(1/!12$5-10z/&1*1&1F/&1-4!2)1%1/-201/02#202)41/#1/02)1(1.2#1%3*2*1%6*110	ejY\LD@OFo`alPH`bHrJJKKJJIKZIKJZJIQYEcasriixFEFB@jjjjjf@@@hhDIJEB@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
q5H)}^q5q5}^q5S(x=.=xiS(.iS~x=S~.=xiS(.i.ix=x>.=S(xi.ix>x=.=S~xhS(.i.h.=x=S~q5.>.iS(h.=.	:Uvzv;SzxvyfzUzNlzvvfbEEzhWEBg:XE6mh1Uzf0OofLUM1lZ6xBRwYnLv2c66dV!KW34A8GJdY4WFFF	0aJ0Q!25k1v!@N09g!lR0OF1v!C209w0gF03Xk2U0DF!t!cF3Z!G_07R0Tk1w!F504o0q03q!KX06J0Sk1w0C! 0kVk@10XmNN4E21FGl48211YJRV8F4HC0W0d4aC11kVJkROZ150YXm0R5633WgV8N4kZJ1YkqY08P5W1W2kaPs66534bXsVJD2YYWvkN8F4AA_ncoJN@qGXkl0TF4@24@YkmcFD7A3FkkoZ8D36H8F6A30kV42PBCIVFX8NFKB22lXWFPL44a0FsdFo4AQ0X0mOBi6C9YkkNZN2441m8VH83WVF8641W0N421J6@J2VFV8242219FL731kFJ842bYV88l04654GskP860V9Nog@C9_I106DB744YW4s16430kVFJA2YX0VH62VnGs44NR@EW6FV88H2ZlWsN4PH471YFFN35VW0BgX40VFlOmZ4e925FllV4N@c31mkVkk2@5M0Yqk8g8cQ6WZ2NZB645Yt0FN84443W1FVDF4X1GWF6928VFFFt04A9WXNc678W09O4j827165WGgZ@68Y8_dFBT7Z160t0Fs9gVG4X4XFNB6D74Y9sNVBcM91_W89Fa2H30Z0k8sR	#f5k!184#Z1!102#V24!4g@!235F#dc!4Z8#1FF#Po!84R#G$9Us!216!218V	01/!1/!8#2//$1!1)41-6$4$4+3.1/11)1//!2#2%22$1$1#1*1/01/1*401/(1&3-2(2!5+1!2!2!101%2/)4!1.1#2,41$2#4!2+1&2+21#1#602$40201#3(1!11#23%2*1*101#2!20604!1,4#1,3#1%1/*21$12-1@1/(1%24,1/08#303%1(2/,1/0201!1/&z%40101012+2&11!1#R$1$2$101!4*1#1,1*2(12#4!2&4011(2&2/54+1!2/%1)2#10105(2!1-5*1(1(4%11%	ekTzBD@IKAchSGNQPH`dHrJIKIQJJZZIIKSIJKQZKRIrabh[jZxGEgTv@BjfZ`hHH@HJEjb@hAB@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>S(xix>S~x>xhxhxix>x>S(xhxhx>S~x>S(xhxhx>xhS~x>S(xhx>.>x>S~xh	=vzxzxx:wtUUvIvj8eyyHIfgbhNdNxM3d05dQke6GZ6VAs3X@ak0TT22H66d122J09k2QVF04!V8W4F0	0Ww0Tk02jV3m!BU06J0Tk03JF1_07g!t!bk3Z!Fh0440FV2d!GE08g0cF3Z!Jc0440FV1D09w0 $8H5W2Nk474XFWNgiP@6WWVlWtN44XXGRV8J48C32lcZJ912V88D1D6VFFFd2H991XkwV8Z4B9441c4HC30Vc8241VJ1m5BBA371t0Fc@cV4A31GsB4PB48W488s8N8z15dFG8GK02D0WVlB62D716Gdc@C1XX2cB4VHY1eVlccB434Y5dkFN9@z2313HsGG0D1WW1sN2235ZY1WZVH334l89022B8m0XFL0s8eX190V8FwJg2J8EVX0NtV_36WYFm0B6@Y5lV9F41274ZWsFy45CXkFBF8L1VZ2gV8B782C1	!110V!X84#4H!2&8#18e#G1#Hu#8J4#DFF#2k!405#S@#9G8!20A!258V	/,2*F/!1!2%2#4//#12$6$21%2)1/,211/$1)2+3(3//(2/01%2*1&2///.1&2!14(1+401//02+1&8!1#2#206)2!2!3,112!202#1302/$8#13$4/#1-4$1,1(1#1#301$2//$1,1!@//+1)4&2!D&1#2$1+3/#1/&12&301,z%2%102*2/D#2(3%1#1!2//(3!1#2)105%102/#1&601!2$1010101/01$2(1//!4/%1%61,	efYRLH@AHlmeDk`LQIe]eeUyvm}nYfacrI[[Ff@BZjjfjjjXBHJ@HNH					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xhx(S=x=.(S(S=x=.(Six=.=x=xix(S>.>xh.(S(S>.=.:0:v(S*`*F	:Uvzv;KztvTfvEvClv9vraDTOgkFCh7x27jVb9PneBsje0JLh3g4wJB4Xl10XWW7IqB24914kF!4!3#	0aJ0Tk03OF1g07g!o40FV2d!DA09w0t!6LV1Q05k0Xk2U0DF# m0VVJPJX62XX1ItFw699VWlBV8R78271CW2GZF730kG8g_qd2414_8FWF2639X0H9@@8590ZK88tF2B3	!210k!2e#402!1!V!24$c@#H5F!8tF!4_5#@Jk!V@k$_#GF#9Gc!224!218V	//(7/$1(1%1%1/*8$3$2*2%3(3/(1(1)501*1///!1&2/////$11$1#3)4&1,1!3//01&1!3.1,1$1/1$5#3$2022102$3/+1&3//02!301/01#3(2//-1!4+71$1)1/,3(1)5+1)1(3-1%4#1(1#1&1(2!2!1#o%6(1101/#2#H$1/%1/%2&1/*3024!1//03/-1$1/)2/$103)4/$1#101$	ek`\L@DHKJ`DCHIP{HihdiihmCEDdhlnIGONemcf`BIZj``hhR`BH@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
H)q5)H}^:v:0q5*F*`}^.i.>q5.>.i}^um~Nu9u9~Nx>xiS(S~x>x>xhS(	;xzhzSzpxxUR@UDE8KAse967H0hYZ@@PxX7AX108Zfa2020XG1d0ky8BoIY5W2V13A!4J01X1J540Z0V0FV	0_!uF03OF1g07#qJ0TF1w!C20@Z0gF03Z02W0DF01LF0T01t07k0xF0 0O0Fk88H93XHO0F84_3FF8gg8EAZ1W0B40VHVtLF483Z150VGFcB663lNZHA163n0sJ8A2Xl8cB@32FN8sV216bVW8wRE62GVR61A70VGW_0c4724W0NZD32XFNcJ52WkNG0Z10W3oVFJB@5XGNZ841WFVF@210F@NlB4763GcgL72WFsJ2PC0VXYbtFR34320VcNDA3YFsJ@21WFcBB60VV@VxI8261	#O0V#8*Z%2#4VP#27F!FWV!4Z8#1F#Vmo#44#9V#13k!206!118V	//%10D/!104/.1/08!10201012//1+1.3)2!103//&2+2%1/+21+2//.1!1#2/401%1&1!1#101/#3$1)2-1&1#11&1#102(1)1#1-2$3.3$1%1%1-2/#4*10101!4-1#11/(2,2!101.5$2/)202.2-15)2/+1//,1,20q%501/01/F!1/1-1!2!2//$1(13&1/403)602$1//+1#1#2%2$2+3,11-5-	egh\L@@D@j`JIlbbTRRRRRLRVTTRPdcgaUVusUMTDEUTDDA@@@					agonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.hxhxix>x=xix=S~xiS(xhS~.>xhS~x>xhxhx>xhS~x>xhS(x>x>S(xhx>x>xh	=vzvzUznvytUlvpQzvfLyHYfowARtdz@GWG19IOX8Fh6V9H12C7k0TR2H864f620J0102P0F2!VV0201F	0WR0Tk025k1v!930D#lR0OF1v!DF09w0t!4OF1r07g0U!4AV110480bk04AF110480eF05NV1_07R0U03F# %sUD212FN4V@UXW3FgV8R78241@FVX0s4R7Z14Vt0GFBC24A2m0WFRV8N4489YW0N@DP1X18NH@I10FW9n4kP34WY41o28E0YkWFZ4FDE93H04Ji34150No4547VVG1VoTS4XGHN44X9413FFN8HJ45YH0BNG510lG882EAm0WVKeJX6@374lkZi430kt8sZyW2XGkRNNBI@b1FwJH60W1WkFRgC4F1kVV225C0kVBD31WlmF84DXoAa08VgF4@EbV8d8V2A4VXGkFoa@1Z1YFBB13A0FHNk831X3VF8NwP4FYl0dN22J13kWc446345t0FN8ZHS741skkD2971VWsoR610FFV6512FWtF820WZ088o22AJ9fGORFJ2142YJ8FFF580VGko@434VVFtFoVC5VVFZ@210VVF812c3VF8d4JM331kR4DI0VFX0Z84C11FWFB4FSZ11VWG1sDK2Xl90Z6279m0W0F	#34V!184#V%2#V8#1ce!201$V4#48#9FF#Ho#44#O8#1Os!2F2!210V	01-2#1$2%2%D1/01&1/$1/01#2!127$1(2/)1%101+1(1,1+1#4)1!1//&101.1%1!2+1+101%2/(1!2/&2+2!101!2+4&3*1/(3&1+1&1!10101)1%202!20201#3,14#1!2!5-2-2!202$104/)1&1&1%7/#2$1,20151)1*4!1(1/+108%31#2//+1,201#2$3/z/&1*1&1H*2&1/!2!2)1%1/-202/02/4/2#1/02)1(1+1!2#1%3*2*1%6%1#110	el^\DD@OF`Pa`H`bHRYg]fU~UvyVuXx\|jZn^aQ``Jjjjji`@@B`PdhTH@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~.>S~x>.hxh.hxhxhS~.>S~x>.hxhxh.>S~x>xh.hx>.>S(xh>.6sx>)\`*,BxhS(S~6363`*	]x<vzEzU<CzQzUirJSzvxyErvjwLzrjoTvrUn9nxDxqjLYr5jY3_8mp@Kw3OGG8VB8uaV0FV	0XZ0IV02OF1v!C_07R0U!3Xk2U0DF!sg0cF3Z!Fi0440FV2U!HE0@40t03c!KW07R0TV1w0CB01Vo0AV1108g0bk3Z& $1FseD@1GWkJ6310WG1N8iN841NN4F@8JVXkto8FL132O0Fc94o9112O0BF@89@JFRFL8EFg0NVRGc2@N0Wk_esF663LC08BF89Z110W1OJkI20GlkF240VVNkRo4DE218cZ234XXRV8V5V1OWXFkswXJ71kFc2210V9cZr82413XGso6@C0ld8RZRHA3FskBDC2VFFNVc@j8_W1FV4D@45ZlkoFG0Z3kF866A30XIBV8V4212YGlND72WkV8441VJ1e08TA81Wl4870W2ls42135bH3VFk88_F3lFcs22B6DlkVsF8DC62ksJN73W0F882183Z1lBXC5110c6HC10XmYck83DXY2k8ZQ82514721sP4673AFGesF4@313IcF265WFkNH136XnFs9Fa@40WNFV885YVG1F8FC5110FJA30kNV2210k@Fo229I	#f0k!18#4Z4!18H#cg#1dc$3F#t8!D_8!19F$2k#K_#O8#9SN#o@!21BV	01(111/*D!11/04$50102201%1!1)1*2!@$5$42///%2*10201&2$2&2&12#1&1/+1//!1$2#101&1&2-1&2%1*1102(101#2.102(1#111%1)401#1/06&3,1!2!1/(2$4)12/12$1/%1+4$1/04//101$4*2$101.7#1)1!1/+2!1-45.1//1%2&101(1#4,1%z4$803(1(3$1!4#1!H!1(101!1#1#1/#14&4*1(1+@!1/&1&202(1.11/01&2/&2$2!15*11!1$1%42&2%	ei[ZBH@DLKNd]Bmc`@cHhhhhdeKEdhcLeELheHdvIEGLf`T^QVjjijBAbjZXJhBbLBBABJj@@					antagonist	CCK1	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=.i.=.iS(.=.>S(.iS~.ixi.>S~S~.ixhS~.>.i.>S~.i.h.>S~S(.i	:Uvzv;SzEvynQTbSvzAxUuHbfbJOSzjw84rnWG1OadFCjZ86c202B@iR3H5aV@430R4GB0A1$_XVV8F0	0mo0AV11!C_06k0Tk03IV2C0ER!qJ0Tk3x!Fh0440FV2d!HD0@40d03Z$ $6@b3VZ65743VFcoLC8WW0VB32VV9kcuZH24WA70Fg8656XGNoD760FVg42D6b0kVRF821VsND421kNR431VV89JPfZ13VVkW8RG8XGFB81A5_WkNZ8@5XWNB@71W0FJ61G68t0FkCgD232Wn30FZ8aC6_kVsD120HWGH4qX0X40N8s42B6b3VWc8B4@4	%k#4+F#4D#59X$4$Y$5$8F$2k$5!2ON$7c!206!219V	021%2/,1J//02//$201!601!2/+1//1//)2#1%4//*3/#3*2!1,3-1/!4&2/,2)1&2051/0101/%301$2/%1#1*4$1102!2/1!12!1021%1/1/&2/!101!1$23/!2,3*201+1!9#1-1+2*1%1)2$7(1!1!1!1$2%1/#1201$3//1$y%20201#1)1201%1!1#F/!1)1)1(1)4(2/$5$1/1#1)3/(2///020104!1!302&12,4#6-	edZ\DH@MDan`PICHhdleDeBhhdmBhdiiPpYXTu]}@AUUUUUM@DLTXBD^DAT@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
D*o2(K}^7tD*r4(K(K}^D*7tr4(K(K}^7t^}r4}^}^r4}^r4^}H)}^}^r4^}	;tzdzOzpxlQR@UHQ0GAse26620hW1@8NzX31X11N0Y!V202G1!Ju8Bo3X412c029#J01014140V0V0F0	0aJ0U!2J03d!C_06k0R!3OF1v07k!o80eF2l!DF0@40t% 24n98PD20k98Vb826115G8kRC5W18F4LBA13H8wT84X0V84216Y3P9B8D45620scD93XVcJ@410Ym044PV24XWl0P@32FVJ22C6alX0k48640WVVgP842W8F8621V882XE0VY4gV8N5Pr2511HkNHA42FsVF40a3nBV8F4247VW0RD721kVR89210N42aGI0Vl0ZL93WWFR4330VNF420VFHcxJ	#10V#8/02#4VP#27F#WV!4Z%F$Ho#44#9V#13k!206#18V	//%10C/!1//$1-8$2#12//1+1.3.3-1/01/!2*1/&1,2//.2&2/!1%1$2%2$1/#9!1+2/#101#11&1.1)1+1%2$2(4%3$1%1%3!1*1-3!203*1#1!4-1$1//)101*1#4$2/)102.2-14%4/.1#1/*301*1,10t%201/01/L!1&3/%1#2!2/,102.2021#1+4#402)602-4//!1#1*2!1-3,1.5%1&	eod\D@@D@f`EdfVUVuWm]fUdt|bjZN^Z````bjhHHB@@@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xixix=xix=xiS(x=x=S(xix=xix=xiS~x=xix=S~xixix=S~xiS(	:UvzfzUzOzEQDIAT5Nvu@CQu22X_09BTjw047m111FXVF1cV84V2!B88R3H5X0@430R40B0A%_VVV8F0	0qJ0Q01v!CD08o0xk03OF1v0Eo012o0FF120@Z018s0cF2Z0DF# %112ZoJ55VFFskB4A5YWccL54WFV42RADh2VW8GXN4A213m9RD25XFk8cX21W3Y0FBB23XVsVH83WFNBB211V85FV115et0Fs8V8LA3WcVD1970FGOF8463218VH952VcF8210F842cBJm0WVF	%k#4+F#4@#59X$4$Y$4$8F$2k$5!2GN$7c!206!219V	01&2/,1D//02//$2$301!2/#1&1//1*1/-2#1///03/#3/+3//04&2#1/%102)1&203/$1/%301$2/*1*4%102!2/$2!1021%2/1!1$1&1%1$1#11)1)301/%1&3*101.90101$2#1/201(1%1)2$7%1$1!1!1$2*1-11201$3//#10q%20211#1)120102&1#F/!1)1/!1)1(2/1#5$1/1#1)4////*20101!1!302(2,3#4-	eg`\DH@MHblc`ICHhdleDeBdeLhdiiPpYYMm@AUUUTt@PqD@a@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
ka8ZS7kaSokEkakakESokESo?gkakaS7kEkakER(SokakE;FkaSoiBS7S7idnY;FnM_ldi	?y:y;tPirzyzjrUyr_vqgkpzhWUFrOZlkQolVEIxO6325ec6cKFV06c6ZZ1L1McJ8W0281222V8F0	0U4!YV0IV02OF1v!9_07g!_F0zF02K03x!FZ02s0FF2f!HE0@40t03c$ #3827123kNRJ961X28BF342310B8HR96250VwVB260kGFsFT34310w43981kNVBN81W2IVNNLAJ0lNkVN3154t0GN84FAB11skwBF41Xl08ZccL5blscZM8261m0WVRV90782811VlVsVD52W08FLAA1V_VcsLH73k8Z28@5_WkH9RuI@X2lFkgk7A41WNs4HDJ@hFkVRGVo251C60FcA8261742mVFJ8140FFkmK44BE0XFss8Nu242NC0WNIGV4A2m0WkIc8eD272m0VkF	#1WV#8$4$2k$D#1hg$v#Fe#4Z5!18F$@k#V4#S1#958!242!218V	//(B2/01!9*2&1)1$1%1A$61#4$1//&2/,1$1)201//!11#8#3/2//02$1%1$11(1/%1!1(401//)4%11/03!2,11%88%1/2/01#101$1103!@/201+2///(1/01#1+202/&2,2!4&4!2/%1(6!2(1&108/-11!1//(1/0131!x%51!1(1%2(10201!F01(1*1&1/&1020602-12+21(2/2/%1%1%2///!6(2/,3-	eb^TLF@LgoD\PIABPpdCIBrP\dLbdLRTVdTnTbTRbVRrpddrupLJMT@EUUUTEPTTdQFaBUCUBq@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S).>x>xhS)x>x>S)xhx>xhS}x>xhx>xh.hS)xhS~x>+`luxhS}.>:ux>.hxh.h.hxhS)S}S}.>x>x>xhS)	=v;xy;fyEzTtzvLzpExzgbJ5zUlzEMuZtFrKagrGTA7enZ6pqP7W_4fYZp8YMUHwS801804ZN6Y0Fk	0Xc0FF03@01404s!qJ0Q01v!C_07R0U!3Xk2W0DF01680OF1q0C!18w0cF3Z0DV01L40Sk1u07k0ok$ 011VFh8j2421lWkTO10kF841A45VVNJmEAVHkFZFHs15A0FsGV4GB1312K89V874m0W0GAF8NF155kG0VViA5Xm8N@4960F8FZhmF6WXWk8VF472@1IX8V4570kGO4Ru48210VVs4A30Vt0N20Vlc90JVF18iFGss4PC15210HsG622W0t8RTF2132YRZ8B5Z12VVp0_B@54Xt0FVASP482W0Yl1BD6A46_msgB93VkN4cHJ8@5n1F6B96m0X0Ls_86637_2O4@253YVkF8LH111FksV26WG10@NC20XYLWkc6@3	#e0V!108#Z8#2H#cZF!1dc$5$v#6ZN!19kF#@k#46#O3#8Ss!24D!218V	01/+1)H!11*1%4$2$2(1!1/!1$@1101%3//01/#101#1$1#1+12&1(2%21#1/$1$2/,101#1!102&1!12%1012*31)2*3)3#1#2#2!101$3/11#601%2/)2(2!4#2$1)15/%2!1!1#5!1/$1!2!2/)1)202204/0101#3*2/(4/!2!4(1!91%4$2%1/)2(2(17#1&1#1!1*3//.1#1#2%31!z4$6(1*3$1*N01(1111!1#1/$30101%1!201/+6/*1)1,1//(1!1/$5010215/,2%1&	eeWZJ@DHKLmhPDECDhIP{HihdhTieHhbheDiDmDedcpIMlCRRKsJt@ESUSULET@TAADPND@@					antagonist	BB1 / BB2	Bombesin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>S~.>.hxh.iS(.>.>x=.=.hS(.iS(S(.>x>.>xhS~x>xixhxhx>xhx>xhS(x>x=S(x=xiS(S~x=x>S~S(	?x:x:x:ijsyjNu;Qdxf4OjyRXUAiJGcqcZ47aVfRdfV0RNMkjYKn2V199Z0GK42!VAH6sVVVF0	0Pg!QR!QV!RZ!fw0mF03OF1g07g!qJ0Q01v!Fi0440FV2l!GF08k0tV3c!GF08k0tV3c!Jk04s0Kk1N0AB% !3ekFN8AU2311s1oBD630YGFoPD4X104@10b3nVF8@@310kFP941VVN@5F6VVGP88476WFsFDB2YFsFD2183F88h4KP2411vcFR8QL0WWVkVsNQ821886110I1GVB5834WW8RT74W18N4NM20V8OB222890V8884110kZF74W18R243108421M70FGQ0821120kNF93110ZF230kk842K8@sFG0B4B493VVWgH@3WHHcJF438VVGc44LRUFVVm04a4C3VXks8ZR4I@YZ0co69233W_1Jg8C1VWks8JNy29911co4LAZ14VYF9w@G9VGmFo24A911lFZHA4X0cF8221FF842H8VFGk44Nc34VVsF874WVsNF6310V8430e3_08JD610ksRH93X0sR@210V882eDK0j3ccFB8125XFk8241FVB@31VkH0p382614X0ONL952lN842B6a5GY4863Y3GXdc46E380WNJD4871fFVNwLN12W18st6Y7X2GBV8Z4PD@ZmN48986ZO0Fc84RIA_kVB431VXlF4247CJZ_0NgCP325X_8FRGc125a2sFRF8B6dlNZDD@20X2BV8J48B13n8gL331mWs844BBm0WVFlgZ951VcN@310F9ccr824132GGcJI3XVG8wZHC43G2NB4G6VlNF8F@B4YWcR443XlkNF4B5aC60FF962ER0YG88cBcR78kNccK22BWVXFV8leO45WkFFRO427W0WFWWOm684VWG0	!282V#68!805!10GV!5@#5sa!12R#8e#4Z4$1#FPo!80_!2Gsk#Mc!26J!21Sk	01/$1-10F-1020301/&2/)6$4!103&1.1#3#1(2!1)3!101(21/01*2(1,5//&4%5&3+4)4/)1/#1!201%1)2&1,1%2(2)1/!1$62%2,1#2%4%1*401$412%4%1#112!103!2!2+4$1&1(1.11/%1//%8$2.6$2(1/!2!5/02%1!6+2+202-1)102$1(2$1!1/!10z%3(1*401-F/6/$4!4%1)1/%1#1!C&102&2!1!12407&40302%2/(1/-1!4.8-1$1(502%5$	ekPqB@@NJaicgb]PD@hlbbTtTVTRbQTNbRVRbRrbbRdtrZqIUMZfjjBXJIjzjj``qH@`z`					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~S~xh.ix>S~S~xhxi.ixix>xhS~.>S~x>xhxh.hS(.ixhS(xix>.>x>xhS(x>x=S(x=xiS(x=x>S(	=jzS:xzUSUzyEsyeNuQ:PVxdC9DyTXU@iKGdqeZ434VeCdfV1RN7wj3Sn2V1A1k0FK4380W8H7dVVcF0	0QB!QF!RZ!aJ0Tk04B0110480eF04J02B0DN0u!4J02B0DN0u!4OF1g07g0zF05B01D05R0L02n& 0m0XVN@B8B5@C12FgV8N5By25W6M98BD611C11NgVE6X0sN44A70VGWc4666_Y8kL1252kF8Zg473WlNgJ952G0B4217Y088d08622GVZX9410kB8PE10VWWs8P721GNoD@220sB21E90V8Fx48D6XX8gN510XX88430X33VF8D751Vl8863W0V48320ZX0424CJ0W0VND76210ND420VsV41H90VH2TB24720VVXF9ROB231gV8g422KEXGsO0P824l11044g1A70m88ND@22X4VwaD3W0842H910WmW0koM2XFVF610_YkF4269DNC0WVLF4@2SC13IO82695P0Ymlc8N6M334VoF174YaF8NLI72VVJ8JD@m0X0FA8eR45XNk8FR8k7AWYWcg8JK1430V@s411XXcoZJHMNY1V44B766c2NVR867VkNFkY8261m0W0F	!280k!H68!805!10FV!5@8!5NX!1HR#8n4#B$8G#FHo!80_!2GNk#Mc!26J!219k	/!1)1*G-10202+1,3/)6$5$3&1/#2#1(2,1!1*22$1//)4#5//&4-2+4)4!1/,2/601/%101/0302/*2$1*7&2/012#24/0501$402%4+302#1%302)4*101)1)1#11011/!1/%1$101$308!101,107$2(1&1/#1!2(4)7(1!1-301+11&1!1-2(1/!10z#205/#301-F$1*6/$2!4$1*1/1$1#1!C01&2-12406&40102+2/!1&1/1#2#4%1(5&1.1$5(1$	ec_ZBH@BIHngieck`ICHhhdmDdhdhhmEDhjUBeeDdpHUtSRkkAADuU[MTtuUUP@E@DDd@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.=S~x=xi.ixiS(x>x=x>.>xiS(xiS(S(S~x=.=xiS~x=xhxixix=xiS~.hxhS~S~xiS~xi.ix>S~S~xi.h	=jzS:xzUSUziEsyfNuv:PVSd4ADyRXU@iKGcqfZ43aVeSdfVFTNKkjWKn2V1A9V0FK4301ZAL6cVVVF0	0QR!QV!fw0mF02J03d!C_06k0R!3OF1g07g!o80eF2l!GF08k0tV3c!GF08k0tV3c!Jk04s0Kk1N0AB$ #6pkVkFXs4625hZNNRB@422lccF742W0R82D7b10VRD420Fl0L73WkV8B1192oVNF684W0cVN53X0sF6510ZWPFim4823MVVsFqg1331XG0gHO7VFkk22A5_VVN8@83XFcRB75WFFV@VK0VV882@EK10VFB@52VVcZB84XFFNB50VVF5NT216fVVF8633VVVZF@21VNZ8610kF822M7AjmssBB671W1VJa@22GVF411VFH0s22BG0VVFRF73218N@72WFcB6310F882iDM0VVNFD2210NVH73X0VB@41VFF84iD0VVWQ88641WVkBD941kVBD43W0FB4cF0VFWc84JikF30s4J@@32Xl0sF92XG886410VF94PYZ130cn0NBV18W3GF8gB29724n98e@C2X0VksSDU50WGVF4D612Yd1dFg5132k88Z2278m0XFG98mE621XNR23123XVFg6983lcg@520k84sPRL9dVkVBBC6A7kVNw8M0X0kcVV@j21Yll44@44YaoGFX8910WlRV8Z4HQ6alkR2186Z1WOBZG71FVF2JB@m0WFKWVy6A3Q0kWNd2474PVkWOgX4743XFX8c48Vk98Vb825111kG4aF7XFFN42B6a0WFZZB4XlcZ810VFGkgv8261m0W0F	!282k#68!805!10GV!5@#4sq!12RF!8YV!4Z%1#FHo!80Z!2Gsk#Ls!26J!21Ok	01//#10G-1020301/&2/)6$4!113&1.1#3#1(2!1)1!104)1$3//-5$2//041$2&3+4)4//2+11!201%1)2$101,1%2.2/%1$7&2,1#1%41$1*402$512%4%3$1%3%1+401*1(1*1#1104-1$1/%1.8!102.5$2(1/102/$2(15+2+202*1!1(1101$1(2$1!1/!10z%201%1*301-F/6/$4!4%1)1/%1#1!C&202&2%42607&60302%2/(1/-1204.7-1-5$1(	ekP~J@@NJaicobPD@ha\bbTtTVTRbQTNbRVRbRrbbRdtrZqIUMZfjjBXJIjzjj``aH@`z`					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
laSplE:alalaSplElES(:ElE:aS6laSp:ESplE:aS6lala:E:ElES6la:ESplES6:alalalE:E:ElE:a:agg:E:ELo:a7ZggLogg	]x<vzUzCqzvvUzAjUhrxzjzjXEbubOMzfcHSfqEK9nhAjBDwnnEziG43VJ0O53noN8F49YZX4G0	0ZB0IV027k1v!8U07g!Z80eF02R03i!C_06k0Tk03Xk2U0DF!sk0tV3c!Fi0440FV2U!Fi0440FV2U!HD09w0cF3Z!HD09w0d03Z!JU06J0R01v0Ds01oR0Q01v08s0bk2Z0DF0 0wm33B1Fl486521ltLF422E2Xl8BJg9341kW4@626_t0Gc@g4P5E12Xk8VGX2COVXkVcoJ9@3lkVBHF97d0lVFN94W2GWVZP6C3Wk8VV4174Y6PJBH7Z140f0HFFRF71lGFqF4D3Z12VWXcx4L0Y2lVF8B83WkFB472Vl0B622VVc8@30VFF5cTo14YH8sN920kNB6210V@0x0212Wl0R@12WFsR@51VVk8@11WKXN44137gVkcciN520sF81A8__7t0BR11520VcZL81XlFV@42VksB42G88aZWZN8G4M0Y1Pc8F68GblFk8BE6@J0VsLF4@37DW2kWGpFD3XZGRV8J42A@1Vcdg@680kNNB624ZIgV8N6FR2812GNcDE92GV8Zc70W4HwV8k4422X0kB@51WFFJB310kcB661ea088@20VGXANBoU82lclFNPJ5Wal8BV211VkgVTMZ110XlF8Z35BXFssD958VW8FokgI27Xn0Fkg2@54dWNO0i2D4VY188cO682@0G0ZXD3Y2m0NZPF6Y0sF4210VN4sa318VVNFt5R2EQ0XkWNkT54E1VVw41211G1B@428710cZH42VW0FB@42FNJ42293oVGRyC3VVF48521I1OV4893W18888411FRJ41VZH0824CI3Y1HRe813YGqXk8663240VZ@@6XGco8LDAb_FVsGsqV522W0cF@921FNBD42X0cRF21W0@O8220WY_WO54A1VVF4@3@7VF8R28@D3YGkk4310H2cJJ@38WlF848AEm0W0Gks836WGXk44c55X0kNJR21108V_0iW26_FGGN4F8E0h0kgB1442X5V9BB511YkksP944Z110ZP442l0ZB330FOlB4211YoKk8tJ2A5VXFkskV440VNtc2462084Na170FlsF4PYZ120VG948A551VJZX12108VgoHN5VFVBP11YGNB210VJ1e6F482290lFZF27Xk8BD90b3k88gxL2E@WIcNc4285C610Nww2A60XGJsF8a754l0V4BA10XHF8RF91XkcgN820V88223VVXNxCR2C5VXpF8ZBDG42W08PDP0XG04N269VkH9qF482I4WkVk@G10XH0FH@35aO0G08J672WFsN462WFc8B21WFF8611VV88210VMGvcNH@6XlFVF4210F84110JHF44TZ21VVkZ6530W8BD51WF8B@20VkN82kJ0VFFO1g2343H10P@510FFkeNDGbFkc8177YVFFFD74XFsZL420VVR830VFHW9HVJ22121toZA4XGmVs8B52WFc8@710kcB@3EFVkFN4310VF42210FGl82127jVVNgHD4XVsRB12WF84220VJmN84X116eh3cJR8@41W0kZDA520kZD311kGtR420WZk891B463W0sRL@4Wkk8610W0V84aI10ZF88xJ	!1d4k#D$K#1@J#Z@#5gc#F5F!Hd#B_$BF$Ak#V5#UN#97s#44!218V	/#1,201#O$2,1-2%11*1-2!6#48$4(2/011-1!1,1$22)2#1%4&1&2!1/$2%1/+2,2%4*2$21!2/&5!4!2041#2!4*1!2-1!1/(2*3#2/0105&4!1/301.3%5$60403#2%1&6#2!4!5/#20101)2#1-6#2.3#3+3/!2$112+2!3$2$3!101/!1+1011+4A+2//&1/-6!102!1&z%3-201!221%2&B!201*1#1$12)1*22$102)2/#8-1*21)@/2/(4/2%1#1#31$1#72$1#2#1,B1,	elq~FD@MOHckj^RG@b_PpLScDrJJKQEQJJZZIIKYJJIJIEIIKPi`SiZ[[GedTuvBBJjYjjjjjjfjHHZbhHEB@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~55x=S~xh.hS~S~.hxh.hxhx>S~.>.hS~.>(SS(S(.>S(.h.=.>.iS(/jH)28L}(Q+b+bL}	:UvzvzyzS:vTtrEzUQsdfUUUixgrFBvAxMDg27dPuqiJ5C2B01G9@cViL3I02@2JDQmGV!Q0G08FXV8V8F0	0aJ0Tk02OF1v!9J0Eo!_F0zF03AF0i044!sg0cF3Z!Fe05g0MV1v!Ne02o0FF1204s0eF0 #BV8J4C@@1Xkko0VD47XO0FsCkF4A2m0WFGNJHH6XlVNF40VF9cso8741mVZNA2Vl0B210bZIlOpF6B9VXW0WN8T83FkF2HA95XX0gTA4XFc841B7a1G0gJH32WNF861VFGl8seLJ1Y208cFHI6aWkVD3864O0GN84FOD_1FF4FE80W21kXA6WkG9B22F@BI0W0Fkol622lBV8N78261U9VVsLF4822GZWGJ8977YjVVJu8B410kVsDA6XW0Z841VVF50a118cVkkRN94XW8ZD6210GlJ4129811sgPJ6WkcF820a4Y0	#90V!28#405!12V$1#18D!123F#X%4#8F$2k$5#G$158(210V	/1/012#@!2/01@)1(50102/!@$5!2082#1,1/2#1//#4//#2.1#8&6/*1&2%1)1,21)2&2-2*4!3/%1.104.2)1.201%88!3!1.11/+1$1!82/-1(1*21,2$1.1/01/1#1//%4*1%1$1/!6/!202@/#1(1/(1/)1.1!z!2!4/#1/D/1%1//20602)1/04%1/!1*32*1/.2)3)1)106012$2.2,101+	ejYTHF@OFh`IABPpdCIBrP\dLbdLRTVdUTtVTRTttRVDdJjVv~aqIj`@jjfjjjjA@JaBZcX`@					not given in publication	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(xhS(.>x>.>`*vl~Sv:l0xhF*~Sx>v:`*xhS(x>x>S(x>xhS~x>.hxhxhx>	=jzUzUvrQESrnUpuOvjHzHuawzQBTQU83pKE8OOeNo@BVH3540ARGaJ6M2@31r@FK80N290Z!@kV0603V	0Z40IV025k1v!8M07g!lN0O01u!BM06J0Tk03Y03a0Dc012o0B0120@Z012o0FF120@Z$ $6bXVV4JB@N6Ek8VVF2J5A1sN428742ndBF64WkVJ2J@@EkV88FD8223GckL82X10J620VF842ZCH1amsVTA6YX1wV8R4639XlcsLA5W2WtFKJG840842F@0VWmFccXC7Z1FB412Vn11W4VL5bkFkJN213WW8wR95Wkc8@517Z0848PYZ120WVPso5561FkBBFF@86G8Z835W0NF4NBB2rF8Nk22@412GckD@30kkV841VkF46XG0VYV88lE82412eG98FE13Yk88k2289m0WkH9xP744X11Wh2C3VFO0wVo5XWWVk8FLF5Xl8ZD43VVN422F8811VRN@54GFV86A7_VFNZJD5XlNc651VF8821G70FGXF8HC52WNN663W0V8B110F@G422EI	#94V!484$4#F$VB#5Wc!223$W#20N#8FF!V2k$4#G8#C5c#F$90V	-2/)I1+1$11#21/$1*1+4$@$1!11/%11+1/01+402!1$3,4!2!2//!111//&1//1-2(1$1%102/(365!1!1/)1/2$1&5&1/#4!2#1!4,2$2(3-2301&2/%2!2$2(3%4)1+101!1//#2#1&3)304!4!1%1#102(21!1/1+6/)1/*1//+11x#2*2/+61//!2/%2/35+5!1/01.6/&1+1!2)1*2/01%2*1#1,9$1(	edZTDL@ADgo`HbRHrBLbbbRVfRRbRTJVRbbKGAefQPttAAUUSTuUUMQU`YQYQlP@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx>S~x>xh.hS~xhx>S(xhw<^}5qtn~U}Hqq^)}H}H^)qqe,rp~XB+y>m1m1B+	:Uvzv;S:vytrEzUQxfjUzUjxgrFRvfxMDgI7dTvqiJ5CeR05I9@cViL3I0DD2JiQmGV8HQ0G08FXV8V8F0	0aJ0Tk02K03x!Bi0440IV03Xk2W0DF!qJ0Tk3x!Fe05g0MV1v!Ne02o0FF1204s0eF% $1Z12VVktFV@8XFVJB2A65W0kwc942G0FZa14WF8Vs22BD8A3kB@1643AVHR82333GVl2R683f3VVsG6X2361XK2w88A4m0WFF88B853GcZJ821FNB420cXoFF4F752GVFD55WFNB8TH10VWs42135eO0Fk9Bkb364FGFW0iH6_VcBRNEZ140t0FV84FB8XlFZ@720kWW8621WYInlga85VWWsB4PDIV4FlkN869421Fc673WkcJ650VFF42cD0VY5F	#90V!28#405!12V$1#19D!123F#Y%4#8F$2k$5#G8#15c(211V	&2/#2%1$B022/01@/!50102/!5$5!206$1//-1(1.42+1-1!2/(4&6(1/012!1!12$1)1,11/$1(102*2!31//$103#2*2(11#1*11&84!3!1.11/+1$1!4)1/02!1(1&1/02$1)21!11/11/1#2/%1.4*11$1$2&2*4%1+2!@/!11//1$1//(z!2!4+2&1/D//.1*402!2(2.3//01!3202/.1(2(13/%4012$2/#1$1101&1%	ebQTHB@CJg@IBRPTdMICHhdhmHjiiDmhdiihdmPqdULl|Bcc@AUUMUUUUPHATHCTKD@@						CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.h.=x=.iS(S(S~.=x>.h.i.>.h.>.h.>.hS~.>xi.hxhS~.>.i.h.=S~xi.iS~x>S~.>.hxhS(xi.hS(.ix>.>	?x:x:x:ijsyjNu;Qdxd4OjyRXUAiRGcqdZ47aVfSdfV0RNMkjYKn2V199Z0GK42!VAL6sVVVF0	0Pg!QR!QV!W80IF02jk39!C_06k0Tk03OF1g07g012s0FF120A4015!Y03a0DV015!Y03a0DV01I!IV1M05V0gk! $m0WVKfR8B46SckksNF8A4YG8sD@4VVF843E77VkNRD74XVsZD43WkVN22G6VFG@F8@64X0ccJD5X0N8820c3JBV8Z78281X80VsFBJ@35m0Z825530c8cg821Wl8JL54WksJD41VVV421J8VVGucB421VkkFD8420sV841W0sCBa10VFls44Pi50WFs8H742GcRD31WFFB4ZH0VFWmZG04723WFFFRC14VVJL41aZFV48R115cAVHFFBD375G04BJD4C4Jk86BC1W0F4FBJ3D8mcF2BB1108NNZDU283o0FoN22533ucFZ82G4_klcNc4192kH044R10W2XkNBH36X1VVF420VNB6210V@O4410WYKVVFF91WkNFB93WkVN621VVF9FV217@VFcNB63WW0VD72WVsN6VJ10VX8444D0VXpFmWH@12WWGcZN@3XG0c840WFN4210cXoRV8R48A4XlkZR350kV463D676lP4N83VGlVtK465VVFo@40_2F88RgoW31FssNN70W2H2PByC0VGVspJT4829ZJ0VBD13YVF8kY82510WX9ce941VN8cNK0H130cNJ8N42Zkl0eK64B5Z0W0VsLT7XGkkcB287m0WFFVg2GAX1Nk8235YV88gn826113lswT65X0cF8LCAm0W0FVcPK@1WcR4215YHlkRXE0WFckH240FGcg229D12GsoL65X1kJ620aXnLms884T17fVc82F54YCVGes4L4b16EFG8Foij50VVkZOD27TVWFWtCX6880WG0	!2D2V!168!805!10GV!5@#5sa!12R#8e#4ZF$1#FHo!80_!2Gvk#Mc!26J!21Ok	01//1!10H-1020201/&2/)6$4!103&1.1#5#1(2!1)3!104)1$3+1*2/$15//&4#102&3+4)4//2,1!201%1!1%2&1&1$1%2/!1/!1$7&2,1#1%4%1*401#1412%4%4$12!103012!2+4,1(1.11/!1!1/!2/!8$2.5$2(1/!2/$2)5+2+202-1)101$1(2$1!1/!10z$12(1*401&1%F!2,6/$4!4%1)1/%1#1!C!1#202&2%22407&40302%2/(1/-1!4.7-1$1(5(2$	ekP~BH@JGHlbnbV^YUP@cIEMDhlmddeDdidhXhhhheJ^ECKMcdRZBBbjjfk@BifiijH`HDd					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
b+27.ixi.=S~S~x=.ixixiS~.=5qx>.ixi.iS~S~.=xh.iS(.=.>S(.>.hS(S~.>.=.hS(.>S(.h.=.>.i.=S(.i	=v;x<vQUrUnzfvhyEbj_oOOjhxI@bufuItmcti@iNJ9MiDN8DMYH0Dq_Z21FlI4z14H0c8lX23#	0aJ0Tk02OF1v!Be0440IV03FV1Q06N!qJ0Q01v!Fi0440FV2d!HE09w0t03c!J90480Ik3O0EN0 #3732coF731FV823C5aWlOoeL1WF90ZWih23110888951lsVD8210V46310JlmQk4Hc13W4HVG0LQ91Y0s8cN2562WscLA4W0NB4210J1H494452E9JFNRB6D23XeN@D@7e40VkGBXX5X0c88F@8W8F8NRBF442Gt8F54108F2210Z1P0FVG8ZFkZF595VFG9G04LhIW20lkwTK60l0J8HC10Xk88VhD1E3WNcc4223YW0VRFA42G8Z6721FF4421VZlXNFHE73GcFH520VF44R@0VX3wV8N782711XH8oN4310kBJ120kGso22AF6_GsZTB33YVs88LH21WVsND83WW8N4740VP1F2310F842185g20sZNB510sN8630VNBwR1168A70Fg9k2EL0XkV	%k#4$4$@N$8F!1BX#27F!8n#44F!18FF#Ak!80J#Of#8Ks!256!250V	11)1/+C1/2#4/%2!1%3(12$C#25$6////01$4%1%2$31)101(2(2,1*2/-1)4-1)1-1&2!15/,1$301*201%1/!11)2!3)3&3(3&1.2$2#202$6(1%2%101!2!2!3/-1#3!31$1*101#30102!22011$1)1/!102!101!4!1$1!B2#206//%4/026$1//(2)1*2*1!210122*z%8/&202#1%R03(1!201/%1/$1/#2&2!1&1,411!1%73/3$31/&2//1#4/2+5-	ekPrFHDLJceXDO`]SP@aVS^rRPqQYJQZHiKSIYQQYKQIYSSpii[XVUZhHJ`HHjjijX@I`bBR`@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(S~x>x>S(S(x>.>xi.hq5S~S~.>C+~Sqqqq^*~SC{S~|H|Hqq^*qq	=fzU;pUTQjnUJnutQHjaXYhbQDDpzX3535OIlf6kY9ZQM03ZMu8AgeHPHCdb21L4e011607NCYJ50VV0	0RZ!WR0Tk025k1v!BM06J0Tk03OF1k07g!t!bk3Z!DA0@N0t!4AF1204B0IV$ #2GeVT97Y2GgV8N4HRH0G11c4BAZ13VXGdFi8D4aVWNqF4B2SB6klcgF495B0Y3es8F6AK4V8VZs275G50X9824CD0XlGt8eEBXYFk48FDC5X1e8HA743XoW8B16Yll0sgyF391VkFsw2B6m0VkIdV8XQ17Xl0FgJk2Ea0Xkak8wa2CCVXFqk9Ja2FCVY0wV8B78241m0X0G89NiH29YlNG0T2D4VY1wV8g7826173WW0RS68Y3kI1Ji63@70k4BVDS1Ba0HtBq4I4	#d6k!1N4$4#44$C#2ge!20n$WB#4J#8FF#@o!404#OV#95s#J2!252V	$2&2/*6#101%1/,21!1%1*1$22#7$2//*2/&1!3*1-4)1&1/1/,2!101014#102&2)1//)1/*2-1$12&3,4/01/52#102/0101$1/301$3/$104//!1*5!10404!1)1(1%3//&21#1+12!7/%4+1/#2)A+2%201/!3,1/+1%1)o.2,1%4&B01201/1.2!2/1/01+5/!1&1)2-1!1/$2/-2(2%3/#1(101+	eg`\LD@M@koHa`H`bHrJJKKQIQQQVJJJsL\MCKGPPEUTsPUAFP`HQeP@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(.hS(x>.>.>S~.>S(xhS(S(S(x>.>.>.>S(S(S(.>}H.>S(x=x>.>S(S(x=.=	;vzv;SzjvytzUjUNzfxUzUjjirOEttiI@iHbl5vb9JCULC21G_@cWETYuF@X2J@GFGFH1v950c0fmNX0G0	0b!vV02R03i!Bh02s0IV03Xk2W0DF012o0G01D07g016J0R01v0Ds016J0R01v0Ds01Xc0AF110480IV2d! #kR8g2@aHVgDBD8TdkVsFJ84T0VVcVNE62lFF621VIWm0cB212ZkoaFA8m0WFFcJ410WXVgTA22VNFsPR8544sVZB76e0Xm08V86@13ZcRg214Y2PW08@4EP618VVFXu4W0FcNNBCC0Y1o8BD0VY1nvwB6@3NC0VcFaFI34WW0VH022S2XGNRZ@21ks863B80V84BN_Z11VVFNJ2211m0oN@5WFFB43G6cWV90TD9ZVkB4JC@841lJHC4YYlkkR8m8BaWskJXEZ11VWkFH4211118ZPB7XVcB62D8cO0G0CF4RF1514MFZBZ412VlkkF84Y21W0ZHG42FVN4416ZVF910	#80V*4#1*1c+f#4Z$8F$2k$5#G%5s!2$218V	//(@(1%4202!4.1!1/&2$301!H!201(1///04*2$14/)4/!2#2&1/,41%1&1/%4)2.202/!1/02(12/%3.1#3-1$B4%1/1$1*101%101$3+2%2.1%1&2/#2$2/#1*12$2+4/(101.6&2/&1//2@/$1/*103//)1%z2$1(6(101!1$1&D+1-1/011+202/+2//#232/!1)1/$3/*201#2!11%4$1!3#1#1!2#1%	elVTL@@DG@Eh\bbTTTRbVLRRVfTLrTt|JzZFAQZjjjjJBbj`B@c@`bh`X`@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
55^**^55H|h/)S/>*]>/*n>/5qwh5p)S(8)SP)*]/>w>*^>/)S>/q5*^*^whH|]<)S>w>/)S>w55S}w>qqP))S)SwhwhH||H>/>w>/>ww>qqqq)S)S)S)S|H>w>w	}y:y:y;Uzrbv:t:xbvnzIrpzvxtqUUxUbt3xvejjzlTsLf2Z0SJIUPMzjSDN_XaRX0G0	0U4!U4!U4!U4!aJ0Tk02OF1v!9_07g!aJ0Tk02R03i!8j0E4!sg0cF3Z!G_07!Tk3i!Je02o0AV0j05g01Hc0Ak1k07g0uF09@V0h02s0FF1204F0Ik1v0@Z# !m0W0RV8J78231m0WVRV8F78271MfkcNcCTp23WMkFsJ4@4pMW2VVnVX@4VF8ssRDr93W1cJ24@67fI8c8@A51cKcV@@E30YGWwc2@42XO0G8DF4@3Z14Vt0FN8KTj351XHWgkC57WF8FgR2LD118F42222XkB64I0VkX0B44CFKXkVJH23W0F8230VVOskw2MF2VNdN4260VV4220VF84kHXAJ0VVFD93VHHk4411VVF82FCG17IcF256YH1c44L2145IFGWF6493G4kNN4C210O9J2110W2084R2160FGH0FBE8YX8B424VW1W0k222Yn1VBDH0VVVZ@165aVVWFRH7VkkNH10a33084DD@bFN44HI10FsV6@CD34KFRH8312193oBS222G0FJHC5_WVF41@8VFNF@40Y2Z0FN26FG@F8NkB824Z0VN8P53WG0RD40XFNVD410ZlXN4445X1FN852WG0FB92Vk85BHa21XW8R6F3W0cJB@210P0d0433VVVRF@20kFBD24W0VNDaB1VXV88WJ4516l0FT74Z0WNchPX@1Y0kF8D931W0F2710VNc29310V9FL213VFFekZT16Xl0ZFI1VVGVwkFX8ZWc88DJ1VFX98JiM5Xl8N830_5VF9F22EB2ZJG0L523_FV9B4127_34FoT@5VkF4ZZH184J8sH27B0VHcB44G@6k18FF@E10Y1eG88J445ZW0Zk921FGGJ4327a0W0NFCN33FcJ869910XGcT310VsocP715VVG9V4ZD3aWF82520kc82R7D0Vb9B8@K2WkVNw22C90aK0o6@G1VGc4FLH29h1FW4H321Xk88ZV4UIWVkdF8420k8ckc9640FscZJ276m0WFF9CBB31lXNF84F20kWV44JMZ13VW5HVBJC14260koVR50Wlcthu4@60X0kkVBE41VWsB40W09cko@83XlsVX26X0GNg829B5WX0gBE73FVB4L9A2XVFBHC730FgJ70aY0F8ZsN36cG1HR4FAS3W1VVVNN48X_208@@4VWWcV44@10WnX1F2KG0GWkN4N1144748GBgC2810GkiF4D2QK3VVoJH@h16CkGFFpHG23V8N4FG0VYmHXFe2511WsB44B0VXXGf8NE0WV88VNF136_0g@BI0VkX0J24B@7HkWNc4F1132O0FV84Z88bFVoRZ317WF8FccIN25VkFsQs4T4840FVZJq5@6lFcgL296m0WkRV8J42h24AkkFJFRf92Fs8NV31710GW0daB4WkVkk642446p0kJ20VkW0ZV4@RW0FgDDE3VXm8N8Zk23WWGAkN884322r88662VXGcF64@A2g50NcD284m0WkIeci64821IR0BP215VVG8iF4@3T312kfk8VB252	#gkk!KKV!20b!27d$D#3CX#2vV!NY#8Zl#8F$To!8V5#Sck!8Ks!26F!2_8V	!102/)11&I/!4!2%1#21+1!1#1.O!20B$1/-101%1!1103#1!1101,4!102+2!11&1*1$1&1$1/.3,4$1.1)501$2!3(3&4201/$1!4!4(1/!1*1&2B03,1!1#22%1$11)11!11/1$2$8!1/#24!1010101-101!3)2#2$11!1*4)101+4$3#21!1#1(12%6,5!I,1(1013+1$109%1+E$2-1-1101)1*3*1.1+z%J/#121%2&g,8(3#13!102%1&G//(201)1!11#1$6(11!1$1!101!1/!1/,2-1!12)12!1$1(5&1%	gope@H@@D@H@HtNNarxbrJIJJIQJIJJIIIIIJJKIQIiISQQYII[XpD|EHbQYBv@lQIuV{Giu{\~ZjjZjjjjBjj`hJh@@@@@Bb`@PDBCE@@					agonist	Opioid delta / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.hxi.iS~S~x=xixix>xix>xix>xix>S(xiS~x>xhxix>xh	:UtzdzOzKxlQR@UHQ0GAseH6620hWA888xX31X10O0X!W202GW424s8Bo3X412c229!840101010LV0V8F0	0WR0Tk025k1v!C20@Z0gF03Z02W0DF!qJ0Tk3x!FM06J0Q01v! $VN6430kFFB3W1044RHD0X1lgaC3X0F4cVKZ13Vt0G08NTC33GkwF8153XW192L3XVFscU823123GcVNB110sk481aZYF8ZaO6YWNF210_YXvkN8B5Z11VW1kVJA40VkJH921VN4wcT77a290F810V9G8f82A1m0W0F	!114V#8J/2#4VP!207F!cWZ!5Z%FF#2k$4#9$13V!246!219V	/,1*A/$1///021!42$2//1+1///!4%2%1/!2*1/.101!2//.1*1.1$1%2%2$1&1)203//#101#13&1$2)1/%1%2$1/$302#1%1/#3-3&2!1#1!4&1%102301//$2#101*1#8$3$1/#201(1%2!14$2$9//*1/,1*1,10l%201%1*1/D!1.3/%2&2/$102*1#2/(1+602!2//02+1#1*2(1(3%1%1+1!5-	fcoqC@FVRTDPRHwHYEEELhTlddeMDenBMZZxH`jjji`@b@@@						D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.ixixix>x=xiS(S~x=x>S(xiS~x=.ixixiS~S~W~zBxh}\ps	:Uvzv;KztvTdzUvClvOvMaDTOgkQCh7z27j0b9QneBkEe0JLC3i5wJBBXl90XWY7IoB24114kFF)	0WR0Tk025k1v!9_07g!lR0OF1v!C10480eF03Xk2U0DF01_c0Lk1R08g0bk3Z& !BV8850a6XkV4NDBY@60cwJDAZ14Vt0G89wRC90ksg4FC8WcFW0GW248K0WVlcc2YIVGVskcPX385HcFoKRq2514Ilkk8942XX1NL55XVV8cR2165t0FN88oBC31H0kH4B7m0Y0RV8k52F25FsN@7884O0FN@ZV4IK0Z0wV8F4	!21Jk!3e4!402!1!V#4$k@!225F!8tJ!4V5#@Jk!V2k$Z#GF#9Gc!2H#218V	1//&7/!301(1%1%1/%1#6$3$1*2%2(3//+501*1*4//.2/-1///%11$11,4&1/*2/&1&1!3.1$2&1$1/1!105#3$2022!2$1$1/04//-2$104/,2//&2/%7%1)1$4/&3&11)8*2*1/&1%4#1(1#1/#1!1#n%6)101/(F$1/%1,2(2&1/*3024!1/*1%3//#1!2/%2/$102)4/$1%1$	fcQA@CEtBHIDYEEEehhmCEDdhlf\lylu{``JVjhHJJDh^H@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hxhS~.>x>.i.hxh.=S~x>xi.ixhS(S~x>S~.>x>x=.hxhS(xi.hS(.iS(S~S~zdW(p3`|}J}\}\`|	=jzS:xzUSUziEuze8uQ:PVxf49DywIUeiKlcqea43ZVeBdfV0RsELj3Km2V1AAkGkK4301V8H6ccV0F0	0aJ0Tk03OF1g07g012c0Lk1T07g012c0FF120@Z018s0cF2Z0DF015!Y03a0DV015!Y03a0DV01I!IV1M05V0gk0 #1Zm231O0Fk8_qV33WeINwH855XW_8RBPK512VkV8DD_810OJ25222Ft88894YWFcB941VNJ420c3o0NBH7320VcL742FkB410VZWXFB273Wl0NH95210V440VV@Fp829F_HkB@314WmF8BBA5XFsRB35X0F8630cZkF48Va21XFVBF42XG0Z873VkVB420VF@kpN4221kNRF43XFsZF51WFV821J80FGXcNTO55GcF82964t0FcDF4H3DA11kgV8V782712W2WBFD3W0kR81B5a1G8kNF311NF@35640848PR212FcRJ82XVcFH70W0FF41I9VFH044Re111VNF8641ksNB731W0B6110FF9RTi110VVF463Wl8VF43WVNF8310V89RVi@36XsVF820FV4gNLzHW1kgV8F48522G8oLA5VW04450VV@8s22BH	!280k!268!B05!12kV!5@#5NX!12R#8X$4$8G#FHo!80_!2GNk#Mc!26J!219k	,2/*G!2*10202!2*2*22/(8!203$3&1+1&3#1(2,1!101)41/-1#1.2+6/*4(2$1+4)4//-120501/%101/!12.2/+6&3/2&4%1!5&40101!5!2$4/!2%3+4+21&1+1#1/&1/%1,108!101.7011%2#2//(2)7%1$1!1!1$202(1$1(11/2/(1!10z!2!4(1)1301-F/6+1/!1)1/)11!D)2&2%10406%240102*2#2/&2/)4.402+1-3-	em_RJ@@DLGI`McgolbbRbRRftTTTRTTRbYTLRVTLjfFAiyeUZhHHjjYjiijjA@J`@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~xi.ix>xiS(x>.=x=xix>S~xiS(xhS~	zwQn6WOK8F4N0J2BBN#N2m!F112#IFV50V#V8411V0X0V9!J0F0816W0V11V8!4%20410W8F0	0PF!ew0k!2IV3r!GG06J0Q01v!G_06k0Tk3x# 0KGsFgA82A1b_FWFGLT482m0WFRV8J78251m0XkRV8J78251	!110V-1!V!42V!4%34$l#4c1)FAV!10Z#14$2V!814#31V	/*2,2///%1/7!1&101/)1/1/1(1$102/&2///+1-2/(1!3/*8/)1/)2)2//-5&1//$101*1!2/0102#2#3/+1//#1&1///2.5/.2$1$1(3#1$1!8/3&31/)1//._%4(4*101101*F(2%1*2$1#1*1)1+1/04$1)1/////(4!1%1(4//+	fjmqB@FRtXDadTRTvbTQbbUNYK@DSSPD@@`J@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
+H6pH++H+HH++H>/*Lm3.pD,D,49S}m3)U~,+^whD,66ukW)66S}+^yAyAwhW)S}w>whwhw>	}y:Ujh<C;Uhjy:vSX:nr@j:qLTvrzQ9fgyxyaovMKzEGEAfx8VS6AmGP1o9l4#V	0WR0Tk02YF3r!C_07R0U!3FF120@Z011R0OF1k07g01480Fk2d0E401MJ0Sk1u07k0pV07AV0s0440SF1u08o0xk0 $38241FG0VsKVN4A2OcFWG04B6WFZFlO04H85H1kFZZ67Z2V88V_4b53F88NLBM99lVNJJ2143239gRA21VF8ZVH44YG0VcB41VcFgJ3146O0G0DF482gR13VZ@4X6E80Xl1tBPJ911Nsc2288m0VkRV8N6kB231Bo8FoV27397YNoF10VX1W6F4F2W8cFld04H8WFZFll04L8DF0kFW4RC311Fcg229@m0VkFFZD951ksoP44VVN4sJ20W1o4@4X6H80YG6N9922F80X0k	#@JV!104#cw!162#zeF!3ge!2Xlk!Hb#8WR!2ANF!FTo!@ZE#GYV!8Ks!@4e!2C8V	&101.1-J!1/1/1)1/#1!4$6$12#1)2&1(101/&1%1/-21#12/%1$3#1/#2$101,1/101!1$2#12#1*2(2!4/!1$1)101&1&1#8(1)102*1*1&1/#101$1,2!304!5,2,2101#401+2.104&1,1/03/!1&3*111!111+2!701(1%2)1/$21(1$6*1//&1//02+10z$3501//!F01/#2,101%1,6)2/#5011.2#2302(16#1%11/*1*1)3/(3%1#1/08&1%	ejU\LH@MDgnJo`HaIe]YefUUeumZFK@gHimkolRX@JjZjbRbJjjbBdACKJ@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
+DZ)>x~S(Shxi.>x>x~Shxh.hx>x~S~Six~Slv~SF|l0`|vl~WB,S~l0l0xh.h~WB,x>S~.>S~.h.hS~	]Uzrv:vnbpvzfzqULjzrwsBzhS@HpMAU3OXOz7EVN450UisB7JMH0@@Gg@lJ028eMJm08@XX06830	0Xo0FF03Y03a0Dc!kR0F03q!C_07g0zF03OF1v0Eo012o0B0120@Z012o0FF120@Z# %6J0VFFD8J@4Gsg@@743oHNFR8JBAc0GF2D@70YH9BF63X1cNcV115_VF84F@22W8sH82VVVF610VV89JJebQ0VcVRFuf52VFB4DC721WNZaA6XFk8830aY088Zv82711X414P71XVl8Z_Ff81WFkVo2N78G8sc22880W0sZJA521NVF320V9t422DF12lt4T94XkcB6LFA763Fo892W098gZ5P3VG0sVBXa@Xl08RND12WWFcB941WFV@610ImVB44G0VYZVFoTF62FkN8420VFBsVRXW11kV	#@0V!18%4)FB#19V$2#F_$kF#8k$2k$4#GAF!c5c#1#219V	&1%101(3(2$L$1,101#1/$1&3!1#1&2$A13!3#1//)1/(1/+1!4%3+201#2&1*1%2#1/%4//-1/$22/!1$331!1)3!40603/1/(3!1#1-4(2#3!22+201!4(3*23,2/!3(30104&1/$3)3%2&1#1/(1*1%7$5)1#1*4$11#2+21(7,1//01//)12(z1!203!1$4(21*1%F1/)1(2/%7*1/!3!1/1#1#41%5//!101.1&2(1%201%2$1/&B)1#	ei[TBL@HahDD\P@arPAdLddLRRVbRvRbbTrRbfbcRdtBbzFnayEV``bjjjjBBhZjbbprHJhvh@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xi.iS~x=xh.hxix>S~.iS~.=.ixi.i.>S~x>xhxix>	;QvQzvStunnqv60t5uoQ64qJ1QiYF2hS1e11F20FG91kL10A7!4Fe40J0V2H!Z4540380D48B040J4V0F0	0Pg!aJ0Tk02J03d!C_07!Tk05AV0p0440FV2f# %2bmPB676433nFooC0WF90RY8261m0X0GGVsCA2XVN8VND9DZ0sBD34XHVtIlF442m0WkMV8_F272m0WkF	#W1k#8+4*h8$3$3#4V%F$2o$4#GV#91s!2$218V	//(@(1&201///#@$2$1*2.1///04//#12+2/-1#101////$4/4//%1(21+1#12*1,1/-1/+11/,1#1-1/.1)13/)2&1//*7/01,1-2!1$11(5+1/-1+1//%1$d%802&1)2!1&1$H//%2.1#2/*3/+202)2/////%2.1%1%3#1#2!30	ffcQ@@IVAdbfbRJbbRaRxKpRuhBBjj`@HPjcQ@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S>x>.(S(S=.=xix(S5q55S~55.ixi.>S~x>.i.hxiS~x>	vzUQvQrvUSvmvyt30n5utAjLyLbQak2Rh_C2!135HO21kU90O610C0c4242m0201a65H02!D4N8!201!V0	0Z40IV025k1v!9_07g!YJ0f!35k1_07g012s0FF120@Z0 03oNQ33Wom8FFA8261XbkVsFNF11YnWFF31_2FN48BNC8cGFoF673Ya4WVH6542t0FNDF4H27414lkkNJ4108V6H910Wn1Xsy722WlF88DC8ZW8cB530n1884DP28bmkoJ20VXFt8JN4M3GG1B4BB122lFkHC5XFVJ4410FH0S0	#15V!184/$1c8!203$3F!4V$8FF#2k$4#G$918!2F#218V	(10102/01%20A////&D$5/1////!1+2$2%2%3/)1/2/1!2/&1/-2(2,5-1//5/!4/(4/$1#10201!1/!1$1//#2,1*2//#1#1/&1)1$2$1/%7//-2(2)6)1/3/#1//+1&h%6(4/+H/$201-2/#1///)3)1-2!1/$1!2//*2/1+2)1#	fakPB@AJADYEDeCMEMMDdejLuXkX@Jjj``bHQpbU@@					agonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~.=.ixi.i.iS(x>S~.>h.>.xixh.iS~x>.>xhxix>xhx>xhS(x>x>S(	=fvUxwjwMLAUUSNlnQPuXCFaBYdeBTz09Dm13Olf6FWV6fMVSaKRWFFvCQQFt12@24cL9Wc5F@0MksVFFF	0dR0ak02J03d!DF0@40t!4OF1g07!Tk04OF1q07g0o!4FV130@Z0wF06FV1404R0SV1v09w01ak0Tk2F0@40kF3Z$ #O0G08S@j3X4k894J2WU0k8ccM82B1m0W0RF48F112Wt0FVDF4N25He1s82BK6m0Z0RV88782912eJFoB@I5OgFWcLF4B2eS12V_Ic8V47C5Y8JP27B3_0HnFs4I3m0WVRV8k5k29L0Wkb2k8V499830s6BP6Cb5VOFCNs231D0G2k4B4R87nFVZF	!1nWk!G88#4@!3NF#V@8#BD#85F!FY$4s#Xk$Po!8kb#GW#9Rw#46!2AQV	/#1/!1C&6&1!1$2/#11%1!1$1-2$1!26*2021#1!2(1!1$1,1+11#2+1)1!101#1.2$3-1%1*1(2#4$1)1#1%1/!1.1%1-1)2!1011#2-3//#14$11&1,11$1/1$60214!3/%1$1%1$1/,2/01!1.2%1/-1%1011*2!3!1&1%2/(1/!1!@#1&1!1+1011/&1//#1&u/*1/9$201*2$1,2$1-6-2!14*301101/!313(151*1+1%2$1///5)12#1$2&4,1	ehVZL@@DNANm`L`\bbTTRfbtRQfRvRbRhxT\|BRJFf~AZ`XJbj``JjjJH@@					antagonist	Adrenergic alpha 1L	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>.>S(S(.=.=S(.ix>.>.=xh\).hs6~O63h.	yyulPWtG8k5k0FA5GN0GVN@m!F0830@0HIX18!3Pk96FWV0@G090JLWF0c0HH1W102V0V6!80424048040V	0Ww0Tk02OF1v!9F0DZ011w0OF1k07g01p40JV1W0740SF2x0CN# #150K4WVV8431_1HVF84J93kV8H81X0lcNr8271m0X0L08oVM61Wl23V8NB1440FkVce4@WlkB8440VGVNn8231m0XVL88wL4267VkFVJ	#a1k!F$2GG!2!V!g1#388#Fo#23#818#4$12o$1#KVF#Fs(210V	/,2*6&1*1/2/!3.4$2//#1/01!1&2011&2$61/03%2/*1//21/$5-2/+1#3/,1.21$1%2//$1+5!301%1(1/.2$1///01,1,1+1042&2%1&1!2!1*5//2!601///.9/(1//1$2!4//g2$4(2/+D//%2#1.1/01+3)1-202/+1/&2/+2#1*2)1!1/-	fakQB@HiDCDrJIJYIZJIQYPtXGIZp@UTDCETB@@					antagonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
ncSrnC8cncncSr8CnCnC8c8cncnc8CnC8cSr8C8c8CS~S48ciiSr8CSrnC8c8cncnc8CnCSrqI8cq]el8CSr8c8cSr	~:UzCr:v:fjUhrxSj:XjburQMzfiISfrEK9rhehCTwnIEzyK532JZO733kN8JZ9YaW0FV	0qJ0Q01v!C10480eF03Xk2U0DF012s0FF1209w012s0FF1209w018s0bk2Z0DF018w0bk3Z0DV01K40OF1r07g0U!5NF1r07k0j03H!S706k0Tk2D09w0d03Z$ #9AXFnFk4i55VkkN@40VVOFksDP3W_kksJ23WlFBVRMZ120t0Gc9sJ@CX0kZRHDK9Z3VVZV275m0VFGNZD730lN8@@21FFFHTD0VY0N8d4L85WVVsLB21V8F@3D67AVGfN4L5Z140ckkGB4833WFZ8DA2VXHZVF8V593lNN@B98m0WFRV8R48H4YHlJB324Z2G10s76XYWVR8444Z_JNJN75X1l0shFk34WXGtBRE62kG1082D93_Y24P@B5B9mksFX8b178nNFcCD2AH_kVsPtg4626ZpcVFXD17XfakFgA825120FcFR74YFsRHA26_08B26DF0ZGW8P7230F8cV210VV8JJT56ZmcJRBG2WVVF6@AA13XGgk@23YGkF48452WFZL9510VN41F8VFNFp8@43Ylt0NB4W09Nsi4K6WWVq1Fe@452O0Fc8gZ440VsB8521l846420ZH084PZA72FsNP711Vkg621743ams8V5Z130t0GV8Bc73_HNFT19@0kHGGCPD43GHVc8D22XVcgF821G8JH40c5FV9C4	!1fak!2BV(1@o#Z@#CCc$KF!FX$Z8!3QG$Pk#44#Ow#d7c!857!218V	,1#1.2%P//)1/)2!4!247!103(2/!1#1)1&3(1$22#2#12#1!2!2&1#1%1/&1#1*2/-3%1*1%1!2/*4!2!1&2*12/0101&2(4&1#1%2#2#2,122&3/#3/022$4$40422*1&2#2!4!7)1/%402//$3%2+3)1(2%2201(2#3#1%1!101/!1%1$12111*4B.1///#1-4!102!1&z%5-201!401!1!1&B1#1*1$2#2*1/2107/-6/5)1)7/1/*1-4*1*110172)2#1*10A)1#	egR~B@@DLOAf^QPDlnlbbbTRRRVvfTTVbbRRtRVTJSDagc`WrLNOHimkUUQPQMTuPTDUSUQDU@TP@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.>S~x>xh.hxiS(x>x>x=.=xhS(xiS(S(x>x>.>xhx>S~xhxix>xhxhx>xhS(x>x=S(x=xiS(x=x>S(	=jzS:xzUSUviEsye8uQ:PVxc49DyR2U@iKGcqeZ434VeBdfV0RN7Jj3Km2V1A1k0FK43!V8H6cVVVF0	0QB!QF!RZ!aJ0Tk03OF1g07g013!FF120@Z015!Y03a0DV015!Y03a0DV01I!IV1M05V0gk! $4qkVkFeo4622j4NNRB2422lO4HC221FB6PD0VY3V8JD@4XFcRR7610F881F580VNVL75W0kZL720kF8D2G4cXAVFV8CS0WWVl5k8D49771soB520VWFZc4242VcRFA4WksF@30VkF4411@YKF8JH33WVsZP91WVc8F30VF@Ns22AJ10cFNg873W0cVD44X0FF8410FHNpHmA23W10dNP@62G88421WIGle5R4I80FVNkJTMD_GFcs428675X1Ve@D0VWlYt0aI30kF4VJ1111mgV8g4@7D_l0ZD410XX042235afGmVBL6o112m1s8D8l112l2V8D8N4YZ8g@20Z22BV8J4i223XW4D42W2WlLF4F2BB@Vlt08135Y5HswaE30Wl8s4gI6_VGNRJDKN4WNVZ4275m0X0G9sZC630884HB9m0WVRV8F4	!280k!F68!805!10FV!5@8!5NX!1HR#8m$4$8G#FHo!80Z!2GNk#Mc!26J!219k	/.1(G-10202/)3/)8$5$3&1/#3#1(2,1!101(22//.4#5//&4-3+4)4!1//*1!801/%101/0102/*2/6&2/01$24%1*501$412%4+2%2%302)4,1)1)1#11/%1/%1&1$108!101,107$2(1/.2(4)5+1+204-11&110101+2$1!1/!10z#205(1*301-H/6/$2!4%1)1/%1#1!C&102&2%12407&40102+2/!1&1/1(4.5&1%1-5(1$	emWZB@@NJako`D@hlbbTtTVTRbQTNbRRrbRrbRdtrZqIeUZfjjBXJJZnjj`@R@HAh					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=S(x>.h.=S~.i.i.>S~6s>.,Bd,)\.h.>.hS(.>.>S(.>S(.h*F0lF*S~0:(S	[vyjxrrzf:epHAHuhhQMKVhZgLl6U7go3t_!YbV2YqgyaapBN0o15cFgc5VaW2410VVXIFL0VW8F0	0PF!_F0zF03OF1g07g!qJ0Q01v!DF0@40t!3Y03a0DV018s0bV2W0DF01Ns0bV2W0B!t!6AV1104B0Y03a0DV% !1Fh1kWBFFSJYW0dBM8211m0VVGm5HA49X0Glp@@4Y4le0RP6433MVWsIkaK37Wd_GFB@7F@12kgV8Z5sc251J2VFgA826124m0BFo14WXNwFBI@m0WkRV8R4HC80V8JH@33GN8kZNc1Aj0H8F9B4FT0YFk8oeA21Fc8@22WFFJ231Vk85FRd2G12kZ@146@32YWccF11Wkc8633WFF4421VK1mXc4o@415lFg8a94W3Wltca6I24FX184PCZ130ql8G0A8251m0WVGpN8X5Z160t0FcDF4N2XF14488sB	!1d1V#8#20V#8F#J@V!44i!2ApV!Fk8!4BW#2F$@k#lZ#WFF!16V#56#b8V	(1/(11$701)2(15,1/,8$201!2$3/+1.4/1)1//(3.4$1#1//&1.2//-2%2201)1)12//,1$2-1#34%3!2//!1+4!41#2/103/.11(21)101!1%1//)6#101*2+1!9&1!3+2!1+1303%1#22#1$6+303/(1#2(1$11+1/1#1$o.1$1$301!1401$10F*102)1.1*1&1#201$102.7#1/$11-1//1//&3(5/#3$1#1%1%	e`\ZBL@IMO@igAkg`IABPpdLbdLRTtrbJbRrfTTPbegeSSwuT@QRu@AMTtQPKD@@					antagonist	NPY	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
^}.>)^xix>xiS(x>x>S(x>g-qq}Zy?ygw<U~ygygw<U~xhx>S~S(xhxhx>x>S~xhx>xhS(x>x=S(	;vzv;x:vyvvUzPtUfQtfEUUhVCDgrx6CEI_2Byi4KpfHLFXx2FCBu4fW0sFWC@XV20Z0d280IF@!V8Fk	0QF!mo0FF1D!C_07!Tk03Xk2W0DF!mF0uF3x!G10480Lk2d!KK0680OF1e0C!1Kw0NF1p0Ao0pV$ 0m0WkFFB6A5XW8o88410tco63257VFl0iE60WVR22A50VG1aF4R2Bg15FV8885410sV672WkFRD3110N44eH0VVNNtVN2FE0YbF8kCJ2@S0X0YmNs543X1FVGoH@95lkdRX2K8m0X0RV8w42320l8RH450W8BNPJ21kN4FT31W34wV8R4H32A3WtkNH583XkHAc4RU161adFFc8446aHFwL634XXF88@3121O4PC95_Vs9Fky28XVWVVNV8k474XswRBF8m0XkRV8J4LLCZ1cBDD97N8X8ORE8251m0ZVNWVF653	!1E0k!N0V!246!1Fe#V7#5V@#3pk!8dc!BW8!1FOF!4Lo!4e4#1gV#9k!@HF#W8k	01/+2)A/%4-1)3!1!102-1$9$101/.1201-12021-81(5%1/01!2&1&1+1/#1$2,2/%12%1/#1#1%201&101+1$11$2/010101%1%1011#2&4&10107#1!1,101#12/1%210102$1/1+1$1(201$1+2$4*101!14!1+1+21.3$1%1/0801/$2/!51)21(35/!1,2*11-11&101/%2!10z*1#1%5#2/C012.1(1)7!1!3!2!131#1*2/10402)12#2(1%1!5%4&1/$1/*1,3(7$1$1/02-	enU^DL@COHdjmhRE`IABPpdLbdJbRrbVTRTvbbrbJbRdT\|JZiYjh@JV`BJfjjjdb`zH@@					not given in publication	CXCR	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}LL}.>x>.iS(xiS(.>.>x>x>S(S(.>x>.iS(.>x>.>.iS(S~.>.=.iS(.i.>x>.>.=S(.i.h.i.>.>S(.h.=.>>xi..>	}ivUzvJnUzeuyXbehbsTBjrV51mcAGVu0QWmZ3Ml56UL8DoG9E_FWB10HV16c0@32FcpWkY8G0	0Pg!Xw0s!2R03i!C_06k0Tk032F3O0EN!qJ0Tk3x!Fh0440FV3O!HD0@40d03Z!G_06k0R03i!F504o0qk3q$ #O0Fs8BFA3Wl8N@22Vkc4632VVN84cK2VF8O5R6@5XG8FH220kkF8720VFG8cZ61X1swF242VVBB31W3lc44LVFB1FkNPB5VkF8gNLFX40lsN4482VFFR45120kR@50WFcGBy210VF8Jm41AVF8GCg@62WVkF4631kVNF42WFFF420VVF5Vgk95JFl0NVLZ3B2o8GJJ824WHFZ8312VcB642W0F4610eYKGtBD6210sc@650Y28824DDm0YVRV8J4T42Al1cGFF4443GFFD730FVBB410VFBB30eZ5F9BN34XFVtc@B5VVNF6288bt0FsDF4J2E2CXsFJPAZ13VZeFFRA82310W18cB83WVVB421W0NBB710VN9NcgE2_FVF6981GNB41C76WVFV6330kNJD22WFkBD22VVF4630g6FN88goF9WVNJ634WW84N4C9VVH9kFc9120sJRu221l8Z422VVGG94TMD5GNck42@6i0Xks8Z227333Yt8T810FF44LHA9k204FJ8554WFg@73WksR82CB0FHllBcf6W1GsdO4U1W0N44FE8i0YVs8k22@33W2GJDE2Z0NBcLJJD21tJFB@677oVwFc20W4GfVV8B413bX088693VGGRes231Xkl5V8V2113G2Wk4K@2GWcliH452	!110k!38$42!1RF#Z@#DBX#1rF!FY8#WF#8FF#Do!8FR#1n#GEk!254!259V	&3+2-1$E/!2!1*2*1%1!7%2#1(15$6*2-20101$3)1+1$1$501#2,3(2!2#1)1#2!1(1$1(1%3&3!4)2/1,1$2%1+4%3&2011*1#3#2$1#1%1!1!402//!1#2#5&1101!103$2(2(4&2)8/$204#2/$2$1)1(1*1$2.101/)1(1&22%1$1!8$2#2%2$7(21$1#202+1011#B1&1/0201#2011/+101+1!2,20z3)1#2)1301&1!1!J01%1)1)1/,201/)102!2/!10211!101#57/%1(401,1&1&4$2%2(5021!1-1&7&1%	eoTzAB@L@hjaXDBammS[P@czPidEPcIICEDdelddhlhlheDiddYdiEKCGHR^YUj`hHjijj`h@HHiZ@`ZH@@					agonist	Adrenergic beta 1 / 2 / 3	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
(S`*F*0:|F*FxiS(.hS(x>x>.=.=xiS(S(xh	zJup258F8V4F4F#N0_082m!F&LF05#1FV841WV0280904J0F1010F0V10224!4$2$1V0k	0RZ!aJ0Tk04NV1_07N0o!5RF1o0Bk0nF3o! 06F4D2O_W1kgV8w782B1O0_6F94A8261	!2X2V!108!21N#82#c1%8#F1#81%@!30N$@V#22#1HV#4F#V5%k	01/!1(1(31.1///02$6///%11+1!101&22/#1%1#1%1/01//0111#1#1+1.1!1%1/$3//%2/.1!2)1/)2$1%1&1#1/#2+1/////,1$1*1/,1/-6011)2#1/+1/!52!1/1(1*1+1+1/-31W%3#1#2/&51!F/)1+2/!32/-2/!1//$1$1///,41/1(1/	fluI@@HDddBTl|rjwxHXKhtm@@AAp@@@					antagonist	mGluR5d ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~S(xi.hxhx>S~.>S~S(.h.ixiS~.>S~.i.hxi.>>xS~x>.hS((Wdz.hxhx>xiJ}3px>	;vzv;x:vyvzEzSvzvjQyQzjirFDyMxeEzI5CTvyjk7zaMzhQwTyki4fzINAW_12pB8B314G408cGZ08!	0Xo0FF02J03d!Bi04w0eF03OF1v0Eo018g0YV2U0DF016J0R01v0Eo01os0L01P08g0YV2U0DF% 06F4D3Z10Vt0FsBC2482AXFWVtg494WXXsNVCmf23W5qtNBL6tKW1VW898u_1111cgF4@7T_X8NgE8251T0YK08g8T81WWlBNDBA0XX0tZu6G13XsNkNVhF0FN8NDBIPZFm0J44C20Xl_P8X6910kVkdwDE52lH902220lGGItB4626bksON2a20VFd042C9	!2bak!L8F!40H!38FV!Y6#1W@#2GF!8fF!4_l#8F#V6o#G_#OVF!hGs!@2#2W9V	.3(3.B.3!1#1(1%2#1!1*2*14$8$2//2&1(1$1/$4(3(1%2///-1//1!2//1,22*1%4+1%2$2#6$1$2)1$702*1$8$102/$1/!22105!103/$214/)1$1-2!101#1)1%1-3/.102/#1015//*3041%3+A/.102+11$8!2+1&1/%z.2/(4!B/)2+2*24/!3/!8/011$202)2%12)2/01)1$15#1/!3(3*1#1$3,2$1!	ejQ\LL@KGFbCL`IAzPAdLbbbbRebfbrVbbbbbaVxd\BaIQq`bHejjZhJjHhHhBb@@					antagonist	GnRH	GnRH (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~S~.hxhxhD{28xi(Q/j.>.iS(.>.>S(	mHPF2G81801k0F201N01080m04FF%HF050V0180841VV02FV8!40F0810k0V142X!4$F3F6!1c0k	0RZ01680OF1q0C!1740ik2w0C4016J0SV1v0Eo$ 06F4F3Z17Vt0FsDF4D3Z160gVHVdF4G3	#Y6V!948!2VN#12#V3$V8#14#N3%8!3F%BV!10V!1G$F0s!806#9GV	01#111/$101%1/1//10103+2$5#11//&1/%1$1&23*1/#2%2///%2(1/)1$1/+3(1/%1/-2(102%1/+12+1!1%101!2/1#1/&2/(1///#1/#1//1&1.201*3)101$2*1!1(1)62*1//)101#1//%W%3/)1%4#D!2+1/01#2!1.33/-1/!1/+1#1$1/&1/%1)2(6$1!1$1/,	fbmXB@FRUhw`RFQQIQJYHjIJgCVSf@Hju`@H@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~xi.ix>xiS(x>.=x=xix>S~S(xixh.=x=S~	zwQn6WOK0F4N0J2BBN010N2m!F1102!IFV50V#V969WV0X0V9!J0F0816l0V31V80V48#F20410Y0F0	0PF!aJ0Q!25k1v!@j0B#Zs0xk045k1_06k0Tk0 BV8g5ck241O0FcDF4627iW3FVx08LC141h60FgA82A1m0WVFs92V2C6VXFwV8N78251m0WFRV8V782A1	!104$VJ$1!1!V!42V!4cF!2Y4#ck#5c1%F!kAV$Z#14$HV!814!230V	/*24+2+1/.1/*6*201/)1/1/1(1$1-1#2%2//1//)1/+3%1-2$5!1!5/!2$1)3/03,1//!3&1//$101*3/+3#3/+1+3/#1#3%1-1/*1%3.41/%3/,2!1$1!5/3&31/)1/01/,a%3(4*101!1*F(2$11/1#1*1)2+1/04.1///,1/*4!12-5*2//	fncIbBFRuDqZ`bHsWlbbRftRbLTRbisKX@bZZBA`@PE@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
i.=.~Si.(Sh.~SF**Fl0.iS(:0.>.>S(.iS(.>.>.h	vzUvvYtKtNCw1J9EEN8l2O@c09F3cY48B3S218V!Pk@6FVW0XG4dV4oFH4X5310W522W8V49!VF2!80F480	0Ww0Tk02bk33!BU06J0Tk03OF1g07g01440FV1M09w01Lk0Tk2U0B40kk0 1Z120t0FVDF4F2wJ12kbXV8F4wJ13VgV8878241m0WVP1F8N4JJ52VVZFcc24_2VFNGFw26WO0FNAk4PJ@12Vk	#WVV!@8#B42!104V(8BD#P5F!@k#84$DJV!F1k#N_#hYV!GGg#3R#1kV	1#1+1%1+1!3%1//&2.3(8$1$1(102.1//013(301,1///%1/+1/,11)102//-1!1/1$2&1$2-2/+1$1.1*1*13&1/,2#1/$1//$101#1-1%1/!1.1!1!1!1$2206!1%1/#1//!7%7#1201//%1*1(1*1,1c%62*1/(F1&1///)2/%5-1/%1//#1$2%1.1/$3)1//0	ffspB@MFRCDrJJIHqQIZIKLxZw`ek@PMMTB@T@ar@					not given in publication	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.h.>x>S~S~.iS(S(.>.>x>S(.iS(/<t8^)D+*F0lF*S~0:(S	:UtzttUlJEw1LAEUN0k2P@uaCFLdW@84HzX74X42AkA4W1V22GZ801J9NVfb7v1WfJ8YV0J018_13J31VW0Fk	0WR0Tk025k1v!FM06J0Q01v!HD0@!cF3Z!KG06c0RV1v0C!1L40O01d0Ak0p!5FV2D0@!cF3Z!O10480G01e07g0bV$ 6ONFsA8281m0WkRV8J782D1m0X0I9_Z6C3m0VFRV8R782D1m0X0KQZ8g5ABW40aI88H4UOZVmcTF4D2BI82FWBHLO2716LFFZm2739ZolBB@H5m0W0RV8k4nA2C16ONGFA82C1BgY8OZE8241m0WkF	#b4F!O6g!738!15u#Xa8!6bN!2W5k!9eV!4C9!2F1F!aIo!4aZ!1OP#83s!D8Z!19ik	01#101!1+6.8,1#2///*31!11*3$1!2)1!1/#1&14&4/$1!4%4%2/05*1#1&2+2.4#1$101/01/21&101!1$3//&1)1/-1,4&302)1$1/$1$2$1$2,2#2#1%1/,1$3/1#2.1//&3101!1.201.1#2$1&1,1%1(A%12&4/#2!2)2!1&1!3/*1&m*1#2$1$1!101*8//*101$1&3/01+3-3#1/03(1#1$1-11#201$1/&1-8$1101&1*11-	egd^HD@BMHlbacm`HaRHrJJIQIQESQVIKQQLRVA^QM]GWPPTPPQUKTtQP@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(S(.hx>.>.>xi.h.hx>S~.>xiS(.hS(x>x>.>.>S(S(S(xhx>.>S~x>S(S(xhS(.>	}yxzUzUr:vUzijzZozxzCzUfWHMtMQmcmb9jSJ3ogEt6DUIm8D@vqaWL1IWMGZF3NcvX%	0WR0Tk025k1v!9_07g!lR0OF1v!C10480eF03Z02U0DF012V0FF120@Z014w0Xk2U0DF01HF0FV1309w0wF% !wg6WkV4NPB7_2VNB6B86kVkVcLF4@2384llkH678Vk8Fs22A@7bYkRB433Xk88ZVJp8XVVd4B2E61WAcNRDiC23W1oO4a11XFt1822B961eFNRBm75418NR9870kGW9gD_AVlGNB4BB34W398w8F838cINRH178VF8FZb82913Wk9BLD1WVkN8356Yk88ksLG2@Z1d4BG0VF90gf826143Fk42@5Z1kFF31VF9t0wH2H1YpFBs@@623PNNZBX@6XVVs8D22084kNNABaH8o8375VF8FRZ660eG1VNsE343XHlNRF3VkN4ZV10W2HwV8B4B329VkH@R64D7VY0N8cs2886L0WNF4aC3AWn846681WlsB4NLQ31pckJR10W1lkNZ8TxCW2l2N52Q4Wk8tB6288m0VkF8R8e3187rFFoM8241	#95V!584)2%@#1he!20n#FW4!4Z$8FF!V@o#V4#S0F!95c#J2!218V	/01/%K/%2/!2,3(11$6$6$2.1/1///2,34&1%501$1///&3/#1&1(2#1-2$1/(202$1101!31&2(1015/1/*4!1#201+105!1$1+11$6$3/&4%2!25.1/!4&4%1//#1/(1201031,1!7$4*21#4/&2!2.8%1$2/$3(1/(1!11/*z#105/#2$1%4#F01/!42&1*2-104%1%2/4032(1011(10103$109/0302%1+2!1&1/#201!1(4$1/&7-	ei[RLD@KHglYDdPH`bHRYg^eU^[eU~yeyXxl|fNvniE``JjjijB`bjZjbb`Dh@@					antagonist	NK2 / NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xix>x>xhx>g-qq}Zy?qqS~x>xixhS~x>x>S~xhx>	zJup258G8V4F4F#N0_082m!F&LF05#1FV841WV0280C24J0F1010F0V10224!4$2$1c0k	0RZ!aJ0Tk03HF1F0E401M40S03B0Bo0x!6NV1_07N0Tk3F0Eo# $m0X0Hcse782W84VTF8O71kVgI82E18okVsHKy462OV_J908X7Z160XKdwR8@4m0WVF	!2X2V!108!21N#@2#e1%8#F1#814$D!30N$@V!522#1IV#4F#Z5#F1k	/$1(1)4.1!1//02&1)2&1#1///&1!101&22/#1%1#3%101.1//0111#1#1#1&1.1)1/$1/$1-2/)21)2)1/(22/#1#1*1(2+2/$1!11/+1(1%1/$31$1(301/$2&1!1/$101104011//&1*4*92!1&2/01.2%11//*11b%2#1/,1!B/,1$1!2%2+56/!2*2/!2%22/,1$1///#1(41/1%101/	fnsHb@BBdUUPRBSJ{KlkK}FJtEL@DtpAEtP@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
(S>x>.(S(S6s>.,B)\.h.>S~.h.hS~.>.h.h.>	uJPl219G0F4F0F24FN010N2m!F011@!2HV50V02FV060VV0210905J1FV014W0VA020Z048!40204!V0Fk	0aJ0Sk025k1v!FM06J0Sk1v!GX07N0Sk3F!Gl07R0jF3I& $38271m0WFRV8k78281m0Z0RV8B782B1m0W0RV94782J1	#64F!124!2VN#m2#W$3c8!204#82%8#10F!FFV!8&8$kF$1%V	/$3/!1/$1/&1/%1!4!1////1$1(1/(2%2%3,1+1#1/(1&1/#4&2+2,21&1101+1(1/*101%3)2!1/-1/2#1/(1/$2/!11$1/,2!2.1%11.1//&11$2-13/%1/)2#1!1%105!1!3//.2.2%1/%Y.2*1101#2(G*2&1/,1!2%2/-101/02//02/%2/+1!1!1*4//#1&	fb}HB@FRtxDPdrmkrmkS`iN|gL@Pt@@@P@@@					antagonist	A1/A3	Adenosine (I Nucleotide-like)	no	gpcr-ligands_DescriptorsNo5Ht
*Fl0.hS(~O:0.>.>lvd,d,S(S(x>:0.=x=xiS(x>x>S(x>xh	:Ut7dOK9J5w0FAQUN01XN2s6BF091C10HsVE8X8HAk961WX0XNVt!R8Fcd17kHW91@VckK0101G3F31$k	0ZF0IV02Ik2l!C_06k0Tk03Z02V0DF01GN0Pk1r07c0U!6NV1_06k0Sk1w0C!1ag0TV2F0@!kF3Z& 038281m0W0RV8F78221m0XVRV8N78281m0Z0RV8k78261KDVW8LF4B2eS11k_PVX6A38dpVO0E82D1MhFXkGTP4H2dZFWVLF4B2MGdVVWJF	#YWV!S88!1VX!107#g2J!5g7#85k!ZV#24N!23%mZ#Hl#lt#9Ts!84M!2dFV	01%1/.5*1&2!1*1!2&1%2)12&11#4$101/)1/)1011)1!3//%1$2*1!1#1(1/%3*5/%201/01&101(3)1!1/////(4%11&1$1!1/(2014!2012%1(1*2/,2!1(6(1#1#12/!1/.111*2.8//01/$1!2%7//+1%1(1/%3/g.101/)B$2/%1)4)3/)1%3&4!2$1!101//(2(1/-1%1/$4.2-1,	figIB@LJuZP@cIEEDeDehXiTlbLD[WjmhIAhjh@Ja@@@					antagonist	mGluR1 / mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xi.iS(x>S~x>.>.=xhxiS(.iS(x>.=.>x>.i	<j;hyiz_qjyjhzhaULdrsO:vo34Ikpr5mqFclljqNbEA32YZoUgIVd0Ke30p9L5AkwGDY144_VR4YFG0	0aJ0Q!2jV3W!C_07!Tk03_k2N09g!sg0d03Z!Kk07g0_k2N0DZ$ !38261m0VkLew885Z120t0GFDF4D3Z12Vt0GFDF4@3Z140jJsFkA8261RekWFJco4E2ECH8NwB	#cNk!6F%6!344#66#7CD$JF!FY#8kF!2H0F#2o!404#GgF!87s!244!25@V	10101/.1012/02#3///@*1#1/#1!1.2#3.3%2$101/(1///$2#201#2$1!102///#2201/01$2//(1//)1$101#2%1/.2$103/+3%1!1#1%1&1+2///1/!101,1+2!502/)1!2-2/!4#101/$1-2(2//.b%6%1,101-H//%1)4/,2*3*3!1+1//$1///!11%201//%1!	ffsQ`@DAAPjSKSKkKklyiuhyjuUAP@`QP@ay@					not given in publication	mGluR4 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>.>S(S(.=x=S(.ixi.=S~x=.i.hxiS~S~x=.hxhxi.i>.ixx>xhx>S(xhS~x>xhxhx>xh	:Uvzv;S:vyvzUzRIUvvvzEjj_ZQRefz2E3kh@IAXV9bYqKFdL6Eo8DJ2HCgDcT31oV14X10211NyV0W8F0	0WR0Tk025k1v!DA0@!t!3Z02W0DF!qJ0Tk3x!FM06J0Q01v!Fi0440FV2d!Fh0440FV3O!F504o0qF3q# 01Z130WIFV666XG0c6211IGdcZs434kkZLFB3VFW9H84c215osVsJu411Y888cF6_CZl8JNNB232kcoF53WksJD217608B8c118VVN428BK231VgP84WFcF22B@0VF8610Y3Jctg46A3253NwB630kVB8LI0VYn10gH94XFVR852VVN8440cYkF88NaC6Xlkc864VkV4@41b33aA48B1121YYG4PA31VV82JD@m0WkQs486@3jWFVcHBqG42k8kVP0Z23W2HlBP96WFV461A80FGlVS0M4Y0cN@FC8G0_FV98Xh27X8VFFs4y25X4H8wP@91VN8ZLIZ11VVG0sZ73W1NcD320V882VGF93GNoL74XFV822B76F4VFZ942M20Zrk90C42280bkFkF2SF4GVR4DD7m0VkFVggC8W0VZ8210FN8saRA9YlkoH52W0F8gV1176F4VFcA8241	#94k#8J#4#1F$4@#5Zu!207F!cW4!14$8FF#@k!80o#18#13k#5L!211V	//(G,1/.1(24/$61#5/)2,1#2*2!1*2.1)4%3//.1/&1#1/!1/-1$121/)1(2!102%12(2201$1,1/(4#4!2/#1024(2$103#2$40201!1+2204#1!2!4//!404$4.1!1(26//01#32#101-18$4*2$4(2*1102&41#31#9*1//&1(1$5%1/(10z#102-101!1(1&D1#1*1/!1/%2#2&102.4!1%2#11(1&2#64#2//02*2#1/$1(5/)1!@&111#	ea]RBB@ALbgmEm`PH`bHzBNYCHhhlmEEhddmDdiDtihdlqpdUM]RsA@UMUUUUKUL@DT@@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
AIeIe]A]ShAIA]A]AIA]AIS>A]ShA]e]ShgMShe]_dgYT~AIOgDaab?UAIIeS>A]AIA]	[r<yzv:hzUznx:jUzxwpU7xez_nyTj7ojyvvbMrxqzeCDzZHIZcTkh9TZVq4fCWd@rk2GbY0lk	0Z80IV02Ak3V!8j0D#qJ0Q01v!DA0@40t!3YV2Z0DF!kZ0r03q!Fj03Z0s03l!KV06c0Rk1r0C!1Kw0Rk1r0Ao0pV$ 038241m0WkJfw8H4a1AW2cgBZP182kkHVsa4G384Fk48852XcJ2LKAUVXJc8RA8271B9mcwFR9G9W3FWKc8L4r172ZNFgDFR22W3kV8DI32G8J@94VIHlcJsCJ3GH8eJ4V3G6FlVZB4RW1613mkGRHV@WZlRV8R7827123kVwZG91VW9FZup91WVmOcsF52WlRV884T56W0Vo8C6XklOJgkRC3G0coKej24151cBXFBWlmFwG0492E44swFJ9Z110XlNg863XlFsN20VIHddokW60WGsf1c4528YkkouC30H2O6F482fAWXVVJN@27ZFlZV6771kcFg_0q71XFkVF612YGVR@741kNR6210VPOKBN97Zm0g663VXX1Hdo4422WVNVZC4WWNR86B@VVHOchLP8VlGFc9qN7X210	#D1F!S44!2BB#Ss#ZD4!5_Z!12LV!ke#41R#@NF!4ik!BXB#NU#V7k!D7Z#18V	$1*12#1/06&1!2!22102!1*2+1(4$13(3$7$8$1,1(101//01%2$1&1/%102+2#1,1//$1!1%21/,1,111$2%22(1#1*1!1+6/%1/!1*5%43,132+1#2(1!1$7$2/$22//)2#2)1/(3%1/#1.522&1$26$2/2/$3/#25/,10202)1/)1!1/)q2,11%1!1302&5%A#2/1&1$101,301/*1#1#4!1/#1!1!5%24,1%1+1$1#1)1/(2%812$10101*1.1#	elVQNH@LEKODbf`XDCAmgo`@cIIKDedieDhdbheEeBaILbjfeceh@JZ@`ZjjfhJ@@@					agonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.hxhS~.>x>S~xhS(xhS~h.>.S~|Fxh|`lv`|}\`|p3}\}\p3}\`|p3	vyQI2IOG8F5kVJACFNF1VNHH04011390V2PV50VV1Nk06F5#FV5!40FcV14WF110@VVc6$1AFJ01VFkk	0PF!Y!IV02OF1v!@O09g!qJ0Sk1w!Ce0@R0o!5NF1Z07R0U03L!Oc06c0Sk1w0@R0o! #38271m0VVRV8V78241m0W0RV8N5Bn5WWktcNX6D38cJsNZL274IBFWVk4J6AgW3kgV8Z5oe27W2kG_Z4J481BdIGB6759Y2kHm1m4I3OBVWkFNj73@1WVcG9yP27X1FN8@HC5GsFZiIZ130t0FcDF4P3Z13Vt0G8DF482A1AA_FGBBJ12Cf_FGRF	#70k!C0V!2V$2@#V4$F1#2_V$B!818#1cF!4FV#a5#G%ls!804!218V	#2(1101(2-2/!101/-1/(7!1&1%302,2/,1,3-3/#1!2*5//*2+12)1!1%11!12/(1*2(13*1&1/01)11!1/%1/5,1//$301&1!2!3/!1%1.1#102///2&1-1%1/01.91+11!1//$6#1$@01//01!1#1!1!1%1/+2,n(1/01$101(D$5)1/,1%3%1&101(4!6$1#1*2!1/#1/111/(1%3.1/!5*1#1!1/&2	ec`Z@@@@LBJ@ldTTRrTTQVrbRrcGFaeg`TWPpEAAQDt@EQD@@@					antagonist	Thrombin PAR-1	Thrombin PAR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>.(Sh.=.~S(Si.i.ix>.>x=.~S~Si.(S(Si.hx>x>x	zpUlMWOKdF4R0F2DTN0W2N2P!F093904LnV58X83FV960WV02C09V4J90V91Ml0V9123ZVL1085F0401VV0F0	0aJ0Q!33F2W0@F!sg0d03Z!GG06J0Q01v!SK05g0Q01v08g0d03Z# !O0FkDF443Z140t0Fs9F4KF141FJNFZ8n12WY0c8RFT2G@6I8wFL@JGbWFVo@275m0WkF	#lqV!H8#40V#@FV!Z3#40@!1@5k!8VF#24*2V#1V#1NF!W2V!224!21BV	//(3/%3*2/.1$6!2&2/+1/-1&1#2$103/$104////*1/%1///*2/!2///.2$101//!2,20201.1)3!2)1/!1(2-2*1&2!1//-2!1+5+101/$1)3/!8022!1*1.1$2+2+1)1/(b%3&13!1%1302-F$1/$1/$4)21$1/&5!1#11&1////1(1/!12$1%3//+	ffcqB@DX|d@QdTRTTTRRbRJMyvXeZjPBBAB`@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
l0*F:0~S.iS(i.S~.>.>S(xh.hxhS(S(x>S~S~S~.=xhxhxhS~x>xhx>xhx>S~	zrzxzdOSlo5w5F@UTN0l2N@u64F09Wce4TvV70X82OV160WX0XKV9VKT9FkGdSWHk91A2ZcJ91c55347WFV0Fk	0PF!_!uF03FV1E0@Z!t!d03Z!G204B0gF3l!K_06k0R01r07k01GN0PF1r07k0nF05NV1_06c0Tk3F! 0m0Y0MXV8V5Z120a42FF8H47pFW8KkB2331t0FkDF4B3Z150W4VFxFJ2624ZWcR6542VVkgPD8Y1cF83A75VVscHI8WlsN64A95VFNgD76XGsgB620FF82VGF7VoNog9660VG8twsc38Wt0G0DF4B3Q172FGVIk4Pc15W0FFFJ673VVgL@10kFB4VFFm0WFKvJ8T4nNW4kVkgBND_VFtFU82@1M9lkNJBu2MB7X8OBF	!230F!92F!2X6!1HB#c2#4Z3$gF!GWc!64@!1GW#C2Z!8mF$cF!9ek!DB4#Q8V	01/!1)1(B/!11$12*2&1/(1$404!1+3!2&1#1*11#41)101+11#3//1+1$1!2//11+11-1.10101(1+1/!1%2)2%1*2&4(1%2.1!2!1$3&1*101#2)101#1!1$14#13$1.11$1/$1/1!3,2$2011!11//!1/$2*12!4(1(2)1/*2)7//01/11/0101-11*q#1%1#1*2)101#@/$2*1$51(1)4$1(2.3!1)2*2032&14+1$2!1%1//#1/1#601/$120207-	e`\VLH@LBAIekm@a`@cIEELheEDmDldcJdi`pixTMuMSAPMQATDUUQ@@@					not given in publication	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>)^H)H).>.hS~.>.h.h.>.hD{28(Q/j.>.iS(.>.>S(.>O(,d)J63	=jxLxu7q5MSYlRJzk9DVL4NZ0V98BMS0514!Gk84lVV0@84C24R0k9650HFWl034#4#3P0k!703V	0Y!FF02OF1v!9_07g!mo0FV2d!DB0DN0uV05RF1o0Bk0nF3o! !40Hnge43926ONG0A8251m0X0H4JN345X7scFVA827132JX0J413_llJNc6L3m0YkQ0k8R4122HtsT@30XId8BLeAZVFlgNPvD1_FwV8R4	#Y0V#8#21$82#c9$8c$1$Y%2!208$2k#37#GFV!108!2V5!214k	/$1-2#B/!1,1/)1#1&1$5$1*8+1//#101#2#2&3+1!1&1!1$1.1//0101#1(1&101,1!1%1/$11$2/)1&203%2/021+1&2/!1&1,1*2,2%1$3(3.3/!1///1$1$1$1//-1,F011-3$41/22*42)8#1/)1(2,801!1//&1q(111(2-4(F$4/+1,1!4/2/$5-1/%3/!1$1///,31)1#1*1.2	egd\L@@FO@`DHdfyue]evUvVa`rrIKhXzyjj`@ff@Bjhb@@@					agonist	S1P1/ S1P4/S1P5 (EDG1 / EDG6 / EDG8)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
xi)^S(xhx>xhS~x>xixhx>xi^}w<~Utnx>xhS(x>x>S(x>xh^}}H}HxhS~x>	>xqxm7o5MSYnRLrk9@V60NZ!98BMS4516!GkN4lVV0@82C64R0k9650HFWl024#4#2H0l!783V	0aJ0Tk02OF1v!8_0Eo!mo0FV2d!DB0DN0uV05RF1o0Bk0nF3o! 03bWBD8H4m0Z0RV8J782H131XtgcC20H410WPj3F1t0Fs8_@b31kFlRPDS2A1O0GFDF4F3@B0VlNOeJ482m0aFRV8w4	#Y0V#8#21$82#c9$8c$1$W%2!208$2k#37#GFV!108#W5!214k	/$1-2#8-2#1!4)1&1/01#1&1$3$1/&1/,2%101#2#2&3+1!1&1!1$1.1//0101#102%3&101,1!1%1/$11$6/)1&203/(2,1!2#2/!44%1,1!5)1*2%1$3(3.3/!1//.214#1$1$1//-1,F011/#41/25*4*8#1.1)1(2.1!1//&1p(111(2/&F//01,1+1&2/$5-1/%3/!1$1/)2$4/#3(31)1#1*1&2&2	eod\LL@GOAkKg`IABPpdLbdJTRVTRrbRrTVTTt|BjZVvjj@Bfh@JjfD`@@					agonist	S1P1/S1P4/S1P5 )EDG1 / EDG6 / EDG8)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
x>xiS(x>x>xjS(`|v:~Svlx>xiS(x>x>S(	mHPF2G81!1k0F201N01080m04FF!2!HF050V!80841VV02FV8!40F0810k0V342X!4$F3F6!1!k	0WR0Tk045k1_07N0Tk04NV1_07N0o!4RF2v0Ak0oF0 !38271m0X0RV8w782@1O0ZaF90A8231	#Y4#94B!20N#12#V3$V8!214#s2#108!3F0k#DV#FV!1G$F0s#F4!29FV	01#101/$101/%11//101-2$6#11//&1/%1$1(3*1,2%2%4//*1/#1/.1/%2$3!1$1&101+2///1/+1,1//1//(1+1///#1/#1//01%1.401*2)1/%1%201)4///(1#1//%T%4(4/1%4#F!2/-1&1/2/-1(1#3$1/+1#1$1#1-1#1/%1)1(5$1!1//!	fdehB@FBdjpHaIe[mvUiqV`q`BJV@@`@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~.h.hspS~.>\}Bz.h.hhx.>>x~Shxhx~Shx>x	;n7ntKds5w0J2hTN0WXN2c1JNGd3424IkV50X028k9610W0eG0_VJJkIV815nFV552WVV412!G1F010W0FV	0_!uF03OF1k07N!qJ0Q01v!DF0@F0t!5NF1p07c0j03J!Sg07J0TV1v09!d03Z! #O0FVDF443Z130t0FcDF4F3Z13Vt0GVDF4D3Z16Vt0GsDF4Z3Z16Vt0HNA9Z4J2m0WVF	#aVV$4!22K#I2#g38!6VV!314$Y8!47Q!2F0V!F@Z!24$1VV!G@s!D05#G5V	//(3/!1//!1/4$1$1//01/.1$2$1%1/01!101(2(2//%1,3//$2,1#2!1!3$1%1%1//#1//-1$101/(1/&102/01)3%1&1%2&21!1&2&1////%21#2(2!2!7&1(1//1$101&5$2*3//+2)2/%1$b%301#1&1$101101!1&F$2(101)1$1$2)2$11&1/)5/(202+1/01.2#1//,301.2/)	ffsp`@DRT@jSKLj{vntyIQgIruRCA@@UP@@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(x>.>.>xhS(S(.hS(x>.>.>.>S(S(S(.>x>.>S(x=x>.>S(S(x=.=	;vzv;SzjvytvTYUNzftUUMbfaoOEtdgI2aHbW5ua9FCU4B01102c0DT3u02X242GFG#f1!80YX0X0G0	0b!vV02R03i!Bh02s0IV03Xk2W0DF016J0R01v0Ds016J0R01v0Ds01Xc0AF110480IV2d# %2F8GN6@9ZlcJHDD6VY2gV8V4F32E0W0VH24W18ZH@10kc4wNXB71oloJF@c15j0G0GV22B5GksRPDMO6kl8OBe3A4kkZRL214ZHVHFoP4E3QfFVcFZ24O0a2cw643YZ08o8PMZ11VXkJFZN32210VT@0_4VNN66BDJ0YrV8g8aK12H1B661VXWOLF4J261VVns8D63W0NZD721VkZB20W4GXaF462A12msWBV87WW0co_82KOVZlc90B2421ckVB844XkVZ441WksN82F7VFFFk22@L	#80V/*1c+d#4Z$8F$2k$5#G%5s(218V	//(@.3!2!4*2/.2$30120B$1(1&1/%1/!4*2$1+1-4/!2//)41%1$201#2/05//$4)1/02(1/#1!3.12!3-1$@&1/1$1*201%101$3+2%2.1%1&3/#2$2.2.321/4/(1/09&3&1.2//08//!2.3///v%3(4*1(11%F)101//1,103&2)2)2//#132/!1/.2/*2%2!1$11)3(1&1%	e`TTL@@DM@NglbbRbTRabRRtrafRdQVUUwsUUUAPTUT@PQ`PPdQTP@@					antagonist	Opioid kappa / m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
<FjFj`<`SmjFSm<F<`<`<`Sm<F<`<FS9<`Smia<_Rm:JRm<_Bg:ZS~9MI]9Y]k3SF<Ik`<9SF<9S	[r<yzv:hzUzvx:jUzxwpU7xez_nyTzbojzvvbMrxqziSDzZmIZcTlh9TZVq4fCWf@rkHGaY0Gk	0Z80IV02Lk1a!8j0D#Xw0s!3OF1g07g!sg0cF3Z!DD0@F0t!4Ak0t0D!wF05N01e07B0Sk3F!KU07B0Sk2x0CN01FZ0FV1E0CZ0xV! !ImFGR4128XK1k8Ba7Z120aZe828R0VaF89RN3Y23W8pt8BF7Z170sFG8B4D5Z13V_atN28D427mVoX90VVF4cqJtI0klF84F8CFa2s8JL414YKGsFJ9@V9308d422E6m0WkQs9062261sVGk84N4SS2Vmk824I5m0WkFdow89VVctR22K825meRD36CVFI844gFBZYkkkO8VUC21FsiF442RMXlc4JP@JVYkksOxJF40FFlBN4L9YnFg@DR7QfFW8F92EFY0VkVNES21182OwZ8F4Z70VcF54BF3kklN22J7m0W0GeGa65334XN44564ls42LIA0_0OBB54Ykco41B861WckD9230kkD@166I0GVi6H21Gd8J165ZVFkcH921GkgB9410F8wqTAHVkVZJP73YX1FVFA5210oD42VYI1c4695210ZN642VkF@2EBbVFl8XE51VkB4221FGlk22PE6e3FVP16630X9BkJ433kk826A9@B3c8FF82E7GsR@22109G422EAEGVVVFNiN5XksF4320mms44cN6D7Xck6B967DHcVFF812WkcVH64Wl8RH52WVF42ZRH	#D1F!S44!2BB#Ss#ZD4!5_Z!12LV!se#41R#@NF!4ik!BXB#NU#V7k!D7Z#58V	$1+2!2/!7&1%22!2!1)12(10201&3%4(3$9$8$1$2&1102#1101/2%1)4%6$1&1$3/102+2/)1/#2(1$1$1/&2/#1%2&2,1-1+1,2(1#1+1013)5&2(3#122/2&11!1$7$2)1+2//)2#1/+3%3%101,2&1+542$101%6$1/2$1/*1(25$11/01#10202#2$1)30201*1/,y2,11%1!13022%1%A03+2-11/0101//01#4!1)1)1111!1%35&1$2!1%11&1)1#2!1/!1&201#802$1#1*1/#	enUQNH@LGHlfaebXD@cod\P@cIICEEddTieDhdbheEeBmKNaieg`Uj``Rf`HFjjijBlMjKbGb@@					agonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xiS(.ix>.=x=.>.ixiS(.i.=x=x>.>S~S(.iS(.i.h.=S~.i	youpLZNG0V4F41#N05082k$818V!G#c!G0860W%424F1F#@0FV!224V48084F!F%F	0ZB0IV02Fk1D!9_07N!aJ0SV03RV340Bw!t40tV3c!DG0DN0u& !382B1m0WVRV8N782B1m0WkRV8V78271m0Y0RV8V782F1MhFX0Hxe442MhFWFFh637al8kRN4PAg11sYKT442PfkX0LF4J23H4JkNJR@@G12m1gP6750jJkOFB	#62)22G#12#V2$V1#1RF!GV$K#2K8$8V#X#2%V0V#4o!111V	//(6////&F%4#2//$2*4////2///*2//!2)2//)4+4/!2/+2,2(4$202.6.2,2$4(4)6(4$2%402////!62/(8*2%2+4!4/$2/(4!2&2&6&2#4////.2&k%6//$L/,2/,2/-4/)42/*2&2///,4//#2&	fcoHP@JLDhBBuRYYYvUVYw}VhmFmjBH@h@XBH@@@					agonist	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xh.=x=x>.ixixh.=x>.iS(xh.=S~x>.i.hxhS~x>.hxhxhx>xhx>xhS~	=dOSSoCw5F2UT8HFYN@P24!91j@02ek50X031kX!1X021VW0lD90cG0CVFF@3!l040WX55B07!V0F0	0PZ!Xc0IV02FV1D!9204s!WR0Tk025k1v!DA0@F0t!45k1_07!Tk055k1_06k0R01v# $CfkX0cF7362t0FkBc4JP141O0FN9Wa738XkFJBPCF@120Xcscb2XYGRV8B6JP24W9Jl8D8E415HWcPC33XGkFRa9C2l8N6415_F894k4HCZ30JB287411lcPK30Wc8ZDH2342G4c9312Hl8BiD@Y2FRRHD534190XA51FN8geL39_ltBV477VFGd0BZJ4_G0FV193ZWFVwXE93kc822A@5W6egB@6LQ15kkJ8ZB0W3lgV8R6J2GC0YVYAB8m71A1VFFBZ517Yt0G88Rc9C2FVB42110F881185Z0FZX78Z0VF441W0V84TN10_Z2JNN6930aJVFV35VX2c84aH4QalFFJR@O16ElVFZBFCFaWFN418@4O0FNDF462MIW1NWw8221kVdR22J@	$4V!10J)44#Z2#4aF!204F!sW#10H#20F#@Z$1#GZ#82s#JJ!258V	04/.3%@,1(8*2%11/&7*1$1+4!10201&11%1&1//2/204////#2,1/2//,1/!1/056/!2%11//#B&1/01&1/!1!103!8-1$42!1/$2.1#2/$2!1-1/01/!2#301*12!5)2&1/0101/*9-1)1(2!1/.2+1.30r!1/02#110101+B+2)2.4/#301/+2/*2$20105//&2(1$1/,102.2!22%101-	eo`TLD@ICBKH`HcjHrJJIIKIQSIHqQ[JQ`RYZBBJijj``Jh@@@					antagonist	MCH	Melanin concentrating Hormone MCH (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hxh.=x=.iS(.=.>S(.>.hS~.>.hS(S~.>x=.i.h.=.i.=.i.=S~.iS(.ixi.=.>S~S~S(xh.>.>)^S(	:UvzvzxzSxvvwvvUnQnj9s_yD7vZZ9OhDw66X2f@3GX084VV8J96D0c0DR3216q!M0k110e14F1NF1V!8!	0Z80IV02OF1v!9_07g!aJ0Tk02K03x!DA09w0t!31k1C0EN012s0FF120@Z0 #3R2V221H8goc332Wt0Gk852E39b1sG082D20Y1k8BX211WcJD72WFF86A2VV@OV22KJ5ZVNgaG30VNBcZ110Vllc8yIBYFkkc4223Z0G8oBC3XFkNF430V8442G@0VHF44Ta46_m1B8420kFB2NA10FW1qF4T24EZHl0@B@20X1k8cN46XVkZH920VFB2210F@O9B8E942cZ8520mWdLF4B3Z14V_pGcBP815XO0FsDF4F2324FNRDC5W0sR841VFX1G06C63lFkF72VkVB41D80FGOsFNA73GFZBA20V882RFDBI0VsGSZI3X4088sKwa2211VsRHO81ksBD30a4FF48JR11XGWkZ82WFF8gP11W2FF8Rs44723FwH630mWk422122IZeNk6@0VX10	#@0V!1-V#8#18Z$F$W$4F#8F$2k$5#GAF!858#1#211V	//(C!1&2)25&6/$1!401&7$6#25$3!1(2///$1//1/&2$4)1/!2!2/2)2,4//02#2!1!2!61*1&1%1/1&2-1/(64%1%1&3#1#1#1#2+2$4!4$102#11-2!3/+4#102//$1/!1/101#21/0H$202!101$1/&3!2(4(292//2+2//#2#2+z%5/%1&5%P$4/1.2/(2/)2!1/$3$5#305/(1/(1#1/%3#3#2/,6$2(	eiSTLB@KJhDC@@afPydAYCIICLedihhdmdeEEDdemiAIBj`\TRUh@JZjjjj@@@Jh``FH@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(}^S~.=xi.i.iS(.=.>S(.>.hS~.>.hS(S~.>.=.i.h.=.i.=.i.=S~.iS(.ixi.=.>S~S~S(xh	:UvzvzxzSxvvwvvUnOnj9u_yD7f_Z9OhDw26X2f@IGX0OZVV8J96D4s0DR3216qW8I0k010e14H0NFFV01#	0Z80IV02OF1v!9_07g!aJ0Tk03Xk2U0DF012s0FF120@Z010Z0Ik3O0EN% 19seG5XlX8nWN4D2Wb0cNJE82717@48NoN2A4m0X0F8ZF96WksRJ64W088411VJXPFFsHEYVckcN8D9ZHsV8410XWc84HL24Y1W0LC3XFNB21C8aVWNZF83WW0ZD920FNF22G@8dm9gP4552W214TO6VkFB2JC0VXHkNcP@7Y1NV@61VVGd4r8291MZ3VF626738NNFR@0Z2217otZ62542VFcsPV71VVB6JD0VY0888HP34YWOkR821FGFs42@A	%k)4&V#8#18V$F$W$4F#8FF#@k!804#GAF!85N!21#210V	/+2+C!2/!1/%3%1!3)2$B#28$3!1&22///$1/(4&1/&2///&2///)2#2!1%B1/!1%1/1/%1/$8!4#3!1(6$2#1#1#1#2+2$4(102#11-2!3//1020301//1/!1/101#21(1(D$2$101$1/*4(4(272//2+2//#2#2+z%@/%1&1%R/%1.2*4,2/)2!1)2*51#1%53/2/.1#1/*3#3/,6-	enU\LH@LONhDG@@cIICEBedihhdmdeEEDdeeMFndZRVUj`@ijjjjh@@@H@@@					not given in publication	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xxh.>>x(Shx=x>x(Six>xhx(S=.(Si.>.>x=.i.(S(Si.>x	zqQl6FOK8F4s!2BBF2V080H040F1#46V440V01%1V!4V0V040F#4V#5021041&60VV8FF	0_F0zF03OF1g07g!qJ0Sk1w!DD0@F0t!7JF1_06k0SV1r07k0o& 0BV8R78251BE20NRCVk21Y0wV8R4V2G882W0FL@B1@81XV88E5@E2VNcB88231VkNJ84YXRV8N4	#20V!908!4V8$H#Z2#44B$4$V$4c#1%2V#41#WN$Hk!804#18V	01//%2-2&4*2/.5$6(201$1/%1//1-1/*2#201/04)1!1/.2#1////$24///03$1#3!1/,154%1//!2.101401!3+2%1%1!1!1*11)2(3///-1/02.31%1-1/#3%11-6+1!1(2/*101#1/%11%1)h1-1)2202$101%I/,1/!1!1%2/#1)5/!13//01///+3(302/031/%	fi{qC@IVJXD`bPqHYEHXdimLhheDlIVRmGU@DSP@@P@@@					antagonist	OX1	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>.>S(xi.ix>x>.>S(xh|`.=|Fl0S~(S=.vl0l.i|FF|`|.=S~.i.hS~	;UvUzvQUjlYyzQYvGlXUGkgJ7njGc0Z7JVb4Ie6EFNEnSW4QMZ0yW48HVGl@X2Fh4PX0X496Ct2AkXF4YFGk	0G8!QF!aJ0Tk02Ak3V!C!440IV03_k2O09g01Lc0RV1n07R0o!5Rk1r0Ag0j03J!Jj0340FV2f0D$ #5RP462XZGkNVE8241AEVsJ6@D0VY1fN8cF280VWVwV8V4@I50mcJV920VdNZgZiDWY0s8cGJn3WX0kG8sE4711kNP898m0VVHRFP6632Cos8FF8aNWkN82BC62YGkgJ@4YGNJ2L9ACWWNoH369XGcF6156_ckH9Z4T916aVcFcK62DBYkWOZ4H9Z130VFkRR30XGskV90VIGFF247EA3Fd4H35W0cZ21B6aGIsFoA8261m0WFRV8F4FU@4W1WN4JAI80FlVR84JX13WJkFRF8@4m0XVRV8N4F126LkGFPhm4421Wd0s6265330HFBTOBW2WRV8c4	!371k!N84!6PB!1@cV!VTV!59s!3Hok!k98!4AB!2yck!BIk!2Y4#G8#c5N!854!2t9V	01$11*1/#@(1!4%1/(1&1(11#1#8$4$1#11-4&1//*2$1%1/)2*1/%1/1*1$1/$1///&1!2!101/&1)3/!1,1*41/%1/)13#1011#12+3,1%3%1&1/&1)10201$1!201)1*1%1/#121(1010114!101$1%2!1,1*2&1*6)2/$1#1-202-101/$1&l#105)1#1$2/B/-6/#2&21&101&201+101!1/*22/)1%1*106#1.1/!7/01$1,3%	ekh^HH@LBIMKGNj`@cIEDdeEdhhXmDiTnEKG@hfnmcjBBbjjjj@@ZLCBOBDj@@					antagonist	P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
oCS2pdpCoCod~;S2oc7CoCoC7cS2ocSt7CoC7cS2S2oc7C7CStS27cocStStoc	:UvzvztxNxnlofEGt0O2OLHF41A_390c@nX50VV1QW06F_W!FV565o08ZV1BW0d10@X4WB!8!1FL10V8F0	0Xs0FF02OF1v!C_06k0Tk03Z02W0DF!qJ0Tk3x!GE09!c03Z! #6F4F3Z15Vt0GsB56462m0XFRV8N62Y231GYkFc8BS28DVsFcG62B5CkVsOBuN4YFkkoO4CPW_0mCB8B4X6hFlNNo443VW10TF30ktVkk	#10V#8*2$42#51@$5$WN#4F$F#82k$4#9$13V!806#15V	02//!2!A/!1&1//+6$31#2&1//#1//$2/!102////)1////-1(2%12$1$2&2!1206/!1.1(2&2*102/(4%204012*1!1#102+1/1#1!1*5/&1!1)3//)1#1.D!4/+4*1!2$101$2$A+3//(2*1&2/#1%v%7/#1(1!4#N1-1//#1%4#2)2$1)402&1#30101)3/%1021/&1,1&1,1(2/,4&11$	e`\TDH@EF`j`IAIe]fV^~Y]{Va`spYY{z@BBBahFBJj@`@@					antagonist	NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=xi.ix=.=S~xiS(.i.ix=x=S~.=xiS(.i.iS~x=.=wkP(|Fs6c+~Yxix=	:UtzdUOzJxlQRQUII0IA8emi0225Z0882z26WVC9HVX0OYXV1FW306o0B02V0V6d0206404e102#4!W0F0	0PZ!Z80IV02OF1w!C_06k0Tk03OF1v07k!t!bk3Z!B90Cg0xV% %5KXBBL7Z13V_GsNeK13Wl8yF4D3Z130YA0FZA82A150ZktgN6E81lcNgD298m0W0Fu_c6B3112OBZI3WFc4cRJ7P@FlFN8N83XW0ZH35XVsB41E5bVmuFeD1331VFVH80WFcZB641kNJF61VF@NdBLIDZlcV2DC7a_kVsFFP9331FNLE3WFGVglDj4W11FV46C40VkB@A32FccF310k@F_A8231	#11k#8#24+8$ce#15$c#4ZF#10F#@V!84B#1A#10k!216#18V	01203*1!201/09!1,1+3/)3.61#2$31*2)1(1/!1#2$1(1*1(2/.1/+1/!1%1101,1(1#1#201$1/%1/$2#1%103-3$7//01#1$2&1/0301+2$1#102$3%304%1+1%3/,3$2#1-2/(201//!211.411-1.1/#1+4%301!3/#2//$30101/!1$r.1/$101#L*3/1)2)1)1/-2011/4)2%64.4%1///-3/(2#4*1!	eod\LH@LJmhDB`@cIIBhhddiidicLdemGKHlfmcej@@@HAbjj`H@@					antagonist	CCR8	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.h.=xhS~x>xixhx>S~x>xh.hS~xhzBW~\)ps3p}\qq~Sx>x>~S{cY~u9{cu9Y~{c{cY~u9	:Uvzv;S:vyvvErTmUfvUzEjz_VJSjjhMDbn_tLjmVk7fiKojn5@CBiLYm5gi1o5VX3K_F1FV!8iXVV8F0	0aJ0Tk02K03x!9J0Eo01540OF1g07g012V0FF1209w018s0bk2Z0DF01Ng0YV2U0@40t!6@02A08s0bk2W0DF$ 06F403Z15Vt0GNDF4@3Z130t0Fc8uc4H10YFwF9B42C2m0WkOdJ8N214Wh0Gf04L4o16g0GNFsPA3A90HVgR4F6451NkiA73YGk8sL35Ym8F893132dY08j35Wg0GfF4L4A72VmmN4cD2Wkm0sgR@DX1koRPD26Y09BDH220kR4NKBm0XkRV8V78281MhFX8JRu4B27BJkOVE8261m0WVF	#d1k#B)18F#ZA#5Vg$7F#c#454$F#V2k#F4#9N#13V$4!218V	.2/%209/%9/,1,@$2$2$3/2*3-1!1-202/(2-4#1/#8+1-1.2%201&1,11!1/1)3#20102#44!1/$2)1$104/!1/%201%881$3#2+2!1#1-1$2$3!82/&1%2/01/2#1%2(1//)1/$1$2(13//*6/$2A!1(1!3(3*2.1//$1)x%2(4*201-D!1/1#1+1*1&207/-8/!2/05+1#101///)6!11#41)10102,2-	ejQRLF@OLekdbc`IABPpdCIBrP\dLbdLRTVdUbbebRrfTRTDdrjfVQqj`@jjifjjZ@BJ@@@						NK1	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xdz(W3pJ}S~.=S~.i.iS~.=.i.i.>.iS~.>.i.>.iS(S~.>.=.h.iS(.>	:UvzvzyxSiznqOyUzPvnALUn99rgYC1bMnM@EHVGGllVJrYD9a6Ka4K_s@WV9@lcJ8V67NmG2Bh8F0lFgV0FF	0aJ0Tk03Z02W0DF012V0FF1407g016J0Sk1v07k018g0YV2W0DF01L80OF1r07k0o!5@02A08s0cF3Z& $8aH61W0gFC1_4XgV804FH92kkVL76ZZmFOkyS52_1RV8F4@f@bl2cX284520ZmVw686Z0W8sb8261C9oVO0C1427W7YWkBHE13XO0H0@28482m0XVJ4F8H4IAY0lts4PE15Xt0GF@284C2m0W0RV8N4	#f0k!18$V6!1GH#V1#18@$1F#f8!45B#1F#V2k!8J5#O$9KN!202!21@V	01/!1/!@/%1#1!2$1/%3+5*3/&1/%101&22&11&104//1//+1-1#110101/1$3101/+1$21$102/2%2%2$1#1!1$6,1//01#3)1$211/5!11*3#1#3&1*1//#2$4/2#3.10101//)102!1)6/)11105*1+1#1%8!1$1//0102/*1$1#1/r(2,1!14&1(H*1&11//%2-2.6&2+201-12.102&1/*1/.4,1#3/)	egdRL@@DLDn`FHdfU[VuvufUlbaSQsrX{Zyjfj@BZ`@@J@`hH@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
)[D+x=S~xivl0lS~x=F|.>`|xixh.iS(x=x>.>.>xixhS(S(x=.>.h0:F|0l(S	<rfzRvzKxM99OUSsWXc2d2YF080C16Ht05A8BFsq8ZO0XFas0h20JFF8c512O_102W8JJV!2F20F02W0FV	0Z40IV02OF1v!Bh04F0IV035V1Z07c015w0NF2x0CN01VZ0Yk3P0DF0u03q$ !3XlJk957X0GcqF4D3Z180d_GFBN6EAcHcF8BH6g30VkJ44JY141O0G8DF4F2rL0FlVOpJJ30lFscgRH51kVJH920FNBoV11775lNcBK70WW0ZV@94X0VZH84X0cg83D4b0W28LD40GN8FJB0VXXk	#74k!F08!161#4HV!V4#5NN#PG$Yc!2Wx#41F!2Pw!@@D!2OOk!c3R!1K#2tGV	*1*1)101$C/%1(102.1#13(1%4$7$3$1#3*1%1*1,1(1(6)4!2,1$101$1,2&11//*101&1$1!1/.2)2204/+1/*4/(2,1$6&1#1(1/!2!302%1$403/#1//!2(201&1&22!1%1%1%1.1*2/,1!8-1!1&22-1*34*4$1!1/$1,101//%2*1!r#2!21/*4&8*1/*6%3/(2/!6!2)1,15(13/01,1//01/013*1!21/02(2	e`T\BD@LMghDAI@@a`HrRPjJISISIIJKGJIJFECO_KUKUTEATUTjP@@					agonist	AT2	Angiotensin AT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>.>xh(Sx>:v:0qqg-*F*`y?}Z.h.>.>.i.>S(*Fl0.hS(:0~S.>.=q5S(.hS(	:UtzdzSzKxtQJAUUQ0GAN@mXDH1dY988HzX58V53QVe6F1X0XGZC21J1NZeWRlFW93AXZV6818ZF3FH!V0Fk	0ZF0IV03FF120@Z!sg0cF3Z!G_07R0Tk1w!KZ07J0Sk1w0CB01M40Rk1r0Ao0pV07JF1_07B0SV1r07g0o& $BV8F5R2EQ0YF_nN8N5Z15Vt0G8DF4823L16L89N82J4MgFXkF4c7Z150t0Gk8kH4@7WcF4310Hn9NoVE@3GNF829BZYXdFg8H90kWskso4D1mN8RaD9J7W0oJDAZ150t0Fc9dm@3X2l@N8cX282B5ZsVB@J543WdBPC4Vkk82LNA	#60k!I2B#VQ#DXV!VBF!1kD#@GV!ceV!BWN#1N#5Lk#4D#11#ctF#34#18V	/$1.1!E/$1.2#21/.3021#1$11/#3)1(1(11!101#1#73)1$1011*2%1#1101(1&1(21/!22&2#1!1%1$101#1!1/(1)11/#1*1%1/!2#1/(3)1#6#1!1,101)105-222$1!301.212#1#1%1%3+1*2,1$201/01)2#1/,2$1#1$3$2/1/2!101#11!1&1!C02//!1.401$1#1#1/#102%z#1/%2!1011!2$29/$1#1)1&1%2&4,1/401/(1(15*2/1/#1#101&1/%61!1$410101,1-	el^VH@@DAIFim`LbbRRTTRRRJrTTTRrbl\|BrJVv^AZfjZj`BjA`bbH@`H`					antagonist	GPR4	GPR40	no	gpcr-ligands_DescriptorsNo5Ht
55q5.ixi.=S~S~x=.ixixiS~.=x>.ixi.iS~S~.=xh.iS(.=.>S(.>.hS(.>S~.=.i.=S(.i.>.=.h	=v;x<vQErSnzfvhyEbj_oFOjhx2@YPfNHsmcta@aNJ9IgDN8DK3H0Da_Z21F0I0j14H0c8VX21#	0Z80IV02OF1v!9_07g!aJ0Tk04AV110480eF04Yk2U0DF0u!52F1204w0qF3q& 094_HFgF641FF4gPL4@6mVsF60Z2H7PZ8B4G8W2b0c8D852_WdoH31VVk8gNLM5eGVNJJ11VVkl08421Wl8sJ942FkB421c4V890420WY56ms8F4G5W43VoZB45Y0VFRH46XG0VB43X0V862G7VFGeLF4D224XVtNJ83XFsJ61173nW0wDE7YkVg@21_Xmlmg8946_0GFZ4DB11I0FFFD81WWFkD630FsB6210V8421M70FGY8BFI7Y18k8620V884RADm0WFKAg8D433XGe0N520Vk8gP30W23I88xiJ25WW0VJDD7Y0cFD71W0V42VD0VXoF	%k#4$4$@F$8F!1BX$3F#Y$4F!18FF#Ak!80J#OA#85N!252!250V	+1/+D/.1,2)3.H#27$3#1&2+1/#2!1/1+1%2$3/+3!2/%1//1)4-1//2!3)161/01&11)2$11/#113%1%3)3&3(3-1(2+2$4(2%1$1!1%2!3)1/%1%11.1-2!1%1)1/!1$1(1$1!@$2/,1*6(2(25$1//(2)1)1.22012+z%C/&2%1%T*102!1/01!2)4//2&2!1/$611!1%63/3$1/%102//3#3*1/06-	ea]\BH@LBmhDGo`@cIICEEdhmEdeidlhhmeDehyeULlsrmTDE@PQUUSU@@DPRT@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
63=x\),d)J`|.>6s6sS(.h`|.>S~.h.hS~.>.h.h.>	zxUnpXyRt9JEG!iNC8dX84AGGN0B0102HH05N0810k0440V0ec0904JF1881G2081909!402(1!VV	0aJ0U!2ZV3r!C104F0TV03OF1v07k!lN0Pk2q!FL06g0TV2q! $1Z110t0G8A84Jm141O0FcDF4D2OBW2qF8VE8251m0WVRV8N4mmBWWVn9_Z6B3BaI8Nom2A4m0W0I9Z8TO630lFf9Z4@2	#V0V!4%2V#10V#B#48e#2J$X8!208#J$HHk#43!2GFF!BA8!2F6!2d0V	)1/-9!2/2+3,1/1&4*1(2/!1////$3,1/&1////%22)1+2//*1/)@!1/*1#1(1&11//$1+1(4/!1%2/,3!2/$1/#3(4///!2/01%21//&202#4%1$1/02/,2!3*1/0d//+D*3/#1%1//01.19021-104)1/&41(21//*1-102$1(1!1.1&	ffsaB@LJ@DYHhideDYdidbTdXLRujVjZ@@@h@@@					allosteric enhancer	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
~UH)b+w<.=}H.iS(qq^).=.>}H}H.iS(^).=	zJup258G8V4F4F2!N0_082m!F$20LF05#1FV841WV028V90JJ0F1090F0V10224!4$2$1!k	0_!uF03OF1k07g01680OF1q0C!1M40S03B0Bo0x! $6F4F3Z13Vt0GsA9Z4A2BaI8O8m2F4m0WVF	!2X0V!108!21N#82#c1%8#F1#81%e!30N$2Z!822#1mV$k#V5%k	01/!1!1$1)3.1!1)1//#2$6////#1!101(2/#1%1#1#101.201//0112#1!11#3&1.1!1%1/$6//%2/.1,1/(1%1%1&1*1,2+2///01//*1$1*1/,1/-5011)2//1/!4#1/1(1//%1/,1W%3#1#1/&51!F//%2)1)1/-2/!1$202(1/#1$1/*1//031/&301/	flup`@HDdCrTl|rjwxHXKhtm@@AAP@@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
h.>xxh.=S~x>xixhx>xiS~x>xh.hxiS~S~x>.hxhxiS(x>S~x>x>S(x>xhS(S~x>x>xhS~x>xixhx>xix>.hhx	:UvzvzxzSxfvwvvUYOnj9sryD7fZZ9OhDw26X2fA3GX085VV8J92D0c0DR3216q!I0k010e14F1NF3V%	0Y!IV02FV1D!9_07g!aJ0Tk02OF1v!DA09w0t!31k1C0EN!kR0IF3q!Fi0440FV2d# #@aFt4q20YYlosNZ_4921WNJ@92VkNg6511kNJ422VZms42239f83HZB@624Z1G4VB510OGB22EAm0YVLXZD6B312l0BJC4XFsR691VYXk824I0VYJRV8R5Fw23W7lmBR8A0VFNNNU82E12XW8o@921FsRD221FGtJ42I0VF8NxB8@6530cHDF2W0Wc84LJ25XGVcTB211NFga30VF8Vsx4IEYk8ccM82713XW0gD74W0sV6311VGtJ62I0VZF88x84C76XNkBDF2VkWd84N@63lNo@260XmN844F0VYYgV8Z5Hv23W1kcVRE@ZVc86JJ0VYXt8wN6F3_6VVVGhPS351VWFkeK62Gm8F8236VkG9N8ND9_2FN8210HldN4BE8aH8g6FC0VFNNZh22JDdFX0NB253XkcJB63WVkV422VkPGR@2K0VVXF44Vg10W1Nka@5XG8B24173VF8kw424WWccB@41FsJ@610Z2F824DHm0WVJ88su_25WVVsgHF7310V820VFGks42A0VXJ0	#@0V!1-V#8#18V$F$W$4F#8F$2k$4#GAF!858#1#211V	//(C!1&2)41&2/$1!802&2$2#2A$5!1(2///$1//+4+4//%4/2)4,8//02#2!1%41*2&1%1/1/%104/%8&1-6#1#1#1#4+2$6(102#11*3!2!3/+8#102//$1/!1/101#21/0F$3$101$1//#@(2@2//2+202//02#2+z.2,1&A%N$2/1.2/#2#2/06&2!2$1.3$@%5/(1/(1#12/02&3#2/,6-	ec_TJD@DchDOiUP@`THrRPsIYQQIISSQHyQQ[QIYRBRQYK[L|kP@UAAEUUUMP@RpQ@iP@@					not given in publication	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
96_.-[96pmc02r96-[u@zW(D-[+.f196x_p9-[96S,_.-[p9x_Gx96-[j4	?v;vzy:rfzy;M:jv:xUxx6zvxInhjzpOqUUxU7fnwvfh7ylPs67HocSRIAQHzUSBw_fqR2010	0UR!ZF0Tk02OF1v!8d0D#b!vV04OF1k07g0vV05@V0j07!Tk3d!Nd02c0Ak110D!xk0@@F0e02s0FF1204F0Ik1v0@Z0s& $m0WFRV8J78241m0WVRV8R78241m0XFRV8Z78251m0VkRV8B78231m0W0RV8N78281m0YVRV8Z782B1m0Z0RV90782A1m0XFRV8J78291m0Y0RV8o78271m0W0RV8V78231m0WVRV8c782@1m0WkRV8R78241	#cVk!FF%4!25_$4#392$HV!Ff#8Vk#@F$Ho!805#GgF!85s!24#258V	!1//01!B1/02!6/$1/%6#5$4$101///,1,3(1/(201/!1#1)1%1!1%3/&11/2102*2(1/-1/01//%102$1/32%1/1$1,1(3$4#2(1)2(101-101(2+1+2,41!1+1&1/#12%1/7/%1.1&1/!A,1&1&1%2*1+2*1)1,6#r%6$4#2*1.B,201*101&2/!2101!1#101/!2$1/1#1(21.101,1/(102/*2)11!3$1(1$1(	egbXB@@F`NOEdfZYUYeUyV\RQSPrpkjihZ[Xyjjjjj@J``hJCCB`PbP`@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(xhS(.>.>x>S~x>.>S(xhS(.>Q7.hS(.>.>S(.>S(.i.>x>.>S~S(S(.i.hx>S~	:UvzvztrSxnvwvQ1vIIEseoy67fh_0Nd@xM5dVYcH8e2F_HV1F3286o8TL226Z4W0H0q41Z2F8F01F0V03!F	0Q8!RF!aJ0Q!2OF1g!DF09w0t!4AV110480eF05@0110480IV2U!OG06!SV1v0BF0o! 06ONFZ84IP50scsKcLC1WVwV8N78251M738NgBN7@aXFV4DJ0W0X1956O923Vc8kL2Y2410GdJqN3VGm8884C96229RXB10m2N844F@7c3tB22663Dp8FV8RJAc0k8NX20W3HB8B8F5Z11VXAFFk42@3113st2D0YYlwV8Z42913XVcT651VN4ka2186WkG4ZA7X18V420a4Y0Gh@5@1kFt4T2L60G1F_NR4422ikVkc@E5m0WFRV8J44J713skB90ZZXF	#74F!13%G!1F8#V@#50e$4V!Ga$48!28FF!G2k$B#B8#1Ys$Z!212k	-2-2*B/%2/&1*1,B#26$1!1/$4!1//$1.2/01)1/)1/.1$4(1/+1(1%1/&81&6#3(1)3&2#1.1$1/(6&1#202)2!1/!2$3$2&21#1)2#5!2!4/*2&2///(1#2/$12.51//,401%2%2!8&1#2.4//-1&22.z%6*10101/!20L#2(2*1!2*1%4/)1$2&6!2(2%2/$601!212$102/-1#1/-1#501-1$1%6&2%	ejYZD@DDECHa`OEI|{HhhhdhhmKCLeeEEDdeiGC@fn`\TRVjBbJbjjj@@@H`@@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xi.=x=x=.=x=.ixixi.=S~x=.i.iS(xiS~x=xiS~x=xiS(x=x=S(	?txmCnp_fElt0pXN@m4V1@hYAcBBMV108c3Gk@2OW!2KV4X5F90l!@!hA!@412h086040FV01#	0WR0Tk025k1v!9_07g!co0xk035k1_07g!o40FV3O!DG0DN0u!32F3O0EN0 !382A1m0WFNk8ww2A2m0WkHos8B5Z150XHX06Y572d80FJ8NCBX2VN6DE50YFF8c_9025W2Jdsi8J4HF0WFFoeH@VkkF662_4HXCB8X5Z130t0GNDF4@3Z170t0FV8R4NUH6kl0VR4Y2CW3VwV8N782A1E0Xsk8VA8241HF0WsHH04K2m0WkF	#BZk!40J#4W#HVk!WV#8Z3!28OF!JV#1VF#21F!V8k!8cR#G7#cWw!@52!2K0k	!1%1/(1$@!1/%2/101%1!3&1&6$1$4//1!1&1/)4!2!1,3$4(2#1/$2$101*2+1/&1/!2//%1/#2%4/)401//)2$302%103%203$1(3$1+5(2-4/#2*1///%2/&1,2/!1!4/2.1!101&2!2.9+1///!101//0l$152/!1)1041!D/!2)1-1-5+3/04!1/&101!1#231/$3.2(2/-1#101/,3%2&	fkaS@I\EEKPQA@cTQdTTRdRLVRbNTtRSEAsl|DBqUTuS@@P@@					not given in publication	mGluR2 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
Q~tn/jx=D{^}.=xiS(x=x>xiS(^}w<~Utn}Hqq^)}H}H^)	zrUtUtOM1J7w0H@QEN0W299u6BFJ1V!4Ls070X!8084WWX6HJZ840B8N09l5k2VW53X024010VF3F60V1!k	0qJ0Q01q!GX06J0SV3F!Gl0Ag0j03G!KE08s0bk2V0DF01Z80Ik2D09w0c03Z& $6F422O_W3FY88xZO261Y4kGJNP61ZGGWZm6JBVZWV90M8271m0X0RV8V78271m0YkF	!1Y4#O48!20P#1H#aA#4V8#14F!NeV!408!3F%DV$V!1GF#F2s!204#9NV	01#101/$101&2.1//101&5%2$6!514$1//01/%1$12&3*1*1*1#102///,1+3)1(1-1,3(1$20201+1///1$2(2#1(1&1$1//1%3$1&1$1-2+1///#11/!1/&2/2.401*2)1/%1(2)3.2+1/(2!10101!1//!c%3(1/1%4#F!2/-1&1/1,1/3(1#2$1/02)1#1!111/#1!1/%1)1(7$1!1(4/)	fa{y@@DXL{p\`rJJJJUJZYYQITYjpXmzuU@DTl@DP@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
}^^}q55q}^}^q5q5=.i.)J63~SO(0l\)i.ix,B,B36|F0l	<TbOKdL5w0GEjuR0lVNPHVBN09Yj80LQX78a0GQo96H1V0YO0CV_Jk0Vw1Rl0l31fX0VK5!1F1JF10603V	0WR0Tk025k1v!BM06J0Tk03OF1r07k!t40tV3e!DG0DN0uV05SF1r07c0U03L& #BV8N78261m0WkRV8F782@1m0X0LQ48H5Y0W2FgV8s4nA25WBkGY44J4UA133GJ8H8OBb0ltJ4P8O17fVGdk4L7Z11Vq1VFk@FR261L1VG0A82D1m0VkRV8F4	#24V!K04#VN!102#y0F!2s@!261V!FXJ#GB!25BF#FZ#4$10V!1Fk!2FX#80V	//(1011.2/-2,1#1!4#31$22#11/////)4$1)1//!1/*1!1)1+1//#1!1/!1/2(2/#31/+2%4&2/$1#101/5$8%106-4#1#6//,4*1*1/-2!2+2%1.6/%4,1/,9/&1////+d$23/01/!D/#2/$2!1#31&1/(2$901/$2+11/1/%2//-1$2$1#1/+	fak`Q@IQSUhH`dQdTTVVTTTRbRaYpsb}``Ji`fA``@@					antagonist	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xhx(SBz~W:v:0sp\}*F*`.i.=.>S~S(.i.i.hS(.=S~.i.=.iS(.=.>S(	:UvznzptKhw3JACCU8l3OPW0BFIdY48DIxX5@V1FP_A61kV0XO49V4pFNZeWMl1W17eW8V51!VF3J010WVFV	0QF!RZ!aJ0Tk03OF1r07k!o40FV2U!DF09w0t!5RF1n0Ak0jF3K!Og07B0Sk1v07k0pF0 !6F483Z150t0Fk@284B2Z70W0LF483Z120t0FsDF4P2i6@FlkR84NX14WFkH08VE35XAXVGJZ2H7VYl489ZNJ431FdB82E7X3kWV4V474m0WVRV8R6PM25WCkH1Ni4A3m0XkHIBV6@7VWGBV8J78291m0YkLsSB6F3m0WkRV8R78261	!1r2k!A8#4V9!3@I#ZX#4@B$j#WV#24R!2GJ#VPk#4_#9c#1vk!@W5#AKk	(102!1/)8/1/#101/.@$201!1//(1/$2&22//%1/&2)2/(1(1)1+101//2/&2#1&1$1*1301!1&1-3/,101,1!21)1,2!11#1*1/1//)3/$1)1&1%3$1/.1+2!7*1*1*21*2(1)51.1&1$3/%41$11/&22(3#q%9-1$2#5103$1!H$1)1/#102)403//%7$1/+1203&1/%1,1!1//%6!1%41/+3010	egdVH@@DFNEBj`LbbbbRQRbbRRNTRPdbfcdVSQusUMTtDaqP@U@@@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
eIS>e]eIeIS>e]gYeIgM_BT~S>e]AIOgeIDaab?Ue]S>AIIeeIeIS>A]S>AIeIA]e]	[r<yzvzjhzUznx:jUzxyrU7xez_nqTj7ojqQvbMrxmzvCDzZHIZcTFj9TZVq4ACdd@rk2GaX0Gk	0Z80IV02Ak3V!8j0D#_!uF03OF1g07#lR0RV3F!DA0@40t!3YV2Z0DF012w0DF3V0E401Kw0Rk1r0Ao0pV065k1e0780Rk1r0C& !BV8F5aJDWX0wV8R78271_VXI88R9qH9W11cWJo4DKWVVNcJSL25WFo8FJ8RHHaVVd4M8211m0WVGmJHT52X1IBg8F4B4aVlsCF33X2WtON66B3PVZ39N8N6ADYFmkcu7393O0Fs8ZPL4320s429@4_FH4k64C3@hFXOc4X6q1A31NG4i2E4E410Og4643Wk8NcIZ16VXWNNTA3VVko494a5n2c9PN2I1VZFwV8N4aBDaVVR6D77995cNVE822161otBR8673GIsFJ8aL91Y3FF8H@13Y2VdJLA531k84JG@2Xl9J454W0kVB530IXOm0cZ5X21@VFN663m0VVIHoc80XYGHvRg673F2YW8L@85@bFVFgF10X2918NL10VsFP750XmWTF4824BY2tBN3143H7Hc8T4LJd0l8NsqMBXFFlFOFw2210Ft4R58428861A65VWFoLA9Z18F@JN@421VZH93XW8JD21VVGtVwDsCXW10VJsKG0WFkZN	#D_F!SB4!2@B#Ss#aT4!5_Z!32LV!kfc!41D#@NF!4io!BXR#Nw#V7o!B6Z#98V	%201&101!1/08&11$2#3!1)12+1-11(2$7$5$1/%101//01%2$11/(2#202.21,1/&3%1%4!1&1#1/(1,1&5%22(1#1*1.6/%1/!1*6&2,102/#1$1!1$6$2/#242*201&2/#2-1/(3/*1)1$52(1$24!201//%3/#27/,101$1%12)1$2(1!1/)q3,1*1302-@#2/1&1$1012)20301$2/$1#1#4/(203)3-1%1/02#1)1/(2#20712$101&2$1.1#	edZ^FH@DLFAEGCkOLamo`HcHhdhdeECLeEEdeLTeQpihdTm]@DUTuUPTCETL@@@					agonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(}^S~.=.iS(.=.>S(.>.hS~.>.hS(S~.>i.>..i.h.=.i.=.i.=S~.iS(.ixi.=.>S~S~S(xh	:UvzvzxzSxvvwvvUnOnjdt_yD7fZZ9OxDw26X2fD3OX08aVV8J96T0c0DR3216qV0I0k010e14F0NF0V11FV0	0aJ0Tk02OF1v!9_07g!dZ0ak03Xk2U0DF!kZ0r03q!Fi0440FV2d# $2B4eQ7_km8YdJ462m0YVNto8D4k66km8o4T8qB5VkVPZPS70lGFcgD43Wl8FL850kNR820c5089822CH2YXNwgA20kN44LB0VXY0VgVI83FVZ64@70FGONggf36_kGNaF4D3X111kWXsk46XXGFFgDA5XHkRF41VVGd422EDFZ3d0B@@53W0scF64X0VkD43VVN42XIG2WXVsq83VVl8s42B10XXl0ZTG82kVZ630VV9cg229Dm0XFF8NBA7XlsZH62VVGd422ED	%V)4&V#8#18V$F$W$4F#8FF#2k$4#GAF!85N!21#210V	/1*2+A!1&2*1/,1!4.B#25$3////01//1/$202$1///02)2!3&2//!12#2!1%B/#1%1/1/%1/$8!1%42-3#1#1(2)302$3(102$1-2!3/)4%102#2//1*2&1/!1#21/0D$2$101&1/01%4(4(27//02%3$2//#2/z%@/%1&5$2R/)1//$2*1!4*2!1)2*1$5%34//$1*13!1/*1#3/,6-	efU\LH@LKFhDC@@cIIKDedihhhd\dhhhddlIHeeTuBScRm@ASUUUUT@@@E@@@@					not given in publication	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
\},d:0~S(S`*hxh.:vF*0:~S~S(Odzi.:v:v~Sdz:v	:UvvnzvtNjnlqAAGl1tX9PVV41IbV98g4K2010e2Ik21ty149J45i4kB08V!20Wc454020d81u1F0F!18!	0p40OF1v!B90CZ0xV03OF1v0Eo013J0FF120CZ$ BV8V78251BmkW0LF4J2n179GVFRE8271	#10k#8$4$F+B@$1F#1%F%F#@k!80K#G3#10s!21#271V	/2/&5!2//)1)4/$2$2///.2/*3+6$12$1%2/!101/(1/02///,1//-22/$1/(3/3$4&1)2/02/$2#2/#1/+101/#1)6/,1/&1(B/.2*12)11#2!209///$2//-b%5!2!1/&2%F$4/&1/$1,1/+1)2*1$11$13/&3///#1(1//+	ffc`a@LPP@HkHYIHXhhdeCddUZlEIUj`j@@HhHTH@@					allosteric enhancer	mGluR1a ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(x=.=.=S(.i.=S~.i.iS~*F*`:v(S5q(S:v:0*F`|*`	?xzvxEzRLENh9zet8UeXH1h39@j2TX580G33G6a!1V_V48@Ha9Vg259VN89I2O4020c2o6#J!80V	0d80xk03OF1v0Eo016J0TF1v07k01Hs0FF1204s0eF05O01s07Z0U03p# %qVG66542t0FV8dX4E7ZkkNgKck26W3XNFTF71kVF61A85t0GFDF4J29I3FkZV80Z3mBV8N78271	!2@0V$8$2#V0V(102$F#FW#40N#9F$kk#46#G$B1c!802!211V	&202*1*4#1!9/$1/)1)6/1131#11/*1-2/*12!11/#1%4/&1/1%1#102101!61#1/&11*2.1%1///.1!4%1-2$2-3#4&1+1/(1202#1$2%2/&1#13)1!1//011/(1//!2/3&3/$2)4*2*2*A//!1$1+2$1/-1&10l.1/+B$2$1/#1!1!1+1&5$4-1)3&1$1+11)2&1///01!101&1$2(1)1/!1-	fmo`a@JrbBPYHYEDeDYhdiedeEEScoQRM\@QL@EMUUATFd@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.>S(.>S(.hS~*`lvS~.>~S:v.h.h.>.>.h.>S~.h.hS~	>trxuay_qhDyw1tqCHumoFGeYd0cSn2WBXX1OkO5mz14d20CaZs_NRl0HH0c54E2Z26969B2HVM0@X4G0	0R4!Ww0Tk02Ak3V!BU06J0Tk03OF1g07g!t!cF3Z!Jj03J0G01v0D!1J40FV130@40u! #2Ky4C22XmOFZA6Vk98Z_Pb81W0wV8Z78251I0XMk8R8B47Z1FVR941VN4kLNXW130gV8R5BKJ1YFlIK@6E3m0VVIGBaZ422BLNFR8FQE911NVJ@B7XksgN73Wk9VskAE81YkwV8g4DUU1ZFwV8B4JqH1YkwV8J782@1DXFWXJo494m0WFFPB2d@2YWRV8o46V58mVd4J	#1WV#84$H!16F$8$Bi#NKF!PX#84$ZFV!V2k#2_#SZF!9Kc!24D!21NV	02&1.2012*9/011101(1/1/%1$3$1%1/#1%3*1/)1/.2/%1//%1(1#1(1&101/!21#1%11&1/(1&12/#1$3/!1#2&1+2&1,1/&11#1&3#1/&1&1/(1(2*1#2101#1+230202!3//$21$1%1!9!1&2/+1)1#4*9+1/*1/1-11-4)10j01#2$2#11(2(1&D///*1#2!1#202.31/)1)1/!102-1!302#2&1/.3#1/$1!1&1%	fmoqb@IEzKsPXfQQIYSJJJIEYQITYXJ\sW@AMTE@SUQDaQAbHE`					antagonist	M1	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xi.=x=x=xixi~M>x`*spc{x=P~|`S(xix=.=x=S(S(zdW(.=p3}J	:Uvzv;SzxvTdzUvSkvtvUbEizgkQChMj2Ej0b9Ive8kEf2RL5Gh9c4BBXmOHY1q7Go020114k1sFe&	0WR0Tk025k1v!9_07g!lR0OF1v!C10480eF03Xk2U0DF01I!FF1205g0Xk! %m0W0JtF8NT5W2G1eS@211WVkqF4F2qM120Yd4FC6X1Wc84L420FktLF4J2a14jVFkG884L60ckRNTL28BlVFoG6YDWXFmHBuG44X410J8P5VkcN8320V84wDUZ11V_0HNo@l37Y0GciF4L3Z160WZVFL92Z0G0s6511XHwV8B5B2IU0ZFgV8F4	#C4V!194$3!1,c@!221F!8d4!4V$8Fk#2k$4#G$91c#H#2W8k	//(@+1/%1#1&3/&6$5$1)22%2(3/#1#1-1#4,2*4)1//$2/-1/%1//&1,4/)1(2/.1!3.1$2&1$1/3!105/2$1/&4*1//!21#104/#1(3(2/(1!122)1+71*2)4%2/2(3)8101//#2%1%4%1!1//#p%5)1/$101!F03!2//#2(2#1!1/*3!2//$5/%1/2/&1)1&1#2)4/+1$	ek`THD@CJm@H`bHrJJKKQQZIPqIJKIccpKi[XzB@jZihHJJHdAJGJ@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}\F*q5`|)J6s6s)J`|(S`|6sF*6sF|630l`|)\)\63	vzUvvfvKxN_83J2E@90lVO8020F1h308BLJV58X1!F16$eC08Z4Rk2Z17JY!112G!J1141!401BV0FV	0aJ0Tk03OF1r07k!o80Ik2d!Kp07R0TV1w0CB$ !6F4F3Z120gaFFcA8281OBVW8I9Z4A2	!120V!1%V@$2V!c0F#88$F$3$88#9$2FV!846#K1#8FN!808!210V	+1%1/$9!11////108$2,1/*1/.1)4!1#1!1)1!1///01/+1/0101/1*1!16/2(1,1//01&1*1*2#1//%1%1&2/.101%2/%11+1+1&1/03+1+2&1*1.7-1/01//7!1#1#1/(1/$1//(e%7/!11011,F/$1/1///!3!1.2#3,2#1+111+2//%2.2&1/$2+20	ffsP@@@QrRIYJJJIQHhzlyOhekUUAI@PAD@@@					antagonist	D1	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hxiS~.>h.xi>x.i.h.=.i.=S(.iS~.hxhS~.>S~xi.h.hxi.>x=S~	jqQl6FOp0F5cV03CS02V080F04!108046V440Vc21#FGV!JX0V040F#4VF081!X0Z1!80I020VV8FF	0Zw0c!3OF1g07g!qJ0Sk1w!DD0@F0t!34V0Z0Eo01aJ0PV1g07R0U03F$ #55q8FF568YO0Fs@lk4D2m0W0FN9V8J97Xc42DF10YXGKc8F4f17DFGVLF4F3Z13VW0H@ZNR722lRV8N42IF_GV88324ZmQF8kJ2@2m0XVGtWJD22YlF	!1@$Q$2V%P#Z6#441$Z$V8$N#1$42V#61$QF#mk!@04#19V	%201/!2+3-2&5*2/%2-4$3$1/+201//01*1/.201+2/!1%403/)12//*1/!4&2///03)2!101&2(1)15&1/+2%2)3$101!1!3)1(2%1#101*1*2(2/#4//,1-2*2#41/$2$3-3+4)4///%1/&1!111(1$1l/1$5!1202$102#10I/,1/%1%1/#103$102!14&1&3//012//1/#2$3(402+1%1/%	fcoI@`MNjNp@bd`rPyHYHhiDkdieEDhemIJKWlzBhBf`@@b`@@@					antagonist	OX	Orexin OX (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~}HS(.ix=.=.>S~xiS(S(S(.i.hS~x=.>.>S~xiS(.hx=x>)H.iS~S(|`|Fl0S(x>.=q5xhS~xh}H	;vzvy:daunTvDUt@fmOmraB4KhYCM_LIZC@2cYOoO6tM1@A6YKYGC_08d9@mk8dJ987XXsV2D1F0FGNW8F0	0aJ0Tk02103q!@H0ER!qJ0R01v!C_07g0zF03903d0Eo013J0FF1407g01FJ0903P0EN0zF0 Jb3kNNBJC@2Wkg@720VGO4gg2NWZnF94F2D30kd4ND7ZZFV4611XXnXl48XH9_klVf44Tn16W13OVF7920O0sWR2DQ0Y0gV8R78291K228cBF663O0GFDF4P2xIW1kgV8N44H74Vko@731FF4kN1150FG1nog4D3XVW8WC0T922WBV8N782619JVVkHZBT341FsiF482pMW3kZs8pu2@2m0XFRV8N6Z2A90WVV	!1i4k!1F$4F#2ZV!60F!2B6$GF#Y8$F$VF!8@o!8BK#GYk#5s!212!235V	&1011(1&102#2$6/12#8/$3*62-4$11#5+1//!1$1&2#1)1.206-1,1!1/%4.1,1/+2!1$1%2,1#1//,2)2/$1#2!2#401)7#1101/#2$2%4#111*6/$2024%1,1#1(1#3!1$2(2+4!1(1/%11+402,1*9!1%302(2%1!1*7*1*D(1/&1(2/#7$1$6/!4%z!1!2$2)5-201#J/!1//&3&4(1%1%2!3#1/!1*3$4/+2,1/01&107011$1#2(1!1.1*	ea]XFI@@XDODd\P@`rPfdEiCZPaBJYAfPydLddLTTRbTRqfrTbcRrdLfdSfPqswrt@PPLPDEQURuPE@|P@@					not given in publication	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
(S>.>x(S(S>.>x>xdz(W}\3pJ}S~)_=xxh)G)GS~x>>xxhxh)Hx>)HH).ixhS~x>xhW~zB}\ps	:Uvzv;S:vyvQUzUvUf:yUnjhoQS:xUEqnYsMdycljziILbSjDR@w6Yn5wmdb1GVHIgI90k03Fr2VW0FV	0Js!WR0Tk025k1v!9_07g!mV0AF11!DF0@F0t!45k1_06k0Tk04Ok2v0Ak0oF04YV2U0@!t!6@01208s0bk2V0DF0 #m0VFGJsN6I34cp8sFZ9Z140t0G08ZcE851FR4FJ8LD0WkHk4Ts16WALsFJ9P2KDX2FO4I8261m0WkGFVy6371FtBU82C190Zoc95N2E3LD0W0Hl@H33Wt0GV@okU371t0Fk99@4AL0XFwV8c5ih24W1Vk8XE31GkoJ210IHGiF482C1B7kkNBU591VGsupi4D260ZocZy432YGYRZ8J4hQW2VVcgPF9XFcNH6@@_O0FV9JPF@WWHWR4ZBrD4FlcOG0P38_VGsaF4D3Z160t0Gc984yE910nNoRC1X5HBV944Z2OHV_kuJ8Z9Z130ZVHPJ4XN@13W5c9Ki2I2QVZpc948	#Y5k#8J(18NF!Z6#5WP!2V5F!seV!55#2FFF!Z2k$4#9F#1IV!60L!21NV	(1+1%1%1$B/2$9)3#1/01!2,2#4$2&2%1#1//&1&1#3!2!3/04%4!1!2(8!12.1$1/!5(1!21)101/&2#11&4+2&2/&2/&1/*2/!9&2-102(1+11$2$3&12#1/+1/(2!2$1///&3.2%1.804!3/-1/022$10209+1/.2%1,3&1&1/!z(1%1*1#412)D)2.1/01-5011#1#17202,5//#13//$102/*1)5(7*1#102!2!11204(1#2	efU^DD@AC@T\RZ]O`HabHrJIJHqQYQIJKIKRJsJIT\FVYMCKDtpAESUUPPQUMRqQ@@@					antagonist	Glucagon	Glucagon (II)	no	gpcr-ligands_DescriptorsNo5Ht
(S=.i.=xix(S=x>x(S>xdz(W3pJ}S~.i.hxh*FS~x>:v*`xhx>	vzUtvtzgzKpzQodOUU@l68@daEHGcV59@HK6E205N@a8Z1mYFXs0w20p0F4cW1FHW142W9FK01!G2#VW8FV	0Z40IV02OF1v!9J0Eo01Kw0Rk1r0Ao0ok05RF1n0Ak0jF3K!Km07B0Sk3F0CJ0 !m0W0RV8F78271m0ZVRV8s782K1m0Y0RV8V782D1m0WVJOks943245sZZ953Xb21Bs954XXH0h895@2G8G4RHFD4l88VDB7	#aXk$V!2%8XF!VW#30B#14#V9#888!2FF#_@k$2#11$VF!23Z#19V	#1//1!9&1%2$1041//)6!104$11%1!1#2/$1(1(202&103#2#5/%1(1/(4)1.1!2$2//$11#2/*1,2/01//5//+54/#3#1/#1.41&2-1//$101&1)1&1$2*1/&1//010801$2&2.1*3#1%2*41$1/&1,1/1/*1*f#1$1#1%1!1011#1*8//+1211011-1#1!1.5//!3(101////#4(6&1/!2+1#	fewXC@MFmGOPRBICDadTabRrbRRbfRQEJshe[vj@BZZZZjJP@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
LGESZGLGLGZGESH[TaH[`YTa`MTaH[`Y\]aVM~HJN`G[WaEROEL_]IEOI]II	]U:fyzvjzhfUzn:TjUzpqKM7xcz_IiSTfojqQvaMrxnUfCDrV2I0cDFb8Ta0q5@S9d@3k@F4X4Gk	0PF!Xw0s!2Ak3V!BY06J0Tk035k1m0C!14w0Xk2U0DF01Kw0Rk1r0Ao0pV054!Z02k0Ak3V!NM06c0RV1n07R0o# !6C48BFF9Z120_dkFR8qGD30cgNNCZ13Vh48wBN7Z110Y5OkP3542t0Fk9gZ89WGVkoL2A7EXFHRa@9546llVZ51VH1t0xPN32GGFcJaC@3l8Z6410HmGNce52alWBRHD@G5WdFJD@IcW0VWu_L6639lWNNVBVJ94VlFNDB245I8ka710V9FockbG1XkN8ZG14211KGsFZ9332314ndNq8A1VX1FFocIAYVVF4HG9m0W0RV8J4CQ1WYFwV8R4oNDYG0d4M8271m0WkFdKkH462C5cG062D3	!2E_k!t84!6DR#8c#VD4!5Wh!32MV!kdc!59R#@ZF!6ak!4Xw#9B#f1o!@3_#99V	/!1*1&10301/2,2/2$1%1(2$@$2$1$2/3*1/.2$11/(4%2/,1!2(2!1(22$1%1)11//$1%3%1/$1-3+3!1*1&1/$3(61%1,1%102*3&1!4$3$2/#2$1&2#2)1$1)2%1-2///2$51$61(101#3!2011.1/04/&29(11/!101+12)11,1/&1#1m1$1(4&1!1011#101%@$1/(1/01)3$1/01%2131*1/010501-1!2/$2#1,1)1/06/&1/#	eodVLL@AEK@dcnem`JsrHJBLbbRaRbTTRjbTVTLhX\BbRZF`@j@bFjjijBbLjJjFbAb@@					antagonist	A3	Adenosine (I Nucleotide-like)	no	gpcr-ligands_DescriptorsNo5Ht
Skh_>_hGSk>Gh_>_>_SkhG>G>Gh_h_>_>_>G>G>_>GW~>_dd>GSkYjgF>_>_kTfbSk>G>_>_>G	?y>x;xTUfzjzv:wwpxvfU@9nSGOoCiwM6zqr01sWch6mJLm18875@VJ8J839k0k23V20W0FV	0PZ!Xo0FF02OF1w!Bh0440IV03OF1v07k!sk0tV3c!Gl0Ag0j03H!Jh02s0FF120@g$ $U71n0J48442XBV8N4y10VHNC0214Yl08oc283VJcB8K864FG98pPN0X2X08NJ2841_lc4BT30VsNVRA1662Im8k2552WXVF445YlVV841VIH8B24DEEgm08F@81220cF473YWcgD71VVN94TX72Z0NRR521GVFgNA1VVl1kN2TF2kFkoX28711VVFFoA8VFNcV478XFGsN44A1VXIwV8F4430WksB233XVVFD9420NF410VV89VNlZ120Xq904I54VVFsntB4@20e0902W11X0t10iWBVlGkcZLG31ksgkFA30XHGnJRI44XO0Fk8sPJF_1GkiF4D2122XtVcC20HH9DF4L2WWW1VV	!1Q0V!18%4$2#V6F!1C8$G#FV$V1!2NF$8k#Z4#18#11$44!23NV	&1/)3%N/#2%1/+1(5%4$@$1/-1$12#1/040102%3#1/!1//01$1//01(1)1/$1!1$1//01/(703/06/!3*1,402#111#1-1/!1$1$2$1!6/$1#2/11*3021&6)1/&1!1(20144(1%1(101+1!2/!1/.101(1022%4$1+1*3/!1-301/*z/01(1!121!1&D)1311*2,8%1$101-2/$302/0401#1!1#104/4/(1&1%21(201(11%601(1!31+17(1$	efUVD@@JBmco`PDLbbTRRbRRQVTRTTRRTjTadRStOpIMKUUUUUUUPLE@APaFEDaAeDQ@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
lv*`:vS~.=S~.h.i)^jw.>Q~/<8t~S-g-gS~/</<xhS~x>	<TbtKcR5o0GACHR0GVNPm0JF09Yc80HQX78X8IAk9631V0@O0904JlFVs1Ln0G90fVZVL028511J110783V	0aJ0U!3Y03a0Dc011J0SF1w0Bo01LJ0Sk1v07k0zF06JF1p07R0TV1w0CN% $m0WFRV8R782@1m0WkRV8c5mf26WO0G8A84POBW2VwV8F4m2GOY1VNoF	#21V!I04!1VR#k2#X0F!88c!12$JYR!23R!3K9$GV!@4$10k#Fo!8GF!1N1V	&1/*1$2!1.1///0204$1$1$1)2//1/01#101/)1!2#1-1%2.1//(1%1&2!1+4+1,2&2//$1&2*2/,1$4!1#11&1/!1$1(301$3!21#3+1!1!1///,1/11%201/04/!1.5*2/#2*1/%8#1/&2///%1,2!e2#13%122/1!41%D/%1!3/!102#1%1/-8!1)1%1.111/#1/.1*1+1#1!12&2//#	fa{Pa@HN[t@PVPrQJIIQZJYKIFXHKQgQsRDD`TDTtP@@					not given in publication	CRTH2	CRTH2 (PGD2-receptor) (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(xhS(.>x>.>Q(}^{Dj/}Hqqg-y?}Z?-xiq5x>q5S(xix>S~xixh	=jzUztTzUTNgUCNauQ2vtQN_cYE46Mn0CAFB!rBZ10WqXd0tV1Jlk885GN0VM!104J4044FH0V90WVFV	0RZ!WR0Tk025k1v!Bh0440IV035k1_07g!sg0d03Z!FL0540Pk1u!Kl07F0n03C0EF$ 01Z13Vq1VFkA8271m0XFHIBa330lWVmRoB4WkFl44227417eBBX72G12kcH888459cWsRB51VFF8gZL615MVG0FOcH720FkgN4DF60coNX5213XBV8F4227728oF610kV4kXOZ16VhGt0B13VWlksxBH20WFZRc2180VGlDF482EC6VkF6630k9GN42I0VZIBV8R782C1m0WVRV8V5eK5X0Nd82327Ya7O4BL631AaJ9RD658VVGst5FF5VG0BRc11W42F	!3QCV!J1B!31X!1@2#Z3#Dbg!225$Y4!@Bg!2F1F!VLs!8HD#KGF!8Es!1t4!2OKk	(102/!1)C/+1#1,1%1&1.2$2)1/01+1/01101&2202!2/!4%4$2/201%1#1/#301%1/01/)2(1$2&21//)5/#1/1/)8&2,1#105/-2!1$1-2//*1!2/+101%1%2(1-1&22!1/!301/#3!2%1!201+1,26#2!1/%1/&1/%1#1%1*n.2&1!101-6#1#402/#2%@$1-1/+10B011)103033*1/*3/!2/0101*1$1%104!21//&	eg`RDL@EMBncA`HbRH|BLbbbRVfVTRbVRabSGAedRTAASSSUUmUD`@@					antagonist	Glucagon	Glucagon (II)	no	gpcr-ligands_DescriptorsNo5Ht
+H6pH++H+HH++H>/*Lm3.pD,D,49S}m3)U~,+^/hD,66ukW)66/>S}+^yAyA/h/hW)S}w>whw>	}y:Ujx<C<hjyUzvSX:nr@j:qLTvrzQ9fgyxyaovrKzEGEAfx8ZS6QmGP1wdY4X0GV	0WR0Tk02FV2d!930D#co0xk03OF1r07k011R0OF1k07g012o0FF120@g01MJ0Sk1u07k0pV07AV0s0440SF1u08o0xk! %m0W0JAgF6@3_6VW0HR4Lx1319kGYo4F4@A0kdRRI75W0G16F4F3Z120ip8Fc9D2FTVXkgV8B78261i0YW08k9D2DTVWFgV8V4@DL_ks4NL110Vkt84POBYWkF210VHlGNFBF74WNNF52VVF4oTP471088@A93GNZ420b2kF48FV14_WNga76W0GFs22@A2430gJK2WX1884@H6j11kVps8L49A61dRF1773_H04BRaAW2GFRJs6C3PB0VkFuV1331FFVXR4Rx14W9kGvo4L4AA0Vcki48Z3FF88JKZ11VdkHQo4P4b18jFFsFFP310FNBDE4WkVRL410ZGN4248I@X1FO4cFAWXWV	#@JV!104#gw!162#zeF!2ce!2Xnk!Hb#BWR!21NF!Fqo!D4E#GYV!8Ks!@4e!2C8V	&101.1&2%H!1,1011/$1/)1!6$7$12#12/)101///,2103012/%1!201!11/#2&1,1/1$1$4#1/2(2!4/!1$1+2&1&1#3(1)1)20111)2&1!2/1012#1)1!2!314!5,2,2101%1+201,1)2$2&5/03/!1&3+1#11101)2!701!2$1%2)1/%1-7#1%1!1/.2//#202+10z$3501/01/F01//#1%1$2&3)1/#5011.2!12201(18#1//!1*11(1/01%4*1!1-@&1%	ef]RLH@MDhT^JjPHaIe]YefUUem]vabpIrJXyzDEF@BjfjhdhhjjjHJPDLlh@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
h.~S>.S(.ix>.=x=.>S~xiS(S(.i.hx>x>S~xi\)s6W~~O	:UvzfzTzS7ZOJ8v3BLkXccV74u_cV08@7wI7124c@F04V0Y8@F18!g0L63202@0KF1VG24014!@NV01!VV	0aJ0Tk02OF1v!DA0@N0t!5JF1W0740jF3L! !2a9o68940WGGGt@I1XXV88JNWJ23W33HRX4550VFcn1c472m0XFF	#D0k!F%8F%V!VB#188#2H$V#41B)1Xk!404#G$cBN#28!210V	(6/.3/%2//*4$C$1$1!9//4/&102(3)1//#4////-2//2,1///04///03&1,1!1)1/01$1)3/1&1/.1!3/&3///2/*8&B//%4&2*4/(1#1///,2(g#10@/)1!2&J//01///&5!1//01#3,1//&1%1/$3/,1-	fakq@@DAjCHiiEEDddemCEZOduzuT@PAASHP@@					antagonist	M	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
iGi_S:iGSliGS:iGj]V:dAXkkNi_]<SliGD?lPi_i_]<iGkM_>i_S(kYGikMS:;M_>	:Uvzv;SzvvytxRvUvUvzrPFtveqQCxUnI1uGV_UlgCGxjg6N4CmBo2P4c1OFVY702mJ1DG8180F0k!W0FV	0WR0Tk03JF1_07g!t!cF3Z!Fh02s0FF1D!FM0540OF1v!GZ07J0j03J$ O0G8CsB4@26nG08FZ9Z130t0GkBRa@321t0G8904TUN1FlFX5P6382VcFoLc2D80Y0gV8k78231Lf1FONDiC28W40HHt@4C3	#zbV!204#2G$2#g7#1lB!229#EW8!17R!2FNF#@s#1a#C$1GV#84!2I0k	!2(1&1,2%8/!3!@-1*20101&1&3&4$1!1-1/$2/.302/%2%4$3/,1$1/01.1)2+1%3/,1104+1/!1!1)2+1,3$1-1)A&102!1/+1#1+1!2/#4!2//*2.2-1%5-1/3&12/1#A(201*4/!1!1#1#1)1D/!1*1(301*2&1//%z%301#12%120201$1!1&D*21#8/&1-1102%1!1)101&4+1/(1*1/+1#1/.1)3*1%1/!1$2	edV\HH@IMLd`HcHhhdUEEdhheeheHiBqqiYUul|}C@PTuTCAEUUTIP@@					antagonist	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xh.hxhx>lv*`H*~S:vS~.>`|.h.h|^.>.>x>S~S(xhxhx>S~xhS~	zyzvTfOM9k5s0LAjSNHkkOAH6B8_9YA@BMjmC0V03Qk90k1cDHKVKZGDW8VXOElG1uG9Vl26GV4459Jm5J$	0WR0Tk025k1v!9F0DZ!_!uF035k1_07g!qJ0R01v!DA0@!t!45k1_06k0Tk07901D06k0Tk2A0@!t& %rLW1FgV8878271iWkW0Fw4Pw15aFG8O_s487VWVwV8N4r924WO0Fs9Fg85c0skgOTI25Y2kFRFw@276GsFgT292VWWZVcoD443VFkiF4B2AB6VNgD11VkNRgFLvH1FlcNZB4H8eVWt4F4B6C@2NRF@A5m0WVFXB@162GcoFHD9NgkW8I1c452N0XqV8RA82612YVtwL54VWt8Vb823123VFkcE6VkO8c631Vl0dc8@C@3Wkl4B351kccgj8291m0VkRV8g4H528EVGkoL4A5m0XkIkg8XJ9W3Ws8g@28622VXk_6F38WXNFsSV2CP0XFV	#W4k!184!53#124V!62#6Z8!2FSF#d%F!2!F#2Z$Z#GV#92s#F4!214V	!2)101#2!1$1*5/!2!41//.4$1#11///.103#1!2!402#2$1%4%201&3+21/%1-2#2(3/02*12-1#2$2!2!3*11)101#1(1%2!1/+3/(61%1#2/$1&5*1$3&1.2#1/$1/#2//$1*2+1.2%1.8/*1//%C$11/%1!1)1*2!1/.1)q%3(2-1,J//%4&201)2%1+1*2-111&404%2!1/&1.2//-1*1#1%1/$	eghXLD@CMNc`H`jHrJJIJPqPiIIPqIEL\FVQYS[PDESAADDDTPPTD@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i}^S(.h.>S~.h.hS~.>.hS~*F*`:v(S:v:0`|*F*`.h.>S~.>.hS(.h.>.=.>S(.h	:UvzvUyzKzxQytOEUDmUfvvaEqM8VJSTrxDAjF5OPzyZlIeLqs9vV8pFR0epGNEWW4VY9JK0108F08@8V381V	0aJ0Tk02oF3T!9J0Eo!o40FV1D!C10480IV04NF1u0Ak0p!5O01f07J0oF3T!LD09!bk2V0DF01qg0SF2D09!bk2V0DF# O0F0DF483Z12Vt0GVDF4N3Z13Vcs8FN@2Y231FJNFR97125W7scFN8z522W7scFc8XpE1ZFmPFVD72X1FFoHM@VGNNB20W31tVwHBC20VVF4990kFFwgT2D_0ks6624YHMV8tF2B224WFgLA2XkVJ4226YVF8ks4@4Ym0wD92VVN881D9bO0FkDF4D3Z110t0G0@Bu4@GVX0qY08L4473lNwa55Z3kF8o62A@7e3184@F55@3O881683CocVBP7Z14VXIFcTD5WkVBZPH168I9FF17@Yt0Fk8G2O9VX8kkN	!1z4k!O9V!708!1AJ#Y2k!6JB!125F!7V#15T!2GSk!VHo!8FS#1RV!50F!@Hb!2fBk	%1/01.A(1,4.1(1/05$6$5$2!1///1$11+5/-3(1(1&4)101/1-1$21(1%1$3$1+1)1!1(11#43#1&1(101/,1)1/$2%1084%2//)2!2!103214/.4)1-1#1$2)2#1.2#2%1)1$1$2+2+2#101#401$1/&1*3,1(4$4/$1!1#4/)1/!1)1(t!1+3$1*101(8*2,1-1(1&102*1-1#B03/01&1%103&2///$1#1*5(5*1(3(602$102#	edZZLL@MCHnilak`IABPpdLbdLRTJbVTTVRbfRVPdcgaUTruT@ETmMUMTuQL@@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.>x>.iS(xi.>.=.iS(S(.>S~x>.>.i.hS(S(S~.=	zxUl7WtK9F4B0J2eB!1280N1!1W$2k04*1W#V#48F#1V#1!4(2$V0FF	0Z40IV02OF1v!9_07g!sg0d03Z!G_06V0SV3F# m0WVRV8V5Z2CO0XkgV8V5Z2CO0XkgV8w4_091XVwV8J4HH95Wd8NRB993J0ZZBD6	#E0k$k!201$8#V1%@$k$W8#2N$V#52s#X4#1%WF!4%G0V	//&17/$1+2//02!F042&1//&2///2/$2///.2#1/(1//*2/&2!1%1///-2&1//$2!1)1////%2/%1/3-1*8*1/%8)3//#4/!7)1%2.2/(1,2%1/$i%@/!1101-N///*3)2/0102///#204-1///%3#1!6/-2$	fakq@@DLxAIeYWenUWT[KZ}ZhHH`@@@@@@					antagonist	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
>xhx(S:0:v`**``|*F63}J.>}\6s.h)\`*`*.i`|`|.>0:}J.>ze6s,d`*.iO~ixO~0:}L.>.i	:tzBasM8iDq41Egn8lcVQIHGo8aOn924L2VMB62M9k10F940P1k1oG2W1cZ9N@G0NFNV!H1X@55RJ35R6030	0_!uF03FF1304s!mo0DV1v!C_07!Tk03OF1k07g!qJ0R01v!C807!uF03Y03a0Dc!sk0tV3e& 04l8CiD552j50Fk9Rc2A3FHVTF4H2h15CkG0Hw4Vp171O0GF9dPR36WfqcFkA8291m0XFGYso6H3m0W0RV8k78291m0WVRV8k782A1m0WkRV8F78271B@FGNJ@E512W8JHA72FsZ@620IW9kFaWAX1Nl422E74_F8d0@3XH193oiF33W__t8H3572a5Noa8@4m0YkHc8skS25aFG8Wce4JAbVX8aF4B2lOW3Va899a2F2m0YFFl0F6H77GFBR@B8	#cVk!7F$2#24ZV!268!282$F$f$Vk#2$HHo#85#GZF!44s!24#250V	-1$3/#C-1!33/)1/$3#2$6#12#1!1/,5/#1/!1//*1$301/&1+5,4*3#12/%1.2%2/02/03/04!3$1,1.1$1!5&22!21+101/%3&9(7*11!3/(3$1-1/#13&1!1%4(1,1+3#1*1$2!9%1$2/,2&1$2)C$1/%2#2#2+1%1$1/01%1!2&2z+4#4/2)H$11*1/0102/#4/-6/(206(4*1!1$2#11$4/#11/$12.401/%1-	efUPI@@@D@iek`XT\bfbbbbTRbRRRraRRTRDbPvSUVwpKUUP@D@AEEUMT@VFEAAEE@@					antagonist	ETA / ETB	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
lv*`~S:vS~.>ix.i.h~S=x.=.iS~.=xi.iS(.ix>S~S~(S>x.h	?xzxx:StzCxOyetzCzUPvgY49znS2Cf8A8PKDZFD_kyd0ug0poa4@7IH91K7dx841120F0VN0940N0V	0UR!dV0ak03OF1v0Eo011N0KF1Z07c014s0Y03a0DZ01J80G01707c0eF0 !NC0WFLF483Z13Vl40FV8PN4Zl20Vc4C3VXlluooD45244Osa8841Y1NFZC71l0R6L@A4amGJNB64Y1ou0V553Xg6VFR86L2e0l0FDA7EdZ0NZBqq9WWVwV8F4	#d0V#NN!42H#S*5@8$1$Yc!2Vt!1wF$Lk!807!2Kk#99w!2J#2C3V	&1%2!1!1!1(3%6//%5,1+1%4$2$2!1/(1(1%1-4+2///)2$1///&1.2/,1///02(12/$1/(4&2//$1$901$3%103+102$1$1/21/1/&1!1*11/1&3+2/%3%3#1#1#1$1&5#2#103.14!401)1.201//-1#1%1*l%3%1/%1&9/%2(1//(11#4*9!1/11$1!1%2*1&1///!3%1(1%1!1$1,101+	fewaa@CXTd@PVPrQQQYJJjJJJKSDiHsY}GTmTuTCPTTTKD@@					antagonist	P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
h.>.~Sh.h.F*~Sv:`*x>xhS(x>x>S(x>xhx>xhx>xhS(x>x>S(	;UvAzOUnxIU4HEFO0IeN8mcXH0_29@8PTV5!121FA61!V30V02I6dFR2A2kF09H2H$V206#_0180V	0qJ0R01v!C10480eF05SF1t07k0n03o!K_07Z0Tk1w0Eo0 !BV8F4495ZlcsN6310N4kXN382mFoTC5VXH9DF4L3Z140W214yG31kG0cV	#X0V!80F)B2#V9#30X$l$98$P!29kF$o#B4#1VV#5k#J4#S1V	/%1/0E101*2*1.3/!1.1&1.1-2//01#1/$1)3/%1(1/*102,1/1/$1+1*2!1(1/!1$1/0206(1)112/%1/.1#2)1%204!2&1,1,3-2/&1/01.1//%1$1-2!9/.2&1!1%3#2$1$8+2/#2$1//(1/010j%2#10102/1*D/%3//!24,14%1(11/&301(13$1,1//)11-1&1202%1/#4$1(	fewPb@AEXDD`drmnrnjlkS`iN|N\@QT@EUUTI@@@					antagonist	D4	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>.>S(xh.hS(x>x>.>.>S(xi|`S(x=|Fl0xiS(x=x>S(	;QfQzt5sB3WoY@0d092NJkF01Ah102V@FV5!V2#6F5W021V02G48FV018V!1F2!WB80@!2$V0Fk	0QF!Xs0FF02OF1k!Ke06o0Rk1r0C!1Kw0Rk1r0Ao0ok! !O0FVAF4Pk15WO0G89BaCNX2GBV8Z5094ZkkNNP915XFG96F4D3Z12Vg0GnF4J4qM110V	!170F!c$608!18c#V6#514!10ZV!V98$8%F!4Fo#X4$cF!81o!82Z#18V	02/01*1(C1/(1/%3/%6$1/$1//011/#2#11-1-1202.1//%1,21/1//2///2%1,6/!1)2&3/)103//04011$2$1/+11(2+2/#1!1.1///!21(1$12)2(1+2&1#102(2)5/,2-1(2&2%102/,c%3%1,2/B/!101/*4)5///)1/(1/,1.2/(15*2/04(1$	fnki@@LDuXHLdTTRRTRrVaRDYS`qjv`@@bJjjA`@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
:0d,(WBzhx)\6sO~.hS~.>.i.h.>.iF|0:(S0l*FS(.h.>.>.i.>.i.>S~	?y:irxUhXHzkxlfMZr4FvZc90eMG@K544FGl8JKZd0Q@BE64w4IC010HNV5434#4@0V1H2k!b0IV	0aJ0Tk02OF1v!Bh04F0IV03Y03a0Dc01Ho0CF110480ek05RF1o0Bk0nF3o$ #1Z17VZHtVi859VkH8le29331q1VFs84fKY13NVwFCB4FkRB29DVFIOLF4F3Z13VdnWg820Y2Wd1k8e5Z13VVbuBBe6I3an8NP27B0FHd5VN462m0YkF	#f0V#8#214#82#c1#198$3$Y%2!20N$2k#27#GNV!118!2V5!210k	%1-1/!9/!1//&1+1$9$101(1+1#1+1/!101#2#2/#1!1&1(1.1/,1#401#1(2&1.1!101#1/$1%4*2-1/2.2(1(1$21/05&1,1(1$1)4#3&3(3/01/101/01/1*1$1$1$1///+F011%1&1%1+1/41)8#1/)1/%2.1/,1q#2#311(2%1(4&F$2//7//%2+7!13//1$1,1$1/)2/#2-31)6.1+1!1	egh\L@@N@h`DDdfvWYWY]e][`RqqKHZYjjh@Ii`@jha@b`P`@					agonist	S1P1	S1P	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~.>S~xh.h.hS~.>xhW~zB}\psx>S(xix>	vyQn21OM0F4c0J3BR8HV080X!F590@04MHF50V829F0410V8XB08V0J0F0814W10A1!n841$H0Z!V0FV	0PJ!Xc0IV025k1v!9_07k01GR0OF1g07g0U!55V1Z06Z0SF3C! !BV8c522BFcFW8TF483Z16Vt0FNDF4B3Z130gkH1124B3844FNx42B4O0ZqF8wA8251m0WVRV8R782@1m0XVF	#24%Z!2%Fg#V2#5W8!204)208#F1F!40V#LX#41F!43s!204#38V	//(2(1&1$8//$1#1%402+4/(1#4!2/&2*2/(2&1/01/011#1/&1/-1!2%1$1/#1*1,1//#4,1/1#1(71!1#22(201$3*11/02)4/!1%1////&1$3,1/$1%11-201/1.1!5/*3/-1&5)2//02/c/*101)1#B/////)2!1/4//(1.1&103//#2//#1&	fj}PA@ENADVBDfYYwy]igIZ|F@@BJZj`P@@					antagonist	CCR4	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.hS(S(x>x>S(xhx>xhx>S(xhx>x>S(xixhx>x>x>xix>xiS(x>x>S(x>xhS(	zTur618G8V4k4F24FNFWVN2m04!11A20LmV1#3Fk141WV021V52KL1Fd0980FcA0224804V245N4F!Y0G0	0Y!IV025k1v!9_07g!_!uF02J03d!9k0Ds!qJ0R01v!HF0@80k03Z!JM06J0R01v0Ds% #6F4F3Z190t0GFDF463Z15Vt0HcA04go19WB0GvF4L5Z130g0IAF4g4o1AB0HNIF4Rk15WO0FkAF4mk1A1O0GNAV4wN1C50I0QV4gN1950H0QR4Nh14WD0J9V4uJ1CWmkGWZ4B5G164kFkLF463Z150d32RBZ7Z120ZFI8ccW9X51HN9ZP2MOZFXVWZy4U2Wk9JJ@O7F6VZVNH83D20VRBkFt1D2WkGN@54WZGWmV8Z5J13W4OJ9D@717kkFH6Q768nVO4BI24XX_9oBXA412GRV8N5@K2HVVkB22420cF4JNB	$ZV!104(260V!H0V#V2!2VG$WF#Fl#V0F#OZ$1#GV#80s!4J2!270V	02/2/#17(1%2!6&1//1/6$1(101-1//)1!2$6,1$2/#2/#1/01(5,2(2&1(1.2%1,2)5/!102,201+1/01/&801$101*1+1+11*5&4.41&4/1&2+2*1)2(1.1-2.1)2(1!A/%4/.16)E//*1!1/1&11/1)w2&1/&1*H$5//4/#3/%6#1!21*1#101$405(2,2(1!1102*1(1#21/.2#1/01*1$1#	edRTJH@EMBIDbf`HaIf]{UeYU}e]fNHlkghHBZX@bjh@J`@HMH					antagonist	Glucagon	Glucagon (II)	no	gpcr-ligands_DescriptorsNo5Ht
vl|FS~lv0l|`~S,BW~`|0l0l}\6sW~)J`|0l6s6sW~,B5q`|	:PnJmsJ884y#VFN2dV8!GJNF!9!HF45!801k04!V0e80CX4JF1881F2F8152910412!1$10BVV	0aJ0Tk02OF1v!@H0ER!_F0zF055V0U06g0TV2q!JL01w0Pk1u0AN$ !38201m0YVRV8w78261m0WkJ88u62B2m0X0RV8Z78261FkkVsLF4H3Z150kkH@44J5Z130l0GW0V463	#V2V!4$2I&V#4#B16#kR#6Y8!@0N#J1#I1V!191#K8k!B1N#F7!2tFV	)1/-1!2!2&2$404)2/1,105$6*1/+1///&1/*1/4)1/!2/.1#1+2/%2/02-21//#1,11/+54%1//%3+1!4//.1-1/&1//!11!1//(B&2/21/3!2&4&2!6*1&1)1////#20g%5//4#H/103#3////0@!12/-3/#1(2$2//+3(102/+1,	fi{aB`NVAbHBJrCYCladTRbTVRbLRRdQFF|T]MTDC@PUB@@@					allosteric enhancer	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~x>xh.hS(xix>.>.=|F|`.hS(S(.ilv.>.>.>.=S(.h	vzUQfQzt5NB3WoY@0d092NJkF01Ah1!V@FV50VV2#6F5W021V02148FV01BV!1F2!WB808!2$V0Fk	0PJ!QF!Xs0FF02OF1g!Kc06c0Rk1r0C!1Kw0Rk1r0Ao0ok$ $BV8F5a_61XkwV8Z4ZG6h118aF4H2G7ZW8sH2210cBgHMZ13Vt0FcA44RCHW2Vqms885Z14Vt0FcDF4@2YE4HFVgI8291	#70F!80V!6$18c#V6#514!10ZV!V88$8%F!4Fk#X4$8$3k!82Z#18V	02/01*1(C/)1/%3/%6$1/$1+1/$11/#2#11/,1!2///(1*21&1//)2/-2/02%1,6/!1)2&3/+3//0401%2$1/2*11/$1/#1/!1///1!3(1$12)2//0102(2)5/,2,11!1#22#1!2%102/,c%3/#3/B-1#101/*4!2%5/+1///%1/&1$1.2/(16*1/04(1$	fnkX@@@XIQVdifUUf]Wv\tEMRm@hJhJPhbH@@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
5q^})H5qH)^})Hh..>5q5q>.~S)^U~)Hhxh.H}55+b<w~S~S)^)^i.H}5555~S)^)^)^h.H}55)^H})^H}55)^	zxxr_aySdfJU516iwCchXN0QlkN0C9926LHV58BF3Wk9Z41V0e1V3XKHO0cB98HFc81284805X@0oF6#6030	0_!uF02J03d!9F0DZ!co0xk03OF1k07g!qJ0R01v!C_07!Tk03H01k0DZ!sk0tV3e!GF08k0tV3c! #610XW4L69XklG8cBL60FNFNm611VmFkB13108F6F9GPB0WNGVkW41kNkoQ82A1m0YFFF84B2WG0cB8410cg261VJWeLF4F2oN14FaV8pV2922bVcOZ@32A1X0B865WGldaF4F3Z120t0GFDF4R2323H0sJ43Yl08410b33gV8N782D1N0XLV8RA8261m0XVI09VVR8WFkd862F7PVYps8o8kS295kGWR4J9Z130a0HGgi4CBVXW6c91T292Aa0WWZq494C0VFocH6W098g429@NgkX0IGV4G2m0WVIdR8ZA56klViF4T2kD5klVTF4D211VGNN8BU22FkZ281110NFLH10FFBFPf9CW30YI0g34@2CFHORk4C3m0WVL3F8Z5Z160aFI1k4aB2W0ltc4PBSB160FVJB72YGk	#8VV!2$B04!24W#24c!282!1@F#8W#80k)kHo#85#GV#80s!262!2_0V	)1)2/#K!2%11&5-4/01%1$103-13,1+2#1&1/011/!4#1,42*1$1+201//#6,5(1%11*2*1&1-3///02&4(1)1/(5&31//$3#2%1A&35(1-5/3/!2)1%1$1&1)1-1&1,1/#1!9%1$201-1+2(1!3*B2/.2)1$1/,1!2%102&1z!3#11!4#41*2-H%1)1%1-6)23(3)3/2!A#1-3!1060A%204/#1$102!4$1/(3(2/02!3#11!1)1,21#	ec_PM@@@DCOFcgohYU\bfbbbRbTLTRRRNbRRRQrTv`USPvrusTaPMP@T@DUUUTtP@PDH					antagonist	ETA	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
O~,dvl0:O~O~vlvl|FS~lv|`~Shxh.~S~Sh.	uoPlHWOG8F4F0F04FN0G0N2m!F#A!2I21#1GV#WV02!CX5J0F#8!V30224041$20F!V0Fk	0WR0Tk025k1v!BM06J0Tk04NV1_07g0o!5NF1l07J0jF3I& 0BV8R78291m0Z0RV8g5Z2HO0Z0gV8B782B1m0ZkRV8B78241	#64k!304!2%F2#V1#3V@!204F#1B$B$1F!V2V$V#1&k#F&V	02//%1&1*3///0103////#2!201(2/1&4,1/)1//%1*2-1#3/&1&1&1/*1,3/#2/!22,102,1%11+1&1#201//04//#2%2*4///-1%2/%5#1/04!1/#1&1!1%18,1*1,1/,11/-W%3!1/1+4#E!1//%2/1/-2/+2/.1/2/#1/)3//+	flupA@IFRBHIDILsoJ|jsfcQSA@Tu@@H@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xh.h.hS~x>.>.>xhx>xhS(x>x>S(x>xhW~zB}\ps	zxUnrYxS9N4D302iR80dXN0u10F093A04LH051V021k0210V0e509X5JdF80W5XF8A10BV041!40H#VV0F0	0PF!WR0Tk025k1v!@C0ER!lR0OF1v!C_06k0Tk03FV2W0Aw# #BV8Z4BG@518ZH988VFGs44PJO@9WsVk2123Y13Ns4M25Fd0oVcN1YoccRM826134H8g6B6WFVB@4B6a3XkcRI6WV90VY82413GY0NFBB18_HVRL454_0848PLN19iWsG06294m0W0RV8c78271m0WFRV8J4iM29fFsG042@5L0Z089e6B4I1FXOB8D0Z0N4RLHN@63VWF6295	#84V$4!18V#2G#Z2#6s6!204$V#4V&F!Z2k$W!2GF$2c!20a!21NV	%2//08/$11/$1/012*1&1/+1+1)1/#102/%4%2)1/)1)2/!12&3.2!1$1!2/#12(1!6/.2/!4%1&2+2/&2#2101,102//011(1-20102///.2.101//$3%1%1(9/%2)1!1/!2$1#9(4!1/,1///)e.2*201-D*5+1-3/#1/-3(1/+2//2%2(5%3/-3//+	fakqA@DekpDPjHrJJIQKEQIYJILdFK^pPLU@ASTD@@					antagonist	PGI2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
(Dt4-[_.yK96Gx9696rj_._.+._._.r<zS96f196S,y[m6_.m6y[j4}[D/l6W-4<F.yZ	<v[yzUuj<jUyyr;xU:Tzrxnrzjv:mUzjzEff;xqynQxzUHhYUKvQTMzjSRP_bqxmFtV	0dV0ak02@F3V!9k0Ds!vR0iF33!G_06k0Sk1w!G_07!Tk3i!Kp07R0TV1w0CB01Hc0D01k07g0uF07@F0e03V0G01p07c0s!9@F0e02s0FF1204F0Tk2d0D! 38241m0W0RV8B78271m0W0RV8J78261m0WkRV8F78261m0XFRV8V78281m0W0RV8R54KLWYkwV8w53326W8cFFc94@R1XkwV8R78291m0XFRV8J78281m0VkRV8Z54@R1XkwV8B78231m0WFRV8R78291m0XkLY08X5Z15VmYFFV9@n61Xklfo8PP15Wk18Fwq2C3I5WcNkq294I6l8O0RB26XWYFwm8L42FNF6@F9CcWcNwDI262at8Fc8	#XVk!QF#4k8!2En#zqF!79f#VMk!HY#8Vw#9N$Ho!@4b#GtF!8Ms!@4B!2C8V	101/*11#1#A!1!1+3024$1-1&1#1.1$3$101)3.1#1&1/%1!11(2!1/01$21$101/$101/#1%3,1*1#1%3%10201/12(21*1/*1(1%1+11(1/04%324/%2/2(901$301/$20101#101(1$101%10101#1.1/101101,11$1)1&1&12%1%106*1*1)1$101!101%1#1&A#3&3+2#1)2&1+2*1/+y)1/214-@/#11$101$102/!212(1$1#4%11!6#1/!1011(22/01%1!1!1!1/$102/*6*1!1-1-	elUZL@@EAchTPNLldTTTRbfRTTQQrRrTTHXd\LR|JBbjFfV~AhJ`fbjjBBjihhbpPHXhLh@@					agonist k, m?  / antagonist delta	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhH)xhx>S~,Bp3W(>.~Sd,c{q5~Sh.hx~S>.~Shx~Sh.hx~S~S	;rUbtKds5w4J@jT80pXN@u1JN1dYD84IuV58X031k8611W0eOVdV4JtIV91SnFVE131V861205G10610W0FV	0Q4!Z80IV02FV1D!8M07g!WR0Tk035k1_07g!t!d03Z!GG06J0Q01v!OG07J0T01u0Bk0x# %1fkFgA82518K0VcLF4F25G92cFJJAZ140t0Fs858h922lBV8V78241m0WkG2scP45XO0G0DF483Z13Vdnl0T8G4XakVNNCXR53G1NVwZRB1l0l0NLPD5l0FNVBHB7lsg2BF6H8H8oFX97AWVkkQBcJ4X2l11W2H51lX0kcsS920sl0NVRFXGN8NVBhQW1FgV9478251m0XkJXka6F3PB0X8IhH4G2m0VkRV8B4	#Y4V!804$C#H2#g3#BV#20J#3f8#JP!2F0F!V2c)5FV!12Z#FK#K4V	,1/*6)1)2//%1#302$2!101$1+4,1/3/1*104!1(2)4%101$1%1/$2/%1/+4/!201/(2/202/%3%2/!2/.3$@&1%6//1$1!102!2#1)2!606#3/*1-2$1/.1//&2201!2.401///$1$1#B$2%1.3.1///$20n01*101*1011,B$1$1&1&1*4/#1%2+1*7$1.2.4011.1)1)2//-31//!2&	fkpa@IAGkpHcdQdTTRbeTraTTRJbSAZLwlADMMM@PUTP@@					antagonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.i.i.=S~S(.i.=O(,d)J63(W	zpUlMWOKdF4R0F0@DN0W282u!F080204Hl010281FV041WV0X809V4J0F0911!c3!2404%2$V0FV	0WR0Tk035k1_07g!t!d03Z!NL0540O01d07J0nF0 #1Zm231O0GcDF4D2TY13kgV8Z78231	!234k#84!2%FB#V2$WA!2V1#FVF!208!1FWF!42V!1m$10F!11F!6F2#30V	,2/*2/*3//4#1%2#1%1/+1#1/)11*3)1-5%2///%3/$1/$2.1%1#2(1/(2!1%2///(1,3#3!1&1$1+1+1+1/,1#1//#2//#2//!1$1/%303///.4/-4//)1/*Q%1(4%1#1+1#8//-1+1-2.5!1///)3.1//-2/*2/	f`qQA@IFDBHtDYEDeMBhej\lz@HZfhP@@					antagonist	mGluR5	mGluR	no	gpcr-ligands_DescriptorsNo5Ht
|F])sp36|F|F*`])spsp18}IN~}KS(.hf,zehy.>u8.>@,.hI)q5H)}^q5}^H)	:UvzvzSzSpztRQzUUNQXNTUx52WhbA9eHzX71XVPQk9XJYW0AGZ527odAZY3TYmdA09VVJR2N0_19JL10V0F0	0Xs0IV025k1v!C_06k0Tk03FF120A4!t!c03Z!DA0@40t!45k1_06k0Tk05B0110480Q01v$ #2S48H5J811kVNR8q@VVksg6298m0WFRV8N4VZAa118VCob37Wt0Fs8FBFDYmFFRX417W0GWDF4P3Z12VmFGW8H473H0kQFB@75DH0VkJc4a451VkVgKBI9610saF46278bFs8BE6VHG8B4BKZ12VfqcFZ9mX252FFkOKmB522W0sJHK83kVZB50_Xmsls8847@_WGZF175WVG908833YlFkV94VF8F411VJGX@4@4D3GFB6F8821GVkHB23GNR8LB10FFNVs	#d4V!FNJ!41Z!3H$Z2#5dP!205#cV#14F$FF#2o$4#O8#17c!206!2W4V	/02,3(D/!1,22)11*1!1%1#4!207$2*5/-11)102%2*2/%5,1//02//*1.1%1&3)1/.1!22+21/#1/!3(1,105$102//,2$2&1,212#2%1/(1)6/011/01//&1%2&1%16!1/-4#1*1$1#11#81*2%1/1+1#5//,1u%3/#1&35&D$1)1%1.3(1102&2/-4/01.2!3//01$1!1$3/,2&3&304/!3&2%	e`\\DH@AECnM`HcHhheDmMEDdhdUULhqHeeUttMA@qUPUDQSUEDEQ@@					agonist	V2	Arginine Vasopressin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
dz}\>xW~ps55>xxi^))^(SixS~x=5555>x>xxhxi)^ixx>S~xhS~x>	:UvLvOqdF5s0LdfCNHlk92maBNp!40gMlLC#1No04l_VD342OV4x0N!W1!WkKXX520G04!@FV!V0F0	0aJ0Tk02OF1v!9_07g!oR0Ik2d!DA0@40t!5902A0@40jk3Z! !BV884HfA6W1VWZeV5XlGViF4F3Z150t0FsDF4D3Z140ZXlFc470llkwgm4C2m0WkRV8V48F6c1kcJDE7m0YVRV8Z4	#11V#8$8#120V#1%D#FKF#W8!444#2$4eV$Z#G1#A08!141!21sV	(1/.2/%1//%1#2$D$3$1(1!3/0101/,1%20101#1///(1//*1)2/)2/,1/+2////%2!1#1,1,1*1111!4$1#1/-4/!2+1012/%2///(1(2*B&8/$1/4/!8///$1+6//0o%@!1$2*1+1#R//$13)1)3+2!1-30302/-101%1*2$2/%1//&3*5#2#1#2/!	fcq@@DTfCHheHmEEDddemFhR`ZiZWkUU@@@@@UR@@@						NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}^b{n2}Z}Z^}n2n2H)~U.>w<^}}^b+.iS(U(^}q5x=.>.=}^}^S(q5.=	xvwzgyknh@Xu1VhXrNvdZCJHrRNkPc910LFKoR0219kN4oOZ09e21a4NF19c11H!FC7cE!5608F8F#2810	0UR!aJ0Tk02903V!C_07g0zF03OF1v0Eo01XF0AF1D05c0s03r! !38291m0XFIBg8H5Z11Vt0G0DF4L2YVW1kYBg8H4YVW3VgV8N78231m0XkRV8V4nA231Hn8FZ8	#B0V!2$405#21$4V#c@!1@1#8Y/V6o$5#G$B0c!22#2W9k	&2*1/!2/$1!2)2//1$6$4$1&1,2////!2%1&6-11//%2%502/!1(1*2&2///)12/%61#1!101)3$2%1+6&113/,2%402)2!1/02//(1/-1#1)3///$1(@&4/&6*3!2&4$2$B/-2/%2/$2%1/0p%7(1/+N/2)1.1%2%203/-6//1/01/$1/%1/!3//#1/	ek`PDL@KD`IAbPNdLbbRbLTTbbtRVVvhxL|zVfv`BIjjAB@@bAAPcp`@					antagonist	P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
|F:0S(xh(Sl0x>x>:v:0xh*F*`.h.>.>S~.h.hxh.>S~S~xh	;xvhtS9k5y5J@EA80K2N@N44F0dYg@8PRV582029V9621!XGVd0lL9Fk33GV0V91A040J40e5J343_0V0Fk	0qJ0TF1w!C10480c!4O01p07R0ok05JF1e0780Sk3F!KZ07V0TF1w0EJ% !BV8k78271m0W0MPZ8P5Z140t0G8DF483Z180t0GN@_q4G2	#70k!O0g!6WN!1eeF!V7F!70A!104#s98!42P#G0F!4mk!8a4#18#Fnk!80Z#G8V	/!2/#2@01$1)2!4&1)1/.4!20104*1+1$1%1+3/!2%4!1+1.2%2///%32&1/#1%1/+1$1+1!5.12/)1#4//+2-2//%1$1$1.1,2-1(1*1,2/(2(1-1/$1$1$1!13/.1/03,108&2/+1/01//*10h01#3)1)1/@&1)1#2+1.11!1!5!1/1(12/*1$2#411$1+1//(2+3+4)1/!3-	fiwI@@I^CDBTsJwnl|kxXKQkASt]AHRTAEUTA@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
vl|FS~lv0l|`~S,BW~`|0l0l}\6sW~,B)J`|O(0l.>6s6s`|	:PnJmsJ884y#V0N2dV80HGJNF%HF45!810k0401V0e809V4JF1081F208152A50412%2010BVV	0aJ0Tk02OF1v!@H0ER!_F0zF055V0U06g0TV2q!JL01w0Pk1u0AN$ $m0V0RV8k782C1m0WVRV8R4V2DG0Y4G08H9Z140t0G8DF4B2WWW1kgV8Z782@180ZX108T84133NV8HEZ130l0GW0V463	#V2k!4$2I1%V#4#B16#kR#6Y8!A0N#J1#I1c!191!1K8k!B1R#F7!2tFV	)1/-1!2!2,404)2/-105$8%1#1/+1///&1/*1/4)1/!1//#1+2/%2/02.1///011/+54%1//%3+1!41//-1-1/&1//!11!1//(8&1/21/3!2.2!6$1$1&1//%1//&20g%5(2/%16#H/103#3//!2/-@!12///!1(2$2!3//(3(102%2*3)1,	fi{aB`NVAbHBLrAYBladTRbTVRbafdRiFF}t]MTDCDEPB@@@					allosteric enhancer	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
(S:v:0`|*F*`}\6s.i.>`|p3`|)J.>S(.h6s.i.>`|S(.h.=.>	zyvzDLtr8uCeZXECSc0Z0SFHFg1693904LeV_0Vk39010k1V72KV0V141FV01JW10cG8VV@610841IJ21VV0FF	0mw0FF1D!GG06J0Q01v!HD09s0d03Z!OG06c0Q01j0780o!6PV1g08s0bV2Z0DF# 38251m0VFRV8R78271m0XVRV8R4Q2@WXVnIZX6736kXcNgB92E1ZFk	!164k!e4V!60c#US#h6#64D!12JF!1W$8N#F1F!6Hk#X4#1s#9Xs!C4Z!35ck	!1(2/+@/02/-101)2.2$1/#1///%1011/!1$6%2//#1/15%1//.4(101/02.1(1#5/,1/02/B&1/%1$102-1$2!401$2+4//,1///,2-1&12%1&1%1+2#2-2&1*3(N&2,1/(3-3(2/,i1#1%1+101/6//%4#1.6/-21%3%1&1#1#1!1//*2%1//%4*1//	fegH`@DXeD@\bbbTRTTRbjvfUFVSzKUP@QDEUT@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
4iWy0D4i4i0DOy.K0bsh2f@t@2Sy-S-S(f@2f2@22@-S2@I.-S-S@2S-n8@t@2-Sx]nnxI	<v[yzUu=jUyzr;xU:T;nrzj;mUU:Uffx:xazvQ:EHhbUrzvUMzjSUtpfrR2N1V	0dV0ak02@F3V!8s0D#b!vV04OF1k07g0vV05SF1r07c0U03L!Je03V0R01v0DZ01LJ0Sk1v07k0zF07@F0e03V0G01p07c0s!7D01104J0Sk1v0CN0s!9@F0e02s0FF1204F0Tk2d0D$ 0BV8c78231m0XFRV8c78251m0XFRV8F78271m0VkRV8Z78271m0W0RV8F78241m0WFRV8J78271m0WkRV8Z78241m0WkRV8V78281m0XFRV8g78251m0XFRV8B782C1m0VkRV8k78261m0XVRV8R782@1m0XVRV8B782B1m0VkRV8g78251m0X0RV8V782A1m0YkJfw8F4O636NW0FOB61XklWZm6FHVYW3Bg8N4BI9WVVoFm2C6DFkNZFm2F60Ybs8kBm2L66JcO8GyBBWXFk	#XVk!IF8#ss!2EY#vgF!39e#aIk!H74!8Ww#ANF!Fqo!@4E#GWk!8Ss!@4c!2C9V	!1#2/01-C!1.3!4$1!1/!1#101*101$6#1,3///$1$120102/(12)1!1!1&2)2+1%1%5%1!2(1#11!102$1(2/#1+1(1,1,1*1$2&1!1&101!1$101$1401#42+1*1*1-602$4/#2!201$11021(1#101#1!11%101+1%1/-1%1/01&3101)1!3*1*1(2*1/%D#3%3/11%1!21%1*12$1$1/+z/!1020101/08/2#1$10101$2/!212(1)4*31&1/11!1010205#1/&1,1&1$1102/11!1$301$2!1!1-4-	ebSTBH@IAeHlg`ICHhdhdhhbmEDihdehmYPqHYhxDeTtL]Mm|Bcc@AUSUUUUATEQTTUGAGe@QBQAU@@						Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(Dt4-[_.yK96Gx9696rj_._.+._._.r<zS96f196S,y[m6_.m6y[j4m6D/zSW-4<f1fu	<v[yzUuj<jUyyr;xU:Tzrxnrzjv:mUzjzEffx:xqynQxzUHhYUKzQTMzjSRP_bqxmFtV	0dV0ak02@F3V!9k0Ds!vR0iF33!G_06k0Sk1w!G_07!Tk3i!Kp07R0TV1w0CB01Hc0D01k07g0uF07@F0e03V0G01p07c0s!9@F0e02s0FF1204F0Tk2d0D! 0O0FVDF483Z11Vt0FsDF483Z12Vt0FkDF4D3Z120t0FkDF4J3Z140t0G0DF483Z140ckH444R49NeFlcPD24D2MCVWFHW8M361t0FsDF4F3Z14Vt0FcDF4F3Z11Vt0G8AJkM371t0FNDF463Z12Vt0FsDF4H3Z15VXIGSJ8E4m0XkQNBB673bY0WNB8233XnX0FkB293bY0NF4@B56lGVNFN93AW4WF90B2J4dlVkBDI7UZWsFFR9E6120NF4645	#XVk!MF$kc!2En#zaF!79f#VMk!HY4!8Vw#9N$Ho!@4b#GlF!8Ms!@4B!2C8V	!1/*1)A!1!1+3024$1-1&1#1,101$3$101)3*1#1!11&1/%1!11(2)1*1$2%101%1#1)101/#1%3,1*1#1%1%10201/12(21*1/*1(2/!1)1/04%323/%1/2(901$301!1/020102#101(1$101%10101#1.1-10101101,11$1)1&1&12%1%105%1#2$1$1.101!101*1&A#3&4+2#1)2&1+2*1)1/0y)1/214#1)@/#11$101&2/!212!1$1)4%11!6#2/$11(22/01)1!2/(102/*6*1!1-1-	elUZL@@EAchTPNLldTTTRbfRTTQQrVRTTHXd\LR|JBbjFfV~AhJ`fbjjBBjihhbpPHXhLh@@					antagonist	Opioid delta / m? / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~}HS(.ix=.=.>S~S(xiS(.i.h.>x=.>S~xiS(.h.hx=x>.>S(x>xhS(x>.>x>xh	zyvvHlNI8V4kVHA4FN0WVNHm040F0292ZLIV5!c2Gk16d#24V52G4_08c98VF0VJ!4X0cV021F0F1FW0F0	0YJ0IV02OF1v!9F0DZ!_!uF02103q!C_07!Tk03OF1k07g010J0IF3P0EN0 %F9alcW0T926Y5llBV72Ylm8yF4J2F1A42NVo157VFcVBLIZ130t0Fk8VTM9XWHVw@4G2VYmBV8N5Z2EO0YFaI88J4733GcsJC6W0N4gaMZ17Vt0FkDF4P2PMaVmFQB4Jl13WO0G8DF4P2Y16FFG0G6a4D2Fg2FO0CXn22WFZFFs9ub2918kHH4y4C3ACX8RFX8CB8l8s8BJ6m0WVF	#e4k!1%4F#2kV!60F*G$18$F%F#8Z!80G#GYk#1s#1#235V	&1/*1$7*2&20103/(2%7!1/02$4//.2/(2#1&1/%11*102!4//01#2,8-1-1*1-2#108/%1.1#12/(1&2-1)5/%2031#1)4/06#1.2/,3,3(5/)2!2#1//)1/$E!1-1)2/*1)@(1/&1//(6/)t%1#102/&2%L$2.1+21!4)2)1.2/02/$404!1&41/)1#4/.401#2*1!1(101(2/#1!	eh\XFD@MhD@jgo`@bxHrRPqQQIIIFIIYEQZSQrrKjYZ@B@J@hHje`HEj@@					antagonist	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xi.ix=S~S~xiS(.iS~.>x>xi.iS(S(x>S~S~x=xi.hx>	;UvUzvUzylzizTXt5qqz24Zq5PjlkaCx0cY5Hm0FlG9mN05A7F14F2B2pl0F230Z4K402F46Y9D0Z0F4V0F0	0ZB0IV02OF1k!9_07g01Hw0FV130@g0wF$ 03x0482VWVplJVF44X40G_F4F4lH13Vcc8L8FQbFlcP28472	$VV!1+6W#F@#2CX#Vl#F1$VF$F$Ho!8V4#GV#8Ks#4#258V	//(9///.1&B$2)1*1&101///!21/*2///*2/-2/*2*4/4/%1&1/3/-2,2///*3&2//)3/04,11(3-1(1*1%2#1-2(2#3!6/.2-2(1)4/*3////%10e%701/01/H/%1#1$1/)3//1/&23%1!2&1*1/-1#3/!2+1#2%1/03+30	fnsa`@A@XGIEDhlihdhedZB}eMZjj`@HBJ@@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
J),Bp3W(.i>.hxp336S~}Jzd*`.hxh36S~S~*`xiS~xi.ix>S~S~W(zd.h}Jp3	:UvzvzyzS:QydjSUTtUAEdrATrgYSBgMxM9@F1cU_iapadTnN6S24x0N4XnI80Wp@Xk1V9F#F20k08W0FV	0XV0FF02FF1D!9_07g!aJ0Tk03Xk2U0DF01740ik2w0C801HV0Xk2U0Aw0t# #wH932NFNLCZ110cHGBm455Xt0G0DF4F3Z140t0H0DF4D3I8W3kgV8V5iR8WX0kFZN@5YlFFD@3VVGccoeu8W118Vd2W70Fk8RFD@7e1sZ8120XGd@xe442BWFO0g@G31X8NoVAU22WImcFk8x629WD3NJN8@4	#f1V!3@8!88Z!1H2V!V3#11D$1F#Y8!4Z#2PF#h3k$Z#Od#I14#44#1sV	/*1!1)H1#1/1///8$1$105///)40202%5%1/+1/$101/1(1/$1&501+1+1/01(2&2(11/01/$5/%2/$2!10101,1/&302#31$1#3-2-4!11,2-2!2.4/&1+1!4&1/(1&201B!4/01//+8////(2/1(2t%501&1&101$1*F/1*4$13)2$4//%4%3,1#1!1(1.12&2//)2/!6*1#1/$3$2	e`RVH@@DFMcgo`LbbbdRrRaRRJbbTVQCFabQRuswsUUUTDDPPLTpH@@					antagonist	AT1	Angiotensin AT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.=xh.h.ix>S~.>.=S(xh.h.iS(x=x>xiS(|`|Fl0`|6s}\^}^}	vyQQ@Itl8NCXVoACGcG1VNFHF4139190V2PV58VX3@F06F5V02GV0@141Fc21BWF09F@VVV4!8J1AF21!40k	0Os!Y!IV02FV1D!8U07g!n40FF1D!FU06J0Q01v!KW06F0Rk1w0CN01_40P01n07N0U03F$ 0BV8F4HpI1X0q0lD6A38CncNVBFyE1WFn0Nc24721NsR898A2pkNVX322X_ZWNBL370VksqF46219WmkZJ27W1F4gDMW1W1k_3k8L5Z13VWGGBVI4ZFd0ZWJ28S0WVYYNZ6D3P0ZnOJ8V7G9W1VX8oa34@XGVwF455ZZ@VFZ@BT26WO0FcDF4H3Z12Vel2g@894m0WFRV8B782B1	#60k!G0o!2Qk#@8#V6#41@#Ho#X8#B1B#BVF!4Fk!9a5#M$Vus$Z!218V	//(@02///01+1!1(9*1%21///#3$3/#1+3$4/03/2/+2/1//$11%1/)11///%1)2#1(1C&1!1!2-4/#1!2*1#1!1$1#4#1,1)1!2#102&1/!1/031/0511/01!3!11-3!2$1/%2/&7)A%1/!3$1!1/.1!1/,n!11//&8$1/!1,6,1%3101+1%6!201//#1!2//)201/-1*4-1(1+1&	fcoHB@BZLTFIdTTRbRbtRlRtLRYJJZm``h`j@jjjA@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>S~S~W(zd.h.h}J`|p3d,}\}\p3`|p3}\F*p3q5}\p3	;UvQOOSo5k40@UHN0GXN8m44FF9YY80HPV702028F9611V02GV4214dFcO12k2F3JAV4VJ!c111J2101!k	0Q4!Z80IV025k1v!8M07g!lR0OF1v!C305!wF05JV1p07R0j03J!OG06J0Q01q07R0o! %O0Fc8x092Z1NNBF5832n9FZ55Vm0l3WN4@2m0XFFFRkD91l0FJ5@6_640FckI23XO0Fs8JBM92l0VD52VF9VZn8241m0YVRV8o447AXmNVF35WV9O0j8241m0WkFHxR44321pmB85530VFVkKHFF0kFkJOJQBW11s84P@4CcXsR6275YdXXB@2592t0FcDF4B2KOb0kcTF4T2sL130gV9B78231	#aZV!U0B!40w#Fa#Z3#5g8!315F!K18!8MO!2G1F!WNV#BW#1c#Nmk!85Z#GNV	//(6/!12-1*1*1,2$3*11$2!22/&1/-102/%4%4%1/,1/&12(3//)1)102(101021#1$1%2/1!1$1+3(1/(1#2$8$1011//#1&2$1/$502//-1//$1/&1.2%23*1!3#1,3#2)1!1%1/%A/+2&1//#1/*h&1$102$2*1*9&1,2/30202.3/$1(1(1.122%1!3/01%1%1&2(7//$401/%11!1-	fegIA@NZMdXHaTQdTTRbRTJVbLRVYKU`q``XhHBjjb@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.izdW(S~p3}Jlv*`9v~SS~.=hxh..i.i~S~S.=i.	:UvzvzuzNjutod91d1taAPVJFIIeV08cHp2580X8@l841RW0eN49c4oFN4c1FH1W112V!4160FF%1!V	0Xs0FF02OF1v!DA09s0t!4NV1r0C!pF05SF1r07c0j03K!KQ08g0bV3!DF0 #1Z140YekFcA8241m0VVRV8g5gi261KWkFZA8281m0Y0FmWDD452JHNFN8a_26cGNFcFTK288FkFoR@0WXGpPJa6431_H0NFRK350kVVV	#aVV!10F!103!34YV!q1V!992!133V!AYN!@LQ!2kJ#VQk!804!2O4V!8ON#3C#p8V	0101/*1%108*11/01!2!2)1*1#1&6#13$103!2/$2/%1-3!1!A/*1#101//%3!2/#4)1%1#1*1$1/%2$1/*2-1&1/&1(1/*1$1+11(11%1!1#1(1011//3/+1(2//!1!1!1/*1/#1)4/01/%1$2%1+2!2/)3!1!1#1)114&1)1*1/k$15%2&2*2%4#@/+101/!24#1/*1%8//#2/(1/,5/#1+501/*102+	fmi@@DD}EhLbbbRfRTLTtRRVYsQoQ[LZvjVjiZ`dDj`@@					antagonist	A1 / A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
6s)J`|F*6s6sl0*F`|`|:0.iS(6s}\.=.>S(.iS(x=.=xi.ix>.=S(S(	;UvOUOSppl60@UIPFGXN8m460F9WW802PV70X138F8613V02GV42149FcG1DWHF1JAXVV480c11AF210140k	0Q4!Y!IV027k1v!C305!wF03Fk1F0E4011w0OF1q07g01MB0Sk2v0Ak0p!6JF1e0780Rk1r0C! !1Z120t0G8DF4D25@3nkkVB70VWGkFZkC651cNVDF244mFNNF712Gd8SLQ2WWVkRN@8CZmcBZD872431FL423VG8oZ4C@_IFk81834DKNFVA8261m0VkF8cXA7Yl8N@815XXk8oeL8YkVss8425ZplcFwA82D1U9VVkFJTL41WkoX199ZVGtZiB10l0gZcHVX12FgV8J78271m0YVI40N6539imkNJCmf261KlcGF8	!16Vk!NBZ!6I4#9g#VL#54P!1GJk!m8#859!2S8F!C9V!1iG#M8#88s!844!2G8V	(1/(1%9/022/01$2*1&1(4$8*1)5#2//&1%1#201/&2$2%4(1(3//#2/0101////,111+2.11#6//+9//01$1,1$2$2.102#1/1)2-2/!1/02/01/+24!1!2#2!3(1(2,401.1#16%2!@&2/+1/!1-1/(1!1l01/!1-1&8$1.4//$3102+1$16//044)2#1/-3%201/%1&1*6%1$1*1$2-	fkXb@B\tYIYkAbYEEDhdeMLcDXdddrVkQSAAQHTAUUUD@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~.>.i.h.=.i.=.iS~.=xi.i.iS~x>.>xhxix>	wNsK44VF8!F0104FN01V8(39#F!8$k060V!8!52!V09#2Fc!2!V04)86030	0aJ0Tk02OF1v!9_07g!t40tV3e$ $O0Fk9JTKAX40kN8P6143bleJBLB14WVFcfN4aX16Y0GNOVw4B371VNRM8281	%V/*892$1$Y8/2k$1#G%F8$2!210V	//&14-2#1//#2.@*1////,2//)1//#2/%2/3//%3%4///01/+2/&1&1/#1!1+234+2(3)4-2(1///4//+6//0F//-2&3*@///,3$3-2/0g%9//2#P///1-2/)3///%2/)3/////&	fns@`@@HR[e]VYYwxHNZmZ@BhH@@@@@@					agonist	EP1 / EP2 / EP3 / EP4	EP (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.i.=.iS~.=.h.i.>.hS~*`lvS~.>:v.h.i.>	:xzCqsp9e4qZ1EiHsVBXC201Z0F1Y920F!V86k2tkO0F!18!1VF0g09W02HF0849$4V2$1086030	0aJ0Tk03OF1k07g!sk0tV3e!Fs0440G01v! $1Je18YWccRR4164HWsFVL263MVXqc8VA82419X0W0P@7VkNB6LC10FWGfcR4AD0X0k	#80V.6*282#VG$Y#80J$8$2o$5#GV$4s!24#250V	*1/1*19/!1//.3#4$1$1/#1//#2////$1//#301*103/(2//$6///)1+1&2!1,1%1&2#21//$3&3!1$3$4/-1#2//)2/04/(1!1-1/@!4(2)1/#2/%7(1/&2///&2*b%401!2/01,F-1///#1+2)301/(1.2////$1.1%2//	fj}A`@@HtdvlkkLkrUzNRmT@ETD@Q@q@@					not given in publication	GPR40	GPR40	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.=.ixi.i.=x=.ixiS~x=xixix=	JFeF2!1*8010N0k+F010V%2*1!F(10204048$2$201F	0Qs!aJ0Q!2R03i!SG06J0PV1k07N0o03i! O0FVDF4N2FG8X0VZI826188LNNFE8261	#2$108$8)W&9!10Z#VW4$9#NV#40V#28#16$ks$4$VV	(2/1/-1!1/*1/%106(3!2///11(1*2/.2%1///%2(2///$2//2//01///3//!3/&1$1.202#2/$1)1&1//#1!1//-13%1&4.1%2#1/!2!1,106%21/04//,1$1/%R%3(2/+E//1+1$2&1//.1/.1////*3//+	f`qq@@BTDAIfUweV\]z@`Z@@@Py@					antagonist	mGluR5	mGluR	no	gpcr-ligands_DescriptorsNo5Ht
=.(Si.>.F|=.i.55lv*`~S:v.>S~`|.hS(.hxhS~.>x>S(x>.hS(xhS~.>x>x>	>U:KxtQTezUQPlvxdI6BDpCYjBBryqEfX5dATv0XYXDLKYJaWCdBdIlElHsmM9a5@MK1B51Ski1C28W0	0PZ!Z80IV02FV1D!8M07g!XF0s!2K03x!BM06J0Tk03OF1g07g!sg0c03Z!DF0@N0t!7901g07g0Xk2V0D!t# 0382A1m0VVRV8k78251m0WVRV8R5gi231HYFFs8t823WNVFFVA8271m0XkRV8c782612Mk8NNE8221@J0WVLF483Z130ebFFJA8261QWK0NJB4q11YkHN46A60hVG0q@55OWVW@Z2132Xt0FN884bF5FFkJ4237K1LcNFBDaDWl0cNF1133cWkZBE3XVF8ZHH2CcWd825733Vo1gJD21Wl8B4DF134Y0oa820V882N9B38Xl4B321H1c84LH4B8Gk8H72Z2F88RZ4AA1VkgLF4W084kHN6FcGsFD173Y_mFZFI3WVVFZHH3B@28oJF41334JOJP6432GVOJkH7XkV422@550IHBV9310G0oV6NCakVN650ZX2GWBR64XlkNHHA0VX2VvSB653H8kOZFD8HZ13G848H98511mF8JDFH252VFsOKBK5VFFF4F98S3VX18J4C4ZVY1FNL6841@F8Bg443k98Z426@m0VkRV8B4	#V4V$4!53#160V!42#6V7!2FSF!Ffc!4ZZ!220F!82V!905#l1#82c!206!21BV	/*1%3%6$1&1$1!6//#1+4$2$3+4/.1/$21%2)2$6%2/3-4#1!101/2%1,1//!1/)1&2/#1+5&2//$2&1*@5%2-1.1!5#4%2$3!4!102%1&2%1//1%501/2///)1#301.3.2/*3&203+A+1*1$1,1%1#2!1103)12/*q$13//!10B%1/1-4/0203!2!1/2%5-11/$6!1-1&1,1//$3(3/)1!2-	e`T\LB@CAkaMC`HbjPZdNiCHhhdiKELhdeIeXhdqpXxdU@PULDQEUTuDPTT@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
(WHr<<4^V2:>Mtn@6B4^4^M2s\S26CMt\sj<pB6B;j2Xs\s\S2S2j<pB6B6Bs\S2S2S2j<6B	zwtr4asK8e4P016gk80dVN0HGFN010924LHV584031k9401V0e0V1XKHG08B98HFc81284805X20JF$6030	0_!uF02J03d!9F0DZ!_!uF02YF3r!C_07!Tk03OF1k07g!qJ0R01v!C807!uF03Y03a0Dc0 $BLNFgA82A12M0WcF4L694W2eF8VCej28WAFGd84LZ14Wt0G0DF483Z150t0GkC8Z452m0YVJW9P673m0WVRV8c4D2GLVYpF8o@2A4A_k8F2215H1WR4JIZ130_ksG44L91YIN8cOP2F60YKF8ZB4LBWY3O82443YWFH@c4Th16WkGNXk4a210VF8iBBAVXXBV8N4g828VHtJBPN153@VH0k4Ph151VHtcBNN91kl0qF4L2gR140VF9GRi1VW1siF4B2MB0H0W089AWY1kps8T4fF_klVTF4D3Z13VZVH3oe4B33apOJ4@J5LVZkVs8VH913GRV8N4JlJ1ZVwV8k4k2N3V_VWF281W0lNVPJM1B20HkcP24WkFRZFC@Aa0Y0ZF4J0W10kJ@C9	#8VV!2$B$20V#24c#82!1@$8W%V)kHo#85#GV#80s!222!2W0V	)1)2/#C!2&1&5//1%1&3-12/)2/.1/!6#1,42*1$1+2//%6,5(2%1+2*1/%3///02/1//!5&21//$3+9&43/&7/3/,1/#1/(1&1,1/&9%1$2/,2(1!3*B2/.2)1$1//2%102(z!3$1!4#41*2-H%1%1!1%1-8)23(3/*2!9/!3$80@%204/+2!4$1/(3/*2&21!2/&2$	ejQPI@@@DCOFcgoh\bfbbbRbTLTRRRNbRRVtBjZFvVnZdJAj@B`@bjjH@HBD					antagonist	ETA / ETB	ET (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
b+}ZS~.=0lvlS(.h*F`|F||F.=.>J)3pxh.i*F*Fx>.=3pxi*Fx>72o2xh	:UvvvzvzOznvyvAGl5vifUZy4bQbVO8xZK@0GFfDIlX1ty1ZOJ45y4sD0BV!20Wc45J028d8Gu1F8F!W8F0	0p40OF1v!B90CZ0xV03OF1v0Eo012s0CF110CZ010J0IF3P0EN# $45@YFw4B@610Y1VT94X0F861B66O0G08VNS@2l0FDF98m0WFIgR8F4H1XGt4B8230N441C46t0GF90TN36YncFVM8271	#10k#8$4$F%4$C@$3F#3%F#8FF#@k!80K#G3#11s!21#271V	/2!2/#@!205.1+1*1)7/$4$4//!1//,1)3+6%2+2//-1(1(1//(1+1+101&1//2021/02/(4!1,3$4&1%1!4+1#14/$2#1)1)2$1/%1/$21)6/%2!1+1&1%1(B/,302*1%1$1#21#9(1/*1/2//-n%5012/*1%G$4/&1/.1+1/!2!1%2*101!1%17/.4/)1$4+1(2%1!3-1#1-	eg`TBL@LAhDMc`@bZPVBLddLTTTRTJrRVrtbfcbQWRuPUPA@TUKPHTDLD@@					agonist	mGluR ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
~Shxh.~S~Sh.~Six~Sh.hx~S~Sh.hx~Six=x~Shx~S	zpzpMWOK9k4R412@RN0V2N2N$919046VV50802GV#1V025V50149FV019VF081$4#40H0F13V8kF	0PF!ZB0IV03PV2q0C#qJ0Tk3x!HE0@F0t03c!K_06c0Q02q0C% $ye462G6XOJFJ8K@ZlFkZBE6m0VVGs8Xe2621d2OFFNK152WK3RBL7Z12VVlOJaD4XVkJ2JG@7bYOgFJ9Z12Vt0GVDF4F3Z13Vcs8G48	#30V!58#20@$P#Z2F!B01!12_V!FW4$N$V#4HV#Y$C$1mk#46#11V	//&16%1/*2//$2%2#1////(11!1&2/02%1//,2/%2$3#11///!5//1#13)1%2)1+1$1(1(4&1///!2$3)1#12020201,1/)1/&3$1)303,1/*1!1+2!8$2#3+1!2$2*1/2$8//!2$1/*2/$1)_%2/#201-C*2//02$1&101!1#2/#2!1/%21)1/01///*1(4//+	ff}Hb@AJ\ENPRFQQIYIQIPiSJcK^`@j@Hij@@@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.=x=S~.iS(xixi.=.=x=S~S(.ixi	yJul619G8k4F0F2!F01082H$1!202k04#1FV#WV#V10JJ0F!80V0c#2404%2$V0FF	0_!uF03OF1k07g!t!d03Z!KG06J0PV1q0C% $6I88B5Z16Vt0Fk8WJP821Gkf9Z4@2m0WVF	#30V!188!208$8#Z2#40A$_#FW%s$V#42Z#X$1V#1ek!406#10V	/(1.3.1!1&2//+4*1///&1/1(1/$2#101.2//$11(2#4//#1/!6//%2///#1/03&1$2/(1&1+2$1.21/*1/#2)1/////)5,101-1,1$1.6/(3//)1$1/01(V%1(5*101)1#E//%2)2)2-2(1!1!2!1/$202(1+2//(1//02/(3/!	fdyP`@D\AYIefUV{Txwfh@@HJ@@@					antagonist	mGluR5	mGluR	no	gpcr-ligands_DescriptorsNo5Ht
H})^qqH}S~~S)^~SF|lv*`:v~SS~.>^}or`+.i.hzd|JK}|J.>`+	:UvzfvUzNMyQTAjESNtmN@97EN_hY0BBIxXC@X!Pk96JV1H@O0OV4ws@Zf7Ln1WK8Al0VJ010101JV88V0FV	0Xo0FF02OF1v!C_07R0U!3Xk2W0DF01J40G01507J0Tk05SF1r07c0U03L$ LD0VVG1VR1220k8NJRbEWXl8R8FAZ120t0G09weL5XGG8N4DCZ140t0FV8_c336k88RDEZ160aocFwZ@10VVcZRiJCY0F48624XXRV8J4wEC108csJ610kFcVcJW820d4NP320FFVVc	#@0V!7$2cR!20XV!g9F!A98#2_$b8#5D#9F$mk!845#KVV!8SN$8!250V	01)1#1/#1!E!1+1/.1/#1018$3$1$1&3/(103)1+1,2$1/!1$1//)1/!1!1-1,1%1$2/#3*1-1-1/&2#1#1&1&1#1/#101.11!6&1/1$1/)101%1/#3-2(101&102/02/!11#2/!1+2!7#1/!4/$2#103#1%227*1//!1/01%21/*n$27/#1/F$1.1/&1%1//$6!1/#2#1&12//$1-1&1/)2/,1-	fmQ@@DFAdTRbVtTTRbRTRKAF\V]^cVuUTuA@DPED@@@					antagonist	MT1 / MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(S~.>v:0:xi.iF*`*S~|FS~.i|`lv.i~S.>S~h..i.hS~	:UvjfzUfNjj1T@fCCN92Q5tKBP_hW#3oVC0F!@G0a41W6mFZN6148FV0I1c!K9@V4VB!8!3FX14V0Fk	0Xo0FF02FF1D!9_07g!no0bk2z!GN05k0bk2W!GE08g0bk3Z! 01al23WO0FcDF482lOW2FgV8Z78271OcWsNgE8261m0XVNdw8P5Z130gkGmRJ4A3EGVWNI44T7KW30mX08a9B30NVoN	#NWk#8k!484#8FV#2#11g#m5$WN!85$2FV!4Xk#Gg#9dV#K#21#11FV	$1!1)3/$C13//!1)1/&6$601!1+1/1%2//013#1(2(1/)1.1/01%2//&1/*11#12.4//,2//,13&1*102(2#3&1&204$101!1/*1$3%1/(2//,1/01+2*1+4/&1(1,2(1)2+201#11#1/%2$8//1,i%5#3.1#5+@)13/1/%4)1011&1!1#1(5,1/#1/$1/20201/)1/#5//+	fewi@@DBexHLbbbbfRbLRJbRrmN|FHymUPTPSPPDP@@					antagonist	A1 / A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
6s)J`|F*6s6sl0*F`|`|~S:0.hS(}\6s.>.>S(.hS(x>.=xh.h	vyQvP1OM8F5c02@CS8FkVO8H0B049W984L@V50V839F10V1V62KV0V141Fc01RWF0cG9VV2410841QJ21!40F	0Q4!Y!IV02FV1D!9204s!Ww0Tk047k1_06k0Tk053F0H06c0Tk2T!KG06c0RV1v0C% $1Z130t0G8DF4D2c15E0G0LF4B3Z11VXa1VX864LXmNBFC633@HGBBE56XXYlJX7321lNsOXh33WZme8R@0Y1WX24uJ12YGFNt6Q4XFFsgR74DWWFwV8w782D1_6VVkGy@49278IFNc@J53aZWVD@J5m0WFRV8V782D1JE0WVLF463Z11Vc8VGF8	!1bFk!OaV!6KW!2F8V!ZL#40B!2HB#Hd8!B0N#J5F!JXV!1Y5#McV!B2w!DGZ!219k	+1%3/$5/02//*2.8$1)104&2&1/$101///!2%4/03//#2%1///(1$1/1+1/,3-1/02+1#A(1//+2*2.502#1/!1!3#2%1&2(1)1/02/)1*1(1%1(3(1$1(1&2#12*1%6)@&2/+1///$1)h$1,1)1&1%8$1,1$1,4/#3!4+102!16!2#2!2*1/%4(21/(1%2(1/&1#1%4$1//%	fegHC@BVsTFIhHLDYEEDhdhihTXcDfRLyNXHJI`hBjh`@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(.ixi.=x=S~.=S~t7S(.ixi.i.ito}Z.>.=.>L}{Db{o2.htoto}Z}Z{Do2}Zo2b{}Z}Zb{	=vzuzxzIzylU0vKQUAyJPH7fi5ksdOx20OFW0H1f7Fh5Z$B6s0TJP2HJ1l42264W820WFF!VV4V0FF	0Xo0FF02AV1D!9_07g!qJ0Sk1w!DF0@40t!4AV110480eF04FV130@Z0wF05SV1r07g0U03F$ 0BX310VsI8291JikVsLF4B2iD50lkF24A50VXuVk41432t0FV88yn3XGH8c722361t0G0DF4F25NbG8J4175YVFGVmg490VWWBV8o782B1HjkWFFkaJ91W8NB20_2mYOZq66VWW0mKy4421hJsJFJ81JCFkVwG2s5WY0kFJLE7XG0ZF430kV4sNR28a1O4@C1WmGG@4ie121W09FP@C_VNFVJF8I_GVgB277YoXFFJ8	#32V!188!2XS!1F2#VEF!3Ce$5#JYN#ZB#1F$Ps#Z4#9$1OF#42#1@V	//#2!2M//#1!1)1-1%@02027$1.2&1!1.1+1$2#1//+1,1&2/#1/$1,1$1.1!2.1#1!2(1$2+2(2$1/#B/!3/01%2&1/#3$11*1$12$2#1#3)3*120131/+210802!2/#1(21/%3(4.1-2!42#2$1%2#1/&2/!7.1-1/&1/+3&2(z%5/1!1&131%I(1(1#1$2/$101%801+2.2/0113%1)5+1#2!1/101!1%2(4/*4*1#1,C&11$	ea[RD@@DOLdPN\bbTTTTTtRRVtTQRVqTRVgdSUVupOtKOKTE@U@UPEPTUUPQTAA@@					antagonist	NK2 / NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xh.hS(x>S~xh.>S~.>S(.h.ixi.>.>S~.hxh.>S~.hxh.h.>x>S~.>S~.hS(.>.=S(	>U:pzxzUvzUzUovjvUiEiUCrSEzrjTDjPbzQzfck7XI5LVpxHW_BAYdQNm1c7tZ2Hm5lTK1kFOGPV0F0	0PZ!XZ0IV02AV1D!8i04s!aJ0Tk03OF1k07g!sg0cF3Z!HE09w0t03c!Jp0480G01v09w% !m0WFRV8J78261m0W0RV8Z6FR23WL0H0N4435XL0HcF42223lKPo8a6181VGk_R4NC14W120x8@60kF4ZHHE5aHkoP275YVmdoqD20WkksFJI6bWcFRP415VV8FRcH572G0kNE24_VF82322Z3W0VsG53l8FVJF@67HOFDBB1VXGkl12P7VVFsNRBB@YWsc454VVWNZgH@61GFc6C11kcJ8217Z3wV8N782@1m0WFL85X693MhFWkKZ4o2215VN88a@233ktFVC2XV848N@B22WNkPA62W8R22B5643WkN2732GZ9G2@45VkG8d1DX121FccwsI7X3GVN8697E1FWNB931Vt9B22280FGdaF463Z11VWlssPQ51VO0g8299	#W0V!F8$4#3DF#W%V8#V1F#f#4Zk!1V%2Z!805#OV#98s#42!258V	.6#1/0119.6!1014$501/#1(2*6#29$203//!101.2+1(203$2*1/$101$101%1)1(12(1,2/1$1+1/)11,1+7!101/2(1/!73-1(D&2.101.1(103$4.101#101)1-1%1,3,1$10306.1$11%1//*1!70103*1/-2/047/)11$1#1/02//+z%5/#1/F#1(2#2/-4!1#401/-5!1/&2!1$13!1#1//-1/*1#3$1,1!1$43-	ej^\B@@L@n`DOFlbbTTbblTrrrRTRbbcRLlRJqIZjjjA`bjjj`@``hH@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxhx>x>S(xhx>x>xiS(|`|Fl0~Sl0lv|`|F	;rurSbdm7w7k95QB0_VN@m0VFJ8VbV4HI05B!1@o84YFV0XN082WJFF8c1OF0W302W404!V0F2#W10VV	0WR0Tk025k1v!BM06J0Tk03PV2q0Bs01M40Rk2w0Ao0nV05FF1305J0Lk3c!O_06c0Rk1v0AN0nV! $BV8g78241m0WkRV88782A1m0W0LI88H4mO150gV8o5Zm25WO0GNA84im1@WBaFFs9Z2DO0Y0gV8B782C1m0a0RV90782E1m0VkRV8F4	!1iJk!I0J#V8#@6V!wVF#VA!22wF!m3B#2N!2F1F!g0V#m4#10V!8kk#p4#t3V	/!1!2$1&2#4&1!1&3/)1$1-1*1////#2#1#8%2&1#2$4//!1.1%101-2!1!2%1/(3/#1%1//!1,2$4///!3/#11+1+21!1&1$1/04//1!1/04////$2/!1!3-1&4/.1401&61$2+2*1.2-1//#10b$1.1$1#21*6/.1)2(1&2/-7/$1$1!1!1/$1&4%2%2(5-1/%41%2,1/%	fnkIA@KN|GHH`dPdsN|kK{JsakAcUlDARuMTtS@@@					antagonist	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx=xiS~x=.ixi\)xi.>S~x>~Os6.i.h}\S~.h	:UvznSzdJbw3q9AUD8WV9@cV8FK8VE04Mp07E250AoN4WHV2Yy88a4KFN8c11F0WY12_80G1040FH010VW0F0	0WR0Tk025k1v!BM06J0Tk035k1_07g015c0Zk2T0B!18s0bV2X0DF01Ns0bV2X0B!t& #1Z10Vt0FVDF4@3Z150t0GNDF4H3Z16Vt0GkDF4H3Z15Vt0GcA9Z4D2m0Y0RV8B782D1m0ZFRV98782B1m0YVRV8B782F1	#VJV!304!2&HV!H0V!4V2!2PHF!@l#2B1#25F!FAV#NZ#G$80c#74!218V	#1/#1.1$1////&1$1%1/#1!1.1.1$1!3/&24!1104.1/(1)1!1/#1*1//%402%4*2$1*2/)1/+1/%2&1$12)1/$42*101!4//01)1/1/2/&6//&2/%B/%12#1#41/#8*8/01/////0d%4+101$1$2*F/%3$1(1/&1)3,1#7+102///-2!1//*4/&3/#	fa{IA@CVCFhHclQdTRVTTTTRRQQhrpXiJv@BZfAhDb`@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.i.iS~.=.iS(.i.=.iS(.=.=.iS(.h	yJPl619G0F4F0F2!N010N2F$112!2k05$FV820WV021V104J0F#2V0V3!2404!8!2#1VVkF	0RZ!lR0SV3F!Ce0AN0o!3Z02Z0DF016J0PV1q0C!1WR0NV1e07N0hV3F$ $O0GVDF4B3Z130t0FN8A44B2m0WVRV8B4GR26WO0G0DF4B2fDbFlsTF4B2e16DVG8H0@5I51Gkc8M68X410	#na#588!30c#F8V!w2#589!20gV#VV!84N!20oF!6AV#e$5$GXo!40B#9JV	//&31%2(1///&2*1+1/.1+1,201/-2%3*1//)1)2#1//1!1//,3+2//*2(1.2222#101/01/%2)1$3,2#21//,2//$1//&11/02!4#1/02/*1.7!3+1(2/&101!1+1$1/01(T.3*301%1!1!1@//%2)1(32/-2*1&3)3/!1%1/$1/%101/$6/(1/!	fleYB@DTDhrY@bLbbRfTJbRfhstX@JZ@Hp@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
h.>xxh.=S~x>xixhx>xiS~x>.hxhxiS~S~x>.hxhxhxiS(S~x>x>S(x>xhS(S~x>x>xhS~x>xixhx>xix>.hhx	:UvzvzxzSxfvwvzUfOnjOsryD7fZZ9OhDy27X2fA3GX085VV8J92D1c0DR3296q!I0k090e14F1NF3V!8!	0Z80IV02OF1v!9_07g!sg0bk3Z!B704o0xV031k1C0EN!qJ0Tk3x!Fi0440FV2d! 1H7I2FNcg4296GWXGwJ@G51YFsoN51XFcR8310FV422H9VVH@N8yB7dlH884RCZ180VVkNBB41VkF881VVVB4610kF44gJLK648NJBDQ94ls8660VHWdLF4R2462X9cV630HHN44TJR89GsBJJ1143O0GF88L94Y18BH43WkF88310V85BXbZ13VWXWFaJ1VVk8ZPHdMVGFVgFJC6ZGFZ@43WFGOB42286t0Fs8JH54ZG0c@431VFB@2184oB8B8D4863H0ZJ83WkVB21173nZBB8D4571nOBL241HGs44JK1B10k4JR@52X1tZPA51FGGB229AWcFVVFJR@D4kcFN2970FG9GtDN3X2G0	#@0V!1-V#8#18V$F$W$4F#8F$2k$5#GAF!B5c#1#211V	&2/(2&C!1&2)42&2/$1!802&2)25$5!1(2!2///01///(4//%4/2)4,8/+5$2#2!12%1*2&1%1/16/$1/(7&1-6#1#1#1#4+2$6(102#11%5&2!3/#2&9#102//$3/!1(1&101#21/0B$2$101$1/&3+4(2D2//2+202//02#2+z!2/)1&B%J!402/1.2*2(2#2/)2!2/$3$@%5(1.1/(1#12/02!3#3#2/,6-	ec_TJJ@DchDOiUP@cJPjdAi@THrRPsIYQQIIQJ[KYQQ[QIYRBRQEK[L|kP@UAAQUUUMP@RpQ@iP@@					not given in publication	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S@z@,)]n1)I18~UH*1n.hkwb++Dw;.>.>{CY(.hY({C	:UvzvvyzRjwtqdzEx9lzAP8b9AUgn49gMx2@BHaNHpfDFwW29L0lg6xZ84YVHP3d42kV0k0124ONV!FBV0F0	0aJ0Tk02OF1v!DF09w0t!3Xk2W0DF017g0Z02U0DF01Hs0G01707g0Xk0 $BV8R78231m0WkRV8N78201m0WVRV8k78241m0XkRV8J78241m0Y0RV8R782A1m0Z0F	#d1V#8%H!1,c@$1F#fN!44$VF#V2k!805#G$958$2!218V	/*1%1%4////&82#2$3///&2/$3/)2(1$1//.2//$1/$1(5/1(10202/(1$2,1(1)1/%34(101!1/,1$3//)2/01)6%4&1%1!2-1//&2/#8!102//)1-4028/,2$1/$1-2/+d%8/#1/F///401/(401*6//$1///!1%1*1/2*1/$1*	fnkQ`@DT@YrSKKJsK{oEV}DmVmUUPs@@@ACE@@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>S(x=.=S(S(.i.>x>.>.=S(wkP(.h|Fs6c+~Y~P	:UvzvzvzSznvwtUGv5vjfyVw0rQibANsqp@5d0Y8Pt96GwlV@N83B4oXTBc3HL5d302o0V82D0NF08!B1#	0WR0Tk02OF1v!Bi0440FV035k1_07g!o80Ik2d!DF09s0t!5Tk2F09s0k03Z& $1Z110ZccVBJ513XE3NoBF7Z150t0GN8ss25ZkcJL595ZrkG0J4B4kP11VgV8B4aO2ZllBNLCZ120t0Fk8e@8423Vc8gKP2BQVXVcWg@6A3m0YFRV8s4PP2W_10oF8521WdDF462CFVVm9ZFF1231pc91i2C2	#14V!1c4$F!240V#8V!1de!20I$XF#J1#cFF!FAk$5#OB#9Gc!442!270V	//&1@/%1!2101101-1/&4$4$1///-1(1&1*1$2#102//$1/+1011#12(1//#1#23$102!4/(101+4/011/01-1)2$201(1/1!1#1*2$1//!2+1/#102*2/)302/1/#1/!4!@/)2$22/1.8+2%3//&2*1#1)1)1#l%6%1&1&1!1*F%2%1-1/)1//!3/1/#2/212/#1)21/!21-3(2/#4,1	fmoqB@IZFdDQdTRVRbTTRRbJrUFF]Fhyp@TtE@tUTQP|P@						H	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~.hS~xix=S~xi.ixiS~x=.>S~xiS(S(.i.hx=x>S~S(.hx>xhS(x>x=S(xhx>	;UvQzvUUzYvyuUlfpQUudLy6YdpiARtfTe5Vl1238X605XV1FW0A3g8LJ2IBV02EH3FVW4280F330XW0X8GF	0PJ!WR0Tk02Fk3V!C_07g0zF045k1_06k0Tk04AV110480c!4AF110480eF05NV1c06c0Tk3F$ #OZ404FP9Z140f60RBB7Z150_pGoB8F47KVWVLF4F24Q8W0WNFr9281O0Gc84JPBX1kJ850_32a@w864315oGVH60YWll8oBC2ZGNw@2@7VkGdNNcG9WlVJB31VHmOTF4P2AKcl0BJVAZ170t0FN92c4F24Xksg@66Y1cZ220aYIRV8J5eU81ZFwV8g78261m0WkFVscC8Xl8N6115YXwV8c4	#74k!82Z!201#F@#VD#5VV!20ZV!83N#88#8lF!JFk#XZ#18#43k!82Z#39k	/301/$E/!1/,1/2)25#1/,1$11&111*11#1!1*1/!21$4%2////#3.1101%1!1/#2(2!4/!1$2&1#31/401&22)1)2-4/!6%2/101&201!1$1011+202#2!2023/1*3#1&1!1/01#1$4)2(2/#1%1+2!9#1%1*2$1!2*202#1$1#1!20C2/&1!2//&1#2)2/z%2(2&1!2!2+1G$1&1!1/$2,1%2)1/012/+1#1$4//&1#1,11#1011&202012$5/,7-	ebQZHL@NIGOClPH`jPvdLbbRrTRbbabbRvrtRTMCEccTprpLL@E@PPUAQUUU@UA|P@@						CCR4	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>x(Shx>x>x(Shx:v:0*F*`.i.>.>S~.h.hxh.>S~S~xh	vzUtv9tO9F5m1J@A1N0G2N@H44F0dW888PRV58!3NV160W!2GV905J9Fk23FV0V90A2404!840342W0V8Fk	0o40FV2V!C_07g0zF04O01p07R0ok05JF1e0780Sk3F$ !6F483Z16Vt0G0DF4F3Z14VZZ20Z8C4	#70k!O0c!6V8!12e#V7F!70A!104$A8#2P#F0F!4Hk!8X4#18$nk!@0Z#G9V	&1*2.2$901.2///$2!10104*1+1$1%1+3.2)2/.4%2,1//03%21&1/#1%1//01!1(1!1.11#3-101%204//+3//-1%1*1.21+2-1(1*1,1,1/#1//#1$1$1#3/.21)1%3-19&2/+101-1//-d01#1(41)1+1#@&1-2//#6!1+1-1.1/2#411*1%1///$1101(4/,3-	fnkHB@AV]xD`drmvjsroSbmNCUl@QM@QUTA@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixiS~xiS~x=xhxix>xhx>S~xhxiS~x>xixhx>xix>xiw<^}tnU(~U	:UQzQvtSNtXnJ27Fd1tV9862401Z018hLT250V13@G24!102J40D0g0FB@14V!120sV04084k11F&F	0UR!qJ0Q01v!G_07R0Tk1w!GQ05k0gF3r!Ji0440FV1D0@Z01LJ0SV1r07k0o% %KskR@51GlNyF4X22SW8FlRJ6R5m0W0KsoJS44XO0HcDF4F25R161lBB6I5m0XFRV8k782J18AFZVVg83EXt0FNApD4N2m0Y0F	#20V!108!2Vg$2V!Z3#708#H5#FW8!208#9F$Ho#4Z#G$8Qs!@F4!211V	%1/)4&8,101//)6+1%4$1(1-1/$1/)6)2/*11/21.32$1&1-1#2/02)2/%2(1///+5(21011$21/!3#2&1+1-1%1*2$1&13!3)1$2%4*1(1#2/,201$1-1/02/$101&3$109102-3#1*1+2(1%1!6%2/!4%1#1.202/.1+v02//1(I$2$101-3/%11*15/(202/2/02&2(42///*21!1#3&101/!1(1$	eol\H@@FGI`DfUvUvUm]VYhXtLbRjZN^ZV`@`@@Jjj`JAX`@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.hS(x=S~19*`lvS~.>:v~S.h.iqq.>x>S(xh	vzMvYflNf81e149718NWV9!kJHVc3!4HJ048#8k56F0Z0dc0106FkH0V3G21!12W$2$F0F8#F	0Y!IV02OF1v!C204w0eF03NV1q0C!14F0Kk1P07g% !38291Q5Y0NRB@E27@VNkBJE3W1lwV8F4NIE9l18XZN4CM0FWFaF4B3Z130XYlRm1531WgV8V4	#20V!30F!52$1$kV#18@!12%2%8*2k!207#K3k#lN!24N!2W0V	/-11(51-1///#1107$7,2#3(3//!3///$2//!2/+1.1/(1-2!2-1!7//*2,2+2/01#41///#3!2/02)1(2/%2+1,2/)1$1/!3//!8//-1(1)5///#1/1/02!1(d01#7//$C//%3/#1/-4!1%1/*4,1#2,3///%5/,4-	ffcp@@@LsdbbRafbbVVthsU`i@`jPhHjH`P`@					antagonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.ixixi.=x=S(.i.=S(.ix=.=.=S(.i.hH)x=.=	jovl60OK0F4N!2BRN0W0N0m$91@246mV50V8210828WV025V0V1610V09DW0VA102Z84d!40F041WY4l0	0WR0Tk027k1v!9k0Ds!ss0d03Z!B90Ck0xV047k1_06k0Tk065k1_06k0R01v0Ds# %dkJt462O0Fk8c4cWB1IVVsM8271CmFVkG04QJ15WO0FN8c4R@FfVlFaF4B2F13p0FcG04TWE5FlFaF46255WFmGNLDA23GN8gVq27ZVWFVcc@@A2X_s8VQ824186n20FT9Z130t0GNDF4D2F19gI0FsJ2B4	!34ZF#F4#4X$FV!52#BV#2P4F!XW#80F#40F#2V!10W#6I$Xk!214!218V	#1//#21%1%3#1-2#1-204.4*3////,21/02(202///(4///%1-5101*2&1!1!1$1$2#1%2!1//,1&4%41*1$1!1+2/04/&4#2,1//.1/)1$1/)1!3!2.4*2$4$1(2//09)1///&5//0Z%2(1*202&51$B/!3*1/!22//%2!1//!4//!1!102//+302*1/-	fncpS@BJkIvR`qHaCXcHhhdmBhhmMHfBBfBBF``aZ@@@					antagonist	CXCR2	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
+DL)2nt8+D+D}^Q(2n2nj//<{D~SU(-g^)h.hx/</<>x~S-ghxix/<~S	:UvzvvxxNxyIJAhSO8l2OPv5UNIdWE9BUzXC@V12Pl@4GkW0XO0x25oGQoe7Ml1WE6@lc04#B1GFFW01!V	0WR0Tk025k1v!8M07g!lR0OF1v!C10480bk03Z02U0DF011R0OF1q07g01K40SF1u0Ak0p! BV8Z78251m0YFRV8Z5Dx271O0FcDF4F2uK12FgV8s5Tp28WO0FsDF482bTW2kW94uDEXXlItw8JR5W1lBV8o78241m0ZFGo4e6G3DH0WVLF4D3Z160brFgBL7Z190t0HcDF462UEW3IVg8J8uK13FV	#raV!284!2XG#1X#i38!1WB!25B#CY8#US!2JPF!VDs!24Z#C0V!1lV!805!1I0k	$1//!8)2/-1//#2$1+2&1)101//!1!1+1*36%4,2*5*1//+1/1/)24(3/+1/+10104/(1(2)5&1021*1$1,21!1!2!1$101#101$2(2#1%2//!3/*1)4/$1/04$112$1(8&1-2)2!1,2#4)19+1%1//)1*1/*n%2%102$1(101*D*2#1%2//1!4/-8//$2$2*1,1(3%1//&3!104/$103$2(	ek`\HL@BNLd`HaRHvbLbbbTRRaTRbQbrRXdtljFVN``hfXI`hjbH@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xhS(S~x>x>.>xh.h|`S(S~S~l0|F.h~Sixi.~S~Sh.	vyUtP1OG8F5k0JA91N0l0O@F04F09W88BHSV58!2Nk960W!2GV9V5J1FVX1Fk0W90A04041084034210V0Fk	0aJ0Tk04FF1205g0c!4O01p07R0ok05JF1e0780Sk3F$ 06F483Z13Vmn8FVA82C1m0X0ON8wm2C2	#70k!O0c!6V8!12e#V7F!70A!134#898#2P#F0F!4HV!8X4#18V#nk!82o#l8V	/!2/$501.2/,3/&6!101/)1$1/!3%12&2)6/.2%2,1//(21&1/#1%1//$1(1!1.11/!2.4//&2/(1/$1%1*1.1,1/&1*1,1/(1(1/$3-1*1#4/%11(1*102!1-17&2/+101$3/*1/+c01#5)1)1+4#B01$1//$101*2211+1-1.1/$511*1%1)1//*11*4/,1-	ffsH@@@XiKIEEEEBdecDeQQoV\VhPUQUL@AH@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS~S(x>.>S(S(x>.>zdW(p3}J~Wdzl0~W~Wl0	uqPlHlOF8F4k0F#N2G082m04FF%2G61#1FV#WV02!9V4J0F&V14225041$202!V8Fk	0aJ0Tk02K03x!GX06J0Tk3F!KW0740SF2x0CB$ !38271m0Y0LF9GZ2G2m0WkRV8w78261	#60k!12#201#k2#W1#38B$4F#18!108$1$Hc!802#1%BF$1%V	01//%1&1-4//*5$5////#2!201(2(1&1/$1/04&101/!1/+2-1#41/%1/02/(2-1/!2/!2-1034+1%11/(201,4#1///,1////&1(1/#7#1!1/01/3!12)1%16,3*1//*11/-Z%3(2*1+5#E!1//+1*2/-2/+2//)1!3(1-1/3(3/#3/&	fj}pC@MNRBPQHXdLbdLRTtrVbRDjslej`BIj@@P@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~:v:0xh*FS(*`.hx>.>.>S~.>xhS(S(.h.hx>.>.>.>S(.>S()^x>	;vzv;xjwQuvCEEDnrvAsBOqJ8bDB6HtaE7G1eDrU6WHkDPtXOX5Kls0cKOPGWYV2W0VKH204F2B81V180k	0WR0Tk02J03d!9F0DZ!XJ0zF035k1_07g!tw0p03Z!KX06o0Qk1v0C!1LZ0SF1u0Ak0p!6IV1d09w0kF3J0DF% 38241m0XkRV8V78221m0WFRV8k782B1m0WkGQgw683EGVWNLF4D3Z15Vt0H8DF4D3Z190ckGXJq483m0X0RV8N562CVVXkX1oa6BDWVVkdBV4H9VZ5c8sFON281O0GkDF4B3Z190YZXNN8B4NC0XkHg4Jt1417ckFc8x623165kFgo422X13Hsk894m0VkH@SN6F327VWkgB480n8kRVcX81YmsN2696	!2qZk!e2Z#2U!17Mk!Vb8!1Z4!2NhV!cbN#IO!2H2F!oPk!2mX#hWk!tko!BVb!2pnV	#1.2!12)1$5/!2!4/)1#12)6%4$2$1*1/(1-1$1$2&1202203!2%21&3(1#2$1/,1(1%1)2%3)1$1/$1(1%102011!1%12/1/!12)1/*2.1!94#201*101*1.3#101!3!1#1(1%2+1&2%1//*4//1/!211-2!5!5&1/-1#3/2$801#1//2%2&1%1/#1/0p%3%3&1*1*A+1/)4/1!1%1*1+81(1-1041(1/%1/1(1!1/(3(6012#14031(1/%	ehRVLB@NE@dbjhlc`HbzP^dOiAIfV]mefWW_iXdTLRZjf``Xi`f`ZJjhh@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>xiS(S~x>x=S(S(x=xiS~x=xi.iS(xiS~S~x=.hxhxiS(x=f.x>S(2I	}jzU:xyUzvUTzbizrtCUEj8hbupGpfidm9ib6KWK1ABAiJnHEVcMZ31a0M629d501lUX208!	0qJ0Tk3x!GG06J0Q01v!HE0@!t03c!Jh02w0FF120@Z0 06F4D2j5VYVkJLAZ13VZYcoeG1Y31YZV8H4_GYWcVVF	#12V#8)18F#Z2#55%MF!FY$_G$F$@k!814#C$_3V#46!219V	&1/,3!9/%1%1//)2$5$15/$1,1/(2.1&2/04%3////$3.1/&1&2+2*2/&2!12)2%6&2&1)1!1/5&1!3-1$2/$2$2&1.6#1%2)1/,11///!201&1$2(111-13/%4(1*302!1%1(2C+1.1//,1!1.1#10o#102$5!4/1!1&B!7%1*1&2/,3(1/$2/$1$1)4&1/&1//,3(2*1#1*104-	ek`TDL@EEo@`I@bPDdLbbbrVTTTRrfabRXxRJVvVN``JjA`bjj`jCH`@					antagonist	M3	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.iS(.>S~.=x=.iS(.hxhS(|`S(S~x>.>l0|F.h`*}J63ps)\	:vQ@Itn8sEmVoACGs110PFmF41IA312V2HV5!X3@086G5V02GV0@G61FV012V!1J@X0c68Z@F43F2501!k	0n40FF1D!GG06J0R01v!Kn07R0ik2w0CF01_40Qk1m07B0Sk3F! 06F483Z14V_5Nwe8845BoNFFD87QdVkcNRVOA6FckoN	!360k!k8Z!48B#9ZV!VB8!118#HFk!V98!63B!2N8#80o#@4#WV#c8k!864!2GcV	(1!10101/&902-12-3.1+11-2$1$1-101)2//%2$11/(63$2///%6///.101/.301-11%2/)1#1*1,B/,401/011&1$1/14/01//.6+1/(5/#1%1/!211+1#2!1&1(1*1*H&2/&1/&1(2!101/,g1/#1/%6/!1/!4/#6/$1)1/01&1/(1(1#4.1/%1/!5/&1/#	fi{i@@JF}EHLdTTTTRblRUtRdzwhih@Hb@fjjB@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(.ixi.=x=S~.=S~t7S(.ixi.i.ito}Z.>L}{Db{o2toto}Z}Z{Do2}Zo2b{	:UvztvuzRCFtTGU0tGGO9uJeF23D508cOt2080V0H0A7Fd441#B6s0RF8VHF1W02224V02F1FF!Vk4V0FF	0Xs0IV02OF1v!920@Z!mo0AV1D!C_07R0U!3Z02W0DF01MN0Sk1v07k0o# $O0FkDF483Z140XP8cBJ6aU11FVOhHQ1XXWRV8Z4883mFk8NBBGdW3FVF8BJE_1kFVHGZ140t0GcDF4N2SL60NVwF46ZWl18V84664j3sNsB842bYccD@8540n30k8G40VFFFN984GVwD216XYOtJ8@42198Hlc281VVG0ZZ	#33V!188!2XS!1F2#V1F!2c@$5#4YN!44B#1%Hs#44#1$1NF$2#1@V	.3/#2!26.6/#1!1)1-1%@02!C$1/*1//03///1/!2/%1/$1,1$1.1/!1#2+1$2+5(2$1/#3/!5/01%@&1!1/%11/12$1(3)3-111/+2!202!2.4#1(21/%4(4.1/042#2$2*1/&2/!7/-1/#3!1/&1#4/z%5/#1&132%I+1)1/*121(1+2,202/0113/5/2!1/101!1,3/,4*1#1,4&11$	edZRH@@DOLg`LbbTTTTTtRUtTrRVJfgdQRuqssTE@U@TAPTUPE@PP@@					antagonist	NK2 / NK3	Neurokinin / Tachykinin / NK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>xiS(.i.hx>.=x=xiS(.iS(x>S~x=.=.>xiS(S(S(.>.>S(.h	yqPlLWOG8F5k0FA5GN0G0N2H04F093A!HnX58!2QV960WV02OVC25J1NVc1Pk1WA0@X4V4!84G3JH10V0FF	0WR0Tk025k1v!8M07g!lR0OF1v!BM06J0Tk04Ik2A0@!t!4IV2A0@40t!5OF1e07N0Tk3F!WE05J0Lk1e07g0Xk2V0DF# !O0FVDF4F2TJ7Vl0TF443Z130bckFZA82D1m0XFNk90w2C2m0YkPcw8L5Z140lYkG4A82B1GkFW8FxZJ7X21BV8R4@mE3l1kVxZ4A@3kW0Ws@4A@7WsNRM8241m0ZFRV8o6B2IE0Z0gV9B78231eYkWNGs@4D@7VWNw4HAZ180t0GcBNw4K2m0YkRV8k78241m0WkRV8s4	!3naV!I8B!2cd!1HiV!Z38!6cE!3@pk!BYN#HD!2FWF!ZHc#XV#10F!1ek!624#16V	!1/*1)1/%1//)1+2$2/#211&2)1/04+202/%6#214%11%1-2!1!1//01/!1&1/01(4(3/+1%1/.1+1/)6$102*5.1%1!12#302$3$1,11!2#13#3/%2,6#1/$1*4&1/(2%3/%9!4/012(23!11+1*2#F!2!1.1//.1*1/0q%2(2%2#1/G//#2(1,4/%1&6&2//-21/$3+1%11,2%2$3/,2%1&	eod\DL@NGInk`HaRHNbLbbbTRRabfbRTrjTXdl|JFZV``@bHBhFbfA@@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
)^S(S~x>*`lvxhS~.>:v~SS~x>.i.hS~xixh.>.>xhx=S~x>	zrzxT_OKcJ5w0GACLR0G0NPm04F09Yc80HQX78X8IQV96AWV02O09V4J10Vs1Ll0l91fXZVLW08711J110683V	0aJ0Tk03Y03a0Dc!kR0HV3q!K_07R0Tk1w0Eo01_40SF1r07c0U03L# !BV8J78261m0XFRV8R782@1m0YFJV8oyX24Wd0Gtw4PX14WnXkFN8V38YW294e4D70Xlk	#AkV!G04!6VN$aV!m4%8#X1#Nb4#1N#1W$FV#41#1Ik#Fo!818#81V	01$1/*1$2$1,1/#11-3.6$1#13$1$1/!2//&1//2/)2$1,1*1/01&1%1&2//)2//)2*2*1//!4&1(1/!10103!3%301$4!2$3+1#101//!3/%1!1,2#1!3!1//&1!2+6)12/#2*1!2/!7///!2$1-1/#1#2!f$15(2/#5&F/&103/!1!4)1$3$1(3)6!1/)1&1%1//-1/&1#1#1&2//#	fi{`Q@EPQtX@`laddabTTTRVRRU`e^rejuLE@DAPt@@@					antagonist	CRTH2	CRTH2 (PGD2-receptor) (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
lvBz~Olv*`lvd,~O:vS~.=~O:0`|.h.id,d,.>:0	:UvzfOUfFbw3LAjEB8WmOQcaBP59W044MxVC6V50@kC4V2c6nr0OZ6J8FVXG5W0WW1AV8241140F3J01V1#	0aJ0Q!2OF1v!CE06k0c!3Xk2V0DF018g0c03!DF% $38221m0W0RV8J78271m0X0RV8k78281m0WkRV8F782E1	#F1k(8$10FV!42V!602#64$l$R1#2F#2@V!4FZ#GF#82s!81J!2M8V	/01/////2,@$3$1$2/+3.5(1+211//$1$2//-1/.1////2#1/#1///!2%1&1*1+1-1!2!3$1!1)1-2//%1022+1/#2/*1/&2*1#6&1)1/+2/!4+1///&2*2%1,_%7%1)1(2%4#H.2/&2)1*1,1,24-2/&2/1//!1%201/#1!4*1/1.	fjcI@@DLEHBSLsMvj~pTeArdkULpA@@T@@@					antagonist	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(w;P~.>s6|`sp*`\)B,c{~MI}36~V*`36])*`36|F36*`36*`])18}IS(.hf,u8.>.>@,~M.hr5[)S(	:Uvzv;S:vyvUUzCvUvvziErUhrSCzrzeEimjOUivglbfqaS5ziDxMRZfnTtzd_3OmBFM39Fp0WJO1gW0FV	0QJ!aJ0Q!23F2U!CG06J0Tk03FV1E0@Z!t!c03Z!Fi0440FV2U!HD09w0cF3Z!OH0640PF1u0Ak0p& $1PZFW4@0VHFB4V1173X3kBDMC0Gmc84ZGZ12VXAVFV8c2Fc0YVXZk86G3210VgD741l8BD6210F86110F@cs22BL5DmsVFJ8z0Z2VVcF244WlVkH43W1FJ4210VN84a@IiVYVFJ8J6Jc120cto8N5Z130VG8ZkE421FZ64A5VVG9V46@6Y1VZT7410V42RGDm0WVJfw8@49271cZ4I22V9Fof828113ncgm46VH196F4H241W51ORaL3XlWd04427Xm8ZL48Y2ltSkF46210W0RJ@4WVVF6822FF44310F@cdJF2CP@0W8N44q122GVoJD6WFNF6110YlP6F4828C_llkJV@7B2l0gPM144HAVV8B4632WkR88420VBF210VN82ZC0VXZkIhD6@3121W0LC6Y0NF6116YYRV8J4	!1jVk!N8%@!1NSF!ZA#7Ve#X5F#u8!6hR!2sGV!L2k$_#98V!13c!10b!21@k	02!101/&11&E&1(101/(1&1/!44#8$3/%3)201*2#1#1#2*2$2%1#201&2//,1!1.1,21$2/)1%2%2&10301%1$3#102#2#2*2!3)1!21!11+1#101/(4&2!1/1#1,12$7$21,201%4#2%2*1-3(31-2!201)1&3/1#1-2$204-1701+1&1*22)201%11$3!2@+202#3/11.2!1.1/$2$z%2&1%2$201!1!2!1020D/%1-1#1(1#1012$1-2%1!9!2&1(1$112(7/02//#1-22+1108!1#101&1%1#5)1#	emPqDH@DFK@cdQY_M`@cHhhhdhdeB\hhdUMEDheMemCKGAidZR^QYVjjjjZhBBZ`hFIjHhLJ@@					agonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hv:0:S~S~F*-j`*l0S~.>:0B,~W.i.hdz.>:v~W.idzdz~W	:UvzvzxzNxzvofhRt8t@OLzIMOQd1E1hUnX5@VV2Plg4GoW0XO0h25oGQZc5MlVWE4@lV1B#B1GFF10W0FV	0Xs0FF025k1v!8M07g!WR0Tk035k1_07g!t!cF3Z!FM06J0SV1v!KG07J0TV2w0CF$ $38291m0WFRV8o78281PB0W8LF4R3Z13Vt0FV@tg4A2C7FWGwT474m0YFRV8F782G1BmkWVLF4D3Z160aMVwBL7Z190t0FN9cu4CCZkWFY_L4C2MhFWNGgcPD241BV8N4ujAWZkl1JsL4Y1Wckl68FXlHNcKHo125W0	#raV!284!2XG#1X#i38!1WB!25B#CY8#US!2JPF!VDs!24Z#C0V!1lV!805!1I0k	02021//!A1(2/-1)1/)2$1!1/1//$1,1+1+6%4/(5*1///,1/)24(3/+1)101.10106/!1/(5&102*21/!21!1(4!1%101$2(2#2//)3//$4/$1/042$12$2(8&1-2)2!1/04)19!1(1#101//02&1!1&1/*p%2%102$12#1!101!1&D1)2#1//&1!41/,8-3/+2*1,1(3%1//&3!1/&104&11$	egh\HL@BNLd`HaRHVbLbbbTRRaTRbQVbRsDfeeWQutDEDsALDUUDP@@					antagonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.i^)}^.h.>S~S(.h.h.>x>S~S~.hS(S(S~5qxh.>.>x>S(.hS*T*54)^^*H}~S)^i.	vzUvfvtldNhmVoAEIs3d2OJHL4GId390ZHTZ5FXX3AF96F5W02OV4e5JOHVA3TnG09J@YWVL118K13J31!80k	0Z40IV02FF1D!9J0Eo!_F0zF03OF1g07g01L40Rk1u07k0pV06FV1406c0TV1w09s01_40PV1m07B0U03F! #1Z12Vt0FVDF483Z14Vt0G0DF4N3Z140t0FsDF4J3Z130t0GsDF4R3Z190t0FkDF4L2@A6YkkJF@U16iksBBH8U14ilFFNBJK0eH0cNVBI7a0c4y576YXXV5HH4Y5WWG0in44X8kGg024@3GVXN048B6@B0L10JX@E6e08W0y126Y2WkdXF5AXWlo4R874	#70k!S2Z!68s!1@8#cDF!49D#2K#VC4!BCB#81F!4Vk!8X5!2GeV!cns!82i!11Bk	01//%E)1&21!8/#101/1!5$8$31)1&1%2)2/*101$1$1/05,3%2/09/,1%2#1/$101//#1!1-2///$1#1+1/(B8%1,4)1&2)1!2(802&1&1%1%2//!21,3/%101/1$1/01!1.3//!1#1!6/%A!1#3*1/1$1,1/1/$2$u#1&1)1/03!8%1$13(1//#4)4!1/2!1&1!1,2%101021/.1-2(1/06#1#4/#2(7&101#	edZR@F@NGNi`IABPpdHiAJPrdLbdLTRbRbtbT\RNbRTa`SUWTruTDEDETDTuUQD@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
(Sh.>x>.~S(S(Sh.>.~S(Shxh.:v:0~S~S*F`|*`h..h.>.>.h	<vfzOUnxnUJQAF90Ie8@0cXH0hV9@8PS258012Ak@4#V3N082HJN0Re3!FW922k!40V20H#V$V	0qJ0R01v!C10480eF04NV1_07R0pk06JF1Z07J0Sk1u0CR0 !BV8F4LF@3m0kD20VHWtFBPM7Z1FZB210HmOTF4D3Z160VXO8uK31F90cV	#20V!1%V8#J2#V8F!38e$l$38#2N#9G$Fo#44#1V$Sk#4$K0V	//1&C102!1&2/-112*1/02/&1-2//!1!9/!1011!1/+1/01!2(1&1,1/1$3,101+102(2+11/&11&2(106/!112/%3/+1&1#1$201#205!1/*2&3-2/&1$2+1///%1$1-1!6)1&1)1/01!3#2*302/+102$1/!1//&10l*1)2/%8.4%2$1/-3,1/51/&301(13/!1////!2-1-40302)	fewQ@@EI@eLjnlrlo{rTZiJN]AAETuTuJU@@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=S~xiS()^jwx=x>Q~/<8t~UxiS(-g-gS~x=/</<xhS~x>	zrzxT_OKco5o0GACHR0G0NPH04F09Yd@0HQX78X8IQV962W!2OV90JJ10Vs9Ll0l90fXZVL!8511J1!603V	0Fs!_!uF03OF1k07g!sk0tV3e!KG06J0Sk1v07k01_40SF1r07c0U03L$ %O0FcDF4D3Z150t0G8DF4L2X6146k8sBoI86l1Vk4J@b7141VkJB45Y0ksJs8JA0GNBH366WkGOTF4B3Z12Vt0G0DF4N3Z130gaFFc8	#@0V!GVB!4VN#2aV!X&8#X$NW$1N#1%FZ#41#1bk#Oo!8&1V	!1(1/+4$1,2///#2$1$1$1/%1//%1$1/-4#12,1!2!2$4)1-10201,4&1-2/01-3!1$2//)2/%1(1/)601$1*1)1%1-301$3!2$3/!1/$1//#1!1/01*1//!1.5*2101+1(1/,9$1/!2////&201f$1)4,1%41%D/$1#3+2%1!2)31/2!1(6!1/$20201&1/////01#21%2,1/%	fakab@MV[t@QdbbbRbbfRvRlDzV`yhI@J`JJX`@@					not given in publication	CRTH2	CRTH2 (PGD2-receptor) (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
ps}JF|pspsF|psF|*`lvS~.>:v~S.h.hhxS~.>~S.hhxh.>.	;tzdUSzoKxQRAzTS8G2N@QaCH1CYE@82tXE@X40Qa8aF120_FVh0F688VWd5W2131AV0c50101J1FL40V0FV	0Z40IV025k1v!9F0DZ!lR0OF1v!DA0@40t!4OF1k07R0U!5O01p07R0U03L& $m0W0K3k8D4c16j0GNICX492m0XkGVcgUBXXWRV8V78261U0Yok8oA82F1m0YFRV8s4a4A5WtBNNCZ11Vt0HN8kqh822W1W14_472O0FV8sDN5XkNgBA1_2HY10gO6XYlH0cgF1XZFNcB@1XXXV	#I4V!584!4VO!116#V%k8!221F#W4#19#18F#HZ#4K#1V#1Fk!80V#E0V	//(9/021-4(1/#2#1012!301!102$11/2!1/!1/!1$21#3/!2%2!1///)11+11(1*11!1/&2$1!2!4/(1(2/!2///41%1%1(1+1-201$2/*21*1)1/#2/!1/0302(21/*1%1.8//2!1#1-3)8/#11/$1/%1#1/(1#h01#201%1*1/D//%2%1/&3/#3,1)1202)2/+1*1!2$1//$2*1#11/02(	fi{Pb@AQRtDQdTRVRbbbVTrtMFZlGL@ETCAQSQ@@@					antagonist	MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
tn{DL}Z)tntny?55L}L)(Sg-n2>x>.D+}ZD+(S(Sn2n2>.D+(Sn2)LD+	:UvzvzrzS_w3TfhUQ@lFOQdYSRGdWECBMxaEAV1VPmR4GmdBqO@xX4JFQZeMMn1W74@W80JF!8FGFF10180V	0WR0Tk025k1v!8_0Eo!lR0OF1v!DF09w0t!45k1_07N0Tk04SF1u0Ak0p!7M01T07J0TV2F09w0t% 1Z120t0GNDF4D3Z110t0FkDF4N3Z15Vt0G0AOR492m0YVRV8R782A1_6VX8LF4B2iQ14VX_08J4P_11VgV8B5Rq25W6nNFdT283@@3FoFT9Z17Vt0GVDF4N3Z18Vt0FN@tg4K2CakWe8P4@4	!2raV!3cR!6HG#1XV!j38!1VB!27R#CfN#US!2L@F#Dc!24X#C2V!1kV!@0_!1n4k	&1//1/%4//)5$14$2$1.1#1/*1&1.4(2$1)4%2,2/*1&1/&1/(1/*21&3(1,1$2/#2(11#1//!1!1!54%102+11/021!1!2!1$102#101$2(2#1//)3(1+204+13%1-1/02%1%1(801/-252&3!1&4)17+3%1//)1-1/&l#114%1&1*1*F.1+1*2.2&2/$1#6/#1/1&1(1/%2%1#2/)3(3!1$4-1!1/	ek`\HJ@BNDh`HbZHVdMi@zPrJJIQYSJIQIYEJQbQPqJhkjBBafBXFJjJ@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>x>S(xh|`v:0:|Fl0F*`*~Shxh.~S~Sh.	vzUtQ1tG9F5k0J@A1N0G2N@k04F0dW@80HRV5#2NV160WV02GZ905J9FV21FV0VA0A0404808Z034210V0Fk	0aJ0Tk03FF120A4!lR0RV3F!Kl07B0Sk2x0CB01WR0PV1m07B0Sk3F# $1Z12Vt0FFDF4B2Hd11k_XJZ673Ih18NRE82B1m0WkRV8s4eh6Xl8cgJ	#7Zk!N8V!62#18c#V7#70B!304#V9V$8#F0F!42k#X4#98$WJ!80Z#98V	/!1/$7*1///+6!101.15///!1$1!101#2/(2%2,1/#2/#21/+1//+1/&3#11&1//#1$1/&11/$1/(1%1*2/#2*302/-1,1/01%1(1(1/#1%1*1#4!1//*2!1%3(7/01/0101$32%14//-Z%5!1/1+4#B///!2&2/-11-1/$5/-1(1-1/!11*5)4//1	fjchB@DXXKPHcHhdheDdlXdj\tZsle`BJij@@h@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>~SF*.i`**Fv:x=J)3pS(S(xi*F*Fx>S~x=3pS(xhxi*F.>x>x>	:UvztzSzKxyvRQUUU8l3O@hgCH2hbD8iPx2E@X5PQ_D6GVV0YO0d06o8sJfYMk3WA3YVc0K2F!G3F1m0V0FV	0Pg!Xs0IV025k1v!8M07g!lR0OF1v!C10480bk03Z02U0DF011R0OF1q07g01740SF2x0CN% $O0G0DF4B3Z170t0G8DF4Z3Z12Vt0Fs9mF492KiFWVHhm4C2m0WVGmg8LL@11l5Oks6@3KVY_Fs8J7Z11Vt0GVDF463Z18Vt0Hc8hPf35W_JNFtL2@3SVXYVo8D69AeYFVcFkKA8110W4kF@5WGVe0q@AX1GcdNRL8YFVJ8F@85@J90FN9Z130c0GJF4F541480FkJF4PV15W2eVNBN6dIX1VVcG02CX0XkgV8B4	!1L6k!N84!2cO#F$Z3#3d8!20JV!2XF!25@!25FF!l@s#4K#C0V!11k!40Z#E2k	//(@/*1/.1+4$5$2//1/!1)1(102/$34%2/-1/&1/#1/%2/1)22&3)1!1-3&1+2$102#4$1$1&3-21(6$101,1%1/$2!2$1&101,2#2%2*1-1(2/*1!1%301%1/-202!11#2&6!7//,1#2$1)7/-1/1+2/+1*t$15/#2!2,F$4*1$2.3/2!3#101/&5!1/$1+3!1%1/!1)2!1*2/0203*4$403/$7(2$	e`\RHD@NADjh`H`zHRYeg[YYWgUYXdTLJFv~``Xj`fBhjjaH@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi)HS~S~8t</xh+DS()^)^.>x>+DD{</S(S((S.=x=x=>.>xS(	:UvzvtpvNCwWJAhUN9l0OPy3SNIdWE9gMzX58VX1PkD4GtW0XO4he5oFQZe5UlWW76@YB84#sFGFF10180V	0Xs0IV025k1v!DF09w0t!3OF1v0Eo011R0OF1q07g017J0TV2w0CF01ZR0SF1u09!bk3Z# 0O0FVDF4L3Z13Vt0GNDF4H3Z150t0FFDF4B3Z16Vt0GcDF4J3Z130t0FNA84LOBW20qI88L5Z12Vt0G8DF4X2mO13VaI8885ABW3kV	#raV#84!22K#GX#i38!2Vi!25BF!CYN#US!2o@k!FDc!24$C0V!5kg!@05!1I3k	&2&3/(1+1!3!2//(1*4$5$1#1*2///&1/(2///+1/(4&1#2%1/,5%1(1,1$1/#2)6#1-103%102.8&102(1!1$1/01%1$1%101*1!7#1&1/!2-3!1/.1)1,1/01%1.4-1,1$5(3/$1A+3%1&1)1/&1#2//1k!2!2%1&1*1*B!4!1%102.1&2)2$1!2.4-601//!1&2/.1$11/%2&3%103!1!1/$2.	fcq@`B\SDDPvPGH[dLbbbTVTrbTRJbTsIJLEI^pPTLpSAQUE@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
36BzS(.h(O.>x>S(.ixi.>S~x>.ixhxifz)Ix>@z1n-,)]S~	=vzy>tQjzwuUAECwfrjwgF4zet@9MQ98wW6ok4WqVm4OV0Z0eJW51807W!l04B280V!1!2V0FV	0aJ0Tk035V1Z06g012o0AV110@g018w0c03Z0DV$ #A5b0NVCal2312VH8VXf9VlGNleJ48223JFg4782FO8g_@ZC1X0k	!210k!4@)18F#Z6#49%MF!FV#20O!1NG$2k#14#C0F!13$B6!29VV	//(C/1.1/+1$2#6$5$1#1(2-1%1/(4*5,2/1#1,3/%1.3$3#1!2$1)1//-104)1(11#1-1101(2/+2#1%1/$1/+2%2)1$2////!21&3//01/.5,1*1!4-1*1$2-2/022-1//%2!1(1/%1*h%503*1%1/@#1%1(3#13/%4/*1,3!1/&1&201$5//4//.2*1#1,1#1)	figPb@LMEH@QdbbTLVTRRbrtQJAsUoQuKSTDEEUQVGHlj`@					antagonist	M3	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
qq-gx>?yZ}xhS(x>.>x>|`S(.iS(l0|F.>.>`*S(	yJup258G0V4F4F2!N050N2k!F!18!HFV58!2FV961WV020VC25J1F!1@kFV10224V44084F20F01W0kk	0qZ0dk2w!GY06F0T03p!KV0680OF1q0C!1aJ0Rk1q07g0U03F!Od07B0U02b0Ak0oV% $38241m0Y0RV8V782B1m0WkRV8V78221m0WVRV8o782D1	#L0k!A2c!6WN#s@#ZW8!38A$7#sA8!22P!2F$4HV!80W#1V#Gsk!815#FQV	01,1+1+2#1/01/%1/)3,1/,1)3-1!402&16//%3)2/%1+2%1$1$2(2105,1/01*1!1)2)1//1+1(3-1*1(1$1//)3*1$1,3-1//2&4*1///14//02/$1/(1!1.7&2/&11/&1&1//10Y%3-11)2*9$1/1*1)2-3-2(1%3%3/#1/*11////!16!2&2)1/%	fjcY@@FZm{IPYHheBhhidedRbc^BdmR`Q@TDP`@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.hxh>.(SS~S~.hxh.>S~.h.hS~*F*`:v(S>x(S:0:v*``**F	?xzvxjzRMjOhOzet8UvmPWh39@j2TX580G33G6aF15VhV48@Lq9VZ251X88O32O4020e2o6#J!F0V	0aJ0Tk02a02Q!@C0ER016J0TF1v07k01Hs0FF1204s0eF05O01s07Z0U03p$ $2T0ZVVZI82415hFWs564B4CCFX1J4R6C53190R94VFV822C8aj50Fk8ZK9212@84T@910X0ZH54Z0kZ63C@0V8G0xF2FT0YFgV8F782B13gFs84I6YZWwV8V78261m0XFF	!2@4V$8$1#V*182)FW8!40P#9F$ms#46#G$818!@02!210V	%1!1*1*43%9*1)1/5.1!6,203113$11//)2/*12!11///!1/1%6&101!11#11&3-1(2!201/#5///.1)1%1&2/#3#2&1+1!1/$21#601$2/-1#1*1!1//01/)1/)2/)3&7!1///!1&3!9//01/!2$101//#10p.3/&1#D*1&1+1!1.1&4$4,41)3&1$1+11)2&1(4//+101$1/1)1/!1-	ec`XD@@F`DlbbbbQffRfVRTTSGDfg`RVTvsPTD@ASUUTEP]D@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
tn{DL}Z)tntny?55L}L)(Sg-n2>x>.D+}ZD+(S(Sn2n2>.}Z(Sn2D+b{	:UvzvUrzK_w3TvhUU@nFOQdXCRG9WECDMxaEAV1VPqR4GmcBqt@xX4o0sVeKMl1W34@l80JF!8FIFF10180V	0WR0Tk025k1v!BM06J0Tk03Z02U0DF!mF0IV3x!FM06J0SV1v!Gf07J0j03J!Of07J0Z02U0B40t% %m0W0RV8g78271m0WkRV8g5a8JWZFwV8878261m0Y0RV8N782B1m0X0Pks8F4mO14VgV8s782@1PfkVkLF462QN14HVJ8R8Df12kX88i@2970WVwV8w782B18okWNLF4g3Z18Vt0FN944RWH12lk8ZF	!1raV!28Z!2HG!11a#iI8#cB!25Bk!CW8#US!2L@F#Dc#4o#Cd#1oZ!80o!1IGk	//(1/%4//)5%4$201!1/#1/*1&11-3-1&104%2,2/!1&1/.1/(2)1/2(3(1,1#22/#201&1#1//!1%6&102$1$111/021!1!2!1$102#1&2(2#1#1/%1-3/$204,3/$101.2%1.801!1,1,252&2*4)17+3%1+101)1/1*1!1/&l#514%1#1!1*1*F,401+1*2.1&2/$1#5//#11&1/.2%1#2/)2(4/&1/#	ek`RHB@BN@dh`HbZHVdMiCHhheEeLheDedTiFIECDjbnhHJFXI`Xjhh@@@					antagonist	CB1	Cannabinoid (I)	no	gpcr-ligands_DescriptorsNo5Ht
|`:vS~lv(Svl:0:vx>*`*Fxh.>.hS(x>S~.i.>S~x>.h.>.hS(	<fxxxhu5T_JqEDgmjXS2uXVF9d3Z04LJp_8XJ1VoN631W1YgXd4VJckV91Kl0V1W210co48Z1F204FBW0FV	0o80Ik2d!G_07R0Tk1w!Fd04s0J03l!KZ07J0Sk1w0CB01M40S03B0Bo0x# %m0WkKAg8J4_I_km0TF4L3Z120dJdZBc63kW3kYwF2693AakVZX621VO98aDD7WX0k	!220V!1B8!2WN#82F!V1F$@$G#81%8!292$Lk#67#GG#8NN!Aa4!290V	*1/(1#A#1(1$1!3/01$4/2%12$3#1*113/$1/%1!111#1#4$2.1)1-1)11/%1)1!1!1/(1%1/#21%1#2/1//.1,1#1-1*7/$1!1/+3$2,21,1#102.1&1&5!1,1&102#1)11,1/-1.302/*1$21/!1)5!111%2$1+1%11/.1/,i&1!2#1(101!1,6(1,1.3/03/.13.4*2!1%1$1+2/&1%101/#1$1(4$1/%34-	fegH`@HDytGldRbtRRRTbTSrfBJtgMKTuPUAUU@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
i.=.~S(Sh.>.(S:0:v`**`*F}J63.>.h`*`*.hS~.>63.h	;trdUSvlKhIRPjBC8l2N0QgBH1C302D2wXC@V!@F0a01!WkV@VFa88V2C5W!1G@l0c4$41F6S0V0FV	0Z40IV02OF1q!9F0DZ!sg0cF3Z!G_07!Sk1w!KZ07J0Sk1w0CN$ !6F4826EfWVVV@26537m1sN@A2VXGgV8V78261341W8NJ2XX1O6F4D3Z150aF@4XA1Wll084BGZ17V_lkJwF3W1l8tgJ4H2aGsZB10YXXRV8F4FABVF8d88F620kN4D@B162tBT70YY08J210XWY0	#20V!1$4aN#16#V%V8#44$W4#5O#9V$PZ#4j#GW#8Gs!804!210V	//(@/!1-4(1/(1!8!301#12$1*1%2%1.1(1.21#3//,1//&1011$1&1#1-101//1/4(2-1/!2#1//+3&1.1/*201$2&1/#3#1%1)1/!22*1/*12(2//!2.4//*3!2(4)5/+2-1)1/1$1/&g%3!11!1101(11.F//01#2%1*1+3#1.3/&1202)1/0101&1-1$1//$2/&2*1(	fakP`@DB@WHhdlhheDddhchrVyjuUST@@PP@@@					agonist partial	MT1 / MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
2f2@SyO(2f2fi4/GSySy=4yS2fS-_/2@2@S-2fS-t@2@S-2ft@2@tf2f	<vfUSxpxx7JOSUU8n3O@vaAF38Yj9TIU2AA050Qre6GXV0Xt8z25JGk0u5IF3l322W80J01V4020F%V	0P#WR0Tk025k1v!BM06J0Tk03Fk1F0E4!oB0J03l!OG06c0RV1r07k0o!6JF1H07J0Sk1w0CN0 6F4B234ZoGBH6743XM0Bs453XW1ORgG8W1l0tGT2D0lFscFRMD1WkcRDEZ140t0GF8JFVD2WFNRTD85cmNgN377Yt0Fs@B4K11410FOgTIA1FFNZNH13a2G0c611XGWDF483Z160t0Gk8BJPD2m0NRaD858IFVN379Yt0FVDF4D3Z13Vt0Fc95mP32WYr9kB@7Z17Vcs8FkA82I1	#64k!U2Z!6cs#Hi#V7F!7Z@!205F!FdB!8K@!281F!_PV!8aW#58#8uk!84Z#18V	%1//08/!2//+1&4$3*1&104/(1!1/03(202*1*6%6//#1/)1/$101*4/*2102$1$1!1*1/!2/$601&1)1/&9$1.211#1+2+3$2/$102$2/*2//%20102%21%1/!2%1%2/!3!3$1+2#2)1!1,1*2020602#2!1///*11/,m.2/+6/$4/1/#1$1/(9#2*1(144)2(1(1/#12(5/+1(4&1!2#1#1(202+	fkHa@NVRVZpQBhcHhheDeECehcDddfRtzJXHIJjfjjjhT@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
}H^)qq55}H}H)^^)qqqq28D{/j(Q.>8tS(b{)^>x.>x>.hxh)^H}x>	vzUvvv:rSxxQT3UTEPkQsAv23Hqh1DCTMUZ5AVCH96eZ1FeNah2cV1J9FZ@IKl91E30KfNJ1104FH0V10VNFV	0PJ!PZ!WR0Tk025k1v!8M07g!dV0ak02K03x!C10480IV045k1_06k0Tk055V1d07J0TV3C$ #3829134HWgc713WWksZPE6YkVVB815XmwV8N542EW0Y0WdkNI5408sRRBYF1Xm88ZJ27514WWZF46YZ1V886B@14ouB@@752_1OBJJ6VX113F4Hk13WO0FV8NH694l8ZH90VV842R7D7d2FNky29421W8kRD4Xks8840VYW9n04Ho13WO0FV8B858Y1d0J@0VkV8oHPHEYklXF4H815XVdVLA32FFZgN2156O0FsDF4P3Z120W1ksLA711NB@JF40YVF8kl42IW0YkVVoXA730V8B81VkGcsr8271m0WkRV8R66427bFGcR18442f0X1k8NA8261@5Xcw8653XWmGcgJ120cscSm@21ZYc90I8251m0WFFGBFF65XN8VJGZ150WHlBPE22VNZZJIZ12Vt0FcDF4J2Df12kV	#2K#Z04!@0N#Fg#V2#5WN!304#B2#208#NGF!Z0k#HZ#40F!1Ak!2W6#3@V	+11)1)2!1!9%101,4//#3$1%2$1(5(3&1&1#1/)2!1(11/&6%2/*1#1/%1%2#1.1.1$1$1.201/.3.1%2///!4%84!1$4*1/,601/,4*2///%6/#11//#5#101/!101(1&2!1&102%3/%7!13*12&1$1#2#2//)101.i)1/101%1&4/!1//&2/!4*3!1,201#4%1%3/#1/!3!1#1$5/&3(3-1-3-	fcopC`BFbBHEDJbMABYCL`VPrJJIJIRiIJQRiQLeYtupPTTuUUUUC@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.>q5.ixi.>S(.i.>.i.>.i.>.i.>S~.iS(.hxh.>.=S(.i.=.>S~.iS(.i.h.=.>S~S(	=tzSznKxzRAAECdG2cPx4b20_Vgce2x2090i2Y40XO1V!FVV@VZ8F4229#8034404V0VH1702!W0FF	0P#U4!Xs0IV02OF1v!9_07g01680PV1q0C!1VJ0IF2A0Cc0t03q# !66XGscBA321NB4NBB1X0FFH922VcZH93Vk84410dYFF8hI82810VWNcPA21kVR641W0cJ22H79O0G0DF4F2132FtFP45WWVN42C5ah60FR86D7dX8kNJBoN13kZvo8D4Q6YXNZV174YYkFNXI41WkF4JD10kWOV8cK6W1kZH41_3XVVRZW55kN42H791YGd8cC320FF2L@Am0WFRV8k782C1m0VkHFlHJ44X08FNN	#I0k!G$64$F@#V3N!398!10L#NX8$9#HlF!4@k!8XB#14$YF#5$10V	!1+3)101011(9.302(1%2/!1041+11B04!402!301/,1/(1/$4/.2.3101/&2/#3/01/)1&2/*1)1//!4/!3/(5&1*1/$2+1$401101,6-21//012.1!1/#1(2%501!1#8/*1013!@/.1#1)4!2$1)7(101)2/*2$1/01/*x!1!@1#101/$1&M$1///$1/-2!1#1/!1)14!1&1#2013#1&4/.4$1.4/*101(2$	elZRBH@LK@jhDFA@@cIICidddhhhdYeEDdejfghPTUjZjj`hB`@@@@@@					agonist	PGI2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
)Jp30lF*F*S~0:p3(Sxh.h)\F*63S~x>S~.>63p3)J)\.h}\6sS~sp|F)JB,3p(W.>	vzUQvAzQUSxWQD@UIAFGQtdH662VhY1B83TV7VX1388X603X4FF_040B9JZ3n4W205HAVVc6010W13FX140F0k	0Q4!dV0ak03OF1r07k!o40FV2d!GG06J0SV1v!Gn07R0U03L!OX06J0Q01n07k0o& !BV8F782@1m0X0Gct2N32XV8V8DD47aHcVX1212G184HC95GNo8FG2W0WdLF4F3Z120t0GF84D6D2WsVDE152HXt48JVD11l2H0@V4W1VskVqD39520sBRB7@aH0gV474YX0GlOHD722GRV8J78271m0YVJQVH673m0X0RV8N4	#60k!S%X#122#V2#4VN$Jk$Z!B_9#1F$@k#45#98$Ik!@04#18V	01//%9%2+1/#22/-5$3/03%2&3(1/#1.2(2/$4$11!102-1,21/!3//)1/&1/&1$1/.1,1/%1&51$71!1-1$1$1#1502+713#1#401(1%104#1%1#1%3#1%1+1/!2//01/+103+3!5/%2*1/-1P#3,1/$2!201$104&1//$1z%3(1&1/#F///!3%24/!4!1/&1/$5(1/.21$1//!1!41(4/!2*201	ed^R@@@@LKKldTRbfbRTTRbSVTUbU@gDdWVSVqpLHPTPDDQPUUUPAP@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>xiS(.i.hx>.=x=xiS(.iS(x>S~x=.=.>xiS(S(S(x=.>.>S(xiS(.h.>	<MftKdN5w0JAjUN0l2O2P_RN1d3j14IrXC8!2Qo960WW0YOVxX_JOQVs3Qk1WE1@eBVJ1084G7JHG0X0GF	0WR0Tk025k1v!8M07g!ZB0s!2IV3r!BM06J0Tk035k1_07g!sg0cF3Z!GE08g0c03Z!K_06c0SV1v0C!24w0KF1M06c0Tk2A0@!t# $6F483Z110t0FkC4a4629baNNRDXI241O0GcDF4H3Z17VZnsdF8B4m0Y0MmN8F5Z160WYJ848E4MCVW8LF4B3Z150t0Fs9d2W3X1GBV94782H14M0WNFGoa35WYekFoA824120IlNsE67313nw68I43__lVFF8GO8Fl8TF4D2GOW2msZ8F86Dg28VoFcB25b2l4BDAZ120fGH8J8D4194lVFX9Z18Vt0GVDF4a2I19bYGVBT9Z11VXQNFkA82J122JdcZ668351VFssL25ZFG8iF4V3Z16Vt0H09Bwn3@1t0GVDF483Z1A0W344D8M4m0WkRV8s4	!3vbV!I8B!6cd!1HiV!Z38!6cE!3@pk!RYN#HD!2HWF!ZHs!2Yg#10F!1vk!624#1DV	!1/*1)3,2$1!1(104/-1+2$3/%1&1)1/01-2)1)306#104%1/%1%1//0101/101$1$3+1#2#4(3/301(1%1,1%4/(2/(7$103*5/)12022202$4$1,11!2#1#33/%2,5#1//4%21/.3%1!1(2109!4/012$1!23!11+1(302#F/%101//,11*1/w%2(2*1/G-2/-1,4/-@&2*1/.1!21&101*3&1*1-2%3$3/,1%1&	elV\BL@NGIng`TPHaRHnbLbbbTRRabfbRTrJRbcXdl|JFZV``@bHBhFbif`P@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
tn{DL}Z)tntny?55L}L)(Sg-n2>x>.D+}ZD+(S(Sn2n2>.D+(Sn2)LD+	:UvzvzrzS_w3yfhUQ@lJOQdYSRGdWECBMpaEAV1VTqR4GmdBqt@xX4KFQacKMl1W74@W80JF!8FGFF10180V	0WR0Tk025k1v!8_0Eo!lR0OF1v!DF09s0t!45k1_07N0Tk04SF1u0Ak0p!7SF1u09!_02T0B!t% !38241m0XkRV8R78221m0WFRV8k782A1m0X0IZV8H5Z170t0FsA84Nm1511rHBBX7Z130gVHQ84X5Z150i_FFNA8231KDVWNGou4@DYVVsVSoK723lBV8w782B1m0Y0RV9478231O0_aF9F8uS26bGkFcF	#raV!3c4!2HG!25XV!i3c#WB!27S#CYs#US!2o@F!VEc!24V!2C0V!9sk!B0_!1M0k	//(1/%4//)5%4$2$1%1,1/)11&1.3-1)4%2/,1*1/.101/%1/*2(3%101,1$2/#21&21#1//!1%54%102)1011/021!1!2(102#101#12#1#2#1/*1-3/$204,3(1+1/02%1%1(801/-252&4*4)17+3%1//)1-1/&k#114%1&2*2*F.1+1*2.1&3/$1#6//$1&1(1/%2%1#2/)3(4!1$4)2#1!1/	ek`RHJ@BNDjh`HbZHVdMi@zPrJJIQYSJIQIYEJQbQPqJhkjBBafBXFJjJ@@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
-QF|~Rvl.ha|.>S~xi.hS(S~x>.>.>xiS(x>xiS(x>x>S(xiS~x>S(xix>x>xi}^yDj/	:UvzfzUrO:QTQ9CCTuPfEWeEmad4JCTzxA5Ql9V8Ki4W0cqaT0eV0oFNJ@nKm9Y_YVk@6B38#3FVV0V4FV	0aJ0Q!2Ik2T!DF0@40t!5AF110480Ik2i!JL06F0PF1p0Bo# !CBmsNkE8261E8ZNNRE826151Gm50567YO0GNDF4H227WXkgeG3442BV8o78261	#T4$F8!202#Fh#VD#51e#24#9V#24c#NG#L2k#H4#C8F!13o!224#f@V	,1/*K/+1/#201*1(6$4$1!2$3,11#1/.1$202!4/02!11)1!1(3.1,1-11/,2(1.1(6,1%1#4!5$201)1$1/3!@/%101$1!2$1#1#1!11+102.2$2!2!12$4&2!101-2//)2(2%2/!1#3401/(1#1$2#21+1!201101/)2+212(2)1/#103$201,101(1/.1#203$x$13/!11&1(@(102,101//1!1/%2216!1!1/%3&1$1#1#1!1$1/%21/01/#3.3%1$13-	elZRHDDBJKJc@Jr@H@zj\BbbtRfbVVtRTatRRRHX|bZzaQifhFBJjjfjjbhDbHIh					antagonist	M3	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~|FS~xiS(lv|`x>~SS~xhS(xhx>x=S~x>S(x=	zrzxT_OKVJ5o0GA9HR0G0NPF04F09We80HOX7828HPV962W!2OV904J0FVs1Hk0lA0fV0VJ#101J2!603k	0Fs!WR0Tk035k1_07g!lR0SV3F!DB0DN0uV06JF1p07R0TV1w0CN01lR0NV1_07N0Sk1w0C& #1Z12Vt0GFDF4D3Z110t0FkDF4N2mO12kgV8c4Bg28Y4kFsHLO251BaFFs9Zm26W6I8GFyH282Hn8FoA8231m0WkRV8J782B1m0WkRV8R782@1	#D4V!GcZ!4Wm#HaV!V$1V8!2X$NXV!81N#90F!FFV!B41#5Ek#to!8FV!219V	01-2/&2%4+1!1/-3/01$1$11#1&1#1)1/+1#3//!2%2$11+2%2#11%1/0102.1#1!1-2/*201%2!4/&11,2$21///(5&1*1)1%1-311$2(3-2//#1/,1-2!3//&2%1.6*2///%8$1///%1//#201b%2(1,1%41%B/$101032/01//+6011#1%1(1,1/2/%2$1//(31%2%1/,	fnsPc@DJrTDPHH[DYEDheEdeLdhjsdeIk@PSUA@qD@@@					antagonist	CRTH2	CRTH2 (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~D+2nxhxh(US~/<.>.hxhS(.hS~S~.>xh.hS(S~.>.>S(	:Uvzv;S:vyvjUxBvTt:yEzUhYUShQz2EYYV@UgwaladLIv1UbCx9s4Xp7VZWf0YoV1B1!413FGN0V0F0	0Xs0FF025k1v!8M07g!WR0Tk035k1_07g!sg0cF3Z!FM06J0Q01v!Fi0480c02z! 0O0G0DF4@3Z16Vt0G0@66492X80WVLF4D2I712kQZ@242Y84GkD894m0W0RV8k782B1NC0X0LF483Z13Vt0GVDF462yI140VgRk6A393VWlOL2342pGsFo8O025a0G8Nh0B811FsRREZ130aHswR471WlcsJRM4YlVN862_2XYGBBH3X20t4RsK340VgPDG7	#15V!J84#8#3H3V!4@#7Wi!28KF#V#4ZF#8FF!Z2k#1g#O9#13c!24_#1wV	02-1!1/010B*1)1///&3$1//(1-2%1#2#102/%6%401%101/(1//%1(1/!1/$42&3/+1+1&1%1$6$1,2/(3$101,3/01,104!1&1011+2#2+1/,3!1//04/.2&3%1.7/$22)1!1&1*1(29(1//*22*1#1/-n%201%2*1!2$1&D!204/)1/01(4/-3-3*1*1#1/+1%3(5#1%1.1)3&1&1,4%1111#	ek`\HL@NADh`HaRHfbLbbbTRRaTtRrtRVXdtlJZvN``XjhFBJjbJCR`@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxix>S~xhxiS~S~xix>S~xixhS~x>xhS(x=.=xi.i	yquGP1OG8F9F!35FN0F0N@H#2832@02A050V03F0@0F1!21V#60F#DV012H02V06!8$440X0GF	0PZ!QJ!Z80IV02FV1D!8M07g!b!vV055k1_07R0Tk1w!K_06k0R01v0Ds01a80OF1g07R0U03F& #1Z14Vt0Fc9o44CTX0WFaF4N3Z11Vb0FG2B2C3m0X0Ik96B2C2m0VkIk9HB2E22XksRaD211VN840aWnJl8oA3XWWFFFB47YWcVJ81VkcBsH113bX3OFPN3Y1WV8B243YGVgL9310NB8418XV88W8H@21lso@95WkkB2P7CG_3cNJ@650W0NoL@72l8F8340YW884DT4D5WdRHB660VVFBLB32X0Z@220kcF2X@10X4WIgy653m0WFRV8N78281m0XFRV8g4V69XlWVLD97431dBLP53XGldcD@8VV90FH89S@VVkFJF8AX2FcB695WkG9Ic4De12W0FNZHH6WWO443A6WFFFcr8231m0VkKGO6693	#Y4V!984#VF$6#V2#4V8!205#c1$48#11F!NFV#45#18#1Hk!80Z#10k	01/02/#6/!11$1/%1/%1$1%1*4.2/1*1!1/1-11!2%2!1!1/,101/%2*2013/1%1/!1$2$2!1!2//$501/03,1/-62//)1#1#11$1(302+2#1%1-1#2//.1*1/#1+11#30303101!1%41+1#1#1,1/,8+1//03/*2(1/h#1/%1&1(F*1/!1&4/#1/#1!2-1/,5&1(101+2&11//*103*1#1$11/$	fi{qB@FZKdDPdrmj{Jv|mNRTFL@@AP@UUP@@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.=.h.i.>.hS~*`lvS~.>:v~S.i.hS~.>.>xh.=)^S(S~x>	zrzxTpOKco5o4GACHR2K0NPH04FF9Yf@0HQa78X0IQV962W!2O0C0JJ10Ws1TlFlA4fX_VL40@511J3!683V	0WR0Tk02K03x!DB0DN0uV045k1_07!Tk04OF1r07g0U!6JF1K07J0Sk1w0CN0 #m0WFRV8Z782A1m0WkRV8Z5R2FQ0YFgV8g78261m0YVRV8w782B1m0YVRV8B5R2IQ0YkgV904	#24k!G0B!4VN#16#V2$VD!220V!FW8!218#10F#JZ#5$WW$Nk!802#1VV	!1#1#1/+2/!1!5/%1$2-5*1$1$1+1///1+1/2%2/%1042.1*21#201,1&1-2/*2(2!4%2#1,1//)1(1/)74%1/+1-301$3!5$3#2-1/$201//1#1/03//&1%1.7*2!1)1/03/%8/.1/.1/,1!210g$12/%1%4&D#1/1#3(2)1,21/1#1&6/(101%1101/2/%1,1/&3(11%2+201/$	fega``K\GLDQVP[H]dDfUufYWWijLuXJX@JdJBJjX`@@						CRTH2	CRTH2	no	gpcr-ligands_DescriptorsNo5Ht
J)3p,Bp3W(.i=.~Si.psi.~SzB}\i.xizBW~ps}\	;jvzSapk7w4qt9EBBa69@cZ9FK8VZ14IK09B080@aN4YFV2Xu0sVVKFk0c5GF1WW!W80J!V0F2#W10VV	0W80IF04P02b0Bs0o!4Nk1Z07V0xF05RF1n0Ak0jF3D!Oc07B0U02b0Bs0o!6JV1n07J0U02w0CF0 $BV8J78281m0W0RV8s782A1m0WkRV8R78211m0WFRV8k78261m0XFRV8V782B1m0XkF	!2aVk!10V!6GJ!1@DV!VW#2XB$Z#sA#21N!2NFF!ZPV!1H$VVF!kFJ!8Og#2AV	+1/#1&3.1.11,2/1,3//02(2(1&1$403!1$9/#1-1/02/,1!1.1/.1///)1$1!1#3.2//)1&3/3#2/,202$1*1/$2/+401!2!1#4/$1/*5%1/(1////%11)1$1$2/11*11!3,12//#10W/$31$1!22///&2%110102/)1%9!1/&1%1#2/2.1)1//01&7/02/$1120	fjcyB@LTdkSoQ@DYHihhUDddXeSfcV]dmSUSMUMLh@@					antagonist	A1 / A2A / A2B / A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.>.iS(.>S~.>.iS(xh.hS(.>.>S~x>S~.>S(.iS(.h.>S~.hS(.>.=	<UztrduCyZmEEUs0_HS2PLg1693904LvVh0Xk3OV96kWV72KVKX5J9NV91Ml1VdG8VVeL11851IJI1VV0FF	0mw0FF1D!GG06J0Q01v!LD09!bV2W0DF01p40OF1e07!SV1v0C!1qc0Tk2D09!bV2W0DF% #m0WVRV8478271m0X0RV8Z782815KFcNcCZm2412_eoBL76E14FV	!1Y4k!3B8!60g!1UR#_6#6BA#Vpk#W$8s!20F#ZHo!4m5#1l#9ek!B4a!35@k	//#2#@,1//01/,201!2/(1//01!1-1*2(1$6$21/(1/,6#1#2/!1*1-4*1!1-2/&2$5////B&2/%1&2*1!1$301401$2)204#1//1(3///101/01,11&1/-2/*1(1$2O(2%1/#102&3-11-1/%n1/%1!1,1!7//%4/#6$1&12%1(40101!31/01///!3%1/.201#3*1/(1&	fcoq`@DXxCQ\bbbTTRRbfbWRfSAVRFkUP@`QEEUT@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S@cJCJc\S@C\S@R~cJCJSfCJCJJCJcc\S@S@S@@S\c@ScJcJCJcJSfJcJcS@C\c\@ScJJCJcc\cJS@@S\c@SJcJCJc@S@S	:xzxyy:jyQzerTufhj:bMump@UQOrKyIcpj3o7_npUFO@5jjs97UPv0s8Ct6le912CBhH0XACBJ01KR2010	0TV!Xw0s!2Ak3V!8j0D#Xw0s!2Ak3V!8j0D#ZB0s!2J03d!9k0Ds!co0xk03IV1M05g!qJ0R01v!Br0D!wF04OF1k07g0vV04Ak0r0D!wF04Ak0r0D!wF06G01O05c0Tk2C0ER$ !CgkkNkP324XZcNNH87421VNcPN521990H2D10XmwV8F4NeD1X288JFZ2DN5kWNc4H8QC4Gl0JD@D83VkNR912FlFs2225aO0FN8sBZ3X338BF687m0X0Fe5D6EAVYG38oT6CE20FRFFEZ14VdkGuJ4P241Vl0R4@BTEdVlFNoLc81lVkZNTW66ks86DE7m0XVGFwHF5ZkVg82@756_FFky283m0VkG1Oe6D8VXW1cJk697dkVkB48CZ130YVXsF8840m8NFU82A1C8okNoE8251C2pcNZX2549VYXe8Z6930kVkqF462M3c0lVwJ486VWWgV8k4AU26WO0FcDF4R2A37HGBRBF1VYWm8oR9494H8B87564h60Fs8eI0bkVd4F61WXks8Zb8261C@VWssX494m0ZFLY08V4977VNBB33VWlFgF29A_6VVkF44uA5YlsB841W0F8873VVH0l4Hf271kkV4@321kl8BD43VVkgD@610N8D220FXFo42AI24214RA40X1s88635_WG90NH6YFs4BJ9@4f0XV8@23W1GkZ66422Hosw8T412VVF8973X0FdFJLCB4FkB820VklVs82BC33WFNxT2C30XlcB8FDoN10VVN9c6B12HNkH45VkFB82D5VFG210J4MWWG0o4B3123W0IFgHA51VcVHA2VVlVo41247cY0s@8E1YFkNgRP3A3XNkD984Z40sRBVj313Gc8c628781W0Nki6B1X1cB88FABVmscD830mGkB4NJSYW20Vtwi8741Vck4F67W0VoeA1Vkc442E57t0FN8Ni8367GkoBF6133t0Fk@48V422Xs8RJF78_lss891ZYHHGZc64WWcBV4FH0_IcVcR341WVk8FVmC45W8cwN@25YVGcR2A7XFcR470W0F8271VJlHN48810WNNa243FkB64182kN48FZP2VlfJJJAZ11VW0F8P8411t0J73VIGV84JRI612HAF8B824X0VVVA3118J463b2nXP08T5L13139ZaI4VlW0lBN4E8VYLV8gFaB25ZFG3F4B817XXksJH4Z3XBV8c7824150k84PC630kgL220YWGklkF37YFGFB4FAZ11VVVkFDEC0W0kZa61810F841557VcVsBLC130kFVccPD221sFH23WHm0841360VG9sK2T395kkBBPB924nWR@3442X0FaH6G6VXVN8VJF_IWY1c8J62251Z20wJM20W19062D@IEVVcLF4821311kFJA7W0Vc83C7VVGVF21348Z@VFN8HS265okFZFD71VWFNJ75WGsN6PD20VWOyF462D2143N8sPQ7WXWgV8R4JG94G1ko4NP1531G8RHV8W0kcZVH75X2t8JH6AVkkd184X1321Nsi374Z0Ft9k6891FF4HC6_3HVF4@@62FcBF72VVcJ42F81084@8A1VXKF84F310VsBD8@2FVR8428YF8B269Jm0W0F8N631VFNRZA70l0FB518XoFkR436Wkkk445VVFo4TE10YFF4268I6jH8ZFJ8821l0VcE50G0RgV4170FGOiF462@3YJWRJP@15YO0FV9ZP64_kkBDFA3VXHF@BNI91kNJVXFC2a0lVwiF340kFksNN4G71mtFF61YX2H8wL6L2W1d0@@F20kNFFLN74W20ZF41VW88241WFs86ZCH20b0VZ4E4WlNgF140VFB4TB0VX4RV8N48211WcZR66WWFBB10VZ1P0BH8220tR8FL6W0F84210V88cL_Z120t0FV8Nki324288oM8261m0XFRV8N78281C18kNwE8241m0X0RV8s4HU6W_VFR6513GWso4P215_WWkNoN58WVGl84NEZ12VXH0J6CAbWlcs90W824lc8o62A6m0X0RV8Z4	!2XVk!7FV!E04!2BcV!XDc!292!1PNV#YB!8Fl#6$Hmo#cb#QZ#9Ms#46!3_0V	(1/.B!2*1#@1//!2!1%1#1%G#1102&301(1#102)1%1$2$1&62#12#11/-1*1%2$1-1/04,3%2!1$101)2/01#1*3*1.B$1///1(1*D2%1%1/01$1$262+E01,1&2#1&31&10102(1#1+2102%1)2-6%21&5-1*C,2!6/01!1-1*11$2*D/#1#1!3#21&6/&1.201%1%10z(6.1#21!101&@!1$2$2/&6#1$4#4$1&1/%A!1-18$20601)1&2/$2.1/&1.1)1/01)2#	e`rpO@@@BMGJimkhT\Y[W_\bbbbTTRbaRTRRTrrvTTrTlrWBebSQpsrnkTaUAPETEUDuUUUUQD@@@					agonist	U2	Neuromedin	no	gpcr-ligands_DescriptorsNo5Ht
.>x>xi.ix>.>S~xiS(.iJ).hx>x=S~36(OxiS(s?x=S(x>}^xT-gL)yg55)L	;tQGtG8k5m0425FN2GVN@m040Fd39@0HLZ58V83Nk969WV0@1Z5VKLW0V88PmFV8482_c4c!X504J48W8F0	0aJ0Tk02J03d!9J0Eo!o40G01v!B90Cg0xV04OF1g07!Tk$ #m0WkKN8pL2A70WkwV8V78261m0YFKN99L2F1XVWFaF4B2S@d1kVZFD2I73VX0sR73YWGFR4DIZ13Vt0G8DF4D3Z120t0Gk8seD36YVGOJR486	!1V0k#F8!24X%F)84#14$3#10F%F#@o!8FC#GY$9s!216!214k	!1/1-1$E/!1!4%3/)3*2#2$2$2//+1,2+1%3+5#1/+1$42-2/#1#1(1.2.1#1$1/#111+1/#1/3/-4+3%54/!1/#2+3$3!41+1!1&11//!2//%12!1*2/)2(1.61*5/)2#3/%9(1/&1/#E%4/3/%p+4!1#1/1%B&1/-2+2&1/(3(1/$202)23/1///01(3(2)91)1/%	eohTLB@LIhDD`@ajPzdAiCIIBhhhdeEhuiAYDcOGL`hkgej@B@JbjjjB`@@					antagonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>S~xhxi.h.iS~.i.=S~S(.i.ixi.>.=S~S~.hxhl;:<	:UvzvzkzOhuYod1Gs8tZ8E4H1G3cV99h@t24O#IF24Fo90Vs4424kF@R0402Ff0H2G808080V8!F!V0F0	0Z80IV02FV1D!9_07g!aJ0Tk03Z02U0DF012s0FF1M0@g0 05qFWsFug492m0WVHK88H5Z180pGsFZ8XS3W28JFC86ZAqcFF9e2@MVWkZ9F8aG30HsVsNVI61WVRJF86ZCKsFF9T2@PVWkYGR8aL30XkVsQ8261	#90V!28#4%29V#4$1@#2G$V*8F$2k$5#G2V!118$H!210V	/#3/#C#6//*2,1)6$3$1+41/////#2,3(3///(2/)1&23#1//.2+5/$1/!2/2&4&1/#5&2)5%1$1/2/01*201/$21////-1!3/B//-2&6*6+2$1//!2!1.1/*p%5/#1(2!6#H-2*3+4(1//)6/02*1&4/$4,2&2//*2//+	fcQ@@DSAdTTTRRNTTTRRVbtZh~sWmj`hBdJBbhJPvci@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
{`:uS}lu)Sul:1:uw>+`+Fwh/>/hS}w>/h/>S}~Gwhwh/hw>/>/hS)	<fjzKjtxTCRHEDCGjet7umFFWd3Z0LyJV5NX010pc631_0YgZd4VJckV91Kl8X11210cR48Z1F204FBW0FV	0Xo0FF03FV1E0@Z016J0Sk1v07k01LF0SF1r07k0ok05RF1o0Bk0nF3o# %O0FsDF4L3Z120Vw8Fw8z5251GlssBF7@166VGFF5RP821H084PBID5308DBI0VZ1klwF9@20cF830_ZXk	!220V!1B8!2WN#82F!V5F$e$1#81%8!29%Lk#67#GG#8NN!AX4!290V	/#7/#G#1//#1/%2%12$9#1*113/$1/%1!111#1#4$2.1)1-1)11/%1)1!1!1/.1&9&1#31%1#2/1/+1)2(1,1#1-1*2$1.1-4/3$1-1,1#102,101&1*1,1&1%1)11,1/-1.302//21/!1)5!11&2$1+2%11-4/1/,n&1!2#1(101&2(6(1,1.3///013-1.1%1$1+2/&1%101/#2$1(4+6.16-	ec`RH@@HBNI`LdRbtRRRTRbbNvfABfdRQSSPuKTuPTEUUTE@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>xhS(.h.hx>.>x>xhS(.iS(x>S~x>.>.>xhS(.hS(S(x>S~.>.>S(xiS(.h	=fzKxS_w3JAjUP8l2O@Q_SN1dYj9BIzXEA212Qm960YW0XOcxX5JOQZu7Qk1lE1AeBVJ1085G3JI10X0GF	0WR0Tk025k1v!8M07g!ZB0s!2IV3r!BM06J0Tk035k1_07g!sg0c03Z!GD08g0cF3Z!K_06c0SV1v0C!1pJ0Kk1e07g0Xk2V0DF% !O0FcDF4D2KOb0ksTF443Z130t0G8DF4P3Z14VYG1wNY55Xt0GsDF4P3Z140ZHm8o8E49oFWcFI0492m0WVRV8c5sJ@1WVwV8N782G1b_FXFFt2GGX1G3XF8HY13WVWlo620Xll0DJ6@8lWcNJBRC@4WWRNTBOF8W0VoG64NWXWV8VHXI251O0Fs8K@MEW1GVdCwE222W0V8lR2@9bkVsaF482lM10lsNVaI@YWNVRJEZ18Vt0Gc8oFU18lNkoQ82I1m0VkLI88L5Z1@0bHNGNXBA1ZWFV8wwE26BkGFaF4X3Z160ZJW8u8I4m0ZFRV8k78241m0_kMONa6G3m0WkRV8o4	!3vaV!I8B!6cf!1HiV!Z38!6cE!3@pk!RYN#mD!2FlF!ZHs!2Yg#10F!9vk!624#1DV	!1/*1)4+1%1!1(1/.21%2$1$3%2.1&2)1/04-3)1+6#104%1/#2(3//01/!1&101!3+1(4(3/+1%1/#41/&2/(8$103*5-1*12022301$4$1,11!2#13!33/#102,6#1/*2$4&1/.3)1(2119!4-2#2)3!11+1!1$3%F)1+101//,1#1&1!1,y%2(2*1/G-2/-1,4/-A&2/,1/2#1#2,3&1*101#1-2$3/!1)3%1&	eb^\BL@NGEnk`TPHaRH~bLbbbTRRabfbRTRQRRfcDegaPsVtD@DQ@U@uETs@`@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x=S~.=xhxi.h.i.>.hS~.>xi.i.hS(S~x=S~.>.=.i.i.hS(S~.>xhx>	;vzvUvUozlvTvIGn5Gt9fLi42P4oOPdAt24V135IN28Fh80GHW4ULs4BN2s!Ff0L0X#2F0F10FHV%	0Z80IV02FV1D!9_07g!_!uF03FV1Q06N!qJ0R01v!DF09w0t!4AV1204s0eF$ $6F4T3Z14Vt0GsAWN462CdZNOFD6V0WYVn3R8PK15Wa30GBw2G@VYlBV8N4DFK41kFNVCZ14Vt0FkDF4H2uK13kY1VwK45X5X8ZBI586VGcnGV44233nVRa@F@W0WVsoJFA31HkFF63X42G8FZ@52kVNR330n1dY04Jo13W3HssNE585FGcn1c442CaVW0FVJ3W31W0weM6X_VFNB5484XkGBD951lFw46163I6V8dV272m0WVF	#91V#8)2!V)V@#2G#8W#4VV*2Z$5#GV#18s$2!218V	1/!3#1-29)1(1,11/%2-202!8$301(141///)4//#1/0202/+2&1+23/(1!11#3#2)1$23/1+4201//&1*6(2)2$9&1/#502.1%3$2/-1/011/#2#12.21)2)1,1/%1!3!2)1!A#1!4!1-1/+22)7+2//01/)1/*x.1/+F03!2(201/$6)1)1/-2#1,3#1020201%19#1$1//)1/!2-3//#1&	eh\\D@@DGI`MlbbbbRQrbbbbRVTvvtLZfFNZhJ@jhJ`jJdcBr`Hah`@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(l0*F:0}^.hS(S(xh.>.>x>x>S(S(S(xh.>x>S(S(.>x>.hS(S~.>.>x>	:Uvzv;SzrvyvvIzKvMvvqULQjjpP8yAwe7_n7ITWkEkrj4HGW95Dw@MoYr4c@YzFUaZW4@O0193FXW5V8kk	0Pg!Xs0IV025k1v!DA0@N0t!3OF1v0Eo011R0OF1q07g01Ho0AV110480gF05N01e07B0Sk3F!Kl07B0Sk2x0CN% 0BV8F6iC241O0G0DF4F3Z15Vi_FG4A8281m0Y0FedBE46XFZFFZ8Pg83G8ck82@6YVYWGB8L77DW1FWHJi842FVtBRBOBZkcZ@20VXWWLF4N3Z170Z@VGJA8231QAVWVHO036VG0FRgD36Z2OBN@30HG99WDO4VV8kZOic0Vk8cFJ6C9_20oF80ZZHFkRD@7W10VD721108sJRI58XOBJD@224mcwX841XHd8gNQHYGGFfGV4@2PB0VVGRJNK24l0NkJ581WW0N315Xmnc8XD2625YI@NN@L5m0VkF	#E4k!N8Z!6XF!18c#VE#7Wg!3VLF!XdV!4_9#SFF!5@s#b4#58$ds!@0Z#1Ck	$101)2#1+2$5/!2/$1#1/(33$81#1$1/1/)1,1(1%11$3$1$2%4%2//#1#2%3&1+1///022&2(1/!1*3.1032/$4#11-1#7#1!1!1)1)2,21%2$1$2011+2%2010101!1!2#1/&4$5.1$1)3/!1/#1%2(1%901!1!3&1-202(21#11$1)A/,101//%1#1#1/1!y01#3!2$5%1#1!2!2$1#I01!4#1/+4,1%1!1+1(1$4.1&1,2/01.1$1-1/%1#4#8&3.2$2-	ebQ^HD@NECBjclTPHajPrJIKJJJZIIIJFEJYJJTLJVQEY][WP@UL@@AQUUULPP@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~.>S~x>xh.hxhxhS(zBW~x>x>ps}\S(	<TbOLWk7w4J9fEB0_09@VV8N580Z04Mp05B#@k84Y0V0Yy08ZZJFF0c1GF1W112V80J50V0F2#W!Vk	1680OF1v0C!16B0O01s0EJ01Zw0Xk2U0@N0jk3Z!WE05J0LV2A09w0dV2z0DF0 38211m0XFRV8Z78281m0XFRV8c4	#H5#IB8!48$4FV!V2V!10L#QKV!RW$48#X$omV#kZ#NW#80N#AF!21NV	02//%1////&3$2$1//#2/#2!4*6/&102+1////(1/01////!2/%1//#2&3&2&2$1&1/(2022!2$21/$1$1%31/-7!2#4//01-5+2/1#1+202//+1/!2%1$2(2/(2/%1/!1(10X%3)1/%4#7//&1#2,1/(1%8#1/%1/+2)101#2//02/4!3//%10	fbmH`@DBedElbbbbfTLRRSAAsEKULtDaQB@@					antagonist	A1 / A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(xix>.>S~x>xh.h.hxh|`|FS~S~l0xh~Shxh.~S~Sh.	vzUtv9tO9F5m1J@A1N0G2N@F44F0dW888PRV58!2NV160W!2GV905J9Fk23NVFV90A0404!840342W0V0Fk	0aJ0Tk02Ik2Z!C10480gF04P01e07R0o!4O01p07R0ok! 0BV8F64R31Wksdw8D4mO12FgV8N4iKJXkVcZM8271m0Y0G9heA46XBaFG48	#70k!O0s!6V#12e#V7F!70A!10ZV#98#2P#F0F!4Hk!8X4#18$nk!80Z#G8V	/!1/$A/(2//*1!6!10104#1%1/01%1+3.2)2)1/+2,1//)1&1#3/%1/$1+1!1$1!1&1*11/!2*4/1/*1/(1/!101%1*1.1,2/&101(1,1$1/!1//,1*1#4//2)1!2!3-16//+3*202//)d%5/#3+4#B/%2.2,1%5!1+1+101.1/2#301*1#101)1//01(11*5/,3-	fnkh@@@XISRTsJrzrkNF|xMV`TEUUT@@p@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(S(.hxh.>.>x>S(.h.hxh.>.>x>S~.h	?tzihnphxUHvH_bCm0yZ3ugYAk4JKKXd@k0Gl96Fm0194A7Z6NZ6Ad22H3g24143VV5308A80GFB$	0WR0Tk02OF1v!BM06J0Tk03FV1E0@Z!t40tV3c!NZ04F0Tk2G0DN0u! %m0VVGe4uB6XWWF8wwK52X1Vc8@Du14eVFsKJT4822XkfVV@91W0VkyF483Z130Z0kBeW90ll0vc4PQ7W1krHc8L4uK130VsV4u92Y0s8ZQ8231S0ZKF8c8	$aV!404)3V$8#1cX!20t$X+1F#2k#V5#G$8Kc!242!210V	02+1!2/%6%1.1$1//$1$4$3$1+3)1/$1$1#1/%2/102$12.2///$2///&2$3!2/+1%2////%3$101-101%1/$3$2(2!1/%2(3.1//.3//&1#1-2!@+2/#2/&1(8/,2*1#1(1//(1#e%6.1/$F01/!2(2$103/01//2/(301&401&1#1$2/$1//-1*1/04-	fns`b@Hb\BHRYWZUY]Yhpwlm`@jjfHJ@H\h@@					agonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S|wh/gw?/>wh/gw?S|/>S*wh/gw?U|1<-cwh6p{`Y(.aU|.@w?S|\{\{2:2:0j0jwhwh{`-c.@S|w?whS|w?whwhw?	:UvzfzTzS:QTOvD5TuuAU9x7XWZ4JCTfhP6II5k0r6V!1o8X0YV0V0ALYq02224HVkIJ808#8FVc0V0F0	0Xo0FF02OF1v!9_07g!aJ0Tk03Xk2W0DF!sg0cF3Z!DA0@40t!4AF110480eF$ 4a1NL86410mH0ZC41F98g_wQ21Wks8JF255XmG4T620Fc821D670W1VkL51FN4ZHHUXW1VVF4434WlFNL742FsFse21VVFB2BDJ1118VTC33FkN83B7W0N8BLTDAX19RJP@412VV8VWJ2AE6kVsN854122l0Z883XVsFD420V8F2ZEI221NsF57XkVV421VYWV44JT@AXGGJJP@5W2VV8VWF2AN30VsTF4H2121W0kD732kVR66110V881I79VFIN4F862FVoH630kkF64E5c1W8ZPT56YH0Fc828890XsVs8D7Z14Vt0G8@Ks2340FFkVkaAAZW8J4194ZVl0VTB62W8NB320k9kos2422FsoL731kkV6320V842aDI0Ve0c86732G8ND24Vk8B451VV886eH0VF8Ns42BP110VF643W18ND730VkF8310V884iG0VYL0849D53W0cJ@7320cJB6310cJ2ZJ2VZ_F	#c0V/0V#B#1dV$F$c#4Z$8F$2k#14#O8$58#F#21BV	!1%1!1/*Q/02#2$1$6+4/!6$H01405$3///$4//-3//1/.1///$1102)1/*1$2)1!3(2*8/1#1&1(1,31-3(1!1$1*106!3/)1(1/.1026$3$1%B.1$5/.1)1)1&B#1!H//%6!1!5#1&6///$2//-z%E!1$1*3*1$T,1//#1%105/-6,1(11!1%1106,1/*1+1#2/$4%4.1,@+12	egTrL@@DJCHPIMLbbRRTTvTbTTTTRRRRVvgTRQvKqHMJKImkUULuUP@E@@TAUUPEPID@@					antagonist	M1 / M2 / M3 / M4 / M5	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hS(.>.>S(.>.h0:S(*`*F:0(S:0:v*`*F.>.h.i.>.>.i.>.iS(	<vjzSxzxUKJHUTEkjYO6umVFWdAhV6TLVK9X01WpcL31W0YgVd6WJ8ks91Sl0V1121!R48g1FH04F0W0FV	0o80Ik2d!G_07R0Tk1w!Fh0440Fk3l!KZ07J0Sk1w0CB01M40S03B0Bo0x# 01Z13VkH1BBJ61J7WFgDBE6m0XkRV8F4FXB50NcNaCB714lF94C2f6XW1NVZLO84G0N440_62ckNk683	!220V!1B8!2WN#82F!V1F#9e$G#81%9!29%Lk#a6#GG#8FN!3a4!290V	/.1(F/$1)1(1/%1$11#105#1*103//.101#1#4/$1)1%1!1-11(1+1*1!1!1(2&1-1/#21%1*2/*1&2121/!4,1#1/1(2/$1/.304!2-1/0102,101#2!1#1%1$2&1&1%1)11,1/!2*1+2!401!1/-1/,50111&1$1+2%11///,k,1*101#201)6%101)1/!3/!14!1/)13/(301!1%1+1$22/%1%1$1-1%112&411/*9-	fmoH`@IJ\LFdiWUevUU]XeMFCDmZjjZZZ@Jjh@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
iS^@^fiSiS^fiS^@^fGAHfiS?CG/^f^f?K?JiSS(?[?\^fO>	;UvUrtUztnzwwIFnWThhj4RZ7OZB9ste52oG0G4rO0F04G1F044B2V66S0204020J0o0184N0k30FFV!8!	0U4!qJ0Tk3x!C_07g0zF05AV0j0440Ik2d! !F17AHOBBJ8I17Dm0NBJ9Z150cs8FJ8hD23W9bkFR8	%V.20V#B#19V$t$1%1#8F%k#V5#G%5c#4#231V	//(9#1////(6//////,4*6//,3+401,2//*4//-1*2%4/$2*2)2!3*2/-1*2$11/#4/!1/(1)301/!2)6//*102/B/.6*2+2#4$8///$4//)2#i%4,1!2*2(F$8/////%4!121/!1/+1//2%1/!2(1/%2%4-	figaA@BbAH]dDfUvVYU^UhpNTejv@BjB`hjhJ@@					not given in publication	M1	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
`|(Sl00l|`F|B,S~,fzfI}36]}s6*`nu*`|`8u|`36s6	vzMvvnnstNdukJ950c9tV9@1FNFIc348gIS248020@lA6!10cc4W80Wo24@502014H218V!80kF#18$	0Z80IV02OF1v!9_07g!oF0KF1v!Ni0440FV1D05R0eF! 0BV8V5Zm241O0FcDF4H3Z12Vt0GF8mNB321aGYBBJB1426JdZN894HVYaN8kN293	!1!V!2$402$VV(182#2F#82+F#22k!205#G2V#G8#2F!210V	*2%1/%9/#1/$3)202!3,8$3/02////401,1&1.2//-4/(2*1//066/$1///,2/#2#4$4//.1///,1/&1&11!4////$1$6208///#1,8///$1//-h%8//$F//%2/$1/%4%4//$3//*2//%1#1)1/(6(	fnk`@@@YIEDeXhhheDbQ`\qjUmUTt@DDAPP`P@						D	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xixhx>xix>S~xiS(.hxhx>x>S~S~S(xhx>xhw<^}tn~Ux>x>x>xhx>S(xhS~x>	{rzyxQGr_Txij4ga7TZBvgdfh2Z0GI0rN20H4011F448204BRHm#G6L0V!82FVk10kFXW3VW0	0WR0Tk02OF1v!920@Z!lR0OF1v!Bj0440wF06FV2D09s0dV3W0DF$ #E5WFoR90YXGkFB4422GNJL71WkVV43110F82eD0VXp_doN82XYlFV8JA4Z1FkJ620VN8sLRCZ30NVRI82@11WFVZL541G8JD52Vkdt86127VVGc44Ja7NZXNRJTAZ150t0G8886131kkZD44W0kR831VkN84210Kls44JkVG2lNV6BG6m0VkRV8o782C1	#15V!5R4)9FV!F2#5_8!20G#FV#4Z%FF#@k!8V4#G$W1c#4#218V	,1!1/!1#C*1/,1#11/(6$7$1!1&2*1!2//%1!3/+2011!2/&10203#101/)13&1$1!1/(4*1&12(2*304-101#2#31/201*1(1&1/3&1/%2$1,2!2$32+1//(1/#12,4/03/!1/#1#12-11@#12#11/#12!1%1!2&12)6/)1-1$2$12/,2/y%7/1/010H$4)1/!5104$1%2.1/#203#1/%1)6!1+101&1(1#1/*2021.4/,5,3	elVRLH@ADgdVohPHaIe]fYU_vUuVzacqJKHZZ@Bj`hHjjnjfHlNBJjAj@@					antagonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(.=xiS~x>xixiS~x>.hS~.=.h.h.=.h.=.h.=.h.=S(.hS~.=.h.h.=.hN~,A)\6s=x(S(S=x	:Uvzv;SxnvwvQGt2nEcems6MU_09NcPx651VW1OV@4l_VV3NVB26o8TJe344Fd162m114$F20LVVV8FV	0QF!aJ0Tk02K03x!C_06k0Tk03Z02W0DF012s0FF120@Z01KJ0NF1p0Ao0pk05KF1X06J0o03M$ $1Z120WWkZBB32Vko@@165n0ksH86WW0cJ730I2OaF4Z3Z170WYGJXE4W084ZFH251kVVH92WksF431VVNB6220KI2c4H732GVFH43W0VB4420VN82cKJNgkW8FBLE@YWkRH310Hm1N8D332FsRL531kN4631Vk85Bu21VFF4Jik231FsZDA4WW08632WFF94q110FF4JegMH@0lVN4@974m0cB8312mV44ZOZ130t0GVDF4F2672lkoLB31kF4gNMZ130W18VHE4XG8NF41VkFBwZT33XW0gR941FVJ@20VVF94aX91WlFJH45WkVF@73W0F94iX921W8ZJ55WVVJB530FH1G1oe2211G9NaC72kW0s62B9m0WFRV8c44542GFsHA4X0cV4PF0VYYV	#70k!1@#2V#1HX#VA#58i$7$d8#4c#8G$2k!804#d$1Yk$a#18V	//#2#D/%42/$1,1%5$21#3!102%1&1,1#1/%2$1)7//01#1+2$4)101!1!4/1!1(22/%1/#1#1!2#102*2$1(2!2$12$2(2*3)1(1/11$134%1,201/%2%201!1!4#1+2&1!2!3//!2*1#1%1/1!1//1$101(401#A$401!1+1/!3!1103#4)17)1021/1+1(1!1!101&1!1%11!1,10z#1*1*2/F!1/(10101.1)1+102#1*712/%1&1#4-1//$1#11!2.4(6*101$13$1!522%1$	en]VHL@I@jod\^`IABPpdLbdLRTvbRrRRTtRVTRRRDT|BNnaQiYj`BJjjjf@BejTb`@@					not given in publication	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.>.hS(.>S(.h.>.>.iS(.>.=x=S(S(.i.>S~.i.hS~	:UtztvOpFCmGJAA1O2G28@H440HgW@88Px648V02Q0A6FVV!FV424o1NJ@2DkGW2L821V4#4F20LV0V8FF	0PJ!WR0Tk02K03x!C10480bk03Z02U0DF011R0OF1g07g01L80P01q07g0o# $ALsFZA8261LhkWsLF4H2RIcVm8TF4@3Z130g0GuNP4@3m0WVNV8ccB23WeHP0F8@4m0VkK89BaM81Yl0FwaH7ZGFJVVFV914GcR64464kVFZY8251m0WVRV8g782D1m0XVRV8V4	#64F#2o!20F#F8#V2#5VP!20ZV!dX#148!20FF!42k#24#B$1Yk#W6!21@V	//(9.1%4//,1!2$1$1/+1#1/%21%1/)5%2%2%2/(1)1-2%1%1#2/$1/&1!12$3!1!1,1)21//4(1/(2)44#10101%4*1/(1!101!4#1/1!1%2//!2/.1/01.1*1$111#4#2$4//#1%3%2!201%1!7&3#2//&1$1//)f%1(4*1/A!2/012/)1!1%6/+102/)1*2//%11#1#1/+3(4$4/1%3-	fegI@`FRTWHH`LaFPSHYEDeMhdieHhxdj\MX\x@b@BjfjhH@@					agonist	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
(Si.=x=.~S(S(Shx>.~S(Shxh.:0:v~S~S*`*Fh..=.h.h.=.=	;xv9zOUnxIUJHAFO0I@N@kcXH0_19@8@RV5!12GV260WVV30VC2MJ8Fo230VFV922F!40V@0220FV0V0Fk	0qJ0R01v!C10480eF04KF1R0A!gk06AF1D05J0Lk1R0A! $382410YWcwRD72kFBccJG64GdBH91VHH1DF4N3Z140VmNwqI41kG0cV	!230V#8#4$1BFV!W8V!30e#2l$18$G#8G%o#1a#9VV!1Kk!@4#251V	(1)3/$D1,2/!2$4//$6/%31-2//%601!1.1//1)1/+1,1/1$1.1+2$1$2+1-1(21/#6/!112!1/!2!1/)2#101%1!104#304!2$1/$1&3#1)2/&1/01//01*1(1$1$1(1!6#1//)1!3#2!1%13*1!1*101#2$1&1///!10k*1.1/8/%2$2/-3,1/21/$20301(13/!1/$1-1/&1%3&1&1#1(4-	fewq@@ENrAJYU]YeUwWdheSghzBBJjZj@H`@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xhxh.>x>S~S~.iS(.>.>x>S(.iS(x>.>S(S(h.>..=	vzUQvAvIMN_V26@EG8FFHO9H440VdW2B83DV50V128$3V4HFV04149FZ2I4W!6F9FV84!8!30X14VFFF	0PJ!Q4!WR0Tk025k1v!8M07g!dV0ak03FF1204s011R0OF1g07g01K40PV1m07g0o& 1Z14VapVgZ86413nHJR66735YVFcyI23X5msJ@JA33lVWZyM92WlKk8_g272m0W0Fst0L7WVVsgRH756lFwR486VkGOAN4Hi13WO0FV8R8VB4lN8RND33Wo8NDH1X0tFgf8271m0YFRV8F44LB82NdBJkO1WWOwNaCZ13Vt0FsDF4@3Z170g6VFFA8261MCVWVIOR4B2m0ZVRV8J78251144X0N164Y5mkgLI632WgV8J78251m0XVRV8Z4	#74F!N2Z!608!108#V6#4VN!204$8$88#8GF!Z0k#XZ#18#83k!88Z#1Bk	01*1,1,7/02///$2$10101,3&201//#2,1#101/6%4%2$3/#2(2-1#4/+1//!201#1/*201-1///(4%9)4//(601*2!1+104*2#2/-1/!6+1/%2/%5%1/-1&2,2/,E#3!211/(21!2!2/1/$1/0h1+1,1/6/!1/-2(4!1.4*2/!1/02//!2#3*1/+1%4/,3-	fegHC@BZBdDPJHUDYEEDeDiUEEXdhfR\GhxHJH@bjjhH@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
hx>x~S(Shxhx:0:v~S*``|*F.>6s}\.iS(.h`|`|.>.>x>.>}\S(S(`|x=.>x>.hS(xh.>	:Uvzv;S:vytxQjTnzvfdzQzxcYURivxUEbG5cBxeaWLfiyt3A2BKoqTer1TEWr0XW15p03F0F08VYWW0kV	0Pg!Z80IV025k1v!8M07g!lR0OF1v!BM06J0Tk03Xk2a0DF012V0FF120A401MB0SF1u0Ak0pF07JF1X06c0Rk1v0C!pF$ !m0WFRV8R78291m0YVRV8w78261m0Y0RV8R4TQS1YFk9dgI48XO0GNDF4H2Na14FgV9V4t8251O0GN9DX4620ZkWkpTJ352VFkkBaC18fmVFsQ8231Dh0WVcH474m0YkRV8k4lB2@W69VGg8uo9WY0wV8B4uo27ZkGFPSu4C2B0Z4XR8N7Z13Vt0Fs84g4L1cVWsZy4B6B0a4XR8c611A3GFBBZ70YFlkcg4A@0XHY09l8b2B1n30Fc8k2Da0XkgV8F782510_VXO9q4C4B0_dV9B822J6YkX0k4RF1681FFZRk2Oa0_kgV8B4	#zZk!92o!305!3H@F!Vj8!CcX!2Va#8f8!4HN!2FlF!Z8k!8X_#98$1k!815#GEV	//%109*2*3)2,2/%40602!2$1!3/)12/#1/#4022,1&4%2011(2/+2)1/01$1-11/$1+2!1$3/+2)1(12,1//*7$101#2(1!5!1/0215#1$1!1120201%1%2*22#1/,3//$3%1+10103$1)2(1)5!9/,1!2#10101+4%2#8///&1$1/#1%1*z%5%1&1#21$121(F/2//%1)1/&C//$6)3%21/$6*1%1(1+2%601$2,1&2(1$	ebQVHD@NE@hgdXPH`zHrJJIQYSJIQIJIEYFIQLRJFIUES[WPPLTpT`uEUTtTP@@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
iS^@^fiSiS^fiS^@^fGAHfiS?CG/^f^f?K?JiSS(?[?\^fO>DD	;UvUrvUzvnzywIkn_Txjj4RqbOqRtwtf5@ol1G4rO0G24G1F044RXV66SFH040H4J0o0184N0k30kFX02810	0U4!Xw0s!3OF1v0Eo!qJ0Tk3x!Ni02w0FF1E0@Z0s# %e2DF81sNcFo2DM_FcNcI82@1m0VkHk94TQ2WGFwNHDQ18YkGmgT4A4MVWqc8J8fE23W@bFFR9T29PVWVV	%V.20V#B#19V$t#F1$V1#8F$Fk#V5#G%5c#4#239V	%5//07#1-1///)8/,5////.4(101///)101,2//*4//$1(1*3%4/$2*2)2!4//)1*2$21/#4/!101/%1)3/$2)6(3//0104/B/.5$2$2+2#4$8///$2//-j%4,1!2*1(F$8+2///05/&4!121/!1/+1(2/-1/!2(1)1+1#1/	few`a@BbfBP{HILkllrj|jtXGJRu[@AUAPTUUAP@@					not given in publication	M1	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhS~.>S~x>xi.hxixhx=xiS~x=.ixixiS(S~S~\}x=x>xh~WS(sphx~Q	>vtUyCkpNUUGtIpWR@LgZ0HCY9@ZTtr_!m1QFA0Fp01AG24eJHZ8s0WHHGd0L8X28V022N50JHp0V0F0	0Z80IV02FV1D!9_07g!qJ0R01v!C20@Z0ek03Z02U0DF01XZ0G01D07!Tk3d& !1x@4GA2VWcVlLS822GBV8w78251m0YkRV8Z5o925cFG8TF4B3Z14Vt0G88kT4K9X10Ze210FG8ghih2214XNV8M586kGckFZN2_GH1FF4B7LVXas8R8ZI230cN4H30kV4kLNhQW10XGRR49XZ2s8oNqS2Z1218@4B6QVX_c8RA8261	#WWk#8$24#4_V#1#2g@$G$Y#40J*2o!405#GVF!90s#42!258V	/#3/#B/%3/&3$1)1#1#202016$11*71//(1/!1/,1///)1!2+2/)1#1#3#1)31//1!2//03/!1/(8&1!2/501(1%1#102$2/%2/)101/404/!2)5/*1.101#1!3!2,B#1%1)1+1/#21)9+2/(1(1/4(1/(10t+1!2*1/D$2/)1%4*1%303/*3!2/*101&8%1*1%101//)102-3/,32,	eod\D@@DGI`FlbbbbRQrbbbRbVTLtLjfFvVNZhJ@jhJ`hjHhKB@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>S~S(xhxi.ix>.>S~|Fxh.h|`lv`*x>`|~Sxh}\6s`|p3`|)J6s`|	vzUvv9tGSF5V0J@EG80G2N8H44F0dY988HTV58V03@F1601V02FV8214OFZ@34W!9FAVVc6!8413F21$k	0P#Z40IV02FV1D!GG06J0SV1v!OG06c0RV1n07k0o!6JF1n07J0TV1w0CN0 01Z130t0G0DF4J2QMakl0Rco472CHVX0FFPJA51NVRFDLKW28oJD@C981cVTBE62BJ0NF@65m0WkRV8J782D1m0VkGfwk653	#70k!S2Z!62s!1@8#V6F!48P$J#V@4!859#9FF!5Pk!8aK#98V#zk!80Z#18V	01//%@/02/01-1*1(4$2*1%2&2/////!6%2/!2//!5/$2%1&2/,101%2(1///03(1/*2&F/01%1,2-2(402(101#304*1%1/+1///#11/-13/2/#2/*2.O&2/#2$101#1-1$1/01&1+o2!1$1+1/$6!101)2$2/2/#7!2/*6-1-1&3/.1!1$2%1/,1(4/#2(1&2%	fcoH@@@Xi[IEEEEBdhllhXhkRUgCVDEQUMU@QDP@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
l0F*~S*Fl0hxh.S(.h:0~S~S~S.>.>h..hS(~Sx>i.S(xh~Sh.~S	;pU_tK9m5k4GEjGNVlXN@H0ZF01Y9@06tX58Z03vk06FWV!FVC2JJc8VV14WFd90AV0c40V2!1FL18603V	0Z40IV02pV3Z!C_07!Tk03Y03a0Dc016J0Sk1v07k01_40O01p07R0U03L$ 1Z12VXVGSc4H4SYW1kYwJ8F55167kG8FF4RP3WH0iF482UXW1VVNPg5462O0Fk8VqR93FV8RTD3B3HkR@85W0GG0c4323mGFXE20V9OJgXcE2VFcVKRHB2FFcsJ	#20V!188#VN#42#V0F!2k@#2G$WF!81N#18$No#45#GV#8Ns!842!250V	//(@1$1&24!1///1!6$1$3$1+1$1)1,2,1)2$2//#2+1*4/01%3012+1&101%1$2#1/+2!1!2/&2/)2&4/!21(2(1$5&2//%1#321#14(3/!1/$2(1*2011$2$3%2///)2#1+1!9/%2/*1#2*8+2+1&2//$101/*l&2&1,4$101%D$1.1/&1//1*7/&1!101%1/#1/,1/%1&1%1//+	fmw`P@D@rwnQQQQQQIHz[IQEBUXOhmT@L@AUMU@@@					antagonist	PGD2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S~vl0lx=F|`|xiS(x=x>S(x>xhx>S~xhxiS~u8un}]}Ifz}Hqq^}}^	;vzfvMUshg3L@jU9Fkm99P1B0WhY9DRMi2480133G3!1W!JZ04H4dNB2P9VF0BI1k!60VDZ1IFV0R0F0F	0PZ!dV0ak03FV1407g!qJ0R01v!DA0@!t!4NV1e06w0o!5FF1208g0c03Z& 0BV8R78221m0WVGKc8T5Z140ba1NBP62Db48RJV@4X70lNNVka72VcksQ82410VFYWNwN5W0FB4FI@0b49Z6868VFGss4TB@61cR8FJ10FX9I_84B3VXFr@F8F7131Yn0GNLa4VW28mRRi371YWdRJI7W090wY8281m0VkRV8N4	!1A0V!_$708!208#V2F!102!104$Y#24c#8k#42w!8X5#lV#89w!42#21VV	&2+1$1232*C%1//)1/+2$1!1(3//+2%4(3#4-1#1,2.1/01/#1*202//)6/#3//$11*3//,4-1/&1/106021#2$1!101/&2-1$1-2/1#2)1,1,1/%1%111(7$11+1#1/.1$4#7#3+2.1#202*101//-m-1/!2)@$2.1!201-2#1#1&101/4$2$21%1/!1(15/.1/2//$401#1!1*1&2)2110	ec`RD@@DNEN`CLbbbTJVRbRfRVReCBfdRSWRvsUP@T@EUUTE@@@					antagonist / inverse agonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(S~x>x>0lvlS(S(`|F||F:vsp\)dzJ}|F|F\)|F	vTPl2G9p8F5k0JA5GN0W0N2m04FG13A!LHV50V02PV86GkV02O0C25J1FVc16l0WA4@VV04#B1IFF101!V	0ZF0IV025k1v!8M07g!WR0Tk025k1v!BM06J0Tk045k1_07N0Tk04RF2w0Ao0p% 0BV8V78281W8VW8LF4B2GMWklGo4D9Z120t0FkDF482HDWJFsJD@79ZWswg5733t0GVDF482aN3VlNPC@4DDVXVwV8R782B1BI0WVLF483Z13Va3VFosJ252CKsFsA8261a60WVGy@4C2Ag3cNcBZuB1XVreR8V4wJ14FV	#aaV!P04!2ZF!112#Y3$d8!25J#FW$R2!2K2F!VDc$m#51%k$4#G1k	/%1/24)2/*2/&1.1//-2/$2(202/%81$4/(5*201%1(1/#1/(1$1-1!24(2/$2/////#6$1#2*1/,2/,104#101//%11/-1%2/.1#2!5%1.5/%4)1!2(1/#A1*1/01/-1//%b.4$1!1$101*B!2+1//!1&2/&1%2////,4%10501/&103%103/+1.	fnsp@`B\LBHUDIbFqFQQQJIIPzIQGLehqZpPTRtE@Q@@@					antagonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
tn{DL}Z)tntny?55L}L)(Sg-n2>x>.D+}ZD+(S(Sn2n2>.D+}Z(Sn2n2b{D+	:UvzvUrzKhw3TvhUU@nGOQdXCRI9WECTMxaEAV1VPrT4GmcBqt@xX4o0sVeKMl1W36@l80JF!8FIFF10180V	0Z40IV025k1v!8M07g!XJ0zF035k1_07g!t!bk3Z!FM06J0SV1v!Gf07J0j03J!Of07J0Z02U0B40t& 0O0FVDF4L3Z13Vt0FFDF4B3Z16Vt0GNDF4F3Z14Vt0GkACX462L0Y708c9N2IJ3kX0S8Z452LWWNO5B2E4m0XVRV8N78231Y7VWNGws4@EXkVsVx2S5XlGkiF4T3Z160qGNFgA82G1m0VkKW88e_191bnVFoyA252O0FkC0c4824@LNNwE612312bH0BL633AId0JD@3KdX0VoFJTT1YVk	!1raV!28o!2HI!11aV!iI8#cB!25Bk!EW8#US!2T@F#Dc#Jo#hd#GoZ!82o!1IGk	/1/&5/%4-2/(105%4$2$1/#1*31/,1(2#1#2$1&104%2,2/!1//&1/(2)1/21&3(11+1$2/#201&1#1/%202)1%74%102*111+2$21!1!2201#21%1&2(2#1/+1,3!1$1&1#104,3/$1/02%1+110802!1,1,25(301(4)17%1$3%1+1/,1*1!1/&o%4%101$1*1*F)1!101/&2.1/,1#6//$101//$2%1/-3(4(4//!	eodRHJ@BN@dh`HaZHNdKiAzPRYeg[YYW]UibQPqJhkjBBafBXFJjhh@@@					antagonist	CB1	Cannabinoid (I)	no	gpcr-ligands_DescriptorsNo5Ht
}\>xW~psxhx>S~xhS(.hxhx>x>S~S~S(xhi>>?x>S~xhS~x>xh	;vvvzszttQfoW1Ft9tZ9E4HGGAc099hPS25O014Ik040R9Fec45@4oF2R@702G2102G8080@0k8!FV0VVFV	0Pg!Z80IV02OF1v!@k0BZ012s0FF1M0A!16B0O01u0EJ0 06F4H3516b0NFcE8251m0XFJ4F8H541780GNH0gM392W8Fw82C624luNFZ66W3kk8oRL@960VZJ430XWtHNgJ42lFsdd6a37WXZvBBT6E7Z3cVVBF6m0WkRV8B4	#90V!28#BV$29V#4#11T#2l#F&8#8F%k$5#G2V!13c#FF!210V	//(D!2$2$2-3-3/*2$3/&1)2//*4/&2///.4202&202$1)1/-1/$2/0201&2!5!201$22#1(3/!23,2)2*2-1/#2%101!1//#2/-4/#3#1/+1///0804/,2/%4*4//2/#21//*20k)1/1&22&8/#5$1+2$2//%2%6/021&1(23////.2%3/#1(2,2	fewq@@HmzCIDehhhddmDdTm`e`~bgMKREAQUUuE@@@					agonist	Opioid mu / delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.ixixhS~x>.hsp\}Bz	zvyvefxMhN2a1J960BJcVN4m64F_cY020MF059!18k10W1W0@109!LVF0V9F210509Z0@B!4!@FX58X0GV	0b!vV04DV1104F0Tk04OF1k07g0vV05Mk1W07J0jF3I$ 382@1m0X0RV8F782B1m0VkRV8J4	!1i0k#F%2#20V!VV#18c$F$3$88*2k$3#K3F$s!2$210V	//(7/!1%1//,2#12,1!1/*2(1&1.3/4/)1&1//)2+1.1&1/+1///(1+2/(3/!1/$1//$1#1/!2/)1/2!2/$2/+2///0304*1/#2/.6/#1/&1///&S#2*1$1$1#3+6/#3/%1(3/(5+1/!1///02*3!3$1//02/,2-	f`iQ@@C^AdTTRbLtrYrVg^`HJjVJ`H`@					agonist	Adrenergic alpha 2 / beta 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xhS(.hxh^}}H.>x>.>.hS(S(xh.>.=x>S(xh.=x>.iS(xh.=S~.=x=x>S~.i.h.=S~.i	>U:pzxzUvzUzUovjvUiEiUBrSEzrjTDjPbzQzfck7XI5LVpxH__B@YdQsm1VMtZ2Hm1lTK1kFOGPV0F0	0PZ!XZ0IV02AV1D!8i04s!aJ0R!2J03d!C_07!Tk03Xk2W0DF018w0bk3Z0DV01IJ0FV1407g0bk$ 38251m0WFRV8N78241m0XFNX08D456ZGt4R976W0VBBHJ51_lVkT@210OFw642661kcJV96420J25A6VVGOVsDUBY1GNc4HBNQ5VlNQ04m381hHdcBR6SYW20gV8N4@4E4klBP48543lH0TG3Y30V8ZRB@FeFs42D6721msVi21VmNF4L9A10kFJ@43XGNR654WkcB821VF@clJ276W1sg4461ks86420FH8h46A9f0co8DA773JVoLA13XlkGC0W511Vsk4NH3fVsF2395ZVF886541GFcL74WkVF4410FHVtF644YGskHA4X0NB21D77O0FkDF4J3Z12Vh0GQ04H4oN13VVVJRC8XH0FB10VkN8sVR_B5lsWFFBH3ZGNFH54WkFFkJN244kkwXE2X2GcF4JJ@DamF4TB96H5YFgFL414XYomVBD612X2YORJ8C@X08NZR210WFsJL553GFF@73VkN58RZ224GNZe733FFFgT316aO0FNDF462@@XlOZ@7242kc8ZZ	#W0V!J8$4#38F#Y%V8$1F#f#4ZV!1V%2Z!805#tV#98s#42!218V	.6#1/011@.6!2014$501/#1(2*2#29#1203011/.101.2/$203$2*1$1$2)1&401%3)1(1)3,5/%1+1/#3$11,11*7$1.12(1/!8/(F&2.1/01*3$5.101#1+1-3%1,3,1$10106&1&1$1//+3)51103*1&1//(47-1*11$1#1&1)2//+z.1*11.D#1,2!1/2)2!1#402/-5/(214!1$13!1#1//-1/*1#3$1,1(42-	efQ\J@@L@n`DOFl\bbTTbblTrrrRTTTTR\qebQRIKUUUPLDUUAUAEAAPP@@					agonist	Ghrelin	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=S(S(.>x=.=S(*Em0.hS(:0~S.=.=S(.hS(x>S(x>xhS~x>xhxhx>	vzUvvv;O:vytCPhBvycDzRQrScYE4juI2CE0498q8aWJWXes0824KlFBc_1H0WY02W09T0204F0881cW0FV	0Pg!QF!Xs0FF025k1v!FM0540OF1v!OG07B0SF1u0Ak0pF07JF1_06c0Rk1q0C!pF% #38251m0XVRV8R782D1m0Y0RV8F4@8D6WVg4310XW1Fd254YGNcHFA0VXHFFNeH42Vko880VY1tVFFI821FVH530mmV84ZOZ12Vt0FsDF4R3Z19VWpORZ2331lX2ZgA44VG0FNOm2C6_0WFZ4F112XcJcGBLH280FGVe5@4M@X0XV44X@yI110Zs8Su252	#a4k!90o!301!2H@F!VaF!Cd@!2VZF!8@c!4Z8!2FlF!Z0k!8m5#98#Vdk!@G5!25AV	02)1*1/D1,1#2///)2//1#22/-106$4/(4%2+1//%1(12/,1/%1*201!1/!1)1-1%1,8,2$1/(9/$3+2/1#4/!11$280102/.11/(1)1!2!2%1*2)1$1)101/1/)2//*B%2/*1!1.2&1/!11.10q#1(4#1!1$2$2*4$12!1/%1,2(1!5/-8/(4!202%2$2/+1#11//(1$5%12/!105&22$	eghZ@H@CKGBn`HcHhdhdXhhdXbdeDePqXyDd]]@ATuLuUUUQL@@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>S~xhxh.h.hS~.h.>S~S(.h.ixi.>.>S~S~.hxhl;:<S~xhS~	:UvzvzszOxvvod1Gt9tZ9E5H1GAcV99x@x24O014IG24Fw9FVs44P4kH@R2602Ff0H2G808080k8!FV%	0Z80IV02FV1D!9_07g!aJ0Tk03FV1Q06N!t!bk3Z!Fi0440Kk2d# !X80WsJNw46244ZGZT@F5m0XVRV8N4Vw4Yl1NaF4J3Z180YoXBR8A4m0XVHlR8aI3VlFsJPDrLW10VNRTC82WNJH420Y1dXo4Jr13W7H0GBg61a11klW04I7WVNoB@C7LhkVVF8PD6ZGNRBA20V9Voli2@LVWkZ9R8aI212FVsQ8261	#90V!28#4%29V#4#11@#2G#8V*8F$2k$5#G2V!118$H!210V	/#3/#C#6/)2/%1/06$4$3+41///)4/)2,1////02/)1(3#1!202//)2///#22/2%24&1/#5/05%2$1/2/012%2!201/$21/-44//!1(201!3#2+B//-2&602(6+2$1//!2/!1/*v%5/,2!6#H13+4/&4(2$1//#6/02*1&7//$1$2//*2//+	eodTH@@DI`LbbbbRQrbbbRRtVJtLjFzfVvZhJ@iB`hjiBdFjNb@@					agonist	Opioid delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxix>u8un}]H}}Ifzqq)^~S~QH}H}b{)^wj	zyzUuAOIAm_V76@EF8FkkO9H4Z0V93ADBM6V580119F10V1!H5!ZG2W0c0ON#XF8k0@20VD45NJX5R2010	0WR0Tk02R03i!C_07!Tk03FV1E0@Z013c0FV1407g01JB0G01k07g0uF055k1_07!Tk3i# #2JN4AOVXFnBg8@4mO12FdOZ8F4Bg12VgV8B6LO24WO0FVDF4F2O_W2FgV8B5Z2BO0X0gV8V4mmBWXVwV8Z78231HY0WnB4N7Z140aONFgA82C1m0W0F	#cZk!104#24#4WV(2V2!20F$3%F#80F!20Z!805#GV#80s#J#250V	02//%8%1+1//.1!12$4!1.1//+1$102&1!2/!2//#1$1/)301/*1//$1//%2////(3&1-1%1#1.1!2$2#1#1#1)4*1.4/!3$1.1#1,2/$1,201!1.1!4+2)4!1&1/.C/-1!1!11/$4/#1/!e2)12!2/2*@!2-1/01$1/2(1$1)1//1&212%2*1(2+1/+102(1%1/,13!1(1	fnk`b@KDbBHRYgUY[YvYpuluJvB@jjB`bHhRH@@					antagonist	D1	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>+CZ)tnG*6r{D63{D)Ik0)Itntn6r>.)Ii.(S7sG*>.>.(S>.i.>.	;UvQztUStlvRQMFvGmdOeLg42IBbd8hyEX510A3QlA0FS!A5V1B34_4NmW@mGG0L96!22HBR9N42n42810	0Fs!Y!IV02OF1v!920@Z!ZB0s!3CF1407g!qJ0Tk3x& 01Z12VX3WReF134F88sR8PH6Fkco42A6fYFWVJwc1331VJQRH864m0XFRV8J48RD_1FJ4185ZJX08BD7Z17Vi_FFc8DC6ZGsgJ620mWN44FLBE92V42B86m0WVRV8N782410Y49NaA10H1d35T30X21BV8N782B1	#f1V!19#8F$24V!V1$c8$1#F1#4VJ#1%2k!105#G3k!91c(2GCV	+1(1+2%@/!1/%1/,2#29+2$2.1/)1/$13/)3%3+11!102/+1/.1/+1$1///%13/21%1!2)1,1*6.1/,2$102$12/#1//%1)1/014+1$1/!1!1/$1#1)2!6$2$101#2,2*1+6#101!@/%1/&201/#1,2,1!n2$1(21/#2%B#11/&1/$2&4/01#7!1&1/$2+5(1/#1,2(1/(1(2(101/07-	fcQA@@cv@H]HYHhhheDleUEDcdaZeXwnch@HHHjjjj`hZH@@						D	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS~.>.h.>S~.h.iS~.>S~.i.h.ixi.=S~S~xh	:UvzvzozSguYwOTDdNuX9K5L41Yg361hLV26A2V0BKG0FJA0R4!Z0VV@41102Y02F8Z#124988F018V0F0	0WR0F!2OF1v!9_07g!sg0cF3Z!Ji03c0FF1407g% %hVWW88FA8241ZXG8NRH254m0X0LtgH9452O0G8998h34Wt0FV8ZqHCZWG8cZqHH23l88oJ	$4V/0k)8#20N$Y$4%F$2k!805#O$858!24#210V	/03/%7*1#1/04(3/+@$3$1/#1/,1/$1$2////-1/!1//(1/03#1+61(2/1//&101/!4!1&1//*2&1//1&3/&1$4$1/+1//*1!2+1%8*2/%3!2$1!2(2)6/*1////(b%9/#1(1!1#H/////)2/1.1&1/02/01//-1*1/)11$	fj}aB@BXADIK[JrkN|eNcdmMUPP@@P@@@					antagonist	MT1 / MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
8u)Ifz1nS(@z}HS~.=.>)]xh.h.iS~S~x>.>.ixixhS(S~S~x>x>xhS(x>S(xh.=x=x>xixhx=x>xi	:Uvzv;S:vyvUEzCnzvvhyErUhrJSjyxXEbmbNTzvilTeqLx9nh8CgTkfn7xi1WGfZ0lK31FGF1J8YZV0F0	0Qw!Z80IV02OF1v!C_06k0Tk03OF1g07g!sg0c03Z!Fi0440FV2U!HD09w0cF3Z!HD09w0d03Z!S706k0Tk2D09w0d03Z! $BV84782C1P0YL08gA8281m0WkRV8J4DlFXW2FV8wMB_GH8dqD472DlkWVFJVF96288RZDAA_HFZ8B1442808h82826e1HFFP9Z13Vt0FcDF4B2tKW40gV8k42BBd2NRNeB@80mcwa7445H30wwM42_1Gl8s@540Vt8TD2ADVXFa1Nw6D3m0XFRV8g4@G6_n8RJDM70ZL1JJ36@Y33lZPB30GmNssS835WV_A8D8E4m0W0RV8R44IBa2FNBDN7N0Y6V8Z8XnAXG20Vh6R351Gse@4452GFVWFLF4@3Z130VXlwoJ5@2t0FkA1c472	!1W4k#B#4A#1@JV!Z@#5Ve#8KF#cc!45#2&Hk#F5#SO#13c!245!31hV	)101,1-A$2,1//1.2!D#25$3#22%2//,101$12#1$2#1%4&1*101%11#1///-1/01!2/%1#5102!1&4#1%2,1&1/.1#1/(2$103)1!11$1!1-2%3$302!1$1#1+2!2!3/*2!1#3#1//&2)101/!2&2+204@/1/201)201012(2!48//#1%3//&2!102!11!1!z%A01#1&2$201%1!4010P.1*1$12#2#2/)1/#7#1&1/(5&1(2/1//0201*1#62)1#1,4-	ea[VL@@DFNHkhP@`\bbbbbRRrbttrRVJbbrRPfcbPvrqrNKOKUTDpS@TEETu@DDDFA@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
.hS(.>S~s6.>S(}\B,\).>p3`|d,:0.h}\F*}\6s:0d,.>`|.h}\.>	vrUG31OG9F5V!2EI8012N0H04!931!2PV50X038!601V!FV02149FV1W4W!1F@VVc6!8113F210V0Fk	0QF!qJ0Sk1w!C204w0ek04JF1_07N0Tk04Rk1r07k0pV07JF1_06k0Rk1q07k0o% !m0W0RV8Z782819ZosNF423WWl1SDM32XGFG90N61VkswU8281m0W0RV8c4F2EA730s8@96m0WVRV8R782D13C5FNJE8281	#60k!S08!4X8#22#V2#4VN$Jk$Z!B59#1%@V#4G#98$mk!@04#18V	//(5/*1)1!2/-6$1*1!1)2/101//02#1#2$2.6$11!1///!5(2/)1!2/*2/&11#1//%4/!2%1!1&1%9/!1.1!2-1(401(1!1!234#1*1*1%1/*2%1/.1/1*103)102!3-1&2/*1!1+R/01//*1%1$1/)o1$3/#3/F*1%1(1/01+26//-1,1&2/01!1/!2%1/.2!1!41//*	fcH@@@TuOIEEEhdhdeEDdndsdeYGUhEAU@DQAEP@@@					antagonist	NPY1	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>x(Shx:0>x>x`*(Sixhx0:F*>xS(*Fhx(S.>x>>x>xxh(SS~x>>xxhxhx>	:UtztzxzKxzvwtUUx8n@OPzgAI@g6E9EPr2EA0_NQ_DaGVVkYs0zX5J1kFc_3FaW30X_0G53F!F20FW0W0FV	0WR0Tk025k1v!8M07g!lR0OF1v!BM06J0Tk03FF120@V!t!cV3Z!KH0740SF2x0CN$ O0FcAhH4A2_aFVcLF4H3Z16Vo0VVF8F4m0X0RV8s52n81ZkwV8Z78271m0Y0PV98V2F2m0W0RV8R782C1m0ZFPV9NV2J2m0W0RV8k78271m0Y0RV945@z2AWO0GVDF462O_W2FgV8s4	#L4k!H04!@4G#FL#o18!1Z8!20FF!VYc#1A!3J5F!W@k$Z#54k#1k$V#90V	//1&9/-1)1/(1*3#11//1&1/$1(102/01#6%4/01/01#1*1/.1*102%1/#4(3)1/01+1)1)402/01/&4$101,11/!21!11$204!1-201%2#12$2)102/01#2%1/-4/01&2,32/$902/#2)3!1,2!14)1@/,11%102/*2)1%1.o!2!2(2$1%1&1&D%2//!1/41-1-5-3/%2/01/$3(5.1/$4&1&1(1#3)1#	eghRHL@NCLfd`HaRHVbLbbbTRRaRbfVVbRsDfaeWQutDDduPLDUUDP@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>.hS(.>.>.hS(.>.hS(.>.>S(S(.>x=S(55S(.i.>.i.>S~.i.hS~	:UvzvzQpOynGL2@0OLOHA6HH40kg1P08Ql64Nk02O1d60VV4!V424w1N480DkFV6J821VB#4F20q!V8FF	0PJ!Xo0FF025k1v!9J0Eo!t!cF3Z!FM06J0Q01v!KX06J0PV1v0C& !kP12FgV8N5Ju27WO0Fk@9X4E6W0WNaF4B2d7eklNTF462d19YpNG0BiFLWVkcw82C6AGW0NkB8QCbGFBNaBEL6lkVNF4E8bFl0TD90VWm0kwRH5ZksFBHI9m0WFRV8N782B1m0XVRV8V5Fo41ZFk	#34#18J!20k#FN#V6#5dQ!20_V!dX#14c!20FF!4Ho#24#c$1fk$a!2W@k	/&1)1#10C/%4,1/#1)1#21#2$1/+1/+1.1/51$2%2%1/04%1/(2/02/!1/-2$3!1!1#2/#1%21#1)1)6//01)44#10111,3/.4101!401011.1!1//!11$2$1/)1&1)1.1*1%1$4)4//*3)2+8///!11//.k%1(4*2.1B/1#1/*1)8(2$2+1!2/%1031*11/,1(1(1/+3#10103/,7,2	fcoq@`FRKdDPFPcHIdLbbRftRRRdTZTRUNFlo\@Q@AUSUUPP@@					agonist	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.>.iS(S~.>.>.hxhS(S(S~|FS~x>xhlv|`S(xhx>~SS~h.xh.hx>xh	;vvtvpxs_eXJAEScAt2NNr4BF1dYAAd6Ta520Y2@!6FIW0XGX8@GZ8FZ2A8VV0A1AkDVZ8V2N0IF20F080k	0ZF0IV025k1v!Bl0440IV03903d0Eo011R0OF1k07g01L!Rk1q07R0o!5RF1n07R0jF3L# $O0FVAhH482m0X0Jnc86D3m0YkRV8R5eb41WFm@cy943X15e4X8D41aZdoB@J5D0XYmZ8D7Z13Vt0FN9OiM341WHGkiF4VGlNyF4@3Z150ZbtBBL6C9bINkJT@@4CY8BJB@4AWmskwB@6	!165k!F2Z!2BK#Na#VCF!1W@!22GF!V98!4IT!281F!_ao#8D#1W#VVk#2Z!2G8V	$1+1%1$2)A/%4-2-1%1+5$3*1(12//-1%10132/%2#1(2+1!1(1/01*1121$1#1+1//*21$1,1(2*1/102$2%1*2#2!2#4+@/!301.1&2$201$1$1/02)2.101/,101&104///$1%1.5$1/1&11*3%2.8/.11/1%1,1/%2%j.103#601$1,9/!1//&11/,1!21$1$1&1!1*2$4/$1*1/#1/3(4!2/#1$3-	fcoI@`NF}EPHaLafPKHYEEDhdeLdeIeUMfRmxLXH@HbFjjj`hMH@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
qqH}}H)^}\F*H}`|p3p3)J)^F*F*F*H})J)Jqq)^F*0lF*H})J0:(S)^)\63H}5563)\)^)^55	~:jzx<Czv<JxzvxexvzMRyvzyZTUqyf9vSDxyjp3rKzB7KA6G8KR69FGmVBVX4X0GV	0aJ0Tk02Ak3V!C_07R0U!3Xk2W0DF!sk0tV3c!Fh02w0FF3V!Jh03J0FF120@Z01MJ0Sk1u07k0ok06CF1204F0SF1u0@Z# 0O0FVDF483Z13Vt0G0DF4L3Z12VX0dgJL3WkF8HJB@42VVca@4XFVF822aXIFFwZMBVVFR44@5_2FekX@21VW0gY82@1m0XkRV8V7826167nWcFH4132t0FsDF483Z15Vt0Gs8s84621co8997YFGc4@4@Bm0YkRV8g782D1m0X0RV8B4N5B7lVcoD8253t0FcDF4X220YG8cL940lcR6211YllsFJ92XG8JD441FsJ8RD0W0FNd4@A4YWNZN940kFF6PD0VY3VFFLC6YGcsH120I1lWc4I@13W1GWBZE9W0W0k4124_0FccF23WG0V633VVsRD2110@Vg229K11GVgTC6XG0F8LD1VY30	#Q0V!18$VR!132#cBF!19c$Q$Y$49#9F$Lk!8Z7#O9#9GN!@48!2A0V	01#1/01+1!I!11!1*1-2+2/$110@$@$2#1*1$1)11/&11(1,1(1#1&1#1/!1(1//*1#1#1,101)2$1)1/$2(1212!2!1#1#1/!2!1$2%1!13/%221%2.1&11/#1$4%102011+1101%1/&1!1%12$2$10102$1/14%1)201$2&11(22+1!7#1%1$1(2&2+2!1-26+1!1-1/,1/)1,z!1!8!2/2-10H$2#1!2&1/%11014!1(1%1/$8102/#2!1$2#3!1)1/02#1-1-2,1%3$2$1/05-	ef]\B@@DHf`ALblbbTRbbrRrTRfRRrTRRJegdWTrvtJIMKUUUUUSTuT@@AT@Q`QPPhQyP@@					antagonist	Adrenergic alpha 2 C	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.>xi.iS~S~.hxhS~0lvl)J`|F||F6s6s`|)J`|}\q4^}}]	;vvv;x7wvqvSPhBYqcey6OmK8YCMbHI0CD0VQ8o86WFX2esW83JKlJ8cC9HtWW02W8F60X04F#1sW0FV	0QF!_!uF03AV1104s01540OF1k07g01_40Rk1p07c0j03K!SG06J0PV1n07N0o03K! $6F4@2EeW2FgV8R6FR241GIsFZ@@U2812AVFw8p@26WO0Fk8PPG3A1t0FcDF4D3Z170cs8FBA82J1	#b0k!90k!301!3H@F!VaF!B8@#V_F!8A8#4c!2FlF!Z0o!8m5#9c#VWk!815!25AV	+1*11.7-1#2/01//&3/,2$2011/-1&4/(2/!1)2/+1)1,3.1//&3%1//+1/$2*2/(A$2.1//$1&1.4&1#2)1!1&3#1#1//2!2/02*1#102)1/1!3(2//%1/07#102!1/%11!1/&1/!11/0h,4#1!101!11#1!1&6$1/+1#4/1011.102+8%13/302!2$1%2//1)3/$4.4&2/,2%	fi{I@@CV\TFRJYJ[QQQHqEQLyYtTt@EMSMUUDpjP@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xhx>x>xix>S(0:v:`*)\F*}\6363p3p3S~)\}\xiS~x>	=jzUzUzjQUUjPEsQnvS8zCHbhfA8PQReUEo5F@n1L429LuO0946os1weIKf8271Ao0VR0A#1LcX4603V	0WR0Tk035k1_07g!qJ0Sk1w!DB0DN0uV05B01104J0SF3L!Kp07R0TV1w0CN0 38241HYFWA84D6w14@0FkLF483Z140dGcFoeS252C60FZ8uX47G1FWgV59Z0kN8F88HVY6Vg8H7Z16VXmtoFS56XYlks8D7YkN482A4_dFGvFL4B3m0VkF	#@4V!104#cw#12k!V8F#d8!22F$i$1B#10F#qk#4E#GdV#Js!@08!210V	//!1$9201.1!2//,1!41#3$1$12*1//%1!1+1/&2$12//$1/$3.2/%1/*2(2!4#1-1$1//1(1//!2&1/#1&1-301$2(3)1%101%1///%1/031/)2+1%1+1!9#1/*12/1,207!1$1%1.3///%101*k#225/%2%4&F$1$1)1/&1/*1&1(6/&2!1(11#1+2/%1)2/(1*11/+3-	fig`b@K]FBHrJIKIQQQIJKXrcMVBUMX@JdJBhibJCb@@					antagonist	PGD2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(S(x>S(qq.=g-y?S(.i}Z?-yg.>.=S~x=.hxixi.>x>S~)^.=^)xi.hxh	:UvyvxrjN7sYLdAUsUkk9PZaJFl@V95hMtL5E0XVAkR5lRZBeT2Bc0oFF8cWGHlWWJ4k12JG658OPFV!V8FF	0_F0zF03OF1v0Eo01HF0AV1D0@40jk05NV1_07N0Tk3F!JZ08g0bk3Z0Eo01_R0Lk1R08g0bk3Z$ !1Z11Vt0Gk9BwPBVGGkiF4H3ABW2kgV8R782E13cI9s@@E5cZkW8LF4F2VX14kYkcy@9XZlRV8N782C1m0YkF	!2Abk!GX8#B@#TFV!sa$8D#mK#8Wk!4ZB#84V!Zvk$_#Glk!N8s!@YN!2WOV	(1/$1)2.4$15&4%2!1/(7)161#1///(1$1%106/&1&301#1/!2-3%2/%1+1!1//&11#1%3#2.3//02)1*2/(8401#1(4#1/%1!1#11$1014!21,2(11!1/*3&2/&1!1$21023-3+1/&1*A&21/%2(106/3$7012%102/&2(1/1.1#1!2$1&r#112/#1/D/1/!2+2!3&2/*105//!9/*21/%1/(1!6(4//+	ehRRHF@AGHfg`ICZPNdKiCzPAdLbbRrdRbbRLVRTtbThXt\Rjzf`@jdJ`Xfjihb`Th@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hS~S~xh.hS~x>S~.>xh.hS(xh.hS(.hx>.>xhx>xhS~x>xhxhx>x>S~xiS(.hxhx>S~x>S~S~S(xhS~	}Ux<quQuU:uzwnSCzvzOUiTrtvrigkUVqeu9zc1SojTj7OPaWWMOnOFK43FGfcFIdcV8F0	0p40OF1v!CG06J0Tk03OF1v0Eo012F0FF120@Z018s0bk2W0DF015!Y03a0DV023J0IV1M05V0YV2U0@40t& %O0FsDF463Z150XJ8wVB6VV90kV2233n1VH4310F8kTN10a39BTA10F9FVf8291WcFW8LF4H2132H0wBA5XGF842C56XWdBgA40kVB42A80FGc44JP122lsgRC3W0V8440VYmF44V116VFGPFJTM9YFsN@20VF9VkmJF51WVkFFJ84X0kcHA2WFkF4TE0VY40tNPE5XkcF220VVWcso844Y1VsR820VV8820VV@9144D@Zlkg84110F8kNNI14oFFsF48962FsVD84XVsB610VF85BLa7iW2FV	#9ak!FD#B$18FV!V8#18f!12tF!8YN#5$8F#V2k#l_#G8k!WKc!2LF!315V	&32)1/$D#1-1!2/01.1(2$6$3$3+102/01/)1$1/&42(4#4!2$1/%1/%1-201(1%3)201/02/*4#1-1&101&5)402/!1+1+9&3/2!20102(8!1$20202014(2+108*3/)1/0101#1!2&1)801/!1!1,104101/0E01+11$24/#201$2#1(4H//#1#1$2#11//*1020z%7!1/2/L!401#2%3(2,1/!1&1/%A)1-102041#604/#2,1$1/-2%22&4/,301+	egTrBD@I@deoHbj`I@bPrJJKKQQQQQJTkIQIZJJJIIDl\VAO_BzjfpPEULsSUUUU@A@AEA@HP@@					antagonist	Adrenergic alpha 1A / 1B / 1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>xhS(.h.hx>.>x>xhS(.iS(x>S~x>.>.>xhS(xhS(S(x>S~|F.>.>S(xi|`lvS(.h	}yjzUvcxTUAQbzU9hfjhBnzXjAHK@znx62Yd5qOgza5oOQZvMQk3lE1AuBVJ10s_G3oI14V0FF	0WR0Tk025k1v!8M07g!Zs0xk035k1_07g!lR0OF1v!DA0@!t!4IV2A0@40t!4Ak1104B0wF05OF1e07N0Tk3F!SK05R0PV1v08g0c03Z& $1Z12VYJuo68649aGNd6@85m0WkGZVV673224FgFP521mcJJDIZ110t0Fk@CBQ0X1GBV8Z782C1m0XFIcwP328lX0kk4Tn5aVlNaF4T3Z16Vt0G0844a_18flkFsFNRM3W1sWeJ4C22rkW8LF4B3Z150_WAgBL@14XG210BB7Z130t0H8Bkk4H2b5VWFLF4D217YXWR6D5Z2m0XVwL22Y1IQFV54521FGXF4JPF11lBV8F5Rn1WYkwV94782C19Y384D1GYZllV99a2FHVYVwV9B78231JikWNLF4c2517Zm0Fls2@4m0ZFRV8k448DXq08NXBBP520WBI82G1m0Y0RV8F782M1m0WkRV8o4	!3vaV!I8B!6cf!1HiV!Z38!7hE!3@pk!RYN#qD!2NlF!ZPs!2Yg#90F!9vk!664#1DV	!1)1/1)8/%1%101/#1*21+2$3/%1&2)1/04-2)1+6#104%1/#2(2//01/!1&101!3+2(4!2$3/+1%1/#4/(2!3/$7$103*5-105(12022301$4$1,11!2#13!33/#102,6#11/.4&1/.3$1#1(1119!4/!2)3!11+1!1$3%F)1+101/+4/1#1&1!1!2)z%2(2*1/G-2/-1$2&4/-A$102/!1)1)1%2(2,3&1*101$4!3!1%2$3/!1*1$1&	en]\BL@NGEnkhZPHaRHAbLbbbTRRabfbRTRQTRTRTXdl|JFZvqI``@bHBhFhjijXDhIb@@					inverse agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
)J`|F*6s6s}\p3)J`|(S}\6s0lF|63p3S~)\)\}\.ixi63S~S~xh	vzUvvfzSrOKj1R@A9C8O2NBN4BH1hW888HRVCNV!AF1601W0XOV825JOFZ@3KX!1GAV0VB!8403J21$k	0P#Z40IV02FV1D!9_07N01440G01p07c01MB0SF1u07k0pV06JF1e0780Rk1w0C$ %m0WFRV8V78241m0XVRV8R78291b5VVsGPR492A3c0NZBhD2815_NFNH53XXndNi55321VVsTN74WF8VFFAF42NNVBE63gIkND@65m0WFRV8R78281m0YVRV8B4TsDWWFk	#70F!S2Z!62s!1@8#WaF!48e$J#VD4!859#9FF!5Pk!8az!2FAV#vs!@0g#18V	01//%G/02//)101(@$2*1%2&2///.1#1(3$2%2101///!2/+1&1/.2/0401%2/01/#7/&2/#6/(1/*12*201!101101#3010102%1%1/+1//&3+1.1)1$12-2//*3!2!2$1)7%12/#4&1/!1#1&1/.m#103!1+1#2)2%B!1+2$3/2/#2!2/*3-1/%3/(1%1!1&1//01(4+2.11&2%	fmoH@@@Xi[IEEEEBdhldeDUjRl{OYkBBhjfjhH@h@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.>x>.hS~.>.i.h.=.i.=.iS(.=.>S(.>.hS~.>.i.h.=.iS~.=.ixi.iS~x>.=xhxi.ix>	;vzv;x:vyvvSrSPU@zhxAAj_ZOUvfh2Bnkf@I02VS6Wm0F8L9HZ0DJ2H0go1RP0JV1BXV2H0V0kV0W0F0	0Xo0FF02FF1D!C_06k0R!3OF1k07g!sg0bk3Z!Fi0440FV2d!F504o0qk3q& !1lkwRE42W0NZXH43WlNRJ532FkNJ30VkF54TXDO90kcOtBU371t0G88x44EMW0WVaF4D2Q@730VwF4@51YVwB75W2X1LF4F23210NZ854W0sZ623W0VF2410FF42kCNNeW8NZDDQ11WkmFse143W0s2HC911G0RHA3X1cV633VkFB2XDG21FsFH72W0VFD73W0VF430VFPd422ELMhFWVLF4B2DGW5GlsB6G562FF8TN4WVc4D41aZYF_8R693	#90k#8$44*B#19c#15$W$42#8FF#@o!8VB#dc#11k#14#10V	//#2#P//$1*2%4.4#2501!3/,1,101/!11#5/$2-1#2-2//%201&1!4)1/)2$1.2#9/%1-1/#9/!1/01%601$12!1.102)2+2$4.11*2!2!3-4/#2/.1)1!2*1/!2#2101.@$2,1/-2.51$201/$202+1)1)1/2#22*z(1//!F-103#3(1/+5/#2)2!1+1*1)44%2/(4/.4/10103$4$1#106)1A01!1(	efY\BH@LLihDMC`@cIIChdleDedhdlhhmDdeHhEEtMcRmP@T@EUUTuUUAP@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.hxh\).h\}s6~O63.>S~.h|`|`s6\}s6|`J)s6)H}J`*S(	vzUvvv:rSzxQit9@UTnMvAtDUqoc_TBTISBC6G18BpiaWHs6mt0B25KGk4eM9PFWb42n1052104G!X1V1N0k	0Q4!WR0Tk02a02Q!9J0Eo!o40FV1D!NM0680OF1q07g0o!6JF1n07J0TV2w0CJ01p40OF1e07B0SV3F0CJ$ $38251m0XFRV8R5eU81Wkm3JTF4421pOVRA572t0GsDF4R3Z130cmGsV8K4O0XnGV8D6BIW33Nk8H@13XVXtZBZQ6XVlckVwX54GFsclB4OI1VcOBKV2@P0WkaY08B5Z11VW3PJPF0VWlNyF4H2295HVFDC31kGFcf8251m0WkRV8s5Dx221O0HVDF4B2kP130V	#b4F!92w!309!3mDk!haJ!DcD!2VZF!8A8#48!3NtF!ZFo!8n5#98$dN!8GC#1QV	/&1%1)7-11%4!1/%1/5!102$2/03//+1-4/(4,1!2-42/(1/!1#2.1///01/,2(201//1/04%@4!11.1%1$101-601&14#1%2(2&1!2*1//*1)3!2(1(2(101#1)101/#2(1%1/*3/%5#302/*320104,2%11/#1/0n,4#1101*1*4!10101/)5/$1!1.1!4*8%11$1*1$2#102$2//01(3/1*3(5&2+2(3&2%	eghZ@B@BMCKF`HcrPBdHiCHhhdhmEEHexcDeDqpYYdUl]@PMTuSUUUQL@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
F*}\p3)JF*F*)Jp3F**Fl0.hS(:0~S.>.>S(.hS(x>S(xhx>x>	;vvv;xEyvqvSPhBYzceyLOnM8YCMbHI0Ci0VQ8oc6WJX2esW83JKlJ8cC9HtWW02W8F60X04F#1sW0FV	0QF!_!uF03AV1104s01540OF1k07g01_40Rk1p07c0j03K!SG06J0PV1n07N0o03K! !O0Fc9PR492m0WkPG88F4Hd12VVCFT6F36L0WsH284C2m0WVHK046L3m0WFRV8R782D11HY0NBE82J1	#b0k!90k!301!3H@F!VaF!B8@#V_F!8A8#4c!2FlF!Z0o!8m5#9c#VWk!815!25AV	+1*11.A-1#2/0101-1/%2/,2$2011/-1&4/(2/!1)2/+1)1,3.1//&3%1//$5%1/$2*1/(A$2.1&4/,1/&4&1#2023%1!1+10101//2!2/02*1#102)1/1!3////07%2!1/%11!1/&1/!11/0j,4#1!1$11#1!1&6$1&1/#1#6/1011.1-8%1/0302!2$1%2//1)3//$4&2/,23$	fegI@@CV\TFRJYJ[QQQHqEQIgKNbf`@ijYjjjI@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
~SF|`*`|vl*`|F:0|`S~H}xiS(l0x=x=S(xiS(zBW~x>ps}\dz:v~Wdzdz~W	<v:vMzjnjyzQYv_jMznoyonQzxko_MRcrh3m6iksEnSv5IMp4zYRRLVeIcm1F_4Ta0X4@89dQ3k2F6Y0Gk	0Zw0h!2Ak3V!8j0D#ZB0s!4CF1Q05k0gk04NF1u0Ak0p!4Ak0t0D!wF05KF1e07B0Sk3F!KU07B0Sk2x0CN% 06F483T311VZGW6643XO0GNDF4D26N0FtkJB@6M0Zak909R2DQ0Y0VNoRF9Z1kRVRGZ13V_98B889445XGkX413XGqPo86433WlVR@484GsB62B4a0FNVF52WGcoL92WFVFwNTSQZ0kkOJcQC220k8NM8221@Y10NsgM3WW18sZB972HNoL@0VHlWNdwN221W4uJk6831f11FV8643O0FF8N4Ze413kFZFE30lW18B46AWkNcB463FcFoNP6K3ocVFI8241Y0X3k8NA8261IfH0NoBx625W2kHPkHY37X1n@8m61Y3lX1Cc63XY1GWd2D72YWF	!275k!Smo!3i8#OeV!kD4!7Ya!12qV!sD8!41E!2PBk!olk!4Xg#tPV!WKN!@L_#1cF	$2!11$1/01%602+1#3(2!2.1*3!103(1109$1$1/+1%1/01+B$3/(1&2/#1//.1!1&1/%1/2,1$104#1%2-1+102$2$2(1$101/%4/$11%1$1(3!101!104!4$2#3!1201///#101&1//$1//#51(2!201!1201#2/21/!1&1)4/,101+1)1!1!1#1#2/,m$1!1#2&1$3$1#2%2011+1$1%1&1140101$1!2%2,11!1$1#102!1/1%1&2/1!1/$1#1/$1*4(8$1*101#1&3)10	eolQB@@LCGHdlbe`IEMLdTTTRRbjtVbRJbRHhl\BbzFn^jjjhDBjejehkA@``bb`@					agonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
2fSy2@2ftf2fS-Sy2@t@Sy2@2@tftf2fS-Sy2@U-(f-SSy@2Syf2-Srj4j@2GwxK_wt@2f@2momo<rxK	]x<vzEjU<CzUzUirJSzvxyErvbwDzrjZTvrUn9mxBpqjLfr5jY2_8up@pw3OGG8WR8uaV0FV	0Xs0FF02@F1D!C_07R0U!3Xk2W0DF012s0FF1209w018g0YV2U0DF018w0cF3Z0DV01_80NF1r07c0U03L!Ni0440Xk2D09w0t& #121BNC7VWlkV64222Hn1gNE6W0VscRwB4YW1gNDCZ10VW1kwV@@0WlsR813X2Xn1VTG5WVNsgU8251G3FFB8N8121G0lTW3X2lBV8N5Js11Wkq08hBC23Wg_cJBB6fR12F88RDiB0WW0k8VNN7Xl04L525Y088Zn824131XNw6AA3XHF8RV275Z2cFR231VcFkN2156YltVH68WWlcR4JF6K3IkVcF275@41VsH42XVVFcNJI@20NZPBBCVXGwV8J4cB6XWk8D654YVV8kcH_3a2NFNRBm16fFcFcBB2J922FO0@66X11O84FIZ13VW0ksRL70kN8650VVFBwPT5@4W0gR94VFN4gRMZ130bscFk9DLI0G1kV8886YlVoH810FFB81183Z0O8V5310kVF32WVk4sV1113J0	#e0k!1%ZJ$H#dg#1dV$3$h8!6_8!19F#V2k#K5#O8V!8SN#J@!21BV	02(11.1+L!1,1$4$501022(1/(3!41#8$4$1/+101/2+1!2011+2/1+1)1(1//-1!2-1/(1$1%1+2$4$6%2-11&1&711%1)5!2*1)7&4,2%1/(401!5!2%12$2*1%11/.404/2%4,1#1-2#1!2&2!2&1$2)3#103)1(1)1,1-43%1//%1)2&10101#1%4,2%z%3(1*2(4#1!8!101/$1)1&1*403(1#1.1@/&2!1)2&2)1$201+1,22/%2$1#5/&2#46&1%	ei[ZJ@@DL@fhPABemlbbbbbbQRfqfbRbfTRdRUXdlb|R~aYEZjfjjjfjffBjBJhPXhLH@@					antagonist	CCK-A	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
n2+D</~S-gU(S(S~/</<.>x>.hxhU(S(xhS~.>S~x>.>x>xhS~	vzUvYvxwf85y1JdCRB8dX82uJOHGc3C10IL0C8!1Ao861FW0es0dX4KlF8c1GH1W512W8861204F#181!V	0Z40IV03FF1D05g!p40OF1v!G_07R0Tk1w!OH07J0Sk1w0Ak0p& O0FcDF4J3Z140l40FV9oL@1XVl_V8Z4sA5VkkNggKLX216Ogg6E3@@ZkNNB	#i0V!H$50n#22F!Z$882#28$38#OP!2G1#ZHk#4A#GW#VFN!2Y5!2W0V	/-1&10B/+1//)14$2-1//)1-8!20901)1/!4/$1/202/!13(1/*1/,101//1+21,2!1/-1.A/&1&1,5(1/+8#2/(1//!1!1*4%5.3///#1-4)1)2/$1D/&201//!1$1//m,1&2*1*4+1!1/#1/!1!4/,281///%1-2.1/3#1-22(1/%2+	fegP@@@PrQQQZIQQYJJYKxXkqQsUTsATQTR`HJ`					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.hxhS~x>xi.iS~|FS~|`.hlv~Wdzl0~W~Wl0	:UvUvtZdN5w0Jd9A80lX9@caNFGcV49BIx2C8#@oN41FW0Xs0cV0pFP0e1GH1W502W80J01!F%1!V	0aJ0Tk03FF1204s!sg0bk3Z!KX06J0Sk1v0Bs01LF0SF1r0Ak0nV06LV1Q05k0Xk2U0DF$ $BV8c78291m0W0RV884t8261O0GN@do46258HFcg@B3VXWdOZ8N4eBc0kVT464D2m0X0RV8k5uZ1WYkkOoo6J1VZVNc8TE51320	!2aVk!3XF!503$2V!p5V!886!124#8tN#6R!2G4V!VHV!84_#Ok$NN!@3C#l0V	01//%5$1!1//.1*1!8#12$1$2,1///#C/.1//11%3!1#1//$1!1&1/%1$2#31,1.101(2/#1+2/(1(2&1/&1!1*1$1101!1&2&1/!2)1/(2/%101*1)2)1//*4(101/0101(1$21/02!2/*1#2!1/101!1/$1/i$35%1#1!12)1%4#@/+1%32!2#1(101!1/!1)28,1/&1//1.1&1%1/#103/,301&1#	figq@@DVBCHhhdleMDhjhdf\}DJ^cZiZifj`@e@@@					antagonist	A1 / A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
*Fl0.iS(:0~S.>.>xhS(S(x>x>xhwkP(zBW~|Fs6ps}\c+~Y	<v;rvyUzib@@hsSTyLOmXKeh9ZZ@3GV_NHN0VFcaH1V1Z0Ze!48FZG11X80512!V#VWF0V#V0Fk	0Pg!Xo0FF04Ak1104B0wF055V1Z07R0TV1w!KV07N0Sk1w0C$ %O0FVAFHP3WWGcfFgJ322W@G88H4pMW2VVFNPI5Y0sRJ23131daF4L3Z13VZNcsB@6O1emNV4BB6	#71F!48#8%@4F!X6F!5Ee#2GV!o2#248$F$Pk#X7!2FW#9tN!2J4#980	1!1$1$1/(N.2//(1%1&101!3!1/-1(1/!1!1&1!2$1/%4)2/(1(1(1+101$1/*1%1/$1#1)1%1/*2!1/9!1/01///6)5#1#1(11!1(301//!3(1/+10101/$11(2%101/&1,1!2/,1/(11)41/06+1/#14/1/!2&10h*21!1%1#1/3&1//*2//%1!1(111)102)2/1//)1&4!3+1!3*1/05-	figqB@LRUD@PeLrznlrjiJBUUoQtCAEUUUUQTGD@@					antagonist	mGluR1	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~.>xh.h.hS(S~x>S~.>.=.ixixh.iS~x>xh.hxiS~x>S~.>.hS~	zyvM8Lsl8eB2ZV7BFc050B0HFV12121#H0V80k1#2F101!V02#F*2!82*8#F	0mw0FF1D!CG06J0Tk05JF1_07R0Tk1w!SG06J0R01q07R0U03F! !6F4B3Z14Vt0G09uB482OBVWNJgm4G2	#20V!108!4V8#K6#W0F!28@$GF#38$s#11%o#45#1V$Fk!84#250V	//02%9/#2+1/1/&1!1///$1///&6%1&2%1/+1*41!1#2/#1$8/!4*1!1-2-2-5#1$1!1%2,1/-D!1/#1//102(301)20B*1&1+1//)3/01//$1/2/%5/+1-M//)1#3+1(1-2,1!o//!1(A//%4/!25//1$4/103)1///&1/-1#1%1&2/(	fmwa@@C@rQQQQIJIVFIQSVQgQ{N`hB`J@bH`@@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
mms@b~DhS.sfGw5ixSSx.Ssf3fIw/]Iw99/]mm/]]/IwIw9999mm]/	<xzqyzjurxzxmYrrixjr4zohzqwkkqf1SqpKHwoOkOaTSdG2E2pe86Y344VBB2owoZ118JRk080vV816NY0	0U4!aJ0Tk02OF1v!8c0@k!sk0tV3e!DB0DN0uV03_k2N0Eo01HV0Ak1109V0f% !6F443Z12Vt0FsDF4D3Z120t0GNDF443Z120t0FVAOR482@IVWF84F7G61FlN84D8517JtcJJAE3Wkm0J4R2152_rVk@884VckWFFls2C22W@8k8P714WWkfFJ8EC0YGNW4T693m0XFRV8F78261m0WkRV8g78241m0WkRV8R4	#80V#8V$4#20V#6$9%QV!FX%1$F$Jk!2V4#p8$48#4#211V	!1//#23/!2!2/05+3$1+B$2$2!3-2//1/)5/#1.2)1.1/%1/)2///-8%1-1//(1)1$2)6!4&201$3!2/+2!4&5(6/.1/(1)1/#3/)1!1$1/!102/8/*1.1104(2)4/1+1/#3.1//0l%@%2%1/&J/////)6/#13$1/+1.3*2+1(1)13&1#4//&	fcaR@ITXZs`RFQRJIFPqEQQQII[AAZzn^zijjZj@@@JBdBLTDHyQh`@					antagonist	mGluR2 / mGluR3 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
*Fl0S(.i:0~S.>.>ix.h~WBz\}sp	<f;hyah5qjT@Eg_6N0daVF1hYF3VIFVMC0JFcm0aWJ20YV080FD8FVVW1X2051258FF!2062!J0V0FV	0qJ0TF1w!Fi0480cF2z!KZ07V0TF1w0EJ# 02O6R33Wt0FV8pq4BD0XVk	!220V#28#8$X+84#V$FW#448#14#4mk#4a#O$958!8$29sV	!2//$5/$4///04!1111////+4!1///+1/,11#3///*1$2.4)4//)1$3#3#1//-1/)1*1*4//%1/.501/////%3/.1/%1*3//+1&2&1//$10Q%3!1!1,1(1&8/.1!1//+1)1,1,1)1&1/(2*1/2+2+2//+	foQQ@@MN@eLr{vxhIUgTCAEMEBQ@@					antagonist	Adrenergic alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
*`S(:v:0x>*F*F*`S(xi.h.>x>S~.>.ixi.>x>}^^}.i.>.iF|0:(S0l	=xU:pzxzyfUUzPpLvAvaCIBC1hhDMvmC3kClQigaX1eTrpowX1w8NVNGSl9WW1@asm5O1cV03Fy10V0FV	0Js!Pg!qJ0Sk1v!Br04B0wF04Rk1r0Ao0pk055V1W07B0TV3M!K204w0Z02U0DF# !m0WkRV8c7823111lcsLJ23G8B61B862lWce67VkV8ZNH19a2tBH2760k8FZb82D1m0WkRV8F4HIG61Fcc6123YgkHY44Z4nNW3FaQ48J59CW1FgV8R78251m0XkRV8w4@463l8oLD22FWOJ22IBm0ZkLOgg6L3	#73k!5@8!8X$HZ#c2V!1g@$1V!Jc#248!210F#PV!8k4#E$1NF#4$9@V	(11(1/!109!101(1&8.1!1-1&51(104$102!1(2+11%1/#1.2/#1//*1/-1+1)1/)1%1&1)11/#11(1/01!1$1$3/#2(1(7&1!1)1#1$11!5&2$2!3$32!1/&1/031/!4!2&1,104/)2!1/$1!1!102+2!3#12!1$1/%1$1$1/4%1$1111!1-1/!4%4!1/&1%1!10m/*1/6/!1.2.201$1102/*4!1/&2#1#13/01/-103$1)103/401/!1$101-	ek`RLH@LBEFiIe`@cIEEDeLmDdUHjeDbFNAO@mcjZZXJBjjjjB@@@					not given in publication	mGluR	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
|Frp])|F|F])nuz@~SzfS(n1s6x>.>|`|`S(S(r6.>S(x>.>S(.>	=fzUxtzjM78CSCBlmA8QoAF4cYI8DPy0B@N110l3a01V2cu0IX!lPN@70@!2F210V2!8%d@#F	0ZB0IV025k1v!BM06J0Tk04G01K07N0Tk04FF1205R0bk04Yk2U0DF0u!5NV1_07N0Tk3F# !O0GcDF4H3Z12Vt0FcDF4P3Z140t0GNDF4R3Z150t0FkDF4R3Z18Vt0GcDF4H3Z11VcH3BBX7Z12Vt0GFA9Z4G288LNO8C2WFW_0k	!12JV!I0g!40@$kV!VV#1c@!22J$X$BN!10FF!6Hk!207#S3V!8Os!8KP!212V	01*1/1)C///.1&4$1#11///02%1$1-3#2!2*2%2%1%1///(101+1!1*111/%3$2301/#1/$1$1#2/)11/)3$301/#1$1-1#1#12/(2)2//+11*4.105+3(1.1%1+4!6,1/!1%1&1/292//////!l4$2(2,2-B1)2.1/.11,1(3%8!2(2$2&21#1$2/&1.1!1$3/$1.2/,2$202%	fmoPb@KUzLDQdTRTrTRTRRVJfUFJMDnZp@USEAQSTA@@@					antagonist	H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=S~xi.i.ix=*FS~xi:v*`x=xix=xix=xiS(x=x=S(	:UvzvztzOwIvwmDFt0Q@N6LN219Z290d@nX51V01G!60_1V!V425o0840WBW0c102241B(J!V0FV	0Pg!Pg!Xs0FF03Z02W0DF016J0Sk1v07k01L40O01r07k0ok$ 0O0FVDF4J3Z130VFcJJA32FsRD62WFk8620Vom2N86782G8g4C1W0kF61283k88p4666_GNgT6110V84PBC1XlNZJ@3XlFRD4B90FH044RR76Xl8wJA610cB2NDB4_HcoFG2W098gZYI2210VWF@@BX1Fo4JE@@WVtZi27VH1W0W0T6YVF4RDD3IbnFVZFw27Y0WFV	#30V!188#X#102#V$1W@$3$V#4Z8#1F$2k#44#9$1GF$2#18V	02//%L#1-1&1/(11/$201$1//1/+1$2#3#1//01/-1//#1,1/)1(5!3/$301+2%2$1.1#C&1*1/1%1(1,201/%1(4!101,1%2!1/+1.2%2#2#1/&1//+1*1#4///02#1*502)1&3&3-101&2-1#1/(20j01/(401-6///#1%4-2.2!1/$3+4//+1&1#2/+1424/*5(2$	fegI@@DZCdFQQJIIJYIEIJIJQg^GMjBBbjjjjF@@					antagonist	CXCR4	CXCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hx>.>S~S~|`S(S(l0|F.>~SS(x>xhS(x>x>xhxh	<v;rzhzbyzUUjcyIRizqhMMdWDSSQUXhmVoHfocZW0Y3XO1t11pQJke3KnWWj19VcFJ090413F0W21!V	0Z40IV02FF1D!8M07g!WR0Tk045k1_06k0Tk06FF1204F0PF1u09s01_80PF1i07c0j03J# 0m0WFPso8H5Z140ekGIZ4F5Z13Vt0FVDF4P3Z160t0FVDF4D28CdIN8JD@9Db2sBFB8666XWoP@F5122Ooa941H1d0ZoEAalHVd0mg72210t5FQ451kFFRNRW9_lFd0J49A72kFD586Z2JGNJN5@2f70FR8	!1b4F!uV4#16!11DF!dD#6c2!2VK#8b#89N!2F1F!ZFo$Z#Oek!93c#B_#Cik	/1/4%H!4/)1/01/&8$4//.1#2+1!1(11!2/#4%2/(51!1%1!1/&1$1///!1#2(1!2/#2%1)1-2$2//+7(12/1/)3$11&1-2#1%1/(11(1+11.1&102//$3$11(1$12/%2,1,1%1(5%1%1/)202/011//%i.2$2(101!1%16/)1%1#301/!2,1*1$4&1/!1101%1/01/$2//-3!1!1-1&7*1!	fegqA@BZ\dDPjHrJJIQIQESHjIILeXKoPPTSTuUUQP@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
9w9/)Ea})a-i~\-=-=p2-i~\a}p2~\~\p2~\p2~\p2	vzUQvQztUSxnQBuU0QFQAsgVw66kh7088@RV5FV1080@610FV1F#248Lo236W!16@k0VB2$1F0k01!V	0Z40IV03OF1r07k012o0FF120@Z01L40Sk1w0Ak0p! $61msJ5552t0FV9kuDAVVF8RJDA752kwH524422Aog6833_XFgJC4WFN42LEA	#@$2%88%V!ZB#1GV#2*11B!2QF%k#44*1$14#10V	//(H!1/#1//.8!104$2$1/)1/*1+2/////*1.1/(1)1!1//022&111,103/#6#101//$2/.2$1.1!1/%4&1%3#1////!4&1/.1$101.3#14///%1$3//&1*1//&2%40d#203-1*2*8/$3////)1/042&1#4/!1/%101//%1!3!2/)81,	ffcp@@@PLeLjjJznJRtFLuDDUUUPP@@					agonist	M1 / M4	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
6s)Jb{3pB,8t}Z.>S~(Xh..i.h~S>.S~	zyTfavtVXN5u0F9W58Nc096VGONF84010HF09N#@kB45FZ0XN0N!JFG0c1FH1WG80c804$F%1!V	0Xo0IV02B01D!@C0ER01680OF1r0CJ01MJ0Sk1u0Ak0pF! 38241m0WVN2F8D5Z130t0GF@FZQ921GBV8V582AV0X0gV8F5P2A90XJV8RB	#a0V!3&1$2#ZV#882%V#X$88!2G$V2k!843#G%NN#1E!210V	01/)2//,31/&21#1,C$1$1/$2/(3/!8/!11///#1!2///$1$2!1/!1//.6&1/&1$3/+8&1/#2-1%5$1!1/1#1///,4//,3///#1//!3///*1/!1!1//%U,1&1*1//&1#1/2!201//06/.1#2/////&201(2/#3+	fhiQ@@AJAdTTTTTJtPeVBtuTttt@@						LT	Leukotriene LT (I)	no	gpcr-ligands_DescriptorsNo5Ht
|`:vS~lv(Svl:0:vx>*`*Fxh.>.hx>S~S(.i.>S~.h.>.hS(	<3htKds5T4JHEDBHhXO2uX0F1d3Z04LJk58X010o8631W0YgVd4VJckV91Kl0V1W21FcJ48Z1F204FBW0FV	0Z40IV03FV1E0@Z016J0Sk1v07k01LF0SF1r07k0ok05RF1o0Bk0nF3o# 0BV8R782A1m0W0FVKHi47VkGVcGmZ350kG0YVaO341t0G89W6c37WbYeVBa6517X0cV72Wk9G8c	!220V!1B8!2WN#82F!V1F$@$1#81%8!29%Lk#67#GG#8NN!AX4!290V	//#2#9#1/08/01/%2!1!12$3#1*113/$1/%1!111#1#4$2.1)1-1)11/%1)1!1!1/.1/#21%1#2/1//.1,1#1-1*8/$1!7/+3$1-1,1#102.1&1*1,1&108#1)11,1/-1%1(302/*1$21/!1)5!11&2$1+1%11/.1/,h&1!2#1(101/6(1,1.3///013/-1%1$1+2/&1%101-1$1$1(402/)14-	fi{I@@HDxtFRIQZIIIJQJ]JXHkR\tmSUATEUP@@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
f^CbR(Ni\g@H>L`AccCc@^@^S=FA@H@H@^S=S=@H@^LhAF=SA`	;UvUzvMzjYjyzQYfpjMzpoyoYfzSso57Rcr_Im6j1kUmOv5IMp0UYB8LV2IcV0Fh0TZ0X4@89d@3l2F720Wk	0Xo0FF02Ak3V!8j0D#ZB0s!3PV2q0C!12w0DF3V0E401Kw0Rk1r0Ao0pV06PV1h07B0Sk2q0C! BV8F4Xz@1XFwV8R78221m0WFIJ8F6A327YtF422WF98V_Pd25WG0FVGTp22W24e8D111Fc4ZJHs77Vl8QWH3331t0FF8WT_3X2l1HwuD4325ZlJT354XaL1cBF7Z110W2PZaF562b610F844m0W0LX8R6@37e58B2@B552W9BT@5XFW8k22@@54q8kH@@50W0sZFA6XVsRH520k9sg429F2YGNkVE5VkVN@LAA320ccNB51W0NN20VF9sZw	#71F!x04!2@8!1OV#cD4!1d$2qV!kA8!41B!2@8F!4kk!4XB#8FF!W4J!86Z#1c0	$2//!C/!3/&1!1!2(3/09*1)2///&2/.1%2/1/$1/#1%201*1////(1#1/%102(1!101/$2-4)1$1$1-5+11!11#5#13(2(2&1-4%101/*1&211//!1!1(1!4(711*3%203/1/1.1)5%1301+1%101+1(8!1,1/&2$e,1/#1)2/&1%1&2+401$2//1/(2&4/1!1.1)1&3$1/+5*1!1(1$1-	fewiP@LF\gHIJuGIEEEDdhjmDbhdRegARN]UUU@aEUUQD`P``aEJ@@					agonist	A2A / A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hx=.=S~S~S(*`S(.>:0*F(SF*>xp3)J|F\)6s	vzUvvvvrzNheXqAEScOOHOSrJRGYfY3Cd3TX520Y4@047FE_4mGV8T1Z8FZ2I0VV071AkBV4801F03FX040F0k	0ZF0IV025k1v!8M07g!dV0ak03BF1104s!lR0OF1v!KV07B0SV1r0C!1M40Rk1r0Ao0pV0 01Z120ko8FZA8281KDVVkG@N633WZKXRBT7I23FkkNZsU9YGFscqF26X3l4fJJ643HbFW@44D7Z13Vt0FV8gwQA2WGVc8XLCakFBRNEZ16Vt0GVDF482gR14keNFP6I3m0WkRV8J782@1HgGkNkBNpCX10kVVcUDY1FsdFoD3X38kcOkHC1Ykk	#64k!H2Z!2BK#Na#VCF!1W@!22FF!V98!4IT!281F!_ak$i#11#VVk#2Z#G8V	$1+1%1,308)1/*2-1%1+1$2*1)2/(1/$1(132/%4#102%2%6/01#1,1+121$1/1//$2%101//02!1/1/)1/(6/!501/&2$801*1/02)2/01/.1&1.1/&2.2%1.5$1/2&111!1/,9/.1(3/,1,3(2%g.3%101$1(3#9//%2/#1/024*1&201$1&1-2/*1(102//(201!4/&1/#	figHA@NF\DDPjHrJJIQIJEKIJZIdkN|EoXH@H`Zjj`jBR@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~xixiS~x=.ispS((S\}Bz}Hhxqq^)~S>x}H(S	]wjxjKOUUyCqYQPzgCFM8kj9hHQ@AD@jGQqDZnEV0fs0hcWo4k8u1OPYl34lY8FK50VFGX0I%V	0WR0Tk025k1v!BZ0440IV035k1_07g015!ZF3a0DV015!ZF3a0DV01GB0RF1p0Ao0pV% !6F4D3Z13VVaA4BD6XW12FWmJ8PF912VFc4657Ca4NFB46636pOwB@6d433sVJ@@4CfI0VgGJu23W64eRBJ6H651V8FB10WGFRcq2IHa0F8F@C6m0VkH2SP693DH0WVGgk4F260kNk8@23Yh0HP8F4123WRV8B4udEWXVwV8F4	!364k!K04#8G#B0V!ZC#3sN!26Gk!kXo!61B!240F!G2k#34#MXV!W0s#KV!290V	//(8&2$2$2///)2$2//$1%1%1(11)1/(4#2*1///!1&1!1/)2/.1#1/(21/!1!2%2#1/#101)1+7&2!13(1(1!1.1401#24#1#401+4//.1%4$3/&3/#3/!28/$3/%4/%1)1)6/%2&11/!1///d/3/*6$1%1.1)2!2/1/0201)8!1/&4%6-1.1+2/$1(4.2%2//$	fikPS@I^rVkPQAHapQdTTVVbbTTjbfsN^CA@UURtsTTAT@@					antagonist	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
hx~S>xixhx(S~S=x>xixi.hx(S~S~S>xh.(S:v:0*F*`.h.>.>.h.>.hS(	=hUUzpUxUNAUUCBpYNPvZ3m6CYhf2uvX7D24QAq@aY0VFXN0eXFL9NstWOkIt93Xc4FL0Vm5J201ZVV0FV	0sg0cF3Z!CD08o0xk04OF1t07g0U!4YV2U0Aw0t!4FV1309w0wF05O01s07Z0U03p!OQ05k0YV2U0Aw0t& !F@DVWsseD@7m0X0FVFDC@2_G1FFA22YXgV844LM27VtVNJCZ14VX0sZTC53HVJZNIZ120W0VV4C521msJF@10l0g8FDE5a0VwH8B121W0JFC3X1FZJK0W0GVwn82@111FcRF31VG8J@421FV8D73dZFF88Pe6912FJDB7XFV4gTMZ130t0Fs9eJ472IEVWsLF4D2P16mVGNG96NA2410	!2tbV!F88#Z6!1VFV#2F#oy!221F!NcN!4FB#3$VuV!1ZV#GVk!118!@52!31NV	$1#2*1/!9/01!1$1%2&1/#1+102$3.2&1)1.2#1&1&16!1,11%1/,1!102+1%1%2!1!11#1$1(2(1!1(3/%2/!2///03!1//(201$3,121#1/14%2$503/+1/!1(1*2,13/%102/,23/)2!3/02%1(2+1&2*5!2!111/$1(1/!113/+3&20n$1!1*1%1!2$1&6/+1%1!1#101,5/#1)9,1(1!12!21$4&1#1#1/$1/!2!1/(4$4/&3#104&	eghRJ@@DLNK@CHlcdfV[[ewyUWZ`SrJijYYijjfjjZ@If@@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)]63F|)])]F|;/+c(P.=S~6s1n.ixi+C+CS~S~1nxiS~xix=5qqqS(xi	=jzUzvzyUET_lSTnkOAIJ2sZd31DDQTl5851dFlA6V108mc012F2lXxDM2F!lH2IGV2J0@0L!V_86830	0Z80IV03OF1k07g!sk0tV3e!C_07g0zF04HF1K07!Tk04FF1205R0eF0 $m0WkRV8Z78251DcoNNVBu2HGckWsNsRZ9242F8sM82@1m0WFRV8g50n294FH0RRu462YbFWkHD24E2m0W0RV904	#V0k!2$42$D0V#8F!11e#XG$Y%J#8N#20o!215#lXV#1s!24N!255V	&1/*1$9/!1!6//)1%4$12#1!3/3/*202/(102!1/$42,1)1-1/%1/&1!1!1//1$23&1$1(1+1&11/2/(1+1(6$301-4/)1#1!113(3&1#1!2$2#2-1//)4*1#102(1//111#1&3!6/.3*1/1$92,1/+1/01//%p2$3(2/+D/+1/*1!1101/#2%7!2#1)2(1)3%62//!2$3/+1(1/,2$201%	ek`XLH@JiMc`ICHhdidhdhddlTiEJFECHbljh@Jib`hjjXB@@@						H1	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xi3pS(J}dzS(yD82ps>x.>xhS(j/.ix>x=S~S(S(.ix>~SF*`*v:	;UvUzvM:YzyzQYf_jUzloyqbAzSkopbRcr_Im4i0kEmSv_IMp0SeB@LV3IVV0F_0TZ0X4@8Wd@3k2F6Y0Gk	0QF!Xw0s!2Ak3V!Fi0440Fk3l!Fj03Z0s03l!FZ0@V0sF3l!KV06c0Rk1r0C!1Kw0Rk1r0Ao0pV$ O0FV8hNV2VVF821944VGlNuK1VV88410a23BV8R5mAF1X0mHhB683CkFWNV4H7Z14VVWdouC30Wmk42110GGlXxF442414YJL663EZZ94FF82@cH1R@B86m0VVG2W2D2XZ1IABk683LZXNk@@85464dkFF3132t0FF9h2J71WH8iF483Z13Vt0Fc8BiaAW08l82110V8cgiDS26W6dFFF8Zz42l1VX9TC2X3G0	#7WF!S04!688!1Os#VD4!5hZ!12qk!k@#41h#@8F!4sk!4XB#8N#cSF!86Z#180	$1#1&2/%B02+12102//&1!1(301108$2$1.1$2,1#2/)2$1/1)2$2///-4(1&1.1%1%1-1#3+202(1-11*101$24#3(1$111/%3/$11*105,1!1$7$2#1#2////%2//01/01-1512&1!3!2$1!2/01#1//03/,102$1%1&141*10101/!2!1%e,101%1#1)1%3/$1-11(1#2//*1/!1!3&2#3+1/!1)1%2/%1+6*11#1%1$1-	fmoXp@LF\gIPRUjl|dTTTRRbJVRVtRIRshyfnjjj`XHjjjKBBBDTh@@					not given in publication	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xix>x>xhx>q555xhx>xhS~x>xixhx>xiS~x>xix>S(xi|FS~lv|`~Wdzdz~W	:UvzfyUzCyzQT@yUURdQvadrAs_hYR46flVCQH8@G_caCV3L_V1zXBR80V151c8VS921049c0F3F08kP0W4FV	0Xo0FF027k1v!9_07k!lw0OF1v!B90Cc0xV045V1Z07c0U!4Xk2F0@80t# $CfW20XFt2J5W1WklRRG7WVkRD20_4XVG0TL810NJB320Y1dVgJB72kkN442VkV882184JBV8R533261O0FV8FeB7ZFkN8510kF4ocPA5Xm8FD23VkkB6220VX1J22HG23Gcwa91VVO9B8910k8cosH@4W2FZD310FFF4410k8F410eYpRV8g782310X1NVDF410NR2210VN8411VV846iHMI@HVNRDX2G0VYkVs8N8XR20FVRFDl72lVNNJB@Y15FF9B2@3WYlWHoR4@2YVk8kN	#D0k!488!444#F$444#52#F1F!XV#@0O#50F#Nk!@Bp#bzF!80F!296#E0V	!1)1.2#2$2C$1.4&3/&103&1&4!1041#4.1+11/1*1,3/.2)2!2$301#2$1#1+1,1/)1*1.1%1!1/$4+10111)101)203)2/)1(1#1!1#2$12&4$1&1#2%2*401+2//$2/05#1(1$1*1$1322$2!2!2&1#2,2)1*7///-2026(1///,1/,s%5!1/*2%F//*202/2/)15!2+1%101#31%13/,1$1$2/!1%1-1!3$1(2-9-	ehR\BL@EBjaILn`LS`HfBLbbRrdJTRVTrTtRRRhXBbvN~A`@ejjjZff`@`PLdT@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
5BS16d5Bl<6BSu6dZ2E43]pd6d3IS1Jt?7pB(S;;5d\22\6BSupd6dSuSu5dpd6dSuSu6B6d6d6dCv\t6B	}y:jj=U<yzox:xjjznrxizrjqUUzUrjmxixqjLvrJjjIpezGAzxIUpt8ghimDX0GV	0Xo0IV03AF1104s!sg0bk3Z!DA0@40t!4OF1r07g0U!4AV110480bk05NF1r07c0U03I!Ni03!G01u07g0U!69!i08g0bk3V0DF01XF0Xk2U0D!t03l!NZ08g0bk3V0DF0wF07AF0i03!FF1204w0eF$ CiH0NgCLc81XkwV805i2F87FWcTF482gR10kgV8F4O881YkoukV6E3BbH1oFX9Z13VhYl0BZ6BK7X0W8FTb2AfFHVTF482A83IkW0w2C5m0WkRV8R7824150nH0FcT182XV88sN2Y5Yk98U8261637W0FV8EI7m0W0Fm2LDV_5c94E8241m0W0GFBN6MJ0_Fc9Bw2E6m0WVLtoV6436@Yl0F88r1543cFRE82A1m0YVGOsu6ADVXGBV8k4sQ2943kFwI8271m0WVQVV844BD15Ys9Fw2H419F8oFkF1A7VHVqF482P1BYF8oBeF19bVH8mZP5JX2W0ckRX3VVs4R115XmoP4s542X1LXN@854ZakVcFBDGG1VcJ@73VFGVsk2631o9F470WXXVB@10X3nbOwJ68311Fk4X_5X0G9BF10WY308JeVA0Wk44H79IAX0NJCPr261CpcFJ@LO22W4PNFZ8r928172ARBa6@RcFlNOlN3C2415nB66538okWVGJiQA1k8kVN	#e2V!148#Z4$H#ci#1hX$F#Ff8!4Z9!1AF$Pk!8_4#QBF!cQs!@6@!21BV	//1&G#1)2#1103$1-1!1&1/2$K2#3+1/302,1.31#1#1%1-1*2-3,1*1,1!1+21&2/,12!2&1#21+201$2+1101,1,1%1,1133!1)1*@6%3+1$1011(1#1)4$5)2!1-101.1#1/!8$4&2)4+1)1!12)2)1#4&1!1)103/-1!3(1/!1025#2!1*3*1/#10302/-2,z-111!21!1023#1!4$2081(10311!1#1.4+1$2&1$2#1#1)8-1%1$1%1!2$31*1&1///$102!25)1!1/%1%1	eePzJ@@DFLcaPGO@albbbbbRbab\rbebRbVbRRc@dbcdUsrIKLoHkUUUUSUUMUUPPLUTWFEAA@eDUDuEuCu@@						D / Adrenergic	Dopamine / Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.S@3@s.S.Sfs@sxS(Uf3Iw4>xS.Tgr6jfsBtBt@sxSgrfsfsxSfsxS@sf3fsfsxS@s	;vzfzOrxxnQRAz3AFOAsiVMLPVhW0@8PRV7OX18@sf640a02O190FT8JofYJn3WG@Ac0VR8101J3R0W$V	0UR!aJ0Sk02J03d!C_06k0R!3FV2d0A4015w0Sk2x0CN012o0KF1Q0ER% 01Z140XWXNm64331VVVXE@Zkk8410VV9cgo8B4bGkoB420V84kRN223GWFk5110N8230b4FF8oyu723W1G98R95X0VZ82163kF88NR121l0ZP752FsRD710FF54V116dD1dwBD7Z130t0GNDF482211lt0HC9W0NF43C76VFFNL862lW06220kN42VH10YZFF4D73WWkV89420VN610VV85FTdZ11Vt0GV8NFT@50kF6294ZVVW8TF9XVVB230VnGdc8BC82l8c692W0FBoR20VFFV_782D1	#T0k!F8$c4#3CV!VL#5pH#2Jk!8Wk!4W8#3J$Fo$B#1s#VIk!224#W8k	/*2*10C.1!11-2%1/,8!105#12$1/1$1#1+1.3&108$3,1/$1%1)2-2&11*1$1&2%1#1*1!102&1,1$21.202%301.1-1$3#1*2&1-1$2$201%2%1+1/!3$2*11!3$1%3!4!1-1#2.1*1&41(1!11//.103.4$2!1.1%102.1%1&14!2!1#1/*1$1//&1,10y%401,2!1+1$F//%2!2//2-3101#1(1%4402)502+1/,1/&2/04/#1#1#7-	edVRD@@I@hi`KdfV]VVU^]}fUhx\BrZFf~aZZjj`XJJhHHXbC@`@					antagonist	Adrenergic alpha 1 / 2	adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhS((Scnx>x>S~.>>xS(xh.i.hS~x>x>S~.>xh.hxhS~x>xhxhx>	=v=vzyvzjfxvzQjMyyzfzvkDxUxeMrmbCiIzUFEj4LSd2RqyuBoAvKl3n53PoBcR01bG41JVY4#V	0Xo0FF03Z02U0DF016J0R01r07k012s0FF120@Z012s0FV2U0@Z01L40Sk1u07k0pV06BF1307!Sk3L0DZ# $O0FVBZq4B2iWkW0G90ECX1Gkdl2N7X2lBV8F78241m0W0H9V8NPFW2G2soBCAVW0kVJGZ150t0FkBgm442W8VW0LF4F2qM11V_nN8F4FE4mG8JR@573GlJZ50WVOFsdgO@WXFqu8L6B3	#31V!G8$eF!1J2#gD#3d@#2GV!Fd4!B_R!21k#Fao#44#9VV!1Ok#42#5@V	*1*1.10L!1)2!1$1/+2/#2$7$1!1.1/+1#1/011$1/(1//)11/!1/-2//0101012/02,1/,2091&1%1!2(101&1#1(1/#1*101%23!301!20101/!1*1-1.20402#11,202!1#1%1*1(3!1#2/011+1!3)11,1/(1-24$101//$1/1(1101.2(r.1/)106!1$201!3&2+2(301+7,1/4(1/01)4!1/(1/%11/#1,301$1/$A$1(	egl\D@@DCK@BlbbbbRbTrRRfblJTeba`UVPqWQusUSPUAUEUUTUHBTQD@@					agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxi.>S~S~x>|F.h.h|`lvS~~S.hi..>~OB,(S.h\)s6	<vvzxrSxjvcfUTjPt3NwzL4IeCWe97iPp72XdH90Xa01X0XKb821B9JmGWCWXFA3A0iNZ81851I07Y0X8GV	0G8!WR0Tk02Fk3V!Ba0440IV03FV2d0A401740Sk2x0CB01WR0OF1g07R0Tk3x& 6F483Z13VXQNFg8XoCW11NZJg933WhXtN28G488occ4@B59AXVc8167YBpFRBB6264Z9BJ40VHHdDF483Z140ql8FN9iJAVW1kV9aS50FskgQ82@1m0WFRV946FR2210XuRk520V91BY82D1	!364F!R04#k$H4#V2V!5VO!20ZF!F3g!4N8!21WF!FFk!2A4!209V!VHk!@15#99V	%2)1!1,2#10G/!1!3$1,1!11/(2!102#1&2$2$4)1//*1/(4%2+1,2!1//1#1&2/+1$101//.1.1(1$6!2//$1!1$5)2!5$101/1-2$1/01!102/01+1/,104!4///1#2#1#10302$1!121&3*12/&21&1-9/-1/+101/1/$i/)11/2//)2&24&2.1-1!1)1*2+6(1/-1+1.2(1$4!4+1/7-	fmoIC@BZ\DXHbTaDHrJJIQQIYHiIRIIbkA]zZxHJbjZjjjJ`@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S{vg0gv?2;GyvgS+2k+Sv?S{v?0?vgvg.dO+S{v?Kz85,Kvgqn-`B.gv{S0?+SS~S-?0?v0gvgv?0?+S+SS{S{S+S+?vvg0?	?yzU:vyxvEbzPzjzCzUjzZwoSvfhPyqIbs6zqs66UqRHCn8@d6ELnH0DiIJPksIF92OFk2ckcV0XFG0	0UR!Xo0FF02OF1v!9_07g!aJ0Tk02a02Q!8j0D#sg0bk3Z!DA0@40t!4AF110480eF06AV0j0440FV2U0D& $287Yll0P82W09Ncg4QH41NJ4D777gHcsFB9Z12VVlG8TE52VkJ83A5_W_t8a420WksyF442222GVwNC6WG88410b2IVctPB5XXlN44678JE0VsF8675X1NkH54W0N881182kN88FZ7h120888@8134G9Ra751FGFVc221WlFsD@3Wl0R880VV858L114dVFN8B@5XFsZH43VVV883192kF48Fc@E168Vk262430FV4853XG8cJ752FV443193VF8lB884W0VNFL730FFkN114aeFGP8k47312X2Zk@D10k8NVV212VVFB@6321FNF72VVcJ621VFHstRBH4EG1V4B48620FFF885XlVRD92VkFB2119Y088dF4620WFFRL7XkFB410bXInF8gye23WVFkSPW571088BFF20VVsJD64XVsBH531VFJ4310KGmiF4H28AWbFVk432430VFFB933VsgJ621Vk8wV3170F8Fh8265WVVJJN7XFVFkNNW15fmVFRBHFK7G1kB4J11430VcJD531l8NB72X0sN4310V85JRfZ14Vt0G8AwXJ341_5lRJ8A45LVVcGGXM3X1l22gaH10GW0k4H956kkNF52WVV44R9D12lFFJA52Wkw81B4a1184LF6Xlss820a2310N8C6X1Nsa215XHofw8@4VCaWVFJNAP511kW1X8653B@2koFB824WGOBD@4WkkJ830VIlGtR@194GlJ21944Wl04iK4aFF44J7@81VWtca8BX2WgV8J4	#c0V*4%V!2B#19V$F#FV$Z$8F$2k$4#O8F#58(218V	)1%1/&J%1111!1$1!4$11/+1&6$H!10A$3+3/%1/02%2.1//1//.2///02%2!3///$1&2(2%1#1)1%10101*1#4%1&31-1+1$4(60204!4*2$1%1*1/*101$4$2%1$B+1!1$1//0202$123.C#1!H//%6!1!3*46#4*22/%2,82,1/0102*z02#E/#1/T!2+1&11*1-2#12&2$1&4*6#1/%1)5//(1+1#1#1+1#2%3,2*2#4+11	eh~|B@@DOH`KImlbbTRbTTJtTtVTrflbbbbRRRvdTBrZzNne]u}mCZjjjZjjjZjj@@@@@j`BLBNBGJNb@@					antagonist	M2 / M3 / M4	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
l0*F:0~S.iS(x=S~.=.>S(xi.ixiS(S(x=S~S~S~x=qqg-xhy?}Zxhx>	=v:r:jzyvUzjxvUvxzyEnjxxsjbyyVEYYfPA0_y05fLbp_NcQ69ykGESWuF91A1ZwJA8sK5YB7lkX0GV	0ZB0s!2J03d!Bh02s0FF04FV130A40wF05OF1g07!Sk1w!JL06Z0Sk1w0Bo01Jw0YV2U0@F0t# #YVW1ke1F8L5Z120ZX2RZ856XZt8VBF7K7W1kVh4R653F32ckg@@5G3298Z@D50W1O8XI43108cTJNL13Ys8kE8281m0WVPck66B3@2mVNV@G3YFkNoVPUMWVFcVJ6C93lNgN186XFk8BHL5841NVH62WFNV82C66VkVFTI50kcgD4110NFwRTSWW0kVNgBH63Fc82720V9Vw8921Xnk	!220F!86#2V6#LR#d2#553$iF!GW8!25@#G1#52o!8mJ#8cF!8fk!BBZ#QcV	3/-1(G011.21/02+1/)604!101,2&1#11)11#41+1+1$3#1%2//&1!3//1101//)1/)1+2,1/1/!4(1%2!1+1%1$3&1,1-301#1)3#14$1.1%1/$102/01%1%2(1!11//!3/$2(1016!2(12&2)1/*2(24///#13!1,1/,l#1%1.1)1%4//%41*2!1#3/-3!101&1*213201%2+1$1!1%1/&21*1)2*501!30201,1$3-	ek`RBH@LBACM@ac`@cIEELheEDmDlibmlFEOBaiejXJAjJjjjjJPbHfh@@					not given in publication	A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(S~.>.>x>.>.h.hS(S(xhS(.>S~x>.>.hxixh.h.>x>.hS(.>.>S(.>.h.>S~.h.hS~.hS~.>	|vyzvzrzvzjzCzQjzqwxUvfxUirGbyMzqtqTUyJkAqAu_LjTmm0gy3JuoJ3GdHxIF2VcsX0X0G0	0Xo0FF02FF1D!8j0D#os0LV1a!C_07!Tk03OF1k07g!sg0bk3Z!DA0@40t!4@0110480eF06@!i08g0bk2W0DF0 06F4@3Z11Vt0FkDF463Z130t0FkACL4D30X0lSB8H6131W6HVBR6132BpNFwB2A30f1kse@J10VWk44HFPKa0F8JR216315NNyA5@0V8Fg226835nGFJ@6@0VFG422B9m0X0HsFZF0Y2ctR422@0FGOGNwLB250890J8b5Wao0JB6L0VFXG1R4wD93kkNBA7A0FGdDF4R3Z130t0Fk9XN4A2BI0VsLF4B21OX4NWB2426Y2H1gc35C3ksGR22I0VZF88wcH@5b0FBH28D3l8GZ22M0V_352sP673PeFkNVBwA25ikG0QKR1331_WW8RQ233VN8kRNF72Wsc@11WG04kVN584lcJF36VFF4gg2210FW4wkDNXk8ccKgO@WX0qtJk6C3VckWFGPR4823BHNsFg91W4WV8wRD@3ksF2HP10kFOJkJ522HFBHD1X0sB2117aFF9O2iC22W2lcNPZ41Ft0ZV	#d0V#8$44*BV!1We#23#Fd#4Z$8F$6o$5#tcF!11s(218V	//1!1#Q/!1!1021/%2/%4$701!4/*1.1!102*1/01,2-2%1+21//#1201&2!3)1//-1$6#1/%2)1/#@/!1/01%61%2/2$12-61$2$6/1,22!3-4(1(404(2.2%1,2*1/202$22/B)2%2//2#3*6%2/)4+1)11#6$2-2%2#1%z(101.1(1013#F/$3/,2&5/-@$3(1+1)6/0202!1#2//(1+10203*1#102(119$101%	eeW\B@@DJH`KG@\bbTbbRRbUbRRRLrVRbRre@adWRswuKKUUUSUUUU@AP@SUAAIP@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>3pxixhdzJ}x>u8>xun}]F|}Ifzps)]ps~SF|}IF|)]	:UvzQvrUNheYqAETdGskOCLLJ1Yj3ABhMaX58XA7AGl1kS_0P5V0w1gW0g1IRYG0eFBkV@L03BS9NJa1BV0F0	0WR0Tk02OF1v!C204w0eF034V2Z0DF011R0OF1g07g01Hs0DV1104F0Tk05AV0u0480G01v!JH06k0Tk2Z0DF$ 0BV8Z78291m0WFRV8J78251m0XFRV84782@1m0XVRV8N782C1m0W0RV8N78291m0YVRV8c78281m0W0RV8g782@1m0XVRV8N78291m0Y0RV8B78271m0Y0RV8s4	#i4V!1R4!8CW#5ZV!66#6cV!22J#iY8#6H#DKF!22s!B15!2G3F!B7c!@F4!215k	03/%202,9&1/%1)1%1/&41#5$1%1(1+1//!1)1!5%1(1!2///$3////,1%4/%3)1-2/01/01/(22!110102+1*1/!21#1/&2*1.1#1-2&1,3&1/!3/)221%1.4!2+3/04-1&1(B//$1/&1//%h$24/0101)1$1@101)11(1/01$2*1/#1#1$2!1/-3!1/01/$1(2(1-1+12&101&1(10201+	fiwQA@BAtBHDDYEEDeDlmDhdhbrWA^CeoQpPTSUPTPEP`qGb@@					antagonist	D1 / D5	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>|`S(S(l0|F.>`*}J63`*`*63`*?)o3(VP(3737P((V	vzUvvfzQzSvYQDAM29JOtPhHqHmXgYHBNQRc7Fk598NY6F140A11!6Jk6J2I4Y30722F48R0A$4Vl0V0FV	0WR0Tk04B0110480eF055k1_07R0Tk1w!KW07R0TV1w0CB0 $6F483A146FFkIOR4@2m0WVRV8B5gKBWY0k	#24V!104#V%2V!cZ#1d#2,48#9FF!F2k#44#G$8Ks$8!21FV	,1/*L!1//-1/$2!205#2//1/#1/!1/(2!101(1.1////!1/(1%6!1&1.402&1-2&1&1#@01%1-1)1)1)2+1$2!2+2(1&2+2(24)2//$1!1/.3/*1&2#1#101*1#4$2#1(1/-1!1+5//1////20j#2*1*1$1&1!61///!1//$2$2#2+1(3$3//1$11//&101!32/,8-	figPB@B^ADYEEDeChdleDddrWAN}t\DEEUUUUPt@@					not given in text	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)ZD+x>S~xh.hxhx>S~.>S~S(xi.hxh.hx=S~.>xhxh.hS~x>xhx>S~S(xixhS~xiS~.ixi	:Uvzv:rO:vwvjEpBvD@Hjh7hU_V41jWl@07Vg8Fa0VCa1k1k0XV4kBN4VV49ZV48V!B4d8F203040Wl0s0	0Zw0gF03OF1g07k!qJ0Tk1w!Ds0AZ0kk03Xk2W0DF!sg0cF3Z!DA0@N0t!32F3P0EN$ 0JRA7Y1NNL910VF4oJPiQ11kWGBqI63GW8kt6J91G0kcOch1WWFn4k8B421WkVZJA4W1NVB41VVH0s210WXZl0oTQ4_0ssZR4542GskTA5VVVB22D4b0G10eI92Vd0ZY82714YGNoH9521c8cV21W3I4Hs8LI141bm94X43WWlV44HF110FNRF93Xl8ZH32VkVF62I7dt0G08FDE42FNZP82VkVF6218340V92e464kG8c8FGH0lH982736VFkFcc422VkkZH751l0N@72WFF98V1169t0FVBco4C20XkVwD54W0sRD23WF9t8810VG1c44Lc4CX508JVE2131k890H6X_VV8J41108J2HBD0VF8B843WkVVD731l0F4420VF9NZ1170FGY4co472m0WVF	#c0F(844$F#V2#5V$86$c#4_F$FF#@k!84Z#83$3k!214#58V	02-11/%A$1101(2$3$3#4+2(3)1$41#4$6!1///////$101/&1%1,3/02)1/%11!3!1,1&101!101(1+3.3$61#1,1(1)1$403$3&1$101#4!11&2!1%303$5(4/!1!1/)2+7*10302,1)7/#1$4#1,102,22!101.1+1)2#1.2(1103!2/,1/!1/02/w)11.3(11%B1+1(3/%2021/&3(3!1#@!11#1/%1$33/4/(1-5/(1!8/,1&1!1!	ebZQJH@LKDak`T\XDCNc`@cIIBheDhhbhUMJhhbdiixEdmPPC@TUMTuTpPSD@@						NPFF	NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
h..>h.xhx>S~xhxh|FS~lv|`~Shxh.~S>.h.h.>.h.	zrUtztUSzKxxQNAUUU@G3NuvaEHHCWC92evaE2X5I3aea!X0aG9z01R9Rk1WCWHW97X2hF58105G207X0V8FV	0_F0zF03OF1r07g!t!bk3Z!G204w0bk2d!Gl07R0jF3I& #Hn8FZ9Zm22WO0FcDF482O_W3FgV8c782@1O0_6F98A82F1m0WVF	#L0k$8#V8!12$k0F!1VD)1cV!408#14$HV#1$1%NF!2%A8V	/$1/!5/$14//*5(103$1//01+1.1(1/&1//4//$1/*31/#1&1#101(1(2/#1+2/.101/+44%1(1!11%1/$2!3$1044/(21//(2,11#4111.12/#1/%12.3%1//#3%1*3#4+1&1///02)1#2-Z/*11.6$1#2+2//#3$1/&13/,1$104,2#1///#2%3(4/#2(4-	ffcIC@IF|UpIADabPrJPqISIZZIKBUhvRuPACSUUE@@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
`|v:~S>xvlhxhx|F>x>xsp\)(Shx>x|F|F\)x>xhx>xhx>xhS~x>xhS~x>xixhx=	:UtztzSzKxxQRAUTU@lAseQa6HHhY98DTza73VC9Q0faFVX03KWB27J9BJ2YEkIW172214J0104104HkVV8FV	0aJ0Q!2K03x!C_07g0U!3FV2d0A4011N0O01f07k018s0cF2Z0DF$ #8F97ZWNoL71VHls84PN475mssFA142XBV8R4247YGW0@64WVNF6PE0VXYgV8F5ck24W0FNcXA321cB4430VFF41194088lE82@1PB0WsLF4B3Z13VVV8ZJD3XGNR44AA118B420VV90pB8394XFRB42WVsB2PBC0VFscH54XksR871WkN50a410FFVtF4542FkNB831G886610VN58g210V842BEN	%k!808#8%G#42#4V4$6k!9VV!6_8#1F$2k!8Bo#dk$3V!2F4#O8V	//#1#C+2$1#7!1&21%1/01$5$6$2$2/$1%20101/*1$1$11&1/*1/!142&1-1$1/#1/2$1/&11!1/022#1%2!1-1/#3(1-1%1!1)34%12/!1.2(2$1024,102(2%1//01+1#1!4/#1/$2/#101.6$2#2#1/+3!2!2.6%11/+1%2(2/(1%1,10t%3011.1201!1#1%F!1/!1%1/!4)1-2*1#3!1&1,1)106)1-1)1+1#1#1/#301$2402*1%2(5-	ehRRHB@ADnei`@brP\dOICIEDddeMHe\ddeLhdlJNIHdo`ZABJjjjjf`@b@@@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=S~.=xi.h.ih.xh=x.>.hS~.>.h.hS~.>.>.hS(.h.>.=.>.h.i.>	=xUzrrzhUAuUzETFQzcQDj645ZFD2NeoA3P5V02rV01HT6FnF0N@8wF1c08@40V14084H1!431@VI20WF	0_!uF02J03d!9F0DZ!o80bk2V!Ce0@R0o!3@F1D0D!16J0R01r07k018w0bk3Z0DV01aV0PV1r07k0dk3F# $6F4P3Z120t0H8CgH4I2DlkVsI9Z4M2m0VVRV8s7826178qNOFE8281m0WFRV8k66W25WO0G8DF4F3Z180t0Fk8x64M4@VXVaF4J2kP12kgV8c5ck2@WO0Fk9NsAIX6WBV8k6RL281O0FkDF4H3Z1AVt0Fk8ye4S2m0XVRV98782A1m0WkF	#6Xk!90V!2Z2#3R#X6$W2$oV#dg!40A#1VF!4HZ#a4#8V$sk!846#18V	/!1*11(B/!4!4/$1//2$1*1-2/101+1!1.3&2-1)2/*1/*3&1$21/&13/%1///#1)2!1//-4!9&1&1(5!1*2,2$602!2023+1)2!201-1/(2+4#4.1&1#21$1+2/#1#1/1/02,2)1#1#26#1,1/1)1*2/)2/n*1/&1(4*1(1#1,6,1#401#2)1#1#1#105%2%2$3$607)4!2-1/(1.2.2*503)1$101(4-	eohZF@@LKO@l`DENmclbbTRRdSTRTVTRRrdlRJFfZjjjh@`HJj`@@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.i.hS~S~.hxh.>S~.hS(.>.=S(.h	yJuK209G0k40402!8#N0F$112!H0V5#2!1!1V021V!141FV010V!2F$4!8!24010V0FF	0PJ!ZB0IV025k1v!KG06J0PV1q0C!1lR0NV1_06c0R01v0C$ #O0GFDF463Z16VcNNFR8WJ2718FGJB4F5Z130t0FcDF4H2WWW20V	#64#10B!30N#J8#e2#4VA!22Z#134#4O%F!JFV#2Z#1V$es!14g!25Ok	$1//!4.1///%14$1///-1+1!1#2/!5%4%2///1$1&12#1+1#2/!101/31/!1/(2//,11/5/#1/01/#1$2.2////%3)1$1/)2,1+3%2!4,1//#1.7///!1//$1!1!1#U2$1(6*1/A*1//$11(4/*1/#1(21/$2/+1/)11/!3//+	fdyqB@BBMpDPdrjjmkTYxL@EU@A@@@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>.>S~xhxhS(.hS(.hxhx>S~x>S~.=S~xhS(.hx>x=~Sh.S(	:UQzAvIUN_V26@EG8FGmO9H440VdY1B8ITV580118F1603V4FFV0610dFg@I#84F9N4c6!8!30X1B0F0F	0Q4!ZF0IV02G01D!@N09g!d80xk03FF1204s!p40OF1v!OG06c0RV1q07g0o% 0382@1P4YkNRBwQ8508B6DC7m0WVRV8R44NC_lVkNJBTI22VFJD@H95mNoB2143X2d18P43X0YdNmF0WGlFsJgOJ1lFsiF4B2123mORT7310N4gJLBW5VkcN86C7ZmFo@520V9Vck4SDcG0cRM826122WsweD3WkV82L9A4EncNJB2493HO4T70W084kJNuK12VgV8J6q2E4VY0gV8F5Fw24WO0Fk88DM@cVNJ@F984631k6823XGk	!1E0k!82V!602!108V!V6F!40@$J$e#2Bc#8FF!60k#m7!2K9$WN!802!214V	01//%D/02#1//&11&2$1$1+3&1///(@2/(6%2$5%1/%2-1#5(1,1$1$1&2//&1#1/)1///*41!20B$101$2)1/#1%601$1$1#1*1%2%2#2.1-1/$2///$2%2//+1//%1H!13!21/)21!2!2/1//&q4.1+6-6//%8*2(6!1.4*2//$2///!1//!3!2/)3-	fkq@@B^bCHhhheEEEEecDUhi^le^v`@HbJJjjhH@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.hS(unx>.>.>u8}IS(.h}]f,q5}^q5}^b{t8~Qwj	vzUOv9zOMGx3Q4HE090H@NBFc220h1088FBV1N01!F3!10V31Z!208FZ20F2#20F!4#V!40F0V0FF	0QF!qJ0Sk1w!C10480eF04FF1407N0Tk06Q01q07R0Tk1w0C$ 0O0FV8FgLD3kVFRLDDBZXVVF220HGGDF483Z14VX2u8L@2X1lVyF4@3Z13VZ2XVZ892VWlRV8R4	#X0V!9F8!4W8!112#Vi#48c$4$2$48#9F$Ho#47!2G9$Qs!@0B!214V	//(K///01/#24$1*1/$3,1//#1//1-1*11%2/,1(1/1/,103,2&1/%1!1/!A)1(1/&1/#2/5-1011,3*2$1(2&1!3/*2&1!1%5/+2+1/01!1(1&2!1!1%1&1//*41/!1/%1)41#1/&1/h/*1#201101%9*2)1.21+23/%1#1)1/!13/4/1//&1/,3)4/!1-	fa{p@@@FsdbbbbRRrURTRirUg^[t@HBhjjj`h@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
>xh..>xh=.(Sh.>.>x>.h.(Si.>x~NA,xh>x.>sp\)s6|F|F\)\)	<v;r:bxyzQWjpEUzpoyobfzSFFmeRcplGmFi9VUOCz_3Id29@B@qV2IVZ8210@Z0WB@N1H23G2H134Wk	0qc0hV3F!B30EV0yF030k3s0EZ012o0Ak0l04401Kw0Rk1r0Ao0pV06N01e07B0Sk2q0C% m0W0MPZ8J4dSW1kcls8T4AgW3FZR48D4HEaY0W8GBc62G1sXOaA341e20VZH53Xt0FFDF4@2vJW30cls8X4HP22kWFF	#6VF!N04#88#@V#VB#3WF#2JV!V8V!41B#@4F!ZVk#2B#V$ZFF!82Z#190	$1+2/%901%22///,1$6$3$1#1/#8$1/,1$2)1/(3!2+1)8.1/!1/$1.2/-1/)1/%11!1$5&1-12!1/!45/$2/01)1!2$8$3/03)2#1(1#1%1)1%1+2!2/.1!3/#@$114*1!2$3/&1//!24/+8102+1/1(1(1!1%1)b5-1%11/#3/%1/.1///*1/+1!1%1(1)1/-1(205-3(11#4%1&	fmwhI@KE[M\DXHZJ\`|G^FRRXqQIKJJQQUYJuUhymUUUUSPHEP@@					agonist	P2Y1	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
xh(S5q~Sh.hx~S~Shxh.~S>.(Sh.>.>x>.h.(S:v:0*F*`.h.>.>.i.>.iS(	]x;yvUQjE:QjUi2nQhnxAvvzi7cH5QElyi2RfZmPAe@HyQgwvnOkItC32cEFT0WmKJ!1a!80V	0XJ0zF03Xk2U0DF!os0YF3r!G_07Z0Tk1w!Fi0440FV2d!KZ07V0TF1w0EJ01_R0Lk1R08g0bk3Z& %k513XVwHA84Z2peNBF3111GNto8F4O2VVcVVC340OFgf8241QAVWVFoX4O3X0sFV94WFN4cR115at0GF@CPI0X41BV8N782211b0tJ84B10N4cBJAL_lsJJ@@3D0lO0@8150GFc227A16G8JBE5X0NBL1B70FGGiF4B238WmFV68640NBgJ11363meRLA550VG0kBN972kVlBL4131NRNN113aVF8g6D4WkNRBJL3VkNN683YYV88lA8291	!2O1k#e8$2#V0V#4#1W@#25#NsF!4ZB#YJV!Vmk#4b#OF#318!@X2!3W8V	!1%2*1/!@.2$14(1/-1+113$2!4/$1,101/-7!101/!1%1//(3!5!1%2!101110301/!1#1+3/%2$3/+1//!3101%1(1(101&1$54%2.1*1*4$12$3/01+1#1-1/#2$1&12/$1)201&2&1$301/$1$3#1%1$101/!20203%2#2)25!2/1!1%1$2!102*4$103/+3&10q$1&1/2$1&6/%1+1201/#4/#1)8,1+11)3&1//*1)1.3(2/,2-	eodTLL@NKMBk`IABPpdLbdLRTrtTRQbRRVTDdbRZzVvjfffjjih@fhHCB@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}Htnb+w<~U~Uw<b+}Hqq^)}H55^)^)55^)	:UfzfUBrKxxQN9OEE8kAce9aAH28V696ut2AA0CF2qeZ!2Fas9uV0JFBF8_1FAW32V18J501!F!8e0V0FV	0lN05k1u!DF09w0t!4FV1E09w0eF05O01p07R0U03I!NL01R0O01r07c0U# $38241m0YVRV8c782A1m0WVRV8J78221m0WkRV90782C1	#M5#18B!2V8!1FB#c%V@!201#We#64O#44k!FHZ!1H2#WV#9FJ!243#A8V	//(6//1,1+3/03$1/+1/.2#1%4-2(1(1/!4////#2(1/)1///$2///-2&1/2!1/$2!3$104/(2%2//#2101.4/#2#1(1/%22$1$2&1/,2/)1(3//!2//01$2/*20T/01(1//&2//#2$1*2,8!1/&2)4,2#1/$1/-2$1)3,2.4*2!	fdeqA@FZBhDP`HRYU]nUrTxKpZZjfjjV@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=.iS(xi.=.=x=S(.ixi.=.=x=.i.=.i.=.=.ix=.=	;UdIsv9e625o2Dm0m8X902VV0Wl8W2V02K!201VFF!41892204k08080802,2&G20W0	0Z40IV02Fk3V!C_07!U!3OF1v07k!mV0IV2g# !sL12VdtJ8R5Z120t0FV91mK322W0Gx4N4XYWF9BRKB2G084HK910Z0OB84121W0G2AHX0c4RFD57YI8kX430V9GJc	%V.4*282$F#F1#80F*2o#44#GV$4s!24#250V	%2/,2#F/!1!3/01$4$1!1.4/#2//+1/$1///!1//%1#1(3/1/-2/-1//)A(4)1/&16/(1,1!4$3)12(4/)3*1!1/5/02%302/,1+1/-3!3$1//+1.7%3/*1%1-2,1/-f&1//#B,3/&1///%3$2+1%1(1/0411////!101/%1/!	fnc``@L`[dbbRRfRRJRdwIV}PPPPQUUAAI@@					not given in publication	S1P (EDG)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~|Fxh|`lv~Shxh.~S>.h.h.>.h.	zrUtzdUSzKxxQNAUUE8G3NeQaAH2CYD92evXE@X5I3aea0120ZFdv01R9Bk1WCW2WA3X0gN70105F!5X0V0FV	0WR0Tk025k1v!DF09w0t!4FV1E09w0eF055k1_07R0Tk1w!KZ07J0Sk1w0CB0 !m0WFMuJ8H5Z170t0FkDF4L3Z12Vt0FkDF462zHW30gV8g78281m0VkRV94782D1m0W0F	#M5V!584#V8!1F2#V%V@!201$e4!4V8#14F!FHZ#4$18#1Fk!202#A8V	//(5/-3/&1/%3$1*1///&1#2/&14&1///$1&1/+1%1&1/0101&1//!1&2/$1+1/+3&1/!11%1-2!34#104(1+2#1(1/02!1*2&2$1!204+1%12//$2$11#2*2/%1/,1(3#701////#3)1$1,X*1.1/4/%2/*2!1$202!1/&13//$4,2#1/$201%1/$2.3/,4-	fbmqA@IVRXDPRHrJJJYHjZIKLEITTpPQLuUQP@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
ps,d=xW~.=.i.=S~.i.iS~.=.i.i.=	vzUQAItm9N6V0q9DH80VX80X#1VV10VK20142018k!lJ!@!1$F8WV02!4(24802$V0F0	0aJ0U!3OF1v07k012s0FV2W0Aw% $2c2980WkW3Bm6B80XWBV8F4	%V$8#8$2+84*V#44*42k#4Z#O$958(29NV	//(4/#2///!4$1///+1/2.1%1////+2&2&3////*4//$6)3(1//-1//-404/&2/01%1#3/5///%2//02////02%4//$1/)3/,T/01(1/D*302//+2//02/04/1/4.2(1-1/,2*1/(1&	f`iP@@@XrQJEQISIXHkSoMU@@@PPPP@					antagonist	Adrenergic alpha 1 / alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=x>S(.hxi.>.>x>S(-h*`x>*F:0;txhF|0:x>xh(S0lxh.h61)Zb+	<j;bUjrd:vYzpf7zpkzJj:xsFX3Jcr_7iTE1sUrUz4IIx2TYB8rV4GecDFSBTa0V4@C9G23u2F4b0Ik	0G8!QF!Z40IV02Ak3V!8j0D#o!FF1D!DB0DN0uV05PV1m07B0Sk3F!Kn07R0ik2w0CF01Ho0Ak0l0440s! !Pw472jVVNNVE8241_6VVcJVZ4A50XFqXBN14626mN8BXE23H0FJLFJM13Hkk8J8YP12Gc8RBBI6WW0J@96W0kFkPOZ110e49kBB6yGVFFVRFVr8Y10kVFkF2W0skFB352XgV884yYGWX0pAV8N20W219lN8@48E2F8JB7830N8gNMZ120Vln4TF134GWQRo70XXWHH92D44X2HuNT82VWmVs4645XG8RN931VVN433c1o0Fh2R910Vt0RBJBZmFV8188Z1fFFBP7Z13Vt0FcAsu4H2W0WsVNk6FX33s8cLFP11Y0nm1420XYGKAN@653g20Wc84494m0XVRV8N4Lm94FNcw22B6QAVVVF6k80X2kF8ZJ_730W1k82486310WwLB35kG8Zb8291	!3E1F!O84!6PB!1@cV!VTV!5WN!3Pqk!kc8!4AB!2Pck!Bpk!6fB$8#V1F!87B!2t90	(1*1/010F(1)3*2!1%1(2*12#1#6$8$201011$4/1*1/.2$1//2/.1/-1$1/////2!1011%1#3*1)7$1,3,1*7&102//&1(4#12!3(1%3%1,1&1/&3#1!2#202$1$2)1/01(1*141(1$1#1-2/.2#1)24)1.2$1/!2$11!2%101/+4h#1/1$1/3/-1/#1&21#1$1)1(4!1/.421//+2,1(1&1*6,1)1/#	fcoXR@LDejsbcWl@QdbbRRbrTQbTRrLxjsjmhHJJjjjjfFIzbIEZFt@@					antagonist	P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~|FS~xhlv|`~Shxh.~S>.h.h.>.h.	zrUtzdUSrKxxQNAUUE8G3NuvaAH2CWB92evXE2X5H3aea01X0aGdv01R9Rk1WCW2W93X0gN58105F205X0V8FV	0t!bk3Z!G204w0bk2d!Gl07R0jF3I!G_07R0Tk3x$ !6F482_6BklcQ9Z492m0XVRV8N78251	#L0F)V8!12$m$1V8*dZ!408#14$2V!1+VFk!2%A9V	/.1(5/-3/,1/3$1*1///!1(1/&1////%1/+1//101+1101/*1&2.4.101/+3&1*101%1/$2!34#104(1)102#21/)2-2,1!20401/12/#1/%12.2/%1/#2/03#6/#1///03)1#2)1#W*1#1*1/4!201/2/*2!1$2$1/&13/,1&4,2#1///#2%2(4*2/04-	fbmIA@FJldpI@d`dsMk}ropTeQSADCSUUE@@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
|F:0S(xhl0x=x>xixhx>S~xhxhx>S~	vzUfvvzgrSxEvolO@j9uE9BCu0IAc!9zHR21N0CF2GqZ0R3VXc0880oHV427G2!120G8FF090F8)V	0PZ!o40FV1D!C10480IV035V1Z07c012s0FF1407c% #1Z120Vnmoa3532c5coJ8@41bL9BFD8LR4kNVcF6LJ70scJM8251m0XFKIc884fRW10V	%V(4/048c#2%3#20N#BF$Hk!807!2FF#B58!2F$d!	//#2#H/#1/$4)2-1#4$2//01/%3(1$1$3///.1$1////%1/////(1/01*1,4/)1/*1//(4/.1.1/*2/2//,1(1/#1///&2!3)4/.3-2&1)T-11(2*1//&22//#4(1*3!1/*1%2/+1/(1//1/,7-	f`q`B@I@BDie]yUqS`jYjjjjap`@					agonist	D2 / D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hx=.=S~S~S(*`S(.>:0*F(SF*p3)J}\6sp3	vzUvvvtlxNhXVoAEGc1O2NRmJ4G3dY38c2TX5!X0@!6F5W02GV8@1Z8FZ230V!30AVBV48!F03F2%k	0Z40IV025k1v!8M07g!n40FF1D!BM06J0Tk05N01n07N0Sk3F!OG0740Rk1r0Ao0pV% #O0FcDF4J3Z140Zr1ZB@6aO30ksOggn37WcVGPBRF33XO0FsDF4821@81lJNBB6m0YVRV8o78241FkkXNLF4D2C8gHVVNF@A7eYFcVJLC2h20BNRB@_YkkcNcHLDXGcR4FA8B0_b8ZJ6H4	#64k!H2Z!2BK#Na#VCF!1W@!22FF!V98!4IT!281F!_Xk$Z#1$VVk#2Z#G8V	$1+1%1.@///#1%1&1#5$2*1)3/(1/$2!2$102/%4#102%2/(1#1$1&1+221$1+1#1//$201%1/%1-1/1&2/01/(8/!501/&2&1*1+1$2)2/01!3//#1.1+1%3/#2%1.5$1/4&111!1/,9/.1//%1/,e12,3%1/$9//%2/#1/02+2&201$1&102/)1/(2/!2/$2$4!1#1.1$3-	fakHA@NF\DDPjHrJJIQIJEKKQILeYw`pP@Q@uUTEAI@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=.iS(S(xi.=S~x>x>x=.i.ixhS~.iS~.>.h.i	vzUQvQztMRxYvwPU3Y1HA8c4T4315Z08d8822021020X!42V0F108288JF3V!2!21#42G0F03!V$F	0ms0FF1D!C_07R0U!3FV2V0@Z01LJ0PV1r07k0o! #O0G0DF483Z160dM0RBP6UVW0kcNKHm224G0	#2$1$2V%@#V2#4V1$ZF$V!4V8#1V#40k#a4*uk!204#18V	/.2(B/!3//01/04$3////&3/-1,1//&1/+2/)1//)1//.1#5+1%1%1!2!1*4#1/(4/&2*1014+1,1/,2/(4/%1$102%6//(1011)1/1*1.1)12$3//.1.2+21.b//!101%C*2&1/!4+21)1/,1/04/4&1(2//01&2+1-3/,4-	fj}p@@@X}dbbbbRRvJbUIZ][pPE@TUUA@@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.ixix>.>xiS(.ix>S~.>.>xixh.hS~.>xhS(x=.hx>xhx>S(xhx>}^H)q5^}q5H)}^}^S(^}	:Uvzv;S:vynUTrDnEfutu6bQ_0ONiix443Fh2G3XV9_XZ44c66BJ8TJ2X1ZNV8704114c1021!FXVW8FF	0aJ0Tk02K03x!C_07R0U!32F3P0EN012s0FF120@Z018s0cF2Z0DF01p40OF1g07N0Sk1w0C& !6F4D2534Wtg8G0VVdFgcHMDaWN8NDB12Y18cND41G0B6420IllsNTECYlNJ810_2mdlN8D5Z12VebFFR84O73GcoH34ZXmFWFP941GFNP110VV4sP115bVVJNNB95WlNcD@3VVF8810c4V89182444GW0XB30VF42PFC596kNwE82C1120VFH@4XFVJD70X0cB2119Z4kNBJA5X0swH440Fc82TF0VY40FNVG@_FcN42@70FGWPtg4@2m0WkG0V8A72ksR844WFFB4TE0VYJBV8N4	#20k!90N!4Z8$H#Z@#5Zg$4$c#4ZN#1FF#@k!845#1Q$Ik!@14#58V	01//%A!1$1,4%3#2/$3)5$4$210104!201/.1)1/(1!1(1/02#101+2$4)1!1/(1%2///-2*24/1+2-3$4$1#3!1$1/&154%1-2/0202)1$3!4$31)221(2!3!1$1#2#11)2#1!131-1/#1/)1&1&101.61#40202+1/#3&1$1(6(1/*1/01#1/&1%1&10z1&1/0201#4102%I.1//#103#1/#1)2!1)3%41!1$1#3143$2)1*2//!1,3%10502/!1#1!5-	ejQZLB@LOFi`XDA`@aJPrdBiCIIBhhddmdiETieEDhemGKOO`TRUjB`hjjjZ@@BB@@@					antagonist	UTII	Urotensin UT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=.ixi.=x=.ixi)JX~X~zA=x,e}\ps	;jvfzBrvs7URF02Ck@884VsXFWc80V2HF01F040VF0F10WV2048!J0F!102!1%J%2$V0FV	0U4!Xo0FF05Mk1W07J0jF3I# #JBM94GsNB297VFGdH18T34VFFkW1FX522G0	#60F#1/VZ#198$F+9+F#V6#F3%N#4$1!	1/+3*J///$1/&2//$2//&3/4/&1/(1///%1(1#1/#3!1/&1//,5#2)1//#1-1-8/%101//+4/#2+3%1/&1)2,1#1/+2$4/////+1.1(8-1/.U#2!2/!1////#4//%1/*1/%1%2///)5(2&1/$2-	fhiQ@@IN@eJjlrkYw`uUUMMU@@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
vl`*v:~Sx>}^^}q5}^}^q5	vzUfvfzBpSwEGJ1N8ENF380dm0FYc!1@@F01#F0FVZ!Y0X08@!40HJ!12!1#8F4%2!20V0FV	12o0FF120@g01Kw0NF1p0Ao0ok0 018CW2088NB	#60F/$VV#108/08$F%F$6#F3$1N!2%1!	//(@&4///(5+2/-1&1/*41)3////////01$2/%1///2/#3////01)2/&4////%2-2/////////.1-3/(3///$10K#2/%2#2#1/!1//.3/-1-3/%2//*2//*3-3-3-	dco@@@sTi]YWBWVfjjh@@					agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
w<28~UH)b+b+w<}Hqq^)}H55^)^)55^)	:UfzfUBrKxxQN9OEE8kAce9aAH28V496ut2AA0CF2qeZ!2Fas9uV0JFBF8W1FAW12V18F501!F!8X0V0FV	0t!bk3Z!FL06F0Sk1w!G204w0bk2d!KZ07J0Sk1w0CB0 $1J812FgV8F782C1m0WVRV8J782@1	#I1#188#V8!10B#c%V@$1#Wc#648$4$HZ#H2#WV#9FJ!242#A8V	//(6/#1+1,1+4/03$1/+1/.1#1%5/&1(1/////&5(1/)1/.2/$2///1,1&1/#1/$2!3$104/(4//&1!21*1%4/#2#1(1/%21$1$2&1$1/&1$1/#1(3//!1//01$2/,S/01(1//&2//#2/-6!1//04,2#1-2$1/.2.301*4.4-	fhyqB@LJ}H@PeLk}rnRcNN}TmSUUS@@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xi.iS~x=S~.=.ixixi\).ix>s6~O.=.i.=S~=x.i.iCDS~~S>.	;UvUzvUvyIzinDmtLUTz5msX_eh7s6NvHt5JnVY11O6I1Fh33k44G69FZG9@WF2C02HocTF8e560Z_JFW0FV	0Pg!Xo0FF04OF1k07R0U!4Ak1307!uF05NF1r07k0j03H& BV8R78241m0W0Ft0@Y2WmNJVJFSN4VcVgFE12WYXFJ8J@v94VksJ4@8gOWFkcOe@482VWFwV8R4	#2V#3+55#_D#37X$k#F14#VO!2OF$No#44$V$5k#54#58V	/!1&1,I/%2!1&1%1/&6+7$1#1*4/+1/*2#11%1/%3&1$3/,1-21+1.11%1/*2)9/(1,8103/1//01/03/1/%1*2&1!1/1(1+1)6.6)1$1/(2//0101101%1!1!2)1//.2&5(1$1//&3,502&1!11-20k/%1#2!101*41&1///)1/(1/1&2)2//+1&1/#101#1!1013)11/02)1#	fep`@MV\CfRJJJJ[IJjQIJJgIFlzoVc[N`jBbZjjjbj```@					antagonist	D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
}J45ps`*}J}Jvl`*v9~S}\p3p3}\	zxun2YtG8s4F0J24H80WVN2m!F0d3920HHV58X021k9611!@9V9XKJlHc89RnFV1021!J1V85!450FV0FV	0_!uF04OF1k07R0U!5SF1r07c0U03I!O204F0SF1u09F0jk$ 38231m0WkRV8F782C1m0XVRV8N4	#20V!I08!4c8#16V!c0F#8@$J$Y%B#14$FZ#4C#GVF!9Fs!@09!290V	1/$1(2(6!1(1%1*1/1%1/////!1+1#2(1*2/*1#202/01/#1,401/#1/+1#2%1/.2/,2$11//01/$1//$1/!1%1/&1(1/(1/)1/#102*1)1.3/$1/#201/$4//1+1/(1!1/)Q/*11!1*16/$1/2/#1-1.3!1)1)1202)1/%1//!1/+2+1(1$1/	foQQ@@NV@eMkZjlEIUgT@QULL@@					antagonist	Adrenergic alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
4q@,-?Y~(Yi.1n36C++CY~V(*F.=.i.=.i	vzUfvfzBrSwEQR18BENcAd4dm3FYc#LHF01P08F0G0Z10WFac08V0J0H085G2901!180B%2!8Wk0sV	0Z40IV03hk2t0BB01Ho0FF1407J0TV055V1d07J0TV3C$ 6F483Z13Vt0GN8BcFCYGc463934ZKX8@87420lcRXF3YFkR420aX3F	#2&V!2%KR#Wa#1dc)8X#208#F1#40F!4mY#FnF!49N!2%YV0	-1/)H%1//$1&1+1%4$2$1!1$2/!1#1*11!1%1!401#2$1(1//$2/1-1&1/!1)1,1.2/&1/$1#1*2/#7//+30301(1&1/,3/////#1%1/!1$111//1#2///1+2//&3/01/$1/,1%1(30U/*3&11/,3////#6!1/-1/$1/1///!4/,4&1%	fdyHB@LDUh@QdbbfRTRNRqPujYjfjjjAb@@					antagonist	NPFF1	NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~^)}^81^}f,)]@,~V18k/)Ik/S(.h~V~V.>.>fz.h	;vzfvMzsLgATAiT9Nkm90Q570WgY16BMX24D2038k50k11484V1VFVW8BW982G0ZF9F02H1XB1080X1NV0F0	0Z40IV02OF1v!9F0DZ!qJ0R01v!DA0@40t!4B01404g0Tk$ $8oO0N152Xt0Fc9RVQ7WVkNR@DqM12VW1RTD5YVNg2H79m0WVRV8J4@XDYl0N2D80VWX63F8F5Z170ZndRR72Vll0yF4@22A2FkkVA6WVOFVc@97Z0so822VkNNB30bWYkNsRI83WVF2HA0VX2V	#80V-2!V)8%F$Y$4V#8F#22o!805#OV#8Ks(210V	1+3*1.D/!101+2*13/(8!202$1/*1/$1/+6*2!1/%1$1$2%1/.11+3/,1.2)8%1//%1&1/3,1&101-3&11-1)1/1&2,1&1/+101/04/!2+2&4/&1&1/+7//,1/#9//1////!h%4/#1/D#2101/!1*2/#1)2/#2-1)202(11///!1//!1*2)1&1-	fak``@D@rdrjwKKNnnCyM^mUUAD@PQAAa@@					antagonist	MT1 / MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(S(S~.>.>x>.>.h.hS(S(xhS(.>S~x>.>.hxixh.h.>x>.hS(.>.>S(.>.h.>S~.h.hS~.hS~.>	|v:vzrzvUjzCzQjzqwxUvfxUirGbyMjqtqyUyJkAqAu_6jMmm0gyfJuoJ3GdLxIF2VcsX0a0I0	0Xo0FF02FF1D!8j0D#qJ0R01v!C_07!Tk03Xk2U0DF!sg0cF3Z!DG0DN0uV04@0110480eF06@!i08g0bk2W0DF0 BV8J4T67Z10gN910HXV84RLK8clFsJa218YO0FNDF4B2BB2k8ZgC2Z5VF9B22A@m0VVRV8N4e84YX0VHD8A0FH1DF4B26g13Vk8VDw2930WVgV8s4BrFWYVk8RFCN27WVGFOZyHA250F48R2153_KdoBV3170VGViF4B27I23soJc2160FFstJRU54WHV824G10YHBV8V5Ju22W@VGQc4H423YGcgLB1X2IFg23225IKIc8@4eS11VVFsmMEXZFFB8LD41_X1BL97AXFVGF42F0VY2qc_B673HCl8NVBBB7Xl0BH95VVF4ke411Fm9ugZ4AI0X0noN8D4M1W3l0V776YYl8s86@YFN8642a432uO8245XHINFZ9ob1WYFksgP942cX8N4432F8BVm2115YosCT@44X8XuV688418Xcoe26@0VVG0VDE9ZVkNJ744aFk9RePM22W31lFsN0Y3GV	#d0V#8$44*B#1We$3#Fd#4Z$8F$6o$4#dcF!11k$2#18V	*2*1)1&P/!2!1022/%2/%4$701103(1//01!102/.11)201)201%1+2//%201&2!3)1//$1(1$6#2)1+201&1/#9!2.1/01%5&3#1%1$2!1.2041$2$8(301$1,22!3-4#11!1&14041/-1,2*1/!2$12/B/2//2#3012&6%2/)4+1)1$3$5-2%2*z(1/01(1!2#F/$3/%1-5/-7$3/$1)6/0202!1#2/%1//203*1#102(11A$101%	eeW\F@@DJH`KG@QY\bbTbbRRbUbRRRLrVRbRre@adWRswuKKUUUSUUUU@AP@SU@`PQIP@@					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>.h.(S~S>.:v:0h.h.*F*`>..h.>h..>.h.>	zrUtzdUSzKxxQNAUUE8G3NeQaAH2CYC92evXE@X5I3aea!20ZF9v!R9Bk1W5W2W93X0gF70105F!1X0V0FV	0t!bk3Z!G204w0bk2d!KG06J0Sk1v07k01LF0SF1r07k0ok$ $1Z12VYA0FZA82D1m0WVRV8g78251	#I1V!188#V8!102#V%V@$1$c#408#14$HZ#4$1$1NF!202#A8V	/$3/!5/$1#1///103$1//-1/#1#2/&1&41///$1&1/+4%1/)101//%1+2/$1+1/+3&1(2)11$1.2!3$104/)1/-1*2,1$4!1-112//*11#2*3$11$1//&1(3#7////%2)1/!X.3*1/6/%2//#4$1&2.13//$4,2#1/-1/$2.31/+4-	fluq@@DLLCHhhhddlddYFUhLVjfj``h@@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.=S~x=.iS(xixi.=.>x>S~S(xixh.>S~.h.>S(.h.=.>.iS(.=.>S(.i.>.=.h.>.h	;vzvzvzxznvyvUHvGQzQzLy67fhn9Tttze3omY3UOn8FbAVAIW0BLsfDo3uR7HeB2OFV1T098K1141mFV0F0	0aJ0U!2J03d!Bh02s0FF03OF1v07k!t!cF3Z!G_06k0R01v!Fi0480eF2l!Ni0440G01g07g0gF$ #BV8F78241m0X0FswgJ6Wl0B42@7_0WmBZN1VVG0oV6M5_G8F88310F44PEC5XkVFPH63FkN2LJA63FVBHe3VkV4cX117_YG88By692lcg8520XHc44aQZ130bH9VHB4331YdoXJ2XXGFOkX771lNoVRGZ130dI2RBL6mO12Fb2k8P5Z130VFt8RD2Wkc8@4210V421G8VFGuF8H@1VVsZJ85WkkF6110F842cJJ65m0VB81Xl8BcXJ24XkN8PC4XkkZ@31b5V89FwFG20lswT641HXc42138aVG8oC813WlNkN6110VR41CA8D_FFcA8241@DHFJFR8242kF4@63Wl0ZH510Vc86110F@lON	#W0V#N$1#3%V6#5d@$5F#WV!4ZX#8F$2o#44#OV#17s!206!21BV	)1)2#1.K/!2//$1-4$61#1&1&1///,11,1&2/)2011/#1#1)1,3*1(3//!2%1/.2$4/3!6101.2/!1$1&1,2)1#1)11$2$2(6*21%1%3!1*1*1!3!303#12,2020101/*1!1/(101,104$5#1,101(1/-6%41/,1,1)1!1$301/!2&z)1/10101#1&J11&23+1%1011#3/#1#2&102.202+1$5#302(14/5//01#1*1#11,3/01%1#A#10111$	ejU\D@@DJe`LTfVYU[u_YVum]TlL|brfVn^aQZ`hJBBJjjh@JHh`Fh@@					not given in publication	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
nC8C8cnc8C8cS48C8CS46_3p==Sr(U4S=iS4ii6G:f4WGp	:UvvQzvUSxnvyeI2nINxdjqL67d_Z0BtABI6lX9WLOm097l0N0W0C2g26L3H0X22421LG1BVG0H080aX0WFF0	0dV0ak03OF1g07g010J0IF3Q0EN01Hc0AV110480eF0 !cLC811VaF4F3Z13VWPNR@87413H94XA31VkBcT116_Z8FZ@8D0VXkN8ZN	%k)4+4#19$14$2*9FF!V@k!80B#G%5s!214!210V	/01/1$C/%2//4!1$12$3$2$2+3/01/&11$1#10105//////1*1/)1)2$1/,201*1//!2/!1/04%3202)1&1!3.2#1$701#12/+1%1(1$2%2*1/!1)1-1-4/*1.3&2!1/%2/.30203#1!1/#3%2/+2/.f.1+1.802/%1/&1)1/!4*2!1//025/.4-1/4/$201/*2-	fa{Pb@LI``@QddatRTLbRTNTdhJXy[uZ`@jjjjbh@@					antagonist	Opioid mu	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
:v:0*F*`.h.>.>S(.i.h.=>x.>>..>.iCE~S	vzUfvfzDrS:QDOOEESPOYzdyQmXckJCPvS8ArGER8Eic1@Bka29uF8J0qJ2I0F3X52FF8JO09#V8VX01!V	0G8!o!FF1D!BK07J0nF05AF0k0440FV2d! !1Z140XGtJBPTA0kl8mRVHC21l4vo8H5Z12VbckFF8	!2X$GF$G#102V!F6#99k!101$2$BN!28p#40k!207#F1#81R!239#1K0	//(D////&2$9/,1#1(2!1/-2/#1+1///-2.1!6)1/,202///032,1$3,1/-2#4///1///02.1$11(7%2%2,1%1/2/(1/#2//%1/)2///02/)101/#W,1(1&1/)2!2/(1#2%2/21/!2!2/!1-3///&1(2-302#31/(41#3+	flmpA@HHB@HhDYHddeDhhdk`e`ncEMKUUUUUT@@					agonist	M4	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
i.>.~S(Si.ixi.~Si.=.i.~S=.(Si.>.=.i.>.i.(S>.~S>x>.i.i.~S`*|F:0S(xil0x>x=xh	]Uzrv;njpQzuvLzH:yzlBfvzeM9o7S@Nf7L6MVAG92PjooEJLI4f7l5@XF48J2UFFF0DVm0a8IV	0qJ0Sk1w!DA09w0t!3Y03a0Dc!qJ0Tk3x!Fh0440FV2U!Fk0440FV2d!KW07R0TV1w0CB% 01Z140e68cBT6RW1Vl0NFkK427Vk4a711lXtH8PDA30VlFQ82E1RakcNoL2@4@GGNNNCPr23W5lWOJ8J45bp8o8@H55EmVJ4@A5m0WFRV8k4gMQWXkwV8F6@U24W4ot84D30GlksJTF2Vl8gL52VVN48RM1V_3muZD86108sk6298463VoB631FO94Z	#@0V!3%V6$2#VV#1c@#@2#NW$Z8#9F$2o#44#O$BKs#28!219V	#1!2/01-C!11-1.4*2/(4!20703!2042+2&1&1//!1#6(1/$2/(1/%1$2/*4*1.1/2025/#2%101!1,3,2!106*1)1#1)1!101#4&2/#3!4#2/2$304%3-5#1%4/0222)1#201///%2!1#6)1&21.3*11/&2%3/%A!2/%2/02/*2$2$4/z!2!301/01$1)1B!4&2%1#1%1%2,2(2/-7#21/&1&4/)1///!3#11033&2/$8)1#	efU\LL@KBdSAi`I@bPXdLbbbfJRfbRrbbbQrbbRw@dRVqpJIMLDPSMUUUMURD@UDFQDDd@					antagonist	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
~SF|`|x=vl~Si.xixixhx>xhx>S~xh	vvTf@Yt6WR2a0J9!BH8090V0FF_c$IFF1#F8F!10_02!8!J0H!102105#N0408#20V!VkFV	0Z40IV03_k2N09g01Kw0NF1p0Ao0ok! 6F4B2D4WGFVaE41VN82N8B58VWdcw4@4	#60F#F$41#1F#kV#108/48+F$2#F3%N!2%1!	#1//#5/%8//#5/,1////03/4//&1//+4!1/&21!3$3/!1///////07!2/01!7/)4//-3-1,2/*8////-4!1/%1/3/-1//01/(2/-T#2/%1//#1#1-4//&2(201/)1/*2///.2%2)2//0	f`qP@@@TRf^}UkEF\ejkjjiABFD@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
f@fuS9j`jFSm<FjFjFj`Zl<`j`j`j`S9jFSm~Yj`mPchPmmVmV	;UvUzvU:YzyzUmfry:hLyqbf:tTxxDznxIn_jOnOmUUhQ7n0xved6yIPs63HZXSJIAPHvESBN_YqR2010	0Xo0FF02@F3V!8j0D#b!vV04OF1k07g0vV05@F0e02w0FF3V!Je02w0R01v0DZ02HZ0@V0i0440FV1407g0eF3V$ !BV8F78241m0W0RV8N78241m0WkRV8Z78251m0XFRV8B78281m0WFRV8B78291m0XFRV8B78251m0VkRV8N78291m0WkPVcB683KAWF8FN9A8W0VVcHXE11YVF8kFay7VW2884T@CbW40VF8P8yB2VVVZF	#VVk!KF%4!25W$6#392$HV!F3#8Vk#8F$Ho!805#GVF!B5s!24#258V	011//$G/!3!4)4/(11+1$7/////!2//0101!1+1)1/01%3/1%11$1-2(1*1/!1#201%2*10201/(1,1#1/!13/(2106!1/$1$7$2+2$2(1011,101#1!11101*1/&1,1,1/01&3*1$3*1*1.2%2/#7!1/(11&1/%201(1/(2!j.1!101/%4/*101&2/!21)1/102%1/%1!1%4//&3)1$1102/#1%1$1$1!1!2*2-	fe`P@B`xXNRJJJIQSIRKeJHeINlgt\eGN`jBjJjjjbjhbbeCBETQH@@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=|`S(S(l0|F.=`*}J63`*`*63`*C/p4(TR(4646R((T	vzUvvfzQrSvYQDAI29JOOPh0qHmXgWFBNQRc7FF588NY6F0Z0311!6JFLJ2I0X30522F!R09#24Vk0V0Fk	13!FF120@Z01L80OF1n07k0o!5NF1n07c0U03I# #1Z120gFG3B4B53FW2FV	#60F!128#V$22#VZ#192.808#9F$2k$4#G2#8KN$8!218V	011/,2&L//!4//#2!205#2+1-1/-1-1(1/!1)11.1////!1*1)1!1%6!2/$20402&1-2/#@(1(1$1)1//%2!2+2(1&2!1(2/#2//(1///*4/1/04$2//)101!1+3///!1/)2/#20h#202/#1$1&1!61.101!1/,1.1/$2$2#2+1-3&1/(1//-101!33/,8-	fa{p@@@X]dbbRatRVRbRRhIgKN[tHJJjjjjah@@					not given in text	ORL-1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>s6\).hB,.>.hF|0:S~xh(S0lS~x>)J55.hS~.>	;jxzyirEyzvzxsfjzeUfrCzHxzuwoJrfGSIxK@w49wxaTSco2Eekc42Y2441BB2pco0158FBF0N0@V816NYV	0G#XV0f!35V1Z07c!sk0tV3e!DB0DN0uV03_k2N0Eo01HV0A01109V0f# #1Z110t0FcDF4D3Z13Vt0FVDF4L2OEV_84JF@sCW31s8Z4274AZk8wR37Xm1121c4G51FWV44FAZ110t0FVDF483Z140_L8sT894m0WFRV8N78281m0XkRV8R78251	!284$8$2J$8#VD$1%3V!HX#@J8$o#VFk!204#VB#2%1G#930	//1%25/!2!2/05+3*5+1$2!3/(2/%1(4*5$5//#2/$101////!1!1/.1//101/01/#1.1%1%4&2&3!2/+2!4&4(6/)21/-2/,3,1+1(1//#3/,1#2!1&1/1/%1+1%11+3.1//3X,204/02///%1/)1/017!21/3//01///1)13&1/*301(1$	fj}`S@EN}dh@a`QFPrQQ[JJQZJsSECVlFfZjjZijj\HDPXbu@R@@					antagonist	mGluR2 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
(S>x>.(Shx(S>.>xxi(S(Shx}H>x>xqqhx}HH}qq^))^qq	;QvQlGUR9VWJ8MH8GFVNdL640Vc71@c2D27V205@FX!1!@110N2eV6433022!H8V!20l8G08F2502010	0PZ!Xs0IV02AV1D!9_07g!b!vV05JF1_07!Tk3i$ !6F483Z14Vk0G@F4D4E84XG4N30VHFt8RaP@50N46F7872mlcDC1VV98RZLEC_l0V@D910Wm0NwDRCVl0sZF2785XmWVc72VH115JT452FZJNoFH2132VXuBy893VVVkm4TY822F88NM8231m0VkF	#V0V!F%2&V)8%F$1+F$2k$4#G0F#5s(210V	.6/(3.6!1*4//(6$9&3/-1//-3/&4*1/2//2!1+1////%6.7///!6/(A/*2#1)1*1$1/&2*1,11/#1/!1/01//*2/107*1*2$1$2+2(2)@//#3///.i%5#1#3/+F/01//(2/,1!3//!1/.2//)1+1/+12-	fasa@@@`RYe[Yu^yf\}F@`jBBJj`aP`@						M3 / M2	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
i.=.~S(Si.ixi.~Si.=.i.~S=.(Si.=.=.i.=.i.(S=.~SH)i.i.~S`*:0|Fl0(OS(B,B,(O	=vzvzUznvyvUnfpQzufLyHrfyzlBdvzeM9k5C@Nf7F4MVAG10PjokDJHI4Y3l522F48J2QFFF0BVm0X8GV	0ZB0s!3OF1r07k!sg0bk3Z!C_07g0zF04AF110480bk04B0110480eF05NF1r07c0U03I# !m0X0L2cJ6E3Djl0NVBDM8WW3kR4I3W0c8RgLW732VcJBJ6m0YkG25DE22ZWFw4Z812XlRV8J782B1m0W0O1k8H4FIa0Vc82773Vlt0B5321kFF220V8Bwg11@82HWoX72WVV8ZXHC@A1sBJN414Y5qt88854I@XNNNBLC97mNVNaBKMY2NVcF8BDcVNRFDC10Xm0	#20V!3%V2$2#VV#1c@#@2#NW$Z8#9F$2o#44#O$BKs#28!219V	#1!2//E!11+201.4*2/(4!207$1.2&1&1//!1#6(102$1,2/(1/%1//+1.1(2&2025/#2%101!1!3/&2!106*1)1#1)1!101#4&1/#3!4#2/2$204/$5#1%4/0202)1#201//*4*2!1#6)1&21+2!3*1/(2%3.1%A!2/1$2/02/1)2$2$4/z!2!301/01$1)1B!4&2!2!1#1%1%202*2(2/-4#21/.4////#2(3#11033/,8)1#	ejY\DL@KBhSA`I@bPXdLbbbfJRfbRrbbRvTTRVxDbRVv~aqI`bBYjjjjjiB@JbCJbBR@					antagonist	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J)s6*Fx>0lF*xiS(0:(Sl0S~x>S(:0d,(WBz(W:0	;j;iru4SjQKcihvaHhHCAlN0P0Z_5HGFl@BkVVoB_28ZCa80c0VJFW0B5GFcZ10V1F0JJ0W0k01#V0FV	0Xw0IV03FF1304s!t40tV3c!DG0DN0u!5JF1W07J0TV3I& %O0FcDF4@3Z15VVoY4N8949c5cBFR8PNaVkVQSP4@2m0WFLs95P2E21_50NPC33ZGk	#22#1*12F#mVF$8#4Ok!HX8#FB!204#4Fo!2V5#21%F!242#9!	//(81,2&8//-103$2$2)1//&1)1!1&1//!111)4/)2/!1!1*1/$1$1/%1/&1+3/*1!103//*1B&2#2/1/,4%104$1////-1/1//%4#2,1$1&1$1//+4/01,202//-2/(_/*1%101&1*2$2!1/(2.6/+A+1-3#202/%2//01//11%1!3//	fju`P@J@PFNQQJJIQREsIRTuSUUTuS@a@@					antagonist	mGluR1 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
vl`*v:~Sl0~Shxh.~S~Si.~Sh.	vzUfvfzBrSxEOR1O8ENFA8cdm0HYc!9@eR01#F0FXZ!Y0X08@!40LJ2212!12!8F4%2!X0V0FV	0Z80IV04AF110480eF05Mk1W07J0jF3I& __kW084B61J@1NNJN114YImcFJ8	#60F/$VV#108/08$F%F$6#F3$1N!2%1!	//(A&4///(5+3/02+1//!41)3////////01/+1/%2/)5/2/(1/%2/$1)2/$102/%1.2/.2/////$2/&5////1-3/(1///&O#4/%1#2#1-1#1/*2///!1-1/%4////2/$3-3-4-	dg@@@sTi]YW\I]ZZjjj@@					agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.hxhxix>|F|``*lv63}Jps`*}JH}}J`*qqL}}Lyggy	:Uvzv;SzjvytzUjSuzvtUjEjjgnQCxzi@EjGj9EQY8Z7fmSL5FhAcYBR2n92X0qAOo02211Bo1sFeWB$	0WR0Tk025k1v!BM06J0Tk03FF120@Z!sg0bk3Z!Fk0440G01v!JF02s0F01209w# #JFG9B4D5Z120t0Fc@C26@X1VN886B6841Ogc30Z2H1XBeT12WlK2V8N541Vl0iF4@3Z14VVlWBeA510kZ8J@0VX2p08tP2B70XVwV8V782@121ncFXC2121cFB51223BV8B5Fc27WFGcs4L9Z140t0GV8FNN81kcR@93VF9Vgn8231m0W0F	!284V!104$4!18c#W2#1c#2%2f4!4c$8kF#Xk!804#G4#81c!2G#219V	*2!2,2+E#3,1/(1//05$1.2*31/1//&1*4/!1/#1&2/-1///-1/#1)2/02+2$1,1!3%1(1$2&1.1#102!205!1%1%2$1/&4/&1%1.2$204/*2/$2)1(22#1/01+2!1%401//$10281///#4)1/!1/g+2,1/04//)2!1$2&401(2/!2!1#2/,5//&2//#2$1#2!22$4*1&2-	figQC@KELBHIDYBLbbbrRfabbRLRYrVdyzNB@jfjjjhjPHaq@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xh.hS(S~S~.>.iS~.ixiS~.>S~.hxh.i.>.>S(	;tzdzSrpxhQR@zU38F38cA7E21_V0@88i2@2X5022X#304F1F0F88BJ3e412!21!8401#104VF$	0Z40IV02J03d!C_06k0U!3OF1k07k!o80bk2l!DA09w0t% %O0FcA_H4C0VFWFa84H213WO0GNAGV462m0W0HkKB8@W1Wk42498A4Yl8J@@10X1gV8N782@1m0WFFgZg683A8Icc@@E5W6G8NoBRD94lkVD50ZYmF	#8/&V2#4V%4F#dV!4V2$F$2o#44$V$3k!204#18V	1/!1/#B/!1#1//.6$2$1///-1*1-2/.1$4*1%101/01,5/(1/////.4/*1*2$3&1011/1.1(2$202%402)1%1#101#1%1!1/#2!1.4.2#3+3,1/1101,21///.22/$1&2(101/+1,11.e2//*B*201(2.2$1/%2/%2/(202)4/22//(2(2&1)201.2!1&4-	fnsP`@DJAWHhhddbhheEmaJBgIVjjj@@@j@@@						MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.i.h.=S~xi.ix>S~x=S~.iS~.i(S>x	;QvAnQURvXQDOI21INk8dHTL2VZo0DN9BG2Z23W0NX8F1B0801#806L3P022242GFG#A#80XV02F10	0dV0ak02R03i!G_07!Tk3i!Ne02o0FF1204s0eF0 0MhFVsJco492m0VkQcF8F3131g48FBP91VV8VVRaD5b1kVNP31W2X0	%V/*18+1*8F$2k$4#G%5s(210V	//(5%1+1!4//*2$3$5/03//-4/1/*2///,21%1&1/%2////*1.1&3/#3,4%5/(1$1*2(701$1+2%2.1-1/)1//2//*102.3&2/&1//04#3+2-1&2///+Z%1(4/+8//,1,102/4//.132/!1/.2/*1%1!1/3(1-	flua@@G@rJIJFQQXiRcKNbf@BjjjhiGBAT@@					antagonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~x=.ixixiS~.=S~S~x=xi.i.ixi.=	:xU9LNn1X604X2DX#2C02VV!1!2&2$F$412F04F28#8V)8#204%2010	0aJ0U!2Ak3V!930D#qJ0R01w$ $swTk3WlW0mNiM7X1lBV8F782417a0twDE6531qtRT8@4	)1+4%2#202$FV#1%F+Z#44$V$4k#4$50V	$2/,101!4/!2///0106$2//////$1////$1/-11#101/1%1/#1/#2/-6,1/-2//*3!3$3%4(4//(1-3/*1//.1,2!1)3!1////01(1///*1-1/U//+D12(2/*2/(1/+1/04%1/*2/%1/-4/01.3*1-	f`qA`@@R]dbbTRbbNEjwjB@hB@aR`@						Adrenergic beta	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=s6(U\)B,xi<w82x=)H+bxiS~x=xixixi	;jv:irvy:yx8DhgiTj7hiVpUcckZ7nG0W3GJ8cIwV3Fd_m24@0VJ4k!10PC05%B40kV82c!VVVFV	14w0i02z0BZ012w0D0110E401Kw0NF1p0Ao0ok% !2BT2312XlJLC5W0FB4J8@B7Ycw4@75	!162F*4$F#VX#1_g#4NF!FX$58+F#Vb#TY$1N!24$9N0	01//%@*1/!1//-2/*1//%1*4/4//!4/+1.102/-2/+1/1,1)2/$2//%3+103/!2#1)2-2&102$3///*2.1!13/%1//*2$1,4&1/)1/01#2/!1!1/+1&221$1//&S#2(1,40101///!2%3/.5+2/)21)1*2%1!1/)1-1#2!1.6/,1,1	fdyY@@NRuYtPYHhhhTdXdbTUjjjYijzQ@aEDCP					agonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~.=hx~S.h.i.>.h.>.h.>.h.>S~.hc{.hS~.hS~.>.h.>S~	=v=jzyvvUYSvzftCzvjf_oOUtdw@@aFbP3Qq8FLUZSkCH@Lk@ER2m02q@R2FN0F02v2k2V!V10FV0	0dV0ak02YF3r!C_07!Tk03AV1D0@k!sg0bk3Z!Ji0440FV2U0@Z$ 1Z12V_LdcBH7K7W1FX@8@H6YWWVkG4710Hl4RVC16Z120kL631GFN4630k88wP115c4o8FFM2Wlm8sS@23C0VFoV811kO14g8K430Vdo4421ksR633W2XF44TWZ130X48sH5A1k91BV8M9WbFFBD84YFk46HIB13lks6310FNFD44WVN8820dZZwV8Z78241	#80V.4%8#3cX$k$d#4ZF#8F$2o#15#Oc$5s!242!258V	)1*1+3%A1+12//$101!101/7$2+1#21/#1/&1%1/&3!2#1$2/!103/%5,1,132-1*2)1&2#3)12+1$1/)2,4/!61/!1#302$2/2!23%1)1#602$3*2/&1(2$2/#2!1/01-1#2///&1!6(2//(1!12$103023//2%1///+m*1/(4&8-1/$203/02$1.4*41/)1(13#1,11///1/03/,1-	fcq`@OUVCW\bbbbQrRRbbQTrcNRUdiZmAPEUUUSUQR@dEH@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hxhx>.>xiS(.iS(x>S~xixh|FS~lv|`~SS~~Sh.qqxhS~x>xhxhx>	:UvvvzUrOzvvT@ESOTtPQEnJBHph_NBBEUmCHk9eQ146d3VDmKVR41ZCFZ2IBWF0h5AmpXBs!61IFq041!V	0Xo0FF02@V1D!C_06k0Sk04RF1r0Ao0pV05101E0CV0qF3q& 03KN3351sFG0B4B5Z120gm@0BV7Z12Vt0GF9hHM4X3l9tJ8F5E@W2FgV8c4	#60F!R$4gN#21#VD#5d9#IJV$4!43B#10F!1gk!88D$dF!ZHk!874#30V	//(A/1$8#2-1!5)3!1.108$2!401(1/(1/1$2(1,1-34#1&1*1#1!3/01-1//!1,1///.1$3-61$4/$1.9(1+1/!2*1104!2!1/1&2,101/+3!1!1)111/%1/01/$3&1&2//2(1+21)3#1////*6/#l+4!1/+6$1)1//)16(2+1(1!1/!1(1$1/33-1(1//$11$4/,6$5&2	fcoHb@LDlFB@AFRRFJJUJYIJQVIHsoAWmZj`BFjjjhh@@					agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~S(.i.hx>.>S~S~|`S(S(.hl0.>|F.>S~.h~S`*hx>.}J(Sqq>.(S	<vv=jzqvUSijY7NNzwgnE9vQ3b6TZK20YPe!ikMV2YKe@@G48FV298VZ0f1AVDmZ8V2N2IF2FH080k	0WR0Tk02J03d!Bl0440IV03Fk1F0E4!mF0uF3x!FM06J0R01v!KK07B0Sk2x0CN01a80OF1n07R0Tk3F! $m0W0RV8V78291m0YkLQ48T5Z13VVW1JyD33VO0RVy6DZG1144B@L7W4m1o427XYGm1468@YkNVFHI95KkNNRCDx23153v4BR6JM8FmcOOcE4VWFciF4H3Z12VlIsFk8yI69G28VsiABYFNcRBDEM9VkkTF4D2Y14kFFsLF462lJXVl0N8FFA3FNgT2212lGONiX@2312G08Pk8W2W0	!175k!l24#cS#Pa#VB#1c2!22lV!V18!BIR#21F$o#AD#1VF!Voo#44!2G8V	02(1,1!102)B,1$2!4/,1/!3$3*1)2//(1#1#20210132/%2,1.1/*1*112*1//01/$21$1///)3!2#1)11#2!2#4+8/!301/&2$201$3!101/02)2.101!2%1#1-1+41$2/&104/#1%1+1!5$1-1/!1!3/%9)1/%1/31$1#1(1&1(1$1%m.1%501$1,@/!102/2,1%1(1(2+1!2%1!1)1025*2$4+2(1*1//$3#1#3)1/!1-	eg`\LB@M@heJc`HaJPrdBiCHhheDeEdiiEjidlqIXEyEA@APRUUUUPTCQ@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~xhxh|FS~lv|`~Shxh.~S>.h.h.>.h.	zrUtzdUSrKxxQNAUUE8G3NuvaAH2CWD92evXE2X5H3aea!X0aG9v01R9Rk1W5W2WA3X0gF58105F205X0V0FV	0WR0Tk03Z02U0DF011R0OF1r07g01480Ik2U0@Z01740Sk2x0CB# $A0k8H5Z12Vt0GkA9Z452m0WFRV8g78281O0ZaF90A8231m0YVF	#L4F$4#V8!1H$k$1V8!2&eV!408#14F!FHV*8$FF!201#A8V	/$3/!5/$1///$103$1//-1.1(1/&12%2///-1/+4/#1+121&1/-1+2*1/2!101/+2&1(2!11%1/$2!3$104/)21//(2,1$4011-112/#1/1$12.2%1//-1&3#4/#1///02)1#2-V.2*1101,6$1/2//#4$1/&13/,1&4,2#1/$1/-2.4/,4-	fluIB@FRMGPHaIe[WnUz\EHLX@aijjb`@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
hx)\6sN~\}.h~SS~.>i..h.h>.~S.>i.~SS(~SS~	;jvzUirrzxzytOjETJU_uhafq28VoxevOLA30Ck@DTV3!JaHNu1co0FFF10FAl1X!8Jl!V022V0X0Y0GV	0Pg!XV0IV02Ak3V!FK06Z0QV3C!G204B0c03l# 06F4D2ABcm0c4B866A29cFD865Vl1BZ94X08NgJL618e0Wk85411l91qD48213FtReE31Vt8ZZBAA61d82383Z7NsFJA8231	#XV#W$4F$F9#8@#@4k!12ok!G18$s!204#4F#1V6#2V#1BF#4F#58V	/02/%@/!1!4///!1!3/$2&2)2!2/(1(2(1///!2011%1!3(1////+2//*1/(3&1/&1&2#7/%205!1/!4$1$31(1//1(104+1.2!1&4#1#12$1*1/.2,3$2.2/#1,1//(2//(1/.X/*1//02-3/#2%3&1/%2!1+1*2)3+1,1+1/)2$2+1!41#4/$105-	fjmIb@HHXFeo@BLdRRRbRTQrdpPwjVjjjjjjBj@@						M / Adrenergic	Muscarinic / Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=S~.h.i.=S~S(.iS~.=.iS~.=.i.i.=.i.=.i.=.i.=.i55	^rzpyzuzbCaqhphbsDSbFxGa3V0aKYqH1HFdfRf7CX92_cC8b80o5XT0g1o4VF405W2@0V181Y4l0	0Xw0IV02FF1D!8i0@k!qJ0Q01v!DA0@F0t!30k3s0EZ0 $1gC24cFFsOgq4E6_FWVk4HAZ130YOsVBB7Z120t0GF842D41kVRD85XVsR2220JHP8J4F922NNL90Vmm044RNCAX3d4@21Z320Fcg@43W8kB5@@VV8G8n8261FVWsN8J8eBWWXkwV8F46E4ZGFZFA410FB2PI0VZIV	#82V*V!1%4D#68V$JF!FXV!408$4$6k$5#l$4Ic!204!219k	2$2//0H)1+1/,1*2&4$4$2,2#1)104/(2////!2)4//,3.2*2/2!7-61/$2//!C!1.42/%27!1#1///105/&1#2//)2!1*3%3.1//&4$21.6$1,1//1+33/+5/.1/*1+g501/&401-8(2/////2/&2+2/!1%1///%1#102//+	fekQR@AZ`cAE@|LddqbafTRVRRRPXmUUM@AUUPbeCB@@					agonist	S1P1/S1P3/S1P4/S1P5	S1P	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi.>x>x>xi}kx>xiS(x>.=xhS(S(S~x>.=>x}\S(psW~.>x=xh	:Uvzv;SzdvytzUfCmzvtMiPbAaoQSxji@7bGbC7Qq90EeZJL52R3c2DR2m94a263FJ#21Kk0F!V%	0Xs0IV02FF1D!8M07g!WR0Tk035k1_07g!ms0FV2U!C10480eF03Xk2U0DF!sg0bk3Z# !1M6W2FW1ww69F0Wl0Wh2Y452O0FcDF4@3Z14VrkcFV88W38XscwJ4C64IFVPDC30kWG8G2VE22l0N8ms524WcncNBZ39X0lkk44G84HVJ683VmlOQBZ4D64kWNaF463Z160dVHlS6438X3FWZXG22Wlsc4NF_18a4kFsE8231m0W0P9826A3m0W0G0WF715l88VHGY0W1kXd4LQ9WGX8k56R2X5FNoF50XYmJ0N8kIE2VNWBOHWBWWFmGx0H4322LeNB86zF1FkVOooJ7WVVkcNTNE21NFDDA7EaW9BD70YY1kksiHD1FksRR	$4V!104/8$VV!2&d4!4Z$8FF#2k$4#O8#81c#F#218V	//(E/#1&1/&101$13#2(106$2//03///!1*4//.2)1/0101!2/.1/*1!1%1/0112/02&2+3*3/(6&2.11!1$1/203$201(5+4//-4$104*2//.2)2$1.13,1(4//)661$1+1$1*1$1*4//+30l/,1-6!1/!2/!2(2&1/(1$4/03)1(5.2/!3#2#1$2!5/01)1#3)4*1&2)1#	fcopa@MQrjXH`dQdTTVVTtTRbtrReYpN^c``JZjjjjZJ`z`@					agonist	Opioid kappa / m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.=S~x=.i.hxiS~x=.hxiS(.>S~x=x>.h.hS(S~.h.>S~	;UvOzOMrxYzRPQH11HA8c4ia20_Z8@c8B220X1230X#2V1F108H884J3X40H0821FV042G2F3101V%	0Xs0IV03OF1g07#o40FV2d!C20@Z0gF$ #AB_HW0820Z4XBV8V4NVA6Fc821854O0Fk9BeL7Ykk82FN8m0YVF	/%4$V@#7VX$oF#1V!40H#8F%o$4$V$7k!244#58V	.3/(G1-3//#2/(6/&1-2/+1/.1/)1%1//%1,3/1(1+1/&2+1/(1/#6/!412/1$4*1/(1/305!1&1,1%2%3-2/02$1.401//!4,1$1$101!2(1104*2//%3$1)22+2/(1//+3-10i*1$2/*8$2/2/+2&3,1/01/&301(17/!1///2/03/02*8-	fi{q@@EZjCIEDdedhhddlUNRbWMZBBJjjjjb`@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xhxix>xhx>xhS~x>xh\)s6S~~Oxi^}w<~Utn	:UvzvzfzSznvydOIf1OUAv0a27Ack1BsWx@2gFb861eB0DA!H50@0k2B42m!2W42HF$90kF&4!	0Ww0Tk037k1_07g!o40FV2d!DA09w0t!4AV110480bk! %m0W0NFkg6736YGP8Z@633O0GsDF4N228XGN8LG782lkN28AAm0ZVRV8w4T690FkoJDI1YlF82@CBm0VkF	%V!204$2.1V2#P$@c#BZ$BF$2k$5#C%1$28#18V	#1+2+2!1&B//#1.1)1-3$1/%1#3//+4,1/02//(3/,41*1/-2)2//#1(2//,1!32(2#111#1#2!1/*25/2$1//#2)1/&2$1,1/03&2/,101/%6///*1%4!4///06/0202/)c%201//018//#2-3$2&11/&2//$4+11/%1$2//$1%2)5/+2$	ffcQB@MQTCDRYWUnY~VcGAKV@BYjjjhjAbH\`					not given in publication	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
|`:vS~x=lvxhxix>xhx>S~xhxhx>S~	vzUfvvzgrOxEvwl9@h9uDdBCP0IAc!8zHR21O0C02IqZ0R1Va80880oHX427G290120G80F010F8)V	0PZ!o40FV1D!C10480IV035V1Z07c012s0FF1407c% $1Z120VZ2oa2532VHdke@30W88ZBH2GBlcVRF2FG5Vcc2814WXFGSJT1XWGRV8J5m29KVWk_vJ884iQ110V	%V/$V$48c#2%3#208#BF$Hk!807!2FF#B58!2F$d!	//#2#H/#1/.2-1#4$2/-4!1/%3(1$1$3///.1////)1!1#1/////!1/01*1,4//$3.1//(4/.1.1(2/03/2//,1(1/#1///&2,4/%1(3-2&1)T-11/#1/%1/2//$4$1-3!1/*1%2///$1//1/,7-	f`q`B@I@BDie_YUqS`jYjjjj`H`@					agonist	D2 / D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.ixh.hS~.=S~x>S~.h.ixh.hxh.>x>S~.hxh.>(S@,@z)I)]1n18.>.i.h.>.>S(.h.>.h	:UvzvzszSxIvwlzFvFvj9yHO07fg39Nwwz20s0W1GG3!_1V840464kWTB2286Fc020N49@08B40F0F2BV0FF	0PZ!Z40IV02OF1v!@C0ER!mo0AV11!C204F0Tk03Z02W0DF01K40OF1r07g0U!6JF1_07N0Sk1w0C$ $38251m0X0RV8R44273l0wB84Vkk8FPGC62kYGkN99X51094RPj64l0d0Jk_@ZG1VWaL4B2m0WVFJVk245X0FVZN43XWNFD9410V82VN1V_ZFkRD24Gak88c8S@WVYGFNLR86l0BRmEZ150_L9sBg61111cgJA411FZF3110@1C0J63WbYNFa282_l09JZJT@XnVdJM8241UckX884T7Z130VFNcD54XFsJF93WFVB420VF@WSF431X0V8J741lNoD331Z3P086D@61ccL20_6X_QB6345X2IW54620GmkvlF442OfkFNVBD6D0GG8B1532X044PL87W5k8@06I50Z1W2p6B472O0FNCNN2341gq8FoA8281C4qF86@D5	#A0V!188#X8!102#V4F!19@$1$Y8#48#9F$2k!845#O$9GN!202!210V	(11%1(3-N.1)11//+401!4$2!11%11*1+2/%1/04-1*2%1*1%1,1&203*1%1!402/+20201//#1!1/3%4$42!1&4&2#2-1/(6!1#2/&101+101#1$3&17+2,51#2/*102/$2&2%2!3/#1(1+1#2,9$11.1!11(1/11*D!1-2%2+2,101*1102-2/z)1/1%211&E1//(2#1+2,1211&2$4-11%301+3*1,1$1/(1#1+1(1#3-11,@#1!112#	en]\D@@DGN`LTfVYeV_]}eUU^wSrrHIHzxFEjB`J@bjjj`BZb@PHdT@@					antagonist	M3	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
F|lv*`:v36S~*`0lF|0:(S0l	vxUYnWUBlGJRIJ08DC8V282d01F180204IG0130B!k8010V0Xc08!JFF!_GF0V3!104J%2#VV0FV	0PF!lN05k1u!C20@40jk065V0M0540O01f07c$ 38281m0VkRV8Z78241m0WFRV8J4	!204#904!2B$2G$X#6V4!204$V4!70O#44F!42k!90l$FF!89$HZ#9NV	//(5/#2&3/////!1/-11*2(2$2/////#2-1.1/////*4//$1,3/$1///////&11/#2//+1/(1////(4!1*4///3/&2!K/*2/+7/*3/#1,7/A!1/&1)2&2/(2%1//-3//+	dk_@PJePbDBDfVumImNfjfi`@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~S(.i.h*Fl0S~S~.iS(:0~Sxh.>.>S(*`S(*F:0x>S(xhx=x>	;vvv;xEyvqvSThBfzseyLOnM8YEMbHI0Ca0VP8oc6WJX2et_8YKKlJ8cCOHtWY02W8FJ0X04F#1kW0FV	0QF!WR0Tk02J03d!Bi0440IV045k1_07!Tk04FF1407N0Tk06JF1n07J0TV2w0CJ01ac0Rk1q07g0o03K! 6F4@3Z120t0G8DF4H3Z13VdbkFk8AJ5WWklGpu693J9mcNVB_851YklKc8T4mO13FaI88X5Z130VaHZD8K4IVXK1J8B6yI11VZs8pFK24Wt0FN8FZVK0VFkkOXn241O0FcDF4D3Z130t0Gk8LVE31Wt0HV@Ow4B2	#b4k!9Ho!31G!3HDF!VaF!Bc@!2V_F!cA8#48!3FlF!Z2o!8mb!2Of$Ws!@1C!21EV	/&1-10G/!1/#1#1/#1012(2,1+1!2-1/-10202/%2&1*1)2+1%2(1)1#1(3.1-2/(2%1//$5%1/$2*1/(8$1.1&401/*12*2*2%211!2!3%1!1#1/*1$3$1)2+1$2.1)1/%3//%1/*5%1!1$1$1*1/+1#1)1$1/0m1+3#1!1!1011#1!1&6$1.2+11!6+2#1!1)1$1-9%1/0302!1+2/&2(11(3/$2.4&2/-3$	fcIB@MFlUPHcHhheDeELeXddXdrQkQSUlDCESSUUUQL@@					antagonist	CRF	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix>S~S~xiS(.hx>x=S(x=xiS(x=x>S(x>xh	vzUQvQztMSxYvwuU2fGPENg4T63dh_2Nd8BX3FX10@0X!43V2G1082884o3X4520229!1B2O0G01!V%	0Z40IV025k1v!Bh02s0FF03FV2d0A4011R0OF1g07g% $684462FB0ck4@B5m0X0RV8B6DQ230VFVNFst4X3FF8ZJ2kGVW8B2DG7BmkWkLF4B28F@HFWB22D5	!104%4/6#5W#204F$V!4V%FF$k$4*3V!204#18V	//(F///$1/04$5///!1/#1/-2/////02/#2#11//1/#221$1+5%22-1/1)2(1$3)2*2/(2%203/(102#1//)1/!4*1!1/%2/#1%1.2$3$1/%5/.3/////!4/b%2//$8/+2(34+2//#2//&4//&1/!2(2/02%1/%@01+	fj}PB@BFADILrsolkkIZMELDEEUUUE@@@						M1 / M4	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
vl`*v:~Sl0~Shxh.~S~Si.~Shxh.~S~Sh.	vzUfvvzgrSxEvwWO8jONA8ghm2Ifc409feR21!1F2FXZ04Y0X08@80Z0LJ2212!120F8GB0F0F02!X0V0FV	0Xs0FF04AF110480eF05Mk1W07J0jF3I& 1yX240FFFJFgYDW0V8NN1112H7@JB663	#60F/$VV#118/08#8F%F$6#F3$1N!2%1!	02//%I&4///(5+4/-1//!41#1$3////////01!1/(1/%2/)2/#6/!1//-3)2#2)1%1/(1#2*2/.24/!2//&2///2$1///*1*1!3/(1//%2/W#2/%1#2#1-1#1/2/-3/-1-1/%2///*4/*3-3+108-	fdep@@@XteKkJ{JxHkPXmMUUUUT@@					agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
F*p3J)~Wx>.>d,S(S(.>S(x=.=xi.ix=.=	:UfzfzBrSxzOROO8EOPA9y9yOHYcZ09P@S29N!N@laZ087VVF18!o0aJX2120W12VV8FB28&V0804V	0UR!Z40IV02FF1D!CZ07J0pV06AF1104F0GF1p0CN% 0KWkFB84jH3W0s44@@1@91sgJ50VHFl89@f6W1FkdBwE7Y0c44F681e4OJFB8aU11kgV8J44DAZmFVB424XV88Vc2B84XswF414XXF	#H$1%8k)VB$dc#2%X$1B#44$qo#4E#F1$FN!@12#1!	//(G/$1/&301/&8$5!101#1*1/+1%4(2102&6%1/02%2/////$1+2/*1///*1///&4&1/&1/$1$1//!1///%2//$4/(1//+2//-1///&2!1/1/X//0101&1(3///!2(6,2%22/01/01///02//#1/,C(2$	fdya@@L@RVYWvUZ\diijjjjf`h`@					agonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
\}zd6sO~x=hxxixix>x=xixiS~x>x=xixiS~x>x=xhxiS(xix>	?wzQxjvxxfE_duihwCSA7AZg0Nv4g2Vn4Y82GHkJLGF8F4082V2842206#20J0482@0s!@#6030	0aJ0Tk02Ak3V!DA09w0t!3Y03a0Dc01Hs0FF2A09w0t# 01ssLDD1ks4VP215Zt0FF9wPE7Z0NF4FA8CkkkNZB227218ZPC7WVF442D6VVGOt1Ff35WZI8VTO0XGlNs45022XFNZPC2WVkN@4110854R2169XVlwZJ2XGlcu66472	#80V*4*4#19%2$X$4$8F$2k$4#O8#818!2$210V	/!1/$K!1+1!2*3%1%1(1(2(6!104$2//.1(2%2(1/////(13(1%2/)1/$3/$2$1//,71*1%1/3!1#3&2)1//301$401%3/)11!1%1/1%2-122/%4//*2!1,4//-2!1#1%2!12/!1/&2)1#1//)j$1503)1/1&@-1)1/#2!6//(5+1/(1///&1!2*2$1$1#1)11/03-	fe{`P@D@mtZSLkjlzrkIFMfuUUUUPPLQ@a@@					agonist	PGE2 ( EP4 )	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=.ixixix=x=xiS~x=xixix=xix=S~xixiS~x=xix=S(xix=S~xixiS~|F|`lv	:UvzvzvzSzIvynUFvKQUvfLu2YfZ6QRtfze5Wl13I9X6F_0Z0206AEw1DJ2IB_Ff722LZ16280F#kV0V0FV	0WR0Tk025k1v!BM06J0Tk03Z02W0DF016J0Sk1v07k012o0FF120@Z012s0FF120@Z01L40O01r07k0ok$ 015cF88@33YFcZH1C76bL1F68E4m0X0RV8F42Q80VVFBF620ONkgv321Y0wV8c422Ba1tBF31ZXHHAVe6432O0Fk84675XGFRD421kF8420WF@GB620Vl1k844AN4Lk8NZBFSO3G20V48@6318JD73VkF44310FV842K6@VF8oJE7YWFN8130nGtc4473X0VZD43X0VF6310V88221A4F8826C10XLXPkw6452@mFZNE133lVFZF84218ZD531FddJ220VV88NR215e1lNgTB7XkVJ62A8VV8Fsr82310VVcZH94X0cND50VVF82219_FF9B42280VGkB4LkYVW3FW1owV0XZWF88DC42W8ZB81VFF46210V844eE1VFWXsBBE54GNg@61VkFF4RFDm0VkRV8F4	#34V!58B#V%2#V8#1Ve!201$VJ#48#9FF#Ho!144#98#1Ok#F2#10V	/&1+2#F#1/%1/(1*1*225$1$1/,1&11/$12#3#1/#4(1//(1/*11!1)1$4//!3%21!1)3-2%2#22&22%1#1&3*1-1!1%2&1101+1$1#1&1#1%202!1/&4#1!2103/!1(2#102$204/)1$1/2/#2#101.6#12$1*4/*1#1(20A%1//#1+1+1#101&2%3)x01/$1!3.1B/+201*2(1$103,22.201&2/1)6//&21!1-1-2$1$142)1#1#1&18-	edVRHD@IOF`Q`H`bHrJJKKJIKJIJEJZIJYL\VNYEWO@ppPEUUUUTp@TeE@dP@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(S~x>x>S(S(x>xiS(x>.>S(xhS(.>x>S(zdW(x=.=p3}J.i	;vzv;pzhvztzUjCmzvtUi@bEZoQCzji@7bOb97Iqc07eaJL52B9c2gR2k98i223FJ04021Jk0F80V2$	0WR0Tk025k1v!BM06J0Tk03AV1209w!o40FV2d!DA09w0t!5J02E09w0t03c& %O0GN9BJ75amckV6122Z3ItJg953W0FVqF4B3Z12VW5GRo110WkVvc4cL@140wF88F464ZIkkL@2430F8cZXc6bG1NYgc4J62FWsa844920XX1Bc96W0NFcN1155iXVFsg2A3m0VkMF9SJ2I2m0Y0FcZaT4XksN2HD10Y2bF95J2D2m0VkRV8F4	$4V!144#4%F$8$VV!2&d4!4Z#18FF#2k$4#G8#81c#F2!218V	*1!2/)D/!1//1&1$2(104$2+1-3+1/1%1/!103*4//.2/-1!2///*1!1,1%1/01%2!3)1%3*1!3.2$3&2!2/1$105-203$301(2+4&1/*1*2$205*2,1,1)1/#2/%3,1(4//)661/&10201/&4//+10i/,1-6/%1/!2(2&1!1/*4/031&2)6&1#1!2&1%1(2)2/.1#3)4/!2)1#	fmwqa@MQRioPQAHaIf]vye]fWYpLQs``JZjjjZhjAb@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)SS)}SS}/hwhS}/>S}/hwh/hS}/>}S)SS}(LS}/hwh/>w>S}/hwh/>S}w>/hw>>/)\S}/hwh/>w>S}/hwh/>S}w>/hw>>/	=xUjrbrxzAjxjp@5HgHf2fDR!ZZ!G086BwV0i!8V2I40Fk!1402Z$o%80c1V0V408!3#	0qJ0Tk1w!C_07g0U!32k3U0EN!kg0rk3q! 382D1m0WkRV8V78281m0WkRV8F4	)1/0V2$5%F#FV%F#2&V!8Z4$7$FF!25$18V	.2/(6!4/!4///8$4$8(8/+2/%2/,2-2/02)@-4+4//+4///02)2//04!@//(8!6#4//4)6$60B(D//6/,2&8&2!804/@/-2+4!2)2!24-2/02$208/2$42+2)404/&2*8(2,2$8#2%z$2/,682%B/02&22&4,2//#8#@!2/&4/(602///$6/.2(2$4%2%	e`TGDBMeXDLO@hdbnch\V]P@bpHpzKmiUgIIKEDhmCHFheDlhiAuDheeEIIhXxm@@ABsUUSUMUUMT@@@						M	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>S~x=|`S(xhS(l0|FS~x>~Slvl0|F|`	:UfzdzDrGzxQTO9ECRkPfAdeAm6cV4B6Ix897G508biZW2cLqu4sV0J0s0epGN9WW0VW04J010VF20c0VV0FV	0mo0FV1D!C10480c!5Ok1d07J0jF3I!LD09!c02W0DF01qZ0SF2D09!c02W0DF# 38201m0W0RV8J782A1m0Y0RV8R6cF2318LO0BB6FX40ksO14JE2310	!1r4F#4#608#TN#V2#10B!104k!9c#24c!20kF!ZHF#mJ#4G#11F!40X!2940	//(9,1/!1/+1(2%8!102)1/%1/)101)101$1(2//01/$2/,1-1)201/01+3.12!22/////)4&2,1/.2#32//.1!1%1+2$4+1/1!1-1/(2//01,1//%2,1/01$1!2,4//-W/*2#5!1/$3,11*3+3//%7%1/-3$3%1!1/&2%2//2%5&104/-1!	fbmh`@DXx[pEYEEDhddikDfBtYNVjiejjjh@@					antagonist	A2B	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.h^)}^.iS~.>.h.i.>.>.i.>S(.iix28D{=x~S/j(Q.>.iS~.>.h.i.>	=vzyrzy:ytmErzPSfrS:hxZwFlfdWMPkG6sofoc45KeJ05I0@c0vL#BD0Jg0HGG8FN!2V0X!V8FF	0Pg!Xs0FF02AF1D!9J0Eo!sg0cF3Z!GX06J0Tk3F!Fi0440Fk3l# #Z6D8XlFwB61Vk842R@D9e1scF70YXGmwo8F411XFsVNC4XG0RD41b3k88o22@Fm0WVIshBJ45X12@Bq531F90VVH_I1YH08gHXI22W2HkBcL582GVBBNF8U_0VJJB@C8lF8VgFv722W1WHJF9BW1lcsLy452OgFVVFVm8AXXcko622547b0sBF611XlckPE3XFsB42172nYQBDE43XFJNFF8	#A$18%4!1F$VC#19g$nF#V%B#8N$Hk#W4$8#1CF#4$12V	,1/*F#1.106//%1#5$1$9$1///#1#2//*3)1!21#6(4//&1)1/(1(1/$1//+1*1(3/!2.2(74%1%1(1+1#1-4012!4#2$1,2#2//%312!1)2$1.101-2//)2!2&1+1.101#3%1%1(4#1/+2#1!102)1!12*1!1/#1%m1*1!1*2%1)5$1#1/01/#1)5-201,5*1.1!1%1+1%2!1/+1!1%4.3$1!3/#3(3(1$	fkpc@NZ[XxIADabPrJPqIKISRJIGJIHTbuv^j@BijjjjjJPx`m@@					not given in publication	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x>.hxhxi.>x>|F|`lv^}x>>x~SS(xhixix.>x>~SS(xh	zyzQuQtnEsdXYqA7FcGskO9LJJ1Y@39DxMDX58037AG31kS40P4V0wGXW082O82F0VHBk0221XBRCNFX1R08!	0PZ!aJ0Tk02J03d!C10480IV03FF1204s012s0DV1407g016J0R01v0Eo% !BV8J4aU7_VcRNHBML_GFVNFTS95FscNHBKJ_WsVNF@TJ5kFcJM8251m0XFFdNcL72FV8VNF4A_GW0N@76YhKsFZA827112ZGJR930m0t1siH@10VkVQ82A1m0XFRV8F5Tp221ALsFFA82D1m0XFF	#90V-2!V)8%F$3%V#8%2o!805#GV#80s!2$211V	&1/+2#D/!1!1/#1/+@01!4/%3///+3)11/&1!1///102//(1$1.1-1%6/+2.12/$1/(6//(1(1!2$1/&2*4$1/#1//+1/01!1//01(4*103/,1!2(2)91//04//(1/%1j2$5$3-1/D#1/#12+2/#2)4/1/+202(121%1/&1/0102$1/!1(1#2/(6-	fi{aB@KDAHILrkjlrjzpRmY[AAEUAPTTPaQFb@@					agonist	D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
>.h.(S~S>.:v:0h.h.*F*`>..h.>h..>S~.h	zrUtzdUSzKxxQNAUEE8G3NeQaAH2CY492etXE@X5G2aea!20ZF9v!R8Bk1W5W2W13X0BN50101F#Y0V0FV	0t!bk3Z!G204w0bk2d!KG06J0Sk1v07k01LF0SF1r07k0ok$ #38241HjkW8Jgm4C2m0WVRV8c78251	#I1V!188#V8!10H#V%c@$1$c#408#14$HZ#4$1$1FF!202#A8V	//(5#5/$1//,2!103$1-2/,2/*2/&1(1///,1//!1/)1/&1/1$1%2$1.1+1/+3&1/!11/$2!3$1042/#2//!1*2,1$4*1%412//*11#2%1#4//&1+1(3#7////%2)1/!X.2*1!1#2(6/%2//#2$1)1-3//$4,2#1/-1/$2!1+31/+4-	fluq@@DLLAIfYU]VYFUhJVjfj`bH@@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
7o]yI--I,S77Iy-]-]Iy3<1cS~2C8i*>S,._.Gu?<3G.ugu?ugu?ugu?S,ug	?xzvxjvxzfE_fuihwUSA7A_g0Pv4g6Vn4Y92GHkJMGF8Fa08HV2842@06#20J24c2@2s!@#6830	0Xw0s!3OF1k07g!sg0bk3Z!DB0DN0uV03903d0Eo01Hs0FF2A09w0t! $kkcE81VkV2210n1V44JPJ43GlV4G143F88gZ2311FNB@73WGFVB52WkNB431@ZFF8w2126BO0FF8NXE65W8N4FG2108No22ABDYld4R923Y1mdsDD8VW0sgU827110c0VFP45XlFND630VkFsX117VVGe8s6XAZFFNRP115476t4BH6JFbH08JJ@14YW8oN@5Wkk442173FF8gwcUI2W1FWmF472	!180V*4!2&4#19%2$Y$4V#8F$2o#84#Oc#81s!2$210V	,1$1*2#1$L$1!1%2!2!4&3,1(1(2(2!1041#2///(2%2(1//!1/01(2/)1301%1%3/)1+1(3/*1//,71/11#2!3#4#3!1#6#1!2)1-1/0301$501%3/)11)1!1+1&2-122%4.4!2//&2/3//*3%1#1%2!13//*2)1/#1/)p.1%5,1&8-11!1)101,2!3)1/-502%1!1-1(11%41//+1!1!2*2%3(1)11/031,	eo`XJL@HbKFkg`IABPpdLbdJbRaTrTTRQRRTdTrjjh@JjjjZjfI@p`H`@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=xiS(.iS(.=S~.=.h.i.>.h.>.hS~.>.i.h.>.i.>S(.iF|0:(S0l	:Uvzv:rSzjvyvUEjNPUPwUTE7jhW2SfcgVAmmWF80XV053m2G_F1088Do3X4CX0229!OB090W0106XVV0F0	0WR0Tk025k1v!Bh02s0FF03FF1209w!o80eF2l!FM06J0Q01v!HD09w0cF3Z& %W8DC@ZW0FVg210VmGOZPQCW0Nkw22C7g30VsLF4@22@VW0BLG4Y0k841175F89Bwm@41m18H40VHX1J94462FXmO0P76837IdcR154XkZFFg8F@A_m0cB21Z_2RV8B6u72311GNoDB8XkNFB420F9lFsqOFX0cd022D632Wd4ZC4WVF4420a_3RV8B6u725111VZ876318c8620FF42VLFB621BH613ZWwV8F4	!104F$J*F$6#5WF!204F!cVZ!5_%FF#2k$4#8%3V!204!218V	/,1*L/$1///02#46$1//,1-3/(1!2&4//2-2)1/0101!2//-3+1!1&2)1#1-4&1#4#1&21,1/!1$2&1$2/11/$3$1(2+102#1%1/#6+101&2*4)2#1/)1/2#101.2$3/#1&1/!1*25/(2/*14//-p(11$1*1#5#1&6/!3/%2&22/(1(1#2-11%202+702//1#2/+2/04%1!4,1$B#2#1$	eghRHD@FKFia`H`bHrJJJYPiYIQIYJZI\BFVEUGWPQAUUUUTuTUHARj@@					antagonist	D2 / D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
ix=x}H(S^)3pB,}H.=(W.i.=S~.iJ).i36S~(O	=v=hzyvzDfBkeQOUjbYAhYFAhKgX36mZ08IG!5A4MGg2ZFec@Z3sJ1X0409F08J012W4146J4V0F0	0Z40IV03Xk2W0DF016J0Q01k07g012s0FF120A401JB0G01k07g0uF% #1@14aVFsLF483Z13VaXV8wM55XmYFFJ8I24WXm08ZFH984Wd8L310HWOF_LFF22G084oT82G0F@HA9m0WFF	!1cVk!2F$12!14W$@#6VX$JF#dV!4ZF#8F$2o$4#Gc#83s!244!25BV	/,1*E*2&101+2(1/&1#6!202$1*101#1(101.1+1.1-2&1,1/%1%11$1/01/#3(1.1//)1////01/(3&1-1,1/1$2/+1/$14/!4//&31-3/!2(1+1!2+2(1*11/,204//)1*3%4/(1-Z&1#2!1#2#101(11%6//#1/-102/#2!1/&1)2////*1*2)1/&1!1$1	fbmP`@DRAEIeYWyefR`icejjj`Hbb`P`@					agonist	MT1/ MT2	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>S(xh,jS(.>S~x>S~.>.hxhxh.h.hS~S~W~zB.>.>xh}\ps.h.h.>	:UvzvzyzS:vTdvEzSsvdzCrUytgkJCjrx2Az0b8PzigoDjFoyCng0oJE4erG2fW_DGl86B114kFV)	0Xo0Lk02OF1v!C10480eF03Xk2U0DF012o0FF1M05g01_R0Lk1R08g0bk3Z$ HINFNA8221L73NNNC@J24mNcVJFAB318kF73ZXmHWoZ8A0WVkoG0482@fVWt04P815X0G8fcJ48F0WVmcV@_DXX1KYV8J5Z120f3VFgq29331mNZF8830NR6LCAA0XORa@F40YW08ZR	!294k#e#486!109V#4#1W@#25F!9tF!4V5#@JV!V2k$Z#GNV!AG8!22F!2W@V	/.1(A/-3%1%1/*6$7$1/#1%3)101$2$1&1+E%1/)1//&2#1#2(2////!1%1-4//&3$1/$1!3/!101&1/+5(2!23!204!1#1)1/-1/(2$1!1//*1/.4.4/1+101$1(3(1)2/%1#3/02$304#1/&1%2*t%5/,2&@02/06&5/%2//2#262-2/$3////%7,202)4/$5+	egdTH@@DO@LbbbbTTLRRRbRrRo@dSVPtrqusURtpUAUERtT@@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
>xxh=x.>S(.i.>.>.hS(.i.>x>S(S~.>.h.i.>.h.>.h.>.h.>S~S(.h.hS~.h.>S~S(	:UvzvzUrSzpQBAQ3ULkAcek6LmJhV08@PxJ312188se4W1a02NW#R8RJfYFH3W161XI0401!F382VV080F	0Js!Xc0IV02K03x!C20@Z0gF04YV2U0Aw0t!5OF1e0780SV3F!OQ05k0YV2U0Aw0t& #sgFA9_W8JBHG9m0VVG0wPK53GcN4HF984kOJu633XlrmN8D4P5a1G0J2753VVVgXC9XG0N8310IHGiF4B2353mNgPA31FtGFc_G0WXkl0VF36YlsgF420Y2GaF4B2251GVcJH5XFcN41C8aX69oR8@4m0XkRV8N4F94X18NB952FkN82D97O0Fs8wa4L4Y18sV60YYXFcZP4511Fo653W0884318ZoFsZ6421G8ZD95WkN86410F@O5B	!2E2F!NFV!64%NV!V6F!4V@!226F!9ss!Bpc$FF!42k#ma#c9#HtF!@_$18V	/,1*@/%J/#1/%@*3$2!4/1+1%2)2)1*4/(2,2/!2-1!5*1,11#2/!2#101%2/01/!20102/(1!1)401#2/*2)1%E4%12&4#1(1!1,1$3$103801.1$2&21//1+4&4/2,2(1/%1/01$2#12/!4*13!1!2$1)3!2!110102//-1/(101*10w!111!1#1/(2$4/+1,2/3!1/*3/1&1$1%62//%2/.1$31&6,2.6-	elZVHL@JIMLacm`IABPpdLbdLRTVdTjVRRTTVrdDdRrn^j`@jjjjjiejb`@@					antagonist	D3 / D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>.hxhxhx>x>72o2xhx>S(xh.>x>x>xhS(xhx>x>S~x>xhxhx>x>xhxh	=jzUrvzjUUUjUCwvPQOvjfeb_cPBTWy@97KC@3WXVh39q1mVHa7k8c4XH8840y@0F4!d102202V806030	0Z40IV025k1v!8M07g!lR0OF1v!DA09w0t!3Y03a0Dc!oB0J03l!B704!xV$ 044WVt8cG22VN4gFL@Hd10J8B860XVkoN@6XGFN85B4VVFlgB4FW1313KGZ8@331WWc@R6440FFciF4F211BWG8ZPA5X0sJ85A6VkVFBHT89YXFZ6376VV9NBHJ_HXH8VgI82@10VG0cJC42FsR822VVV90L4111ZWcFTF4VFkoVR311F8kJFPQ@YHl0JNAZ11Vt0GN88@562l0g@84VVVB2RD4VFFN_4HI91H0d88327VVGWR4JHoA2H8VsI8231m0W0FFJH44YGtN@B25XHkFoTFA3GNJ61@4_0kFwBH33kcJL520nG9dgsU131Fsc4854Z18cF94Xk8B42E57VFNFFD51l8ZH811kV82VA10X4FFF8G4W0sgJ63XFF44TC20Xo0	#@7#1@4#1Z!10V#F@#1VV!20k#VX4#JJ#8oF#2k!484#B3F!V_#751!211V	/)3-J/!201#1/,3(1%6!103$4///(2,2$1/#4%2/!1/$1*1%3+1!1/)1//1!1%1$4!2#2/&12%32#@/!1#2/0106&2-1$202$1#2!1%301$6$1!3-4*2/+3%201$401#4/(4/!1/22$1&1$1!2/%4/*1.5//////#o//03!3%6)1/+1%1,1*1,1$5101#1$1+22!201#2(1)2/#2!1+3&1/%1/!2)4-	fo`s@@rU{h}`bBQ@`cHhhlmHUEEhdeDbdf\``IZijjfjjHFh@@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
c{5q~S(Si.ix>x>.~S~S(S(Sixi.>.~S~S(Si.=.(SS(.h.>.>.hS(.>.>S(.h.>.>.h.>S(	;vzvzvzxznvyvUHvGQzQzLy67fhn9Tttze3omY3UOn8FbAVAIW0BLsfDo3uR7HeB2OFV1T098K1141mFV0F0	0aJ0U!2J03d!Bh02s0FF03OF1v07k!t!cF3Z!G_06k0R01v!Fi0480eF2l!Ni0440G01g07g0gF$ $6F483Z120t0G08RXHAY10V82984VX28aP0VWlksFZC@XFNNF920FGW0kP@0WGO4TA41V9OF22G0VYnGck843A1886HH10YmVFgJ34EVWsoT821kc8Ze10W3YwV8N4sIBY1NJNNBRE5HFFJH@2B5kckJ@6Z3XBV8N5BIK1XkpvJ8H4oN13FgV8N44773lVg@31WkVF@40VJ2H0BH92290VRP83Wl8F8210kGdN22GH5_2NRF822GN8cXJ252kF8L@52l8cD1175VF9FwLC20XFgPB4W09OF22HB12lNPF423X1FwJ2410N44PL0VZJMmN8J5Z120aa9J88D40VWFR@10VkkRH851FNB@31VF@dV22I0VYpk	#W0V#N$1#3%V6#5d@$5F#WV!4ZX#8F$2o#44#OV#17s!206!21BV	)1)2#1.K/!2//$1-4$61#1&1&1///,11,1&2/)2011/#1#1)1,3*1//+2%1/.2$4+4&61012-2/!1$1&1/&1#1)11$2$2(6+1%1%3!1*1*1!3!303#12,2020101!2/&1!1!1/$101,104$1#1,101(1/-6%41/2+1,1)1!1$301/*z)1/10101#1&J11&23+1%1011#3/#1#2&10201,202+11#5020302(14/5//01#1*1#11,3-1!1%1#A#10111$	ejU\D@@DJe`LTfVYU[u_YVum]TlL|brfVn^aQZ`hJBBJjjh@JHhpHgdFh@@						D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.hxhS~5qxigyM{rq	;jhzwi_i6w5pxsfBga680cbVNKN0Z1VHF0IC4JFVq843J20Xc080V40F0g11H7V10V18FF4#2$170YV	0Xs0f!3QV3B0D8!sk0tV3e!OZ06s0T03B0D80x! #F0XrFc8D7Z110c0Gd_J493F1rcNRE82418YccNZB	#@$c/0V%8$4$FW%8!2&3k#86#F$848$4#5!	//(3/!2//(4#1+213!1///+1*3/$1)1&1///!1(3)3//!3///%2$3(2/.2/(3&1///!4(3+3///5,1,32////)3/////-4////!10H//#1.1//02(1//%6///&1////#2//+	dcMB@BdD{Tf{Y^UZjficJ@@					antagonist	mGluR1 alpha / mGluR5a ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
hx>x~Shx(Six~S>xhx(S>x(S:v:0*F*`.h.>.>.h.>.hS(	=hUSzpKxUNAUUC8KXNPQZ3H0CYhA2XvX7@24QAq8a20VFVF0eXFL98clW9VHd91Xc4F60Vm5J!140V0FV	0sg0bk3Z!DA0@40t!3IV2C0ER016J0TF1v07k01Kg0M02A09w0t!5O01s07Z0U03p! !67bFd0sBA6m0W0FkoTD53GO0VPGZ150W0t8H9631Vg44A85t0Fk@28472m0WkJ08q82A2A8o8cFV81C2nd0VB@6m0VVGGkBBCZ1WckBN983WFwP21_42gV8N4	!2t1k#e8$2!1V0V#4$k@#21F!NcF!40B#34V!VmV!14V#GF#108!@22!318V	$1#2*101/4/01!1+2/1&1.111$3//01//#19!1,3&1/,1/01%1%2!1!11#1$1(2(1+3/%2////01%1//(2&3.1*2)142$101!4/-1/!1/#4,13/$1!2%5$1/03/,301//+1&2*5!2#1/.1/01103/+3&10e$1!1*1%1!2$1&6/+1%1201#1.2/#1)8,1(1!11)2&1(1//(2!1/(2-1/30101&	fakPP@DJAJs\bbbRLrTRRRrcN^CdkUKMTt@SP@@@					antagonist	OT	Oxytocin OT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
}Z?yZ}q5qq~Si.qq~Shx	vvTfefz6_SXa1JO!EJ@094VoFF_c#2IF011!F8F!10_02088!J0H!102505#80B08#20V01VFkV	0Z80f!3_k2N09g01Kw0NF1p0Ao0ok! !6F4B2FG42ckJH@WWW1VV	#60F/$VV#11c*2%8+F$6#F3%N!2%1!	//(5*1//.5#2&2+1////%3/4/////+1/#11(1/01#2//////,1/$1/2+4////*2///#3///$4//*3///&2(1///&I#2%3&3#3!1////&1/&2*1//$2/01/+2/-2$1!3//+	dmO@@@iTigo\inejjjPbFh@					agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xh.hx>S~.>xhxh.hS~u8.>un}].hS(}Ifz.>.>S(	;Sv9zOUnxIU4HEHO0He8@HcX20h39@8NE!8213GFA!10V90V40H0d0J3@@HF0820F!20V@52!FVNV0F0	0Pg!qJ0R01v!C10480eF05FF1204F0Gk1v! !WFwLH6YGFJ22A5_t0FV8BLCA_GsND194Zt0FN8NLC7Y1kgL5253XgV8R4	#10V#8%F!24%8#38e$l$3%k#8F$2o$5#GV#15s#4#250V	/#1.1#J////%1%1//%2//+3.1!1/,1+1/)1,2/1/$1-2(1+1/(11)1(9/!102,1//!1)1/104!1//!3-1/.1)4/!1/-1#1$1*1!1!3!102#1//&4.5//1$1/01//(20b*1.1/6/%3/%13$4%4,1/01%2/301(25/!1//1//02/%1%4,1	fj}Q@@MAAdbbRRfRTRROIAcdmAAEUUUE@@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi7+x>x>j/(QS(xhxiH}?-?-x=x>x>qq(Qxixh	:Uvzv;S:vyvzEjUvzvzCzUnzjrJCzvxvEjm7wDUzj4DjyyQ1swDxyjqArKvA35YApPpSHC0GFWJcY4#V	0Z40IV02pV3Z!C_07R0U!4CF110480eF05SF1r07c0U03L!Jp0440SF3L0DF01YJ0FV1407J0TV2d& #m0WFRV8F78241m0W0RV8J78271m0WkRV8R78241m0XkRV8R78221m0W0RV8R78271FVX8N8N@6W2218J@4BB73FW10Z@52693FcJ8NJB	#Q0V!18#2cx!112#c8F!1dc#23$bF#1B#9F$yk!B4E#GdV!9GN!@0c!2E0V	/01/%D!1/!2$1!1)101*1+1!4$3$1$11/-1/!1/+1/1#1(1////.2$1/-3!1/(2/01/#1(1)1!1$1.2&1-212*1/2$1*2-101%2//!2/$104&1%11/1&3/!1#2*3$1$112/#1+1!101*223///,2//%e%3%1,1/8$1.1/&11)2//5!1/#2,2!11)11/.3/$101-2/)2!3-	ffkQ@@DA@dsKLrjkkE\d{HRqjuTCTETUQRFTJH@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.h|FS~S~lv|`.h.h~Shxh.~S>.h.h.>.h.	zrUtzdUSrKxxQNAUUE8G3NuvaAH2CW692evXE2X5F2aea01X0aGdv21R8Rk1W5W2W33X0cN58181F204X0V0FV	0WR0Tk025k1v!DF09w0t!45k1_07R0Tk04FV1E09w0eF04RF1r0Ao0ok0 !1ABW2FgV8F782D1m0WVRV8J6LO251O0FkA84Vm161O0FVDF4L3Z140gaFG4A8241m0YVRV8R4	#L4F$4!2V9!1H$k$1V8!2&eV!408#15F!kHV$8$8$FF!229#ANV	//(5////,3$1*1///!1(1/&14%2///,21///1+121//*1&2!2/(3!101,5-3&102*1%1/$2!3$104$1.2#11//(2,1$401/12/#1/3$12/%1-11,1/(3#6/#1*1//%3)1#2,1W*1.1/4$1/2/-1$5$1/&13/,2&4,2#1/$2/-2.401/*4-	fbmIA@BBldpHaTQdTTRTRltRVYK`hi``Xijjb`@@					antagonist	H4	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xi.i.h.>.>.h.>S~.ixi*FS~S~F*:vxh*`l0*F:0S(	:UvzvrvzSvfvytrMfSPxQxMUPEfaoQCtfD@7pF7C7Iq94EhVR050R3c27B2H9222LAFR!82AFk#V&	0UR!Xo0FF025k1v!8M07g!mo0AV11!BM06J0Tk03FF120@Z# #8L51lkZH83WkFBkFNUXW1VX24i65W08JVFF56X1sc856WkV8822720F8Nz82311YH98e712kW8c828@2_l8B@B5VW8FF310VGsVz82315c2GBFTD0W30c8cU8241cZkW0F9HPA2GG8iF462BA4l9gJ174YW_NVkH562ZdFVBJ6gR120WCg8D4g8bW0VVGej25W2fFFF8	#84V!104$4*4#1d#2&X4)8FF#2k$4#G8$1c!2F#210V	/1/&H//-1$1&1$2(108$1+1/!2////4*1/!2/2/&1%1012/+2/-1!2%21%1/-2+2&3%2#1/(2&1)1.1/!1$1/&4#1///04////$2%2.3#203&1&4!1/!1/!261(1-1-1,7#1!2#1!21/,i/*101-6#1//$2(2&1/%1&2%2/-2.2/!3#2)1!5!1/!1$1#1)401/4)1#	figaA@HjADDbLbbbrrfbbTTtjYpNTezNB@ijjjjhjPXcu@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
,S77Iy-]-]Iy3<1cS~2C8i*>S,._.Gu?<3G.ugu?ugu?ugu?S,ug	?xzQxjvxxfE_duihwUSA7AZg2Nv4g2Vn4Y92GHkJMGF8F4082V2842206!220J0482@0s!@#6030	0WR0Tk02Ak3V!BM06J0Tk03Xk2U0DF!sk0tV3e!Ji0440Xk2U0DF$ #2FwF7E11kFVPGZ110c10ceE4W1lVt4cD3ZW8V81954VVJ0FH842W8RD731kVF810c3k88p8XM@3GkZNR4163bMccBH6243FkkL962l08220b3F848JVNFdFkVcFu_GWWkmcws6H5W0sR4@B20XHF8@B834110ZD442G8N2320kFG8Va4CWINV@D243kF8o82A@m0VkJ@14693	#84V!104$4*4#1d#202$X$4$8FF#2k$4#O8#818!2G#210V	,3$1.1$K$1)1!2*3,1(1(2(2!104$2///(2%2(1/&2%2///)13(1%2/)1+1(302$3!1.1+1//71/11/3!1#4&2)1-11/301$401%3/)11)1.1&2-122/%4!2//01$2/3///01#1%2!14*1/.2)1/#1/(1k%1(4/#1&8-1-101,2!2)1,1/503%1!1/(1//&1.1!2*2.1)11/031,	fmg`R@KRSMXHcHhdhULeEDdTdeJL}F@BjjjfjibPH`q@@					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
xiS~x=xh.hxix>S~x=xi.iS~S~.=.ixi.iS(S~x>.=.>xhxiS(x>.>.hS(S~.>.=xi.iS(.=.i	~x:jxyzvzUUvjzyzUhzhj@QrUrRbzatoTEmTp1ltAdbjRbq0@e0q@ZF0K93IJSekAdX0V0F0	0ZB0IV025k1v!8M07g!mo0AV11!BM06J0Tk03FV2U0@Z!sg0bk3Z!DA0@40t!3Y03a0DV012o0FF120@g$ %BHHC5WVB21980V88BLOT311FXHVeG47VFF8BLDePWFlNR4m4B50XVpnF465359ZG8FP9P511ka2NP683m0WFHd046F5bFWcRJ334Z2YVNT66YGm0Z4RF1I23FNFB733fVGQN4F44CblFBR244220VViH222cRBHF9a60VcG9LDB23lBV8o7828165nsZ2C13Z0NF46B@8_0FOFT2GBVYmN8k62@7142Fw872Xm2NJ@4F5VYXosVBO465VGFes4Tq15W5IFw4@2XVVNZJIZ120WlOFiD5A10sBBX230FlON4X@DX1Gd0B@1222Ft8FF42lkw41@6_1WFosN33GkcsKqQ342FFcVVuI5Z1VFRFEZ120WIcoN951WFRZRIZ13VVVNBTA5Yl8B@71VVOkw22C1VFW@BVs4421YG94TC420c444B5VVG9cReC84WkJ6294ZX21oaN2321VNZHA6XlNZ@43W0F44TAEKCkWFB4F621WlcgD932l8B@3C8VVcFs210WXJVNN8D5XWNoH61WFN42TAE	#c4V$4!104*B#3tV!2Fm$d#4Z1#8HF!V2k#W4#G8#85c#4#21BV	01%1/.O)1/.11)1-2!2$8$3/01)1#1&1$1/*2!2/!4%22/$2)1!1//01/,3012%2-2(1$2$1/01+5*32%71%1)12#2%4*104&3/#3!2/$2$40202#2&1%2/%1(101012(4*2&4/0103$2*1/!32$1,2!3*1!1&2$1#1101/+46+2/-1//&2-30z2-201(3(1&6$1(101$2/+2&71-2-6.1)21)6,2)1,102*1/,1$4$4$1)1&@&1%	efYRBD@EGIekOHTPHbRHrJJIIZYQSSQII[ZJIQGL\MSCK@xpDEULuUUUUTuQU`HQlP]P@@					antagonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>.>S~xhS(.h>x.h>/S~x>S~n^xh~Ux>S~S(xhxhS~x>xhxhx>kPS(.>x>.hS~.h	:UvzvzyzSyzvytuEbSuverCzQdzZoJKzhW@8rHaR0yVcJLCmB41nl@W4Q4VV0Dg2J8VJ0F81H488X0c2Wk0s0	0Xo0FF02AV1D!9_07g!sg0cF3Z!DA0@40t!3Xk2a0DF0 $AbHVZZ@95EfmkNJCDYCWWFns8gPs23WWlNgVI40ls8B1A45Z50cu882VWWGvNy693GFVVVLF482T713WO8LB1XX1lNReC7WWcF48@5_O0Fk@S6Q35WXkkkeA51Vd10J426Vk8Fcn82A1	#c0V)44$F$4#1d+d#4Z$8F$2k$Z#G8#858(218V	02.2/#10J%1)11/,1(1-8$C$4#1#1!1,1/,2///(1/&1/)1.2#1!6/*2.1//.342/!32/031.2&603$3!1/4/%3&4//(1/203)9$@$203/)4/4/$21/#4//-2/042#2&3/%2/1//.z%503#3,3(2&@/1/$1%6!6//(@//$1*1%2///%2,6*12,8$5$2%	ebVVL@@DGFko`PKJlbbTTTTTrjttQbRATVVga`PRVqsUUUSUUM@@uUTHDDQD@@					antagonist	NPFF1 / NPFF2	NPFF	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x=S~xi.ixix>S~~Sxix=S~x>xixix=S~x>xixhxiS~x=x>	xvwzgyqqjEuy9dhVbExchhK1rOBmPs010R!uR424BmRFoPB0N20GV#10V0FH12F8J80104208!28!6030	0UR!aJ0Tk02Ak3V!8j0D#sk0tV3e!Jh02w0FF3V0ER0 %85ZHt4HA2Z3HBF8864D1aXNoF620kOFsdmf2510l8ZcC6Xl8J830a3Y0T48H4n18dVGkg4L611210ZLA4Xl8BB810FF54RXZ713md88NA142ZPNFR83Y21W0mdBTD24kV8ZJIX111kb2k8P4j1W4m9BP6E5	#B0V#1%4$9$4$92#2$8V/02k$4#G8V!808#2#2W0k	/&1/D.1!3*1$1*401/$6$8$2/.2$2#1#110101!1201+@/#1/1+2!11/*1(3.2/)202$2//1.202$1%1/%2//+3&2/!1/&3&5(4#1)2%2/#2$1$1!1/)2/05.1/*4/4/0101/&202)1&22&2!2&1/////n%513!11/-@02//*2!6%1#1)1/!5//-1/(1&3(1//)1#1/0101+	fcwAP@@Z}MZSLlznskJllDO[UUSMUTDCDXPPP`QBIVd					agonist	PGE2 ( EP4 )	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
72o2xh.hx>.>S~xhx>xhx>xhS~x>xhx>S~xhxh|FS~lv|`~SS~xh	:UvztzUnGMhnD@ESC8VHO8z0B04_W846LeVC3V82901Vd1V62KVFV1498V01CWF0c19VV64V!61GJ41VW0F0	0Z80IV03OF1g07g!l80c03Z!HD0@40d03Z!JH06k0Tk2V0DF01FJ0A01D0Cc0xV$ #20XGFwN94WVkNH210nm1s8FIA4Gsg82954hpcFg86261WsgH731VsN4310J226F423Z16VVkVcRE521FJF230F9kkv8251m0WkRV8N44242WcgL83WkVB481VJ2F44VYZ12Vmn8FsA8251m0X0F	!1D0F!1J$BI$J#46#D4$26F!2X8#5H#64F#@s!81J#8IF!43s!@14#19V	/#1/#B$1)1/02/$3/4#46#4+2%31&2/)2.1011//01//#1/#2,1%1/!3/$2%1&1&2/#1)1,3$4/!1/#4#6&2)1/%2+11#401/)2/-1)1!3(1#1/&1/#1/&2$11%202)2#1/%2$11$2*1#3%101.1#4%1$1/-1(1/0g$1%1,1201&1%6,2*1#1!103!2/#1!1/%1#4!22%1!101/#43/&1&2.2&101&1/!402//)	fmgHQ@LZ]vBKC@DEBLddJbJRTrbRfRVsUoUjjjf`BJZH@@					not given in publication	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
hx>x~Shx(S\/ix>x~S>x5qx=~S(S>.ix}^hx>x~Sx>hxhx(Shx	:UvzvruzSvnvytrIvMvxAzLULEvirOBxSzQ2xH3hEOnEJzCVN414z6s_7TAHN2If4@tPKVP1UBS8N0XXC!V0	0Xo0FF02OF1v!@C0ER!mc0AF11!DF0@N0t!9@V0h02s0FF1207g0YF2d0ER0 01Z15Vt0FcDF4L3Z120t0GcDF4D3Z12Vt0FkDF4D3Z130kYVJ2874X_G84FZ88g130V8cB74@208cVLc@31YFk	#80V*4#1%B#192$1$Y8$4#8F$2k!805#G8#858!202!210V	//(H(1,2)4/(1)1!1#16$2///1/$1&1*2%1/)1(1%2/!2/!1$1/&2/&1/&2/%11/#4(2)1/&11$102/3!6/04%1$5&1/)111/#1&1$3$2!2/011/1*1,1/,402(1//0202$31%1#6+2#301*1%1&3.3*2!2/&k/$1/$16-2#1//&4/-5//$2,1#101/!3(1/-3%2/,4,1	feoP`@FCAwHhhhheDeBeeMMrRgZ|dkYmAQEQUUSTUXpQpbQ@@					not given in publication	Opioid m? / delta / kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
=xxh>x.>S(.i.>.>.hS(.i.=x=S(S~.>.h.i.>.h.>.h.>.h.>S~S(.h.hS~	:UvztzUrKzpQBAQ3ULkAcek66XJhV08@@xJ312188ce4W1X!FW#R8RJYY!2W161XG0401!F382VV080F	0Xc0IV02K03x!C20@Z0gF04YV2U0Aw0t!5OF1e0780SV3F!SQ05k0YV2I09w0jk3Z! !31VkgLG73GN4cV1113IBV844B9641NgVA20XWs424BB641FweD53Xls@B8D4H9_WFgT5753WksVHE92FcgD2164V890r826111WVgNC5XFsZ84B90FH1dhwA35WVFNV@65XGNoH62WFF82VE0VFWXLF4B2231l0VLB52VsV6310Yls44JV6WYlVVcI82A1	!272F!80V!64%NV!V6F!4V@!226F!1ss!Bpc$FF!42k#ma#c9#2dF!@_$18V	/,1!1&@/%B//#1%@*3$2%1,1+1/2/$5/(2,2$1,2-1-1,11#3/!2#101%2/01/!20102/(1!1)401#2/*2)1%94%1(4#1(1!1,3$301!1!801.1$1&21//,4&4&2.1!5!2(1/%1/01$2#12/.3!1!2$1)3!2#10102////&1,10o!311!1/,2$4/+1,2/3!1/*2/1&1$1%6////!1#1$3(6,2$1)602+	eohVHL@JIMLacm`IABPpdLbdLRTVdTjVRRTTVDdRrn^j`@jjjjjieJ@@@					antagonist	D3 / D2	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>xiS(x>x=S(|`|Fl0=x~S`*~Sixhx~Sxhx>umM(~Mm1m1~MM(	:UvzfzUzSzjQT@zUETsvvhQMDe_hYNBTUitElm5fAQYVV3WDTK1FZ8Bd6L3I5f@0w39ol2TF1B119JeW!8!	12c0FF120@Z014w0Xk2V0DF016J0Q01v0Eo01mc0Ik1g07g0Xk2V0DF$ !6F4B3Z10Vt0FsBZq452CmFVsJZq462	#c0V!H$41#32$46#59%D$_*8F$2o$4#G$87c$4!211V	!2#1!1/&1$K/%2///2$5#21////%1$1/&1!2&1,1//.2/03011/(1%6/*4/(2&1)32@3/02#1/#2&1/20202/&3$1&1%2%1%1%2//!2$1/.1*1//101%1(3/.2*1%1!1%2$5/01//!22!1/$2/020k.2/(1!61)1//!201(21/-2$2#2#1&1+103!1-102+1#1//&101%2-1-6-	fewQB@AAlBPrJIJYRIIGIQIITXJW`cg@AUTuUUUEP@@					antagonist	ORL1	Orphanin , Nociceptin ORL	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.=x=/jxi+DQ~x=H)8ttn)^S(xix>D{x=xiS~x>xix>S~xixhS~x>xix>	:xzxyyyzjuzUdxkjUxihhMQxvgmPs012o!uSBTCsmNkoQ4FNV4GV#11V0FH30F8J@#4208V%2010	0G#UR!aJ0Tk02Ak3V!8j0D#oZ0J03l!GF08k0tV3c!Jh02w0FF3V0ER0 #8NHF4XWVgV6@60FGGNoZH@WV8J631WFGVk42@C10FF86841kkRD23W0VF6420k8B42N7BO0FN84467WFsgV@4WkFN4RAD231tRT81W0O8w82260VFFZ21237kZFFc823210VoLE510cR8320kH8h4VUD5FVccJap92W10XwR2923XN8gJ6311lNRD7420kRB71VVF82aC0VFWHg184626cGNoJ96610kFVVp@23WO0FN84297YWNVLB420WVckFB74WNg64110c863D6b2AVFN89H71Y0le8LJ20W0ssD2B8__VNNVC8BKWFFcV22561WVcZRA4XFsRD61VYWs424BFFcJ08FJ874Z318N61W2G98B8C6Y1soB340kNFoLPYR12G88RB	!2B0V#1$24#29$4$92#2G#@X$J4$V$6k$4#GCV!808#7#2W1k	!1)1/*H/!4-4&101(1$1$1%4$8$22,2$2&11-2(2!1-4///#1)12(1-1%2+3/+2,11#2/*11.21/*4/1#1&1$3(4102#2//*2&601!1!2.11//*21.1$3$1(1!1!2-1/(4,2!4%1!1#1/!201/1+4+101#1/*2#201/021/*r.2,1-8$1&1+2/%301&211&3212/4021-1&24//!1/3/+2/$3$11$1(10101+	eo`PFH@EGOHbk`@cIDdeDhhhUdYeDeBmKEmjjjfifjh@JhHhHDHlHrH`|`					agonist	PGE2 ( EP4 )	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
5q^}.=.ixiS(S~.=x=.i.ixi.>x=.ixi.>x=.ixiS~.>x=.h.iS(xi.>	:UvzvzwzSxjvwtvCb9mj9w5w@7AZZ0OzBg2020Y82G2!60V0J82B0V0TJ2204Z!20F018204F02!VWk0s0	0Z40IV02OF1v!Ds0AZ0kk03Xk2U0DF012s0FF120@Z% %Q0Wpk8J88445WsoT640XWk444AB11ldBTB@2F88cNJO@8GkVJH@B6W2d0D224FF42N9B10cVVNF642ksRD421VNF421VJWs444BKEAXsNZE82410VWNwLF71GNR8LC0VXY1k8LE@Y1XNF4X28W3V88k229A	%V/F$8#11V*W$5$8F$2k$Z#O8#818(210V	02%3(1/%N%1//%1&1/06#23$2////01///!1$1/+1/01(2/)1/$3)201-1/(1.2#7$1,13/!1#303$11//)502$101(3#1.2!4/#1-2*1#2$1/04/1/!1$1/04$2,1/*2!2-421*3!1+1(2(2/-2$2#2!1(o%5/#1(2&@-1/*1!2016//(5/(1+5/01/$1//$1#1#5/,601)10	fkoi@@DVJoXDfYYu]UUeV]Vf]jjjjjj``X`@@					not given in publication	Opioid m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.hS(x>.>.>s6\).h*`B,qq*F:0S~}H}^qq^)S~}H}Hxi^)S~}Hxhqq}HH}qqH}}Hqqqq}H	<v:v;nzizUnfp;vmqqrezntDBzUcrhnrAhOvEnQD5AUt2aUTtLwQvwYHGh2T_gXL1fu5KGp7qL1!V	0U4!aJ0Tk02FV2d!C305!wF04FV1D05R0MV04AF0j0As0wV05OF1k07R0Tk1w!KW06F0Sk1w0CN01Ho0Fk1k07g0uF! !6F4F3Z120t0FVDB2432m0XkRV8R4PU8ZW0J820VHWOGJgB61l88413VVF4oV117752d4N91VkkFZV3170FGOOSBI70VV4RLD3AY1lJa6142m698u144VkFsdVkLAW1GF84FB34Z2GNRC10XGl88@53Xl8RP94WFNBom2115VF44248dYK0GB30VGkstkkB710scRTDSB2X8ZD375YVtNw@2532oX0FN424321VFoV@6YVcF421Vk9t0w6B85XVR82110OO422276W10kZC52Vk84JP0W0Xs44110WH@8NHG94l0N610VFV8oa11VFlu08yP82FsF81984t0Fs884331l0ZJ731kk8@RT1VkN8220VH2c44LirF2VF4JJ@vJW2kgV8N78281DH0WsFVNH5WlF4L611kN42RI0VFX20Pc@32WYHd0@H41l082JF@10l0ZT@2XFsJ8410VN84119_F89422BK	!1X8k!YG8#V6!2K6#W6#3cD#3HV!Nh#BnN#GFF#Ho!445#OkF!BSs!@6d!25@V	!11!1(1/&E/011.2/1/!8!106*1&1*1//-6$1-1#1!1101)1.4/#1)311011!1/01&11$1!1&1$1#102!1/&1#1#1)12#2,1!2!5#2$1&101*1+4$1/)11%3$2&3!114!1/01!1+1//%11&3#401#1/!1!1)1-1&211#1011#3!4$4/#1)1%2012/!8/01&6!1#1#2(1/%12,111!101$1z%5%1&101101#11!1&D#1//%101#1(3/(4#15$1(1!1&24&106&2%1#1)101011(1#1*1+1,41$1#1)1&6-	enSRB@@ECDe`KLmldTRbRRTrfJbRRrRtVbRhXDtTl|BFViYhJBRjjjjjjZ@BIaB`bRbAz@					antagonist	Adrenergic alpha 2A	Adrenergic	no	gpcr-ligands_DescriptorsNo5Ht
D{)LS(xh.>S(.>x>.iS(S(0:F|x>x>S(0l(Sixxj.>>x>xS~q5,jhxqq~S0:F|~Sqq0l(Sq5	:Uvzv:rSzjvyvUEjSuUvxhyUbjjpFS:geEnnjRDArdtDrqIMCHx2g@io3nK_b2Z39o0MRX8Gn0WRcnZW0F0	0aJ0Q!3YV2V0DF012s0FF120@g016k0YV2V0DF010J0IF3P0EN01Ho0AV110480eF$ 17CVVl0TF4D28J40lGBV475F7Y0g6@B50Vm0R8556Vk8B72VIW1k@X9421W4R48D4@JVlGVLB76m0VFJI0H8432FJNFZ8FHF1Y10sT443Yt0Fc@RcU4X21BV8N4	%F#4F#4#1FF#4D#5_V#24F#cV!4_$8FF!2Pk!80K#8N$3k!214#18V	/-1)R$5//$1&1#4.4$9#33/-1/!4(3)1/#1*1)1//2)1&1//$1$11+101#6111%1+2#4%2!1!2!2&21.2!@1.202!3.1#11&1/+51!201)3$3!2*2,2%1%1#4/,3///!1!2/$102.3$1/+1.1!1+21&1&1+1/&4/!201/%20z%3/#1,1!8(1%2/&2*2$1/(1&2!102#2#2&1-64/+1!4$2+1#1#2#5201011&3%5/$1&7-	ejYZLH@LIMHghD@`@cIICeEDhdhildhediddmGHdnmhRT\UjjjjfB`jJjjjJpXHxhVH@@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~S~xhS~xiS~xi.iS~S~.hxhx>xhS(x>x>S(	;xzdzSxnSQMJ3ABG8F28@IVV02_0Z@88h202!1F420F1!10V20kV88JH@#10202%2024!V0X0G0	0ZB0s!3OF1k07g!o40FV2d!DA0@40t% #VcNLE82l8gF310IGWcRXO7WXc465944rVFFV8253m0W0FNRJA6XVcFD821kVB4TC0VXZ0WFc44Vlkg2915XVF8Vk	#10V#8*4%8#30e$l#FW$Zk#2F$2o$4#1V#1Ck#4$58V	//#1#G/!1-41//#2$1$1,1/!1)1///!3*101/01(2/,1,2)1%1/-1///#1/#7/!102,203%1&1.101/(20104!3//!2%1&1/!22*1#1$1/011!2//$1-3!3$1(1/!1.3+1!3///&1/%1-1%b*1#1*1/8/%2/)2)41(3/#212/(1&124%1+1$1/*1//021)1#1+13-	ff}Q`@DAAPVQQIYIQIPjIJsbuZjj@BjjH@@						H	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
jFS9j`@1jFjFf@S9j`ZlS9jFS9jF~Y<FjFS9j`j`mPchVmk]	?v;vzy:rfzy;M:jv:xUxxDzvxInhjzrOqUUxU7fnxvfh7ynPs67HZeSRIAPHzESBw_fqR2F10	0UR!dV0ak02@F3V!9k0Ds016J0R01v0Ds01Hc0Ak1k07g0uF06@F0e02w0FF3V0ER02HZ0@V0i0440FV1407g0eF3V$ $6F483Z120t0FVDF4B3Z13Vt0FVDF4H3Z14Vt0FcDF463Z11Vt0FNDF483Z130t0G0CVN492UdFWVFmNB36Wjn8kBR7B630m8PlNB351t0G0DF463Z12Vt0G8DF4H3Z130q1VFw8	#cVk!FF%4!25_$4#392$HV!Ff#8Vk#@F$Ho!805#GgF!85s!24#258V	!1*1%1$1,A/!2!4&1/#1%11*11$3$1+3///+2#2/)2)1!1(1*2)2%1!1%3%1/11$1(102!2,1%1/$1/*1/(1,1/04%22%2/2/)6012#4(1*1!2(1011,101#1!11//-101/1/01&1/3*1*1/+201*27#3/&11)2&1*12*1/(2!h/!101/%4/*101#2!2/!21)1)4*2/%1#1!1%4///01$1102/*2$1$1!1-1-	fio`P@B`IXNQQQIRYJIQS]JLepSl~KEOQmUUPUPUUQQDQQRbUCb@@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>xh>xx>hxxhx>xhS(x>x>S(x>xhx>xhx>xhx>xh	<hryxdjo75p7eH7mcX9J0GV0W_892V!KFG60HWFFF4J1080204F081@#2F08!42#V2020210160Y0	0Z40IV03OF1k07g!mV0IV2g!DB0DN0uV$ !7@g8@4FCW3o9V8L8oN12VVF4P2421l8L61VkVB6TJE3_GsZL9630N4cc1195VmlBVF23Vd0kV	#80V*4#4%B#292$F$Y#80F*2o#15#Gc$4s!24#250V	//#1#J1/01!3$4//*4*1/01//!1/01!1///201//#301#1(3/1/-5-81//%1/0A/!13/1%6!1#1/1/%3!3%13(3//(2-403%1*3%3////*1!6$1//*111-3/+1#2////!e!1#1//#8*2//#3+1/!2)3/*1(11/011////!1/(1/!	fn}a`@J@QyImkvUuUVsfjj`@jjh`R`@						S1P (EDG)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
)ZZ)xh.hx>.>S~xhS~x>xhxhx>xhx>xhS(x>xhxh>xh.~S>.	<vxT:Z6tzDYPUl8ZHh2_X80B54d64510862g2GXJ0Q0F7140K0F88!1#F08&VkX20FVO!W0F0	0mw0FV1D!C_07!Tk051F0g04s0qV3q!J502k0IV3P0EN0 !11NkRB6Y0kN84A80FGlVkcLBZ0FBRHDgHY0l8R4D8JZ20kkO1m@3VksksQ8281	!204k(14$4%2$4%1#F1%F%F#8Z!80J#1k%k#5$70V	//(501!3/$1/#2&6/8#8B#4/,1///-1(1)1-1/%1.1&1$2(11.6+1/&6/+2/&6/#1$1/!8#@//!1$4/05///02!1/!6/!1(2)102#1+2#1/02-106////03%202/&2///#2!2*d(1//!8////$101/#12/&1)26////$2.2*2/01-	fisQQ@LI`aqZ`BLaFRREQFIKIQYRFFlmUP@UUKTP|P@					antagonist	mGluR	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
Sqp[mD9bSq9D9b9b9D9D9b9b9D9DS59bP(;@Ho9Dh>:c5Q9D9b[p6K>h>h6K	=vzyr<ytvE:uSfzS:jzgxNxjxhMPuG7srvzcJ5SuJJ5MZ@c1zLXH@RT1Ji0HGG8IN843k0e!V8FF	0Pg!Xs0FF02AF1D!9J0Eo!sg0bk3Z!Fi0440Fk3l!KX06J0SV1v0C!1Z80G01707N0Tk2U$ !1Z120XHdZRM30GlNs48D7Xm0JN831FOVcn8241m0WkHugi@0XXlRV8c7826113WVR@26WFsV8410VF44319WonoN8L4fMXVl0NK2b71GG8F4DB3B6HG0H21Z228@B8@4F3YJcsBBB110W91XN4722ElG0D@756llkNV4264m0WFFW9P232Y2VF8HEZ12VW3GcXE6Y21VFZaH63lsFVH513Zi_FFF9gg11X0kFJZC42VNVV20W0V8sF1111J2dVX_43XA70FF8	#A0V!188#4R!1F$VC#19g$nF#Y$4R#cs$Hk!8W7#G9#9CN#4#212V	%2%1/1)H#1)1&6$2//11!5*9$1//$101%1$1#1-1$2/2$3!1%1202$6(4/1/%1$1/.1%1/$1//+11/!3/!2.11&74%1%1,1&1#1+114012!4#1/*1//10202!1)2$1/#1)1/-1,2!21/%1%1*13,1(5/.12#1!102#1$1!12//01$10q1*2(2$1%1)4$1#1///5/)1#2*1.1&102+1%2%1/(1!1%42*1!3(3$1$1#1#2%104!2$1$	eod\DL@NCAoG`IABPpdLbdLRRRRttbbQrbRDdLlZzn^j`@jijjjjjJd@bFj@@					not given in publication	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
w<ygQ(xh/<t8^)D+.>x=.hS(xi.>S~.hS(.iS~.>.>S(	>ryzUvrvrxrYrruKfv6b0fzoukRj1CU21K7tL1m0qD98G2E2hXc4a6Lq08DGoeV4180G90k20@V8160Y0	0aJ0U!2@02g!C_07g0U!3Y03a0Dc!sk0tV3e!Nc02s0FF120@Z0f! #2ZH22WO0Fc9wXM@21FsfSN490VWVn9JTO5VlVslFsY70V8kcQ8221EgmFNRE82418f3FkFJ1132YZdVX654VFFkkRmL411kcF193Z_29kc620VG0cY8241@Yq0c6@A1VXGV	#91V#8$44*8#10c$3#FX8!4V%F$Fk#54#1$11*1BV	*1/,4/!2!2#1/-1!3)601!203!2!3//)1/$1////%3&1//)1(1%1(12&1//!1/#3/$6,1$1/#1#3&2//!3#2$112!4(@+1//*3$1/////#402#1(202/2/%1/&2///03//2/f/#1%1/D!2&3///$5/(6/#4/2/21////!12%12!1#104/)	fnsPP@B\@`ulbfdrRRbabTQxINZmZjji`@@HDXhDP@					antagonist	mGluR	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>xhS(.i.hx>.>S~xhS~xhx>xhS~x>xhS(	=ttyfH7yWJ1fjw8G09HPW821c0V0V0p28B0V1HF044W101H0FZZF080F2020c!224-X0G0	0Xs0IV02OF1v!930D#t!cF3Z!GE08g0bk3Z# 0D7B_WcFF@0ZYkF8kc8763GcZHA210VB410VJ1m2x2I32W_mOka8133FF8VU8261HaocNgB25541kRH83X0V8820bYYpfR885Z120fLsFc8	#91V!28#404#21$1#10@!321V!FV8$4*2k$4#10F!11%2#18V	/*1%2%9/!1&2//+3$5$2//*1.1+4)101#1/////$1#1/)2-2&2//,2#3/$2/!2/!1$5&2//%1%3$3*3//%1/#4/$101.1/#3/(1*2!4/01/(12/#54/)2%1/-2&21/*d3-2!1&1(1!1!18//%2/#2#2)2.603$3/.2.2///#4.202.301-20101#	fn}Q`@DEAkNQQJJIKRiIJZJLuAPQMTuDBDPm@					agonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xix=x=xiS(x>x=.=xh.ix=.=S(xix>xhh.xh>x	?vUua3pymim9LOqxVLWV!C3sHcGHq1020Y1FG62104A3F05Rmd0VN0F2089V084Vm!@560Z1J4X8G0	0Pg!XV0IV02FF1D!8j0D#co0xk04OF1k07g0zF0 !O0FkAg4LQ14YVFsNRoNKX2G5@ZN643XCpcFF8BE9618ZB520mVtFNwBHXkVkkN8CAWZFkVg@31lW9@664824Y0c88@53FcJH81109sVwBD773cF8D970YGlBFI60kNVcDJWWW1FVNsHB630kgH61VFGcRr8231	#c0k!5F%6#4%D#28X$k#F_8$F*2o$4#GVF#4s!242!25AV	$101)2/1$@-1#1!4*101/%1+4$2$1///#1/(101/&2/-11+102-1/-1*2////02%2&1(2/$1/#2#@$101.35/%4*3(2+1-1#201%1#4/.1$104,103(101/-12,1!2/.2*1/01#5!2(1-2//(1/.b.2*1/601)1#21,2/*1/-20102,1(1)1!1////!2%1(1/,2-	ffmab@HbexDadTRTrbrRaRdhr@BfjjjhaZ`@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
,@_*~X:vhxp3}JF|zdpspsS(xiF|x>x>xix>xiS(x>.>xh.hS~x>.>xh55q5S(.h.>.h.>.h.>.h	~:jzyqzvzhzjjzhfoh:hvErzxcy:kh6eyTr1m_chiDqnrLve4o6doG6Kl1o3X9Tcf0W0F0	0Js!Z40IV03OF1g07g!sg0bk3Z!DA0@40t!3Y03a0DV012c0FF1209w010J0IF3N0EN01Hc0FV1g07g0q& 06F4@3Z12Vt0GF8gkEE4V8koNZCAaXFdB22G64cIGk416434NG4BP627gH14JX@nF4Fl0NdD9B3kFkJQ82@1m0YkRV8J50w41Wkpn48653m0W0Lew8D5Z13VYX1V8N23Glcs9eT7X3WBV8g4453YGNgH92WFs84120VH9022DH0VFVRFC52GNF8630VF8610VF@d822EL0VW0ocA52G8B6426Z0848PTIDcWsBJL@122GsoHB5WlF84210IlOsNLF741cZ8210VF8oNP21WlNcL75VkVN8NL310F82213YZltw8ZGHW3l0FoVD4A4HW0BZDEEdX0VgFJKD5VsR8D87m0W0R0F8H4E9cJ0W4F433XFVJP83X0sFD71Vo1k424A0VXJk	#c0k!F0V#54!18$VD#5hX#1qF!Fd#6Z1#8FF#Eo!8VR#O8F!87s#54!218V	(1/.N2*1)@02(2*14(4.@$3$5!4)1&2,1-2%1&2+101)1!1*2%102/!1//!5.1#1//$5!1)101,2#1!1//!A/!1#2/#90104!3#2+2!2+22*1$601$12/!1!6!2/&1&101404+31&4101+2%1/)1!2%31+1!3#1/.1/,31*1/!3-1///$z!1!3/#1(1&8/1.1$1)1!1&2,3%11$106!1(101+1)34/&1/02/#101$1-3$2,12%103&1$2	enY\FH@LHjhDLaio`@cIICMDdhlmeMDeEiEFddnIMG@hej``hjfjfjfjjb`Jh@@					agonist	Ghrelin 1a	GHS Ghrelin (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixiS~.=S~xi.iS(xi.=S~.>x>.hxhS(.i.iS(xiS~S~x>.hxix>xi	xvwUcTqnEEuX9cx6mAr@hz_HLJZXRf9HFc2Nnl32_COkFFAB0P110J3@W080882F2!94G1!2051803642010	0Xo0FF02FF1D!8j0D#ZB0s!2R03i!Be0440IV04OF1k07g0vV05AF0j03!FF3V! $38281m0YkRV8N78281m0VkRV8Z52z21XVoJ88L4VG7kFVsF42Fjl1NaF463U2W2VgV94782@1V80F8FN8461Hl8J64VVVF6NDB232GwT531VG8ZZ2LT4G18V4DA73msVH80VF9VZk4863W8R@72W0VJ4310VF441J4@11FsX96XkFNB2A8VkFFsqy5221O0G8DF4T25jW2FgV8N6y523W0VskaA5XWNB640a3kV426AE	#V0V#F/04$9+3/02k$5#G0F!44s!2$210V	01&1%2/&N/!3!6/.1%1#2$4$@///01/&1$202//)1#1$3,1*1*2&1-1/%1*2#3//%102*302/19/&1.2!19%2%1*22//3,2)2//-1$4(301//&26,2*2,3!4$1///+6%1/*1-1)1/-1)r/2.4*6/01%2,4-1$1,2///#31+1/#2&2/!2*2#2,1/*4-	fkA`@@EgdTTRTVbTbbRjvVSNVcelAAUUUUUUTUbaEbLt@@					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~S~72o2xh.hx>xhS~x>xhxhx>xhS~x>xhx>S(xhx>xhx>	:UvzfyUrCyzQT@yCUR9QvadMAc_hWJ42dlV9IF88F_cXCV3L611k0BN80V!288VK8#49c0F2!8V20W4F0	0Xo0FF02FF1D!8U07g!lw0OF1v!DA0@80t!32F3P0EN0 2BqQ31F8ksQ826168Hkw8430m216F4B211WHOBPC60lF8gTMZ11VW1ssX961kFR@2164kF48VR9Q7G0VVF4753lNkH921kVF420b_08990413WksgJ@62G0J8310J2V44RY18ZVl0Px8F33WZ5doBN@15210N4uNDY2lF8ZR6ND2W8VJ41ZY2F	#B0F(244#F$448#5$k0F!2V#80G#J0F#8k!80K#6EF$F!21$50V	//!1$J$1+1*3#2(2!2(3&1&8$4$4.1-1//#1/01!1$5#1-2(101+101+1//(12(1.1!2/.3#2#1!11)1&2%3$5#2//#2!3&22#1-1+2#102*403/$2//,24/!1/1!3$1%2&1/+1#1%2$2///*23(1/////$2$j%2!3/!2&1%8/1/+2/-1,4!1&1#1%101(1!13//!1$2/)1-1!3$1/#1!9-	fcwpQ@IEkpV^`qBAFQQQJQWJIKJYJYIb`q``VJjjZfjH@@						NPY	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixhx=S~xixhx=S~x>S(xix>xhxhx>xhx>xhx>S(xh.>x>S~x>xhxh	=tUzrpzxUTQzUEDmAQeQiDu7C_N@Tvzi37m1@AVvZV3Xi2tY2ZGyOBkfdKO6Wd29kc0JH1@55141VZV8F0	0XJ0zF03FV2d0A401Ng0YV2U0@40t!5OF1g07!Tk3x!WD05R0M02A08s0bk2W0DF# $26b20g@93440FF8P20W2YBV84446J31kcHDF1VVWc84LJGA_Hk8JJD111lnvRR6736bHtBFJ730kkks46542G8cHA4XWOVw42C0VVWGxw4J51410F8RH@5XlNkH92VF9kk4124c3LdRH10Y1lV	$aF!FB%2!24NV#@#4Vs#24F!9_k!4_F#8F#VHZ!5GZ$cF!V2k!254#59V	(1/.A/%4.1//%3#13//,1(11!1+1$1*2-2/(22/(1)1%2%2-101//01/012/*101,4#204!1$1%1%1.1$64$12/5(3*1!22!3$3.101!3%1#102*1,1)3/!40104(2#1/(2/!101#1&2!2$2/)2(104/1#34//#1010101%21&2.104)1)10n2&1%2*1/6//#1$2*1$1!1/*8/(201$1#602//.21*1$2(4(4/)1!62,	eohRLB@IDfefIm`IBrP\dOICHhdideEHe\deEEMjNHdckh@bjjjjjfZbP@@					antagonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
psF|*`lvS~:v:vS~lv=x=.F|(S(S)\ps>.F|F|(Sps=.=x(S(S>x(S>.>x	;QvQzvMSzYvyvQ0YMPUfh4yLbfboFRtdBU0llYZ69X9FDUZGH60S@c@6L2H44!4X1J21g2N1k010VX22010	0Xo0IV02OF1g!Bh02s0FF03AF120@Z!mF0eF3V!Fc0440FV2d!Fc02o0FV2l& 38251m0WkM2k8H5Z11Vt0FsAWN432UdFWVIx@47299XGcFT8_UW3VgV8R78281RA0WkLF4L2h17WGe868@5M44V4FX8CQc0lcPkTEA0lHVcOXg3@1t0Fk8kiA3@0l0VXG0Y3HF	*4)10F$D#51V$6/8F%k$4*3V$4#10V	//!2$I#1*6!1!1///6$F/$1+1&2/,1(1*2$1.1/01//+1%1/*12!1*1/1#1(4(2&2/+2/$1$1%1+5/(2!5&3*1$3$1!3#1/#2%2//3#10101/101$201/%@!1-1(1+1!2*1%21&2/!2(1)3#2/&3/012/,1/%s%3//03!@//#302*1)2,1/)1$1/$7///*203/(3!1/&108)1#	egd\H@@DIH`DeeUkUgU{WZa`RQrKJjYZjjjj``bjjjbHhhXHJbr@@					agonist	ORL	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(S~x>x>S(S(x>xiS(x>.=xhS(S(S~x>.=xh>x	:Uvzv;SzfvydzUfCsrQxMLP7AakQCxji@7rFb57Iq90Ef4JJ10R3c2BR2m90X063FJ!8015F0F!V%	0WR0Tk025k1v!BM06J0Tk03Xk2U0DF012s0FF1209w012s0IV1E0@Z$ #BV8N4kaHWWVwV8J4RMBZk8c8D@20X20tVy_45XALsFV8849YmsVN23ZXkV48FL5C908oaBA6CcocNZE823185md88@E6VVF4FJHK5750VsI82B1m0VkRV8F4	$4V!104/4#1W#2&d4!4Z$8FF#2k$4#O$81c#F#218V	)1$3/(B.3/,1%1&1$2(107$1.1///$1/*4/%2///&1!2///)31!1/)15/02+31%3*3*1,601$1/)1$1,4$1*2+4(101//!2&4////$2/%3,1(4/*1-261/&1////#1#10b&2/$1-6/%2/!2/3/-2//$1.202/$2(12/%3!2$1#2/,2)1#	ff}QA@MQTBHIDILsnwLl|s`\pPEMUUUD`qCj@@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(S:0:v*`*F19+d191mmuX(+dmu19+d19*_T(E|:0*Ev:G*ze~S}Hxiy>xiR~y>	:xjxyyirEyjOdxseEzeEj59zGoXPs21HmFOnS5@oBIooZPD8kX48k040V2!G29030J1PFF&2#683V	0J4!Xw0s!2Ak3V!BL01R0TV03Y03a0Dc011N05k1Z07c01Xk0AF0j0440s03x& %VJ32204T14W0WNkg4O662cR840ZY2FF8@332FFV@51WFsR@52VVNB410VL1c44JmA9YFFZ@92Y0c8440b2ngV8842230VFNH531Vc4D33WFs8621VV89VT316gVLlwL354XgFGONa933X0FNVHB4X0VJF@1W0FF6210JlHQ04PE7YVsVVM82311ZWs8HD7WkNF8126XnG0kVO81VNZ4HD10Y2V8ge62W1VVPHG3W0VNo62@C0ZXX0o20YX1mv0i346VkGNfFkN33WVF88D742W0ZF63W0V8wZ430VF8JNcn0g0l8RC2442246swB@C10XkF8ZR	#84V!104!205!209$R$dX!22%X#20O#4JF#Hk!106!2GFV#4c!@%d0V	,1/*K.1!3!2$1/104/1+@$1+4&2&11/)32!4#1%B-2%3/.1)1(1/0301$1.1/04/,2/!4,21&103/#3/-1!2(15&1//*3061#4(3-1%2-1$203(2+12+1!2#1,4.1/$1$4)2+1#2&1&4&2&1122(1-1(1/%1)101!1/2/.t.1/)2#31//1(2/!3/(6!1/&3*1$201/%201$102,1/$1/!1(3/(	e`TPBL@MLgo`Ha@HzdLbbRrdTQrTTTJrRRaEBeaUUMUUUMUUSULu`DQEPeP`yCH					agonist	PGE2	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=S(xiS(.i.=x=.=.=S(S(xi.i.=.i.=	vyTve2tK1Ng2103208Fc094FF!X918!L!4N!21G10F1V#V04041F#8XF08)840H#Wk0sF	0Z40IV03hk2t0BB01Ho0FF1407N0Tk05JF1c07N0Tk3F$ 1Z120t0FsA5a4@234mlBX4120O8FZ6qGVVkcFJTV28Z20VBP5412Wk	#60F#2k!2%KN#VZ$ce$V#8X%8)52k#XY#F3$VN!2%1!	/#1,31$C%1!1///)2!4$2$1#1////01%1/1)2$2///.3#1//1/(2//)2/+11/&3*503/.2/3!1/+2//%2/*201//2//!1*1(1///&6#1&3//,2//)U/&1!1041,2///*2/+103/!101!2!1/*1/(1/+11,5)32$1+7-	fdyh@@@XHZvRJJIIIQMJgEN@bJijhhNH@@					antagonist	NPFF	NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
J),Ap3X(=.~Xe,u9{dN(u9X~u9N({d{du9X~{du9{d	zxzrLYsK9X4T4J2gT80WVN6H0VN193C24InV18!31k9601V0e1Z0XFHl0V08N20V80214c20V@ZJ0404NW0F0	0o40Fk1D!C104F0Tk03OF1k07g!sg0cV3Z!DA0@80t!4Kk2A0@80t! !O0FFDF443Z12VeMNFV9Hv23W@MNFc962AVVXFZN8e2282GkFWNLF482AE4Y18JR@5B4YkJZBB68_nlsFX8YVW20YngL693	!1V0k!2F%4!2KV$8V!282!1@HV!8Y%l*eo#15#GXF$s!26#250V	/+1+F//+402)1-2*2*5//1,3,2$1*1.1)121/+1/!1/(4$1,4/-1/!2%101%2#1/!7*7%1(2/2&3//01!202*3/02/.1/#4/2#5/*1-2//1!3///!1-7/+2/)301!2//&b(2//!4/2/)1/%1/&7/!3&1/,2//,1/$2//1*	ffcQ`@DDArJSK[sKN~diYpTmTlAAUUQ@@@						P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(xh.>x>x>.hxh|`.>|Fl0~Sh.hx~S~Sh.hx	zyzUyQtlCshHbo37Fs1lVO8LF013939@xJyX180133GA6Fx!@4V4iGXW0c@8@HFc920H4V20XDRBF!4S!V0	0PZ!ZB0IV03FF1204s!o40FV1D!Bi04F0Tk03OF1k07g!t!dV3Z# 38261m0XVRV8F4BBC348gNTB3AbZFcJJ@HQakksN8qT3bVckwN4TFbFsccJex91WkkG_qA1XWGRV8Z5y_23WEocFc8XG6alsc4DD70YGdByD43YlwV8w78291m0WFN2F8852G110bs91@2D2	#V0k-24%4$82$1$Y8$o#8%2o!B05#GV#80s!242!252V	//#2#G//*1/+6$2$1////,1*1//-1/,102!1/!2$2//1.2////1(1/(7$401)2/-1#1$2/&1*4/)2(3/$3#1/01#1#2!1%2/.12-1$1//#3+732//4/!2$13//%c+4/*2!14///(103)4/!13$1/02021(12/11/$1/(1/$2/,6-	ff}P`@D^@sHihhdddbhddIUgMAAEUUUEAu@@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
,Bp3W(.h>.~S.>h.h..hS(~S~Shxh.	vzUfvfzBrSwEQRGNBEOeAd4duIFYc!16HF01@08F0FZZ18bFac08V0J0k085G2801!18FB08#2!8Wk0sV	0Xo0IV03hk2t0BB01Ho0FF1407J0TV055V1d07J0TV3C$ #m0W0RV8R5gi251CVGG4u473YbFVcHJX4F3YY0NkJ	#2&V!2%KR#WX#1dc)8X#208#F1#40F!4mY#FnF!49N!2%YV0	-1/)8%1(6/)1)1*1101)8$1!1/(1#1.1)4%2$1///.1/%1/!1)1,1//&1/$2/////50311/1/,3/$1/////-111/6)1)2///1(2!2//&3+3$1/(1+1,1,1#Q/*1(2%2/&2////!6!1/*1/(1/&1/)1/04)1/!2-	f`qHB@LDUh@QdbbfRTRlqRQjYjfjjaH`@					antagonist	NPFF1	NPFF (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
96-[_.9696_.4jG.I-,S_x4<l(2<,SI-4j	xvyQcQqnE9uX9wd6H9McgA5HLJZYiY92VK2G0R22_9GG0kUC8N#408W0808F21040C0G2P0XBC080Y0O20W0	0Xs0f!2R03i!G_07!Tk3i!Re02o0AV1404s0Tk2g$ !266452FkkW0LF463Z11VcNNFVA82A1	%V.1%4$9+3/02k$5#G$84s!2$210V	/,1$2$B/011!4///%4#1,1&11/.1$2/02%1$2,2///,2//%2,2(2/*2/)2/!6/!2-2)4)2-2/1/1//&2012%1%2(1/.1!1%1/!1//)13///01.6)1/%21/1!1//,X.2$1/%601*2!1)1#1/*1////!1/!1-1%2+1//01*2/02-	fdea@@K@RYVve_ZLdXLX@JjjjJqpbUAj@@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>.>~Sh..h.>.h.>.h.>.h.>.hS~xi.iS~S~xi.i.iS~xhx>xh	<rvzSvnJErR3eB5cFX8JU1W01_803e0V20H0V1VF0k451F80V!FV8840802V$F!8!2(XFG0	0Z40IV02aF2Q!9k0Ds!sg0cF3Z!G_07!Tk3i# 10WFFXH3XG8F@21VkF50ZWZ11VVVJVF4@5YlFZH52Wk8F22E@0F8G58213Wl0wL842VsJ8PP10FF82@JHb_FVVF422111NZN64XG8R82ECVVFBBi10W553lN@_32XGFNJF93Y18JB72WkcB420VF@ON22IJ1VKOZ@F33XWk8J@731WNR@731VcJ850VVF82eO0V_pV	#80V!2&4!24$24#392$F$Y#84k#8F$2o$4#Gc$1s!24#250V	//(U/!1+202//$4!2%11+3////)301-2!4/!1(1/,5+13/1&201!2/B01$2///*1$M/!5/01%3!1#1//*3%1301/.1//!12-31$3/01/$4//!3(1//+1.5/+5////&q!1!11/!1/6!1&1#1-1/+3/!4*2/*1(5*103%1$1/%1!3/1/01/02%1/!	fkoa`@D@BwHhdhbddddhdhbdf\kujjjjj`BJj`@@						CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
7cSs7C7coc7c7CS~7C7coc7CSsoCS37cocS37CoCoC4[7CS3S3oCocS3oCSsoCS3ocoCS3ocoCSs	~x:jzy;UzvjzyzUhzhjTQLUpwbzatFJErEM1ns19bBTbm0@e4L2V02Gd3I4SeF1dm2V0F0	0XZ0IV02AF1D!8M07g!WR0Tk03AF0i044!lR0OF1v!C209w0eF03Xk2U0DF!sk0tV3c!HE0@40t03c! $84C4XFs@610XWdIGN4331W2WRZS11GlNtCoM34WWIXBm7542t0Fc8C4674WG9V4DB2331ssPH31kdG022D0VXY5N8hm282282OJ4B53XGkOgw8A2WWknksB33WoHNFkA82816XXu4@10VVc4@LBAHVZ18Zc6BBVXWF8BHC63GFJ@C3VFN8sV116VFG22k4TXA12kn1RT6F72VWco4LCZ120XVO4sL5A1084210Y3kVN8NP33bnNsBB733VkkRPC9Z1FN8JE10YHk_48HE12WX2GBXQ40Wl0yF48233aWG84891mGlDF4D232Y2NgF542VVB6220F@0h3824123lswe40YYlcJB6A@2bmO84@B8208NVV243Y0sZJ@5WWFB62D80kGc44LVqD3VVVcF672XkkBD952ksV430VJ28824C0VXJkFBD45420V67310kB62F6cO0Fc8F8G@41FRB33_4FN48RNp6cVlNO4cbAX3G0W8T954lWdZ4JD282Hsc4K32XH1@J24J4XFX9B4TN15Y0lGgJF9VVFcZHH11VW8wJ842ksV42274V8B66D10XoV	#c4V$4!14%F$B#3tV!2Fk$d#4Z1!10HF!V2k#V4#O$8Cc#42!218V	011$1/.H/%4$5#22/1/1#1#B$3.1#1-1$1/*1$2!11%2*4%2*2*2&1$1/,1#1)2*1%1.1#11#2(1/%1%1&10305+2%41/13#2/#B&3/#2/(2$50202#2(1$23/+1&2(2/!4#4)2!101$2*2/!22$1,1!3*1*2)1101(1/!56+1//1)2/&3!2&1(z3-2*1(1#1!6!101(101$20201/&4$4041/,6/%1#2)4,3)1!2#2&2/(1/$3*1/48)1!1	enY\JD@EGIkO@h\PHbRHrJJIIZYQSSIJQMQQIESQcbj[xF@`jifjjjjjjZbdEbMb@@					not given in publication	MC3 / MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>xi.i.hx=.=S(xi.iS~.=xi.iS(.ix>S~S~(S>x.h	>rtzStuvxtr7tOPgtz5MUTvgb4OdQS2Ed0E8PJD4FDp0u11kg2Wo6J@33H3WJ7dw85G5Q0FFVN0d46N30	0UR!dV0ak03Y03a0Dc!qJ0Tk3x!NJ02k0FF1205R0eF! $1Do4WX0sH88D4HAWFlVJkO33Y0oXgR4542X6l0g88445FtRD@B51WcF2@6@0mY8NRDXI2318Is8BJH811lRV8F4	#h0V#8F$I#1V$H#18@#21#8Y$V$8FV#2k$5#G$11c!22#2W1V	&1/1(3%4/!1/!5//4$4$2/.1/!1/#2*1/%1/.1//$12/-2//)1-1/%2%2!2)2*1&3!1,3&2/%2,102#601$3(3&1#402$1$11//01/*1,1.12//!1%3*1/#117(102!1,3!4%4////+1*3$e%3/,1&8#1/-201(1/.4*7301/*1%2,3%2/,3!1/&1(1/,21*10	fakaa@ARTD@PfPrJJIKQFJJJKSLDWmVuMTuPMAQDBFD					antagonist	P2Y12	P2Y (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
|F\)sp36|F|F*`spspF|0:(S0l	vpUlnWSS9F4B302DR80V2N0u!F091A04L2V51V031#10V0X5080149FV0W5W!@104V04#40H!1VV0F0	0PF!WR0Tk03FV2W0Aw01GR0JF1_06k0Tk$ !38291m0W0J88e6272m0WFRV8J78251	!204V$4#8V#2G#42#6V4!204$V#6(F!42k$W#1F$2V#HZ#1NV	,1/*4/$1//(1/////+1$1/!2%4///02/2//$1////&5+4)1//(3)2*1+1///2#1////.11//%1!1!1.3+1)2//*7(4!1)1////,N.2*201-6*5/*3/#1%1/&1//01!2//2%1.3/-3!2&2//	dg@`BWPbLbbbRRaSB]pPQMQ@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
J)s6*F|`0lF*q50:(Sl0}^:0d,(WBz(WBz(W	zxzbrbzBluJS7G4ciCcZ28291nN0N0ZV4HG0G@BF0Vo8Z20V0X80c0VJF10B5GF0Z10V1!J40V0k%V0FV	0Z40IV03FF1304s!t40tV3c!DG0DN0u!5JF1W07J0TV3I& $m0WFL3F8@5Z15Ve_18BH6HV4VkVO_4c37WVZ9FgL552VWH8HY311lkt_eG2X1G08oLK941FV4HG9	#22#1*12F#mVF$8#4Ok!HX8#FC!204#4Fo!2V5#21%F!242!29!	//(E-2///(6*2)1//&1)1!1&1//!111//#2/!1!1//1/+1/&1#1//!1!107//%1#16&2#3/1/,4%104*1)1///%221$1/2/)2+4/02$1,1#1///(12.2//-2/#1#W&2/!1#101)1*2$2!1/(2//+A+1-3%2/%3//01//11//*	fly`P@J@QYvQQJIJKFYIBduSUTuT`@@					antagonist	mGluR1 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.i.=S~xhxix>S~xixhx>S~xh	xvurBrkr8@2o0pCZn8mVVN0H108pF0d2V42K146011k!HK0880210W2!8Z882!F0V03#X480F010160Y0	0b!vV02R03i!Bc04s0f!3Y03a0Dc016J0R01v0Ds% 488kci241ko8FVA8241m0VkJF8p42ACWVW0X52W34Wt0FN@44U315WFo8FgA8241	#8VV/+8*FW/02k$5#G$84s(210V	//02%2/!3!3///+1!3/////)4////&4,2/.4/-1&1/%1-2/#3-1#1/6&1//&3*4(3-4/)102////#1/.4&1)3/%4//*6///05///0O&1-1/$61///)1/#1)3//#1&6*1)1///)1//+	do~B@BAC_HiiMhdh]mjj@HbLh@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
|F:0S((Sl0.h.>.h.>.>.i.h.>.>.i	vzUQfQzuESyY9qtT0AKejA5VyFVYinF0kG081O120BGW8l4EVQ2!428VH!V02104!4!80@#20VFBVFF0	0OV!aJ0Tk03G01v09V012s0FV2W0Aw0 $WJ241O0GNDF482WWW1FgV8878261	%V#28#8$3%4#194*X#44*42k$_#O$218!2$21NV	!26//#6////&4$1////,2$4//+4/%2/)2//,1/06.2/&4//+1!1/!3/&1%2/04#6///.2////!1//.4///*1!1!4%4/,3&1+5//*T%4/#1/8//4//%2///&1//2///$2//+	f`yP@@@XRenuUWEF\Uiwfjjj@J@@@					antagonist	Adrenergic alpha 1 / alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
SwrA4erereSwSwrArereSwJureAr1\llSwrA(JJuJuJurereJ1erllrAl:1JArwSJ1J1erer1JwS	;UvQzvU:IzynQFn5uUeE4uX7Ab4ODxB5!1F16K0X1FJ9V1404NH8@0F0F!F18!40180k28@F0FX0W0F0	0PV!PV!Xs0FF02AV11!C_07!Tk03FF120@V!o40FV2c& $4cw@f4321J1Je8E2WGFNgRJVKWZ1FJ8P@@1E1FccVL51GmkJ@4I2VZHkcJJ6S541FOZJL2A1FHVJ4ZJ5@WMNVg@292VWWVcgLF4D40cJBiF2XkmOG0g4S541FcFk52WFmOAJ4Pe15WFG8Nc4T_7alFVcKoe221ImcFF90VCWY1F8cF@551aXkcg551GXFJ4VJL52Vn90V4L51FcJFXH_56kcJ@BI50ZGkccgV52WXcJ@4H8b_FVsJ0y532Wd80FN8eK@WHcJ@DF7	%V$8)J$48#212$G#V1%G*8o!20Z#1ZF!4Ko#4$74V	04//%g1/)1,1/#2-1601/$1-2/1-2/+1%6/)1-1+1!1!2#1%1%2)1%1%1&4(2/$6+1,1*3/#L0401-31,1/.4#6/$2&8!1!1/%2/&2/0802!102.1&2,2,2//&1!6///25,103%2.4)201#4.1//2*z(101)2/%8//%2#1(1%B&1/&1/)1(16/!1////!6#1%1/0G-	en]VH@@ECKGLb`LdTRRVRbTTTRRRVtTJRVxdZvFNQiIYhHHjjjjjjjjjhj`@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xh.ixiS~S~.>.h.i.>.h.>.h.>.h.>S~.hS(xh.>.>S~S(.h.>.>.i.h	;QvQztUSxYvwAUHf1sftgLL633hYA@hwDX38X11AOn0FS30@KW0B0cd4w3e4320229F0860YBS8107VR2V10	0J8!PZ!WR0Tk025k1v!9k0Ds!o80eF2l!Fi0440G01v!FM06J0Q01v!G_07!Tk3i# %44C5XkcZF551FVJ630VJGmDF4@255Z1swR941084gXL41_28c8A2WVkN810b2Ie1F8D4E85lsoT30VHGODF462622lcRB@0WWNBB31VVV82ZCHm0X0FF44C@WlFBB621FFZ@2F4c10cgHB4X0cRD72VFN842G6ct0FN88HB7YWcoF41W0GW0mXI2310VFBFB5118JD33W0sF4110kF5JLe11X1cZD83Wl8Z@21VVF841I7dt0FN8RJE6ZGFg8520FGWBm2Y2510FNJHD2WG8F692WkV46310VF5JRfZ120t0Fs8NXJC3W8N2FF8m0W0HdZcO2VFVsZU829173Z0oB821FG8s22A@242OVR@21VG98Zm2AF138NRJ42230kNZT@73G8NF610YGlclNP1YWFccN@H6Z20gF410Hl1OZ4Nd52WFBJ@B433GckX65VkVB620b33V8JHD5YGcc@72VVF82TEEm0W0F	!104V$J/2#4sF!206F!c3Z!5V$8FF#2k!805#G$87s!204!218V	$1/!2#1*G/!101///02#44$1//1+1/#1&2!41/04%2#2$1.2.2/!2&101!2/(201/#3*1,102$1/!12%1&3#21/01/!1$3,2/(1!12)3$1/$102#1%2(1$1$3#1)1&2*402+1011/!2$1#1)2#101*1#5$3$1/%1.2!1+A///%2/,101*10w2&1%3(1/!B)2(3&1$1$4!201$2(1.2)1/$1%11*17121//#2+1)1$2#1,3#101#102.7-	ehR\HD@FKD`PH`bHrJJJYPiYIIQQIIPiK`Prr[Y{zBHJjjjjjp@bbCH`@						D2 / D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>.h.>.h.>=xhx.hS(.>.>.hS(S(.>.>S((S>xS(.>.=S(S(	<j;jjzjhTj:jzBXU5QrwHfzvO22FapvRHm_flGtJAE5PQeIoG2t0cV@N2I#O0Q8s12A55853442010	0b!vV03@V1104s014w0Xk2U0DF016J0R01v0Ds01Xo0B01104s0Kk1Q!Rd02o0B01D07!Tk3d$ #m0W0RV8J7828111WkwTE4WkVF231VIWGk8BE71WcwL410V8J61E6bXFtVXF510N8DJ@@m0XVRV8s7826157mOJN21VH0t6F4D3Z140t0FN88@D8XGccL51W0F82R9Dm0XFF	#c0k!2K%5!249#24#392#2F$Y#80k*2o$5#GcF!45s!24#2_0V	/$1/!C/!1019$1//$2*7$1$1/-1#1!1.3*2$12)11////01(3//*101/(1)1/+1!3#1/431/$1-1$C&1/22/!211$302!3*3#101$2$1+1/4&1!2,101(3-1(1(6/*1////.59/01.1/*1!1//!s4/$11(4!2&402///%302$3)301+903%1/01!1$5*1&2#1(2&2//-1/%1-2#10	eg`XL@@D@HllbbbJRdTJTRVdRJPRUSVqsUUUPAEUUUD`@@						CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.iS~.=.ixiS(.iS~S~.>xh	:nU@Mlm8@2kVLC0Vk1VVB#J0G20V0Z5!V!2!F01mF!84#V#1#2!V44!204648!V#X0G0	0aJ0Tk02D03V!Fi04s0Ik2f# %hQW10W@pP673m0WVF	%V/+8%1#F1/02k$4#G$808(218V	//(2/!1//&3+6$4////////////////04&3#4///%2/(4///*1/////&1////02/4//013*2(1)2//////#N%5/#2/@//%2//////&2!1//.1/#1&201%2-2*3	dcNH@FAIfYWgZ`hHD`cB@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.hx>.>.>S(|`S(S(.h.=|Fl0.>.h.>S~	;UvUzvUma3pymDX94FqxVLVV!C3kHcG0X182010FG02104A3k0_NXc0VF8F2(8F!2160Z0JBX0G0	0Pg!Xs0IV02Ak3V!C104F0Tk03OF1k07g# $O0FVAB4JY711km114W4520G90cL5XkcFZHHH651W48251HGG8WXIB21W0cgah7XXVV8VN@S7aWcckF424YbckFJA8231	#V0k!5F%4!24%@#28X$k#F3%k*2o$4#GVF#4s!24#258V	//01%A/!1//&1&2#2$5///.2/!1///%1!1/,14/+21&1/-1/////!23/#2#52//&1/02///01//#1$1/*11/(2&2,1!3+4//!1,1#5#1&1-2)1$1/4&1/.W+4!1*1/601//!33&2////%1)1!1///1/02.1&3/$6(2$	fdy``@G@edbbTRbbMTEhujBHhjjJEJ@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xi.>x>x=xhxiS~x=xix=S~S(xi.iS~x=S~xixixh.hx>W~zB}\ps	]U:vzxzUzyQUQzQrAEzZcUBudzQ9rJ_dMhmV4bAH5H5qa7l6iLXm884c6@VHJ0911$2Fe0a0I0	0J4!WR0Tk025k1v!BM06J0Tk03FF1209w!sg0bk3Z!DF0@40t!3Y03a0Dc0 $6@19N@420m0d24Xd3X20F8JKLn31WFkNlHV30lWF44F1134C_0NBF7Z120W2W0qG2W1lcF6499m0WkHZo66B3661PVN@C531X9gHA80V98o62A10XHwV8Z4cQPWYVkFRVX2XW14VPGZ11Vb1WFi62340FJ8NGZ15Vt0H094ZAB7GH0iF463Z120VlVkwF@0V882JA@KC0kNoE82@1m0WFG1FF77bGct0R6A941kJ8861mWtFZV@310Y04FH8	#d5V!484$4*4#1W@!2V3$eR!4Z$8FF#2k!104#9$11V#F2#18V	//(I/!4!2#1//+2#12$3/$1,1!1&1)3*1/+4&2(2///3+1$3//+1!2(1//!2,2&2$1/01#2(8*301$3!12+2!2$1+1#301$4(3-4*2/%1+4&4&8&1$2)4//#22$1/3/%4,1/01*6#1//1//!1/*m/*1(1!1#6+1#1#3/#2(4&1#2)2.7.2/$2(1!2#1/%2-1*1/#2/!2)3&1%	fkPQ@E^dyoPQAHcHhhlmLhhmDdhkDf\jOYxHBZijjfjhjFb@@					antagonist	CCK	CCK (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(v:0:F*|``**`h.\}s6=.36>.|`3p|`i.s6\}|`s6zfE*|Ef,f,|EE*	=v:rUzjvyvUhjxuUQxCyUbjzxFS:gcSmlYR@9bdkDaaIM9Hx2B@io2IK__2Z39k0IB281F2WJVnZ2010	0Z80IV02OF1g!930D#ss0c03Z!Gg08s0c03Z!Jh02s0FF120@Z$ 6F4D2wJ11kgV8478261F@n0NNBJbC_0VcJKBy24WO0FcDF4B26@bZsFJDAZ16Vt0FcDF4@26B7I102B96m0X0F	%F#4)10F#4D#51V#24$V$4$8F#22k$4$N$3V$4#18V	/-1)M,1$1/&1&2/#4$8#21+2/01/!4//&1/$1/#2/%1/)2/(1,101#6101%1+2#4%201#1*21.2!@/!1/(3&1//,3$2!2201&2,2%1//(2///!3/(102+2!3$1/+1.1!1+21/+3//*2/(20q%21//1!8.2/%42,2!2//2$2#2#2$101-5/,1(2+1#1#2#1$13!2#3%3/,6-	ek`\D@@DLD`LlbbbbTRRbQQrbRRHXlbBRvNZjbbJbjjj`iB`bP`@					antagonist	ORL1	Orphanin , Nociceptin ORL (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>xiS(.iS(.=S~.>.h.i.>.h.>.h.>S(.>x>.iS(S(x=x=S(	:UvzdzUrKzxQT@zEEBkQteQ6Eu5hWHBDQxVA3X588ciZV3XL2tWFV0RNBoAbKG2VY29V0B401010186VVV0F0	0WR0Tk025k1v!C20@Z0gF045k1_06k0Tk05Xk2D09w0cF3Z!WD05R0M02A08s0bk2W0DF$ !6F4226421tBNA3WVV421C76W1NVaC62G8J830VIGlcNg69_l0w2FA85ZVlRT@6W21O4sg47212GFwNE51GNJ421aYYF8ZHG6XWFgB420k882TBEm0VkPcw8B445XldBH8320VB410b43VNcLG531cJB40W0F4sVSZ11Vp20FcA8241	!30aF!F0J*FV#2#4VN!226F!cko!5_%FF!V2k#GZ#80F!X3V!204!218V	/,1*A,1&1///02#43$3//1+1,1+1)1!2!2&4//2+2+1/0101!2/!2/.1$101*2#2$1/!1&1+2+1/1(1$4&2$2%1,2/013!102/$1020101%21/!3-3&2)24-1/+2-22!101.2$3*1/12-2!1*25$2////-1,10i$1!1%1*1/6/!3,3(2&2!2/.1#8/1&1$1%602//$2/+2/04%1%2.6#1)	fmwHa@FVRvjpQAHcHhhieBeddeEEdnBM[hxH`jjjjYiJ@@					not given in publication	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.=x=S(.iS(xix>.>.=x=.hW(zd}Jp3\}3p	<v;r:hzyzUjjgqEzsdcdrAxWFQBkBXd_HpFe3IVGF1_YlFNZP28LZ2XF41!2058FF10206248F%	0Z80IV02OF1k!C209w0jk04Ak1307!uF$ $1V14W0FkLF482RHc0lFF488rF3Fl8TF4@2MAb2NF8B86	#8s#3$88#261V!1@#20a$m$W#BVF$F#BGo#2Z#FW#F5k#4$5NV	/*1,9/!1///#4#12/02//%3*1(1$2!3+4&4//+2/!2$1/(1/201/!4//+1,1!1.1/.201!1#1*1/.1$2&2/!1/%2/&1/01/+1//1,2!2)1/$21//2/(1//!1&1/+3!W%2/,1&8/%1)101!2//101.101/02%2)4.2/1)1,1.12+2*1/01-	fdeP`@CVAsIEEEEmieCSdmN}PUACUTTDD@@					antagonist	Adrenergic alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xi.=x=x=xixix=xiS(x=x=S(x=xiS~x=xix=S(xix=S~xiS(xiS~x=x=xiS(	{QzyrzTvBrzSfIuXzAh3uTB:2_A1l2KuU6HWV_3DV30MosDJPQQJ0sA32J0W4!60H0V0YNX0G0	0WR0Tk025k1v!9_07g!Xw0s!3Xk2W0DF!t!cF3Z!FM06J0R01v!Fj0440FV2d!OP05k0Tk2F0@40t& &XWVPF7W0V4ZN115511FgPC520sRF410VGl4sCT251O0FF88aP5Xm8R62970F8Fgg8@5X1VoF42X0cF620VF@9178271134dZP71YX1k8VgO821NN4HF9m0XFGG9TN45X5O0463522_q0sD32Y3GWGWHN46X8KOVB@7Z12VVFkkRH92FNRB21a2n0cNLE5WFkRB62VkN8610VJWmLF4D3Z140VGdRiA@X1lFsFJ58WWFg482W10F420c4J3eJcD452O0FN8F@A42lFZD321G8F820VZHH8FDG74GsgB51_4HW18uC5Y0ksw42C81WW8cP64WVVJB620VF8420dYokNo@98WGFRD9210FB2TIEm0YFRV8B48@4W1NoD921kcR450b_F848ZX1353NcLD3VV9G8cef63VVJNVB33XWVkH33X0s4F3110844ZGHm0W0F	!23ak!G8Z!40H#40V!1@#3VX!22lV!sYJ!2ZG#8FF#2o!80Z#OeF!9Ks!@42!2_8V	*2&1/#1A/!1-1/1/#4$4$2-1/$1//101/(4!1$301/01.1%1&11%1)1!1/02/%1!11$1&1!1/.2!122#2!2202)11$3&11)3)1%3$302.1.2#11&101!4,1)4*201+1101%1)4$104&1/01$11//#22!13,5!91#4/4/+1-9$2,2/&1+1/+1.t%4/#2/D,1/1/+1*1!2.602$1010201+1&104/,1)2/1)3!2.3!1&1/05*1!	ehR\BD@GLmaHjo`H`bHRYg]e][VyegVNKGMcg`XHBjjjjZPhDJH@j@@					H1: antagonist  / CCR3: not given in pubication	CCR3 / H1	CCR (I Peptide) / Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>.hS~*`lv.>S~:vS(.i.h.=.>S~.i	=fzOzwoYSJ@THAFNXO4HL40VhY928FXX392039F1!320@1k0VGXW@g18N2H0809408P0V@548434NV0F0	0qJ0R01v!C307!uF04B01104F0Tk04IV2A0@40t! %A@7GtF8B70VWGlt0VC5XGNBBH79m0WkFsksQ51kVF2H79m0W0RV8F4	#VVk!KF)24%2#19+Y$4k$F$Ho$5#OVF#5s!24#250V	*2+1#2+B1///&1&1+2$1*301/&2//&1//&1%1%1&1/$3#201/%23#2//!1(2/#1!1.1/!3//02$1#2&1.2&1/!3&3%11/#13.2#1/#3&1!1)2/04#1///#2!3+2///$6-1//(1//+X!1(2#1)1,1!402//(102//+3+2%1&2)1///#1#1/02*1/,1-	flua`@D@LEIgVYYvuZ]DJVjjB`hhhLH@@					agonist	MT1	Melatonin  MT (I)	no	gpcr-ligands_DescriptorsNo5Ht
.hS~.>.ixi.h.=x=.ixiS~.=S~.h.i.h.>S~.h.iS~.>.=S~0lF*.i.i0:(SS~.i.>S~S(.i.h.=S~	;xzxzxrpxzUwfUEE8oENidaELHhWZA@uxXA@X5N@afZ3FX0aO9u0ky8RovYKG3l129V8FS01k1J740X01!V	0Z80bk02J03d!C_06k0R!3FV2d0A4!sg0bV3Z!DF09w0t!4Nk1Z07V0xF05Lk2A09s0k03Z$ #Ss66F3kVkWcLF4B3Z110ebFGBA82F12Y0VksH51FN42LBA10VsFH84WlFN844Vk8N420VK2044P114f0FcVPH3Wl0FD511FF443G7VFGeFgVK@3W8N22964Wl8Gka@83lNB8489VFH844TN10VkcFH722VcF6320kVF441VVF9Rc10VFm04210X2rVNRHC3W0sF873VVV8sk11W0F842143pVVZTC54WNcD20_ZXvkN8D4221WcsN92218RB3C90VH1k44110kFZD61WVcJD32WFcJ4210VF5Za20VVlvV8D62WFsNH531VkJ4310kNB410f4F888Rk31XWVwL@4X0FV6210IltuWPE33Wt0FkDF4H3V2120g8B885Z15VVFFoZD4XFcV8710kF8wPT54Y1Nc881X0cB423Wk8C4XX10XG0RD651kkcD21W0NF2ZH0VV8NtJ	#O1#18%2#41V!JHV!5WP#D7F!PtV!6gO$J#VQo$Z#8Z#13k!236!118V	)1#1/&10K/!1$1$1012/!2(1(4!125#14//1+1-631(@$3/01&1%1/!2-2!1,3!1,2/!1%1/$2&21/02%1$1+1/#6.2*1*1$1&2%1,201!4.2!4$404,3$1%1%1-1/2!51!4&202#8-1+2%5/%1$111.2$2/!1%102.21,12!2!1/#1*11(1/$3,1,20z$1201%2$1*1!2&8/%2+2!2!212/!1/!1%6&1/403)@02)2/)1*101,102,1#6/,@%1%1	eaSVB@@DBIHbo`Jil\bbbRrTRRVRTTtRRUTTRSGGdQwusuOKUKUUUUMTuUAAER@@@					antagonist	Adrenergic alpha 1 / 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>x>S(x>xhS~x>xhxhx>xhx>xiS(x=x>S(xhx>xhx>S~S(xhxi.=S~S~S~	?v;IzyrUmf4MUUvHuXb@h2dTcdzeWBGp359e6F4@W12#mH9DJHm040V922F4W20W20L#a0XcG0	0RZ!ZB0s!2J03d!C_07!Tk03Xk2W0DF012w0FF120@Z016J0R01v0Eo% 0vJW2FWFwiQ8W0Fsw42C878Y14J@753Yl1FD76Xm30Z413@0FGdVgs932I08JFE8m0XkF8N6772WNkD910VNB620cZFF8x8F645WsgL412HWkB4NLu3cklFTF4B2289n8ZFBF657oVsB26335qOcB@6CB93FVwFRL4aG8ZF38640F8B8A73kscD7410GlV422@VFGm8BBB8ZFFZLB5VHm9PBDu371t0FkDF4N2192YVCFBH6	$2k!2&2#4%8F!3WX!1@kV!Ph8!4VF#8F$@o!104#1VF#5k!16$59V	,1.2)2C!2.2%1-2$1/+20301!1/$1-1%1(2/024!103/%1!202/#1//%4+21//%103&2+14/#1/51&20201#2!1&201&1/0111#321$1/01,2%11$1$4$1%1(2$2&21,3*1(201!1/$1)3$1$2.1$1$2$21,2!7$4/)2*1/!1!822-1//$11-1/,u%20101.1(1%1D/-1&6+21$32/-201$10102)10203%1!3////,1(3*1/04$101%	eh\\BH@K@`^Lbe`ICHhdleDedhdhThhddZFCKCgh@JjjjifBBKH`|H`j`					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~S(.>x>.ixi.>S~S~x>.i.hxiS~x>xiS(x>S~xixhx>S~S(xi	>ryzSvzvzt26MRvxizry7am44kKedG20KG5GJP!AlFF1V1018c401FF#c04064!4!2!V220b4I0	0Pg!Xo0FF02CF1D!9_07g!Xw0s!3ZF3a0Dc!kB0F03s& #281Zmd4D85VmWc44JLO_W1FVFkaFDY104VLF@333WwBBB110W96F4B2C1fJc8JH@57f11N@B96NgkWFFmR8121WBV8N5Rq23W0VNZP@6XW0RH420VN8wR11680FOcqN5WVG0VVH574XFwD51VXWk84NL334X1JT72VkF4gL114a5pG0Z874NgkWNGqD452m0WkRV8B443DYY1B@20ZXV88Vc	#11V!18$9V$c$C%e$W#Hk8$4*5k#H4#G$A88!102!2W8V	//(D)1(2/%1/032)2$6$5%2#1/.1(1//%1/*1/01/$3,1//)10103/+1#1/#1%1(1*61/12/&15&11/!101)1!204(4!5!2$3)22/%1+1/-1//*201,303$2#1+4/(1/#3)1)4%1/02(1/*3$3,1/!h2-3*1#1&1#8///*@)1/#4//$1/(2//,2,101/,8(1$	fe{aR@KPQH\p^FRREJJIY[QSISPsj}Zjjjjh@ahPrcq@@					not given in publication	GABA B	GABA (III)	no	gpcr-ligands_DescriptorsNo5Ht
x=xiS(S~x=x>.>S(.hS~.>.i.h.=.i.=.i.=.i.=S(.iS~.=.i.iS~.>xh	;tzdzOzpxGQR3U0Q0GAseHV222g32@88x211011F0@0FW!31V!Lk0BJ2e2!d220248*k0V0F0	0WR0Tk025k1v!920@Z!_!uF035k1_07g!qJ0R01v!DF0@40t& #m0WVFVwaK63VcJ610_YmkNgJ95YWVR8410k8F42F88O0GNDF4B2222GckJ81VkkN861VYmk841390VH2NJmO9Wm88RJD5AVksogB1Y2Gl8mg2341VFVcZ46XW0JF92109kws2444GssTB30k884PCC0W0kVFB630sVF130VN50V116ct0FN88D43XlNcD420kVR@310V882cF0VY_FsJcx3XWWFFNJH6YH0JH3@9VVFG0k242X10gVB3X0c8ki11VFF4220Z3_BV8B4472WlFkJ81WFVF8410Z2s84e110Vm844PeB9kFVVcI8241	#15V#84)F+V@!203$WJ!4Zk$FF#2o!104#9V#19k#F2#18V	,1*1.D/!1&2//+4$2$2/*1$1//+1#1-4*101.2!4(1011/%1)1!3//.1&4!1.1+2%2$2&12*3//#11$13&1.1/%1%2$2*1(2012*1-1$3-2&2!1#1!4/#1//$20102&1$1#6$4/(1,1$2.@//*1/,1$13#1)1!10p(1%2*1+1#D!1/-1#2)12(102+2.2!1/$302(17//&201)2#1+1/3*10101$4!3#5-	eg`\DD@IGLjm`H`bHRYfe]UVyVvAKGEchHHjjjjX@bH@@@						D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>.h.h.>.hO~,B^}}^)\6s^}q5(S.>.hS~.>	<xzq:jurxzxqnzriSzrHzkhzqwvkqd3SnpKHxp9kOaUSdG2E6of82Y344cBB2qco6118JBk080fk816NY0	0U4!WR0Tk025k1v!8c0@k!lR0OF1v!DB0DN0uV03Y03a0Dc!tR0a03x!Jc02w0FF2N0@k% #1Z110t0FcDF4D3Z13Vt0FVDF4L2d0elsVcFLU27elsFkFcfGVW1FXc4cu18WO0FFDF483Z120t0G0@V4PD1GG8dJcV36aVGNVkVR8X3nN8kJPAB6Gk4PD@7@_IsOFLE282t0FN8gDOC1GVg4F98KVZ3tg8P6X414bF8wBDnJ0W1cXc4iCL14kwV8B5F227hkNFkI8241m0W0RV8R78251m0Y0RV8V78251EeYVNZE82A1	#84V!48Z$4#2%6$d#20QV!FX4$1$FF!VJo!2V4#_8$4V#J$11V	01#1$1/*24#1-2!2/,1%12,3!1$2!3.1////,41////)1!1!1//*101,1!101/*101*502!2/3/*1(6&2!1&2-1,2!4&5(6-41+5+1$1)3&1#4,1//.1&2$1,1!3%1.4/#1!3/!6,1+1/$103/01/.b//+63/$1.2!2+1#1/-6/$3$1(1/!1%1&3%2//$14&1/,1-	fakaS@KRbeoPQAH`ladTTVVRbdVbltYspPy``JjjfjXhbbMD^hCP@					antagonist	mGluR2 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
f@fuS9j`jFSm<FjFjFj`Zl<`j`S9j`j`jFSm~Yj`mP	;UvUzvU:YzyzUmfry:hLTqbf:OPxx6vnxInbjOlOkUUhP5l0wQed6y1PN6I2Z0SJGAPHvESBN5XaR2010	0Xw0s!2J03d!C_07!Tk05@V0h02w0FF3V!Je02w0R01v0DZ02Hc0AF0i0440FV1404w0Tk2d$ $BV8J78251m0W0RV8N78241m0WkRV8k78281m0XkRV8N78281m0WFRV8878281m0XVF	#VVk!KF%4!25W$6#392$H$3#80k#8F$Ho!805#GVF!B5s!24#250V	/.102%B/!2!2//)1%1$8/&1///*5//&11/$1/#1#22.1/////02!1+2/(1+11#1/#32/&11&1/!3$3&2)2-101%201$1)11101/*1///!1012#113/3*1/%1/#2*6!1,1///01#1.1$1!3!d/$1/01#4)2/1)12#101/$2$1+1!1-1*203&101*1%1+1/1$1011/,1*2!1!2*4-	ffka`@B`x[IEEEDhhdeErRdoVRFNRtEPUTUUQUQAEBFTJHcP@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.h.>x>S~S~S(S(xix>.>x>x>S(x>.>xh.hx>.>	:UtzdUSzJxxQR9UUU8GANuva9H2BYE9NHv2Ae05NQZeaGXXFYO1xX7o1R0eW302W32Xk8FK1104F20FF%	0Q#Z80IV025k1v!8M07g!o40FV1D!C10480IV035k1_07g!sg0bk3Z!OD05V0Xk2U0Aw0t# #O0FNDF4F2XW12FVYC@84321HnNT4532YpHB8456XXKXg8864FAW8oFB8VAdkV4JP@5Hd2V8J@AZ13VcVGB84D5Z120W2PFiB1VWlFt8iQAWkF4RJEZ160t0GkDF482EJ8VVNJX@SE9kF4JXAZ13Vt0Fk@Ky442m0X0FVpJR4W1WFklLM5XF8kZO429W0WVgV8g78241m0WFRV8o78241JikVVJ944A2m0ZFRV8c4	!297V!LB4#82!3F7k#2$XT!2@Kk!8t#4VF#@0k!Z2V#VZ#GWV!14s!2@G#1Nk	/#2.1#B//-2/(4$2$1#1&2/+1(1+2(10202/#4$12/&1+1//%1/%40202/%21&1)3//304//0101/&@$101,1%1/!102!2$1$121&1&2*4!1/-22//$1//&2*2*3/%2)1!1/,6%11/*4////g.2-13*16!2!2/.2+1&1/&1%6%1!1/*4//&2(5/)1*3/,6-	fikqA@NBRDDPjHrJJIQIJFIJqIIdcN``XjfZjjH@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
.ixi.=S~x=.i.iS(xiS~x=.ixi.=x=S~.i.=	;UvUUvUma1pym@m14kqhV4VV!50tHg502!2021FF02!416F05NV808F#F08(V202FV1!X0G0	0Pg!Xs0IV02Ak3V!C_07!Tk03Fk1F0E4# !ZV120V@8eW4XZ0F8oPu2@3VX0VcZHE9YGkFH3@8_1nOJRE7VWlNt@69321W1NVTI9YG0NVV1174YYWNaF552c8VFJA8231	$VV!1+4V$@#20X$k#F1%F+Z$5#GV#84s#4#258V	//01%91/02.1//#2$5/&1//////+1(1/,1,3/1#1//(8/02//&3/0232/!2#62///)3///02$1/-1$2//01/*2,2!6//.1,1#3#1/%2$2#1/-1/1-X/*1*101!801/1/!3/)1-2//#23(21/!2///!2.1&3+1(6(2$	flya`@M@EGIEDdhbdeD^JhHJJjjHTh@@					antagonist	Adrenergic beta 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.i.>S~S(.i.h.>S~.>S~.hS(xh.>x>.=S(.hS(x>.>S(S(x>.>	=vU:rzxjmQUzjCH@QPzifl2CnyAnHveE6mbIAbBg1DXVXQcv8nRAsVtdhlnlA1kVcN701VKFX011FV0F0	0PF!WR0Tk02J03d!DA09w0t!3Fk1F0E4!oB0J03l!NM0540OF1g07!Tk07IV1N05k0Xk2U0Aw0t% $6F4F25D6JVNJB@888GkcZBC63c5ck8@65Ial9J8@C567ntV4@55m0VVRV8Z4aWE4G0cVpeD@21GBV8s7826172nd0RB1YZWkdckQ420Ft8U82F1PB0VsLF482J9a2FN453Z2X0kcaPA1W08VLFo15B0G0ICX482m0WFRV8F4FLC6m8ccJPN@aH0ccM8251m0XkRV8J4	!3N4k!40B#BF$GV!ZX#4oJ!22Lk!lWk!60X#20F!4@Z$Z#GVk!F6k!@ro!21Rk	-1/)9/!4$2$2//(4$2$1//#1$2/#1%102+101)4/*402/,1!1#12,3/%2*2/1$1)1-1//-2*1%3$11*8&102(101/+2!1$4!2/#4+2/%1*2$1,4//$1/#1%1!1(2/2!1(1+1/*8%1/!1&1/1//02(1$g/*101-4/!1/!2&1!101%2$2#4/#5/!1$246(1/$21)1&1/$2$1/!3!2(2/6-	fe{pR@BZBks^`bLbbbRbTJTtqbRSAAcAAEMSMUUD@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
dz}\>xW~s6psxh|`J}x>v:xhzdS~x>v:xhzdx>v:xhO(zdx>	xvwjgyqabEuy9dxVbExeCCK1KOgmPs012F!uS42B8kNFZP4FFV4FV#10V0FH10F8J8#4%2#6030	0UR!Z40IV02Ak3V!8j0D#sk0tV3e!Jh02w0FF3V0ER0 !eOCXlF86DD7m0XkFFoL24XWWF221W0lck61247t0FN8ZcKBXkNN410_3XgV8c4a765IcF830ZXmFNBDA4XVsgH62W0c82TI1VV8Nt8agEWW10WJJ67XY8FD194Zt0FN8kaO7YVc8FFC8m0YFRV8N4a7BXYNVNX30W3X0	#B,4$9$4$12#2$8V/04F$4#18V)2$W0F	//(N.1!3/%1*1$101)4$8$22/!2(101$1%2(2!2-4////(1-1!3!2,1/*2-1#4/*42//+E/$101.1#5102#2//*3&501!1!3///$11%1-32*1+4//*4)1,1!1/&2/!1/(101#1//01/02!1/(h/,1//(2/!2-1*12/5+1$1///,3/01//+1*301+	fisAP@@R\wjSLjkkNjldXuUTuUUTuDPPRaeAbHR`						PGE1	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
~Sh.hx~S>.~Shxh.~Si.ix~Shxx>ix.h	;UHUGn9F0kVLs6FNHkkRVL640F02dHg52L1#11F80X1!241410e!9F0@#VZ0202X4V401FV240X0G0	0Pg!XV0IV02D03V!990D#b!vV04OF1k07g0vV0 #1Z11Vt0FkAhH452m0WkRV8c5Hk51XFoF8q42A2G0Z8F8o866A3WksR634XXJJ88F4X15FVG0H84RUG12VkNsmD74VkNVFFXW11FgV8B4	%V//!1#F3%4+c!205#G$80s(218V	/02/%4/!3!4///%2//%1//+3///(1(11/#2/.1//$2/%1///%1/&2&9/(5!1/!4*3/!12!2/)1#4/.1&4//!2/&2,2!3/%1*101/!1)6//#1//(1/%T3/)1$2*6$1*2,1&2/#2////#1/-12-2*1&3/#1/,1#2)	fhqa`@C@DiIfU~uigHBBjjhaJ`@					agonist	Adrenergic beta	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>.>S(xiS(5q(Sx>.>x>.>S(xiS(xiS(.=}_=xS(S(|G|Gx>=xS(S(	:xzdyyvjiyYh@jTmfrBXU5HqoFeUzO2FN2pnRHm_dlGOFAD5PAe3oI2t0cV8N2I2!O0Q8k12A55853442010	0b!vV03@V0h044016J0R01v0Ds01Xo0B01104s0Kk1Q!Rd02o0B01D07!Tk3d& $38251m0WFRV8V782B1m0ZFRV8Z78261m0X0RV8B782A1	#c0k!2K%5!249#24#292#2F$3#80k*2o$5#GVF!44s!24#2_0V	*1/,G-10101015$1//#62*@.1/#3,1.3*2$1/.3///&3.1(1/$1/&1#9/$2/6%101$1&13//(7.1/,2,2/&2&1/)146.6/!3/&1///.1%1/!1(1/09!2/-1#3%1.1.1/%q1.2!311,21%404//#1/030206/0105&4#1!1/!1(2+1/#2//////!	echPD@@@CLdTTbbQbRJdrRtUDbe`TWTprpvuATQQUUUUTMREADa@@						CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxh.>S~S~xhxhx>S(xhx>S~xhS(x>x>zdW(>.~Sp3}J	:Uvzv;RzvvytzUfSszQvMi83AgJQ9x7j@7jGb97He805f04J10B1c2DB2m90X163FJ#294F0F)	0WR0Tk025k1v!Bh0440IV035k1_07g!o80Lk2d!Ji04w0Xk2U0DF$ 0674tJFD8pMW2FW8VZJ7XkNF8135XHl9@4742X6GnZ48910WlFksZZ10X0F4H99Rcl0NcB235YmNgF55WFV8kL31123gV8B46@C41NoH14VFGNZhwa26121koVC7WF888220nGGiF46269WZkJJV36WVNVgb8241	$4V!104$2.1V2!22$8d4!4Z$8FF#2k$4#O$81c#H#218V	/1/&7#3/,1/01/%10@$1-2(1//.4/(4///&2!1/!1!2///*3!1/*1$102)2/#3*1/!1$7&1/)1/!3$1*2+4/#1/)2$504/&3/(1$2-2/%3,1(4//)26/(1/*1/1/+10f/*101-6//%6!2!2,1/$5&42/!2.403.201-2%2)21//!2%1%2/)3#	fasQA@MATBHIDILsnwMkLkNM{A@TuUUUPpLP@					agonist	Opioid kappa	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.iS~x>S~.>5qxhxi.iS()LZ}x>.>.>?y-gxhS(x>xh	?yzU:QyhvhMzszEx9MUirqsoCDjgMgm03s6SXsq2bPRJ7F4VW0EKHH120FoE1k1H9J6J!gkVX120W0	0Xo0FF02OF1v!920@k!XF0s!3Xk2U0DF012o0FF1209w0 !6F4@3Z13Vt0FV90ig7X1V88FJsm61l1F84F11332meNe4232k88ZSNs241O0FsDF4B221Z3lc8D242k88Z_gi25WJXFFN8W291W0kW1HP50F84VRGO11FVVNF	#80V*4*4#19%1#FY$Z$@F$2k$4#O8#818!2$218V	//02%H/031!2#1/-2&1$8$5$1//////)2$2&1//*13///!2$2/.2/)2/!1//,2&121/01!4*1)1$202-1/02//!2////!1.1!1,4$204.1/%2/!2/03/2/08//&2%g%5//$@/$101!1/&4$2/#3+2#2/#202)4/01////#2!1+5,7-	fakP`@D]@sHhhiDmEEdde\ktZiruUUATEQTTLD@@					antagonist	M3 / M1	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
q5.>xi.ix=S~.=S~xi.iS(.hxhx=S~xi.hx=.>S(xiS~x=xhxix>xhS~x>xhxhx>xhS~}^x>	=vzxzxx:wvUUzQIEsezyA79hbgufczqA30hfIDeXOZHk5FWq@ok9DoHe@4Hl82#CYeGkL040FmF1#	0U4!XV0IV02J03d!C209w0eF03Xk2U0DF01540OF1k07g012s0FF120@Z01FZ0FV1E0CZ0xV0 $ldBkL50VF4410a3nBV8N4@@91GNZ8841kVF42D90VH1s4TSC2mFkZPJM1WXkmcsXA6WGc46H@10X2W0wuI8WFV421@4_HY08BB63AX1skD93XFV441C5at0FcDF4P29721NRB111Fc84311FNJ4210F@l1Q8261B21cwB60WF88NLD20XkF8ZoZ752l0RB2210NF2430o1k44LX23X1WBZC4WmI0824K0VFX9gC245210l8ZLA320kc86110F86XK0VZJ_8NVX1XYlK8S6G45X0VkJJ@5WkF8461VFN86610kF84gL10VXN44XmNGa20VJG@k3W0VcsK0DCWX0JNFCZ12VpVGFc8473G5Wk843@VX1W1Jc4@70F84FG8	%k$8#4$8$V@#1ZV)Fd8!4Vk#2FF#@o!8V4#1b$1k!25$58V	/%1&2)F/!1!402/#2&103/1!26$3(2%1//!1+1012/1%3/+4%2*1/*1,4+1+1//)1&1(2*2/01%2&2*21/&B1%1%103*1+2#424$3$5022$1-4&2!24//02.1!4/#1+2#2#1/$1#2%102(2$1/*2/#4$2@!1///-102-4/z/&1101!202#1%4#2(5(2.2+2&2,5-103!1/$203(273%2#1$1/-2)2/0101%4&3/!109-	ej^RJH@LJe`XDGHb`@cIICEEhheTdhXdlhdliCOIeo`Uj`bJJijjjjjb`@@					antagonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
d]SgdIB]d]d]dISgdISgB]d]S(BIdIB]S?d]SgBIdI@XX@d]EEEEdIX@S?EEBI@ZZ@S?QgBHHBBIdIQ??Q@NN@N@@N	~:UzEq:uUzjjUhrzS:jijaurOArfcHMYrEM9nhfhgDwn3Eji4658HWO633oN8JZAYbV8k0	0WR0Tk02Q02q!9J0Eo!qJ0Q01v!C204w0eF03Xk2W0DF012s0FF1209w018s0bk2Z0DF018w0bk3Z0DV01GR0OF1g07g0hV$ $TH4alsVDD779VaFsJ2C@XWN82320Y1Wfk4Pc15W5lFG4HO@X0VccU8251T@0VkHc4NUC120pfR8B4h7_10gJT@hQW2kVFFJ42XlVZL941VN842F681VscTA83FVBB410YGOcRB@2XVkZ@530VNJ@22VVN8210f35Vk8NC42l8V84210V88110JWHFRqJ@4VNFRJDA6XkncNNC40F8NN799aO0HFDF4D3Z16VdW9gq8L40VG88H73X0kR@211FFB6710FPdF420WZ6BV8N44FAWlVkVDA50XH0Fo855YFNV61@@21cJ81133F88d44L30lsNL487XkVRB254aVZsFk8CE0FW8k4233XkFNB@4Xl8F840VV8442K5eXkVsJA0VVF42J4VFGlJ630VW1mLF462W17a3NFkT2@49Vb0sJ26ND11Vg810W0G8oos62@0YkJX6332m5F8xo2A20WG88@45XWNZD4210V8410V_1PV8cB3F31VRD25B0FVZN8IBm0WFRV8B4FDB2VWoNJ@143XWFF6D4W0k4R521kGks4225VVG@8Rc73XkVJD@5WFWVZk4d0bW1OV44860VkscF841kkgF6210N842H690GcVLA1WF8JHA2a5VkN86FEm0XFRV8F4	#cak!14Z!41$2kF!Z@#5hZ!20J#FY$Z#1@GF#@k$5#OR#c7c#K6!258V	%1%1/*L1/$4)1/#1-2014#27!103*13/-1$103-12(22%12!25%2$101!1*1(5!1#1&22.1,1!2/(11/$2#2!4!1#1%2#201#1+1%1011$22(5&1*1$1/2174%302%1%1#2$1(1#1$5!204034+11%2#1!2!5/-1#2*1#1$1)2&1#2&2#1)1)1$13.3#12*1/)3%2!1*6A/,1&1//!2!1%3$201!2$z$131/!201%1&B101/02$1*4*2(3/(1$7*1(101#1)52!2,3/$1/-1%3#1#6(101/09(3$	egXvBB@BDbgdRWHllPHaRPtdCICHhhmEiEXeEMhddldheDidTdqpl\KJ[[A@UUULuUUUUMUP@PPVD@@					antagonist	CGRP	calcitonin gene-related peptide, CGRP (II)	no	gpcr-ligands_DescriptorsNo5Ht
ugu?SzS,ug7ougSzu?]y-IzT7o7o]--IyI7o]-(EyI1gS,]-1?1?yIS,1gy]I-1?1?o7o71gI-o7I-y]-Io7o7S,y]	[rr;yvUjjBqU:WiirPhWqD@vxX3Tn_NDhv4IHe_3QG84Hz8RovnJG3l329W80S01m1L1Z0m01#	0WR0KV02OF1k!9F0DZ!qJ0Q01k!C20@Z0g!3FV2d0A4!sg0bV3Z!Fj04B0R03d!VM05N0L02A09B0bV3!DF% 0WVmG81Vk4VL1144t0FF8ZkJ83VkF8FC10XXFcFaF7Z1NF6220I1lV4452XG0NF551kNN621VVF8230V_mPsJTHB3kkN@210HldRgm4723C2GN4@65fYFW8F4@43YGd4D510kcF@4E9VF84BT116dW0dBJE4XG0FBJM110F4FZ1187VVVR@521ks8B631kFN412VFF8210g6089N210WZb0W0cD5WG8BD320V9d8r2323W0FVFL442W0RB43W0kB410VJmk84139A0FFNHA4YGNVB71VkF461G90VH044Pa10WBF8B@52W18V@52110F842WFNGFs31B0kHf08866YlNZL32WVF4430VVF5BRaeK40ksN8432WGFcD53WFkJ@73VVF4410f50891U82612238gL56WkNN@1B4aO0FV8NJL4XG0ZD52W0WVgk451VVsJD73WkNR@711FkB430e_V888ai6JZlFJ86441H088822WFsF4731FVJB221FcF240VL3F84k2115F89822ES0VkaFB842WG0BB60WVcB8321FVJ242A6V848i10W50895r823142m9ZLF1WV84cF1135t0FV88@@351coD5310N441E77Y6XFBB6462l8RJA3X0VB42175FV88ZV10VVVgD862FsRD71VV8882I9VFH0424BL32GW0N671VVJ4516WnF	!20ZV!G%43#J1k!REc!7_n!3@yF!PlV!6ZG#3J$Qo!40Z#9ZF!97k!2a4#58V	/$1$1(1010P%1+3,1/#2)2&81#6#14%1/)1+1.3)2$5%1.1/,4$1(122.103,5!1,301!1101&2%2%4&7/!202#1/03/#8.2/%1$201#1101,2#1$2.2!4$403$21%3$1!1!1%1-3/#31#1,802+1/$2/#11#211+1!5$4#101/!302.2-14/*11(211/+102!1)1+310z$1401+101(1!2&F/+1)2!2$1#1)11&10101%101#501$1/404&10A02//$1$1%1.2#12+6*1/0A,1	eg\vBH@JFA@mjRFeiPHcHhhihhTdlddhddihddlUEDepHxDl]BScSk[RuUUUUUUTEAQPPPtQ@TP@@					antagonist	Adrenergic alpha 1A / 1B	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S-2@t@2ftfSy2@t@Sy2f2ftftf2@Syt@2ftf2@t@Sy2f8n@2@~.I]x2ftf2@t@8n8n2@2f]x2f2@8n.I8nn|8F.]].IxxIIx.].]Ix	:UvzvzwzSxvvwtzBvOuj9zMy67vgb0Ohyh24u0Y5PFf0FEWVO440s2cZD422ILV1079F0180N4k$28V0F0	0aJ0Tk02OF1v!9_07g!mo0AV11!Bh02s0FF03Xk2W0DF!sg0cF3Z!Fp0440Tk2d!Fp0440Tk2d& #WkkFB83WkcF@421VkF4120FF42iQ0Va08426J0VYr0Oho810WWkk84C55WFc893VVN82RJ10ZYkFFVB7_0cZ821VVGdJ21297WY3NN457XVqsFtJ2B3KDVWNFBJ@2XGFV882WksF4110F85Bc118e3ekFN8DQ84HcB428710GW88DA4XlFNH9210VB210VVHGJ22CIIikFNcB8O75HsR6DE10YHBV8N48E821kkL61VVs8kVN238nNk@52450N98Z89AalcZB50VXXF44VMZ140t0G08WmK72310v4cG461VGFcBB431G0FF52W0cB@32W0NB610VFN42oQ0V_k89Cn824110dFG0JA92kVZ642_aF89J21297WkmBwG20Gm8s42942G8ND91WVcRD5186kF9Z22K0VZ4pGwPB0XY1FFFBPAY18F@4@A0VFGBn82412VVcJB522FkJ@7110VN4520FHe022T0VV8OZ212@hWFYNTG2Y4WVF@JHC62lcgH7110OOZ212@b@4NcR1562Vl8RB@32Vsc@830VF4411964VF4LV@3W8F83@A50FV4B52WVFRF531F88@521FF44110F842sS0Vak89Ss	#10V#8%H*4#198$1$Y$4$8F$2k$5#O$918!2$214V	//(Z-4/!4//$@!40B$2/////+4//*32//)4/%2#2//(2)2.4$6+8$402#4-6!2/,2/&2*8)2$2(2-2*2//!4#2/(4%6/!2#6%2+2/#B(202!2#2%202/#2$404!2$B/(8/+4*2/4%2$2$z%8!2$2)2202%2&N/4/.4)4,2!2,42,22%602+22$2//*2-1%2!8*4/,F&22$	ebsrD@@DJfiPBlbbRbbRRtvRbrbbbbRvrQRbbbvVcegasuwtIMKIkmoj^[UTEAETuUUUPPUUU@DEA@aD\gTFTtIbju`@					antagonist	M3	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
8t^}(Q/jxhD{S~x>S~.ixh.hxhS(xhS~.>S~x>x=.ixhS(x=	]xzxzU9zUxCouvPU6EHMgkxCznU@ADPjGQqigmEYHis0xcWo40Bf7OPfW54lv8F451VFGV0Q0VV8F0	0UR!Z40IV03CF1104s!qJ0Tk3x!FC05V0bk2W!GF08k0tV3c! #O0Fs8STd1VWGVcLy492NfkNNgB8nLWWFpnN8D413aGm4T472Ycb8ZBD6415H8sDI510GFNc8O@71VgNDBFQ7VkkTF4B273eYccJF2111Go2oV673VWGBV8F4	!2x2k#@#4%8FV!V2$BU#25F!NlN!811#8FV!V2k#W_#G8k!WGc!2aF!2W9V	&11/.A/!1/.101/&2$3//&2%2,1&1*2/!1%1(1(1*1-1/-1/#2$2+1////!2)4$1-11,2*7$102#2/01/#401$3(201#2$104/-3///1#3/!1/$801/!3-1&72/!2*12)6/01#2//$3$1/,1#e)1%3)1-206!402#2/+2$1-1%1*2+8!1/&2%3////)2%2(2/+1$2)	fikQc@DXtFH@al`NPrJJIJIQQJYHzTcB}ZjjfBZBbREB@@					antagonist	CCR2B	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
~V_d=FS9=`iFS9i`=FiFiFS9=`i`i`=F=FiFS9iF=`i`S9S9:ZiFiFS9k[kKS9b>`=mSF=`i`=`=9SmSmS`=`=`i	;j;er:3:pOXYrTUbx4PmbfmRkwtdBQkoOpZa9mO2BUh!40Nc026LHm040L4X!F18HOWF!W0X!4!	0mo0FF1D!Bh0440IV04FV1E0@Z0fV04FV1E0@Z0fV04IV2B0DN0u!4IV2B0DN0u!5AF0i02w0FF1D!Jh02s0Ak1104s0 %JXFFc8T8XWW1V84J@iH4FkcO@Z472d0ZXF8o8T2LWVFXN4H536VVGFx8Z482@6ncJ8E6630Vc8FH9Z1VV28A4_X6dFZ880VWWGcF8ZlCWklVhJT482117e4FJ82TbVVBJX@11AWW0gcU8WWlt6F463Z140_tNFk42@3d4VWFI5N7351VGVFBT_IWklNp8Z472m0VkFs8aq2231oVH184N4HD51FVTB@60Z@NNgE8251	/+V6#1h%F#FV#4V1$F$8F#V4*1$4#2180	/.1(J/%802/&2*1#1%402!D$201%81/!1!12$1//(6/&2/+4(1/#1/2&42&101-1*1!1*1!2)1@+302//)1%2!1%116%1$8!1#2,2!2/%1!602!204(6/#1#102*481#2)2*1!62(2-1/%3#4/$2&4(801(2/(4/1/!2!1+4/$10201&1//*z$21$1(2)1!48//%1&1/&1)2(601$6/#104!12(74&1%4#1!1*1#1$1)2.6+1012.4,6-	ekPrBDBIJdUTBHVPLRCD@zCjiUg@LhmEDhddhehXdYhedhhd]MGHjbfmcg`YUVjjjjjjjjjjjZjjjeFBNJMJGJDbFjEjCbGb@Z@@						H	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
>.hx.hx>xhS(x>x>S(x>xhS(x>S(x>S(.>x>.hS(|`S(x>.>l0|FS(S(~S.>lvl0|F|`	~vvUzSzUfzhyf:ioSxzvx@AbOjTUjyddyvqqu5yfBp6wKXoGRzjZ0oo0KOg5G0@X0sVVW8F0	0Xo0FF02OF1v!C10480IV03ZF3a0DV!kF0xV3x!Fi03B0cF2z!HA08s0bk3Z!Ni03B0Xk2D09w0t% O0F8DF483Z12VVH1ZiF60GmVF24C980YOwD343_0c8oVJA7aVkND62VVF82PEC95ll0R820H0t1wRA92l8kZ@27756Hsoi223XGwV8o5ej231CKsFJ8knBWXFlssHA5WVkZ@3@@WVHF42336721lRT72X0FVD1A4_ZltReA333VV48FFI872cJ@176WFG10ccK9Y08VBFC1VXmRV8R782617X1scND20ks4cT516VFGNF4HPgR12VVps8L5E@W1VWF@4FA6W0V8452Vl0k4410Z2044RZ17WGl4J842W08gL114a3ItBkB56XXVG4H52XVkF496a3kNB26AE	#82k!2C8!88Z#@FV#8#1_q!10t#8c8!BZF#eF#gIk#l_#Gf#N5F!@K2!11RV	-1/(1I/&4+1!1.4-221#6$5$1#1)2/)2.1!1$1-1//#2.301//.2!1/*2&2%1,12#101$1!12#102/01&2!1.1&1&11&3&31+13+11#2!131%2$6#10112/)3(2#1/$2-21#2/!4/)2)4$1&4%1!6*11//$1#2*3!102#10101/#2/08+1/(1(u!1)1,1#5$5%8///!6&2+12&1(7101/&1!5!1!201$2*1//1101/02!1#1#4/,4*2!	elVRFD@@bjedLMCLm`@bBPrRRqIYSIIQQSQIIESHRQkjYZEFV@BZjijifjjJ`@@					antagonist	A1	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.hxh.>x>.hxh.>S~x>S(.hxh.hS(xhS~x>xhS~x>xhx>}^^)^)	;j;grUxzvSxtEjtPAByCzA6vcc0OfNh2eQ4j8@m@k461F0F1F80V48JX2FHY102$84!F$X06030	0G#Xo0FF02Ak3V!DA09w0t!3Y03a0Dc01Hs0FF2A09w0t% !sFFGDXmNFVPGZ110VW94TCAVm08ZLH1iWVl8NB6F1YGcgDD1_4FF8H6CC1LW0NcBiW2XmVJ4DB70WkcJ@932G8JB92VVN8431V_1F44Fe116o0NFE30XGO9X84221l@08cR6231g0GQ08483cX0Vsg4@6k11oFB8BA0VXGk88XA0XkGRNA2VFOcco	!2B+26#89#VJ#112#2$@V$B%k$XF$Z#9B$1$3$W90	//(N#1-2,72(1%1!1/&6$2+1.1/#1&2-4/1/(2///3!2*1//+11!6/*121(1//061/01011$11)1#2!2#21.1!6!1/!301$411%302/#1/!1*1&2.2/&5/01!1/$2)1!1&2/!1+1(2/!201//1#1+1/.1-10i+1//.11/(1!2!1/$2/!5!1/,1#1*1+1#3!1)2//#1!1#1/*105+10	fe{`R@JJ]{H@cIDdeDhhiduLeEXHyuUUMSSUUUHDPdb@X					agonist	PGE2 (EP4)	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
~WBz\}spxhS~x>.ixixhS~S~x>xhxhxhx>xhx>xhx>xhx>xhx>g-qq}Zy?S~xi.iS~S~.h.h	;jvjzBrvpSUB59iCco2d@dXnH0s04dDIK0GA0S0VLBZ10VFacFe!JFH487GF8W5!G84F01!F%1!V	0U4!U4!U4011J0QV1p0Bo011J0QV1p0Bo01Z40FV1E05c0Lk2d!O10480Ik1P05g0eF% $10F8J4531VcRB351kcZB52V_20844CL10VFJB531FsJB9420sJ43H8VVFFs22B10FW@yF4D3Z140VFVF67210kVF43W1FN621VVF84gBL11Fcg@942VNF8521FVB6419YF88dF235XG0gH54W0sR6810V@8_422F2@31Z6364YWOt0BH611YGsJP78XFs825C5VFG1k8266YVskZ64X0GVck222YGsZaF5WFN4kJN73AY0FLBB0VXGkVh@N1WkFRVJ4144XkFxZ4@4417bn1Bi8@510l0kDD3XFcVD540VF42X9G111ckT86YkcZ410aXnFoBJ698VWW0sdBU60GW0kaq462	#X0F!p$6kV$2F#2F!832#20V!89$BN!284#40V!1V6#n3V!1RR#7F#_!	&2#2*6/M///%202!4!2,4-2-2,4.2/08////4/&8!4*2/06//902//!3//40A8//*2#2//(402$4$522//2/.4/!2+2#2%6/,2&2)2(8$4/(2#2+2//02.7///6/%x,2/%2//%2-204!2(2/+48202/&5)4+3$2//-4$4+2!62/+2-	ejQVJD@HDCEkdZKDja`@`xHrQIIJIIIHiIIIJIPqIK@`qpzyGFejZjjjjjZYjjj@@@					agonist	M1 / M2 / M3 / M4	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.ix=.=xiS(.ix=.=(SFfB>(S>xhx~Sd<`j~Sx>xiS~.hS~	;jztzirILDvR1cihBF08JBW1V1c0V1dHV20D0V!H!401F$VVV084F102V/$X0G0	0Xs0IV02FF1D!930D#sg0cF3Z$ 1pVL32WVF8B@33WVkV@93WVc8@31VF84421B4V88w42CP0VkFJ@31X0cBD52WFFR612VVN8610VLXc44a20W3k88ptVo221O0FV84422WVsN652WksJ4710kcJ220WKms424J10ZV89022DR	#8&8$4$9#1$102#2$FV$V%F$2J$4#10F#1*l80	//(O/!1-2,F/&4!202$1//*1/+F/1/////(101$2/!6,62///(1/%9/!2/(5&1/.3/!2&1,26/!1(4/012-3%1/012/!3//#2/$1/)4//01///01//$l.4*1(11//1+2///!2&3/!3////#B+4.1,1/&1%	fes``@D@ddrlojjjjjuUUMMMMUPHPQSYByP					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
xhx>S~S(xh.ixiS~x>S~.=xh.i.ix>.>xh.iS~S~.>.i0lF*.=S~0:(S.i.iS~.iS~.>xh.h.i.>	;xzxzxrpxzUwfUEE8oENudaELHhWa9@uxXA@X5N@aeZ3HX0aO9u0Vx8RovYKG3l329W8FK01k1F5!X01!V	0WR0KV025k1v!C209w0g!3FV2d0A4!sg0bV3Z!DF09w0t!45k1_06k0Tk04Nk1Z07V0xF085k1L05V0Xk2I09s0k03Z& 02WbklsNBLL751FFB21VFF4oTP631kcZJ73X0sB450VVF8410VF844kIN3MVWVLF4B223X0sZBC3WFkRB21VVF4220e50848RhZ110VVYwq4582WXtRX6510k441A7_ebFFs889C_20c@50VXWOF8875YGNVH33W0VB4310JHVB4Z_Z13VWkcZNA5XVs8@311kF462G88X2toa831F90gWFw23WN0VFV88@4XGNgH821kVF6PL10ZV888TWX1110dGc8H4@32ldBJ4210cJ@NF10FWdk44@63GsgP820kc8oVP12VkcRD741W8ND52VVP1k4310FF44DJMm0VkFFJB64WkkZH611FkR4510F85Fc10VF8VxVHA83WsRP420kN4kRNVL_VkkN4843XGFcF@220FZ8310F85BX117VFGeiF462B8W49s8BB60X18oJF6XFk8830VIX8B4TTD76oFgJHAZ120VWVZRH82kcJ640a3330PB6631VW0cJG3XGFZ813Vk9t0w	!3O_V!G84#43#J1k!R3c!5VA!3@EF!PsV!6Z9#3JF!VQo!40Z#94F!93V!2a6!118V	-1%1-1#G%1+2,1//%41#5$5%1/)1+1-6*7/&12//2-102-31.5!1,201!1011/$1&1!1.2$21$2+1&2+401/(1*1$2&202,2#2$3.4!4$305%1+1021!1%1/.2!52!4&2%801(1!1/!502/#22#111.3$2/+5.2.3/*1)201/-5,1,20z2#1201+1*1*8/%2$1(3#202!1-11+1%101#8/(101&10@02//$2$1%1.2/06%101/#@01(101	en]VLD@JFA@fobBn`HcFHrJJJZJEIKIJKQQIHyQQ[`QpKXy{zefejjjjjZfjj``FX@@@					antagonist	Adrenergic alpha 1 / alpha 2	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
7cSs7C7c7c7C7cSs7C7c7c7C7cHq:?3Q8d7CT(S37c<<j<7C7c7CSs7c7cSs7CSs7C4[S3Ss7coc	:Uvzv;SyzvytmSrUPxfrUzUhxaoSKfdWU8kG2tKxZd455eS27l1@d4fB0V0DB0JBWH1FcFR0V1c0X20V8F0	0Xo0IV02OF1v!9J0Eo!_F0zF03AF0k044!sg0cF3Z!C_07g0zF05@!h0440FV2f! $4b28DFGk84N9Z12VXFnJX8H3X0WkkXs472kVXFN8R92e@Vl18VZPFA510J@195ZVFJNFB952l0Z841W0VF220VF8F4cD0VY0F8dRwAJWY288cF84441Nk@73W0Fg430VJ1N44FX54a2OJL624320VRH84XG0R842W0cB2110F89FR2160VGHloNe364FGFV8697XlVRH520l8F81E67t0GN85RLE0GGFcF4H62lFc843W0F86RF10FFNl4lB2413mksBA62kNF6JA@m0WVRV8N4KP22W0nVNa315Ws4ZRIG9W1FWHx@64521l1VRD71VFF82A55Wl1JZA71VNF@2A55WZl8HJ432WV	#91V#8%4!1&5#1dB$1F#Y#4V4#8F$2k$5#G8#11c!2$219V	/-1#1$D01/#9!1//&@*B$1$2$1///01#1//$2.5(8)11$3/)3%5)1,112//*4/!1/%1041!2//$201%A8%1.1/&2*1!82(1&4$2#2/(1,2.1$1#11)311#1+2#1//#106/$1)2*7+2#2$@201$2/2+1-1/,4,1!z%2/#2(1$20D$4&1//01(206/)1#4$1*3!1)2%2+1//(1&4.7%202/*108-	enUTHN@@jb`IBFPQdLY@fPidFYCHhdlhdlhehhibhdhmHiJFMC@hkgh@Jjjjijh@JjjJ@@@						CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
hx~S>xhxhx(S>x~Shxix>x~S~Shxhxh.>x~S~Si.ixh..>h.xh	<LUOr9k5sVMuACFHkkCVL6B0J10VHg7VL408010F!X1V60JW05Fg!1F80V!V_0202V406#V202X0G0	0Pg!XV0IV02D03V!C_07!Tk05Ik2E09w0t03d!KE08w0bk3Z0DZ$ $q2FOVYXk8gE8281m0X0L08pc2A2A63GkFL9Z130X0HWgFE7X18koH2@83V_38ZRH92YW88cRy2CXVXVZ4F8F483Zn0RoBB4VXGksZTM471WVZ4HDU15GFFsH28452m0VkF	%V*2!20F#2,1#FW%V#V$F2Z#84#GV#88s#82!218V	/02/%4/!1!4.2,4/(8#12///(6/+4//%102&11(1/#2,2//#6$1//*2,6+6/$1/&2&A&2/5/%4$6$5/#2//04/(2%1&4/-2#2/&2///201/$1(@4-1//(1/#1/02$g/*102-602-2!2)1/+3/-6/02(2(21/04///.1#3/,1#2)	fekqP@LIrAFoQrJIQPiQKQSZHrJLuT@QUMUUDKT@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~0lvl5q`|F|*_S~xiH}455qS~x>(SS~xh.h	;j;irUyzvzxsjbzPUYr5zNhzmwZKvdWUPrKas4joG6DUDJ2EHWVW6f6oV0Bi2JcVF35c0BG#@c81aNn0	0OV!ms0IV2g!DA0@40t!3Y03a0Dc!sk0tV3e!Jc02k0FF2N0Eo$ 01Z12Ver8FR9L2ARVXF_2Ng653A0Wtk8J8aa9_FVcVKHv25131ZkBH6@D7W0Voc4253O0FVDF442fRW1VgV8J4ZaJ110cVdmS222G0	#c+44*4#11%2#FX#4Z$8F$HF!204#c8F#1*190	//03%3/!2!12#1///5$3!3,1&1#1/)3/////01////*1,2//!1.3#201//03/(601$3-1)4-1!6&5(6//&1/$2,301&3///////$101$1*1#5///!3$3//%1$U/*1-2//301#32///!8///&14/,2-4,12&2-2/,	fleQR@AQUjso@dLbbbVbbTLlIRcJjjffZjYBaEAJJTLhCP@					agonist	mGluR2 ( groupe II )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=.hxh.>w<^}S(.htn8t~U.>x>)Lb{.hxh8t8t.>x>S~b{.h5q)HH)5q)H^}	<rfzRvjKxMS1tUCsWXd2d2fF180C16Lp05A8BFYq8Z90XFaw0c60JF088512OZ11218JFV042FF#2W0FV	0Z40IV02OF1v!Bh04F0IV035V1Z07c014w0Xk2U0DF01VZ0Yk3P0DF0u03q$ 0_o9JBC1YYGwV8R6NN27W9_l0BN6BG8lcJJaAS3W1Vbk8dB282PfkW0LF4F33FW3FYY4P61XWlG0cLG41W8cJ520Y2844RPS6XVkwLB1Z2H0FRN65WW0N8A2W0kR41F480VPBPE4Vl8FBJB@	#14k$8!161$H)48N#NF$W8!2Vx#41F!2Pw!@@E!2OOk!83R!1K#2tGV	*1*1)101$D/%2*2.102013(1%4$9$4$1#3*1%1*1,1!3$1(2,2,1$1/$2&11/1/)201/1//)24/-1$3/$4/&12,1$8&2#1/+2!302%3$5*3$1$1//!2*12%1&22!1%1%1#101.1*2/,1!8,11!1&22-1+4)54$1!1/$1///%2*1!r&2/$1%4&8*1/*6%3//+8032)1,1*3/21,1/1/1/012-2/!2)	e`XTJD@LKhDAIC`@a`HrRPjJISISIIJKGJZJFECKUKUTEATUMR@@@					agonist	AT2	Angiotensin AT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
h.xh.>>x.hS~.>.h.>.h(S,B0l)JW~B,>xxh,dx>J}xhS~x>xiS~.hxhS~S~xh	>yzriizSqzcjCte7CMcnt8nvs434HV0uS2@48oNFhPh4FXJkZF4010V0GH10k8J8#_022&Y0G0	0UR!aJ0R!2Ak3V!8j0D!1Ho0Ak110D!xk061F1C08g0qV3Z0EN$ $X893msV8210XWdF8DA3WlNV@921FcF431VVF5BJanLW0l8NVLC960kFB22VXltTF462oC5Vl0N843120kND4420kF461Vk8F620VF89ZN215C0IOFkD110VBZLIS2VVl0N4BEA3GO4H2252XVFRHI7Wl8RF80VFV4sJSZ11V_5@B88A4MCVVkFsBIAXGcB4510V9Vgk	#C0F!1%4Z#J9$6#252#2FF!8W%F%F#Ro!80R#1cV$k#7$_0k	//(C1/022,2&1$4&4!1+6$8$42/!2(1-2(2/08!1,1/!201-141$1-1$2$1$12+11.1(202-1/1.2(1+1!1/!2/#31/%3&2/1.2/09$1/(2/!22#1&1$13/$2$1+1.6&1/!4,1!2%101(1,202)202%11*1(1!101#1-2-2#1-1!2/(1!r%3$1/&1#1!@02.1/-4/&2/4!1/&1!1&4/.4(3$1/4/$1+2$1*101+	e`XXNH@LHDF@jni`@cIICidddhhhTmLeDeEd}|mSUMTuMUP@PQXQxQdPtP`hyP						PG	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(x>S~x>36|`S(J)d,l0|F>.~Sh.hxh.~S~Sh.	:UvzvzyzSzxQytQEUBnUfAdiAq7gZJCynx@A7G5NTayZWauLru8tV6o0s4erGNEW_02W8FK31!F2880VV0FV	0Z40IV02OF1v!Fi0480bk2z!Kd0740SF2x0CB01Jw0YV2U0@!t!7Ik1d07J0YV2U0@!t! $6F423Z120t0FkDF483Z12Vt0FsDF4N3Z16Vt0FsDF4R3314cFFsH5249FVWko@52693WcFVVH44ZWFW3kk	!1q5k!H4c!28N#TRV!V3#30B!10Jk!1c#658#HFF!Z2k#mx#SGF!15s!40W!2AQV	//(6/#1+1//%6$4$1)2/$1#2.1)2(2%21/!2+1////*1-1#3//*2.1!2%1/02.201%1/(3&1$1&3+1#1&1%3$1%1(202)1//,1&3$1/(1/$1+2/&4#1-1%1-1$201(1&2,1,1!1//$1/,10a#106!1(1%11&1#4010@/)1$11$2//%2+6/)1&1!1&2)1(1+1,102/-5&1/%2,	ffsi@@DXDjpDfYfu]vuYIVcVKUjjefj@Bhaj`@					antagonist	A3	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
.>x>S(.hxh.>x>.>W~zB.h~Sh.}\ps	;rnYzSOt4x7F2DD9FkXN2c05FVC3Z20F0X102!8o901#e10d0k2cFVGVFH$8#F!X14@4040VFF0	0dR0ak03OF1k07g!o80cF2z# 01V4OB14WAFmNJ8@4m0WVF	#V0k!4%8V#6kV#3$B4#V$FW#4VF)4@o$V#G_k$s#4#25NV	/#3/#5&4///.4.6,1#1/01%1!301!3$1(1$1///.1/&1$2/(1//%2&2///04-3//)4-11/*106&1//.201//)1/01(1/-2/1!3/.1//03//$1$1///(S%3/#1/8*5////014*1/*1)2//2///$2//#1&	f`iQ@@IJ@eLllmhmFl{uADLUQP@@					agonist	Adrenergic alpha 1	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
HA[@>QCEN>A^U>@KAHT~gNe^A^XgX?gXeHShShAHDDgNe^S>A^A^A^S>eHAHA^	;j;irUyyvxxsjjzuEEr1rOxzsw40ivlUnz5awBzRJ4Tj8qeU8k0lJf6g1GP7XK8kt94N08FV2420@0a0I0	0UR!Xo0Lk02LF3h!Bh0440IV03IV1M05g!mZ0IV3V!DA0@40t!3Y03a0Dc01Xs0Kk2A0@40t03r& 0PYHVR8362YO0FF8liB40FNJ8F58Q8W0FF@9Z120dYWg64532_@0FV8@D0cIccBDC0VWX4R48F4ADAFkVJN114YO0GF8543Ca1H846136W0GN44HKZ150XKtFT8E0X0WNqF4N3Z12Vel9Jg8B10FW842468m0WkHmc8NP310l0fSP462m0WkRV8Z5FM9WVccw82B1VXWwV8Z4chB1Yl0B8NAZ13Vt0FcDF483Z11VeJFRT870VFVVqF4B2B9d11VJ@@ZV12FgV8g78251m0XFF	#g4#G08$7$9V!1B$1X#22#8X$4$@N$XJ#14#98V#1$2F#l60	//0104#7(1$2#3!4/!202-103!1+G$4!3//.2,4%8/2,41//#1,1.1*201&1-12)12/&3/$4-1)2/$41%1&2/C&3//,1$6%303/$1//&2$4%1(1//+1%2%3/$1!1,2+2/,2#1///$1/%1/$220t/#1%1/3/+4#1.2&3-1#1(1#E7(6//06+1#1,1//4,201//#102$	e`TXF@@D@AIGJflbbTRTQbdTTttRTIiEFTvssULuUUULsUUTHPPiQhPYQXQePUP|PaQMP					antagonist	CCR5	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~S(.i.hS~S~.ixiS~.=S~x=.ixiS(.ixiS(xi.=S~S~.i.h.=.iS~.=.i.i.>.iS~.>.h.i.>	}Ux;xquvuU:uzwkxCzvz8UETrOvrigkUVqeu9zcWSJzRj7OPbWW7Gn8JK43kFvVNQcVV8FF	0oB0J03l!C_07g0zF04B0110480eF04NV1_07N0o!4YV2U0@40t!4J02B0DN0u!7CF1M05V0YV2U0@40t& #16E11kgV8B782@1121lNX931FVN41B7VVGV44JR11210kVB52FcF6310FH1422CG110tZg752199082D10FWOVFPQ92WFc810VHl9N4BC5_GsRN62VHls44NN225nGB@84VV9FVdVo23WO0G0@lk472m0X0F8FD94WW8gH94W0N881F70FGV44JZ26XlkcPC410cB8N@Bl0VVkFOTi331_tNFc42830W1FsTB5W0sFD30VYXV44X117VFGe88LG8ZW8VF61_4F88wgXE25dYcFVF	#Aak!GD8!B09!18FV!VP#1Bj!12tF!NWN!858#8F#V2k#lb#G9k!WKs!2LF!3WCV	01$1*1!1$101)G#1(101!2///#6$5$401/-1/&101/,4&1,1(3$1)1/#201,1011!2$1%1)10111.2/*40401/%101&21(402/!1&2#1+4&3$1/12+102#20201015(2+205*3/)1/0101#1/$304/!1!1+1104!1-110501!2&211%5/#2!1#2#22&47//#1#1$2#2//+1020z#203!1#2&2#2/D!401#2$13/%102/1&1/%A)1&1%124031%4//01$1/-2%22&5/,5(1$	ea]ZJD@I@dcl_Hbjn`I@bPrJJKKQQQQQJUYKYQIYQIL\VA@pl|pPEULsSUUUUP@ED@a@@					antagonist	Adrenergic alpha 1 A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
dz}\>xW~s6psxhzdJ}x>x=xhxhS~x>x=xhx>.>xhx>x=xhS(xhx>x>	:wjgyyXbjuuCdxVbAziCCM1KOgmPs010FFGuS82B8kNJZP4NFV4FV0F010c0FH1VF8J8H!44)2010	0UR!Z40IV02FF1D!8j0D#Xw0s!4J02B0DN0u!5AF0j0440s03r# #23PNH240kW0s22B9RA0WFF4HE64l90B41VV9Vw42CCm0VkIG10@4WFFt422E8f3VW8FwBT4YkVVJ295ZVFJF4433WVkF673WksRF43VV8B410VFA0_ZJVEYWVcRJD2IF4FdBL60VH1GBwBE351W10ZHD5WlFRDC164088sr8241JcINNcCDx231O0FN8kkZ41VFF8FC10FWGHhm4C2m0WVG0gPN5X0k84A25Y2tsBZ6C3	#B%2%4$9$4$16#2$8V/04F$4#18V)6F#W0F	/&3/J.3!3!6/!1/2+4!408$22,1$2(1(1$2(201.8/-1$2/3/!1%1$202/#1/(202/(2/$2+1//9(1+1,1(91%3/2-203(2&5$1!3!1/*1/-1/!1$301&2-1//4/&1!1*1+2)2(1/(101/$1/1/02!1/(n/+1-1/*2%2/(3,12/4%1/#2///#3/+2//01*201!2(	fcgAP@@R\N^QQQIIKIQZQHiQXcFjjfjjijZhbBBTLhLPbUf@						PG	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
.>S(.hx>.>.>.i.h.>.hS(.>.>S(.>.iS(.>.=S(.=S(.i.=72o2.i.=S~.i.iS~.i	}yzUUzCrUzezyfbE_ZUPjez2d2Ht@I_XVO_mb5FWr@Uw8DJ3D9BBV@20F011eG2H2!GXkW0F0	0WR0Tk025k1v!CG06J0Tk045k1_07!Tk04AV110480bk04Ak110480eF062F2D09w0qV3Z0EN% 03bWN88C4m0WkLuc66633c3cgX20Y_1kT48J46@DGs8JTAZ140VZNVqL334WaY08P414YIlVN210mI8F4iJ535HcoPC30V9GFcZhGVW1FVFBGB7GkJRVEZ11VVF8FVI7YW0o4JQ110Y1VByQ541F42FL8m0YFI3RZ3492O0FN8RHHGZFVls2110kFdVj8241	#14k#44#6F#4F$@#3VX!2FkV!VW4#5F#8FF#@o!80B#9f$5k!25#2_0V	/2/!2#D$2/&3/)3/#241#3(5/1//&1201/*4%401/2!1!2/*1&1)1!1/02$21//01!1&2-101$1#121&2!2!3#201$13*1/01%4&1-4$1+2$2%201!402/$4&2!4-1/(2!4/,3/012/#2$1/8$2$1*5/+11+2@$1!1//-11/)5/u%3/2,1%D/+201/+1/-2021#101222,1!1%43//%2&1*2/*3*1.108-	edZ\BL@GBnaFie`H`bHFBLbbbrrbRrbRrfTabRsGEcfQWpLDAUUUUSRp@QP@@@						CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hv:0:S~S~F*`**`l0B,~Wl0(Ol0zBW(0:,d~W	vzTvevzrjBjq1JO5GTKd1QMmLFFrcnA0FMH81F12JPW86Guh0HO0CH5J1m0c1HN1W702V808080B0H0k!1F0V	0Z40IV025k1v!8M07g!dV0ak02a02Q!BM06J0Tk05JV1l0Ak0jF3J# !m0X0H08hRZ0WWl18ca81clc8VLFh15d1VNBD869_W8gBH30XGO@Os232WcNNFNA824121m8VeC43kc4cFJH7Y28oL24W2G9DF4N3Z120Vm9BF8I@ZlkNwRBGB120dBg43WYmBV8R4F8Z310sVJZHHYkkkkNiK@5lVcRJPIH6kccRJ46E4WksN384Z1FtpD66Y41V	#a6V!P04!24F!102F!V7$Vc!24F$W$82!2F0F!V@k$X#51%k!224#11V	//&26////&4$6%1#1//!1/$2(202011/!4%3//#1//02#1///02(1//!1/#2///05$1&1&1/,B!1/%1!102////,1%1//$102/%3%101%1%2)1!1%1/!1!61-3-1)B/#1//%h.2$2*1&4!6!21//-1&1/028*2///!1#1/$2#2#501/&1#2%3)1@1.15-	figpA@NBLBHUDYEEDhdeBXheEDrVcEjwlDCEUUUUPuAq@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
G.b(2S7Cfn4If8rIrIStS24]r]@8fnr]4I@8IrrI]4\3f82S]4sJtSjj\3	:xjxyyirjy:fxsjbziUbrCzvhyHwJpMV1SurSqwZEotZPTzJXUml816W244VBi4FcJ0IJVFJGVcZA8802010	0XZ0s!2Ak3V!8j0D#mo0Ak11!Bh0440IV03@F0j0D#sk0tV3c!DB0DN0u!3Y03a0DV!mZ0Ck3l!Jd02w0Y03a0DV01Xw0Ck2B0D!tV3c!Vd02o0Ak1D08k0s03a0DV% O0GFDF4B3Z140t0FkDF483Z120t0FsDF4J3Z110t0FcDF4L3Z110t0GFDF4B3Z160t0FFDF4J3Z14Vt0FsDF4H3Z150t0FVDF4D3Z120t0FNDF4@3Z140t0FkCkF4A2Bkl0NRDNF41WVvVV8B5B440kkO_aF422115FF6B3OeG0NZE8291m0WFRV8B78231m0WFRV8R782@1m0WFOOZ8B5Z130t0FcDF4B3Z120t0G0DF4B3Z13Vt0FN8Xc8351t0FcDF4N3Z110t0G0DF4B3Z150t0FVDF4N3Z140aONFVA8241m0WkRV8B782@1m0W0RV8N78241m0Y0RV8N78231WaG0NcE8271m0WVRV8g4	#8F#1&4#Vc#V6$9$2FV#X4$1#2%JF#VZ#8B$MV#4#21!	//02%8/!3!7+1*2/(1$I$3//+2,2$4//%1$2*1*1#2)1!1//$1*1,11)1/*1!1/01,1#1-1//%9&3/(2(21!1+@#4#6/*3&2(1&1*2!6!2-1%1(4)2#1/*16+1$1!1$2%2&2+1&1/+301(1$1/!3%2%2&1%1-1+m)1/01/&2#1$1,1%6#1)1!3//6*1.4%3102$1#2#1/$102+1/)1//*1#1#2	eglPE@@@DJE@hjaimlbbTbRdTRrbRVvQaGDefcegdRQWSUUUUUUUMMUU@@@					antagonist	PAF	platelet activating factor PAF (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=.i.=.i.=.i.=.i0:F|0l(S.i.>S~.i.hS~	zxzpb_yBWYJU5G4cBSc5284d1VF088402HF05F4F0V48o5VV0X808!40F0811F0V102*22#703k	0sk0tV3e!GX06J0SV3F!Kl07F0n03C0EF# BV8R4@5@62cg8DF30V8Nkc231YWNFV45YFN86PG2VYkF8o22A0VXJF	!2e$108!21R$2#c5$1c#F$8W%@!30N$1k#26#1QV#4F!205#W0k	01/+1%1!E&1&2!1//(1#12$4*1$1)1//(3!101(2/)1$1#1011/1//041$1!11&1/$101%1,6&3////@/!1/#1#1&2$1&1/(1#3&302%3////%1%3%1$1*5/,1!1/*201*2//1/!1#1/1%101////$Z%3*1.1$41!8//,2//+51*1%1//////(3,1,1/	fjmq`@CVBAFdfuUVWYVsleZjjij@A@@@					agonist	MC4	Melanocortin  MC (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(x=.=.i.=S(.iS~.=xi.i.ix=.=.=xi.i.i.=.=.i	zxwr4asKde46416aHBV9VN0HW#9A920FHV104031k1641!A1V0XKHW0c88N2F89!84V21V@44060JF6030	0ZB0IV02Fk1D!9304s!co0xk03OF1k07g!sk0tV3e$ 3Z9wc8@10WlJ8s4n432O0Fk842OAcW8JRV116Z@bFFR9Ju26W3l0JLH6YFFV@J8@NC0VsHBHs341ZakFcs28390Zkc8yG2XYHk8gU6123W5KHFBJ7Z160fqcFw8	#cVk!2F%4!24$24$82*W8$k*Ho$5#GVF$s!242!252V	//(C/!1%2//,6)12#1///#2/#3/!4/-1$1-102+303/-6$1$2////02#1/$1//+7$102.2/*3%16!1#24/$1//)1/!9#1,5(1-6//6//01//!6//////#a//+4/01+2/+2.1-5#1,1$2063%201/(1%1/////#1%1(	ffm@p@@HXktTfunYUUuLyjfBBJjh@@						M	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi.>x>x>.hS(xhxi.>S~x>.hxhxi.>x>0lF*xh0:(Sxh.hS~.>	;UvQzvU:1zymUFf1IUPdHcX79hK9DcWTV1VF133028040V3140@I296Z2k$B20F4802V2o6#F!c!	0RZ!aJ0Tk02Ik2d!Fi0440FV2d!G_07!Tk3x# #1lRwH22lWNkNPJ82lso810_32W5k8@5Z14VW490L@62FF8ZXH26ZFsVTC5WVF4420b4IgV8w4sP2E2m8Z63135m11N@844GkV44@CVVFGV22KCm0WVF	#12V*4#4%8#2VX$l$38!4VF#8F$8o$4#1V#45k!24$59V	!1#2&3/(9.3///,5-1/01/2/)2/*402/(1.1/&1/-1///!1%1+1/)3#402(2)2.2(52/(1)2#1%1$402011&1.4*1/*2/*401.2!1(1/)1/#1!8!4,2/!3%2!1/!A4/1//!21+1/1.m*1/%1)B/%1!2)102/3032/.1/01&1)4/423//44/&2(3&21102$1*1-	fcoqA@HcfPD`JPrJJIJIFIIKQIIFLdEK^pPTTDDUUuAPZP@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xix>.i.>S~.i.h.>S~.iS(.>.=S(.=S(.i28D{S(/j(QS(.>.>x>.hS~.>.i.h.>	=v?yuvEryPUfhUzjjx_gFwvdgUPmn5daAqV47IuJF_H08c8iL3m4BD0Ji1HG1BHO!210iV0V8F0	0Pg!Xs0FF02K03x!Bh0440IV03OF1g07g!o80bk2l!DA09w0t!4AV1104B0wF$ #1FsQ5WVVFRHD8AYlkoL730mGODF4@298ZG0V@83WVVF6ND10Y3QkN8J4jPW1VV98kK7YkV82H994VXAN8N8494gnccVJ4824m8t6185Z0kcgH992W0F4410kF8420VJlXNVuL37e08FkKk3JWXVwV8N44221WWcPB21VFgkNNEV_0l0Nim452d30kNRCsQ5VW1V_g@432WXWGBmC7W1lsB4PFwJ110d0k8H6511W40wkF50lW8lgPG55FkB41964W3mkFC540FFkkJ487_1kcF6110F8oR1167D5VFF8	#80V*4*D#5WZ$qF#cV!4ZV#8F$2k#V4#W8$7V!244#18V	//(J#1&1)6//%1!67$2$@$1.1)1//!1*1/*3*2/4(11/,1)2$1/1!1&1/1/02!1/*1/#3/!2/!1$74%101!11!1(21$201#101)205012024#1,1%1-1!1/&202!12(2014*1/)1/)11+2!3&1!3/.3%1$1101%3!1(1.1#2#1!102)1!1)1//w+1!1*1%1)8$1/2.6$2-4/-2/*1)4+1%2//!1&2$201%4(3/0203!1$7(1$	edZ\DL@IOIhhPIABPpdLbdLRTtrVTtbRVbLRPbcgcWPLMT@QUTuUUUUQT`dPuP@@					antagonist	CCR2	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
.>.iS(.>S~.=S(.h.=S(.i.>x>.=.hzdW(.>p3}J	yyurTbOG0k5k4F911N0K08@F!F08W080Ht258#Pk960WV!N0924JGN0c12F1W102X4V44080F2!11!Vk	0Z80IV03P02b0C#sg0bk3Z!GY06F0T03p!OX06V0SV1v0@R0o!6LV1Q05k0Xk2U0DF$ $6F4J2mO120gV8V78221m0Y0LPw4693m0Y0RV8478291m0YVRV8N782C1BVYY88kgO24VVFsiF482cT13VV	!360k#Xo!702!280V!n5V!91@#2k#sfF#2T$4V!ZHV#2X#lH#GVN!@2$l80	//(3/(1//*1&11$1+2(1/0103-1!4*@&1*1+3%2$3/+3/,1+5!1//&1$1////(1/%3+3$201/*1/11$2!1#1$1101///04!2#4/.21#1#2/#1)1/%21/#1//3#1%5!4//1!1$1/!1-1/010Z$3)2$1/%3//#202$2-1/&1#205%3/#1)2/01/!1*2/#1/4)1//0	fj}H`@DF\d@TfYWye[UgG^rUjehBBZhP@@					antagonist	A1 / A2A	Adenosine (I Nucleotid-like)	no	gpcr-ligands_DescriptorsNo5Ht
)\hxO~366s.hS~.>xh.h.hS~.>xhzBW~ps}\	vrUlnlUxOG5x3FAEDO0l2N2c01FFC34!LFX18X!PZ96Gk!XG0d04J8FVdVLG1W102V0VJ#9024#W0FV	0QF!qJ0Q01v!C20@40jk06JV1W06F0SF2w0CF$ $nFXO452O0Fs@F4O014WAakFNA8261m0WFF	#aVV)8k#2HV!V3#4V4!104F#Yc!43N!2F$40V$V#KGV!FPV!@04#GSV	!1/%1-5//#2/#1#3)4$2////0101(5$1///.2/,2&1/$11//2!1$1$1*1/.44,3/$1#1)1$5.1.1///01//%1/(1(6(1//&2#1)302!3$3///+3//$1#1/$3//#X%3-2$2$11)8$101!5.1///!1*2//$3/01-2//4/#5/!1/(	fluh@@@PexNRJIFJIKZIXijtTsUAADuI@@@					agonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
`||`:vS~x=lvxixiF|x>~Sxix=S~x>xixix=S~xixhS~x=x>xi	;j;irzyjUjxsjExiUjK9zvgXus05HFV8uURLBVnos4NDoJXBHk#d0V0k2A4F8F804%V0A!2X0G0	0UR!Z40IV02Ak3V!HE0@40t03c!GF08k0tV3c!Jh02w0FF3V0ER$ 0H9B6WsR840ZY2OWV8F4122VkoJ631W8J662VVF44Z9Hm0VkFcVZM820kZ420VY1WX0wU421l10lDC@1lWkk84311ksNF531VsJ652WFNJ4cE10F8Ng2123gYq9BV86420HNskJ5221d6F462232HVZL@3Xl0442C4adoWVBJ7Z130Vl1cPO4YFO0wV	#8F+4$O$4$92#2FV#V$41!10F$6F$4#98$5$42!2W0F	//(L/!2-6+24*1#1101#4$6$3,1%2*1+2+1-4,2//&1&1-1*1)1)1#2/#202,1///&1/%7//*14&3/(1/02&6(2/$2&11*2.1031*1!22$1$1+3/&1/!2+21/01!1.2)2$2/-101/-1$1/02/+h101!1/#1!1.2(1%1%1//#1&5!2/611/(3&101/02/)1/)2.1$3/&101+	fek`p@O@dis^iLrjnlzjsdXuUUMMUTuVDDDhYQAR@					agonist	PG	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
x=S(xix=x=S(xixi^}w<~Utnx>xhS~x>xhS(S~x>xhxhx>xhS~x>xhS(	:UvzvzjrS:vyvtEzSmU9vzyEzUcoFSjvx2C2VYN@ceg14Xa6FdP80o0TJ@M5oZVG60n0GJ21FF0WFaXVW8FV	0Xo0IV03Xk2U0DF012s0FF1209w01640Pk2w0CF016J0SV1v0Eo01Jw0YV2U0@F0t% !xA4FlcRZq462m0X0Jnc865325X0wBB3VkNBBLB10XY2doFI5XXVsF8DDaS12kV8VB8D82Fk8FB20XXFVF40X3FF8cwNP26FNcwL@2Vl1GDF4@2aS13VV8kBHE6WFV4F72VkNR613Vo1sB4P215d1lOJD78Y4Vkk8512Y2wV8V78241	#XVF#4#2X$1F#V@8!18V!114V#W$59!2NF$@k!144#8R#41Z$Z#11V	//02%8/!1,1//$32#2A$21,2/!1/(1%1$3/201+4%2(1#1/)1-5,1$1*1$101/)1,1!103/+3/014-1%1/(7&2(1*133/%3$20202#2%103&1$2!2/2/02/-1/)1$2,5%11+2$1/!1)41$1#2+1(25-1//-1-1%2*2$l.2$1$1$1*6!1#1(3&1022/-3&1/%5//$2+1$1#1/01/1/!3(5$1+3)14-	fkha@ARlGoi`dFRFQQIQFIYJZJYKJZTyhs^pAERtuUUMQP@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>.hS(.>.>S(.>.hS(.>.=S(.=.i.=S~.i.hS~	:UQzQzsUSxYvwtQ1YGHj8c4y23fZZ0Nd8g2#102FX0F42V9F1082V0DJ2202#20F0102H0F$V08040	0aJ0Tk02bk3Z!Fi0440FV2U!Fh0440FV2d! %WbFVNND69@111FaF4@3L7120VGxDK1VF8sk42@8@a2dRB168VF8FkV	%V/%8#18V*V$4$8F$2k$4#O8$18!2$210V	//#2#D(2///-6#25$1////01$2//02////(2///!2/%2/)2&2/.1/01-1/&2#2)2%2$1#3/*2!4(2///(2/)2//*4$2$1//!4/!2///&2/#1%4/b01#504-1/#@/+201/062////,4)1+3//#2/*2*2.108$1(	fj}Q@@DB@dlklkkJlxZvRmUUUU@AP@@					antagonist	M2	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
b+27xi.ix=.=S~xiS(.i.hx=.=x=S~xix=yjx=xiS~x=xiS(x=x>S(xix>x=xh	:UvzfzUzOyzQTAiESNOuQ6dlA8bhY048GlX9Dm80Fl96SV1HA30GZ4kc8Zd02Q0VK80F0VRd203F04VF8Y0F0	0aJ0Tk03OF1g07g!sg0cF3Z!B90Cc0xV04AF1104F0Tk! %V8NPH8218Z@42VYGs44PR2l11FVFNPL@3WNR420_Xmk8BD952W90H820kF8230cYV88lA827121WW0PC3WksN611aY3RV8F44632mNZFA220NF4217YV88l042@l0WkVFF88410kRL93Xks84118Z0F8s22B0VX_0	#B0k)44#G*1C%4F#u$6F#@FF#@k!90K#O3#2Ks!214!250V	01/01&4%1$H$1/&3*1-3.8$21#4/-1/-1,114%1)2/+1,1!1$3/0111//)2$2+4&6%3/!1.3/3$9//&1!1#1#1.1#1+2/0501/01&103//&2!3$101#1$201!13&1!1+2&1/1%1.61//*1$2*1!26(101/2///-1$4!r%6103/1#3#21%F,2///1,1,3!1+1,1%123/01//&1,2,3*4/02&1%	e`T\JHDLILhDKGJ`@bRWNrRPjIQIQZiISQISIZ^K[O_KTEALUTuT@ADCQ@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x>.>S(xhS(.h.>x>.>x>.>S(xiS(xhS(.=x>S(S(x>S(	yywM0JsG9V4mZ0A6FNH5VR6H040F1392!Ho180V1Ok86F10180V52G2_0dV8@2!14@07cX40@4K80F482010	0Z40IV02R03i!CG06J0Tk04OF1k07g0vV05901D07!Tk3d& 38251m0WFRV8V78271m0VkRV8R44C@_lcoJ68540H1VsK1WV90NV6G@2YG4NV60W3H0W4oI3YW884H79	%k!2&5!2D$28#89$V1$Yc$o$2$2w$1#GV#10s!24#251V	)1)1/#A/!2!3(1//#1014///#1&1,1-1+1,4/(1%1/,3,2/$2!301/)1////!701$1*31*1+9/1//)2/&2)2/!1/.3%2.4*1(3!1&1/-4//&1/)E/-3/13-1//#g%3(3#101/$@!1&1/01/$11#314/2/01/%1(4//2//////!	fns@`@@FrQQRJIFIHkKJdeVCF`jHHHJj@@@					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>.h.>.h(S,B0l)JW~B,>x,dxhJ}x>xhS~x>xhx>xhx>xhx>	xvwjgyqabEuD9dpVaEx@CE51nGZXPN!FF08kS5044GoF48BF4240k(k21$804F&2#6030	0UR!Z40IV02Ak3V!8j0D#sk0tV3e!Fh02w0FF3V$ 02lBkO210FsoU82310WWdVT@41l8F4LAAm0VkFkoXP7X0kN210_Y2kL88B4274m9NJ71VkGG0c2110kkJH33WkkR621WV8J@2J@VVNB4157VFGYF8477ZHNZJ92_4kF88V1176W0FgTC9YlFN420a3n0YC894420WNVRH3118R83310Okos6H8Z_F4NHBJI_H0BJD@PFXXVZ4B@6	#8,5$9$4$12#20V#V/!F$4#18/W!	/,1*R.1!3-2+24.1#1!4$8$2/#2/-1$2!1*4/)1/%1#1&1/,3/#2/#1202/!5,101//02/%C&2/2/!5&21//)3&501%5/$2/#2.101.31$21/6%1%101/!1&4+1,3(3.2)2*1-2///#1*2-1/l!1!1//&2%1+1/#1!2/&1/#51///1+1/////*2-	fm{AP@@HLGNQSIIIQQPkJYIIV\uTuUUTuUTRUBjMDNh`q@					agonist	PGFP	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~.h.iS~.>.i.hS~.=.iS~.ixiS~.iix.h>.	[UmaCpymii9LFqxVTWV01h3kHcIVq50X0V0kG021W4A3k15Nac0VF9KY#W#8o!2160Z4K4X0G0	0Pg!XV0IV02Ak3V!DA0@F0t!4OF1g07!Tk07FF1406k0Tk2A0@F0t! $O0FVDF443Z130Z4sh48@4G5X1kFD8Y84210JL@G8WH8W0LA2XkcccZ@Y841NgNL514YZGW4N8H2ZFcJ@565_8NNFV8@FGWYX0gL6@2VX1kdl4F2XlW0kJXR2ZFd4RN51548NNFJA8231	!1c0k!M$416!16$4@#68X$o#FW%F*2o$4#GVF#7s#44!25BV	/02/%9/!1!4*2(1,204+2!202$1//01//*2*1+2!1/,11#1/(1+1/01//%2!1/////01/!2#7&1/5/%4(103/+1-1%1#4.2&2&1$304.1&1101/$1)21+1!2///,1#4021(1-2.11/&1/._.1%2#201$1(601!1*21(1#2/+1/,2/!1&1)1!1/.1//!2+1!2/,2-	fjmQ`@DA@irSJvm{ZuQdmMT@QUUUDKT@@						Adrenergic	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(5qxhS(x=.=xiS(S(w<^}.>tnS(~US(}Hx>xiS(q555qqg-S~x>y?}ZxiS~x>xhxix>	?y;vzyhzTtexUEUMqZQQgfWdhvz6Y@Fo9ylv6H_d5IN4C04wG84uIQFnl56@m5WT!sVG0V2F8V8FV	0Xs0FF02OF1v!9J0Eo!_F0zF03Z02W0DF012w0FF130E401K40O01p07c0pV! 0hRF673m0WFJvJF6B3m0X0Ik8sHDHW0kcVQ82@1m0YFHNkHt1XXWRV98782B1m0X0Lc8geP241t0GcDF4B3Z130bLd8BJ659@l8cF677Yt0Fk8cRI6bWckkN63KZo0dJJ@8P1ZZN90F	#31V!M$2@G!1J1V!gAF!3WB#2oV!JYB!15D!21F#Fus#Z7#CVV!15J#4$12V	02#2$1*2/H*1)18.1&1$1,5#1%3$1/,1//1(2/05//%8/,2//$1$3/01+2,202/-1#1.6*1&1!3$2(1#1088#101,2-5+1#104!2!8/&11//)3$1!1/$1%102)1/+3#1,1!4//*601/!1602!21/&1/!1!6&1!1/!1$2)w1/01&1(1!1#6///!2&51$2,1)7(2$3+1102#101/%1/.1+4!3%6(2/#21&4&11$	elVTDF@EEni`IABPpdBiBjPZdLbdLTRbtRRRdtTjqbRdLl|vNaQj``djjjjZjjajAH`@					antagonist	CB1	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hS~x>S~.>.ixh.i.hS~S~x>S~.>xh.i.hx>.=xh.ix>.=S~xh.i.ix>.=S~S~S(.i.hS~	;vzv;x:vyvzUj9nzvzUjAEUZkCEzxzXA7HbQ7qYcFTAHDJdniGf5BRYu0@e342k44N91YJNBk09e0V0F0	0Z40IV02OF1v!9F0DZ!_!uF02J03d!C_07!Tk03Xk2U0DF!sg0cF3Z!GE08g0bk3Z!Ni0480Ik2A09w0t! %m0VVH_08D4J15o0G8LF463Z130t0Fk8Xi4G2VYVs8V8aL10klkc8F66X5V9p06H30YVF8gZg2I40ZMsR8R8MLb0F8JX@FQ0Wc8L278YYkINs4mT0W5V94X148VV8FocJH2@Zm94Z257Yt0Fk9KTQ124VF90Jak32V8oNZ3183Y0INJNX3AZGsG8210VG1dF4i4KBZkXGw44E6m0WVRV8g4GL0W_VN88a@lAW6Hc4@6J521VkoFsSF15ks9B21284_VI8V4iUIW51BV8N78271m0WkG5R8H1211W4@V8LL2W211NNPWDXY0N8c8280VWX2kV8I613Wt0G0@tg4A2m0XkRV8s4234Xll4P731VcN2P@C0Vl0NHC6XlcF4420VV90HV438Z0gB6743VFVsTK5XlNN@2A55VFV842421cgL7210VB6420Zm844Rc210VcNB62XG8VF62VVNJ6210VHl5N2231VcND561W0JH511Fe9J4111ZK088624I1FkZH@3WksJ621WFc86VK0VZKF8NDA5Z1FRH631kWcw22CD	#cVV)4*2$1d%9$d8!4ZV$F$Ho$5#OV#85s(2W8V	/-1&20L/!3-2$1,1/041#4$3/)2///!6/*2//#1/&3,2%202//%3-41#1(1)101/&1%9*111$1&2.16&3.1#1/(3$601$4%2/042/)1(16*1!31/2%1-1%22,2%1/8!4#1//)1%1&2901%1.1$1)1(4//(1(z(4#1,1&23&B,1/(6/#2&2-1#2!6/!5#1606(23#1+41%1/)1%2(201&1(3&2!1(1)1$1&	efQ\F@@DFG@CKOh\\bbbbRRTtJRVRTRRTVRs@fUUpKUUUKAAEPPTUUAAaP@@						FSH	Follicle stimulating hormone FSH (I)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xixiS~x=wkP(S~|Fs6xic+ps~Y	;QvArQUOvYAD8301LskfCHJ62VZVFDB54G0GF1W0N!V308N4!4$40P02!Z01JG28F04!80X!2010	0b!vV03@V1104s!o80Ik2d!G_07!Tk3i! 03wDT341ZnYJBB6EZY0kcTF462LBalVsJH@2BCXVVVF	%V/%4#19+3*8F$2k$4#G$81s!2$210V	//(B/!1!2//)12$2$2//////&1$2///,2/$1/2//&2///&3/(1/!4!1$1.2$1%3.2$1//!1-1//+4.2///+3&2/&1/01.4/!2///3/.V%1(4)1/0803#2*2/#4/0101!1//01/,12/01//02/02.1/#3&41-	fhia@@M@rJIJFQIJJcGA`@jjjbap`@						Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
ShA]e]AIeI>S]Ae]IAIAeI]A>Se]IAIA]AIeeI>S>Sb(>Se]X?IeeIAIe]A]eIShDbDDe]DD]e]AhShS]A]ehShS]AIe]e]eeI]edNIee]ShDbbbbb	{j<TjzyzAhUUq7fjzODzUDQ6wTIbjOntJUhVN4W0SHgd6T3POXI2B3OFG0P0vDScN2XXR$	0Xo0FF02AF11!Be02o0FF03@V0h044!qJ0R01v!C_07!Tk03Y03a0DZ!sk0tV3d!Ve02o0AV110480G01v0@Z022c0AF0i0440FV1407g0eF$ &V8BD45WG0V87510sB4420FF5Jce10W1NZXF72kVN6NK0VVX9mhm492NC0W8FJNB3_0sgL71W09WBk81GaXVN@287Z0F84@4921VVD74WFFB421950F99E8251m0WVFVRc9AY1cJ82@95O0Fc84873Xl0kF921lc4D3EA7VWOBeG4X0cB61A8_t0Fk84854YFWBN64XFNB4RJDm0W0FF8B621G0RF52X0cJ8210VVF221AZk88xV223VksR@532WkZ@51WFm9B22G0VYJoF8q42A2110VZ84221cFH620VNN421d_0N9822FKm0X0FF@c@92WksBB71VkNV661VkNB610V_XN44XlZ120ekGfZ4L424110Z8A210kRJ910FFS4ZYZ140VFF8663XksFD6210sB840WkVB2gIL11FF8452WVc8H71VkcJ6311FNB4iL0VF88FX217i0VKN8B32XVkNH731G8J422VkN82cK0VZKZW1H512WGFWZH6E20HO02K644VVV8234WkFRL54XlFV82G@0VHHG4e4A0YWWgB26240F8HV6221W8ND65XFNFB721kH9N22J0VZKFV4214WVsJ@43XFsJ8510VF842LA0V84BZ118C@psF@8@4ID0kNRB22i2VVF84621FFNB52XVcJ@621FF8210g_6V8B87310sVF@51kV4B61VV@OB2128@YJ8cBT4@YVVVZR4230Vc8F62Vl0VH72VkkB420V_XXlO24AL0X0qm8N6A30VVF8GP430FF8@531VVF8531VcFD110V882kJR10F8F822VVc8D511VVVD22WF8J450g_k88210XZMV	#80V*4!25%4#392$F$Y#80k#cF$2o!805#Gc#85s!24#250V	/)2-u/%4)@4/&4,2$B$2,2#2022/.2!2-2$4+4//#2!2%2%2/$2*202//)2$8#4)2,4+2+2$2,J(4$2#2.2&2(202-6!B/(4!20@02$24!2+2)22,2)2#20402%2)2*2+2/2//04#2#6)42!2/!2*6.2#@/6&2!2#2+6/-4/&z/$2#2!2-B/*2)2/$6/)2#4022(2-2(242/&2-6//&6%2$4$2+2$8-	gevE@P@@IfX@`~@lbbRbRRfRdRRRRJrTTrtrTrdRRRNTR`pDJMIgQXbIBiQkuFsIbpz\uPPQUUUUUTuT@EUUUUTUQULKA@R`iPjHMT^j@@					kappa: agonist/ m?: partial agonist	Opioid kappa/ m?	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~x>.ixi.>S~S~.iS(xhsp.>.>x>\}BzS(.iS(.>S~.h.>S~.h.i	zyvI@Itl8sB2Vo3BFc01VNFHF0139392VFHV180V31F16F5!@0V0XG2WFc0882G090204V60V8442!4NV0FF	0QF!ZF0IV02G01D!9F0DZ!ms0FF1D!C104F0Tk03OF1k07g!qc0SV3F$ #1Z140t0GVDF482gM2FksPlk4F2LBkcOBE8281m0WVRV8Z4JdL1G1kaF4B2cT11kY@O86@36gZFBFH8X8W2L88RE8261WcFWNI5a4E22_69cFH8FFZZ8VgI82B1m0WFRV8o782G18i3NNBE82C1T@0W8H66462	#Y4k!I0V!611!2FA#VAF!A98!104V!838$c#FY#42w#X7#GW#1_w!208!214V	/,2*O/!1/&2/&1!401#1//02/,2/!@/-102)1//+1(3/#2//02///06//&1/(9+2/4/!1(11$1$2/%2!1,1///!2)1%2//!1)4/04/01!2.1.A//-3/+1/1&m01)8#5)1/6!1*1/0101!@#1.5&1$1)1/.202(1/$2#2%1///%3*1$1,1!1#3$	fmwq@@AVJCIEMDhdeDeLUmDnJmGpZB@BBhjjjB@@					antagonist	CRF1	CRF (II)	no	gpcr-ligands_DescriptorsNo5Ht
S~x>xi.>.h.>.h.>.h.>.h.>.h.>.h.>.h.>.h.>.h	:UdntrgnGG7IBk0250F!4V8260V#@$F04%9-4*F!8#2&Y4G0	0Pg!Z40IV030k1!EV# 012X0kZFA4XVsJ@32VV894k21A9B688BF610WlNwXB6X0sF220b4nV	/0V*B#11V/%8F$5F$4*1*1!	//(X)1///!1)4*1+1/04/////////)1/&1&1)L.1%4//-5!R/%1/#24///(143///$1/+2!3.2//-4////(1//+A/1//,1%10b/*1%201////////&2/////#101//+	ffuab@NPQ`GaddeRRRRRRRRZjjjjjj@@					agonist	S1P1 (EDG1)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
82o2.hxi.=S~x=.hxixiS~.=x=.h.h.=.h.=.hN~,A)\6s=x(S(S=x>.(S(S>.(S>x	;vvv;xyzQyvTTUSvzfqvTMoWjYO7exI23PH@IOtpVtr7Je8V9ZRsdHBW8N2IV40CF0HPdeBE1P0W2NW0F0	0P4!Xo0FF02OF1v!9F0DZ!qJ0R01v!B90Cc0xV04AV0k0440jk05AV0k0440G01v! 5cJ432112GFgA31Vc821B7a10lgiF5X0F4ZR115_O0FVDF4D233YlkcPD510V841C86t0GF8eo4C20W0ssF@3Wl8RF6210850a10W44gV8N48762WNkH94VVk861D80F8Fp04453l8oPC4VkF842D6VFGOyF4D2121l8RHA6XFVB8630k894VX21XFcRH72XW8B@220Vs8422@4_2dO0H20WWNlVob522G3QBR843X0H@Fa94X1lcs48DFYW0R8720mltNGT4CJW0NNZLo@241O0Fc8BDPE5k8Z2FA85LVWNFc4_P18111lcB5@Ykk4ZP115_D_FFN8	$4k!228!8BZ!2F0V#6#1C4$6F#f$4k#8FF!BAo!80p#Of#O5s!218!2CFV	/#2#1(1!1!J$1,1)3#1/$3&21%6$73#2&1(11/$1%1.1(1$2/!1/#1$20120101#1/1+1)1!3)4101//01&2%101/%11*2+404%1.102#11$1*1011%21#1$102#1)1#2#1,301/(1/%104+11#2#11.2#1)2!1/#1,1/&105&1//%2-1#6(1$1)4&1*1///&x%3/#1!1%1%F*1-1+2/#1!1+1-1!1!101,20402031!10123.1////$3$1,102&A&1%	edV\LH@LDbhD@P@cIIBhdeEeldhddeLediYxDutml}|mPPTUUMUP@TUB@dB`@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
xh}H.>S(xi.>x=xiS~x=xixix>xiS~x>xhxix>xhx>xhx>xhx>	xvqUcIkm9@@21o02m0m9VA40V!Wk8d0V0FK0F2!1GF!41892206V#8!V2/!10120W0	0Z40IV02OF1v!9_07g!XV0f!2Fk3V!930D% !mpV653m0W0RV8F4NrC1l1FVtgQ2X2W2K88J4JFAkmNOG4g124W7uJ8Z5Z140VWcse852l8N42AB_Vlcke@5YGNF41AB_WoNFP86Xl11cWJ2L@138R4@F6A82lJ4@@5	%V/%4$8&V!F38/2k$5#G%48!2$210V	//(J/!2!2///4/,1//!2/$1!1/////*1(4*2#2/%4(304+8.1//)9/!24%4/5/(1/%2*2+1///,1*3%404/&6///4!F!801///+8//////#l//+F///+1//$4/+2/041//$1.4-1&4//#	fe{``@L@Xdm[lklkjjZr\uUT@D@EUP@@@					agonist	S1P (EDG)	S1P (Endothelial differentiation gene EDG (I))	no	gpcr-ligands_DescriptorsNo5Ht
S(xhx>.>x>ot7tS(xhS(xh.>x>.>x>xhS(x>x>S(x>	:xzdyyvjiiYh2jTmfrBXU5HqoFeUvO20F2pnRHm_dlGOFAD5PAe3oG2t0cV8N2I#O0@0k12A4585144$	0Z40IV03OF1k07g01Xo0B01104s0Kk1Q!Rd02o0B01D07!Tk3d! !1Z120t0FcDF4F21452t0P850HG98RaL84Gk88FC826YH0B31YWWk	#c0k#K%5!249$4#292#2F$3#80k*2o$5#GVF#4s!24#2_0V	/#1.1#E-1&3/%1/)4$4)1$1$3//+3*21#1/.3/!1//#1,201/(1//!2/#2%101/+7013.4.1(8//,2,1/#1/1&1%1$14*1-3%2!3/&1///!4/!1//-5!2////)1/%f%1)2!311,2&602.1*1(1/0301,1/4#1.1%1(3+1//////02/$	ffcA@@@YHhiEDbdllljRT[pZBhbJjjhTTHdP@					not given in publication	CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
S~.hxhx>S~xhxiS~|F|`lvxi>x(Shx	xvyzBrkqd@2q0pBanRmdV90HW48pkfd0VLHK486018FO0a_W89224aV0W0941@HFcFBdX5225!41NH01960Y0	0aJ0Tk02902g!DB0DN0uV03ZF3a0Dc01HF0FF1407g0f# !BV8g78251m0YVRV885ej261O0FVDF483Z130cNNFRA8261	#80V*4)1%82$1#FX8$4*2k$5#G$848!202!210V	/#1.2#4/302!2!2//$5/!2!301$1/////////!2///////////1(3&2(1/*2042*4(6//////+2/$2.1.4+2/-1%3#1*6///03*3$3$301&2/Q!2(2!1/01)6///1)2#1/)6///&1////#1!1//(	f`q`P@C@P{vQSQISIPs`eZZ@BjfJBj@@					antagonist	mGluR1 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
xix=S~xi.ixix=S~.h.=S~S~xiS(.ixix=S~.=.=xixi.i	:xjxyyirjyjzfxshbziUbpCUvgiHwF_I80SsmSmwV9ZsZPTnJV2FG#W240V8V4F8402G!F!VV3#2010	0Xo0FF02@F3V!Bh0440IV03Ak1104s!sk0tV3c!Fd02o0FF3V! #38251S@VW0LF48269bX0wN174YYpWwD2532XLmJB@7Z11Vt0Fc9uB4925_3dJ4A10m116F4D3Z15Vt0Gs8NXE96Fkc6FD8m0WVF	#8,4*4$9%FV#V%1*4F#V4$8$4$4#21!	//&1S/!1012.2//1$8$1/)2///(1)1-1%2-1/.1/)2//%2/01!1/-8+2$10@//+71%1/1//03(2//031/.2!3///%1!3,202/%4$1//.2$2,1+2///!1+1%1#h//#1//-8/0207)1!1+1#201/(1/&2&1///2(1+1/&@-	fasA`@@HedTRbbdRLVbVRLDoVjjjjjjjiFBJT@@						M	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>S(.iS(xix=.=.>x=x>S(S(S(xi.=x=x>S(xi.>x=S(xiS(.=x=x>S(xiS~.ixi.>S~x>xhxix>	:UvzvzyzS:vytvUrCnzAzUjAjUZkSSzCx2@rHbOMqXcFUAH8J1lj2d4BRYm0DX342kL4F9134N8k01VVV0F0	0Z40IV02FF1D!9_07g!aJ0Tk03Xk2U0DF014w0Xk2U0DF01Jw0YV2U0@40t!6AV1D04w0Xk2U0DF0 0NE5WWNwH@4VV9O0j82315W0VFLF6210ZB20VV9ssz82310YFYN8NB7XGNkB41_4088sr8261AE1FVFD8H72n0FTB75YeFGOh2483JVXpG48D6LT14GNR8R8tKW20_09FoW27WeFHOBiH372O0G08cBJD3Wc862152mV8@k410VFcJ6DZ3218oD240kNB421VFF4220VK1vVwT81a2kNRV10VklV44JLHA42sVB40Z2X0c86A431sk88210Od0430WY088_4461VV8RJ52Y1FRD610V88621@Z5FFRL94X1cRD641VF8sXRrB5FksN82911lVcHA5Xk9WJ6330V8cx46221ksgHA43GFF641VJ220NBJ6XGNkX41532_Oo6A41GW0k424h0VVFJB22WFsN633VkkZ4210kc4210VaXF424ET	#d0k#8$41!18F#V5#1d8$1F!4d8!4_4#8F$2s$5#O$958(218V	/-1)Q//%3-1/0@$7$3*1/&1%1//%1&4-24/02+1-2-11&1#3)1(2$11/$6-41%2#1011/!1/02#E+1%3&2/8&31/!1/%204$3/1/22/(1)4#1$1#3//01,2!2)4/&B!4/.201+3-481.2*1/*2*102-1#1&1!z!11#1#102*2%211&F/$2/*1)21/%1%602*1#32.103#1+42/%1)1/01%1#11#4&2!2#1#1(201)10	ei]RL@@DF@RPKL\bbbbbRVtrRVRTRVaTTVVXDrjn^ZjjjXHHjB@jfjhDLJBB@@					agonist	FSH	Follicle stimulating hormone FSH (I)	no	gpcr-ligands_DescriptorsNo5Ht
x>xhS(S~.>x>.hS(S(S~.>x=.h.h.>.h.>.hS~.>.hi.>.	>tqSu6w5rgaSNHKJB28Y98pV3h081lLc88!GZ862V1@102K2ZO085F02!cJ0201V0J#F4Vk08XFG0	0aJ0Tk02OF1v!@M0D#tR0ak3V!DA0@40t!4J02G0DN0u% 08VmS55FksgR48A31FsD@5VXWWLF48268Z1VoLC4VmGWDF483Z10VbckFR8wdD1WklmlH6A378KsJFJ9Z13VbZHFBT64C9o0W8FHAHcGFd4M8281	#91V#8%4!12,@$1F!FYc)2F$2k$4#10V!11$42#18V	//!1#44*1&2/(3/*43#11#2,2//////////$106&1-1,2/&2&2/&4$1*1(1/#10201/!2$102.1/$3$2&4(2(42-2)3/)2/$1/01//-1$1#2!B034//!1/$1$8///*3/-1)f%4(1*1/F////-4*4/*2)1&1#1#2///$2&4&104//(2	fak`P@H`QfjSK\l{zmuHsoMzuA@@ATuPP@@					antagonist	B1	Bradykinin (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
72o2.ixi.>x>.ixi.>.i.>.i.>(S:v:0*F*`1n18)I)]`*@,6363`*	zxUlnWzStGJUIJ2DBS8W2N4dV3F0h3!6HFV5@08!F9a9VVFYc0@V048FV853F0V10210VBW!202!G0W0FV	0G8!PF!Z40IV02OF1v!F504!qV3q!K!4F0SF1u07g01GN0PF1p07c0nF! $1Z120VkW4gF8WVVF8JF0VYXkN8TH7YWcF8410n2F44TQZ13Vt0Fc88878ZGsg@8110F822E8bWFWBR95YVcJ6420F9l0s847XlcVD841kFR4217ZnwF88@431WlNwTA2VkcN@31VV@1F22HGm0WFRV8Z4B8C7Wcc4214Y2RV8g4J@9ZlkZB410k842PBCm0X0RV8F4246ZlNwJ92W0N8kg2114ngV8N4875XGFgD421kkR6617_kF9K382C1	#A0k!18#64$JgV!sA#9EB$GF!838!20R#F_F!68s!BmL#GIF!19N!23$3GV	01/01)20101$L$4.2/#1(1#3(1%7#2%2!101)101)2#1.1+2)1$1/01/*1+1/%1#11//$1)1*1!4&2$1/%1*4/(9/.3+2#11.1-2#2/0201)1&1/#1%1//01#1!201-1102/1!11!1/)1$2!3/)11,11&2*1#31&1/!201/#1/-1(11&l01#3-1$1(24%8,1,1//!4&2-1#3!3//02301&2/%1/!1$1)1$1*3!1/-1)	fcopc@LVCA@@cpPLHrRPiIYIIQIIJIKQRtZ}kUUUUMUA@L@@@					antagonist	NPY5	NPY (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~.>S~xhxh.h.hS~x>S~.>S(.h.hS(.>.>.>x>.h.hS(.>x>.>S(S(.=S(x>S(xhx>x>xh|`|Fl0	;vzv;xzvvyvzSvRvzQzMyEzjgYCUh:eCvGWAQKf0kbcqmU9q3JylDJ2IOqpfoI8qB7@0cT048Jm_1V0k0	0Z80f!3OF1k07g!qJ0R01v!DF09w0t!3Xk2W0DF012o0FF1209w012s0FF120@Z013c0R01v0Dg0 #ws71XVvFc8N4234m8wP95VkN8gPMZ12Vsk8FJ9P@B511caF4J2277I9Z24773t0FcDF4P3Z120Vc9Z42232WgV8Z78281m0WVRV8F4JlDVW08NJBY@5XkVsI8281c50WcLF4F24I0FmFJTF8WGGO08453Y1NwD510VFB630W0FV4c9Jm0WVFFZc84XZlsF86E31G84F@9Ca60W8HZ4TO27FlFVFN5@W0Ns42410kV@RAD	#h0k#8$22$9V#C#11e#2G#8Y8#44#8F$2o$4#tc#91s#22!2W4V	01$1(3/&U/1,1/!2/$41#701!2)1/,2*1#3.2$2/&2//#1/&2!2(1/02*1(22*1601$213!1$1/102)1!511-4!A2#1,1-101&2&2!1/1*201!21%201!3*1/#2!3-2/1!6$1)21!1*1&2(2/$3)115/6#24/)102)2$10102&402801)201011!1-1%1(1/#1/*z$14#1.1(2&D*22$2/#2&1)102/02#1&6+102+202&7/01/%3(1/*101%4$1/&7%111$	emPrL@@D@n`PHflbbbbRRfaRfRbVVfRrTRRRdLt\RJfv~AeUZhJBbjhXHjjfjj`J`DH`Q`					antagonist	CCR1	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
mPZ:`jD=FjE(:@`jfA;I:JFjH8;];]`jN9@eFj:L`j@fL:	;j;ir:E:ptibhTUbxCvnbAmRkxvd4@krSp4aAot6BQp42R2OcV26JFH04VL4!F05809WkX0X0X02010	0Z40IV02Ak3V!DB0DN0u!4IV2B0DN0u!6AV0j0440Ik2d0D$ m0X0RV8N5Vo251O0FNDF4L2oN11VV89N6H83WVkH62VVGNck2242W8cF541VcNH61VVH8S426DfG8N6D9712GlNNF5W0k44LA0VXI0	#8$1&4)VD#1CV$m#FV$V1#8F$NF#V4$8$5$4#2180	&1/.1J/!1-2#1/-107$8$2,101/*1,2%1///.1///)2//$1!5.1/)21/#3$1!A*1&2/(6&2/01/&13022#501%5/!1%1//01%1(31/&1/1/%1!4//////,1/01.201//$e*1+1*15.1/$1///*25%2$2%1!2#2/)101%1/(2/#4%1(12#2#1/1+1!1	fasaP@K@QIKTfUeeyW][Ug^ZjjjjjjZ`@@					agonist	M	Muscarinic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
MPx=.=S~.h.i.=S(.iO~,B)\6s)H5qH))H)HH))H5q)H5q)H5q)H5q	<vvzyzrrzpysPzUBnqdahadLKB0xFi3G2AG040OqNZdZV6jX1UYgx0o80Z12TVW025!401V2H20F81Y5lV	0Z40IV02OF1v!8p0@k!kB0y03t!KW0740SF2x0CB% #@kGQZ4H5Z12VqVVNBB7Z13V_0P46X57WkGcnSP4B2CX0sRLK5W22N42137_VFNcD83XVkcD6210kF421954VO8L83Wm8ZL410I2c44a118b420O8F20FW0kV	#L0k(2%G2#V5#18N#2FF!F3c$8$_$2k$7#l1$FN!204!291V	(1/.I&101#2///&14$2$1/01+6/,201(2/1//02)4//,2&1+4010101*1(7!1*41+1*2/,5!C%11*42/%26/#11*101*101(14//02//#2!1*3!2!3(2//-4/!1!801011/#1/+2)14/(1!5/$1!1$1&11/.n!1/&1/8/////&102(1/!1&2%1+1/#1+2(1/&103/,1-	fcgpQ@AJtcAJ@VX^FARSESQKJIKIIIHudyZjij`@jjiH\H@@					agonist	S1P1	S1P	no	gpcr-ligands_DescriptorsNo5Ht
>xhx(S>x~S=x=.hxhx(S(S~S>.hx(S>x>.(S(S>.(S>.h.>.h.~OB,\)pss6)J	=vzt:xnzRvQGlGQ@cj4yX2f_V9@d8x2#16I020FV3V1F54PLk8DJ22#d820F$c2k2!FV%	0aJ0Tk03OF1k07g!t!bk3Z!Fi0440IV2d!Jh0440FV1D09w# #3XFcFA7XkkF4JO0V_mwV8J4gH2E1Wt8X20Y5k89JaPM28W22VkcF72090cY82E1m0XVGlc8k574HV8210Z3mgV8N78281	#10V#8*4%8#30e$l$W8#4F#8F$2o$4#9V#15k#42#50V	//4&H1/!1//-1)@$1,1#1////*1,1#3-1//%1+21.21&1!1$2#2#2/!2)201&1!2-1/!2/!51%2(2&6&1.2#1!2#1)1%2$204//3*2!2/#2!1/01///)1!1,1!D!6//-1#2%3#9&1#2/#2/#2/!1/*w*1//F/$7//$2$4,2*21!2/%101$213/401/01%2/)4.2&4-1%5-	e`\TD@@DI`JdfYeU}yWUVYiCMKLbcgfjB`b`@jjjjBPVHvH@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x>S(xi.>x>x>.hxhxi.>S~x>.hxhxi.>x>0lF*xh0:(Sxh.hS~.>	;UvQzvU:1zymUFf1IUPdHcX79hK9DcWTV1VF133028040V3140@I296Z2k$B20F4!2V2o6#F!c!	0RZ!aJ0Tk02Ik2d!Fi0440FV2d!G_07!Tk3x# !9W@F4WFssgR6695lW0F91ZYV88gc9V22WO0G08KDK52GNFRaD284kkoVC60mHk44ZKZ17VcZ0GsRE2WaWG9VB96ZWNZ4HR9m0WVF	#12V*4#4%8#2VX$l$38!4VF#8F$8o$4#1V$5k!24$59V	&1&3/(9.3/%1//%5-1/01%1)2/)2%1/#302/(1//&1/-1///)1+1,3+3#202(202&2/(42/%101)2$1*602011&1)1$2*1-1+1/,1.2!1(1//-1!A!5//31$1/%94/1//!21+1/$1%2#l*1//D/%1!3)102$1*3031/.1/)1)4/521!1/,24/&1(3&21102/1-	fmwqB@@}FPDadTTRRVbRRtRRQcA^cUlDDTDDUUuAPjP@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xh.hx>S~S~S(xh.ix>xhS(S~x>xhS(x>x=S(z;xhx>xhS~.ixiS~S~.hxhS~vl0lF|`|:v(S`|F|0l*`	}T<wUQvzvyfTxSfUDcvz2E6Gp@vjiq1WeqrQ_waMKCwFetANPcA2X#11W202218nJW8FV	0Xs0IV025k1v!BM06J0Tk03FV2U0@Z!sg0bk3Z!DF0@40t!4AF0k0440IV04OF1k07g0zF05RF1o0Bk0nF3o# #1Z13VWdd4BB6OFZXsVkF8A740ko@54W0V882DA70WNsVC6XG8J820a4I0FZ@@42ksZH73VVNB6110V@OWBRX2W10FT221V88kaN6C_0VoP62W2Gs84PJ891FskN4420sR62CBag6VFN8gT31WFoH389424NoTD40kW0gVJH2XlcsN820VF4keNpFYVl0TF4@222X10ZL@4WFsJ@30VVFB6ZM0V_4k88H@6Y18ZF@20kV8210VJX2F48321l0ZL63W0s84610FF84210FA1V22LOm0WVMXV8L46D@Hs8JN@23W0sVN9421888710V846ZM10FXXV4873XGsgF8510c863184V89144111FsRH83X0kR@31VV8B220VFF9Vk10W5Lams8@4Q5@G8oJH@9EZ294F1750FG16F462D9YkkJ8A4WFVF2NL0V_3FlRX@53VsN420VI1tV4DA5WGNcF721ksF82186Z6Y0885Z120mYFFR9@z2514KloD884	#Y5V#84!21$J2#d9#2Ve!20l$f8!4VH!208F#3o!126#1lV!1Zk!247#_9k	#2%2*2,1#G//$1%3)1/4$@$3//1/(20111(2021)1&1!2%12$1.1012-1/0101#101%1/2//)1!1)101+11!204$1&2!7%202&1*3$1)1#1#6#12022#1%11%1&1)1$12$402)1*4*1*1011!1,2!6&1*4011$1$1//)21#11&1$7!602!2/&1%1%102#1.9#2,1+101$1*1!8.1/+10z%34101#1*1#1#1&D/13#2.1)1)1%1%12.61/02$101(151#1,1/#1(3#1/%211&5(1!2(1$105&1%	eeWZBD@AGL`X^KNdPHbzPrJJIQGQPqIYIIQIPjIYQILRIYGOHx|bpPLUMUUU@DSSUTQTBa@@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
8D8bS48D8D[5S48brS8D8D[58brS8D[58b==qKSr9Cii[58bT(====5Ki=D8DnK5=iK5q[4Sb84Sbni=DnK54S	;vzv;OLzQydiUC8sq82vWARKg3C6eMn29E2411q8ZKJWHe80v!pWNBdd1H0V58VF0BL0e4CFF010OX0l0	0Xs0f!2AV2g!9k0Ds!b!vV03Xk2W0DF!sg0cF3Z!DA0@40t!5JF1_07!Tk3i!KG06J0R01v0Ds01Zs0L02A0@40jk3Z! $@BBaFVs@32ZYk88oc6A9akksN13ZYmFFB@33218cD940VkB@51VVF5FkdZ11VVlWVe541kVZ22163I0N8JG9aFc8B8@7VF8FkkeNHZG1FV46@43GFZP@3W0s86RL0VZnt08gs282254koPA64Y1I2Bs6132Gcc8gy28210WNRNC531NZ841a_k89JsBR96lsF4D972329FLH6Vk88cXJ263HON8A3108B6NFB10FVB6721l0sD421FVB6310kN9No11Aft0FV8B429Zm0cF6354kc942126am0Gtk4L421XVkcP952l8N4410Yn044eV17YncZH90W2HNR24F0VYIBV8F4421VkFRB86XFVF861W08B6320FHt_R25@_lFNH251FWO8210WYYVFFJ@62GNcF43W0F861FAVFHPBJ4TU15W0VLN84311VckD@3VkF8B111FFJ422VFA1dZ@HF5lkRNNB10VksRN85X18R@72VkH1V42L0V_0899E827131224aC11F98cb82410W0ksgD6Y0kF6LJAm0XkF8@g442XVsgJ83W0VFD417akV88k11@0FHHW8eW63V8kkQ82710VksVL95X1VVB31WVF50i11@c_lVsiI11WlV44JF222HNoPC5X0lGJ22I0VZIBV8F42120l8cH84YG0B8420kF58m11Adt0GN88695YGVsJ74WFF42RJD	!2N4V!208!8B5%V(1NH#26$vF!4Z2#8F#83k$_#O0V!PKs!2W#218k	/)1(2$G!4-12/*2/-4$5-22&1%2,1-1!1%201/.4//*202.8//#304)1/2-2)2%4//#4(2(14/&2D&3,102!1/#2*5/4%F//-6*20205!B-2$4.1*4#5%2/+4.4)1/2!2*4N%1!4*1+1!1/-1/.z1+1(2#301-8//!4+2*4/-C/014/42)1&2*1/&204*1$1,6%20402/-20	ecWVJ@@DJGOFa`Dbe]\bbTTrRrRRbfffrbbbbbbmUGBHkLkTsUUULuUP@QDPU@@@@					agonist	Opioid m? / delta	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=.hxh.>w<^}S(.htn8t~U.>x>)Lb{.hxh8t8t.>x>S~b{.h5q)H6s>.\},B)\	=fzRvzSxMS9vUSslXc@d3fF3cVC9DHx25A8BFnq@ZO0YFas4h20JF8Be512O_12218JFV!XF!F02W0FV	0Z40IV02OF1v!Bh04F0IV035V1Z07c!sg0bk3Z!K10480Xk2U0DF01VZ0Yk3P0DF0u03q# !3GH4LG32Glct4ZL9X1V8RNEZ110t0FsDF4V3Z17Vdq8kBN68Dd2FR4BH699nNg@@H5i20VkIw4J_1415tcFVA8281m0X0MXR26B3CfX0N8@750XW8kP95XVsF@40VV850RV2631cgDD420s4430b3nXckF8@XWkF2H891XFkk8A3218Z@@30F9sVw26H2GsJB@21FGNgg	#94k#88!161!10H)48N#NGF#W8!2Zx#4GF!2Pw!@@D!2OOk!93R!1K#2tGV	*1*1)101$H/%1*2.1#13(1%4$7$4$1#3*1%1*1,1(14&211*2,1$101/!2%111(1//0101&1(1//)22/-1/*4/(2,1$6&2#1/+2!302%1$5/%1.1/!2*12%1&22101%1%1%1.1*2/,1!8-1!1&22%2&1+4%4#4$1!1/$1,1(1/.2*130t&21/*4&8*1/*6%3$1//%8!2)1,1)236/1,1//01/012$3#11!21/02(2	eh\TJD@LMhDAIG`@a`HrRPjJISISIIJKGJJIPph[xEZiZj`hJbjfd`@@					agonist	AT2	Angiotensin AT (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
(Qb+H)28x=.=xiS(.iS(x=x=S~.=S(xi.i.i.=	<vxUyzpzpzROG1z5r19Pqg0kM8F08bUO21103OPW@41tV0288A84J4FG0WFF5W1222B!4!F82!X0W0FV	0YJ0IV03JF1_07g!o80eF2f!Kl07F0n03C0EF$ 0167W21s8NE82816b2WsFR9162fqcFJ@ZH22W6ONFo8	#H0V(21$82#V1$V8$1$1#4$2&6V#22#1GV#4F!1c4#A8V	//(6//*1/+2$3///02(1%101(2/#1*5/!2$1/,3#1011!1/1-1/)2/)1/!3/)3/!2#1+1&4%1#2!31$1/(1%1$1.1%2/1)1/04/$2(1.2+1//*401(1///$16#1/1!1#11%1///+11Y%2(6*1+1#8/)1$1/*5/01+2//$4(1#1$1$1///,41/+3-	fbmI@@HDedFRIQZJIJZYGAC^SfehJBbjb`r`@					antagonist	mGluR5 ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
O~}Jzd.hhxS~.>xh.h.hx>.>xhzBW~ps}\	zpzpn_USOl4S7F2DDO0p2N2c01F0C34!HFX10X!FZ961VV0X10d04J8FW9VLG0V102!VJ4!1024#V0FV	0QF!qJ0Q01v!C20@40jk05NF1Y07F0nF3p! 59ou6@3m0WkK88lq292m0WkRV8N78251	#@0V!1$28V#@FV!V34!7VB$4F!FXV!408)42c$V#G1V!F2k!@04#1SV	//(6//#2//!4//(1/-401(4$1.1//.1/,2.5,1/,1#2!1/%1/.4-3/$1/#5.2$1)1/$1/+1//%2/(1%1*1/)3,6#1+2303$3//(2/!3&1/,1#1///)U#103/#2%1)8&1!5.1///&1%2%3/#1)3//2/(1+1.4//+	fdeI@@LB]xBTswJKbbcAcSHPQMTP@@					agonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~xi.i.>S~S(.i.hxhS~.>x>.i.iS(xh.=.>.>x>(S>xS(S(xh	yywM4JsG9V4mZ1A6FNH5VR6H040F93920FHo180V3Ok96FW01@0V52G2_0dc8@HFc94@27cX4V@4K80F4N6030	0Z40IV02R03i!CG06J0Tk03ZF3a0Dc016J0R01v0Ds01HF0IV1k07g0uF0 %O0FcBgm4@2m0WVRV8J78281m0YFRV8N78231m0WFRV8R42B@_GO8N48540IWcwB54VkFsko6_AXl082192ZVY1gBL7VVG0sVFNE6VVN4D97	%k!2&5!2E$28#892#V1#4Yc$o$2$2w$1#GV#10w!242!251V	/&1/A/!2!3//,2014%1#1///1#1(1-3+1,4//+1/3//%3/)101////!701/31*1+@&1//,2$4(3(2)4$2/$2/,3%2$1)4*1(3*1$12/&4!1/*1/.1!G/-3/13+301!3.1)1%k%3(3#111/01!9///0211#313/1%1%3/*1(1/////)2//)	feg@P@@HYYInYnueUYTRgQsuhHHjB`jJH@@					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
u?ugS,u?u?S,u?ugSzu?ugugu?ugu?ugu?ugSzu?ugSzu?ugugS~u?3jsj_xGxxG	:UvzvzxzSxzQRQQSSNnf8evs2Hm_098Diw052V11Qk@ZGlVVAJVA06J8TRX25X0W132m40402080204VVW8FV	0qJ0Q01v!C_07g0zF04AF110480eF04YV2W0@F0t!5JV1l0Ag0j03J# %D5I0lNN8@C330kgJ95W0VB4RC10XYl1BuH4X0k8VDF22XFsNF84218J4130nmc84338VVGs824BK0VW94ZC7WVkN62B76N0VFZA8271m0WkFFNLA84GFV8545Y2k84B672lNZB721VkB4228Z088t8	#X0k!14$1F$H#ZA#58V#4J#1W$4#2NF$2k$5#KN$3c!306!21OV	//&1D//02/3/#2!30501!2/#1&1#1/*11101#1031$1/(2#1/!1///!3///-401$2!21/%103(2$4!202//$1%2&1/&2-1%1$1$1-22$21%3/)1$101+1#1*1!6%301.1%1,1$101.901!4#2#1/2*1.32$7%1$1!1!1$2*1-11!2//)10t010302021$1$2#1201101%1#F/,11/01)1(2/1#3/(1)144/01///2)1(702(2,2#5$1(	ehR^HH@KHbckgol`IAIe]YWUVvUnvhXLlfv^~`@jjjjZ@HZha@@@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
)Jp36sF*}\)J)Jp30lF*}\F*S~0:(Sxh)\6363)\	;U3AOG9Z50402UH801X80m20F012d202H0582031F06012#V02F8cF0198!F9F204V20WX$11N3010	0Mg!aJ0Tk02jV3W!C_07!Tk03FV1E0@Z# !3CZpcVZ632330HcciB0Z0NcZL314_O0G084q7BcGH0B64B7m0X0RV8R42DGZ38B6D@1VX2BV8F78251m0W0F	#80V*2!240V#2#85@$G#FY8#Fk%F#VZ)GVV$s#4#258V	/%1$1$2%3//(1/-4$3/03!1!4//+12#202//,1(1//#201,1(2&1/1/+1//#1/$1$2/,1(3$1%2%4%3/*3$2#2*1/02.1*3101/*1////*1!7.102,1//09,1/!11////0a%4$21/!2*D/$2/4/0101#1*3-1$1/$1(21/02//+2/&2/,4-	fj}P`@AV@GIEDdeMEDTlnJ]{IZBBbfh@@A@r@					antagonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
x=.=xiS(.ix=x=.=S(.ix=.=zdW(S(.ip3}JS~.=.ixi.iS(.=.=.iS(.i.=	=jzSrzpzUOEvzEsR28HdpzNVS8BW2HO2UAgRPdq8Z40ZFYN8eV0JNG0g1KmHZ980VVJK4#W3H080V0FV	0G8!qJ0SV1v!DB0DN0u!4Mk1W0Ao0pV04J02B0DN0u!5AF1D05R0L02n$ $SL23111NFD7711Ng6A20VOl422E0VYJ0FJcA7XFsF4510VFJ4110ZWXLF4B2rLW1kVcgNHCX10B62@7VVGdN88D4YlVwJ73Vmlc84LN11XlksT721FVZ8410Yl9yF4D222_Hdo@9242VN8VZ46B_mNo271ZXXFcJ6A84H0V@62VY11aF4R2W37mkN4B66m0WVF	!2D2F!GD8$5!30FV!l$1N2#2JV!@X$5O#1WF!FNo!8ZZ#1AF#Jk!27o#11k	/+2+9-10101!2+1//)5$2!3#3)1)3$504/%1+4)4/$11/021//1/$1+4)4/(1!2*206/*1/$2%3/!11/&7&2#1(1*4#11+201!104&14/!2+202/&2%13*1!401/01//%6$1!2$2!1!4$1)1//%11)2+1/.11$1/*1/#1q#2/%1)1%@$2*5///#21.1!B!1%2*1$303%1!1(1&1-1/$11,2!3+3//+	eoh\BH@MHjeOCk`@cIEDdedeEDmCEElh^IHdnijBBJjYVjjfbXBb@@					antagonist	PAF	platelet activating factor PAF (I)	no	gpcr-ligands_DescriptorsNo5Ht
.h.>S~S(.h.hS~S~xi.iS~x>S~.>xh.hS(xi.hS(.ix>.>xix>xiS~x>xhxix>x>S~xixh.hx>S~S~S~.h	~x<qzUuU<wnSx;SziTrtvrjgkUVreyAzc1SojUj7QTa_W7OnAGp43FGfcFIdcV8F0	0aJ0Tk03Y03a0DV!qJ0Tk3x!FZ0440FV2d!HD09w0cF3Z!GF08k0tV3c!NZ04F0Tk2B0DN0u!8CF1D05R0L02D09w0cF3Z! #4_6W_GVo4730kFBVJMZ13VVm0Zo811kV8D30VkV8wP215cO0FN8OF611lNV48252Vc8Vhej24W2ZVVV870VV4ZLIZ12VVFVgPC@YFNRB5A7VVGdVJkT5XlFB@F98OgFW0F8@D4YHFg6620FN882E5VFG@4G04@2m0XFFFoPC6YW0s6410F9cco4R9VW2NF467VW0N@F@Bm0VVFNgiF21FNV831VVFF64F5c2oc8494Wl88851a1nBV8N4443Z1t4F711kFB6PB1VVW844DV7@50s8H@3Vkc4gV20W3FFF8HUZ12VVkNsHD930F84220kVB2VF0VYF848Da476GNRN520Vk84NB0VVFNVz8281111FcH9521NZ6410VV50R20W2ogV8R4	#9ak!FD#B$1@kV!W8#18f!12tF!8YN#5$8F#X2k#l_#G8k!dKc!2LF!315V	&1*1/$G#1-1!1$1$2%101*1#2+4$3$4$2%1/#1-1*1$1+2*41#1/01/!1!1/%1%2)1(1%3)201/02+3-4#1/%101&2)403.3!1+2+5&4-20201!102(3(20202016(4+104*3/(11/0101#1!2&1)301-1#1!1&2$104101/0701*111%4/#2&2#102%4@01$1/+1#1$2#1/2/*1020z%4021/201-D01401#3%3&2-1/101&1/%C)1-103041$14/#2,1$1/(1$2%22&4$2)1,301+	eeWRFD@I@deoHbj`ZPI@bPrJJKKQQQQQJTkIQIZIQQHl\VAO_XlbrpPEULsSUUUUPL@UD@a@@					antagonist	Adrenergic alpha 1A / 1B / 1D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S(x>.>qqg-.iS(y?S~}Z.>.>xiS(^}w<.>~Utn.hS(.>.>S(	:UvzvzuzSznvydQIn1OUAv0a27AZk9BsWx@2ZFb8M1X8FiA01H54D6k2R42m!2d42FF$90k#F%F	0aJ0Tk03FF120@Z!t!bk3Z!Fi0440FV2U!GX06J0SV3F& 6F4X3Z17Vt0FV88k40XG0V624YkFJBRBDK73F4226234XtgLG231WgV8V78291m0WVHNc883YmVs6H89	#31V!188!208)V1#3V@$5$d8!4Z8#8F$2k$4#9$11F$2#18V	01-2,101&B&1&1///&4$3$1/%1#3/,1/+1/(1//03/,1!2/1*1*2//02,2&2//+21!3(12$1,1$1/%5)1%2$1//#2)1$1/02$1/$2/-1&401(101/#@!2)2//1&2#1%5!2(2/#1/#6/!1/*j%3//$F!1$1!2//%3$2&11/&2/,1#1!4/2/*2//)3&405/+1$	figq@@DVJCHhhhhdmmDdhTaJLyN^cZhJ`bj`@bHDH@@					antagonist / inverse agonist	H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
.h.hS~.>.h.h.>.h.>S~.h.iS~.iS~xiS~-iS~.=.h.h.=S~	vzMQvAnPUNv2QDF3F1FOs890c22VZ09BN9R$101F2%9#22#R2H0202420F$8%VV!V!	0RZ!aJ0Tk02OF1v!Jh0440FV1D0@Z0 06kWFZJ311lNsBeA2YFkoHA30Xm1TF4F2I7110VDA2Wl8J2NKBm0YkRV8N4	$2V/*18+18)8F$@k$5#G%18!2$210V	//(C////,5/&1/)2/)2/%13$2////-2.21(1+2/&4+1/(1$1&3%4(2)121$2/22/(1/*101//%2!1/1/0101.2///+1/0H!84//,2.94///$1+1/1,10k)1/$3+F/)2+2/!31,1//+2(23/4///$2(1%2&4/$4-	fi{P@@@IRVUvUuUeYgCV[w`@`@jjjhJER@@						H1 / H3	Histamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
xhS~x>xhxhx>xhx>}^^)^)x>xhx>xhS(x>.>S(xh.hx>.hhx>.xhx>S~S(xhxhx>S~S~S~	?v;GzynUmfqMUzuLeXbAx2tysWzy1hH_YW986H42102821suAD4I2040k9V2F4VX0WX0J0V140VcF0	0RZ!U4!XZ0IV02J03d!C_07!Tk03Ak120@Z!sg0cF3Z!G_07!Tk3x$ $@9@4GW0D5212WdLF4H289c2NkF173YVFJ8R@B5Y1ck841_5VN9F242810Gc44LWZ15VXVlFeD72Wm8F24C910W8RD84XFVkD620FNC0a118VFNFpDF6A1XVkVZRD6W1VgJ420Y1laF4B220YFtgLB61VN441173IY3Bm69357HtcJ265Y3FHlG09C24GG8W0A0WXs4VV4213HVFVTAB2GsV45@758_FFRk25323JdNT864Y4WsgwP57XXHlc@4AVWlkV4NGZ11VVFJV8F66XGcRH730kGWR42K10FXFB24E10FWXWNC8371W0V8s35a1kNZa20W3XwV8N782B10WFNJw10h0G9BZ@436FsdGe2H6	$2k!2&2#4%@F#5X!1@HV!P_8#ZG#8F$@o!1V4#1cF#1k!16$59V	,1!22*2%2!2A!2.1!4!1%21+1/1!1&203$1//*1(2/024!103/)2/%1//%4!1)1)1/+1)2&1#14/#1/11+1#2*201&1(1*1#821$1/51/#11$1$4$1!1!1(2$2&11,3/#201/$4101$1#31#1$2&1&1$1$2$21!1)1!7/$1)2*101)1%1!822//01/01#1*1/!2)z%201/01$2!1%1D.2/01!14+21#432/$1(201+3&10204)4/)1/!1$1/(11(3*1/43#1!1%	ebV\BH@MOL^Dlk`ICHhdleEdeDeEeHkEDdcPpii}C@AUUUTtuPPQYDCaDET@					antagonist	CCR3	CCR (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
S(.>x>.ixi.>S~x>.iS(xi.>x=.=x>S~xiS(S(xixh.>S~	<rfzUvmJhMUPiCCsVmO09gj8_B3064MVVC28!cF5VV0VL3_0FVF6Vc!51V04kG8V020106048JVK2V0F0	0Z40IV03OF1k07g!qJ0R01v!Fu07!Tk3f!LA08w0cF3Z0DV# $GkFVsIx@492m0W0OGc8H5Z120t0G08JZq2YFckNN48C8Wkc@DC752HWBZA50m1l08BDA3XkkFFE8	#V0k)2%FV#Z$1%F$Y8#41!1%V2o$4#tV#80s#62!210V	//(@//02/#1/B$202!2///*2*1%2&2.2,1$1//+2/!201*2.2/#4//(2-11&4//%1$3&2///!4///02/!14-22.1&1(2/$4/)1!6#1)1/204%1*1+26/01/01%2///(f%62!2$1)1/F*5%2/+2/1/)4+1-2,1.1(2+1//,1//#1&	fak`P@L@QrJSJl|lwJzNVuzuTuT@P@D@@@					allosteric enhancer	mGluR1a ( groupe I )	mGluR (III)	no	gpcr-ligands_DescriptorsNo5Ht
xi.iS~x=S~.=.ixixi.i.iS~x=.=xh.hxiS~S~x=0lvlxi`|F|x=xi	:UvztzvzKzlfTfUHv1GINfH6668hG9BcIzX7ZXf3Q0Y8FW@02G_4@5w9BZ3lBWIc0HNm40J018l01JL10V0F0	0ms0FV1D!C10480IV03OF1g07g!qJ0Q01v!C10480eF03Z02W0DF010s0Q01v0A8# 06F4J23I7lskJF@1CW0lJc421F8J2N8Bm0W0RV8N4NPEXl0F6483ZO0FVDF4P2S7blNR411Z1mBV8V44TD@G1kWlTN321VVNRDA6XWFgH4210V4wLTeG60lFN8TSD_kFkwQ8251c50WNGle@4X11@1F8D54F11kVWBTICYFNsoR	#E0V!18%F#2%2#4V@#25F#VV!4ZF#8F#82k$4#13k!13V!2Fa#19k	//!1$D/!1&1//+6$4$1/&1!31/.1+1#2&1/(1+2.102!2/+1+101//&1%2/%1!101202%2%1%1+3/!2!3)1$1!104&1.1!1&15)1%2#21*1/102//&4$1$2%101*1#1!1/-3,2.5&2(1/2%1*101*6+101/#2&1)4/01102!2-101#n%2/#1)2%D!3&2/!1-2$21%1-2.2!2(1/(4%1////.3)4/$1+	fcqB@NIKd@QdbbbbRRvbvbfRQirUmNGN`B@HJijjjB`X`@					agonist	Opioid	Opioid (I Peptide)	no	gpcr-ligands_DescriptorsNo5Ht
dz}\>xW~s6psxhzdJ}x>x=xhxhx>x=q5xh.=xhx>x=xhS(xhx>	xvwjgyqabEui9dxVbEzeCCK1KOgXPs012F0KuS42B8kFFZP4FFV6FV#10V0F210F8J82)2#6030	0UR!Z40IV02Ak3V!Bd04s0s!3Y03a0Dc01Ho0Ak110D!xk$ $6XdVR7211lkuCy235WX0VND942W8g8610kV463G5VFG@LF462CA5Hcs640VXGt98kPE0GG8dFcO42kNBH195ZVF88B73X1NB@22X10JB52VVPVs22AKIEVVsFc4Z7XVs8F230Hl9TF462B681No@43VV9FgcqkB0G1caF4B2ABZX0o4240FWFoc	#8,4$9$4$12#2%V/04F$4#18V.W0F	//(N.3!3!3$1%1%1*1$1+4$6$22/!2(1-2(2!2,14////(1-1!3/1/(202/!4/*2//,C%3//1#71%3#2!1(1/)3&501%3,11//*3!101,201(1+4//*2/!1#1!1/&2//+102/01/#1/02!1/(j/,2!1//$2/!2*3&1&2-108!1(1////!2///01+1*201+	fekAP@@RCtZSLjkjmOkIFMUUMUUUSTQEABFDNhaJ@						PG	Prostaglandin PG (I Prostanoid)	no	gpcr-ligands_DescriptorsNo5Ht
.hqqq5.>}^H)q5q5H)zdm0y?~Q[)q5}^q5}^H)q5q5H)q5}^c{h.~S>.h.h.}^>.b{t8~Qwj{D	?tzxxIzwnUFvFzj9ymN0Mfg39Nwyz25s0d3GGA49_WV2BV864oWTB238JFc122H41@c8B40H!2BW0FV	0PZ!aJ0Tk02OF1v!Bh02s0FF03FV1407g!t!cF3Z!B704o0xV06JF1l07F0n03C0EF$ !5XGFsP241FsJ6220FOtk212Bct0Gc89BH53lc4Rk20W5F89BcBF3ZH8FB93W0F44PJCm0XkHI0P572YkF8kO0JDZW28XWDI12516Xk8653QfFWNLF4F2673mkJRD10VF4go11B0FHWiF4B2G6clccF279VVH94oi4B20WlcoLC4118RH210YY1qF4D2JN2VNw4BH10YlwV8F4AI4Vl1kV8a5H3G0N82155FF9BgB37Y2FgH92WFV8kaOZ170_FHNg7121lNyF462MI9Vl0NgJHC_k88FFF8m0X0F	#f0V!18#21%2#c5#11@$1#4Y8#4L!28N$2k!836#OIk!958#17!211k	/&1.2I/$2$2.1+4!1+2$411!3!1///$1!3011&2$41!1)1*1/021$31&1-1(11%1!13/+4)3///!1!2$2$41&1!4+2-1/(3&1,11(1(4$201#1$4(2$1/#3/+4#102/$211#22#11/(1/1#102.701!11%2+1//&9#3/#2$4%2.1*1&1/*z)2$2*1%201502#D1//(2#1(2!3#2(1201&2!105!1*11%201$5%3///&1/-4-1+40@#1!112#	efURBH@GNhTXDIlP@cIICLeLdldhdleMDeMLlIIXyTt|CbRm@AUUUUTpACSEDaEFh@@					antagonist	D3	Dopamine (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
?y}Z.hqqZ}S~.>xh.h.hS~.>xh.hW~zB}\ps	<vxUzUl6xjLfDEt0pHw2c09FSC3Z68IFX9B2c0NZ96IV03X10t0oMBFVtVHF1V102!VF!X142Z040V0FV	0Xw0IV035V1Z07c!qJ0R01v!C20@40jk$ !4F8ks2@HVX0ofw8N5Z140t0Fk@Ky472m0XVF	#80k!4%8V#6kV#3V#44#V$FWc!6VT$2F!4NZ!80Z#G_V!F8k#Z2#COV	/1/&5$3////04$2//01+1/!401(6$1011/.1/%1/!3)1$2.5//.2(1/1/1,54//$1,2$5!3+1//$1//-2!1/2!2//!1,1/3/2,2!3/.3//03/&2/!1/*1!1/)X%3$3!5*1/8/////)2011!3/#1%1!2//2///$2*1//	fluQB@OAD@HrQQJFIKSSHeEFbfiP`bfjJFb@@					not given in publication	Adrenergic alpha 2A / alpha 2C	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
,dpsW~.>>xS(.>S(.hx>.>.>W(zd.h}J36p3\)	vrUlvWUSOG5x3FAEDO0l2N@c01F0CY480HOX18X!PZ96GV!XG0d04J8FVdVLG1W102V0VJ#1024#V0FV	0QF!ZJ0IV03OF1g07g!o80cF2z!GW06F0SF3L# $8ltRq8@4m0WkKF8lo292m0WVFVo4FA50sRHH99LhkW0LF4D3Z13Vt0Fc@ca49I0WVk	#@0V!3$28k#2FV!c3#6VB#24F#Yc!41@)4Hc#4V#KGV!F@k!@04#1SV	//(7//#2//!4$1(4(2//.1011&6$1/1//-1/,2$3/01$11/+1#2!1$1/1/.41,3/$1#1)2$5.1#1*1.1//01)4/+1/(1(2(1#1&1/*2#1+2!3$3///+3//$1#1/$2-1/$_%3/#2%1)8$101!5.1*2//(2)2//$5//2///$4-1#1)31,	fbmH@@@XY[IEElhheEhcbaoARuUAAIUP`@@					agonist	Adrenergic alpha 1A	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
S~.ixi.>S~S~.iS(xixi.>S~.=x>5qhxS(xi.iS(S(x>S(x=S(	RuwQV@mGA80X1886F9H9VN4H440V4292!HF1N!W9F0601!8#212W080882!10@0KV2$1802482010	0Y!IV02FF1D!9k0Ds!mc0FF1D!CG06J0Tk04OF1k07g0vV$ 6F4F3Z130t0GsDF463Z13Vt0G88ZRJCYVcFDF@85YklBa34WV84D2B760Y3FZ4542VWFkaC9WkkJ8JA10XHqQ48D5Z13Vt0GcAB4Hl1310W90aE411V8ZV21VV844B9E	%V*1*B#89+38/2s$1#G$10s!2$211V	//(B/!1!6//%1#2$4$6//-3!1///*4(2)1$3//!12//,1.3////(9/&1/#C/!3$22/!1,1/&2)3//!16-3/%2/#6//)8/*3/(2,D//01/(1/-1&10n%3$2!3/4*B///*3/%6/&1/!21!1/,2&2//1.1//)	fe{A@@@EBPdHdHbPfQBIBHJHcIVcA@ADUEUU@@@					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
.i.=S~.ixi.i.=S~S~.ixi.iS~x>S~.ixiS(xi.i.>x>xix>5qixS(x>S(x=	zyxzoysGfe4m_1ADFNHCVR6H4Z0k139X!Io1N8VWOk86FW0180V52KH_0dV8@2Fg14@2McX40@4K80H482010	0Z40IV02OF1v!9k0Ds!mc0FF1D!C104B0IV03ZF3a0DV016J0R01v0Ds01HF0IV1k07g0uF0 #1Z12Vt0GNDF4N27NeklsNRcGE6GGsdH4D321t0GFDF4B3Z19V_llRgG5@Xt0FkDF463Z150_lkkuK562t0G8DF4@2rLW1kgV8N4cpCWXVwV8s782715YXcFa@3X0d8gZiG6ZXkVNJB57ZkkJJ8@X0GGBc86521FcLA6XFk82PKC7CJ8NVB@F6XWGwP185Z13NgP19W2884JD@	%k!2&5!2D$2B#892#VO#4Yc$o$2$2w#V5#GW#10s!242!251V	)1#1/1(G/!2!9#12/*1)201016*1//+1#1,1-1+11/(1/(2/&3//!2!3%1///&2%21/(@01/01*1*1C&1/22/0101+4(201#1&2)2)2/%1/13!1/!101(1(9!1&1/*1!4//&1-1*C+1$1)202!101*13-1//#u1,1!10101)4*@!1//)2$11#315#1+101*2!1/$102(2/#2+2&3/////*	eohPB@@@D@dlbbTRRTLRbbfZdQRdL|BrZZ``hBbJJjjH@@@					agonist	CB1 / CB2	Cannabinoid CB (I)	no	gpcr-ligands_DescriptorsNo5Ht
O(s6.>}\B,\),d0:*`S(:0*F	vxUW3WO4WF4R0J08@B0V280cV0F18#4HF01808!k8410V0Xc08V0J0F0811F0V1!1!J%2$V4FV	0Ww0TV027k1u!FL01w0O01u!KU0640SF2x0CB$ #38291OBVW8LF462mO130gV8B78241	!1E0F#2$G2#86V!w8#108!2FF#2V#@88#4%Fk!183!2JI%N$1#92F	//(4//3/,2///1/-112$4#4/4//-1/&4//!1%1/+1(2/(2//&2#5/$1,2/$1//////(2+3)2,2/1/(1/*5//////+1//$1#1,K#2*1*1/+5&3///01/#6!1///$1///)5(2//+	dk]@pILLPlQ`cHhhiUDj[SifjVh@@					agonist	Adrenergic alpha 2D	Adrenergic (I Amine)	no	gpcr-ligands_DescriptorsNo5Ht
<datawarrior properties>
<axisColumn_2D View_0="<unassigned>">
<axisColumn_2D View_1="<unassigned>">
<axisColumn_3D View_0="<unassigned>">
<axisColumn_3D View_1="<unassigned>">
<axisColumn_3D View_2="<unassigned>">
<chartType_2D View="scatter">
<chartType_3D View="scatter">
<columnWidth_Table_DatasetName="78">
<columnWidth_Table_Reference="78">
<columnWidth_Table_Structure="98">
<columnWidth_Table_TestData="78">
<columnWidth_Table_affinity="78">
<columnWidth_Table_company="78">
<columnWidth_Table_drug="78">
<columnWidth_Table_mode of action="78">
<columnWidth_Table_receptor="78">
<columnWidth_Table_receptor class="78">
<detailView="height[Data]=0.5;height[Structure]=0.5">
<mainSplitting="0.71928">
<mainView="Table">
<mainViewCount="4">
<mainViewDockInfo0="root">
<mainViewDockInfo1="Table	center">
<mainViewDockInfo2="2D View	center">
<mainViewDockInfo3="3D View	center">
<mainViewName0="Table">
<mainViewName1="2D View">
<mainViewName2="3D View">
<mainViewName3="Structures">
<mainViewType0="tableView">
<mainViewType1="2Dview">
<mainViewType2="3Dview">
<mainViewType3="structureView">
<rightSplitting="0.65904">
<rotationMatrix_3D View00="1">
<rotationMatrix_3D View01="0">
<rotationMatrix_3D View02="0">
<rotationMatrix_3D View10="0">
<rotationMatrix_3D View11="1">
<rotationMatrix_3D View12="0">
<rotationMatrix_3D View20="0">
<rotationMatrix_3D View21="0">
<rotationMatrix_3D View22="1">
<rowHeight_Table="80">
<structureGridColumn_Structures="Structure">
<structureGridColumns_Structures="6">
</datawarrior properties>
